{"columns":["record_id","title","first_author","year","decision","reason_code","role","populations","harms_outcomes","flags","confidence","round","reviewer","note","rounds"],"rows":[["R0000064","Improvement of Chronic Spontaneous Urticaria After Glucagon-Like Peptide 1 Receptor Agonist Therapy: Report of Two Cases.","Kwiek B","2026","inventory_only","N5","other",null,null,null,"high","first","opus-5.5-agent01","report of two patients whose urticaria resolved after starting semaglutide or tirzepatide; case report",1],["R0000239","Glucagon-like peptide-1 receptor agonist use and clinical outcomes after posterior cervical spinal fusion for degenerative pathologies: A large cohort retrospective analysis.","Rajkovic C","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent01","GLP-1 RA users versus nonusers before cervical fusion; outcomes pseudoarthrosis, readmission, infection, none in harms list",1],["R0000309","Ocular complications associated with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) - Clinical evidence and insights.","Maideen NMP","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent01","self described narrative review of ocular adverse events of GLP-1 RAs without pooled contrast",1],["R0000385","Musculoskeletal Outcomes of Glucagon-Like Peptide-1 Receptor Agonists Versus Other Antiobesity Agents in Nondiabetic Adults.","Wu JS","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent01","cohort of GLP-1 RA versus other obesity drugs; osteoporosis, fracture and disc outcomes only, no listed harm",1],["R0000468","Prognostic impact of glucagon-like peptide-1 receptor (GLP1R) expression on cancer survival and its implications for GLP-1R agonist therapy: an integrative analysis across multiple tumor types.","Ungvari Z","2025","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent01","tumor GLP1R gene expression and survival analysis; no drug exposure studied",1],["R0000123","GLP-1 Receptor Agonists or Dual GLP-1/GIP Receptor Agonists vs. SGLT2 Inhibitors in Patients with Atrial Fibrillation and HFpEF: A Propensity-Matched Real-World Analysis.","Ahmed F","2026","include_harms",null,"primary_report",null,"O121",null,"high","first","opus-5.5-agent01","active comparator new user cohort, GLP-1 RA or tirzepatide versus SGLT2 inhibitor in AF with HFpEF, acute kidney injury reported",1],["R0000078","Differential Biliary Adverse Event Signals Among Glp-1 Receptor Agonists: A FAERS Disproportionality Analysis.","Alvina","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent08","FAERS disproportionality analysis of biliary events across GLP-1 receptor agonists",1],["R0000145","Small-Molecule Oral Versus Injectable Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists: Comparative Efficacy, Safety, and Future Clinical Perspectives.","Patel D","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent08","narrative review of oral small molecule versus injectable GLP-1 receptor agonists",1],["R0000198","Assessing the risk of diabetic retinopathy progression with GLP-1 receptor agonists: a systematic review and meta-analysis.","Yang Q","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent08","systematic review and meta-analysis of GLP-1 receptor agonists and retinopathy progression; PubMed and Cochrane searched",1],["R0000272","Effects of GLP-1 receptor agonists on body weight and cardiovascular outcomes: a review.","van Maren SJF","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent08","narrative review of GLP-1 receptor agonists on weight and cardiovascular outcomes",1],["R0000426","Glucagon-Like Peptide-1 Receptor Agonist Use Does Not Impact Spine Surgery Outcomes: A Systematic Review and Meta-Analysis.","Ibrahim S","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent08","systematic review and meta-analysis of GLP-1 receptor agonist users versus nonusers in spine surgery",1],["R0000496","Efficacy and Safety of Glucagon-Like Peptide 1 Receptor Agonists in Parkinson Disease: A Systematic Review and Meta-Analysis.","Raza H","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent08","systematic review and meta-analysis of RCTs of GLP-1 receptor agonists versus placebo in Parkinson disease",1],["R0000025","Role of Oral Glucagon-Like Peptide-1 Receptor Agonists in Weight Management for Individuals With Overweight or Obesity Without Diabetes: A Network Meta-Analysis of Randomized Controlled Trials.","Kamrul-Hasan ABM","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent06","frequentist NMA of RCTs of oral GLP-1 RAs versus placebo for weight in adults without diabetes, multiple databases searched",1],["R0000076","Hypertensive disorders of pregnancy and GLP-1 receptor agonist timing: a systematic review and meta-analysis.","Pisani D","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent06","systematic review and meta-analysis of cohorts on periconception GLP-1 RA exposure and hypertensive disorders of pregnancy, five databases",1],["R0000186","Long-Term Glucagon-Like Peptide 1 Receptor Agonist Use Is Not Associated With Increased Risk of Thyroid Cancer in Adults With Type 2 Diabetes.","Pollack R","2025","include_harms",null,"primary_report",null,"O32B",null,"high","first","opus-5.5-agent06","TriNetX propensity matched cohort of long term GLP-1 RA users versus active comparators in T2D; thyroid cancer outcome",1],["R0000267","Impact of glucagon-like peptide-1 receptor agonists on outcomes following anterior cervical discectomy and fusion: a systematic review and meta-analysis.","Duru DO","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent06","systematic review and meta-analysis of cohorts on perioperative GLP-1 RA use and ACDF outcomes such as pseudarthrosis",1],["R0000331","Prehospital glucagon-like peptide-1 receptor agonists are not associated with reduced inpatient opioid exposure but with shorter hospital length of stay after total joint arthroplasty.","Vaknin N","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent06","matched cohort of GLP-1 RA users versus nonusers after joint arthroplasty; outcomes opioid use, pain, length of stay only",1],["R0000411","Impact of Semaglutide, Liraglutide and Tirzepatide on Cardiometabolic Outcomes: A Comparative Narrative Review.","Bawadi H","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent06","self described narrative review of semaglutide, liraglutide and tirzepatide; qualitative synthesis without meta-analysis",1],["R0000494","The Influence of Glucagon-like Peptide-1 Receptor Agonists on Outcomes Following Trigger Finger Release.","Dameron LS","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent06","TriNetX matched cohort of trigger finger release with versus without GLP-1 RA; scarring, pain, wound outcomes not in harms list",1],["R0000071","Prescribing of GLP-1 and GIP/GLP-1 Receptor Agonists and Other Glucose-Lowering Drugs Requiring Special Caution in Elderly Japanese People With Type 2 Diabetes: A Preliminary Report.","Sato M","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent05","descriptive cross sectional prescribing pattern study in older adults; no outcome comparison by exposure",1],["R0000138","Use of Glucagon-Like Peptide-1 Receptor Agonists and Risk of Parkinson's Disease: Scandinavian Cohort Study.","Engström A","2026","inventory_only","N6","other",null,null,null,"high","first","opus-5.5-agent05","active comparator new user cohort versus sulfonylureas; only outcome is incident Parkinson disease, not a listed harm",1],["R0000181","Glucagon-like Peptide-1 Receptor Agonists and Alcohol Use Outcomes: A Systematic Review of Clinical Evidence.","Altami IK","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent05","systematic review searching PubMed and Web of Science with criteria; synthesizes GLP-1 RA effects on alcohol use",1],["R0000261","Evaluating Glucagon-Like Peptide-1 Receptor Agonist Safety Before Upper Endoscopy: A Systematic Review and Meta-Analysis.","Ahmed Z","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent05","meta-analysis of comparative studies of GLP-1 RA exposure versus none on retained gastric content at endoscopy",1],["R0000483","Glucagon-like peptide-1 receptor agonists for primary cardiovascular disease prevention in type 2 diabetes, a systematic review.","Grenet G","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent05","registered systematic review of placebo controlled GLP-1 RA outcome trials with pooled MACE in primary prevention",1],["R0000023","Association Between Baseline Glucagon-like Peptide-1 Receptor Agonist Use and Newly Documented Depression Diagnosis in Adults with Type 2 Diabetes: A Multi-State Medicaid Cohort Study.","Ndiulor M","2026","inventory_only","N6","other",null,null,null,"high","first","opus-5.5-agent05","Medicaid cohort of GLP-1 RA users versus nonusers with new depression as the only outcome; no suicidality or other listed harm",1],["R0000065","A clinical and experimental investigation of liraglutide effects on the brain-kidney axis.","Greenwood MP","2026","inventory_only","N1","primary_report",null,null,null,"high","first","opus-5.5-agent02","open label before and after liraglutide study in healthy adults plus rat experiments; no concurrent control",1],["R0000173","Orforglipron: A Comprehensive Review of an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity and Type 2 Diabetes.","Kansakar U","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent02","narrative review of orforglipron pharmacology and trials without systematic search",1],["R0000240","Glucagon-like peptide-1 receptor agonists and the risk of Parkinson's disease in patients with type 2 diabetes: a systematic review and meta-analysis of large-scale real-world data.","Chen Y","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent02","systematic review and meta-analysis of cohort and case control studies of GLP-1 RA and Parkinson risk; four databases searched",1],["R0000310","Novel pharmacotherapies for opioid use disorder and opioid withdrawal.","Shen MR","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent02","narrative review of novel opioid use disorder pharmacotherapies including incretin drugs",1],["R0000469","GLP-1 receptor agonists in stroke prevention: a narrative review on emerging therapeutic frontiers.","Chikatimalla R","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent02","narrative review of GLP-1 RA and stroke prevention, authors state it is not systematic",1],["R0000069","Association of GLP-1 Receptor Agonist Use with Hypersomnolence: A Real-world Cohort Analysis.","Kamel-Abusalha L","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent04","TriNetX matched cohort GLP-1 RA vs none, sleep outcomes, iron deficiency and parkinsonism only, none in harms list",1],["R0000132","The Influence of GLP-1 Agonists on Human Mesenchymal Stem Cells: A Systematic Review.","Weber L","2026","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent04","systematic review restricted to in vitro human stem cell experiments",1],["R0000179","Sustained glucagon-like peptide-1 receptor agonist treatment improves glycemic control and reduces all-cause mortality compared to dipeptidyl peptidase-4 inhibitors: A real-world target trial emulation in type 2 diabetes.","Sørensen KK","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent04","Danish target trial emulation GLP-1 RA vs DPP-4i, HbA1c improvement and all cause mortality, no eligible harms outcome",1],["R0000405","Incretin-Based Therapies in Doxorubicin-Induced Cardiotoxicity: A Systematic Review of GLP-1 and Dual GIP/GLP-1 Agonists.","Khatami S","2026","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent04","systematic review found only rodent doxorubicin studies, no human study included",1],["R0000480","Glucagon-like peptide-1 receptor agonists in patients with heart failure with reduced ejection fraction.","Kassab J","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent04","TriNetX HFrEF cohort GLP-1 RA vs naive, mortality, HF and arrhythmia outcomes, none in harms list",1],["R0000036","Cardiovascular protection beyond glucose lowering: GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonism in contemporary cardiology.","Li M","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent09","narrative review of cardiovascular evidence for GLP-1 agonists and tirzepatide, no systematic search",1],["R0000082","Beyond Weight Loss: Gut Microenvironment Modulation to Enhance Cardiometabolic Outcomes and Long-Term Adherence During Incretin-Based Therapy.","Geraci C","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent09","narrative review on gut microbiota and incretin therapy tolerability, authors state no systematic review",1],["R0000146","Use of Glucagon-Like Peptide-1 Receptor Agonists in Danish Adolescents and Young Adults 2018-2025.","Kildegaard H","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent09","descriptive drug utilization study of GLP-1 agonist use in Danish youth without exposure comparison",1],["R0000204","Multi-Database Pharmacovigilance Analysis of Gastroesophageal Reflux Disease Associated with GLP-1 Receptor Agonists: A Cross-National Signal Validation Study.","Choi JG","2026","inventory_only","N5","other",null,null,null,"high","first","opus-5.5-agent09","disproportionality analysis of reflux reports in three pharmacovigilance databases",1],["R0000274","Real-World Comparative Weight Loss of GLP-1 Receptor Agonists in the All of Us Research Program: A Retrospective Cohort Study.","Hwang I","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent09","new user cohort comparing five GLP-1 agonists on weight loss only, no eligible harms outcome",1],["R0000341","Potential nephroprotective mechanisms of orforglipron, an oral non-peptide GLP-1 receptor agonist.","Ramadurgum P","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent09","perspective article on possible renal mechanisms of orforglipron, no primary data",1],["R0000430","Evolving incretin-based therapies in Japan: optimizing treatment strategies for diverse clinical and socioeconomical profiles in type 2 diabetes.","Seno Y","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent09","narrative review of incretin therapies in Japanese type 2 diabetes care",1],["R0000498","Comparative Cardiovascular Effectiveness of Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors in Diabetes Mellitus.","Bu F","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent09","multinational new user cohort comparing GLP-1 agonists and SGLT2 inhibitors on MACE, no eligible harms outcome",1],["R0000038","Anti-Obesity Medications in Longevity and Aesthetic Medicine.","Bijoch J","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent10","self described narrative review on anti obesity drugs in longevity and aesthetics; not a trial despite class",1],["R0000147","Use of Glucagon-Like Peptide 1 Receptor Agonists and the Associated Risk of Hospitalisation in Bipolar Disorder, From a Nationwide Cohort, 2009-2024.","Taipale H","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent10","Swedish within individual register cohort in bipolar disorder; psychiatric hospitalization and sick leave only, no harms_nrs outcome",1],["R0000205","Weight regain following discontinuation of glucagon-like peptide-1 receptor agonists in adults who are overweight or obese: a systematic review and meta-analysis.","Qi H","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent10","systematic review and meta-analysis of weight regain after GLP-1 RA discontinuation versus continuation in RCTs",1],["R0000345","GLP-1RA- and Incretin-Based Therapies Within Lifestyle Interventions for Adults with Overweight or Obesity: A Systematic Review and Meta-Analysis.","Bruna-Mejias A","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent10","PROSPERO registered meta-analysis of GLP-1 RA plus lifestyle versus control on weight in obesity",1],["R0000433","Association of Tirzepatide versus Semaglutide with Risk of Asthma Exacerbation in Patients with Asthma and Type 2 Diabetes: A US Multicenter Retrospective Cohort Study.","Hung CT","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent10","TriNetX new user cohort tirzepatide versus semaglutide; asthma exacerbation outcomes only, none in harms_nrs",1],["R0000500","Risk of protein intake deficiency during treatment with GLP-1 and GIP/GLP-1 receptor agonists: considerations for secondary sarcopenia.","Prokopidis K","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent10","narrative review of protein intake and sarcopenia with incretin drugs; no systematic search or primary data",1],["R0000542","Glucagon-like Peptide-1 Receptor Agonists in Liver Transplant Recipients: A Retrospective Cohort Study.","Sheashaa H","2026","include_harms",null,"primary_report",null,"O121; O34",null,"high","first","opus-5.5-agent01","liver transplant recipients starting GLP-1 RA versus nonusers, matched cohort; acute renal failure and ischemic optic neuropathy reported",1],["R0000582","Current and forthcoming pharmacotherapies for adolescent obesity: Evidence-based review.","Fuentes-Mendoza JM","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent01","self described narrative minireview of adolescent obesity drugs with purposive selection, no pooled contrast",1],["R0000725","GLP-1 Receptor Agonists and Musculoskeletal Outcomes: A Systematic Literature Review and Meta-Analysis.","Beaudart C","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent01","registered systematic review and meta-analysis of GLP-1 RA RCTs and cohorts on musculoskeletal outcomes, MEDLINE Embase CENTRAL searched",1],["R0000794","Glucagon-Like Peptide-1 Receptor Agonists and Ocular Outcomes: Metabolic Transition, Retinal Vulnerability, and Risk-Stratified Monitoring.","Song SJ","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent01","narrative review of ocular outcomes of GLP-1 based therapies, no systematic search or pooling",1],["R0000853","The Association Between Glucagon-like Peptide-1 Receptor Agonists and Clinical Outcomes in Patients with Thoracic Aortic Aneurysm.","Raslan MA","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent01","matched cohort of GLP-1 RA users versus nonusers with thoracic aortic aneurysm; mortality and dissection only",1],["R0000988","Association Between GLP-1 Receptor Agonist Use and Postpartum Pelvic Complications: A Global Matched Cohort Study","Hammad MAM","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent01","matched cohort of postpartum GLP-1 RA users versus nonusers; urinary infection and pelvic pain outcomes, none in harms list",1],["R0000326","Association between glucagon-like peptide-1 receptor agonist use and peri-operative pulmonary aspiration: a systematic review and meta-analysis.","Elkin J","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent04","systematic review and meta-analysis of six databases, GLP-1 RA exposure and aspiration or residual gastric content, pooled odds ratios",1],["R0000045","Patients With Ileal Pouch-Anal Anastomosis Have Decreased Bowel Frequency on Glucagon-Like Peptide-1 Receptor Agonist Therapy.","Chaudhry E","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent14","retrospective cohort of 20 pouch patients on GLP-1 RA, before and after bowel frequency, no comparison group",1],["R0000100","Class-Wide Impaired Gastric Emptying Signal Across Nine GLP-1 Receptor Agonist Agents: Indication-Stratified Pharmacovigilance Analysis of 6,868 Cases in FDA FAERS (2004-2024) with Cross-National Validation","Eduardo I","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent14","FAERS disproportionality analysis of impaired gastric emptying across GLP-1 RA products",1],["R0000155","Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists After Bowel Obstruction or Ileus: A Nationwide, Real-World, Database Study.","Matsuo Y","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent14","claims cohort of GLP-1 RA users hospitalized for ileus, determinants of discontinuation, no unexposed comparison",1],["R0000293",null,null,null,"inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent14","FAERS disproportionality analysis of biliary events across GLP-1 RAs",1],["R0000439","Appetite Suppression by GLP-1 Receptor Agonists: Role of Delayed Gastric Emptying.","Friedman MI","2026","include_nma",null,"secondary_report","P02",null,"mechanistic","high","first","opus-5.5-agent14","secondary analysis of 16 week placebo controlled liraglutide RCT in obesity, gastric emptying and appetite",1],["R0000529","Glucagon-Like Peptide-1 Receptor Agonists and Risk of Adverse Maternal Pregnancy Outcomes: A Systematic Review and Meta-analysis.","Hattler E","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent14","systematic review and meta-analysis of GLP-1 RA exposure and maternal pregnancy outcomes, PubMed and Embase searched",1],["R0000178","Glucagon-Like Peptide-1 Receptor Agonists Improve Cardiovascular Outcomes in Heart Failure with Preserved Ejection Fraction, Independent of Diabetes: A Systematic Review and Meta-Analysis.","Shokravi A","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent03","systematic review with MEDLINE and Embase search pooling GLP-1 RA and tirzepatide effects in HFpEF",1],["R0000247","Time-restricted eating in adults with type 2 diabetes mellitus on concomitant glucagon-like peptide-1 receptor agonists: case report.","Laing KL","2026","inventory_only","N5","other",null,null,null,"high","first","opus-5.5-agent03","case report of three trial participants doing time restricted eating on stable GLP-1 RA background",1],["R0000324","Clinical effects of glucagon-like peptide-1 receptor agonist in type 2 diabetes with low body mass index: findings from large-scale emulated target trials.","Tsai MH","2026","include_harms",null,"primary_report",null,"O121",null,"high","first","opus-5.5-agent03","TriNetX target trial emulation, new user GLP-1 RA vs DPP4i in T2D with BMI 30 or less; AKI is a secondary outcome",1],["R0000401","Glucagon-Like Peptide-1 Receptor Agonist Therapy Reduces Fibrosis-4 Index in Metabolic Dysfunction-Associated Steatotic Liver Disease.","Weng J","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent03","retrospective single group cohort of GLP-1 RA users with MASLD, FIB-4 before and after, no comparison group",1],["R0000475","Risk of Age-Related Ocular Diseases in Non-Diabetic Adults With Obesity Using Glucagon-Like Peptide 1 Receptor Agonists.","Chen KE","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent03","TriNetX cohort GLP-1 RA vs other weight loss drugs in nondiabetic older adults; ocular outcomes not in harms list",1],["R0000554","Molecular Characterization of the Effect of Glucagon-Like Peptide-1 Receptor Agonist Semaglutide in the Nephrotoxic Serum Nephritis Mouse Model.","Martinez JM","2026","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent06","mouse nephrotoxic serum nephritis model treated with semaglutide or enalapril; animal study only",1],["R0000600","Clinical outcomes associated with GLP-1 receptor agonist use in metabolic dysfunction-associated steatohepatitis: A multinational cohort study.","Khan SA","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent06","TriNetX matched cohort of GLP-1 RA users versus nonusers with MASH; ascites, HCC, mortality only, HCC alone is not the any cancer outcome",1],["R0000679","Glucagon-Like Peptide-1 Receptor Agonists in Plastic Surgery: Perioperative Considerations and Safety Protocols.","Davila Diaz R","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent06","narrative review of perioperative GLP-1 RA management in plastic surgery; no systematic synthesis",1],["R0000744","Metabolic Benefits vs. Cardiovascular Uncertainty: A Critical Review of GLP-1 Receptor Agonists in Type 1 Diabetes.","Wójcik-Sosnowska E","2026","include_review",null,"systematic_review",null,null,"umbrella_review","high","first","opus-5.5-agent06","umbrella review of systematic reviews and MR studies of GLP-1 RAs in type 1 diabetes; MEDLINE, Embase, Cochrane searched with PICO criteria",1],["R0000876","Assessing the shadows: A meta-analysis of GLP-1 agonists and suicidal ideation.","Alansari AO","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent06","meta-analysis of studies comparing suicidal ideation and suicide with GLP-1 RAs versus other drugs; six databases, PICOS criteria",1],["R0000935","Impact of glucagon-like peptide-1 receptor agonists on colonoscopy outcomes: a systematic review and meta-analysis.","Abdulraheem A","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent06","registered systematic review and meta-analysis of GLP-1 RA use and bowel preparation quality at colonoscopy",1],["R0001004","A systematic review and meta-analyses of glucagon-like peptide-1 receptor agonists in acute myocardial infarction.","Bhullar JK","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent06","systematic review and meta-analysis of GLP-1 RAs in acute myocardial infarction; pooled RCTs for infarct size versus placebo",1],["R0000092","Cohort Study: Risk of Gallstones and Biliary Complications With Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes.","Eldesouki MH","2026","include_harms",null,"primary_report","P01","O28; O29",null,"high","first","opus-5.5-agent12","TriNetX matched cohort of GLP-1RA plus oral agents vs oral agents only in T2D, gallstone, cholecystitis and pancreatitis outcomes",1],["R0000212","Use of glucagon-like peptide-1 receptor agonists is associated with inadequate bowel preparation for colonoscopy in patients with diabetes.","Ogawa O","2026","inventory_only","N6","primary_report","P01",null,null,"high","first","opus-5.5-agent12","retrospective matched cohort of GLP-1RA users vs nonusers, outcome inadequate colonoscopy bowel preparation, not a listed harm",1],["R0000507","A Pharmacovigilance Analysis of Ocular Adverse Events Associated with GLP-1 Receptor Agonists.","Virk A","2026","inventory_only","N5","other",null,null,null,"high","first","opus-5.5-agent12","FAERS disproportionality analysis of ocular adverse events with GLP-1RAs",1],["R0000171","Comparative efficacy of tirzepatide and glucagon-like peptide-1 receptor agonists on cardiovascular outcomes in patients with type 2 diabetes: a systematic review and network meta-analysis.","Shokravi A","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent20","network meta-analysis of CVOTs comparing tirzepatide and GLP-1 RAs in type 2 diabetes, MEDLINE and Embase search",1],["R0000238","GLP-1 (Glucagon-Like Peptide-1) and GIP (Glucose-Dependent Insulinotropic Polypeptide)/GLP-1 Receptor Agonists for Antipsychotic-Induced Weight Gain: A Narrative Review.","Buczkowska A","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent20","narrative review of incretin drugs for antipsychotic weight gain, no systematic methods",1],["R0000376","Do glucagon-like peptide-1 receptor agonists influence cervical fusion outcomes? A systematic review and meta-analysis.","Alves MLM","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent20","meta-analysis of cohort studies of perioperative GLP-1 RA use in cervical fusion, three databases searched",1],["R0000460","Glucagon-like Peptide-1 Receptor Agonists and Risk of Tuberculosis in Type 2 Diabetes.","Liao KM","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent20","TriNetX new user cohort of GLP-1 RA vs other drugs, outcome tuberculosis only, not a listed harm",1],["R0000034","A real-world propensity analysis of the impact of GLP-1 receptor agonists on cancer therapy-related cardiac dysfunction.","Wu JY","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent07","TriNetX matched cohort of GLP-1RA users vs nonusers with cardiotoxic cancer therapy; cardiac dysfunction outcomes, no listed harm",1],["R0000140","Glucagon-Like Peptide-1 Receptor Agonists in Inflammatory Bowel Disease: A Narrative Review.","Desai A","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent07","narrative review of GLP-1RA use in inflammatory bowel disease, no systematic methods",1],["R0000335","Glucagon-like peptide-1 receptor agonists for weight loss in end-stage heart failure patients considered for heart transplantation.","Jeyakumar S","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent07","retrospective series of nine heart failure patients given semaglutide before transplant listing, pre post only",1],["R0000420","GLP-1 Receptor Agonists in Diabetic Lower Extremity Peripheral Artery Disease: From Mechanisms to Clinical Practice.","Pan J","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent07","narrative mechanistic and clinical review on GLP-1RA in diabetic peripheral artery disease without eligibility criteria",1],["R0000151","Effect of glucagon-like peptide-1 receptor agonists on heart rate in non-diabetic individuals with overweight or obesity: a systematic review and pairwise and network meta-analysis of randomized controlled trials.","Zhang Y","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent12","registered SR with pairwise and network meta-analysis of GLP-1RA RCTs vs placebo on heart rate in obesity without diabetes",1],["R0000035","Prescription Sequence Symmetry Analysis of Glucagon-Like Peptide-1 Receptor Agonists and Neuropsychiatric Conditions.","Alfonso Arvez MJ","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent08","prescription sequence symmetry analysis; outcomes are psychotropic drug initiation proxies, none in harms list",1],["R0000559","Hair Loss Associated With Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Use: A Systematic Review.","Alsuwailem OA","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent08","systematic review of hair loss with GLP-1 receptor agonists; three named databases and eligibility criteria",1],["R0000604","Metabolic Reversal of Functional Hypogonadism? GLP-1 Receptor Agonists and Male Reproductive Endocrinology-A Systematic Review.","Zafrani Z","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent08","PRISMA systematic review of GLP-1 receptor agonists and male reproductive hormones; PubMed and Cochrane searched",1],["R0000681","GLP-1 Receptor Agonists Post-Bariatric Surgery (GRABS) Trial: Rationale, Design and Baseline Characteristics.","Samuels JM","2026","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent08","design and baseline paper of randomized tirzepatide versus standard care trial after gastric bypass; no outcome results",1],["R0000821","Glucagon-like peptide-1 receptor agonists and gastric emptying time: a systematic review and meta-analysis of prospective studies.","Chen A","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent08","systematic review and meta-analysis of GLP-1 receptor agonists and gastric emptying half time; six databases",1],["R0000882","Glucagon-like peptide-1 receptor agonists and risk of depression: a systematic review and meta-analysis.","Bi Z","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent08","systematic review and meta-analysis of GLP-1 receptor agonists and depression risk; six databases searched",1],["R0000067","Glucagon-Like Peptide-1 Receptor Agonists and Risk of Mental Health Disorders in Type 2 Diabetes: Active Comparator, New User Cohort Study.","Kim C","2026","include_harms",null,"primary_report",null,"O35A; O35B",null,"high","first","opus-5.5-agent03","Korean claims active comparator new user cohort vs DPP4i and SGLT2i; suicide assessed, no events in GLP-1 arm",1],["R0000041","Bowel Obstruction/Ileus Associated With the Use of Glucagon-Like Peptide-1 Receptor Agonists: A Nationwide Database Study.","Matsuo Y","2026","include_harms",null,"primary_report",null,"O37B",null,"high","first","opus-5.5-agent11","Japanese claims active comparator new user cohort, GLP-1RA versus SGLT2i, bowel obstruction or ileus, propensity weighted",1],["R0000150","Evaluation of the safety profile of glucagon-like peptide-1 receptor agonists: a focus on thyroid cancer-related adverse events by using the European pharmacovigilance database.","Anatriello A","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent11","EudraVigilance disproportionality analysis of thyroid cancer reports across GLP-1RAs and tirzepatide",1],["R0000211","758. Use of glucagon-like peptide 1 receptor agonists and the associated outcomes in bipolar disorder, from a nationwide cohort, 2009-2024",null,"2026","inventory_only","N6","conference_abstract",null,null,"abstract_only","high","first","opus-5.5-agent11","Swedish within individual cohort in bipolar disorder; psychiatric hospitalization and sick leave only, no listed harms outcome",1],["R0000504","GLP-1 Receptor Agonists in Metabolic Dysfunction-Associated Steatotic Liver Disease: Bridging Hepatic and Cardiovascular Outcomes.","Amorim Moreira Alves G","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent11","narrative review of GLP-1RAs in MASLD and cardiovascular outcomes without systematic search",1],["R0000059","Glucagon-like peptide-1 receptor agonist use and risk of gynecologic cancers: a meta-analysis of multinational real-world cohort studies.","Li R","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent19","meta-analysis of cohort studies on GLP-1 RA use and gynecologic cancer risk, PubMed and Embase searched, PROSPERO registered",1],["R0000119","Association of Glucagon-like Peptide-1 Receptor Agonist Use with Stroke and Mortality Outcomes in Asymptomatic Intracranial Atherosclerotic Disease: Propensity Score-Matched Real-World Analysis.","Rai P","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent19","TriNetX matched cohort of GLP-1 RA users vs nonusers with intracranial stenosis; outcomes stroke and mortality only, no listed harm",1],["R0000232","Incretin-Based Therapy and Thyroid Cancer Risk: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.","Eisa N","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent19","systematic review and meta-analysis of RCTs of incretin drugs vs control on thyroid cancer, PubMed Embase searched",1],["R0000305","Glucagon-like peptide-1 receptor agonist treatment reduces body weight and improves glycaemic outcomes in patients with concurrent overweight/obesity and type 1 diabetes: A systematic review and meta-analysis.","Purcell AR","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent19","meta-analysis of RCTs of GLP-1 RA added to insulin in type 1 diabetes with overweight; MEDLINE Embase CENTRAL Scopus searched",1],["R0000366","Protocol for Novel Perioperative Optimization of Obese Osteoarthritic Patients pending Total Knee Replacement with glucagon-like peptide-1 receptor agonist (NPO-OOPS-TKR) : a pilot randomized controlled trial.","Lau LCM","2026","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent19","protocol of pilot RCT of semaglutide vs usual care before knee replacement in obese adults; no results",1],["R0000454","New Amylin-Based Agonists for the Treatment of Obesity and Type 2 Diabetes Mellitus.","Panou T","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent19","narrative review of amylin based agonists including CagriSema and amycretin; not systematic",1],["R0000495","Effects of Incretin-Based Therapies on Testosterone Levels and Incretin Response in Men with Hypogonadism: A Systematic Literature Review Following PRISMA 2020 Guidelines.","La Vignera S","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent07","PRISMA review across three databases with eligibility criteria on incretin therapy and testosterone in men, includes RCTs",1],["R0000121","GLP-1 Receptor Agonists and Dual GIP/GLP-1 Receptor Agonists in Children and Adolescents with Obesity: Clinical Outcomes and the Impact of Nutritional and Behavioral Co-Interventions-A Systematic Review.","Myśliwczyk D","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent20","PRISMA review of PubMed Scopus Embase on GLP-1 RA in pediatric obesity, registered in PROSPERO, narrative synthesis",1],["R0000288","Incretin-Based Therapies in Obesity-Related Heart Failure With Preserved Ejection Fraction (HFpEF): A Systematic Review of Emerging Cardiometabolic Disease Modification Beyond Glycemic Control.","Hemdev V","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent12","PRISMA SR searching three databases with eligibility criteria, narrative synthesis of semaglutide and tirzepatide RCTs in obesity HFpEF",1],["R0000111","Hair Loss in Patients on Glucagon-Like Peptide 1 Receptor Agonists: Understanding Risks and Managing Outcomes.","Piraccini BM","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent17","commentary on hair loss with GLP-1 RAs; no own data or systematic search",1],["R0000164","Glucagon-Like Peptide-1 Receptor Agonists: Their Potential Role in Prediabetes.","Panou T","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent17","narrative review of GLP-1 RAs in prediabetes; keyword search without eligibility criteria or synthesis",1],["R0000230","Glucagon-like peptide-1 receptor agonists in movement disorders: From Parkinson's disease to the broader spectrum - Mechanisms, evidence, and future directions.","Dahshan A","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent17","self described narrative review of GLP-1 RAs in movement disorders",1],["R0000348","Glucagon-like peptide-1 receptor agonist and respiratory complications after endoscopy: A Japanese nationwide cohort study.","Hisada H","2026","include_harms",null,"primary_report","P01","O36A",null,"high","first","opus-5.5-agent12","JMDC procedure cohort of GLP-1RA users vs nonusers undergoing EGD, respiratory complications including aspiration pneumonia",1],["R0000363","Beyond Weight Loss: Thromboinflammation as a Candidate Mechanism for the Cardiovascular Benefit of GLP-1 Receptor Agonists.","Melnikov I","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent17","narrative review on thromboinflammation as a cardiovascular mechanism of GLP-1 RAs",1],["R0000044","Oral small-molecule GLP-1 receptor agonists: a new Frontier in cardiometabolic medicine.","Guo J","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent13","self described narrative nonsystematic review of oral small molecule GLP-1 agonists",1],["R0000290","Effects of GLP-1 Receptor Agonists on Psoriasis: An \"Agent-Specific\" Systematic Review of the Literature.","Marani A","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent13","PRISMA systematic review in PubMed and Scopus of GLP-1 agonists in psoriasis with narrative synthesis",1],["R0000438","Tirzepatide for obesity without diabetes: mechanistic insights, clinical evidence, and future directions.","He WT","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent13","narrative review of tirzepatide in obesity without diabetes",1],["R0000508","Glucagon-like Peptide-1 Receptor Agonists Are Not Associated with Increased Risk of Acute Pancreatitis or Pancreatic Complications, Including Pancreatic Cancer, in Type 2 Diabetes: A Global Propensity-Matched Cohort Study.","Sun Y","2026","include_harms",null,"primary_report",null,"O29; O38",null,"high","first","opus-5.5-agent13","TriNetX propensity matched new initiator cohort GLP-1 agonists vs SGLT2 inhibitors, acute pancreatitis and pancreatic cancer",1],["R0000109","Effects of Glucagon-Like Peptide-1 Receptor Agonist Use After Transient Ischemic Attack on Risks of Subsequent Ischemic Stroke and Mortality.","Kakadiya J","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent16","TriNetX cohort of GLP-1RA users vs nonusers after TIA; stroke, mortality and utilization only, no listed harm",1],["R0000160","Glucagon-like peptide-1 receptor agonist versus other anti-diabetic agents on patients with prostate cancer undergoing androgen-deprivation therapy.","Huang SC","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent16","active comparator cohort in prostate cancer on ADT; mortality, MACE, MAKE without AKI, thrombosis; no listed harm",1],["R0000228","Oral Glucagon-Like Peptide-1 Receptor Agonists for Preventing Cardiorenal Complications.","Odeleye V","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent16","narrative review of oral GLP-1RA cardiorenal trials, no systematic search",1],["R0000531","Beyond weight loss: predictors of treatment satisfaction and patient-reported outcomes in incretin-based therapies. A cross-sectional study.","Kapan A","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent16","cross sectional online survey of semaglutide or tirzepatide users on satisfaction",1],["R0000676","Adjunctive use of glucagon-like peptide-1 receptor agonists after bariatric surgery: updated systematic review and meta-analysis of randomized controlled trials.","Arora S","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent05","registered meta-analysis of RCTs of liraglutide versus placebo after bariatric surgery searching three named databases",1],["R0000863","Neuropsychiatric Effects of Glucagon-Like Peptide-1 Receptor Agonists in Schizophrenia-Spectrum Disorders: A Systematic Review.","Alsanosi ZY","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent05","systematic review of RCTs of GLP-1 RA added to antipsychotics in schizophrenia searching four named databases",1],["R0000934","Dementia progression with GLP-1 receptor agonists in people with mild cognitive impairment and type 2 diabetes: target-trial emulation study.","Schechter M","2026","inventory_only","N6","other",null,null,null,"high","first","opus-5.5-agent05","target trial emulation cohort GLP-1 RA versus DPP-4 inhibitor in MCI; dementia outcomes only, not a listed harm",1],["R0001002","Duration of GLP-1 Receptor Agonist Therapy and Nephrolithiasis Risk in Type 2 Diabetes: A Multicenter Retrospective Cohort Study","Othman L","2026","inventory_only","N6","other",null,null,null,"high","first","opus-5.5-agent05","TriNetX cohort comparing GLP-1 RA exposure durations and nonexposure; nephrolithiasis only outcome, not a listed harm",1],["R0001048","Beyond Diabetes: A Review of Emerging Indications for Glucagon-Like Peptide-1 Receptor Agonists.","West L","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent01","narrative overview of emerging GLP-1 RA indications without search methods or pooled analysis",1],["R0001180","Metabolic effects of GLP-1 receptor agonists in rheumatology patients and inflammatory outcomes: a single-centre retrospective cohort.","Retuerto-Guerrero M","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent01","retrospective cohort of GLP-1 RA treated rheumatology patients with paired before and after analyses, no unexposed comparison group",1],["R0001251","Efficacy and safety of glucagon-like peptide-1 receptor agonists in Parkinson's disease: a systematic review and meta-analysis of randomized placebo-controlled clinical trials.","Stefanou MI","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent01","registered systematic review and meta-analysis of placebo controlled GLP-1 RA RCTs in Parkinson disease, MEDLINE and Scopus searched",1],["R0001302","Differential Acute Kidney Injury Profiles of GLP-1RAs and SGLT2is: A Network Meta-Analysis.","Liang CS","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent01","Bayesian network meta-analysis of RCTs comparing GLP-1 RAs and SGLT2 inhibitors for acute kidney injury, eight databases searched",1],["R0001445","The novel GLP-1/GIP dual receptor agonist DA5-CH is superior to tirzepatide and exendin-4 in the 6-OHDA Parkinson rat model.","Lingyu Z","2026","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent01","6-OHDA rat model comparing DA5-CH, tirzepatide and exendin-4; animal study only",1],["R0001512","Exploring the neuroprotective role of GLP-1 agonists against Alzheimer's disease: Real-world evidence from a propensity-matched cohort.","AbuAlrob MA","2025","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent01","matched cohort of GLP-1 RA users versus nonusers aged 50 or more; incident dementia only",1],["R0000544","Incretin-Based Therapies Versus Bariatric and Metabolic Surgery for Obesity and Type 2 Diabetes Mellitus: A Head-to-Head Systematic Review of Glycaemic, Cardiovascular, Hepatic, Weight, and Quality-of-Life Outcomes.","Alsayed O","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent02","systematic review of RCTs and matched cohorts comparing incretin drugs with bariatric surgery; four databases searched; pooled MACE contrast",1],["R0000662","Evaluating the Rates of Pancreatitis and Pancreatic Cancer Among GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of Randomised Controlled Trials.","Wen J","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent02","systematic review and meta-analysis of RCTs on pancreatitis and pancreatic cancer with GLP-1 RA; three databases searched",1],["R0000729","Glucagon-like peptide-1 receptor agonists and advanced liver outcomes in type 2 diabetes: a systematic review and exploratory meta-analysis.","Hu JH","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent02","registered systematic review and meta-analysis of cohort studies of GLP-1 RA vs comparators on advanced liver outcomes in T2D",1],["R0000913","Risk of Dementia after initiation of GLP-1 RA versus long-acting insulin in patients with type 2 Diabetes mellitus.","Lin CH","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent02","Taiwan new user cohort GLP-1 RA vs long acting insulin; outcome dementia only, not a listed harm",1],["R0000992","Glucagon-Like Peptide-1 Receptor Agonists in Hip and Knee Arthroplasty: A Comprehensive Systematic Review and Meta-Analysis of Perioperative and Postoperative Outcomes.","Wajda B","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent02","systematic review and meta-analysis of cohorts on perioperative GLP-1 RA in hip and knee arthroplasty; three databases searched",1],["R0000055","Specialty-based variation in glucagon-like Peptide-1 receptor agonist prescribing practices for adolescent obesity in Saudi Arabia.","Kalagi F","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent18","cross sectional survey of clinicians on prescribing practices; no patient exposure comparison",1],["R0000560","Clinical outcomes of glucagon-like peptide-1 receptor agonist therapy in kidney transplant recipients: a systematic review and meta-analysis.","Kanbay M","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent09","PRISMA systematic review and meta-analysis of GLP-1 agonists in kidney transplant recipients, five databases searched",1],["R0000168","Not All GLP-1 Receptor Agonists Are Alike: Real-World Evidence of Differential Endocrine and Dermatologic Safety.","Lee N","2026","inventory_only","N5","other",null,null,null,"high","first","opus-5.5-agent18","FAERS disproportionality analysis of alopecia and reproductive events across six GLP-1 RAs",1],["R0000365","The Effects of GLP-1 Receptor Agonists on Retinal Microvascular Alterations.","Lampsas S","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent18","narrative review of retinal microvascular effects; non systematic search, no synthesis; not a trial despite class",1],["R0000534","Glucagon-like peptide-1 receptor agonists and cardiovascular outcomes in dialysis patients with type 2 diabetes: a real-world propensity score-matched study.","Chen JJ","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent18","new user cohort GLP-1 RA vs DPP-4i in dialysis T2D; MACE, mortality, sepsis only, no listed harms outcome",1],["R0000606","Glucagon-like peptide-1 receptor agonist-induced cholecystitis and cholelithiasis: a real-world pharmacovigilance analysis using the FAERS database.","Tao C","2025","inventory_only","N5","other",null,null,null,"high","first","opus-5.5-agent09","FAERS disproportionality analysis of cholecystitis and cholelithiasis reports with GLP-1 agonists",1],["R0000686","Cancer outcomes and biological mechanisms among patients with type 2 diabetes mellitus using glucagon-like peptide-1 receptor agonists: a systematic review and meta-analysis.","Eze ED","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent09","PRISMA systematic review and meta-analysis of cancer risk with GLP-1 agonists in type 2 diabetes",1],["R0000822","Medication Safety and Perioperative Risk Management of GLP-1 Receptor Agonists: A Pharmacist-Led Framework for Individualized Care.","Shen N","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent09","narrative review proposing a pharmacist led perioperative framework for GLP-1 agonists",1],["R0000883","Association Between Glucagon-Like Peptide-1 Receptor Agonists and Clinical Outcomes in Patients with Chronic Obstructive Pulmonary Disease and Obesity.","Huang SC","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent09","TriNetX cohort in COPD with obesity, GLP-1 versus other weight loss drugs, mortality and respiratory outcomes only",1],["R0000299","Association Between Glucagon-Like Peptide-1 Receptor Agonists and Suicidality: A Systematic Review.","Chan TH","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent17","registered systematic review of observational studies on GLP-1 RA use and suicidality with named databases; narrative synthesis",1],["R0000446","Glucagon-like peptide-1 receptor agonists and tirzepatide are associated with reduced mortality, cardiovascular, and psychiatric risks in patients with hidradenitis suppurativa and type 2 diabetes and/or obesity: a retrospective cohort study.","Brouer IC","2026","include_harms",null,"primary_report",null,"O35A",null,"high","first","opus-5.5-agent17","TriNetX propensity matched cohort in hidradenitis with diabetes or obesity, GLP-1 RA versus other metabolic drugs; reports suicidal ideation",1],["R0000047","A Clinical Comprehensive Evaluation of Long-Acting GLP-1 Receptor Agonists in Type 2 Diabetes Management.","Chen Q","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent15","Delphi weighted multi criteria drug evaluation scoring five agents for formulary choice; not a primary comparative study",1],["R0000159","Renal Effects of Glucagon-like Peptide-1 Receptor Agonists in Diabetic Kidney Disease: A Narrative Review of Mechanisms and Clinical Evidence.","Braha A","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent15","narrative review of renal effects in diabetic kidney disease; authors state no meta-analysis or formal synthesis",1],["R0000225","Treatment of Bile Acid Diarrhea With Glucagon-Like Peptide 1 Receptor Agonists: A Promising Yet Understudied Approach.","Ellegaard AM","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent15","narrative review of GLP-1 RA use for bile acid diarrhea summarizing earlier trial and registry work",1],["R0000294","Assessing Awareness, Confidence and Utilization of Compounded GLP-1 and Dual GIP/GLP-1 Receptor Agonists Among Healthcare Clinicians and Pharmacists: A Comprehensive Survey Study.","Umbreit A","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent15","cross sectional survey of clinicians on compounded incretin drugs; no patient exposure or comparison",1],["R0000357","Effect of GLP-1 Receptor Agonists in Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-Analysis.","Behers BJ","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent15","systematic review and meta-analysis of six placebo controlled RCTs of GLP-1 RAs in HFpEF; four databases searched",1],["R0000356","Semaglutide as adjunctive therapy to catheter ablation in obesity-related paroxysmal atrial fibrillation.","Ciconte G","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent14","propensity matched cohort semaglutide vs none at AF ablation, outcome arrhythmia recurrence and weight, no harms_nrs outcome",1],["R0000567","Trends in glucagon-like peptide-1 receptor agonist utilization and expenditure in Croatia.","Belančić A","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent14","national drug utilization and expenditure trends of GLP-1 RAs, no exposure comparison",1],["R0000624","Beyond weight loss: Patient-reported psychosocial and behavioral outcomes of glucagon-like peptide-1 receptor agonists in real-world use","Griffiths K","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent14","cross sectional online survey of GLP-1 RA users on psychosocial outcomes, no comparison group",1],["R0000702","Cardiovascular outcomes associated With GLP-1 and dual GLP-1/GIP receptor agonists in patients with type 2 diabetes and inflammatory bowel disease: A retrospective real-world cohort study.","Kazi MAI","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent14","TriNetX matched cohort of incretin users vs nonusers with T2D and IBD, cardiovascular outcomes only, no harms_nrs outcome",1],["R0000775","GLP-1 Receptor Agonists and Endoscopy: Understanding Gastric Stasis, Aspiration Risk, and Contemporary Peri-Procedural Guidance.","Beig J","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent14","narrative review of GLP-1 RAs and endoscopy aspiration risk, authors state no formal systematic methods",1],["R0000795","Glucagon-like peptide-1 receptor agonist use and clinical outcomes after lung transplantation: A single-center cohort study.","Miyashita Y","2026","include_harms",null,"primary_report",null,"O121",null,"high","first","opus-5.5-agent02","single center lung transplant cohort GLP-1 RA users vs nonusers with adjusted acute kidney injury comparison; prevalent users, not new user design",1],["R0000892","Oral small molecule GLP-1 receptor agonist aleniglipron in people with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trial.","Rosenstock J","2026","include_nma",null,"primary_report","P02",null,null,"high","first","opus-5.5-agent14","phase 2b placebo controlled RCT of oral aleniglipron three doses in overweight or obesity, 36 weeks",1],["R0000966","Efficacy and safety of glucagon-like peptide-1 receptor agonists for diabetic cardiomyopathy: a protocol for systematic review and meta-analysis.","Tang B","2026","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent14","protocol of a systematic review of GLP-1 RAs for diabetic cardiomyopathy, no results",1],["R0000114","Glucagon-like Peptide-1 Receptor Agonist Use and Pancreatic Cancer Risk in Patients with Chronic Pancreatitis.","Ailawadi S","2026","include_harms",null,"primary_report",null,"O38",null,"high","first","opus-5.5-agent18","TriNetX retrospective cohort of chronic pancreatitis patients, GLP-1 RA users vs nonusers, pancreatic cancer incidence; index dates differ between groups",1],["R0000545","Dietary Strategies and Nutritional Management in Patients Receiving GLP-1 and Dual GIP/GLP-1 Receptor Agonists as Adjuncts to Lifestyle Interventions: A Systematic Review of Randomised Clinical Trials.","de Paulo RS","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent03","systematic review of RCTs searching four named databases; synthesizes GI adverse effects of GLP-1 and dual agonists vs comparators",1],["R0000591","Cardiorenal protective effects of glucagon-like peptide-1 receptor agonists in chronic kidney disease: a systematic review and meta-analysis.","Wang Y","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent03","meta-analysis of RCTs of GLP-1 RA vs placebo or usual care in CKD with named database search",1],["R0000664","ABSTRACT NUMBER: ESOC2026A1557 EFFICACY AND SAFETY OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS ON STROKE RISK AND CEREBROVASCULAR OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: A NETWORK META-ANALYSIS",null,"2026","include_review",null,"systematic_review",null,null,"abstract_only","high","first","opus-5.5-agent03","conference abstract of network meta-analysis of GLP-1 RA RCTs vs placebo in T2D, four databases searched",1],["R0000807","Traditional Chinese medicine acupoint pasting for preventing and treating gastrointestinal reactions in type II diabetes mellitus patients undergoing glucagon-like peptide-1 receptor agonist therapy: A clinical study.","Zheng S","2025","inventory_only","N3","primary_report","P01",null,null,"high","first","opus-5.5-agent03","randomized TCM acupoint plaster vs placebo vs control, all on new GLP-1 RA therapy; GLP-1 regimen unchanged",1],["R0000859","Efficacy of GLP-1 Receptor agonists in treating Obstructive sleep apnea: A systematic review and meta-analysis of cardiometabolic and respiratory outcomes.","Dandamudi M","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent03","meta-analysis of four RCTs of GLP-1 RA vs placebo in obstructive sleep apnea with named database search",1],["R0000917","Glucagon-like Peptide-1 Receptor Agonists and Colorectal Cancer Risk.","Winkelman JW","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent03","narrative review of GLP-1 RA and colorectal cancer evidence without systematic methods",1],["R0000993","One-year usage patterns of SGLT-2 inhibitors and GLP-1 receptor agonists in individuals with type 2 diabetes in a real-world population.","Donnelly LA","2026","exclude","E2","primary_report",null,null,null,"high","first","opus-5.5-agent03","drug utilization study of adherence and discontinuation patterns; no comparison between exposure groups made",1],["R0000548","The Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Co-Transporter-2 Inhibitors on Lean Body Mass in Humans: A Systematic Review and Meta-Analysis of Randomised Controlled Trials.","Jobanputra R","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent04","registered systematic review and meta-analysis of RCTs, GLP-1 RA or SGLT2i vs control on lean body mass, pooled mean differences",1],["R0000595","Therapeutic Effects of Glucagon-like Peptide-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: A Systematic Review.","Mahoon D","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent04","registered systematic review of four databases with PICOS criteria on GLP-1 RA in MASLD or MASH, narrative synthesis",1],["R0000736","Pharmacovigilance analysis of neurological adverse events associated with GLP-1 receptor agonists based on the FDA Adverse Event Reporting System.","Chen H","2025","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent04","FAERS disproportionality analysis of neurological adverse event signals for six GLP-1 RAs",1],["R0000862","GLP-1 and GIP class drugs have neuroprotective properties in Alzheimer's and Parkinson's disease.","Hölscher C","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent04","narrative review of GLP-1 and GIP drugs in Alzheimer and Parkinson disease, no systematic methods",1],["R0000923","Associations Between Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) and Cancer Risk: A Systematic Review and Meta-Analysis.","Lalani I","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent04","registered systematic review and meta-analysis of observational studies, GLP-1 RA use and cancer incidence, pooled relative risks",1],["R0000996","Changes in Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Exposures Following Recent Demand for Weight Management: A Retrospective Review of California Poison Control System Data.","Ho RY","2025","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent04","poison center case review of GLP-1 RA exposures with time series of call counts, no exposure comparison group",1],["R0000296","Impact of Glucagon-Like Peptide-1 Receptor Agonists on Mental Health: A Systematic Review of Psychiatric Safety and Antidepressant Potential.","Quadir A","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent16","systematic review of psychiatric outcomes with GLP-1RA; PubMed, Google Scholar, ScienceDirect searched; narrative synthesis of 11 studies",1],["R0000361","Association of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and neurogenesis: a systematic review.","Au HCT","2025","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent16","systematic review whose eligibility table admits only animal studies of neurogenesis",1],["R0000444","Pregnancy outcomes following maternal GLP-1 receptor agonist exposure: a systematic review and meta-analysis.","Uysal N","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent16","systematic review and meta-analysis of pregnancy outcomes after GLP-1RA exposure; PubMed, Embase and others searched",1],["R0001122","Evidence-Based Positioning of Sodium-Glucose Co-transporter 2 Inhibitors and Glucagon-Like Peptide 1 Receptor Agonists in the Management of Chronic Kidney Disease with Type 2 Diabetes and Overweight or Obesity: A Systematic Literature Review.","Handelsman Y","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent06","registered systematic literature review comparing SGLT2 inhibitors and GLP-1 RAs in CKD with T2D and obesity; MEDLINE, Embase, Cochrane",1],["R0001260","Effect of GLP-1RA on blood eosinophil levels in adults: a real-world study.","Wu Y","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent06","retrospective before and after study of semaglutide initiators on eosinophil counts; no comparison group",1],["R0001394","Evaluating Suicidal Risk in GLP-1RA Therapy: An Umbrella Review of Meta-Analytic Evidence.","Ștefănescu C","2025","include_review",null,"systematic_review",null,null,"umbrella_review","high","first","opus-5.5-agent06","umbrella review of reviews and meta-analyses on GLP-1 RAs and suicidality; many named databases and inclusion criteria",1],["R0001458","Liraglutide and renal mitochondrial homeostasis: targeting the \"metabolism-inflammation-lithogenesis\" axis in metabolic syndrome.","Wang F","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent06","narrative mechanistic review of liraglutide and renal mitochondria in nephrolithiasis; no primary data",1],["R0001524","Social Media Discussions of Anti-Diabetic Drugs and the Popularity of GLP-1 Therapies: Content Analysis.","Stallion C","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent06","content analysis of social media posts on antidiabetic drugs; no exposure comparison or drug administration",1],["R0000453","Assessment of thyroid cancer risk associated with glucagon-like peptide 1 receptor agonist use.","Vilsbøll T","2026","include_nma",null,"pooled_analysis","P01; P02","O32B",null,"high","first","opus-5.5-agent18","sponsor IPD pool of liraglutide and semaglutide RCTs for thyroid cancer, plus MarketScan new user cohort vs SGLT2i also eligible for harms",1],["R0001019","The effectiveness of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on binge eating in patients with obesity: a systematic review and meta-analysis.","Emptage I","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent08","systematic review and meta-analysis of RCTs of GLP-1 receptor agonists on binge eating; four databases searched",1],["R0001065","Risk of Anaphylaxis Among New Users of GLP-1 Receptor Agonists: A Cohort Study.","Anthony MS","2024","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent08","new user claims cohort comparing anaphylaxis rates across GLP-1 receptor agonists; anaphylaxis not in harms list",1],["R0001128","Glucagon-Like Peptide-1 Receptor Agonists Across the Heart Failure Spectrum: A Systematic Review and Meta-Analysis.","Muller Ferreira V","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent08","systematic review and meta-analysis of randomized GLP-1 receptor agonist versus placebo evidence in heart failure",1],["R0001200","Rewriting Diabetes Therapy: How Incretin Modulation is Transforming Cardiovascular and Renal Outcomes.","Miramontes-González JP","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent08","narrative review of incretin therapies and cardiorenal outcomes; no systematic search",1],["R0001268","Cost-effectiveness of sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists for patients with high cardiovascular risk and type 2 diabetes in Canada.","McNally ES","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent08","microsimulation cost effectiveness analysis of SGLT2 inhibitors and GLP-1 receptor agonists",1],["R0001330","Cardiovascular and kidney outcomes of GLP-1 receptor agonists in adults with obesity: A target trial emulation study.","Tang H","2025","include_harms",null,"primary_report",null,"O29; O35A; O121",null,"high","first","opus-5.5-agent08","target trial emulation of new GLP-1 RA versus other antiobesity drug users; pancreatitis, suicidality and AKI reported",1],["R0001398","Ocular disorders during treatment with GLP-1 receptor agonists: a systematic review and meta-analysis of observational studies.","Anatriello A","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent08","systematic review and meta-analysis of observational studies on ocular events with GLP-1 receptor agonists",1],["R0001464","Glucagon like peptide-1 receptor agonist therapy and long-term renal outcomes after radical nephrectomy: a propensity-matched cohort analysis.","Ahmad NB","2026","include_harms",null,"primary_report",null,"O121",null,"high","first","opus-5.5-agent08","TriNetX matched cohort after radical nephrectomy, perioperative GLP-1 RA users versus nonusers; AKI reported; prevalent use design",1],["R0000687","Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists Following Bariatric Surgery: A Systematic Review and Meta-Analysis.","Bilal AR","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent10","meta-analysis of RCTs of GLP-1 RA versus placebo after bariatric surgery, PubMed Scopus CENTRAL searched",1],["R0000759","Comparison of Mazdutide and Dulaglutide for Type 2 Diabetes: a GRADE assessed systematic review and meta-analysis of randomized controlled trials","Hassan A","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent10","meta-analysis of RCTs comparing mazdutide with dulaglutide in type 2 diabetes with named database search",1],["R0000824","ABSTRACT NUMBER: ESOC2026LT58 LT58 - GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONIST IN ACUTE LARGE VESSEL OCCLUSION STROKE TREATED BY REPERFUSION THERAPIES (GALLOP-2) – A MULTICENTER, RANDOMIZED, OPEN-LABEL, BLINDED END-POINT TRIAL",null,"2026","include_nma",null,"conference_abstract","P99",null,"abstract_only","high","first","opus-5.5-agent10","GALLOP-2 randomized PROBE trial semaglutide plus thrombectomy versus thrombectomy alone in ischemic stroke; 90 day mRS and death",1],["R0000884","Effects of Glucagon-Like Peptide-1 Receptor Agonist on Bone Metabolism and the Expression of Insulin Receptor Substrate 1 in an Osteoporotic Rat Model.","Ye Y","2026","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent10","ovariectomized rat model given exendin 4; animal study only",1],["R0000959","The impact of glucagon-like peptide-1 receptor agonists on objective physical activity in adults: a systematic review and exploratory meta-analysis.","Kim H","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent10","PROSPERO registered meta-analysis of GLP-1 RA versus control on objective physical activity, PubMed and Embase searched",1],["R0000603","Effect of glucagon-like peptide-1 receptor agonists on major adverse cardiovascular events in adults with type 2 diabetes and established atherosclerotic cardiovascular disease: systematic review and meta-analysis of randomised trials.","Montenegro-Avila A","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent07","PROSPERO registered meta-analysis of RCTs of GLP-1RA vs placebo on MACE in type 2 diabetes with ASCVD",1],["R0000680","GLP-1 and Dual GIP/GLP-1 Receptor Agonists in Pediatric Obesity: From Neuroendocrine Mechanisms to Clinical Application.","Myśliwczyk D","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent07","narrative review of incretin drugs in pediatric obesity based on a targeted nonsystematic search",1],["R0000819","The combination of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors: a narrative review of existing meta-analysis.","Avogaro A","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent07","narrative overview of published meta-analyses on GLP-1RA plus SGLT2 inhibitor combination without systematic methods",1],["R0000877","Association of glucagon-like peptide-1 receptor agonists with atrial fibrillation recurrence after catheter ablation: a systematic review and meta-analysis.","He D","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent07","meta-analysis of cohorts and trials on GLP-1RA use vs nonuse and AF recurrence after ablation, eight databases",1],["R0000936","Direct effects of glucagon-like Peptide-1 receptor agonists on mitochondrial function in human-derived in vitro models: A systematic review and meta-analysis.","Greenblatt ZL","2026","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent07","systematic review and meta-analysis restricted to human derived in vitro cell and tissue models of mitochondrial function",1],["R0001018","Glucagon‐like peptide‐1 receptor agonists for neurological disorders: a systematic review and meta‐analysis","Manolopoulos A","2025","include_review",null,"systematic_review",null,null,"abstract_only","high","first","opus-5.5-agent07","conference abstract of meta-analysis of RCTs of GLP-1RA vs placebo in neurological disorders",1],["R0000581","Combination cardiometabolic therapy in type 2 diabetes: optimizing SGLT2 inhibitor and GLP‑1 receptor agonist use.","Porterfield LR","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent20","narrative review of combined SGLT2 inhibitor and GLP-1 RA therapy, no systematic methods",1],["R0001560","Early cancer risk reduction after GLP-1RA use: Signal or bias?: Letter to the editor on \"Glucagon-like peptide 1 receptor agonist and reduced liver and non-liver complications in adults with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease: a target trial emulation study\".","Jean SS","2026","inventory_only","N9","ancillary",null,null,null,"high","first","opus-5.5-agent01","letter questioning early cancer curve separation in a target trial emulation of GLP-1 RA versus DPP-4 inhibitors",1],["R0000723","Association between GLP-1 receptor agonists and alcohol-related hospitalisations among adults with alcohol use disorder: multi-target trial emulation study.","Rodriguez PJ","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent20","target trial emulations of semaglutide or tirzepatide vs comparators in AUD, outcome alcohol related hospitalization only",1],["R0000785","Immunometabolic Modulation in Obese Asthma: How GLP-1 Receptor Agonists Could Influence Systemic and Pulmonary Immune Phenotypes.","O'Brien H","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent20","narrative review of GLP-1 RA immunometabolic effects in obese asthma",1],["R0000911","Glucagon-Like Peptide-1 Receptor Agonists and Hepatocellular Carcinoma Prevention: A Meta-Analysis and Clinical Decision Framework.","Dalbeni A","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent20","meta-analysis of cohort studies of GLP-1 RA users vs nonusers on hepatocellular carcinoma, three databases searched",1],["R0001627","Reassessing cancer risk with GLP-1 receptor agonists: a comprehensive meta-analysis of gastrointestinal malignancies.","Wali AF","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent01","systematic review and meta-analysis of GLP-1 RA RCTs on gastrointestinal cancers, PubMed Embase Scopus searched",1],["R0001674","Predictive factors of body weight loss in patients with type 2 diabetes treated with GLP-1 receptor agonists: a 52-week prospective real-life study.","Vozza A","2025","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent01","prospective observational cohort of GLP-1 RA initiators comparing responders with nonresponders, no unexposed comparison group",1],["R0001801","Endogenous Incretin Secretagogue Compositions as a Mechanistic Class Versus Pharmacological Incretin Receptor Agonists for Weight Reduction in Overweight Adults: A Real-World Observational Cohort Analysis of a Nutraceutical Composition (Trimsulin) and Comparison with Published Outcomes for Semaglutide and Tirzepatide","Kaufman RC","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent01","uncontrolled cohort taking a nutraceutical incretin secretagogue compared with published GLP-1 RA data; no GLP-1 RA given or studied",1],["R0001867","Glucagon-like peptide 1 receptor agonist: A potential game changer for cholangiocarcinoma.","Trakoonsenathong R","2024","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent01","editorial discussing GLP-1 RA and cholangiocarcinoma evidence and mechanisms",1],["R0001931","Cardiovascular risk reduction with glucagon-like peptide-1 receptor agonists is proportional to HbA1c lowering in type 2 diabetes: An updated meta-regression analysis incorporating FLOW and SOUL trials.","Hasebe M","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent01","registered meta-analysis and meta-regression of placebo controlled GLP-1 RA outcome trials, PubMed and Embase searched",1],["R0001992","Letter to the editor on \"Glucagon-like peptide 1 receptor agonist and reduced liver and non-liver complications in adults with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease: a target trial emulation study\".","Wang C","2026","inventory_only","N9","ancillary",null,null,null,"high","first","opus-5.5-agent01","letter raising methodological concerns about a target trial emulation of GLP-1 RA versus DPP-4 inhibitors in MASLD",1],["R0000983","Diabetes-type-specific thyroid safety of GLP-1 receptor agonists: evidence from a large real-world cohort.","Hsieh HI","2026","include_harms",null,"primary_report",null,"O32B",null,"high","first","opus-5.5-agent20","target trial emulation TriNetX GLP-1 RA vs usual care or SGLT2i, thyroid cancer among outcomes; PSM adjusted",1],["R0001045","Adherence and Persistence Among Individuals Living With Type 2 Diabetes and Using a Free Combination of Basal Insulin and an Injectable Glucagon-Like Peptide-1 Receptor Agonist Versus a Fixed-Ratio Combination Therapy: A Japanese Database Study.","Miyatsuka T","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent20","Japanese claims new user cohort of free vs fixed ratio insulin GLP-1 RA combination, adherence and persistence only",1],["R0001066","GLP-1 receptor agonists and risk of suicide or suicide attempts - A nationwide cohort and self-controlled case series study.","Stanislaus C","2026","include_harms",null,"primary_report",null,"O35A; O35B",null,"high","first","opus-5.5-agent09","Danish new user active comparator cohorts versus SGLT2 and DPP-4 inhibitors plus self controlled case series, suicide or attempts composite",1],["R0001131","Unexpected cardiovascular risks of glucagon-like peptide-1 receptor agonist and aspirin co-administration in individuals with obesity, with and without type 2 diabetes: A propensity score matched cohort study.","Lin CM","2025","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent09","TriNetX cohort comparing GLP-1 plus aspirin with GLP-1 alone, contrast is aspirin, cardiovascular and bleeding outcomes only",1],["R0001204","Evaluating the Ocular Safety Profile of Glucagon-Like Peptide-1 Receptor Agonists","Khan Z","2025","include_harms",null,"primary_report",null,"O33",null,"high","first","opus-5.5-agent09","TriNetX new user cohorts versus SGLT2 or DPP-4 inhibitors on diabetic retinopathy, macular degeneration and glaucoma; preprint",1],["R0001399","Atypical retrobulbar optic neuropathy after semaglutide escalation.","Channabasappa S","2026","inventory_only","N5","other",null,null,null,"high","first","opus-5.5-agent09","case report of optic neuropathy after semaglutide dose escalation",1],["R0001465","Semaglutide and diabetic retinopathy: an OHDSI network study.","Cai CX","2025","include_harms",null,"primary_report",null,"O33",null,"high","first","opus-5.5-agent09","OHDSI new user active comparator cohort of semaglutide versus other drugs on proliferative retinopathy and macular edema",1],["R0001530","Comparative efficacy and safety of glucagon-like peptide 1 based drugs for weight loss in adults with overweight or obesity without diabetes: network meta-analysis of randomised controlled trials.","Chen D","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent09","PRISMA NMA of randomized trials of GLP-1 based drugs for weight loss in adults without diabetes",1],["R0000562","Glucagon-like peptide-1 receptor agonists and major limb events in adults with type 2 diabetes and peripheral artery disease: a systematic review and meta-analysis of RCTs and cohort studies.","Caruso P","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent11","PRISMA registered meta-analysis of RCTs and cohorts, GLP-1RA versus control on limb events in diabetes with PAD; MEDLINE, Embase, CENTRAL",1],["R0000613","Safety and Efficacy of GLP-1 Receptor Agonists in Adults With Epilepsy, Obesity, and Type 2 Diabetes.","Son H","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent11","All of Us propensity matched new user cohort in epilepsy; seizure control, weight and HbA1c only, no listed harms outcome",1],["R0000763","Injection-site and dermatologic reactions associated with glucagon-like peptide-1 receptor agonists: Insights from meta-analysis of randomised controlled trials and real-world evidence.","Taj S","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent11","registered meta-analysis of RCTs on injection site and skin reactions, GLP-1RA versus comparators, plus FAERS analysis",1],["R0000825","Glucagon-like peptide-1 receptor agonists improve hepatic histology and metabolic parameters in type 2 diabetes with MASLD: a meta-analysis of randomized controlled trials.","Zou M","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent11","meta-analysis of 11 RCTs, GLP-1RA versus control in diabetes with MASLD, six named databases",1],["R0000885","Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, and Atrial Fibrillation: An Umbrella Review With Methodological Appraisal of Overlapping Meta-Analyses.","Ramzy D","2026","include_review",null,"systematic_review",null,null,"umbrella_review","high","first","opus-5.5-agent11","umbrella review of meta-analyses on GLP-1RA and atrial fibrillation; MEDLINE, Embase, Cochrane, Epistemonikos searched",1],["R0000962","Indications, efficacy, and safety of glucagon-like peptide-1 receptor agonists in respiratory diseases: A systematic review.","Esmaeel MN","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent11","PRISMA systematic review of five RCTs of GLP-1RA in respiratory disease with named database search",1],["R0001026","Dietary Intake as an Undermeasured Potential Mediator: The Ethical Case for Complete and Transparent Dietary Reporting in GLP-1 Receptor Agonist Trials.","Strosahl JN","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent11","perspective article on dietary intake reporting in GLP-1RA trials; no primary data",1],["R0000596","Improving Medication Classification in GLP-1RA Research: Feasibility of a Photo-Review Protocol.","Katz JM","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent05","cross sectional online survey validating self reported GLP-1 RA type against photos; drug utilization without exposure comparison",1],["R0001058","Effects of glucagon-like peptide-1 receptor agonists on alcohol consumption: a systematic review and meta-analysis.","Eshraghi R","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent04","registered systematic review and meta-analysis of RCTs and observational studies, GLP-1 RA effects on alcohol outcomes, pooled analysis",1],["R0001119","The Impact of Glucagon-like Peptide-1 Receptor Agonists on Cardiovascular-Kidney-Metabolic Health in Romanian Patients with Type 2 Diabetes: A Retrospective Study.","Lixandru N","2025","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent04","retrospective single group of 150 GLP-1 RA treated patients assessed before and after 12 months, no comparison group",1],["R0001194","Dynamics of Body Composition and Metabolic Risk in Adolescents With Obesity Under GLP-1 Receptor Agonist Therapy.","Lopez A","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent04","retrospective adolescent obesity cohort GLP-1 RA vs lifestyle only, body composition and metabolic outcomes, no eligible harms outcome",1],["R0001195","Comparative Gynecological Safety of the Dual GIP/GLP-1 Receptor Agonist Tirzepatide vs. the GLP-1 Receptor Agonist Semaglutide: A Real-World Pharmacovigilance Analysis (2022-2025).","Makkena HB","2026","inventory_only","N5","other",null,null,null,"high","first","opus-5.5-agent05","FAERS disproportionality analysis of gynecological bleeding reports for tirzepatide versus semaglutide",1],["R0001257","Use of GLP-1 Receptor Agonists is Associated with an Increased Rate of Upper Eyelid Blepharoplasty.","Almeida VFA","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent04","TriNetX matched cohort GLP-1 RA vs none, outcome blepharoplasty only, not in harms list",1],["R0001316","Effect of glucagon-like peptide-1 receptor agonists on body weight and urinary albumin-to-creatinine ratio in patients with and without type 2 diabetes: A systematic review and meta-analysis.","Huang R","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent04","systematic review and meta-analysis of RCTs, GLP-1 RA vs placebo or standard care on weight and albuminuria",1],["R0001383","Beyond Glycemic Control: Real-World 12-Month Effects of Insulin Glargine/Lixisenatide on Weight, Endogenous Insulin Secretion, and Albuminuria.","Ozturk S","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent04","retrospective single group of iGlarLixi initiators followed 12 months, no comparison group",1],["R0001393","Impact of GLP-1 Receptor Agonists on Suicide Behavior: A Meta-Analysis Based on Randomized Controlled Trials.","Chen J","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent05","registered meta-analysis of RCTs on suicidal behavior with GLP-1 RA versus control searching named databases",1],["R0001451","Real-world and computational identification of herbal candidates associated with adverse event patterns in glucagon-like peptide-1 therapy for obesity.","Park J","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent04","FAERS disproportionality analysis with network modeling of herb and adverse event links",1],["R0001519","Perioperative anesthesia management of GLP-1 receptor agonists: a systematic review of potential risks.","Merhavy ZI","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent04","systematic review of five databases with eligibility criteria on GLP-1 RA and perioperative aspiration or regurgitation",1],["R0001082","Risk factors for drug-related impaired gastric emptying: a pharmacovigilance analysis of the FDA adverse event reporting system.","Chen JH","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent14","FAERS pharmacovigilance analysis of drug related impaired gastric emptying including GLP-1 RAs",1],["R0001153","Real-world insights into incretin-based therapy: Associations between changes in taste perception and appetite regulation in individuals with obesity and overweight: A cross-sectional study.","Kapan A","2025","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent14","cross sectional online survey of taste and appetite among incretin therapy users",1],["R0001224","Evaluating the impact of GLP-1 receptor agonists in combination with total neoadjuvant therapy for locally advanced rectal cancer.","Temperley HC","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent14","narrative review on GLP-1 RAs combined with neoadjuvant therapy for rectal cancer",1],["R0001283","Psychiatric Adverse Events and Administration Challenges Associated with GLP-1 Receptor Agonists for Weight Loss: A Real-World Analysis.","Hindi A","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent14","FAERS disproportionality analysis of psychiatric and administration adverse events of GLP-1 RAs for weight loss",1],["R0001347","Combined GLP-1 Receptor Agonist and SGLT2 Inhibitor Therapy for Adults with Type 2 Diabetes and Chronic Obstructive Pulmonary Disease: A Large-Scale Target Trial Emulation","Bai H","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent14","TriNetX target trial emulation GLP-1 RA plus SGLT2i vs SGLT2i in T2D and COPD, mortality and respiratory outcomes only",1],["R0001425","Evaluating the Cardiovascular Benefits of Innovator Semaglutide 2.4 mg (Recombinant DNA (r-DNA)) in Patients With Overweight or Obesity: A Critical Review of Current Evidence.","Teli B","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent14","narrative review of semaglutide 2.4 mg cardiovascular evidence, evidence synthesized narratively without systematic review methods",1],["R0001488","Glucagon Like Peptide-1 Receptor Agonists for Sarcopenia and Muscle Wasting Disorders: A Systematic Review of Efficacy and Mechanisms.","Maihemuti A","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent14","systematic review searching PubMed, Embase, Web of Science with inclusion criteria, clinical and preclinical GLP-1 RA effects on muscle",1],["R0000565","GLP-1 Receptor Agonists and Risk of Skin Cancer in Adults With Type 2 Diabetes: A Target Trial Emulation.","Tang H","2026","inventory_only","N6","primary_report","P01",null,null,"high","first","opus-5.5-agent12","TTE of GLP-1RA vs SGLT2i or DPP4i new users, outcomes melanoma and nonmelanoma skin cancer only, not a listed harm",1],["R0000615","Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists for incident dementia: A retrospective multicohort study.","Anagnostakis F","2026","inventory_only","N6","primary_report","P01",null,null,"high","first","opus-5.5-agent12","new user active comparator cohort GLP-1RA vs SGLT2i, outcome dementia only",1],["R0000697","Cardioprotective mechanisms and effects of glucagon-like peptide-1 receptor agonists in autoimmune rheumatic diseases.","Karacabeyli D","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent12","narrative review of cardioprotective mechanisms of GLP-1RAs in autoimmune rheumatic disease",1],["R0000768","Cardiorenal Mortality and Safety Outcomes of GLP-1 Receptor Agonists in Type 2 Diabetes With BMI Below 27 kg/m2: A Target Trial Emulation.","Chen SC","2026","include_harms",null,"primary_report","P01","O37A; O121; O33; O35A",null,"high","first","opus-5.5-agent12","TTE of GLP-1RA new users vs DPP4i, SGLT2i or usual care in lean T2D, safety panel with gastroparesis, AKI, retinopathy, suicidality",1],["R0000829","Gastrointestinal adverse events associated with GLP-1 RA in non-diabetic patients with overweight or obesity: a systematic review and network meta-analysis.","Ismaiel A","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent12","PRISMA SR and dose response NMA of GLP-1RA trials on gastrointestinal adverse events in obesity without diabetes",1],["R0000887","Health Technology Assessment: Evaluation of 7 Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus.","Xie Z","2024","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent12","health technology assessment scoring seven GLP-1RAs on multiple attributes, no synthesized contrast",1],["R0000963","Glucagon-like peptide 1 receptor agonist discontinuation and risks of major adverse cardiovascular events in adults with type 2 diabetes: target trial emulation.","Xie Y","2026","inventory_only","N6","primary_report","P01",null,null,"high","first","opus-5.5-agent12","TTE of GLP-1RA continuation patterns vs sulfonylurea, outcome MACE only",1],["R0001028","Efficacy and safety of GLP-1 receptor agonists in patients with metabolic-associated fatty liver diseases: an umbrella review.","Wu H","2026","include_review",null,"systematic_review",null,null,"umbrella_review","high","first","opus-5.5-agent12","registered umbrella review of SRs of GLP-1RAs in MASLD, five databases searched",1],["R0000707","Semaglutide as adjunct treatment for obesity in adolescents receiving antipsychotic medication (the GOAL trial): protocol for a single-arm, open-label feasibility study.","Giraldi LV","2026","inventory_only","N1","protocol_or_design",null,null,null,"high","first","opus-5.5-agent16","protocol of single arm open label semaglutide feasibility study in adolescents on antipsychotics; alternative N8",1],["R0000780","Risk of peripheral vestibular disorders and hearing impairment among users of glucagon-like peptide-1 receptor agonists.","Huang JY","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent16","TriNetX cohort of GLP-1RA users vs nonusers; vestibular disorders, dizziness and hearing loss not listed harms",1],["R0000847","Post Weight Loss Body Contouring Surgery: Complication Rates Following Bariatric Surgery, Injectable Glucagon-like Peptide-1 Receptor Agonist Pharmacotherapy, Combination Therapy, and Lifestyle Modification.","Abbott EN","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent16","single center cohort comparing weight loss modalities before body contouring; postoperative complications only, no listed harm",1],["R0000901","GLP-1 receptor agonists in Alzheimer's and Parkinson's disease: endocrine pathways, clinical evidence, and future directions.","Gandhi A","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent16","narrative review of GLP-1RAs in Alzheimer and Parkinson disease without systematic search",1],["R0000969","Effects of glucagon-like peptide-1 receptor agonists on psychiatric disorders: a systematic review.","Lee S","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent16","systematic review of GLP-1RAs in psychiatric and neurocognitive disorders; PubMed, OVID, Embase searched with eligibility table",1],["R0001032","The effects of glucagon-like peptide-1 receptor agonists (GLP1-RAs) on alcohol-related outcomes: a systematic review and meta-analysis.","Sinha B","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent16","PROSPERO registered systematic review and meta-analysis of GLP-1RAs on alcohol outcomes; PubMed, Embase, Cochrane",1],["R0001053","GLP-1 Receptor Agonists and SGLT-2 Inhibitors in Diabetic Nephropathy: A Comparative Study.","Alghadeer SG","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent03","retrospective cohort GLP-1 RA vs SGLT2i in early diabetic nephropathy; lab markers only, no listed harm outcome",1],["R0001115","Blamed but not at fault: anti-obesity medication adverse effects misidentified as perioperative complications - a comprehensive review and medicolegal warning for anesthesiologists.","Kwak HJ","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent03","narrative review of perioperative anti-obesity drug adverse effects; no systematic methods",1],["R0001184","Use of Semaglutide and Tirzepatide in Rheumatic and Musculoskeletal Diseases: Insights on Initiation Patterns and Weight Loss From the Rheumatology Informatics System for Effectiveness Registry.","McCormick NP","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent03","registry cohort comparing semaglutide and tirzepatide weight change in rheumatic disease; effectiveness only",1],["R0001254","Thyroid Cancer Risk in Patients With Type 2 Diabetes Taking Glucagon-Like Peptide 1 Receptor Agonists.","Sciscent BY","2026","include_harms",null,"primary_report",null,"O32B",null,"high","first","opus-5.5-agent03","TriNetX matched cohorts GLP-1 RA vs SGLT2i, metformin, DPP4i in T2D; 5 year thyroid cancer risk",1],["R0001309","Comparative Cardiovascular Outcomes of GLP-1 Receptor Agonists Versus Bariatric Surgery: A Systematic Review and Network Meta-Analysis.","Shirmohammadi E","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent03","systematic review and NMA of GLP-1 RA vs bariatric surgery for cardiovascular outcomes, four databases searched",1],["R0001381","Glucagon-like peptide-1 receptor agonists decrease hyperinsulinemia and hyperandrogenemia in dehydroepiandrosterone-induced polycystic ovary syndrome mice and are associated with mitigating inflammation and inducing browning of white adipose tissue†.","Zhang Y","2023","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent03","mouse PCOS model treated with liraglutide or semaglutide; animal only",1],["R0001447","Approved and Emerging Hormone-Based Anti-Obesity Medications: A Review Article.","Sidrak WR","2024","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent03","narrative review of approved and emerging hormone based anti-obesity drugs",1],["R0001517","Glucagon-like peptide-1 receptor agonists for weight management in mental illness: a network meta-analysis.","Kishi T","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent03","network meta-analysis of RCTs of GLP-1 RA in mental illness with obesity, PubMed Cochrane Embase searched",1],["R0000566","Glucagon-like peptide-1 receptor agonists in psoriasis and psoriatic arthritis: emerging evidence and future research opportunities.","Ciancio G","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent13","self described narrative review of GLP-1 agonists in psoriasis and psoriatic arthritis",1],["R0000616","The effect of GLP-1 receptor agonists on autophagy: insights gathered from research evaluating neurodegenerative disorders with these agents.","Sioufi MC","2026","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent13","systematic review restricted to cell and animal models of Alzheimer and Parkinson disease",1],["R0000771","Immunometabolic reprogramming via GLP-1 receptor agonists in people with HIV: A multidimensional systemic framework.","Sun L","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent13","narrative review of GLP-1 agonists and immunometabolism in people with HIV",1],["R0000834","Comparative effectiveness of GLP-1 receptor agonists versus mineralocorticoid receptor antagonists as fourth-line pharmacological therapy in patients with resistant hypertension and overweight or obesity: a retrospective multicenter cohort study in the USA.","Tian Z","2026","include_harms",null,"primary_report",null,"O121",null,"high","first","opus-5.5-agent13","TriNetX new initiator cohort GLP-1 agonists vs MRAs in resistant hypertension reporting acute kidney injury",1],["R0000890","Beyond Weight Loss: Glucagon-Like Peptide-1 Receptor Agonists and Antipsychotic Adherence in Schizophrenia.","López-Ibor I","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent13","editorial on GLP-1 agonists and antipsychotic adherence",1],["R0000964","Real-World Evidence of the GLP-1RA/SGLT2-i Therapy versus Standard Care: A Retrospective Cohort Study.","Mahmoud NM","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent13","retrospective cohort GLP-1 or SGLT2 therapy vs standard care, outcomes HbA1c, weight, BP, GI symptoms only",1],["R0001050","GLP-1 Receptor Agonists in Brazil: Landscape of Consumption, Safety and Regulation.","Hurtado RL","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent02","Brazilian descriptive regulatory surveillance of GLP-1 RA sales, pharmacovigilance reports and falsified products; no comparison group",1],["R0001107","Effect of Combination Therapy with SGLT2 Inhibitors and GLP-1 Receptor Agonists on Myocardial Infarction and Stroke in Type 2 Diabetes: A Systematic Review and Meta-Analysis.","Ghafoury R","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent02","registered systematic review and meta-analysis of SGLT2 inhibitor plus GLP-1 RA combination vs monotherapy on MI and stroke",1],["R0001306","Role of GLP-1 receptor agonists in the prevention and treatment of obesity-related cancer.","Muscogiuri G","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent02","narrative review of GLP-1 RA in obesity related cancer prevention and treatment",1],["R0001380","Cardiovascular Efficacy of GLP-1 Receptor Agonists by Kidney Function: An Updated Meta-Analysis of Randomized Trials Including the SOUL Trial.","Hasebe M","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent02","registered meta-analysis of placebo controlled GLP-1 RA outcome trials pooling MACE by kidney function strata",1],["R0001446","Prolonged Dysesthesia After Massive Accidental Semaglutide Overdose: A Case Report.","Quarenghi M","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent02","case report of accidental semaglutide overdose with dysesthesia",1],["R0001514","Antecedent glucagon-like peptide-1 receptor agonist use and risk of sepsis-induced cardiomyopathy in type 2 diabetes: a United States real-world active-comparator cohort study.","Wu JY","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent02","active comparator cohort GLP-1 RA vs DPP-4 inhibitor; outcomes sepsis cardiomyopathy, heart failure, mortality, no listed harm",1],["R0001637","Evaluating the Effects of Glucagon-Like Peptide 1 Receptor Agonists as a Secondary Prevention in Peripheral Arterial Disease: A Meta-Analysis.","Elliott B","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent06","registered meta-analysis of RCTs of GLP-1 RAs versus control on major adverse limb events in diabetes with PAD",1],["R0001824","The use of GLP-1 receptor agonists and co-agonists in adults without diabetes: a systematic review and network meta-analysis protocol.","Moiz A","2026","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent06","registered protocol of a systematic review and NMA of GLP-1 RAs and co-agonists in adults without diabetes; no results",1],["R0001950","Efficacy of the GLP-1 receptor agonist, semaglutide, in abstinence from illicit and nonprescribed opioids in an outpatient population with OUD: a randomized, double-blind, placebo-controlled clinical trial protocol.","Freet CS","2025","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent06","protocol of a placebo controlled RCT of semaglutide for opioid use disorder on MOUD; no results",1],["R0000580","Safety Assessment of Glucagon-Like Peptide 1 Receptor Agonists Based on the FAERS Database: Focus on Tumorigenic Risk in Subpopulations.","Li Z","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent19","FAERS disproportionality analysis of GLP-1 RA adverse event reports focused on tumors; spontaneous report design",1],["R0000649","Periconceptional use of GLP-1 receptor agonists and the risk of major congenital malformations: a systematic review and meta-analysis.","Liu X","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent19","systematic review and meta-analysis of periconceptional GLP-1 RA exposure and congenital malformations; PubMed Embase Web of Science searched",1],["R0000719","GLP-1 Receptor Agonists and the Ocular Surface: A Narrative Review of Restoration, Remodeling, and Clinical Implications.","Bair H","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent19","narrative review of GLP-1 RA and ocular surface with purposive selection, no systematic eligibility criteria",1],["R0000851","The risk of depression, anxiety, and suicidal behavior in patients with obesity on glucagon like peptide-1 receptor agonist therapy.","Kornelius E","2024","include_harms",null,"primary_report",null,"O35A",null,"high","first","opus-5.5-agent19","TriNetX cohort of obese GLP-1 RA new users vs nonusers, 1:1 propensity matched; suicidal behavior reported; nonuser comparator stratum",1],["R0000981","GLP-1 Receptor Agonists in Cardiac Surgery: From Metabolic Drug to Potential Perioperative Cardioprotective Agent.","Androutsopoulou V","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent19","narrative review of GLP-1 RA in cardiac surgery; authors state no systematic review was done",1],["R0001043","A Text Messaging-Based Program to Transition From Basal Insulin to Glucagon-Like Peptide-1 Receptor Agonists in Safety-Net Diabetes Care: Pilot Quality Improvement Intervention Study.","Levy N","2026","inventory_only","N1","primary_report",null,null,null,"high","first","opus-5.5-agent19","single arm pilot text messaging program switching basal insulin to GLP-1 RA; no comparison group",1],["R0000575","Do Preoperative Glucagon-Like Peptide-1 Receptor Agonists Influence Lumbar Fusion Outcomes? A Systematic Review and Meta-Analysis.","Alves MLM","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent17","registered review and meta-analysis searching PubMed, Embase, Cochrane on preoperative GLP-1 RA exposure and lumbar fusion outcomes",1],["R0000714","Glucagon-Like Peptide-1 Receptor Agonists Versus Bariatric Surgery in Patients With Obesity and Heart Failure With Preserved Ejection Fraction.","Ibrahim R","2025","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent17","TriNetX matched cohort of GLP-1 RA versus bariatric surgery in obese HFpEF; heart failure, death, MI, stroke outcomes only",1],["R0000782","Mortality and Serious Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists: A Pharmacovigilance Study Using the FDA Adverse Event Reporting System.","Bhattacharyya M","2024","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent17","FAERS disproportionality analysis of mortality and serious adverse event reports across GLP-1 RAs",1],["R0000848","GLP-1 receptor agonists as multisystem therapies: from glycemic control to cardiorenal, neuroimmune, and metabolic disease.","Zarei M","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent17","self described narrative review of multisystem effects of GLP-1 RAs",1],["R0000905","An overview of randomized clinical trials of fixed-ratio combinations of basal insulin plus GLP-1RA (injectable therapy): Lessons for advancing therapy in people with type 2 diabetes.","Bolli GB","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent17","narrative overview of fixed ratio insulin plus GLP-1 RA trials without systematic search",1],["R0000974","Chilean Multidisciplinary Consensus on the Use of GLP-1 Receptor Agonists: Recommendations Based on the GRADE Methodology.","Cabrera S","2026","exclude","E3","other",null,null,"non_english","high","first","opus-5.5-agent17","Chilean multisociety consensus recommendations on GLP-1 RA use; guideline document",1],["R0001037","Therapeutic potential of GLP-1 receptor agonists and SGLT2 inhibitors in diabetic neuropathy: a critical appraisal.","Ziegler D","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent17","narrative critical appraisal of GLP-1 RAs and SGLT2 inhibitors in diabetic neuropathy",1],["R0000579","Weight loss and cardiovascular outcomes with incretin-based therapies after metabolic and bariatric surgery: a nationwide US cohort study.","Gillikin A","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent18","EHR cohort after bariatric surgery comparing tirzepatide vs semaglutide weight loss and users vs nonusers for MACE; no listed harms outcome",1],["R0000641","Effect of glucagon-like peptide 1 receptor agonists on systolic blood pressure in patients with obesity, with or without diabetes: A systematic review and network meta-analysis.","Ali A","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent18","systematic review and NMA of placebo controlled GLP-1 RA RCTs on systolic blood pressure; MEDLINE and CENTRAL searched",1],["R0000783","For Weight Loss: Why Do GLP-1 Agonists Work, and How Can We Make Them Work Better?","Giang C","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent18","narrative review of GLP-1 drug design and weight loss biology; tables summarize selected trials, not a trial report",1],["R0000850","GLP-1 Receptor Agonists Versus SGLT2 Inhibitors in Diabetes and Chronic Pancreatitis: A Real World Cohort Study of Pancreatic Outcomes","Dhali A","2026","include_harms",null,"primary_report",null,"O29; O38",null,"high","first","opus-5.5-agent18","TriNetX matched cohort of GLP-1 RA vs SGLT2i in diabetes with chronic pancreatitis; recurrent acute pancreatitis and pancreatic cancer reported",1],["R0000906","Glucagon-like peptide 1 receptor agonists switching patterns in type two diabetes: A retrospective real-world study.","Kassem S","2025","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent18","retrospective cohort of patients switching between GLP-1 RAs with pre post HbA1c only; no concurrent comparison group",1],["R0000976","Comparative Cardiovascular Outcomes and Safety Profiles of Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Trials.","Mohamed Abdalla SA","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent18","systematic review and meta-analysis of placebo controlled GLP-1 RA CVOTs in T2D; MEDLINE, Embase, CENTRAL searched",1],["R0001038","Assessing the efficacy of large language models in data extraction for a meta-analysis on the role of glucagon-like peptide-1 receptor agonists in heart failure",null,"2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent18","methods study testing language model accuracy for data extraction; does not report a synthesized drug contrast",1],["R0001529","Glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors combination therapy for adults with type 2 diabetes mellitus: a network meta-analysis.","Osman AA","2025","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent08","Cochrane protocol for a network meta-analysis of GLP-1 RA, SGLT2i and combination therapy; no results",1],["R0001582","Cardiovascular Benefits of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Type 2 Diabetes Mellitus With Atherosclerotic Cardiovascular Disease: A Systematic Review of Randomized Controlled Trials.","Ahmad M","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent08","PRISMA systematic review of RCTs of GLP-1 receptor agonists on cardiovascular outcomes; four named databases searched",1],["R0001643","GLP-1 Agonists in Adolescent Obesity: A Narrative Review of Single, Dual, and Triple Agonists.","Abid M","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent08","self described narrative review of incretin agonists in adolescent obesity",1],["R0001696","Association Between Glucagon-Like Peptide-1 Receptor Agonists and Major Adverse Cardiovascular Outcomes Based on Race and Sex Among Patients With and Without Diabetes Mellitus: A Meta-Analysis of Nine Randomized Controlled Trials.","Jaiswal V","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent08","meta-analysis of placebo controlled GLP-1 RA RCTs on MACE by race and sex; PubMed and Scopus searched",1],["R0001765","Polish healthcare professionals' perceptions of GLP-1 receptor agonists in cardiometabolic risk reduction: a cross-sectional online survey in Poland.","Pucek WF","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent08","cross sectional survey of health professional perceptions of GLP-1 receptor agonists; no exposure comparison",1],["R0001829","GLP-1 receptor agonists and pulmonary hypertension in diabetes: A promising therapeutic strategy.","Albulushi A","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent08","narrative review of GLP-1 receptor agonists and pulmonary hypertension",1],["R0001889","Characteristics and outcomes of cubital tunnel decompression in diabetic patients receiving glucagon-like peptide-1 receptor agonists.","Shabbir R","2025","include_harms",null,"primary_report",null,"O37A",null,"high","first","opus-5.5-agent08","TriNetX matched cohort of GLP-1 RA users versus nonusers at cubital tunnel release; gastroparesis among complications; prevalent use",1],["R0001959","Tirzepatide and risk of newly diagnosed aortic stenosis in patients with obesity: a multi-institutional real-world cohort study.","Wu JY","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent08","active comparator new user cohort of tirzepatide versus GLP-1 RA on aortic stenosis; skin cancer only as negative control",1],["R0000558","An Observational Study of Cardiovascular Outcomes of Tirzepatide vs Glucagon-Like Peptide-1 Receptor Agonists.","Dani SS","2025","include_harms",null,"primary_report",null,"O121; O28; O29; O33",null,"high","first","opus-5.5-agent07","TriNetX new user cohort tirzepatide vs GLP-1RA; reports AKI, gallbladder, pancreatic disorders, retinopathy; comparator also GLP-1 containing",1],["R0001121","Oral nonpeptide GLP-1 receptor agonist VCT220 for obesity treatment: a randomized, double-blind, phase II trial.","Ji L","2026","include_nma",null,"primary_report","P02",null,null,"high","first","opus-5.5-agent05","phase 2 placebo controlled RCT of oral nonpeptide agonist VCT220 doses in adults with overweight or obesity, 16 weeks",1],["R0001126","Glucagon-like peptide-1 receptor agonists and obesity paradox in heart failure with preserved ejection fraction: a systematic review.","Hullon D","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent07","PRISMA systematic review of trials and cohorts of GLP-1RA vs placebo or usual care in obese HFpEF, four databases",1],["R0001199","What is the 'real-world' experience with fixed-ratio combination therapy (insulin + GLP-1 receptor agonist) in routine clinical practice? Take-home messages for clinicians regarding key outcomes.","Frias JP","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent07","narrative review of selected real world studies of insulin GLP-1RA fixed ratio combinations",1],["R0001267","A preliminary study of the physiological and perceptual effects of GLP-1 receptor agonists during alcohol consumption in people with obesity.","Quddos F","2025","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent07","nonrandomized pilot comparing GLP-1RA users with controls during alcohol challenge; breath alcohol and subjective effects, no listed harm",1],["R0001397","Safety and efficacy of glucagon-like peptide-1 receptor agonists in individuals with type 2 diabetes mellitus fasting during Ramadan: a systematic review and meta-analysis.","Kamrul-Hasan ABM","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent07","PROSPERO registered meta-analysis of GLP-1RA vs other glucose lowering drugs during Ramadan fasting in type 2 diabetes",1],["R0001457","Cancer Incidence Among Users of Glucagon-Like Peptide-1 Receptor Agonists.","Rashid Z","2026","include_harms",null,"other",null,"O32B; O38; O39",null,"high","first","opus-5.5-agent05","claims cohort of GLP-1 RA initiators versus insulin users reporting thyroid, pancreatic and overall cancer incidence; new user status to check",1],["R0001460","GLP-1RA may open a new era for MASLD treatment: Editorial on \"Glucagon-like peptide 1 receptor agonist and reduced liver and non-liver complications in adults with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease: a target trial emulation study\".","Feng Y","2026","inventory_only","N9","ancillary",null,null,null,"high","first","opus-5.5-agent07","editorial commenting on a target trial emulation of GLP-1RA in type 2 diabetes with MASLD",1],["R0001521","Obesity Treatment With Bariatric Surgery vs GLP-1 Receptor Agonists.","Barrett TS","2025","inventory_only","N6","other",null,null,null,"high","first","opus-5.5-agent05","claims cohort bariatric surgery versus GLP-1 RA on weight loss and costs; no listed harm outcome",1],["R0001573","Effect of lixisenatide on arterial stiffness in people with type 2 diabetes and kidney disease: Results of a randomised controlled trial.","Fountoulakis N","2026","include_nma",null,"primary_report","P01; P08A",null,"mechanistic","high","first","opus-5.5-agent05","single center placebo controlled RCT of lixisenatide in type 2 diabetes with CKD; arterial stiffness primary, HbA1c reported",1],["R0001634","Neurodegeneration onset with glucagon-like peptide-1 receptor agonists in people with type 2 diabetes: a real-world multinational cohort study.","Schechter M","2025","inventory_only","N6","other",null,null,null,"high","first","opus-5.5-agent05","new initiator cohort GLP-1 RA versus DPP-4 inhibitor or basal insulin; neurodegeneration outcomes and controls only, no listed harm",1],["R0001683","A Narrative Review on GLP-1 Receptor Agonists for Obesity in Older Women: Maximizing Weight Loss While Preserving Lean Mass.","Moscucci F","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent05","self described narrative review on GLP-1 RA in older women selecting articles by relevance without eligibility criteria",1],["R0001748","The safety and efficacy of semaglutide in people with schizophrenia spectrum disorders: systematic review and meta-analysis of randomised controlled trials.","Trott M","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent05","preregistered meta-analysis of placebo controlled semaglutide RCTs in schizophrenia spectrum disorders, five named databases",1],["R0001812","Risk of Depression With Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Compared to Other Antidiabetic Medications in Adults With Type 2 Diabetes: A Systematic Review and Meta-Analysis.","Ferrer Zavala GM","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent05","meta-analysis of GLP-1 RA versus other antidiabetic drugs on incident depression, five named databases",1],["R0001076","Effects of GLP-1 Receptor Agonists on Breast Reconstruction Outcomes: A Large-Database Retrospective Study.","Hamzeh BF","2026","inventory_only","N6","primary_report","P99",null,null,"high","first","opus-5.5-agent12","TriNetX matched cohort of GLP-1RA users vs nonusers undergoing breast reconstruction, surgical complications only",1],["R0001092","Impact of monotherapy and combination therapy with glucagon-like peptide-1 receptor agonists on exosomal and non-exosomal MicroRNA signatures in type 2 diabetes mellitus: a systematic review.","Yu H","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent20","PROSPERO registered review of four databases on GLP-1 RA treated vs untreated miRNA changes in human and animal T2DM",1],["R0001143","GLP-1 receptor agonists in kidney transplant recipients with post-transplant diabetes: efficacy and safety outcomes from a retrospective cohort study.","Navarrete RET","2026","inventory_only","N5","primary_report","P99",null,null,"high","first","opus-5.5-agent12","single center retrospective cohort of kidney transplant recipients starting GLP-1RA, before and after comparison without control group",1],["R0001218","Glucagon-like peptide-1 receptor agonists for the treatment of opioid use disorders: a systematic review.","Au HCT","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent12","PRISMA SR of GLP-1RAs in opioid use disorder searching multiple named databases, synthesizes human and preclinical studies",1],["R0001275","Efficacy and safety of GLP-1 receptor agonists in the treatment of obese patients with chronic heart failure: a meta-analysis.","Jia A","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent12","PRISMA meta-analysis of RCTs of GLP-1RAs vs control in obese patients with chronic heart failure",1],["R0001301","Early Weight Regain After GLP-1 Receptor Agonist Discontinuation: Mechanisms and Implications for Treatment De-Escalation Strategies.","Damhof MA","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent20","narrative review of weight regain after GLP-1 RA discontinuation",1],["R0001342","Evaluating the Use of GLP-1 Receptor Agonists in Wolfram syndrome Patients.","Lee L","2026","inventory_only","N6","primary_report","P99",null,null,"high","first","opus-5.5-agent12","registry cohort of Wolfram syndrome comparing GLP-1RA treated vs insulin only, disease progression outcomes, no listed harm",1],["R0001374","A Health Technology Assessment Based on Chinese Guidelines: Glucagon-Like Peptide-1 Receptor Agonist in the Treatment of Type 2 Diabetes Complicated with Cardiovascular Disease.","Xie Z","2022","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent20","health technology assessment scoring GLP-1 RAs on drug properties and price, not a primary study or systematic review",1],["R0001411","Dercum Disease: Exploratory Therapeutic Approaches in the Absence of Standardized Medical Treatment-A Single Center Case Series.","Magnatta A","2026","inventory_only","N5","primary_report","P99",null,null,"high","first","opus-5.5-agent12","case series of five Dercum disease patients, some receiving semaglutide or tirzepatide",1],["R0001442","Impact of Glucagon-Like Peptide-1 Receptor Agonists on Knee Arthroplasty Outcomes.","Zaffar H","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent20","PRISMA meta-analysis of cohort studies of GLP-1 RA users vs nonusers undergoing knee arthroplasty, four databases",1],["R0001486","Glucagon-like peptide-1 (GLP-1) receptor agonists in inflammatory bowel disease: mechanisms, clinical implications, and therapeutic potential.","Colwill M","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent12","narrative review of GLP-1RAs in inflammatory bowel disease",1],["R0001505","Beyond Weight Loss: Tirzepatide as a Metabolic Disease-Modifying Strategy for Metabolic Dysfunction-Associated Steatohepatitis: A Narrative Review.","Ahmed Z","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent20","self described narrative perspective review of tirzepatide in MASH",1],["R0001557","Impact of Sleeping Habits on the Weight Loss Effect of Oral Glucagon-Like Peptide-1 Receptor Agonists Among Obese Patients: An Observational Study in Japan.","Takakura K","2025","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent20","retrospective clinic cohort of semaglutide users only, sleep habits vs weight loss, no unexposed comparison group",1],["R0000569","Glucagon-Like Peptide-1 Agonists and the Incidence of Atrial Fibrillation in Obese Patients With Heart Failure With Preserved Ejection Fraction and No Diabetes.","Rassam F","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent15","TriNetX matched cohort of GLP-1 RA users versus nonusers with HFpEF and obesity; only atrial fibrillation and mortality assessed",1],["R0000633","Risk of Hearing Loss in Patients Treated with Exendin-4 Derivatives: A Network Meta-Analysis of Glucagon-like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors.","Chen JJ","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent15","Bayesian network meta-analysis of 29 RCTs of GLP-1 RAs and SGLT2 inhibitors on hearing loss; multiple databases searched",1],["R0000704","Effect of Glucagon-Like Peptide 1 Receptor Agonists on Patients With Rheumatoid Arthritis.","Kellner DA","2025","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent15","retrospective chart review in rheumatoid arthritis, GLP-1 RA takers versus nontakers; disease activity and cardiovascular markers only",1],["R0000777","Efficacy of GLP-1 receptor agonists in Parkinson's disease: a systematic review and exploratory network meta-analysis of randomized controlled trials.","Ali M","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent15","systematic review with pairwise and network meta-analysis of five RCTs of GLP-1 RAs in Parkinson disease",1],["R0000842","Combined Glucagon-like Peptide-1 Receptor Agonist and Sodium-Glucose Cotransporter-2 Inhibitor Use and Survival.","Reule S","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent15","Veterans cohort comparing GLP-1 RA, SGLT2i or combined use versus neither; all cause mortality is the only outcome",1],["R0000896","Unintentional periconceptional exposure to glucagon-like peptide-1 receptor agonists and adverse pregnancy outcomes: A nationwide cohort study in Taiwan.","Chou YC","2026","include_harms",null,"primary_report",null,"O120",null,"high","first","opus-5.5-agent15","nationwide Taiwan pregnancy cohort, periconceptional GLP-1 RA versus insulin exposure; major congenital malformations reported",1],["R0000967","Recent advances in the treatment of chronic liver diseases: focus on MASLD/MASH-related fibrosis.","Jędrysik M","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent15","narrative review of incretin based therapies for MASLD and MASH fibrosis without systematic methods",1],["R0001031","Oral glucagon-like peptide-1 receptor agonists and combinations of entero-pancreatic hormones as treatments for adults with type 2 diabetes: where are we now?","Gogineni P","2024","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent15","expert opinion review of oral GLP-1 RAs and multi agonists for type 2 diabetes",1],["R0000634","Association of Glucagon-Like Peptide-1 Receptor Agonists With Cancer Risk in Older Adults With Type 2 Diabetes.","Lu Y","2026","include_harms",null,"primary_report",null,"O32B; O38; O39",null,"high","first","opus-5.5-agent16","new user active comparator Medicare cohort versus SGLT2i or DPP4i; thyroid, pancreatic and overall cancer",1],["R0001084","Incretin-based cardiovascular protection beyond diabetes: evidence, mechanisms, and therapeutic frontiers from GLP-1 receptor agonists to multi-agonist therapy.","Qiu L","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent16","critical narrative review of incretin cardiovascular protection, explicitly not systematic, no eligibility criteria",1],["R0001231","Efficacy and safety of GLP-1 receptor agonists in Parkinson's disease: a systematic review and meta-analysis of randomized clinical trials.","Mendonça MF","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent16","PROSPERO registered systematic review and meta-analysis of GLP-1RA RCTs in Parkinson disease",1],["R0001288","Efficacy and Safety of Once-Weekly IcoSema Versus Once-Daily IDegLira in People with Type 2 Diabetes: Systematic Literature Review and Network Meta-analysis.","Kandalam S","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent16","systematic literature review and Bayesian NMA of IcoSema versus IDegLira in type 2 diabetes",1],["R0001351","The potential role of GLP-1 receptor agonists in substance use disorders - a systematic review.","Völker KM","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent16","PROSPERO registered systematic review of GLP-1RAs in substance use disorders, includes six clinical studies",1],["R0001429","Efficacy and safety of GLP-1 receptor agonists in MASH with fibrosis: A systematic review and meta-analysis.","Dos Santos Borges R","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent16","systematic review and meta-analysis of placebo controlled GLP-1RA RCTs in MASH with fibrosis",1],["R0001490","Glucagon-like Peptide-1 receptor agonists for the prevention and treatment of Parkinson's disease.","Lee S","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent16","review with named database search, two screeners and eligibility table covering clinical GLP-1RA studies in Parkinson disease",1],["R0001583","Glucagon-Like Peptide-1 Receptor Agonists Reduce Liver Stiffness in a Pediatric Metabolic Dysfunction-Associated Liver Disease Cohort and Normalize Disease-Associated Core Gene Expression in an Experimental Model.","Findling E","2026","inventory_only","N5","other",null,null,null,"high","first","opus-5.5-agent09","retrospective series of seven children with MASLD on GLP-1 agonists without comparison group plus mouse transcriptomics",1],["R0001644","Semaglutide versus other GLP-1 receptor agonists in patients with MASLD.","Kuo CC","2025","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent09","TriNetX cohort of semaglutide versus other GLP-1 agonists in MASLD, mortality, MACE, end stage kidney and liver outcomes only",1],["R0001698","The Gastrointestinal Safety of Orforglipron, a GLP-1 Receptor Agonist, in Adults With or Without Type 2 Diabetes: A Network Meta-Analysis of Randomized Controlled Trials.","Hageen AW","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent09","PRISMA network meta-analysis of orforglipron randomized trials on gastrointestinal, hepatic and pancreatic safety",1],["R0001894","Can Dual Incretin Receptor Agonists Exert Better Cardiovascular Protection than Selective GLP-1 Receptor Agonists? Highlights from SURPASS-CVOT.","Fadini GP","2025","inventory_only","N9","ancillary",null,null,null,"high","first","opus-5.5-agent09","commentary interpreting SURPASS-CVOT results of tirzepatide versus dulaglutide, no new data",1],["R0002007","Neuropsychiatric adverse events associated with Glucagon-like peptide-1 receptor agonists: a pharmacovigilance analysis of the FDA Adverse Event Reporting System database.","Lu W","2025","inventory_only","N5","other",null,null,null,"high","first","opus-5.5-agent09","FAERS disproportionality analysis of neuropsychiatric adverse event reports with GLP-1 agonists",1],["R0001562","Glucagon-Like Peptide-1 Receptor Agonists and Alcohol Use: A Real-Word Observational Study in a Large, Integrated Health Care System.","Palzes VA","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent02","matched cohort of new GLP-1 RA users vs untreated adults; outcome change in alcohol consumption only, no listed harm",1],["R0001628","Glucagon-like peptide-1 receptor agonists as add-on therapy to insulin for type 1 diabetes mellitus: a systematic review and meta-analysis.","Rebelos E","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent02","registered systematic review and meta-analysis of RCTs of GLP-1 RA add on to insulin vs placebo in type 1 diabetes",1],["R0001675","Glucagon-like peptide-1 receptor agonists in patients with anthracycline related cardiac dysfunction.","Scalia IG","2025","include_harms",null,"primary_report",null,"O121",null,"high","first","opus-5.5-agent02","TriNetX matched cohort GLP-1 RA vs no GLP-1 RA in anthracycline cardiotoxicity; reports acute renal failure; new user status unclear",1],["R0001733","Combined Use of Glp-1 Receptor Agonists and Sglt2 Inhibitors in Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis of Observational Cohort Studies","ÇİFTÇİOĞLU M","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent02","systematic review and meta-analysis of cohort studies of GLP-1 RA plus SGLT2 inhibitor vs monotherapy; four databases searched",1],["R0001802","Comparative Renal Safety of Tirzepatide and Semaglutide: An FDA Adverse Event Reporting System (FAERS)-Disproportionality Study.","Gandhi A","2025","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent02","FAERS disproportionality analysis of acute kidney injury reports with tirzepatide vs semaglutide",1],["R0001870","Fat and lean mass changes during incretin-based therapy with structured exercise and nutritional support: A retrospective real-world pilot study.","Kucuk Yetgin M","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent02","retrospective chart review of 11 incretin users with exercise program; no control group",1],["R0001941","The GLP-1-Mitochondria Axis in Metabolic Aging.","Chang R","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent02","narrative review of GLP-1 RA and mitochondrial function in metabolic aging",1],["R0001993","Reply to correspondence on \"Glucagon-like peptide 1 receptor agonist and reduced liver and non-liver complications in adults with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease: a target trial emulation study\".","Yao X","2026","inventory_only","N9","ancillary",null,null,null,"high","first","opus-5.5-agent02","reply letter about a target trial emulation of GLP-1 RA in MASLD with type 2 diabetes",1],["R0001659","Real-world treatment trajectories preceding GLP-1 receptor agonist initiation in type 2 diabetes: A descriptive UK population-based cohort study on adherence to national clinical guidelines.","Ulrich FS","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent14","descriptive UK cohort of treatment trajectories before GLP-1 RA initiation, prescribing study without exposure comparison",1],["R0001714","Is there still room for pioglitazone in contemporary type 2 diabetes management?","Caruso I","2026","inventory_only","N9","ancillary",null,null,null,"high","first","opus-5.5-agent14","letter commenting on a target trial emulation of GLP-1 RA vs pioglitazone",1],["R0001784","All-cause mortality and cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes and heart failure with reduced ejection fraction.","Vignarajah A","2025","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent14","active comparator new user cohort GLP-1 RA vs DPP4i in T2D with HFrEF, mortality and cardiovascular outcomes only",1],["R0001839","Association between GLP-1 receptor agonist use and substance use disorders among individuals with type 2 diabetes or obesity: a nested case-control study in the All of Us research program.","Abegaz TM","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent14","nested case control on GLP-1 RA exposure and substance use disorder diagnoses, no harms_nrs outcome",1],["R0001911","Hyperdilute Radiesse Preserves Facial Volume in Glucagon-Like Peptide-1 Receptor Agonist Users Undergoing Rapid Weight Loss.","Durairaj KK","2025","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent14","case series of four GLP-1 RA users receiving facial filler",1],["R0001978","Glucagon-Like Peptide-1 Analogs Associated with a Reduced Risk of Legal Blindness in Type 2 Diabetics with Cardiovascular Risks.","Jarrett E","2026","include_harms",null,"primary_report",null,"O34",null,"high","first","opus-5.5-agent14","TriNetX matched cohort GLP-1 RA users vs nonusers in T2D, ischemic optic neuropathy and legal blindness outcomes",1],["R0002049","The MUSCLE-GLP1-CKD study: design and rationale of a prospective real-world cohort evaluating muscle health during GLP-1 receptor agonist therapy in chronic kidney disease and type 2 diabetes","Macía-Heras M","2026","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent06","design and rationale of a prospective cohort of semaglutide initiators versus nonexposed controls with CKD and T2D; no results",1],["R0001682","Tirzepatide safety in EudraVigilance: descriptive and disproportionality analysis of preferred terms related to suboptimal treatment outcomes and drug-use-related issues.","Popa Ilie IR","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent04","EudraVigilance disproportionality analysis of tirzepatide drug use related reports vs other GLP-1 RAs",1],["R0001743","Disproportionality Analysis of Tirzepatide vs. Semaglutide and Liraglutide: System Organ Class-Level Post-Marketing Reporting Patterns in EudraVigilance.","Marin RC","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent04","EudraVigilance disproportionality analysis of tirzepatide vs semaglutide and liraglutide by organ class",1],["R0001811","Combination therapy with sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists in heart failure patients with type 2 diabetes.","Kishimori T","2025","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent04","TriNetX cohort SGLT2i plus GLP-1 RA vs SGLT2i alone in HF with diabetes, death and hospitalization only",1],["R0001996","Comparative Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists in Children and Adolescents with Obesity or Overweight: A Systematic Review and Network Meta-Analysis.","Liu L","2024","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent04","registered systematic review and network meta-analysis of pediatric RCTs comparing GLP-1 RAs and placebo",1],["R0002103","Semaglutide Exposure During Pregnancy: Results from the FAERS Database.","Zinzi A","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent06","FAERS descriptive and disproportionality analysis of semaglutide exposure in pregnancy",1],["R0002226","GLP-1 receptor agonists for smoking cessation: a narrative review of weight management potential.","Ahmed GU","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent06","narrative review of GLP-1 RAs for smoking cessation and weight gain",1],["R0002286","Comparative efficacy and safety of three fixed-ratio combination products in type 2 diabetes: A network meta-analysis.","Wang X","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent06","systematic review and NMA of RCTs comparing IDegLira, iGlarLixi and IDegAsp with components in T2D",1],["R0002362","GLP-1 Receptor Agonists in Acute Ischemic Stroke and Secondary Stroke Prevention: A Narrative Review of Preclinical and Clinical Evidence.","Samanidou V","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent06","self described narrative review of GLP-1 RAs in ischemic stroke; qualitative synthesis without meta-analysis",1],["R0002491","Fall Reporting with GLP-1 Receptor Agonists in Older Adults: A FDA Adverse Event Reporting System (FAERS) Disproportionality Analysis","Gedik TE","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent06","FAERS disproportionality analysis of falls by age among GLP-1 RA users",1],["R0001071","Cardiorenal Safety Markers With Injectable Glucagon-Like Peptide-1 (GLP-1) Agonists in Type 2 Diabetes: A Network Meta-Analysis.","Rai A","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent10","frequentist network meta-analysis of RCTs of injectable GLP-1 RAs on MACE and renal outcomes, five databases searched",1],["R0001132","Effect of glucagon-like peptide-1 receptor agonists on cigarette smoking consumption in type 2 diabetes patients: study protocol of a randomized, parallel -controlled clinical trial.","Chen D","2026","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent10","protocol of RCT of GLP-1 RA versus DPP-4 inhibitor on smoking in type 2 diabetes, recruiting, no results",1],["R0001209","Effect of GLP-1 receptor agonists on upper gastrointestinal endoscopy outcomes: a systematic review and meta-analysis.","Malandris K","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent10","PROSPERO registered meta-analysis of GLP-1 RA users versus nonusers for retained gastric content at endoscopy",1],["R0001272","Comparative Safety of Glucagon-Like Peptide 1 Receptor Agonists (GLP-1-RAs) in Type 2 Diabetes and Chronic Weight Management: A Real-World Data Study.","Hurwitz SR","2025","include_harms",null,"primary_report",null,"O28; O29; O32B; O35A; O37A; O37B",null,"high","first","opus-5.5-agent10","new user active comparator claims cohort GLP-1 RA versus SGLT2i and other weight drugs; biliary, pancreatitis, thyroid cancer, suicidality, GI outcomes",1],["R0001333","Comparative effectiveness of tirzepatide versus GLP-1 receptor agonists on the risk of venous thromboembolism in patients with obesity: a real-world cohort study.","Wu JY","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent10","TriNetX new user cohort tirzepatide versus GLP-1 RA in obesity; VTE and mortality only, no harms_nrs outcome",1],["R0001531","GLP-1 and dual GIP/GLP-1 receptor agonists' psychopharmacology and putative neuropsychiatric associated effects: a Bradford Hill-informed, systematic, evaluation.","Schifano F","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent10","Bradford Hill narrative appraisal of neuropsychiatric effects mixing animal and human data; no eligibility criteria stated",1],["R0002043","Assessment of cardiovascular event reduction with SGLT2 inhibitors compared to GLP-1 receptor agonists in type 2 diabetes mellitus.","Prasad Vudathaneni VK","2025","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent01","retrospective cohort of SGLT2 inhibitor versus GLP-1 RA users; MACE, HbA1c and heart failure admission only",1],["R0002154","Glucagon-like peptide-1 receptor agonists and mental health: a narrative review of emerging benefits and risks.","Kim J","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent01","narrative review of psychiatric benefits and risks of GLP-1 RAs without systematic methods",1],["R0002205","Correspondence to editorial on \"Glucagon-like peptide 1 receptor agonist and reduced liver and non-liver complications in adults with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease: a target trial emulation study\".","Mao X","2026","inventory_only","N9","ancillary",null,null,null,"high","first","opus-5.5-agent01","authors reply to an editorial on their GLP-1 RA versus DPP-4 inhibitor target trial emulation in MASLD",1],["R0002274","Liraglutide and Recurrent Stroke by Baseline Insulin Resistance: A Post Hoc Analysis of the LAMP Trial.","Lu L","2026","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent01","post hoc analysis of LAMP RCT, liraglutide plus standard care versus standard care after minor stroke in type 2 diabetes",1],["R0002409","Efficacy and safety of bofanglutide, a GLP-1 receptor agonist, in Chinese adults with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trial.","Ji L","2026","include_nma",null,"primary_report","P02",null,null,"high","first","opus-5.5-agent01","phase 2b double blind RCT of bofanglutide doses versus placebo in Chinese adults with overweight or obesity",1],["R0002474","GIP/GLP-1RA as adjunctive to automated insulin delivery in adults with Type 1 diabetes (the AID-JUNCT trial): Study protocol for a prospective, randomized, clinical trial.","Fragozo-Ramos MC","2025","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent01","protocol of open label RCT of tirzepatide added to automated insulin delivery versus standard care in type 1 diabetes",1],["R0001078","Cutaneous Allodynia Associated With GLP-1RA Tirzepatide for Weight Management: A Case Series.","Chakrabarti MP","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent13","case series of two patients with allodynia on tirzepatide",1],["R0001220","GLP-1 receptor agonists in primary care: readiness, equity, and the risk of a two-tiered obesity treatment landscape.","Ahmed MM","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent13","narrative review on primary care access and equity for GLP-1 agonists",1],["R0001276","Body Mass Index-Dependent Effect of Glucagon-Like Peptide 1 Receptor Agonist Therapy on Bowel Preparation Quality.","Vikash FNU","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent13","retrospective colonoscopy cohort GLP-1 users vs nonusers, bowel preparation and adenoma detection only",1],["R0001344","Association of GLP-1 Receptor Agonists With Hepatic Decompensation in the All of Us Research Program.","Hwang I","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent13","active comparator new user cohort GLP-1 vs DPP-4 inhibitors, hepatic decompensation only",1],["R0001417","Exploration of the Effects of SGLT-2 Inhibitors and GLP-1 Receptor Agonists on Coronary Inflammation in Type 2 Diabetes Patients Based on the Peri-Coronary Fat Attenuation Index.","Wang T","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent13","cross sectional CCTA comparison of SGLT2 and GLP-1 users vs nonusers on pericoronary fat attenuation",1],["R0001487","Metabolic and Glycemic Effects of Orforglipron, a GLP-1 Receptor Agonist, in Adults With or Without Diabetes: A Network Meta-Analysis of Randomised Clinical Trials.","Hageen AW","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent13","PROSPERO registered network meta-analysis of orforglipron RCTs from four databases",1],["R0001540","Muscle loss and GLP-1R agonists use.","Rossi G","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent13","narrative review of muscle loss with GLP-1 agonists",1],["R0001625","GLP-1 receptor agonist use and overall survival among women with type 2 diabetes and breast cancer: a retrospective cohort study.","Nelson RA","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent20","single center matched cohort of GLP-1 RA exposure after breast cancer, outcome overall mortality only, no listed harm",1],["R0001669","Effects of tirzepatide therapy on body weight and body composition in adults with overweight and obesity.","Corso H","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent20","retrospective clinic series of 35 tirzepatide users with body composition, no comparison group",1],["R0001726","Effectiveness of SGLT2 inhibitors, incretin-based therapies, and finerenone on cardiorenal outcomes: a meta-analysis and network meta-analysis.","Shokravi A","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent20","meta-analysis and NMA of RCTs of SGLT2i, incretin drugs and finerenone on cardiorenal outcomes, MEDLINE and CENTRAL",1],["R0001799","The efficacy and safety of danuglipron and orforglipron in patients with type 2 diabetes and obesity: a systematic review and meta-analysis.","Zhou J","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent20","meta-analysis of placebo controlled RCTs of danuglipron and orforglipron, four databases searched",1],["R0001865","Population-Level Interest in Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Using Google Trends Statistics in a 12-Month Retrospective Analysis: An Infodemiology and Infoveillance Study.","Shareef LG","2024","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent20","Google Trends search interest analysis of GLP-1 RA brand names, no drug exposure studied",1],["R0001925","GLP-1 agonist-associated presentations to unscheduled care: An opportunistic pilot study.","Thomas O","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent20","opportunistic case series of emergency presentations in GLP-1 or GIP/GLP-1 users, no comparison group",1],["R0002041","Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Obesity Management in Adults With and Without Type 2 Diabetes: A Systematic Review.","Velji-Ibrahim J","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent20","PROSPERO registered systematic review of RCTs of GLP-1 RAs vs placebo for obesity, narrative synthesis",1],["R0001086","Efficacy and safety of GLP-1 agonists in the treatment of T2DM: A systematic review and network meta-analysis.","Ren X","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent18","registered systematic review and Bayesian NMA of GLP-1 RA RCTs in T2D; multiple named databases searched",1],["R0001168","Effects of glucagon-like PEPTIDE-1 receptor agonists on incidence of hepatocellular carcinoma and liver decompensation in patients with diabetes: A systematic review and META-analysis.","Pasta A","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent18","systematic review and meta-analysis of comparative studies, GLP-1 RA vs other glucose lowering drugs, on HCC and liver decompensation",1],["R0001239","Semaglutide Prevents Aortic Rupture and Dissection in the Angiotensin II Mouse Model.","Balboa Ramilo A","2026","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent18","apolipoprotein E deficient mouse model of aortic aneurysm treated with semaglutide; no human participants",1],["R0001290","Angiogenic T cells and cognitive function in older adults with type 2 diabetes treated with GLP-1 receptor agonists.","Longo M","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent18","cross sectional study of older T2D adults on GLP-1 RA plus metformin vs metformin; Tang cells and cognition",1],["R0001493","Estimated Glomerular Filtration Rate Change and Heart Failure Events With GLP-1 Receptor Agonists: A Meta-Analysis and Meta-Regression of Randomised Controlled Trials.","Hasebe M","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent18","registered meta-analysis and meta-regression of placebo controlled GLP-1 RA RCTs on heart failure events; PubMed and Embase searched",1],["R0001552","Association Between Glucagon-Like Peptide-1 Receptor Agonists and Risk of Arrhythmias.","Jaiswal V","2025","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent18","TriNetX matched cohort of obese GLP-1 RA users vs nonusers on cardiac arrest and arrhythmias; no listed harms outcome",1],["R0001581","Deep Venous Thrombosis Within Two Weeks of Initiating Oral Semaglutide (Rybelsus): A Case Report.","Alsermani M","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent07","case report of deep vein thrombosis in an adolescent after starting oral semaglutide",1],["R0001695","Inflammatory optic neuritis and scleritis following commencement of semaglutide: a case report.","Maher CB","2025","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent07","case report of optic neuritis and scleritis after starting semaglutide",1],["R0001752","Neuropsychiatric Outcomes Associated with GLP-1 Receptor Agonists in Adults with Overweight or Obesity: A Systematic Review.","Lubo C","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent07","PROSPERO registered PRISMA review of neuropsychiatric outcomes with GLP-1RA in adults with overweight or obesity",1],["R0001886","Real-world trends in glucagon-like peptide-1 receptor agonists prescribing in acute kidney disease: a global federated-network study of dialysis-requiring acute kidney injury survivors.","Pan HC","2025","include_harms",null,"primary_report",null,"O37A",null,"high","first","opus-5.5-agent07","TriNetX cohort of GLP-1RA initiators vs nonusers after dialysis requiring AKI; mainly prescribing trends but compares gastroparesis risk",1],["R0001951","Psychiatric effects of GLP-1 receptor agonists: A systematic review of emerging evidence.","Sa B","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent07","systematic review across four named databases of psychiatric outcomes with GLP-1RA including RCTs",1],["R0002004","Discovery of AMG 133, a Glucose-Dependent Insulinotropic Polypeptide Receptor Antagonist and Glucagon-Like Peptide 1 Receptor Agonist Antibody-Drug Conjugate for the Treatment of Obesity.","Wu B","2026","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent08","discovery chemistry of AMG 133 with efficacy tested only in obese mice and monkeys",1],["R0002053","Enhanced cardioprotective effects of resveratrol and liraglutide against isoproterenol-induced myocardial injury: role of oxidative stress, inflammation, and mitochondrial function","El-Deen AEN","2026","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent08","randomized rat experiment of liraglutide and resveratrol in isoproterenol myocardial injury",1],["R0002108","Association of GLP-1 receptor agonists with risk of intestinal obstruction in patients with type 2 diabetes mellitus: a retrospective cohort study.","Gao Z","2025","include_harms",null,"primary_report",null,"O37B",null,"high","first","opus-5.5-agent08","TriNetX cohort comparing GLP-1 RA with six other antidiabetic classes for intestinal obstruction in type 2 diabetes",1],["R0002169","Clinical impact of tirzepatide on patients with chronic obstructive pulmonary disease.","Wu JY","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent08","TriNetX matched cohort of tirzepatide versus standard care in COPD; exacerbations, pneumonia, mortality; no harms list outcome",1],["R0002234","Correspondence to letter to the editor 1 on \"Glucagon-like peptide 1 receptor agonist and reduced liver and non-liver complications in adults with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease: a target trial emulation study\".","Mao X","2026","inventory_only","N9","ancillary",null,null,null,"high","first","opus-5.5-agent08","authors reply to letter on target trial emulation of GLP-1 RA in MASLD with cancer outcomes",1],["R0002293","Expectations and Outcomes From Glucagon-Like Peptide-1 Receptor Agonists As Adjunct Treatment for Type 1 Diabetes - Case Presentations.","Seetharaman S","2025","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent08","single center case series of GLP-1 RA as adjunct in young people with type 1 diabetes",1],["R0002375","Role of glucagon-like peptide-1 receptor agonists in Alzheimer's disease and Parkinson's disease.","Hong CT","2024","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent08","narrative review of GLP-1 receptor agonists in Alzheimer and Parkinson disease",1],["R0002422","Investigating the Incremental Cost and Utilization Burden of Obstructive Sleep Apnea in Overweight to Severely Obese Patients.","Kim HSJ","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent08","claims cost study of obstructive sleep apnea burden; GLP-1 RA use only a stratifier, not the exposure",1],["R0001629","GLP-1 Receptor Agonists Reduce Aortic Dissection and Hypertensive Crisis in Diabetic Patients with Aortic Aneurysm: A Retrospective Cohort Study.","Tsai YF","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent03","TriNetX new user cohort GLP-1 RA vs DPP4i in aortic aneurysm; aortic events, hypertensive crisis, mortality only",1],["R0001677","Use of glucagon-like peptide-1 receptor agonists in idiopathic intracranial hypertension : a systematic review.","Ognard J","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent03","systematic review of GLP-1 RA in idiopathic intracranial hypertension with three databases searched, includes an RCT vs placebo",1],["R0001738","Real-World Body Composition and Blood Pressure Changes Following Glucagon-Like Peptide 1 Receptor Agonist Initiation: A Causal Inference Study of Connected Device Data.","Chabassier A","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent03","device data cohort of GLP-1 RA users matched to nonusers; body composition and blood pressure only",1],["R0001871","Cardiovascular outcomes of SGLT2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes and a history of myocardial infarction: a systematic review and network meta-analysis of randomized controlled trials.","Ren Y","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent03","systematic review and NMA of RCTs comparing SGLT2i and GLP-1 RA in T2D with prior MI",1],["R0001994","GLP-1 Receptor Agonist Therapy and Surgical Procedure Rates in Hidradenitis Suppurativa","Sidhu KS","2025","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent03","TriNetX matched cohort GLP-1 RA vs controls in hidradenitis suppurativa; surgical procedure rates only",1],["R0001135","Glucagon-like peptide receptor agonists (GLP-1RAs) as cardiovascular risk modifiers in obstructive sleep apnea and obesity: a real-world study.","Ahn J","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent11","TriNetX matched cohort in OSA with obesity; heart failure, pulmonary hypertension, death, stroke, MI only; no listed harms outcome",1],["R0001211","Glucagon-Like Peptide-1 Receptor Agonists in the Prevention of Ischemic Stroke: Therapeutic Potential and Mechanisms.","Lin Z","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent11","narrative review of GLP-1RAs and ischemic stroke; authors state systematic methods were not followed",1],["R0001273","Glucagon-like peptide-1 receptor agonists linked to a reduced risk of developing asthma among patients with type 2 diabetes.","Cheng YS","2025","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent11","Taiwan claims cohort of GLP-1RA versus other drugs on incident asthma; no listed harms outcome",1],["R0001338","Pharmacovigilance study of GLP-1 receptor agonists for metabolic and nutritional adverse events.","He L","2024","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent11","FAERS disproportionality analysis of metabolic and nutritional adverse events across GLP-1RAs",1],["R0001403","Concomitant use of SGLT2 inhibitors and GLP-1 receptor agonists in patients with heart failure.","Khademi R","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent11","narrative review on combined SGLT2i and GLP-1RA use in heart failure without systematic search",1],["R0001534","Exploring Dietary Intake in Adults with Type 2 Diabetes Using GLP-1 Receptor Agonists: A Cross-Sectional Analysis.","Ponzo V","2025","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent11","cross sectional study of dietary intake in diabetes, GLP-1RA users versus oral agent users",1],["R0001593","Oral Nutritional Supplements and Body Composition Outcomes Among GLP-1 Receptor Agonist Users: Real-World Evidence.","Hong K","2026","inventory_only","N5","primary_report","P99",null,null,"high","first","opus-5.5-agent12","retrospective cohort of GLP-1RA users comparing oral nutritional supplement vs none, no GLP-1 unexposed comparison; alternative N6",1],["R0001653","Long-Term Cardiovascular Outcomes of Glucagon-Like Peptide-1 Receptor Agonists in Non-diabetic Obesity: A Systematic Review and Meta-Analysis.","Tom-Ayegunle K","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent12","SR and meta-analysis of GLP-1RA RCTs in nondiabetic obesity searching four named databases, MACE outcome",1],["R0001708","Disease-modifying anti-diabetic drugs (DMADDs): bridging the SIMPLE approach to disease interception.","Koca N","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent12","opinion letter proposing a disease modifying antidiabetic drug concept",1],["R0001775","Added Value to GLP-1 Receptor Agonist: Intermittent Fasting and Lifestyle Modification to Improve Therapeutic Effects and Outcomes.","Cozma D","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent12","narrative integrative review of GLP-1RA plus intermittent fasting, search explicitly not systematic",1],["R0001834","Dapagliflozin associates with heart rate variability decline in T2DM patients on GLP-1 receptor agonist therapy: a prospective observational study.","Wang Y","2026","inventory_only","N5","primary_report","P01",null,null,"high","first","opus-5.5-agent12","prospective cohort, all start GLP-1RA, groups by prior dapagliflozin, HRV outcomes; no GLP-1 unexposed comparison, alternative N6",1],["R0001965","Investigating the association between incretin-based therapies and thyroid cancer incidence among US Medicare beneficiaries with diabetes.","Acheampong CO","2025","include_harms",null,"primary_report","P01","O32B",null,"high","first","opus-5.5-agent12","Medicare active comparator new user cohort GLP-1RA vs SGLT2i, thyroid cancer incidence",1],["R0002020","Semaglutide or Tirzepatide and Optic Nerve and Visual Pathway Disorders in Type 2 Diabetes.","Wang L","2025","include_harms",null,"primary_report","P01","O34",null,"high","first","opus-5.5-agent12","TTE of semaglutide or tirzepatide vs other antidiabetic drugs in T2D, NAION and optic nerve disorders",1],["R0002045","Investigating the impact of Glucagon-like peptide-1 therapy on total shoulder arthroplasty outcomes.","Chebi P","2026","include_harms",null,"primary_report",null,"O121",null,"high","first","opus-5.5-agent02","claims cohort of shoulder arthroplasty, GLP-1 RA users at surgery vs matched nonusers; reports acute kidney injury; prevalent use",1],["R0002094","Real-World Sex Differences in Response to Treatment with Glucagon-like Peptide-1 Receptor Agonists: Analysis of Single-Center Outpatient Case Series.","Inceu GV","2025","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent02","single center retrospective case series of GLP-1 RA initiators comparing response by sex; no unexposed group",1],["R0002155","Risk of Hepatocellular Carcinoma with Glucagon-like Peptide-1 receptor agonist treatment in patients: a systematic review and meta-analysis.","Shabil M","2024","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent02","systematic review and meta-analysis of GLP-1 RA vs other therapy and hepatocellular carcinoma risk; three databases searched",1],["R0002206","Efficacy and safety of incretin-based therapies in patients with type 2 diabetes mellitus: a network meta-analysis based on clinical trials.","Wu X","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent02","registered Bayesian network meta-analysis of RCTs of incretin drugs in type 2 diabetes",1],["R0002276","Glucagon-Like Peptide-1 Receptor Agonists and Risk of Venous Thromboembolism: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.","Liu Y","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent02","registered meta-analysis of RCTs of GLP-1 RA vs placebo or other drugs on venous thromboembolism",1],["R0002341","Association of Baseline Comorbidities With First-Year Adherence to GLP-1 Receptor Agonists in Patients With Diabetes or Obesity: A Retrospective Cohort Study.","Mai Z","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent02","adherence study among GLP-1 RA initiators by baseline comorbidity; drug utilization without exposure comparison",1],["R0002411","Titration of Basal and Prandial Insulin Doses With the Initiation of Glucagon-Like Peptide-1 Receptor Agonist Therapy.","Hill AC","2024","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent02","retrospective chart review of insulin dose before and after GLP-1 RA start; no comparison group",1],["R0002476","Safety and efficacy of GZR18, a long-acting GLP-1 analog, in Chinese patients with type 2 diabetes: A randomized, double-blind, phase 1b/2a trial.","Liu M","2026","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent02","randomized double blind placebo controlled phase 1b/2a trial of GZR18 in type 2 diabetes with HbA1c outcome",1],["R0002055","Suspected Biphasic Anaphylaxis Following the First Known Dose of Tirzepatide: A Case Report and Brief Review of Reported Hypersensitivity Reactions.","Al-Rashid AH","2026","inventory_only","N5","other",null,null,null,"high","first","opus-5.5-agent09","case report of suspected biphasic anaphylaxis after first tirzepatide dose",1],["R0002047","Semaglutide Versus Other Glucagon-Like Peptide-1 Agonists for Weight Loss in Type 2 Diabetes Patients: A Systematic Review and Meta-Analysis.","Wen J","2024","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent04","systematic review and meta-analysis of three databases comparing semaglutide with other GLP-1 RAs for weight loss in type 2 diabetes",1],["R0002112","Comprehensive evaluation of GLP-1 receptor agonists: an umbrella review of clinical outcomes across multiple diseases.","Kong F","2026","include_review",null,"systematic_review",null,null,"umbrella_review","high","first","opus-5.5-agent09","PROSPERO registered umbrella review of 123 meta-analyses of GLP-1 agonists, five databases searched",1],["R0002238","Efficacy of glucagon-like peptide-1 receptor agonists for prevention of stroke among patients with and without diabetes: A meta-analysis with the SELECT and FLOW trails.","Gera A","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent09","PRISMA meta-analysis of randomized trials of GLP-1 agonists on stroke, PubMed and Embase searched",1],["R0002376","Comparative efficacy and safety of glucagon-like peptide 1 receptor agonists for the treatment of type 2 diabetes: A network meta-analysis.","Chen H","2023","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent09","PROSPERO registered NMA of weekly GLP-1 agonists in type 2 diabetes randomized trials",1],["R0002423","Effects of glucagon-like peptide-1 receptor agonists on patients with metabolic dysfunction-associated steatohepatitis: protocol for a systematic review and sequential meta-analysis.","Wang MJ","2025","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent09","protocol for systematic review and sequential meta-analysis of GLP-1 agonists in biopsy proven MASH, no results",1],["R0002504","Comparative Effectiveness of Bariatric Surgery Versus GLP-1 Receptor Agonists in Reducing the Risk of New-Onset of NASH: A Retrospective Multinational Cohort Study From North America and Europe.","Hussein A","2025","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent09","TriNetX cohort of bariatric surgery versus GLP-1 agonists on incident NASH, cirrhosis, hepatocellular carcinoma and death; no eligible harm",1],["R0001549","Efficacy and Safety of Tirzepatide Compared with GLP-1 RAs in Patients with Type 2 Diabetes Treated with Basal Insulin: A Network Meta-analysis.","Osumili B","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent16","systematic literature review and NMA of tirzepatide versus GLP-1RAs on basal insulin; Cochrane, Embase, MEDLINE searched",1],["R0002100","Long-Term Health Care Utilization Costs of GLP-1RA Use vs Bariatric Metabolic Surgery.","Wolff Sagy Y","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent04","Clalit cohort GLP-1 RA vs bariatric surgery, health care costs and BMI only, no eligible harms outcome",1],["R0002210","Incretin-based therapies for the treatment of obesity-related diseases.","Caruso I","2024","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent04","narrative review of incretin therapies for obesity related diseases without systematic methods",1],["R0002282","Early GLP-1 Agonist Use and Cancer Risk in Type 2 Diabetes: A Real-World Data Cohort Study.","Chuang CH","2025","include_harms",null,"primary_report",null,"O39; O38",null,"high","first","opus-5.5-agent04","TriNetX matched cohort early GLP-1 RA vs non use in type 2 diabetes, overall and site specific cancer incl pancreatic",1],["R0002346","Renal Outcomes of GLP-1 Receptor Agonists and Tirzepatide Across CKD Stages and Metabolic Phenotypes (Type 2 Diabetes and/or Overweight/Obesity): A Scoping Review.","Rico-Fontalvo J","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent04","scoping review with protocol, three databases, PCC criteria, RoB and GRADE on renal outcomes of GLP-1 RAs and tirzepatide",1],["R0002413","SGLT2 inhibitors versus GLP-1 receptor agonists for major adverse cardiovascular events in type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.","Ahmed AAO","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent04","registered systematic review and meta-analysis of RCTs of SGLT2i or GLP-1 RA vs placebo on MACE with indirect comparison",1],["R0002485","Cardiometabolic Benefits and Risks of Sodium-Glucose Co-Transporter-2 (SGLT-2) Inhibitor and Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Combination Therapy in Type 2 Diabetes: A Systematic Review.","Tantawy D","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent04","systematic review of four databases of RCTs of SGLT2i plus GLP-1 RA combination therapy in type 2 diabetes",1],["R0001612","Glucagon-Like Peptide-1 Receptor Agonists Improve MASH and Liver Fibrosis: A Meta-Analysis of Randomised Controlled Trials.","Mantovani A","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent16","registered systematic review and meta-analysis of GLP-1RA RCTs in MASLD or MASH; PubMed, Web of Science searched",1],["R0001788","Glucagon-Like Peptide-1 Receptor Agonists and Peri-Procedural Aspiration Risk.","Ho CN","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent16","systematic review with PubMed search, dual screening and pooled risk ratios of GLP-1RA and periprocedural aspiration",1],["R0001914","Beyond Single-Class Therapy: Real-World Combined Use of GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 2 Diabetes and Atherosclerotic Cardiovascular Disease.","Vournas G","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent16","cross sectional snapshot of inpatients by GLP-1RA and SGLT2i use, factors associated with combined therapy",1],["R0001981","Comparative Efficacy and Safety of Different Orforglipron Doses in Patients With Type 2 Diabetes Mellitus and Obesity: A Systematic Review and Network Meta-Analysis.","Tantoush M","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent16","systematic review and NMA of orforglipron doses versus placebo; PubMed, Embase, Scopus and others searched",1],["R0001088","Trends in Sodium-Glucose Cotransporter 2 Inhibitor and Glucagon‑Like Peptide‑1 Receptor Agonist Prescription Rates Among Patients With Type 2 Diabetes: An Epic Cosmos Real-World Data Analysis, 2014-2024.","Zhang DS","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent19","prescribing trend analysis of SGLT2 inhibitors and GLP-1 RA in Epic Cosmos; utilization only, no exposure outcome comparison",1],["R0001169","Effect of Glucagon-Like Peptide-1 Receptor Agonists on Renal and Cardiovascular Risk Factors in Patients With Type 2 Diabetes Mellitus: A Retrospective Study.","Yuan D","2025","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent19","retrospective before and after record review of GLP-1 RA users with type 2 diabetes; no comparison group",1],["R0001244","Ocular complications from glucagon-like peptide-1 receptor agonists: Clinical evidence, potential mechanisms, and clinical recommendations.","Wu TE","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent19","narrative review of ocular complications of GLP-1 RA with no systematic search or eligibility criteria",1],["R0001292","Sex Differences in the Efficacy of Glucagon-Like Peptide-1 Receptor Agonists for Weight Reduction: A Systematic Review and Meta-Analysis.","Yang Y","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent19","meta-analysis of GLP-1 RA RCTs on sex differences in weight loss; PubMed Embase Cochrane searched, PROSPERO registered",1],["R0001439","GLP‑1 receptor agonist therapy and 2‑year structural outcomes after arthroscopic rotator cuff repair in type 2 diabetes.","Yang MY","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent19","TriNetX new user cohort GLP-1 RA vs active comparator after rotator cuff repair; outcomes revision and retear only",1],["R0001502","Early Signal Detection in GLP-1 Receptor Agonists in Spain: A Comparative Bayesian Disproportionality Analysis in 2024 and 2025","Jimenez-Serrania M","2025","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent19","Bayesian disproportionality analysis of Spanish spontaneous reports for GLP-1 RA; preprint",1],["R0002027","Correspondence to letter to the editor 2 on \"Glucagon-like peptide 1 receptor agonist and reduced liver and non-liver complications in adults with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease: a target trial emulation study\".","Mao X","2026","inventory_only","N9","ancillary",null,null,null,"high","first","opus-5.5-agent14","authors reply to a letter about their target trial emulation of GLP-1 RA in T2D with MASLD",1],["R0002065","Investigation into the efficacy and safety profile of oral small-molecule GLP-1 receptor agonists in type 2 diabetes and obesity: a systematic review and meta-analysis.","Li L","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent14","systematic review and meta-analysis of RCTs of oral small molecule GLP-1 RAs in T2D and obesity, six databases searched",1],["R0002132","Repurposing GLP-1 receptor agonists for alcohol use disorder: a systematic review and meta-analysis.","Nasrollahizadeh A","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent14","systematic review and meta-analysis of GLP-1 RA use and alcohol use disorder outcomes, five databases, PROSPERO registered",1],["R0002251","If the evidence is there, why are GLP-1 receptor agonists not on-label for hip and knee osteoarthritis in overweight patients?","Ursini F","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent14","viewpoint arguing for GLP-1 RA labeling in hip and knee osteoarthritis, no primary data",1],["R0002311","Liraglutide-Induced Acute Hepatocellular Injury With Positive Rechallenge: A Case Report and Literature Review.","Adi M","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent14","case report of liraglutide induced hepatocellular injury with positive rechallenge",1],["R0002456","Glucagon-like Peptide-1 receptor agonists for obstructive sleep apnea in patients with obesity and type 2 diabetes mellitus: a systematic review and meta-analysis.","Yang R","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent14","PROSPERO registered systematic review and meta-analysis of GLP-1 RA for sleep apnea in obesity and T2D, ten sources searched",1],["R0002546","Dysesthesia associated with GLP-1 agonist therapies: data-mining analysis and literature review.","Laroche ML","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent06","VigiBase disproportionality analysis and French case review of dysesthesia with GLP-1 RAs; spontaneous reports only",1],["R0002616","The GLP-1 Agonist Exenatide Is Associated with Improved Adherence to Health Behavior and Lifestyle Treatment in Adolescents with Obesity: A Randomized Controlled Trial.","Stenlid R","2026","include_nma",null,"secondary_report","P03",null,null,"high","first","opus-5.5-agent06","prespecified secondary outcomes of Combat-JUDO, double blind RCT of exenatide versus placebo plus lifestyle in adolescents with obesity",1],["R0002677","Assessing the Oncological Safety of Glucagon-Like Peptide-1 Receptor Agonists: A Systematic Review and Meta-Analysis.","Jaradat JH","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent06","systematic review and meta-analysis of RCTs of GLP-1 RAs versus placebo on cancer incidence; PubMed, Scopus, Cochrane",1],["R0002755","Beyond glycemic control: clinical cardiovascular effects of tirzepatide-a narrative review.","Alawad AO","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent06","narrative review of cardiovascular effects of tirzepatide; no primary data or systematic synthesis",1],["R0002829","Real-world effectiveness of GLP-1 receptor agonist-based treatment strategies on \"time in range\" in patients with type 2 diabetes.","Chen Y","2024","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent06","propensity matched retrospective cohort of GLP-1 RA versus oral drugs in T2D; time in range effectiveness only",1],["R0002943","Obesity, anti-obesity medications, and atrial fibrillation: Recent advances.","Siaravas KC","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent06","narrative review on obesity, anti-obesity drugs and atrial fibrillation",1],["R0002996","Cardiometabolic and RAAS-Targeted Therapy in Thoracic Aortic Aneurysm: Propensity-Matched Associations with Survival and Major Cardiovascular Events.","Abdul Nabi H","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent06","propensity matched cohort in thoracic aortic aneurysm comparing GLP-1 RA users; mortality and MACE only",1],["R0001595","Real-world prescribing patterns of SGLT2 inhibitors and GLP-1 receptor agonists in Type 2 diabetes with various ASCVD subtypes from a large tertiary referral center.","Avenatti E","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent13","prescribing pattern study of SGLT2 inhibitors and GLP-1 agonists with prescription as outcome, no exposure comparison",1],["R0001656","Impact of Glucagon-Like Peptide-1 Receptor Agonists on Hip Arthroplasty Outcomes: A Systematic Review and Meta-Analysis.","Zaffar H","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent13","systematic review and meta-analysis of cohorts comparing GLP-1 users vs nonusers in hip arthroplasty",1],["R0001710","New Drugs on the Block: Dietary Management and Nutritional Considerations During the Use of Anti-Obesity Medication.","Pardali EC","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent13","narrative review of dietary management during incretin therapy",1],["R0001779","Real-world Evidence for Improvements in Inflammation and Anemia Biomarkers After the Initiation of GLP-1RA in Patients Receiving Hemodialysis.","Lama S","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent13","matched cohort GLP-1 initiators vs nonusers on hemodialysis, inflammation and anemia markers only",1],["R0001838","Glucagon-like peptide-1 receptor agonists in total joint arthroplasty: a comprehensive systematic review of what orthopaedic surgeons should know.","Abdelaziz O","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent13","PROSPERO registered systematic review of cohorts comparing GLP-1 users vs controls in joint arthroplasty",1],["R0001909","Effects of lifestyle and glucagon-like Peptide-1 receptor agonist-based therapies on waist circumference: A systematic review and meta-analysis.","Ghosal S","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent13","PubMed based meta-analysis of RCTs pooling GLP-1 based therapy vs comparators on waist circumference",1],["R0001970","Adenoma and Sessile Serrated Polyp Detection Rates in Adults Using Glucagon-Like Peptide-1 Receptor Agonists.","Garg S","2025","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent13","colonoscopy cohort GLP-1 users vs nonusers, bowel preparation and lesion detection only",1],["R0002026","Tirzepatide Persistence and Associated Changes in Clinical Outcomes in US Adults With Obesity or Overweight: A 6-Month Claims Database Analysis.","Gibble TH","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent13","descriptive claims cohort of tirzepatide initiators without an untreated or active comparator group",1],["R0002535","The effect of beinaglutide as an glucagon-like peptide-1 receptor agonists on cardiometabolic factors: a systematic review and meta-analysis.","Xu Y","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent01","systematic review and meta-analysis of beinaglutide RCTs on cardiometabolic factors, PubMed Web of Science Scopus Embase searched",1],["R0002596","Physician Perceptions of the Safety and Efficacy of GLP-1 Receptor Agonists: Underestimation of Cardiovascular Risk Reduction and Discrepancies with Clinical Evidence.","Krishnan S","2025","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent01","questionnaire of physician perceptions of semaglutide and tirzepatide compared with trial figures; no patient exposure comparison",1],["R0002739","Comparative cardiovascular outcomes of semaglutide to dulaglutide in patients with type 2 diabetes.","Kishimori T","2025","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent01","matched new user cohort of semaglutide versus dulaglutide; death, MI, stroke and heart failure only",1],["R0002814","Evaluating GLP-1 receptor agonists versus metformin as first-line therapy for reducing dementia risk in type 2 diabetes.","Sun M","2025","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent01","matched cohort of first line GLP-1 RA versus metformin initiators; dementia outcomes only, observational not randomized",1],["R0002861","Effects of GLP-1 receptor agonists on cardiometabolic outcomes in heart transplant recipients: A systematic review and meta-analysis of observational studies.","Dalal N","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent01","registered systematic review and meta-analysis of observational GLP-1 RA studies in heart transplant recipients, four databases searched",1],["R0002927","Glucagon-like peptide 1 receptor agonists and cancer risk: advancing precision medicine through mechanistic understanding and clinical evidence.","Lin A","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent01","narrative review of GLP-1 RA cancer risk and mechanisms without systematic methods",1],["R0002984","GLP-1 Receptor Agonists and Sight-Threatening Ophthalmic Complications in Patients With Type 2 Diabetes.","Ramsey DJ","2025","include_harms",null,"primary_report",null,"O33; O34",null,"high","first","opus-5.5-agent01","matched cohort of GLP-1 RA users versus comparators with type 2 diabetes; diabetic retinopathy complications and NAION reported",1],["R0002082","Incretin Hormones GLP-1 and GIP Normalize Energy Utilization and Reduce Inflammation in the Brain in Alzheimer's Disease and Parkinson's Disease: From Repurposed GLP-1 Receptor Agonists to Novel Dual GLP-1/GIP Receptor Agonists as Potential Disease-Modifying Therapies.","Hölscher C","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent20","narrative review of incretin agonists in Alzheimer and Parkinson disease",1],["R0001085","GLP-1 receptor agonists in osteoarthritis and psoriatic disease: the missing link between obesity and inflammation?","Angelopoulos A","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent17","self described narrative review of GLP-1 RAs in osteoarthritis and psoriatic disease",1],["R0002147","GLP-1 RA Plus SGLT2i Versus Monotherapy in MASLD and Type 2 Diabetes: Three Pairwise Target Trial Emulations.","Alkuwaiti MA","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent20","TriNetX target trial emulations of GLP-1 RA plus SGLT2i vs monotherapy in MASLD, outcomes mortality MACE liver and HCC, none listed",1],["R0002204","GLP-1 receptor agonists and obstructive lung disease: Beyond metabolic control to respiratory outcomes.","Georgakopoulou VE","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent20","narrative review of GLP-1 RAs and COPD or asthma outcomes",1],["R0002273","Comparative cardiovascular efficacy of antidiabetic therapies in type 2 diabetes: a systematic review and network meta-analysis of randomized trials.","Mohammadi D","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent20","PROSPERO registered NMA of RCTs of antidiabetic classes including GLP-1 RAs on cardiovascular outcomes, five databases",1],["R0002405","Established and emerging pharmacologic options and unmet needs in HFpEF and HFmrEF.","Sauer AJ","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent20","narrative review of pharmacologic options in HFpEF and HFmrEF",1],["R0002470","Pancreatitis Risk Associated with GLP-1 Receptor Agonists, Considered as a Single Class, in a Comorbidity-Free Subgroup of Type 2 Diabetes Patients in the United States: A Propensity Score-Matched Analysis.","Ayoub M","2025","include_harms",null,"primary_report",null,"O29",null,"high","first","opus-5.5-agent20","TriNetX propensity matched cohort of GLP-1 RA users vs nonusers with T2DM, pancreatitis outcome",1],["R0002534","Evaluating the Evolving Real-World Adverse Events of GLP-1RAs Using FDA Adverse Event Reporting System (FAERS).","Stone D","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent20","FAERS disproportionality analysis of GLP-1 RA adverse events",1],["R0001167","Glucagon-Like Peptide-1 Receptor Agonists and Fragility Fracture Risk in Type 2 Diabetes.","Hamad CD","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent17","target trial emulation of GLP-1 RA versus DPP-4 inhibitor initiation; fragility fracture is the only outcome, not a listed harm",1],["R0001236","Once-Weekly Semaglutide in Patients with Cardiovascular-Kidney-Metabolic Syndrome: A Real-World Study.","Trenas-Calero A","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent17","matched real world cohort of semaglutide versus no GLP-1 RA in cardiorenal metabolic syndrome; heart failure and kidney events only",1],["R0001436","The association between glucose-dependent insulinotropic polypeptide and/or glucagon-like peptide-1 receptor agonist prescriptions and substance-related outcomes in patients with opioid and alcohol use disorders: A real-world data analysis.","Qeadan F","2025","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent17","EHR cohort of GIP or GLP-1 RA prescription versus none in opioid or alcohol use disorder; overdose and intoxication outcomes",1],["R0001491","Association between eating behavior patterns and the therapeutic efficacy of GLP-1 receptor agonists in individuals with type 2 diabetes: a multicenter prospective observational study.","Koide Y","2025","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent17","prospective observational cohort of people starting GLP-1 RAs without a comparison group; before and after analysis",1],["R0001083","Fixed BMI eligibility criteria for GLP-1 receptor agonist trials and estimated trial-eligible proportions in Asian and non-Asian populations: A cross-sectional analysis.","Huh KY","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent15","cross sectional analysis of trial registry BMI criteria against national survey data; no GLP-1 RA exposure studied",1],["R0001157","Glucagon-like peptide-1 receptor agonists and pancreatic outcomes in chronic pancreatitis: a real-world cohort study.","Dhali A","2026","include_harms",null,"primary_report",null,"O29; O37A; O38",null,"high","first","opus-5.5-agent15","TriNetX matched cohort in chronic pancreatitis, GLP-1 RA users versus nonusers; acute pancreatitis, pancreatic cancer and gastroparesis reported",1],["R0001225","Assessment of the Drug-Drug Interaction Potential of Lotiglipron (PF-07081532) with Midazolam, Omeprazole, Dabigatran, Rosuvastatin, and the Oral Contraceptives Levonorgestrel and Ethinyl Estradiol.","Cronenberger C","2026","inventory_only","N1","primary_report",null,null,null,"high","first","opus-5.5-agent15","two open label fixed sequence phase 1 drug interaction studies of lotiglipron and semaglutide; no randomized or concurrent comparator",1],["R0001285","A Systematic Review and Meta-Analysis of Efficacy and Safety of Liraglutide in Patients with Type 2 Diabetes Mellitus.","Joshi S","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent15","registered systematic review and meta-analysis of 25 RCTs of liraglutide 1.2 or 1.8 mg in type 2 diabetes",1],["R0001350","The Impact of GLP-1 Receptor Agonists on Esophagogastroduodenoscopy Outcomes: A Retrospective Cohort Study in a Predominantly African American Population.","El Sabagh A","2026","include_harms",null,"primary_report",null,"O36A; O36B",null,"high","first","opus-5.5-agent15","cohort of EGD procedures, GLP-1 RA use within 7 days versus none; retained gastric content and aspiration assessed",1],["R0001544","Glucagon-like peptide-1 receptor agonists and kidney outcomes.","MacIsaac RJ","2024","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent15","narrative review of kidney outcomes from GLP-1 RA cardiovascular outcome trials",1],["R0001616","Efficacy and safety of glucagon-like peptide 1 receptor agonists across all health outcomes in type 2 diabetes: An umbrella review and evidence map of randomised controlled trials.","Yeo D","2026","include_review",null,"systematic_review",null,null,"umbrella_review","high","first","opus-5.5-agent18","registered umbrella review of meta-analyses of GLP-1 RA RCTs in T2D; PubMed, Embase, CINAHL searched, effects recalculated",1],["R0001723","Comparative Risk of Psoriatic Arthritis in Type 2 Diabetes: An Emulated Target Trial of SGLT2 Inhibitors vs. GLP-1 Receptor Agonists.","Yen FS","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent18","TriNetX target trial emulation SGLT2i vs GLP-1 RA in T2D; psoriatic arthritis and psoriasis only, not listed harms; not an RCT",1],["R0001792","Impact of Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) on Increased Residual Gastric Content in Patients With and Without Concurrent Colonoscopy: A Retrospective Case-Control Study.","Chang S","2026","include_harms",null,"primary_report",null,"O36B",null,"high","first","opus-5.5-agent18","single center case control study of increased retained gastric content at endoscopy by GLP-1 RA use",1],["R0001920","The Potential Impact of GLP-1 Receptor Agonists on Exacerbation Risk in Patients with COPD and Type 2 Diabetes: A Real-World Population-Based Observational Study.","Alcázar-Navarrete B","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent18","matched UK primary care cohort of GLP-1 RA initiators vs naive in COPD with T2D; exacerbations only; not an RCT",1],["R0002036","Impact of Glucagon-Like Peptide-1 Receptor Agonists on Liver-Related Outcomes, Laboratory and Physiologic Parameters in Metabolic Dysfunction-Associated Steatohepatitis: A Systematic Review and Meta-Analysis.","Wang MJ","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent18","registered systematic review and meta-analysis of placebo controlled GLP-1 RA RCTs in MASH; four named databases",1],["R0002058","Effectiveness of GLP-1 Receptor Agonists in Patients With Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis of Randomised Controlled Trials.","Buragohain S","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent12","PRISMA SR and meta-analysis of RCTs of GLP-1RAs vs metformin or placebo in PCOS, seven databases searched",1],["R0002120","Postpartum GLP-1 receptor agonists and SGLT-2 therapies in women with prior gestational diabetes: current evidence and uncertainties.","Vanlaer Y","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent12","narrative commentary on postpartum GLP-1RA and SGLT2 therapy after gestational diabetes, no primary data or systematic search",1],["R0002177","Impact of semaglutide introduction on the use of triptans: an interrupted-time series.","Roland N","2026","inventory_only","N5","primary_report","P02",null,null,"high","first","opus-5.5-agent12","Danish registry interrupted time series of semaglutide initiators, before and after triptan use, no concurrent control",1],["R0002246","Digital multicriteria evaluation of negotiated medicines using Chinese mini-HTA: application of structured methodologies in assessing once-weekly GLP-1 RAs for improved clinical decision-making.","Li X","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent12","mini health technology assessment scoring four weekly GLP-1RAs by expert weights, not a primary study or SR",1],["R0002304","Glucagon-like Peptide-1 Receptor Agonists Associated Gastrointestinal Adverse Events: A Cross-Sectional Analysis of the National Institutes of Health All of Us Cohort.","Aldhaleei WA","2024","inventory_only","N5","primary_report","P01",null,null,"high","first","opus-5.5-agent12","self described cross sectional analysis of GI events among GLP-1RA users comparing agents, no non GLP-1 comparator",1],["R0002384","GLP-1 receptor agonists and risk of all cause and cause specific acute pancreatitis: target trial emulation.","Xie Y","2026","include_harms",null,"primary_report","P01","O29",null,"high","first","opus-5.5-agent12","VA TTE of GLP-1RA vs sulfonylurea initiators in T2D, all cause and cause specific acute pancreatitis",1],["R0002046","Contemporary medical therapy for heart failure with mildly reduced or preserved ejection fraction.","Beavers CJ","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent03","narrative review of medical therapy for HFmrEF and HFpEF including GLP-1 RA",1],["R0002096","Comparative effects of SGLT2 inhibitors and incretin-based therapies on dementia risk in type 2 diabetes: a systematic review and meta-analysis.","Song K","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent03","systematic review and meta-analysis of SGLT2i vs GLP-1 RA and DPP4i on dementia, three databases searched",1],["R0002157","Comprehensive pharmacovigilance assessment of pairwise drug-drug interactions and acute pancreatitis in the FDA adverse event reporting system: focus on incretin-based drugs.","Kazume I","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent03","FAERS disproportionality analysis of drug interactions and acute pancreatitis with GLP-1 RA and DPP4i",1],["R0002208","The potential adverse effects of hypodermic glucagon-like peptide -1 receptor agonist on patients with type 2 diabetes: A population-based study.","Cheng Z","2024","include_harms",null,"primary_report",null,"O29; O32B",null,"high","first","opus-5.5-agent03","Shenzhen cohort GLP-1 RA vs metformin only or insulin only users in T2D; pancreatitis and thyroid cancer reported",1],["R0002277","Comparison of the efficacy and safety of 10 glucagon-like peptide-1 receptor agonists as add-on to metformin in patients with type 2 diabetes: a systematic review.","Xie Z","2023","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent03","NMA of RCTs of ten GLP-1 RA as metformin add-on in T2D with three databases searched",1],["R0002412","Cardio-kidney-metabolic protective effects of semaglutide across the spectrum of chronic kidney disease.","Economos H","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent03","narrative review of semaglutide cardio kidney metabolic effects in CKD",1],["R0002482","Effects of SGLT-2 inhibitors and GLP-1 receptor agonists on liver function in patients with non-alcoholic fatty liver disease and type 2 diabetes.","Guo W","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent03","matched cohort SGLT2i vs GLP-1 RA in NAFLD with T2D; liver enzyme changes only",1],["R0002030","Use of Glucagon-Like Peptide-1 (GLP-1) Agonists in Modulating Preexisting Dermatologic Disease: A Systematic Review.","Tassavor B","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent16","PRISMA systematic review of GLP-1RAs in preexisting skin disease; PubMed, CINAHL, MEDLINE, Cochrane searched",1],["R0002068","GLP-1RA use improves outcomes post partial nephrectomy in T2DM patients with RCC: A TriNetX study.","Kwon S","2026","include_harms",null,"primary_report",null,"O121; O37B",null,"high","first","opus-5.5-agent16","TriNetX matched cohort of GLP-1RA users vs nonusers after partial nephrectomy; reports acute kidney injury and ileus",1],["R0002136","Letter to the editor on \"Glucagon-like peptide 1 receptor agonist and reduced liver and non-liver complications in adults with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease: a target trial emulation study\".","Yao X","2026","inventory_only","N9","ancillary",null,null,null,"high","first","opus-5.5-agent16","letter commenting on a target trial emulation of GLP-1RA versus DPP-4i in MASLD",1],["R0002194","Racial and demographic disparities in glp-1ra use among breast cancer patients with Type 2 Diabetes.","Hundal J","2025","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent16","utilization study of racial disparities in receiving GLP-1RA; outcome is prescription, no exposure comparison",1],["R0002256","GLP-1 Receptor Agonists in Neurological Disorders: From Mechanisms to Clinical Translation.","Li P","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent16","narrative review of GLP-1RAs in neurological disorders without systematic methods",1],["R0002329","Comparison of Pediatric and Adult Glucagon-Like Peptide-1 Receptor Agonist Exposures Reported To United States Poison Centers, 2017-2024.","Senthilkumar A","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent16","poison center exposure reports for GLP-1RAs comparing children and adults; spontaneous report analysis",1],["R0002390","Cardiovascular and Kidney Outcomes of Glucagon-Like Peptide 1 Receptor Agonist Therapy in Type 2 Diabetes Mellitus and Chronic Kidney Disease: A Systematic Review and Meta-Analysis.","Felix N","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent16","PROSPERO registered systematic review and meta-analysis of GLP-1RA RCTs in T2D with CKD",1],["R0002003","Glucagon-Like Peptide-1 Receptor Agonists vs Dipeptidyl Peptidase-4 Inhibitor Use on Risk of Asthma Exacerbation Among Diabetic Patients with Co-Morbid Asthma in Hong Kong.","Kwok WC","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent07","Hong Kong cohort of GLP-1RA vs DPP-4 inhibitor users with asthma and diabetes; asthma exacerbation outcomes only",1],["R0002052","Real-World Weight Loss and Telehealth Platform Utilization Patterns of Long-Term GLP-1 Receptor Agonist Treatment of self pay patients : A Retrospective Analysis","Patil P","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent07","retrospective telehealth cohort comparing semaglutide and tirzepatide weight loss; no listed harm outcome, not randomized",1],["R0002168","In Silico Exploration of Therapeutics for GLP-1 Receptor Agonist-Induced Nausea and Their in Vivo Validation in Mice.","Shibui N","2025","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent07","FAERS pharmacovigilance analysis of comedications and GLP-1RA nausea plus mouse pica experiments",1],["R0002232","Cardiovascular and renal outcomes of combined SGLT2 inhibitors and GLP-1 receptor agonists versus monotherapy in patients with type 2 diabetes mellitus: a network meta-analysis.","Chuang MH","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent07","PROSPERO registered network meta-analysis of RCTs of SGLT2i, GLP-1RA and combination in type 2 diabetes",1],["R0002289","All-Cause Mortality and Gastrointestinal Adverse Effects in Adults With Type 2 Diabetes on Glucagon-Like Peptide-1 Receptor Agonists vs Sodium-Glucose Cotransporter-2 Inhibitors.","Garg S","2025","include_harms",null,"primary_report",null,"O37A; O37B; O29; O28",null,"high","first","opus-5.5-agent07","TriNetX matched cohort GLP-1RA vs SGLT2i in type 2 diabetes; gastroparesis, ileus, obstruction, pancreatitis, biliary outcomes",1],["R0002365","Clinical Efficacy of a Flavo-Proxylane Topical Regimen Pre- and Post-ultrasound Procedure for Subjects Undergoing Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Therapy.","Moradi A","2026","inventory_only","N3","primary_report",null,null,null,"high","first","opus-5.5-agent07","randomized split face topical regimen vs placebo in ongoing GLP-1RA users; GLP-1 regimen unchanged between arms",1],["R0002421","Perioperative Optimization Strategies in Major Genitourinary Cancer Surgery.","Yellu A","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent07","narrative review of perioperative optimization in genitourinary cancer surgery including GLP-1RA as one topic",1],["R0001665","Adjunctive Dulaglutide in Relapsing-Remitting Multiple Sclerosis: A Randomized Open-Label Proof-of-Concept Trial.","Šiarnik P","2026","include_nma",null,"primary_report","P99",null,null,"high","first","opus-5.5-agent18","open label RCT of add on dulaglutide vs no add on in relapsing remitting multiple sclerosis on natalizumab; weight and adverse events reported",1],["R0002540","Safety and efficacy of glucagon-like peptide 1 receptor agonists in solid organ transplant recipients with diabetes mellitus: a systematic review and meta-analysis.","Usman M","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent04","systematic review and meta-analysis of three databases on GLP-1 RA safety and efficacy after solid organ transplant, pooled estimates",1],["R0002610","Glucagon-like peptide-1 receptor agonists and suicide risk in individuals with diabetes and Cannabis use disorder.","Dhruva Y","2025","include_harms",null,"primary_report",null,"O35A",null,"high","first","opus-5.5-agent04","TriNetX cohort of type 2 diabetes, GLP-1 RA exposed vs unexposed, adjusted hazard of suicide attempt",1],["R0002671","Innovative Diabetes Therapies and Impact on Peripheral and Autonomic Diabetic Neuropathies: A State-of-the-Art Review.","Vekic J","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent04","self described narrative review of new diabetes drugs and diabetic neuropathy, no systematic methods",1],["R0002748","Gastric Neoplasm Risk with DPP-4 Inhibitors, GLP-1 Receptor Agonists, and SGLT2 Inhibitors: Network Meta-Analysis of Randomized Trials.","Hung CM","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent04","registered systematic review and network meta-analysis of RCTs on gastric neoplasm risk incl GLP-1 RA vs control",1],["R0002825","Cost-effectiveness analysis of once-daily oral semaglutide versus placebo and subcutaneous glucagon-like peptide-1 receptor agonists added to insulin in patients with type 2 diabetes in China.","Feng Z","2023","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent04","cost effectiveness simulation using UKPDS model of oral semaglutide vs placebo and injectable GLP-1 RAs",1],["R0002870","Patient characteristics and early experiences with anti-obesity medications: the CAMP study.","Tewksbury C","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent04","EHR description of semaglutide or tirzepatide prescribees and access survey, drug utilization without exposure comparison",1],["R0002940","How do glucagon-like Peptide-1 receptor agonists affect measures of muscle mass in individuals with, and without, type 2 diabetes: A systematic review and meta-analysis.","Anyiam O","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent04","registered systematic review and meta-analysis of six sources on GLP-1 RA effects on muscle and fat mass",1],["R0002992","Efficacy of Luseogliflozin Added to Semaglutide in Patients With Metabolic Dysfunction-Associated Steatohepatitis and Type 2 Diabetes Mellitus: A Randomised, Open-Label Trial.","Miyake T","2026","inventory_only","N3","primary_report",null,null,null,"high","first","opus-5.5-agent04","RCT of luseogliflozin added to semaglutide vs semaglutide alone in MASH with diabetes, GLP-1 RA identical in both arms",1],["R0001986","Dulaglutide vs insulin in adolescents with thalassaemia-induced diabetes: effect on metabolism and atherogenesis (DIADEMA).","Adly AAM","2026","include_nma",null,"primary_report","P99",null,null,"high","first","opus-5.5-agent18","open label RCT of dulaglutide vs basal bolus insulin in adolescents with thalassemia related diabetes; HbA1c reported; secondary diabetes, not P04",1],["R0001881","Peri-Procedural Fasting and Gastric Ultrasound Strategies in Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Users: A Systematic Review With Qualitative Synthesis.","Abdallah OW","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent05","systematic review with four named databases synthesizing withholding and fasting strategies on residual gastric content in GLP-1 RA users",1],["R0002101","HRS-7535 for Type 2 Diabetes Inadequately Controlled With Metformin: A Randomized Clinical Trial.","Guo L","2026","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent05","phase 2 placebo controlled RCT of four doses of oral HRS-7535 added to metformin in type 2 diabetes, 16 weeks",1],["R0002165","GLP-1RAs: antidiabetic drug crossover-new hope for chronic inflammatory airway diseases.","Chen Y","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent05","narrative review of GLP-1 RA in airway diseases with loosely described search and no eligibility criteria",1],["R0002283","Impact of Perioperative Glucagon-Like Peptide-1 Receptor Agonists on Postoperative Outcomes Following Carpal Tunnel Release.","Bank NC","2025","inventory_only","N6","other",null,null,null,"high","first","opus-5.5-agent05","TriNetX cohort of carpal tunnel release with versus without perioperative GLP-1 RA; wound and nerve outcomes only",1],["R0002555","Effectiveness of GLP-1 RAs and SGLT2 inhibitors in preventing T2DM in high-risk patients: an updated systematic review and meta-analysis.","Tsironikos GI","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent09","PRISMA systematic review and meta-analysis of randomized trials of GLP-1 agonists and SGLT2 inhibitors for diabetes prevention",1],["R0002622","Racial and Ethnic Disparities in Medication Adherence Among Medicare Advantage Enrollees With Diabetes.","Essien UR","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent09","Medicare cohort on racial disparities in medication adherence, no GLP-1 exposure comparison for outcomes",1],["R0002884","Kidney Outcomes With Glucagon-Like Peptide-1 Receptor Agonists Versus Other Glucose-Lowering Agents in People With Type 2 Diabetes: A Systematic Review and Meta-Analysis of Real-World Data.","Fishkin A","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent09","PROSPERO registered meta-analysis of cohort studies on kidney outcomes with GLP-1 agonists versus other agents",1],["R0002950","Efficacy and Safety of Once-Weekly Semaglutide Versus Basal Insulin and Other GLP-1 Receptor Agonists in Adults With Type 2 Diabetes Uncontrolled on Oral Antidiabetic Drugs: A Systematic Review and Pairwise Meta-Analysis.","Aljulajil FA","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent09","systematic review with pairwise meta-analyses of RCTs of weekly semaglutide versus insulin and other GLP-1 agonists",1],["R0003006","Semaglutide attenuates a proteomics-based dementia risk signature in older adults with overweight or obesity and cardiovascular disease without diabetes: A post hoc analysis of the SELECT phase 3 trial.","Jiménez-Mausbach M","2026","include_nma",null,"secondary_report","P02",null,null,"high","first","opus-5.5-agent09","post hoc proteomic dementia risk analysis of SELECT randomized semaglutide versus placebo trial",1],["R0002502","Comparative Effectiveness of Metformin versus GLP-1 Receptor Agonists in Treating Antipsychotic-Induced Metabolic Disturbances: A Systematic Review and Network Meta-Analysis","Chen Y","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent08","systematic review and network meta-analysis of RCTs of metformin and GLP-1 RAs for antipsychotic metabolic disturbance",1],["R0002620","Comparing Out-of-Pocket Costs and Health-Related Quality of Life Between Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes.","Hu S","2025","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent08","cross sectional MEPS survey comparing costs and quality of life between SGLT2i and GLP-1 RA users",1],["R0002768","Pulmonary adverse events associated with GLP-1 receptor agonists: a systematic review of respiratory safety signals.","Ahuja A","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent08","PROSPERO registered systematic review of respiratory adverse events with GLP-1 RAs; PubMed, Embase, Scopus searched",1],["R0002837","GLP-1 receptor agonists in patients with chronic kidney disease and either overweight or obesity.","Abasheva D","2024","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent08","narrative review of GLP-1 receptor agonists in CKD with overweight or obesity",1],["R0002883","Efficacy of Glucagon-like Peptide-1 Receptor Agonists in Overweight/Obese and/or T2DM Adolescents: A Meta-analysis Based on Randomized Controlled Trials.","Dai M","2024","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent08","meta-analysis of RCTs of GLP-1 RA versus placebo in adolescents with obesity or type 2 diabetes; four databases",1],["R0002949","Exploring the clinical effectiveness of glucagon-like peptide-1 receptor agonists in managing cardiovascular complications: an updated comprehensive review and future directives.","Joshi N","2024","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent08","narrative review of GLP-1 receptor agonists and cardiovascular complications",1],["R0002636","Comparative Outcomes of Glucagon-Like Peptide-1 Receptor Agonists to Dipeptidyl Peptidase 4 Inhibitors in Patients With Heart Failure and Type 2 Diabetes.","Kishimori T","2025","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent14","TriNetX cohort GLP-1 RA vs DPP-4i initiators with HF and T2D, death and hospitalization only",1],["R0002701","Association of incretin-based therapies with hepatobiliary disorders among patients with type 2 diabetes: a case series from the FDA adverse event reporting system.","Liang Y","2024","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent14","FAERS analysis of hepatobiliary adverse event reports with incretin therapies",1],["R0002791","Cost-Effectiveness of Obesity Treatments: Glucagon-Like Peptide-1 Receptor Agonists, Endoscopic Sleeve Gastroplasty, and Metabolic/Bariatric Surgery.","Huh YJ","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent14","review of cost effectiveness evidence for GLP-1 RAs, endoscopic and bariatric surgery",1],["R0002847","Characterizing Geographic Variation in GLP-1 Receptor Agonist Prescribing Using Interpretable Machine Learning","Chu Z","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent14","geographic variation in GLP-1 RA prescribing analyzed with machine learning, no exposure comparison",1],["R0002902","Glucagon-like peptide-1 receptor agonist in myocardial infarction and atherosclerotic cardiovascular disease risk reduction: a comprehensive meta-analysis of number needed to treat, efficacy and safety.","Tang ASP","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent14","systematic review and meta-analysis of RCTs of GLP-1 RA on myocardial infarction, Medline and Embase searched",1],["R0002972","Effects of Oral Semaglutide on Dietary Intake and Body Composition in Japanese People With Type 2 Diabetes: A Prospective Observational Study in Clinical Practice.","Sawada M","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent14","prospective observational before and after study of oral semaglutide in 25 Japanese T2D patients, no comparison group",1],["R0001592","Clinical Evidence for GLP-1 Receptor Agonists in Alzheimer's Disease: A Systematic Review.","Liang Y","2024","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent11","PRISMA systematic review of GLP-1RA RCTs in Alzheimer disease; PubMed, Embase, Cochrane searched with stated criteria",1],["R0001651","Effect of glucagon-like peptide-1 receptor agonists on gastric mucosal visibility during upper endoscopy in Asian patients with diabetes.","Oh YE","2025","include_harms",null,"primary_report",null,"O36B; O36A",null,"high","first","opus-5.5-agent11","propensity matched endoscopy cohort, GLP-1RA versus DPP-4i users; inadequate mucosal visibility from residue and aspiration assessed",1],["R0001707","The long-term cardiovascular safety and efficacy of glucagon-like peptide-1 (GLP-1) receptor agonists in high-risk cardiovascular populations: a systematic review and meta-analysis.","Peter K","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent11","registered meta-analysis of placebo controlled GLP-1RA cardiovascular outcome trials; three named databases",1],["R0001768","Semaglutide and Follow-On Peptide Therapeutics: Balancing Innovation, Regulation, and Clinical Outcomes.","Teli B","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent11","narrative review of regulation and manufacturing of follow-on semaglutide products",1],["R0001833","Glucagon-like peptide-1 agonists in children with obesity and type 2 diabetes. an umbrella review.","Mirghani H","2026","include_review",null,"systematic_review",null,null,"umbrella_review","high","first","opus-5.5-agent11","umbrella review of meta-analyses of GLP-1RAs in pediatric obesity and diabetes; three named databases",1],["R0001898","Exploring the Use of GLP-1-Based Interventions for Obesity: A Qualitative Analysis of ClinicalTrials.gov Data.","Alourfi NM","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent11","descriptive and thematic analysis of ClinicalTrials.gov registrations; no exposure comparison or participants; alternative E3 meta-research",1],["R0001964","M4 drug discovery: human drug predictions from integrated preclinical insights exemplified with a GLP-1R agonist","Silfvergren O","2025","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent11","modeling framework built on cell culture and animal exenatide data; no new human study",1],["R0002015","The Influence of Glucagon-like Peptide-1 Receptor Agonists and Other Incretin Hormone Agonists on Body Composition.","Chrysavgis L","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent11","narrative review of incretin agonists and body composition without systematic methods",1],["R0003115","Efficacy of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists on proteinuria and weight in a diabetes cohort.","Lu DF","2025","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent06","clinic cohort comparing GLP-1 RA, SGLT2 inhibitor and matched controls in T2D; albuminuria, eGFR, glucose, weight only",1],["R0003230","Patients With Severe Obesity Are Made Eligible for Complex Abdominal Wall Repair After Preoptimization With GLP-1 Agonists: Results of a Bicentric Pilot Study.","Romain B","2025","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent06","preoperative GLP-1 RA group versus historical cohort before hernia repair; weight loss and surgical complications not in harms list",1],["R0003294","Projected reduction in major adverse cardiovascular events among high-risk U.S. adults with type 2 diabetes eligible for oral semaglutide: a SOUL trial-based analysis using NHANES (1988-2018) cycles.","Al-Jarshawi M","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent06","modeling study projecting MACE reduction by applying SOUL trial effects to NHANES population",1],["R0003366","Association of GLP-1 Receptor Agonists With Risk of Suicidal Ideation and Behaviour: A Systematic Review and Meta-Analysis.","Bushi G","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent06","systematic review and meta-analysis of observational studies on GLP-1 RAs and suicidal ideation or behavior; three databases",1],["R0003433","Retrospective real-world database study to examine the prevalence and incidence of cardiovascular diseases and medication prescription in Japanese patients with type 2 diabetes.","Komatsu M","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent06","descriptive database study of CVD prevalence, incidence and prescription patterns in Japanese T2D; no GLP-1 RA exposure comparison",1],["R0002063","GLP-1 Receptor Agonists - Good for Body Weight, Bad for Micronutrient Status?","Kerlikowsky F","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent13","perspective style brief report summarizing evidence on GLP-1 agonists and micronutrient status, no systematic synthesis",1],["R0002121","Dapagliflozin Alone or Combined With Semaglutide: Cardiovascular and Renal Outcomes Among Patients With Type 2 Diabetes Mellitus in a 6-Month Real-World Retrospective Cohort Study in Saudi Arabia.","Alharajin R","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent13","retrospective cohort dapagliflozin alone vs with semaglutide, glycemic, cardiovascular and renal function outcomes only",1],["R0002179","GLP-1RA plus SGLT2i combination therapy and liver fibrosis progression in MASLD with type 2 diabetes.","Choi J","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent13","cohort GLP-1 plus SGLT2 inhibitor vs GLP-1 alone in MASLD, fibrosis progression and hepatic complications only",1],["R0002250","Cardiovascular and Cerebrovascular Outcomes Risk Reduction Associated With Semaglutide vs Tirzepatide: A Target Trial Emulation.","Azzam AY","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent13","target trial emulation semaglutide vs tirzepatide with cardiovascular and cerebrovascular outcomes only",1],["R0002307","Evaluating the clinical effects of GLP-1 receptor agonists for Alzheimer's and Parkinson's diseases using minimal clinically important difference: systematic review and meta-analysis.","Elghanam Y","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent13","PROSPERO registered meta-analysis of RCTs of GLP-1 agonists in Alzheimer and Parkinson disease",1],["R0002386","Glucagon-like Peptide-1 Receptor Agonists and Suicidal Ideation: Analysis of Real-Word Data Collected in the European Pharmacovigilance Database.","Ruggiero R","2024","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent13","EudraVigilance disproportionality analysis of suicidal events across GLP-1 agonists",1],["R0002452","Ketoacidosis Risk in Non-diabetic Patients Using Semaglutide Versus Tirzepatide for Obesity: A Disproportionality Analysis of the FDA Adverse Event Reporting System.","Makhmutov A","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent13","FAERS disproportionality analysis of ketoacidosis with semaglutide vs tirzepatide",1],["R0002515","Real-World Comparisons Between Glucagon-Like Peptide-1 Receptor Agonists and Other Glucose-Lowering Agents in Type 2 Diabetes: Retrospective Analyses of Cardiovascular and Economic Outcomes in England.","Connolly D","2025","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent13","CPRD cohort GLP-1 vs DPP-4 inhibitors or basal insulin, MACE, death and costs only",1],["R0002594","Gastrointestinal Safety Assessment of GLP-1 Receptor Agonists in the US: A Real-World Adverse Events Analysis from the FAERS Database.","Osei SP","2024","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent20","FAERS pharmacovigilance disproportionality analysis of GLP-1 RA gastrointestinal adverse events",1],["R0001605","The association between glucagon-like peptide-1 receptor agonists and reported musculoskeletal adverse events: a systematic review and meta-analysis of randomized controlled trials.","Cao M","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent15","registered systematic review and meta-analysis of 43 RCTs of GLP-1 receptor based agonists on musculoskeletal adverse events",1],["R0001660","Knowledge, attitudes, and practices of Saudi physicians toward the use of SGLT-2 inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes mellitus: a nationwide cross-sectional study.","Alrasheed MA","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent15","knowledge, attitude and practice survey of physicians about SGLT2i and GLP-1 RA prescribing; no patient exposure comparison",1],["R0002735","A Review and Meta-Analysis of the Safety and Efficacy of Using Glucagon-like Peptide-1 Receptor Agonists.","Hu EH","2024","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent20","narrative overview of GLP-1 RA trials despite meta-analysis label, no methods or search described",1],["R0002813","Glucagon-like peptide 1 receptor agonists and the clinical outcomes of inflammatory bowel disease: a systematic review and meta-analysis.","Bayoumy AB","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent20","PRISMA meta-analysis of GLP-1 RA use and IBD outcomes, four databases searched, OSF registered",1],["R0002860","GLP-1 Receptor Agonist Use in Patients Undergoing Distal Radius Fracture Surgery: A Retrospective Review of Perioperative Considerations.","Khak M","2025","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent20","retrospective distal radius surgery review, complications abstracted only for 46 GLP-1 RA users, no comparison for aspiration",1],["R0002924","Glucagon-like peptide-1 receptor agonists for prevention of heart failure events in type 2 diabetes and/or obesity.","Raveendra K","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent20","PROSPERO registered meta-analysis of placebo controlled GLP-1 RA RCTs on heart failure events",1],["R0002983","Impact of GLP-1 Receptor Agonist Therapy on Atrial Fibrillation Recurrence After Catheter Ablation in Obese Patients: A Real-World Data Analysis.","Venier S","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent20","TriNetX matched cohort of GLP-1 RA users vs nonusers after AF ablation, arrhythmia HF and mortality outcomes only",1],["R0001715","Impact of Glucagon-Like Peptide-1 Receptor Agonist Exposure on Gastrointestinal Outcomes Among ICU Patients: A Multicenter Matched Cohort Study.","Gmehlin CG","2025","include_harms",null,"primary_report",null,"O37B",null,"high","first","opus-5.5-agent15","matched ICU cohort, pre admission GLP-1 RA exposure versus none; ileus and obstruction among gastrointestinal outcomes",1],["R0001786","Systematic Review Evaluating the Effects of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Use on the Postoperative Outcomes of Patients Undergoing Arthroplasty Procedures.","Tabor H","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent15","PRISMA systematic review of four sources on preoperative GLP-1 RA use and arthroplasty outcomes; narrative synthesis of 15 cohorts",1],["R0001912","Initiation of GLP-1 Receptor Agonists Treatment after Bariatric Metabolic Surgery and Major Adverse Cardiac Events.","Reges O","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent15","Clalit matched cohort after bariatric surgery, GLP-1 RA initiators versus nonusers; MACE, mortality, BMI and HbA1c only",1],["R0001979","Systematic Review: Efficacy, Safety and Metabolic Outcomes of GLP-1 Receptor Agonists in Inflammatory Bowel Disease.","Maracle B","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent15","registered PRISMA systematic review of GLP-1 RA outcomes in inflammatory bowel disease, mostly cohorts comparing users and nonusers",1],["R0002028","Responses to GLP-1RA in White and Black Adults With Obesity: Insights From Generalized Additive Mixed Models of EHR Data.","Mallette JH","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent15","EHR cohort of GLP-1 RA users only, comparing White and Black adults; no unexposed or active comparator group",1],["R0002658","Relative efficacy of GLP-1 and GLP-1/GIP receptor agonists in the prevention of alcohol-use disorders using a target trial emulation approach.","Henney AE","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent02","target trial emulations of incretin drugs vs DPP-4 inhibitor on incident alcohol use disorder; no listed harm outcome",1],["R0002818","GZR18, a GLP-1 analog with once-weekly or bi-weekly dosing for body weight management: A randomized, placebo-controlled, phase 1b/2a trial.","Ji L","2026","include_nma",null,"primary_report","P02",null,null,"high","first","opus-5.5-agent02","randomized placebo controlled phase 1b/2a trial of GZR18 weekly or biweekly in adults with overweight or obesity",1],["R0002865","Clinical Outcomes Associated with GLP-1 Receptor Agonist Exposure in Non-Diabetic Patients with Chronic Pancreatitis: A Retrospective Cohort Study.","Dhali A","2026","include_harms",null,"primary_report",null,"O29; O38",null,"high","first","opus-5.5-agent02","TriNetX matched cohort GLP-1 RA exposed vs unexposed nondiabetic chronic pancreatitis; acute pancreatitis and pancreatic cancer reported; exposure not new user",1],["R0002930","Real-world clinical outcomes of tirzepatide administration in older patients with type 2 diabetes, with a focus on the risk of hypoglycemia and weight loss-related parameters.","Kitsunai H","2026","inventory_only","N5","secondary_report",null,null,null,"high","first","opus-5.5-agent02","secondary analysis of retrospective observational single group tirzepatide study in older adults; no comparison group",1],["R0002985","Impact of Glucagon-like Peptide-1 Receptor Agonists on Mental Illness: Evidence from a Mendelian Randomization Study.","Xiang L","2025","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent02","Mendelian randomization using GLP1R genetic variants as drug proxy; no drug exposure",1],["R0001617","Intraductal Papillary Mucinous Neoplasms and GLP-1 Receptor Agonists: Navigating Therapeutic Uncertainty in Diabetes Management.","Tassone F","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent19","viewpoint essay on GLP-1 RA use in patients with pancreatic IPMN; opinion, no primary data",1],["R0001793","Machine learning algorithms for predicting glycemic control and weight loss outcomes in GLP-1 receptor agonist users.","Abegaz TM","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent19","machine learning prediction of response among GLP-1 RA initiators in All of Us; no comparison group",1],["R0001855","Risk of Non-Arteritic Anterior Ischemic Optic Neuropathy in Idiopathic Intracranial Hypertension Patients Treated with GLP-1 Receptor Agonists.","Al-Harbi FA","2026","include_harms",null,"primary_report",null,"O34",null,"high","first","opus-5.5-agent19","TriNetX cohort of IIH patients, GLP-1 RA from first prescription vs unexposed, propensity matched; NAION primary outcome",1],["R0001922","Who Wins the Battle Against Obesity? A Network Meta-Analysis Comparing Tirzepatide and Semaglutide.","Bernardi JC","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent19","network meta-analysis of RCTs of tirzepatide and semaglutide in obesity; PubMed Embase Cochrane searched",1],["R0002037","Glucagon-like peptide-1 receptor agonists and pancreatitis: A reconcilable divorce.","Mehta AE","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent19","narrative CME review on GLP-1 RA and pancreatitis without systematic methods",1],["R0003047","Management of Obesity in Psoriasis Consultations.","Nicolau J","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent04","editorial style narrative commentary proposing obesity management algorithm in psoriasis, no primary data or systematic methods",1],["R0003103","Risk of major adverse cardiovascular events and all-cause mortality under treatment with GLP-1 RAs or the dual GIP/GLP-1 receptor agonist tirzepatide in overweight or obese adults without diabetes: a systematic review and meta-analysis.","Stefanou MI","2024","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent04","registered systematic review and meta-analysis of placebo controlled RCTs of GLP-1 RA or tirzepatide in obesity without diabetes, MACE and mortality",1],["R0003164","GLP-1 Receptor Agonists in Kidney Transplant Recipients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis on Mortality and Major Adverse Kidney Events","Aliyeva T","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent04","systematic review and meta-analysis of three databases, cohort studies of GLP-1 RA in kidney transplant recipients, pooled hazard ratios",1],["R0003223","Potential protective role of GLP-1 receptor agonists for lithium-induced nephrotoxicity: a population-based observational study.","McIntyre RS","2025","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent04","FAERS disproportionality analysis of renal adverse event reports for lithium and semaglutide",1],["R0003287","Medication Adherence to Semaglutide versus Empagliflozin in Adults with Type 2 Diabetes: A Retrospective Observational Study in Saudi Arabia.","Ali MAS","2025","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent04","retrospective comparison of semaglutide vs empagliflozin users on adherence, HbA1c and BMI, no eligible harms outcome",1],["R0003359","Glucagon-like peptide-1 receptor agonists are associated with fewer venous thromboembolic events and limb complications in obese patients with chronic venous insufficiency.","Micalo L","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent04","TriNetX matched cohort GLP-1 RA vs none in venous insufficiency, DVT, PE, ulcers, infection, mortality, none in harms list",1],["R0003429","Effects of subcutaneous or oral semaglutide on cardiovascular outcomes in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials.","Tan S","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent04","registered meta-analysis of RCTs of oral or subcutaneous semaglutide on cardiovascular outcomes, pooled hazard ratios",1],["R0003491","Real‑World Safety Signals of Tirzepatide Versus GLP‑1RAs: A Machine Learning Analysis of FDA FAERS Data","Wang SY","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent04","FAERS pharmacovigilance analysis with machine learning comparing tirzepatide and other GLP-1 RA report patterns",1],["R0002525","Glucagon-Like Peptide 1 Receptor Agonists and Chronic Lower Respiratory Disease Among Type 2 Diabetes Patients: Replication and Reliability Assessment Across a Research Network.","Conover MM","2025","inventory_only","N6","secondary_report",null,null,null,"high","first","opus-5.5-agent16","replication and network extension of new user GLP-1RA versus DPP4i cohort; chronic lower respiratory disease outcomes only, not a systematic review",1],["R0002586","What Are the Experiences, Views and Perceptions of Patients, Carers and Clinicians of Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs)? A Scoping Review.","Febrey S","2025","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent16","scoping review of qualitative studies on experiences with GLP-1RAs; no exposure comparison synthesized; alternative include_review",1],["R0002645","Semaglutide in Diabetic Kidney Disease: Integrating Clinical Evidence with Mechanistic Insights.","Bin Dayel FF","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent16","narrative review of semaglutide in diabetic kidney disease without systematic methods",1],["R0002714","Incremental effects of SGLT2 inhibitors, GLP-1 receptor agonists, and pioglitazone in type 2 diabetes and MASLD across Asian study settings: a systematic review and meta-analysis.","Zheng H","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent16","registered systematic review and pairwise meta-analysis of add-on GLP-1RA, SGLT2i or pioglitazone RCTs in Asian T2D with MASLD",1],["R0002852","Exploration of the potential association between GLP-1 receptor agonists and suicidal or self-injurious behaviors: a pharmacovigilance study based on the FDA Adverse Event Reporting System database.","Zhou J","2024","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent16","FAERS disproportionality analysis of GLP-1RAs and suicidal or self injurious behavior",1],["R0002908","Efficacy and safety of semaglutide for obesity and hyperphagia in adults with Prader-Willi syndrome.","Ahmed S","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent16","retrospective uncontrolled cohort of 12 adults with Prader-Willi syndrome on semaglutide, pre post comparison only",1],["R0002975","Long-Term Efficacy Trajectories of GLP-1 Receptor Agonists: A Systematic Review and Network Meta-Analysis.","Li Z","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent16","PROSPERO registered systematic review and NMA of GLP-1RA versus placebo RCTs in T2D over follow up periods",1],["R0002511","Glucagon-like peptide-1 receptor agonist in large vessel occlusion treated by reperfusion therapy-a phase 2 randomized trial.","Wang H","2025","include_nma",null,"primary_report","P99",null,null,"high","first","opus-5.5-agent12","phase 2 open label RCT semaglutide plus reperfusion vs reperfusion alone in large vessel occlusion stroke, reports serious adverse events",1],["R0002697","Novel Use of Glucagon-Like Peptide-1 (GLP-1) and Dual Glucose-Dependent Insulinotropic Polypeptide (GIP)/GLP-1 Receptor Agonists in Maturity-Onset Diabetes of the Young (MODY).","Hilal A","2025","inventory_only","N5","primary_report","P99",null,null,"high","first","opus-5.5-agent12","case series of six MODY patients treated with GLP-1RA or tirzepatide",1],["R0002788","Efficacy and safety of tirzepatide in subjects with type 2 diabetes and chronic kidney disease: a prospective, two-arm observational study.","Oe Y","2025","inventory_only","N6","primary_report","P08A",null,null,"high","first","opus-5.5-agent12","prospective nonrandomized two arm study, patient chosen switch to tirzepatide vs continued dulaglutide in T2D CKD, glycemic outcomes",1],["R0002843","Glucagon-Like Peptide-1 Receptor Agonist-Experienced Adults with Type 2 Diabetes Switching to Once-Weekly Semaglutide in a Real-World Setting: SURE Program Post Hoc Analysis.","Rudofsky G","2025","inventory_only","N5","secondary_report","P01",null,null,"high","first","opus-5.5-agent12","post hoc analysis of single arm observational SURE program, GLP-1RA experienced switchers to semaglutide",1],["R0002894","Real-world effectiveness of GLP-1RAs on Time in Range in pati ents with type 2 diabetes: A retrospective study","Chen Y","2023","inventory_only","N6","primary_report","P01",null,null,"high","first","opus-5.5-agent12","retrospective matched cohort GLP-1RA vs oral agents in T2D, time in range outcomes, no listed harm",1],["R0002966","Using large language models to assess public perceptions around glucagon-like peptide-1 receptor agonists on social media.","Somani S","2024","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent12","topic modeling of Reddit discussions about GLP-1RAs, no drug exposure comparison",1],["R0003095","Use of SGLT2 inhibitors and GLP-1 receptor agonists in patients with ischaemic heart disease and type 2 diabetes in Swedish primary care: a cross-sectional analysis of regional primary care registry data (QregPV).","Andersson T","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent01","cross sectional registry analysis of SGLT2 inhibitor and GLP-1 RA dispensing rates and costs; drug utilization without exposure comparison",1],["R0003154","Cardiorenal Protection in Type 2 Diabetes: A Systematic Review Comparing Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors.","Branigan P","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent01","systematic review comparing GLP-1 RAs and SGLT2 inhibitors on cardiorenal outcomes with structured narrative synthesis, three databases searched",1],["R0003277","Novel antidiabetic agents and the risk of respiratory diseases: a systematic review and meta-analysis of 27 randomized controlled trials.","Yu Z","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent01","registered pairwise and network meta-analysis of large RCTs of GLP-1 RAs, SGLT2i and DPP-4i on respiratory diseases",1],["R0003350","Temporal Changes in SGLT2 Inhibitor and GLP-1 Receptor Agonist Use in Patients with Chronic Kidney Disease and Type 2 Diabetes, 2012-2023: A US Cohort Study.","Johannes CB","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent01","descriptive drug utilization study of SGLT2i and GLP-1 RA new users in CKD with diabetes; no comparative outcome analysis",1],["R0003487","Efficacy of 12 months therapy with glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on weight regain after bariatric surgery: a real-world retrospective observational study.","Jensen AB","2025","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent01","retrospective GLP-1 RA treated cohort after bariatric surgery with before and after weight analysis; liraglutide versus semaglutide secondary, alternative N6",1],["R0002538","Cardiovascular and renal outcomes of dual combination therapies with glucagon-like peptide-1 receptor agonists and sodium-glucose transport protein 2 inhibitors: a systematic review and meta-analysis.","Shokravi A","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent03","systematic review and meta-analysis of GLP-1 RA plus SGLT2i combination vs monotherapy, MEDLINE and Embase searched",1],["R0002609","Advances in the Pharmacological Treatment of Heart Failure With Preserved Ejection Fraction.","Valente V","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent03","narrative review of pharmacological treatment of HFpEF",1],["R0002668","Dose-Escalation Regimens for Incretin Mimetics in Type 2 Diabetes Are Associated With Tolerance for Nausea and Vomiting.","Nauck MA","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent03","dose response curve fitting of nausea and vomiting from published trials without own named database search",1],["R0002824","Additive Benefits of Control-IQ+ AID to GLP-1 Receptor Agonist Use in Adults With Type 2 Diabetes.","Graham TE","2025","inventory_only","N3","secondary_report","P01",null,null,"high","first","opus-5.5-agent03","subgroup of RCT of automated insulin delivery vs CGM in GLP-1 RA users; GLP-1 continued unchanged in both arms",1],["R0002866","Muscle health in the modern era of incretin-based therapies.","De Girolamo G","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent03","self described narrative review of incretin therapy effects on skeletal muscle",1],["R0002934","Recent advances in mineralocorticoid receptor antagonists for heart failure with preserved ejection fraction: focus on finerenone in the era of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists.","Wang TY","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent03","narrative review of finerenone in HFpEF alongside SGLT2i and GLP-1 RA",1],["R0002990","The Risk of Vestibular Disorders with Semaglutide and Tirzepatide: Findings from a Large Real-World Cohort.","Toraih EA","2025","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent03","TriNetX matched cohort semaglutide or tirzepatide vs nonusers; vestibular disorders only, not a listed harm",1],["R0001289","HRS-7535, an oral small-molecule GLP-1 receptor agonist, in Chinese adults with obesity without diabetes: a randomized, double-blind, placebo-controlled phase 2 trial.","Gu W","2026","include_nma",null,"primary_report","P02",null,null,"high","first","opus-5.5-agent17","phase 2 placebo controlled RCT of four oral HRS-7535 doses in Chinese adults with obesity without diabetes, 26 weeks",1],["R0001721","THR-β Agonists vs Incretin Therapies for Noncirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH): A Biopsy-Anchored Systematic Review With Grading of Recommendations Assessment, Development and Evaluation (GRADE) Certainty.","Alzaki AA","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent17","registered systematic review of RCTs in biopsy confirmed MASH including GLP-1 RAs and tirzepatide, PubMed Embase CENTRAL search with GRADE",1],["R0001790","Medical Management of Obesity: A Comprehensive Review of Food and Drug Administration (FDA)-Approved and Investigational Therapies.","Raza SS","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent17","self described narrative review of approved and investigational obesity drugs",1],["R0001845","GLP-1 Receptor Agonists Versus DPP-4 Inhibitors and Incident Dementia Risk in COVID-19 Survivors with Type 2 Diabetes: A Target Trial Emulation Study.","Hung KC","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent17","target trial emulation of GLP-1 RA versus DPP-4 inhibitor in COVID survivors with diabetes; dementia, glycemic and mortality outcomes only",1],["R0001919","Incidence of Glaucoma in Type 2 Diabetes Patients Treated With GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis.","Asif M","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent17","registered systematic review and meta-analysis of observational studies on glaucoma with GLP-1 RA versus other glucose lowering drugs",1],["R0001984","Fixed-ratio combinations of basal insulin and glucagon-like peptide-1 receptor agonists as a promising strategy for treating diabetes.","Nomoto H","2023","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent17","narrative review of fixed ratio basal insulin and GLP-1 RA combinations without systematic search",1],["R0001590","Aesthetic Use of Poly-L-Lactic Acid and Hyaluronic Acid Fillers in Medication-Driven Weight Loss Due to GLP-1 Receptor Agonists: Real-World Case Series from Latin America.","Avelar LET","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent10","retrospective case series of 15 women on GLP-1 RA treated with facial fillers; no comparison group",1],["R0001648","Sodium-Glucose Cotransporter 2 Inhibitors Prevent Nephrolithiasis in Patients with Diabetes: A TriNetX-Based Real-World Global Comparison.","Liu CM","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent10","TriNetX cohort SGLT2i versus DPP-4i and GLP-1 RA; nephrolithiasis outcome only, not in harms_nrs",1],["R0001702","Comparative effects of SGLT2 inhibitors and GLP-1 receptor agonists on osteoarthritis risk in patients with type 2 diabetes mellitus: A multi-institutional cohort study.","Jao WY","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent10","TriNetX new user cohort SGLT2i versus GLP-1 RA; osteoarthritis and arthroplasty outcomes only",1],["R0001767","Association between different GLP-1 receptor agonists and acute pancreatitis: case series and real-world pharmacovigilance analysis.","Guo H","2024","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent10","case series from literature plus FAERS disproportionality analysis of pancreatitis with GLP-1 RAs",1],["R0001832","Orforglipron for obesity treatment in older patients ≥65 years with or without type 2 diabetes: A post hoc subgroup analysis of the ATTAIN-1 and ATTAIN-2 trials.","Horn DB","2026","include_nma",null,"secondary_report","P02; P01",null,null,"high","first","opus-5.5-agent10","post hoc age 65 plus subgroup of ATTAIN-1 and ATTAIN-2 RCTs orforglipron versus placebo; weight and HbA1c",1],["R0001962","A retrospective analysis of combination therapy with GLP-1 receptor agonists and SGLT2 inhibitors versus SGLT2 inhibitor monotherapy in patients with MASLD.","Wu JY","2025","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent10","TriNetX cohort GLP-1 RA plus SGLT2i versus SGLT2i in MASLD; MACE, kidney failure, liver events, HCC only",1],["R0002011","Neurobeachin (NBEA) is a novel gene associated with GLP-1 receptor agonist associated weight loss.","Mariam-Smith A","2025","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent10","genetic association study within GLP-1 RA users only; weight response by NBEA score, no exposure comparison",1],["R0002548","Real-World Effectiveness of Tirzepatide versus Semaglutide on HbA1c and Weight in Patients with Type 2 Diabetes.","Hoog MM","2025","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent07","claims cohort of tirzepatide vs semaglutide initiators with HbA1c and weight outcomes only",1],["R0002619","A Hypothesis That Glucagon-like Peptide-1 Receptor Agonists Exert Immediate and Multifaceted Effects by Activating Adenosine Monophosphate-Activate Protein Kinase (AMPK).","Schooling CM","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent07","hypothesis paper proposing AMPK activation as GLP-1RA mechanism; no primary data",1],["R0002681","Incretin-based therapies for the management of cardiometabolic disease in the clinic: Past, present, and future.","Psaltis JP","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent07","narrative review of incretin therapies in cardiometabolic disease",1],["R0002757","Inflammatory biomarker response to GLP-1 receptor agonists versus other glucose-lowering medications in patients with type 2 diabetes: a systematic review and meta-analysis.","Alrasheed T","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent07","PROSPERO registered meta-analysis of RCTs of GLP-1RA vs other drugs or placebo on inflammatory biomarkers in type 2 diabetes",1],["R0002832","Various GLP-1 Receptor Agonist Preference Use with a Special Focus on Oral and Subcutaneous Forms in Poland.","Nowak K","2025","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent07","descriptive drug utilization study of GLP-1RA prescriptions in Poland without an exposure outcome comparison",1],["R0002945","Comparative neuroprotective effects of antidiabetic medications on Parkinson's disease risk: a Bayesian network meta-analysis.","Lee SH","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent07","PROSPERO registered Bayesian network meta-analysis of cohorts comparing antidiabetic classes including GLP-1RA on Parkinson risk",1],["R0003092","Reply to correspondence on \"Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: a network meta-analysis\".","Ren TY","2024","inventory_only","N9","ancillary",null,null,null,"high","first","opus-5.5-agent20","authors reply to correspondence on a network meta-analysis of GLP-1 RAs vs thiazolidinediones in MASLD",1],["R0003152","Weight Loss-Dependent Changes in Body Composition and Bone Health in People With Obesity and Type 1 Diabetes Treated With Liraglutide, Semaglutide, or Tirzepatide.","Al Ozairi E","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent20","prospective observational before and after study of GLP-1 RA or tirzepatide in type 1 diabetes with obesity, no unexposed comparison",1],["R0003216","Model-based network meta-analysis: Joint estimation of dose-response and time-course relationships.","Strathe A","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent20","statistical methods paper proposing dose and time course MBNMA, illustrated on seven GLP-1 RA obesity trials without systematic search",1],["R0003268","Pharmacokinetic Characteristics of a Once-Weekly Combination Therapy of Insulin Icodec and Semaglutide Versus Its Separate Components in Chinese Individuals with Type 2 Diabetes.","Wang F","2025","include_nma",null,"primary_report","P01",null,"mechanistic; crossover","high","first","opus-5.5-agent20","randomized double blind three period crossover PK study of IcoSema vs icodec vs semaglutide in T2D, adverse events reported",1],["R0003341","Association of glucagon-like peptide-1 receptor agonist use with patient-reported outcomes after lumbar decompression or fusion.","Parker J","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent20","single center matched cohort of GLP-1 RA users vs nonusers after lumbar surgery, PROMs and readmissions only",1],["R0003420","Dulaglutide versus empagliflozin as add-on therapy to metformin and sulfonylurea in type 2 diabetes: a randomized pilot study with exploratory metabolomic and microbiome analyses.","Jun JE","2026","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent20","randomized open label pilot trial of dulaglutide vs empagliflozin added to metformin and sulfonylurea, HbA1c at 12 weeks",1],["R0003486","Effects of glucagon-like peptide 1 receptor agonists on testicular dysfunction: A systematic review and meta-analysis.","Salvio G","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent20","PROSPERO registered meta-analysis of GLP-1 RA effects on testosterone and sperm, three databases",1],["R0003540","Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Use and Inflammatory Markers Among U.S. Adults: A National Health and Nutrition Examination Survey (NHANES)-Based Analysis.","Youkhana S","2025","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent20","NHANES cross sectional analysis of GLP-1 RA use and hs-CRP",1],["R0003002","Renal or Hepatic Impairment Does Not Affect Pharmacokinetics, Safety, or Tolerability of Subcutaneous Cagrilintide.","Nielsen MJF","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent08","phase 1 pharmacokinetic studies of single dose cagrilintide alone in renal or hepatic impairment; no GLP-1 RA given",1],["R0003056","Association between dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 receptor agonists and COVID-19 infection and adverse outcomes: a cohort study.","Thompson W","2025","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent08","Ontario cohort of DPP4i or GLP-1 RA versus SGLT2i or SU users; COVID-19 infection and severity outcomes only",1],["R0003117","Cardiometabolic Comorbidities in COPD: Focus on Diabetes, GLP-1 Receptor Agonists, SGLT-2 Inhibitors and Antidiabetic Drugs.","Kallieri M","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent08","self described narrative review of COPD and type 2 diabetes therapies",1],["R0003299","GLP-1 Receptor Agonists and Clinical Outcomes after Endovascular Treatment of Unruptured Aneurysms in Type 2 Diabetes.","Perng PS","2025","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent08","TriNetX matched cohort of GLP-1 RA users after aneurysm coiling; mortality, hemorrhage, hydrocephalus; no harms list outcome",1],["R0003563","Glucagon-like Receptor-1 agonists for obesity: Weight loss outcomes, tolerability, side effects, and risks.","Ghusn W","2024","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent06","clinical narrative review of GLP-1 RA side effects for obesity with expert opinion; no eligibility criteria or synthesis",1],["R0003628","Effect of liraglutide on depressive symptoms in overweight or obese patients with type 2 diabetes: protocol for a pilot randomized controlled trial.","Fang W","2025","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent06","protocol of a pilot placebo controlled RCT of liraglutide for depressive symptoms in T2D with obesity; no results",1],["R0003692","Combination of Glucagon-Like Peptide 1 Receptor Agonist and Thiazolidinedione for Mortality and Cardiovascular Outcomes in Patients With Type 2 Diabetes.","Li JX","2025","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent06","Taiwan cohort of GLP-1 RA plus thiazolidinedione versus monotherapy or nonuse; mortality, cardiovascular and hypoglycemia outcomes only",1],["R0003777","Long-term prognostic impact of glucagon-like peptide-1 receptor agonist before ST-segment elevation myocardial infarction in patients with type 2 diabetes: a nationwide cohort study.","Madsen JM","2025","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent06","Danish cohort of STEMI patients with versus without prior GLP-1 RA; mortality, stroke, MI, heart failure outcomes only",1],["R0003852","A scoping review of obesity policies and reimbursement landscape: global insights and lessons for Thailand.","Rawdaree P","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent06","scoping review of obesity policies and drug reimbursement; no GLP-1 RA exposure comparison",1],["R0003910","Effectiveness & safety of semaglutide in weight reduction in obese nondiabetic patients: A systematic review and meta-analysis.","Naz F","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent06","systematic review and meta-analysis of RCTs of semaglutide versus placebo for weight in adults without diabetes",1],["R0004056","Glucagon-Like Peptide-1 Receptor Agonists for Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: A Meta-Analysis.","Wong C","2021","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent06","meta-analysis of RCTs and cohorts of GLP-1 RAs versus comparators for NAFLD in T2D; Medline, Embase, CENTRAL searched",1],["R0003118","Beyond Skin Laxity: GLP-1 Receptor Agonist-Induced Lean Mass Depletion and Surgical Tissue Quality in Aesthetic Surgery: A Narrative Review.","Cuggy C","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent09","self described narrative review on lean mass loss with GLP-1 agonists in aesthetic surgery",1],["R0003187","8007 The Effect of Glucagon-Like Peptide-1 Receptor Agonists in Reducing Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Bayesian Network Meta-Analysis",null,"2024","include_review",null,"systematic_review",null,null,"abstract_only","high","first","opus-5.5-agent09","congress abstract of Bayesian NMA of GLP-1 agonist cardiovascular outcome trials, three databases named",1],["R0003236","Factors Associated With Initiation of Sodium-Glucose Cotransporter 2 Inhibitor and Glucagon-Like Peptide 1 Receptor Agonists in Patients With Diabetes and Kidney Disease: A Post Hoc Analysis of the Kidney CHAMP Trial.","Lavenburg LU","2025","exclude","E2","secondary_report",null,null,null,"high","first","opus-5.5-agent09","post hoc analysis of cluster trial of care management, GLP-1 and SGLT2 initiation is the outcome not an exposure",1],["R0003380","Glucagon-like receptor-1 agonists and impotence: A meta-analysis.","Mirghani HO","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent09","meta-analysis of studies of GLP-1 agonists on erectile dysfunction with three named databases and criteria, controls included",1],["R0003502","A Review on Semaglutide: An Oral Glucagon-Like Peptide 1 Receptor Agonist in Management of Type 2 Diabetes Mellitus.","Kalra S","2020","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent09","narrative review of oral semaglutide pharmacology and PIONEER program",1],["R0002574","Incretin-based therapies for individuals with obesity and heart failure with mildly reduced or preserved ejection fraction: A systematic review and meta-analysis of randomized controlled trials.","Costa TA","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent13","systematic review and meta-analysis of RCTs of incretin therapies in obesity with HFpEF",1],["R0002633","Glucagon-like peptide-1 receptor agonists therapy to attenuate the risk of knee osteoarthritis and total knee replacement in type 2 diabetes mellitus: A nation-wide population-based cohort study.","Lin CP","2025","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent13","Taiwan claims cohort GLP-1 users vs nonusers with type 2 diabetes, knee osteoarthritis and knee replacement only",1],["R0002698","Weight Regain After GLP-1-Based Therapy Discontinuation: Failure, Physiology, or Follow-Up Gap.","Quimbayo-Cifuentes AF","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent13","editorial on weight regain after stopping GLP-1 based therapy",1],["R0002790","Comparative effectiveness of pharmacotherapy for heart failure with preserved ejection fraction: A systematic review and network meta-analysis.","Chen SH","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent13","PROSPERO registered network meta-analysis of HFpEF pharmacotherapy RCTs including GLP-1 agonists",1],["R0002844","Association Between Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists and Atrial Fibrillation Adverse Events: A Systematic Review and Meta-Analysis of Randomized Trials.","Aiwuyo HO","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent13","systematic review and meta-analysis of GLP-1 agonist RCTs on atrial fibrillation events",1],["R0002895","Nutritional deficiencies and muscle loss in adults with type 2 diabetes using GLP-1 receptor agonists: A retrospective observational study.","Scott Butsch W","2025","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent13","claims cohort of GLP-1 initiators with matched metformin comparison, nutritional deficiencies only",1],["R0002970","Effects of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Neurohumoral and Mitochondrial Activation in Patients With Diabetes.","Ikonomidis I","2025","inventory_only","N6","secondary_report",null,null,null,"high","first","opus-5.5-agent13","propensity matched observational cohort liraglutide, empagliflozin, combination or insulin, cardiac biomarkers and strain only",1],["R0003075","Sex differences in the efficacy of GLP-1 receptor agonists: A systematic review and meta-analysis of cardiovascular and renal outcome trials.","Siddiqui HF","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent14","PROSPERO registered meta-analysis of placebo controlled GLP-1 RA outcome trials by sex, Medline Scopus Cochrane searched",1],["R0003134","GLP-1 receptor agonists in kidney transplant recipients with type 2 diabetes mellitus: a systematic review and meta-analysis on mortality and major adverse kidney events.","Aliyeva T","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent14","systematic review and meta-analysis of cohort studies of GLP-1 RA in kidney transplant recipients, PubMed Embase Cochrane",1],["R0003196","A systematic review of GLP-1 on anthropometrics, metabolic and endocrine parameters in patients with PCOS.","Bader S","2024","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent14","systematic review of GLP-1 RA vs metformin or placebo in PCOS, Medline PubMed Central Cochrane searched with PICOS criteria",1],["R0003254","Clinical Profile of Documented Diabetic Peripheral Neuropathy by GLP-1-Based Medication Status: A Cross-Sectional Study.","Ferician AC","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent14","retrospective cross sectional snapshot comparing neuropathy patients by GLP-1 medication status",1],["R0003391","Efficacy and Safety of Glucagon-Like Peptide-1 Agonists for Psychiatric Symptoms: A Systematic Review.","Meshkat S","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent14","systematic review of GLP-1 RA effects on psychiatric symptoms, MEDLINE PsycINFO Embase searched with inclusion criteria",1],["R0003462","SGLT2 inhibitors, GLP-1 receptor agonists, and their combination in diabetic cardiomyopathy: A prospective cohort study.","Zhang A","2025","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent14","prospective cohort SGLT2i, GLP-1 RA, combination vs neither in diabetic cardiomyopathy, death and HF hospitalization only",1],["R0002078","Reduced Complications and Improved Survival With Postoperative GLP-1 Receptor Agonist Use Following Lumbar Arthrodesis.","Proffitt EB","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent18","TriNetX matched cohort of postoperative GLP-1 RA users vs nonusers after lumbar fusion; infections, VTE, mortality; no listed harms outcome",1],["R0002266","Glucagon-like Peptide-1 Receptor Agonists: Exciting Avenues Beyond Weight Loss.","Sundararaman L","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent18","narrative review of GLP-1 RA effects beyond weight loss; no systematic search",1],["R0002334","Liraglutide vs Semaglutide vs Dulaglutide in Veterans With Type 2 Diabetes.","Derington CG","2025","include_harms",null,"primary_report",null,"O28; O29; O37A; O37B",null,"high","first","opus-5.5-agent18","VA active comparator new user target trial emulation of liraglutide vs semaglutide vs dulaglutide; GI harms reported; head to head within class",1],["R0002401","Acute Pancreatitis Associated With Semaglutide in a Patient With Multimorbidity: A Case Report.","Lo SC","2026","inventory_only","N5","other",null,null,null,"high","first","opus-5.5-agent18","single case report of acute pancreatitis on semaglutide; not a trial despite class",1],["R0003028","Effectiveness and safety of glucagon-like peptide 1 receptor agonists in patients with type 2 diabetes: evidence from a retrospective real-world study.","Jiang Y","2024","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent16","retrospective single center cohort of GLP-1RA users comparing agents on HbA1c and weight; no listed harm",1],["R0003137","Safety and effectiveness in an uncontrolled setting of glucagon-like-peptide-1 receptor agonists in patients with familial partial lipodystrophy: Real-life experience from a national reference network.","Lamothe S","2025","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent16","uncontrolled retrospective cohort of GLP-1RA in familial partial lipodystrophy, before and after comparison",1],["R0003200","Correspondence to editorial on \"Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: a network meta-analysis\".","Kim H","2024","inventory_only","N9","ancillary",null,null,null,"high","first","opus-5.5-agent16","authors reply concerning a network meta-analysis of GLP-1RAs versus thiazolidinediones in NAFLD",1],["R0003257","Glucagon-like peptide-1 receptor agonism improves lung cancer outcomes and tumor growth control.","Pachimatla AG","2025","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent16","matched NSCLC cohorts of GLP-1RA users vs nonusers plus mouse work; recurrence and survival outcomes only",1],["R0003322","Clinical development of oral semaglutide for the treatment of type 2 diabetes mellitus: focusing on early phase clinical trials.","Won H","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent16","narrative review of oral semaglutide clinical development without systematic search",1],["R0003402","Efficacy and safety of GLP-1 receptor agonists for adolescents and children with obesity: a meta-analysis of randomized controlled trials.","Chen Q","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent16","systematic review and meta-analysis of placebo controlled GLP-1RA RCTs in pediatric obesity",1],["R0003473","Efficacy and Safety of GLP-1 Receptor Agonists and SGLT-2 Inhibitors in the Treatment of Diabetes Mellitus and Obesity in Liver Transplant Recipients: A Systematic Review.","Garlatti Costa E","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent16","PROSPERO registered systematic review of GLP-1RAs and SGLT2i in liver transplant recipients",1],["R0003043","New-Onset Nonarteritic Anterior Ischemic Optic Neuropathy and Initiators of Semaglutide in US Veterans With Type 2 Diabetes.","Heberer K","2026","include_harms",null,"primary_report",null,"O34",null,"high","first","opus-5.5-agent02","active comparator new user target trial emulation of semaglutide vs SGLT2 inhibitor in veterans with T2D; NAION outcome",1],["R0003101","Impact of Tirzepatide on FIB-4 in Patients with Type 2 Diabetes: A Comparison between GLP-1RA-naïve and GLP-1RA Switch Initiation in a Retrospective Cohort.","Ito H","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent02","retrospective tirzepatide cohort comparing GLP-1 RA naive vs switched patients on FIB-4, HbA1c, weight; no listed harm",1],["R0003158","Trends in the use of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists among ischemic stroke patients.","Ding Q","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent02","facility level trend analysis of SGLT2 inhibitor and GLP-1 RA prescribing after ischemic stroke; utilization without exposure comparison",1],["R0003218","One-year weight loss and metabolic outcomes after laparoscopic sleeve gastrectomy in adolescents compared with young adults: A propensity score-matched cohort study.","Taki-Eldin A","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent02","sleeve gastrectomy outcomes adolescents vs young adults; GLP-1 RA use only a matching covariate, not the studied exposure",1],["R0003281","Weight loss mediates improvement in proinsulin processing during GLP-1 receptor agonist treatment.","Liu R","2025","include_nma",null,"primary_report","P02",null,null,"high","first","opus-5.5-agent02","randomized 24 week trial of liraglutide plus metformin vs metformin with lifestyle in adults with obesity without diabetes; weight reported",1],["R0003355","Weight Loss in Primary Total Hip and Knee Arthroplasty: A Comparative Study of Glucagon-Like Peptide-1 Receptor Agonists and Bariatric Surgery.","Ledford CK","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent02","arthroplasty cohort comparing perioperative GLP-1 RA, bariatric surgery and no intervention on readmission and reoperation only",1],["R0003424","Effect of glucagon-like peptide-1 receptor agonists in osteoarthritis: A systematic review of pre-clinical and human studies.","Cheng J","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent02","registered systematic review of preclinical and human studies of GLP-1 RA in osteoarthritis; three databases searched, qualitative synthesis",1],["R0003488","Comparing Glucagon-like peptide-1 receptor agonists versus metformin in drug-naive patients: A nationwide cohort study.","Sørensen KK","2024","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent02","Danish registry cohort of GLP-1 RA vs metformin initiators; add on therapy, adherence and biomarkers, no listed harm",1],["R0003014","Effects of Combined Therapy with SGLT2i and GLP-1RAs on Atrial Fibrillation Recurrence After Catheter Ablation in Diabetic Cohorts: One-Year Outcomes from Continuous Monitoring.","Sardu C","2025","inventory_only","N6","primary_report","P01",null,null,"high","first","opus-5.5-agent12","prospective cohort of T2D after AF ablation comparing SGLT2i, GLP-1RA and combination users, AF recurrence outcome only",1],["R0003068","Association between GLP-1 RAs and DPP-4 inhibitors with biliary disorders: pharmacovigilance analysis.","He L","2025","inventory_only","N5","other",null,null,null,"high","first","opus-5.5-agent12","FAERS disproportionality analysis of biliary events with GLP-1RAs and DPP4 inhibitors",1],["R0003130","Real-World Effectiveness of Finerenone Added to SGLT2 Inhibitor and GLP-1 Receptor Agonist Therapy in Individuals with Type 2 Diabetes and Chronic Kidney Disease.","Nakhleh A","2025","inventory_only","N5","primary_report","P08A",null,null,"high","first","opus-5.5-agent12","retrospective single group cohort adding finerenone on SGLT2i plus GLP-1RA background, no GLP-1 comparison",1],["R0003193","Glucagon-like Peptide-1 Receptor Agonists-A Potential New Medication for Pediatric Metabolic-Dysfunction-Associated Steatotic Liver Disease (MASLD).","Choi E","2024","inventory_only","N5","primary_report","P03",null,null,"high","first","opus-5.5-agent12","retrospective pediatric case series of nine patients started on GLP-1RA with elevated ALT",1],["R0003245","The relationship between the use of GLP-1 receptor agonists and the incidence of respiratory illness: a meta-analysis of randomized controlled trials.","Yu M","2023","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent12","registered meta-analysis of RCTs of GLP-1RAs vs control on respiratory disease events, multiple databases",1],["R0003311","The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications.","Jalleh RJ","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent12","narrative review of GLP-1RA adverse effects and mechanisms",1],["R0003383","Optimising GLP-1RA Efficacy: A Meta-Analysis of Baseline Age and HbA1c as Predictors of MACE Reduction in T2DM.","Ghosal S","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent12","PRISMA SR and meta-regression of placebo controlled GLP-1RA cardiovascular outcome trials in T2D, PubMed and Google Scholar",1],["R0003455","Glucagon-like peptide 1 receptor agonists and thyroid cancer: is it the time to be concerned?","Lisco G","2023","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent12","perspective review on GLP-1RAs and thyroid cancer, no systematic search",1],["R0003558","Glucagon-Like Peptide-1 Receptor Agonists for Bile Acid Diarrhea: Emerging Evidence and Clinical Implications.","Omeludike EK","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent04","self described narrative review of GLP-1 RA for bile acid diarrhea, no systematic methods",1],["R0003624","Real-world evaluation of clinical outcomes in Dutch patients with type 2 diabetes treated with oral semaglutide: A retrospective, observational cohort study using the PHARMO data network.","Postema A","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent04","PHARMO single group of oral semaglutide initiators with change from baseline, no comparison group",1],["R0003683","Upcoming drug targets for kidney protective effects in chronic kidney disease.","Nardone M","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent04","narrative review of emerging kidney protective drug targets including GLP-1 RA",1],["R0003767","Exploration of factors associated with eGFR slope improvement before and after intensive treatment of patients with diabetic nephropathy at high risk of disease progression: a retrospective cohort study.","Kiku M","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent04","retrospective cohort of 64 diabetic nephropathy patients, GLP-1 RA use associated with eGFR slope, no eligible harms outcome",1],["R0003847","Relative Effectiveness and Safety of the GLP-1 (Glucagon-Like Peptide 1) Receptor Agonists, Semaglutide and Liraglutide in the Treatment of Obese Type 2 Diabetics: A Prospective Observational Cohort Study in Poland.","Hoffmann K","2025","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent04","prospective nonrandomized semaglutide vs liraglutide cohort, HbA1c, BMI and GI adverse effects only, none in harms list",1],["R0003906","Effects of glucagon-like peptide-1 receptor agonists on liver-related and cardiovascular mortality in patients with type 2 diabetes.","Yen FS","2024","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent04","Taiwan NHIRD matched cohort GLP-1 RA vs nonuse, cirrhosis, HCC, MACE and mortality, no listed harms outcome",1],["R0003967","Risk of bone fracture by using dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes mellitus: a network meta-analysis of population-based cohort studies.","Mostafa MEA","2024","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent04","registered systematic review and network meta-analysis of cohort studies on fracture risk with GLP-1 RA, DPP-4i, SGLT2i",1],["R0004052","Comparative effectiveness of GLP-1 receptor agonists and dual agonists in the treatment of patients with metabolic dysfunction associated steatohepatitis: a systematic review and meta-analysis.","Li M","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent04","registered systematic review and meta-analysis of RCTs of GLP-1 RA and dual agonists vs placebo in biopsy proven MASH",1],["R0002067","Leveraging Real-World Evidence to Inform Regulatory, Clinical, and Coverage Decisions Related to Glucagon-like Peptide-1-Based Therapies: Synopsis of a National Institute of Diabetes and Digestive and Kidney Diseases Workshop.","Arterburn D","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent15","synopsis of an NIDDK workshop on real world evidence; stored file holds workshop materials and speaker biographies, no primary data",1],["R0002135","Incretin Mimetics in Cancer and Cardiovascular Disease: JACC: CardioOncology State-of-the-Art Review.","Leong D","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent15","state of the art narrative review of incretin drugs in cancer and cardiovascular disease",1],["R0002252","Association of GLP-1 receptor agonists with intentional self-harm in patients with type 2 diabetes: a Sentinel Distributed Database study.","Kuzucan A","2026","include_harms",null,"primary_report",null,"O35A",null,"high","first","opus-5.5-agent15","Sentinel active comparator new user cohort, GLP-1 RA versus SGLT2i or DPP-4i in type 2 diabetes; intentional self harm outcome",1],["R0002389","Comparative gastrointestinal adverse effects of GLP-1 receptor agonists and multi-target analogs in type 2 diabetes: a Bayesian network meta-analysis.","Xie X","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent15","registered Bayesian network meta-analysis of 48 RCTs comparing gastrointestinal adverse events across GLP-1 RAs in type 2 diabetes",1],["R0002457","Bariatric Surgery in the Era of GLP1RA: A Narrative Review.","Muhundan M","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent15","narrative review of bariatric surgery and GLP-1 RA pharmacotherapy for obesity without systematic methods",1],["R0002347","The role of glucagon-like peptide-1 receptor agonists in weight regain treatment or prevention after bariatric surgery: a systematic review and meta-analysis.","Mousavi A","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent05","registered meta-analysis of GLP-1 RA versus placebo or control for weight regain after bariatric surgery, three named databases",1],["R0002415","Low baseline HbA1c and reduced eGFR are associated with relatively unfavorable body recomposition after SGLT2 inhibitor therapy in type 2 diabetes.","Gobaru M","2026","inventory_only","N6","other",null,null,null,"high","first","opus-5.5-agent05","retrospective registry cohort comparing SGLT2i, GLP-1 RA and add-on on body composition; no listed harm outcome",1],["R0002488","Cost-Effectiveness and Budget-Impact Analysis of Semaglutide in Heart Failure with Preserved Ejection Fraction and Obesity in the German Health-Care System.","Estler B","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent05","Markov cost effectiveness and budget impact model of semaglutide in HFpEF based on trial data",1],["R0002614","Effects of GLP-1 receptor agonists on neurological complications of diabetes.","García-Casares N","2023","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent05","systematic review of GLP-1 RA trials on stroke, cognition and neuropathy with three named databases and criteria",1],["R0002674","Body Composition Changes After Bariatric Surgery or Treatment With GLP-1 Receptor Agonists.","Wang Z","2026","inventory_only","N6","other",null,null,null,"high","first","opus-5.5-agent05","single center cohort comparing bariatric surgery with semaglutide or tirzepatide on body composition; no listed harm",1],["R0002751","Digital Behavioral Infrastructure for Glucagon-Like Peptide-1 Pharmacotherapy: Viewpoint on Persistence, Tolerability, and Postcessation Durability.","Cook G","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent05","viewpoint proposing digital behavioral programs alongside GLP-1 RA therapy; no primary data",1],["R0002826","GLP-1RA Liraglutide Attenuates Sepsis by Modulating Gut Microbiota and Associated Metabolites.","Gong B","2026","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent05","liraglutide tested only in septic mice; human samples measured endogenous GLP-1 and citrulline without drug exposure",1],["R0003163","Sex-Based Differences in SGLT2i and GLP-1RA Use and Mortality in T2DM with Atherosclerotic Cardiovascular Disease.","Vaknin-Assa H","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent03","Israeli T2D ASCVD cohort relating SGLT2i and GLP-1 RA dispensing to mortality by sex; no listed harm",1],["R0003221","Risk of Aspiration Pneumonitis After Elective Esophagogastroduodenoscopy in Patients on Glucagon-Like Peptide-1 Receptor Agonists.","Al Sakka Amini R","2024","include_harms",null,"primary_report",null,"O36A",null,"high","first","opus-5.5-agent03","TriNetX matched cohort of outpatient EGD in GLP-1 RA users vs nonusers; aspiration pneumonitis outcome",1],["R0003285","Comparative analysis of glucagon-like peptide-1 receptor agonists, metformin, and inositol in improving anthropometric and metabolic outcomes in women with polycystic ovary syndrome: a network meta-analysis.","Omarion A","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent03","NMA of RCTs of GLP-1 RA, metformin and inositol in PCOS with three databases searched",1],["R0003356","Efficacy and safety of orforglipron in obesity with type 2 diabetes mellitus: a GRADE-assessed meta-analysis of randomized controlled trials.","Emara A","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent03","meta-analysis of RCTs of orforglipron vs placebo in obesity with T2D, four databases searched",1],["R0003427","Heterogeneity in response to GLP-1 receptor agonists in type 2 diabetes in real-world clinical practice: insights from the DPV register - an IMI-SOPHIA study.","Heni M","2025","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent03","registry cohort of GLP-1 RA initiators classified by response; no comparison group",1],["R0003501","Association between glucagon-like peptide-1 receptor agonists use and change in alcohol consumption: a systematic review.","Subhani M","2024","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent08","PROSPERO registered systematic review of GLP-1 RA use and alcohol consumption; Medline, Embase, PsycINFO searched",1],["R0003569","Semaglutide-associated kidney injury.","Begum F","2024","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent08","two case reports of semaglutide associated interstitial nephritis with a FAERS summary",1],["R0003633","Impact of SGLT2i and GLP-1RA on liver-related events in patients with MASLD and type 2 diabetes: A network meta-analysis.","Li L","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent08","pairwise and Bayesian network meta-analysis of observational studies of glucose lowering drugs on liver events in MASLD",1],["R0003695","A Scoping Review of GLP-1 Receptor Agonists: Are They Associated with Increased Gastric Contents, Regurgitation, and Aspiration Events?","Chang MG","2024","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent08","PRISMA-ScR scoping review with five databases comparing gastric residue and aspiration in GLP-1 RA users and nonusers",1],["R0003863","Effect of Semaglutide on the Inflammatory Biomarker High-Sensitivity CRP in Patients With Established Cardiovascular Disease and Overweight or Obesity in SELECT: A Prespecified Secondary Analysis.","Plutzky J","2026","include_nma",null,"secondary_report","P02",null,null,"high","first","opus-5.5-agent08","prespecified SELECT secondary analysis of hsCRP with randomized semaglutide versus placebo in obesity with CVD, no diabetes",1],["R0003917","Acute Pancreatitis in a Patient Taking Semaglutide.","Patel F","2023","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent08","single case report of acute pancreatitis after starting semaglutide",1],["R0003976","Sex differences in trial representation and the cardiovascular effectiveness of newer glucose-lowering agents in patients with and without type 2 diabetes: A systematic review and meta-analysis of cardiovascular outcome trials.","Zawadka M","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent08","systematic review and meta-analysis of SGLT2i and GLP-1 RA cardiovascular outcome trials by sex; MEDLINE, Embase, CENTRAL",1],["R0002080","GLP-1 Receptor Agonist Exposure and Diabetic Retinopathy Progression: An American Academy of Ophthalmology IRIS® Registry (Intelligent Research in Sight) Analysis","Ross C","2026","include_harms",null,"primary_report",null,"O33",null,"high","first","opus-5.5-agent19","IRIS registry cohort of eyes with diabetic retinopathy, prior GLP-1 RA users excluded, time varying exposure vs unexposed; progression, PRP, vitrectomy",1],["R0002146","GLP-1R Agonists for Weight Loss in Psychiatric Disorders: A Systematic Review and Meta-analysis.","Müller Alves K","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent19","meta-analysis of RCTs of GLP-1 RA vs control for weight in psychiatric disorders; PubMed Embase Cochrane searched, PROSPERO registered",1],["R0002203","Oral vs. Subcutaneous Semaglutide for Obesity Treatment: A Systematic Review of Efficacy, Safety, and Patient-Oriented Outcomes.","La Vignera S","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent19","systematic review of oral vs subcutaneous semaglutide or placebo in obesity; PubMed and other named sources, PICO criteria",1],["R0002272","Identifying Provider Prescribing Practices for GLP-1RAs and SGLT-2is in Patients With Type 2 Diabetes to Address Pharmacoinequity.","Wongsirisakul P","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent19","qualitative interviews of primary care providers about GLP-1 RA and SGLT2 inhibitor prescribing; no exposure comparison",1],["R0002336","A Systematic Review on GLP-1 Receptor Agonists in Reproductive Health: Integrating IVF Data, Ovarian Physiology and Molecular Mechanisms.","Voros C","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent19","systematic review of GLP-1 RA in reproductive health including RCTs vs metformin or placebo; PubMed Scopus Web of Science, PROSPERO",1],["R0002403","How do GLP-1 receptor agonists influence the progression of shoulder pathology? A matched cohort analysis.","Davis WR","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent19","TriNetX matched cohort GLP-1 RA users vs nonusers; shoulder osteoarthritis, capsulitis, cuff tears, fractures; no listed harm",1],["R0003508","SAT-631 Glucagon-Like Peptide-1 Receptor Agonist Liraglutide for the Treatment of Weight Regain After Bariatric Surgery: A Systematic Review and Meta-Analysis",null,"2024","include_review",null,"systematic_review",null,null,"abstract_only","high","first","opus-5.5-agent14","conference abstract of systematic review and meta-analysis of liraglutide for weight regain after bariatric surgery, four databases searched",1],["R0003588","Effects of Incretin-Based Therapies, Diet and Exercise Interventions, and Bariatric Surgery on Fat-Free Mass in Adults With Overweight or Obesity: A Systematic Review and Meta-Analysis.","Busk-Cirera L","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent14","systematic review and meta-analysis of RCTs on fat free mass including incretin therapy vs placebo, PubMed Cochrane Embase",1],["R0003657","Postoperative Aspiration Pneumonia Among Adults Using GLP-1 Receptor Agonists.","Chen YH","2025","include_harms",null,"primary_report",null,"O36A",null,"high","first","opus-5.5-agent14","MarketScan surgical cohort preoperative GLP-1 RA users vs nonusers, postoperative aspiration pneumonia",1],["R0003723","Dionysus or apollo, skeletal muscle mass changes in type 2 diabetes with sarcopenia receiving GLP-1 receptor agonist: systematic review and meta-analysis.","Wang Y","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent14","PROSPERO registered meta-analysis of RCTs of GLP-1 RA on muscle mass in T2D with sarcopenia",1],["R0003804","Peer Review for \"Thyroid Hyperplasia and Neoplasm Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists in the Food and Drug Administration Adverse Event Reporting System: Retrospective Analysis\".","Anonymous","2024","inventory_only","N9","ancillary",null,null,null,"high","first","opus-5.5-agent14","peer review report on a FAERS analysis of thyroid events with GLP-1 RAs",1],["R0003880","Real-world treatment-transition pathways and dosing patterns of insulin degludec/liraglutide in Chinese adults with type 2 diabetes.","Zhang J","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent14","registry of IDegLira initiators described by prior treatment pathway, no unexposed comparison group",1],["R0003937","Comparative Effectiveness of Bariatric Metabolic Surgery Versus Glucagon-Like Peptide-1 Receptor Agonists on Cardiovascular Outcomes and Mortality: A Meta-Analysis.","Saeed L","2024","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent14","meta-analysis of observational studies comparing bariatric surgery vs GLP-1 RA on MACE and mortality, Medline Embase CENTRAL",1],["R0004015","GLP-1RAs caused gastrointestinal adverse reactions of drug withdrawal: a system review and network meta-analysis.","Zhang Z","2023","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent14","PROSPERO registered network meta-analysis of RCTs on GLP-1 RA withdrawal due to gastrointestinal adverse events",1],["R0002035","GLP-1 receptor agonists and cardiovascular outcomes in Asian, Black or African American, and White populations: An updated meta-analysis including the SOUL trial.","Hasebe M","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent17","registered meta-analysis of placebo controlled GLP-1 RA cardiovascular outcome trials by race, PubMed and Embase search",1],["R0002075","Glucagon-like peptide-1 receptor agonists reduce major adverse cardiovascular events and worsening heart failure in patients with heart failure: an umbrella meta-analysis.","Sun C","2026","include_review",null,"systematic_review",null,null,"umbrella_review","high","first","opus-5.5-agent17","registered umbrella review of meta-analyses of GLP-1 RAs in heart failure with pooled estimates for MACE and worsening heart failure",1],["R0002141","Comparative Effects of SGLT2 Inhibitors and GLP-1 Receptor Agonists on Composite Surrogate Markers of Insulin Resistance: A Real-World Study Using METS-IR and SPISE.","Voziki D","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent17","retrospective cohort of GLP-1 RA versus SGLT2 inhibitor starters; insulin resistance indices, BMI and HbA1c only",1],["R0002195","Dual GIP/GLP1-RA, GCGR/GLP-1 RA and GLP1-RA for the Treatment of Metabolic Dysfunction-associated Steatotic Liver Disease with Type 2 Diabetes: A Systematic Review and Meta-analysis.","Gunawan B","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent17","registered systematic review and meta-analysis of RCTs of GLP-1 RA based agonists in MASLD with diabetes, four databases searched",1],["R0002264","Glucagon-like peptide-1 receptor agonist use prior to spinal surgery results in reduced postoperative length of stay: A propensity-score matched analysis.","Goldman SN","2025","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent17","propensity matched cohort of preoperative GLP-1 RA use versus none in spine surgery; length of stay, reoperation, readmission only",1],["R0002395","Factors Associated with GLP-1 Receptor Agonist Use in Patients with Type 2 Diabetes and Established Atherosclerotic Cardiovascular Disease: A Retrospective Propensity-Score Matched Analysis.","Vournas G","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent17","cross sectional analysis of factors associated with GLP-1 RA prescribing in diabetes with ASCVD; no exposure outcome comparison",1],["R0002459","GLP-1 Receptor Agonist Therapy and Cardiorenal Outcomes in Patients ≥ 80 Years Old With Type 2 Diabetes.","Chen JC","2026","include_harms",null,"primary_report",null,"O121; O29; O28",null,"high","first","opus-5.5-agent17","TriNetX new user active comparator cohort, GLP-1 RA versus DPP-4 inhibitor in people aged 80 plus; reports AKI, pancreatitis, cholecystitis",1],["R0003055","Tirzepatide and reduced risk of pulmonary embolism and deep vein thrombosis: a multicenter U.S. cohort study.","Kahkedjian F","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent07","TriNetX cohort of tirzepatide initiators vs lifestyle only; venous thromboembolism outcomes, none listed as harms",1],["R0003116","Efficacy and safety of anti-prediabetic drugs in patients with prediabetes: a Bayesian network meta-analysis.","Wu Y","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent07","PROSPERO registered Bayesian NMA of RCTs of drugs including GLP-1RA in prediabetes",1],["R0003171","Vascular and Myocardial Function in Patients with Type 2 Diabetes and Ischemic Stroke Treated with Dulaglutide or Empagliflozin.","Pavlidis G","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent07","observational cohort dulaglutide vs empagliflozin after stroke in T2D; vascular and strain measures only",1],["R0003233","Beyond Weight Loss: Early Real-World Evidence of Semaglutide in Obesity.","Boroghină SC","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent07","prospective observational series of semaglutide initiators with obesity, before after only without comparator",1],["R0003297","Comparative Efficacy and Safety of Glucagon Receptor Agonists on Metabolic Outcomes: A Network Meta-Analysis of Randomised Controlled Trials.","Abulehia A","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent07","NMA of RCTs of glucagon receptor co-agonists with GLP-1 activity such as retatrutide, survodutide, mazdutide vs placebo",1],["R0003372","Evidence Report on the Safety of Gastrointestinal Endoscopy in Patients on Glucagon-like Peptide-1 Receptor Agonists: A Systematic Review and Meta-Analysis.","Tarar ZI","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent07","meta-analysis of studies comparing GLP-1RA users vs controls on retained gastric content and aspiration at endoscopy",1],["R0003435","Comparative Efficacy and Safety of Liraglutide Versus Metformin in Women With Polyendocrine Metabolic Ovarian Syndrome (PMOS): A Systematic Review and Meta-Analysis of Randomized Controlled Trials.","Banerjee I","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent07","PROSPERO registered meta-analysis of RCTs of liraglutide vs metformin in PCOS",1],["R0003541","GLP-1 Agonists as Potential Neuromodulators in Development of Parkinson's Disease: A Nationwide Cohort Study.","Gamborg M","2025","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent01","nationwide active comparator new user cohort of GLP-1 RA versus DPP-4 inhibitors; Parkinson disease and death only",1],["R0003676","Association of glucagon-like peptide-1 receptor agonists with cardiovascular and kidney outcomes in type 2 diabetic kidney transplant recipients.","Lin LC","2025","include_harms",null,"primary_report",null,"O29; O35A; O33",null,"high","first","opus-5.5-agent01","matched cohort of kidney transplant recipients starting GLP-1 RA versus nonusers; pancreatitis, suicide and retinopathy reported as safety outcomes",1],["R0003755","Dosing Patterns of Dulaglutide and Semaglutide in Patients with Type 2 Diabetes Mellitus in France and Italy: A Retrospective Cohort Study.","Khare S","2025","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent01","prescription database study of dulaglutide and semaglutide dosing patterns; drug utilization without exposure comparison",1],["R0003843","The Heart-Kidney Axis in Heart Failure and Chronic Kidney Disease: Mechanisms, Mediators, and Therapeutic Implications.","Fan A","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent01","narrative review of heart kidney axis mechanisms and therapies, no synthesized GLP-1 RA contrast",1],["R0003900","Efficacy of Different Doses and Forms of the GLP-1 Receptor Agonist Semaglutide in Weight Reduction Among Non-diabetic Obese or Overweight Populations.","Fatima N","2024","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent01","PRISMA systematic review of semaglutide weight loss trials in nondiabetic adults, PubMed PMC and Cochrane searched",1],["R0003964","Gastrointestinal safety of semaglutide and tirzepatide vs. placebo in obese individuals without diabetes: a systematic review and meta analysis.","Safwan M","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent01","registered meta-analysis of semaglutide and tirzepatide versus placebo RCTs for gastrointestinal and biliary safety",1],["R0004036","Patient-reported endometriosis symptom change during GLP-1 receptor agonist use, and its relationship to weight loss: an international cross-sectional survey (GLEAM)","Baudoin B","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent01","cross sectional online survey of people with endometriosis using GLP-1 RAs about symptom change",1],["R0003613","Comparative efficacy and tolerability of currently approved incretin mimetics: A systematic analysis of placebo-controlled clinical trials.","Kang YM","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent20","PROSPERO registered systematic analysis of placebo controlled phase 3 RCTs of incretin drugs in T2D, PubMed search",1],["R0003673","Distinct effects of semaglutide and tirzepatide on metabolic and inflammatory gene expression in brown adipose tissue of mice fed a high-fat, high-fructose diet.","Ma T","2025","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent20","randomized mouse experiment of semaglutide vs tirzepatide on brown adipose tissue, no humans",1],["R0003897","Semaglutide-associated risk of nonarteritic anterior ischemic optic neuropathy in patients with type 2 diabetes: A systematic review and meta-analysis of observational studies.","Chrzanowski J","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent20","PROSPERO registered meta-analysis of observational studies on semaglutide and NAION risk, three databases",1],["R0003950","Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may reduce the risk of developing cancer-related lymphedema following axillary lymph node dissection (ALND).","Brown S","2024","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent20","single center cohort after axillary dissection, GLP-1 RA users vs nonusers, outcome lymphedema only",1],["R0004032","Comparative Pharmacological and Pharmaceutical Perspectives on Antidiabetic Therapies in Humans, Dogs, and Cats.","Kim I","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent20","narrative comparative review of antidiabetic therapies in humans dogs and cats",1],["R0004105","SGLT2 Inhibitors and External Genital Infection in Male Patients With Type 2 Diabetes.","Cheng TH","2025","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent20","Taiwan claims new user cohort of SGLT2i vs GLP-1 RA, outcome male genital infection only, not a listed harm",1],["R0002877","The Potential Role of Glucagon-Like Peptide-1 (GLP-1) Agonists for Polycystic Ovary Syndrome.","Rahim S","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent05","self described narrative review on GLP-1 RA in PCOS summarizing selected PubMed trials without formal synthesis",1],["R0002942","Association of glucagon-like peptide-1 receptor agonists with atrial fibrillation, cardiac arrest, and ventricular fibrillation: Casual evidence from a drug target Mendelian randomization.","Zhang X","2025","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent05","two sample Mendelian randomization using GLP1R genetic proxies; no drug given or drug exposure studied",1],["R0002995","Comparative effectiveness and safety of sodium-glucose cotransporter 2 inhibitors vs glucagon-like peptide 1 receptor agonists in elderly patients with type 2 diabetes mellitus: a meta-analysis.","Wang Y","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent05","registered meta-analysis comparing SGLT2 inhibitors with GLP-1 RA in older adults with type 2 diabetes, three named databases",1],["R0003048","Improvement of irritable bowel syndrome with glucagon like peptide-1 receptor agonists: a systematic review and meta-analysis.","Mostafa MEA","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent05","registered meta-analysis of GLP-1 analog ROSE-010 versus placebo in irritable bowel syndrome, named databases",1],["R0003108","A meta-analysis on the risk of esophageal cancer in type 2 diabetes patients treated with GLP-1 receptor agonists.","Wu Q","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent05","registered meta-analysis of RCTs of GLP-1 RA versus control on esophageal cancer, five named databases",1],["R0003228","Semaglutide and major adverse cardiovascular events in patients with and without DM: A systematic review and meta-analysis.","Li Y","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent05","meta-analysis of semaglutide RCTs on MACE with safety pooling, searching named databases and registries",1],["R0003293","Confounding Factors in the Association Between Glucagon-Like Peptide-1 Receptor Agonist Use and Retained Gastric Contents in Asymptomatic Patients Undergoing Upper Gastrointestinal Endoscopy: A Retrospective Study.","Elimihele TA","2024","include_harms",null,"other",null,"O36B",null,"high","first","opus-5.5-agent05","single center cohort of endoscopies with odds of retained gastric content by GLP-1 RA use; confounders handled descriptively",1],["R0002116","Effects of Resmetirom on Metabolic-Dysfunction Associated Steatohepatitis in Patients With Weight Loss and/or Diabetes Taking Glucagon-Like Peptide-1 Receptor Agonists and Other Diabetes Therapies: A Secondary Analysis of the MAESTRO-NASH Trial.","Noureddin M","2025","inventory_only","N3","secondary_report",null,null,null,"high","first","opus-5.5-agent11","MAESTRO-NASH secondary analysis; randomized resmetirom versus placebo with GLP-1RA only as stable background",1],["R0002174","Insulin, Semaglutide and Dapagliflozin in Adults With Type 1 Diabetes: Design and Methods of Triple Therapy for Type 1 Diabetes (TTT1)-An International Phase 3 Clinical Trial.","Timmons JG","2026","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent11","design and methods paper of TTT1 semaglutide and dapagliflozin trial in type 1 diabetes; no results",1],["R0002244","Liraglutide and Exenatide in Alzheimer's Disease and Mild Cognitive Impairment: A Systematic Review and Meta-Analysis of Cognitive Outcomes.","Santos P","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent11","registered meta-analysis of RCTs of liraglutide or exenatide versus placebo on cognition in AD or MCI",1],["R0002303","Survival and Recurrence With GLP-1 Receptor Agonists in Breast Cancer.","Tatum KL","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent11","TriNetX matched cohort of GLP-1RA use in breast cancer patients; mortality and recurrence only, no listed harms outcome",1],["R0002509","Association of Periprocedural GLP-1 Receptor Agonist Therapy With 1-Year Major Adverse Cardiovascular Events After Carotid Artery Stenting: A Propensity-Matched Analysis.","Ghuman A","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent11","TriNetX matched cohort after carotid stenting; MACE components and mortality only, no listed harms outcome",1],["R0002113","No Mid-Term Benefits of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Following Total Joint Arthroplasty: A Systematic Review.","Leggieri F","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent10","systematic review of cohorts comparing GLP-1 RA users with nonusers after joint arthroplasty, qualitative synthesis",1],["R0002173","Effects of Glucagon-Like Peptide-1 Receptor Agonists on Perioperative Outcomes in Hip and Knee Arthroplasty: A Systematic Review and Meta-Analysis","Brady A","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent10","systematic review and meta-analysis of GLP-1 RA users versus nonusers on arthroplasty perioperative outcomes",1],["R0002241","Glucose-Lowering Therapies and Cognitive Decline: From Molecular Mechanisms to Clinical Evidence and Future Perspectives.","Grasso M","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent10","narrative review of glucose lowering drugs and cognitive decline; no methods or systematic search",1],["R0002377","Effects of semaglutide, a GLP-1 receptor agonist, on food preferences in Japanese subjects with type 2 diabetes and visceral fat accumulation.","Hara T","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent10","small retrospective comparison semaglutide versus no GLP-1 RA on food preference and weight; no harms_nrs outcome",1],["R0002435","Effect of glucagon-like peptide-1 receptor agonists on vascular risk factors among adults with type 2 diabetes and established atherosclerotic cardiovascular disease.","King A","2025","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent10","EHR cohorts of once weekly GLP-1 RA initiators with pre post risk factor changes; no comparison group",1],["R0002505","Sociodemographic and Socioeconomic Disparities in Incretin Therapy Utilization Among Hospitalized Adults in the United States: A Nationwide Inpatient Sample Analysis","Sachdeva S","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent10","cross sectional study of incretin utilization disparities in inpatients; no exposure outcome comparison",1],["R0003072","Current Status of Glucagon-like Peptide-1 Receptor Agonists in Metabolic Dysfunction-associated Steatotic Liver Disease: A Clinical Perspective.","Wang MW","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent13","clinical perspective narrative review of GLP-1 agonists in MASLD",1],["R0003132","The Effect of Weight Loss and Metabolic Interventions on Recurrence After Atrial Fibrillation Ablation.","Fu S","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent13","self described nonsystematic narrative review of weight loss and metabolic drugs after AF ablation",1],["R0003195","Emerging therapeutic potential of glucagon-like Peptide-1 receptor agonists in knee osteoarthritis: a systematic review.","Li Y","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent13","PROSPERO registered systematic review of GLP-1 agonists in knee osteoarthritis including clinical studies",1],["R0003253","Impact of Baseline GLP-1 Receptor Agonist Use on Albuminuria Reduction and Safety With Simultaneous Initiation of Finerenone and Empagliflozin in Type 2 Diabetes and Chronic Kidney Disease (CONFIDENCE Trial).","Agarwal R","2025","inventory_only","N3","secondary_report",null,null,null,"high","first","opus-5.5-agent13","CONFIDENCE subgroup by baseline GLP-1 use; randomized arms finerenone, empagliflozin or both, GLP-1 regimen not randomized",1],["R0003312","Once-Weekly Semaglutide in Adults With Daily Cigarette Use: A Randomized Clinical Trial.","Hendershot CS","2026","include_nma",null,"primary_report","P14B",null,null,"high","first","opus-5.5-agent13","placebo controlled RCT of semaglutide for 9 weeks in daily smokers reporting weight and HbA1c",1],["R0003389","Glucagon-like peptide-1 receptor agonists in patients with heart failure with reduced ejection fraction – real world outcomes","Hammer Y","2025","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent13","Clalit matched cohort GLP-1 users vs nonusers with HFrEF, death and heart failure hospitalization only",1],["R0003458","GLP-1 agonists and changes in body mass and composition in adults with overweight or obesity with or without type 2 diabetes mellitus: a systematic review and meta-analysis.","Sawicka-Gutaj N","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent13","PROSPERO registered systematic review and meta-analysis of GLP-1 agonists on weight and body composition",1],["R0003507","Potential of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Mitigating Metabolic Side Effects Associated With Clozapine or Olanzapine Therapy: A Literature Review.","Meftah A","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent13","literature review of GLP-1 agonists with clozapine or olanzapine without formal eligibility criteria or systematic synthesis",1],["R0004200","Gambling Disorder as a Behaviorally Driven Systemic Medical Condition: From Reward Circuitry to Multi-System Morbidity.","Ballerio M","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent06","narrative hypothesis generating review of gambling disorder somatic morbidity with GLP-1 RA speculation",1],["R0004266","Diabetes Medication Regimen Complexity and Glycemic Outcomes among Medically Underserved Latino Adults: Implications for Pharmacoequity.","Wisseh C","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent06","cross sectional chart review of medication regimen complexity and glycemic control; no GLP-1 RA exposure comparison",1],["R0004430","Effects of Tirzepatide vs Semaglutide on β-Cell Function, Insulin Sensitivity, and Glucose Control During a Meal Test.","Mather KJ","2024","include_nma",null,"secondary_report","P01",null,"mechanistic","high","first","opus-5.5-agent06","meal test analyses from double blind randomized trial of tirzepatide versus semaglutide versus placebo in T2D on metformin",1],["R0004503","Clinical Outcomes of Tirzepatide or GLP-1 Receptor Agonists in Individuals With Type 2 Diabetes.","Chuang MH","2024","include_harms",null,"primary_report",null,"O121",null,"high","first","opus-5.5-agent06","TriNetX matched cohort of tirzepatide versus GLP-1 RA initiators in T2D; acute kidney injury reported among outcomes",1],["R0004575","The Interplay Between GLP-1-Based Therapies, the Gut Microbiome, and MASLD/MASH in Type 2 Diabetes Mellitus: A Narrative Review.","Dinkov B","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent06","self described narrative review of GLP-1 therapies, microbiome and MASLD; no quantitative synthesis",1],["R0004632","Antidiabetic Treatment and Prevention of Ischemic Stroke: A Systematic Review.","Prentza V","2024","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent06","systematic review of antidiabetic drugs including GLP-1 RAs and ischemic stroke prevention; PubMed, Cochrane, Scopus with PICO",1],["R0002461","Real-world titration, persistence & weight loss of semaglutide and tirzepatide in an academic obesity clinic.","Samuels JM","2025","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent18","single center cohort of semaglutide or tirzepatide users on persistence, titration and weight; no unexposed or active comparator group",1],["R0002532","Trends in Glucagon-like peptide-1 Receptor Agonists for Weight Loss Prior to Total Joint Arthroplasty","Playter K","2025","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent18","claims study of trends and predictors of GLP-1 RA or bariatric surgery use before arthroplasty; utilization only, no outcome comparison",1],["R0002590","Risk of depression with GLP-1 receptor agonists use in overweight or obese adults with type 2 diabetes: A new-user, active-comparator cohort study.","Chang Y","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent18","TriNetX new user cohort GLP-1 RA vs SGLT2i; incident depression and mortality, no listed harms outcome such as suicidality",1],["R0002650","SUN-665 Meta-Analysis of Psychiatric and Quality of Life Outcomes in Patients With Obesity and Diabetes Treated With Glucagon-Like Peptide 1 Receptor Agonists",null,"2025","include_review",null,"systematic_review",null,null,"abstract_only","high","first","opus-5.5-agent18","conference abstract of meta-analysis of placebo controlled GLP-1 RA RCTs on psychiatric events and quality of life; four databases searched",1],["R0002719","Cardiovascular Outcomes and Safety of GLP-1 Receptor Agonists in Elderly Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis.","Gao W","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent18","registered systematic review and meta-analysis of GLP-1 RA RCTs in older adults with T2D; MACE and safety pooled",1],["R0002807","A systematic review on the role of glucagon-like peptide-1 receptor agonists on alcohol-related behaviors: potential therapeutic strategy for alcohol use disorder.","Zheng YJ","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent18","PRISMA systematic review of preclinical and clinical studies of GLP-1 RAs on alcohol behaviors; named databases; narrative synthesis",1],["R0002855","Risk of Thyroid Tumors With GLP-1 Receptor Agonists: A Retrospective Cohort Study.","Morales DR","2025","include_harms",null,"primary_report",null,"O32B",null,"high","first","opus-5.5-agent18","LEGEND-T2DM active comparator new user cohorts GLP-1 RA vs SGLT2i, DPP-4i, sulfonylureas; thyroid tumors and malignancy",1],["R0002912","Sustained weight loss exceeding 100 kg with sequential incretin-based therapy in Prader-Willi syndrome.","Yovera-Aldana M","2026","inventory_only","N5","other",null,null,null,"high","first","opus-5.5-agent18","single case report of Prader-Willi patient with weight loss on sequential retatrutide, oral semaglutide and dulaglutide",1],["R0003513","Differential Effects of GLP-1 Receptor Agonists on Cancer Risk in Obesity: A Nationwide Analysis of 1.1 Million Patients.","Levy S","2024","include_harms",null,"primary_report",null,"O39; O32B",null,"high","first","opus-5.5-agent16","TriNetX matched cohort of GLP-1RA users vs nonusers with obesity; incidence of malignant neoplasms overall and by site including thyroid",1],["R0003595","Glucagon-like peptide-1 receptor agonists (GLP-1RAs) as treatment for nicotine cessation in psychiatric populations: a systematic review.","Lee S","2024","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent16","PRISMA systematic review of GLP-1RAs for nicotine cessation with named databases and eligibility table including humans",1],["R0003659","Glucagon-like peptide-1 receptor agonists in the perioperative period: Implications for the anaesthesiologist.","Gariani K","2024","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent16","letter giving perioperative opinion on GLP-1RAs, not a primary study",1],["R0003737","Traditional and Modern Predictors of Atherosclerotic Cardiovascular Disease in Patients with T2D and MASLD.","Vulpescu Diaconu CT","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent16","cross sectional study of ASCVD predictors including GLP-1RA use in T2D with MASLD",1],["R0003822","Comparative Effectiveness of CagriSegma, Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta-Analysis of Randomized Clinical Trials.","Hamarsheh S","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent16","registered systematic review and NMA of tirzepatide, semaglutide, CagriSema RCTs in obesity",1],["R0003885","Impact of co-administration of proton pump inhibitors on efficacy and safety of oral semaglutide in patients with type 2 diabetes: a single-center retrospective study","Yokoyama T","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent16","retrospective matched comparison of PPI co-use on oral semaglutide; HbA1c, weight and GI discontinuation, no listed harm",1],["R0003940","Tirzepatide and the risk of asthma exacerbations in patients with type 2 diabetes.","Liao KM","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent16","TriNetX new user cohort of tirzepatide vs other agents; asthma exacerbation and mortality only",1],["R0004018","Association between glucagon-like peptide-1 receptor agonist use and progression of monoclonal gammopathy of uncertain significance to multiple myeloma among patients with diabetes.","Grandhi N","2024","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent16","VHA matched cohort of GLP-1RA use and progression of MGUS to myeloma; no listed harm outcome",1],["R0002654","GLP-1 Receptor Agonists Initiation and Risk of Acute Pancreatitis and Pancreatic Cancer: A Real-World Comparative Study.","Faour O","2025","include_harms",null,"primary_report",null,"O29; O38",null,"high","first","opus-5.5-agent19","VA new user active comparator cohort GLP-1 RA vs DPP-4 inhibitor, propensity matched; acute pancreatitis and pancreatic cancer",1],["R0002721","Glucagon-like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes in Youth.","Berman C","2023","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent19","narrative review of GLP-1 RA for youth onset type 2 diabetes; no systematic methods or primary data",1],["R0002858","Combination of GLP-1 receptor agonists and SGLT2 inhibitors in cardiometabolic disease: synergistic, additive, or non-additive effects? A narrative review.","Stamouli E","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent19","narrative review of combined GLP-1 RA and SGLT2 inhibitor therapy; self described narrative",1],["R0002922","Glucagon-like Peptide-1 and Dual GIP/GLP-1 Receptor Agonists in Brain: Exploring the Expanding Role and Safety in Neuropsychiatry.","Tudosie AC","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent19","narrative review of central nervous system actions and neuropsychiatric safety of incretin agonists; no systematic methods",1],["R0002981","Tirzepatide Versus Semaglutide on Weight Loss in Type 2 Diabetes Patients: A Systematic Review and Meta-Analysis of Direct Comparative Studies.","Wen J","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent19","meta-analysis of studies directly comparing tirzepatide and semaglutide weight loss in type 2 diabetes; PubMed Embase Cochrane searched",1],["R0003035","Comparative cardiovascular effectiveness of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors in atherosclerotic cardiovascular disease phenotypes: a systematic review and meta-analysis.","Lin YM","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent19","meta-analysis of RCTs of GLP-1 RA or SGLT2 inhibitors vs placebo on MACE in atherosclerotic disease; Cochrane Embase PubMed searched",1],["R0003761","Real world study of GLP-1 receptor agonists in overweight or obese type 2 diabetes by using repeated measurement analysis of variance.","Yang W","2024","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent03","RCT by random number table, metformin vs metformin plus dulaglutide or semaglutide in overweight T2D, 12 months",1],["R0003904","Utilization and clinical characteristics of patients with type 2 diabetes and chronic kidney disease prescribed finerenone in the United States.","Kovesdy CP","2026","exclude","E2","primary_report",null,null,null,"high","first","opus-5.5-agent03","finerenone utilization study; GLP-1 RA only described as concomitant medication, no exposure comparison",1],["R0003966","Switching to iGlarLixi versus continuation of a daily or weekly glucagon-like peptide-1 receptor agonist (GLP-1 RA) in insufficiently controlled type 2 diabetes: A LixiLan-G trial subgroup analysis by HbA1c and GLP-1 RA use at screening.","Rosenstock J","2021","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent03","subgroup analysis of LixiLan-G RCT, switch to iGlarLixi vs continued GLP-1 RA in T2D",1],["R0004043","SEMA-RENAL: Real-World Effects of Subcutaneous Semaglutide on Kidney Outcomes","Poon KV","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent03","retrospective single group cohort of semaglutide initiators with pre post kidney markers, no comparison group",1],["R0004118","The Impact of Glucagon-Like Peptide-1 Receptor Agonist on the Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus: A Meta-Analysis and Systematic Review.","Rahman A","2023","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent04","systematic review and meta-analysis of observational studies of GLP-1 RA vs other glucose lowering drugs on cardiovascular events",1],["R0004261","Effects of glucagon-like peptide-1 receptor agonists on cardiovascular outcomes in high-risk type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.","Chen X","2024","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent04","registered systematic review and meta-analysis of RCTs of GLP-1 RA in high risk type 2 diabetes, pooled cardiovascular hazard ratios",1],["R0004334","The Roles of Incretin Hormones GIP and GLP-1 in Metabolic and Cardiovascular Health: A Comprehensive Review.","Yamanouchi D","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent04","comprehensive narrative review of GIP and GLP-1 physiology and cardiovascular evidence, no systematic methods",1],["R0004425","Cardiovascular Protective Properties of GLP-1 Receptor Agonists: More than Just Diabetic and Weight Loss Drugs.","Le R","2024","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent04","narrative review of cardiovascular protective properties of GLP-1 RAs",1],["R0004628","Prescribing Patterns of SGLT2 Inhibitors and GLP-1 Receptor Agonists in Patients With T2DM and ASCVD in South Korea.","Eom YR","2025","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent04","Korean claims cross sectional study of SGLT2i and GLP-1 RA prescribing patterns, drug utilization without exposure comparison",1],["R0004106","Evaluation of an oral small-molecule glucagon-like peptide-1 receptor agonist, lotiglipron, for type 2 diabetes and obesity: A dose-ranging, phase 2, randomized, placebo-controlled study.","Amin NB","2025","include_nma",null,"primary_report","P01; P02",null,null,"high","first","opus-5.5-agent01","phase 2 double blind dose ranging RCT of oral lotiglipron versus placebo in type 2 diabetes and obesity cohorts",1],["R0004187","Effects of Weekly Semaglutide and Tirzepatide Therapy on APRI and FIB-4 Scores in Adults with Obesity: A Real-World 12-Month Study","Kotan R","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent01","retrospective treated only cohort of semaglutide or tirzepatide with before and after fibrosis scores, no comparison group",1],["R0004243","Therapeutic role of semaglutide in metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis: A systematic review and meta-analysis of placebo-controlled trials with GRADE evidence assessment.","Khan S","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent01","registered meta-analysis of placebo controlled semaglutide RCTs in MASLD or MASH, PubMed Scopus CENTRAL searched",1],["R0004322",null,null,null,"exclude","E1","other",null,null,null,"high","first","opus-5.5-agent01","drug discrimination experiments in rats with semaglutide, tirzepatide and retatrutide; animal study only",1],["R0004413","Impact of GAD-65 antibody detection on antihyperglycemic therapy in T2D.","Halliburton S","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent01","before and after count of antihyperglycemic drug classes after GAD-65 antibody detection; prescribing study without exposure comparison",1],["R0004491","Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: A real-world disproportionality study based on FDA adverse event reporting system database.","Liu L","2022","inventory_only","N5","other",null,null,null,"high","first","opus-5.5-agent01","FAERS disproportionality analysis of gastrointestinal adverse events across GLP-1 RAs",1],["R0004556","Comparison of efficacy and safety of insulin degludec/liraglutide and insulin glargine U-100/lixisenatide in individuals with type 2 diabetes mellitus using professional continuous glucose monitoring.","Kawaguchi Y","2024","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent01","open label RCT of insulin degludec liraglutide versus insulin glargine lixisenatide fixed ratio combinations in type 2 diabetes",1],["R0004622","Effects of GLP-1 receptor agonist therapy on resolution of steatohepatitis in non-alcoholic fatty liver disease: a systematic review and meta-analysis.","Potter KJ","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent01","registered systematic review and meta-analysis of GLP-1 RA RCTs on NASH resolution, Medline Embase CENTRAL searched",1],["R0003621","Study design, rationale, and baseline characteristics of ATTAIN-HYPERTENSION, a phase 3 trial of the oral GLP-1 receptor agonist orforglipron for hypertension.","Laffin L","2026","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent03","design, rationale and baseline paper of ATTAIN-HYPERTENSION orforglipron vs placebo RCTs; no outcome results",1],["R0003506","Acute onset of neovascular age-related macular degeneration after initiation of tirzepatide.","Takebayashi K","2026","inventory_only","N5","primary_report","P01",null,null,"high","first","opus-5.5-agent12","case report of neovascular macular degeneration after starting tirzepatide",1],["R0003571","GLP-1 receptor agonists and coronary plaques regression in diabetic patients after acute coronary syndromes.","Gitto M","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent09","prospective registry comparing GLP-1 treated and untreated diabetic ACS patients on coronary plaque change, no eligible harm",1],["R0003635","GLP-1 Receptor Agonist Utilization for Obesity Among Medicaid Beneficiaries in Rural vs. Urban U.S. States, 2020–2024","Moka AO","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent09","Medicaid prescribing trend analysis of obesity GLP-1 drugs by rurality, utilization study without exposure comparison",1],["R0003708","Comparison of three types of drugs for cardiovascular and renal benefits in type 2 diabetes mellitus.","An XD","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent09","PROSPERO registered NMA of RCTs comparing GLP-1 agonists, SGLT2 inhibitors and finerenone on cardiorenal outcomes",1],["R0003868","Comparative Effectiveness of SGLT2i and GLP-1RA on Blood Pressure in Hypertensive Patients with Type 2 Diabetes: A Saudi Multicenter Retrospective Study.","Alshehri G","2025","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent09","retrospective cohort of SGLT2 versus GLP-1 initiators on blood pressure and unspecified adverse events, no eligible harm",1],["R0003922","Sodium-glucose cotransporter 2 inhibitors in diabetic kidney disease.","Kim DW","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent09","narrative review of SGLT2 inhibitors in diabetic kidney disease",1],["R0004065","A Nationwide Danish Comparative Effectiveness Study of GLP-1 RA, SGLT2i and DPP-4i Treatment on Risk of Stroke, Myocardial Infarction and Mortality in Type 2 Diabetes.","Hastrup S","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent09","Danish new user cohort of GLP-1, SGLT2 and DPP-4 inhibitors on stroke, infarction and mortality only",1],["R0003584","Prescribing Patterns and Adverse Effects of Semaglutide: A Real-World Comparative Evaluation.","Whorton A","2025","inventory_only","N5","primary_report","P01",null,null,"high","first","opus-5.5-agent12","retrospective service evaluation of semaglutide prescribing, before and after HbA1c and weight, no comparison group",1],["R0003651","Impact of GLP-1 Receptor Agonists in Gastrointestinal Endoscopy: An Updated Review.","Singh S","2024","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent12","narrative review of GLP-1RAs and gastrointestinal endoscopy guidance and studies",1],["R0003713","Clinical features modifying the cardiovascular benefits of GLP-1 receptor agonists: a systematic review and meta-analysis.","Kalayci A","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent12","registered SR and meta-regression of placebo controlled GLP-1RA CVOTs in T2D, three databases",1],["R0003877","Evaluating the Effect on Total Daily Insulin Dose in Adult Patients with Type 1 Diabetes Managed with Metformin and/or GLP-1 or GLP-1/GIP Receptor Agonists.","Ahmed M","2025","inventory_only","N6","primary_report","P05",null,null,"high","first","opus-5.5-agent12","retrospective cohort in T1D comparing metformin, GLP-1RA and combination add on, insulin dose and hypoglycemia, no listed harm",1],["R0003929","Effectiveness and safety of combining SGLT2 inhibitors and GLP-1 receptor agonists in individuals with type 2 diabetes: a systematic review and meta-analysis of cohort studies.","Colombijn JMT","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent12","registered SR and meta-analysis of cohort studies comparing SGLT2i plus GLP-1RA vs monotherapy in T2D",1],["R0004083","The Effect of Semaglutide on Antipsychotic-Induced Weight Gain and Other Metabolic Parameters, among a Cohort of Inpatients.","De R","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent14","retrospective chart review of inpatients on antipsychotics started on semaglutide, no comparison group",1],["R0003550","Comparative Efficacy and Safety of Tirzepatide versus Semaglutide: A Systematic Review and Meta-Analysis with Cardiometabolic Implications.","Baba AH","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent02","registered systematic review and meta-analysis of head to head RCTs of tirzepatide vs semaglutide",1],["R0004153","Effects of GLP-1 Agonists on mortality and arrhythmias in patients with Type II diabetes.","Al-Sadawi MA","2023","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent14","systematic review and meta-analysis of RCTs of GLP-1 RA on mortality and arrhythmias in T2D, multiple databases searched",1],["R0004225","Impact of incretin therapies on biochemical and imaging outcomes in metabolic dysfunction-associated steatotic liver disease.","Tesoro NA","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent14","systematic review and meta-analysis of RCTs of incretin therapy vs placebo or other drugs in MASLD, PubMed Scopus Embase",1],["R0004295","Treatment with orforglipron, an oral glucagon like peptide-1 receptor agonist, is associated with improvements of CV risk biomarkers in participants with type 2 diabetes or obesity without diabetes.","Wharton S","2025","include_nma",null,"secondary_report","P01; P02",null,null,"high","first","opus-5.5-agent14","exploratory analysis of two phase 2 RCTs of orforglipron vs placebo or dulaglutide, cardiovascular biomarkers",1],["R0004363","Role of Novel Glucagon-like Peptide-1 Receptor Analogue Polyethylene Glycol Loxenatide in Type 2 Diabetes: A Systematic Review and Meta-analysis.","Dutta D","2023","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent14","PROSPERO registered meta-analysis of RCTs of peg-loxenatide in T2D, several databases searched",1],["R0004470","Cardiovascular Outcomes of Tirzepatide vs Semaglutide in Obesity Without Type 2 Diabetes: A Matched Cohort Study","Chen S","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent14","TriNetX active comparator cohort tirzepatide vs semaglutide in obesity, MACE, AF and CKD progression only",1],["R0004534","Comparative Efficacy and Safety of Tirzepatide Versus Dulaglutide in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis.","Qazi S","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent14","PROSPERO registered meta-analysis of RCTs of tirzepatide vs dulaglutide in T2D",1],["R0004604","The hidden link between diabetes and dementia: Findings from recent epidemiological studies.","Tseng CH","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent14","narrative review of diabetes and dementia epidemiology",1],["R0003679","Withholding or continuing glucose-lowering drugs for elective surgery in patients with type 2 diabetes mellitus: a secondary analysis of the MOPED international, prospective, observational study.","Buggy DJ","2026","inventory_only","N6","secondary_report",null,null,null,"high","first","opus-5.5-agent02","MOPED secondary analysis of continuing vs withholding GLP-1 RA and other drugs before surgery; days at home and complications, aspiration not reported",1],["R0003756","Diet, nutrition, and hormone therapy for prostate cancer: a systematic review with implications for future interventions.","Pahulu I","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent02","systematic review of diet trials during androgen deprivation; no included trial evaluated a GLP-1 RA",1],["R0003903","Weight maintenance on cost-effective antiobesity medications after 1 year of GLP-1 receptor agonist therapy: a real-world study.","Paddu NU","2024","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent02","real world single cohort followed on generic antiobesity drugs after a year of GLP-1 RA; no comparison group",1],["R0004040","Real-World Effectiveness of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists (OW GLP-1RAs) in Comparison with Dipeptidyl Peptidase-4 Inhibitors (DPP-4is) for Glycemic Control and Weight Outcomes in Type 2 Diabetes Mellitus (RELATE).","Tan X","2024","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent02","claims and EMR cohort of once weekly GLP-1 RA vs DPP-4 inhibitor on HbA1c and weight; no listed harm",1],["R0003564","The Impact of Contemporary Glucagon-like Peptide-1 Receptor Agonists on the Onset, Severity, and Conversion to Arthroplasty in Hip and Knee Osteoarthritis.","Porto JR","2025","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent07","TriNetX matched cohort of GLP-1RA use vs none in obesity; osteoarthritis and arthroplasty outcomes, no listed harm",1],["R0003632","Comparative Effectiveness of Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitors and Glucagon-like Peptide-1 (GLP-1) Receptor Agonists in Reducing Adverse Cardiovascular Events in Type 2 Diabetes.","Shah SZ","2025","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent07","retrospective single hospital cohort SGLT2i vs GLP-1RA in T2D; MACE and cardiometabolic outcomes only",1],["R0003694","The Antiobesity Effect and Safety of GLP-1 Receptor Agonist in Overweight/Obese Adolescents Without Diabetes Mellitus: A Systematic Review and Meta-Analysis.","Katole NT","2024","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent07","meta-analysis of RCTs of GLP-1RA for obesity in adolescents without diabetes",1],["R0003780","Impact of semaglutide pretreatment on reproductive outcomes in women with overweight and obesity with infertility: a real-world multicenter cohort study.","Wu YC","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent07","TriNetX cohort of semaglutide pretreatment vs matched controls in infertile women; pregnancy, live birth, miscarriage, no malformations",1],["R0003853","[Fixed ratio combinations GLP-1RA and basal insulin: literature review].","Kurkin DV","2024","exclude","E3","other",null,null,"non_english","high","first","opus-5.5-agent07","Russian narrative literature review of insulin GLP-1RA fixed ratio combinations",1],["R0003916","Evaluating Glycemic Control Efficacy and Safety of the Oral Small Molecule Glucagon-Like Peptide 1 Receptor Agonist Danuglipron in Type 2 Diabetes Patients: A Systemic Review and Meta-Analysis.","Fatima H","2023","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent07","PRISMA meta-analysis of RCTs of danuglipron vs placebo in type 2 diabetes",1],["R0003975","Preventive effect of liraglutide on postoperative delirium in elderly patients undergoing cardiac surgery: protocol for a single-centre, randomised, double-blind, placebo-controlled trial.","Bai S","2026","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent07","protocol of a placebo controlled RCT of perioperative liraglutide for delirium after cardiac surgery",1],["R0002584","Incretin-based therapies in diabetic kidney disease: toward integrated cardio-kidney-metabolic disease modification.","Kim Y","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent15","narrative review article on incretin based therapies in diabetic kidney disease from a study group",1],["R0002642","Exploring the effects of glucagon-like peptide-1 receptor agonists on ventricular arrhythmias: a propensity score-matched analysis.","Tan MC","2025","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent15","TriNetX matched cohort with ventricular arrhythmias, GLP-1 RA users versus nonusers; mortality, hospitalization and cardiac events only",1],["R0002708","Cardiometabolic 2.0: Redefining Cardiovascular Prevention Through SGLT-2 Inhibitors and GLP-1 Receptor Agonists.","Tanasescu MD","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent15","self described narrative review of SGLT2i and GLP-1 RAs in cardiovascular prevention, no formal synthesis",1],["R0002795","Real-world use of semaglutide in patients with type 2 diabetes and end-stage renal disease: a multicenter retrospective cohort study.","Alkhezi O","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent15","retrospective case series of 17 semaglutide users with type 2 diabetes and ESRD; no comparison group",1],["R0002851","Pulmonary artery pressure trajectories in heart failure patients treated with GLP-1 receptor agonists.","Jiang H","2025","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent15","nine heart failure patients with pressure sensors before and after semaglutide or tirzepatide; no comparator",1],["R0002904","The Impact of Glucagon-Like Peptide-1 (GLP-1) Agonists on Acne, Hidradenitis, and Sebaceous Activity.","Jabin A","2026","inventory_only","N1","primary_report",null,null,null,"high","first","opus-5.5-agent15","prospective single arm study of semaglutide on acne, hidradenitis and sebum; before and after comparison only",1],["R0002974","Comparative Effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-Like Peptide-1 Receptor Agonists in Reducing Cardiovascular Events in Patients With Type 2 Diabetes.","Khan HU","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent15","PRISMA systematic review and meta-analysis of 11 cohorts comparing SGLT2i with GLP-1 RAs for stroke; three databases searched",1],["R0003022","Association Between GLP-1RAs and Postoperative Complications Following Operative Ankle Fracture Fixation: A Retrospective Cohort Study.","Monteiro SK","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent15","TriNetX matched cohort after ankle fracture fixation, GLP-1 RA exposure versus none; orthopedic complications only",1],["R0002557","GLP-1 receptor agonists in the context of cancer: the road ahead.","Miousse IR","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent10","narrative overview of GLP-1 RAs, cancer metabolism and cachexia; no systematic methods",1],["R0002623","GLP-1 Receptor Agonists for the Prevention of New-Onset Heart Failure: A Systematic Review and Meta-Analysis of Placebo-Controlled Randomized Clinical Trials.","Neves JS","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent10","meta-analysis of placebo controlled GLP-1 RA RCTs on new onset heart failure; PubMed search with PICO criteria",1],["R0002687","Orforglipron for the treatment of moderate-to-severe obstructive sleep apnea in adults with obesity or overweight: Study design and baseline characteristics of ATTAIN-OSA, a phase 3 trial.","Malhotra A","2026","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent10","design and baseline paper of ATTAIN-OSA RCTs orforglipron versus placebo in sleep apnea; no outcome results",1],["R0002840","Efficacy of the GLP-1 receptor agonist, semaglutide, in abstinence from illicit and nonprescribed opioids in an outpatient population with treatment-refractory OUD: A randomized, double-blind, placebo-controlled clinical trial protocol.","Freet CS","2025","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent10","protocol of placebo controlled RCT of semaglutide for opioid abstinence in opioid use disorder",1],["R0002885","Personalized Combination of a Ketogenic Diet and Low-Dose Semaglutide for Cardiometabolic Health: A Retrospective Case Series.","Parker G","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent10","retrospective case series of seven patients on ketogenic diet plus low dose semaglutide; no comparison group",1],["R0002952","Efficacy and hypoglycaemia outcomes with once-weekly insulin icodec versus once-daily basal insulin in type 2 diabetes according to baseline glucagon-like peptide-1 receptor agonist and sodium-glucose co-transporter-2 inhibitor use: A post hoc analysis of ONWARDS 1-5.","Vilsbøll T","2025","inventory_only","N3","secondary_report",null,null,null,"high","first","opus-5.5-agent10","post hoc of ONWARDS RCTs icodec versus daily basal insulin by baseline GLP-1 RA use; GLP-1 regimen not randomized",1],["R0003007","Use of Glucagon-Like Peptide-1 Receptor Agonists Does Not Increase the Risk of Cancer in Patients with Type 2 Diabetes Mellitus.","Kim M","2025","include_harms",null,"primary_report",null,"O32A; O32B; O38; O39",null,"high","first","opus-5.5-agent10","Korean claims cohort GLP-1 RA users versus other glucose lowering drug users; incident cancer incl pancreatic and thyroid",1],["R0003365","Glucagon-like peptide-1 receptor agonists and the risk of erectile dysfunction: a drug target Mendelian randomization study.","An H","2024","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent05","drug target Mendelian randomization of GLP1R genetic proxies and erectile dysfunction; no drug exposure studied",1],["R0003430","Repurposing semaglutide as an adjunctive treatment for cocaine use disorder: protocol for a randomised controlled trial.","Yammine L","2026","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent05","protocol of placebo controlled RCT of semaglutide added to CBT for cocaine use disorder; no results",1],["R0003562","The role of GLP-1 receptor agonists in IBD-related surgery and IBD-related complications of inflammatory bowel disease among patients with metabolic comorbidities: a systematic review and meta-analysis.","Yang M","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent05","registered meta-analysis of cohorts comparing GLP-1 RA users with nonusers in IBD on surgery and complications",1],["R0003689","Comparative evaluation of liraglutide plus metformin combination therapy versus metformin monotherapy in patients with type 2 diabetes mellitus: A retrospective clinical study.","Mai T","2026","inventory_only","N6","other",null,null,null,"high","first","opus-5.5-agent05","retrospective comparison of liraglutide plus metformin versus metformin on glycemia and general adverse events; no listed harm",1],["R0003774","Is it necessary to stop glucagon-like peptide-1 receptor agonists prior to endoscopic procedure? A retrospective study.","Ghazanfar H","2024","inventory_only","N5","other",null,null,null,"high","first","opus-5.5-agent05","chart review of GLP-1 RA users only comparing liquid versus regular diet before endoscopy; no unexposed comparison",1],["R0003851","Use of glucagon-like peptide-1 receptor agonists in patients with left ventricular assist devices.","Ibrahim R","2025","inventory_only","N6","other",null,null,null,"high","first","opus-5.5-agent05","TriNetX cohort of LVAD recipients with versus without GLP-1 RA; transplant, heart failure and mortality outcomes only",1],["R0004064","Effect of treatment duration on the associations between three modern antidiabetic drugs and survival outcomes of lung cancer in China.","Chen Z","2025","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent08","retrospective cohort of lung cancer patients with diabetes by GLP-1 RA, DPP-4i, SGLT2i duration; survival outcomes only",1],["R0004131","Diabetic kidney disease within the framework of cardio-kidney-metabolic health: a paradigm shift.","Braga JR","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent08","narrative review of diabetic kidney disease therapies within cardio kidney metabolic framework",1],["R0004209","Occurrence of Gastrointestinal Adverse Events Upon GLP-1 Receptor Agonist Initiation With Concomitant Metformin Use: A Post Hoc Analysis of LEADER, STEP 2, SUSTAIN-6, and PIONEER 6.","Klein KR","2024","include_nma",null,"pooled_analysis","P01",null,null,"high","first","opus-5.5-agent08","post hoc pooled analysis of four placebo controlled GLP-1 RA trials on GI adverse events by metformin use",1],["R0004439","Weight Loss Efficacy of Tirzepatide Compared to Placebo or GLP-1 Receptor Agonists in Adults With Obesity or Overweight: A Meta-Analysis of Randomized Controlled Trials With ≥ 20 Weeks Treatment Duration.","Khawaji A","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent08","meta-analysis of RCTs of tirzepatide versus placebo or GLP-1 RA in obesity; PubMed, Embase, CENTRAL searched",1],["R0004505","Evaluating biased agonism of glucagon-like peptide-1 (GLP-1) receptors to improve cellular bioenergetics: A systematic review.","Wong S","2025","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent08","systematic review of in vitro and animal studies of biased GLP-1 receptor agonism and bioenergetics",1],["R0004586","Sexual Safety Signals of Common Antidiabetic Drugs: Insights From FAERS Disproportionality Analysis.","Lin S","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent08","FAERS disproportionality analysis of erectile dysfunction with antidiabetic drugs including GLP-1 RAs",1],["R0004186","How to individualize renoprotective therapy in obese patients with chronic kidney disease: a commentary by the Diabesity Working Group of the ERA.","Morales E","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent20","working group commentary and narrative review of GLP-1 RAs in obese CKD",1],["R0004242","Long-term effectiveness of iGlarLixi treatment in people with type 2 diabetes in the United States: The soli-durability 24-month observational study.","Malik RA","2025","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent20","retrospective single cohort of iGlarLixi initiators, before and after HbA1c, no comparison group",1],["R0004321","Clinical characteristics and outcomes of patients with type 2 diabetes mellitus and chronic kidney disease from two new-user medication cohorts: a retrospective cohort study using regional electronic health records database in China.","Deng X","2025","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent20","descriptive new user cohorts of SGLT2i and GLP-1 RA in T2D with CKD, no formal comparison, CV and kidney failure outcomes",1],["R0004395","Pharmacologic Treatments for the Preservation of Lean Body Mass During Weight Loss.","Arora G","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent20","self described narrative review of drugs to preserve lean mass during weight loss",1],["R0004490","GLP-1 RAs and Cardiovascular and Kidney Outcomes by Body Mass Index in Type 2 Diabetes.","Chen TH","2025","include_harms",null,"primary_report",null,"O29",null,"high","first","opus-5.5-agent20","new user active comparator cohort GLP-1 RA vs DPP-4i in Taiwan, pancreatitis secondary outcome; PSM by BMI strata",1],["R0004554","Modulation of metabolic syndrome components by oral semaglutide in hypothyroid-T2DM patients: a retrospective analysis.","Tilici DM","2025","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent20","retrospective single arm cohort of oral semaglutide in hypothyroid T2D patients, no comparison group",1],["R0004619","Once-Weekly Semaglutide Versus Once-Daily Liraglutide for Weight Loss in Adults: A Meta-Analysis of Randomized Controlled Trials.","Hashmi TM","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent20","PROSPERO registered meta-analysis of RCTs of semaglutide weekly vs liraglutide daily, three databases",1],["R0004681","Effects of Semaglutide and Tirzepatide on Bone Metabolism in Type 2 Diabetic Mice.","Lv F","2024","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent20","diabetic mouse study of semaglutide and tirzepatide on bone",1],["R0003655","Beyond Glycemic Control: Concurrent GLP-1 Receptor Agonist Use Is Associated with Reduced Urinary Adverse Events Following OnabotulinumtoxinA Treatment in Non-Diabetic Adults with Overactive Bladder.","Hammad MAM","2025","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent13","TriNetX cohort botulinum toxin with vs without GLP-1 agonist in overactive bladder, urinary retention and UTI only",1],["R0003721","Incidence of Gastrointestinal Adverse Events and Healthcare Resource Utilization in Patients Using Glucagon-Like Peptide-1 Analogs: A Real-World Study.","Nathani P","2026","include_harms",null,"primary_report",null,"O28; O29; O37A; O37B",null,"high","first","opus-5.5-agent13","TriNetX matched cohort GLP-1 users vs never users reporting gastroparesis, pancreatitis, bowel obstruction and cholecystitis",1],["R0003803","Glucagon-Like Peptide-1 Receptor Agonists and Major Adverse Cardiovascular Events in Patients With and Without Diabetes: A Meta-Analysis of Randomized-Controlled Trials.","Hosseinpour A","2024","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent13","PROSPERO registered meta-analysis of placebo controlled GLP-1 agonist RCTs on cardiovascular events",1],["R0003878","Antidiabetic drug and chronic respiratory disease in type 2 diabetes: a network meta-analysis and Mendelian randomization analysis.","Patel I","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent13","PROSPERO registered network meta-analysis of antidiabetic drug classes including GLP-1 agonists on chronic respiratory disease",1],["R0004076","Comparative Efficacy of Semaglutide Versus Liraglutide or Efinopegdutide on Weight Loss in Obese Patients: A Systematic Review and Meta-Analysis.","Wen J","2024","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent13","PRISMA systematic review and meta-analysis of semaglutide vs liraglutide or efinopegdutide head to head studies",1],["R0002528","Effect of GLP-1 agonists on testosterone levels: a systematic review and meta-analysis.","Orra SH","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent17","registered systematic review and meta-analysis pooling testosterone change with GLP-1 RA treatment, four databases searched",1],["R0002587","Efficacy of Metabolic and Bariatric Surgery Compared with GLP-1 Receptor Agonist Treatment in Preventing Mortality and Major Adverse Cardiac Events Among Individuals with Obesity and Type 2 Diabetes: A Systematic Review and Meta-analysis.","Chadwick J","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent17","registered systematic review and meta-analysis comparing bariatric surgery with GLP-1 RA on mortality and MACE in obesity with diabetes",1],["R0002649","Comparative effectiveness of tirzepatide and DPP-4 inhibitors in type 2 diabetes with heart failure.","Mortada I","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent17","TriNetX matched cohort of tirzepatide versus DPP-4 inhibitor in diabetes with heart failure; mortality, hospitalization, MACE only",1],["R0002804","Health Disparity Clusters of Off Label Prescriptions for Glucagon-Like Peptide 1 Receptor Agonists.","Spinelli KJ","2025","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent17","county level claims analysis of off label GLP-1 RA prescribing and disparities; no exposure outcome comparison",1],["R0002853","Cardiovascular Risk Reduction With Tirzepatide, a Dual GIP/GLP-1 Agonist, in Patients With Type 2 Diabetes Mellitus.","Terui S","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent17","narrative review of tirzepatide SURPASS trials and cardiovascular risk",1],["R0002911","Emerging Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors on Male Sexual Hormones and Behaviors: Systematic Review and Meta-Analysis.","Corona G","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent17","systematic review and meta-analysis with Medline search and criteria on GLP-1 RAs and SGLT2 inhibitors for male hormones and sexual function",1],["R0002978","Real-world outcomes of hybrid obesity care using digital coaching and GLP-1 therapy in a multi-ethnic Asian setting.","Ali SH","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent17","real world cohort of a GLP-1 RA plus digital coaching program without an untreated comparison group",1],["R0004706","Efficacy and Safety of Dulaglutide for Weight Reduction Among Diabetic Patients in Saudi Arabia: A Retrospective Cohort Study.","Alonazi GK","2025","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent06","retrospective single group cohort of dulaglutide users in T2D with before and after BMI and HbA1c; no comparison group",1],["R0004764","Impact of polyethylene glycol loxenatide on cardiovascular outcomes in patients with type 2 diabetes: study protocol for a multicentre, randomised, double-blind, placebo-controlled trial (BALANCE-3).","Xie Y","2023","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent06","protocol of BALANCE-3, placebo controlled CVOT of PEG-loxenatide in T2D; no results",1],["R0004819","Integrating incretin-based therapies into comprehensive obesity care: an EASO position statement.","Correia JC","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent06","EASO position statement on integrating incretin therapies into obesity care",1],["R0004880","Knowledge, Counseling Practice, Perceived Barriers, and Clinical Decision-Making of Community Pharmacists in Saudi Arabia Regarding Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors.","Alhomoud IS","2025","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent06","cross sectional survey of community pharmacists knowledge about GLP-1 RAs and SGLT2 inhibitors; no exposure comparison",1],["R0004962","A Systematic Review and Meta-Analysis Evaluating the Role of GLP-1 Receptor Agonists in Substance Use Disorders.","Sarma I","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent06","systematic review and meta-analysis of RCTs of GLP-1 RAs versus placebo for alcohol and tobacco use disorders",1],["R0005022","Effects of GLP-1 Receptor Agonists on Muscle Mass, Strength, and Quality in MASLD: A Systematic Review.","Iorra F","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent06","systematic review of GLP-1 RA studies on muscle outcomes in MASLD; MEDLINE, Embase, Cochrane with criteria, narrative synthesis",1],["R0002560","Association between GLP-1 receptor agonists as a class and colorectal cancer risk: a meta-analysis of retrospective cohort studies.","Zhong Y","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent11","PRISMA meta-analysis of cohort studies on GLP-1RA use and colorectal cancer risk; five named sources searched",1],["R0002624","SAT-147 The Effect of Glucagon-Like Peptide-1 Receptor Agonists on Erectile Dysfunction and Testosterone Levels: A Systematic Review and Meta-Analysis",null,"2025","include_review",null,"systematic_review",null,null,"abstract_only","high","first","opus-5.5-agent11","registered meta-analysis abstract of GLP-1RA versus placebo or other drugs on erectile function and testosterone; three named databases",1],["R0002785","Time to Treatment Intensification with Glucagon-Like Peptide-1 Receptor Agonists Versus Comparators in People with Type 2 Diabetes Treated with Metformin.","Ostrominski JW","2025","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent11","US EMR matched cohort of GLP-1RA versus other add on drugs; treatment intensification, HbA1c and BMI only",1],["R0002842","Is Weight Loss the Main Driver for A1C Improvement by Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists? A 2.5-Year Analysis in Real-World Clinical Practice.","Al-Badri M","2025","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent11","retrospective series of continuous GLP-1RA users stratified by weight change tertile; no comparator group",1],["R0002886","Physical Fitness with Exercise and GLP-1 Receptor Agonist Treatment Alone or Combined After Diet-Induced Weight Loss: A Secondary Analysis of a Randomized Controlled Trial in Adults with Obesity.","Jensen SBK","2026","include_nma",null,"secondary_report","P02",null,null,"high","first","opus-5.5-agent11","S-LiTE secondary analysis; randomized liraglutide versus placebo with or without exercise after diet induced weight loss",1],["R0002955","The Effects of Combined Antihypertensive and Antidiabetic Therapies on Cardiovascular Outcomes: A Systematic Review and Meta-Analysis.","Hsieh WC","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent11","registered meta-analysis with prespecified synthesis of GLP-1RA outcome trials versus placebo; MEDLINE, Embase, Scopus",1],["R0004693","Safety, efficacy, and cardiovascular benefits of combination therapy with SGLT-2 inhibitors and GLP-1 receptor agonists in patients with diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials.","Mousavi A","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent04","registered systematic review and meta-analysis of RCTs comparing SGLT2i plus GLP-1 RA with monotherapy or usual care",1],["R0004813","Weight Loss Patterns and Clinical Outcomes of GLP1 Receptor Agonists in Breast Cancer Survivors.","Sukumar JS","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent04","breast cancer survivor cohort, matched GLP-1 RA users vs nonusers on disease free and overall survival, no eligible harms outcome",1],["R0004959","Gastrointestinal side effects of the non-peptide GLP-1 receptor agonists: A systematic review and meta-analysis.","Bhattarai HB","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent04","systematic review and meta-analysis of RCTs of danuglipron and orforglipron on gastrointestinal adverse effects, pooled odds ratios",1],["R0005018","The Effect of Glucagon-like-Peptide-1 Receptor Agonists on Diabetic Retinopathy Progression, Central Subfield Thickness, and Response to Intravitreal Injections.","Michaeli T","2024","include_harms",null,"primary_report",null,"O33",null,"high","first","opus-5.5-agent04","retrospective GLP-1 RA new users vs untreated controls with diabetic retinopathy, progression and complications compared",1],["R0005071","Non-antiarrhythmic pharmacotherapy in cardio-renal-metabolic disease and incident atrial fibrillation: a trial meta-analysis.","Raveendra K","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent04","registered meta-analysis of RCTs of cardio renal metabolic drugs incl GLP-1 RA on incident atrial fibrillation",1],["R0005153","Trends in diabetes medication prescribing from 2018 to 2021: A cross-sectional analysis.","Riad J","2024","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent04","repeated cross sectional analysis of Canadian diabetes drug dispensing trends, drug utilization without exposure comparison",1],["R0002979","Efficacy of GLP-1 Receptor Agonist-Based Therapies on Cardiovascular Events and Cardiometabolic Parameters in Obese Individuals Without Diabetes: A Meta-Analysis of Randomized Controlled Trials.","Yin Y","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent18","meta-analysis of placebo controlled RCTs of GLP-1 RA based drugs in nondiabetic obesity; four named databases; CV events pooled",1],["R0003146","Comparison of cardiovascular outcomes between once-weekly semaglutide and dulaglutide in adults with type 2 diabetes and established atherosclerotic cardiovascular disease in the United States.","Tan X","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent18","Optum new initiator cohort semaglutide vs dulaglutide in T2D with ASCVD; MACE outcomes only, no listed harms outcome",1],["R0003208","The Effect of Semaglutide on Pancreatic β-Cell Function in Adults with Type 2 Diabetes: A Systematic Review and Meta-Analysis.","Abusedera O","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent18","registered systematic review and meta-analysis of semaglutide RCTs on beta cell function in T2D; PubMed, Embase, Scopus",1],["R0003331","The Role of SGLT2 Inhibitors in the Prevention of Type 2 Diabetes: A Narrative Review of Current Evidence.","Owczarczyk-Durma AC","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent18","narrative review of SGLT2 inhibitors in prediabetes; GLP-1 RAs only mentioned in passing; also E3",1],["R0003410","Enhanced renoprotective effects of combined glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus: Real-world evidence.","Jhu JY","2025","include_harms",null,"primary_report",null,"O121",null,"high","first","opus-5.5-agent18","TriNetX matched cohort of GLP-1 RA plus SGLT2i vs SGLT2i alone in T2D; acute kidney injury reported",1],["R0002591","MON-527 Association of Acute kidney injury with commonly prescribed glucagon-like peptide 1 receptor Agonists: A Pharmacovigilance Analysis",null,"2025","inventory_only","N5","conference_abstract",null,null,"abstract_only","high","first","opus-5.5-agent19","FAERS disproportionality analysis of acute kidney injury reports across GLP-1 RAs; meeting abstract",1],["R0003089","GLP-1 receptor agonists in Parkinson's disease: a meta-analysis revealing motor benefit and highlighting mood improvement.","Chen Y","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent19","meta-analysis of RCTs of GLP-1 RA vs placebo in Parkinson disease; PubMed Embase Cochrane searched, PROSPERO registered",1],["R0003151","Racial and ethnic disparities in early uptake of GLP-1 receptor agonists in patients with and without MASLD","Boateng S","2025","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent19","racial and ethnic disparities in GLP-1 RA prescription uptake in All of Us; utilization outcome, no exposure comparison",1],["R0003210","Insulin-glucagon-like peptide-1 receptor agonist relay and glucagon-like peptide-1 receptor agonist first regimens in individuals with type 2 diabetes: A randomized, open-label trial study.","Takeshita Y","2022","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent19","open label RCT in poorly controlled type 2 diabetes: degludec then liraglutide vs liraglutide for 24 weeks; HbA1c primary",1],["R0003265","Influence of glucagon-like peptide-1 receptor agonists on renal parameters: a meta-analysis of randomized controlled trials.","Li W","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent19","meta-analysis of RCTs of GLP-1 RA vs placebo or other drugs on renal parameters in type 2 diabetes; PubMed Cochrane Web of Science",1],["R0003340","Rates of, Reasons for, and Reactions to Discontinuation of GLP-1 Receptor Agonists: A Narrative Review.","Heisey HD","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent19","narrative review of GLP-1 RA discontinuation and persistence literature; authors state a non systematic approach",1],["R0003414","Sodium-Glucose Cotransporter 2 Inhibitors and Reduced Fibromyalgia Risk in Patients With Diabetes: A Target Trial Emulation Study.","Jhang YS","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent19","TriNetX target trial emulation SGLT2 inhibitor vs GLP-1 RA new users; fibromyalgia outcome only, no listed harm",1],["R0003485","Efficacy and safety of GLP-1 receptor agonists on weight management and metabolic parameters in PCOS women: a meta-analysis of randomized controlled trials.","Lin S","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent19","meta-analysis of RCTs of GLP-1 RA vs metformin or placebo in PCOS; PubMed Embase Cochrane Web of Science searched",1],["R0003907","Impact of ADA Guidelines and Medication Shortage on GLP-1 Receptor Agonists Prescribing Trends in the UK: A Time-Series Analysis with Country-Specific Insights.","Ibrahim ARN","2024","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent05","time series of national GLP-1 RA prescribing rates in the UK; drug utilization without exposure comparison",1],["R0004190","GLP-1 RA Prescribing Errors in a Multidisciplinary Digital Weight-Loss Service: A Retrospective Quantitative Analysis.","Talay L","2024","exclude","E2","primary_report",null,null,null,"high","first","opus-5.5-agent03","audit of GLP-1 RA prescribing errors in a digital weight loss service; no exposure comparison on health outcomes",1],["R0004258","Comparative Cardio-Renal Outcomes of Type 2 Diabetes Patients Administered Glucagon-Like Peptide-1 Receptor Agonists: A Network Meta-Analysis.","Zhuo C","2021","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent03","systematic review and NMA of GLP-1 RA cardiovascular outcome trials, four databases searched",1],["R0004327","Comparative efficacy and safety of GLP-1 receptor agonists for weight reduction: A model-based meta-analysis of placebo-controlled trials.","Guo H","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent03","model based meta-analysis of placebo controlled GLP-1 RA obesity RCTs with PubMed and Embase search and criteria",1],["R0004424","Efficacy and safety of glucagon-like peptide-1 receptor agonists on prediabetes: a systematic review and meta-analysis of randomized controlled trials.","Salamah HM","2024","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent03","meta-analysis of RCTs of GLP-1 RA vs placebo or lifestyle in prediabetes, four databases searched",1],["R0004494","Efficacy of lifestyle modification combined with GLP-1 receptor agonists on body weight and cardiometabolic biomarkers in individuals with overweight or obesity: a systematic review and meta-analysis.","Chu J","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent03","meta-analysis of RCTs of GLP-1 RA plus lifestyle vs placebo plus lifestyle in overweight or obesity",1],["R0004625","Glucagon-like peptide-1 receptor agonists improve metabolic dysfunction-associated steatotic liver disease outcomes.","Havranek B","2025","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent03","TriNetX matched cohort GLP-1 RA vs nonusers with MASLD; cardiovascular, portal hypertension and mortality only",1],["R0003970","Switch from premixed insulin analogue to degludec-liraglutide combination: a CGM study.","Kravos Tramšek NA","2025","inventory_only","N1","other",null,null,null,"high","first","opus-5.5-agent05","single arm prospective switch from premixed insulin to iDegLira with CGM over 24 weeks; no concurrent comparator",1],["R0004054","Comparison of glucagon-like peptide-1 receptor agonists vs. placebo on any cardiovascular events in overweight or obese non-diabetic patients: a systematic review and meta-analysis.","Kelkar R","2024","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent05","registered meta-analysis of placebo controlled GLP-1 RA RCTs on cardiovascular events in nondiabetic obesity, named databases",1],["R0004120","Role of Glucagon-Like Peptide-1 Receptor Agonists on the Weight Loss of Individuals With Type 2 Diabetes: A Systematic Review.","Irfan H","2023","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent05","PRISMA systematic review of GLP-1 RA studies on weight in type 2 diabetes searching PubMed and Google Scholar",1],["R0004264","Effect of iGlarLixi on continuous glucose monitoring-measured time in range in insulin-naive adults with suboptimally controlled type 2 diabetes.","Frías JP","2025","inventory_only","N1","other",null,null,null,"high","first","opus-5.5-agent05","single arm open label phase 4 study of iGlarLixi with CGM time in range over 16 weeks",1],["R0004428","Characterization of treatment intensified (add-on to metformin) adults with type 2 diabetes in Thailand: A cross-sectional real-world study (CONVERGE).","Sriphrapradang C","2025","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent05","descriptive cross sectional chart review of add-on glucose lowering drug use in Thailand; no exposure comparison of outcomes",1],["R0004075","Semaglutide Adherence and Cardiovascular Diseases in Patients With Type 2 Diabetes: Evidence From Real-World Data in Japan.","Masudo C","2025","inventory_only","N6","primary_report","P01",null,null,"high","first","opus-5.5-agent12","claims cohort of semaglutide users comparing good vs poor adherence, cardiovascular events only",1],["R0004144","Glucagon-like peptide 1 receptor agonists and the potential risk of pancreatic carcinoma: a pharmacovigilance study using the FDA Adverse Event Reporting System and literature visualization analysis.","Cao M","2023","inventory_only","N5","other",null,null,null,"high","first","opus-5.5-agent12","FAERS disproportionality analysis of pancreatic carcinoma reports with GLP-1RAs",1],["R0004287","Treatment satisfaction and time in range after 16 weeks of treatment with iGlarLixi in insulin-naive adults with suboptimally controlled type 2 diabetes.","Shah VN","2025","inventory_only","N1","secondary_report","P01",null,null,"high","first","opus-5.5-agent12","exploratory analysis of single arm phase 4 Soli-CGM study of iGlarLixi, treatment satisfaction",1],["R0004358","Risk factor screening and prediction modeling of gastrointestinal adverse reactions caused by GLP-1RAs.","Gao R","2024","inventory_only","N5","primary_report","P01",null,null,"high","first","opus-5.5-agent12","risk prediction model for GI side effects among GLP-1RA users only, no comparison group",1],["R0004461","Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial.","Aronne LJ","2026","include_nma",null,"primary_report","P02W",null,null,"high","first","opus-5.5-agent12","double blind RCT orforglipron vs placebo for weight maintenance after tirzepatide or semaglutide in SURMOUNT-5",1],["R0004600","Effects of Glucagon-Like Peptide-1 Receptor Agonists on Bone Metabolism in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis.","Li X","2024","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent12","registered SR and meta-analysis of RCTs of GLP-1RAs vs other drugs or placebo on bone metabolism in T2D",1],["R0004161","Efficacy and Safety of CagriSema for Metabolic Outcomes: Systematic Review and Pairwise Meta-Analysis of Randomized Controlled Trials.","Shao C","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent16","PROSPERO registered systematic review and pairwise meta-analysis of CagriSema RCTs",1],["R0004304","Oral GLP-1RA TERN-601 for Adults With Obesity/Overweight: Placebo-Controlled, Multiple-Ascending-Dose, Phase 1 and 2 Studies.","Garvey WT","2026","include_nma",null,"primary_report","P02",null,null,"high","first","opus-5.5-agent16","phase 1 and phase 2 randomized placebo controlled trials of oral TERN-601 in adults with obesity without diabetes",1],["R0004369","Efficacy and safety of orforglipron, an oral small-molecule GLP-1 receptor agonist, on cardiometabolic outcomes: a meta-analysis and systematic review.","Alper A","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent16","PROSPERO registered systematic review and meta-analysis of placebo controlled orforglipron trials",1],["R0004474","Dipeptidyl Peptidase-4 (DPP-4) Inhibitors Versus Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Following Orthopedic Shoulder Surgery: A Comparative Analysis.","Mahatme RJ","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent16","TriNetX matched cohort of DPP-4i vs GLP-1RA after shoulder surgery; reoperation and opioid use only",1],["R0004538","The influence of the glucagon-like peptide-1 receptor agonist, liraglutide, on dietary patterns and nutrient intakes in patients with obesity and prediabetes: A secondary analysis of a randomized controlled trial.","Richardson KM","2025","include_nma",null,"secondary_report","P02",null,null,"high","first","opus-5.5-agent16","secondary analysis of RCT randomizing liraglutide vs caloric restriction vs sitagliptin in obesity with prediabetes; dietary intake",1],["R0004611","Real-World Weight Loss Observed With Semaglutide and Tirzepatide in Patients with Overweight or Obesity and Without Type 2 Diabetes (SHAPE).","Ng CD","2025","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent16","claims cohort describing weight change with semaglutide 2.4 mg or tirzepatide; weight only, no listed harm",1],["R0005208","Comparative Efficacy of GLP-1 Receptor Agonists, Exercise, and Their Combination on Body Composition and Glucolipid Metabolism in Adults With Overweight or Obesity: A Network Meta-Analysis of Randomized Controlled Trials.","Vandoni M","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent06","registered NMA of RCTs comparing GLP-1 RAs, exercise and combination on body composition in adults with overweight or obesity",1],["R0005278","Effect on Hemoglobin A1c (HbA1c) and Body Weight After Discontinuation of Tirzepatide, a Novel Glucose-Dependent Insulinotropic Peptide (GIP) and Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist: A Single-Center Case Series Study.","Kubota M","2023","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent06","single site follow up of SURPASS J-mono participants randomized to tirzepatide doses or dulaglutide; HbA1c and weight after stopping",1],["R0005362","Glucagon-like peptide 1 receptor agonist and reduced liver and non-liver complications in adults with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease: a target trial emulation study.","Mao X","2025","include_harms",null,"primary_report",null,"O39",null,"high","first","opus-5.5-agent06","target trial emulation of GLP-1 RA versus DPP-4 inhibitor initiators with T2D and MASLD; HCC and non-liver cancer outcomes",1],["R0005435","Effects of Tirzepatide on Metabolic Parameters in Patients with Psoriasis and Obesity: 24-Week Real-World Study.","Gisondi P","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent06","prospective real world single group study of tirzepatide in psoriasis with obesity; no comparison group",1],["R0005499","The weight reduction mediated by anti-obesity medication and the cardiovascular outcome.","Guo Y","2024","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent06","registered meta-analysis of RCTs of anti-obesity drugs incl GLP-1 RAs relating weight loss to cardiovascular outcomes",1],["R0005569","Real-world use and effectiveness of tirzepatide among individuals without type 2 diabetes: Results from the Optum Market Clarity database.","Hankosky ER","2025","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent06","descriptive claims cohort of tirzepatide utilization and weight change without diabetes; no comparison group",1],["R0005622","Reporting patterns of suicide- and self-injury-related events involving liraglutide, semaglutide, and tirzepatide: data from the European pharmacovigilance database.","Scavone C","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent06","EudraVigilance analysis of suicide and self-injury reports across liraglutide, semaglutide and tirzepatide",1],["R0005680","SELECT: Glucagon-like peptide-1 receptor agonist in obese patients with cardiovascular disease in the absence of diabetes.","Kotit S","2024","inventory_only","N9","ancillary",null,null,null,"high","first","opus-5.5-agent06","commentary summarizing the SELECT semaglutide trial results with lessons learned; no new data",1],["R0004063","Knowledge gap and prescribing patterns of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors among Chinese doctors.","Liu J","2024","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent07","online survey of Chinese doctors on knowledge and prescribing of GLP-1RA and SGLT2i; no patient exposure comparison",1],["R0004125","Effectiveness and Safety of Combined Semaglutide and Dapagliflozin Therapy in Type 2 Diabetes: A Retrospective Cohort Study.","Alzahrani M","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent07","retrospective single group cohort on semaglutide plus dapagliflozin with paired before after comparisons, no comparator",1],["R0004270","Relationship between Glucagon-like Peptide-1 Receptor Agonists and Cardiovascular Disease in Chronic Respiratory Disease and Diabetes.","Yeh JJ","2024","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent07","Taiwan NHIRD cohort of GLP-1RA users vs nonusers with respiratory disease and diabetes; stroke and cardiac outcomes only",1],["R0004342","Evaluating Cardiovascular Benefits of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) in Type 2 Diabetes Mellitus: A Systematic Review.","Sreenivasan C","2024","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent07","PRISMA systematic review across named databases of cardiovascular effects of GLP-1RA in type 2 diabetes",1],["R0004435","The Promise of Adjunct Medications in Improving Type 1 Diabetes Outcomes: Glucagon-Like Peptide Receptor Agonists.","Seetharaman S","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent07","meeting report style narrative review of GLP-1RA as adjunct in type 1 diabetes",1],["R0004578","Semaglutide vs. dulaglutide for glycemic and weight control in patients with type 2 diabetes mellitus: A systematic review and meta‑analysis.","Xia L","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent07","PRISMA meta-analysis comparing semaglutide with dulaglutide on HbA1c and weight in type 2 diabetes",1],["R0004658","Effects of Tirzepatide on Patients With Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease: A Retrospective Cohort Study.","Okuma H","2025","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent14","retrospective before and after study of switching from GLP-1 RA to tirzepatide in T2D with MASLD, no comparison group",1],["R0004791","Comparing the effectiveness of long-term use of daily and weekly glucagon-like peptide-1 receptor agonists treatments in patients with nonalcoholic fatty liver disease and type 2 diabetes mellitus: a network meta-analysis.","Yuan X","2023","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent14","network meta-analysis of RCTs of daily and weekly GLP-1 RAs in NAFLD with T2D, PubMed Cochrane Embase searched",1],["R0004856","Randomised trial comparing weight loss through lifestyle and GLP-1 receptor agonist therapy in people with MASLD.","Moolla A","2025","include_nma",null,"primary_report","P09",null,"mechanistic","high","first","opus-5.5-agent14","randomized phase 2a trial of liraglutide vs matched lifestyle weight loss in MASLD without diabetes, 12 weeks",1],["R0004923","Treatment persistence in patients with type 2 diabetes treated with glucagon-like peptide-1 receptor agonists in clinical practice in Sweden.","Svensson AM","2021","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent14","Swedish registry cohort comparing persistence across GLP-1 RA agents, HbA1c and weight only",1],["R0004981","The concomitant use of sodium-glucose co-transporter 2 inhibitors improved the renal outcome of Japanese patients with type 2 diabetes treated with glucagon-like peptide 1 receptor agonists.","Kobayashi K","2023","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent14","matched cohort of GLP-1 RA users with vs without SGLT2i, albuminuria and eGFR decline only",1],["R0005051","Identifying High-Risk Obese Individuals Without Diabetes for GLP-1RA Therapy Using Coronary CTA.","Blair CV","2025","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent14","CCTA registry of obese people without diabetes, semaglutide benefit only projected from SELECT, no drug exposure",1],["R0005106","Effects of the glucagon-like peptide-1 receptor agonist dulaglutide on sexuality in healthy men: a randomised, double-blind, placebo-controlled crossover study.","Lengsfeld S","2024","include_nma",null,"primary_report","P99",null,"crossover; mechanistic","high","first","opus-5.5-agent14","placebo controlled crossover RCT of dulaglutide on sexual function in healthy men, adverse events reported",1],["R0003076","Exercise maintains LEAP2 levels after weight loss in females with obesity.","Holt J","2026","include_nma",null,"secondary_report","P02",null,"mechanistic","high","first","opus-5.5-agent15","secondary analysis of S-LiTE RCT, liraglutide, exercise, combination or placebo after diet induced weight loss; LEAP2 hormone outcomes",1],["R0003135","Low uptake and disparities in therapeutic inertia of cardiorenal protective diabetes medications for patients with type 2 diabetes and above-target hemoglobin A1c.","German J","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent15","EHR study of therapeutic inertia in new SGLT2i or GLP-1 RA prescribing by race; prescribing only, no exposure outcome comparison",1],["R0003255","SGLT2 inhibitors and GLP-1 receptor agonists: impact on mortality in diabetic patients with cardiovascular disease.","Arow Z","2025","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent15","Clalit cohort with type 2 diabetes and ASCVD comparing SGLT2i, GLP-1 RA, both or neither; all cause mortality only",1],["R0003318","Evidence for reduced migraine reporting with GLP-1 receptor agonists","Chen H","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent15","FAERS and JADER disproportionality analysis of migraine reports with docking work; no randomization or cohort design",1],["R0003396","Use of GLP-1 receptor agonist and risk of osteoporosis among patients with type 2 diabetes: a real-world study.","Chen M","2025","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent15","single hospital cohort of type 2 diabetes, GLP-1 RA users versus nonusers; incident osteoporosis only, not a harms list outcome",1],["R0003079","Cardiovascular and Kidney Outcomes and Mortality With Long-Acting Injectable and Oral Glucagon-Like Peptide 1 Receptor Agonists in Individuals With Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Trials.","Lee MMY","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent17","systematic review and meta-analysis of RCTs of injectable and oral GLP-1 RAs on cardiovascular, kidney and mortality outcomes in type 2 diabetes",1],["R0003139","GLP-1 receptor agonists as an adjunct to bariatric surgery for weight loss and metabolic outcome improvement: a systematic review and meta-analysis.","Tan YW","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent17","systematic review and meta-analysis of GLP-1 RAs for weight regain after bariatric surgery, four databases searched",1],["R0003206","Efficacy and safety of orforglipron 12 mg versus orforglipron 36 mg maintenance dose among patients with obesity with or without diabetes: a systematic review and comprehensive meta-analysis.","Hegaz MG","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent17","registered meta-analysis of RCTs comparing orforglipron 12 mg with 36 mg in obesity, four databases searched",1],["R0003259","Do GLP-1 agonists affect perioperative risk in spine surgery? A systematic review and meta-analysis.","Ononogbu-Uche FC","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent17","registered meta-analysis of cohorts comparing perioperative GLP-1 RA use versus none in spine surgery",1],["R0003329","Efficacy and Safety of Efpeglenatide in Patients With Type 2 Diabetes and Obesity: A Systematic Review.","Narayan N","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent17","systematic review of efpeglenatide trials in diabetes and obesity with PubMed, Scopus, Web of Science search and criteria",1],["R0003409","GLP-1 Receptor Agonist Exposures Are Increasingly Common and Generally Associated with Mild Symptoms: A Single Poison Center Experience.","Marshall S","2024","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent17","single poison center case series of GLP-1 RA exposures, descriptive only",1],["R0004751","Initial Pharmacological Strategies in People with Early Type 2 Diabetes Mellitus: A Systematic Review and Network Meta-Analysis.","Choi JH","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent20","PROSPERO registered NMA of RCTs of initial drug regimens including GLP-1 RA in early T2D",1],["R0004807","Pharmacokinetic Properties of a Once-Weekly Fixed-Ratio Combination of Insulin Icodec and Semaglutide Compared with Separate Administration of Each Component in Individuals with Type 2 Diabetes Mellitus.","Westergaard L","2024","include_nma",null,"primary_report","P01",null,"mechanistic; crossover","high","first","opus-5.5-agent20","randomized double blind three period crossover PK study of IcoSema vs icodec vs semaglutide in T2D, GI adverse events reported",1],["R0004866","Efficacy and safety profile of Glucagon-Like Peptide-1 Receptor Agonist in obese Type-2 diabetes patients from a private institution in Karachi.","Qasim SF","2023","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent20","prospective clinic cohort comparing liraglutide, dulaglutide and IDegLira users on weight and HbA1c, no listed harm outcome",1],["R0004940","Impact of iGlarLixi on Glycaemic Control Depth and Variability in Asian Pacific People With Type 2 Diabetes: A Post Hoc Analysis of LixiLan-O-AP and LixiLan-L-CN.","Ni J","2026","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent20","post hoc analysis of two randomized phase 3 trials of iGlarLixi vs insulin glargine or lixisenatide in Asian T2D",1],["R0005006","Dual metformin and glucagon-like peptide-1 receptor agonist therapy reduces mortality and hepatic complications in cirrhotic patients with diabetes mellitus.","Huynh DJ","2023","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent20","TriNetX matched cohort of metformin plus GLP-1 RA vs metformin in cirrhosis, outcomes mortality decompensation and HCC",1],["R0005061","Integrated Genetic and Protein Mechanisms Underlying Glucagon-like Peptide-1 Receptor Agonists in Treating Diabetes Mellitus and Weight Loss.","Francis L","2025","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent20","in silico gene and protein interaction database analysis of GLP-1 receptor pathways",1],["R0005139","Economic burden of type 2 diabetes management in France according to clinical characteristics.","Guerci B","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent20","claims based cost of illness study of T2D in France, GLP-1 RA only described as prescribing share",1],["R0005186","Disproportionality analysis of infection associated with antidiabetic drug use patterns.","Kim TH","2025","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent20","VigiBase disproportionality analysis of infections across antidiabetic drug classes including GLP-1 RAs",1],["R0003060","Impact of Adding GLP-1 Receptor Agonists to Insulin Therapy on Cardiovascular and Microvascular Outcomes in Type 2 Diabetes: A Nationwide Cohort Study from Taiwan.","Yen FS","2025","include_harms",null,"primary_report",null,"O33",null,"high","first","opus-5.5-agent10","Taiwan claims new user cohort GLP-1 RA versus DPP-4i added to insulin; sight threatening retinopathy among outcomes",1],["R0003121","Exploring glucagon-like peptide-1 receptor agonists as potential disease-modifying agent in psychiatric and neurodevelopmental conditions: evidence from a drug target Mendelian randomization.","Zhang L","2025","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent10","drug target Mendelian randomization using GLP1R eQTLs; no drug administered or observed exposure",1],["R0003188","Efficacy and safety of novel antidiabetic drugs in patients with type 2 diabetes and chronic kidney disease: a network meta-analysis.","Zhu X","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent10","PROSPERO registered Bayesian NMA of RCTs of SGLT2i, GLP-1 RA and DPP-4i in diabetic CKD",1],["R0003242","Bone mineral density and turnover response to GLP-1 receptor agonists in older adults with overweight/obesity and prediabetes/type 2 diabetes: a 20-week pilot trial post hoc analysis.","Dinkla L","2025","include_nma",null,"secondary_report","P01; P06",null,null,"high","first","opus-5.5-agent10","post hoc of pilot RCT semaglutide plus lifestyle versus lifestyle in older adults with prediabetes or T2D; weight and BMD; population mix",1],["R0003305","Effect of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists and Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors on Atherosclerotic Cardiovascular Risk Among Patients With Type 2 Diabetes in Primary Health Care Settings in Jeddah, Saudi Arabia.","A Ljohani R","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent10","retrospective cohort semaglutide versus dapagliflozin; ASCVD risk score and metabolic changes, no harms_nrs outcome",1],["R0003381","Peri-Procedural Safety of GLP-1 Receptor Agonists in Elective Endoscopy: A Multicenter Retrospective Cohort Study.","Kalsi H","2025","include_harms",null,"primary_report",null,"O36A",null,"high","first","opus-5.5-agent10","procedure cohort of elective endoscopy in GLP-1 RA users versus nonusers; aspiration primary outcome",1],["R0003453","GLP-1 receptor agonist increase retained gastric contents on EGD and same-day colonoscopy reduces this risk.","Ukwade D","2025","include_harms",null,"primary_report",null,"O36B",null,"high","first","opus-5.5-agent10","procedure cohort of outpatient EGD comparing GLP-1 RA users with nonusers for retained gastric contents",1],["R0003504","Elective peri-operative management of adults taking glucagon-like peptide-1 receptor agonists, glucose-dependent insulinotropic peptide agonists and sodium-glucose cotransporter-2 inhibitors: a multidisciplinary consensus statement: A consensus statement from the Association of Anaesthetists, Association of British Clinical Diabetologists, British Obesity and Metabolic Surgery Society, Centre for Perioperative Care, Joint British Diabetes Societies for Inpatient Care, Royal College of Anaesthetists, Society for Obesity and Bariatric Anaesthesia and UK Clinical Pharmacy Association.","El-Boghdadly K","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent10","multidisciplinary Delphi consensus statement on perioperative management of GLP-1 RA users",1],["R0004708","Superior cardiovascular protection with GLP-1 RAs over SGLT2 inhibitors in DM and HFpEF: A propensity score matching study.","Li AC","2025","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent08","TriNetX matched cohort of GLP-1 RA versus SGLT2i in diabetes with HFpEF; cardiovascular and mortality outcomes only",1],["R0004773","Utilization of glucagon-like peptide-1 receptor agonists in children and adolescents in China: a real-world study.","Yan Y","2023","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent08","descriptive drug utilization study of GLP-1 RA prescriptions in Chinese children without exposure comparison",1],["R0004835","Obesity, Metabolic Syndrome, Diabetes and Kidney Stones: Strengthening Links Over Time?","Colin IM","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent08","narrative review linking obesity, metabolic syndrome, diabetes and kidney stones",1],["R0004964","The impact of semaglutide on liver outcomes in patients with or at risk of MASH: a dose and duration response meta-analysis of randomized trials.","Kan R","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent08","dose response meta-analysis of semaglutide RCTs on liver outcomes; PubMed, Embase, Cochrane searched",1],["R0005028","Effect of Medications for Type 2 Diabetes on Cardiovascular Events and Mortality: A Comprehensive Pairwise and Network Meta-Analysis.","Silverii GA","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent08","pairwise and network meta-analysis of diabetes drug RCTs incl GLP-1 RA on MACE and mortality",1],["R0005093","Finerenone in patients across the spectrum of chronic kidney disease and type 2 diabetes by glucagon-like peptide-1 receptor agonist use.","Rossing P","2023","inventory_only","N3","secondary_report",null,null,null,"high","first","opus-5.5-agent08","pooled FIDELIO and FIGARO analysis of finerenone versus placebo by baseline GLP-1 RA use; GLP-1 regimen not randomized",1],["R0004132","Sleep and obesity-known interactions and open questions.","Schmickl CN","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent09","narrative review on sleep, sleep apnea and obesity including incretin therapy",1],["R0004215","Efficacy and safety of cAMP signalling-biased GLP-1 analogue ecnoglutide monotherapy versus placebo in patients with type 2 diabetes (EECOH-1): a randomised, double-blind, placebo-controlled, phase 3 trial","Bing s","2025","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent09","phase 3 double blind RCT of ecnoglutide monotherapy versus placebo in type 2 diabetes, preprint",1],["R0004275","Prescribing trends of cardioprotective medications among patients with diabetes and ASCVD in primary care setting in Qatar.","Jaam M","2025","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent09","cross sectional prescribing rates of cardioprotective drugs in Qatar primary care, no exposure comparison",1],["R0004448","Effects of GLP-1 Analogues and Agonists on the Gut Microbiota: A Systematic Review.","Gofron KK","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent09","PRISMA systematic review of GLP-1 drugs and gut microbiota with PubMed and Scopus search, animal and human studies",1],["R0004512","Short-Term Associations Between Fat-Free Mass Preservation and Glycaemic Markers During Tirzepatide Therapy: A Secondary Exploratory Analysis.","Schiavo L","2026","inventory_only","N1","secondary_report",null,null,null,"high","first","opus-5.5-agent09","secondary analysis of nonrandomized study where both groups took tirzepatide with different diets, no GLP-1 comparison",1],["R0004591","Comparative estimate of glucose-lowering therapies on risk of incident pneumonia and severe sepsis: an analysis of real-world cohort data.","Henney AE","2024","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent09","TriNetX active comparator cohort of GLP-1 or SGLT2 versus DPP-4 inhibitors on pneumonia and sepsis only",1],["R0004642","Semaglutide for primary prevention of major adverse cardiac and cerebrovascular events in patients with type 2 diabetes and comorbid rheumatoid arthritis: a target-trial emulation.","Malik F","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent09","TriNetX target trial emulation of semaglutide versus other second line drugs on MACCE in rheumatoid arthritis",1],["R0003484","Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis.","Yao H","2024","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent18","registered systematic review and NMA of GLP-1 RA RCTs in T2D on glycemia, weight, lipids; four named databases",1],["R0003606","Efficacy and Safety of GLP-1 and Dual GIP/GLP-1 Receptor Agonists in Idiopathic Intracranial Hypertension: A Systematic Review and Meta-Analysis.","Stefanou MI","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent18","registered systematic review and meta-analysis of GLP-1 and dual agonists vs standard care in idiopathic intracranial hypertension; MEDLINE and Scopus",1],["R0003662","Insulin Versus Established GLP-1 Receptor Agonists, DPP-4 Inhibitors, and SGLT-2 Inhibitors for Uncontrolled Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.","Ahmed A","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent18","systematic review and meta-analysis of RCTs of GLP-1 RAs, DPP-4i, SGLT2i vs insulin in T2D; GLP-1 vs insulin subgroup pooled",1],["R0003827","Factors and Disparities Influencing Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-like Peptide 1 Receptor Agonists Initiation in the United States: A Scoping Review of Evidence.","Moore J","2025","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent18","scoping review of disparities in SGLT2i and GLP-1 RA initiation; prescribing focus, no treatment contrast; also E3",1],["R0003893","Impact of GLP-1 receptor agonists on patients with intraductal papillary mucinous neoplasms: Study protocol for a multicentric cohort study.","Lagger M","2026","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent18","protocol of retrospective multicenter cohort on GLP-1 RA use and IPMN progression; no results",1],["R0003945","Higher Compliance with Treatment Administration Instructions for Injectable Dulaglutide versus Oral Semaglutide Reported by People with Type 2 Diabetes in Clinical Practice Settings in Spain: The TRU-Experience Study.","Díaz-Cerezo S","2025","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent18","cross sectional study comparing administration compliance with dulaglutide vs oral semaglutide in T2D",1],["R0003844","A phase 1 single and multiple ascending dose study of orforglipron in Japanese participants with type 2 diabetes.","Ohwaki K","2026","include_nma",null,"primary_report","P01",null,"mechanistic","high","first","opus-5.5-agent02","randomized double blind placebo controlled phase 1 orforglipron study in Japanese T2D reporting HbA1c, weight and adverse events",1],["R0004114","MON-301 Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes in Children and Adolescents: A Meta-Analysis of Randomized Controlled Trials",null,"2024","include_review",null,"systematic_review",null,null,"abstract_only","high","first","opus-5.5-agent02","conference abstract of a meta-analysis of RCTs of GLP-1 RA vs placebo in pediatric type 2 diabetes; three databases searched",1],["R0004189","Glucagon-like peptide-1 receptor agonists, but not dipeptidyl peptidase-4 inhibitors, reduce alcohol intake.","Farokhnia M","2025","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent02","VA cohort of GLP-1 RA vs DPP-4 inhibitor or unexposed on AUDIT-C change plus rodent work; no listed harm",1],["R0004251","GLP-1 guidelines amid an obesity epidemic: a poor fit for the Global South.","Shrisunder R","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent02","letter giving opinion on WHO GLP-1 RA obesity guideline for the Global South",1],["R0004326","Considering the use of GLP-1 receptor agonists in women with obesity prior to pregnancy: a narrative review.","Price SAL","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent02","narrative review of GLP-1 RA use before pregnancy in women with obesity",1],["R0004419","Incretin based therapy and pancreatic cancer: Realising the reality.","Suryadevara V","2022","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent02","narrative review of incretin therapies and pancreatic cancer risk",1],["R0004492","Evaluation of bone health and fracture risk in type 2 diabetes: a network meta-analysis of anti-diabetic treatments versus placebo.","Oh S","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent02","registered network meta-analysis of RCTs of antidiabetic drugs including GLP-1 RA vs placebo on fractures and bone density",1],["R0004558","Magnitude and Determinants of Weight Loss Response to GLP-1/GIP Receptor Agonists in India: A Real-World Time-to-Event Analysis.","Jarso G","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent02","retrospective cohort comparing tirzepatide and semaglutide weight loss in Indian adults; no listed harm outcome",1],["R0004150","Tirzepatide as Adjunct to Insulin in Adults With Type 1 Diabetes and Overweight or Obesity: A Systematic Review of Randomized and Real-World Evidence.","Acucella GA","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent13","PROSPERO registered systematic review of tirzepatide adjunct to insulin in type 1 diabetes, five databases",1],["R0004221","Effect of oral semaglutide on cardiometabolic risk factors in overweight and obese individuals with or without diabetes: a systematic review and meta-analysis.","Seighali N","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent13","PROSPERO registered meta-analysis of RCTs of oral semaglutide vs placebo in overweight or obesity",1],["R0004288","Heart failure with preserved ejection fraction: current insights and emerging therapeutic directions.","Kim J","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent13","brief narrative review of HFpEF therapeutics including rodent models",1],["R0004527","Adverse events administering glucagon-like peptide-1 receptor agonists: a cross-sectional study.","Mattingly TJ","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent13","cross sectional FAERS analysis of GLP-1 vs insulin adverse event reports",1],["R0004602","Efpeglenatide and Clinical Outcomes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial.","Lam CSP","2022","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent13","AMPLITUDE-O exploratory analysis of efpeglenatide vs placebo by SGLT2 inhibitor use in type 2 diabetes",1],["R0004657","Recent trends in GLP-1 RA and SGLT2i use among people with type 2 diabetes and atherosclerotic cardiovascular disease in the USA.","King A","2024","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent13","drug utilization trend study of GLP-1 and SGLT2 prescribing after ASCVD, no exposure outcome comparison",1],["R0004691","Glucagon-like peptide 1 receptor agonists and the potential risk of pancreatic carcinoma: a real-world pharmacovigilance study of post-marketing surveillance data","Cao M","2022","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent03","FAERS disproportionality analysis of GLP-1 RA and pancreatic carcinoma reports",1],["R0004756","Risk of Psychiatric Worsening With GLP-1 Receptor Agonist Use in Patients With Type 2 Diabetes and Treated Depression.","Chang Y","2026","include_harms",null,"primary_report",null,"O35A",null,"high","first","opus-5.5-agent03","TriNetX active comparator new user cohort GLP-1 RA vs SGLT2i in T2D with treated depression; suicidality primary outcome",1],["R0004812","Effects of Once-Weekly Semaglutide on Cardiovascular Risk Factors and Metabolic Dysfunction-Associated Steatotic Liver Disease in Japanese Patients with Type 2 Diabetes: A Retrospective Longitudinal Study Based on Real-World Data.","Katsuyama H","2024","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent03","single center before and after study of semaglutide initiators in Japanese T2D, no comparison group",1],["R0004873","Glucagon-like peptide 1 receptor agonists and venous thromboembolism in type 2 diabetes: a target trial emulation.","Chiang CH","2025","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent03","target trial emulation GLP-1 RA vs DPP4i in T2D; venous thromboembolism only, not a listed harm",1],["R0005012","Exploring potential associations between GLP-1RAs and depressive disorders: a pharmacovigilance study based on FAERS and VigiBase data.","Wang M","2025","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent03","FAERS and VigiBase disproportionality analysis of GLP-1 RA and depressive disorders",1],["R0005070","Long-Term Effectiveness of Once-Weekly Semaglutide in Patients With Type 2 Diabetes Previously Treated With Insulin. A Multicentre Real-World Study.","Bonora BM","2025","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent03","multicenter retrospective single group study of semaglutide initiation in insulin treated T2D, no comparator",1],["R0005152","The Use of Glucagon-like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus Does Not Increase the Risk of Pancreatic Cancer: A U.S.-Based Cohort Study.","Ayoub M","2024","include_harms",null,"primary_report",null,"O38",null,"high","first","opus-5.5-agent03","TriNetX matched cohort GLP-1 RA vs non users in T2D; 7 year pancreatic cancer risk",1],["R0004498","HIF-1α exerts a double-edged sword regulatory role in hippocampal neuronal PANoptosis of Alzheimer's disease through HK2/VDAC1/NLRP3 axis and RIPK3 signal","Chao YL","2025","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent05","preprint on neuronal PANoptosis in an Alzheimer mouse model; semaglutide tested only in mice",1],["R0004571","Epicardial Adipose Tissue as a Cardiometabolic Target in Atrial Fibrillation: Implications for Ablation Strategies and Emerging Metabolic Therapies.","Cacciapuoti F","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent05","narrative structured review of epicardial fat in atrial fibrillation including metabolic therapies; no systematic synthesis",1],["R0004629","Efficacy and safety of glucagon-like peptide-1 receptor agonists in the elderly versus non-elderly patients with type 2 diabetes mellitus: insights from a systematic review.","Wang Y","2024","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent05","meta-analysis comparing GLP-1 RA efficacy and safety in elderly versus younger patients, three named databases",1],["R0004763","Active surveillance of drug safety in healthcare data: Sequential monitoring of bacterial and serious urinary tract infection risk in sodium-glucose cotransporter 2 inhibitor users.","Le H","2026","inventory_only","N6","other",null,null,null,"high","first","opus-5.5-agent05","sequential cohorts of SGLT2i versus DPP-4i or GLP-1 RA comparators on urinary tract infection; no listed harm",1],["R0004816","Once-weekly glucagon-like peptide-1 receptor agonists vs dipeptidyl peptidase-4 inhibitors: cardiovascular effects in people with diabetes and cardiovascular disease.","Tan X","2023","inventory_only","N6","other",null,null,null,"high","first","opus-5.5-agent05","claims cohort once weekly GLP-1 RA versus DPP-4i in ASCVD on stroke, MI and costs; no listed harm",1],["R0004877","Efficacy and Safety of Glucagon-Like Peptide 1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus: A Network Meta-analysis.","Jiang Y","2021","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent05","network meta-analysis of RCTs of GLP-1 RA regimens in type 2 diabetes searching MEDLINE, Embase and CENTRAL",1],["R0004961","Expanding therapeutic horizons: glucagon-like peptide-1 receptor agonists and sodium glucose transporter-2 inhibitors in poly cystic ovarian syndrome: a comprehensive review including systematic review and network meta-analysis of randomized clinical trials.","Sridharan K","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent05","registered network meta-analysis of RCTs of GLP-1 RA and SGLT2i in PCOS with named databases",1],["R0004672","The Effect of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists on the Lipid Profile of Diabetic Patients Using Statins: A Retrospective Cohort Study in the Diabetic Center of King Salman Bin Abdulaziz Hospital, Saudi Arabia.","Albahli OM","2024","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent16","retrospective before and after cohort of dulaglutide on lipids in statin treated T2D, no comparison group",1],["R0004795","Comparison of GLP-1 Receptor Agonists, SGLT-2 Inhibitors, and DPP-4 Inhibitors as an Add-On Drug to Insulin Combined With Oral Hypoglycemic Drugs: Umbrella Review.","Chai S","2024","include_review",null,"systematic_review",null,null,"umbrella_review","high","first","opus-5.5-agent16","PROSPERO registered umbrella review of meta-analyses of GLP-1RA, SGLT2i, DPP-4i added to insulin",1],["R0004859","Gastrointestinal adverse events associated with GLP-1 receptor agonists in metabolic dysfunction-associated steatotic liver disease (MASLD): a systematic review and meta-analysis.","Huang X","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent16","systematic review and meta-analysis of GI adverse events in GLP-1RA RCTs for MASLD",1],["R0004925","The Dispensing Error Rate in an App-Based, Semaglutide-Supported Weight-Loss Service: A Retrospective Cohort Study.","Talay L","2024","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent16","service evaluation of semaglutide dispensing error rates; no exposure comparison",1],["R0004988","Digital Engagement and Predictors of Semaglutide Persistence and Weight Loss in Severe Obesity: 48-Week Observational Study.","Tournayre S","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent16","prospective single cohort initiating semaglutide, compares digital engagement levels, no comparator to the drug",1],["R0005053","Do GLP-1 Analogs Have a Place in the Treatment of PCOS? New Insights and Promising Therapies.","Szczesnowicz A","2023","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent16","narrative review of GLP-1 analogs in PCOS",1],["R0005114","Hemoglobin A1c and Weight Changes Associated With Grocery Delivery and Low-Carbohydrate Education in Adults With Type 2 Diabetes and Food Insecurity: Observational Quality Improvement Cohort Study.","Waselewski M","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent16","uncontrolled grocery delivery program in T2D; GLP-1RA use only a stratification variable, not the studied exposure",1],["R0005194","Glucagon-Like Peptide-1 Receptor Agonist Use is Not Associated With Increased Complications After Total Knee Arthroplasty in Patients With Type-2 Diabetes.","Heo KY","2024","include_harms",null,"primary_report",null,"O121",null,"high","first","opus-5.5-agent04","MarketScan matched procedure cohort of TKA patients on GLP-1 RA vs not, 90 day complications incl acute kidney injury",1],["R0005275","Pharmacological treatment patterns, factors associated with glycemic control, and renal function parameters in a real-world cohort of Hispanic adults with type 2 diabetes.","Diaz-Martinez J","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent04","cross sectional clinic study of treatment patterns and glycemic control in Hispanic adults with type 2 diabetes",1],["R0005489","Cardiovascular and renal outcomes of glucagon-like peptide 1 receptor agonists among patients with and without type 2 diabetes mellitus: A meta-analysis of randomized placebo-controlled trials.","Rivera FB","2024","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent04","registered meta-analysis of placebo controlled GLP-1 RA RCTs on cardiovascular and renal outcomes with and without diabetes",1],["R0005565","Disproportionality Analysis From World Health Organization Data on Semaglutide, Liraglutide, and Suicidality.","Schoretsanitis G","2024","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent04","VigiBase disproportionality analysis of suicidality reports with semaglutide and liraglutide",1],["R0005619","SGLT2 Inhibitor and GLP-1 Receptor Agonist Prescriptions in Newly Diagnosed Type 2 Diabetes Patients With Cardiorenal Risks: A Cross-Sectional Study.","Müller F","2025","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent04","cross sectional EMR study of SGLT2i and GLP-1 RA prescription rates and predictors, drug utilization without exposure comparison",1],["R0005674","Budget Impact Analysis of Intensification with iGlarLixi Compared to Alternative Treatment Strategies Among Patients with Type 2 Diabetes Mellitus.","Ken-Opurum J","2023","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent04","budget impact model of iGlarLixi intensification from a US payer perspective",1],["R0004682","Preventing Type 2 Diabetes in At-Risk Cardiorenal Populations.","de Silva D","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent01","narrative review of diabetes prevention in CKD, studies chosen for topical relevance without systematic search",1],["R0004752","Comparative Efficacy of Metabolic/Bariatric Surgery Versus GLP-1 Receptor Agonists: A Network Meta-Analysis of Randomized Controlled Trials.","Sabatella L","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent01","registered network meta-analysis of RCTs comparing bariatric surgery and GLP-1 RAs with lifestyle, four databases searched",1],["R0004808","Efficacy of glucagon-like peptide 1 analogues in psoriasis: A cohort study.","Bar D","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent01","retrospective cohort of psoriasis patients with obesity given GLP-1 RA versus untreated controls; skin response outcomes only",1],["R0004868","Pulse of Progress: A Systematic Review of Glucagon-Like Peptide-1 Receptor Agonists in Cardiovascular Health.","Sabina M","2024","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent01","titled systematic review but no search or eligibility methods; narrative walk through of cardiovascular outcome trials",1],["R0004949","Bariatric Metabolic Surgery vs Glucagon-Like Peptide-1 Receptor Agonists and Mortality.","Dicker D","2024","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent01","matched cohort of bariatric surgery versus GLP-1 RA in obesity with diabetes; mortality and MACE only",1],["R0005008","Nephroprotective effects of GLP-1 receptor agonists in patients receiving lithium treatment: a multinational cohort study using the TriNetX network.","McIntyre RS","2026","include_harms",null,"primary_report",null,"O121",null,"high","first","opus-5.5-agent01","matched cohort of lithium users initiating GLP-1 RA versus lithium alone; renal composite with acute kidney injury category reported",1],["R0005062","GLP-1 receptor agonists and clinical outcomes in adults with Crohn's disease and obesity: a propensity score-matched real-world cohort study.","Ganju N","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent01","new user cohort of GLP-1 RA versus nonusers with Crohn disease and obesity; mortality, utilization and drug use outcomes only",1],["R0005147","Barriers in prescribing antidiabetic medications with cardiovascular benefits: practice, experience, and attitudes of GPs in Croatia.","Kurevija T","2025","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent01","survey of general practitioners on prescribing SGLT2i and GLP-1 RA; prescribing study without exposure comparison",1],["R0005770","Tirzepatide for Older Adults with Type 2 Diabetes and Without Obesity: A Post Hoc Analysis of the SURPASS Clinical Trials.","Rasouli N","2025","include_nma",null,"pooled_analysis","P01",null,null,"high","first","opus-5.5-agent06","post hoc pooled subgroup of older adults without obesity across randomized SURPASS-1 to -5 tirzepatide trials",1],["R0005852","Contemporary Classification of Glucagon-Like Peptide 1 Receptor Agonists (GLP1RAs).","Kalra S","2021","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent06","narrative communication proposing a classification of GLP-1 RAs; no primary data",1],["R0005932","Effect of glucagon-like peptide-1 receptor agonists on fat distribution in patients with type 2 diabetes: A systematic review and meta-analysis.","Duan K","2022","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent06","registered systematic review and meta-analysis of RCTs of GLP-1 RAs versus control on visceral and subcutaneous fat in T2D",1],["R0005990","Glucagon-Like Peptide-1 Receptor Agonists and Pancreatic Cancer Risk in Patients With Type 2 Diabetes.","Dankner R","2024","include_harms",null,"primary_report",null,"O38",null,"high","first","opus-5.5-agent06","Clalit historical cohort of GLP-1 RA versus basal insulin in T2D; pancreatic cancer incidence",1],["R0006058","Adverse events in different administration routes of semaglutide: a pharmacovigilance study based on the FDA adverse event reporting system.","Niu K","2024","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent06","FAERS disproportionality comparison of oral versus subcutaneous semaglutide adverse event reports",1],["R0006174","Semaglutide (Ozempic®) Use in Denmark 2018 Through 2023 ‒ User Trends and off-Label Prescribing for Weight Loss.","Mailhac A","2024","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent06","Danish registry drug utilization study of semaglutide user trends and off label use; no exposure outcome comparison",1],["R0006230","Cost-Effectiveness of iGlarLixi in People with Type 2 Diabetes Mellitus Suboptimally Controlled on Basal Insulin Plus Metformin in the UK.","McCrimmon RJ","2021","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent06","cost-effectiveness modeling of iGlarLixi versus other GLP-1 RA insulin combinations in the UK",1],["R0004654","Gallstone Occurrence Versus Clinically Significant Biliary Disease With GLP-1 Receptor Agonists in Type 2 Diabetes and Obesity: A Propensity-Matched Cohort Study With Phenotype and Quantitative-Bias Analysis","Onwuzo C","2026","include_harms",null,"primary_report","P01; P02","O28",null,"high","first","opus-5.5-agent12","TriNetX matched cohort of GLP-1RA users vs nonusers with T2D or obesity, cholelithiasis, cholecystitis and other biliary outcomes",1],["R0004789","A worldwide perspective on clinical characteristics and treatment of youth with monogenic diabetes in the SWEET registry.","Deng L","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent12","registry description of treatment patterns in youth monogenic diabetes, GLP-1RA use only tallied, no exposure comparison",1],["R0004848","Cognitive protection of incretin-based therapies in patients with type 2 diabetes mellitus: A systematic review and meta-analysis based on clinical studies.","Chai S","2023","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent12","registered SR and meta-analysis of RCTs and cohorts of incretin therapies including GLP-1RAs vs other drugs on cognition in T2D",1],["R0004918","The IDEAL (Insulin therapy DE-intensificAtion with iglarLixi) Randomised Controlled Trial-Study Design and Protocol.","Novodvorský P","2024","inventory_only","N8","protocol_or_design","P01",null,null,"high","first","opus-5.5-agent12","design and protocol of IDEAL RCT of iGlarLixi vs continued basal bolus insulin in T2D, no results",1],["R0004976","Effects of glucagon-like peptide-1 on systemic hemodynamics, kidney function, and intrarenal oxygenation in sheep with sepsis-associated acute kidney injury.","Hulst AH","2025","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent12","randomized experiment of native GLP-1 infusion in sheep with septic acute kidney injury",1],["R0005047","Therapeutic monoclonal antibodies for diabetic kidney disease: a narrative review from basic mechanisms to clinical evidence.","Yang XH","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent12","narrative review of monoclonal antibodies for diabetic kidney disease, GLP-1RAs only background",1],["R0005102","Cardioprotective effects of glucagon-like peptide 1 receptor agonists in heart failure: Myth or truth?","Nesti L","2024","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent12","editorial narrative on GLP-1RAs in heart failure",1],["R0004023","Baseline vitamin D status is associated with glycemic and weight loss outcomes in patients with type 2 diabetes treated with semaglutide.","Israel A","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent18","retrospective cohort of semaglutide initiators stratified by baseline vitamin D; no unexposed or active comparator group",1],["R0003524","Socioeconomic aspects of incretin-based therapy.","Karagiannis T","2023","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent17","narrative review of socioeconomic disparities in incretin therapy uptake",1],["R0004102","An Assessment of Semaglutide Safety Based on Real World Data: From Popularity to Spontaneous Reporting in EudraVigilance Database.","Butuca A","2024","inventory_only","N5","other",null,null,null,"high","first","opus-5.5-agent18","Google Trends and EudraVigilance spontaneous report disproportionality analysis of semaglutide vs other GLP-1 RAs",1],["R0004169","Retrospective review of seven patients with obesity simultaneously treated with a combination of a glucagon-like peptide-1 receptor agonist and a meal replacement product.","Bacus C","2024","inventory_only","N5","other",null,null,null,"high","first","opus-5.5-agent18","case series of seven patients with obesity using a GLP-1 RA with meal replacement products",1],["R0004237","Effectiveness and Safety of Once-Weekly Semaglutide in Japanese Patients with Type 2 Diabetes: A Retrospective Observational Multicenter Study (ORIGAMI Study).","Iwata Y","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent18","retrospective multicenter cohort of semaglutide users, pre post HbA1c and weight; subgroups only, no comparator group",1],["R0004312","Pharmacological therapy in the obese patient: is it only a matter of fat loss?","Borghi C","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent18","narrative review of incretin drug trials in obesity; summarizes published trials, not a trial report",1],["R0004376","Ecological momentary assessment and cue-elicited drug craving as primary endpoints: study protocol for a randomized, double-blind, placebo-controlled clinical trial testing the efficacy of a GLP-1 receptor agonist in opioid use disorder.","Freet CS","2024","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent18","protocol of double blind placebo controlled RCT of liraglutide for craving in opioid use disorder; no results",1],["R0004486","Effectiveness and safety of the combination of sodium-glucose transport protein 2 inhibitors and glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of observational studies.","Ahmad A","2024","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent18","registered systematic review and meta-analysis of observational studies of SGLT2i plus GLP-1 RA vs monotherapy in T2D",1],["R0004545","Reasons for discontinuing tirzepatide in randomized controlled trials: A systematic review and meta-analysis.","Kamrul-Hasan ABM","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent18","registered systematic review and meta-analysis of tirzepatide RCTs on discontinuation vs placebo, insulin, GLP-1 RAs",1],["R0003600","GLP-1 receptor agonists in Parkinson's disease progression: a meta-analysis with trial sequential analysis of randomized controlled trials.","Tsai WW","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent17","systematic review and meta-analysis of placebo controlled RCTs of GLP-1 RAs in Parkinson disease, three databases searched",1],["R0003660","Cost-utility of IDegLira versus alternative basal insulin intensification therapies in patients with type 2 diabetes mellitus uncontrolled on basal insulin in a Chinese setting.","Weng J","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent17","cost utility Markov model of IDegLira versus other intensification options in China",1],["R0003738","Long-term cancer risk in users of GLP-1 agonists in Denmark: a nationwide emulated trial.","Gamborg M","2025","include_harms",null,"primary_report",null,"O39",null,"high","first","opus-5.5-agent17","Danish nationwide emulated trial, new user GLP-1 RA versus DPP-4 inhibitor, ten year overall cancer risk",1],["R0003826","Efficacy and Safety of Intensifying Once-Weekly Insulin Icodec Treatment With Once-Weekly Semaglutide in Adults With Type 2 Diabetes: A Single-Arm, Open-Label, Treat-to-Target, Phase 3b Trial (ONWARDS 8).","Strojek K","2026","inventory_only","N1","primary_report",null,null,null,"high","first","opus-5.5-agent17","single arm phase 3b trial adding semaglutide to insulin icodec after a run in, no concurrent comparator",1],["R0003890","Authors' Response to Peer Reviews of \"Thyroid Hyperplasia and Neoplasm Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists in the Food and Drug Administration Adverse Event Reporting System: Retrospective Analysis\".","Makunts T","2024","inventory_only","N9","ancillary",null,null,null,"high","first","opus-5.5-agent17","authors response to peer review of a FAERS thyroid neoplasm disproportionality study, an in scope inventory record",1],["R0003942","Insulin therapy DE-intensificAtion with iGlarLixi: A phase 4, open-label, parallel-group randomised controlled trial.","Novodvorský P","2026","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent17","open label phase 4 RCT switching multiple daily insulin to iGlarLixi versus continuing insulin regimen, 24 weeks",1],["R0004019","Modulation of metabolic, inflammatory and fibrotic pathways by semaglutide in metabolic dysfunction-associated steatohepatitis.","Jara M","2025","include_nma",null,"secondary_report","P09",null,"mechanistic","high","first","opus-5.5-agent17","proteomic secondary analysis of the phase 2b semaglutide versus placebo MASH trial with MASH resolution; also preclinical models",1],["R0003197","Glycaemic Changes After Semaglutide Discontinuation in Adults With Type 1 Diabetes Using Automated Insulin Delivery: Analysis of the ADJUST-T1D Extension Study.","Montaser E","2026","include_nma",null,"secondary_report","P05",null,null,"high","first","opus-5.5-agent15","post hoc follow up of ADJUST-T1D RCT comparing glycemia after semaglutide discontinuation versus former placebo arm",1],["R0003509","Temporal and subgroup disparities in mediation effects on cardiovascular outcomes with liraglutide and semaglutide: a post-hoc analysis of LEADER and SUSTAIN-6 trials.","Peng ZY","2025","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent15","post hoc causal mediation analysis of LEADER and SUSTAIN-6 placebo controlled RCTs on MACE in type 2 diabetes",1],["R0003658","A Single-Center, Blinded, Placebo-Controlled Study Evaluating Cosmetic Efficacy and Safety of a Novel Topical GLPSGLT in Glucagon-Like Peptide-1 Analog-Treated Patients.","Semersky A","2025","inventory_only","N3","primary_report",null,null,null,"high","first","opus-5.5-agent15","split face placebo controlled trial of a topical serum in patients already on GLP-1 RA or SGLT2i; GLP-1 regimen unchanged",1],["R0003726","Comparative Weight Change With Initiation and Adherence to Common Medications for Type 2 Diabetes.","Sneed NM","2025","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent15","target trial emulation of adding GLP-1 RA, SGLT2i, DPP-4i, insulin or sulfonylurea to metformin; weight change is the only outcome",1],["R0003806","Exploratory Analysis of Liraglutide Effects on Obstructive Sleep Apnea and Health-Related Quality of Life in Individuals With Obesity and COPD: A Secondary Analysis of a Randomised Controlled Trial.","Wolsing SK","2026","include_nma",null,"secondary_report","P02",null,null,"high","first","opus-5.5-agent15","secondary analysis of RCT of liraglutide 3.0 mg versus placebo in overweight or obese adults with COPD without diabetes; sleep apnea outcomes",1],["R0003884","GLP-1 receptor agonists and myocardial metabolism in atrial fibrillation.","Zhong J","2024","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent15","narrative review of myocardial metabolism and GLP-1 RAs in atrial fibrillation",1],["R0003938","Semaglutide versus resmetirom for noncirrhotic MASH with moderate to advanced fibrosis: a cost-effectiveness analysis.","Njei B","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent15","Markov cost effectiveness model comparing semaglutide, resmetirom and standard care in MASH; economic evaluation",1],["R0005075","The effect of GLP-1 receptor agonists on renal outcomes: a systematic review and meta-analysis.","Sasaki T","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent05","meta-analysis of GLP-1 RA RCTs on renal outcomes searching MEDLINE, Embase and CENTRAL",1],["R0005154","Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Obese Patients Without Diabetes: A Systematic Review and Meta-Analysis.","Mohamed Ali Elbashir R","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent05","meta-analysis of RCTs of GLP-1 RA in obesity without diabetes searching four named databases",1],["R0005277","Quality of life, morbidity, mortality, and long-term prognosis after craniopharyngioma.","Müller HL","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent05","narrative review of outcomes after craniopharyngioma discussing semaglutide and setmelanotide",1],["R0005353","Diabetes management in maternally inherited diabetes and deafness (MIDD): A review and a proposed treatment algorithm.","Chaudhry A","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent05","narrative review with proposed treatment algorithm for maternally inherited diabetes and deafness",1],["R0005434","Population pharmacokinetics of the GIP/GLP receptor agonist tirzepatide.","Schneck K","2024","inventory_only","N2","other",null,null,null,"high","first","opus-5.5-agent05","population pharmacokinetic model of tirzepatide pooled from 19 studies; no review outcome analyzed",1],["R0005492","Investigating the functional connectivity between central glucagon-like peptide-1 (GLP-1) and glutamatergic signaling: a systematic review.","Wong S","2026","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent05","systematic review of GLP-1 RA and glutamatergic signaling; only in vitro and animal studies included, no human studies",1],["R0004639","Fiscal Impact of Expanded Medicare Coverage for GLP-1 Receptor Agonists to Treat Obesity.","Hwang JH","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent07","microsimulation budget impact model of Medicare coverage for GLP-1RA in obesity",1],["R0004707","A Remotely Delivered GLP-1RA-Supported Specialist Weight Management Program in Adults Living With Obesity: Retrospective Service Evaluation.","Richards R","2025","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent07","retrospective single group evaluation of a remote semaglutide supported weight program, no concurrent comparator",1],["R0004768","Uptake of novel evidence-based therapies in patients with type 2 diabetes after a cardiovascular event: insights from CANHEART.","Thompson W","2025","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent07","population cohort describing uptake of SGLT2i and GLP-1RA after cardiovascular events; utilization only, no exposure outcome comparison",1],["R0004833","[Oral semaglutide - Rybelsus®, the first GLP-1 receptor agonist for oral use in clinical practice].","Karásek D","2022","exclude","E3","other",null,null,"non_english","high","first","opus-5.5-agent07","Czech narrative overview of oral semaglutide in clinical practice",1],["R0004890","Comparison of semaglutide and lifestyle counseling for weight loss using electronic health records","Powell W","2025","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent07","EHR cohort comparing semaglutide with lifestyle counseling on 10 percent weight loss; not randomized, no listed harm",1],["R0004963","The Real-World Impact of Glucagon-Like Peptide 1 Receptor Agonists on Asthma Control in People with High-Risk Asthma and Obesity.","Kaplan A","2025","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent07","matched database cohort of GLP-1RA exposed vs unexposed adults with asthma and obesity; asthma control outcomes only",1],["R0005026","Effects of GLP-1 Receptor Agonists in Alcohol Use Disorder.","Klausen MK","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent07","focused narrative review of GLP-1RA evidence in alcohol use disorder",1],["R0005092","Glucagon-like peptide-1 receptor agonists and risk of substance use disorders among US veterans with type 2 diabetes: cohort study.","Cai M","2026","include_harms",null,"primary_report",null,"O35A",null,"high","first","opus-5.5-agent07","VA new user active comparator target trial emulations GLP-1RA vs SGLT2i; substance use outcomes and suicidal ideation or attempt",1],["R0003578","Incidence of Barrett's esophagus and esophageal cancer following sleeve gastrectomy versus liraglutide therapy.","Butt E","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent10","TriNetX cohort liraglutide versus sleeve gastrectomy; Barrett esophagus and esophageal cancer only, not harms_nrs outcomes",1],["R0003641","GLP-1 Receptor Agonists and Noncardiometabolic Outcomes: An Umbrella Review of Meta-Analyses.","Yang K","2026","include_review",null,"systematic_review",null,null,"umbrella_review","high","first","opus-5.5-agent10","PROSPERO registered umbrella review of meta-analyses of GLP-1 RA RCTs on noncardiometabolic outcomes",1],["R0003709","Association of semaglutide use with kidney outcomes in adults with ADPKD: A propensity score-matched real-world study.","Chen TP","2026","include_harms",null,"primary_report",null,"O121",null,"high","first","opus-5.5-agent10","TriNetX matched cohort semaglutide users versus nonusers with ADPKD; acute kidney injury among outcomes, comparator nonusers",1],["R0003788","Emerging Treatments for Obesity: the Role of GLP1 Receptor Agonists on Stroke.","Mariscal M","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent10","narrative review of GLP-1 RAs and stroke; no search methods or primary data",1],["R0003873","GLP-1 Receptor Agonists in Mood Disorders: A Psychiatric Perspective.","Carmellini P","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent10","self described narrative review of GLP-1 RAs in mood disorders including preclinical data",1],["R0003924","Factors influencing the selection of an SGLT2i vs. a GLP-1RA as cardioprotective agent in patients with type 2 diabetes.","Agarwal S","2025","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent10","EHR study of predictors of prescribing SGLT2i versus GLP-1 RA; no outcome comparison by exposure",1],["R0003985","Gastrointestinal adverse events with insulin glargine/lixisenatide fixed-ratio combination versus glucagon-like peptide-1 receptor agonists in people with type 2 diabetes mellitus: A network meta-analysis.","Rayner CK","2021","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent10","Bayesian NMA of RCTs comparing GI adverse events of iGlarLixi with GLP-1 RAs, MEDLINE EMBASE CENTRAL searched",1],["R0004072","Association of glucagon-like peptide-1 receptor agonist treatment with gastric residue in an esophagogastroduodenoscopy.","Kobori T","2023","include_harms",null,"primary_report",null,"O36B",null,"high","first","opus-5.5-agent10","propensity matched comparison of diabetic EGD patients with versus without GLP-1 RA; gastric residue outcome",1],["R0005261","Psychiatric adverse events associated with GLP-1 receptor agonists: a real-world pharmacovigilance study based on the FDA Adverse Event Reporting System database.","Chen W","2024","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent20","FAERS disproportionality analysis of psychiatric adverse events with GLP-1 RAs",1],["R0005335","Dosing Patterns of Dulaglutide and Semaglutide in Patients with Type 2 Diabetes in the United Kingdom and Germany: A Retrospective Cohort Study.","Barrett A","2023","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent20","IQVIA prescription data describing dosing patterns of dulaglutide and semaglutide, drug utilization without exposure comparison",1],["R0005481","Hypoglycemia following the use of glucagon-like peptide-1 receptor agonists: a real-world analysis of post-marketing surveillance data.","Zhao Z","2021","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent20","FAERS disproportionality analysis of hypoglycemia across GLP-1 RAs",1],["R0005559","Systemic medications and dementia risk: a systematic umbrella review.","Belessiotis-Richards C","2025","include_review",null,"systematic_review",null,null,"umbrella_review","high","first","opus-5.5-agent20","PROSPERO registered umbrella review of meta-analyses of systemic drugs including GLP-1 RAs on dementia risk",1],["R0005665","Comparative efficacy of GLP-1 RAs/SGLT-2 inhibitors in reducing cardiovascular events in type 2 diabetes according to baseline use of metformin: a systematic review and meta-analysis of randomized controlled trials.","Zhang Y","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent20","meta-analysis of placebo controlled CVOTs of SGLT2i or GLP-1 RA by baseline metformin, four databases",1],["R0005745","A Dose of Perspective: A Multinational Survey of Patient and Clinician Views on Combination Therapy in CKD.","Shah NA","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent20","cross sectional survey of patient and clinician views on CKD combination therapy, no drug exposure comparison",1],["R0005175","Implementation of guideline-recommended organ-protective therapy in people with type 2 diabetes and cardiovascular disease, heart failure, or kidney disease: real-world evidence from a German University Hospital.","Suliman K","2025","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent14","hospital data study of guideline uptake of SGLT2i and GLP-1 RA, prescribing rates without exposure outcome comparison",1],["R0005239","Sodium-Glucose Cotransporter-2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy in Type 2 Diabetes: Protocol for a Kidney End Points Real-world Study (COMBi-KID Study).","Feher M","2022","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent14","protocol of a real world cohort on SGLT2i plus GLP-1 RA combination and kidney endpoints, no results",1],["R0005311","Patterns of new glucagon-like peptide-1 receptor agonist use in patients with type 2 diabetes during 2014-2019 from a US database: prescriber and patient characteristics.","Lingvay I","2023","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent14","descriptive claims study of new GLP-1 RA initiation rates and prescriber specialty, no exposure comparison",1],["R0005388","Improving glycemic control: transitioning from dulaglutide to tirzepatide in patients with type 2 diabetes undergoing hemodialysis.","Otsuka E","2024","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent14","retrospective before and after CGM study of switching dulaglutide to tirzepatide in 14 hemodialysis patients",1],["R0005586","Glucagon-like peptide-1 receptor agonist use is associated with lower blood ferritin levels in people with type 2 diabetes and hemochromatosis: a nationwide register-based study.","Bain SC","2023","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent14","Danish register study of GLP-1 RA exposure and ferritin and phlebotomy intervals in hemochromatosis, no harms_nrs outcome",1],["R0005639","Clinical Consequences of Delayed Gastric Emptying With GLP-1 Receptor Agonists and Tirzepatide.","Jalleh RJ","2024","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent14","narrative review of gastric emptying consequences of GLP-1 RAs based on a PubMed search without selection criteria",1],["R0005177","First-line treatment with sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists in type 2 diabetic population at low risk of cardiovascular disease: a meta-analysis.","Deng R","2024","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent16","PROSPERO registered systematic review and meta-analysis of first line SGLT2i and GLP-1RA RCTs in low risk T2D",1],["R0005244","Acute Unilateral NAION following Tirzepatide Therapy: A Case Report.","Valášková J","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent16","case report of NAION after tirzepatide",1],["R0005319","Future of Stroke Prevention: 7 Updates in the 2024 AHA/ASA Primary Prevention of Stroke Guideline.","Razavi AC","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent16","review summarizing 2024 stroke prevention guideline updates, not a primary study",1],["R0005391","Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial.","Hendershot CS","2025","include_nma",null,"primary_report","P14A",null,null,"high","first","opus-5.5-agent16","phase 2 double blind RCT of semaglutide vs placebo in adults with alcohol use disorder",1],["R0005472","Effect of glucagon-like peptide 1 receptor agonists on albuminuria in adult patients with type 2 diabetes mellitus: A systematic review and meta-analysis.","Yuan D","2022","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent16","registered systematic review and meta-analysis of GLP-1RA RCTs on albuminuria in T2D",1],["R0005544","The Weight of Cardiovascular Diseases: Addressing the Global Cardiovascular Crisis Associated with Obesity.","Lopez-Jimenez F","2025","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent16","descriptive GBD and survey epidemiology of obesity and CVD; GLP-1RAs mentioned only in policy discussion",1],["R0005592","Pharmacologic Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease in the Context of Type 2 Diabetes.","Malandris K","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent16","narrative review of pharmacologic MASLD treatment in T2D",1],["R0005643","Dual GIP/GLP-1 receptor agonist tirzepatide ameliorates hepatic steatosis and inflammatory responses in a MASLD mouse model associated with the CCL2/CCR2 axis.","Pan Y","2026","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent16","mouse MASLD model randomized to tirzepatide or semaglutide; no human data",1],["R0005266","Effects of GLP-1 on ovarian dysfunction in polycystic ovary syndrome: A protocol for systematic review and meta-analysis.","Zhang C","2023","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent03","protocol of systematic review of GLP-1 RA plus metformin vs metformin in PCOS; no results",1],["R0005350","Dietary intake patterns and nutritional adequacy among adults with overweight or obesity treated with GLP-1 or dual GIP/GLP-1 receptor agonists- preliminary study.","Korus S","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent03","online cross sectional food diary survey of GLP-1 or tirzepatide users, no comparison group",1],["R0005428","Cardiovascular Events in Adults with Type 2 Diabetes and ASCVD Initiating Once-Weekly Semaglutide vs DPP-4is in the USA.","Inzucchi SE","2025","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent03","claims cohorts semaglutide vs DPP4i in T2D with ASCVD; cardiovascular events, resource use and costs only",1],["R0005488","PPAR-alpha/gamma agonists, glucagon-like peptide-1 receptor agonists and metformin for non-alcoholic fatty liver disease: A network meta-analysis.","Zhang ZY","2023","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent03","NMA of RCTs comparing saroglitazar, GLP-1 RA and metformin in NAFLD with three databases searched",1],["R0005563","Predictors of Responsiveness to GLP-1 Receptor Agonists in Insulin-Treated Patients with Type 2 Diabetes.","Gavigan C","2023","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent03","retrospective single group chart review of GLP-1 RA added to insulin, no comparison group",1],["R0005568","SGLT2 inhibitors and incretin-based therapies for metabolic dysfunction-associated steatohepatitis: a systematic review.","Cruz AM","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent05","registered systematic review with search strategy and criteria synthesizing incretin and SGLT2i trials versus placebo in MASH",1],["R0005618","Association of GLP-1 receptor agonists with herpes risks in diabetes mellitus: a target trial emulation.","Huang CH","2025","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent03","TriNetX target trial emulation GLP-1 RA vs DPP4i or SGLT2i; herpes infections only, not a listed harm",1],["R0005671","Evaluation of a nurse-led chronic kidney disease clinic: a single-centre cohort study.","Wallace H","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent03","nurse led CKD clinic evaluation; GLP-1 RA only a prescribing process measure, no exposure comparison",1],["R0005620","Less frequent dosing of GLP-1 receptor agonists as a viable weight maintenance strategy.","Wu CC","2025","inventory_only","N5","other",null,null,null,"high","first","opus-5.5-agent05","two patient case series of reduced dosing frequency of incretin drugs plus a simulation model",1],["R0005676","Effect of Polyethylene Glycol Loxenatide Treatment on Body Weight in Patients With Type 2 Diabetes With Different Body Mass Index: A Retrospective Real-World Study.","Xu P","2026","inventory_only","N6","other",null,null,null,"high","first","opus-5.5-agent05","retrospective matched comparison of PEG-loxenatide versus SGLT2i on weight and HbA1c; no listed harm",1],["R0005851","Once-weekly IcoSema versus once-weekly semaglutide in adults with type 2 diabetes: the COMBINE 2 randomised clinical trial.","Lingvay I","2025","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent05","COMBINE 2 phase 3a RCT of IcoSema versus semaglutide 1.0 mg in type 2 diabetes on prior GLP-1 RA, 52 weeks",1],["R0005931","Safety of Drugs in Breastfeeding Women With CKD.","Parnizari P","2025","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent05","review of lactation safety of CKD drugs found no human data on GLP-1 RA; no GLP-1 RA evidence synthesized",1],["R0005989","Comparative analysis of IDegLira versus insulin glargine in short-term intensive therapy for overweight or obese patients with type 2 diabetes mellitus.","Sun Y","2026","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent05","RCT of IDegLira versus glargine, both with aspart, for seven day intensive therapy in overweight type 2 diabetes",1],["R0006055","Efficacy of CagriSema for Reaching Anthropometric Treatment Targets and Cardiometabolic Outcomes: A Secondary, Post hoc Analysis of REDEFINE 1.","Busetto L","2026","include_nma",null,"secondary_report","P02",null,null,"high","first","opus-5.5-agent05","post hoc analysis of REDEFINE 1 RCT of CagriSema, semaglutide, cagrilintide or placebo in obesity without diabetes",1],["R0004850","Mechanistic Insights Into the Cardioprotective Effects of Modern Glucose-Lowering Drugs in Type 2 Diabetes: A Systematic Review.","Ratnala M","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent13","PRISMA systematic review in four databases of mechanistic RCTs of glucose lowering drugs including GLP-1 agonists",1],["R0004922","Non-alcoholic fatty liver disease risk with GLP-1 receptor agonists and SGLT-2 inhibitors in type 2 diabetes: a nationwide nested case-control study.","Chang KC","2024","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent13","nested case control of GLP-1 or SGLT2 use and incident NAFLD, outcome not in harms list",1],["R0004978","Adjunctive Treatment with GLP-1 and Dual GLP-1/GIP Receptor Agonists for People with Type 1 Diabetes: Consensus Report and Practical Guidelines for Safe Use.","Garg SK","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent13","consensus report and practical guidance on adjunctive GLP-1 therapy in type 1 diabetes",1],["R0005104","Diabetes Mellitus in Kidney Transplant Recipients: New Horizons in Treatment.","Sanchez-Baya M","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent13","narrative review of diabetes treatment in kidney transplant recipients",1],["R0005172","Safety and efficacy of glucagon-like peptide-1 receptor agonists among kidney transplant recipients: a systematic review and meta-analysis.","Krisanapan P","2024","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent13","PROSPERO registered meta-analysis of GLP-1 agonist studies in kidney transplant recipients",1],["R0003122","Glucagon-Like Peptide-1 Receptor Agonists Lead to Gastrointestinal Benefits in Patients with Type 2 Diabetes: A Real-World Study.","Hsu JH","2025","include_harms",null,"primary_report",null,"O29; O28",null,"high","first","opus-5.5-agent11","TriNetX new user active comparator cohort, GLP-1RA versus DPP-4i; acute pancreatitis and biliary disease among outcomes",1],["R0003306","Advances in GLP-1 receptor agonists for pain treatment and their future potential.","He Y","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent11","narrative review of GLP-1RAs for pain conditions",1],["R0003382","ABSTRACT NUMBER: ESOC2026A2308 GLP-1 OR DUAL GIP/GLP-1 RECEPTOR AGONIST IN ACUTE ISCHAEMIC STROKE: A SYSTEMATIC REVIEW AND META-ANALYSIS OF PRE-CLINICAL STUDIES",null,"2026","exclude","E1","systematic_review",null,null,"abstract_only","high","first","opus-5.5-agent11","meta-analysis abstract of rodent experimental stroke studies only",1],["R0004783","A Systematic Review of Semaglutide's Influence on Cognitive Function in Preclinical Animal Models and Cell-Line Studies.","Tipa RO","2024","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent09","systematic review restricted to preclinical animal and cell line studies of semaglutide and cognition",1],["R0004836","GLP-1RA and SGLT2i utilization in people with type 2 diabetes with atherosclerotic cardiovascular disease (ASCVD) or at high risk of ASCVD in the Gulf Region: Results from the PACT-MEA studys.","Al-Dahi WA","2025","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent09","cross sectional utilization of GLP-1 and SGLT2 drugs in Gulf diabetes patients without exposure comparison",1],["R0004900","Expert meeting report: epidemiology and management of acquired hypothalamic obesity.","Müller HL","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent09","expert meeting report on acquired hypothalamic obesity without primary data or systematic review",1],["R0004968","Cost-Effectiveness of iGlarLixi Versus iDegLira in Type 2 Diabetes Mellitus Inadequately Controlled by GLP-1 Receptor Agonists and Oral Antihyperglycemic Therapy.","McCrimmon RJ","2021","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent09","cost effectiveness modeling of iGlarLixi versus iDegLira using Core Diabetes Model",1],["R0005033","Drug-Drug Interactions Between Glucagon-Like Peptide 1 Receptor Agonists and Oral Medications: A Systematic Review.","Calvarysky B","2024","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent09","PROSPERO registered systematic review of pharmacokinetic interactions of GLP-1 agonists with oral drugs, PubMed and Embase",1],["R0005164","Evaluation of safety of preoperative GLP-1 receptor agonists in patients undergoing elective surgery: a systematic review, meta-analysis and meta-regression.","Kamarajah SK","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent09","PROSPERO registered meta-analysis of preoperative GLP-1 agonist safety in elective surgery, several databases",1],["R0005170","Comparison of the blood pressure management between sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists.","Kobayashi K","2022","inventory_only","N6","secondary_report","P01",null,null,"high","first","opus-5.5-agent12","retrospective weighted comparison of SGLT2i vs GLP-1RA treated T2D, blood pressure control and eGFR, no listed harm",1],["R0005296","Long-Term Cardiovascular Outcomes of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Type 2 Diabetes: A Systematic Review.","Tariq S","2024","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent12","SR of RCTs and observational studies of GLP-1RAs vs placebo or other drugs on MACE in T2D with pooled risk ratio",1],["R0005382","Gastrointestinal safety evaluation of semaglutide for the treatment of type 2 diabetes mellitus: A meta-analysis.","Huang X","2024","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent12","PRISMA meta-analysis of semaglutide RCTs vs placebo or other drugs on GI adverse events in T2D",1],["R0005582","Disparities in SGLT2 Inhibitor or Glucagon-Like Peptide 1 Receptor Agonist Initiation Among Medicare-Insured Adults With CKD in the United States.","Zhao JZ","2023","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent12","Medicare drug utilization study of factors associated with SGLT2i, GLP-1RA or sulfonylurea initiation, no outcome comparison",1],["R0005635","Outcomes of retained gastrointestinal debris during upper endoscopy.","Jacob JS","2025","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent12","endoscopy cohort comparing patients with vs without retained debris, GLP-1RA not the studied exposure",1],["R0003535","The efficacy and safety of GLP-1 receptor agonists in youth with type 2 diabetes: a meta-analysis.","Yugar LBT","2024","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent19","meta-analysis of placebo controlled RCTs of GLP-1 RA in youth with type 2 diabetes; PubMed Embase CENTRAL searched, PROSPERO",1],["R0003610","Efficacy and Safety of Oral Semaglutide in the Management of Diabetes and Obesity: A Comprehensive Meta-analysis of Real-world Evidence.","Jena S","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent19","meta-analysis of real world studies of oral semaglutide in type 2 diabetes; PubMed Embase Cochrane and others searched, PROSPERO registered",1],["R0003663","Structure-Based Discovery of Orthosteric Non-Peptide GLP-1R Agonists via Integrated Virtual Screening and Molecular Dynamics.","Alturki MS","2025","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent19","virtual screening and molecular dynamics of natural products at the GLP-1 receptor; in silico only",1],["R0003835","Epigenetic Aging and Treatment Response to Semaglutide in the SLIM LIVER Study.","Corley M","2025","inventory_only","N1","secondary_report",null,null,null,"high","first","opus-5.5-agent19","post hoc epigenetic analysis of SLIM LIVER, a single arm semaglutide trial in people with HIV and MASLD",1],["R0005162","Race and ethnicity and pharmacy dispensing of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes.","Rodriguez LA","2024","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent08","dispensing disparities study with race as exposure and SGLT2i or GLP-1 RA dispensing as outcome",1],["R0005213","Erythrocytosis and thromboembolic risks associated with SGLT2 inhibitors in type 2 diabetes.","Chen YH","2025","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent08","TriNetX cohort of SGLT2i versus GLP-1 RA or DPP4i users; erythrocytosis and thrombosis outcomes not in harms list",1],["R0005284","Comparative cardiovascular outcomes and safety of hypoglycemic drug classes in patients with type 2 diabetes and hypertension: a multicenter cohort analysis.","Wei Z","2025","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent08","OHDSI new user cohort of add-on drug classes incl GLP-1 RA; MACE and ten safety conditions, none in harms list",1],["R0005502","Management of Obesity in Menopausal Women: Implications for Metabolic Health and Minimally Invasive Surgery.","Huang HW","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent08","narrative review of obesity management in menopausal women",1],["R0005576","What should the doctor prescribe-formula diet or antidiabetics? Effectiveness of formula diet-based lifestyle intervention vs. pharmacological antiglycemic therapy on weight loss and HbA1c reduction in type 2 diabetes patients-a systematic review.","Kempf K","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent08","PRISMA systematic review comparing formula diet with GLP-1 RA, tirzepatide and SGLT2i trials on weight and HbA1c; PubMed searched",1],["R0005626","Dose-response and time-course effects of ecnoglutide in type 2 diabetes: a systematic review and meta-analysis of efficacy.","Feng Y","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent08","systematic review and meta-analysis of ecnoglutide RCTs in type 2 diabetes; four databases searched",1],["R0004685","Body Composition Changes During GLP-1 Receptor Agonist Therapy in Pediatric Obesity: A Pilot Study.","Pascu BM","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent02","retrospective single group study of semaglutide body composition in adolescents with obesity; no comparison group",1],["R0004753","Tirzepatide for fertility-sparing treatment in obese/overweight patients with endometrial cancer and atypical hyperplasia: a phase II single-arm clinical trial protocol.","Zheng J","2025","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent02","protocol of single arm phase II tirzepatide trial with fertility sparing treatment for endometrial lesions",1],["R0004809","Impact of GLP-1 Agonists on Male Reproductive Health-A Narrative Review.","Varnum AA","2023","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent02","self described non systematic narrative review of GLP-1 RA and male reproduction",1],["R0004869","GLP-1 Receptor Agonists Induce Growth Hormone Secretion in Healthy Volunteers.","Heinla K","2023","inventory_only","N1","secondary_report",null,null,null,"high","first","opus-5.5-agent02","post hoc analysis of two single group open label exenatide and liraglutide studies in healthy volunteers",1],["R0005010","Advancing Heart Failure Care: Breakthroughs and Emerging Strategies.","Tedeschi A","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent02","narrative review of heart failure therapeutic advances",1],["R0005064","Combining GLP-1 receptor agonists and SGLT-2 inhibitors for cardiovascular disease prevention in type 2 diabetes: A systematic review with multiple network meta-regressions.","Zhu JJ","2024","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent02","registered systematic review with network meta-regression of cardiovascular outcome trials of GLP-1 RA and SGLT2 inhibitors",1],["R0004216","SPIRIT: Assessing Clinical Parameters Associated with Using IDegLira in Patients with Type 2 Diabetes in a Real-World Setting in Colombia.","Ramírez-Rincón A","2024","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent10","single arm retrospective chart review of IDegLira initiators in Colombia; no comparison group",1],["R0004279","Therapeutic Targeting of Inflammaging and Emerging Strategies for Managing Age-Related Multimorbidity: A Narrative Review.","Ayoub NR","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent10","self described narrative review of inflammaging therapies; no primary data",1],["R0004355","Efficacy and safety of HRS-7535, an oral small-molecule GLP-1 receptor agonist, in patients with diabetic kidney disease (SOLID-DKD): a randomised, double-blind, placebo-controlled, phase 2 trial.","Lv R","2026","include_nma",null,"primary_report","P08A",null,null,"high","first","opus-5.5-agent10","phase 2 double blind RCT oral HRS-7535 two doses versus placebo in diabetic kidney disease; UACR outcome",1],["R0004450","Comparative Cardiovascular and Renal Outcomes of Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: A Systematic Review.","Khan HK","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent10","PRISMA systematic review of RCTs comparing SGLT2i and GLP-1 RA cardiorenal outcomes; PubMed Embase Cochrane searched",1],["R0004592","Association of glucagon-like peptide-1 receptor agonists with suicidal ideation and self-injury in individuals with diabetes and obesity: a propensity-weighted, population-based cohort study.","Hurtado I","2024","include_harms",null,"primary_report",null,"O35A",null,"high","first","opus-5.5-agent10","new user active comparator cohort GLP-1 RA versus SGLT2i in Valencia; suicidal ideation and self injury outcome",1],["R0004643","Thyroid Hyperplasia and Neoplasm Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists in the Food and Drug Administration Adverse Event Reporting System: Retrospective Analysis.","Makunts T","2024","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent10","FAERS disproportionality analysis of thyroid neoplasm reports with GLP-1 RAs versus SGLT2i",1],["R0005848","Pillar Risk-Based Treatment for Chronic Kidney Disease in People With Type 2 Diabetes: A Narrative Review.","Cheng AYY","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent04","narrative review of pillar risk based CKD treatment in type 2 diabetes",1],["R0005928","Polyethylene Glycol Loxenatide Selectively Reduces Adiposity While Preserving Lean Body Mass in Type 2 Diabetes: A 12-Week Clinical Study.","Gu R","2026","inventory_only","N1","primary_report",null,null,null,"high","first","opus-5.5-agent04","single arm 12 week study of PEG loxenatide added to existing therapy, before and after comparison only",1],["R0006171","Emerging Role of Dual Glucagon-Like Peptide-1 (GLP-1)/Glucose-Dependent Insulinotropic Polypeptide (GIP) Receptor Agonists in Cardiovascular Prevention.","Contreras Figueroa N","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent04","narrative review of dual GLP-1 and GIP agonists in cardiovascular prevention",1],["R0006226","Clinical characteristics, treatment patterns, and healthcare utilization among children, adolescents, and young adults with obesity in the United States.","Gibble TH","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent04","descriptive claims analysis of youth obesity characteristics, treatment patterns and costs, no GLP-1 RA exposure comparison",1],["R0004617","Glucagon-Like Peptide-1 (GLP-1) Agents and Cardiovascular Risk in Non-diabetic Patients: A Descriptive Analysis of National Health and Nutrition Examination Survey (NHANES), 2011-2018.","Disu F","2025","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent18","NHANES descriptive analysis in obese adults without diabetes; no GLP-1 RA users found, so no exposure comparison",1],["R0004676","Can glucagon-like peptide-1 receptor agonists cause acute kidney injury? An analytical study based on post-marketing approval pharmacovigilance data.","Dong S","2022","inventory_only","N5","other",null,null,null,"high","first","opus-5.5-agent18","FAERS disproportionality analysis of acute kidney injury reports across GLP-1 RAs",1],["R0004744","Suboptimal physician adherence to evidence-based guidelines for managing cardiorenal comorbidities in diabetes care: A retrospective single-center study in Taiwan.","Shen ZY","2025","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent18","single center study of physician prescribing adherence to cardiorenal guidelines; prescribing determinants only, no drug outcome comparison",1],["R0004801","Medical treatment for diabetic acute kidney disease from 2012 to 2024: advances, prescription trends, and future directions.","Pan HC","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent18","narrative review of drug therapy and prescription trends in diabetic acute kidney disease",1],["R0004931","Digital engagement enhances dual GIP/GLP-1 receptor agonist and GLP-1 receptor agonist efficacy: A retrospective cohort analysis of a digital weight loss service on outcomes and safety.","Johnson H","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent18","digital weight loss service cohort of tirzepatide or semaglutide users by app engagement; no drug exposure comparison group",1],["R0004991","Semaglutide in Heart Failure With Preserved Ejection Fraction: Emerging Evidence and Clinical Implications.","Arty F","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent18","narrative review of semaglutide trials in HFpEF; not a trial report",1],["R0005059","Exploratory real-world experience with GLP-1 receptor agonists vs. metformin in youth with new-onset type 2 diabetes: a single-center retrospective study.","Tejeji I","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent18","retrospective pediatric cohort of GLP-1 RA vs metformin monotherapy in new onset youth T2D; HbA1c and BMI only",1],["R0006172","Effectiveness, safety, and treatment patterns of GLP-1 receptor agonists in adolescents with obesity: a multicenter retrospective study from Saudi Arabia.","Kalagi F","2026","inventory_only","N6","other",null,null,null,"high","first","opus-5.5-agent05","retrospective adolescent obesity series comparing GLP-1 RA agents on weight and BMI z score; no listed harm",1],["R0006227","Association of semaglutide with reduced incidence and relapse of cannabis use disorder in real-world populations: a retrospective cohort study.","Wang W","2024","inventory_only","N6","other",null,null,null,"high","first","opus-5.5-agent05","TriNetX cohort semaglutide versus non GLP-1 drugs on incident and recurrent cannabis use disorder; no listed harm",1],["R0006280","Uptake of Goal-Directed Therapies in a Multidisciplinary and Interdisciplinary Cardiology-Renal-Endocrine Clinic: A Research Letter.","Ouimet JP","2025","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent05","clinic chart review of therapy uptake and risk factor changes between visits; drug utilization without exposure comparison",1],["R0006367","GLP1R Gene Expression and Kidney Disease Progression.","Triozzi JL","2024","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent05","genetic association study using GLP1R expression score as drug proxy; no drug exposure studied",1],["R0006503","Factors Influencing the Choice of Glucose-Lowering Medications Among Physicians Treating Patients With Type 2 Diabetes.","AlSofiani ME","2024","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent05","cross sectional physician survey of factors in choosing glucose lowering drugs; no drug exposure studied",1],["R0005707","Evolving trends of antidiabetic agents stratified by age, kidney function and body mass index: Insights from a nationwide claims database.","Aoyama K","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent14","Japanese claims study of antidiabetic prescribing trends, no exposure outcome comparison",1],["R0005808","Effect of weight loss and liraglutide on neutrophil gelatinase-associated lipocalin levels among individuals with overweight and knee osteoarthritis: Exploratory analyses of a randomized controlled trial.","Poulsen AS","2025","include_nma",null,"secondary_report","P11",null,null,"high","first","opus-5.5-agent14","secondary analysis of LOSE-IT RCT of liraglutide vs placebo after low calorie diet in knee osteoarthritis, NGAL biomarker",1],["R0005892","Assessment of Glucagon-like Peptide-1 Receptor Agonists in Veterans Taking Basal/Bolus Insulin Regimens.","Castek SL","2022","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent14","retrospective record review of veterans adding GLP-1 RA to basal bolus insulin, no comparison group",1],["R0005957","Risk factors for hepatocellular carcinoma: an umbrella review of systematic review and meta-analysis.","Wang J","2025","include_review",null,"systematic_review",null,null,"umbrella_review","high","first","opus-5.5-agent14","umbrella review of meta-analyses of HCC risk factors including GLP-1 RA use, four databases searched",1],["R0006016","Metabolic remodeling of glycerophospholipids acts as a signature of dulaglutide and liraglutide treatment in recent-onset type 2 diabetes mellitus.","Du J","2022","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent14","nonrandomized comparison of dulaglutide vs liraglutide chosen by patients, metabolomics in new T2D, no harms_nrs outcome",1],["R0006074","Association of 14-day continuous glucose monitoring-derived postprandial hyperglycemic area with 6-month change in urinary albumin-to-creatinine ratio in patients with newly diagnosed type 2 diabetes mellitus.","Yu T","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent14","CGM postprandial hyperglycemia and albuminuria study, GLP-1 RA only an adjustment covariate, not a studied exposure",1],["R0006132","The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Patients with Type 2 Diabetes (TROPHIES): Patient disposition, clinical characteristics and treatment persistence at 12 months.","Guerci B","2022","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent14","prospective two cohort observational study of dulaglutide and liraglutide initiators, persistence and HbA1c, no harms_nrs outcome",1],["R0004101","Direct comparison two fixed-ratio combination glucagon-like peptide receptor agonist and basal insulin on glycemic and non glycemic parameters in type 2 diabetes.","Risovic I","2023","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent17","retrospective comparison of iDegLira versus iGlarLixi switch groups by prior insulin; glycemic and weight outcomes only",1],["R0004167","Long term cost-effectiveness analysis of IDegLira in the treatment of type 2 diabetes patients compared to GLP-1RA added to basal insulin after IDegLira entered the national reimbursement drug list in China.","Xiao D","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent17","long term cost effectiveness model of IDegLira versus GLP-1 RA plus basal insulin in China",1],["R0004236","Analysis of the efficacy and safety of liraglutide, semaglutide, and tirzepatide for the treatment of overweight and obesity: a systematic review and network meta-analysis.","Pałka W","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent17","registered systematic review and network meta-analysis of phase 3 RCTs of liraglutide, semaglutide, tirzepatide in obesity",1],["R0004375","Molecular mechanisms of semaglutide and liraglutide as a therapeutic option for obesity.","Tamayo-Trujillo R","2024","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent17","minireview of molecular mechanisms of semaglutide and liraglutide with unstructured search",1],["R0004540","A phase 1 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of danuglipron (PF-06882961), an oral small-molecule glucagon-like peptide-1 receptor agonist, in Japanese adults with type 2 diabetes mellitus.","Ono R","2023","include_nma",null,"primary_report","P01",null,"mechanistic","high","first","opus-5.5-agent17","phase 1 placebo controlled RCT of danuglipron doses in Japanese adults with type 2 diabetes over 8 weeks; adverse events, HbA1c, weight",1],["R0004614","Current Status of Delay in Injectable Therapy among Type 2 Diabetes Mellitus Patients in South Korea: Multicenter Retrospective Study (2015-2021).","Choi JH","2025","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent17","multicenter retrospective cohort of insulin versus GLP-1 RA initiation after oral drugs; therapeutic inertia and HbA1c only",1],["R0005211","Glucagon-like peptide 1 (GLP-1) receptor agonists in experimental Alzheimer's disease models: a systematic review and meta-analysis of preclinical studies.","Kong F","2023","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent07","systematic review and meta-analysis restricted to rodent Alzheimer models treated with GLP-1RA",1],["R0005281","The Effect of Glucagon-Like Peptide-1 Receptor Agonists on Diabetic Retinopathy at a Tertiary Care Center.","Joo JH","2024","include_harms",null,"primary_report",null,"O33",null,"high","first","opus-5.5-agent07","propensity matched cohort of GLP-1RA vs SGLT2i initiators at an eye institute; diabetic retinopathy worsening outcome",1],["R0005366","Real-world cardiovascular effectiveness of sustained glucagon-like peptide 1 GLP-1 receptor agonist usage in type 2 diabetes.","Sørensen KK","2025","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent07","Danish target trial emulation of sustained GLP-1RA vs DPP-4i use; cardiovascular and mortality outcomes only",1],["R0005501","Cardiovascular Disease & Diabetes Statistics in Korea: Nationwide Data 2010 to 2019.","Kim JH","2024","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent07","national statistics on CVD incidence and treatment rates in Korean diabetes; GLP-1RA use only described",1],["R0005625","Protocol for a double-blind placebo-controlled randomised controlled trial assessing the impact of oral semaglutide in amyloid positivity (ISAP) in community dwelling UK adults.","Koychev I","2024","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent07","protocol of placebo controlled RCT of oral semaglutide in amyloid positive older adults",1],["R0005767","Dual Glucagon and GLP-1 Receptor Agonist Survodutide Improves Biomarkers of Beta-Cell Function and Insulin Sensitivity in People With Type 2 Diabetes or Living With Overweight/Obesity.","Ekinci EI","2026","include_nma",null,"secondary_report","P01; P02",null,null,"high","first","opus-5.5-agent04","post hoc biomarker analysis of two phase 2 RCTs of survodutide vs placebo or semaglutide, reports fasting glucose and weight",1],["R0005839","Multi-target Mechanisms and Clinical Evidence for Ganzaoning Granule in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Narrative Review.","Zhao H","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent20","narrative review of a traditional Chinese medicine granule for MASLD, GLP-1 RAs only mentioned as context",1],["R0005919","Virtual shared medical appointments for obesity and GLP-1 medications: A scalable method for optimizing care delivery.","Mirsky J","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent20","retrospective single site cohort of virtual group visits for GLP-1 medication users, descriptive, no comparison group",1],["R0005977","Weight Loss That Lasts: Reviewing the Long-Term Impact of GLP-1 Receptor Agonists.","Shah MY","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent20","PRISMA systematic review of long term GLP-1 RA RCTs in obesity, PubMed CENTRAL Embase searched, narrative synthesis",1],["R0006091","GLP-1 receptor agonists and the risk for cancer: A meta-analysis of randomized controlled trials.","Silverii GA","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent20","meta-analysis of RCTs of GLP-1 RA vs comparators on cancer incidence, PubMed Embase CENTRAL searched",1],["R0006160","Comparing the risk of gastroparesis following different modalities for treating obesity: semaglutide versus bupropion-naltrexone versus sleeve gastrectomy - a retrospective cohort study.","Aneke-Nash C","2025","include_harms",null,"primary_report",null,"O37A",null,"high","first","opus-5.5-agent20","MarketScan cohort of semaglutide vs bupropion-naltrexone vs sleeve gastrectomy in obesity, gastroparesis outcome, adjusted Cox",1],["R0006218","Glucagon-like peptide-1 receptor analogues and beyond: emerging obesity pharmacotherapies.","Abburi K","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent20","narrative review of emerging obesity pharmacotherapies",1],["R0006270","Perioperative GLP-1 Receptor Agonist Use is Associated With Reduced Revisions and Complications Following ACDF: A Propensity-Matched Analysis.","Kim MT","2026","include_harms",null,"primary_report",null,"O121",null,"high","first","opus-5.5-agent20","TriNetX matched cohort of GLP-1 RA users vs nonusers undergoing ACDF in T2D, acute kidney injury among medical complications",1],["R0006376","Safe and Appropriate Use of GLP-1 RAs in Treating Adult Patients With Type 2 Diabetes and Macrovascular Disease.","LaSalle J","2022","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent06","sponsored video roundtable abstract on GLP-1 RA use in T2D with macrovascular disease; educational opinion",1],["R0006433","A Review of Oral Semaglutide Available Evidence: A New Era of Management of Diabetes with Peptide in a Pill Form.","Kalra S","2022","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent06","narrative mini review of oral semaglutide evidence and place in therapy",1],["R0006504","PIONEER REAL UK: A Multi-Centre, Prospective, Real-World Study of Once-Daily Oral Semaglutide Use in Adults with Type 2 Diabetes.","Saravanan P","2024","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent06","PIONEER REAL UK, noninterventional single arm prospective cohort of oral semaglutide in T2D; no comparison group",1],["R0006593","PSUN270 Magnified Risk of Pancreatitis by GLP-1: A Case of Necrotizing Pancreatitis in a Patient on Dulaglutide with Baseline Elevated Triglycerides",null,"2022","inventory_only","N5","conference_abstract",null,null,"abstract_only","high","first","opus-5.5-agent06","conference abstract case report of necrotizing pancreatitis on dulaglutide with hypertriglyceridemia",1],["R0006643","Hypoglycemia Risk With SGLT2 Inhibitors or Glucagon-Like Peptide 1 Receptor Agonists Versus Sulfonylureas Among Medicare Insured Adults With CKD in the United States.","Zhao JZ","2022","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent06","Medicare cohort of SGLT2 inhibitor or GLP-1 RA versus sulfonylurea in CKD with T2D; hypoglycemia outcome only",1],["R0006774","Semaglutide for the treatment of antipsychotic-associated weight gain in patients not responding to metformin - a case series.","Prasad F","2023","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent06","retrospective case series of semaglutide for antipsychotic weight gain after metformin failure; no comparison group",1],["R0004104","Risk-Benefit Trade-offs of GLP-1RAs and SGLT-2is in Type 2 Diabetes Mellitus (T2D): Systematic Review, Meta-Analysis, and Net Benefit Modeling.","Ghosal S","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent19","meta-analysis of placebo controlled CVOTs of GLP-1 RA and SGLT2 inhibitors in type 2 diabetes with net benefit; PubMed CENTRAL, PROSPERO",1],["R0004320","Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: A network meta-analysis.","Park MJ","2023","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent19","network meta-analysis of RCTs of GLP-1 RA and thiazolidinediones in NAFLD; PubMed Embase Web of Science Scopus searched",1],["R0004388","Effect of glucagon-like peptide-1 receptor agonists on glycemic control, and weight reduction in adults: A multivariate meta-analysis.","Yeh TL","2023","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent19","multivariate meta-analysis of placebo controlled RCTs of GLP-1 RA on HbA1c and weight; Medline Embase Cochrane searched",1],["R0004552","Association Between GLP1 RAs Use and Risk of Colorectal Cancer: A Systematic Review and Meta-Analysis.","Bushi G","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent19","meta-analysis of cohort and case control studies of GLP-1 RA vs other drugs on colorectal cancer; PubMed Embase Web of Science",1],["R0005188","Translating Guidelines into Practice: A Prospective Real-World Study of a Romanian Cohort Treated with GLP-1 RAs.","Popoviciu MS","2025","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent01","prospective observational cohort comparing exenatide, semaglutide and dulaglutide users; HbA1c, weight and waist outcomes only",1],["R0006279","Anti-diabetic agents and the risks of dementia in patients with type 2 diabetes: a systematic review and network meta-analysis of observational studies and randomized controlled trials.","Li Z","2024","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent04","registered systematic review and network meta-analysis of observational studies and RCTs of antidiabetic drugs incl GLP-1 RA on dementia",1],["R0005340","The real-world safety profile of tirzepatide: pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database.","Caruso I","2024","inventory_only","N5","other",null,null,null,"high","first","opus-5.5-agent01","FAERS disproportionality analysis of tirzepatide gastrointestinal, pancreatobiliary, retinal and thyroid reports",1],["R0005483","Prior Use of GLP-1 Receptor Agonists versus SGLT2 Inhibitors and Clinical Outcomes After Sepsis in Patients with Type 2 Diabetes: A Propensity Score-Matched Cohort Study.","Liu HH","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent01","matched cohort of prior GLP-1 RA versus SGLT2i use before sepsis; mortality, MACE, MAKE and ICU outcomes only",1],["R0005667","Preventing all-cause hospitalizations in type 2 diabetes with sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: A narrative review and proposed clinical approach.","Schechter M","2022","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent01","self described narrative review of SGLT2i and GLP-1 RA effects on all cause hospitalization",1],["R0006366","Recent Trends in the Prevention and Management of Obesity Among Adults: A Systematic Review.","Shankar G","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent04","PRISMA systematic review of three databases on adult obesity management incl GLP-1 RA trials, narrative synthesis",1],["R0006430","Glucometabolic outcomes of GLP-1 receptor agonist-based therapies in patients with type 2 diabetes: a systematic review and network meta-analysis.","Caruso I","2023","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent04","registered systematic review and network meta-analysis of RCTs of GLP-1 RA based therapies in type 2 diabetes",1],["R0006498","GLP-1 analog therapy and hemoglobin levels: Insights from a retrospective study.","Almuammar SA","2025","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent04","retrospective single group of GLP-1 RA users with hemoglobin change from baseline, no comparison group",1],["R0006582","A systematic review of the safety of tirzepatide-a new dual GLP1 and GIP agonist - is its safety profile acceptable?","Meng Z","2023","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent04","systematic review of RCTs of tirzepatide vs placebo or other drugs with pooled safety risk ratios",1],["R0006636","Oral Semaglutide Use in Type 2 Diabetes: A Pooled Analysis of Clinical and Patient-Reported Outcomes from Seven PIONEER REAL Prospective Real-World Studies.","Rudofsky G","2025","inventory_only","N5","pooled_analysis",null,null,null,"high","first","opus-5.5-agent04","pooled analysis of seven noninterventional single arm oral semaglutide studies, no comparison group",1],["R0003582","Cellulite as a Possible Biomarker of Metabolic Dysfunction: Redefining Body Remodeling in the Glucagon-Like Peptide-1 Era Through the Cellulite Removal Medical Protocol-G21 Concept.","Adamidis N","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent11","editorial proposing a conceptual cellulite protocol in the GLP-1 era; no data",1],["R0005716","Glucagon-like peptide-1 receptor-agonists treatment for cardio-metabolic parameters in schizophrenia patients: a systematic review and meta-analysis.","Khaity A","2023","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent16","PROSPERO registered systematic review and meta-analysis of placebo controlled GLP-1RA RCTs in antipsychotic treated schizophrenia",1],["R0003646","GLP-1 receptor agonists and pancreatic beta cell apoptosis in diabetes mellitus: a systematic review and meta-analysis of preclinical studies.","Rea N","2025","exclude","E1","systematic_review",null,null,null,"high","first","opus-5.5-agent11","meta-analysis limited to in vitro human beta cell culture studies of GLP-1RAs; no human participants",1],["R0003711","Retrospective Assessment of Food Noise Changes After Initiation of Injectable Semaglutide for Weight Management in the USA: The INFORM Survey.","Arnaut T","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent11","cross sectional online survey of semaglutide users recalling food noise before and after; no comparator",1],["R0003789","A machine learning model for optimizing treatment of patients with poorly controlled type 2 diabetes.","Shi J","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent11","ChinaMAP cohort of SGLT2i or GLP-1RA users used to build a selection score; HbA1c outcomes only",1],["R0003876","Glucagon-like Peptide-1 Receptor Agonist Treatment With Semaglutide in Type 1 Diabetes.","Raven LM","2023","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent11","single case report of semaglutide in type 1 diabetes",1],["R0003925","Semaglutide, tirzepatide, and retatrutide attenuate the interoceptive effects of alcohol in male and female rats.","Windram M","2026","exclude","E1","primary_report",null,null,null,"high","first","opus-5.5-agent11","drug discrimination experiments in rats with semaglutide, tirzepatide and retatrutide",1],["R0004002","Glucagon-Like Peptide-1 Agonist Use in Adults With Congenital Heart Disease: Effect, Safety, and Outcomes.","Thapa R","2025","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent11","single center retrospective cohort of GLP-1RA users with congenital heart disease; no comparison group",1],["R0004073","Weight trajectories after last tirzepatide or semaglutide prescription across a federated health network.","Murugadoss K","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent11","descriptive weight trajectories after last semaglutide or tirzepatide prescription; no comparison group",1],["R0005818","Generalizability of the Results of Cardiovascular Outcome Trials of Glucagon-Like Peptide 1 Receptor Agonists in Chinese Patients with Type 2 Diabetes Mellitus.","Cai X","2021","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent16","cross sectional eligibility analysis of a Chinese T2D survey against GLP-1RA outcome trial criteria; no GLP-1RA exposure",1],["R0005910","Prediabetes and diabetes mellitus type II after ischemic stroke.","Moelgg K","2025","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent16","stroke registry study of glycemic status progression; GLP-1RAs discussed only regarding trial eligibility",1],["R0005963","Emerging Evidence for the Use of Antidiabetic Drugs, Glucagon-like Peptide 1 Receptor Agonists, for the Treatment of Alzheimer's Disease.","Colin IM","2023","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent16","narrative review of GLP-1RAs for Alzheimer disease",1],["R0006022","The Emerging Role of Glucagon-like Peptide-1 Receptor Agonists for the Management of NAFLD.","Patel Chavez C","2022","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent16","narrative minireview of GLP-1RAs in NAFLD for endocrinologists",1],["R0006078","Comparative effectiveness of metabolic bariatric surgery versus incretin-based and medical therapies for weight loss and glycemic outcomes: a systematic review and meta-analysis","Alshahrani SD","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent16","systematic review and meta-analysis of bariatric surgery versus incretin and medical therapy; PubMed, Scopus, Web of Science",1],["R0006148","Efficacy and Safety of GLP-1 Receptor Agonists for the Management of Knee Osteoarthritis: A Systematic Review and Meta-Analysis","Singh MP","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent16","systematic review and meta-analysis of GLP-1RA RCTs in knee osteoarthritis; MEDLINE, Embase, Cochrane searched",1],["R0006205","Effect of Hemoglobin A1c Reduction or Weight Reduction on Blood Pressure in Glucagon-Like Peptide-1 Receptor Agonist and Sodium-Glucose Cotransporter-2 Inhibitor Treatment in Type 2 Diabetes Mellitus: A Meta-Analysis.","Hu M","2020","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent16","PROSPERO registered meta-analysis and meta-regression of GLP-1RA and SGLT2i RCTs on blood pressure in T2D",1],["R0005235","The Effect of Semaglutide and GLP-1 RAs on Risk of Nonarteritic Anterior Ischemic Optic Neuropathy.","Abbass NJ","2025","include_harms",null,"primary_report",null,"O34",null,"high","first","opus-5.5-agent13","TriNetX matched cohort GLP-1 or semaglutide users vs other glucose lowering drug users reporting NAION",1],["R0005309","Comparative Efficacy and Safety of Tirzepatide Versus Semaglutide for Obesity: A Systematic Review.","Mohamed Abdalla SA","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent13","PRISMA systematic review in four databases of tirzepatide vs semaglutide comparative studies in obesity",1],["R0005462","Glucagon-like-peptide-1 receptor agonists versus dipeptidyl peptidase-4 inhibitors and cardiovascular outcomes in diabetes in relation to achieved glycemic control. A Danish nationwide study.","Zareini B","2024","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent13","Danish registry cohort GLP-1 vs DPP-4 inhibitors, cardiovascular composite by achieved HbA1c only",1],["R0005584","Safety and Efficacy of Semaglutide in Patients With Chronic Kidney Disease, With or Without Type 2 Diabetes: A Systematic Review and Meta-Analysis.","Abdullah A","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent13","PROSPERO registered meta-analysis of semaglutide RCTs in chronic kidney disease",1],["R0005702","Glucagon-like peptide-1 receptor agonists as add-on therapy to insulin for type 1 diabetes mellitus.","Tan X","2023","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent13","PROSPERO registered meta-analysis of GLP-1 adjunct RCTs in type 1 diabetes",1],["R0005217","Declining Bariatric Surgery Volumes and Shifting Practice Patterns: A Five-Year Analysis of Over One Million Procedures.","Wills MV","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent09","registry trend analysis of bariatric surgery volumes, GLP-1 drugs mentioned only as background, no exposure",1],["R0005289","Glucagon-like peptide-1 receptor agonists and the risk of atrial fibrillation in adults with diabetes: a real-world study.","Xu Y","2024","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent09","real world cohort of GLP-1 agonists versus comparator drugs on incident atrial fibrillation only",1],["R0005373","Pancreatitis with use of new diabetic medications: a real-world data study using the post-marketing FDA adverse event reporting system (FAERS) database.","Alenzi KA","2024","inventory_only","N5","other",null,null,null,"high","first","opus-5.5-agent09","FAERS disproportionality analysis of pancreatitis with GLP-1, SGLT2 and DPP-4 drugs",1],["R0005449","Effects of glucagon-like peptide-1 receptor agonists on glucose excursion and inflammation in overweight or obese type 2 diabetic patients.","Huang XM","2023","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent09","retrospective comparison of weekly versus daily GLP-1 agonists on glucose excursion and inflammation markers, no eligible harm",1],["R0005509","Psychiatric adverse events linked to glucagon-like peptide 1 analogues: a disproportionality analysis in American, Canadian and Australian adverse event databases.","Katranski J","2025","inventory_only","N5","other",null,null,null,"high","first","opus-5.5-agent09","disproportionality analysis of psychiatric adverse event reports in three national databases",1],["R0005629","Adverse Events of Oral GLP-1 Receptor Agonist (Semaglutide Tablets): A Real-World Study Based on FAERS from 2019 to 2023.","Xiong S","2024","inventory_only","N5","other",null,null,null,"high","first","opus-5.5-agent09","FAERS disproportionality analysis of oral semaglutide adverse event reports",1],["R0005689","Liraglutide in Acute Minor Ischemic Stroke or High-Risk Transient Ischemic Attack With Type 2 Diabetes: The LAMP Randomized Clinical Trial.","Zhu H","2026","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent09","LAMP open label RCT of liraglutide plus standard therapy versus standard therapy after minor stroke or TIA in type 2 diabetes",1],["R0006705","Pulmonary outcomes of incretin-based therapies in COPD patients receiving single-inhaler triple therapy.","See XY","2025","include_harms",null,"other",null,"O37A; O28; O29; O37B",null,"high","first","opus-5.5-agent05","TriNetX cohort GLP-1 RA versus DPP-4i in COPD with diabetes; safety outcomes gastroparesis, biliary disease, pancreatitis, bowel obstruction",1],["R0006847","Risk of major adverse limb events in patients with type 2 diabetes mellitus receiving sodium glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists: A population-based retrospective cohort study.","Lee YC","2022","inventory_only","N6","other",null,null,null,"high","first","opus-5.5-agent05","Taiwanese cohort SGLT2i versus GLP-1 RA or DPP-4i on limb ischemia and amputation; no listed harm",1],["R0006905","The Effect of Semaglutide on Blood Pressure in Patients without Diabetes: A Systematic Review and Meta-Analysis.","Kennedy C","2023","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent05","registered meta-analysis of placebo controlled semaglutide RCTs on blood pressure in adults without diabetes",1],["R0006966","Effects of exercise and liraglutide on vascular health and inflammation during weight loss maintenance: a prespecified secondary analysis of the S-LiTE trial.","Sandsdal RM","2026","include_nma",null,"secondary_report","P02",null,null,"high","first","opus-5.5-agent05","secondary analysis of S-LiTE RCT of exercise, liraglutide, both or placebo for weight maintenance after diet induced loss",1],["R0007034","Effect of polyethylene glycol loxenatide on weight loss in super-obese patients with type 2 diabetes: a randomized controlled trial.","Liu Z","2026","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent05","single blind RCT of two PEG-loxenatide doses versus placebo in super obese type 2 diabetes, 24 weeks",1],["R0005699","Utilization of glucagon-like peptide-1 receptor agonists and changes in clinical characteristics in patients with type 2 diabetes by chronic kidney disease stage in Japan: A descriptive observational study using a nationwide electronic medical records database.","Hirose N","2022","inventory_only","N5","primary_report","P01",null,null,"high","first","opus-5.5-agent12","descriptive EMR cohort of GLP-1RA initiators by CKD stage, persistence and before after changes, no comparison group",1],["R0005804","Effects of newer anti-hyperglycemic agents on cardiovascular outcomes in older adults: Systematic review and meta-analysis.","Bilal A","2024","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent12","registered SR and meta-analysis of CVOTs of DPP4i, GLP-1RA and SGLT2i vs placebo in older adults",1],["R0005885","Burden of long-term conditions and management of people with overweight and obesity: Data from the United Kingdom primary care cohort of the IMPACT-O study.","Khunti K","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent12","descriptive primary care cohort of obesity complications and management, GLP-1RA use only counted, no exposure comparison",1],["R0005953","Efficacy and tolerability of oral semaglutide in Japanese patients with type 2 diabetes mellitus: Analysis report from diabetes specialist clinics.","Inokuchi T","2024","inventory_only","N5","primary_report","P01",null,null,"high","first","opus-5.5-agent12","retrospective single drug cohort of oral semaglutide users, before after changes and BMI subgroup comparison, no unexposed group",1],["R0006069","The effectiveness of sodium-glucose co-transporter 2 inhibitors on cardiorenal outcomes: an updated systematic review and meta-analysis.","Ali MU","2024","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent12","updated SR and meta-analysis of placebo controlled SGLT2i and GLP-1RA outcome trials with GRADE",1],["R0006128","Comparative Efficacy and Safety of Tirzepatide in Asian and Non-Asian Adults With Obesity Without Diabetes: A Systematic Review and Meta-Analysis.","Kamrul-Hasan ABM","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent12","registered SR and meta-analysis of SURMOUNT RCTs of tirzepatide vs placebo by Asian vs non Asian",1],["R0006187","The dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide improves cardiovascular risk biomarkers in patients with type 2 diabetes: A post hoc analysis.","Wilson JM","2022","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent12","post hoc biomarker analysis of phase 2b RCT of tirzepatide doses vs dulaglutide vs placebo in T2D",1],["R0005847","Pharmacotherapy for Obesity: Recent Updates.","Fredrick TW","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent03","self described narrative review of obesity pharmacotherapy",1],["R0005926","Comparative pharmacovigilance analysis of suicidality-related adverse events among GLP-1 and non-GLP-1 anti-obesity drugs in the FDA Adverse Event Reporting System.","Seijas-Amigo J","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent03","FAERS disproportionality analysis of suicidality reports with GLP-1 vs non GLP-1 anti-obesity drugs",1],["R0005983","Comparative Effects of Dulaglutide and Semaglutide on Renal Function Decline and Proteinuria Reduction in Diabetic Patients: A Retrospective Cohort Study.","Sue YM","2025","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent03","retrospective cohort dulaglutide vs semaglutide in diabetes; eGFR, UACR and death only",1],["R0006052","A meta-analytic review of the safety and efficacy of semaglutide in type 2 diabetes mellitus and chronic kidney disease patients.","Ashraf T","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent03","PRISMA meta-analysis of three RCTs of semaglutide vs placebo in T2D with CKD; search strategy section present",1],["R0006101","Effect of video conferencing between primary and secondary care specialists on type 2 diabetes medication.","Prætorius T","2025","exclude","E2","primary_report",null,null,null,"high","first","opus-5.5-agent03","cluster RCT of specialist video conferencing; GLP-1 RA prescribing is an outcome, not an assigned intervention",1],["R0006221","Real-World Effectiveness of Tirzepatide in Japanese Patients with Type 2 Diabetes: A Multicenter Retrospective Observational Study.","Takahashi N","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent03","multicenter retrospective before and after study of tirzepatide in Japanese T2D, no comparison group",1],["R0005683","GLP-1 Receptor Agonists in the Management of Post-bariatric Weight Regain and Dysglycemia: A Systematic Review and Meta-Analysis.","Natche J","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent08","PRISMA systematic review and meta-analysis of GLP-1 RA after bariatric surgery; MEDLINE, Embase, CENTRAL, Web of Science searched",1],["R0005785","Plant-Based Nutrition Alleviates Gastrointestinal Symptoms and Enhances Protein Intake during GLP-1 Therapy.","Withrow NA","2026","inventory_only","N1","primary_report",null,null,null,"high","first","opus-5.5-agent08","single arm pilot of plant based protein shake in people already on semaglutide; no control group",1],["R0005861","Pulsatile liraglutide on a biased tirzepatide background: a hypothesis.","Kopitovic I","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent08","hypothesis paper proposing pulsatile liraglutide on tirzepatide background; no data",1],["R0005938","The effect of SGLT2 inhibitors, GLP-1 receptor agonists, or DPP-4 inhibitors on stroke risk in type 2 diabetes: a nationwide longitudinal cohort study in Sweden with contextualisation analysis.","Mavridis A","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent08","Swedish registry cohort of SGLT2i, GLP-1 RA, DPP-4i and stroke; stroke not in harms list",1],["R0005999","Effects of Anti-Diabetic Drugs on Erectile Dysfunction: A Systematic Review and Meta-Analysis.","Yang B","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent08","systematic review and meta-analysis of antidiabetic drugs incl GLP-1 RA versus metformin on erectile dysfunction",1],["R0006061","The impact of glucagon-like peptide-1 receptor agonists in the patients undergoing anesthesia or sedation: systematic review and meta-analysis.","do Nascimento TS","2024","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent08","PROSPERO registered meta-analysis of GLP-1 RA versus control in anesthesia or sedation; MEDLINE, Embase, Cochrane",1],["R0006176","Changes in Cardiovascular Risk Factors and Health Care Expenditures Among Patients Prescribed Semaglutide.","Lu Y","2025","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent08","staggered difference in differences cohort of semaglutide initiators; risk factors and expenditures only",1],["R0004711","Exploring factors predicting the effectiveness of oral semaglutide in Japanese individuals with type 2 diabetes switching from dipeptidyl peptidase 4 inhibitors: a pilot study.","Hirotsu T","2025","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent10","prospective observational study of patients switched to oral semaglutide comparing target achievers with nonachievers; no unexposed group",1],["R0004787","Exendin-4 averts all-trans-retinal-driven damage to photoreceptors and the retina via the GLP-1R/PKA/CREB1 signaling axis.","He B","2026","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent10","exendin 4 in photoreceptor cell line and knockout mice; no human data",1],["R0004839","Lower fall and femoral fracture risks with semaglutide and tirzepatide compared with DPP-4 inhibitors in older adults with type 2 diabetes.","Chen HY","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent10","TriNetX matched cohort semaglutide or tirzepatide versus DPP-4i in older adults; femoral fracture and falls only",1],["R0004971","Early worsening of diabetic retinopathy in individuals with type 2 diabetes treated with tirzepatide: a real-world cohort study.","Buckley AJ","2025","include_harms",null,"primary_report",null,"O33",null,"high","first","opus-5.5-agent10","matched cohort tirzepatide exposed versus unexposed type 2 diabetes; new onset proliferative retinopathy and progression",1],["R0005037","Clinical and Metabolic Effects of Incretin-Based Pharmacotherapy in Normal-Weight Patients With Type 2 Diabetes: A Real-World Analysis.","Carson E","2025","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent10","retrospective chart review of normal weight T2D patients starting incretin drugs; pre post changes, no comparison group",1],["R0005095","Amylin-based obesity therapy: a meta-analysis of Cagrilintide and CagriSema versus placebo.","Yaseen M","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent10","PROSPERO registered meta-analysis of RCTs of cagrilintide and CagriSema versus placebo in obesity",1],["R0004673","Effect of Glucagon-like Peptide-1 Receptor Agonists on Cardio-Metabolic Risk Factors among Obese/Overweight Individuals Treated with Antipsychotic Drug Classes: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials.","Patoulias D","2023","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent17","registered meta-analysis of RCTs of GLP-1 RAs versus control in people on antipsychotics with overweight, PubMed and Cochrane searched",1],["R0004743","Evidence-based SGLT2 inhibitor and GLP-1 receptor agonist use by race in the VA healthcare system.","Bolden DM","2025","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent17","VA cohort of trial concordant SGLT2 inhibitor or GLP-1 RA prescribing by race; prescription is the outcome",1],["R0004797","Semaglutide Improves Lipid Subfraction Profiles in Type 2 Diabetes: Insights from a One-Year Follow-Up Study.","Tóth LI","2025","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent17","single center 52 week RCT of semaglutide versus sitagliptin added to metformin in obese type 2 diabetes; lipid subfractions, BMI, HbA1c",1],["R0004861","Utilization Trends of Glucose-Lowering Medications Among Adult Kidney Transplant Recipients with Type 2 Diabetes in the United States.","Hansrivijit P","2025","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent17","ecologic claims study of glucose lowering drug utilization trends in kidney transplant recipients",1],["R0004928","Discontinuation and Reinitiation of Dual-Labeled GLP-1 Receptor Agonists Among US Adults With Overweight or Obesity.","Rodriguez PJ","2025","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent17","cohort of GLP-1 RA new users describing discontinuation and reinitiation rates and predictors; drug utilization without exposure comparison",1],["R0004990","Effect of long-acting versus short-acting glucagon-like peptide-1 receptor agonists on improving body weight and related metabolic parameters in type 2 diabetes: A head-to-head meta-analysis.","Yuan X","2023","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent17","meta-analysis of head to head RCTs of long versus short acting GLP-1 RAs in type 2 diabetes, four databases searched",1],["R0005055","Clinical Efficacy of Glucagon-like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes: A Meta-analysis.","Shi L","2023","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent17","meta-analysis of RCTs comparing GLP-1 RAs with basal insulin in type 2 diabetes, MEDLINE, Embase, CENTRAL searched",1],["R0005116","Comparative Safety of GLP-1/GIP Co-Agonists Versus GLP-1 Receptor Agonists for Weight Loss in Patients with Obesity or Overweight: A Systematic Review.","Xie Z","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent17","registered network meta-analysis of RCTs comparing safety of tirzepatide with semaglutide and liraglutide in obesity",1],["R0006856","Exploring the association between weight loss-inducing medications and multiple sclerosis: insights from the FDA adverse event reporting system database.","Shirani A","2024","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent06","FAERS disproportionality analysis of weight loss drugs incl GLP-1 RAs and multiple sclerosis reports",1],["R0006908","Retrospective Analysis of the Effectiveness of Oral Semaglutide in Type 2 Diabetes Mellitus and Its Effect on Cardiometabolic Parameters in Japanese Clinical Settings.","Yamada H","2023","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent06","single center retrospective before and after study of oral semaglutide in Japanese T2D; no comparison group",1],["R0006975","Efsubaglutide alfa added to metformin improves glycaemia with β-cell functional responses in type 2 diabetes: a randomised, double-blind, placebo-controlled, two-stage adaptive phase 2b/3 trial (SUPER 2).","Jia W","2026","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent06","SUPER 2, double blind adaptive phase 2b/3 RCT of efsubaglutide alfa versus placebo added to metformin in T2D",1],["R0007040","Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Diabetes and Obesity: Implications for Periodontology and Family Dentistry.","Almohammad AA","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent06","narrative review of GLP-1 RAs and periodontal health; no primary data",1],["R0007110","Gastrointestinal Adverse Effects of Anti-Obesity Medications in Non-Diabetic Adults: A Systematic Review.","Takrori E","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent06","registered systematic review of GI adverse effects of anti-obesity drugs incl GLP-1 RAs in adults without diabetes",1],["R0007165","Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis.","Karagiannis T","2022","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent06","registered systematic review and meta-analysis of RCTs of tirzepatide versus placebo or other drugs in T2D",1],["R0007231","Initiation of the Fixed Combination IDegLira in Patients with Type 2 Diabetes on Prior Injectable Therapy: Insights from the EASY French Real-World Study.","Tramunt B","2022","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent06","retrospective chart review of IDegLira initiation after prior injectables; single group before and after changes",1],["R0007292","Trends in antidiabetes medication use among hospitalised patients with type 2 diabetes: a retrospective single-centre cohort study.","Meier N","2024","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent06","single center drug utilization trend study of antidiabetes medications in hospitalized T2D; no exposure outcome comparison",1],["R0006704","Association between weight reduction achieved with tirzepatide and quality of life in adults with obesity: Results from the SURMOUNT-1 study.","Gudzune KA","2025","include_nma",null,"secondary_report","P02",null,null,"high","first","opus-5.5-agent04","secondary analysis of SURMOUNT-1 RCT tirzepatide vs placebo on patient reported outcomes incl SF-36 by weight loss category",1],["R0006767","No calcitonin change in a person taking dulaglutide diagnosed with pre-existing medullary thyroid cancer.","Sherman SI","2018","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent04","case report of pre-existing medullary thyroid cancer in a dulaglutide trial participant",1],["R0006840","Comparative Effectiveness of Antidiabetic Drugs as an Additional Therapy to Metformin in Women with Polycystic Ovary Syndrome: A Systematic Review of Metabolic Approaches.","Heidarpour M","2024","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent04","registered systematic review of RCTs in PCOS comparing metformin plus other antidiabetic drugs incl GLP-1 RA",1],["R0006903","Rebound or Retention: A Meta-Analysis of Weight Regain After the Discontinuation of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists and Other Anti-obesity Drugs.","Kolli RT","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent04","meta-analysis with five database search on weight regain after stopping semaglutide, liraglutide, exenatide or orlistat",1],["R0006962","The effects of GLP-1 agonists on HbA1c and insulin dose among patients with type 1 diabetes.","Alhowiti A","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent04","systematic review and meta-analysis of RCTs of GLP-1 RA vs placebo in type 1 diabetes on HbA1c and insulin dose",1],["R0007108","Comparative Efficacy of Tirzepatide Versus Semaglutide for Weight Loss in Adults With Overweight or Obesity: A Systematic Review and Meta-Analysis of Head-to-Head Studies.","Paccola GP","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent04","registered systematic review and meta-analysis of head to head studies of tirzepatide vs semaglutide for weight loss",1],["R0007162","Digital Microsteps as Scalable Adjuncts for Adults Using GLP-1 Receptor Agonists: A Randomized Clinical Trial.","Adam M","2026","inventory_only","N3","primary_report",null,null,null,"high","first","opus-5.5-agent04","RCT of digital behavior prompts vs control among GLP-1 RA users, GLP-1 RA not part of randomized contrast",1],["R0006314","Preoperative liraglutide modulates control of fat and glucose metabolism during cardiopulmonary bypass surgery.","van Wilpe R","2025","include_nma",null,"secondary_report","P99",null,"mechanistic","high","first","opus-5.5-agent14","substudy of GLOBE RCT of perioperative liraglutide vs placebo in cardiac surgery, mixed diabetes status, metabolic hormones",1],["R0006404","Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetes.","Mahapatra MK","2022","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent14","narrative review of semaglutide in type 2 diabetes",1],["R0006547","Cardiovascular effects of incretin-based drugs in patients with and without a history of heart failure: a protocol for a systematic review, meta-analysis and trial sequential analysis of randomised controlled trials.","El-Sheikh M","2025","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent14","protocol of systematic review and trial sequential analysis of incretin drugs by heart failure history, no results",1],["R0006612","Insulin/Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy for the Treatment of Type 2 Diabetes: Are Two Agents Better Than One?","Aroda VR","2018","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent14","narrative review of insulin and GLP-1 RA fixed ratio combinations",1],["R0006672","Drug Repositioning and Repurposing for Disease-Modifying Effects in Parkinson's Disease.","Jeong SH","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent14","narrative review of drug repurposing for Parkinson disease",1],["R0006733","Exploring the Therapeutic Potential of Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists in Polycystic Ovary Syndrome.","Akel M","2024","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent14","scoping review with PubMed search, RCT eligibility criteria and PRISMA, summarizing GLP-1 RA trials in PCOS",1],["R0004016","Glucagon-like peptide-1 receptor agonist therapy in patients with type 2 diabetes and advanced CKD: kidney and cardiovascular outcomes in a real-world setting.","Hsiao CC","2025","include_harms",null,"primary_report",null,"O34",null,"high","first","opus-5.5-agent15","TriNetX new user matched cohort in type 2 diabetes with advanced CKD, GLP-1 RA users versus nonusers; ischemic optic neuropathy among outcomes",1],["R0004086","Differential effects of GLP-1 receptor agonists on diabetic osteopathy in type 2 diabetes: a patient-stratified network meta-analysis.","Alalwani YJ","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent15","systematic review and network meta-analysis of 33 RCTs of GLP-1 RAs on bone outcomes in type 2 diabetes",1],["R0004158","Real-World Clinical Effectiveness of Glucagon-Like Peptide-1 Receptor Agonist on Mild-to-Moderate Diabetic Kidney Disease in Patients with Type 2 Diabetes: A Retrospective, Single-Arm Clinical Trial [Letter].","Aguilar Castañeda RD","2024","inventory_only","N9","ancillary",null,null,null,"high","first","opus-5.5-agent15","letter to the editor commenting on a single arm GLP-1 RA study in diabetic kidney disease",1],["R0004301","Interest in Treatment with GLP-1 Receptor Agonists for the Management of Insufficient Weight Loss or Weight Regain After Bariatric Surgery.","Abdallah H","2025","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent15","retrospective series of 100 bariatric patients given semaglutide or dulaglutide for weight regain; no comparison group",1],["R0004473","Diabetes Mellitus in Kidney Transplant Recipients and New Hypoglycemic Agent Options.","Bartoli G","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent15","narrative review of new glucose lowering agents in kidney transplant recipients with diabetes",1],["R0004537","Cardiovascular risk profiles: A cross-sectional study evaluating the generalizability of the glucagon-like peptide-1 receptor agonist cardiovascular outcome trials REWIND, LEADER and SUSTAIN-6 to the real-world type 2 diabetes population in the United Kingdom.","Webb J","2022","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent15","cross sectional CPRD study of eligibility for GLP-1 RA outcome trials; descriptive, no exposure outcome comparison",1],["R0005681","Change on glycosylated hemoglob with glucagon-like peptide-1 receptor agonists affecting the progress of diabetes retinopathy in type 2 diabetes– A systematic review and meta-analysis","Wang w","2024","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent07","preprint meta-analysis of 20 RCTs of GLP-1RA on diabetic retinopathy risk by HbA1c reduction in type 2 diabetes",1],["R0005776","Exploring Connections Between Weight-Loss Medications and Thyroid Cancer: A Look at the FDA Adverse Event Reporting System Database.","Abi Zeid Daou C","2025","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent07","FAERS disproportionality analysis of thyroid cancer reports with GLP-1RA and other weight loss drugs",1],["R0005853","Missing Opportunity for Nephroprotective Therapy in Patients With Non-Dialysis CKD Under Stable Nephrology Care.","De Nicola L","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent07","Italian CKD clinic cohort describing therapeutic inertia including GLP-1RA initiation; no exposure outcome comparison",1],["R0005936","The efficacy and safety of oral semaglutide for glycaemic management in adults with type 2 diabetes compared to subcutaneous semaglutide, placebo, and other GLP-1 RA comparators: A systematic review and network meta-analysis.","Alhindi Y","2022","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent07","network meta-analysis of RCTs comparing oral and subcutaneous semaglutide with placebo and other GLP-1RA in T2D",1],["R0005992","Glucagon-Like Peptide-1 Receptor Agonist Utilization in Type 2 Diabetes in Japan: A Retrospective Database Analysis (JDDM 57).","Ishigaki Y","2021","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent07","Japanese database cohort of GLP-1RA initiators describing persistence and pre post HbA1c without comparator",1],["R0006060","Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy.","Cai CX","2025","include_harms",null,"primary_report",null,"O34",null,"high","first","opus-5.5-agent07","OHDSI multi database active comparator new user cohort and self controlled case series of semaglutide and NAION",1],["R0006117","Holistic Management of Obesity in Patients with Incidental Cancer After Unprovoked Deep Vein Thrombosis: A Cardiometabolic and Antithrombotic Framework.","Geraci C","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent07","narrative review proposing management framework for obesity, unprovoked DVT and occult cancer",1],["R0007109","Comparative Efficacy and Safety of Cardio-Renoprotective Pharmacological Interventions in Chronic Kidney Disease: An Umbrella Review of Network Meta-Analyses and a Multicriteria Decision Analysis.","Bellos I","2024","include_review",null,"systematic_review",null,null,"umbrella_review","high","first","opus-5.5-agent05","umbrella review of network meta-analyses of SGLT2i, GLP-1 RA and nsMRA in CKD with registered protocol",1],["R0007163","Cardioprotective glucose-lowering drugs, statins, and risk of first-time atherosclerotic cardiovascular disease in Denmark: a nationwide cohort study.","Ternhamar T","2025","inventory_only","N6","other",null,null,null,"high","first","opus-5.5-agent05","Danish active comparator cohort of SGLT2i or GLP-1 RA with or without statin versus DPP-4i on first ASCVD; no listed harm",1],["R0007229","Effect of diabetes medications on the risk of developing dementia, mild cognitive impairment, or cognitive decline: A systematic review and meta-analysis.","Hui EK","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent05","registered meta-analysis of diabetes drugs including GLP-1 RA versus placebo on dementia, three named databases",1],["R0007289","Guts, Glucose, and Gallbladders: The Protective Role of GLP-1/GIP Receptor Agonists Against Biliary Complications in Patients with Type 2 Diabetes and Inflammatory Bowel Disease.","Kazi MAI","2025","include_harms",null,"other",null,"O28",null,"high","first","opus-5.5-agent05","TriNetX cohort of semaglutide or tirzepatide users versus nonusers with diabetes and IBD on gallstone and biliary complications",1],["R0007363","Efficacy and Safety of Tirzepatide in Patients with Type 2 Diabetes: Analysis of SURPASS-AP-Combo by Different Subgroups.","Bi Y","2024","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent05","post hoc subgroup analysis of SURPASS-AP-Combo RCT of tirzepatide doses versus insulin glargine",1],["R0007424","Disparities in Use of Novel Diabetes Medications by Insurance: A Nationally Representative Cohort Study.","Bepo L","2024","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent05","cross sectional survey analysis of SGLT2i and GLP-1 RA use by insurance and race; drug utilization only",1],["R0005132","Review article: role of glucagon-like peptide-1 receptor agonists in non-alcoholic steatohepatitis, obesity and diabetes-what hepatologists need to know.","Barritt AS","2022","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent18","narrative review of GLP-1 RAs in NASH, obesity and diabetes; PubMed search compiled without eligibility criteria or synthesis",1],["R0005181","Glucagon-Like Peptide 1 Receptor Agonist Usage in Type 2 Diabetes in Primary Care for the UK and Beyond: A Narrative Review.","Fernando K","2021","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent18","narrative review of GLP-1 RA use in UK primary care with practical guidance",1],["R0005259","An Update on Semaglutide Research: A Bibliometric Analysis and a Literature Review.","Dagli N","2023","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent18","bibliometric analysis and literature summary of semaglutide research; no synthesized treatment contrast",1],["R0005332","Comparison of the blood pressure management between sodium glucose co-transporter 2 inhibitors and glucagon-like peptide 1 receptor agonists","Kobayashi K","2022","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent18","retrospective weighted cohort comparing SGLT2i vs GLP-1 RA on blood pressure control in Japanese T2D; no listed harms outcome",1],["R0005397","Therapeutic management of atypical antipsychotic‑related metabolic dysfunctions using GLP‑1 receptor agonists: A systematic review.","Vasiliu O","2023","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent18","PRISMA systematic review of GLP-1 RAs for antipsychotic related metabolic dysfunction; three named databases and registers; GRADE graded synthesis",1],["R0005553","Impact of treatment with GLP-1RAs on suicide attempts in adults persons with type 2 diabetes: A retrospective comparative effectiveness study based on a global TriNetX health research database.","Nassar M","2024","include_harms",null,"primary_report",null,"O35A",null,"high","first","opus-5.5-agent18","TriNetX matched cohort GLP-1 RA vs DPP-4i in T2D on suicide attempts; observational despite class",1],["R0005597","Obstetrician-Gynecologists' Strategies for Patient Initiation and Maintenance of Antiobesity Treatment with Glucagon-Like Peptide-1 Receptor Agonists.","Gill L","2021","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent18","narrative review for gynecologists on liraglutide 3.0 mg initiation and maintenance",1],["R0004677","THU338 Risks Of Stroke, Its Subtypes And Atrial Fibrillation Associated With Glucagon-like Peptide 1 Receptor Agonists Versus Sodium-glucose Cotransporter 2 Inhibitors: A Real-world Population-based Study In Hong Kong",null,"2023","inventory_only","N6","conference_abstract",null,null,"abstract_only","high","first","opus-5.5-agent19","Hong Kong new user matched cohort GLP-1 RA vs SGLT2 inhibitor; stroke and atrial fibrillation only, no listed harm; meeting abstract",1],["R0004750","A Systematic Review on Disease-Modifying Therapies in Parkinsonian Disorders.","Eijsvogel PPNM","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent19","systematic review without meta-analysis of disease modifying trials in parkinsonian disorders incl GLP-1 RA; four named databases, PROSPERO",1],["R0004806","New kidneys, old risks: cardiovascular challenges after transplantation.","Van Craenenbroeck AH","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent19","narrative review of cardiovascular risk after kidney transplantation; no systematic methods",1],["R0004998","Glucagon-like peptide-1 receptor agonists and risk of suicidality among patients with type 2 diabetes: active comparator, new user cohort study.","Shapiro SB","2025","include_harms",null,"primary_report",null,"O35A; O35B",null,"high","first","opus-5.5-agent19","CPRD active comparator new user cohorts GLP-1 RA vs DPP-4 or SGLT2 inhibitors, propensity weighted; suicidal ideation, self harm, suicide",1],["R0005060","The Efficacy and Safety of the Combination Therapy With GLP-1 Receptor Agonists and SGLT-2 Inhibitors in Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis.","Li C","2022","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent19","meta-analysis of RCTs of GLP-1 RA plus SGLT2 inhibitor vs monotherapy in type 2 diabetes; seven named databases",1],["R0005138","Once-weekly semaglutide versus placebo for the treatment of type 2 diabetes and chronic kidney disease in Denmark: A long-term cost-effectiveness analysis based on FLOW.","Rossing P","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent19","cost effectiveness simulation of semaglutide vs placebo based on FLOW; economic evaluation, no new trial data",1],["R0005789","Tirzepatide Prescribing Practices and Efficacy in Patients with Diabetes and Chronic Kidney Disease at a Large Tertiary Care Center in the United States.","Kosaraju SA","2024","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent09","retrospective tirzepatide cohort in diabetes with CKD without comparison group, prescribing patterns and before after changes",1],["R0005869","Treatment with glucagon-like peptide-1 receptor agonists and incidence of dementia: Data from pooled double-blind randomized controlled trials and nationwide disease and prescription registers.","Nørgaard CH","2022","include_nma",null,"pooled_analysis","P01",null,null,"high","first","opus-5.5-agent09","pooled LEADER, SUSTAIN-6 and PIONEER 6 placebo controlled trials on dementia plus Danish registry cohort",1],["R0005942","Comparative efficacy of 5 sodium glucose cotransporter 2 inhibitor and 7 glucagon-like peptide 1 receptor agonists interventions on cardiorenal outcomes in type 2 diabetes patients: A network meta-analysis based on cardiovascular or renal outcome trials.","Duan XY","2021","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent09","Bayesian NMA of SGLT2 and GLP-1 cardiovascular outcome trials, PubMed and Embase searched",1],["R0006005","Real-World Efficacy of Glucagon-like Peptide-1 (GLP-1) Receptor Agonist, Dulaglutide, on Metabolic Parameters in Japanese Patients with Type 2 Diabetes: A Retrospective Longitudinal Study.","Katsuyama H","2023","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent09","retrospective before and after study of dulaglutide in Japanese type 2 diabetes without comparison group",1],["R0006063","Clinical Efficacy of Sodium-Glucose Cotransporter 2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy in Type 2 Diabetes Mellitus: Real-World Study (Diabetes Metab J 2022;46: 658-62).","Kim HS","2022","inventory_only","N9","ancillary",null,null,null,"high","first","opus-5.5-agent09","authors reply to letter about their real world SGLT2 plus GLP-1 combination study",1],["R0006121","Clinical Factors Associated with Body-weight Reduction Induced by Semaglutide 1.0 mg Weekly in Patients with Type 2 Diabetes Mellitus.","Kurinami N","2025","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent09","retrospective single group semaglutide cohort exploring predictors of weight loss, no comparison group",1],["R0006178","GLP-1 receptor agonists-SGLT-2 inhibitors combination therapy and cardiovascular events after acute myocardial infarction: an observational study in patients with type 2 diabetes.","Marfella R","2024","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent09","prospective observational study of SGLT2 plus GLP-1 combination versus monotherapy after MI on MACE only",1],["R0006237","Glucagon-Like Peptide 1 Receptor Agonists Versus Sodium-Glucose Cotransporter 2 Inhibitors for Atherosclerotic Cardiovascular Disease in Patients With Type 2 Diabetes.","Yanai H","2023","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent09","narrative review comparing GLP-1 agonists and SGLT2 inhibitors for cardiovascular prevention without systematic search",1],["R0005806","Efficacy of three modern anti-diabetic drugs on survival outcomes of lung cancer patients with type 2 diabetes in China.","Chen Z","2025","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent13","retrospective cohort of lung cancer patients with diabetes by GLP-1, DPP-4 and SGLT2 regimens, survival and progression only",1],["R0006015","Chronic semaglutide alters ingestive behavior without impairing taste function in mice.","Acosta AA","2026","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent13","study of chronic semaglutide in diet induced obese mice only",1],["R0006072","Clinical Efficacy of Sodium-Glucose Cotransporter 2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy in Type 2 Diabetes Mellitus: Real-World Study (Diabetes Metab J 2022;46: 658-62).","Kawada T","2022","inventory_only","N9","ancillary",null,null,null,"high","first","opus-5.5-agent13","letter commenting on a real world study of SGLT2 inhibitor plus GLP-1 combination therapy",1],["R0006130","Real-World Use of GLP-1 Receptor Agonist Liraglutide in Adolescents with Obesity: A First Longitudinal Single-Center Analysis from Switzerland.","Noordam C","2025","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent13","retrospective single center series of adolescents on liraglutide without a comparison group",1],["R0006192","Semaglutide and major adverse cardiovascular events in patients with and without DM: a systematic review and meta-analysis","Li Y","2024","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent13","preprint meta-analysis of semaglutide RCTs on MACE from four named databases",1],["R0006241","Comparative effectiveness of semaglutide versus liraglutide, dulaglutide or tirzepatide: a systematic review and meta-analysis.","Karimi MA","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent13","OSF registered meta-analysis comparing semaglutide with liraglutide, dulaglutide or tirzepatide",1],["R0005150","Diabetic retinopathy severity is associated with renal function deterioration in patients with diabetic kidney disease: a retrospective cohort study.","Yu L","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent02","cohort of retinopathy severity and kidney decline in DKD; GLP-1 RA use only an adjustment covariate",1],["R0005189","Consequences of weight cycling in patients with obesity and the potential impact of high protein diet: a health economic assessment from a US societal perspective.","Schwander B","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent02","Markov health economic model of weight cycling and protein supplement after GLP-1 RA weight loss",1],["R0005265","Oral Semaglutide, the First Ingestible Glucagon-Like Peptide-1 Receptor Agonist: Could It Be a Magic Bullet for Type 2 Diabetes?","Kim HS","2021","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent02","narrative review of oral semaglutide pharmacology and PIONEER trials",1],["R0005423","The effects of non-insulin anti-diabetic medications on the diabetic microvascular complications: a systematic review and meta-analysis of randomized clinical trials.","Wen S","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent02","systematic review and meta-analysis of RCTs of non insulin drugs including GLP-1 RA on microvascular complications",1],["R0005487","Impact of GLP-1 receptor agonist-based therapies on cardiovascular and renal outcomes in diabetic and non-diabetic patients with CKD.","Siniukovich A","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent02","systematic review and meta-analysis of placebo controlled GLP-1 RA outcome trials by CKD status; PubMed searched with criteria",1],["R0005562","Exenatide Once Weekly for Management of Type 2 Diabetes: A Review.","Inaishi J","2022","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent02","narrative mini review of exenatide once weekly in type 2 diabetes",1],["R0005617","Impact of disease duration and β-cell reserve on the efficacy of switching to iGlarLixi in adults with type 2 diabetes on glucagon-like peptide-1 receptor agonist therapy: Exploratory analyses from the LixiLan-G trial.","Del Prato S","2020","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent02","exploratory analysis of LixiLan-G RCT, switch to iGlarLixi vs continued GLP-1 RA in type 2 diabetes",1],["R0006356","Infertility Improvement after Medical Weight Loss in Women and Men: A Review of the Literature.","Pavli P","2024","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent20","narrative literature review of medical weight loss and fertility",1],["R0006479","Effect of Adherence to Oral Semaglutide on Glycemic Control in People With Type 2 Diabetes Treated With Metformin: Protocol for an Open-Label Clinical Trial.","Holdt-Caspersen NS","2025","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent20","protocol of nonrandomized single arm study of oral semaglutide adherence in T2D",1],["R0006626","Use of iGlarLixi for the Management of Type 2 Diabetes in Japanese Clinical Practice: Prior Treatment Subgroup Analysis of the SPARTA Japan Study.","Miyoshi H","2023","inventory_only","N5","secondary_report",null,null,null,"high","first","opus-5.5-agent20","subgroup analysis of retrospective single arm iGlarLixi study by prior therapy, no unexposed comparison",1],["R0006695","KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease in Children and Adults: a commentary from the European Renal Best Practice (ERBP).","Iatridi F","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent20","guideline commentary on KDIGO 2024 CKD evaluation",1],["R0006755","Expert Opinion on Current Trends in the Use of Insulin in the Management of People with Type 2 Diabetes from the South-Eastern European Region and Israel.","Tabak AG","2024","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent20","expert advisory board opinion on insulin use in T2D",1],["R0006821","Clinical Efficacy of Sodium-Glucose Cotransporter 2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy in Type 2 Diabetes Mellitus: Real-World Study.","Kim HS","2022","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent20","retrospective single arm review of SGLT2i plus dulaglutide combination, before and after, no comparison",1],["R0006240","Hepatic Safety of Orforglipron in Adults With Obesity or Overweight and/or Type 2 Diabetes: A Pooled Analysis of the Orforglipron Phase 3 Clinical Trials.","Wharton S","2026","include_nma",null,"pooled_analysis","P01; P02",null,null,"high","first","opus-5.5-agent12","pooled hepatic safety analysis of seven orforglipron phase 3 RCTs vs placebo and active comparators",1],["R0006399","Changes in food cravings, dietary quality, body composition, and dietary intake during GLP-1 receptor agonist therapy: The CRAVE study.","Babazadeh D","2026","inventory_only","N5","primary_report","P02",null,null,"high","first","opus-5.5-agent12","prospective observational single group of semaglutide or tirzepatide initiators, diet and body composition changes",1],["R0006454","Influence of GLP1 receptor rs6923761 and rs761387 genetic variants on oral semaglutide response in patients with type 2 diabetes.","Candido R","2026","inventory_only","N5","primary_report","P01",null,null,"high","first","opus-5.5-agent12","retrospective cohort of oral semaglutide users analyzed by GLP1R genotype, no unexposed comparison",1],["R0006534","Efficacy of the Glucagon-Like Peptide-1 Receptor Agonists Liraglutide and Semaglutide for the Treatment of Weight Regain After Bariatric surgery: a Retrospective Observational Study.","Jensen AB","2023","inventory_only","N5","primary_report","P02",null,null,"high","first","opus-5.5-agent12","retrospective single center series of GLP-1RA for weight regain after bariatric surgery, before and after, no control",1],["R0006607","Superior weight loss with once-weekly semaglutide versus other glucagon-like peptide-1 receptor agonists is independent of gastrointestinal adverse events.","Lingvay I","2020","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent12","post hoc mediation analysis of SUSTAIN 3, 7 and 10 RCTs, semaglutide vs other GLP-1RAs, weight and GI events",1],["R0006666","Efficacy and safety of albiglutide, a once-weekly glucagon-like peptide-1 receptor agonist, in patients with type 2 diabetes: A systematic review and meta-analysis.","Kamrul-Hasan ABM","2024","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent12","registered SR and meta-analysis of albiglutide RCTs vs placebo or active comparators in T2D",1],["R0006727","Is there a role for glucagon-like peptide-1 receptor agonists in the management of diabetic nephropathy?","Veneti S","2020","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent12","editorial on GLP-1RAs in diabetic nephropathy",1],["R0006278","Risk of diabetic retinopathy and diabetic macular oedema with sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists in type 2 diabetes: a real-world data study from a global federated database.","Eleftheriadou A","2024","include_harms",null,"primary_report",null,"O33",null,"high","first","opus-5.5-agent03","TriNetX matched cohorts GLP-1 RA plus insulin vs insulin alone in T2D; diabetic retinopathy and macular edema outcomes",1],["R0006496","Pilot study of epigenetic aging and treatment response to semaglutide in the SLIM LIVER study.","Corley MJ","2026","inventory_only","N1","secondary_report",null,null,null,"high","first","opus-5.5-agent03","post hoc analysis of single arm SLIM LIVER semaglutide trial in people with HIV and MASLD",1],["R0006581","Trajectory of the body weight after drug discontinuation in the treatment of anti-obesity medications.","Wu H","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent03","meta-analysis of RCTs of anti-obesity drugs incl. GLP-1 RA on weight regain after stopping, five sources searched",1],["R0006633","Disproportionality analysis of GLP-1 receptor agonists combined with metformin based on the FAERS database.","Liu B","2025","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent03","FAERS disproportionality analysis of GLP-1 RA with metformin vs monotherapy",1],["R0006251","Evaluating prediction of short-term tolerability of five type 2 diabetes drug classes using routine clinical features: UK population-based study.","Cardoso P","2025","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent16","CPRD cohort of five T2D drug class initiators predicting early discontinuation; no listed harm outcome",1],["R0006329","Semaglutide in Obesity and Type 2 Diabetes Management: A Systematic Review of Clinical Outcomes.","Gundapaneni SRC","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent16","systematic review of semaglutide trials in obesity; PubMed, Scopus, Web of Science searched with inclusion criteria",1],["R0006409","New perspectives in the management of diabetic nephropathy.","Psyllaki A","2024","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent16","editorial on management of diabetic nephropathy",1],["R0006472","Effects of semaglutide in patients with chronic ankle instability: evidence from a prospective cohort.","Zhang J","2025","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent16","prospective cohort of semaglutide exposure vs none in chronic ankle instability; functional scores only, not randomized",1],["R0006558","Comparison of Effects of Injectable Semaglutide and Dulaglutide on Oxidative Stress and Glucose Variability in Patients with Type 2 Diabetes Mellitus: A Prospective Preliminary Study.","Omachi T","2024","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent16","open label RCT switching dulaglutide to semaglutide vs continuing dulaglutide in T2D; HbA1c and glucose variability",1],["R0006744","GLP-1 receptor agonists for weight loss: A systematic review and meta-analysis of randomized controlled trials.","Ahmad N","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent16","PRISMA systematic review with PubMed search, pairwise and network meta-analysis of GLP-1 based agents for weight loss",1],["R0005178","Mortality and persistence in therapy in elderly subjects with type 2 diabetes receiving gliflozins or incretins.","Del Zoppo A","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent17","retrospective cohort of people aged 80 plus starting SGLT2 inhibitor or GLP-1 RA; mortality, persistence and renal function only",1],["R0005250","Comparative efficacy of multiple drugs for non-alcoholic fatty liver disease: a Bayesian network meta-analysis.","Xiao Z","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent17","registered Bayesian network meta-analysis of RCTs of glucose lowering drugs including GLP-1 RAs in NAFLD",1],["R0005323","The Impact of Glucagon-like Peptide-1 (GLP-1) Receptor Agonists on Body Composition in Individuals with Overweight and Obesity: A Systematic Review and Meta-Analysis.","Woźniak M","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent17","registered meta-analysis of RCTs of GLP-1 RAs on body composition in obesity without diabetes, five databases searched",1],["R0005396","Metabolic rebound after GLP-1 receptor agonist discontinuation: a systematic review and meta-analysis.","Tzang CC","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent17","registered meta-analysis of RCTs quantifying metabolic rebound after GLP-1 RA discontinuation, five sources searched",1],["R0005474","Effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on podocytes, inflammation, and oxidative stress in patients with diabetic nephropathy (DN).","Liu J","2022","include_nma",null,"primary_report","P08A",null,null,"high","first","opus-5.5-agent17","RCT by random number table of liraglutide added to conventional therapy versus conventional therapy in diabetic nephropathy, 12 weeks",1],["R0005552","Novel Amylin-Based Therapies for Weight Management in Adults With Overweight or Obesity Without Diabetes: A Network Meta-Analysis.","Kamrul-Hasan ABM","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent17","registered network meta-analysis of amylin based therapies including CagriSema and amycretin versus placebo in obesity",1],["R0007621","Safety of Semaglutide.","Smits MM","2021","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent05","narrative review of semaglutide safety across trial programs and real world data without systematic methods",1],["R0006290","Cinchonine, a Potential Oral Small-Molecule Glucagon-Like Peptide-1 Receptor Agonist, Lowers Blood Glucose and Ameliorates Non-Alcoholic Steatohepatitis.","Xue H","2023","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent08","cinchonine screened as GLP-1R agonist in silico, rat islets and mice only",1],["R0006444","Inflammatory proteins associated with Alzheimer's disease reduced by a GLP1 receptor agonist: a post hoc analysis of the EXSCEL randomized placebo controlled trial.","Koychev I","2024","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent08","post hoc EXSCEL proteomic analysis of randomized exenatide weekly versus placebo in type 2 diabetes",1],["R0006514","Real-world prescriptions of GLP-1RAs and SGLT2is in type 2 diabetes prioritise BMI and age over cardiorenal risk: a machine learning-based large cohort analysis.","Tuccinardi D","2025","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent08","cross sectional machine learning analysis of SGLT2i and GLP-1 RA prescribing determinants; no exposure comparison",1],["R0007703","Cardiometabolic Profiles of Oral and Subcutaneous Glucagon-Like Peptide-1 Receptor Mono-Agonists in Adults With Overweight or Obesity: A Systematic Review and Network Meta-Analysis.","Lu Y","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent05","registered network meta-analysis of RCTs of GLP-1 receptor mono-agonists in overweight or obesity, three named databases",1],["R0007837","The Road towards Triple Agonists: Glucagon-Like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide and Glucagon Receptor - An Update.","Jakubowska A","2024","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent05","narrative review of GLP-1, dual and triple incretin agonists for obesity",1],["R0007894","SGLT2i and GLP-1 RA therapy in type 1 diabetes and reno-vascular outcomes: a real-world study.","Anson M","2023","include_harms",null,"other",null,"O29",null,"high","first","opus-5.5-agent05","TriNetX cohort of adults with type 1 diabetes on SGLT2i versus GLP-1 RA; safety outcomes include acute pancreatitis",1],["R0007971","Efficacy, safety and cardiovascular outcomes of once-daily oral semaglutide in patients with type 2 diabetes: The PIONEER programme.","Thethi TK","2020","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent05","narrative review summarizing the PIONEER trial programme of oral semaglutide without pooled analysis",1],["R0008037","GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs.","Giugliano D","2021","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent05","meta-analysis of eight GLP-1 RA cardiovascular outcome trials versus placebo searching named databases",1],["R0008089","Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial.","Rosenstock J","2020","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent05","26 week RCT of albiglutide plus glargine replacing prandial lispro versus basal bolus insulin in type 2 diabetes",1],["R0007225","Evaluating Guideline Alignment by Analyzing Patient Profiles of Elderly People with Type 2 Diabetes and Chronic Kidney Disease Treated or Not with SGLT2 Inhibitors.","Vafeidou K","2025","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent04","record review comparing SGLT2i users and nonusers in elderly CKD, GLP-1 RA only a recorded co-medication, not an exposure",1],["R0007285","Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus: A Position Statement of the Korean Diabetes Association.","Kim HJ","2017","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent04","position statement of the Korean Diabetes Association on GLP-1 RA use in type 2 diabetes",1],["R0007362","GLP-1 receptor agonists in atherosclerotic cardiovascular disease and diabetes mellitus or obesity: investigation of the potential role in a German inpatient dataset.","Oettinger V","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent04","German inpatient data estimating how many ASCVD patients qualify for GLP-1 RA, no drug exposure studied",1],["R0007488","Tirzepatide as a novel effective and safe strategy for treating obesity: a systematic review and meta-analysis of randomized controlled trials.","Cai W","2024","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent04","systematic review and meta-analysis of RCTs of tirzepatide vs GLP-1 RA, placebo or insulin in obesity",1],["R0007546","Management of Poststroke Hyperglycemia: Results of the TEXAIS Randomized Clinical Trial.","Bladin CF","2023","include_nma",null,"primary_report","P99",null,null,"high","first","opus-5.5-agent04","TEXAIS RCT of exenatide vs standard care in acute ischemic stroke, P99 acute stroke population, reports hypoglycemia and adverse events",1],["R0007620","Use of GLP-1 Receptor Agonists for the Management of Type 1 Diabetes: A Pediatric Perspective.","Shenker MN","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent04","narrative review of GLP-1 RA use in pediatric type 1 diabetes",1],["R0007692","Efficacy and Safety of Injectable Dulaglutide 1.5 mg among Type 2 Diabetes Patients in Clinics at King Saud Medical City, Riyadh, Saudi Arabia","Albargawi MS","2023","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent04","retrospective single arm cohort of dulaglutide users with before and after measures, no comparison group",1],["R0006468","[Effectiveness of GLP-1 receptor agonists in managing patients with type 2 diabetes].","Bejarano Romero F","2025","inventory_only","N5","primary_report",null,null,"non_english","high","first","opus-5.5-agent14","Spanish retrospective primary care record study of GLP-1 RA users, before and after HbA1c and weight, no comparison group",1],["R0006800","Effectiveness and Safety of Once-Weekly Semaglutide in Japanese Patients with Type 2 Diabetes in Treatment Intensification: A Retrospective Observational Single-Center Study.","Yamada H","2022","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent14","retrospective single center cohort of semaglutide initiators in Japanese T2D, before and after, no comparison group",1],["R0006867","Twelve-month analysis of real-world evidence from a telehealth obesity-treatment provider using antiobesity medications.","Ard JD","2024","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent14","retrospective case series of telehealth patients on antiobesity medications, weight change and side effects",1],["R0007005","Risk of Diabetic Retinopathy between Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists.","Lin TY","2023","include_harms",null,"primary_report",null,"O33",null,"high","first","opus-5.5-agent14","target trial emulation SGLT2i vs GLP-1 RA new users in T2D, diabetic retinopathy and vitreoretinal intervention outcomes",1],["R0007067","Post-Initiation Care Patterns and Weight Loss With Semaglutide and Tirzepatide for Obesity in Clinical Practice","Yang H","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent14","EHR cohort describing care patterns and weight loss of semaglutide vs tirzepatide initiators, no harms_nrs outcome",1],["R0007141","Comparative effectiveness of glucagon-like peptide-1 receptor agonists on body composition and anthropometric indices: A protocol for a systematic review and network meta-analysis of randomized controlled trials.","Wachiraphansakul N","2024","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent14","protocol of a network meta-analysis of GLP-1 RAs on body composition, no results",1],["R0007200","Effects of glucose-lowering agents on cardiovascular and renal outcomes in subjects with type 2 diabetes: An updated meta-analysis of randomized controlled trials with external adjudication of events.","Mannucci E","2023","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent14","meta-analysis of RCTs of glucose lowering agents including GLP-1 RA on cardiovascular and renal outcomes, MEDLINE Embase searched",1],["R0005218","Obesity and Cancer: Mechanisms, Epidemiological Evidence, and Potential Risk Reduction.","Lim JS","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent10","self described narrative review of obesity and cancer; not a trial despite class",1],["R0005292","Glucagon-Like Peptide-1 Receptor Agonists Combined With Personalized Digital Health Care for the Treatment of Metabolic Syndrome in Adults With Obesity: Retrospective Observational Study.","Zakaria H","2025","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent10","retrospective digital program cohort comparing tirzepatide with semaglutide users; metabolic syndrome measures, no harms_nrs outcome",1],["R0005510","High-Dose Semaglutide (Up to 16 mg) in People With Type 2 Diabetes and Overweight or Obesity: A Randomized, Placebo-Controlled, Phase 2 Trial.","Aroda VR","2025","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent10","phase 2 RCT semaglutide 2, 8, 16 mg versus placebo in T2D with obesity on metformin; HbA1c and weight",1],["R0005580","Cost-effectiveness of iGlarLixi vs. IDegAsp in individuals with type 2 diabetes: a BRAVO model-based evaluation.","Qin J","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent10","BRAVO model cost effectiveness of iGlarLixi versus IDegAsp; economic simulation",1],["R0005690","Bone Health After Exercise Alone, GLP-1 Receptor Agonist Treatment, or Combination Treatment: A Secondary Analysis of a Randomized Clinical Trial.","Jensen SBK","2024","include_nma",null,"secondary_report","P02",null,null,"high","first","opus-5.5-agent10","secondary analysis of RCT liraglutide, exercise, combination or placebo after diet induced weight loss; bone density and weight",1],["R0006231","Impact of GLP-1 Receptor Agonists on Whole-Gut Gastrointestinal Motility Using Wireless Motility Capsule: A Descriptive Single-Center Case Series.","Cymbal M","2025","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent07","retrospective case series of ten GLP-1RA users undergoing wireless motility capsule testing",1],["R0005749","Utilization Trends of Dual GIP/GLP-1 Receptor Agonist, Newer Glucose-Lowering Medications, and Anti-Obesity Medications Among Patients With Chronic Kidney Disease With and Without Type 2 Diabetes.","Hansrivijit P","2025","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent01","descriptive claims study of tirzepatide and other glucose lowering drug utilization trends in CKD; no exposure comparison",1],["R0005844","Association of glucagon-like peptide-1 agonist therapy with postsurgical outcomes following multilevel correction for adult spinal deformity: a propensity score-matched analysis.","D'Amico C","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent01","matched cohort of GLP-1 RA users versus nonusers undergoing spinal deformity surgery; fusion, hardware, infection and readmission outcomes",1],["R0005979","Tirzepatide Versus Semaglutide for Weight Loss in Overweight and Obese Adults: A Systematic Review and Meta-Analysis of Direct Comparative Studies.","Munawar N","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent01","systematic review and meta-analysis of direct tirzepatide versus semaglutide comparisons for weight loss, four databases searched",1],["R0006049","The Wedding Bells Sound Really Good! iGlarLixi Fixed-Ratio Combination in the Treatment of Type 2 Diabetes: A Narrative Review.","Kwiendacz H","2023","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent01","self described narrative review of iGlarLixi trials and real world data",1],["R0006095","Efficacy and Safety of Oral Small Molecule Glucagon-Like Peptide 1 Receptor Agonist Danuglipron for Glycemic Control Among Patients With Type 2 Diabetes: A Randomized Clinical Trial.","Saxena AR","2023","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent01","phase 2b double blind RCT of oral danuglipron doses versus placebo in type 2 diabetes",1],["R0006168","Cardiovascular Safety and Benefits of Semaglutide in Patients With Type 2 Diabetes: Findings From SUSTAIN 6 and PIONEER 6.","Nauck MA","2021","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent01","narrative review of SUSTAIN 6 and PIONEER 6 cardiovascular findings for semaglutide",1],["R0006219","Effect of GLP-1RA on diabetes retinopathy with blood glucose variation at different levels of baseline HbAlc– A systematic review and meta-analysis","Wang W","2024","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent01","meta-analysis of GLP-1 RA RCTs on diabetic retinopathy with Embase PubMed Cochrane search and stated inclusion criteria",1],["R0006283","Impact of perioperative GLP-1 agonist use on pseudarthrosis rates following single-level anterior cervical discectomy and fusion: a propensity-matched cohort study.","Amasa S","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent07","TriNetX matched cohort of perioperative GLP-1RA use vs none in cervical fusion; pseudarthrosis outcome only",1],["R0006443","Effect of glucagon like peptide-1 receptor agonist exenatide, used as an intracranial pressure lowering agent, on cognition in Idiopathic Intracranial Hypertension.","Grech O","2024","include_nma",null,"secondary_report","P99",null,null,"high","first","opus-5.5-agent07","exploratory cognition analysis of the placebo controlled exenatide IIH Pressure RCT in idiopathic intracranial hypertension",1],["R0006508","Comparing Glucagon-Like Peptide-1 Receptor Agonists to Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure With Preserved Ejection Fraction: A Systematic Review.","Al-Shudifat M","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent07","PRISMA systematic review in three databases comparing GLP-1RA and SGLT2i in HFpEF",1],["R0006595","Titratable fixed-ratio combination of basal insulin plus a glucagon-like peptide-1 receptor agonist: A novel, simplified alternative to premix insulin for type 2 diabetes.","Gomez-Peralta F","2021","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent07","narrative review of basal insulin GLP-1RA fixed ratio combinations vs premix insulin",1],["R0006645","Novel Antidiabetic Drugs and the Risk of Diabetic Retinopathy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.","Małyszczak A","2024","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent07","PROSPERO registered meta-analysis of RCTs of GLP-1RA, SGLT2i and DPP-4i on diabetic retinopathy",1],["R0006712","The significance of finerenone as a novel therapeutic option in diabetic kidney disease: a scoping review with emphasis on cardiorenal outcomes of the finerenone phase 3 trials.","Arici M","2024","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent07","expert scoping review of finerenone trials; GLP-1RA appears only as background therapy",1],["R0006798","Real-World Safety Concerns of Tirzepatide: A Retrospective Analysis of FAERS Data (2022-2025).","Almansour HA","2025","inventory_only","N5","other",null,null,null,"high","first","opus-5.5-agent12","FAERS disproportionality analysis of tirzepatide adverse event reports",1],["R0006864","GLP-1 receptor agonist use does not increase risk of respiratory complications post-endoscopy.","Velji-Ibrahim J","2025","include_harms",null,"primary_report","P01; P02","O36A",null,"high","first","opus-5.5-agent12","TriNetX matched procedure cohort of GLP-1RA users vs never users before endoscopy, aspiration pneumonitis outcome",1],["R0006927","Comparative Effectiveness of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors Versus Glucagon-Like Peptide-1 (GLP-1) Agonists on Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Systematic Review and Network Meta-Analysis.","Alqurain AA","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent12","SR and network meta-analysis of placebo controlled SGLT2i and GLP-1RA outcome trials in T2D",1],["R0006999","The Impact of Web-Based Continuing Medical Education Using Patient Simulation on Real-World Treatment Selection in Type 2 Diabetes: Retrospective Case-Control Analysis.","Lucero KS","2023","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent12","evaluation of physician education on GLP-1RA prescribing, outcome is prescribing behavior not drug exposure",1],["R0007056","Comparative effects of glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors on heart failure with preserved ejection fraction in diabetic patients: a meta-analysis.","Albulushi A","2024","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent12","PRISMA meta-analysis of GLP-1RA and SGLT2i vs placebo studies in diabetic HFpEF, four databases",1],["R0007135","Tirzepatide safety in type 2 diabetes: a disproportionality analysis of adverse events using the FDA FAERS database.","Zhang Z","2025","inventory_only","N5","other",null,null,null,"high","first","opus-5.5-agent12","FAERS disproportionality analysis of tirzepatide adverse events in T2D",1],["R0007246","The efficacy and safety of combined GLP-1RA and basal insulin therapy among inadequately controlled T2D with premixed insulin therapy.","Liu JS","2023","inventory_only","N1","primary_report","P01",null,null,"high","first","opus-5.5-agent12","single arm open label switch from premixed insulin to liraglutide plus basal insulin, CGM outcomes",1],["R0007365","SAT-528 Real-world Treatment Patterns Of Tirzepatide Versus Semaglutide In GLP-1 RA-naive Patients With T2D",null,"2025","inventory_only","N6","conference_abstract",null,null,"abstract_only","high","first","opus-5.5-agent06","conference abstract of matched cohort of tirzepatide versus semaglutide initiators in T2D; adherence and persistence only",1],["R0004217","Impact of Fibrotic Metabolic Dysfunction-Associated Steatohepatitis as a New Indication on Semaglutide Eligibility in the US Adult Population.","van Kleef LA","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent11","NHANES cross sectional estimate of semaglutide eligibility; no drug exposure studied",1],["R0004285","GLP-1 receptor agonists at immune checkpoint inhibitor initiation with immune-related and supportive-care outcomes in patients with cancer and overweight or obesity without diabetes: a target trial emulation.","Lin YJ","2026","include_harms",null,"primary_report",null,"O121",null,"high","first","opus-5.5-agent11","TriNetX target trial emulation, GLP-1RA at checkpoint inhibitor start versus none in obesity without diabetes; acute kidney injury reported",1],["R0004357","Socioeconomic and Demographic Inequalities in Off-Label Prescription of Glucagon-Like Peptide-1 Receptor Agonists: A Swedish Descriptive Cohort Study.","Pazzagli L","2025","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent11","descriptive Swedish register study of characteristics of on and off label GLP-1RA users; no exposure comparison",1],["R0004524","An experimental investigation of the stigmatization of weight loss and regain from GLP-1 receptor agonist use and cessation.","Standen EC","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent11","randomized vignette experiments on weight stigma; participants received no GLP-1RA",1],["R0004593","Risk of all-cause death and pancreatic events following GLP-1 RA initiation in people with obesity or type 2 diabetes: observations from a federated research network.","Tartaglia E","2025","include_harms",null,"primary_report",null,"O29; O38",null,"high","first","opus-5.5-agent11","TriNetX matched cohort of GLP-1RA initiators versus non users; acute and chronic pancreatitis and pancreatic cancer",1],["R0004649","The effects of glucagon-like peptide-1 receptor agonists on adipose tissues in patients with type 2 diabetes: A meta-analysis of randomised controlled trials.","Liu F","2022","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent11","registered meta-analysis of RCTs of GLP-1RA versus placebo or standard care on visceral and subcutaneous fat",1],["R0007425","Long-term management of type 2 diabetes with glucagon-like peptide-1 receptor agonists.","Courtney H","2017","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent06","narrative review of long term phase 3 data for GLP-1 RAs in T2D",1],["R0007623","Kidney outcomes associated with sodium-glucose cotransporter 2 inhibitors versus glucagon-like peptide 1 receptor agonists: A real-world population-based analysis.","Lui DTW","2022","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent06","Hong Kong new user cohort of SGLT2 inhibitor versus GLP-1 RA; composite kidney outcomes and eGFR slope only",1],["R0007704","Twelve-month analysis of real-world evidence from a commercial telehealth obesity treatment provider","Ard J","2024","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent06","retrospective telehealth cohort of anti-obesity medication initiators, mostly GLP-1 RA based; no comparison group",1],["R0007764","Utilization Patterns of Glucagon-Like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus in Italy: A Retrospective Cohort Study.","Federici MO","2018","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent06","Italian prescription database study of GLP-1 RA utilization and persistence; descriptive, no outcome comparison",1],["R0007839","Diabetes, Adiposity, and Functional Phenotypes in HFpEF: A Systematic Review of Recent Treatment-Response Evidence.","Goshe M","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent06","systematic review of treatment response by phenotype in HFpEF incl tirzepatide and semaglutide trials; three databases",1],["R0005647","Structural Biophysics-Guided Computational Design of Semaglutide Analogues to Enhance GLP-1R Activation","Li W","2025","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent18","computational structural modeling of semaglutide analogues binding the GLP-1 receptor; in silico only",1],["R0005725","Tirzepatide and Cancer Risk in Individuals with and without Diabetes: A Systematic Review and Meta-Analysis.","Kamrul-Hasan ABM","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent18","registered systematic review and meta-analysis of tirzepatide RCTs on cancer risk vs placebo or active comparators",1],["R0005826","Oral Semaglutide: Dosage in Special Situations.","Kalra S","2022","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent18","commentary on practical oral semaglutide dosing in special situations; opinion, no data",1],["R0005913","Effects of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes and nonalcoholic fatty liver disease: A cohort study.","Naguib R","2025","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent18","cohort comparing SGLT2i vs other oral drugs in T2D with NAFLD; GLP-1 RA users explicitly excluded",1],["R0006036","Glucagon-like peptide-1 receptor agonists as a disease-modifying therapy for knee osteoarthritis mediated by weight loss: findings from the Shanghai Osteoarthritis Cohort.","Zhu H","2023","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent18","prospective osteoarthritis cohort of T2D patients with vs without GLP-1 RA; knee surgery, WOMAC, weight; no listed harms",1],["R0006080","Cardiorenal Outcomes With Tirzepatide Compared With Dulaglutide in Patients With Diabetes and Cardiovascular Disease: A Post Hoc Analysis of the SURPASS-CVOT Randomized Clinical Trial.","Nissen SE","2026","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent18","post hoc analysis of SURPASS-CVOT double blind RCT, tirzepatide vs dulaglutide, cardiorenal adverse outcomes in T2D with CVD",1],["R0006154","Effects of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: Results of the LEADER and SUSTAIN 6 trials.","Verma S","2020","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent18","post hoc BMI subgroup analyses of LEADER and SUSTAIN 6 placebo controlled RCTs; CV and kidney outcomes",1],["R0005668","Sex differences in risk of cardiovascular events and mortality with sodium glucose co-transporter-2 inhibitors versus glucagon-like peptide 1 receptor agonists in Australians with type 2 diabetes: a population-based cohort study.","Sharma A","2023","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent02","Victorian population cohort of SGLT2 inhibitor vs GLP-1 RA users on MACE and mortality by sex; no listed harm",1],["R0005750","Efficacy of Tirzepatide Dual GIP/GLP-1 Receptor Agonist in Patients With Idiopathic Intracranial Hypertension. A Real-World Propensity Score-Matched Study.","Azzam AY","2025","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent02","TriNetX matched cohort tirzepatide vs standard care in idiopathic intracranial hypertension; papilledema, vision, headache outcomes",1],["R0005845","Efficacy of Semaglutide in Treating Obesity: A Systematic Review of Randomized Controlled Trials (RCTs).","Anam M","2022","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent02","systematic review of semaglutide RCTs in obesity with named databases and eligibility criteria",1],["R0005921","Efficacy and safety of danuglipron (PF-06882961) in adults with obesity: A randomized, placebo-controlled, dose-ranging phase 2b study.","Buckeridge C","2025","include_nma",null,"primary_report","P02",null,null,"high","first","opus-5.5-agent02","randomized double blind placebo controlled phase 2b dose ranging trial of danuglipron in adults with obesity",1],["R0005980","Cardioprotective Glucose-Lowering Agents and Dementia Risk: A Systematic Review and Meta-Analysis.","Seminer A","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent02","registered systematic review and meta-analysis of RCTs of glucose lowering drugs including GLP-1 RA on dementia",1],["R0006050","First-in-Human Study of a Long-Acting GLP-1 Receptor Agonist (TE-8105) in Overweight or Obese Adults Without Type 2 Diabetes Mellitus.","Chuang YS","2026","inventory_only","N1","primary_report",null,null,null,"high","first","opus-5.5-agent02","open label first in human single and multiple ascending dose study of TE-8105 without randomized or placebo arm",1],["R0006096","Gastric ultrasound: Enhancing preoperative risk assessment and patient safety.","Kar Man Chan L","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent02","narrative educational article on gastric ultrasound for aspiration risk assessment",1],["R0006169","Tirzepatide cardiovascular benefits and adverse events assessment: a Bayesian network meta-analysis","gong x","2024","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent02","Bayesian network meta-analysis of tirzepatide RCTs on cardiovascular and adverse events; four sources searched",1],["R0008191","Weight-dependent and weight-independent effects of dulaglutide on blood pressure in patients with type 2 diabetes.","Ferdinand KC","2023","include_nma",null,"pooled_analysis","P01",null,null,"high","first","opus-5.5-agent05","sponsor mediation meta-analysis of five placebo controlled dulaglutide RCTs plus AWARD-11 dose comparison; no systematic search",1],["R0008432","Clinical efficacy and safety of sodium-glucose cotransporter protein-2 (SGLT-2) inhibitor, glucagon-like peptide-1 (GLP-1) receptor agonist, and Finerenone in type 2 diabetes mellitus with non-dialysis chronic kidney disease: a network meta-analysis of randomized clinical trials.","Guo J","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent05","registered network meta-analysis of SGLT2i, GLP-1 RA and finerenone RCTs in diabetic CKD, seven named databases",1],["R0008664","Semaglutide treatment attenuates vessel remodelling in ApoE-/- mice following vascular injury and blood flow perturbation.","Jensen DM","2022","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent05","semaglutide tested in ApoE knockout mice; human material limited to vessel tissue and cultured cells",1],["R0008733","Comparing Machine Learning and Advanced Methods with Traditional Methods to Generate Weights in Inverse Probability of Treatment Weighting: The INFORM Study.","Kwak D","2024","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent05","methods paper comparing machine learning propensity weighting approaches using an existing GLP-1 RA versus DPP-4i cohort",1],["R0006881","Renal effects and safety of tirzepatide in subjects with and without diabetes: A systematic review and meta-analysis.","Kamrul-Hasan A","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent16","PROSPERO registered systematic review and meta-analysis of tirzepatide RCTs on renal outcomes",1],["R0006940","Update on the Present and Future Pharmacologic Treatment of Parkinson's Disease.","Müller T","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent16","narrative review of Parkinson disease pharmacotherapy",1],["R0007012","Association of glucagon-like peptide-1 receptor agonists with risk of cancers-evidence from a drug target Mendelian randomization and clinical trials.","Sun Y","2024","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent16","drug target Mendelian randomization plus systematic review and meta-analysis of GLP-1RA RCTs for cancer; PubMed, Embase, Cochrane",1],["R0007076","PSUN188 Evaluating Response to GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus Managed at a Veterans Affairs Hospital",null,"2022","inventory_only","N5","conference_abstract",null,null,"abstract_only","high","first","opus-5.5-agent16","conference abstract of retrospective VA cohort describing response to GLP-1RA add-on, no comparison group",1],["R0007144","Comparing Efficacy and Safety of Different Doses of Tirzepatide for the Treatment of Type 2 Diabetes Mellitus: A Meta-Analysis of Randomized Controlled Trials.","Khan Z","2023","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent16","systematic review and network meta-analysis of tirzepatide dose RCTs in T2D; PubMed, Cochrane, Embase",1],["R0007257","Association of Premorbid GLP-1RA and SGLT-2i Prescription Alone and in Combination with COVID-19 Severity.","Klein KR","2024","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent16","N3C cohort comparing prior GLP-1RA, SGLT2i or DPP4i prescription on COVID-19 severity; no listed harm",1],["R0006309","High glucose promotes the progression of colorectal cancer by activating the BMP4 signaling and inhibited by glucagon-like peptide-1 receptor agonist.","Ma B","2023","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent13","liraglutide tested only in colorectal cancer cell lines and diabetic mice; human samples had no GLP-1 exposure",1],["R0006462","Antidiabetic Drug Associations With Heart Failure Outcomes: Real-World Evidence Study Using Electronic Health Records.","Jodlowska-Siewert E","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent13","EHR cohort GLP-1 vs DPP-4 inhibitors and sulfonylureas vs insulin, heart failure outcomes only",1],["R0006543","The prescribing pattern of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in patient with type two diabetes mellitus: A two-center retrospective cross-sectional study.","Korayem GB","2022","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent13","cross sectional prescribing pattern study of SGLT2 inhibitors and GLP-1 agonists, no exposure outcome comparison",1],["R0006608","Ethnic Variations in Cardiovascular and Renal Outcomes From Newer Glucose-Lowering Drugs: A Meta-Analysis of Randomized Outcome Trials.","Tang H","2023","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent13","meta-analysis of cardiovascular and renal outcome trials by ethnicity searched in three databases, includes GLP-1 trials",1],["R0006671","Dietary intake patterns and nutritional adequacy among adults with overweight or obesity treated with GLP-1 or dual GIP/GLP-1 receptor agonists","Stachowska Es","2025","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent13","online survey of dietary intake among GLP-1 or dual agonist users without a comparison group",1],["R0006729","Glycaemic and non-glycaemic efficacy of once-weekly GLP-1 receptor agonists in people with type 2 diabetes.","Patel D","2020","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent13","narrative review of once weekly GLP-1 agonist trial programs",1],["R0006799","Treatment of Hypothalamic Obesity With GLP-1 Analogs.","Dimitri P","2024","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent13","self described nonsystematic review of GLP-1 agonists in hypothalamic obesity",1],["R0006301","Incidence of GLP-1 receptor agonist use by women of reproductive age attending general practices in Australia, 2011-2022: a retrospective open cohort study.","Thapaliya K","2025","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent09","prescribing incidence and contraception overlap among Australian women starting GLP-1 drugs, utilization without exposure comparison",1],["R0006394","Semaglutide Once-Weekly Persistence and Adherence Versus Other GLP-1 RAs in Patients with Type 2 Diabetes in a US Real-World Setting.","Uzoigwe C","2021","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent09","claims cohort comparing persistence and adherence of semaglutide versus other GLP-1 agonists, no harms outcome",1],["R0006527","Indirect comparison of glucagon like peptide-1 receptor agonists regarding cardiovascular safety and mortality in patients with type 2 diabetes mellitus: network meta-analysis.","Alfayez OM","2020","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent09","Bayesian NMA of GLP-1 cardiovascular outcome trials identified through PubMed search",1],["R0006599","Effectiveness and safety of GLP-1 receptor agonists in craniopharyngioma patients with obesity: A multicentre real-world study.","Lambert F","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent09","retrospective multicentre cohort of GLP-1 treated craniopharyngioma obesity patients without untreated comparison group",1],["R0006648","Cardiovascular outcomes trials with glucagon-like peptide-1 receptor agonists: A comparison of study designs, populations and results.","Pantalone KM","2020","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent09","narrative review comparing designs and results of GLP-1 cardiovascular outcome trials",1],["R0006785","Is There a Risk for Semaglutide Misuse? Focus on the Food and Drug Administration's FDA Adverse Events Reporting System (FAERS) Pharmacovigilance Dataset.","Chiappini S","2023","inventory_only","N5","other",null,null,null,"high","first","opus-5.5-agent09","FAERS disproportionality analysis of misuse and abuse reports for semaglutide and comparators",1],["R0006895","Efficacy and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in overweight/obese patients with or without diabetes mellitus: a systematic review and network meta-analysis.","Ma H","2023","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent20","PROSPERO registered NMA of RCTs of GLP-1 RAs vs SGLT2i in overweight or obese adults, four databases",1],["R0006953","Treatment Patterns and Glycaemic Control Between 2015 and 2019 in Tianjin, China: A Real-World Study of Adults with Type 2 Diabetes.","Zhang Q","2025","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent20","cross sectional treatment pattern and glycemic trend study in Tianjin, drug utilization without exposure comparison",1],["R0007021","Effect of the Glucagon-Like Peptide-1 Receptor Agonists on Autonomic Function in Subjects with Diabetes: A Systematic Review and Meta-Analysis.","Greco C","2022","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent20","PROSPERO registered meta-analysis of GLP-1 RA effects on autonomic function in diabetes, Medline Embase Cochrane",1],["R0007093","In silico prediction of optimal multifactorial intervention in chronic kidney disease.","Latosinska A","2025","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent20","in silico simulation of drug effects including GLP-1 RA on urinary peptide classifier, no drug actually given",1],["R0007150","Causal relationship between novel antidiabetic drugs and ischemic stroke: a drug-targeted Mendelian randomization study.","Yu Z","2024","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent20","drug target Mendelian randomization of GLP-1R and stroke, no drug exposure studied",1],["R0007214","Tirzepatide in Hispanic/Latino Patients With Type 2 Diabetes: A Subgroup Analysis of the SURPASS Program.","Frías JP","2024","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent20","subgroup analysis by Hispanic ethnicity of randomized SURPASS-1 to 4 trials of tirzepatide vs placebo or active comparators",1],["R0007347","Liraglutide does not increase heart rate of diabetic patients during acute myocardial infarction.","Li Q","2024","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent20","retrospective AMI cohort of liraglutide vs no liraglutide in T2D, heart rate and blood pressure only",1],["R0004663","Glucagon-like peptide-1 receptor agonists before upper gastrointestinal endoscopy and risk of pulmonary aspiration or discontinuation of procedure: cohort study.","Alkabbani W","2024","include_harms",null,"primary_report",null,"O36A",null,"high","first","opus-5.5-agent15","claims cohort of upper endoscopies, GLP-1 RA versus SGLT2i use within 30 days; pulmonary aspiration primary outcome",1],["R0004794","R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 17.","Arora P","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent15","editorial roundup on real world evidence for health technology assessment, briefly discussing GLP-1 RA studies",1],["R0004924","Orforglipron, a novel non-peptide oral daily glucagon-like peptide-1 receptor agonist as an anti-obesity medicine: A systematic review and meta-analysis.","Dutta D","2024","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent15","registered systematic review and meta-analysis of three RCTs of orforglipron versus placebo or active comparator for obesity",1],["R0004985","Questioning the kidney-protective effects of tolvaptan: a testable hypothesis to revisit the current narrative.","Groothof D","2025","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent15","perspective on tolvaptan trial interpretation in polycystic kidney disease; GLP-1 RAs only mentioned in passing",1],["R0005052","From the SELECT study to SOUL: different administration methods of semaglutide but same efficacy?","Gatto L","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent15","narrative review of semaglutide trials from SELECT to SOUL across formulations",1],["R0005183","Protection against stroke with glucagon-like peptide-1 receptor agonists: a comprehensive review of potential mechanisms.","Vergès B","2022","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent19","narrative review of mechanisms of stroke protection by GLP-1 RA; no systematic methods",1],["R0006835","Exploring the risk of depression and suicide/self-injury in patients receiving GLP-1RAs combined with metformin versus GLP-1RA monotherapy: a real-word analysis of the FAERS database.","Ji W","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent03","FAERS disproportionality analysis of depression and suicide reports with GLP-1 RA plus metformin vs GLP-1 alone",1],["R0005333","GLP-1R Agonists and Their Therapeutic Potential in Inflammatory Bowel Disease and Other Immune-Mediated Inflammatory Diseases, a Systematic Review of the Literature.","Thin L","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent19","systematic review of GLP-1 RA in IBD and other immune diseases; PubMed Embase Cochrane searched, PROSPERO registered",1],["R0005409","Comparative Effectiveness of Individual Sodium Glucose Transporter 2 Inhibitors on Cardiovascular Outcomes in Type 2 Diabetes With Moderate Cardiovascular Risk: Emulation of a Target Trial.","Zehra A","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent19","target trial emulation comparing individual SGLT2 inhibitors; GLP-1 RA only a background covariate, not an exposure",1],["R0005479","Chronic cardiorenal syndrome: cardio-renal protective effect of SGLT2i.","Zhu Y","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent19","narrative review of SGLT2 inhibitors in cardiorenal syndrome; no systematic search",1],["R0005604","Data from network meta-analyses can inform clinical practice guidelines and decision-making in diabetes management: perspectives of the taskforce of the guideline workshop.","Ceriello A","2023","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent19","letter giving guideline workshop perspective on network meta-analyses in diabetes; opinion",1],["R0005661","The effects of GLP-1 receptor agonists on metabolic inflammatory markers in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.","Zhao F","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent19","meta-analysis of RCTs of GLP-1 RA vs placebo or other drugs on inflammatory markers in type 2 diabetes; five named databases",1],["R0005721","Efficacy and Safety of Glucagon-Like Peptide 1 Agonists in a Retrospective Study of Patients With Familial Partial Lipodystrophy.","Foss-Freitas MC","2024","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent17","retrospective before and after study of GLP-1 RA in lipodystrophy and matched diabetes patients, all exposed; pancreatitis cases noted",1],["R0005819","Advancements in pharmacological treatment of NAFLD/MASLD: a focus on metabolic and liver-targeted interventions.","Ciardullo S","2024","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent17","self described narrative review of drug treatment for NAFLD and MASLD",1],["R0005912","Effect of antidiabetic drugs in Alzheimer´s disease: a systematic review of preclinical and clinical studies.","Corraliza-Gomez M","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent17","registered PRISMA systematic review with PubMed search and criteria on antidiabetic drugs including GLP-1 RAs in Alzheimer disease",1],["R0005967","Association of glucagon-like peptide-1 receptor agonists with cardiac arrhythmias in patients with type 2 diabetes or obesity: a systematic review and meta-analysis of randomized controlled trials.","Wu S","2022","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent17","registered meta-analysis of RCTs of GLP-1 RAs versus control on arrhythmias in diabetes or obesity",1],["R0006029","Prevention of cardiovascular events in heart failure with mildly reduced or preserved ejection fraction: a comprehensive network meta-analysis of eight randomized controlled trials using reconstructed individual patient's data.","Diallo A","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent17","registered network meta-analysis of large placebo controlled RCTs including GLP-1 RAs in HFmrEF and HFpEF using reconstructed IPD",1],["R0006079","What is the pipeline for future medications for obesity?","Melson E","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent17","narrative review of the obesity drug development pipeline",1],["R0006150","Emerging Therapies in Autosomal Dominant Polycystic Kidney Disease.","Chen CY","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent17","narrative review of emerging therapies for polycystic kidney disease",1],["R0006959","Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists.","Liu QK","2024","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent03","narrative review of mechanisms and uses of GLP-1 and dual GIP/GLP-1 agonists",1],["R0007030","Antidiabetic Medication and Asthma Attacks.","Lee B","2025","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent03","CPRD self controlled case series and cohort of diabetes drugs incl. GLP-1 RA; asthma attacks only",1],["R0007106","Effects of GLP-1 Receptor Agonists vs Metformin in Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis.","Almubaddil K","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent03","meta-analysis of four RCTs of GLP-1 RA vs metformin in PCOS; PubMed, Web of Science, Scopus searched",1],["R0007223","Real-World Evidence of Tirzepatide in Indian Adults With Type 2 Diabetes: Significant Early Glycemic and Cardiometabolic Benefits.","Chandra KP","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent03","multicenter retrospective before and after study of tirzepatide in Indian T2D, no comparison group",1],["R0007284","Comparative effectiveness of multiple different treatment regimens for nonalcoholic fatty liver disease with type 2 diabetes mellitus: a systematic review and Bayesian network meta-analysis of randomised controlled trials.","Deng M","2023","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent03","Bayesian NMA of RCTs for NAFLD with T2D incl. exenatide and liraglutide, four databases searched",1],["R0007757","Additional Effect of Luseogliflozin on Semaglutide in Nonalcoholic Steatohepatitis Complicated by Type 2 Diabetes Mellitus: An Open-Label, Randomized, Parallel-Group Study.","Miyake T","2022","inventory_only","N3","protocol_or_design",null,null,null,"high","first","opus-5.5-agent04","protocol of RCT adding luseogliflozin to semaglutide vs semaglutide alone in NASH with diabetes, GLP-1 RA same in both arms",1],["R0007836","Comparative Efficacy of Novel Antidiabetic Drugs on Albuminuria Outcomes in Type 2 Diabetes: A Systematic Review.","Liu G","2023","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent04","systematic review of placebo controlled RCTs of SGLT2i, GLP-1 RA and DPP-4i on albuminuria, qualitative comparison",1],["R0007892","Glucagon-like peptide-1 receptor agonists are not associated with retinal adverse events in the FDA Adverse Event Reporting System.","Fadini GP","2018","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent04","FAERS disproportionality analysis of retinal adverse event reports with GLP-1 RA vs other glucose lowering drugs",1],["R0007970","Glucagon-like peptide-1 receptor agonist, liraglutide, attenuated retinal thickening in spontaneously diabetic Torii fatty rats.","Inoue K","2022","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent04","randomized experiment in diabetic Torii fatty rats comparing liraglutide with insulin and hydralazine, animal only",1],["R0008029","The Efficacy of Treatment Intensification by Quadruple Oral Therapy Compared to GLP-1RA Therapy in Poorly Controlled Type 2 Diabetes Mellitus Patients: A Real-world Data Study.","Kim M","2023","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent04","retrospective comparison of quadruple oral therapy vs dulaglutide based triple therapy, HbA1c and adverse events only",1],["R0008088","COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint (CONFIDENCE) trial: baseline clinical characteristics.","Agarwal R","2025","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent04","baseline characteristics of CONFIDENCE RCT of finerenone and empagliflozin, no GLP-1 RA intervention or exposure",1],["R0008190","Mental health changes after 4 months of weight loss treatment with the glucagon-like peptide-1 analogue liraglutide 3.0 mg.","Kuckuck S","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent04","observational single group of liraglutide 3.0 mg users with mental health change over 4 months, no comparison group",1],["R0008282","A potential association between tirzepatide and hypercalcemia in the setting of chronic hydrochlorothiazide use.","Nduma B","2025","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent04","case report of severe hypercalcemia after tirzepatide initiation with chronic hydrochlorothiazide",1],["R0006209","Cardiovascular-Kidney-Metabolic Disease Burden in Children and Adults Following Heart Transplantation.","Huang S","2025","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent17","single center heart transplant cohort; BMI trajectory after GLP-1 RA initiation described without a comparison group",1],["R0006780","Efficacy of GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists in managing MALFD: a meta-analysis of randomized controlled trials.","Tamilwanan S","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent08","systematic review and meta-analysis of RCTs of GLP-1 RA and dual agonists in fatty liver disease; four databases",1],["R0006858","Long-term adherence to glucose-lowering medications in adults with diabetes: A data linkage study.","Lee CMY","2025","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent08","adherence by glucose lowering drug class in 45 and Up cohort; drug utilization without exposure outcome comparison",1],["R0006915","Changing the approach to type 2 diabetes treatment: A comparison of glucagon-like peptide-1 receptor agonists and sulphonylureas across the continuum of care.","Orsini Federici M","2021","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent08","narrative review comparing GLP-1 RAs with sulphonylureas in type 2 diabetes",1],["R0006979","Role and impact of a specialized cardiometabolic clinic in managing high-risk patients with type 2 diabetes and atherosclerotic cardiovascular disease.","Modarressi T","2024","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent08","retrospective audit of a cardiometabolic clinic reporting uptake of GLP-1 RA and other drugs; utilization only",1],["R0007044","Protective Effects of Home T2DM Treatment with Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Co-transporter-2 Inhibitors Against Intensive Care Unit Admission and Mortality in the Acute Phase of the COVID-19 Pandemic: A Retrospective Observational Study in Italy.","Monda VM","2023","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent08","Italian retrospective cohort of GLP-1 RA, SGLT2i or DPP4i users hospitalized for COVID-19; ICU and death only",1],["R0007125","Effects of incretin-based therapies on β-cell function in type 1 diabetes mellitus: a systematic review and meta-analysis.","Wu Y","2021","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent08","meta-analysis of RCTs of GLP-1 RA or DPP-4i versus placebo on beta cell function in type 1 diabetes",1],["R0007171","ODP171 Choosing GLP-1RA Over Insulin for Patients with Type 2 Diabetes and Severe Hyperglycemia",null,"2022","inventory_only","N5","conference_abstract",null,null,"abstract_only","high","first","opus-5.5-agent08","conference abstract case series of seven patients starting GLP-1 RA with HbA1c above 10 percent",1],["R0007235","Visceral Adiposity and Renal Health: From Pathophysiological Mechanisms to Novel Therapeutic Strategies.","Marques Vidas M","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent08","narrative review of visceral adiposity and kidney disease with therapies overview",1],["R0006272","The Effects of Cardioprotective Antidiabetic Therapy on Microbiota in Patients with Type 2 Diabetes Mellitus-A Systematic Review.","Bica IC","2023","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent01","registered systematic review of SGLT2i and GLP-1 RA trials on gut microbiota in type 2 diabetes, MEDLINE WoS Cochrane searched",1],["R0006360","Effects of switching from liraglutide to semaglutide or dulaglutide in patients with type 2 diabetes: A randomized controlled trial.","Iijima T","2023","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent01","open label RCT switching from liraglutide to semaglutide versus dulaglutide in type 2 diabetes",1],["R0006424","CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1.","Verma S","2026","include_nma",null,"secondary_report","P02",null,null,"high","first","opus-5.5-agent01","secondary and post hoc blood pressure analysis of REDEFINE 1 RCT, CagriSema versus semaglutide, cagrilintide or placebo",1],["R0006482","Efficacy and safety of GLP-1 analog ecnoglutide in adults with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 2 trial.","Zhu D","2024","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent01","phase 2 double blind RCT of ecnoglutide doses versus placebo in type 2 diabetes",1],["R0006572","Effects of Liraglutide, Empagliflozin and Their Combination on Left Atrial Strain and Arterial Function.","Katogiannis K","2024","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent01","RCT of insulin, liraglutide, empagliflozin or liraglutide plus empagliflozin on metformin in type 2 diabetes",1],["R0006756","Real-world use of liraglutide for weight management according to label in the United Kingdom: A cohort study using the Clinical Practice Research Datalink primary care databases.","Murray-Thomas T","2025","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent01","descriptive drug utilization study of Saxenda and Victoza initiators in UK primary care; no exposure comparison of outcomes",1],["R0006212","Dietary intake by patients taking GLP-1 and dual GIP/GLP-1 receptor agonists: A narrative review and discussion of research needs.","Christensen S","2024","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent18","narrative review of dietary intake studies in people taking GLP-1 or dual agonists",1],["R0006262","Structural Biophysics-Guided Computational Design of Semaglutide Analogues to Enhance GLP-1R Activation","Li W","2024","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent18","computational modeling of semaglutide analogues binding the receptor; in silico only; same preprint as R0005647",1],["R0006411","Comparative Efficacy and Safety of Ecnoglutide in Type 2 Diabetes: A Systematic Review and Meta-Analysis.","Kumar M","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent18","registered systematic review and meta-analysis of ecnoglutide RCTs in T2D vs placebo or active comparators",1],["R0006475","The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease.","Rossing P","2023","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent18","FLOW trial rationale, design and baseline data; semaglutide vs placebo in T2D with CKD; no outcome results",1],["R0006560","Tirzepatide and Cardiovascular Outcomes: A Narrative Review of Mechanisms, Efficacy and Implications for Heart Failure Management.","Abdul-Hafez HA","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent18","narrative review of tirzepatide mechanisms and trials in heart failure; not a trial report",1],["R0006621","Safety and Efficacy of GLP-1 Receptor Agonists in Type 2 Diabetes Mellitus with Advanced and End-Stage Kidney Disease: A Systematic Review and Meta-Analysis.","Krisanapan P","2024","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent18","registered systematic review and meta-analysis of GLP-1 RA trials and cohorts in T2D with advanced CKD or ESKD",1],["R0006689","The Effects of Oral Semaglutide on Hepatic Fibrosis in Subjects with Type 2 Diabetes in Real-World Clinical Practice: A Post Hoc Analysis of the Sapporo-Oral SEMA Study.","Kitsunai H","2025","inventory_only","N5","secondary_report",null,null,null,"high","first","opus-5.5-agent18","post hoc analysis of retrospective single arm oral semaglutide cohort; pre post liver indices, no comparator group",1],["R0008901","Association Between Glucagon-Like Peptide 1 Receptor Agonist and Sodium-Glucose Cotransporter 2 Inhibitor Use and COVID-19 Outcomes.","Kahkoska AR","2021","inventory_only","N6","other",null,null,null,"high","first","opus-5.5-agent05","N3C cohort of prior GLP-1 RA or SGLT2i versus DPP-4i use and COVID-19 mortality and hospitalization; no listed harm",1],["R0008976","Use of GLP-1 receptor agonists and subsequent risk of alcohol-related events. A nationwide register-based cohort and self-controlled case series study.","Wium-Andersen IK","2022","inventory_only","N6","other",null,null,null,"high","first","opus-5.5-agent05","Danish new user cohort and self controlled series of GLP-1 RA versus DPP-4i on alcohol related events; not a listed harm",1],["R0009040","Effect of Liraglutide on Vascular Inflammation Evaluated by [64Cu]DOTATATE.","Zobel EH","2021","include_nma",null,"secondary_report","P01",null,"mechanistic","high","first","opus-5.5-agent05","PET substudy of placebo controlled RCT of liraglutide in type 2 diabetes; reports weight and HbA1c",1],["R0009313","Similar effectiveness of dapagliflozin and GLP-1 receptor agonists concerning combined endpoints in routine clinical practice: A multicentre retrospective study.","Fadini GP","2019","inventory_only","N6","other",null,null,null,"high","first","opus-5.5-agent05","DARWIN-T2D retrospective comparison of dapagliflozin versus GLP-1 RA on composite HbA1c, weight and blood pressure; no listed harm",1],["R0006778","Glucagon-like Peptide-1 Receptor Agonists and Cardioprotective Benefit in Patients With Type 2 Diabetes Without Baseline Metformin: An Update Meta-analysis","Cobo AL","2021","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent07","preprint meta-analysis of GLP-1RA cardiovascular outcome trials in metformin naive type 2 diabetes",1],["R0006857","Free Versus Fixed-Ratio Combination of Basal Insulin and GLP-1 Receptor Agonists in Type 2 Diabetes Uncontrolled With GLP-1 Receptor Agonists: A Systematic Review and Indirect Treatment Comparison.","Jung HN","2022","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent07","systematic review with indirect comparison of free vs fixed ratio basal insulin GLP-1RA vs continuing GLP-1RA",1],["R0006911","A Possible Advantage of Glucagon-Like Peptide 1 Receptor Agonist in Kidney Transplant Recipients With Type 2 Diabetes","Sato T","2021","inventory_only","N6","conference_abstract",null,null,"abstract_only","high","first","opus-5.5-agent07","abstract of matched cohort of GLP-1RA vs other drugs in kidney transplant recipients; graft function only",1],["R0006978","Respiratory Effects of Treatment with a Glucagon-Like Peptide-1 Receptor Agonist in Patients Suffering from Obesity and Chronic Obstructive Pulmonary Disease.","Altintas Dogan AD","2022","include_nma",null,"primary_report","P02",null,null,"high","first","opus-5.5-agent07","double blind RCT of liraglutide 3.0 mg vs placebo for 40 weeks in obesity with COPD, diabetes excluded",1],["R0007122","Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis.","Yamada T","2021","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent07","network meta-analysis of RCTs of SGLT2i and GLP-1RA in type 2 diabetes with CKD",1],["R0007168","The risk of incident atrial fibrillation in patients with type 2 diabetes treated with sodium glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors: a nationwide cohort study.","Chan YH","2022","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent07","Taiwan matched cohorts of GLP-1RA vs SGLT2i or DPP-4i; incident atrial fibrillation only",1],["R0007233","Racial, ethnic and regional differences in the effect of sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide 1 receptor agonists on cardiovascular and renal outcomes: a systematic review and meta-analysis of cardiovascular outcome trials.","Kunutsor SK","2024","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent07","PROSPERO registered meta-analysis of SGLT2i and GLP-1RA cardiovascular outcome trials by race and region",1],["R0007249","Inadequate Use of Newer Treatments and Glycemic Control by Cardiovascular Risk and Sociodemographic Groups in US Adults with Diabetes in the NIH Precision Medicine Initiative All of Us Research Program.","Devineni D","2024","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent14","All of Us cross sectional study of SGLT2i and GLP-1 RA use proportions by risk group, no exposure outcome comparison",1],["R0007387","Antidiabetic Molecule Efficacy in Patients with Type 2 Diabetes Mellitus-A Real-Life Clinical Practice Study.","Salmen T","2023","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent14","retrospective outpatient comparison of SGLT2i, GLP-1 RA and metformin effects on BMI and glycemia, no harms_nrs outcome",1],["R0007464","Real-world comparison of GLP-1 agonists versus physical activity in metabolic dysfunction-associated steatotic liver disease.","Chen JN","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent14","retrospective MASLD cohort GLP-1 RA vs physical activity, BMI and liver metrics only",1],["R0007572","Cardiovascular benefits of semaglutide: a systematic review and meta-analysis of randomized controlled trials.","Sadraei S","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent14","PROSPERO registered meta-analysis of semaglutide RCTs on cardiovascular outcomes, PubMed Scopus Web of Science",1],["R0007660","Time to Reach Glycaemic and Body Weight Loss Thresholds with Tirzepatide in Patients with Type 2 Diabetes: A Pre-planned Exploratory Analysis of SURPASS-2 and SURPASS-3.","Viljoen A","2023","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent14","preplanned exploratory analysis of SURPASS-2 and SURPASS-3 RCTs, time to HbA1c and weight thresholds",1],["R0005792","Glucagon-Like Peptide-1 Agonist vs. Placebo and Pulmonary Decline After Open-Heart Surgery: A Substudy of the GLORIOUS Randomised Clinical Trial.","Mikkelsen AD","2026","include_nma",null,"secondary_report","P99",null,null,"high","first","opus-5.5-agent10","substudy of GLORIOUS RCT perioperative exenatide infusion versus placebo in open heart surgery; pulmonary function outcomes",1],["R0005872","Glucagon-like-peptide-1 (GLP-1) receptor agonist use and the risk of pulmonary aspiration in patients undergoing surgery.","Wright JD","2025","include_harms",null,"primary_report",null,"O36A",null,"high","first","opus-5.5-agent10","MarketScan surgical procedure cohort with versus without preoperative GLP-1 RA; aspiration pneumonia within 7 days",1],["R0005944","Investigating the association between GLP-1 receptor agonists and mood disorders: A study integrating real-world data and Mendelian randomization.","Zheng X","2025","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent10","FAERS disproportionality plus Mendelian randomization of GLP-1 RAs and mood outcomes; no comparative cohort",1],["R0006067","Efficacy and safety of polyethylene glycol loxenatide in type 2 diabetic patients: a systematic review and meta-analysis of randomized controlled trials.","Salamah HM","2023","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent10","PROSPERO registered meta-analysis of RCTs of PEG loxenatide versus placebo or metformin in T2D",1],["R0006123","Weight Loss Effect of GLP-1 RAs With Endoscopic Bariatric Therapy and Bariatric Surgeries.","Imam A","2023","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent10","systematic review of studies comparing bariatric surgery or endoscopic therapy with versus without liraglutide; named databases",1],["R0006238","The use of semaglutide as an add-on therapy in patients with latent autoimmune diabetes in adults.","Lunati ME","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent10","retrospective series of LADA patients adding semaglutide to insulin; pre post changes without comparison group",1],["R0007317","Ceramides are decreased after liraglutide treatment in people with type 2 diabetes: a post hoc analysis of two randomized clinical trials.","Wretlind A","2023","include_nma",null,"secondary_report","P01",null,"crossover","high","first","opus-5.5-agent12","post hoc ceramide analysis of two placebo controlled liraglutide RCTs in T2D, one crossover and one parallel",1],["R0007384","A Real-World Observational Study Evaluating the Probability of Glycemic Control with Basal Insulin or Glucagon-Like Peptide-1 Receptor Agonist in Japanese Patients with Type 2 Diabetes.","Baxter M","2020","inventory_only","N6","primary_report","P01",null,null,"high","first","opus-5.5-agent12","Japanese EMR cohort of basal insulin vs GLP-1RA initiators, probability of HbA1c control, no listed harm",1],["R0007449","The Long-Term Cost-Effectiveness of Oral Semaglutide Versus Lower-Cost Liraglutide in the UK.","Elnaggar M","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent12","cost effectiveness modeling of oral semaglutide vs liraglutide using PRIME T2D model",1],["R0007504","Real-world effectiveness of adding newer generation GLP-1RA to SGLT2i in type 2 diabetes.","Chaiyakunapruk N","2025","inventory_only","N6","primary_report","P01",null,null,"high","first","opus-5.5-agent12","claims cohort of GLP-1RA added to SGLT2i vs SGLT2i alone, MACE, glycemic, weight and renal outcomes, no listed harm",1],["R0007565","Cardiovascular outcomes with SGLT2 inhibitors versus DPP4 inhibitors and GLP-1 receptor agonists in patients with heart failure with reduced and preserved ejection fraction.","Gonzalez J","2023","inventory_only","N6","primary_report","P07A; P07B",null,null,"high","first","opus-5.5-agent12","Medicare new user cohorts SGLT2i vs GLP-1RA or DPP4i in HFrEF and HFpEF, heart failure and MI or stroke outcomes",1],["R0007651","One Year's Treatment with the Glucagon-Like Peptide 1 Receptor Agonist Liraglutide Decreases Hepatic Fat Content in Women with Nonalcoholic Fatty Liver Disease and Prior Gestational Diabetes Mellitus in a Randomized, Placebo-Controlled Trial.","Vedtofte L","2020","include_nma",null,"secondary_report","P02",null,null,"high","first","opus-5.5-agent12","prespecified secondary analysis of 1 year RCT liraglutide vs placebo in nondiabetic overweight women with prior GDM, liver fat and weight",1],["R0007787","GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art.","Nauck MA","2021","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent12","state of the art narrative review of GLP-1RAs in T2D",1],["R0006865","Effect of the GLP-1 receptor agonist exenatide on pro-inflammatory and metabolic biomarkers in individuals with alcohol use disorder: Post hoc results from a randomized, double-blinded, placebo-controlled clinical trial.","Hviid MEB","2025","include_nma",null,"secondary_report","P14A",null,null,"high","first","opus-5.5-agent13","post hoc biomarker analysis of placebo controlled RCT of exenatide once weekly in alcohol use disorder",1],["R0006934","3-point major cardiovascular event outcome for patients with T2D treated with dipeptidyl peptidase-4 inhibitor or glucagon-like peptide-1 receptor agonist in addition to metformin monotherapy.","El Sanadi CE","2020","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent13","EHR cohort DPP-4 inhibitor vs GLP-1 agonist added to metformin, 3 point MACE only",1],["R0007004","Characteristics of new users of recent antidiabetic drugs in Canada and the United Kingdom.","Brunetti VC","2022","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent13","descriptive study of baseline characteristics of new users of SGLT2, DPP-4 and GLP-1 drugs, no outcome comparison",1],["R0007065","GLP-1 agonists for smoking cessation and post-cessation weight management: A systematic review and meta-analysis of randomized trials.","Heshmati J","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent13","PROSPERO registered meta-analysis of GLP-1 agonist RCTs for smoking cessation and weight",1],["R0007136","Efficacy and Safety of Once-Weekly Efpeglenatide Monotherapy Versus Placebo in Type 2 Diabetes: The AMPLITUDE-M Randomized Controlled Trial.","Frias JP","2022","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent13","AMPLITUDE-M phase 3 RCT of efpeglenatide three doses vs placebo in type 2 diabetes",1],["R0007198","Adherence and persistence among patients with type 2 diabetes initiating dulaglutide compared with semaglutide and exenatide BCise: 6-month follow-up from US real-world data.","Mody R","2021","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent13","claims cohort comparing adherence and persistence of dulaglutide vs semaglutide or exenatide BCise only",1],["R0007247","Insights into a possible role of glucagon-like peptide-1 receptor agonists in the treatment of depression.","Detka J","2021","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent13","narrative review of possible antidepressant effects of GLP-1 agonists",1],["R0007320","Effects of finerenone and glucagon-like peptide 1 receptor agonists on cardiovascular and renal outcomes in type 2 diabetes mellitus: a systematic review and meta-analysis.","Gu X","2024","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent13","PROSPERO registered meta-analysis of finerenone and GLP-1 agonist outcome RCTs",1],["R0004740","The Effect of Semaglutide With Lifestyle Intervention on the Physical Health of Patients Treated With Antipsychotic Drugs in a Secure Mental Health Setting: Protocol for an Uncontrolled Pretest-Posttest Pilot Mixed Methods Study.","Brenisin K","2025","inventory_only","N8","protocol_or_design","P15",null,null,"high","first","opus-5.5-agent15","protocol of uncontrolled pre post pilot of semaglutide plus lifestyle for antipsychotic weight gain; no results, design also N1",1],["R0005110","Can glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors help in mitigating the risk of atrial fibrillation in patients with diabetes?","Thotamgari SR","2022","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent15","FAERS disproportionality analysis of atrial fibrillation reports with GLP-1 RAs and DPP-4 inhibitors",1],["R0005176","GLP-1 receptor agonist therapy for obesity via direct-to-consumer telemedicine: Clinical characteristics and treatment outcomes.","Gratzke M","2025","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent15","retrospective survey of telemedicine liraglutide users only; weight and side effects without a comparison group",1],["R0005317","Real-world outcomes of addition of insulin glargine 300 U/mL (Gla-300) to glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy in people with type 2 diabetes: The DELIVER-G study.","Bailey TS","2022","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent15","EHR before and after study adding glargine 300 to existing GLP-1 RA therapy; no comparison group, GLP-1 regimen unchanged",1],["R0005390","Analysis of Psychiatric Adverse Events for Semaglutide, Liraglutide, and Tirzepatide Reported to the EudraVigilance Database","Tobaiqy M","2023","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent15","descriptive EudraVigilance analysis of psychiatric adverse event reports with semaglutide, liraglutide and tirzepatide",1],["R0005471","Venous thromboembolism with modern glucose-lowering agents in diabetes: active-comparator evidence beyond placebo-based meta-analyses.","Boccatonda A","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent15","meta-analysis of six active comparator studies of GLP-1 RAs or SGLT2i versus DPP-4i on venous thromboembolism; five databases searched",1],["R0005530","Glucagon-Like Peptide 1 Receptor Agonist (GLP1RA) Exposure and Outcomes in Type 2 Diabetes: A Systematic Review of Population-Based Observational Studies.","Caparrotta TM","2021","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent15","registered systematic review of 22 population based observational studies of GLP-1 RA exposure on mortality, CVD, pancreatitis and cancer",1],["R0007895","Role of incretins and glucagon receptor agonists in metabolic dysfunction-associated steatotic liver disease: Opportunities and challenges.","Xie C","2024","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent06","narrative review of incretin and glucagon receptor agonists in MASLD",1],["R0007972","Persistent disparities in diabetes medication receipt by socio-economic disadvantage in Australia.","Morton JI","2022","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent06","registry linked drug utilization study of GLP-1 RA and SGLT2 inhibitor receipt by socioeconomic disadvantage",1],["R0008042","Improved glycaemic control in people with type 2 diabetes initiating or switching to IDegAsp in a real-world setting in China.","Guo L","2025","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent06","single arm noninterventional study of IDegAsp insulin initiation; GLP-1 RA only as prior therapy, not the exposure",1],["R0008106","Endotypic Trait Responses to 12-Month Tirzepatide Treatment for an Obese Patient with Obstructive Sleep Apnea: A Case Report.","Hsu Y","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent06","case report of endotypic sleep apnea traits in one SURMOUNT-OSA participant on tirzepatide",1],["R0008200","A Retrospective Study of Glucagon-Like Peptide 1 Receptor Agonists for the Management of Diabetes After Transplantation.","Thangavelu T","2020","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent06","retrospective case series of 19 transplant recipients treated with GLP-1 RAs; no comparison group",1],["R0008290","The different colorectal tumor risk related to GLP-1 receptor agonists and SGLT2 inhibitors use: a network meta-analysis of 68 randomized controlled trials.","Hung CM","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent06","NMA of 68 RCTs comparing GLP-1 RAs and SGLT2 inhibitors on colorectal tumor incidence; multiple databases",1],["R0008370","Medullary Carcinoma of Thyroid Due to GLP-1 Receptor Agonist","Vemula H","2021","inventory_only","N5","conference_abstract",null,null,"abstract_only","high","first","opus-5.5-agent06","conference abstract case report of medullary thyroid carcinoma after dulaglutide",1],["R0008437","Nutritional priorities to support GLP-1 therapy for obesity: A joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society.","Mozaffarian D","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent06","joint society expert advisory on nutritional priorities with GLP-1 therapy",1],["R0004716","DIVINE-pilot trial: a phase 2 multicentre, randomised pilot trial of pharmacotherapy and physical activity monitoring conducted in women with recent gestational diabetes and increased risk of type 2 diabetes recruited from tertiary referral hospitals in Australia.","Chen AX","2025","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent11","protocol of DIVINE-pilot factorial RCT, metformin versus metformin plus semaglutide after gestational diabetes; no results",1],["R0004788","Establishing a Relationship between In Vitro Potency in Cell-Based Assays and Clinical Efficacious Concentrations for Approved GLP-1 Receptor Agonists.","Boianelli A","2024","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent11","in vitro potency assays related to literature pharmacokinetic and efficacy data by modeling; no new human study",1],["R0004843","Effect of Switching to Once-Weekly Semaglutide on Non-Alcoholic Fatty Liver Disease: The SWITCH-SEMA 1 Subanalysis.","Nomoto H","2023","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent11","SWITCH-SEMA 1 subanalysis; randomized switch to semaglutide versus continuing liraglutide or dulaglutide, suspected NAFLD subgroup",1],["R0004913","Target Trial Emulations of GLP-1 and Dual GLP-1/GIP Agonists to Reduce Major Adverse Liver Outcomes in Type 2 Diabetes.","Henney AE","2025","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent11","target trial emulations of incretin drugs versus DPP-4i on major adverse liver outcomes; HCC only within liver composite, no listed harm",1],["R0005046","Safety and efficacy of glucagon-like peptide-1 receptor agonists in patients with obstructive sleep apnea: a systematic review and meta-analysis of randomized controlled trials.","Altobaishat O","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent11","registered meta-analysis of placebo controlled GLP-1RA RCTs in obstructive sleep apnea; five named databases",1],["R0005100","Glucagon-Like Peptide-1 Receptor Agonist Ameliorates 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP) Neurotoxicity Through Enhancing Mitophagy Flux and Reducing α-Synuclein and Oxidative Stress.","Lin TK","2021","exclude","E1","primary_report",null,null,null,"high","first","opus-5.5-agent11","MPTP mouse model experiments with liraglutide",1],["R0005169","Sodium-Glucose Cotransporter 2 Inhibitors, Erythrocytosis, and Thrombosis in Adults With Type 2 Diabetes.","Lewis M","2025","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent11","Clalit new user cohort of SGLT2i versus DPP-4i or GLP-1RA comparators; erythrocytosis and thrombosis only",1],["R0007402","Real-World Impact of GLP-1 Receptor Agonists on Endoscopic Patient Outcomes in an Ambulatory Setting: A Retrospective Study at a Large Tertiary Center.","Robalino Gonzaga E","2024","include_harms",null,"primary_report",null,"O36A; O36B",null,"high","first","opus-5.5-agent20","retrospective cohort of elective EGD procedures comparing GLP-1 RA users vs nonusers, food retention and aspiration outcomes",1],["R0007529","The Efficacy and Safety of Tirzepatide in Patients with Diabetes and/or Obesity: Systematic Review and Meta-Analysis of Randomized Clinical Trials.","Liu L","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent20","PROSPERO registered meta-analysis of RCTs of tirzepatide vs placebo, GLP-1 RA or insulin, three databases",1],["R0007588","Short-term effect of polyethylene glycol loxenatide on weight loss in overweight or obese patients with type 2 diabetes: An open-label, parallel-arm, randomized, metformin-controlled trial.","Cai H","2023","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent20","open label RCT of PEG-loxenatide 0.3 mg vs metformin in overweight or obese T2D, weight at 16 weeks",1],["R0007678","Effectiveness and Safety of Antidiabetic Medications in Hidradenitis Suppurativa: A Systematic Review.","Almukhadeb E","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent20","PRISMA systematic review of antidiabetic drugs including GLP-1 RAs in hidradenitis suppurativa, five databases",1],["R0007744","Use of incretin receptor agonists in patients submitted to metabolic bariatric surgery - a systematic review and meta-analysis.","Santos-Pereira M","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent20","PROSPERO registered meta-analysis of liraglutide semaglutide tirzepatide after bariatric surgery, three databases",1],["R0007813","Clinical Efficacy of Polyethylene Glycol Loxenatide in the Treatment of Obese or Overweight Patients with Type 2 Diabetes Mellitus.","Song X","2023","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent20","RCT of PEG-loxenatide added to metformin and insulin vs metformin and insulin in overweight T2D, 6 months",1],["R0007880","GLP-1 receptor agonists for Alzheimer's disease: Lessons from trials and translational challenges.","Stringhi R","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent20","short commentary on GLP-1 RA trials in Alzheimer disease",1],["R0007358","Once-Daily Oral Semaglutide Versus Injectable GLP-1 RAs in People with Type 2 Diabetes Inadequately Controlled on Basal Insulin: Systematic Review and Network Meta-analysis.","Chubb B","2021","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent03","systematic review and NMA of oral semaglutide vs injectable GLP-1 RA on basal insulin; MEDLINE, Embase, Cochrane searched",1],["R0007412","Glycemic Control and the Weight Benefit of a Daily 7 mg Dose of Oral Semaglutide Versus an Alternate-Day 14 mg Dose of Oral Semaglutide From an Ambulatory Glucose Monitoring Data: A Retrospective Cohort Study From Eastern India.","RoyChaudhuri S","2023","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent03","retrospective within patient comparison of daily 7 mg vs alternate day 14 mg oral semaglutide in 11 patients, no concurrent group",1],["R0007484","GLP-1 Receptor Agonist Treatment in Morbid Obesity and Type 2 Diabetes Due to Pathogenic Homozygous Melanocortin-4 Receptor Mutation: A Case Report.","Iepsen EW","2020","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent03","case report of liraglutide 3 mg in a woman with homozygous MC4R mutation obesity and T2D",1],["R0007544","GLP-1 AND CIRRHOSIS: EFFECTS ON MORTALITY AND LIVER-RELATED COMPLICATIONS.","Onwuzo CN","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent03","TriNetX matched cohort GLP-1 RA vs nonusers with cirrhosis; mortality and cirrhosis complications only",1],["R0007619","Efficacy of glucagon-like-peptide-1 agonists for weight loss in adults with CHD.","Varghese P","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent03","retrospective single group cohort of GLP-1 RA users with congenital heart disease, compared only by complexity",1],["R0007690","Superior Cardiorenal Protection With Tirzepatide Over Dulaglutide in Heart Failure With Preserved Ejection Fraction: A Large-Scale Propensity Score-Matched Real-World Analysis.","Khalil I","2026","include_harms",null,"primary_report",null,"O29",null,"high","first","opus-5.5-agent03","TriNetX new user cohort tirzepatide vs dulaglutide in HFpEF; acute pancreatitis among outcomes",1],["R0007749","Psychiatric Safety of Tirzepatide in People With Obesity and No Known Major Psychopathology: A Post Hoc Analysis of SURMOUNT.","Wadden TA","2026","include_nma",null,"pooled_analysis","P02; P01",null,null,"high","first","opus-5.5-agent03","post hoc pooled analysis of SURMOUNT-1, -2, -3 RCTs, tirzepatide vs placebo; psychiatric safety outcomes",1],["R0007831","Comparison between liraglutide and dulaglutide on the incidence or progression of eye and kidney complications.","Katamine A","2026","include_harms",null,"primary_report",null,"O33",null,"high","first","opus-5.5-agent03","retrospective new user cohort liraglutide vs dulaglutide in Japanese T2D; incidence or progression of retinopathy",1],["R0009516","Glucagon-like peptide-1 receptor agonists as add-on therapy to basal insulin in patients with type 2 diabetes: a systematic review.","Berlie H","2012","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent05","systematic review of trials of GLP-1 RA added to basal insulin searching PubMed and Cochrane databases with criteria",1],["R0009592","Pre-admission glucagon-like peptide-1 receptor agonist (GLP-1RA) and mortality from coronavirus disease 2019 (Covid-19): A systematic review, meta-analysis, and meta-regression.","Hariyanto TI","2021","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent05","registered meta-analysis of preadmission GLP-1 RA versus other antidiabetic drugs on COVID-19 mortality, three named databases",1],["R0009679","Targeting epicardial adipose tissue: A potential therapeutic strategy for heart failure with preserved ejection fraction with type 2 diabetes mellitus.","Shi YJ","2023","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent05","narrative review on targeting epicardial fat in HFpEF with diabetes including GLP-1 RA among options",1],["R0009785","Diagnosis 101: diabetic kidney disease.","Lerma EV","2022","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent05","editorial on diagnosis of diabetic kidney disease; no primary data",1],["R0009950","Characteristics of patients prescribed SGLT-2i and/or GLP-1RA among cardiology clinics in the US: insights from the COORDINATE-diabetes trial.","Nelson AJ","2025","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent05","analysis of factors associated with SGLT2i and GLP-1 RA prescribing pooled across arms of an implementation trial; drug utilization only",1],["R0010046","Inpatient safety, effectiveness of SGLT2 inhibitors and GLP-1 RAs in type 2 diabetes: ENDOCARE, a pragmatic prospective cohort study.","Moreno-Pérez Ó","2026","inventory_only","N6","other",null,null,null,"high","first","opus-5.5-agent05","prospective inpatient cohort of oral agents including SGLT2i or GLP-1 RA versus insulin only; hypoglycemia and DKA outcomes, no listed harm",1],["R0010119","Network and Pairwise Meta-Analysis of the Association Between Novel Hypoglycemic Agents and Atrial Fibrillation Risk in Patients With Type 2 Diabetes Mellitus.","Ye X","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent05","registered network meta-analysis of SGLT2i, GLP-1 RA and DPP-4i on atrial fibrillation, named databases",1],["R0007330","Effects of GLP-1 Receptor Agonists on Bone Mineral Density in Patients with Type 2 Diabetes Mellitus: A 52-Week Clinical Study.","Cai TT","2021","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent16","single blind RCT randomizing T2D to exenatide, dulaglutide, insulin glargine or placebo for 52 weeks; BMD and HbA1c",1],["R0007522","GLP-1 Receptor Agonists Are Associated With Lower Early Revision Risk Compared to Bariatric Surgery Following Total Hip Arthroplasty: A Retrospective Cohort Study.","Brahmbhatt S","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent16","TriNetX matched cohort of GLP-1RA users vs prior bariatric surgery before hip arthroplasty; revision and wound outcomes only",1],["R0007798","Outcomes in GLP-1 RA-Experienced Patients Switching to Once-Weekly Semaglutide in a Real-World Setting: The Retrospective, Observational EXPERT Study.","Lingvay I","2021","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent16","retrospective before and after study of switching to semaglutide from other GLP-1RA, no concurrent comparator",1],["R0008361","Use of iGlarLixi for Management of Type 2 Diabetes in Japanese Clinical Practice: SPARTA Japan, a Retrospective Observational Study.","Matsuhisa M","2023","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent04","SPARTA Japan noncomparative retrospective study of iGlarLixi users with before and after HbA1c, no comparison group",1],["R0008428","Clinical assessment of liraglutide use in prediabetic and obese schizophrenic patients: A systematic literature review and meta-analysis","Abbas A","2023","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent04","systematic review and meta-analysis of three databases on liraglutide vs placebo in schizophrenia with obesity or prediabetes",1],["R0008509","GLP-1RA and Liver Fibrosis Progression in MASLD and Type 2 Diabetes: Target Trial Emulation Using Propensity Score Matching.","Choi J","2025","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent04","target trial emulation GLP-1 RA vs DPP-4i in MASLD with diabetes, fibrosis progression and liver events only, no listed harm",1],["R0008578","Consensus Recommendations on GLP-1 RA Use in the Management of Type 2 Diabetes Mellitus: South Asian Task Force.","Kalra S","2019","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent04","South Asian expert consensus recommendations on GLP-1 RA use in type 2 diabetes",1],["R0008662","Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.","Garvey WT","2023","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent04","SURMOUNT-2 double blind placebo controlled phase 3 RCT of tirzepatide for obesity in type 2 diabetes",1],["R0008731","Efficacy of pharmacotherapies in improving liver fibrosis among patients with MASLD and fibrosis stages of F1-F3: systematic review and network meta-analysis.","Sun XY","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent04","registered systematic review and network meta-analysis of RCTs of MASLD drugs incl semaglutide, tirzepatide, survodutide on fibrosis",1],["R0008805","Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes in the UK.","Johansen P","2020","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent04","cost effectiveness modeling of semaglutide vs liraglutide using CORE Diabetes Model",1],["R0008898","Prescribing SGLT2 Inhibitors in Patients With CKD: Expanding Indications and Practical Considerations.","Yau K","2022","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent04","narrative review on prescribing SGLT2 inhibitors in CKD, GLP-1 RA mentioned only as combination option",1],["R0006220","Tirzepatide Associated With Reduced Albuminuria in Participants With Type 2 Diabetes: Pooled Post Hoc Analysis From the Randomized Active- and Placebo-Controlled SURPASS-1-5 Clinical Trials.","Apperloo EM","2025","include_nma",null,"pooled_analysis","P01",null,null,"high","first","opus-5.5-agent02","pooled post hoc analysis of SURPASS 1 to 5 RCTs of tirzepatide vs placebo or active comparators on albuminuria",1],["R0006275","Assessment of Exenatide Extended-Release for Maintenance of Diabetic Remission in Cats.","Gilor C","2025","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent02","randomized placebo controlled exenatide extended release study in client owned diabetic cats",1],["R0006362","Tirzepatide in dermatology: cutaneous adverse events, emerging therapeutic roles, and cosmetic implications - A comprehensive review.","El-Amawy HS","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent02","self described narrative review of tirzepatide in dermatology",1],["R0006425","Real-world national trends and socio-economic factors preference of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in China.","Li C","2022","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent02","cross sectional prescription trend analysis of SGLT2 inhibitor vs GLP-1 RA preference in China; utilization only",1],["R0006488","GLP-1 RAs in Spain: A Short Narrative Review of Their Use in Real Clinical Practice.","Romera I","2023","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent02","short narrative review of GLP-1 RA use in Spanish practice",1],["R0006628","Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists.","Madsbad S","2016","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent02","narrative review of head to head GLP-1 RA trials without systematic search",1],["R0006700","Potential Mediators for Treatment Effects of Novel Diabetes Medications on Cardiovascular and Renal Outcomes: A Meta-Regression Analysis.","Rodriguez-Valadez JM","2024","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent02","registered systematic review with meta-regression of GLP-1 RA and SGLT2 inhibitor outcome trials; PubMed searched",1],["R0005744","Cotadutide promotes glycogenolysis in people with overweight or obesity diagnosed with type 2 diabetes.","Parker VER","2023","include_nma",null,"primary_report","P01",null,"mechanistic","high","first","opus-5.5-agent19","phase 2a RCT of cotadutide vs placebo and vs liraglutide in overweight type 2 diabetes; hepatic glycogen primary, weight and safety reported",1],["R0005837","Assessing the quality and reliability of health information on GLP-1 receptor agonists on TikTok and Bilibili: a cross-sectional analysis of the public health infodemic.","Peng G","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent19","cross sectional quality assessment of GLP-1 videos on Chinese social media; no drug exposure studied in people",1],["R0006040","Kidney outcomes with GLP-1 receptor agonists in people with type 2 diabetes already receiving SGLT2 inhibitors: a target trial emulation study using UK primary care data.","Jansz TT","2026","include_harms",null,"primary_report",null,"O29; O33",null,"high","first","opus-5.5-agent19","CPRD target trial emulation, new users of GLP-1 RA vs DPP-4i or sulfonylurea on SGLT2i background; pancreatitis and incident retinopathy",1],["R0006087","Weight Loss and Maintenance Related to the Mechanism of Action of Glucagon-Like Peptide 1 Receptor Agonists.","Ard J","2021","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent19","narrative review of GLP-1 RA mechanism for weight loss aimed at primary care",1],["R0006159","The Impact of GLP-1 Receptor Agonists (GLP-1 RAs) on Mental Health: A Systematic Review","Tempia Valenta S","2025","include_review",null,"systematic_review",null,null,"abstract_only","high","first","opus-5.5-agent19","systematic review abstract of GLP-1 RA and mental health outcomes; PubMed and Web of Science searched with criteria",1],["R0006215","Comparative Safety of GLP-1 Receptor Agonists Across Gastrointestinal, Renal and Pancreatic Systems.","Shokr H","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent19","FAERS disproportionality analysis of gastrointestinal, renal, pancreatic events across GLP-1 RAs",1],["R0007294","Comparative efficacy of glucose-lowering drugs on liver steatosis as assessed by means of magnetic resonance imaging in patients with type 2 diabetes mellitus: systematic review and network meta-analysis.","Malandris K","2023","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent08","systematic review and network meta-analysis of glucose lowering drug RCTs incl GLP-1 RA on MRI liver fat",1],["R0007370","SAT-529 Real-world Treatment Patterns Of Tirzepatide Versus Semaglutide In GLP-1 RA-experienced Patients With T2D",null,"2025","inventory_only","N6","conference_abstract",null,null,"abstract_only","high","first","opus-5.5-agent08","abstract of matched claims cohort of tirzepatide versus semaglutide; adherence, persistence and switching only",1],["R0007427","The effect of liraglutide and sitagliptin on oxidative stress in persons with type 2 diabetes.","Sivalingam S","2021","include_nma",null,"secondary_report","P01; P08A",null,"crossover","high","first","opus-5.5-agent08","post hoc of two randomized trials of liraglutide versus placebo or sitagliptin on urinary oxidative stress markers",1],["R0007496","Characteristics predicting the efficacy of SGLT-2 inhibitors versus GLP-1 receptor agonists on major adverse cardiovascular events in type 2 diabetes mellitus: a meta-analysis study.","Sohn M","2023","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent08","meta-analysis of SGLT2i and GLP-1 RA cardiovascular outcome trials by baseline characteristics",1],["R0007553","Comparative Effectiveness of SGLT2 Inhibitors and Semaglutide in Diabetic Nephropathy: A Retrospective Observational Study.","Joseph J","2025","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent08","retrospective comparison of five semaglutide and five SGLT2i patients with diabetic nephropathy; renal outcomes only",1],["R0007629","Association of Glucose-Lowering Therapy with Myocardial Work Recovery and Reverse Remodeling After STEMI.","Buz BF","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent08","STEMI cohort by preadmission glucose lowering class incl GLP-1 RA; echo remodeling and MACE only",1],["R0007708","Adverse Events Related to Tirzepatide.","Mishra R","2023","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent08","systematic review and meta-regression of tirzepatide trial adverse event rates by dose; five databases",1],["R0007770","Effect of metabolic status on response to SIV infection and antiretroviral therapy in nonhuman primates.","Webb GM","2024","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent08","rhesus macaque study of obesity and SIV infection with antiretroviral therapy",1],["R0006259","Dipeptidyl Peptidase-4 Inhibitors, Glucagon-like Peptide-1 Receptor Agonists, and Sodium-Glucose Cotransporter-2 Inhibitors and COVID-19 Outcomes.","Foresta A","2023","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent17","Lombardy administrative cohort of DPP-4 inhibitor, GLP-1 RA, SGLT2 inhibitor users with COVID-19; mortality and hospitalization only",1],["R0006331","Rethinking the Diabetes-Cardiovascular Disease Continuum: Toward Integrated Care.","Caturano A","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent17","perspective article on integrated care for the diabetes and cardiovascular continuum",1],["R0006474","Efficacy and Hypoglycaemia Outcomes With Once-Weekly IcoSema Versus Comparators in Individuals With Type 2 Diabetes by Kidney and Liver Function: A Post Hoc Analysis of the COMBINE 1-3 Trials.","Ji L","2026","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent17","post hoc subgroup analysis of COMBINE 1 to 3 RCTs of IcoSema versus comparators by kidney and liver function",1],["R0006559","The effect of semaglutide on blood pressure in patients with type-2 diabetes: a systematic review and meta-analysis.","Wu W","2024","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent17","registered meta-analysis of RCTs of semaglutide versus placebo or other drugs on blood pressure in type 2 diabetes",1],["R0006618","Multicenter, Retrospective, observational study to evaluate the real-world use and effectiveness of a fixed-ratio combination of insulin degludec/liraglutide (IDegLira) in the Pakistani population with Type-2 diabetes (T2D).","Raja UY","2025","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent17","multicenter retrospective single group study of IDegLira in Pakistan without comparison group",1],["R0006684","Hypoglycemic agents and bone health; an umbrella systematic review of the clinical trials' meta-analysis studies.","Khashayar P","2024","include_review",null,"systematic_review",null,null,"umbrella_review","high","first","opus-5.5-agent17","umbrella review of meta-analyses of RCTs of antidiabetic drugs including GLP-1 RAs on bone health, five databases",1],["R0006859","Comparison of the Completeness of Spontaneously Reported Adverse Drug Reactions by Consumers, Healthcare Professionals, and Pharmaceutical Companies: An Evaluation of Databases From Two High-Income Countries.","Dedefo MG","2025","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent09","study of completeness of spontaneous adverse reaction reports by reporter type, no GLP-1 exposure effect studied",1],["R0006992","Dosing, treatment patterns and safety of finerenone use in routine care: an interim analysis of the prospective, real-world and observational FINE-REAL study.","Wheeler DC","2025","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent09","single arm observational finerenone study, GLP-1 agonists only listed as concomitant medication",1],["R0007048","Cardiovascular outcomes with exenatide in type 2 diabetes according to ejection fraction: The EXSCEL trial.","Neves JS","2025","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent09","post hoc EXSCEL analysis of exenatide versus placebo cardiovascular outcomes by ejection fraction",1],["R0007126","Heterogeneity amongst GLP-1 RA cardiovascular outcome trials results: can definition of established cardiovascular disease be the missing link?","Melo M","2021","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent09","narrative review of design heterogeneity across GLP-1 cardiovascular outcome trials",1],["R0007175","Glucagon-like peptide-1 receptor agonists, inflammation, and kidney diseases: evidence from Mendelian randomization.","Yao YX","2025","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent09","Mendelian randomization using GLP1R genetic proxies, no drug given or drug exposure studied",1],["R0007239","Dose-response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial.","Blüher M","2024","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent09","phase II RCT of survodutide doses versus placebo and open label semaglutide in type 2 diabetes on metformin",1],["R0007293","Multi-modal neo-adjuvant anti-obesity medications may be more effective than medically supervised weight loss or GLP-1 therapy alone in preparing BMI≥70 patients for metabolic surgery.","Kachmar M","2025","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent07","retrospective comparison of GLP-1RA monotherapy, combined medications and lifestyle before metabolic surgery; weight loss only",1],["R0007367","Efficacy and safety of tirzepatide in patients with type 2 diabetes mellitus: A bayesian network meta-analysis.","Guan R","2022","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent07","Bayesian network meta-analysis of RCTs of tirzepatide vs GLP-1RA, insulin or placebo in type 2 diabetes",1],["R0007426","Once-weekly 2.4 mg Semaglutide for Weight Management in Obesity: A Game Changer?","Colin IM","2022","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent07","narrative review of the semaglutide 2.4 mg STEP programme in obesity",1],["R0007495","Histological concordance of medial arterial calcification between tibial and peroneal arteries in advanced peripheral arterial disease.","Adler S","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent07","histology pilot of arterial calcification in amputated limbs; GLP-1RA use only recorded as a clinical variable",1],["R0007551","Meeting the Challenge of Virtual Diabetes Care: A Consensus Viewpoint on the Positioning and Value of Oral Semaglutide in Routine Clinical Practice.","Evans M","2022","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent07","consensus viewpoint on positioning oral semaglutide in virtual diabetes care",1],["R0007625","Is there a role for glucagon-like peptide-1 receptor agonists in the treatment of male infertility?","Cannarella R","2021","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent07","commentary on potential role of GLP-1RA in male infertility without primary data",1],["R0007706","GLP-1 Receptor Agonists and Suicide Risk in Adults With Chronic Pain: A New User Cohort Across Multi-System EHR data","Verma A",null,"include_harms",null,"conference_abstract",null,"O35A","abstract_only","high","first","opus-5.5-agent07","abstract of TriNetX new user cohort of GLP-1RA vs other anti obesity drugs in chronic pain; suicidal ideation and attempt",1],["R0006823","Genetic Assessment of Oesophageal Safety of GLP-1 and GIP Receptor Perturbation: A Drug-Target Mendelian Randomisation Study.","Lee H","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent01","drug target Mendelian randomization using genetic proxies of GLP-1 and GIP receptor expression; no drug exposure studied",1],["R0006896","Sociodemographic disparities in semaglutide and tirzepatide prescription for obesity treatment.","Le MT","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent01","claims study of disparities in semaglutide and tirzepatide prescribing; prescribing study without exposure outcome comparison",1],["R0006955","Efficacy and safety of canagliflozin as add-on therapy to a glucagon-like peptide-1 receptor agonist in Japanese patients with type 2 diabetes mellitus: A 52-week, open-label, phase IV study.","Harashima SI","2018","inventory_only","N1","primary_report",null,null,null,"high","first","opus-5.5-agent01","single arm open label phase IV study of canagliflozin added to liraglutide in Japanese type 2 diabetes",1],["R0007024","A Review on the Efficacy and Safety of Oral Semaglutide.","Niman S","2021","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent01","narrative review of oral semaglutide PIONEER trial results without systematic methods",1],["R0007101","Do GLP-1 Receptor Agonists Increase the Risk of Breast Cancer? A Systematic Review and Meta-analysis.","Piccoli GF","2021","include_review",null,"systematic_review",null,null,"abstract_only","high","first","opus-5.5-agent01","abstract of systematic review and meta-analysis of GLP-1 RA RCTs on breast neoplasms, four databases searched",1],["R0007154","The Effect of Tirzepatide on Weight, Lipid Metabolism and Blood Pressure in Overweight/Obese Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis.","Lv X","2024","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent01","registered meta-analysis of tirzepatide RCTs on weight, lipids and blood pressure in type 2 diabetes, four databases searched",1],["R0007216","Impact of Digital Engagement on Weight Loss Outcomes in Obesity Management Among Individuals Using GLP-1 and Dual GLP-1/GIP Receptor Agonist Therapy: Retrospective Cohort Service Evaluation Study.","Johnson H","2025","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent01","retrospective comparison of engaged versus nonengaged digital program users all on semaglutide or tirzepatide; weight outcomes only",1],["R0007279","Gastrointestinal disorders potentially associated with Semaglutide: an analysis from the Eudravigilance Database.","Cabral Lopes A","2023","inventory_only","N5","other",null,null,null,"high","first","opus-5.5-agent01","Eudravigilance spontaneous report analysis of semaglutide gastrointestinal adverse reactions",1],["R0007854","Analysis of long noncoding RNA-associated competing endogenous RNA network in glucagon-like peptide-1 receptor agonist-mediated protection in β cells.","Cui LJ","2020","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent12","in vitro microarray study of rat INS-1 beta cells treated with geniposide",1],["R0007991","Effects of CT-388, a once-weekly signaling-biased dual GLP-1/GIP receptor agonist, on weight loss and glycemic control in preclinical models and participants with obesity.","Chakravarthy MV","2026","include_nma",null,"primary_report","P02",null,"mechanistic","high","first","opus-5.5-agent12","phase 1 placebo controlled RCT of CT-388 in obesity with preclinical work, reports weight change and adverse events",1],["R0008057","Effects of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12-Month Treatment.","Ikonomidis I","2020","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent12","RCT of insulin, liraglutide, empagliflozin or liraglutide plus empagliflozin added to metformin in T2D, vascular outcomes and HbA1c",1],["R0008139","Liraglutide Effectiveness in Type 2 Diabetes: Insights from a Real-World Cohort of Portuguese Patients.","Silva-Nunes J","2022","inventory_only","N5","primary_report","P01",null,null,"high","first","opus-5.5-agent12","retrospective multicenter single drug cohort of liraglutide users, before and after HbA1c and weight",1],["R0008230","2024 UPDATE: the Brazilian Diabetes Society position on the management of metabolic dysfunction-associated steatotic liver disease (MASLD) in people with prediabetes or type 2 diabetes.","Godoy-Matos AF","2024","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent12","Brazilian Diabetes Society guideline update on MASLD management",1],["R0008394","Abstract 25: Glycemic variability of oral semaglutide versus empagliflozin: A post hoc analysis of PIONEER 2",null,"2022","include_nma",null,"conference_abstract","P01",null,"abstract_only","high","first","opus-5.5-agent12","conference abstract of post hoc glycemic variability analysis of PIONEER 2 RCT oral semaglutide vs empagliflozin",1],["R0006815","Agent- and Dose-Specific Intestinal Obstruction Safety of GLP-1 Receptor Agonists and SGLT2 Inhibitors: A Network Meta-Analysis of Randomized Trials.","Chen JJ","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent18","registered NMA of RCTs on intestinal obstruction with individual GLP-1 RAs and SGLT2i by dose; eight databases",1],["R0006883","GLP-1 agonist, semaglutide use in acute pulmonary embolism recovery: a four-week proof-of-concept study including proteomic profiling.","Samaranayake CB","2026","inventory_only","N2","primary_report",null,null,null,"high","first","opus-5.5-agent18","nonrandomized clinician allocated pilot of semaglutide added to anticoagulation in acute PE; proteomic and imaging markers only; alternative N6",1],["R0006946","Long-Term Cost-Effectiveness of Subcutaneous Once-Weekly Semaglutide Versus Polyethylene Glycol Loxenatide for Treatment of Type 2 Diabetes Mellitus in China.","Liu L","2023","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent18","cost effectiveness modeling of semaglutide vs PEG-loxenatide in China using a diabetes cohort model",1],["R0007017","Efficacy and Safety of Escalating the Dose of Oral Semaglutide from 7 to 14 mg: A Single-Center, Retrospective Observational Study.","Sato G","2024","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent18","single center retrospective cohort of oral semaglutide escalation 7 to 14 mg; pre post HbA1c, no comparator group",1],["R0007085","GLP-1 and Dual GLP-1/GIP Receptor Agonists in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Systematic Review and Meta-Analysis.","Ahmed M","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent18","research letter reporting PRISMA meta-analysis of GLP-1 and dual agonist RCTs in HFpEF; PubMed, Embase, Cochrane searched",1],["R0007147","Liraglutide, a glucagon-like peptide 1 receptor agonist, exerts analgesic, anti-inflammatory and anti-degradative actions in osteoarthritis.","Meurot C","2022","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent18","mouse osteoarthritis model and in vitro cell work with liraglutide; human tissue only ex vivo",1],["R0007207","GIP in Cardiovascular and Kidney Disease: From Physiology to Pharmacology.","De Fano M","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent18","narrative review of GIP physiology and tirzepatide cardiorenal trial evidence",1],["R0007795","Prescription Fills Among Patients With Type 2 Diabetes After Hospitalization for Acute Coronary Syndrome.","Kelsey MD","2024","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent14","Medicare study of cardiovascular and glucose lowering prescription fill patterns after ACS, utilization only",1],["R0007864","SGLT2is vs. GLP1RAs Reduce Cardiovascular and All-Cause Mortality.","Qiu M","2021","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent14","PROSPERO registered meta-analysis of matched cohort studies SGLT2i vs GLP-1 RA, PubMed and Embase searched",1],["R0007926","Improvement in treatment satisfaction after switching from liraglutide to dulaglutide in patients with type 2 diabetes: A randomized controlled trial.","Takase T","2019","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent14","12 week open label RCT continuing liraglutide vs switching to dulaglutide in Japanese T2D",1],["R0007999","Association between use of liraglutide and liver fibrosis in patients with type 2 diabetes.","Tan Y","2022","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent14","prospective cohort liraglutide users vs nonusers in T2D, liver fibrosis scores only",1],["R0008061","Glucagon-like peptide-1 receptor analog use is associated with reduced thromboembolic events compared with dipeptidyl peptidase-4 inhibitors in rheumatoid arthritis patients: A global retrospective cohort study.","Wang Q","2025","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent14","TriNetX cohort GLP-1 RA vs DPP-4i in rheumatoid arthritis with T2D, thromboembolic events only",1],["R0008154","Therapeutic landscape evolution for steatotic liver disease: from lifestyle interventions to precision pharmacotherapy.","Bong SHS","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent14","narrative review of therapies for steatotic liver disease",1],["R0008236","The Effectiveness and Safety of Exenatide Versus Metformin in Patients with Polycystic Ovary Syndrome: A Meta-Analysis of Randomized Controlled Trials.","Ye ZR","2023","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent14","PROSPERO registered meta-analysis of RCTs of exenatide vs metformin in PCOS, six databases searched",1],["R0010217","Effects of Liraglutide on Myocardial Function After Cardiac Surgery: A Secondary Analysis of the Randomised Controlled GLOBE Trial.","Hulst AH","2020","include_nma",null,"secondary_report","P99",null,null,"high","first","opus-5.5-agent05","prespecified secondary analysis of GLOBE RCT of perioperative liraglutide versus placebo in cardiac surgery patients; P99 surgical population",1],["R0010290","Effectiveness, treatment durability, and treatment costs of canagliflozin and glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes in the USA.","Singhal M","2019","inventory_only","N6","other",null,null,null,"high","first","opus-5.5-agent05","claims cohort canagliflozin versus GLP-1 RA on HbA1c, durability and costs; no listed harm",1],["R0010392","Study Design and Baseline Characteristics of Patients with T2DM in the Post-marketing Safety Study of Dulaglutide in China (TRUST-CHN).","Guo L","2022","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent05","design and baseline characteristics of single arm dulaglutide postmarketing safety study in China; no outcome results",1],["R0010608","Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide 1 mg Versus Liraglutide 1.8 mg: A Health Economic Analysis in the UK.","Evans M","2023","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent05","Core Diabetes Model cost effectiveness analysis of semaglutide versus liraglutide in the UK",1],["R0010854","Type 2 diabetes pharmacotherapy trends in high-risk subgroups.","Bae J","2022","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent05","claims based trends in diabetes drug utilization across risk subgroups; no exposure outcome comparison",1],["R0007964","Impact of Simultaneous Versus Sequential Initiation of Basal Insulin and Glucagon-like Peptide-1 Receptor Agonists on HbA1c in Type 2 Diabetes: A Retrospective Observational Study.","Peng XV","2020","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent03","retrospective cohorts comparing timing of GLP-1 RA start with basal insulin; HbA1c outcomes only",1],["R0008025","Exenatide as an adjunct to nicotine patch for smoking cessation and prevention of postcessation weight gain among treatment-seeking smokers with pre-diabetes and/or overweight: study protocol for a randomised, placebo-controlled clinical trial.","Yammine L","2023","inventory_only","N8","protocol_or_design","P14B",null,null,"high","first","opus-5.5-agent03","protocol of RCT of exenatide vs placebo with nicotine patch for smoking cessation; no results",1],["R0008086","Effects of Semaglutide and Empagliflozin on Inflammatory Markers in Patients with Type 2 Diabetes.","Reppo I","2023","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent03","nonrandomized prospective comparison semaglutide vs empagliflozin in T2D; inflammatory markers only",1],["R0008184","Effect of GLP-1 RA and SGLT2I on Biomarkers of Oxidative Stress in T2DM: A Systematic Review and Meta-analysis.","Wei H","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent03","meta-analysis of RCTs of GLP-1 RA and SGLT2i on oxidative stress markers, four databases searched",1],["R0008359","The dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes.","Wilson JM","2020","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent03","post hoc biomarker analysis of phase 2b RCT of tirzepatide vs dulaglutide vs placebo in T2D",1],["R0008426","Association between use of novel glucose-lowering drugs and COVID-19 hospitalization and death in patients with type 2 diabetes: a nationwide registry analysis.","Ferrannini G","2022","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent03","Swedish registry matched cohort of GLP-1 RA users vs nonusers; COVID-19 hospitalization and death only",1],["R0008975","A Relative Cost of Control Analysis of IDegLira versus Other Forms of Basal Insulin Intensification in Mexico.","Garnica-Cuellar JC","2023","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent04","cost of control economic analysis of IDegLira vs other insulin intensification using trial inputs",1],["R0009037","GLP-1 Receptor Analogs: Evidence Linking to Effect on Metabolic and Reproductive Functions in Patients with PCOS and Obesity.","Celik O","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent04","PRISMA systematic review of four databases on GLP-1 RA in PCOS with obesity, narrative synthesis of metabolic and reproductive effects",1],["R0009121","Semaglutide vs tirzepatide in patients with obesity and HFpEF: a report from a global federated research network.","Monzo L","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent04","TriNetX matched cohort semaglutide vs tirzepatide in obesity with HFpEF, death and HF hospitalization only",1],["R0009198","Increased vision impairment reports linked to semaglutide: analysis of FDA adverse event data.","Massy M","2025","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent04","FAERS disproportionality analysis of vision impairment reports with semaglutide vs other drugs",1],["R0009302","A meta-analysis of the effects of glucagon-like-peptide 1 receptor agonist (GLP1-RA) in nonalcoholic fatty liver disease (NAFLD) with type 2 diabetes (T2D).","Ghosal S","2021","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent04","registered meta-analysis of RCTs of GLP-1 RA vs control in NAFLD with type 2 diabetes",1],["R0009502","Impact of Semaglutide on fat mass, lean mass and muscle function in patients with obesity: The SEMALEAN study.","Alissou M","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent04","SEMALEAN prospective single group of semaglutide 2.4 mg users with body composition change, no comparison group",1],["R0009590","Pharmacovigilance of semaglutide: A descriptive analysis of WHO-VigiAccess reports.","Alorfi NM","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent04","descriptive VigiAccess analysis of semaglutide adverse reaction reports",1],["R0007385","SGLT2 Inhibitors and GLP-1 Receptor Agonists in PAD: A State-of-the-Art Review.","Caturano A","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent13","self described narrative review of SGLT2 inhibitors and GLP-1 agonists in peripheral artery disease",1],["R0008517","Cardiorenal outcomes of weight loss interventions in people with CKD and type 2 diabetes.","Wilkinson TJ","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent06","TriNetX matched cohorts of semaglutide, tirzepatide or bariatric surgery versus DPP-4 inhibitor in CKD with T2D; ESRD, MI, stroke, death only",1],["R0007462","Tirzepatide and cardiometabolic parameters in obesity: Summary of current evidence.","Sattar N","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent13","narrative review of tirzepatide effects on cardiometabolic parameters",1],["R0007507","DA5-CH and Semaglutide Protect against Neurodegeneration and Reduce α-Synuclein Levels in the 6-OHDA Parkinson's Disease Rat Model.","Zhang L","2022","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent13","semaglutide and dual agonist tested only in a 6-OHDA rat model of Parkinson disease",1],["R0007654","GLP-1 Agonists in Cardiovascular Diseases: Mechanisms, Clinical Evidence, and Emerging Therapies.","Yang HM","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent13","narrative review of GLP-1 agonist mechanisms and cardiovascular evidence without systematic methods",1],["R0007722","The new bridge to hernia surgery: achieving preoperative weight optimization with GLP-1 receptor agonists for abdominal wall hernia repair.","Spurzem GJ","2025","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent13","single center retrospective series of GLP-1 use before hernia repair without comparison group",1],["R0007790","Oral TIX100 protects against obesity-associated glucose intolerance and diet-induced adiposity.","Jo S","2025","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent13","mouse study of TXNIP inhibitor TIX100, no human participants",1],["R0007857","Weight loss maintenance after tirzepatide cessation in people with overweight/obesity: a real-world follow-up of the phase 3 SURMOUNT-CN trial.","Chen C","2025","include_nma",null,"secondary_report","P02",null,null,"high","first","opus-5.5-agent13","off treatment follow-up of SURMOUNT-CN analyzed by randomized tirzepatide 10 or 15 mg vs placebo groups",1],["R0008585","Emerging role of GLP-1 agonists in cardio-metabolic therapy - Focus on Semaglutide.","Odigwe C","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent06","narrative review of semaglutide in cardiometabolic therapy",1],["R0008666","Determining whether the effect of liraglutide on non-alcoholic fatty liver disease depends on reductions in the body mass index.","Shiomi M","2020","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent06","retrospective single group study of liraglutide in T2D with NAFLD stratified by BMI change; no comparison group",1],["R0008740","Shifts in Incident Glucose Lowering Drug Initiation in Type 2 Diabetes From 2014 to 2024: A Population-Based Study.","Hamblin PS","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent06","Australian dispensing data study of incident glucose lowering drug initiation trends; no exposure outcome comparison",1],["R0008810","Effect of Glucagon-like peptide-1 agonist (liriglutide) on weight and glycemic control among adults with type 2 diabetes mellitus attending primary care center at security forces hospital in Riyadh, Saudi Arabia.","Alanazi NK","2020","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent06","retrospective chart review of liraglutide users with pre post BMI and HbA1c; single group, not randomized",1],["R0008905","Adherence to antihyperglycemic medications and glucagon-like peptide 1-receptor agonists in type 2 diabetes: clinical consequences and strategies for improvement.","Giorgino F","2018","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent06","narrative review of adherence to antihyperglycemic medications and GLP-1 RAs",1],["R0008979","Cost-Effectiveness of Pharmacologic Therapies for Metabolic Dysfunction-Associated Steatohepatitis With Significant Fibrosis in the United States.","Abdeen AA","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent06","Markov cost-effectiveness model of resmetirom, semaglutide and tirzepatide for MASH",1],["R0009042","Approved Anti-Obesity Medications in 2022 KSSO Guidelines and the Promise of Phase 3 Clinical Trials: Anti-Obesity Drugs in the Sky and on the Horizon.","Jeon E","2023","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent06","narrative review of approved and pipeline anti-obesity medications per Korean guidelines",1],["R0007947","Meta-analysis assessing the effectiveness of SGLT2i+GLP1RA combination therapy versus monotherapy on cardiovascular and cerebrovascular outcomes in diabetic patients.","Du L","2022","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent20","opinion article containing PRISMA meta-analysis of SGLT2i plus GLP-1 RA vs monotherapy on CV outcomes, three databases searched",1],["R0008014","Multi-target-directed drugs: new additions in 2025 and post-marketing safety surveillance of drugs marketed in 2022-2024.","Ryszkiewicz P","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent20","narrative review of multi target drugs and their pharmacovigilance literature",1],["R0008074","Epidemiological, Pathophysiological, and Clinical Considerations on the Interplay between Thyroid Disorders and Type 2 Diabetes Mellitus.","Grigoriadis G","2023","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent20","narrative review of thyroid disorders and T2D interplay",1],["R0008264","Safety and efficacy of switching from dulaglutide to tirzepatide across clinically relevant baseline characteristics in participants with T2D: subgroup analysis of SURPASS-SWITCH.","Violante-Ortiz R","2026","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent20","prespecified subgroup analysis of randomized SURPASS-SWITCH trial, switch to tirzepatide vs escalate dulaglutide",1],["R0008494","Findings Interpretation Concerns Regarding the Emulated Target Trial of SGLT2 Inhibitors vs GLP-1 Receptor Agonists in Psoriatic Arthritis [Response to Letter].","Yen FS","2026","inventory_only","N9","ancillary",null,null,null,"high","first","opus-5.5-agent20","authors reply to letter on target trial emulation of SGLT2i vs GLP-1 RA in psoriatic arthritis",1],["R0005587","Real-World Treatment Patterns according to Clinical Practice Guidelines in Patients with Type 2 Diabetes Mellitus and Established Cardiovascular Disease in Korea: Multicenter, Retrospective, Observational Study.","Yang YS","2024","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent15","multicenter retrospective study of SGLT2i and GLP-1 RA prescribing rates after cardiovascular events; utilization only, no exposure outcome comparison",1],["R0005640","Weight loss in people with type 1 diabetes over 12 months: Real-world data comparing tirzepatide, semaglutide and liraglutide.","Al Ozairi E","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent15","nonrandomized real world comparison of tirzepatide, semaglutide, liraglutide and usual care in type 1 diabetes; weight, HbA1c, DKA only",1],["R0005715","Cardiovascular risk associated with glucagon-like peptide-1 receptor agonists versus other conventional glucose-lowering drugs in patients with type-2 diabetes: protocol for a nationwide observational comparative study in routine care.","Danchin N","2025","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent15","protocol of French SNDS comparative cohort of GLP-1 RA versus other glucose lowering drugs on cardiovascular outcomes; no results",1],["R0005817","The impact of sodium glucose co-transporter 2 inhibitors and glucagon-like peptide 1 receptor agonists on insulin utilisation and costs in Australia: a national retrospective observational cross-sectional study.","Hamblin PS","2024","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent15","national insulin utilization and cost trend analysis in Australia; no individual GLP-1 RA exposure comparison",1],["R0005898","Safety and Efficacy of Sodium-Glucose Transport Protein 2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Diabetic Kidney Transplant Recipients: Synthesis of Evidence.","Bellos I","2024","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent15","systematic review and meta-analysis of SGLT2i and GLP-1 RA studies in kidney transplant recipients; five databases searched",1],["R0006020","Berberine as a multi-target therapeutic agent for obesity: from pharmacological mechanisms to clinical evidence.","Kong Y","2025","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent15","narrative review of berberine for obesity; GLP-1 RAs mentioned only as context",1],["R0006265","The effect of GLP-1RA exenatide on Idiopathic Intracranial Hypertension: Randomised Clinical Trial","Mitchell JL","2022","include_nma",null,"primary_report","P99",null,null,"high","first","opus-5.5-agent19","double blind placebo controlled RCT of exenatide in women with idiopathic intracranial hypertension; P99 condition, intracranial pressure primary",1],["R0006355","Risk of Fracture With Dipeptidyl Peptidase-4 Inhibitors, Glucagon-like Peptide-1 Receptor Agonists, or Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Network Meta-analysis Combining 177 Randomized Controlled Trials With a Median Follow-Up of 26 weeks.","Chai S","2022","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent19","network meta-analysis of RCTs of DPP-4i, GLP-1 RA, SGLT2i vs placebo or other drugs on fracture; Medline Embase Cochrane searched",1],["R0006420","Durable Effects of iGlarLixi Up to 52 Weeks in Type 2 Diabetes: The LixiLan-G Extension Study.","Blonde L","2021","inventory_only","N1","extension",null,null,null,"high","first","opus-5.5-agent19","single arm 26 week extension of LixiLan-G iGlarLixi arm only; randomized comparison not kept",1],["R0006566","The Effect of Glucagon-Like Peptide 1 Receptor Agonists on Weight Loss in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison Meta-Analysis.","Potts JE","2015","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent19","mixed treatment comparison meta-analysis of RCTs of GLP-1 RA vs comparators on weight in type 2 diabetes; Medline Embase searched",1],["R0006623","Impact of Liraglutide to Semaglutide Conversion on Glycemic Control and Cost Savings at a Veterans Affairs Medical Center.","Hardin M","2023","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent19","retrospective chart review of veterans switched from liraglutide to semaglutide, before and after HbA1c and cost; no comparison group",1],["R0006750","Comparison of Safety Profile of Semaglutide, Tirzepatide, and Liraglutide in Obese Patients: FAERS Database Investigation",null,null,"inventory_only","N5","conference_abstract",null,null,"abstract_only","high","first","opus-5.5-agent19","FAERS comparison of adverse event reports for semaglutide, tirzepatide, liraglutide in obesity; spontaneous reports; abstract",1],["R0006813","Safety and Efficacy of Efpeglenatide in Patients With Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials.","Escobar J","2023","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent17","PRISMA meta-analysis of efpeglenatide RCTs in type 2 diabetes, Web of Science, PubMed, Scopus searched",1],["R0006882","Optimizing Obesity Management With GLP-1 Agonist Medication Through Mobile Health Technology, Nutrition Therapy, and Progressive Strength Training: A Retrospective Program Review.","Edens ES","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent17","retrospective chart review of a lifestyle program for patients on GLP-1 RAs without comparison group",1],["R0007015","Efficacy and Safety of Dual and Triple Glucagon-Like Peptide-1-Based Polyagonists in Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis: A Systematic Review and Meta-Analysis.","Santos Solis R","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent17","meta-analysis of placebo controlled RCTs of dual and triple GLP-1 based agonists in MASLD or MASH, four sources searched",1],["R0007077","Effects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT trial.","Borlaug BA","2025","include_nma",null,"secondary_report","P07A",null,null,"high","first","opus-5.5-agent17","mechanistic secondary analysis of SUMMIT RCT of tirzepatide versus placebo in HFpEF with obesity; blood pressure, kidney function",1],["R0007146","Effects and plasma proteomic analysis of GLP-1RA versus CPA/EE, in combination with metformin, on overweight PCOS women: a randomized controlled trial.","Liao M","2024","include_nma",null,"primary_report","P12",null,null,"high","first","opus-5.5-agent17","open label RCT by random number table of liraglutide plus metformin versus cyproterone ethinylestradiol plus metformin in overweight PCOS",1],["R0007203","Translating iGlarLixi Evidence for the Management of Frequent Clinical Scenarios in Type 2 Diabetes.","Skolnik N","2021","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent17","narrative review of iGlarLixi evidence through clinical scenarios",1],["R0007261","Incretin-Based Therapies in Obesity-Related Obstructive Sleep Apnea: A Narrative Review of Evidence Tiers and Mechanistic Plausibility.","Zhang X","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent17","self described narrative non systematic review of incretin therapy in obstructive sleep apnea",1],["R0006303","Glycemic Control, Weight Management, Cardiovascular Safety, and Cost-Effectiveness of Semaglutide for Patients with Type 2 Diabetes Mellitus: A Rapid Review and Meta-analysis of Real-World Studies.","Wang S","2024","include_review",null,"systematic_review",null,null,"umbrella_review","high","first","opus-5.5-agent10","PROSPERO registered rapid review of semaglutide meta-analyses plus meta-analysis of real world cohorts; four databases searched",1],["R0006529","Efficacy of Semaglutide in a Subcutaneous and an Oral Formulation.","Meier JJ","2021","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent10","narrative review of SUSTAIN and PIONEER semaglutide trial results; no systematic search",1],["R0006601","Real-World Patterns of Basal Insulin Use with Other Diabetes Medications Among People with Type 2 Diabetes Between 2014 and 2020.","Schapiro D","2023","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent10","claims study of basal insulin initiation and diabetes drug utilization patterns; no exposure outcome comparison",1],["R0006657","Larger effect size in composite kidney outcomes than in major cardiovascular events associated with sodium-glucose cotransporter-2 (SGLT2) inhibitors compared with glucagon-like peptide-1 receptor agonists (GLP-1RAs): A pooled analysis of type 2 diabetes trials.","Diallo A","2023","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent10","PROSPERO registered meta-analysis of placebo controlled SGLT2i and GLP-1 RA outcome trials; MEDLINE searched",1],["R0006718","Cardiovascular and mortality benefits of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide 1 receptor agonists as third-step glucose-lowering medicine in patients with type 2 diabetes: a retrospective cohort analysis.","McCormick TA","2024","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent10","Kaiser active comparator new user cohort third step GLP-1 RA or SGLT2i versus DPP-4i, insulin, TZD; mortality, MACE, HF only",1],["R0006757","Risk of stroke and retinopathy during GLP-1 receptor agonist cardiovascular outcome trials: An eight RCTs meta-analysis.","Wei J","2022","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent02","registered meta-analysis of GLP-1 RA cardiovascular outcome trials on stroke and retinopathy; four databases searched",1],["R0006788","The Possible Effect of the Long-Term Use of Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) on Hba1c and Lipid Profile in Type 2 Diabetes Mellitus: A Retrospective Study in KAUH, Jeddah, Saudi Arabia.","Ajabnoor GMA","2023","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent10","retrospective series of GLP-1 RA users split by statin use; pre post HbA1c and lipids, no unexposed group",1],["R0006834","The therapeutic effects of glucagon-like peptide-1 receptor agonists and metformin on polycystic ovary syndrome: A protocol for systematic review and meta-analysis.","Ma R","2021","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent02","systematic review and meta-analysis of RCTs of GLP-1 RA vs metformin in PCOS; titled protocol but reports pooled results",1],["R0006897","Glucagon-Like Peptide 1 Receptor Agonists and 13 Obesity-Associated Cancers in Patients With Type 2 Diabetes.","Wang L","2024","include_harms",null,"primary_report",null,"O38; O32B",null,"high","first","opus-5.5-agent02","TriNetX cohort GLP-1 RA vs insulin or metformin on 13 obesity associated cancers, reporting pancreatic and thyroid cancer",1],["R0006956","Association of Prescription Co-payment With Adherence to Glucagon-Like Peptide-1 Receptor Agonist and Sodium-Glucose Cotransporter-2 Inhibitor Therapies in Patients With Heart Failure and Diabetes.","Essien UR","2023","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent02","claims cohort of co-payment level and adherence to GLP-1 RA or SGLT2 inhibitor; utilization without exposure comparison",1],["R0007026","Insulin DEgludec/LIraglutide versus multiple daily insulin injections in the transition from hospital to outpatient management assessed by continuous glucose monitoring: the DELI transition trial.","Gómez-Medina AM","2025","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent02","open label RCT of IDegLira vs multiple daily insulin injections after hospital discharge in type 2 diabetes",1],["R0007103","Mechanisms and possible hepatoprotective effects of glucagon-like peptide-1 receptor agonists and other incretin receptor agonists in non-alcoholic fatty liver disease.","Targher G","2023","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent02","narrative review of incretin receptor agonist mechanisms and trials in NAFLD",1],["R0007155","Glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes: Past, present, and future.","Kalra S","2016","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent02","narrative review of GLP-1 RA class in type 2 diabetes based on PubMed search without eligibility criteria",1],["R0007219","Comparative dementia risk with GLP1 receptor agonists, SGLT2 inhibitors, or DPP4 inhibitors: a population-based cohort study.","Wu CY","2025","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent02","CPRD active comparator new user emulation of GLP-1 RA vs SGLT2 inhibitor or DPP-4 inhibitor; dementia outcome only",1],["R0010958","Preadmission use of antidiabetic medications and mortality among patients with COVID-19 having type 2 diabetes: A meta-analysis.","Nguyen NN","2022","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent05","meta-analysis of preadmission antidiabetic drugs including GLP-1 RA versus nonuse on COVID-19 mortality, four named databases",1],["R0011038","Glucagon-like peptide-1 agonists' effects on glycemic control, weight loss, and beta cells function in type 1 diabetes.","Mirghani HO","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent05","meta-analysis of GLP-1 RA versus control in type 1 diabetes on HbA1c and weight, named databases and criteria",1],["R0011109","Need for and design of a trial to test efficacy of weight loss interventions for cancer prevention: an international consensus using expert nominal group and Delphi methods.","Harris M","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent05","expert Delphi consensus on design of a weight loss cancer prevention trial; no primary data on drug effects",1],["R0011218","Body weight management and safety with efpeglenatide in adults without diabetes: A phase II randomized study.","Pratley RE","2019","include_nma",null,"primary_report","P02",null,null,"high","first","opus-5.5-agent05","phase 2 placebo controlled RCT of four efpeglenatide regimens in adults with obesity without diabetes, 20 weeks",1],["R0011424","Similar weight loss with semaglutide regardless of diabetes and cardiometabolic risk parameters in individuals with metabolic dysfunction-associated steatotic liver disease: Post hoc analysis of three randomised controlled trials.","Armstrong MJ","2025","include_nma",null,"pooled_analysis","P09",null,null,"high","first","opus-5.5-agent05","post hoc pooled analysis of three placebo controlled semaglutide RCTs in MASLD or MASH on weight change by diabetes status",1],["R0011623","CVOT Summit Report 2023: new cardiovascular, kidney, and metabolic outcomes.","Schnell O","2024","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent05","congress summit report summarizing outcome trials; no primary data",1],["R0005226","The Impact of Antidiabetic Therapy on Liver Injury, Steatosis, and Fibrosis in Patients with Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease.","Albai O","2025","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent11","prospective observational comparison of antidiabetic drug groups in diabetes with MASLD; steatosis, fibrosis and metabolic measures only",1],["R0005293","Semaglutide normalizes increased cardiomyocyte calcium transients in a rat model of high fat diet-induced obesity.","Sequeira V","2025","exclude","E1","primary_report",null,null,null,"high","first","opus-5.5-agent11","rat obesity model randomized to semaglutide or vehicle; cardiomyocyte experiments only",1],["R0005380","Triple Agonism Based Therapies for Obesity.","Goldney J","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent11","narrative review of triple agonist therapies for obesity",1],["R0005458","Greater lean-body-mass decline with tirzepatide than semaglutide in routine care, revealed by body-composition digital phenotyping","Murugadoss K","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent11","EHR cohort comparing tirzepatide and semaglutide users on lean body mass change; no listed harms outcome",1],["R0005523","Prospects of late-stage development agents in the treatment of metabolic dysfunction-associated steatohepatitis.","Lee B","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent11","narrative review of late stage MASH drug development",1],["R0005581","Retrospective Study of IDegLira, a New Fixed-Ratio Combination, in Japanese Patients With Type 2 Diabetes Mellitus: Analysis of Background Factors Affecting Effectiveness After 6 Months of Treatment.","Yamada H","2023","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent11","single center retrospective series of IDegLira initiators; no comparison group",1],["R0005632","Incretins and microvascular complications of diabetes: neuropathy, nephropathy, retinopathy and microangiopathy.","Goldney J","2023","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent11","narrative review of incretin therapies and microvascular complications",1],["R0005694","Comment on Ostrominski et al. Comparative Effectiveness of Tirzepatide Versus Dulaglutide or Semaglutide on Major Cardiovascular Events in Type 2 Diabetes and Cardiovascular Disease: Insights From Two Target-Trial Emulations.","Zhang Y","2026","inventory_only","N9","ancillary",null,null,null,"high","first","opus-5.5-agent11","letter commenting on a tirzepatide target trial emulation study that is itself in scope for inventory",1],["R0008459","Efficacy and Acceptability of Glycemic Control of Glucagon-Like Peptide-1 Receptor Agonists among Type 2 Diabetes: A Systematic Review and Network Meta-Analysis.","Li Z","2016","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent12","registered SR and network meta-analysis of GLP-1RA RCTs vs placebo or other drugs on hypoglycemia and glycemic control in T2D",1],["R0008535","Outcomes of Unicompartmental Knee Arthroplasty in Patients Receiving Glucagon-like Peptide 1 Agonist Therapy: A Matched Cohort Study.","Heo KY","2026","include_harms",null,"primary_report","P01; P02","O36A",null,"high","first","opus-5.5-agent12","claims matched cohort of GLP-1RA users vs controls undergoing knee arthroplasty, outcomes include pulmonary aspiration",1],["R0008617","Retatrutide-Associated Improvements in Cardiovascular Risk Biomarkers in Adults With Obesity With or Without Type 2 Diabetes.","Ruotolo G","2026","include_nma",null,"secondary_report","P01; P02",null,null,"high","first","opus-5.5-agent12","post hoc biomarker analysis of two phase 2 RCTs of retatrutide vs placebo or dulaglutide with and without T2D",1],["R0008690","Liraglutide in Adults With Obesity: A Multicentre, Single-Arm, Post-Marketing Surveillance Study in Taiwan.","Tu ST","2026","inventory_only","N5","primary_report","P02",null,null,"high","first","opus-5.5-agent12","single arm noninterventional post marketing surveillance of liraglutide in adults with obesity in Taiwan",1],["R0008931","Efficacy and safety of liraglutide in type 1 diabetes by baseline characteristics in the ADJUNCT ONE and ADJUNCT TWO randomized controlled trials.","Dejgaard TF","2021","include_nma",null,"secondary_report","P05",null,null,"high","first","opus-5.5-agent12","post hoc subgroup analysis of ADJUNCT ONE and TWO RCTs of liraglutide vs placebo in type 1 diabetes",1],["R0008397","Effect of liraglutide on expression of inflammatory genes in type 2 diabetes.","Zobel EH","2021","include_nma",null,"secondary_report","P01",null,"mechanistic","high","first","opus-5.5-agent14","substudy of 26 week placebo controlled RCT of liraglutide in T2D, inflammatory gene expression in PBMCs",1],["R0008473","Disease-modifying effect, safety and optimal dose of oral semaglutide tablets for patients with Parkinson's disease (MOST-ABLE study): protocol for a randomised, double-blind, placebo-controlled study.","Kimura Y","2025","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent14","protocol of phase 2 placebo controlled RCT of oral semaglutide in Parkinson disease",1],["R0008542","Insulin degludec/liraglutide (IDegLira) for the treatment of type 2 diabetes.","Gough SC","2016","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent14","narrative drug review of insulin degludec/liraglutide fixed ratio combination",1],["R0008694","Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by GLP-1RA treatment: A subgroup analysis from the FIDELIO-DKD trial.","Rossing P","2022","inventory_only","N3","secondary_report","P08A",null,null,"high","first","opus-5.5-agent14","FIDELIO-DKD subgroup analysis by baseline GLP-1 RA use, randomized contrast finerenone vs placebo",1],["R0008853","Glucagon-like peptide-1 receptor agonists compared with basal insulins for the treatment of type 2 diabetes mellitus: a systematic review and meta-analysis.","Singh S","2017","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent14","systematic review and meta-analysis of RCTs of GLP-1 RAs vs basal insulin in T2D, MEDLINE Embase CENTRAL",1],["R0008939","Values, preferences and burden of treatment for the initiation of GLP-1 receptor agonists and SGLT-2 inhibitors in adult patients with type 2 diabetes: a systematic review.","González-González JG","2021","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent14","PROSPERO registered systematic review of patient preferences for GLP-1 RA vs other glucose lowering options",1],["R0007272","GLP-1RA may have varying effects on cardiac structure in patients with ASCVD depending on BMI.","Xu L","2024","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent18","retrospective matched cohort of ASCVD patients with vs without GLP-1 RA; weight and echocardiographic outcomes, no listed harms",1],["R0007399","Beyond Weight Loss: Holistic Impacts of a Digital Weight Management Programme Integrating Tirzepatide.","Sikorska LM","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent18","single arm service evaluation of tirzepatide within a digital weight programme; 12 month pre post outcomes, no comparator",1],["R0007470","Healthcare costs and hospitalizations in US patients with type 2 diabetes and cardiovascular disease: A retrospective database study (OFFSET).","Evans M","2022","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent18","MarketScan cohort GLP-1 RA initiators vs other glucose lowering drugs after CVD admission; costs and hospitalizations only",1],["R0007526","How Does Diabetes Affect Daily Life? A Beyond-A1C Perspective on Unmet Needs.","Gopisetty D","2018","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent18","online survey on daily life burden of diabetes; no GLP-1 RA exposure comparison; stored abstract describes a different review",1],["R0007585","Impact of semaglutide on weight and functional outcomes among obese heart failure patients: a propensity scores matching analysis.","Balata M","2024","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent18","retrospective matched cohort of obese heart failure patients, semaglutide add on vs control; weight, NYHA, walk distance; not randomized",1],["R0007730","Efficacy and Safety of Once-Weekly Semaglutide Versus Once-Daily Sitagliptin as Metformin Add-on in a Korean Population with Type 2 Diabetes.","Lee BW","2024","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent18","post hoc Korean subgroup of randomized trial of semaglutide 0.5 and 1.0 mg vs sitagliptin on metformin",1],["R0007842","[Safety Management of Incretin-Based Obesity Therapy: Expert Consensus on the Use of Semaglutide and Tirzepatide].","Troshina EA","2026","exclude","E3","other",null,null,"non_english","high","first","opus-5.5-agent07","Russian expert consensus on safety management of semaglutide and tirzepatide in obesity",1],["R0007848","The Impact of GLP1 Agonists on Bone Metabolism: A Systematic Review.","Daniilopoulou I","2022","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent08","systematic review of GLP-1 RA and bone metabolism; PubMed, Google Scholar and CENTRAL searched; narrative synthesis of trials",1],["R0007900","The efficacy and safety of novel antidiabetic agents in polycystic ovary syndrome: a network meta-analysis.","Lin J","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent07","PROSPERO registered network meta-analysis of RCTs of SGLT2i, GLP-1RA and DPP-4i in PCOS",1],["R0007907","Liraglutide, a glucagon-like peptide-1 receptor agonist, inhibits bone loss in an animal model of osteoporosis with or without diabetes.","Wu Z","2024","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent08","systematic review and meta-analysis of liraglutide in animal models of osteoporosis only",1],["R0007978","GLP-1 Agonists and Cardiovascular Risk Markers in U.S. Adults: National Health and Nutrition Examination Survey (NHANES) 2011-2018.","Telakeng Tekengne BO","2025","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent07","NHANES cross sectional comparison of cardiovascular risk markers in GLP-1RA users vs nonusers",1],["R0008508","Low-Carbohydrate Nutrition Counseling With Continuous Glucose Monitoring to Improve Metabolic Health Among Veterans With Type 2 Diabetes: Pilot Quality Improvement Initiative Study.","Turner CD","2025","exclude","E2","primary_report",null,null,null,"high","first","opus-5.5-agent03","pre post QI pilot of low carbohydrate counseling with CGM in insulin treated veterans; no GLP-1 RA exposure contrast",1],["R0008114","Effectiveness and Safety of GLP-1 Receptor Agonists in Patients with Type 1 Diabetes.","Almohareb SN","2024","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent07","retrospective single group cohort of GLP-1RA add on in type 1 diabetes with before after outcomes",1],["R0008120","Systematic review and meta-analysis for prevention of cardiovascular complications using GLP-1 receptor agonists and SGLT-2 inhibitors in obese diabetic patients.","Uneda K","2021","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent08","systematic review and network meta-analysis of GLP-1 RA and SGLT2i trials on MACE in obese diabetes subgroups",1],["R0008201","The promise of incretin-based pharmacotherapies for metabolic dysfunction-associated fatty liver disease.","Elangovan H","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent07","narrative literature review of incretin therapies in MAFLD and MASH",1],["R0008203","Factors Associated with Response to SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Veterans with Type 2 Diabetes Mellitus.","Arora G","2025","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent08","VA retrospective comparison of GLP-1 RA versus SGLT2i treatment response; drug specific adverse events only within arms",1],["R0008294","Comparison of the renal outcomes of novel antidiabetic agents in patients with type 2 diabetes with chronic kidney disease: A systematic review and network meta-analysis of randomized controlled trials.","Lin R","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent07","PROSPERO registered network meta-analysis of RCTs of DPP-4i, GLP-1RA and SGLT2i on renal outcomes in T2D with CKD",1],["R0008303","Real-World Comparison of Short-Term Adverse Events, Treatment Persistence, and Efficacy of Semaglutide and Tirzepatide: A Nationwide Multicenter Study.","Hepşen S","2026","include_harms",null,"primary_report",null,"O29",null,"high","first","opus-5.5-agent08","multicenter new user cohort of semaglutide versus tirzepatide in obesity; acute pancreatitis among adverse events; hepatobiliary events also reported",1],["R0008375","A Network Meta-analysis Comparing Exenatide Once Weekly with Other GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus.","Kayaniyil S","2016","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent08","Bayesian network meta-analysis of RCTs comparing exenatide weekly with other GLP-1 RAs on metformin background",1],["R0008577","The Impact and Safety of GLP-1 Agents and Breast Cancer.","Parsons K","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent03","narrative review of obesity, GLP-1 agents and breast cancer without eligibility based synthesis",1],["R0008715","Effect of the GLP-1 receptor agonist semaglutide on metabolic disturbances in clozapine-treated or olanzapine-treated patients with a schizophrenia spectrum disorder: study protocol of a placebo-controlled, randomised clinical trial (SemaPsychiatry).","Sass MR","2023","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent20","protocol of placebo controlled RCT of semaglutide in clozapine or olanzapine treated schizophrenia",1],["R0008729","Real-World Prescribing Patterns of SGLT2 Inhibitors and GLP-1 Receptor Agonists in Older Adults with Type 2 Diabetes and Cardiometabolic Disease.","Alhomoud IS","2025","exclude","E2","primary_report",null,null,null,"high","first","opus-5.5-agent03","cross sectional prescribing pattern study of SGLT2i and GLP-1 RA use in older adults",1],["R0008800","Cardiorenal Protection in Diabetic Kidney Disease.","Lee JF","2021","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent03","narrative review of cardiorenal protection drugs in diabetic kidney disease",1],["R0008867","[Analysis of cardiovascular safety of novel glucose-lowering medications].","Mkrtumyan AM","2019","exclude","E3","other",null,null,"non_english","high","first","opus-5.5-agent20","Russian narrative seminar review of cardiovascular outcome trials of glucose lowering drugs",1],["R0008892","Association of Glucagon-like Peptide 1 Analogs and Agonists Administered for Obesity with Weight Loss and Adverse Events: A Systematic Review and Network Meta-analysis.","Vosoughi K","2021","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent03","systematic review and NMA of RCTs of seven GLP-1 agents for weight loss, MEDLINE, Embase, Scopus searched",1],["R0008956","PHARMACOVIGILANCE SIGNALS OF SEMAGLUTIDE AND OTHER GLP-1 RECEPTOR AGONISTS: AN ANALYSIS OF THE FOOD AND DRUG ADMINISTRATION (FDA) ADVERSE EVENTS REPORTING SYSTEM (FAERS) DATASET",null,"2025","inventory_only","N5","conference_abstract",null,null,"abstract_only","high","first","opus-5.5-agent20","conference abstract of FAERS disproportionality analysis of semaglutide misuse signals",1],["R0008972","Long-Acting Glucagon-Like Peptide-1 Receptor Agonists Suppress Voluntary Alcohol Intake in Male Wistar Rats.","Marty VN","2020","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent03","rat study of liraglutide and semaglutide on alcohol intake; animal only",1],["R0009013","The Preventive Effects of GLP-1 Receptor Agonists and SGLT2 Inhibitors on Cancer Metastasis: A Network Meta-Analysis of 67 Randomized Controlled Trials.","Hsu CW","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent20","PROSPERO registered NMA of 67 RCTs of GLP-1 RAs and SGLT2i on metastatic cancer, eight databases",1],["R0009032","A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults.","McGowan B","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent03","NMA of RCTs of obesity medications incl. semaglutide, liraglutide, tirzepatide; Medline and Embase searched",1],["R0009106","Increased Healthcare Resource Use and Costs After Discontinuation of Liraglutide in Patients with Type 2 Diabetes from a Commercial- and Medicaid-Insured Claims Database.","Uzoigwe C","2022","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent20","claims before and after cohort of liraglutide discontinuers, healthcare use and costs, no comparison group",1],["R0007924","Identification of a pathogenic founder variant in the WFS1 gene that causes Wolfram syndrome in the Druze population.","Halabi I","2025","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent13","case series of five Wolfram syndrome patients, one treated with a GLP-1 agonist",1],["R0008060","Pharmacometabolomic profiles in type 2 diabetic subjects treated with liraglutide or glimepiride.","Jendle J","2021","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent13","post hoc metabolomics analysis of RCT of liraglutide vs glimepiride added to metformin in type 2 diabetes",1],["R0008143","Current Perspectives on GLP-1 Agonists in Contemporary Clinical Practice from Science and Mechanistic Foundations To Optimal Translation.","Abu-Nejim H","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent13","focused narrative review of GLP-1 agonist mechanisms and clinical translation",1],["R0008233","iGlarLixi reduces residual hyperglycemia in Japanese patients with type 2 diabetes uncontrolled on basal insulin: A post-hoc analysis of the LixiLan JP-L trial.","Yabe D","2021","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent13","post hoc analysis of LixiLan JP-L RCT of iGlarLixi vs insulin glargine in Japanese type 2 diabetes",1],["R0008319","Blood phosphatidylethanol measurements indicate GLP-1 receptor stimulation causes delayed decreases in alcohol consumption.","Jensen ME","2025","include_nma",null,"secondary_report","P14A",null,null,"high","first","opus-5.5-agent13","secondary analysis of placebo controlled RCT of exenatide in alcohol use disorder with obesity",1],["R0008395","The first successful desensitization protocol in exenatide allergy: a case report.","Yeğit OO","2023","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent13","case report of two patients desensitized to exenatide allergy",1],["R0008468","Effects of GLP-1 receptor agonists on arrhythmias and its subtypes in patients with type 2 diabetes: A systematic review and meta-analysis.","Wei J","2022","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent13","meta-analysis of GLP-1 agonist cardiovascular outcome RCTs on arrhythmias from four databases",1],["R0007283","evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer’s disease","Cummings JL","2024","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent02","design paper of evoke and evoke plus placebo controlled semaglutide trials in early Alzheimer disease without results",1],["R0007332","Patient-perceived benefits and risks of off-label use of SGLT2 inhibitors and GLP-1 receptor agonists in type 1 diabetes: a structured qualitative assessment.","Edwards K","2023","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent17","chart review with structured telephone interviews on perceived benefits of off label GLP-1 RA or SGLT2 inhibitor in type 1 diabetes; qualitative, no exposure comparison",1],["R0007394","Oral Semaglutide Induces Loss of Body Fat Mass Without Affecting Muscle Mass in Patients With Type 2 Diabetes.","Uchiyama S","2023","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent17","retrospective single group study of oral semaglutide on body composition in Japanese type 2 diabetes",1],["R0007406","Semaglutide slows epigenetic aging in a randomized trial of HIV-associated lipohypertrophy.","Corley MJ","2026","include_nma",null,"secondary_report","P99",null,null,"high","first","opus-5.5-agent02","post hoc epigenetic analysis of placebo controlled RCT of semaglutide in HIV associated lipohypertrophy; P99 HIV lipohypertrophy",1],["R0007536","Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for the management of nonalcoholic fatty liver disease (NAFLD): A systematic review.","Lv X","2020","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent02","systematic review of GLP-1 RA trials in NAFLD with named databases and criteria, narrative synthesis",1],["R0007687","Real-World HbA1c Changes Among Type 2 Diabetes Mellitus Patients Initiating Treatment With a 1.0 Mg Weekly Dose of Semaglutide for Diabetes.","Gronroos NN","2024","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent02","retrospective claims study of HbA1c change after semaglutide 1 mg initiation; single group, no comparator",1],["R0007747","Subpopulation Differences in the Cardiovascular Efficacy of Long-Acting Glucagon-Like Peptide 1 Receptor Agonists in Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis.","He L","2020","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent02","registered systematic review and meta-analysis of long acting GLP-1 RA outcome trials by subpopulation; six databases searched",1],["R0007467","The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Design and Baseline Characteristics.","García-Pérez LE","2021","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent17","design and baseline characteristics paper of the TROPHIES dulaglutide versus liraglutide observational cohort, no outcome results",1],["R0007525","GLP-1 Receptor Agonists: Encouraging Signals for Treating Alcohol Use Disorder.","Lira MC","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent17","editorial perspective on GLP-1 RAs for alcohol use disorder",1],["R0007581","The efficacy and safety of beinaglutide alone or in combination with insulin glargine in Chinese patients with type 2 diabetes mellitus who are inadequately controlled with oral antihyperglycemic therapy: A multicenter, open-label, randomized trial.","Liu X","2023","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent17","open label RCT of beinaglutide versus insulin glargine for 8 weeks then combination in Chinese type 2 diabetes",1],["R0007666","Retinopathy risk factors in patients with type 2 diabetes on liraglutide.","Mahzari MM","2024","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent17","single group retrospective cohort of liraglutide users assessing retinopathy risk factors, no comparison group",1],["R0007728","Insulin glargine/lixisenatide fixed-ratio combination improves glycaemic variability and control without increasing hypoglycaemia.","Aronson R","2019","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent17","post hoc glycemic variability analysis of LixiLan-O and LixiLan-L RCTs comparing iGlarLixi with its components",1],["R0007799","Randomized open-label trial of semaglutide and dapagliflozin in patients with type 2 diabetes of different pathophysiology.","Dwibedi C","2024","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent17","open label RCT of semaglutide versus dapagliflozin in type 2 diabetes subgroups for 6 months",1],["R0009678","Postoperative Weight Loss After Antiobesity Medications and Revision Risk After Joint Replacement.","Xie D","2025","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent04","IMRD cohort of antiobesity drug initiators incl GLP-1 RA after joint replacement, weight loss categories vs revision risk, no listed harm",1],["R0009871","High unmet treatment needs in patients with chronic kidney disease and type 2 diabetes: real-world evidence from a US claims database.","Fried L","2023","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent04","US claims study of drug initiation and discontinuation patterns and outcome rates in CKD with diabetes, no GLP-1 RA exposure comparison",1],["R0009947","Noninsulin-based antihyperglycemic medications in patients with diabetes and COVID-19: A systematic review and meta-analysis.","Nassar M","2023","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent04","systematic review and meta-analysis of four databases on noninsulin glucose lowering drugs incl GLP-1 RA in COVID-19",1],["R0010215","Recent advances in new-onset diabetes mellitus after kidney transplantation.","Montada-Atin T","2021","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent04","narrative review of post transplant diabetes management incl GLP-1 RA",1],["R0010288","Changing Patterns of Antihyperglycaemic Treatment among Patients with Type 2 Diabetes in Hungary between 2015 and 2020-Nationwide Data from a Register-Based Analysis.","Jermendy G","2022","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent04","Hungarian nationwide register analysis of antidiabetic prescribing patterns, drug utilization only",1],["R0007353","Effects of glucagon-like peptide 1 receptor agonists and sodium glucose cotransporter 2 inhibitors on major adverse cardiovascular events in type 2 diabetes by race, ethnicity, and region: A meta-analysis.","Qiu M","2020","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent01","registered meta-analysis of GLP-1 RA and SGLT2i outcome RCTs on MACE by race and region, PubMed and Embase searched",1],["R0007405","Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial.","Wadden TA","2023","include_nma",null,"primary_report","P02",null,null,"high","first","opus-5.5-agent01","SURMOUNT-3 double blind RCT of tirzepatide versus placebo after intensive lifestyle lead in, adults with obesity without diabetes",1],["R0007479","Psychiatric adverse events associated with semaglutide, liraglutide and tirzepatide: a pharmacovigilance analysis of individual case safety reports submitted to the EudraVigilance database.","Tobaiqy M","2024","inventory_only","N5","other",null,null,null,"high","first","opus-5.5-agent01","descriptive analysis of EudraVigilance spontaneous reports of psychiatric events with GLP-1 RAs",1],["R0007531","Patient-Reported Outcomes in People with Type 2 Diabetes Receiving Tirzepatide in the SURPASS Clinical Trial Programme.","Boye KS","2023","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent01","patient reported outcome analyses of SURPASS-1 to 5 RCTs, tirzepatide versus placebo, semaglutide or insulin",1],["R0007685","GLP-1 receptor agonists and cancer: current clinical evidence and translational opportunities for preclinical research.","Valencia-Rincón E","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent01","narrative review of GLP-1 RA cancer evidence and preclinical research",1],["R0007814","Effects of antidiabetic agents on steatosis and fibrosis biomarkers in type 2 diabetes: A real-world data analysis.","Colosimo S","2021","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent01","retrospective cohort switched to DPP-4i, GLP-1 RA or SGLT2i versus maintained therapy; liver biomarker outcomes only",1],["R0007936","RF28 | PSUN182 Risk of Pancreatitis After Glp-1 Receptor Agonist in Individuals With Known History of Pancreatitis",null,"2022","inventory_only","N5","conference_abstract",null,null,"abstract_only","high","first","opus-5.5-agent16","conference abstract of chart review of recurrent pancreatitis among GLP-1RA users with prior pancreatitis, no comparison group",1],["R0008002","Glucagon-like peptide-1 receptor agonists and the risk of cardiovascular events in diabetes patients surviving an acute myocardial infarction.","Trevisan M","2021","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent16","SWEDEHEART registry cohort of GLP-1RA users vs standard care after MI; cardiovascular composite only",1],["R0008064","Association between circulating sex hormone levels and diabetic kidney disease in men and postmenopausal women with type 2 diabetes mellitus.","Shi Y","2025","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent16","cross sectional study of sex hormones and diabetic kidney disease; GLP-1RA use only a covariate",1],["R0008249","Clinical Phenotypes May be Able to Identify Populations With Nonalcoholic Fatty Liver-Spectrum Disease.","Geyer BM","2025","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent16","EHR phenotyping study of NAFLD; GLP-1RA prescription only described, not studied as exposure",1],["R0008328","Real-world use of once-weekly semaglutide in patients with type 2 diabetes: pooled analysis of data from four SURE studies by baseline characteristic subgroups.","Yale JF","2022","inventory_only","N5","pooled_analysis",null,null,null,"high","first","opus-5.5-agent16","pooled analysis of four single arm real world SURE semaglutide studies by baseline subgroups",1],["R0008403","Treatment discontinuation among users of GLP-1 receptor agonists and SGLT2 inhibitors in a national population of individuals with type 2 diabetes.","Lim CE","2025","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent16","Swedish register study describing discontinuation of GLP-1RA and SGLT2i separately; utilization without exposure comparison",1],["R0006820","Semaglutide 2.4 mg in Participants With Metabolic Dysfunction-Associated Steatohepatitis: Baseline Characteristics and Design of the Phase 3 ESSENCE Trial.","Newsome PN","2024","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent19","design and baseline characteristics of ESSENCE phase 3 RCT of semaglutide vs placebo in MASH; no outcome results",1],["R0006886","Risk of Alzheimer's Disease and Alzheimer's Disease‐Related Dementias with liraglutide compared to semaglutide and dulaglutide in veterans with type 2 diabetes: An emulated clinical trial observational study","Sarwal A","2025","inventory_only","N6","conference_abstract",null,null,"abstract_only","high","first","opus-5.5-agent19","VA new user emulation comparing liraglutide, semaglutide, dulaglutide initiators; dementia and death only, no listed harm; abstract",1],["R0006951","Guideline-Recommended Disease-Modifying Therapies for Patients with Cardiorenal Disease: A Call-to-Action Narrative Review.","Wanner C","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent19","call to action narrative review on guideline directed therapy in cardiorenal disease",1],["R0007018","Efficacy and Safety of Injectable Dulaglutide 1.5 mg Among Type 2 Diabetes Patients in Clinics at King Saud Medical City, Riyadh, Saudi Arabia.","Albargawi MS","2024","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent19","retrospective single arm cohort of dulaglutide users in Saudi clinics; before and after outcomes, no comparison group",1],["R0007088","Therapeutic horizons in metabolic dysfunction-associated steatohepatitis.","Newsome PN","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent19","narrative review of drug development for MASH including incretin agonists",1],["R0007213","Prevalence of SGLT2 inhibitor and GLP1 receptor agonist prescriptions in type 2 diabetes patients with and without chronic kidney disease: Analysis of an Australian primary care dataset.","Wallace H","2025","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent19","prevalence of SGLT2i and GLP-1 RA prescriptions by CKD status in Australian primary care; utilization only",1],["R0007273","Semaglutide-eye-catching results.","Cigrovski Berkovic M","2023","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent19","minireview of semaglutide and diabetic retinopathy with practice suggestions; no systematic methods",1],["R0009133","Apitegromab for lean mass preservation during tirzepatide-induced weight loss: a randomized, double-blind, placebo-controlled phase 2 trial.","Pratley RE","2026","inventory_only","N3","primary_report",null,null,null,"high","first","opus-5.5-agent06","EMBRAZE RCT of apitegromab versus placebo with tirzepatide in both arms; randomized contrast does not change the GLP-1 regimen",1],["R0009201","Liver function effects of SGLT2 inhibitor and GLP-1 receptor agonist combination treatment in patients with type 2 diabetes (post hoc analysis of RECAP study).","Tsuriya D","2025","inventory_only","N6","secondary_report",null,null,null,"high","first","opus-5.5-agent06","post hoc of RECAP retrospective cohort comparing GLP-1 RA first versus SGLT2 inhibitor first combination; liver enzymes and FIB-4 only",1],["R0009316","Glucagon-like peptide 1 receptor activation: anti-inflammatory effects in the brain.","Diz-Chaves Y","2024","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent06","narrative review of GLP-1 receptor anti-inflammatory effects in the brain, mainly preclinical",1],["R0009423","A Dual GLP-1/GIP Receptor Agonist Is More Effective than Liraglutide in the A53T Mouse Model of Parkinson's Disease.","Zhang Z","2023","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent06","A53T transgenic mouse study comparing dual GLP-1/GIP agonist with liraglutide; animal only",1],["R0009599","Glycemic Control Following GLP-1 RA or Basal Insulin Initiation in Real-World Practice: A Retrospective, Observational, Longitudinal Cohort Study.","Peng XV","2020","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent06","US and UK database cohorts initiating GLP-1 RA or basal insulin; HbA1c control outcomes only",1],["R0009685","Assessing the Compliance of Physicians With the American Diabetes Association (ADA) Guidelines in Prescribing Cardioprotective Antihyperglycemic Agents to Diabetic Patients at a University Hospital in Jeddah, Saudi Arabia.","Sheikh AM","2023","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent06","records review of physician adherence to ADA prescribing of cardioprotective agents; no exposure outcome comparison",1],["R0009787","Evaluating the bioequivalence and safety of liraglutide injection versus Victoza® in healthy Chinese subjects: a randomized, open, two-cycle, self-crossover phase I clinical trial.","Liu C","2023","include_nma",null,"primary_report","P99",null,"mechanistic; crossover","high","first","opus-5.5-agent06","randomized crossover bioequivalence trial of test liraglutide versus Victoza in healthy Chinese volunteers; reports adverse events",1],["R0011726","Treatment pattern trends of medications for type 2 diabetes in British Columbia, Canada.","Carney G","2022","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent05","longitudinal drug utilization study of glucose lowering treatment sequences in British Columbia; no exposure outcome comparison",1],["R0011837","Computing and interpreting the Number Needed to Treat for Cardiovascular Outcomes Trials : Perspective on GLP-1 RA and SGLT-2i therapies.","Ludwig L","2020","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent05","methods editorial on computing number needed to treat from GLP-1 RA and SGLT2i outcome trials",1],["R0011927","Psychosocial Outcomes in Telemedicine and Long-Acting Incretin-Specific Behavioral Intervention.","Heinberg LJ","2026","inventory_only","N1","other",null,null,null,"high","first","opus-5.5-agent05","single arm pragmatic trial of telehealth semaglutide or tirzepatide with behavioral program on psychosocial outcomes",1],["R0012033","Comparison of non-insulin antidiabetic agents as an add-on drug to insulin therapy in type 2 diabetes: a network meta-analysis.","Yoon JH","2018","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent05","network meta-analysis of RCTs of non-insulin agents including GLP-1 RA added to insulin, named databases",1],["R0012314","Liraglutide restores impaired associative learning in individuals with obesity.","Hanssen R","2023","inventory_only","N2","other",null,null,"crossover","high","first","opus-5.5-agent05","single dose liraglutide versus placebo crossover fMRI study of associative learning; glucose, insulin and hunger only",1],["R0012429","Diabetic kidney disease: update on clinical management and non-glycaemic effects of newer medications for type 2 diabetes.","de Bhailís ÁM","2021","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent05","narrative review of diabetic kidney disease management with relevance based PubMed selection",1],["R0009185","Comparison of cardiometabolic benefits and tolerability in patients on sustained low doses of semaglutide or tirzepatide.","Murugadoss K","2026","include_harms",null,"primary_report",null,"O121",null,"high","first","opus-5.5-agent20","matched EHR cohort of sustained low dose tirzepatide vs semaglutide, acute kidney injury among compared adverse events",1],["R0009272","Tirzepatide - a dual GIP/GLP-1 receptor agonist - a new antidiabetic drug with potential metabolic activity in the treatment of type 2 diabetes.","Nowak M","2022","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent20","narrative review of tirzepatide pharmacology and trial results",1],["R0009381","GLP-1 Agonist As Adjunct To Antidepressants In Patients With Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial.","Saad A",null,"include_nma",null,"conference_abstract","P99",null,"abstract_only","high","first","opus-5.5-agent20","abstract of double blind RCT of liraglutide 3 mg vs placebo added to escitalopram in MDD with BMI 27 or more",1],["R0009494","Discovery of ecnoglutide - A novel, long-acting, cAMP-biased glucagon-like peptide-1 (GLP-1) analog.","Guo W","2023","include_nma",null,"primary_report","P99",null,"mechanistic","high","first","opus-5.5-agent20","discovery paper with randomized placebo controlled SAD and MAD phase 1 of ecnoglutide in healthy volunteers, adverse events reported",1],["R0009577","The impacts of new antidiabetic drugs on the risk of ischemic and hemorrhagic strokes: a comprehensive review and meta-analysis of clinical trials.","Azhari HF","2024","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent20","PROSPERO registered meta-analysis of RCTs of SGLT2i, GLP-1 RA and DPP-4i on stroke risk, six databases",1],["R0009658","Efficacy and Safety of Orforglipron in Obese Adults With or Without Diabetes: A Systematic Review and Meta-Analysis.","Pandey RK","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent20","PROSPERO registered meta-analysis of placebo controlled RCTs of orforglipron, four sources searched",1],["R0009759","GLP-1 Receptor Agonist Exenatide Protects Against Doxorubicin-Induced Cardiotoxicity Through the SIRT1 Pathway: An Electrocardiographic, 99mTc-PYP Scintigraphic, and Biochemical Study.","Salmanoglu M","2026","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent20","randomized rat experiment of exenatide against doxorubicin cardiotoxicity",1],["R0009859","CVOT summit report 2024: new cardiovascular, kidney, and metabolic outcomes.","Schnell O","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent20","congress summit report on cardiovascular kidney metabolic outcome trials",1],["R0007941","Modern glucose-lowering drugs in liver transplant recipients: improvement in weight, glycemic control, and potentially allograft steatosis.","Atthota S","2023","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent18","retrospective pre post chart review of liver transplant recipients on GLP-1 RA or SGLT2i; no comparator group",1],["R0008006","Glucagon-like Peptide-1 analogues and delipidation of coronary atheroma in statin-treated type 2 diabetic patients with coronary artery disease: The prespecified sub-analysis of the OPTIMAL randomized clinical trial.","Kataoka Y","2024","inventory_only","N3","secondary_report",null,null,null,"high","first","opus-5.5-agent18","OPTIMAL RCT randomized CGM vs HbA1c guided care; GLP-1 RA use compared nonrandomly, so randomized contrast is not a GLP-1 regimen",1],["R0008165","Perioperative Use of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Lower Readmission Rates After Coronary Artery Bypass Grafting (CABG) in Adults With Congenital Heart Disease.","Yan JH","2025","include_harms",null,"primary_report",null,"O29; O37A; O121",null,"high","first","opus-5.5-agent18","TriNetX matched cohort of perioperative GLP-1 RA vs none in congenital heart disease CABG; pancreatitis, gastroparesis, AKI reported",1],["R0008257","Asian Subpopulations May Exhibit Greater Cardiovascular Benefit from Long-Acting Glucagon-Like Peptide 1 Receptor Agonists: A Meta-Analysis of Cardiovascular Outcome Trials.","Kang YM","2019","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent18","meta-analysis of three selected CVOTs without a database search or eligibility criteria",1],["R0008330","Real-world treatment satisfaction and experience with once-weekly tirzepatide: Insights from prescribing physicians and people with obesity or overweight.","Gibble TH","2026","inventory_only","N5","other",null,null,null,"high","first","opus-5.5-agent18","cross sectional physician and patient survey of tirzepatide satisfaction in obesity",1],["R0009057","Early Insight Into the Retrospective Data of a Case Series on Type 2 Diabetes Mellitus on Alternate-Day Dosing of Oral Semaglutide: Utopia or Reality?","RoyChaudhuri S","2023","inventory_only","N5","primary_report","P01",null,null,"high","first","opus-5.5-agent12","self described case series of ten patients on alternate day oral semaglutide, on vs off days CGM",1],["R0009161","Sex Differences in Renal Outcomes and Metabolic Markers by Combination Therapy with SGLT2 Inhibitors and GLP-1 Receptor Agonists in Individuals with Type 2 Diabetes: A Post-Hoc Analysis of the RECAP Study.","Muta Y","2025","inventory_only","N5","secondary_report","P01",null,null,"high","first","opus-5.5-agent12","post hoc of RECAP cohort of SGLT2i plus GLP-1RA users comparing males vs females, no GLP-1 unexposed group",1],["R0009215","Long-Term Clinical Outcomes and Real-World Effectiveness of Tirzepatide in Adults With Overweight or Obesity: A Systematic Review.","Olaniyi AO","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent12","SR of tirzepatide RCTs and real world studies in obesity, four databases, narrative SWiM synthesis",1],["R0009350","GLP-1RAs and cardiovascular risk reduction in psoriasis: A retrospective cohort study.","Ma EJ","2026","inventory_only","N6","primary_report","P99",null,null,"high","first","opus-5.5-agent12","research letter, TriNetX matched cohort of GLP-1RA users vs nonusers with psoriasis, MACE outcome only",1],["R0009439","Letter to \"Perioperative GLP-1 Receptor Agonist Use Is Associated With Reduced Revisions and Complications Following ACDF: A Propensity-Matched Analysis\".","Zhou Y","2026","inventory_only","N9","ancillary",null,null,null,"high","first","opus-5.5-agent12","letter commenting on a GLP-1RA ACDF cohort study, which is itself an inventory study",1],["R0009551","Response to the Letter to the Editor on \"Perioperative GLP-1 Receptor Agonist Use is Associated with Reduced Revisions and Complications Following ACDF: A Propensity-Matched Analysis\".","Kim MT","2026","inventory_only","N9","ancillary",null,null,null,"high","first","opus-5.5-agent12","authors reply to letter about their GLP-1RA ACDF cohort study",1],["R0009708","Precision Medicine in Overlap Syndrome (COPD-Obstructive Sleep Apnea): From Phenotypes and Endotypes to Treatable Traits.","Afloarei CA","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent12","self described narrative review of COPD and sleep apnea overlap syndrome",1],["R0008443","Association of dual SGLT-2 inhibitor and GLP-1 receptor agonist therapy with colon cancer risk in post-polypectomy patients with diabetes: a target trial emulation.","Wang CH","2026","include_harms",null,"primary_report",null,"O29; O121",null,"high","first","opus-5.5-agent08","TriNetX new user TTE of SGLT2i plus GLP-1 RA versus SGLT2i alone after polypectomy; AKI and acute pancreatitis secondary outcomes",1],["R0008541","Ceramides and phospholipids are downregulated with liraglutide treatment: results from the LiraFlame randomized controlled trial.","Zobel EH","2021","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent13","LiraFlame placebo controlled RCT of liraglutide in type 2 diabetes, lipidomics secondary end point",1],["R0008592","Effects of glucagon-like peptide-1 receptor agonists on body weight: a meta-analysis.","Monami M","2012","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent08","meta-analysis of RCTs of GLP-1 RAs versus placebo or active drugs on body weight; Medline, Cochrane, Embase",1],["R0008620","Findings Interpretation Concerns Regarding the Emulated Target Trial of SGLT2 Inhibitors vs GLP-1 Receptor Agonists in Psoriatic Arthritis [Letter].","Lymperopoulos A","2026","inventory_only","N9","ancillary",null,null,null,"high","first","opus-5.5-agent13","letter commenting on a target trial emulation of SGLT2 inhibitors vs GLP-1 agonists for psoriatic arthritis",1],["R0008674","Side Effects Associated with Liraglutide Treatment for Obesity as Well as Diabetes.","Seo YG","2021","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent08","narrative review of liraglutide side effects",1],["R0008691","Effectiveness of IGlarLixi, a Fixed-Ratio Combination of Insulin Glargine 100 U/mL and Lixisenatide, in People with Type 2 Diabetes.","Kis JT","2021","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent13","non-interventional single group study of iGlarLixi effectiveness without comparison group",1],["R0008844","Hypoglycemic agents and glycemic variability in individuals with type 2 diabetes: A systematic review and network meta-analysis.","Oh S","2022","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent13","PROSPERO registered network meta-analysis of glucose lowering classes including GLP-1 agonists on glycemic variability",1],["R0008922","The gynecologic tumor risk related to GLP-1 receptor agonists and SGLT2 inhibitors use: a network meta-analysis of 91 randomized controlled trials.","Tseng PT","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent08","network meta-analysis of 91 RCTs of GLP-1 RAs and SGLT2i on gynecologic tumors; eight databases searched",1],["R0008935","Efficacy and Safety of Tirzepatide in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Phase II/III Trials.","Bhagavathula AS","2021","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent13","systematic review and meta-analysis of tirzepatide phase 2 and 3 RCTs in type 2 diabetes from four databases",1],["R0008999","Refractory Dysmenorrhea Managed With a Glucagon-Like Peptide-1 Agonist: A Case Report.","Tran M","2025","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent13","case report of semaglutide for refractory dysmenorrhea",1],["R0009063","Orally Administered Semaglutide Versus GLP-1 RAs in Patients with Type 2 Diabetes Previously Receiving 1-2 Oral Antidiabetics: Systematic Review and Network Meta-Analysis.","Nuhoho S","2019","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent13","systematic literature review and Bayesian network meta-analysis of oral semaglutide vs injectable GLP-1 agonists",1],["R0008441","Magnitude of slowing gastric emptying by glucagon-like peptide-1 receptor agonists determines the amelioration of postprandial glucose excursion in Japanese patients with type 2 diabetes.","Suganuma Y","2020","inventory_only","N1","primary_report",null,null,null,"high","first","opus-5.5-agent07","open label study giving GLP-1RA to eight T2D patients with before after gastric emptying; no randomized or concurrent drug comparator",1],["R0012531","Effects of exendin-4, a glucagon like peptide-1 receptor agonist, on neutrophil count and inflammatory cytokines in a rat model of endotoxemia.","Yanay O","2015","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent05","exendin-4 tested in a rat endotoxemia model only",1],["R0008520","Risk of Malignant Neoplasia with Glucagon-Like Peptide-1 Receptor Agonist Treatment in Patients with Type 2 Diabetes: A Meta-Analysis.","Liu Y","2019","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent07","PROSPERO registered meta-analysis of RCTs of GLP-1RA vs placebo or other drugs on malignant neoplasia in T2D",1],["R0008588","A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes.","Aroda VR","2022","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent07","narrative review of SNAC technology and oral semaglutide development",1],["R0008672","Pathogenesis-Informed Phenotype-Guided Therapy for MASH: A Three-Axis Translational Framework Within the MASLD Spectrum.","Zhao Z","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent07","narrative review proposing a three axis framework for MASH pharmacotherapy",1],["R0008744","Effects of Treatment with Liraglutide on Health-Related Quality of Life and Obstructive Sleep Apnea in People with Obesity and Chronic Obstructive Pulmonary Disease","Dogan ADA","2022","include_nma",null,"secondary_report","P02; P10",null,null,"high","first","opus-5.5-agent07","preprint secondary report of the liraglutide vs placebo RCT in obesity with COPD; sleep apnea indices and SF-36",1],["R0008813","Semaglutide - properties, action and chromatographic analysis.","Wasilewska B","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent07","narrative review of semaglutide properties and chromatographic assay methods",1],["R0008906","Risk of heart failure hospitalization among users of dipeptidyl peptidase-4 inhibitors compared to glucagon-like peptide-1 receptor agonists.","Dawwas GK","2018","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent07","MarketScan new user cohort DPP-4i vs GLP-1RA; heart failure hospitalization only",1],["R0009195","The Effect of GLP-1 Agonists on Patients with Metabolic-Associated Steatotic Liver Disease: A Systematic Review and Meta-Analysis.","Tornea DA","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent03","meta-analysis of RCTs of GLP-1, dual and triple agonists in MASLD or MASH; PubMed, Scopus, Web of Science",1],["R0009299","Comparison of cardiovascular outcomes of new antihyperglycemic agents in Type 2 Diabetes Mellitus: a meta-analysis.","Zhou Z","2024","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent03","meta-analysis comparing SGLT2i and GLP-1 RA cardiovascular outcomes in T2D; five databases searched",1],["R0009406","Beyond Weight Loss: Comparative Effects of Tirzepatide Plus Low-Energy Ketogenic Versus Low-Calorie Diet on Hepatic Steatosis and Stiffness in MASLD.","Schiavo L","2025","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent03","nonrandomized comparison of ketogenic vs low calorie diet in tirzepatide treated MASLD; GLP-1 regimen same in both groups",1],["R0009500","Benefit of insulin glargine/lixisenatide for reducing residual hyperglycaemia in Japan: Post hoc analysis of the LixiLan JP-O2 trial.","Iizuka K","2021","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent03","post hoc analysis of LixiLan JP-O2 RCT, iGlarLixi vs insulin glargine in Japanese T2D",1],["R0009676","ANDREW: A Multicenter, Prospective, Observational Study in Patients with Type 2 Diabetes on Persistent Treatment with Dulaglutide.","Bossi AC","2020","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent03","prospective observational single group cohort of dulaglutide initiators, no comparison group",1],["R0012603","The association between pre-pregnancy use of obesity medications and gestational weight gain: a retrospective cohort study","Piccinini-Vallis H","2026","inventory_only","N6","other",null,null,null,"high","first","opus-5.5-agent05","matched pregnancy cohort of prepregnancy obesity drug use including GLP-1 RA on gestational weight gain and obstetric outcomes; no malformation outcome",1],["R0012687","Efficacy and safety of the glucagon-like peptide-1 receptor agonist lixisenatide versus the dipeptidyl peptidase-4 inhibitor sitagliptin in young (<50 years) obese patients with type 2 diabetes mellitus.","Van Gaal L","2014","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent05","24 week double blind RCT of lixisenatide versus sitagliptin in young obese adults with type 2 diabetes on metformin",1],["R0012788","Liraglutide treatment reduced interleukin-6 in adults with type 1 diabetes but did not improve established autonomic or polyneuropathy.","Brock C","2019","include_nma",null,"primary_report","P05",null,null,"high","first","opus-5.5-agent05","26 week placebo controlled RCT of liraglutide in type 1 diabetes with polyneuropathy; reports weight change",1],["R0012954","Impact of GLP-1RA on the Risk of Adverse Liver Outcomes Among Patients With Alcohol-Associated Liver Disease and Type 2 Diabetes.","Rashid Z","2025","inventory_only","N6","other",null,null,null,"high","first","opus-5.5-agent05","claims cohort GLP-1 RA versus no GLP-1 RA in alcohol associated liver disease on adverse liver outcomes; no listed harm",1],["R0013046","GLP-1a: Going beyond Traditional Use.","Laurindo LF","2022","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent05","systematic review of GLP-1 RA trials in nondiabetic conditions searching PubMed, Embase and Cochrane with criteria",1],["R0013149","Metabolic surgery may protect against admission for COVID-19 in persons with nonalcoholic fatty liver disease.","Tignanelli CJ","2021","inventory_only","N6","other",null,null,null,"high","first","opus-5.5-agent05","retrospective COVID-19 cohort assessing metabolic surgery and prior GLP-1 RA use on hospitalization; no listed harm",1],["R0006143","Oral Semaglutide and Cardiovascular Outcomes in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial.","Marx N","2025","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent15","prespecified SGLT2i subgroup analyses of the SOUL RCT of oral semaglutide versus placebo in type 2 diabetes",1],["R0009881","Effect of Semaglutide versus placebo on psychotic symptoms and quality of life - a pre-specified secondary analysis of HISTORI: A randomized clinical trial in people with pre-diabetes and schizophrenia","Uhrenholt N","2022","inventory_only","N8","protocol_or_design",null,null,"abstract_only","high","first","opus-5.5-agent06","conference abstract describing design of HISTORI semaglutide versus placebo RCT in schizophrenia with prediabetes; results not yet available",1],["R0006203","Prescribing Patterns of SGLT2 inhibitors and GLP-1 receptor agonists in Patients with T2DM and ASCVD in South Korea","Eom YR","2024","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent15","claims based prescribing pattern study of SGLT2i and GLP-1 RA uptake in Korea; utilization determinants only",1],["R0006249","Fixed-ratio combination of insulin glargine plus lixisenatide (iGlarLixi) improves ß-cell function in people with type 2 diabetes.","Ferrannini E","2022","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent15","secondary beta cell analysis of LixiLan-G RCT, switch to iGlarLixi versus continued GLP-1 RA; HbA1c and weight reported",1],["R0006405","The difference in type 2 diabetes care between the National Health Insurance beneficiaries and public assistance recipients in Japan: A retrospective cohort study based on claims data in a municipality.","Yamaoka T","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent15","claims study comparing diabetes care between insurance groups; GLP-1 RA use is a care process outcome, not an exposure",1],["R0006469","Time-dependent effect of GLP-1 receptor agonists on cardiovascular benefits: a real-world study.","Piccini S","2023","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent15","single center cohort of GLP-1 RA initiators only, cessation modeled as time dependent; no unexposed or active comparator group",1],["R0006554","Real-world prescribing patterns and early weight and blood pressure outcomes of GLP-1-based therapies: a retrospective observational study in the United Arab Emirates.","Almemari S","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent15","retrospective prescribing and early outcome study comparing GLP-1 RA molecules and tirzepatide; weight and blood pressure only",1],["R0006614","Treatment Patterns and Persistence With GLP-1 RA Treatments Among Patients With Type 2 Diabetes in France: A Retrospective Cohort Analysis.","Zimner Rapuch S","2021","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent15","pharmacy claims study of persistence and treatment patterns across GLP-1 RAs; drug utilization outcomes only",1],["R0009952","γδ T-cell interferon-γ production reflects metabolic improvement during SGLT2 inhibitor-based therapy in type 2 diabetes.","Troskot Cuculić M","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent06","prospective nonrandomized comparison of SGLT2 inhibitor alone versus with GLP-1 RA on gamma delta T cells; no listed harms",1],["R0010049","A single centre retrospective study of the long‑term weight and pregnancy-related outcomes in women of reproductive age before and after liraglutide exposure.","Chukir T","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent06","retrospective comparison of pregnancies before versus after liraglutide in the same women; no malformation outcome reported",1],["R0010122","MON-646 Novel Use of GLP-1 Receptor Agonist Therapy in MODY-1 (HNF4A Mutation)","Broome D","2020","inventory_only","N5","conference_abstract",null,null,"abstract_only","high","first","opus-5.5-agent06","conference abstract of two case reports of GLP-1 RA therapy in HNF4A MODY",1],["R0010221","Near-normalization of glycaemic control with glucagon-like peptide-1 receptor agonist treatment combined with exercise in patients with type 2 diabetes.","Mensberg P","2017","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent06","double blind RCT of liraglutide versus placebo both with supervised exercise for 16 weeks in T2D; HbA1c primary",1],["R0010292","Efficacy and safety of GLP-1 receptor agonists combined with SGLT-2 inhibitors in elderly patients with type 2 diabetes: a meta-analysis.","Wu Y","2024","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent06","meta-analysis of RCTs of GLP-1 RA plus SGLT2 inhibitor versus monotherapy in older adults with T2D; four databases",1],["R0010415","Efficacy and safety of sodium-glucose cotransporter 2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) in patients with type 2 diabetes: a systematic review and network meta-analysis study protocol.","Hussein H","2018","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent06","registered protocol for systematic review and NMA of SGLT2 inhibitors and GLP-1 RAs in T2D; no results",1],["R0010493","SUN-659 Comparative Efficacy and Safety of Tirzepatide vs Retatrutide in Weight Loss: A Network Meta-Analysis of Clinical Trials",null,"2025","include_review",null,"systematic_review",null,null,"abstract_only","high","first","opus-5.5-agent06","conference abstract of NMA comparing tirzepatide and retatrutide for weight loss; named databases searched",1],["R0007875","Comparative efficacy and safety of weekly dulaglutide versus weekly insulin in type 2 diabetes: A network meta-analysis of randomized clinical trials.","Ayesh H","2024","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent17","registered network meta-analysis of RCTs comparing weekly dulaglutide and weekly insulin with daily insulin, four databases searched",1],["R0007940","Use of SGLT2 Inhibitors vs GLP-1 RAs and Anemia in Patients With Diabetes and CKD.","Hu JC","2024","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent17","Taiwanese EHR cohort of SGLT2 inhibitor versus GLP-1 RA initiators in diabetes with CKD; anemia outcome only",1],["R0008004","Impact of semaglutide withdrawal on cardiometabolic profile and physiology of energy balance: Recovery effects after semaglutide termination - The REST trial study protocol.","Yevusiak T","2026","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent17","protocol of the REST RCT of gradual versus abrupt semaglutide withdrawal in obesity, no results",1],["R0008068","Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.","Lincoff AM","2023","include_nma",null,"primary_report","P02",null,null,"high","first","opus-5.5-agent17","SELECT placebo controlled RCT of semaglutide on cardiovascular outcomes in overweight or obesity without diabetes",1],["R0008252","12-Month Weight Loss and Adherence Predictors in a Real-World UK Tirzepatide-Supported Digital Obesity Service: A Retrospective Cohort Analysis.","Talay L","2025","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent17","retrospective cohort of a tirzepatide supported digital weight service with adherence predictors, no comparison group",1],["R0008329","The Efficacy of IDegLira (Insulin Degludec/Liraglutide Combination) in Adults with Type 2 Diabetes Inadequately Controlled with a GLP-1 Receptor Agonist and Oral Therapy: DUAL III Randomized Clinical Trial.","Linjawi S","2017","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent17","DUAL III open label RCT of IDegLira versus unchanged GLP-1 RA therapy in type 2 diabetes, 26 weeks",1],["R0008405","Response To \"Superior Cerebrovascular Outcomes with Tirzepatide Versus Semaglutide: A Call for Cautious Interpretation of Observational Data\".","Hussein MH","2026","inventory_only","N9","ancillary",null,null,null,"high","first","opus-5.5-agent17","authors reply to a letter on their tirzepatide versus semaglutide post CABG observational study",1],["R0007817","Real-world effectiveness and safety of low-dose tirzepatide in Japanese people with type 2 diabetes: a multicenter, retrospective, single-arm, observational study-East Shizuoka Tirzepatide (ESTATE) study.","Iwamoto T","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent02","multicenter retrospective single arm observational study of low dose tirzepatide in Japanese T2D",1],["R0007883","Impact of GLP-1 Receptor Agonists on Psoriasis and Cardiovascular Comorbidities: A Narrative Review.","Haran K","2024","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent02","self described narrative review of GLP-1 RA in psoriasis and cardiovascular comorbidity using PubMed searches",1],["R0007962","Pancreatitis Incidence in the Exenatide BID, Exenatide QW, and Exenatide QW Suspension Development Programs: Pooled Analysis of 35 Clinical Trials.","Vetter ML","2019","include_nma",null,"pooled_analysis","P01",null,null,"high","first","opus-5.5-agent02","pooled analysis of 35 randomized controlled exenatide trials vs placebo or non incretin comparators on pancreatitis in T2D",1],["R0008019","The Risk of Aspiration Is Low With Continuing Semaglutide During Elective Eye Surgery When Patients Receive Only Moderate Sedation.","Zapp C","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent02","retrospective case series of semaglutide users undergoing eye surgery assessing aspiration; no comparison group",1],["R0008085","Cardio-Protective Effect of GLP-1 Agonists in OSA Patients: A Study of Cardiovascular Risk.","Lane M","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent02","TriNetX OSA cohorts with vs without GLP-1 RA on cardiovascular events; no listed harm outcome",1],["R0008177","Up and down waves of glycemic control and lower-extremity amputation in diabetes.","Caruso P","2021","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent02","editorial on glycemic control trends and amputation in diabetes",1],["R0008277","Glucagon-like peptide-1 (GLP-1) receptor agonists and cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of double-blind, randomized, placebo-controlled clinical trials.","Qin J","2022","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent02","meta-analysis of placebo controlled GLP-1 RA outcome trials on cardiovascular events; PubMed and Embase searched",1],["R0008358","Comparative Effects of Exercise and GLP-1 RAs on Type 2 Diabetic Rat Model: A Systematic Review.","Afzal S","2025","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent02","systematic review of exercise and GLP-1 RA studies in diabetic rat models only",1],["R0009000","Clinical factors associated with the occurrence of nausea and vomiting in type 2 diabetes patients treated with glucagon-like peptide-1 receptor agonists.","Shiomi M","2019","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent14","retrospective cohort of GLP-1 RA initiators examining risk factors for nausea and vomiting, no unexposed comparison",1],["R0009065","Adherence to Treatment Guidelines Among Patients With Type 2 Diabetes Attending a Tertiary Hospital in Jeddah, Saudi Arabia.","Radi S","2024","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent14","chart review of adherence to diabetes care guidelines and prescribing rates, no exposure outcome comparison",1],["R0009172","Growth differentiation factor 15 is not modified after weight loss induced by liraglutide in South Asians and Europids with type 2 diabetes mellitus.","Hoekx CA","2024","include_nma",null,"pooled_analysis","P01",null,"mechanistic","high","first","opus-5.5-agent14","secondary analysis pooling two placebo controlled RCTs of liraglutide in T2D, GDF15 and weight",1],["R0009220","Early Clinical Experience of Finerenone in People with Chronic Kidney Disease and Type 2 Diabetes in Japan-A Multi-Cohort Study from the FOUNTAIN (FinerenOne mUltidatabase NeTwork for Evidence generAtIoN) Platform.","Sato A","2024","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent14","descriptive cohort of finerenone new users, GLP-1 RA only a baseline characteristic",1],["R0009357","Exploring the Synergistic Approach of Dual GLP-1 Agonist with Degludec Basal Insulin for Early Type 1 Diabetes Treatment for Albumin-Insulin Producing Cells Expression","Ahmed A","2023","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent14","commentary proposing semaglutide with degludec in early type 1 diabetes, no new data",1],["R0009451","Prevalence and incidence of heart failure in type 2 diabetes patients: results from a nationwide prospective cohort-the DIABET-IC study.","Gonzalez-Manzanares R","2024","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent14","prospective cohort of heart failure prevalence and incidence in T2D, GLP-1 RA not studied as exposure",1],["R0009556","Cognitive signs and symptoms in people with a psychiatric diagnosis on semaglutide: a retrospective cohort study of 13 007 patients in the USA.","De Giorgi R","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent14","EHR cohort semaglutide vs other antidiabetics or none in psychiatric patients, cognitive outcomes only",1],["R0009627","Use and effectiveness of a fixed-ratio combination of insulin degludec/liraglutide (IDegLira) in a real-world population with type 2 diabetes: Results from a European, multicentre, retrospective chart review study.","Price H","2018","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent14","retrospective chart review of IDegLira initiators, before and after HbA1c and weight, no comparison group",1],["R0013251","Mechanism of action of Imeglimin: A novel therapeutic agent for type 2 diabetes.","Hallakou-Bozec S","2021","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent05","narrative review of imeglimin mechanism; GLP-1 mentioned only as comparator in animal work",1],["R0013368","A randomised, controlled, double blind study to assess mechanistic effects of combination therapy of dapagliflozin with exenatide QW versus dapagliflozin alone in obese patients with type 2 diabetes mellitus (RESILIENT): study protocol.","Brown E","2021","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent05","protocol of placebo controlled RCT of exenatide QW plus dapagliflozin versus dapagliflozin in obese type 2 diabetes; no results",1],["R0013447","Risk of neoplasms with semaglutide in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.","Zhong Y","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent05","registered meta-analysis of semaglutide RCTs in type 2 diabetes on neoplasm risk, four named databases",1],["R0013534","The Effect of Tirzepatide on Body Composition in People with Overweight and Obesity: A Systematic Review of Randomized, Controlled Studies.","Rochira V","2024","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent05","registered systematic review of tirzepatide RCTs on body composition with narrative synthesis and named search",1],["R0013625","Systematic AI-Driven Drug Repurposing via Clinical Trial Data Mining: A Framework and Six Cross-Therapeutic Case Studies","Gote V","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent05","AI tool and framework for drug repurposing by mining trial registry records; computational methods paper without patient data",1],["R0013810","Treatment of the disease of obesity in patients with type 1 diabetes with tirzepatide: a protocol for a randomised controlled trial in a single-centre setting.","Al Ozairi E","2026","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent05","protocol of placebo controlled RCT of tirzepatide in type 1 diabetes with obesity; no results",1],["R0005799","Real-world observations of GLP-1 receptor agonists and SGLT-2 inhibitors as potential treatments for Alzheimer's disease.","Zhang P","2025","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent11","claims and EHR initiator cohorts of GLP-1RA, SGLT2i and DPP-4i; Alzheimer disease risk only, no listed harms outcome",1],["R0006012","Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled Trials.","Mantovani A","2021","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent11","registered meta-analysis of RCTs of GLP-1RAs in NAFLD or NASH; PubMed, Scopus, ClinicalTrials.gov searched",1],["R0006068","The Effects of Switching from Dipeptidyl Peptidase-4 Inhibitors to Glucagon-Like Peptide-1 Receptor Agonists on Bone Mineral Density in Diabetic Patients.","Huang CF","2023","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent11","matched cohort switching DPP-4i to GLP-1RA versus continuing; bone density and HbA1c only",1],["R0006124","Glucagon-like peptide-1 receptor agonists and diabetic retinopathy: nationwide cohort and Mendelian randomization studies.","Zheng D","2023","include_harms",null,"primary_report",null,"O33",null,"high","first","opus-5.5-agent11","Swedish register cohort of GLP-1RA users versus matched non users with diabetic retinopathy outcome, plus Mendelian randomization",1],["R0006185","Obesity pharmacotherapy in older adults: a narrative review of evidence.","Henney AE","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent11","narrative review of obesity pharmacotherapy in older adults",1],["R0009044","Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).","Davies MJ","2022","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent08","ADA and EASD consensus report on hyperglycemia management in type 2 diabetes",1],["R0009141","Appetite, eating attitudes, and eating behaviours during treatment with retatrutide in adults with type 2 diabetes: Results of a phase 2 study.","Kanu C","2025","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent08","prespecified exploratory appetite analyses of phase 2 RCT of retatrutide versus placebo and dulaglutide in type 2 diabetes",1],["R0009206","CGM-derived postprandial glucose with IcoSema versus other insulin regimens: a post hoc analysis of COMBINE 1 and 3.","De Block C","2026","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent08","post hoc CGM analysis of COMBINE 1 and 3 RCTs of IcoSema versus icodec or basal bolus insulin",1],["R0009332","Effects of GLP-1 receptor agonists on cardiovascular outcomes in patients with type 2 diabetes and chronic kidney disease: A systematic review and meta-analysis.","Kelly M","2022","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent08","systematic review and meta-analysis of GLP-1 RA RCTs on cardiovascular outcomes in diabetes with CKD; four databases",1],["R0009527","Efficacy and Safety of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.","Zhu Y","2021","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent08","systematic review and meta-analysis of GLP-1 RA RCTs in type 2 diabetes with NAFLD; five databases",1],["R0009607","Associations of Semaglutide With Skeletal Outcomes in People With Obesity, With and Without Type 2 Diabetes: A Target Trial Emulation.","Huang YN","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent08","TriNetX target trial emulation of semaglutide versus comparators on fractures, osteoporosis, osteoarthritis, gout",1],["R0009699","Relationship Between Frailty and Diabetic Pharmacologic Therapy in Older Adults with Type 2 Diabetes: A Cross-Sectional Study.","Nishimura A","2024","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent08","cross sectional study of diabetes drug classes incl GLP-1 RA and frailty in older adults",1],["R0006994","Cardiovascular autonomic neuropathy in diabetes: an update with a focus on management.","Eleftheriadou A","2024","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent10","narrative update on cardiovascular autonomic neuropathy management; no systematic methods",1],["R0007049","A meta-analysis evaluating indirectly GLP-1 receptor agonists and arrhythmias in patients with type 2 diabetes and myocardial infarction.","Liu Z","2022","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent10","meta-analysis of placebo controlled GLP-1 RA RCTs on arrhythmias in T2D with MI; four databases searched",1],["R0007128","The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs.","Giugliano D","2022","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent10","network meta-analysis of 23 outcome trials of DPP-4i, GLP-1 RA and SGLT2i; PubMed Embase Cochrane searched",1],["R0007177","Diabetes and Stroke: Impact of Novel Therapies for the Treatment of Type 2 Diabetes Mellitus.","Vieira IH","2024","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent10","narrative review of novel diabetes drugs and stroke; no search methods",1],["R0007243","Critical Evaluation of \"GLP-1 and Dual GLP-1/GIP Receptor Agonists in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Systematic Review and Meta-Analysis\".","Bibi Z","2025","inventory_only","N9","ancillary",null,null,null,"high","first","opus-5.5-agent10","letter commenting on a systematic review and meta-analysis of GLP-1 and dual agonists in HFpEF",1],["R0007308","Clinical Considerations When Initiating and Titrating Insulin Degludec/Liraglutide (IDegLira) in People with Type 2 Diabetes.","Harris S","2020","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent10","narrative clinical review of initiating and titrating IDegLira; no systematic methods",1],["R0009170","Efficacy of SGLT2 Inhibitors, GLP-1 Receptor Agonists, DPP-4 Inhibitors, and Sulfonylureas on Moderate-to-Severe COPD Exacerbations Among Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis.","Pirera E","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent13","PROSPERO registered network meta-analysis of observational studies of glucose lowering classes incl GLP-1 on COPD exacerbations",1],["R0009216","Network meta-analysis on the effects of finerenone versus SGLT2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease.","Zhang Y","2022","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent13","PROSPERO registered network meta-analysis of finerenone, SGLT2 inhibitor and GLP-1 RCTs in diabetic CKD",1],["R0009352","Comment on: The association between GLP-1 receptor agonists and fractures: a nationwide Danish nested case-control study.","Chen G","2026","inventory_only","N9","ancillary",null,null,null,"high","first","opus-5.5-agent13","letter commenting on a Danish nested case control study of GLP-1 agonists and fractures",1],["R0009552","7358 Profile of Circulating miRNAs Associated with Body Weight Reduction in Type 2 Diabetes Patients Treated with GLP-1 Receptor Agonist Dulaglutide: Secondary Analysis of AWARD-7 Trial",null,"2024","include_nma",null,"conference_abstract","P01; P08A",null,"abstract_only","high","first","opus-5.5-agent13","abstract of AWARD-7 secondary analysis, randomized dulaglutide vs insulin glargine in type 2 diabetes with CKD",1],["R0009625","Glucocentric Drugs in Cardiovascular Disease Protection and Heart Failure.","Talha KM","2022","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent13","narrative review of cardiovascular evidence for glucose lowering drug classes",1],["R0009713","Comparisons of clinical outcomes between newly diagnosed early- and late-onset T2DM: a real-world study from the Shanghai Hospital Link Database.","Tao X","2024","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent13","descriptive EHR study of prescriptions and comorbidities in early vs late onset diabetes, no GLP-1 exposure comparison",1],["R0009810","Impact of Glucagon-Like Peptide 1 Agonist Deprescription in Type 2 Diabetes in a Real-World Setting: A Propensity Score Matched Cohort Study.","McKenzie AL","2024","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent13","propensity matched cohort GLP-1 deprescription vs continuation, HbA1c and weight only",1],["R0009134","Associations between income/employment status and diabetes care processes, health behaviors, and health outcomes in Japan: A cross-sectional study using claims data linked to a questionnaire survey.","Yamaoka T","2024","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent07","cross sectional claims and survey study of income and diabetes care; GLP-1RA use only as a care process outcome",1],["R0009202","Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes.","Nicholls SJ","2025","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent07","SURPASS-CVOT double blind RCT of tirzepatide vs dulaglutide in type 2 diabetes with ASCVD",1],["R0009322","Tirzepatide as Monotherapy Improved Markers of Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes (SURPASS-1).","Lee CJ","2023","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent07","post hoc biomarker analysis of SURPASS-1 RCT of tirzepatide doses vs placebo in type 2 diabetes",1],["R0009425","Clinical Characteristics and Glycemic Outcomes of Patients with Type 2 Diabetes Requiring Maximum Dose Insulin Glargine/Lixisenatide Fixed-Ratio Combination or Insulin Glargine in the LixiLan-L Trial.","Blonde L","2019","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent07","post hoc analysis of LixiLan-L RCT of iGlarLixi vs insulin glargine by maximum dose subgroup",1],["R0009520","Efficacy and safety of iGlarLixi versus IDegAsp: Results of a systematic literature review and indirect treatment comparison.","Home PD","2021","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent07","systematic review with Bayesian indirect comparison of iGlarLixi vs IDegAsp from RCTs",1],["R0009606","Difference in Gastrointestinal Risk Associated with Use of GLP-1 Receptor Agonists: A Real-World Pharmacovigilance Study.","Zhou Y","2022","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent07","FAERS disproportionality analysis comparing gastrointestinal reports for semaglutide and liraglutide",1],["R0009687","Cardiorenal and other diabetes related outcomes with SGLT-2 inhibitors compared to GLP-1 receptor agonists in type 2 diabetes: nationwide observational study.","Lugner M","2021","include_harms",null,"primary_report",null,"O33",null,"high","first","opus-5.5-agent07","Swedish new user cohort GLP-1RA vs SGLT2i in T2D; outcomes include diabetic retinopathy hospitalization",1],["R0010389","Making a case for the combined use of SGLT2 inhibitors and GLP1 receptor agonists for cardiorenal protection.","Sridhar VS","2020","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent04","narrative review arguing for combined SGLT2i and GLP-1 RA use for cardiorenal protection",1],["R0010712","Long-Term Effectiveness of Liraglutide for Weight Management and Glycemic Control in Type 2 Diabetes.","Mirabelli M","2019","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent06","retrospective single group five year liraglutide cohort in T2D; no comparison group",1],["R0010800","GLP-1 receptor agonist-associated tumor adverse events: A real-world study from 2004 to 2021 based on FAERS.","Yang Z","2022","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent06","FAERS disproportionality analysis of GLP-1 RA associated tumor reports",1],["R0010867","Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study.","Thein D","2020","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent06","Danish registry cohort of add-on GLP-1 RA and other agents after metformin; HF, MACE, mortality only; observational not RCT",1],["R0010965","The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission.","Chuong V","2023","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent06","mouse and rat experiments of semaglutide on alcohol drinking and GABA transmission",1],["R0011041","Microvascular Outcomes of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Type 2 Diabetes: A Systematic Review of Retinopathy and Nephropathy Evidence.","Arif A","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent06","systematic review of RCTs of GLP-1 RAs on retinopathy and nephropathy in T2D; PubMed, Embase, CENTRAL",1],["R0011121","Plasma volume status in type 2 diabetes and its association with antidiabetic therapy.","Cutruzzolà A","2025","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent06","cross sectional study of plasma volume status by antidiabetic therapy incl GLP-1 RA in T2D",1],["R0011224","Weekly Subcutaneous VK2735, a GIP/GLP-1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13-Week VENTURE Study.","Bays HE","2026","include_nma",null,"primary_report","P02",null,null,"high","first","opus-5.5-agent06","VENTURE phase 2 double blind RCT of VK2735 doses versus placebo in obesity without diabetes over 13 weeks",1],["R0010600","Pharmacological interventions for addressing pediatric and adolescent obesity: A systematic review and network meta-analysis.","Yang S","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent04","registered systematic review and network meta-analysis of pediatric obesity drug RCTs incl semaglutide, liraglutide, exenatide",1],["R0010707","Impact of AIFA Note 100 on innovative antidiabetic prescribing eligibility in two Italian local health authorities: drug utilization and patient characteristics.","Bruno GM","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent04","Italian administrative data on antidiabetic prescribing before and after AIFA Note 100, drug utilization only",1],["R0010794","Real-World Off-Label Use of Semaglutide for Weight Reduction: User Behavior, Effectiveness, and Satisfaction.","Al-Qaaneh AM","2025","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent04","cross sectional survey of off label semaglutide users on use patterns, weight loss and satisfaction, no comparison group",1],["R0010852","Laparoscopic adjustable gastric banding with liraglutide in adults with obesity and type 2 diabetes (GLIDE): a pilot randomised placebo controlled trial.","Coelho C","2023","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent04","GLIDE pilot double blind RCT of liraglutide vs placebo after gastric banding in obesity with type 2 diabetes",1],["R0010957","The GLP-1-mediated gut-kidney cross talk in humans: mechanistic insight.","Hinrichs GR","2024","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent04","narrative review of renal mechanistic effects of GLP-1 in humans without systematic methods",1],["R0011037","Semaglutide treatment for PRevention Of Toxicity in high-dosE Chemotherapy with autologous haematopoietic stem-cell Transplantation (PROTECT): study protocol for a randomised, double-blind, placebo-controlled, investigator-initiated study.","Sørum ME","2024","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent04","protocol of PROTECT RCT of semaglutide vs placebo for chemotherapy mucositis in lymphoma autologous transplant",1],["R0009941","443. Do people living with HIV lose weight on GLP-1 agonist therapy?",null,"2022","inventory_only","N5","conference_abstract",null,null,"abstract_only","high","first","opus-5.5-agent03","abstract of chart review of GLP-1 RA starters with HIV; comparison group not yet analyzed",1],["R0010034","Effect of the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide on alcohol consumption in alcohol-preferring male vervet monkeys.","Fink-Jensen A","2025","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent03","vervet monkey study of semaglutide on alcohol intake; animal only",1],["R0010113","Tirzepatide compared with semaglutide and 10-year cardiovascular disease risk reduction in obesity: post-hoc analysis of the SURMOUNT-5 trial.","Mamas MA","2025","include_nma",null,"secondary_report","P02",null,null,"high","first","opus-5.5-agent03","post hoc analysis of SURMOUNT-5 RCT, tirzepatide vs semaglutide in obesity without diabetes",1],["R0010282","Efficacy and tolerability of tirzepatide, a dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes: A 12-week, randomized, double-blind, placebo-controlled study to evaluate different dose-escalation regimens.","Frias JP","2020","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent03","12 week double blind RCT of three tirzepatide escalation regimens vs placebo in T2D",1],["R0010388","Transformer-based models for ADR detection: cross-drug validation and benchmarking against large language models.","Kim M","2025","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent03","NLP model benchmarking for adverse reaction detection in tweets about GLP-1 RA; no exposure comparison",1],["R0010483","Effect of beinaglutide, a thrice-daily GLP-1 receptor agonist, on body weight and metabolic parameters: A systematic review and meta-analysis.","Kamrul-Hasan ABM","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent03","meta-analysis of RCTs of beinaglutide vs control in overweight or obesity; MEDLINE, Scopus, CENTRAL searched",1],["R0007476","Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: A review of their kidney and heart protection.","Michos ED","2023","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent19","narrative review of GLP-1 RA kidney and heart protection in diabetic kidney disease",1],["R0007528","GLP-1 Receptor Agonists in Fibromyalgia: Opioid Sparing Signals from Real World Data","Verma A",null,"inventory_only","N6","conference_abstract",null,null,"abstract_only","high","first","opus-5.5-agent19","TriNetX cohort of fibromyalgia patients, GLP-1 RA initiators vs other anti obesity drugs; opioid and care use outcomes; abstract",1],["R0007677","No Heavy Drinking Days and Percentage of Days Abstinent in a Randomized Trial of Adjunctive Ketamine for Alcohol Use Disorder: Secondary Analysis of the KARE Trial","Morgan CJ","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent19","secondary analysis of ketamine RCT in alcohol use disorder; GLP-1 RA trials only cited for comparison",1],["R0007735","Automated Insulin Delivery in Adults With Type 2 Diabetes: A Nonrandomized Clinical Trial.","Pasquel FJ","2025","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent19","single arm trial of automated insulin delivery in type 2 diabetes; GLP-1 RA only background therapy",1],["R0007811","Effects of Sodium-Glucose Cotransporter Inhibitor/Glucagon-Like Peptide-1 Receptor Agonist Add-On to Insulin Therapy on Glucose Homeostasis and Body Weight in Patients With Type 1 Diabetes: A Network Meta-Analysis.","Kim YJ","2020","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent19","network meta-analysis of RCTs of add-on SGLT inhibitors, GLP-1 RA, metformin to insulin in type 1 diabetes; named databases",1],["R0007882","A Systems Pharmacology Model of Aging Identifies Optimal Combination Therapies With Secondary Benefits on Weight Loss and Metabolic Health.","Goryanin I","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent01","quantitative systems pharmacology simulation model of aging calibrated to published semaglutide trial data",1],["R0008017","HbA1c reduction with tirzepatide in people with type 2 diabetes: The contribution of weight loss assessed by a mediation analysis.","Vilsbøll T","2025","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent01","post hoc mediation analysis of SURPASS-1, 2 and 5 RCTs, tirzepatide versus placebo or semaglutide",1],["R0008083","Neurological Manifestation of Incretin-Based Therapies in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis.","Gao L","2019","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent01","registered network meta-analysis of incretin based therapy RCTs on dizziness and headache, Medline Embase Cochrane searched",1],["R0008275","Glucagon-Like Peptide-1 Receptor Agonist Use and Renal Impairment: A Retrospective Analysis of an Electronic Health Records Database in the U.S. Population.","Boye KS","2018","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent01","matched EHR cohort of GLP-1 RA versus other glucose lowering drug initiators; eGFR and HbA1c change only",1],["R0008346","Effects of efpeglenatide versus liraglutide on gastric emptying, glucose metabolism and beta-cell function in people with type 2 diabetes: an exploratory, randomized phase Ib study.","Hompesch M","2021","include_nma",null,"primary_report","P01",null,"mechanistic","high","first","opus-5.5-agent01","phase Ib RCT of efpeglenatide versus placebo on gastric emptying in type 2 diabetes, with HbA1c and adverse events",1],["R0008422","Effect of GLP-1 receptor agonists at doses for obesity management on muscle health: systematic review and meta-analysis of randomized controlled trials (RCTs).","Laverde LP","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent01","registered meta-analysis of placebo controlled GLP-1 RA obesity RCTs on lean mass, PubMed Embase LILACS searched",1],["R0008553","Nor-ursodeoxycholic acid in hepatobiliary diseases: A narrative review.","Malakar S","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent16","narrative review of nor-ursodeoxycholic acid; GLP-1RAs mentioned only as context",1],["R0008639","Combination therapy as a new standard of care in diabetic and non-diabetic chronic kidney disease.","Neuen BL","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent16","narrative review of combination therapy in chronic kidney disease",1],["R0008703","Once-Weekly Semaglutide Use in Patients with Type 2 Diabetes: Results from the SURE Spain Multicentre, Prospective, Observational Study.","Bellido V","2022","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent16","SURE Spain prospective single arm noninterventional study of once weekly semaglutide",1],["R0008780","Anti-obesity medications and cognitive disorder risk: a discrepancy between RCTs and real-world evidence.","Li C","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent16","PROSPERO registered systematic review and meta-analysis of anti obesity medications including GLP-1RAs and cognitive disorders",1],["R0008860","Effect of liraglutide on atherosclerosis in patients with impaired glucose tolerance: A double‑blind, randomized controlled clinical trial.","Sun L","2023","include_nma",null,"primary_report","P02",null,null,"high","first","opus-5.5-agent16","RCT of liraglutide vs lifestyle intervention in overweight or obese adults with impaired glucose tolerance",1],["R0008944","Early use of oral semaglutide in the UK: A cost-effectiveness analysis versus continuing metformin and SGLT-2 inhibitor therapy.","Ren H","2023","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent16","cost effectiveness modeling of oral semaglutide using PIONEER 4 data",1],["R0009006","iGlarLixi provides improved early glycaemic control after 12 weeks of treatment compared with basal insulin in Asian people with type 2 diabetes: A post hoc analysis of the LixiLan-O-AP and LixiLan-L-CN studies.","Song L","2025","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent16","post hoc analysis of two open label RCTs of iGlarLixi vs insulin glargine in Asian T2D",1],["R0009927","Role of a Dual Glucose-Dependent Insulinotropic Peptide (GIP)/Glucagon-like Peptide-1 Receptor Agonist (Twincretin) in Glycemic Control: From Pathophysiology to Treatment.","Pelle MC","2021","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent20","narrative review of GIP and GLP-1 physiology and tirzepatide trials",1],["R0010275","Glucagon-like peptide 1 receptor agonist use and risk of thyroid cancer: Scandinavian cohort study.","Pasternak B","2024","include_harms",null,"primary_report",null,"O32B",null,"high","first","opus-5.5-agent20","Scandinavian active comparator new user cohort of GLP-1 RA vs DPP-4i, thyroid cancer outcome, PS weighted",1],["R0010375","Glucagon-like peptide-1 analogues: a new way to quit smoking? (SKIP)-a structured summary of a study protocol for a randomized controlled study.","Lengsfeld S","2023","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent20","protocol summary of placebo controlled RCT of dulaglutide for smoking cessation with varenicline",1],["R0010468","The association of socioeconomic disadvantage and remoteness with receipt of type 2 diabetes medications in Australia: a nationwide registry study.","Morton JI","2021","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent20","Australian registry study of sociodemographic disparities in dispensing of diabetes drugs, drug utilization only",1],["R0010579","Real-World Effectiveness of Dulaglutide in Patients with Type 2 Diabetes Mellitus: A Literature Review.","Robinson S","2020","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent20","protocol driven literature review of real world dulaglutide evidence, MEDLINE and EMBASE searched with criteria",1],["R0007371","GLP-1RA in JBMMSCs promoted osteogenic differentiation via modulating CREB and BRD4 signaling mediated proliferation and stemness.","Liu H","2025","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent09","rat and stem cell experiments with semaglutide and bioinformatics, no human participants",1],["R0007431","Effect of different hypoglycemic drugs and insulin on the risk of new-onset atrial fibrillation in people with diabetes: a network meta-analysis.","Lv Q","2024","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent09","PRISMA NMA of glucose lowering drugs including GLP-1 agonists on incident atrial fibrillation, four databases",1],["R0007500","Expected Health Benefits of SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Older Adults.","Dadwani RS","2023","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent09","UKPDS simulation model of expected benefits of GLP-1 and SGLT2 drugs in older adults",1],["R0007554","Weekly Semaglutide vs. Liraglutide Efficacy Profile: A Network Meta-Analysis.","Alsugair HA","2021","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent09","Bayesian NMA of RCTs of weekly semaglutide versus liraglutide, three databases searched",1],["R0007635","Projecting the incidence and costs of major cardiovascular and kidney complications of type 2 diabetes with widespread SGLT2i and GLP-1 RA use: a cost-effectiveness analysis.","Morton JI","2023","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent09","microsimulation cost effectiveness analysis of widespread SGLT2 and GLP-1 use in Australia",1],["R0007710","Treatment of diabetes mellitus has borne much fruit in the prevention of cardiovascular disease.","Yagyu H","2022","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent09","narrative review of diabetes treatments and cardiovascular prevention",1],["R0007772","Cardiac autonomic neuropathy in patients with SGA-treated schizophrenia: a randomized controlled trial of 30 weeks' treatment with semaglutide.","Ganeshalingam AA","2026","include_nma",null,"secondary_report","P15",null,null,"high","first","opus-5.5-agent09","HISTORI double blind RCT of semaglutide versus placebo in schizophrenia on antipsychotics with prediabetes, autonomic neuropathy outcome",1],["R0007849","Pancreatic Safety of Tirzepatide and Its Effects on Islet Cell Function: A Systematic Review and Meta-Analysis.","Kamrul-Hasan ABM","2024","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent09","systematic review and meta-analysis of tirzepatide RCTs on pancreatitis and islet function, several databases",1],["R0008487","Gaps in Evidence-Based Therapy Use in Insured Patients in the United States With Type 2 Diabetes Mellitus and Atherosclerotic Cardiovascular Disease.","Nelson AJ","2021","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent18","claims study of prescription rates of evidence based therapies with simulated benefit; utilization only, no exposure outcome comparison",1],["R0008560","Tirzepatide Benefit for Early Glycemic and Weight Management in People with T2D in Japan: Rationale, Design, and Baseline Characteristics of T-BEAT Study.","Waki H","2026","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent18","design and baseline data of ongoing observational T-BEAT study, tirzepatide vs oral semaglutide; no outcome results",1],["R0008647","Cost-Consequence Analysis of Semaglutide vs. Liraglutide for Managing Obese Prediabetic and Diabetic Patients in Saudi Arabia: A Single-Center Study.","Bawazeer N","2025","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent18","retrospective chart review semaglutide 1 mg vs liraglutide 3 mg; HbA1c, weight and costs; no listed harms outcome",1],["R0008710","iGlarLixi effectively reduces residual hyperglycaemia in patients with type 2 diabetes on basal insulin: A post hoc analysis from the LixiLan-L study.","Morea N","2020","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent18","post hoc analysis of LixiLan-L open label RCT, iGlarLixi vs insulin glargine on residual hyperglycemia in T2D",1],["R0008784","Influence of chronic kidney disease and its severity on the efficacy of semaglutide in type 2 diabetes patients: a multicenter real-world study.","García de Lucas MD","2023","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent18","ambispective cohort of semaglutide users with vs without CKD; all exposed, no drug comparator group",1],["R0008863","Effects of GLP-1RA Treatment on Long-Term Post-PCI Prognosis in T2DM Patients: A Propensity Score Matching Study.","Fang B","2025","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent18","single center matched cohort of T2D after PCI with vs without GLP-1 RA; adverse cardiovascular events only",1],["R0006678","Multinational patterns of second line antihyperglycaemic drug initiation across cardiovascular risk groups: federated pharmacoepidemiological evaluation in LEGEND-T2DM.","Khera R","2023","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent15","LEGEND-T2DM federated analysis of second line drug initiation trends across risk groups; utilization only",1],["R0009807","[Real-world evidence on pharmacological appropriateness in type 2 diabetes mellitus and cardiovascular disease].","Pintos C","2023","exclude","E2","other",null,null,"non_english","high","first","opus-5.5-agent12","Spanish cross sectional study of prescribing appropriateness of cardioprotective antidiabetic drugs, no outcome comparison by exposure",1],["R0009902","Real-world evidence for comparative safety of second-line antihyperglycemic agents in older adults with type 2 diabetes.","Kim C","2026","include_harms",null,"primary_report","P01","O29",null,"high","first","opus-5.5-agent12","multinational new user cohort of second line GLP-1RA, SGLT2i, DPP4i and sulfonylureas in older T2D, safety outcomes include acute pancreatitis",1],["R0009994","Outpatient Dispensing Patterns and Changes in Tirzepatide Strength Mix in Japan: A Study Using the National Open Claims Data.","Omura T","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent12","descriptive analysis of national tirzepatide dispensing quantities and strength mix, no exposure comparison",1],["R0010078","Use of SGLT2 Inhibitors Reduces Heart Failure and Hospitalization: A Multicenter, Real-World Evidence Study.","Blanco CA","2023","inventory_only","N6","primary_report","P01",null,null,"high","first","opus-5.5-agent12","EMR cohort comparing SGLT2i, GLP-1RA, both or neither in T2D with CVD, heart failure and hospitalization outcomes",1],["R0010318","The Association Between Antidiabetic Agents and Clinical Outcomes of COVID-19 Patients With Diabetes: A Bayesian Network Meta-Analysis.","Chen Y","2022","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent12","registered pairwise and Bayesian network meta-analysis of antidiabetic agents including GLP-1RA on COVID-19 outcomes",1],["R0010444","Association of semaglutide with retained gastric contents on endoscopy: Retrospective analysis.","Gu GH","2025","include_harms",null,"primary_report","P01; P02","O36B",null,"high","first","opus-5.5-agent12","matched procedure study of semaglutide users vs referents undergoing EGD, retained gastric contents",1],["R0013989","CAPTURE: a multinational, cross-sectional study of cardiovascular disease prevalence in adults with type 2 diabetes across 13 countries.","Mosenzon O","2021","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent05","CAPTURE cross sectional survey of CVD prevalence and glucose lowering drug use; no exposure outcome comparison",1],["R0006740","Incretin-Based Therapies and Post-Bariatric Surgery Alcohol Use Disorder.","Fakhoury B","2025","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent15","TriNetX matched cohort after bariatric surgery, incretin therapy versus other antiobesity drugs; alcohol use disorder outcomes only",1],["R0006803","Pharmacokinetics and Safety of iGlarLixi in Healthy Chinese Participants: Results of a Phase 1 Randomized Study.","Xie P","2023","include_nma",null,"primary_report","P99",null,"mechanistic","high","first","opus-5.5-agent15","phase 1 RCT of two iGlarLixi dose ratios in healthy Chinese adults; pharmacokinetics plus adverse events reported",1],["R0006868","GLP-1 receptor agonists or SGLT2-inhibitors? Evaluation of a personalized treatment algorithm for individuals with type 2 diabetes: a registry-based cohort study.","Mori T","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent15","DPV registry new user cohort of GLP-1 RA versus SGLT2i initiators; nonfatal ASCVD events only, treatment algorithm evaluation",1],["R0007006","Use of GLP-1 Receptor Agonists and SGLT2 Inhibitors Among Patients with Type 1 Diabetes: A Nationwide Register-Based Cohort Study.","Lim CE","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent15","Swedish register study of GLP-1 RA and SGLT2i use prevalence in type 1 diabetes; DKA reported only for SGLT2i users",1],["R0007143","Semaglutide reduces cardiovascular events regardless of metformin use: a post hoc subgroup analysis of SUSTAIN 6 and PIONEER 6.","Husain M","2022","include_nma",null,"pooled_analysis","P01",null,null,"high","first","opus-5.5-agent15","post hoc pooled SUSTAIN 6 and PIONEER 6 metformin subgroups plus trial level synthesis of seven CVOTs without systematic search",1],["R0014072","New Fuels for a Failing Engine: The Impact of Novel Heart Failure Drugs on Functional Capacity.","Baracchini N","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent05","narrative critical synthesis of heart failure drugs on exercise capacity without systematic eligibility or pooling",1],["R0014176","Postprandial Glucagon Reductions Correlate to Reductions in Postprandial Glucose and Glycated Hemoglobin with Lixisenatide Treatment in Type 2 Diabetes Mellitus: A Post Hoc Analysis.","Ahrén B","2016","include_nma",null,"pooled_analysis","P01",null,null,"high","first","opus-5.5-agent05","post hoc pooled analysis of GetGoal-M and GetGoal-S placebo controlled lixisenatide RCTs on glucagon and HbA1c",1],["R0014258","Evaluating the Impact of Novel Incretin Therapies on Cardiovascular Outcomes in Type 2 Diabetes: An Early Systematic Review.","Salmen T","2024","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent05","registered systematic review of tirzepatide and retatrutide trials on cardiovascular risk in type 2 diabetes, two named databases",1],["R0014363","Tirzepatide and Metformin Effects on Hunger and BMI in an Adolescent with Hyperphagia and Severe Obesity due to MC4R Deficiency: A Case Report.","van der Walle EEPL","2026","inventory_only","N5","other",null,null,null,"high","first","opus-5.5-agent05","single adolescent case report of tirzepatide and metformin for MC4R deficiency obesity",1],["R0014519","Investigation of Thyroid Disorders in Women with Diabetes in the United Arab Emirates: A Retrospective Cross-Sectional Study.","Mussa BM","2025","inventory_only","N5","other",null,null,null,"high","first","opus-5.5-agent05","retrospective cross sectional chart study of thyroid dysfunction by diabetes medication in women; cross sectional design",1],["R0014651","Effects of once-weekly dulaglutide on kidney function in patients with type 2 diabetes in phase II and III clinical trials.","Tuttle KR","2017","include_nma",null,"pooled_analysis","P01",null,null,"high","first","opus-5.5-agent05","integrated analysis of dulaglutide phase 2 and 3 RCTs versus placebo and active comparators on kidney function and renal adverse events",1],["R0006305","A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings.","Véniant MM","2024","include_nma",null,"primary_report","P02",null,"mechanistic","high","first","opus-5.5-agent11","phase 1 randomized placebo controlled trial of maridebart cafraglutide in obesity reporting weight and safety; also preclinical work",1],["R0006397","Association of GLP-1 receptor agonist use with psychiatric outcomes in adults with type 2 diabetes: a target trial emulation.","Tang H","2026","include_harms",null,"primary_report",null,"O35A",null,"high","first","opus-5.5-agent11","target trial emulation of GLP-1RA versus SGLT2i or DPP-4i initiators; psychiatric outcomes include suicidal ideation",1],["R0006532","Effects of Once-Weekly Semaglutide on Kidney Disease Outcomes by KDIGO Risk Category in the SUSTAIN 6 Trial.","Tuttle KR","2024","include_nma",null,"secondary_report","P01; P08A",null,null,"high","first","opus-5.5-agent11","SUSTAIN 6 post hoc analysis by KDIGO risk category; randomized semaglutide versus placebo",1],["R0006662","Efficacy and Safety of Cagrilintide Alone and in Combination with Semaglutide (Cagrisema) as Anti-Obesity Medications: A Systematic Review and Meta-Analysis.","Dutta D","2024","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent11","registered meta-analysis of RCTs of cagrilintide and cagrilintide semaglutide versus semaglutide or placebo",1],["R0006725","Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists and Thyroid Function Tests: A Systematic Review Identifying a Critical Evidence Gap.","Salama S","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent11","systematic review with four named sources of GLP-1RA effects on thyroid function including RCTs; narrative synthesis",1],["R0006793","Divergent Risks of Hematologic Malignancies Associated with GLP-1 Receptor Agonists and SGLT2 Inhibitors: Preliminary Findings from a Pilot Network Meta-Analysis.","Lin PY","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent11","registered network meta-analysis of RCTs of GLP-1RAs and SGLT2i on hematologic malignancy; eight named databases",1],["R0008709","Efficacy of SGLT2 inhibitors, GLP-1 receptor agonists, and aerobic exercise for moderate-to-severe obstructive sleep apnea in overweight or obese patients: a network meta-analysis.","Zheng J","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent17","network meta-analysis of RCTs of SGLT2 inhibitors, GLP-1 RAs and exercise for obstructive sleep apnea, four databases",1],["R0008861","Euglycemic Ketoacidosis Following the Use of Counterfeit Semaglutide for Weight Loss.","Sterckx M","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent17","case report of euglycemic ketoacidosis after counterfeit semaglutide",1],["R0008946","Low discontinuation rate of tirzepatide treatment in Japanese patients with diabetes mellitus; importance of traditional Japanese diet.","Hiraide T","2025","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent17","single group real world report of tirzepatide discontinuation and diet in Japanese diabetes patients",1],["R0009008","How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes?: Completed and Ongoing Mechanistic Trials.","Lee MMY","2020","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent17","narrative review of completed and ongoing mechanistic trials of SGLT2 inhibitors and GLP-1 RAs",1],["R0011337","Pharmacokinetics, Safety, and Tolerability of Oral Semaglutide in Subjects With Hepatic Impairment.","Baekdal TA","2018","inventory_only","N1","primary_report",null,null,null,"high","first","opus-5.5-agent06","open label PK study of oral semaglutide in hepatic impairment groups versus normal function; all receive drug, no randomized comparison",1],["R0011556","A Systematic Literature Review and Network Meta-Analysis Comparing Once-Weekly Semaglutide with Other GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Previously Receiving Basal Insulin.","Witkowski M","2018","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent06","SLR based Bayesian NMA of once weekly semaglutide versus other GLP-1 RAs added to basal insulin in T2D",1],["R0011625","Novel glucose-lowering drugs and the risk of acute kidney injury in routine care; the Stockholm CREAtinine Measurements (SCREAM) project.","Alkas J","2023","include_harms",null,"primary_report",null,"O121",null,"high","first","opus-5.5-agent06","SCREAM new user cohort of SGLT2 inhibitor, GLP-1 RA and DPP-4 inhibitor initiators; acute kidney injury outcome",1],["R0011729","Development of a Follow-Up Protocol for Patients Treated with Injectable Semaglutide for Weight Loss: Design of a Research Study in Community Pharmacy.","Acuña Elvira N","2026","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent06","design of a planned community pharmacy quasi experimental follow up of semaglutide or tirzepatide users; no results",1],["R0011840","Efficacy and safety of iGlarLixi versus IDegAsp in people with type 2 diabetes inadequately controlled with basal insulin: A systematic literature review and network meta-analysis of non-Asian studies.","Home P","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent06","SLR and NMA of RCTs comparing iGlarLixi with IDegAsp after basal insulin in T2D",1],["R0011933","Dose-Dependent Efficacy and Safety of Tirzepatide for Weight Loss in Non-diabetic Adults With Obesity: A Systematic Review and Meta-analysis of Randomized Controlled Trials.","Kasagga A","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent06","systematic review and meta-analysis of RCTs of tirzepatide doses versus placebo in obesity without diabetes",1],["R0012038","Informing and Empowering Patients and Clinicians to Make Evidence-Supported Outcome-Based Decisions in Relation to SGLT2 Inhibitor Therapies: The Use of the Novel Years of Drug administration (YoDa) Concept.","Varadhan L","2022","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent06","review proposing years of drug administration metric for SGLT2 inhibitor trials; no GLP-1 RA focus",1],["R0008423","The global clinical trial landscape for non-alcoholic fatty liver disease (NAFLD): current status and future prospects.","Sun J","2025","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent02","landscape analysis of registered NAFLD trials with docking and transcriptome work; no drug exposure studied in people",1],["R0008502","Efficacy and Safety of iGlarLixi Versus IDegAsp by Baseline Age, Disease Duration and HbA1c in Chinese People With Type 2 Diabetes: Post Hoc Analyses of the Soli-D Study.","Zhang S","2026","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent02","post hoc subgroup analyses of Soli-D RCT of iGlarLixi vs IDegAsp in Chinese adults with type 2 diabetes",1],["R0008572","Obesity burden among heart failure patients in an urban safety net hospital: Implications for GLP-1 agonist therapy.","Yee T","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent02","cross sectional record query of obesity burden and GLP-1 RA eligibility in heart failure admissions; no drug exposure",1],["R0008725","Comparative effectiveness of tirzepatide and semaglutide for obesity management in US clinical practice: a 6-month retrospective cohort study.","le Roux CW","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent02","Truveta cohort of tirzepatide vs semaglutide initiators on 6 month weight and cardiometabolic change; no listed harm",1],["R0008968","Liraglutide for Lower Limb Perfusion in People With Type 2 Diabetes and Peripheral Artery Disease: The STARDUST Randomized Clinical Trial.","Caruso P","2024","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent02","open label RCT of liraglutide vs conventional care on foot perfusion in type 2 diabetes with peripheral artery disease",1],["R0009714","Favorable impact of long-term SGLT2 inhibitor for NAFLD complicated by diabetes mellitus: A 5-year follow-up study.","Akuta N","2022","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent14","case series of six NAFLD patients on long term canagliflozin, GLP-1 RA added in two, no comparison group",1],["R0009905","The Effects of Tirzepatide on Lipid Profile: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.","Mahar MU","2024","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent14","PROSPERO registered meta-analysis of tirzepatide RCTs on lipids, PubMed and ClinicalTrials.gov searched",1],["R0010010","Tolerability and Effectiveness of Switching to Dulaglutide in Patients With Type 2 Diabetes Inadequately Controlled With Insulin Therapy.","Kim Y","2022","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent14","retrospective single arm study of switching insulin to dulaglutide, groups defined by later insulin resumption",1],["R0010154","Changes in Heart Rate Associated with Exenatide Once Weekly: Pooled Analysis of Clinical Data in Patients with Type 2 Diabetes.","Marso SP","2018","include_nma",null,"pooled_analysis","P01",null,null,"high","first","opus-5.5-agent14","pooled post hoc analysis of 11 RCTs of exenatide once weekly vs comparators, heart rate changes",1],["R0010251","Cardiovascular and kidney benefits of GLP-1 receptor agonists across large randomized placebo-controlled trials.","Yoshiji S","2025","inventory_only","N9","ancillary",null,null,null,"high","first","opus-5.5-agent14","commentary on a meta-analysis of GLP-1 RA cardiovascular and kidney outcome trials",1],["R0010323","Five comparative cohorts to assess the risk of genital tract infections associated with sodium-glucose cotransporter-2 inhibitors initiation in type 2 diabetes mellitus.","Alkabbani W","2022","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent14","new user cohorts SGLT2i vs comparators including GLP-1 RA, genital tract infections only",1],["R0009794","Peritoneal Incretin Deficiency and Tirzepatide as a Multi-Axis Adjuvant Hypothesis in Treatment-Refractory Endometriosis: A Mechanistic Framework Linking Metabolism, Immunity, Fibrosis, and Nociception.","Jacobsen L","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent08","mechanistic hypothesis paper proposing tirzepatide for refractory endometriosis; no data",1],["R0009788","Weight changes following antidiabetic mediation use: Real-world evidence from health system data.","Lyu B","2022","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent07","health system cohort of GLP-1RA, SGLT2i, DPP-4i and sulfonylurea initiators; weight change outcomes only",1],["R0009885","The Antiobesity Effect of GLP-1 Receptor Agonists Alone or in Combination with Metformin in Overweight /Obese Women with Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis.","Lyu X","2021","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent08","PROSPERO registered meta-analysis of RCTs of GLP-1 RA with or without metformin versus metformin in PCOS",1],["R0009967","HbA1c Change and Diabetic Retinopathy During GLP-1 Receptor Agonist Cardiovascular Outcome Trials: A Meta-analysis and Meta-regression.","Bethel MA","2021","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent08","systematic review and meta-regression of placebo controlled GLP-1 RA CVOTs on retinopathy; MEDLINE, Embase, Cochrane",1],["R0010056","Efficacy and safety of efpeglenatide in key patient subgroups from the BALANCE randomized trial, stratified by pre-diabetes status, BMI, and age at baseline.","Pratley RE","2022","include_nma",null,"secondary_report","P02; P06",null,null,"high","first","opus-5.5-agent08","BALANCE subgroup analyses of randomized efpeglenatide doses versus placebo by prediabetes, BMI and age",1],["R0010136","ABSTRACT NUMBER: ESOC2026A262 STROKE RISK WITH SGLT2I, GLP-1RA, AND DPP-4I IN TYPE 2 DIABETES: REAL-WORLD LONGITUDINAL ESTIMATES IN THE CONTEXT OF TRIAL AND OBSERVATIONAL EVIDENCE",null,"2026","inventory_only","N6","conference_abstract",null,null,"abstract_only","high","first","opus-5.5-agent08","conference abstract of Swedish registry cohort of SGLT2i, GLP-1 RA, DPP-4i and stroke; no harms list outcome",1],["R0010232","Increased risk of hair loss with GLP-1 receptor agonists: A real-world multicenter TrinetX cohort study.","Vidal SI","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent08","TriNetX matched cohort letter of GLP-1 RA users versus nonusers on nonscarring hair loss",1],["R0010425","Current Drug Development Pipeline for MASLD and MASH: Focusing on Cardiovascular Comorbidities.","Prikhodko VA","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent08","narrative review of MASLD and MASH drug pipeline with cardiovascular focus",1],["R0009882","Refining the link between obesity and heart failure: insights from GLP-1 receptor agonist trials and studies adopting direct adiposity measures.","Pugliese NR","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent07","narrative review on obesity, heart failure and GLP-1RA trials with epicardial fat",1],["R0009954","Adiponectin may play a crucial role in the metabolic effects of GLP-1RAs treatment in patients with Type 2 Diabetes Mellitus: a preliminary longitudinal study.","Al Refaie A","2025","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent07","prospective single group cohort of T2D patients starting dulaglutide or semaglutide with 12 month before after measures",1],["R0010052","Risk of Thyroid Cancer Associated with Use of Liraglutide and Other Antidiabetic Drugs in a US Commercially Insured Population.","Funch D","2021","include_harms",null,"primary_report",null,"O32B",null,"high","first","opus-5.5-agent07","claims based new user cohorts of liraglutide vs other antidiabetics with thyroid cancer outcome",1],["R0010224","Diabetes and Stroke: What Are the Connections?","Mosenzon O","2023","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent07","narrative review of diabetes and stroke including GLP-1RA prevention evidence",1],["R0010293","Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER.","Shaman AM","2022","include_nma",null,"pooled_analysis","P01",null,null,"high","first","opus-5.5-agent07","pooled analysis of SUSTAIN 6 and LEADER placebo controlled RCTs on kidney outcomes in type 2 diabetes",1],["R0010420","CVOT Summit Report 2025: advances along the cardiovascular-kidney-metabolic disease continuum.","Schnell O","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent07","conference summit report summarizing cardiovascular kidney metabolic trials and guidelines",1],["R0010525","Understanding reasons for initiation and experience with tirzepatide among individuals with obesity or overweight: Results from the PERCEPTIONS survey.","Gibble TH","2026","inventory_only","N5","primary_report","P02",null,null,"high","first","opus-5.5-agent12","baseline cross sectional survey of tirzepatide initiators with obesity, no comparison group",1],["R0010640","The prevalence of cardiovascular disease and antidiabetes treatment characteristics among a large type 2 diabetes population in the United States.","Weng W","2019","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent12","cross sectional claims analysis of ASCVD prevalence and antidiabetic drug use, no exposure outcome comparison",1],["R0010743","Effects of Renal Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide.","Urva S","2021","inventory_only","N1","primary_report","P99",null,null,"high","first","opus-5.5-agent12","open label single dose tirzepatide PK study by renal function group, all exposed, no drug comparison; alternative N2",1],["R0010810","Health care resource utilization and health care costs among digital weight-loss intervention participants and nonparticipants.","Tak C","2025","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent12","matched claims study of digital weight program participation, GLP-1RA claims only an outcome",1],["R0010903","SGLT2 Inhibitors and the Clinical Implications of Associated Weight Loss in Type 2 Diabetes: A Narrative Review.","Janež A","2021","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent12","narrative review of SGLT2 inhibitor weight loss, GLP-1RAs not studied",1],["R0011071","Long- and Short-Term Cost-Effectiveness of Once-Weekly Semaglutide versus Dulaglutide for the Treatment of Type 2 Diabetes in China: A Hypothetical Modeling Exercise.","Hu Y","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent12","cost effectiveness modeling of semaglutide vs dulaglutide in China",1],["R0011165","Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging.","Flint A","2021","include_nma",null,"primary_report","P09",null,null,"high","first","opus-5.5-agent12","72 week double blind RCT semaglutide vs placebo in NAFLD, liver stiffness, steatosis, weight and HbA1c",1],["R0009086","Gastrointestinal adverse events associated with tirzepatide: A bibliometric and pharmacovigilance analysis.","Shen P","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent16","FAERS disproportionality and bibliometric analysis of tirzepatide gastrointestinal adverse events",1],["R0009176","Impact on HbA1c and body weight of switching from other GLP-1 receptor agonists to semaglutide: A model-based approach.","Overgaard RV","2019","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent16","exposure response modeling simulating switches to semaglutide from other GLP-1RAs; simulated outcomes only",1],["R0009233","Generalizability of glucagon-like peptide-1 receptor agonist cardiovascular outcome trials to the overall type 2 diabetes population in the United States.","Boye KS","2019","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent16","claims based generalizability analysis of GLP-1RA outcome trial eligibility; no drug exposure studied",1],["R0009359","The Role of Antidiabetic Therapies in Mild Cognitive Impairment and Alzheimer's Disease: A Systematic Review of Metformin, Pioglitazone, and GLP-1 Receptor Agonists.","Mahoon DA","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent16","PROSPERO registered systematic review of metformin, pioglitazone and GLP-1RA studies in MCI and Alzheimer disease",1],["R0009459","GLP-1-based incretin therapy is associated with lower incident Alzheimer's disease and cardiorenal events in adults with documented neuropsychiatric, cognitive, or sensory risk.","Murugadoss K","2026","include_harms",null,"primary_report",null,"O121",null,"high","first","opus-5.5-agent16","new user target trial emulation of GLP-1 based therapy vs other antidiabetics; reports acute kidney injury alongside dementia",1],["R0009564","Response to the Letter to the Editor for \"Association of GLP-1 Receptor Agonist Use With Risk of Lumbar Degenerative Disease and Spine Surgery in Patients With Type 2 Diabetes: A Propensity Score-Matched Cohort Study\".","Chang Y","2026","inventory_only","N9","ancillary",null,null,null,"high","first","opus-5.5-agent16","authors reply about a matched cohort of GLP-1RA use and lumbar degenerative disease",1],["R0009646","Improved health-related quality of life with tirzepatide versus semaglutide in adults with obesity or overweight from the SURMOUNT-5 trial.","Shukla AP","2026","include_nma",null,"secondary_report","P02",null,null,"high","first","opus-5.5-agent16","secondary analysis of SURMOUNT-5 RCT tirzepatide vs semaglutide in obesity without diabetes; quality of life",1],["R0009724","Old and new classes of glucose-lowering agents as treatments for non-alcoholic fatty liver disease: A narrative review.","Miao L","2022","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent16","narrative review of glucose lowering drugs for NAFLD",1],["R0007879","Advances in the Insulin-Heart Axis: Current Therapies and Future Directions.","Caturano A","2024","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent19","broad review of insulin heart axis therapies; databases searched but studies chosen by relevance, no eligibility criteria or synthesis",1],["R0007942","The role of glucagon-like peptide-1 receptor (GLP-1R) agonists in enhancing endothelial function: a potential avenue for improving heart failure with preserved ejection fraction (HFpEF).","Hullon D","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent19","narrative review of GLP-1 RA and endothelial function in HFpEF; no systematic methods",1],["R0008013","Atrial fibrillation reporting with semaglutide versus tirzepatide in eudravigilance: a comparative disproportionality analysis",null,"2026","inventory_only","N5","conference_abstract",null,null,"abstract_only","high","first","opus-5.5-agent19","EudraVigilance disproportionality comparison of atrial fibrillation reports for semaglutide and tirzepatide; abstract",1],["R0008073","Tirzepatide for the treatment of obesity: Rationale and design of the SURMOUNT clinical development program.","le Roux CW","2023","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent19","rationale and design with baseline data of SURMOUNT phase 3 RCTs of tirzepatide vs placebo; no efficacy results",1],["R0008168","O-SEMA-FAST: A Prospective, Non-interventional Study Investigating Oral Semaglutide Use in Adults with Type 2 Diabetes Mellitus During Ramadan.","Hassanein M","2025","inventory_only","N1","primary_report",null,null,null,"high","first","opus-5.5-agent19","prospective single arm non interventional study of oral semaglutide during Ramadan; no comparison group",1],["R0008259","Comparing the Efficacy and Safety of Glucagon-Like Peptide 1 Receptor Agonists with Sodium-Glucose Cotransporter 2 Inhibitors for Obese Type 2 Diabetes Patients Uncontrolled on Metformin: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.","Ding L","2020","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent19","meta-analysis of RCTs comparing GLP-1 RA vs SGLT2 inhibitors in obese type 2 diabetes on metformin; PubMed Embase CENTRAL",1],["R0008331","All GLP-1 Agonists Should, Theoretically, Cure Alzheimer's Dementia but Dulaglutide Might Be More Effective Than the Others.","Fessel J","2024","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent19","opinion review arguing GLP-1 agonists could cure Alzheimer disease; no primary data or systematic methods",1],["R0008413","Increasing skeletal muscle mass and strength during incretin-based weight loss.","Mendias CL","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent19","retrospective case series of men on tirzepatide plus testosterone and exercise; no comparison group",1],["R0011107","Demographic Mix of Care Homes and Personalised Use of SGLT-2 Inhibitors and GLP-1RAs in Residents with Type 2 Diabetes Mellitus.","Sinclair AJ","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent04","narrative review on personalized SGLT2i and GLP-1 RA use in care home residents with diabetes",1],["R0011213","Long-acting exenatide does not prevent cognitive decline in mild cognitive impairment: a proof-of-concept clinical trial.","Dei Cas A","2024","include_nma",null,"primary_report","P99",null,null,"high","first","opus-5.5-agent04","open label RCT of exenatide extended release vs no treatment in mild cognitive impairment, P99 MCI not confirmed Alzheimer, ADAS-Cog reported",1],["R0011331","Efficacy and Safety of Dulaglutide Compared to Liraglutide: A Systematic Review and Meta-analysis in Patients with Type 2 Diabetes Mellitus.","Taheri S","2019","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent04","systematic review and meta-analysis of RCTs comparing dulaglutide with liraglutide in type 2 diabetes",1],["R0011411","Budget Impact of Oral Semaglutide Intensification versus Sitagliptin among US Patients with Type 2 Diabetes Mellitus Uncontrolled with Metformin.","Wehler E","2021","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent04","budget impact model of oral semaglutide vs sitagliptin using CORE Diabetes Model",1],["R0011544","Tirzepatide: A Double Agonist for Various People Living with Type 2 Diabetes.","Strollo F","2024","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent04","short commentary summarizing tirzepatide trial data in type 2 diabetes",1],["R0011622","Association of glucagon-like peptide receptor 1 agonist therapy with the presence of gastric contents in fasting patients undergoing endoscopy under anesthesia care: a historical cohort study.","Wu F","2024","include_harms",null,"primary_report",null,"O36B",null,"high","first","opus-5.5-agent04","historical EGD procedure cohort comparing GLP-1 RA users with later starters on retained gastric contents",1],["R0011723","Preference for Oral and Injectable GLP-1 RA Therapy Profiles in Japanese Patients with Type 2 Diabetes: A Discrete Choice Experiment.","Igarashi A","2021","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent04","discrete choice experiment of hypothetical oral vs injectable GLP-1 RA profiles in drug naive patients, no exposure",1],["R0011832","Tirzepatide versus other anti-diabetic agents for the prevention of diabetic foot complications in patients with type 2 diabetes.","Kuo CY","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent04","TriNetX new user cohorts tirzepatide vs other agents, diabetic foot complications only, none in harms list",1],["R0010596","[Side effects and pharmacovigilance of GLP1 agonists].","Maria Tablado MA","2026","exclude","E4","ancillary",null,null,"non_english","high","first","opus-5.5-agent03","Spanish letter correcting errors in an editorial on GLP-1 adverse effects; parent editorial is out of scope",1],["R0010704","Effect of bariatric surgery and pharmacological treatments on cardiovascular risk factors for adults with overweight and obesity: a systematic review and network meta-analysis.","Yang Y","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent03","NMA of RCTs of bariatric surgery and drugs incl. liraglutide and semaglutide in obesity; four databases searched",1],["R0010792","Patient Perceptions of Ozempic (Semaglutide) for Weight Loss: Mixed Methods Analysis of Online Medication Reviews.","Armanious AJ","2026","exclude","E2","primary_report",null,null,null,"high","first","opus-5.5-agent03","mixed methods analysis of online Ozempic user reviews; qualitative, no exposure comparison",1],["R0010848","Cost-Effectiveness of Tirzepatide Versus Liraglutide, Both Adjunct to Diet and Exercise, for Patients with Obesity or Overweight: A UK Perspective.","Capehorn M","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent03","cost effectiveness simulation model of tirzepatide vs liraglutide for obesity, UK perspective",1],["R0010956","Muscle Loss in Obesity Therapy as a Therapeutic Target: Trial Design and Endpoints for Regulatory Discussions.","von Haehling S","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent03","meeting report on muscle loss with incretin obesity therapy and regulatory trial endpoints",1],["R0011033","Liraglutide in mild to moderate Alzheimer's disease: a phase 2b clinical trial.","Edison P","2026","include_nma",null,"primary_report","P13A",null,null,"high","first","opus-5.5-agent03","ELAD phase 2b double blind RCT of liraglutide vs placebo for 52 weeks in mild to moderate Alzheimer disease",1],["R0011106","Women and Diabetes: Preventing Heart Disease in a New Era of Therapies.","Galati G","2021","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent03","narrative review of cardiovascular prevention therapies for women with diabetes",1],["R0011211","Design and rationale for the randomised, double-blinded, placebo-controlled Liraglutide to Improve corONary haemodynamics during Exercise streSS (LIONESS) crossover study.","Myat A","2015","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent03","design and rationale paper of LIONESS crossover RCT of liraglutide vs placebo in stable angina; no results",1],["R0009904","The short-term cost-effectiveness of once-weekly semaglutide versus once-weekly dulaglutide for the treatment of type 2 diabetes mellitus in Colombian adults.","Liebisch-Rey H","2023","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent13","cost of control economic evaluation of semaglutide vs dulaglutide using SUSTAIN 7 data",1],["R0010008","Long-term safety and efficacy of the sodium-glucose cotransporter 2 inhibitor, tofogliflozin, added on glucagon-like peptide-1 receptor agonist in Japanese patients with type 2 diabetes mellitus: A 52-week open-label, multicenter, post-marketing clinical study.","Terauchi Y","2019","inventory_only","N1","primary_report",null,null,null,"high","first","opus-5.5-agent13","single arm post-marketing study of tofogliflozin added to GLP-1 agonist therapy",1],["R0010079","The clinical development program of lixisenatide: a once-daily glucagon-like Peptide-1 receptor agonist.","Bain SC","2014","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent13","narrative review of the lixisenatide clinical development program",1],["R0010246","Design considerations for future renoprotection trials in the era of multiple therapies for chronic kidney disease.","Zhu D","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent13","review of design considerations for future kidney trials",1],["R0010319","Effects of glucagon-like peptide-1 receptor agonists on weight loss in patients with type 2 diabetes: a systematic review and network meta-analysis.","Sun F","2015","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent13","network meta-analysis of GLP-1 agonist RCTs on weight in type 2 diabetes from four databases",1],["R0010446","Efficacy of Weight-Lowering Agents on Fat Distribution: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.","Qiao X","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent13","network meta-analysis of weight lowering drug RCTs including GLP-1 agonists on fat distribution",1],["R0010526","Clinical Benefits of Treating Patients with Type 2 Diabetes Mellitus with iGlarLixi: A Patient-Level Simulation Study.","Chauhan A","2023","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent13","Monte Carlo patient level simulation of iGlarLixi effects in real world cohorts",1],["R0009099","The adverse effects associated with tirzepatide use in patients at increased risk of cardiovascular events: a systematic review with meta-analysis and Trial Sequential Analysis.","Sillassen CDB","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent18","registered systematic review with meta-analysis and TSA of tirzepatide vs placebo RCTs on adverse effects; six databases",1],["R0009247","Semaglutide Plus Low-Dose Metformin Combination Therapy for the Treatment of Obesity and Prediabetes in a Woman with Partial Deletion of the X Chromosome Long Arm.","Marzolla V","2026","inventory_only","N5","other",null,null,null,"high","first","opus-5.5-agent18","case report of semaglutide plus metformin in a woman with partial Xq deletion and obesity",1],["R0009465","Efficacy and Safety of Novel Twincretin Tirzepatide, a Dual GIP/GLP-1 Receptor Agonist, as an Anti-obesity Medicine in Individuals Without Diabetes: A Systematic Review and Meta-analysis.","Dutta D","2024","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent18","registered systematic review and meta-analysis of tirzepatide vs placebo RCTs in obesity without diabetes; named databases",1],["R0009574","Trends in Glucagon-Like Peptide-1 Agonist Use and BMI Among Obese Adults With Type 2 Diabetes: Analysis of the 2010-2015 National Ambulatory Medical Care Survey (NAMCS), Adjusted for Cardiovascular Comorbidity.","Eneh V","2025","inventory_only","N5","other",null,null,null,"high","first","opus-5.5-agent18","cross sectional NAMCS analysis of GLP-1 RA prescribing and BMI among obese adults with T2D",1],["R0009650","Geographic variation and racial disparities in adoption of newer glucose-lowering drugs with cardiovascular benefits among US Medicare beneficiaries with type 2 diabetes.","Chen WH","2024","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent18","Medicare claims study of geographic and racial variation in initiation of newer glucose lowering drugs; utilization only",1],["R0007381","Effects of semaglutide on kidney disease in type 2 diabetes: a randomized placebo-controlled trial.","Tuttle KR","2026","include_nma",null,"primary_report","P08A",null,"mechanistic","high","first","opus-5.5-agent10","52 week RCT semaglutide 1 mg versus placebo in T2D with CKD; kidney MRI, biopsy and transcriptomic mechanistic outcomes",1],["R0008497","Metabolic dysfunction and the use of adjunct medications in type 1 diabetes.","Luk A","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent01","self described narrative review of adjunct metformin, GLP-1 RA and SGLT2i use in type 1 diabetes",1],["R0007432","Efficacy and safety of cAMP signalling-biased GLP-1 analogue ecnoglutide monotherapy versus placebo in patients with type 2 diabetes (EECOH-1): a multi-centre, randomised, double-blind, placebo-controlled, phase 3 trial.","Zhu D","2026","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent10","phase 3 double blind RCT ecnoglutide 0.6 and 1.2 mg versus placebo in T2D; HbA1c at 24 weeks",1],["R0007501","The concentration-dependent protective effects by new generation hypoglycemic agents on delirium, depression, dementia and coma: evidence from a network meta-analysis.","Tseng PT","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent10","PROSPERO registered NMA of RCTs of GLP-1 RAs and SGLT2i on delirium, depression, dementia; eight databases searched",1],["R0007559","Cardiovascular and Renal Effectiveness of GLP-1 Receptor Agonists vs. Other Glucose-Lowering Drugs in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Real-World Studies.","Caruso I","2022","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent10","systematic review and meta-analysis of real world studies GLP-1 RA versus other glucose lowering drugs; PubMed and Web of Science",1],["R0007636","Experimental drugs for the treatment of idiopathic intracranial hypertension (IIH): shedding light on phase I and II trials.","Khatkar P","2023","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent10","expert opinion review of experimental IIH drugs including exenatide trials; no systematic methods",1],["R0007711","Fixed-Ratio Combination of Insulin and GLP-1 RA in Patients with Longstanding Type 2 Diabetes: A Subanalysis of LixiLan-L.","Blonde L","2020","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent10","post hoc by diabetes duration of LixiLan-L RCT iGlarLixi versus insulin glargine; HbA1c and hypoglycemia",1],["R0007850","Incretin Hormone Secretion in Women with Polycystic Ovary Syndrome: Roles of Obesity, Insulin Sensitivity and Treatment with Metformin and GLP-1s.","Etrusco A","2024","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent10","self described narrative review of incretins, metformin and GLP-1 RAs in PCOS",1],["R0008652","GLP-1 Receptor Agonist Use and Risk of Suicide Death.","Ueda P","2024","include_harms",null,"primary_report",null,"O35B",null,"high","first","opus-5.5-agent01","Swedish and Danish active comparator new user cohort of GLP-1 RA versus SGLT2i initiators; suicide death outcome",1],["R0008722","Continuous Glucose Monitoring Frequency and Glycemic Control in People With Type 2 Diabetes.","Hirsch IB","2025","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent01","cross sectional study of CGM use frequency and HbA1c; GLP-1 RA appears only as a covariate, not an exposure",1],["R0008793","Cardiovascular outcomes of semaglutide and tirzepatide in type 2 diabetes mellitus and obesity: a systematic review and meta-analysis.","Zhou XY","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent01","registered meta-analysis of semaglutide and tirzepatide RCTs on cardiovascular outcomes, six sources searched",1],["R0008885","Comparison of pharmacological therapies in metabolic dysfunction-associated steatohepatitis for fibrosis regression and MASH resolution: Systematic review and network meta-analysis.","Souza M","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent01","registered network meta-analysis of MASH drug RCTs including semaglutide, tirzepatide and survodutide, PubMed and Embase searched",1],["R0008958","MON-LB032 Real World Evidence Data on the Role of Sodium/Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonist in Chronic Kidney Disease Stage 3 Patients beyond Glycemic Control, at Glycemia Clinic- Kuwait","Shaghouli A","2019","inventory_only","N6","conference_abstract",null,null,"abstract_only","high","first","opus-5.5-agent01","abstract of small retrospective comparison of GLP-1 RA, SGLT2i or both in CKD stage 3; eGFR, HbA1c and albuminuria only",1],["R0009017","GLP-1 RAs and SGLT-2 Inhibitors for Insulin Resistance in Nonalcoholic Fatty Liver Disease: Systematic Review and Network Meta-Analysis.","Yan H","2022","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent01","registered network meta-analysis of GLP-1 RA and SGLT2i RCTs on insulin resistance in NAFLD",1],["R0007912","Persistence with IDegLira in Patients in Clinical Practice: A Nationwide Observational Study in Sweden.","Eliasson B","2020","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent09","Swedish registry cohort of IDegLira initiators describing persistence and before after changes, no comparison group",1],["R0008052","Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria.","Neuen BL","2024","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent09","actuarial modeling of lifetime benefits of combined SGLT2, GLP-1 and finerenone therapy from trial estimates",1],["R0008128","Pancreatitis in Patients Receiving Tirzepatide (Mounjaro): A One-Year Audit in a UK District General Hospital.","Hossain A","2025","inventory_only","N5","other",null,null,null,"high","first","opus-5.5-agent09","single centre audit of pancreatitis admissions describing tirzepatide exposed cases, no comparison cohort",1],["R0008212","Predictors of weight reduction effectiveness with liraglutide in diabetes mellitus type 2 patients: a retrospective cohort study.","Wangpattanamongkol P","2025","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent09","retrospective single group liraglutide cohort on predictors of weight loss, no comparison group",1],["R0008307","Efficacy of cardiometabolic drugs in reduction of epicardial adipose tissue: a systematic review and meta-analysis.","Myasoedova VA","2023","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent09","PRISMA meta-analysis of GLP-1, SGLT2 and statin effects on epicardial fat, three databases searched",1],["R0008382","GLP-1 Agonists and the Risk of Pulmonary Aspiration during Elective Upper Endoscopy: A Systematic Review and Meta-analysis.","Elmati PR","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent09","PROSPERO registered meta-analysis of GLP-1 use and pulmonary aspiration at endoscopy, three databases searched",1],["R0008445","Glucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research.","Levin PA","2017","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent09","systematic review of comparative effectiveness of GLP-1 agonists versus other diabetes drugs, MEDLINE and Embase",1],["R0010699","Impact of virtual patient engagement on glycemic control in type 2 diabetes: a retrospective observational study from GluCare hybrid care model.","Zakaria H","2025","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent20","retrospective study of virtual engagement in a hybrid diabetes care model, GLP-1 RA use only a descriptive covariate",1],["R0014721","Effect of dulaglutide in promoting abstinence during smoking cessation: a single-centre, randomized, double-blind, placebo-controlled, parallel group trial.","Lengsfeld S","2023","include_nma",null,"primary_report","P14B",null,null,"high","first","opus-5.5-agent05","placebo controlled RCT of dulaglutide added to varenicline and counselling for smoking cessation, 12 weeks",1],["R0010779","Evaluation of three mechanisms of action (SGLT2 inhibitors, GLP-1 receptor agonists, and sulfonylureas) in treating type 2 diabetes with heart failure: a systematic review and network meta-analysis of RCTs.","Gao H","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent20","PROSPERO registered Bayesian NMA of RCTs of SGLT2i, semaglutide and glimepiride in T2D with heart failure",1],["R0010829","Cost-effectiveness of liraglutide versus lixisenatide as add-on therapies to basal insulin in type 2 diabetes.","Ericsson Å","2018","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent20","Swedish cohort model cost effectiveness analysis of liraglutide vs lixisenatide added to basal insulin",1],["R0010944","Modeling the Long-Term Cost-Effectiveness of IDegLira in Patients with Type 2 Diabetes Who are Failing To Meet Glycemic Targets on Basal Insulin Alone in The Netherlands.","Hunt B","2017","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent20","CORE model cost effectiveness analysis of IDegLira vs basal bolus insulin in the Netherlands",1],["R0011008","Real-World Effectiveness and Safety of iGlarLixi in People With Type 2 Diabetes in LATAM Region: A Subanalysis of the SUCCESS Study.","Arteaga-Diaz JM","2026","inventory_only","N5","secondary_report",null,null,null,"high","first","opus-5.5-agent20","regional subanalysis of prospective single arm observational iGlarLixi study, no comparison group",1],["R0011099","Semaglutide and Diabetic Retinopathy Risk: Evidence from FAERS Database Analysis and Protective Effects on High Glucose-Stimulated Retinal Microvascular Endothelial Cells","Yue X","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent20","FAERS disproportionality analysis of semaglutide and retinopathy plus in vitro endothelial cell experiments",1],["R0011310","Semaglutide use linked to lower COVID-19 and influenza severity with better renal outcomes after pandemic or seasonal infection.","Matson R","2026","include_harms",null,"primary_report",null,"O121",null,"high","first","opus-5.5-agent20","matched EHR cohort of prior semaglutide vs metformin users after COVID-19 or influenza, acute kidney injury reported",1],["R0014795","Reduction of prevalence of patients meeting the criteria for metabolic syndrome with tirzepatide: a post hoc analysis from the SURPASS Clinical Trial Program.","Nicholls SJ","2024","include_nma",null,"pooled_analysis","P01",null,null,"high","first","opus-5.5-agent05","post hoc pooled analysis of SURPASS 1 to 5 RCTs of tirzepatide versus placebo, semaglutide or insulin on metabolic syndrome",1],["R0014959","Exendin-4 Promotes Schwann Cell Survival/Migration and Myelination In Vitro.","Takaku S","2021","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent05","in vitro study of exendin-4 on rat Schwann cells and dorsal root ganglion neurons",1],["R0015060","Pharmacokinetic Properties of Liraglutide as Adjunct to Insulin in Subjects with Type 1 Diabetes Mellitus.","Mader JK","2016","inventory_only","N2","secondary_report",null,null,"crossover","high","first","opus-5.5-agent05","pharmacokinetic report of placebo controlled crossover liraglutide trial in type 1 diabetes; only PK endpoints here",1],["R0015176","Topic and Sentiment Trends in Semaglutide Discussions on X: Subpopulation-Based Longitudinal Analysis.","Momeni P","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent05","sentiment and topic analysis of social media posts about semaglutide; no drug exposure outcome comparison",1],["R0015265","The relation between tirzepatide and adverse cardiovascular events or renal adverse events: a meta-analysis based on randomized controlled trials.","Liu L","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent05","registered meta-analysis of tirzepatide RCTs on cardiovascular and renal adverse events, named databases",1],["R0015345","Prevalence of Incretin-Mimetic and Sodium-Glucose-Transporter-2-Inhibitor Therapy in German Hospitalized Type-2 Diabetics Following Myocardial Revascularization: An Observational Study.","Pliquett RU","2021","inventory_only","N6","other",null,null,null,"high","first","opus-5.5-agent05","observational cohort after revascularization comparing incretin mimetic, insulin or oral therapy on mortality and hypoglycemia; no listed harm",1],["R0007201","evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer's disease.","Cummings JL","2025","inventory_only","N8","protocol_or_design","P13A",null,null,"high","first","opus-5.5-agent15","design paper of evoke and evoke+ placebo controlled RCTs of oral semaglutide in early Alzheimer disease; no outcome results",1],["R0007256","Association between antidiabetic drugs and cancer risk in patients with type 2 diabetes mellitus: A systematic review and network meta-analysis.","An XD","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent15","registered systematic review and network meta-analysis of 87 RCTs of antidiabetic classes including GLP-1 RAs on cancer risk",1],["R0007389","Protocol for a randomised, double-blinded, controlled trial of youth with childhood-onset obesity treated with semaglutide 2.4 mg/week: the RESETTLE trial.","Byberg S","2024","inventory_only","N8","protocol_or_design","P02",null,null,"high","first","opus-5.5-agent15","protocol of RESETTLE RCT of semaglutide 2.4 mg versus placebo in young adults with childhood onset obesity",1],["R0007465","Non-inferiority and clinical superiority of glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors: Systematic analysis of cardiorenal outcome trials in type 2 diabetes.","Zaccardi F","2022","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent15","systematic search of PubMed and CENTRAL for GLP-1 RA and SGLT2i outcome trials with Bayesian reanalysis of reconstructed data",1],["R0007514","Noninsulin antidiabetic prescription patterns in Colombia: a cross-sectional study.","Machado-Alba JE","2024","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent15","cross sectional dispensing study of noninsulin antidiabetic prescription patterns in Colombia; utilization only",1],["R0007576","Real-World Effectiveness Analysis of Switching From Liraglutide or Dulaglutide to Semaglutide in Patients With Type 2 Diabetes Mellitus: The Retrospective REALISE-DM Study.","Jain AB","2021","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent15","retrospective chart review of patients switching from liraglutide or dulaglutide to semaglutide; before and after, no concurrent comparator",1],["R0007664","Structural and dynamic features of cagrilintide binding to calcitonin and amylin receptors.","Cao J","2025","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent15","cryo electron microscopy and cell assays of cagrilintide binding amylin and calcitonin receptors; in vitro only",1],["R0012145","Tirzepatide for the treatment of adults with type 2 diabetes: An endocrine perspective.","De Block C","2023","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent06","narrative review of tirzepatide efficacy and safety in T2D from an endocrine perspective",1],["R0012247","Metabolic Control and Adherence to Therapy in Type 2 Diabetes Mellitus Patients Using IDegLira in a Real-World Setting.","Melzer-Cohen C","2020","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent06","retrospective single group database study of IDegLira initiators with before and after HbA1c; not randomized",1],["R0012325","The long-term cost-effectiveness of oral semaglutide versus empagliflozin and dulaglutide in Portugal.","Malkin SJP","2022","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent06","cost-effectiveness modeling of oral semaglutide versus empagliflozin and dulaglutide in Portugal",1],["R0012436","Semaglutide and Tirzepatide reduce alcohol consumption in individuals with obesity.","Quddos F","2023","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent06","social media analysis plus remote survey comparing semaglutide or tirzepatide users with controls on alcohol intake; no listed harms",1],["R0012533","Exenatide once weekly decreases urinary albumin excretion in patients with type 2 diabetes and elevated albuminuria: Pooled analysis of randomized active controlled clinical trials.","van der Aart-van der Beek AB","2020","include_nma",null,"pooled_analysis","P01; P08A",null,null,"high","first","opus-5.5-agent06","post hoc pooled analysis of six randomized trials of exenatide weekly versus non GLP-1 comparators in T2D with albuminuria",1],["R0012605","Challenges in Modelling the Cost Effectiveness of Pharmacotherapies for Obesity.","Pennington B","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent06","methods review of challenges in cost-effectiveness modeling of obesity pharmacotherapies",1],["R0012690","Current gaps in management and timely referral of cardiorenal complications among people with type 2 diabetes mellitus in the Middle East and African countries: Expert recommendations.","Sonmez A","2022","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent06","expert consensus recommendations on cardiorenal complications of T2D in MENA and Africa",1],["R0012789","Tirzepatide on ingestive behavior in adults with overweight or obesity: a randomized 6-week phase 1 trial.","Martin CK","2025","include_nma",null,"primary_report","P02",null,"mechanistic","high","first","opus-5.5-agent06","phase 1 RCT of tirzepatide versus placebo versus liraglutide on energy intake in adults with overweight without diabetes",1],["R0011268","The Long-Term Cost-Effectiveness of Tirzepatide 5 mg versus Dulaglutide 0.75 mg for the Treatment of People with Type 2 Diabetes in Japan.","Aranishi T","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent12","cost utility modeling of tirzepatide vs dulaglutide in Japan based on SURPASS J-mono",1],["R0011371","LEAN mass Preservation with Resistance Exercise and Protein during semaglutide and tirzepatide therapy (LEAN-PREP study): a protocol for a randomised controlled trial.","Alawadhi AA","2026","inventory_only","N3","protocol_or_design","P02",null,null,"high","first","opus-5.5-agent12","protocol of RCT of exercise and protein arms on top of semaglutide or tirzepatide in all arms; alternative N8",1],["R0011467","Update to Evidence-Based Secondary Prevention Strategies After Acute Coronary Syndrome.","Fitchett DH","2020","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent12","narrative update of secondary prevention after acute coronary syndrome, explicitly not systematic",1],["R0011576","Comprehensive analysis of real-world data on liraglutide treatment in patients with obesity: a multicenter national study.","Hepşen S","2025","inventory_only","N5","primary_report","P02",null,null,"high","first","opus-5.5-agent12","retrospective multicenter single drug cohort of liraglutide for obesity, before and after weight and side effects",1],["R0011658","Obesity update: cardiovascular risk and therapeutic innovations (focus on semaglutide and tirzepatide).","Di Odoardo LAF","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent12","narrative update on semaglutide and tirzepatide in obesity and cardiovascular risk",1],["R0011754","Once-weekly glucagon-like peptide-1 receptor agonist dulaglutide significantly decreases glycated haemoglobin compared with once-daily liraglutide in Japanese patients with type 2 diabetes: 52 weeks of treatment in a randomized phase III study.","Odawara M","2016","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent12","52 week report of phase 3 RCT of dulaglutide vs liraglutide vs placebo in Japanese T2D",1],["R0011873","Efficacy and safety of PEGylated exenatide injection (PB-119) in treatment-naive type 2 diabetes mellitus patients: a Phase II randomised, double-blind, parallel, placebo-controlled study.","Ji L","2021","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent12","phase 2 double blind RCT of three PB-119 PEGylated exenatide doses vs placebo in drug naive T2D",1],["R0011969","Efficacy of polyethylene glycol loxenatide versus insulin glargine on glycemic control in patients with type 2 diabetes: a randomized, open-label, parallel-group trial.","Zhang S","2023","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent12","open label RCT of PEG-loxenatide vs insulin glargine on metformin in T2D, CGM time in range",1],["R0010447","One Year of Exercise After Weight Loss Increases Postprandial GLP-1 Secretion in Contrast to Usual Activity or GLP-1 Receptor Agonist Treatment.","Holt J","2026","include_nma",null,"secondary_report","P02",null,"mechanistic","high","first","opus-5.5-agent14","exploratory analysis of S-LITE RCT of liraglutide, exercise, combination or placebo after diet induced weight loss, postprandial GLP-1",1],["R0010533","A Significant Effect of Oral Semaglutide on Cardiovascular Risk Factors in Patients With Type 2 Diabetes.","Yanai H","2022","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent14","retrospective before and after study of 47 oral semaglutide users, no comparison group",1],["R0010643","Recommendations for Early and Comprehensive Management of Type 2 Diabetes and Its Related Cardio-Renal Complications.","Abu-Alfa AK","2023","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent14","national consensus statement on T2D cardio renal management",1],["R0010758","Glucagon-Like Peptide-1 (GLP-1)-Based Therapies and Heart Failure Outcomes: A Scoping Review of Contemporary Randomized Controlled Trials.","Patel J","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent14","scoping review of RCTs of GLP-1 based therapies on heart failure outcomes, PubMed Google Scholar CINAHL with inclusion criteria",1],["R0010814","Malnutrition is Common in Patients Utilizing Glucagon-Like Peptide-1 Agonists Prior to Total Joint Arthroplasty.","Jodoin Z","2025","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent14","chart review comparing preoperative nutrition in GLP-1 RA users vs nonusers before arthroplasty, no harms_nrs outcome",1],["R0010911","RF32 | PSUN59 Glucagon-Like Peptide-1 Analogues: A New Way to Quit Smoking? SKIP – a Randomised Controlled Study",null,"2022","include_nma",null,"conference_abstract","P14B",null,"abstract_only","high","first","opus-5.5-agent14","conference abstract of placebo controlled RCT of dulaglutide added to varenicline for smoking cessation",1],["R0010993","Therapeutic modulation of the gut-brain axis in alcohol use disorder: A systematic review.","Bhandari P","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent14","PROSPERO registered systematic review of gut brain axis interventions including GLP-1 RA trials in alcohol use disorder",1],["R0011086","Exenatide and renal outcomes in patients with type 2 diabetes and diabetic kidney disease: a multi-center, randomized, parallel study","Wang X","2020","include_nma",null,"primary_report","P08A; P01",null,null,"high","first","opus-5.5-agent14","multicenter RCT of exenatide plus glargine vs lispro plus glargine in T2D with diabetic kidney disease, 24 weeks",1],["R0010619","Effects of Insulin Plus Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in Treating Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis.","Wang W","2017","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent08","meta-analysis of RCTs of insulin plus GLP-1 RA versus control in type 1 diabetes; Embase, PubMed, Cochrane",1],["R0010719","Efficacy and Safety of Once-Weekly IcoSema in Adults With Type 2 Diabetes: A Systematic Review and Meta-Analysis.","Kamrul-Hasan ABM","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent08","PROSPERO registered meta-analysis of IcoSema RCTs versus components or basal bolus insulin; several databases",1],["R0010875","Comparative efficacy of 5 sodium-glucose cotransporter protein-2 (SGLT-2) inhibitor and 4 glucagon-like peptide-1 (GLP-1) receptor agonist drugs in non-alcoholic fatty liver disease: A GRADE-assessed systematic review and network meta-analysis of randomized controlled trials.","Gu Y","2023","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent08","network meta-analysis of RCTs of SGLT2i and GLP-1 RAs in NAFLD; four databases",1],["R0010970","Pharmacological mechanisms and clinical impacts of antidiabetic drugs on colorectal cancer risk: a systematic review.","Yang Y","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent08","self described narrative synthesis of antidiabetic drugs and colorectal cancer risk",1],["R0011056","Protocol for a randomised controlled trial of the combined effects of the GLP-1 receptor agonist liraglutide and exercise on maintenance of weight loss and health after a very low-calorie diet.","Jensen SBK","2019","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent08","protocol of S-LiTE RCT of liraglutide, exercise, both or placebo for weight maintenance after VLCD",1],["R0011129","Global trends and hotspots of treatment for nonalcoholic fatty liver disease: A bibliometric and visualization analysis (2010-2023).","Dai JJ","2023","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent08","bibliometric analysis of NAFLD treatment literature",1],["R0006861","Semaglutide and Tirzepatide in a Remote Weight Management Program: 12-Month Retrospective Observational Study.","Richards R","2025","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent11","retrospective comparison of tirzepatide and semaglutide cohorts in a remote program; weight, behavior and side effects only",1],["R0008795","Comparative effects of weight loss and incretin-based therapies on vascular endothelial function, fibrinolysis and inflammation in individuals with obesity and prediabetes: A randomized controlled trial.","Mashayekhi M","2023","include_nma",null,"primary_report","P02",null,"mechanistic","high","first","opus-5.5-agent02","randomized trial of liraglutide vs hypocaloric diet vs sitagliptin in obesity with prediabetes; vascular and weight outcomes",1],["R0010495","Effects of Semaglutide on Stroke Subtypes in Type 2 Diabetes: Post Hoc Analysis of the Randomized SUSTAIN 6 and PIONEER 6.","Strain WD","2022","include_nma",null,"pooled_analysis","P01",null,null,"high","first","opus-5.5-agent07","post hoc pooled analysis of SUSTAIN 6 and PIONEER 6 placebo controlled RCTs on stroke subtypes in type 2 diabetes",1],["R0010615","Acute Effects of Lixisenatide on Energy Intake in Healthy Subjects and Patients with Type 2 Diabetes: Relationship to Gastric Emptying and Intragastric Distribution.","Jalleh R","2020","include_nma",null,"primary_report","P01; P99",null,"mechanistic; crossover","high","first","opus-5.5-agent07","randomized double blind crossover of single dose lixisenatide vs placebo in healthy and T2D adults; gastric emptying, energy intake, nausea",1],["R0010641","Efficacy and safety of autoinjected exenatide once-weekly suspension versus sitagliptin or placebo with metformin in patients with type 2 diabetes: The DURATION-NEO-2 randomized clinical study.","Gadde KM","2017","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent13","DURATION-NEO-2 RCT of exenatide once weekly autoinjector vs sitagliptin or placebo on metformin",1],["R0010718","Novel Therapeutic Strategies for Patients With CKD and Diabetes Mellitus.","Kugathasan L","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent07","narrative review of novel therapies including incretins for CKD with diabetes",1],["R0010871","Therapeutic Effects of Semaglutide on Nonalcoholic Fatty Liver Disease with Type 2 Diabetes Mellitus and Obesity: An Open-Label Controlled Trial.","Gad AI","2024","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent07","nonrandomized open label controlled study of oral or injectable semaglutide vs pioglitazone or vitamin E in NAFLD; no listed harm",1],["R0010966","Improved postprandial glucose metabolism in type 2 diabetes by the dual glucagon-like peptide-1/glucagon receptor agonist SAR425899 in comparison with liraglutide.","Schiavon M","2021","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent07","meal test substudy of phase 2b RCT of SAR425899 dual agonist vs liraglutide vs placebo in type 2 diabetes",1],["R0011123","How to execute research projects in clinical practice in a large medium secure forensic psychiatric facility","Brandt-Christensn A","2022","exclude","E2","other",null,null,"abstract_only","high","first","opus-5.5-agent07","conference abstract describing qualitative experience of executing a nonrandomized GLP-1RA trial; no outcome comparison",1],["R0015430","Treatment patterns and associated factors in 14 668 people with type 2 diabetes initiating a second-line therapy: Results from the global DISCOVER study programme.","Nicolucci A","2019","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent05","DISCOVER analysis of second line glucose lowering treatment patterns and their predictors; drug utilization only",1],["R0006922","Micronutrient risk with GLP-1 receptor and dual incretin agonists in obesity: Mechanistic pathways, clinical signals, and a monitoring framework.","Simancas-Racines D","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent11","narrative clinical review of micronutrient risk with incretin drugs",1],["R0006997","Effects of GLP1RAs on pregnancy rate and menstrual cyclicity in women with polycystic ovary syndrome: a meta-analysis and systematic review.","Zhou L","2023","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent11","meta-analysis of RCTs of GLP-1RAs versus control in PCOS; four named databases",1],["R0007053","Kidney function loss and albuminuria progression with GLP-1 receptor agonists versus basal insulin in patients with type 2 diabetes: real-world evidence.","Schechter M","2023","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent11","Maccabi matched cohort of GLP-1RA versus basal insulin initiators; eGFR loss, kidney failure and albuminuria only",1],["R0007134","Cardiovascular and Renal Outcomes with SGLT-2 Inhibitors versus GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease: A Systematic Review and Network Meta-analysis","Yamada T","2020","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent11","network meta-analysis of RCTs comparing SGLT2i and GLP-1RAs in diabetes with CKD; PubMed, Embase, Cochrane searched",1],["R0007179","Efficacy and Safety of Semaglutide for the Management of Obese Patients With Type 2 Diabetes and Chronic Heart Failure in Real-World Clinical Practice.","Pérez-Belmonte LM","2022","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent11","retrospective single group study of semaglutide in diabetes, obesity and heart failure; no comparator",1],["R0007244","Study protocol for the investigator-initiated Danish pragmatic randomised STENO INTEN-CT trial: does screening and intervention for subclinical coronary artery disease in type 2 diabetes reduce cardiovascular events?","Funck KL","2025","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent11","protocol of STENO INTEN-CT trial of CAC guided intensification including GLP-1RA versus standard care; no results",1],["R0007989","Semaglutide vs Endoscopic Sleeve Gastroplasty for Weight Loss.","Haseeb M","2024","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent10","Markov cost effectiveness model of semaglutide versus endoscopic sleeve gastroplasty; economic evaluation",1],["R0008054","Associations Between Antidiabetic Pharmacotherapy and Hearing Thresholds in Adult Hearing-Impaired Patients With Type 2 Diabetes.","Martines F","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent10","single time audiometry records comparing hearing thresholds by antidiabetic drug class; cross sectional design",1],["R0008131","Effects of weight control interventions on cardiovascular outcomes: an umbrella review of systematic reviews and meta-analyses.","Chen X","2025","include_review",null,"systematic_review",null,null,"umbrella_review","high","first","opus-5.5-agent10","PROSPERO registered umbrella review of meta-analyses of weight control interventions including GLP-1 RAs on CV outcomes",1],["R0008220","Postmarket safety profile of suicide/self-injury for GLP-1 receptor agonist: a real-world pharmacovigilance analysis.","Chen C","2023","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent10","FAERS disproportionality analysis of suicide and self injury reports with GLP-1 RAs",1],["R0008308","Real-World Evaluation of Glycemic Outcomes and Extra-Glycemic Parameters in Diabetic Patients Treated with the Combined Formulation Degludec-Liraglutide (Ideglira).","Zenari L","2021","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent10","retrospective multicenter cohort of IDegLira switchers grouped by prior insulin regimen; no unexposed comparison",1],["R0008386","Once-Weekly Semaglutide Use in Type 2 Diabetes: Real-World Data from the SURE Netherlands Observational Study.","Wolffenbuttel BHR","2023","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent10","SURE Netherlands prospective single arm observational study of once weekly semaglutide in T2D",1],["R0008457","Comparative Efficacy and Tolerability of Tirzepatide Versus Semaglutide at Varying Doses for Weight Loss in Non-diabetic Adults With Obesity: A Network Meta-Analysis of Randomized Controlled Trials.","Kasagga A","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent10","network meta-analysis of RCTs of tirzepatide and semaglutide doses versus placebo in nondiabetic obesity",1],["R0009113","The potential role of incretin-based therapies for polycystic ovary syndrome: a narrative review of the current evidence.","Abdalla MA","2021","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent02","self described narrative review of incretin therapies in PCOS including animal studies",1],["R0009191","Effects of new hypoglycemic drugs on cardiac remodeling: a systematic review and network meta-analysis.","Huang YL","2023","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent02","registered network meta-analysis of RCTs and cohorts of GLP-1 RA, SGLT2 inhibitors and DPP-4 inhibitors on cardiac remodeling",1],["R0009285","Effect of Antidiabetic Drugs on Bone Health in Patients with Normal Renal Function and in Chronic Kidney Disease (CKD): Insight into Clinical Challenges in the Treatment of Type 2 Diabetes.","Cipriani C","2023","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent02","narrative review of antidiabetic drugs and bone health in normal kidney function and CKD",1],["R0009390","Prevalence of Obesity and Related Conditions and GLP-1 Use in Medicare Fee-for-Service Beneficiaries.","Kim S","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent02","Medicare claims prevalence of GLP-1 RA use and eligibility; utilization without exposure comparison",1],["R0009497","Glucagon-like peptide-1 receptor agonists and pancreatic cancer: a meta-analysis with trial sequential analysis.","Pinto LC","2019","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent02","registered meta-analysis with trial sequential analysis of GLP-1 RA RCTs on pancreatic cancer",1],["R0009586","The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials.","Min T","2021","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent02","narrative review of tirzepatide early trials and SURPASS programme",1],["R0009733","Efficacy and safety of once-monthly efpeglenatide in patients with type 2 diabetes: Results of a phase 2 placebo-controlled, 16-week randomized dose-finding study.","Del Prato S","2020","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent18","phase 2 double blind RCT of once monthly efpeglenatide 8, 12, 16 mg vs placebo on metformin in T2D; HbA1c, weight",1],["R0009843","Polyethylene glycol loxenatide (PEX168) in subjects with renal impairment: A pharmacokinetic study.","Wang J","2019","inventory_only","N1","primary_report",null,null,null,"high","first","opus-5.5-agent16","nonrandomized phase 1 single dose PK study of PEX168 by renal function group; no comparison of drug regimens",1],["R0010751","Gastrointestinal Tolerability of Once-Weekly Dulaglutide 3.0 mg and 4.5 mg: A Post Hoc Analysis of the Incidence and Prevalence of Nausea, Vomiting, and Diarrhea in AWARD-11.","Van J","2021","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent13","post hoc GI tolerability analysis of AWARD-11 RCT randomizing dulaglutide 1.5, 3.0 or 4.5 mg",1],["R0010909","Real-world data of tirzepatide in obesity management: a multicenter study by the Italian Society of Obesity - Campania Region.","Barrea L","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent13","retrospective multicenter series of tirzepatide users without comparison group",1],["R0010985","Does semaglutide reduce alcohol intake in Danish patients with alcohol use disorder and comorbid obesity? Trial protocol of a randomised, double-blinded, placebo-controlled clinical trial (the SEMALCO trial).","Klausen MK","2025","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent13","protocol of SEMALCO placebo controlled RCT of semaglutide in alcohol use disorder with obesity",1],["R0011078","The Use of GLP1R Agonists for the Treatment of Type 2 Diabetes in Kidney Transplant Recipients.","Kukla A","2020","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent13","retrospective series of 17 kidney transplant recipients started on GLP-1 agonists without comparison group",1],["R0011180","Dulaglutide 1.5 mg Significantly Improves Glycemic Control and Lowers LDL-Cholesterol and Body Weight in Romanian Patients with Type 2 Diabetes.","Bobu AM","2025","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent13","retrospective before after review of dulaglutide in 55 patients without comparison group",1],["R0011275","Real-world effectiveness of tirzepatide versus semaglutide for weight loss in overweight or obese patients in an ambulatory care setting.","Trinh H","2025","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent13","retrospective EHR cohort tirzepatide vs semaglutide, weight outcomes only",1],["R0015507","SEMASEARCH Study Design: Real-World Evaluation of Semaglutide 2.4 mg in Adults With Severe Obesity Underrepresented in Clinical Trials.","Bel Lassen P","2026","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent05","design paper of SEMASEARCH retrospective cohort of semaglutide 2.4 mg in severe obesity; no outcome results",1],["R0015622","Moving Mendelian Randomization From Traditional Risk Factors to Molecular Targets for Drug Development and Clinical Trials in Nephrology.","Berube AJ","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent05","narrative review of Mendelian randomization for drug targets in nephrology",1],["R0015737","Real-World Effectiveness and Safety of Finerenone in People With Type 2 Diabetes and Chronic Kidney Disease: A Spanish Multicentre Retrospective Observational Study (MEDFINE-RWD).","Moreno-Pérez O","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent05","real world cohort of finerenone initiators; GLP-1 RA appears only as background therapy, not as studied exposure",1],["R0016031","The therapeutic potential of GLP-1 receptor biased agonism.","Jones B","2022","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent05","narrative review of biased GLP-1 receptor agonism based mainly on cellular and animal studies",1],["R0016109","Pharmacologic Treatment of Pulmonary Hypertension Due to Heart Failure with Preserved Ejection Fraction: Are There More Arrows on Our Bow?","Masarone D","2024","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent05","narrative review of drug treatment for pulmonary hypertension in HFpEF",1],["R0009852","Efficacy and Safety of Tirzepatide Versus Dulaglutide in Type 2 Diabetes With or Without Established Atherosclerotic Cardiovascular Disease: A Network Meta-Analysis of Randomized Clinical Trials.","Hageen AW","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent18","registered NMA of RCTs comparing tirzepatide doses vs dulaglutide in T2D; four named databases",1],["R0009914","Rationale for, Initiation and Titration of the Basal Insulin/GLP-1RA Fixed-Ratio Combination Products, IDegLira and IGlarLixi, for the Management of Type 2 Diabetes.","Valentine V","2017","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent16","narrative review on initiating IDegLira and iGlarLixi; PubMed search without eligibility criteria",1],["R0009919","Early Dose Escalation of Tirzepatide after Switching from Semaglutide in Type 2 Diabetes Mellitus.","Kurinami N","2025","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent18","retrospective series of 15 patients switched from semaglutide to tirzepatide, grouped by maintenance dose; no comparator",1],["R0010020","Semaglutide Injection Once-Weekly for Weight Management in Adults: Results From A Randomized Phase III, Active-Controlled Study.","Ambika Gopalakrishnan U","2026","include_nma",null,"primary_report","P99",null,null,"high","first","opus-5.5-agent16","randomized phase 3 noninferiority trial of test semaglutide vs Wegovy for weight management; T2D share unclear, likely P02",1],["R0010026","Associations of semaglutide with first-time diagnosis of Alzheimer's disease in patients with type 2 diabetes: Target trial emulation using nationwide real-world data in the US.","Wang W","2024","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent18","target trial emulations of semaglutide vs other antidiabetic drugs on incident Alzheimer diagnosis; no listed harms outcome",1],["R0010089","Evaluating the long-term cost-effectiveness of fixed-ratio combination insulin degludec/liraglutide (IDegLira) versus other treatment regimens in the chinese type 2 diabetes patients.","Wei R","2023","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent16","cost effectiveness modeling of IDegLira using DUAL trial data",1],["R0010176","Semaglutide in the Real World: Attitudes of the Population.","Rušić D","2025","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent16","cross sectional population survey of awareness and attitudes toward semaglutide; no exposure comparison",1],["R0010183","Effect of liraglutide on blood pressure: a meta-analysis of liraglutide randomized controlled trials.","Zhao X","2019","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent18","meta-analysis of placebo controlled liraglutide RCTs on blood pressure; PubMed search with stated inclusion criteria",1],["R0010268","Effects of GLP-1 Agonists on Patients with Hidradenitis Suppurativa: A Systematic Review.","Caliezi A","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent16","systematic review of GLP-1RAs in hidradenitis suppurativa; Embase and PubMed searched with exclusion rules",1],["R0010273","Real-world effectiveness and safety of tirzepatide in Japanese patients with type 2 diabetes: A multi-site retrospective study.","Minakata Y","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent18","multi site retrospective single arm cohort of tirzepatide in Japanese T2D; no comparator, not a trial",1],["R0010341","Adherence to GLP-1 receptor agonist therapy administered by once-daily or once-weekly injection in patients with type 2 diabetes in Germany.","Qiao Q","2016","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent16","prescription database cohort comparing adherence to exenatide once weekly vs liraglutide once daily; no listed harm",1],["R0010358","Clinical efficacy of tirzepatide for weight regain and suboptimal glycemic control following laparoscopic sleeve gastrectomy: a case series of three patients with obesity-associated type 2 diabetes.","Fujishiro M","2026","inventory_only","N5","other",null,null,null,"high","first","opus-5.5-agent18","case series of three patients given tirzepatide for weight regain after sleeve gastrectomy",1],["R0010456","Incidence of stroke, subsequent clinical outcomes and health care resource utilization in people with type 2 diabetes: a real-world database study in France: \"INSIST\" study.","Mohammedi K","2024","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent16","SNDS cohort on stroke burden in T2D; GLP-1RA only in treatment pattern description",1],["R0008489","Cost-effectiveness of semaglutide versus dulaglutide for Type 2 Diabetes in China: A Markov Model analysis.","Chen Q","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent19","Markov cost effectiveness model of semaglutide vs dulaglutide in China; economic evaluation",1],["R0008561","Myoprotective Fat-Loss Phenotypes in Obesity-Associated Type 2 Diabetes: A 12-Month Real-World Cohort Study of Metformin-Based Treatment Regimens.","Bujdei-Tebeică I","2026","inventory_only","N6","secondary_report",null,null,null,"high","first","opus-5.5-agent19","prospective observational cohort comparing metformin based regimens incl GLP-1 RA on body composition; no listed harm",1],["R0008648","Mechanisms underlying the blood pressure lowering effects of dapagliflozin, exenatide, and their combination in people with type 2 diabetes: a secondary analysis of a randomized trial.","van Ruiten CC","2022","include_nma",null,"secondary_report","P01",null,"mechanistic","high","first","opus-5.5-agent19","secondary analysis of DECREASE RCT of dapagliflozin, exenatide, combination vs placebo in obese type 2 diabetes; blood pressure mechanisms",1],["R0008714","Ultrasound assessment of preoperative gastric volume in fasted diabetic surgical patients: A prospective observational cohort study on the effects of glucagon-like peptide-1 agonists on gastric emptying.","Wolla CD","2025","include_harms",null,"primary_report",null,"O36A; O36B",null,"high","first","opus-5.5-agent19","prospective surgical cohort of diabetic patients on GLP-1 RA vs not; gastric ultrasound full stomach and intraoperative aspiration",1],["R0008864","Abstract 138: Efficacy of oral semaglutide according to race: An exploratory subgroup analysis of the PIONEER trial program",null,"2022","include_nma",null,"conference_abstract","P01",null,"abstract_only","high","first","opus-5.5-agent19","exploratory race subgroup analysis of PIONEER RCTs of oral semaglutide vs placebo or active comparators; HbA1c and weight",1],["R0008951","Impact of Time of Injection on the Efficacy and Safety of iGlarLixi Versus IDegAsp in Chinese People With Type 2 Diabetes: Exploratory Analysis of the Soli-D Study.","Li X","2026","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent19","exploratory injection time analysis of Soli-D RCT of iGlarLixi vs IDegAsp in Chinese type 2 diabetes",1],["R0009012","Understanding the Work of the Pharmacovigilance Risk Assessment Committee (PRAC): A Quantitative Review of the Post-Authorisation Safety Evaluation of Antidiabetic Drugs from 2012 to 2022.","Le H","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent19","quantitative review of EU pharmacovigilance committee minutes on antidiabetic drug safety; regulatory document analysis",1],["R0011397","Beyond disease treatment and prevention: From geroscience and molecular hallmarks to gerotherapeutics and precision geromedicine.","Peng LN","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent20","narrative review of geroscience and gerotherapeutics",1],["R0011507","Weight Loss Effects of Once-Weekly Semaglutide 2.4 mg in Adults with and Without Type 2 Diabetes: A Systematic Review and Meta-Analysis.","Hong B","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent20","PROSPERO registered meta-analysis of semaglutide 2.4 mg vs placebo RCTs by diabetes status, PubMed search",1],["R0011604","Cost per Patient Achieving Treatment Targets and Number Needed to Treat with Tirzepatide Versus Semaglutide 1 mg in Patients with Type 2 Diabetes in the United States.","Mody RR","2023","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent20","cost per responder and NNT economic analysis using published SURPASS-2 results, not a new trial report",1],["R0011809","The association between GLP-1R expression and cardiovascular-kidney-metabolic-related diseases in non-diabetic and non-obese population: evidence triangulation using Mendelian randomization, observational and polygenic score association analysis.","Chen Z","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent20","Mendelian randomization and polygenic analysis of GLP-1R expression, no drug exposure",1],["R0011907","Signals of gastroesophageal reflux disease caused by incretin-based drugs: a disproportionality analysis using the Japanese adverse drug event report database.","Noguchi Y","2018","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent20","JADER disproportionality analysis of GERD-like symptoms with GLP-1 RAs and DPP-4i",1],["R0012006","Clinical Translation of Cardiovascular Outcome Trials in Type 2 Diabetes: Is There More or Is There Less Than Meets the Eye?","Ferrannini E","2021","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent20","methodological discussion article on interpreting cardiovascular outcome trials",1],["R0012105","Efficacy and safety of liraglutide, a once-daily human glucagon-like peptide-1 receptor agonist, in African-American people with Type 2 diabetes: a meta-analysis of sub-population data from seven phase III trials.","Shomali ME","2017","include_nma",null,"pooled_analysis","P01",null,null,"high","first","opus-5.5-agent20","patient level pooled subgroup analysis of seven randomized liraglutide phase 3 trials in African American participants",1],["R0008524","Separate and combined effects of semaglutide and empagliflozin on kidney oxygenation and perfusion in people with type 2 diabetes: a randomised trial.","Gullaksen S","2023","include_nma",null,"primary_report","P01",null,"mechanistic","high","first","opus-5.5-agent09","placebo controlled RCT of semaglutide, empagliflozin or both on kidney oxygenation in type 2 diabetes, serious adverse events reported",1],["R0008593","Incretin-based therapies for patients with type 1 diabetes: a meta-analysis.","Liu L","2019","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent09","meta-analysis of RCTs of incretin drugs including GLP-1 agonists added to insulin in type 1 diabetes, three databases",1],["R0008682","Resmetirom: An Update on Therapy for Metabolic Dysfunction-Associated Steatohepatitis (MASH).","Van Kleef LA","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent09","narrative review of resmetirom for MASH",1],["R0008759","Clinical Outcomes of GLP-1 Receptor Agonist and SGLT2 Inhibitor Combination Therapy in Heart Failure: A Real-World Propensity-Matched TriNetX Analysis.","Ahmed F","2026","include_harms",null,"primary_report",null,"O121; O33",null,"high","first","opus-5.5-agent09","TriNetX new user cohort of SGLT2 plus GLP-1 versus SGLT2 alone in heart failure, acute kidney failure and retinopathy reported",1],["R0008822","Negative Consequences of Removing GLP-1 RA Obesity Coverage: A Cross-Sectional Cohort Comparison Study.","Francis JM","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent09","cross sectional survey of employees after loss of GLP-1 obesity coverage, no exposure comparison",1],["R0008928","The Cost-Effectiveness of Subcutaneous Semaglutide Versus Empagliflozin in Type 2 Diabetes Uncontrolled on Metformin Alone in Denmark.","Ehlers LH","2022","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent09","Core Diabetes Model cost effectiveness of semaglutide versus empagliflozin in Denmark",1],["R0009050","Associations of antidiabetic drugs with diabetic retinopathy in people with type 2 diabetes: an umbrella review and meta-analysis.","Tan L","2023","include_review",null,"systematic_review",null,null,"umbrella_review","high","first","opus-5.5-agent09","PROSPERO umbrella review and meta-analysis of antidiabetic drugs including GLP-1 agonists and retinopathy",1],["R0009177","Improvement of Left Ventricular Global Longitudinal Strain after 6-Month Therapy with GLP-1RAs Semaglutide and Dulaglutide in Type 2 Diabetes Mellitus: A Pilot Study.","Basile P","2023","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent17","single group prospective observational echocardiography study of semaglutide or dulaglutide starters without comparison group",1],["R0009245","Association of Glucose-Lowering Drugs With Outcomes in Patients With Diabetes Before Hospitalization for COVID-19: A Systematic Review and Network Meta-analysis.","Zhu Z","2022","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent17","systematic review and network meta-analysis of observational studies of glucose lowering drugs including GLP-1 RAs and COVID-19 outcomes",1],["R0009464","Comment on \"Association of GLP-1 Receptor Agonist Use With Risk of Lumbar Degenerative Disease and Spine Surgery in Patients With Type 2 Diabetes: A Propensity Score-Matched Cohort Study\".","Li X","2026","inventory_only","N9","ancillary",null,null,null,"high","first","opus-5.5-agent17","letter commenting on a matched cohort of GLP-1 RA use and lumbar degenerative disease",1],["R0011410","Bone Status in Obese, Non-diabetic, Antipsychotic-Treated Patients, and Effects of the Glucagon-Like Peptide-1 Receptor Agonist Exenatide on Bone Turnover Markers and Bone Mineral Density.","Eriksson R","2018","include_nma",null,"secondary_report","P15",null,null,"high","first","opus-5.5-agent03","planned secondary analysis of TAO RCT, exenatide weekly vs placebo in obese antipsychotic treated schizophrenia; bone outcomes",1],["R0011618","GLP-1 RA Treatment Patterns Among Type 2 Diabetes Patients in Five European Countries.","Divino V","2017","exclude","E2","primary_report",null,null,null,"high","first","opus-5.5-agent03","descriptive treatment pattern and persistence study of GLP-1 RA initiators in five countries; drug utilization only",1],["R0011721","Heterogeneity of antidiabetic treatment effect on the risk of major adverse cardiovascular events in type 2 diabetes: a systematic review and meta-analysis.","D'Andrea E","2020","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent03","meta-analysis of subgroup results of GLP-1 RA and SGLT2i placebo controlled CVOTs; Medline and Embase searched",1],["R0011830","The \"Real-World\" Effect of Anti-hyperglycemic Drugs on the Development of Chronic Kidney Disease in a Retrospective Cohort of Patients With Incident Diabetes: A Research Letter.","Dahiya A","2025","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent03","research letter cohort of incident diabetes comparing drug classes incl. GLP-1 RA; composite chronic kidney outcome only",1],["R0011919","Dietary fibers to boost endogenous GLP-1 secretion and satiety: a scoping review.","de Jong JCBC","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent03","scoping review of dietary fibers and endogenous GLP-1 secretion; no GLP-1 receptor agonist drug",1],["R0012019","Real-world effectiveness of IDegLira compared with intensified conventional insulin therapy in adults with type 2 diabetes: a retrospective cohort study.","Szépkúti S","2022","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent03","retrospective cohort IDegLira vs historical intensified insulin in T2D; HbA1c, weight, hypoglycemia only",1],["R0009111","Combining GLP-1 Receptor Agonists and SGLT2 Inhibitors for Cardiorenal Prevention: Evidence From Randomized Outcomes Trials.","Gerstein HC","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent01","editorial summarizing GLP-1 RA and SGLT2i outcome trials with illustrative combined hazard calculation",1],["R0009188","Use of once-weekly semaglutide in patients with type 2 diabetes in routine clinical practice: Results from the SURE Canada multicentre, prospective, observational study.","Yale JF","2021","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent01","SURE Canada prospective observational single group cohort of semaglutide initiators in type 2 diabetes",1],["R0009280","The Dipeptidyl Peptidase-4 Inhibitor Saxagliptin as a Candidate Treatment for Disorders of Consciousness: A Deep Learning and Retrospective Clinical Analysis.","Toker D","2025","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent01","deep learning screen plus retrospective coma cohort comparing incretin based drugs including GLP-1 analogues with other drugs; coma recovery only",1],["R0009388","Upper and/or lower gastrointestinal adverse events with glucagon-like peptide-1 receptor agonists: Incidence and consequences.","Horowitz M","2017","include_nma",null,"pooled_analysis","P01",null,null,"high","first","opus-5.5-agent01","post hoc pooled analysis of exenatide once weekly versus twice daily RCTs and DURATION-6 versus liraglutide; gastrointestinal adverse events",1],["R0009496","Systolic blood pressure reduction with tirzepatide in patients with type 2 diabetes: insights from SURPASS clinical program.","Lingvay I","2023","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent01","post hoc mediation analysis of blood pressure across SURPASS-1 to 5 RCTs of tirzepatide",1],["R0009581","Randomised, cOntrolled Multicentre trial of 26 weeks subcutaneous liraglutide (a glucagon-like peptide-1 receptor Agonist), with or without contiNuous positive airway pressure (CPAP), in patients with type 2 diabetes mellitus (T2DM) and obstructive sleep apnoEa (OSA) (ROMANCE): study protocol assessing the effects of weight loss on the apnea-hypnoea index (AHI).","Sprung VS","2020","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent01","protocol of ROMANCE factorial RCT of liraglutide with or without CPAP in type 2 diabetes with sleep apnea",1],["R0009659","The comparative efficacy of SGLT-2 inhibitors and GLP-1 receptor agonists on metabolic benefits in T2DM patients: a systematic review and network meta-analysis.","Tong J","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent01","registered Bayesian network meta-analysis of SGLT2i and GLP-1 RA RCTs on metabolic outcomes in type 2 diabetes",1],["R0009766","The residual cardiorenal risk in type 2 diabetes.","Giugliano D","2021","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent01","commentary on removed and residual cardiorenal risk with newer diabetes drugs",1],["R0012027","Sodium-glucose co-transporter-2 inhibitors reduce the risk of new-onset stroke in patients with type 2 diabetes: A population-based cohort study.","Lin TK","2022","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent04","Taiwan cohort of SGLT2i users vs nonusers on stroke, GLP-1 RA only a co-medication subgroup, not the studied exposure",1],["R0012135","DUAL II China: Superior HbA1c reductions and weight loss with insulin degludec/liraglutide (IDegLira) versus insulin degludec in a randomized trial of Chinese people with type 2 diabetes inadequately controlled on basal insulin.","Pei Y","2021","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent04","DUAL II China double blind RCT of IDegLira vs insulin degludec in type 2 diabetes on basal insulin",1],["R0012229","Management of post-transplant diabetes: immunosuppression, early prevention, and novel antidiabetics.","Hecking M","2021","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent04","narrative review of post transplant diabetes management incl SGLT2i and GLP-1 RA",1],["R0012311","Post-cessation Weight Regain After Weight Management Medications: A Systematic Review and Meta-Analysis.","Patel H","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent04","systematic review and meta-analysis of five databases on weight regain after stopping semaglutide, liraglutide or tirzepatide",1],["R0012524","Body weight course in the DIAbetes and LifEstyle Cohort Twente (DIALECT-1)-A 20-year observational study.","Gant CM","2019","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent04","DIALECT-1 cohort BMI course by GLP-1 RA, insulin or SGLT2i initiation, weight outcome only, no listed harm",1],["R0012602","From In Vitro Efficacy to Long-Term HbA1c Response for GLP-1R/GlucagonR Agonism Using the 4GI-HbA1c Systems Model.","Bosch R","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent04","pharmacometric systems modeling of glucose and HbA1c for cotadutide and liraglutide using trial data",1],["R0007725","Amelioration of muscle wasting by glucagon-like peptide-1 receptor agonist in muscle atrophy.","Hong Y","2019","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent15","mouse models and C2C12 myotube experiments of exendin-4 and dulaglutide on muscle atrophy; no human data",1],["R0007796","Non-clinical and first-in-human characterization of ECC5004/AZD5004, a novel once-daily, oral small-molecule GLP-1 receptor agonist.","Haggag AZ","2025","include_nma",null,"primary_report","P01; P99",null,"mechanistic","high","first","opus-5.5-agent15","first in human placebo controlled RCT of oral ECC5004 in healthy volunteers and type 2 diabetes; glucose, weight and adverse events reported",1],["R0007931","Semaglutide Slows Epigenetic Aging in People with HIV-associated lipohypertrophy: Evidence from a Randomized Controlled Trial.","Corley MJ","2025","include_nma",null,"secondary_report","P99",null,null,"high","first","opus-5.5-agent15","post hoc epigenetic analysis of phase 2b RCT of semaglutide versus placebo in HIV associated lipohypertrophy",1],["R0008000","Novel Antidiabetic Drug Approvals in 2025: Clinical Evidence, Regulatory Milestones, and Global Market Implications","HAIT A","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent15","structured review of 2025 antidiabetic regulatory approvals and market projections; no primary or synthesized comparison",1],["R0008062","Evaluation of Out-of-Pocket Costs and Treatment Intensification With an SGLT2 Inhibitor or GLP-1 RA in Patients With Type 2 Diabetes and Cardiovascular Disease.","Luo J","2023","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent15","claims cohort of out of pocket cost and initiation of SGLT2i or GLP-1 RA; prescribing outcome only",1],["R0008237","Comparative Efficacy of Semaglutide and Tirzepatide in Chinese Adults with Obesity without Diabetes: A Real-World Observational Study.","Yao Z","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent15","retrospective cohort comparing semaglutide versus tirzepatide in nondiabetic obesity; weight, fat and general GI adverse events only",1],["R0012857","Efficacy and safety of lixisenatide in Japanese patients with type 2 diabetes mellitus inadequately controlled by sulfonylurea with or without metformin: Subanalysis of GetGoal-S.","Onishi Y","2015","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent06","Japanese subanalysis of GetGoal-S, double blind RCT of lixisenatide versus placebo on sulfonylurea in T2D",1],["R0012959","Large-scale evidence generation and evaluation across a network of databases for type 2 diabetes mellitus (LEGEND-T2DM): a protocol for a series of multinational, real-world comparative cardiovascular effectiveness and safety studies.","Khera R","2022","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent06","protocol of LEGEND-T2DM multinational new user cohort comparisons of second line T2D drug classes; no results",1],["R0013371","Investigating the Association Between Semaglutide Use and Mood Disorders in Polyendocrine Metabolic Ovarian Syndrome: A Retrospective Cohort Study​.","Raj FP","2026","include_harms",null,"primary_report",null,"O35A",null,"high","first","opus-5.5-agent06","TriNetX matched cohort of semaglutide versus metformin in PCOS; suicidal ideation among mood outcomes",1],["R0013449","Liraglutide improves the beta-cell function without increasing insulin secretion during a mixed meal in patients, who exhibit well-controlled type 2 diabetes and coronary artery disease.","Anholm C","2019","include_nma",null,"primary_report","P01",null,"crossover; mechanistic","high","first","opus-5.5-agent06","placebo controlled crossover RCT of liraglutide in T2D with coronary artery disease; beta cell function meal test",1],["R0013537","Sulodexide for Diabetic-Induced Disabilities: A Systematic Review and Meta-Analysis.","Bignamini AA","2021","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent06","systematic review and meta-analysis of sulodexide for diabetic complications; no GLP-1 RA intervention",1],["R0011182","Advances in reducing cardiovascular risk in the management of patients with type 2 diabetes mellitus.","Hu Y","2019","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent14","narrative review of SGLT2i and GLP-1 RA cardiovascular outcome trials",1],["R0011380","Reversable Bilateral Ischemic Optic Neuropathy Following Semaglutide Discontinuation with Crowded Optic Discs","Alsakran WA","2025","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent14","case report of bilateral ischemic optic neuropathy during semaglutide use",1],["R0011480","Failure of GLP-1 Agonist Therapy to Improve Weight in a 3-Year-Old Patient With Tumor-Related Obesity.","Petlansky R","2025","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent14","case report of liraglutide in a 3 year old with tumor related obesity",1],["R0011580","Early-Onset Type 2 Diabetes and Tirzepatide Treatment: A Post Hoc Analysis From the SURPASS Clinical Trial Program.","Zeitler P","2024","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent14","post hoc analysis of SURPASS-1 to 3 RCTs by early vs later onset T2D, tirzepatide vs comparators",1],["R0011669","Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.","Shi Q","2023","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent14","PROSPERO registered network meta-analysis of RCTs of T2D drugs including GLP-1 RA and tirzepatide",1],["R0011767","Treatment of Heart Failure with Sodium-Glucose Cotransporter 2 Inhibitors and Other Anti-diabetic Drugs.","Zelniker TA","2019","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent14","narrative review of SGLT2i and other antidiabetics in heart failure",1],["R0011879","Glucagon-Like Peptide-1 Analogues and the Risk of Recurrent Pancreatitis in Diabetic Patients With History of Pancreatitis or Elevated Lipase: Retrospective Cohort Analysis.","Calvarysky B","2026","include_harms",null,"primary_report",null,"O29",null,"high","first","opus-5.5-agent14","Clalit cohort of diabetics with prior pancreatitis or high lipase, time varying GLP-1 RA initiation vs nonuse, recurrent pancreatitis",1],["R0012070","Use of Lipid-, Blood Pressure-, and Glucose-Lowering Pharmacotherapy in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease.","Nelson AJ","2022","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent12","PCORnet cohort describing use of preventive pharmacotherapy including GLP-1RA in T2D with ASCVD, utilization only",1],["R0012263","Initiating or Switching to Insulin Degludec/Insulin Aspart in Adults with Type 2 Diabetes: A Real-World, Prospective, Non-interventional Study Across Six Countries.","Fulcher GR","2022","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent12","single arm noninterventional study of insulin degludec aspart initiation, GLP-1RA only a prior therapy",1],["R0012347","SGLT2 inhibitors, semaglutide, and finerenone in diabetic kidney disease: a Bayesian network meta-analysis.","He Z","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent12","PRISMA-NMA Bayesian network meta-analysis of SGLT2i, semaglutide and finerenone phase 3 trials in diabetic kidney disease",1],["R0012460","Efficacy and safety of switching to iGlarLixi from premixed insulins in people with type 2 diabetes: The Soli-SWITCH study.","Haluzík M","2025","inventory_only","N1","primary_report","P01",null,null,"high","first","opus-5.5-agent12","single arm phase 4 study switching from premixed insulin to iGlarLixi",1],["R0012554","The impact of semaglutide on wound healing in diabetes related foot ulcer patients: A TriNetX database study.","Lewis JE","2025","inventory_only","N6","primary_report","P01",null,null,"high","first","opus-5.5-agent12","TriNetX cohort of semaglutide users vs nonusers with diabetic foot ulcers, wound and amputation outcomes only",1],["R0012648","Real-World Effectiveness and 12-Month Persistence of a Semaglutide-Supported Digital Weight-Loss Service: A Retrospective Cohort Study in Germany.","Talay L","2026","inventory_only","N5","primary_report","P02",null,null,"high","first","opus-5.5-agent12","retrospective single arm cohort of semaglutide digital weight loss service, no control group",1],["R0012728","Managing Cardiovascular Risk in Type 2 Diabetes: What Do the Cardiovascular Outcome Trials Mean for Australian Practice?","Deed G","2019","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent12","expert opinion review of CVOT implications for Australian practice",1],["R0009861","Effect of Semaglutide Combined With Conventional Insulin Therapy on Blood Glucose Control and Renal Function in Elderly Patients With Type 2 Diabetes.","Ye L","2026","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent01","RCT of semaglutide plus insulin versus insulin alone in elderly type 2 diabetes",1],["R0009932","Effects of GLP-1 Receptor Agonists on Hair Loss and Regrowth: A Systematic Review.","Branyiczky MK","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent01","registered PRISMA systematic review of GLP-1 RA studies on hair loss and regrowth, Embase and MEDLINE searched",1],["R0010029","Insulin degludec/liraglutide versus its monotherapy on T2D patients: A lifetime cost-utility analysis in China.","Han G","2022","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent01","lifetime cost utility simulation of IDegLira versus components using UKPDS outcomes model; economic evaluation",1],["R0010103","Obesity Treatments and Weight Changes in Clinical Practice After Discontinuation of Semaglutide or Tirzepatide.","Gasoyan H","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent01","retrospective cohort describing treatments and weight change after semaglutide or tirzepatide discontinuation, no comparison group",1],["R0010205","Cardiovascular adverse event reporting profile of tirzepatide: a real-world pharmacovigilance analysis of heart failure, arrhythmias, and ischemic events.","Chen D","2026","inventory_only","N5","other",null,null,null,"high","first","opus-5.5-agent01","FAERS disproportionality analysis of tirzepatide cardiovascular adverse event reports",1],["R0010276","Glycemic control, weight-loss effects, and safety of cotadutide in individuals with type 2 diabetes: A systematic review and meta-analysis.","Kamrul-Hasan ABM","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent01","registered meta-analysis of cotadutide RCTs in type 2 diabetes, five sources searched",1],["R0010377","OR28-4 Efficacy and Safety of Tirzepatide Versus Semaglutide in a Hispanic or Latino Population: A Prespecified Subgroup Analysis of SURPASS-2",null,"2022","include_nma",null,"conference_abstract","P01",null,"abstract_only","high","first","opus-5.5-agent01","abstract of prespecified Hispanic or Latino subgroup of SURPASS-2 RCT, tirzepatide versus semaglutide",1],["R0010478","Effect of exenatide twice daily and dapagliflozin, alone and in combination, on markers of kidney function in obese patients with type 2 diabetes: A prespecified secondary analysis of a randomized controlled clinical trial.","van Ruiten CC","2021","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent01","prespecified kidney secondary analysis of DECREASE RCT, exenatide, dapagliflozin, both or placebo in type 2 diabetes",1],["R0007438","Combination of exercise and GLP-1 receptor agonist treatment reduces severity of metabolic syndrome, abdominal obesity, and inflammation: a randomized controlled trial.","Sandsdal RM","2023","include_nma",null,"secondary_report","P02",null,null,"high","first","opus-5.5-agent11","S-LiTE secondary outcomes; randomized liraglutide versus placebo with or without exercise after diet induced weight loss",1],["R0007502","Effects of GLP-1 Receptor Agonists on Paediatric Population in a Real World Setting.","Barajas AG","2025","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent11","retrospective chart review of pediatric type 2 diabetes patients started on GLP-1RA; no comparator",1],["R0007563","The effect of GLP-1 agonist on idiopathic intracranial hypertension: a systematic review and meta-analysis.","Ahmad J","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent11","registered meta-analysis of GLP-1RA plus standard therapy versus standard therapy in idiopathic intracranial hypertension; four named databases",1],["R0007647","Challenging Clinical Perspectives in Type 2 Diabetes with Tirzepatide, a First-in-Class Twincretin.","MacIsaac RJ","2023","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent11","narrative review of tirzepatide place in type 2 diabetes care",1],["R0007713","Comparative Cardiovascular Pharmacovigilance of Semaglutide and Tirzepatide: A Food and Drug Administration Adverse Event Reporting System (FAERS) Database Analysis (2022-2026).","Singla A","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent11","FAERS disproportionality comparison of cardiac reports for semaglutide and tirzepatide",1],["R0007853","Effect of Semaglutide on Physical Function, Body Composition, and Biomarkers of Aging in Older Adults With Overweight and Insulin Resistance: Protocol for an Open-Labeled Randomized Controlled Trial.","Cortes TM","2024","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent11","protocol of pilot RCT of semaglutide plus lifestyle counseling versus counseling alone in older adults",1],["R0009100","Obesity: a gender-view.","Muscogiuri G","2024","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent19","short narrative review of gender differences in obesity and its drug treatment; selected publications only",1],["R0009184","A study on pharmacokinetics, pharmacodynamics and safety of lixisenatide in children and adolescents with type 2 diabetes.","Barrientos-Pérez M","2022","include_nma",null,"primary_report","P04",null,"mechanistic","high","first","opus-5.5-agent19","phase 1 randomized placebo controlled PK and PD study of lixisenatide in youth with type 2 diabetes; HbA1c, weight, nausea reported",1],["R0009270","GLP-1 physiology informs the pharmacotherapy of obesity.","Drucker DJ","2022","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent19","narrative review of GLP-1 physiology and obesity pharmacotherapy",1],["R0009380","Dipeptidyl peptidase-4 inhibitors and gallbladder or biliary disease in type 2 diabetes: systematic review and pairwise and network meta-analysis of randomised controlled trials.","He L","2022","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent19","pairwise and network meta-analysis of RCTs incl GLP-1 RA on gallbladder and biliary disease; PubMed Embase Web of Science CENTRAL",1],["R0009486","Effects of incretin-based therapeutic agents including tirzepatide on renal outcomes in patients with type 2 diabetes: A systemic review and meta-analysis.","Mima A","2023","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent19","network meta-analysis of RCTs of incretin drugs vs placebo or others on renal outcomes; MEDLINE and Cochrane searched",1],["R0009651","Glucagon-Like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes: Prescription According to Reimbursement Constraints and Guideline Recommendations in Catalonia.","Franch-Nadal J","2019","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent19","retrospective cohort of GLP-1 RA initiators in Catalan primary care, HbA1c and weight change; no comparison group",1],["R0009745","Exploratory Study Analyzing the Urinary Peptidome of T2DM Patients Suggests Changes in ECM but Also Inflammatory and Metabolic Pathways Following GLP-1R Agonist Treatment.","Lohia S","2023","inventory_only","N5","secondary_report",null,null,null,"high","first","opus-5.5-agent19","pre and post GLP-1 RA urinary peptidome in 32 patients from an observational cohort; no comparison group",1],["R0011376","Efficacy of Off-Label Therapy for Non-alcoholic Fatty Liver Disease in Improving Non-invasive and Invasive Biomarkers: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.","Luo Q","2022","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent13","PROSPERO registered network meta-analysis of NAFLD RCTs including GLP-1 agonists from four databases",1],["R0011468","Liraglutide-Induced Weight Loss May be Affected by Autonomic Regulation in Type 1 Diabetes.","Hansen CS","2019","include_nma",null,"secondary_report","P05",null,null,"high","first","opus-5.5-agent13","secondary analysis of Lira-1 placebo controlled RCT of liraglutide in overweight type 1 diabetes",1],["R0011577","Feasibility of Simplification From a Basal-Bolus Insulin Regimen to a Fixed-Ratio Formulation of Basal Insulin Plus a GLP-1RA or to Basal Insulin Plus an SGLT2 Inhibitor: BEYOND, a Randomized, Pragmatic Trial.","Giugliano D","2021","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent13","BEYOND pragmatic RCT of fixed ratio basal insulin plus GLP-1 vs basal plus SGLT2 vs basal bolus insulin",1],["R0011662","Comparative Efficacy of Tirzepatide vs. Semaglutide in Reducing Body Weight in Humans: A Systematic Review and Meta-Analysis of Clinical Trials and Real-World Data.","Aamir AB","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent13","OSF registered meta-analysis of tirzepatide vs semaglutide RCTs and cohorts from three databases",1],["R0011764","Metabolic health in people living with type 1 diabetes in Belgium: a repeated cross-sectional study.","Lavens A","2024","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent13","repeated cross sectional audit of metabolic health in type 1 diabetes, GLP-1 use only described, not an exposure",1],["R0011878","Real-world usage of sulphonylureas in Asian patients with type 2 diabetes using the Joint Asia Diabetes Evaluation (JADE) register.","Lim LL","2023","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent13","cross sectional study of sulphonylurea use patterns, GLP-1 users excluded",1],["R0011970","Utility of Pharmacological Agents for Diabetes Mellitus in the Prevention of Alzheimer's Disease: Comparison of Metformin, Glucagon-Like Peptide-1 (GLP-1) Agonists, Insulin, and Sulfonylureas.","DiGiovanni A","2025","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent13","TriNetX cohort comparing metformin with GLP-1 analogs and others for Alzheimer disease and mortality only",1],["R0012079","A narrative review of new treatment options for chronic kidney disease in type 2 diabetes.","Persson F","2021","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent13","narrative review of new treatments for CKD in type 2 diabetes",1],["R0010565","Glucagon-like peptide-1 (GLP-1) receptor agonists and cardiovascular events in patients with type 2 diabetes mellitus: A meta-analysis of double-blind, randomized, placebo-controlled clinical trials","Qin J","2020","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent18","preprint meta-analysis of placebo controlled GLP-1 RA CVOTs in T2D; PubMed and Embase searched",1],["R0010688","Semaglutide and Non-arteritic Anterior Ischemic Optic Neuropathy: A Systematic Review.","Hidalgo Ramos RA","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent18","PRISMA systematic review of semaglutide and NAION; named databases and criteria; narrative synthesis of cohort contrasts",1],["R0010772","Sodium-glucose cotransporter-2 inhibitors and risk for genitourinary infections in older adults with type 2 diabetes.","Varshney N","2021","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent18","new user cohort SGLT2i vs GLP-1 RA in older adults with T2D; genitourinary infections only, not a listed harm",1],["R0010922","Efficacy and safety of semaglutide: real-world tertiary care experience from Saudi Arabia.","Butt MI","2024","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent18","retrospective single arm review of semaglutide users in Saudi tertiary care; pre post weight and HbA1c",1],["R0008608","A Review of Weight Loss With Glucagon-Like Peptide 1 Agonist Therapy: Is There a Role for Its Preoperative Use in Gynecology?","Sinha A","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent10","self described narrative review of GLP-1 RA weight loss for preoperative gynecology use",1],["R0008760","Management of Patients with Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide, Exenatide ER, Liraglutide and Lixisenatide: A Cost-Effectiveness Analysis in the Danish Setting.","Gæde P","2019","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent10","CORE Diabetes Model cost effectiveness of semaglutide versus other GLP-1 RAs in Denmark; simulation",1],["R0008828","Disrupting the adiposopathy-inflammation loop: a translational immunometabolic framework for inflammatory disease.","Corrao S","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent10","editorial commentary proposing an immunometabolic framework citing tirzepatide psoriatic arthritis trial",1],["R0008929","Comparative efficacy of novel antidiabetic drugs on cardiovascular and renal outcomes in patients with diabetic kidney disease: A systematic review and network meta-analysis.","Cao H","2022","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent10","registered network meta-analysis of SGLT2i, GLP-1 RA and DPP-4i outcome trials in diabetic kidney disease; MEDLINE searched",1],["R0008994","Efficacy and Safety of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists for Spinal Fusion Outcomes: A Comprehensive Meta-Analysis.","Zahed M","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent10","meta-analysis of studies comparing GLP-1 RA users with nonusers in spinal fusion; five databases searched",1],["R0009051","Comment on Hong et al. Differential Effect of GLP-1 Receptor Agonists and SGLT2 Inhibitors on Lower-Extremity Amputation Outcomes in Type 2 Diabetes: A Nationwide Retrospective Cohort Study. Diabetes Care 2025;48:1728-1736.","García de Lucas MD","2026","inventory_only","N9","ancillary",null,null,null,"high","first","opus-5.5-agent10","letter commenting on Hong et al nationwide cohort of GLP-1 RA versus SGLT2i and amputation",1],["R0010542","Effects of Digitization of Self-Monitoring of Blood Glucose Records Using a Mobile App and the Cloud System on Outpatient Management of Diabetes: Single-Armed Prospective Study.","Handa T","2024","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent16","single arm study of a glucose monitoring app; GLP-1RA only background therapy, not the studied intervention; alternative N1",1],["R0010673","Advancing Therapy in Suboptimally Controlled Basal Insulin-Treated Type 2 Diabetes: Clinical Outcomes With iGlarLixi Versus Premix BIAsp 30 in the SoliMix Randomized Controlled Trial.","Rosenstock J","2021","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent16","SoliMix open label RCT of iGlarLixi vs premix BIAsp 30 in basal insulin treated T2D",1],["R0010761","Cost-effectiveness of semaglutide 2.4 mg versus liraglutide 3 mg for the treatment of obesity in Greece.","Papantoniou P","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent16","Markov cost effectiveness model of semaglutide 2.4 mg vs liraglutide 3 mg in Greece",1],["R0010820","Effects of Hepatic Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide.","Urva S","2022","inventory_only","N1","primary_report",null,null,null,"high","first","opus-5.5-agent16","nonrandomized single dose PK study of tirzepatide by hepatic function group, no comparison of drug regimens",1],["R0010918","Semaglutide Injection in Indian Patients With Type 2 Diabetes Mellitus: A Randomised, Phase III, Active-Controlled Study.","Ambika Gopalakrishnan U","2026","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent16","randomized phase 3 trial of test semaglutide vs Ozempic in Indian T2D on metformin",1],["R0010996","Effect of GLP-1 receptor agonist treatment on body weight in obese antipsychotic-treated patients with schizophrenia: a randomized, placebo-controlled trial.","Ishøy PL","2017","include_nma",null,"primary_report","P15",null,null,"high","first","opus-5.5-agent16","double blind RCT of exenatide once weekly vs placebo in obese antipsychotic treated schizophrenia",1],["R0011190","Comparative Efficacy of Promising Targets in the Treatment of Metabolic Dysfunction-associated Steatotic Liver Disease and Steatohepatitis: A Systematic Review and Network Meta-analysis.","Ni W","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent16","PROSPERO registered systematic review and NMA of MASLD drug RCTs including GLP-1 based agonists",1],["R0011232","Joint TOS/OMA/OAC Expert Guidance Statement on the Pharmacological Management of United States Adults With Overweight or Obesity Using the GRADE Approach.","Alexander L","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent07","GRADE based expert guidance statement on obesity pharmacotherapy; guideline rather than a systematic review",1],["R0011347","GLP-1RA Promotes Osteogenic Differentiation of Jaw Bone Marrow Mesenchymal Stem Cells by Modulating CREB/YAP/STAT3/BRD4-Mediated Proliferation and Stemness for Osteoporosis Treatment","Liu H","2025","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent07","preprint of rat osteoporosis model and jaw bone marrow stem cells treated with semaglutide",1],["R0011430","Swiss recommendations of the Society for Endocrinology and Diabetes (SGED/SSED) for the treatment of type 2 diabetes mellitus (2023).","Gastaldi G","2023","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent07","Swiss society treatment recommendations for type 2 diabetes",1],["R0011560","Newer glucose-lowering drugs reduce the risk of late-onset seizure and epilepsy: A meta-analysis.","Sindhu U","2024","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent07","meta-analysis of placebo controlled outcome RCTs of DPP-4i, GLP-1RA and SGLT2i on seizures and epilepsy",1],["R0011626","Metabolic Outcomes in Patients With Type 2 Diabetes Prescribed Incretin-Based Therapy and Referred or Not to a Weight Management Clinic: A Single-Center Retrospective Analyses.","Robinson KM","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent07","retrospective cohort of incretin users with vs without weight management clinic referral; A1c, weight, LDL only",1],["R0011732","The treatment of type 2 diabetes in the presence of renal impairment: what we should know about newer therapies.","Davies M","2016","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent07","narrative review of newer diabetes drugs in renal impairment",1],["R0011854","Effects of glucagon-like peptide-1 analogue treatment in genetic obesity: A case series.","Welling MS","2021","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent07","case series of four adults with genetic obesity treated with liraglutide 3.0 mg",1],["R0011936","Effects of Newer Antidiabetic Drugs on Endothelial Function and Arterial Stiffness: A Systematic Review and Meta-Analysis.","Batzias K","2018","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent07","PRISMA meta-analysis of studies of DPP-4i, GLP-1RA and SGLT2i on endothelial function and arterial stiffness",1],["R0012296","Evaluation of Consistency of Treatment Response Across Regions-the LEADER Trial in Relation to the ICH E17 Guideline.","Nielsen HK","2021","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent20","regional consistency analysis of the randomized placebo controlled LEADER trial of liraglutide",1],["R0012391","Long-Term clinical efficacy of liraglutide for type 2 diabetes: real-world evidence and outcomes from Pakistan.","Butt MD","2024","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent20","retrospective single arm cohort of liraglutide initiators in Pakistan, no comparison group",1],["R0012497","Untangling obese asthma: Design of proof-of-concept study of semaglutide in poorly controlled asthma.","Tomasello A","2026","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent20","design and rationale paper of placebo controlled GATA-3 trial of semaglutide in obese asthma, no results",1],["R0012591","Durability of Glucose-Lowering Effect of the First Administration of Dulaglutide: A Retrospective, Single-Center, Single-Arm Study.","Matsushita M","2018","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent20","retrospective single arm CGM study after first dulaglutide dose in 15 inpatients",1],["R0012678","Hospitalization in adults aged 75 years and older with type 2 diabetes: the role of kidney impairment and glycemic control.","Magamba B","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent20","Swedish cohort of older T2D on HbA1c, CKD and hospitalization, incretin drugs only a pooled covariate",1],["R0012835","Systematic Review and Meta-Analysis of the Efficacy and Safety of Metformin and GLP-1 Analogues in Children and Adolescents with Diabetes Mellitus Type 2.","Carydias E","2022","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent20","PROSPERO registered meta-analysis of RCTs of metformin and GLP-1 analogues in pediatric T2D, four databases",1],["R0012125","Lixisenatide - A New Glucagon-like Peptide 1 Receptor Agonist in the Treatment of Type 2 Diabetes.","Vidal J","2013","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent03","sponsor funded narrative review of lixisenatide in type 2 diabetes",1],["R0012224","Genetic predictors of GLP1 receptor agonist weight loss and side effects.","Su QJ","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent03","GWAS of self reported weight loss and side effects among GLP-1 RA users; no unexposed comparison group",1],["R0012310","Glucagon-like peptide-1 mimetics, optimal for Asian type 2 diabetes patients with and without overweight/obesity: meta-analysis of randomized controlled trials.","Zhang F","2017","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent03","meta-analysis of RCTs of GLP-1 RA in Asian T2D by BMI; EMBASE, MEDLINE, CENTRAL searched",1],["R0012521","Naltrexone/Bupropion, Liraglutide, or Semaglutide as Adjuvant Therapy After Metabolic and Bariatric Surgery: An Observational Study.","Brancatisano A","2025","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent03","observational comparison of naltrexone bupropion, liraglutide and semaglutide after bariatric surgery; weight outcomes only",1],["R0012599","GLP-1 and GIP Changes after Sleeve Gastrectomy and Weight Regain in Adolescents. Do we need a Boost?","Shehata M","2025","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent03","adolescent sleeve gastrectomy cohort; semaglutide given only to weight regain group, before and after without comparator",1],["R0012685","Impact of baseline glycated haemoglobin, diabetes duration and body mass index on clinical outcomes in the LixiLan-O trial testing a titratable fixed-ratio combination of insulin glargine/lixisenatide (iGlarLixi) vs insulin glargine and lixisenatide monocomponents.","Davies MJ","2017","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent03","subgroup analysis of LixiLan-O RCT, iGlarLixi vs glargine vs lixisenatide in T2D on oral therapy",1],["R0012778","Dumping Syndrome After Bariatric Surgery: Advanced Nutritional Perspectives and Integrated Pharmacological Management.","Cano R","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent03","narrative review of dumping syndrome management after bariatric surgery",1],["R0009770","Editorial: Global Obesity Rates Continue to Rise with Challenges for New Drug Treatments Including GLP-1 Receptor Agonists.","Parums DV","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent02","editorial on global obesity and GLP-1 RA treatment challenges",1],["R0009851","Improvement in Helicobacter pylori Eradication Among Adults Receiving Semaglutide: A Population-Based Propensity-Score-Adjusted Analysis.","Ness A","2025","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent17","Clalit matched cohort of GLP-1 RA exposure versus none on Helicobacter pylori eradication success only",1],["R0009864","Dulaglutide as an Effective Replacement for Prandial Insulin in Kidney Transplant Recipients with Type 2 Diabetes Mellitus: A Retrospective Review.","Kim HS","2021","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent02","retrospective single group chart review of switch from prandial insulin to dulaglutide in kidney transplant recipients",1],["R0009935","The Efficacy of Glucagon-like Peptide-1 Based Therapies in Heart Failure Across the Spectrum of Left Ventricular Ejection Fraction: A Systematic Review and Meta-Analysis.","Christophides T","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent02","registered systematic review and meta-analysis of RCTs of GLP-1 based therapies in heart failure by ejection fraction",1],["R0010022","Protocol for a randomised, double-blinded, placebo-controlled, double-dummy 6-week clinical trial comparing the treatment effects of the glucagon-like peptide 1 receptor agonist liraglutide versus the bile acid sequestrant colesevelam on bile acid malabsorption.","Kårhus ML","2021","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent17","protocol of a double dummy RCT of liraglutide versus colesevelam for bile acid malabsorption, no results",1],["R0010033","Effects of Tirzepatide on Body Composition, Metabolic Parameters, and Sleep Outcomes: A Real-World One-Year Prospective Study.","Adamidis N","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent02","prospective real world single group tirzepatide cohort followed one year; no comparison group, not randomized",1],["R0010091","Association of tirzepatide and the risk of suicide in a real-world cohort.","Yu WS","2025","include_harms",null,"primary_report",null,"O35A",null,"high","first","opus-5.5-agent17","TriNetX matched cohort of tirzepatide versus non GLP-1 anti-obesity drugs on suicidal ideation or attempts",1],["R0010178","68 Ga-NODAGA-EXENDIN-4 PET/CT in the Detection or the Exclusion of Occult Sporadic Insulinomas.","Aveline C","2025","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent17","diagnostic exendin-4 radiotracer PET study for insulinoma localization, not a therapeutic GLP-1 RA exposure",1],["R0010211","Liraglutide and polycystic ovary syndrome: is it only a matter of body weight?","Pugliese G","2023","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent02","narrative review of liraglutide in polycystic ovary syndrome",1],["R0010269","Efficacy and Safety of Mazdutide for Type 2 Diabetes: a GRADE assessed systematic review and meta-analysis of randomized controlled trials","Mahmood A","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent17","preprint systematic review and meta-analysis of RCTs of mazdutide in type 2 diabetes with GRADE",1],["R0010280","Renoprotective effects of combination treatment with sodium-glucose cotransporter inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes mellitus according to preceding medication.","Kobayashi K","2023","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent02","retrospective cohort of GLP-1 RA preceding vs SGLT2 inhibitor preceding combination therapy on renal composite; no listed harm",1],["R0010347","Improved Glycaemic Control with IDegLira in Chinese Adults with Type 2 Diabetes in Real-World Settings: A Retrospective, Database Cohort Study.","Wang S","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent17","retrospective database cohort of IDegLira users in Tianjin without comparison group",1],["R0010460","Impact of the COVID-19 pandemic on the glycemic control in people with diabetes mellitus: A retrospective cohort study.","Ohkuma K","2023","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent17","retrospective cohort on glycemic control before and during the COVID-19 pandemic; no GLP-1 RA exposure analysis found",1],["R0016199","Tirzepatide and health-related quality of life in adults with obesity or overweight: Results from the SURMOUNT-3 phase 3 randomized trial.","Gibble TH","2025","include_nma",null,"secondary_report","P02",null,null,"high","first","opus-5.5-agent05","SURMOUNT-3 secondary report of quality of life with tirzepatide versus placebo after lifestyle lead in, 72 weeks",1],["R0016316","Mechanisms and clinical efficacy of lixisenatide for the management of type 2 diabetes.","Horowitz M","2013","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent05","narrative review of lixisenatide mechanisms and clinical efficacy",1],["R0016423","GLP-1 Receptor Agonists and Kidney Protection.","Greco EV","2019","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent05","narrative review of GLP-1 RA and kidney protection in type 2 diabetes",1],["R0016514","The impact of morbid obesity and metabolic syndrome in elective spine surgery outcomes: A systematic review.","Ferraz VR","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent05","systematic review of morbid obesity versus nonobese spine surgery outcomes; GLP-1 RA only mentioned as future option",1],["R0016603","Tirzepatide for the treatment of adults living with concurrent type 1 diabetes and overweight or obesity (TZP-T1D): a double-blind, placebo-matched randomised controlled trial protocol.","Purcell AR","2025","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent05","protocol of placebo controlled RCT of tirzepatide in type 1 diabetes with overweight or obesity; no results",1],["R0016691","Obesity-Mediated Inflammation and Its Influence on Inflammatory Bowel Disease: Pathophysiology, Clinical Impact, and Therapeutic Implications.","Casas-Deza D","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent05","narrative review of obesity and inflammatory bowel disease including metabolic drugs",1],["R0016783","A Systematic Review and Meta-Analysis of Semaglutide Effects on Adipose Tissue and Emerging Effects on Brain and Cognition.","Saghazadeh A","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent05","meta-analysis of semaglutide studies on adipose tissue and cognition searching four named databases with criteria",1],["R0016906","Efficacy and safety of oral semaglutide in Chinese participants with type 2 diabetes: Subgroup analyses by baseline characteristics in the PIONEER 11 and 12 randomised controlled trials.","Ji L","2025","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent05","post hoc subgroup analysis of PIONEER 11 and 12 RCTs of oral semaglutide versus placebo or sitagliptin in Chinese participants",1],["R0011236","[Efficacy of treatment with glucagon-like peptide receptor agonists-1 in Asian patients with type 2 diabetes mellitus].","Khamnueva LY","2023","exclude","E3","other",null,null,"non_english","high","first","opus-5.5-agent08","Russian narrative review of GLP-1 receptor agonist efficacy in Asian patients with type 2 diabetes",1],["R0011350","Impact of renal function on antidiabetic drug selection in Japan: A real-world analysis using the J-DREAMS database.","Kubota M","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent08","J-DREAMS prescribing pattern study of antidiabetic classes by renal function; utilization only",1],["R0011445","Protective effects of the GLP-1 mimetic exendin-4 in Parkinson's disease.","Athauda D","2018","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent08","narrative review of exenatide neuroprotection in Parkinson disease",1],["R0011566","Efficacy and safety of glucagon-like peptide-1 (GLP-1) agonists in pediatric obesity: A systematic review and meta-analysis.","Sukkar GA","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent08","PROSPERO registered meta-analysis of RCTs of GLP-1 RA versus placebo in pediatric obesity; four databases",1],["R0011856","Impact of Hospitalization on Continuation of SGLT2 Inhibitors and GLP-1 Receptor Agonists for Comorbidities in Patients with Type 2 Diabetes.","Murphy BL","2024","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent08","descriptive chart review of SGLT2i and GLP-1 RA continuation after hospitalization; utilization only",1],["R0008325","Sgemaglutide in type 2 diabetes - is it the best glucagon-like peptide 1 receptor agonist (GLP-1R agonist)?","Doggrell SA","2018","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent15","expert opinion review of semaglutide in type 2 diabetes",1],["R0008399","Effects of Dapagliflozin and Combination Therapy With Exenatide on Food-Cue Induced Brain Activation in Patients With Type 2 Diabetes.","van Ruiten CC","2022","include_nma",null,"primary_report","P01",null,"mechanistic","high","first","opus-5.5-agent15","four arm placebo controlled RCT of dapagliflozin, exenatide, both or placebo in obese type 2 diabetes; fMRI food cue responses",1],["R0008476","Glucagon-Like Peptide-1 Receptor Agonist, Liraglutide, Attenuated Diabetic Retinal Edema in Spontaneously Diabetic Torii Fatty Rats","Inoue K","2021","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent15","randomized rat study of liraglutide versus insulin plus hydralazine on diabetic retinal edema; animals only",1],["R0008551","Beyond GLP-1: efficacy and safety of dual and triple incretin agonists in personalized type 2 diabetes care-a systematic review and network meta-analysis.","Yan K","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent15","registered systematic review and network meta-analysis of RCTs of dual and triple incretin agonists in type 2 diabetes",1],["R0008631","Effect of Oral Semaglutide on the Pharmacokinetics of Levonorgestrel and Ethinylestradiol in Healthy Postmenopausal Women and Furosemide and Rosuvastatin in Healthy Subjects.","Jordy AB","2021","inventory_only","N1","primary_report",null,null,null,"high","first","opus-5.5-agent15","two one sequence crossover drug interaction trials of oral semaglutide in healthy subjects; no randomized comparison",1],["R0008698","Factors associated with weight loss response to GLP-1 analogues for obesity treatment: a retrospective cohort analysis.","Squire P","2025","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent15","retrospective cohort of semaglutide or liraglutide users only, examining predictors of weight loss; no comparator",1],["R0008775","Case report: Long-term efficacy and safety of semaglutide in the treatment of syndromic obesity in Prader Willi syndrome - case series and literature review.","Koceva A","2024","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent15","case series of three Prader Willi patients treated with semaglutide with literature review",1],["R0008855","Effects of semaglutide, empagliflozin and their combination on renal diffusion-weighted MRI and total kidney volume in patients with type 2 diabetes: a post hoc analysis from a 32 week randomised trial.","Vernstrøm L","2024","include_nma",null,"secondary_report","P01",null,"mechanistic","high","first","opus-5.5-agent15","post hoc MRI substudy of SEMPA RCT, semaglutide, empagliflozin, combination or placebo in type 2 diabetes",1],["R0012807","Rationale, design and baseline characteristics of REMODEL, a mechanism-of-action trial with semaglutide in people with type 2 diabetes and chronic kidney disease.","Cherney DZI","2025","inventory_only","N8","protocol_or_design","P08A",null,null,"high","first","opus-5.5-agent12","rationale, design and baseline characteristics of REMODEL mechanistic RCT of semaglutide vs placebo in T2D with CKD, no outcomes",1],["R0012886","Liver Fat Changes in Patients With Type 2 Diabetes by Presence of Genetic Hepatic Steatosis: A Post Hoc Analysis of SURPASS-3 MRI.","Cusi K","2026","include_nma",null,"secondary_report","P01; P09",null,null,"high","first","opus-5.5-agent12","post hoc genotype analysis of SURPASS-3 MRI substudy, tirzepatide vs insulin degludec in T2D with MASLD",1],["R0012986","Efficacy and Safety of Semaglutide in Glycemic Control and Body Weight Management Among Obese Type 2 Diabetes Patients Initiated or Switched to Semaglutide From Other GLP-1 Receptor Agonists","Okamoto A","2021","inventory_only","N5","primary_report","P01",null,null,"high","first","opus-5.5-agent12","retrospective single drug cohort of patients initiating or switching to semaglutide, before and after comparison",1],["R0013078","The efficacy of GLP-1RAs for the management of postprandial hypoglycemia following bariatric surgery: a systematic review.","Llewellyn DC","2023","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent12","registered SR of GLP-1RAs for postprandial hypoglycemia after bariatric surgery, five databases, narrative synthesis",1],["R0013179","Guidelines adherence in the prevention and management of chronic kidney disease in patients with diabetes mellitus on the background of recent European recommendations - a registry-based analysis.","Bramlage P","2021","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent12","registry analysis of guideline adherence in diabetic CKD, GLP-1RA use only tallied",1],["R0013291","Evaluating the Long-Term Cost-Effectiveness of Daily Administered GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes in the United Kingdom.","Hunt B","2017","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent12","cost effectiveness modeling of daily GLP-1RAs in UK using NMA inputs",1],["R0013390","Safety of Semaglutide After Dialysis Initiation: An Individual-Level Pooled Analysis.","Klein KR","2026","include_nma",null,"pooled_analysis","P01; P02; P08A",null,null,"high","first","opus-5.5-agent12","post hoc pooled analysis of SUSTAIN-6, SELECT, FLOW and SOUL participants starting dialysis, semaglutide vs placebo safety",1],["R0013464","The Sweet Side of Constipation: Colonic Motor Dysfunction in Diabetes Mellitus.","De Fano M","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent12","self described narrative review of constipation in diabetes including GLP-1RA effects",1],["R0007917","Appetite and its Regulation: Are there Palatable Interventions for Heart Failure?","Lee MMY","2024","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent11","narrative review of appetite regulation and weight loss interventions in heart failure",1],["R0009855","Differential effects of semaglutide and colchicine on atrial remodeling in rats with reduced ejection fraction after myocardial infarction.","Levi O","2026","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent19","randomized experiment of semaglutide and colchicine in post infarction rats; animal study only",1],["R0011972","Semaglutide combined with empagliflozin vs. monotherapy for non-alcoholic fatty liver disease in type 2 diabetes: Study protocol for a randomized clinical trial.","Lin YH","2024","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent14","protocol of RCT of semaglutide plus empagliflozin vs each alone in NAFLD with T2D, no results",1],["R0007990","Real-World Adherence and Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists Therapy in Type 2 Diabetes Mellitus Patients in the United States.","Weiss T","2020","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent11","claims based adherence and discontinuation study of GLP-1RA initiators; drug utilization without exposure comparison",1],["R0008056","Effects of switching from a dipeptidyl peptidase-4 inhibitor to oral semaglutide on glucose metabolism in patients with type 2 diabetes: protocol for a multicentre, prospective, randomised, open-label, parallel-group comparison study (the SWITCH-SEMA 2 study).","Nomoto H","2022","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent11","protocol of SWITCH-SEMA 2 RCT, switching DPP-4i to oral semaglutide versus continuing; no results",1],["R0008138","Incretin Receptor Agonist, Semaglutide, as a Treatment for Alectinib-Induced Excessive Weight Gain. A Case Report.","Lee ATM","2025","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent11","case report of semaglutide for alectinib related weight gain with gallstone pancreatitis",1],["R0008225","ODP222 Liragluitde Increased IL-1RA Concentrations in Obese Type 2 Diabetes: A Small Randomized Controlled Trial",null,"2022","include_nma",null,"conference_abstract","P01",null,"abstract_only","high","first","opus-5.5-agent11","abstract of small RCT, liraglutide versus standard therapy in obese type 2 diabetes for 12 weeks",1],["R0008310","Outcomes of Beinaglutide on Weight Loss in Patients With Diabetes or Obesity: A Systematic Review and Meta-Analysis.","Wen J","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent11","PRISMA meta-analysis of beinaglutide studies including RCTs versus comparators; PubMed, Scopus, Embase, Cochrane searched",1],["R0008387","Efficacy and safety of GLP-1RAs, SGLT2is, and nsMRAs for cardiovascular and renal outcomes in T2DM with CKD: a systematic review and network meta-analysis.","Chen H","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent11","registered network meta-analysis of RCTs of GLP-1RAs, SGLT2i and nsMRAs in diabetes with CKD",1],["R0008458","Alopecia Risk With GLP‐1 Receptor Agonists: A Disproportionality Analysis Using the FDA Adverse Event Reporting System (FAERS)","Gupta A","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent11","FAERS disproportionality analysis of alopecia reports with GLP-1RAs",1],["R0009923","Efficacy of Polyethylene Glycol Loxenatide in Combination with Basal Insulin in Patients with Type 2 Diabetes Mellitus: A Retrospective Real-World Study.","Liu X","2025","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent19","retrospective propensity matched comparison of PEG-loxenatide plus basal insulin vs basal insulin alone; HbA1c and weight, no listed harm",1],["R0010027","Safety and efficacy of 24 weeks of pemvidutide in metabolic dysfunction-associated steatotic liver disease: A randomized, controlled clinical trial.","Browne SK","2025","include_nma",null,"extension","P09",null,null,"high","first","opus-5.5-agent19","double blind 12 week extension of randomized placebo controlled pemvidutide trial in MASLD keeping randomized arms",1],["R0010100","The impact of glucagon-like peptide-1 (GLP-1) agonists in the treatment of eating disorders: a systematic review and meta-analysis.","Radkhah H","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent19","meta-analysis of GLP-1 RA studies vs controls in binge eating disorder; PubMed Scopus Web of Science Cochrane searched",1],["R0010188","Antidiabetic Drugs for the Risk of Alzheimer Disease in Patients With Type 2 DM Using FAERS.","Akimoto H","2020","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent19","FAERS analysis of Alzheimer disease reports by antidiabetic monotherapy incl GLP-1 RA; spontaneous reports",1],["R0010274","Pharmacological management of type 2 diabetes mellitus in children and adolescents: A systematic review and network meta-analysis.","Gagnon CA","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent19","network meta-analysis of RCTs of drugs incl GLP-1 RA for pediatric type 2 diabetes; PubMed Embase Scopus, PROSPERO",1],["R0010465","Combination therapy with once-weekly glucagon like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a case series.","Lajthia E","2019","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent19","retrospective case series of once weekly GLP-1 RA combined with DPP-4 inhibitors; no comparison group",1],["R0012083","The Discovery and Development of Liraglutide and Semaglutide.","Knudsen LB","2019","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent14","narrative review of the discovery and development of liraglutide and semaglutide",1],["R0012167","A Qualitative Analysis of Patient Experiences Using Semaglutide 2.4 mg for Weight Loss.","Plenn E","2025","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent14","qualitative analysis of Reddit posts by semaglutide users, no exposure comparison",1],["R0012273","Novel pharmacological therapy in type 2 diabetes mellitus with established cardiovascular disease: Current evidence.","Pozo L","2019","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent14","narrative review of novel antidiabetic drugs in T2D with cardiovascular disease",1],["R0012360","Targeting the DPP-4-GLP-1 pathway improves exercise tolerance in heart failure patients: a systematic review and meta-analysis.","Chen C","2019","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent14","systematic review and meta-analysis of RCTs of DPP-4i or GLP-1 RA on exercise tolerance in heart failure",1],["R0012465","A cost-effectiveness analysis of behavioural, pharmacological, and surgical obesity treatments in Canada.","Gupta N","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent14","Markov model cost effectiveness analysis of obesity treatments including semaglutide and tirzepatide",1],["R0012661","Effects of insulin and exenatide therapy on glycemic control and β-cell function in patients newly diagnosed with type 2 diabetes and severe hyperglycemia.","Wu TH","2026","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent14","open label RCT of exenatide vs insulin after intensive insulin in newly diagnosed T2D with severe hyperglycemia",1],["R0013816","Popularity of Surgical and Pharmacological Obesity Treatment Methods Searched by Google Users: the Retrospective Analysis of Google Trends Statistics in 2004-2022.","Kamiński M","2024","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent06","Google Trends infodemiology study of obesity treatment search popularity; no drug exposure comparison",1],["R0013920","Efficacy and safety of glucagon-like peptide 1 agonists for Parkinson's disease: a systematic review and meta-analysis.","Nogueira LOS","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent06","registered systematic review and meta-analysis of RCTs of GLP-1 RAs versus placebo in Parkinson disease",1],["R0013991","Emulating real-world GLP-1 efficacy in type 2 diabetes through causal learning and virtual patients.","MacLellan CR","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent06","generative AI virtual trial simulation emulating LEAD-5 from real world data; modeling study, not a randomized trial",1],["R0014077","Exenatide versus Insulin Lispro Added to Basal Insulin in a Subgroup of Korean Patients with Type 2 Diabetes Mellitus.","Yoon KH","2017","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent06","Korean subgroup of randomized open label trial of exenatide twice daily versus insulin lispro added to glargine",1],["R0014187","Tirzepatide and SGLT2 Inhibitors for Heart Failure With Preserved Ejection Fraction and Obesity: Entering a New Cardiometabolic Therapeutic Era.","Mohamed ZI","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent06","narrative review of tirzepatide and SGLT2 inhibitors in HFpEF with obesity",1],["R0014265","Risk phenotypes of diabetes and association with COVID-19 severity and death: an update of a living systematic review and meta-analysis.","Schlesinger S","2023","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent06","living systematic review and meta-analysis of diabetes phenotypes and COVID-19 death incl pooled GLP-1 RA use estimate",1],["R0011287","Safety and tolerability of exenatide once weekly in patients with type 2 diabetes: an integrated analysis of 4,328 patients.","MacConell L","2015","include_nma",null,"pooled_analysis","P01",null,null,"high","first","opus-5.5-agent16","integrated safety analysis of eight randomized phase 3 exenatide once weekly trials vs other GLP-1RAs and non GLP-1 comparators",1],["R0011383","INnoVative trial design for testing the Efficacy, Safety and Tolerability of 6-month treatment with incretin-based therapy to prevent type 1 DIAbetes in autoantibody positive participants: A protocol for three parallel double-blind, randomised controlled trials (INVESTDIA).","Kero J","2022","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent16","protocol for three placebo controlled RCTs of liraglutide in early stage type 1 diabetes",1],["R0011584","Glycaemic target attainment in people with Type 2 diabetes treated with insulin glargine/lixisenatide fixed-ratio combination: a post hoc analysis of the LixiLan-O and LixiLan-L trials.","Davidson JA","2020","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent16","post hoc analysis of LixiLan-O and LixiLan-L RCTs of iGlarLixi vs glargine or lixisenatide",1],["R0011684","GLP-1 Promotes Cortical and Medullary Perfusion in the Human Kidney and Maintains Renal Oxygenation During NaCl Loading.","Haddock B","2023","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent16","randomized crossover infusion of native GLP-1 vs placebo in healthy men; not a therapeutic GLP-1RA",1],["R0011775","Age, sex, race, BMI, and duration of diabetes differences in cardiovascular outcomes with glucose lowering drugs in type 2 diabetes: A systematic review and meta-analysis.","Diallo A","2022","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent16","PROSPERO registered systematic review and meta-analysis of GLP-1RA and SGLT2i CVOT subgroups; MEDLINE searched",1],["R0011984","Glycemic Control, Preexisting Cardiovascular Disease, and Risk of Major Cardiovascular Events in Patients with Type 2 Diabetes Mellitus: Systematic Review With Meta-Analysis of Cardiovascular Outcome Trials and Intensive Glucose Control Trials.","Giugliano D","2019","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent16","systematic review and meta-analysis of CVOTs including GLP-1RA vs placebo by prior CVD; PubMed, EMBASE, CENTRAL",1],["R0010581",null,null,null,"inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent01","12 month longitudinal treated only cohort of dulaglutide or semaglutide in type 2 diabetes with before and after measures",1],["R0010780","Real-world effects of incretin-based Obesity medications on body composition.","Bhatti R","2025","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent01","retrospective comparison of semaglutide and tirzepatide users on body composition and weight",1],["R0010845","Efficacy evaluation and mechanistic investigation of transcutaneous auricular vagus nerve stimulation in enhancing the therapeutic effects of semaglutide and reducing its gastrointestinal side effects: a randomized controlled trial protocol.","Tian X","2025","inventory_only","N3","protocol_or_design",null,null,null,"high","first","opus-5.5-agent01","protocol of RCT of active versus sham vagus nerve stimulation with semaglutide in both arms; GLP-1 regimen unchanged",1],["R0011013","Dapiglutide, a dual GLP-1 and GLP-2 receptor agonist, for obesity: a randomised, double-blind, placebo-controlled parallel-group, proof-of-concept trial.","Nielsen CK","2026","include_nma",null,"primary_report","P02",null,null,"high","first","opus-5.5-agent01","phase IIa double blind RCT of dapiglutide 4 or 6 mg versus placebo in adults with obesity without diabetes",1],["R0011101","Effects of dulaglutide on alcohol consumption during smoking cessation.","Probst L","2023","include_nma",null,"secondary_report","P14B",null,null,"high","first","opus-5.5-agent01","predefined secondary alcohol analysis of double blind RCT of dulaglutide versus placebo for smoking cessation",1],["R0011209","Clinical Pharmacokinetics of Oral Semaglutide: Analyses of Data from Clinical Pharmacology Trials.","Overgaard RV","2021","inventory_only","N2","pooled_analysis",null,null,null,"high","first","opus-5.5-agent01","population pharmacokinetic model of oral semaglutide pooled from clinical pharmacology trials; no review outcome",1],["R0012686","Impact of semaglutide and dulaglutide shortages on Pharmaceutical Benefits Scheme prescriptions supplied for type 2 diabetes treatment.","Phakey S","2024","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent04","analysis of PBS prescription volumes for semaglutide and dulaglutide during shortages, drug utilization only",1],["R0012784","Glucagon-like peptide-1 receptor agonists and cardiovascular events: a meta-analysis of randomized clinical trials.","Monami M","2011","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent04","meta-analysis of RCTs from three databases of GLP-1 RA vs placebo or comparators on major cardiovascular events",1],["R0012853","SPIRIT – Assessing clinical parameters associated with using IDegLira in patients with Type 2 Diabetes in a real-world setting in Colombia: a single arm, retrospective, chart review study","Ramírez A","2023","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent04","SPIRIT single arm retrospective chart review of IDegLira initiators, before and after comparison only",1],["R0013045","Use of Canagliflozin in Combination With and Compared to Incretin-Based Therapies in Type 2 Diabetes.","Pratley RE","2017","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent04","narrative review of canagliflozin with or vs incretin based therapies",1],["R0013131","GLP-1 receptor agonists, polycystic ovary syndrome and reproductive dysfunction: Current research and future horizons.","Papaetis GS","2022","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent04","narrative review of GLP-1 RA in PCOS and reproductive dysfunction",1],["R0013239","Cardiovascular outcomes in trials of new antidiabetic drug classes: a network meta-analysis.","Fei Y","2019","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent04","registered network meta-analysis of cardiovascular outcome trials of GLP-1 RA, SGLT2i and DPP-4i",1],["R0013365","Contemporary (2019) prevalence of cardiovascular disease in adults with type 2 diabetes in Brazil: the cross-sectional CAPTURE study.","Vencio S","2022","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent04","CAPTURE Brazil cross sectional CVD prevalence in type 2 diabetes, GLP-1 RA only described as prescription rate",1],["R0017082","Trends and projections of the global burden of T2DM-associated CKD related to high BMI: A global burden of disease study 2021.","Zhang J","2025","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent05","Global Burden of Disease analysis of diabetic CKD attributable to high BMI; no drug exposure studied",1],["R0017188","Efficacy of dulaglutide on vascular health indexes in subjects with type 2 diabetes: A randomized trial.","Tuttolomondo A","2020","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent05","preprint of RCT of dulaglutide added to conventional therapy versus conventional therapy alone in type 2 diabetes; HbA1c and vascular indices",1],["R0017316","Semaglutide use before single-level lumbar fusion associated with fewer readmissions and 90-day costs.","Ng MK","2025","include_harms",null,"other",null,"O121",null,"high","first","opus-5.5-agent05","claims cohort of semaglutide users versus matched controls undergoing lumbar fusion reporting 90 day acute kidney injury; prevalent users",1],["R0017412","Incretin therapy for type 2 diabetes in Spain: a cost-effectiveness analysis of liraglutide versus sitagliptin.","Mezquita Raya P","2013","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent05","cost effectiveness model of liraglutide versus sitagliptin in Spain using trial inputs",1],["R0017513","Does glucagon-like peptide-1 (GLP-1) receptor agonist stimulation reduce alcohol intake in patients with alcohol dependence: study protocol of a randomised, double-blinded, placebo-controlled clinical trial.","Antonsen KK","2018","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent05","protocol of placebo controlled RCT of exenatide once weekly in alcohol dependence; no results",1],["R0017574","Comment on \"Associations of semaglutide with first-time diagnosis of Alzheimer's disease in patients with type 2 diabetes: Target trial emulation using nationwide real-world data in the US\".","Salehi-Abargouei A","2025","inventory_only","N9","ancillary",null,null,null,"high","first","opus-5.5-agent05","letter commenting on a target trial emulation of semaglutide and Alzheimer disease",1],["R0017706","The safety and efficacy of liraglutide combined with metformin in clinical treatment of polycystic ovary syndrome patients: a meta-analysis.","Huang R","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent05","registered meta-analysis of RCTs of liraglutide plus metformin versus metformin in PCOS, eight named databases",1],["R0012161","Efficacy and safety of switching to iGlarLixi from premixed insulin therapy in patients with type 2 diabetes: A real-world experience.","Huang CJ","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent13","retrospective before after series of 40 patients switched from premixed insulin to iGlarLixi, no comparison group",1],["R0012356","Oral Semaglutide Reduces HbA1c and Body Weight in Patients with Type 2 Diabetes Regardless of Background Glucose-Lowering Medication: PIONEER Subgroup Analyses.","Pratley RE","2021","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent13","post hoc subgroup analyses of PIONEER 3, 4, 5, 7, 8 RCTs of oral semaglutide vs comparators by background medication",1],["R0012464","Dulaglutide as an Add-on to Insulin in Type 2 Diabetes; Clinical Efficacy and Parameters Affecting the Response in Real-World Practice.","Lee J","2019","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent13","retrospective single group series of dulaglutide added to insulin, no comparison group",1],["R0012560","DUAL I China: Improved glycemic control with IDegLira versus its individual components in a randomized trial with Chinese participants with type 2 diabetes uncontrolled on oral antidiabetic drugs.","Wang W","2022","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent13","DUAL I China RCT of IDegLira vs degludec vs liraglutide in type 2 diabetes",1],["R0012730","Once-weekly albiglutide in the management of type 2 diabetes: patient considerations.","Woodward HN","2014","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent13","narrative drug review of albiglutide pharmacology and trials",1],["R0012808","Peer Referral Pathways and 6-Month Outcomes in a Tirzepatide-Supported Digital Weight Loss Service: Retrospective Cohort Study.","Talay L","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent13","cohort of tirzepatide digital service users compared by peer referral, adherence and weight only",1],["R0011199","Comparison of Glucose Lowering Efficacy of Human GLP-1 Agonist in Taiwan Type 2 Diabetes Patients after Switching from DPP-4 Inhibitor Use or Non-Use.","Tsai CJ","2022","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent18","cohort of GLP-1 RA initiators compared by prior DPP-4i use; all exposed, no drug comparator group",1],["R0011389","Achievement of the ESC recommendations for secondary prevention of cardiovascular risk factors in high-risk patients with type 2 diabetes: A real-world national cohort analysis.","Salem AM","2023","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent18","Welsh cohort assessing achievement of secondary prevention targets and prescribing rates after PCI; no GLP-1 RA exposure comparison",1],["R0011503","Survodutide for the Treatment of Obesity Disease in Japanese Participants: Rationale, Design and Baseline Characteristics of the Phase 3 SYNCHRONIZE-JP Trial.","Yokote K","2026","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent18","design and baseline characteristics of SYNCHRONIZE-JP phase 3 RCT of survodutide vs placebo; no outcome results",1],["R0011598","Fasting GLP-1 Levels and Albuminuria Are Negatively Associated in Patients with Type 2 Diabetes Mellitus.","Jang CW","2024","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent18","cross sectional study of endogenous fasting GLP-1 levels and albuminuria; GLP-1 RA users excluded",1],["R0011693","Glucagonlike peptide-1 receptor agonists versus dipeptidyl peptidase-4 inhibitors in ischemic strokes with diabetes 2.","Hastrup S","2024","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent18","Danish cohort of stroke patients with prior GLP-1 RA vs DPP-4i use; stroke severity and mortality only",1],["R0011797","Exenatide Once Weekly in the Treatment of Patients with Multiple System Atrophy.","Vijiaratnam N","2025","include_nma",null,"primary_report","P99",null,null,"high","first","opus-5.5-agent18","single center open label RCT of exenatide once weekly vs control in multiple system atrophy; UMSARS and quality of life",1],["R0011905","A GLP1 receptor agonist diabetes drug ameliorates neurodegeneration in a mouse model of infantile neurometabolic disease.","Poupon-Bejuit L","2022","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent18","semaglutide in a mouse model of infantile neuroaxonal dystrophy; animal study only",1],["R0013029","The Effect of Retatrutide on Kidney Parameters in Participants With Type 2 Diabetes Mellitus and/or Obesity.","Heerspink HJL","2025","include_nma",null,"secondary_report","P01; P02",null,null,"high","first","opus-5.5-agent20","post hoc kidney analysis of two randomized phase 2 retatrutide trials vs placebo or dulaglutide",1],["R0013112","A Network Meta-Analysis Comparing Semaglutide Once-Weekly with Other GLP-1 Receptor Agonists in Japanese Patients with Type 2 Diabetes.","Webb N","2018","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent20","NMA from systematic search of MEDLINE Embase Cochrane comparing semaglutide with other GLP-1 RAs in Japanese T2D",1],["R0013229","Semaglutide s.c. Once-Weekly in Type 2 Diabetes: A Population Pharmacokinetic Analysis.","Carlsson Petri KC","2018","inventory_only","N2","secondary_report",null,null,null,"high","first","opus-5.5-agent20","population PK model of semaglutide arms from five SUSTAIN trials, covariates of exposure only, no review outcome contrast",1],["R0013317","Health-Related Quality of Life and Work-Related Outcomes in People with Obesity or Overweight Treated with Tirzepatide or Other Obesity Medications: United States Results from the Adelphi Real World Obesity Disease Specific Programme™.","Gibble TH","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent20","cross sectional Adelphi survey describing HRQoL by tirzepatide, other obesity drug or none",1],["R0013418","Effect of a single dose of insulin glargine/lixisenatide fixed ratio combination (iGlarLixi) on postprandial glucodynamic response in Japanese patients with type 2 diabetes mellitus: A phase I randomized trial.","Inoue M","2019","include_nma",null,"primary_report","P01",null,"mechanistic; crossover","high","first","opus-5.5-agent20","randomized four period crossover of iGlarLixi doses vs glargine vs placebo in Japanese T2D, hypoglycemia and safety reported",1],["R0013506","Efficacy and Safety of Retatrutide in the Treatment of Diabetes and/or Obesity Comorbid with Chronic Kidney disease: a Systematic Review and Meta-Analysis.","Pallavi K","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent20","systematic review and meta-analysis of retatrutide RCTs in diabetes or obesity with CKD",1],["R0013593","Real-World Use of Semaglutide for Weight Management: Dose Titration, Discontinuation Patterns and Weight Changes.","Skandov MD","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent20","single practice retrospective cohort of semaglutide for weight management, no comparison group",1],["R0012851","The efficacy of single pharmacist medication review among type II diabetic patients who take six chronic medications or more: a case-control study.","Harmatz D","2022","exclude","E2","primary_report",null,null,null,"high","first","opus-5.5-agent03","matched study of pharmacist medication review in polypharmacy T2D; GLP-1 RA starts are a prescribing outcome only",1],["R0012933","Obesity, Polycystic Ovary Syndrome, and Infertility: A New Avenue for GLP-1 Receptor Agonists.","Cena H","2020","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent03","self described narrative review of GLP-1 RA for obesity, PCOS and infertility",1],["R0013043","Effect of short-term tirzepatide treatment on mean platelet volume in patients with obesity: a retrospective controlled study.","Demircan F","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent03","retrospective controlled study tirzepatide vs untreated obesity; mean platelet volume and BMI only",1],["R0013128","Analysis of tirzepatide in the US FDA adverse event reporting system (FAERS): a focus on overall patient population and sex-specific subgroups.","Ou Y","2024","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent03","FAERS disproportionality analysis of tirzepatide adverse event reports",1],["R0013236","Evaluating the Impact of Tirzepatide on Clinical Outcomes in Patients With Heart Failure.","Bin Abdul Malik MH","2025","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent03","prospective single group observational study of tirzepatide in heart failure, no comparator",1],["R0013351","Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple-ascending-dose phase 1b trial.","Ji L","2022","include_nma",null,"primary_report","P02",null,null,"high","first","opus-5.5-agent03","phase 1b randomized placebo controlled multiple ascending dose trial of mazdutide 9 and 10 mg in Chinese adults with obesity",1],["R0013441","Effectiveness and safety of iGlarLixi in people with type 2 diabetes not at target on basal insulin and oral antidiabetic therapy in a prospective observational trial.","Seufert J","2025","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent03","prospective single arm noninterventional study of switching to iGlarLixi from basal insulin oral therapy",1],["R0013524","Decreases in circulating ANGPTL3/8 concentrations following retatrutide treatment parallel reductions in serum lipids.","Wen Y","2025","include_nma",null,"secondary_report","P01; P02",null,"mechanistic","high","first","opus-5.5-agent03","post hoc biomarker analysis of two phase 2 retatrutide RCTs vs placebo or dulaglutide; lipids and ANGPTL proteins",1],["R0009147","Decreased risk of post-thyroidectomy hypocalcemia with history of GLP-1RA use.","Ayo-Ajibola O","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent10","TriNetX thyroidectomy cohort with versus without prior GLP-1 RA; postoperative hypocalcemia only, no harms_nrs outcome",1],["R0009210","The vascular function effects of adding exenatide or meal insulin to basal insulin therapy in early type 2 diabetes.","Retnakaran R","2023","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent10","PREVAIL RCT glargine alone versus plus lispro versus plus exenatide in early T2D; vascular function and BP ancillary outcomes",1],["R0009432","Efficacy and safety of visepegenatide as an add-on therapy to metformin in patients with type 2 diabetes: a randomised, double-blind, parallel, placebo-controlled, phase 3 study.","Cai X","2024","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent10","phase 3 double blind RCT visepegenatide versus placebo added to metformin in Chinese T2D; HbA1c at 24 weeks",1],["R0009547","Effects of a Dulaglutide plus Calorie-Restricted Diet versus a Calorie-Restricted Diet on Visceral Fat and Metabolic Profiles in Women with Polycystic Ovary Syndrome: A Randomized Controlled Trial.","Zhang Y","2023","include_nma",null,"primary_report","P12",null,null,"high","first","opus-5.5-agent10","open label RCT dulaglutide plus calorie restriction versus calorie restriction alone in overweight PCOS",1],["R0009617","Effects of semaglutide on mortality, cardiovascular, and kidney outcomes across the cardio-kidney-metabolic continuum: a systematic review and meta-analysis.","Marzano F","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent10","meta-analysis of placebo controlled semaglutide RCTs on mortality, CV and kidney outcomes with systematic search",1],["R0009702","Real-World Treatment Patterns of Glucose-Lowering Agents Among Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease or At Risk for Cardiovascular Disease: An Observational, Cross-Sectional, Retrospective Study.","Nair R","2022","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent10","cross sectional claims study of glucose lowering drug utilization trends; no exposure outcome comparison",1],["R0009798","Evaluating the long-term cost-effectiveness of fixed-ratio combination insulin degludec/liraglutide (IDegLira) for type 2 diabetes in Spain based on real-world clinical evidence.","Raya PM","2019","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent10","CORE Diabetes Model cost effectiveness of IDegLira in Spain based on audit data; simulation",1],["R0012057","Changes in glomerular filtration rate in patients with body mass index ≥35 kg/m2 treated with metabolic and bariatric surgery versus GLP-1 agonist at 1-year follow-up.","Henao-Carrillo DC","2024","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent08","retrospective cohort comparing liraglutide 3 mg with bariatric surgery on GFR change at one year; no harms list outcome",1],["R0012151","SUN-576 Glucagon-like Peptide-1 (GLP-1) Receptor Agonists For Alcohol Use Disorder: a Systematic Review and Meta-analysis",null,"2025","include_review",null,"systematic_review",null,null,"abstract_only","high","first","opus-5.5-agent08","conference abstract of systematic review and meta-analysis of GLP-1 RAs for alcohol use disorder; four databases",1],["R0012252","Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis.","Sattar N","2022","include_nma",null,"pooled_analysis","P01",null,null,"high","first","opus-5.5-agent08","prespecified pooled meta-analysis of seven SURPASS RCTs of tirzepatide versus control on MACE; sponsor program without search",1],["R0012333","Achieving postprandial glucose control with lixisenatide improves glycemic control in patients with type 2 diabetes on basal insulin: a post-hoc analysis of pooled data.","Davidson JA","2020","include_nma",null,"pooled_analysis","P01",null,null,"high","first","opus-5.5-agent08","post hoc pooled analysis of three GetGoal RCTs of lixisenatide versus placebo on basal insulin",1],["R0012440","Comparative effectiveness of incretin-based therapies and the risk of death and cardiovascular events in 38,233 metformin monotherapy users.","Gamble JM","2016","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent08","CPRD new user cohort of GLP-1 RA or DPP4i versus SU after metformin; mortality and cardiovascular events only",1],["R0012545","Real-world implementation of the 2020 KDIGO guidelines for diabetes management in chronic kidney disease: a single-center retrospective study.","Levin-Iaina N","2025","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent08","single center audit of KDIGO guideline drug utilization incl GLP-1 RA in CKD; utilization only",1],["R0012621","Efficacy of IDegLira Versus IDegAsp Therapy in Patients with Type 2 Diabetes: A Randomized Crossover Study by isCGM.","Kawaguchi Y","2022","include_nma",null,"primary_report","P01",null,"crossover","high","first","opus-5.5-agent08","randomized crossover trial of IDegLira versus IDegAsp in type 2 diabetes with isCGM outcomes",1],["R0012710","Liraglutide and Βeta-Cell Function in Young Adults With Long-Standing Type 1 Diabetes and Residual C-Peptide: A Blinded, Randomized Controlled Trial.","Caballero-Corbalán J","2026","include_nma",null,"primary_report","P05",null,null,"high","first","opus-5.5-agent08","blinded RCT of liraglutide versus placebo for 52 weeks in long standing type 1 diabetes",1],["R0010550","Semaglutide once weekly in people with type 2 diabetes: Real-world analysis of the Canadian LMC diabetes registry (SPARE study).","Brown RE","2020","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent17","retrospective registry cohort of semaglutide initiators without comparison group",1],["R0010822","Retraction Note: Effect of combined GLP-1 analogue and bupropion/naltrexone on weight loss: a retrospective cohort study.","Naude J","2026","inventory_only","N9","ancillary",null,null,"retracted","high","first","opus-5.5-agent17","retraction note for a retrospective cohort of GLP-1 RA plus bupropion naltrexone on weight loss",1],["R0010920","Efficacy and safety of different doses of tirzepatide in patients with type 2 diabetes mellitus: a systematic review and network meta-analysis","Zhu J","2024","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent17","preprint systematic review and network meta-analysis of tirzepatide doses in type 2 diabetes RCTs",1],["R0010997","Weekly glucagon-like peptide-1 receptor agonist albiglutide as monotherapy improves glycemic parameters in Japanese patients with type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled study.","Nino A","2017","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent17","phase 3 double blind RCT of albiglutide 30 and 50 mg versus placebo with open label liraglutide reference in Japanese type 2 diabetes",1],["R0013562","Safety and Efficacy of Exenatide Once Weekly in Participants with Type 2 Diabetes and Stage 2/3 Chronic Kidney Disease.","Guja C","2020","include_nma",null,"pooled_analysis","P01; P08A",null,null,"high","first","opus-5.5-agent12","post hoc pooled analysis of eight phase 3 RCTs of exenatide once weekly vs placebo or non GLP-1 comparators by CKD stage",1],["R0010482","Patient-Level Multidimensional Response Phenotypes in Obesity-Associated Type 2 Diabetes: A 12-Month Real-World Cohort Study.","Bujdei-Tebeică I","2026","inventory_only","N6","secondary_report",null,null,null,"high","first","opus-5.5-agent02","secondary analysis of observational T2D cohort describing response phenotypes across drug classes including GLP-1 RA; no listed harm",1],["R0010593","Effects of Switching from Liraglutide or Dulaglutide to Subcutaneous Semaglutide on Glucose Metabolism and Treatment Satisfaction in Patients with Type 2 Diabetes: Protocol for a Multicenter, Prospective, Randomized, Open-Label, Blinded-Endpoint, Parallel-Group Comparison Study (The SWITCH-SEMA 1 Study).","Nomoto H","2021","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent02","protocol of SWITCH-SEMA 1 randomized trial switching liraglutide or dulaglutide to semaglutide; no results",1],["R0010703","Comparative Effectiveness and Safety of Oral Versus Subcutaneous Semaglutide in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis.","Karedath J","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent02","systematic review and meta-analysis of oral vs subcutaneous semaglutide in T2D; four databases searched",1],["R0010790","Clinical effects of antidiabetic drugs on psoriasis: The perspective of evidence-based medicine.","Zhang MX","2021","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent02","editorial on antidiabetic drugs and psoriasis",1],["R0010847","Adolescents with obesity treated with exenatide maintain endogenous GLP-1, reduce DPP-4, and improve glycemic control.","Stenlid R","2023","include_nma",null,"secondary_report","P03",null,null,"high","first","opus-5.5-agent02","preplanned substudy of Combat-JUDO placebo controlled RCT of exenatide in adolescents with obesity",1],["R0011025","Glucagon-like peptide-1 receptor: mechanisms and advances in therapy.","Zheng Z","2024","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent02","narrative review of GLP-1 receptor biology and therapeutic advances",1],["R0013664","Longitudinal Changes in Body Composition, Adaptive Thermogenesis, and Muscle Strength in Patients with Obesity Treated with Semaglutide.","Filippi-Arriaga F","2026","inventory_only","N6","primary_report","P02",null,null,"high","first","opus-5.5-agent12","retrospective nonrandomized comparison of lifestyle plus semaglutide vs lifestyle alone, body composition and strength, no listed harm",1],["R0013755","Comparative Analysis of Glucagon Receptor Agonists vs. Resmetirom in MASLD and MASH: Network Meta-Analysis of Clinical Trials.","Andonie CR","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent12","registered NMA of RCTs of dual and triple incretin glucagon agonists and resmetirom vs placebo in MASLD and MASH",1],["R0013836","Semaglutide in Adolescents Living With Obesity: A Real-World Data Study Exploring Predictors of Treatment Response.","Cimador V","2026","inventory_only","N5","primary_report","P03",null,null,"high","first","opus-5.5-agent12","research letter on routine care cohort of adolescents treated with semaglutide, no comparison group",1],["R0014015","Proteomic pathways across the ejection fraction spectrum in patients with heart failure and diabetes mellitus: an EXSCEL trial substudy.","Peters AE","2025","include_nma",null,"secondary_report","P01; P07A; P07B",null,null,"high","first","opus-5.5-agent12","EXSCEL proteomic substudy in participants with heart failure, exenatide vs placebo, by ejection fraction group",1],["R0014102","Bedtime-to-Morning Glucose Difference and iGlarLixi in Type 2 Diabetes: Post Hoc Analysis of LixiLan-L.","Zisman A","2018","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent12","post hoc analysis of LixiLan-L RCT, iGlarLixi vs insulin glargine, bedtime to morning glucose",1],["R0014206","Efficacy and tolerability of the new autoinjected suspension of exenatide once weekly versus exenatide twice daily in patients with type 2 diabetes.","Wysham CH","2018","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent12","open label RCT of exenatide once weekly autoinjector vs exenatide twice daily in T2D, HbA1c and GI events",1],["R0012047","Lifetime Health Effects and Cost-Effectiveness of Tirzepatide and Semaglutide in US Adults.","Hwang JH","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent07","microsimulation cost effectiveness analysis of tirzepatide, semaglutide and other anti obesity drugs",1],["R0012150","Efficacy and Safety of Liraglutide and Semaglutide on Weight Loss in People with Obesity or Overweight: A Systematic Review.","Xie Z","2022","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent07","PROSPERO registered network meta-analysis of RCTs of semaglutide and liraglutide doses for weight loss",1],["R0012248","Comparing GLP-1 agonists versus other weight loss interventions on risk of atrial fibrillation recurrence after catheter ablation: a meta-analysis.","Li HY","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent07","PRISMA meta-analysis of RCTs and cohorts comparing perioperative GLP-1RA and other weight loss approaches on AF recurrence",1],["R0012329","Evaluation of clinical relevance of weight nadirs and weight regain during 3 years of treatment with tirzepatide in participants with obesity or overweight and prediabetes.","Aronne LJ","2026","include_nma",null,"secondary_report","P06; P02",null,null,"high","first","opus-5.5-agent07","post hoc analysis of SURMOUNT-1 three year RCT of tirzepatide vs placebo in obesity with prediabetes; weight regain from nadir",1],["R0012534","Efimosfermin for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH): Mechanism of Action, Clinical Development and Emerging Therapeutic Potential.","Alamgir M","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent07","narrative review of the FGF21 analogue efimosfermin for MASH; GLP-1RA only mentioned as context",1],["R0012617","Reply to the comment of Wilbrink et al. on Retrospective analysis of liraglutide and basal insulin combination therapy in Japanese type 2 diabetes: The association between remaining β-cell function and the achievement of the HbA1c target 1 year after initiation.","Usui R","2018","inventory_only","N9","ancillary",null,null,null,"high","first","opus-5.5-agent07","authors reply to a comment on their retrospective liraglutide plus basal insulin study",1],["R0012703","Comparison of the Effectiveness of Once-Daily Alogliptin/Metformin and Twice-Daily Anagliptin/Metformin Combination Tablet in a Randomized, Parallel-Group, Open-Label Trial in Japanese Patients with Type 2 Diabetes.","Yamazaki S","2022","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent07","RCT comparing two DPP-4 inhibitor metformin combination tablets; GLP-1RA users excluded and not studied",1],["R0008942","Glycemic and Economic Outcomes in Elderly Patients with Type 2 Diabetes Initiating Dulaglutide Versus Basal Insulin in a Real-World Setting in the United States: The DISPEL-Advance Study.","Hoog M","2023","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent15","matched claims cohort of elderly patients initiating dulaglutide versus basal insulin; HbA1c, resource use and costs only",1],["R0009004","Emerging role of GLP-1 mono, dual, and triple agonists in the management of MASH-related fibrosis.","Tavaglione F","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent15","narrative review of GLP-1 mono, dual and triple agonist trials in MASH fibrosis",1],["R0009076","The cost-effectiveness of second line diabetes medication added to standard therapy in preventing type 2 diabetes related nephropathy in Germany.","Hille H","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent15","Markov microsimulation cost effectiveness model of empagliflozin, semaglutide and tirzepatide for nephropathy prevention",1],["R0009227","Comparison of Glucose-Lowering Drugs as Second-Line Treatment for Type 2 Diabetes: A Systematic Review and Meta-Analysis.","Gu S","2022","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent15","registered systematic review and meta-analysis of RCTs of add on drugs including GLP-1 RAs to metformin in Chinese type 2 diabetes",1],["R0009358","GLP-1 RA Treatment and Dosing Patterns Among Type 2 Diabetes Patients in Six Countries: A Retrospective Analysis of Pharmacy Claims Data.","Divino V","2019","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent15","pharmacy claims study of GLP-1 RA persistence and dosing patterns in six countries; utilization only",1],["R0009560","Use of GLP1 receptor agonists in early pregnancy and reproductive safety: a multicentre, observational, prospective cohort study based on the databases of six Teratology Information Services.","Dao K","2024","include_harms",null,"primary_report",null,"O120",null,"high","first","opus-5.5-agent15","prospective teratology service cohort, first trimester GLP-1 RA exposure versus diabetic and obese reference pregnancies; major birth defects",1],["R0009207","The impact of oral semaglutide on glycemic control and weight reduction: a database analysis of dosing effects in Japanese individuals with type 2 diabetes.","Ishiguro M","2025","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent09","retrospective comparison of oral semaglutide maintenance doses on HbA1c and weight, no eligible harm",1],["R0009340","A phase 1b randomised controlled trial of a glucagon-like peptide-1 and glucagon receptor dual agonist IBI362 (LY3305677) in Chinese patients with type 2 diabetes.","Jiang H","2022","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent09","phase 1b RCT of mazdutide versus placebo with open label dulaglutide in Chinese type 2 diabetes",1],["R0009540","Effect of Orally Administered Semaglutide Versus Dulaglutide on Diabetes-Related Quality of Life in Japanese Patients with Type 2 Diabetes: The PIONEER 10 Randomized, Active-Controlled Trial.","Ishii H","2021","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent09","PIONEER 10 quality of life analysis of oral semaglutide versus dulaglutide randomized trial in Japan",1],["R0009610","Comparison of the Efficacy of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Metabolic Associated Fatty Liver Disease: Updated Systematic Review and Meta-Analysis.","Dai Y","2020","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent09","PROSPERO registered meta-analysis of RCTs of GLP-1 agonists in fatty liver disease, four databases",1],["R0009701","Toward Precision Obesity Pharmacotherapy: Using the Eating Behavior Phenotype Scale (EFCA) in Real-World Clinical Practice.","Pineda-Wieselberg RJ","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent09","retrospective comparison of anti-obesity drugs including semaglutide and tirzepatide on eating behavior scores, no harms",1],["R0009796","Insights into the early use of oral semaglutide in routine clinical practice: The IGNITE study.","Aroda VR","2021","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent09","IGNITE retrospective EHR cohort of oral semaglutide users without comparison group",1],["R0017817","Glucagon-like peptide analogues for type 2 diabetes mellitus: systematic review and meta-analysis.","Shyangdan DS","2010","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent05","meta-analysis of RCTs of GLP-1 analogues versus placebo or other agents in type 2 diabetes, four named databases",1],["R0018014","5184 Tirzepatide Improved Mental and Psychosocial Health-Related Quality of Life in Adults with Obesity or Overweight: Results from the SURMOUNT-4 phase 3 Trial",null,"2024","include_nma",null,"conference_abstract","P02W",null,"abstract_only","high","first","opus-5.5-agent05","abstract of SURMOUNT-4 randomized withdrawal of tirzepatide versus placebo after lead in; quality of life outcomes",1],["R0018110","Patient-Centered Outcomes in Heart Failure Pharmacotherapy: A Meta-Analysis of Randomized Controlled Trials.","Kido K","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent05","meta-analysis of heart failure drug RCTs including GLP-1 RA versus placebo on KCCQ, three named databases",1],["R0018231","De-intensification of basal-bolus therapy by replacing prandial insulin with once-weekly subcutaneous semaglutide in individuals with well-controlled type 2 diabetes: A single-centre, open-label randomised trial (TRANSITION-T2D).","Rodriguez P","2025","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent05","TRANSITION-T2D RCT replacing prandial insulin with semaglutide plus degludec versus continued basal bolus insulin, 26 weeks",1],["R0018457","Efficacy and Safety of Adding Empagliflozin to Liraglutide on Renal Function in Patients with Advanced-Stage Type 2 Diabetic Kidney Disease: A Randomized Controlled Trial.","Sunagawa K","2024","inventory_only","N3","other",null,null,null,"high","first","opus-5.5-agent05","RCT adding empagliflozin to liraglutide versus liraglutide alone; randomized contrast does not change the GLP-1 RA regimen",1],["R0018576","Incretin based drugs and the risk of pancreatic cancer: international multicentre cohort study.","Azoulay L","2016","include_harms",null,"other",null,"O38",null,"high","first","opus-5.5-agent05","CNODES multisite cohort with nested case control of incretin drugs including GLP-1 RA versus sulfonylureas on pancreatic cancer",1],["R0014366","Effects of exenatide on coronary stent's endothelialization in subjects with type 2 diabetes: a randomized controlled trial. The Rebuild study.","Santos-Pardo I","2023","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent06","Rebuild open label RCT of weekly exenatide plus standard care versus standard care after coronary stenting in T2D",1],["R0014440","Ligand-Specific Factors Influencing GLP-1 Receptor Post-Endocytic Trafficking and Degradation in Pancreatic Beta Cells.","Fang Z","2020","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent06","in vitro beta cell and HEK293 experiments on GLP-1 receptor trafficking with different agonists",1],["R0014655","The effect of GLP-1 receptor agonists in pre-clinical rodent models of Parkinson's disease: A systematic review and meta-analysis.","Dahiya S","2022","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent06","systematic review and meta-analysis of GLP-1 RAs in rodent Parkinson models only",1],["R0014722","Liraglutide and Dulaglutide therapy in addition to SGLT-2 inhibitor and metformin treatment in Indian type 2 diabetics: a real world retrospective observational study.","Ghosal S","2018","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent06","retrospective case note comparison of liraglutide versus dulaglutide added to metformin and SGLT2 inhibitor; glycemic and weight outcomes only",1],["R0014802","Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as add-on to metformin in patients with type 2 diabetes in SUSTAIN China: A 30-week, double-blind, phase 3a, randomized trial.","Ji L","2021","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent06","SUSTAIN China double blind RCT of semaglutide 0.5 and 1.0 mg versus sitagliptin added to metformin in T2D",1],["R0014908","Effect of dulaglutide in promoting abstinence during smoking cessation: 12-month follow-up of a single-centre, randomised, double-blind, placebo-controlled, parallel group trial.","Lüthi H","2024","include_nma",null,"secondary_report","P14B",null,null,"high","first","opus-5.5-agent06","12 month follow-up of double blind RCT of dulaglutide versus placebo with varenicline for smoking cessation",1],["R0014961","Comparative efficacy and safety of antidiabetic drugs for obese patients with knee osteoarthritis: a network meta-analysis of randomized controlled trials.","Jiang G","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent06","NMA of RCTs of antidiabetic drugs incl semaglutide and liraglutide for knee osteoarthritis in obesity",1],["R0010569","Novel glucose-lowering drugs for non-alcoholic fatty liver disease.","Fu ZD","2021","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent19","meta-analysis of RCTs of DPP-4i, GLP-1 RA, SGLT2i vs placebo or other drugs in NAFLD; MEDLINE CENTRAL Embase searched",1],["R0010696","Impact of Contextual-Level Social Determinants of Health on Newer Antidiabetic Drug Adoption in Patients with Type 2 Diabetes.","Li Y","2023","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent19","social determinants of initiating SGLT2i or GLP-1 RA in OneFlorida; prescribing outcome only, no exposure comparison",1],["R0010778","Efficacy and Safety in a Real-World Study of the New Oral Formulation of Semaglutide in Patients with Chronic Kidney Disease and Type 2 Diabetes Mellitus.","Marques Vidas M","2024","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent19","retrospective oral semaglutide vs historical matched subcutaneous semaglutide in diabetic CKD; efficacy and GI intolerance, no listed harm",1],["R0010930","Survodutide for Obesity in Chinese Adults: Phase 3 Randomized Trial Design and Baseline Characteristics (SYNCHRONIZE™-CN).","Ji L","2026","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent19","design and baseline characteristics of SYNCHRONIZE-CN RCT of survodutide vs placebo in Chinese adults with obesity",1],["R0011001","MON-591 Effect of Liraglutide Treatment on Proglucagon-Derived Peptides","Kim S","2020","include_nma",null,"conference_abstract","P02",null,"mechanistic; abstract_only","high","first","opus-5.5-agent19","RCT abstract of liraglutide vs placebo for 14 weeks in overweight adults with prediabetes; proglucagon peptides, weight reported",1],["R0011098","Increased autoantibodies against incretin indicate poor prognosis in patients with diabetes.","Takemoto M","2025","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent19","autoantibodies against endogenous incretins as prognostic markers in diabetes; no GLP-1 RA exposure studied",1],["R0011200","Association between Dapagliflozin, Cardiac Biomarkers and Cardiac Remodeling in Patients with Diabetes Mellitus and Heart Failure.","Xanthopoulos A","2023","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent19","observational study of dapagliflozin vs no SGLT2i in heart failure with diabetes; GLP-1 RA users excluded",1],["R0012091","Expert Opinion on the Therapeutic Use of the Fixed-Ratio Combination of Insulin Glargine 100 U/mL and Lixisenatide: a Central/Eastern European Perspective.","Haluzík M","2020","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent16","expert consensus on practical use of iGlarLixi, not a primary study",1],["R0012178","Comparative ocular outcomes of tirzepatide versus other anti-obesity medications in people with obesity.","Huang YN","2025","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent16","TriNetX matched cohorts of tirzepatide vs semaglutide or other anti obesity drugs; cataract and visual outcomes, no NAION",1],["R0012286","Efficacy of Mazdutide in Nondiabetic Adults with Overweight or Obesity: A Meta-Analysis","Yassin MN","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent16","meta-analysis of mazdutide placebo controlled RCTs; PubMed, Scopus, Web of Science searched",1],["R0012475","Characteristics and Dosing Patterns of Tirzepatide Users with Type 2 Diabetes in the United States.","Mody R","2025","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent16","descriptive claims study of tirzepatide user characteristics and dosing patterns; utilization without comparison",1],["R0012569","Use of IDegLira to Intensify, Simplify, and Increase Appropriateness of Type 2 Diabetes Therapy: A Real-Life Experience.","Romano I","2024","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent16","retrospective chart review of IDegLira initiation, before and after only",1],["R0012665","Post hoc efficacy and safety analysis of insulin glargine/lixisenatide fixed- ratio combination in North American patients compared with the rest of world.","Dailey G","2019","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent16","post hoc regional analysis of LixiLan-O and LixiLan-L RCTs of iGlarLixi vs glargine or lixisenatide",1],["R0012746","Glucose-lowering drug use, glycemic outcomes, and severe hypoglycemia: 18-Year trends in 0·9 million adults with Diabetes in Hong Kong (2002-2019).","Yang A","2022","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent16","population trends in glucose lowering drug use and glycemic outcomes in Hong Kong; no GLP-1RA exposure comparison",1],["R0011315","Management of obesity with semaglutide or metformin in patients with antipsychotic-induced weight gain (MOSA): a non-randomised open-label pilot study.","Campforts B","2024","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent01","nonrandomized prospective cohort of oral semaglutide versus metformin for antipsychotic weight gain; weight and mild nausea only",1],["R0011399","Once-weekly semaglutide versus placebo in adults with increased fracture risk: a randomised, double-blinded, two-centre, phase 2 trial.","Hansen MS","2024","include_nma",null,"primary_report","P99",null,null,"high","first","opus-5.5-agent01","phase 2 double blind RCT of semaglutide versus placebo in adults with increased fracture risk without diabetes; osteopenia population",1],["R0011607","Oral small-molecule GLP-1 receptor agonist safiglipron in early type 2 diabetes: a randomized, double-blind, placebo-controlled trial.","Yu M","2026","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent01","OUTSTAND-1 phase 3 double blind RCT of oral safiglipron doses versus placebo in early type 2 diabetes",1],["R0011716","Pharmacokinetic and dose-finding studies on efpeglenatide in patients with type 2 diabetes.","Yoon KH","2020","include_nma",null,"primary_report","P01",null,"mechanistic","high","first","opus-5.5-agent01","two phase 2 placebo controlled RCTs of efpeglenatide dose finding and PK in type 2 diabetes with glucose and safety outcomes",1],["R0011912","OR19-05 Efficacy of Tirzepatide versus Semaglutide in Achieving Therapeutic Targets in Type 2 Diabetes: a post hoc analysis of SURPASS-2 Trial",null,"2025","include_nma",null,"conference_abstract","P01",null,"abstract_only","high","first","opus-5.5-agent01","abstract of post hoc SURPASS-2 analysis of target attainment, tirzepatide versus semaglutide RCT",1],["R0008534","Decreased Risk of Anxiety in Diabetic Patients Receiving Glucagon-like Peptide-1 Receptor Agonist: A Nationwide, Population-Based Cohort Study.","Tsai WH","2022","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent11","Taiwan claims matched cohort of GLP-1RA users versus non users; depression and anxiety only, no suicide outcome",1],["R0008613","Risk of lower limb amputation in diabetic patients using SGLT2 inhibitors versus DPP4 inhibitors or GLP-1 agonists: a meta-analysis of 2 million patients.","Lu Y","2023","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent11","registered meta-analysis of observational studies of SGLT2i versus DPP-4i or GLP-1RA on amputation; five named databases",1],["R0008685","GLP1 receptor agonists and SGLT2 inhibitors for the prevention or delay of type 2 diabetes mellitus onset: a systematic review and meta-analysis.","Ghobar F","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent11","registered meta-analysis of RCTs of GLP-1RAs or SGLT2i versus control in prediabetes; three named databases",1],["R0008761","Once-Weekly Subcutaneous Semaglutide 2.4 mg Injection is Cost-Effective for Weight Management in Spain.","Altés A","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent11","Markov model cost effectiveness analysis of semaglutide 2.4 mg in Spain",1],["R0008930","Glucagon-like peptide-1 receptor agonist, exendin-4, reduces reinstatement of heroin seeking behavior in rats","Douton JE","2019","exclude","E1","primary_report",null,null,null,"high","first","opus-5.5-agent11","rat experiments of exendin-4 on heroin seeking",1],["R0008995","Effectiveness and clinical benefits of new anti-diabetic drugs: A real life experience.","Piazzolla G","2022","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent11","retrospective clinic comparison of SGLT2i and GLP-1RA initiators; metabolic effectiveness measures only",1],["R0009054","Glucagon-like peptide-1 (GLP-1) receptor agonists for headache and pain disorders: a systematic review.","Halloum W","2024","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent11","systematic review of GLP-1RAs in headache and pain with PubMed and Embase search; includes human studies",1],["R0011192","Efficacy of Modern Diabetes Treatments DPP-4i, SGLT-2i, and GLP-1RA in White and Asian Patients With Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials.","Gan S","2020","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent17","meta-analysis of placebo controlled RCTs of DPP-4 inhibitors, SGLT2 inhibitors and GLP-1 RAs by ethnicity, PubMed search with criteria",1],["R0011288","The effect of GLP-1RA exenatide on idiopathic intracranial hypertension: a randomized clinical trial.","Mitchell JL","2023","include_nma",null,"primary_report","P99",null,null,"high","first","opus-5.5-agent17","placebo controlled RCT of exenatide in women with idiopathic intracranial hypertension and obesity; P99 condition not listed",1],["R0011387","Reassessing the risk-modifying effects of novel antidiabetic agents on asthma-COPD overlap syndrome: a dose-stratified network meta-analysis of 316,832 adults from 128 randomised trials.","Zeng BY","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent17","registered network meta-analysis of RCTs of glucose lowering drugs including GLP-1 RAs on asthma and COPD events",1],["R0011492","Insulin Sensitivity and Beta-Cell Function Following Tirzepatide in Japanese Patients with Type 2 Diabetes: A SURPASS J-mono Analysis.","Hamamoto Y","2025","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent17","prespecified analysis of SURPASS J-mono RCT of tirzepatide doses versus dulaglutide on insulin sensitivity; mislabeled case report",1],["R0011590","Cardiac safety of chronic inhibition of the myostatin-activin pathway with bimagrumab in healthy older adults.","Rooks D","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent17","placebo controlled RCT of bimagrumab in healthy older adults; GLP-1 RAs only mentioned as context",1],["R0011689","Design of glucagon-like Peptide-1 receptor agonist for diabetes mellitus from traditional chinese medicine.","Tang HC","2014","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent17","in silico docking and molecular dynamics screening of traditional Chinese medicine compounds for GLP-1 receptor agonism",1],["R0011777","Normalisation of glucose metabolism by exendin-4 in the chronic phase after stroke promotes functional recovery in male diabetic mice.","Augestad IL","2022","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent17","mouse study of exendin-4 after experimental stroke",1],["R0011901","Once-weekly glucagon-like peptide-1 receptor agonist dulaglutide is non-inferior to once-daily liraglutide and superior to placebo in Japanese patients with type 2 diabetes: a 26-week randomized phase III study.","Miyagawa J","2015","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent17","phase 3 RCT of dulaglutide versus placebo and open label liraglutide in Japanese type 2 diabetes, 26 weeks",1],["R0011989","Safety and efficacy of the combination of the glucagon-like peptide-1 receptor agonist liraglutide with an oral antidiabetic drug in Japanese patients with type 2 diabetes: Post-hoc analysis of a randomized, 52-week, open-label, parallel-group trial.","Kiyosue A","2018","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent18","post hoc analysis of open label RCT of liraglutide plus OAD vs additional OAD in Japanese T2D; adverse events, HbA1c",1],["R0012101","Drug-induced gastric motility disorders: A disproportionality analysis from the FAERS and CVARD databases.","Qian Z","2026","inventory_only","N5","other",null,null,null,"high","first","opus-5.5-agent18","FAERS and Canadian pharmacovigilance disproportionality analysis of drug induced gastric motility disorders including GLP-1 RAs",1],["R0012188","MON-183 Effect of GLP-1 Receptor Agonists on Anthropometric, Metabolic and Fertility Parameters in Polycystic Ovarian Syndrome: A Systematic Review and Meta-Analysis",null,"2025","include_review",null,"systematic_review",null,null,"abstract_only","high","first","opus-5.5-agent18","conference abstract of systematic review and meta-analysis of GLP-1 RA trials in PCOS; PubMed and Cochrane searched",1],["R0012291","Beyond glycated haemoglobin: Modelling contemporary management of type 2 diabetes with the updated Cardiff model.","McEwan P","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent18","health economic simulation model update for T2D treatment pathways; modeling only",1],["R0012387","Effect of 26 Weeks of Liraglutide Treatment on Coronary Artery Inflammation in Type 2 Diabetes Quantified by [64Cu]Cu-DOTATATE PET/CT: Results from the LIRAFLAME Trial.","Jensen JK","2021","include_nma",null,"secondary_report","P01",null,"mechanistic","high","first","opus-5.5-agent18","PET substudy of LIRAFLAME double blind RCT, liraglutide vs placebo in T2D; coronary inflammation with HbA1c measured",1],["R0012492","Drug repurposing for disease-modifying effects in multiple system atrophy.","Jeong SH","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent18","narrative review of repurposed drugs for multiple system atrophy; not a trial report",1],["R0012572","Semaglutide Treatment Effects on Liver Fat Content in Obese Subjects with Metabolic-Associated Steatotic Liver Disease (MASLD).","Dusilová T","2024","include_nma",null,"primary_report","P02",null,"mechanistic; crossover","high","first","opus-5.5-agent18","randomized order crossover of semaglutide vs diet in obese nondiabetic men with MASLD; weight and liver fat reported",1],["R0012673","Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials.","Sattar N","2021","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent18","registered systematic review and meta-analysis of GLP-1 RA CVOTs in T2D on CV, mortality, kidney outcomes",1],["R0013698","Effectiveness in Real World of Once Weekly Semaglutide in People with Type 2 Diabetes: Glucagon-Like Peptide Receptor Agonist Naïve or Switchers from Other Glucagon-Like Peptide Receptor Agonists: Results from a Retrospective Observational Study in Umbria.","Di Loreto C","2022","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent20","retrospective multicenter cohort of semaglutide users, naive and switcher subgroups, before and after, no unexposed comparison",1],["R0013790","Research Progress on the GIP/GLP-1 Receptor Coagonist Tirzepatide, a Rising Star in Type 2 Diabetes.","Ma Z","2023","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent20","narrative review of tirzepatide research progress",1],["R0013892","Efficacy and safety of the fixed-ratio combination of insulin degludec and liraglutide by baseline glycated hemoglobin, body mass index and age in Japanese individuals with type 2 diabetes: A subgroup analysis of two phase III trials.","Komatsu M","2021","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent20","subgroup analysis of randomized DUAL I and II Japan trials of IDegLira vs degludec or liraglutide",1],["R0013975","The Role of Antidiabetic Drugs in Bone Health: Assessing the Risk of Osteoporosis Subtypes and Fractures Using Mendelian Randomization.","Deng G","2025","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent20","Mendelian randomization of genetically proxied antidiabetic drugs on osteoporosis, no drug exposure",1],["R0014047","Antihyperglycemic agent therapy for adult patients with type 2 diabetes mellitus 2017: a position statement of the Korean Diabetes Association.","Ko SH","2017","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent20","Korean Diabetes Association position statement and guideline on antihyperglycemic agents",1],["R0014145","Shifts in waist-to-height ratio categories within tirzepatide groups: a post-hoc analysis of SURMOUNT-1.","Sattar N","2026","include_nma",null,"secondary_report","P02",null,null,"high","first","opus-5.5-agent20","post hoc waist to height ratio analysis of randomized placebo controlled SURMOUNT-1 trial of tirzepatide",1],["R0014230","Liraglutide 3.0 mg (Saxenda©) for Weight Loss and Remission of Pre-Diabetes. Real-World Clinical Evaluation of Effectiveness among Patients Awaiting Bariatric Surgery.","Wilmington R","2024","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent20","retrospective single arm evaluation of liraglutide 3 mg before bariatric surgery, no comparison group",1],["R0014333","Population Pharmacokinetics of an Extended-Release Formulation of Exenatide Following Single- and Multiple-Dose Administration.","Cirincione B","2017","inventory_only","N2","secondary_report",null,null,null,"high","first","opus-5.5-agent20","population PK modeling of extended release exenatide from two trials, concentrations only, no review outcome",1],["R0012742","Impact of Semaglutide on Osteoarthritis Risk in Obese Patients: A Retrospective Cohort Study","Baser O","2023","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent14","Medicare cohort semaglutide users vs no antiobesity medication in obesity, osteoarthritis incidence only",1],["R0012809","Liraglutide Protects Against Diastolic Dysfunction and Improves Ventricular Protein Translation.","Rutledge C","2024","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent14","mouse model of angiotensin induced diastolic dysfunction treated with liraglutide",1],["R0013084","Genetic and Clinical Determinants of Variation in Drug Response in Type 2 Diabetes: Insights From the Scottish and UK Biobank Cohorts.","Garg S","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent14","cohort study of clinical and genetic predictors of HbA1c response within drug classes including GLP-1 RA initiators, no exposure contrast",1],["R0013295","ODP259 Evaluating the Efficacy and Safety of Long-Acting GLP-1 Receptor Agonist in T1DM Patients",null,"2022","inventory_only","N5","conference_abstract",null,null,"abstract_only","high","first","opus-5.5-agent14","conference abstract of retrospective before and after chart review of long acting GLP-1 RA in type 1 diabetes",1],["R0013395","Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3.","Carvas AO","2025","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent14","mouse study of cagrilintide and salmon calcitonin in RAMP knockout mice",1],["R0013533","The effects of GLP-1 analogues in obese, insulin-using type 2 diabetes in relation to eating behaviour.","de Boer SA","2016","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent04","prospective observational single group of insulin treated patients starting exenatide or liraglutide, no comparison group",1],["R0013617","Concurrent initiation of tirzepatide and biologics improves patient-reported outcomes in obese psoriatic arthritis: a propensity score-matched study.","Venerito V","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent04","matched comparison of tirzepatide plus biologic vs biologic alone in obese psoriatic arthritis, disease activity outcomes only",1],["R0013711","Long-Term Effectiveness and Safety of Once Weekly Dulaglutide as Add-on to Metformin or Metformin Plus Insulin Secretagogues in Obesity and Type 2 Diabetes","Mirabelli M","2021","inventory_only","N6","conference_abstract",null,null,null,"high","first","opus-5.5-agent04","retrospective dulaglutide cohort with matched liraglutide comparison, HbA1c, weight and discontinuation only",1],["R0013913","Weight loss outcomes with tirzepatide in women with and without self-reported polycystic ovary syndrome.","Clift AK","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent04","digital service cohort of tirzepatide users compared by PCOS status, no drug exposure comparison group",1],["R0009890","GLP-1 Receptor Agonists: A New Treatment in Parkinson's Disease.","Kalinderi K","2024","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent10","self described narrative review of GLP-1 RAs in Parkinson disease mixing preclinical and clinical data",1],["R0010064","Association of glucagon-like peptide-1 (GLP-1) receptor agonists and diabetic retinopathy (DR) - a systematic review and meta-analysis.","Alwafi H","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent10","PROSPERO registered meta-analysis of RCTs and observational studies of GLP-1 RAs and diabetic retinopathy",1],["R0010146","Eliminating exogenous insulin therapy in patients with type 2 diabetes by duodenal ablation and GLP-1RA decreases risk scores for cardiovascular events.","Meiring S","2022","inventory_only","N1","secondary_report",null,null,null,"high","first","opus-5.5-agent10","substudy of single arm INSPIRE trial duodenal mucosal resurfacing plus liraglutide replacing insulin; pre post CV risk",1],["R0010300","Epicardial adipose tissue in contemporary cardiology.","Iacobellis G","2022","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent10","narrative review of epicardial adipose tissue in cardiology mentioning GLP-1 RAs as targets",1],["R0010439","Exploring a Suitable Marker of Glycemic Response to Dulaglutide in Patients with Type 2 Diabetes: A Retrospective Study.","Yoshiji S","2022","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent10","retrospective single group of dulaglutide initiators examining C-peptide predictors of HbA1c response",1],["R0014066","LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept.","Coskun T","2018","include_nma",null,"primary_report","P01; P99",null,"mechanistic","high","first","opus-5.5-agent04","phase 1 RCT of LY3298176 tirzepatide vs placebo with dulaglutide control in healthy volunteers and type 2 diabetes, reports HbA1c and weight",1],["R0013597","Comparative Effects of Weight Loss and Incretin-Based Therapies on Vascular Endothelial Function, Fibrinolysis, and Inflammation: A Randomized, Controlled Trial","Mashayekhi M","2022","include_nma",null,"primary_report","P99",null,"mechanistic","high","first","opus-5.5-agent03","preprint RCT liraglutide vs hypocaloric diet vs sitagliptin for 14 weeks in obesity; endothelial endpoints and weight; population code uncertain",1],["R0013708","Incidence of new onset type 2 diabetes in adults living with obesity treated with tirzepatide or semaglutide: real world evidence from an international retrospective cohort study.","Anson M","2024","include_harms",null,"primary_report",null,"O29; O33; O35A",null,"high","first","opus-5.5-agent03","TriNetX active comparator new user cohort tirzepatide vs semaglutide; pancreatitis, retinopathy, suicidal ideation outcomes",1],["R0013806","A real-world data analysis of tirzepatide in the FDA adverse event reporting system (FAERS) database.","Liu L","2024","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent03","FAERS disproportionality analysis of tirzepatide adverse event reports",1],["R0013986","Glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide dual receptor agonist DA-CH5 is superior to exendin-4 in protecting neurons in the 6-hydroxydopamine rat Parkinson model.","Zhang LY","2021","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent03","cell line and rat Parkinson model of exendin-4 and DA-CH5; no humans",1],["R0014060","Glucagon-like peptide-1 receptor agonist treatment prevents glucocorticoid-induced glucose intolerance and islet-cell dysfunction in humans.","van Raalte DH","2011","inventory_only","N2","primary_report","P99",null,"mechanistic; crossover","high","first","opus-5.5-agent03","randomized crossover in eight healthy men of IV exenatide with prednisolone; glucose tolerance and islet function only",1],["R0014163","Intensification of Basal Insulin Therapy with Lixisenatide in Patients with Type 2 Diabetes in a Real-World Setting: The BASAL-LIXI Study.","Bellido D","2018","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent03","retrospective single group study of lixisenatide added to basal insulin, no comparator",1],["R0014246","The Body weight Reducing Effects of Tirzepatide in People with and without Type 2 Diabetes: A Review on Efficacy and Adverse Effects.","Jensen TL","2024","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent03","narrative review of tirzepatide weight effects and adverse events from trial programs",1],["R0018674","Glycemic and Cost Outcomes among Hispanic/Latino People with Type 2 Diabetes in the USA Initiating Dulaglutide versus Basal Insulin: a Real-World Study.","Hoog M","2024","inventory_only","N6","other",null,null,null,"high","first","opus-5.5-agent05","claims cohort dulaglutide versus basal insulin in Hispanic adults on HbA1c and costs; no listed harm",1],["R0019154","Real-world characteristics, modern antidiabetic treatment patterns, and comorbidities of patients with type 2 diabetes in central and Eastern Europe: retrospective cross-sectional and longitudinal evaluations in the CORDIALLY® study.","Prázný M","2022","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent05","CORDIALLY chart review of characteristics and treatment patterns of new SGLT2i, DPP-4i or GLP-1 RA users; drug utilization only",1],["R0019285","Once-weekly Subcutaneous Semaglutide 2.4 mg Reduces Body Weight in Adults with Overweight or Obesity Regardless of Baseline Characteristics (STEP 1)","Kushner R","2021","include_nma",null,"conference_abstract","P02",null,"abstract_only","high","first","opus-5.5-agent05","abstract of STEP 1 post hoc subgroup analysis of semaglutide 2.4 mg versus placebo weight loss",1],["R0019363","Outcomes of obesity medications in those with low response to a low-energy diet meal replacement programme: An observational study.","Shand J","2026","inventory_only","N6","other",null,null,null,"high","first","opus-5.5-agent05","retrospective service evaluation of liraglutide or naltrexone bupropion after low diet response; weight outcomes only",1],["R0019463","US eligibility and preventable cardiovascular disease events from semaglutide in type 2 diabetes.","Karthikeyan H","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent05","modeling of preventable CVD events by applying SUSTAIN-6 rates to NHANES eligible population",1],["R0014298","Evaluating the therapeutic impact of tirzepatide in people with partial lipodystrophy.","Mandour MO","2026","inventory_only","N5","primary_report","P99",null,null,"high","first","opus-5.5-agent12","retrospective single center series of partial lipodystrophy patients treated with tirzepatide, before and after",1],["R0014381","Latest advances and controversies of exercise therapy in the management of type 2 diabetes.","Hao J","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent12","mini review of exercise therapy in T2D, GLP-1RAs only mentioned as future direction",1],["R0014488","Comparative thromboembolic risk and polypharmacy-related drug-drug interaction signals among antidiabetic medications: a large-scale FAERS pharmacovigilance study.","Bafail D","2026","inventory_only","N5","other",null,null,null,"high","first","opus-5.5-agent12","FAERS disproportionality analysis of thromboembolic signals across antidiabetic drugs including GLP-1RAs",1],["R0014556","Efficacy and safety of once-weekly tirzepatide for weight management compared to placebo: An updated systematic review and meta-analysis including the latest SURMOUNT-2 trial.","Qin W","2024","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent12","registered SR and meta-analysis of tirzepatide vs placebo RCTs for weight management",1],["R0014677","Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes.","Heise T","2023","include_nma",null,"secondary_report","P01",null,"mechanistic","high","first","opus-5.5-agent12","secondary analysis of mechanistic RCT tirzepatide vs semaglutide vs placebo in T2D, body weight, composition and appetite",1],["R0014749","Ertugliflozin Compared to Other Anti-hyperglycemic Agents as Monotherapy and Add-on Therapy in Type 2 Diabetes: A Systematic Literature Review and Network Meta-Analysis.","McNeill AM","2019","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent12","SLR and Bayesian NMA of ertugliflozin vs other agents including GLP-1RAs in T2D, three databases",1],["R0012888","Impact of baseline characteristics and beta-cell function on the efficacy and safety of subcutaneous once-weekly semaglutide: A patient-level, pooled analysis of the SUSTAIN 1-5 trials.","Aroda VR","2020","include_nma",null,"pooled_analysis","P01",null,null,"high","first","opus-5.5-agent13","patient level pooled post hoc analysis of SUSTAIN 1-5 RCTs comparing randomized semaglutide 0.5 and 1.0 mg",1],["R0012987","Efficacy and safety of tirzepatide in overweight or obese adults without diabetes: systematic review and meta-analysis of randomized controlled trials","Liu L","2024","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent13","preprint meta-analysis of tirzepatide RCTs in obesity without diabetes searched in PubMed, Embase and Cochrane",1],["R0013188","Co-treating opioid and alcohol use disorders in the United States, 1960-2026: A historical policy review in the glucagon-like peptide-1 (GLP-1) era.","Qeadan F","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent13","narrative historical policy review of co-treatment of opioid and alcohol use disorders",1],["R0013293","Real-World Weight Loss Among Patients Initiating Semaglutide 2.4 mg and Enrolled in WeGoTogether, a Digital Self-Support Application.","Toliver JC","2025","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent13","retrospective noninterventional cohort of semaglutide 2.4 mg app users without comparison group",1],["R0013394","The potential of GLP-1 receptor agonists in type 2 diabetes and chronic kidney disease: from randomised trials to clinical practice.","von Scholten BJ","2022","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent13","narrative review of GLP-1 agonist kidney evidence in type 2 diabetes with CKD",1],["R0013468","Tirzepatide and Cardiometabolic Effects in Obese Non-diabetic Adults: A Systematic Review, Meta-Analysis, and Narrative Synthesis of Cardiovascular Outcomes.","Chaparala P","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent13","systematic review and meta-analysis of tirzepatide RCTs in obesity without diabetes searched in PubMed and Cochrane",1],["R0013565","Tirzepatide Efficacy and Tolerability According to Early Weight Response: A Post Hoc Analysis of the SURMOUNT-1 and SURMOUNT-2 Trials.","Kokkinos A","2026","include_nma",null,"secondary_report","P02; P01",null,null,"high","first","opus-5.5-agent13","post hoc analysis of SURMOUNT-1 and SURMOUNT-2 placebo controlled RCTs of tirzepatide by early weight response",1],["R0015188","Obesity treatment as a bridge to solid organ transplantation: A comparison of bariatric surgery to medical therapy.","Roddy KL","2025","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent06","descriptive retrospective case series of 19 transplant candidates given semaglutide, tirzepatide or bariatric surgery; not randomized",1],["R0015266","Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial.","Heymsfield SB","2026","include_nma",null,"primary_report","P02",null,null,"high","first","opus-5.5-agent06","BELIEVE phase 2 double blind RCT of bimagrumab, semaglutide doses and combinations versus placebo in obesity without diabetes",1],["R0015348","Estimated Oral Semaglutide Exposure Has Distinct Relationships With Glycaemic Response, Weight Loss and Gastrointestinal Tolerability.","Fadini GP","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent06","retrospective single group cohort of oral semaglutide initiators modeling exposure response; no comparison group",1],["R0015435","Counterregulatory response to hypoglycemia during a hypoglycemic clamp in people with type 2 diabetes treated with tirzepatide.","Pieber TR","2025","include_nma",null,"primary_report","P01",null,"crossover; mechanistic","high","first","opus-5.5-agent06","double blind crossover RCT of tirzepatide versus placebo with hypoglycemic clamp in T2D; HbA1c reported",1],["R0015511","Effectiveness and adherence in a tirzepatide-supported digital weight-loss programme in Australia: A real-world observational study.","Talay L","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent06","retrospective single group cohort of tirzepatide digital weight loss program users; no comparison group",1],["R0015624","A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond.","Prasad-Reddy L","2015","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent06","narrative clinical review of GLP-1 RA efficacy and safety",1],["R0015740","Effects of semaglutide in obesity-related heart failure with preserved ejection fraction across the age spectrum: Findings from the STEP-HFpEF programme.","Pandey A","2025","include_nma",null,"pooled_analysis","P07A",null,null,"high","first","opus-5.5-agent06","prespecified pooled age subanalysis of STEP-HFpEF and STEP-HFpEF DM RCTs of semaglutide versus placebo",1],["R0012794","Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.","Raparelli V","2020","include_harms",null,"primary_report",null,"O29; O121",null,"high","first","opus-5.5-agent08","MarketScan new user cohort of GLP-1 RA, SGLT2i, DPP4i versus SU after metformin; safety composite incl pancreatitis and AKI with event rates",1],["R0012860","New anti-diabetic agents for the treatment of non-alcoholic fatty liver disease: a systematic review and network meta-analysis of randomized controlled trials.","Kongmalai T","2023","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent08","PROSPERO registered network meta-analysis of RCTs of new antidiabetic agents incl GLP-1 RA in NAFLD",1],["R0013051","Glycemic variability in newly diagnosed diabetic cats treated with the glucagon-like peptide-1 analogue exenatide extended release.","Krämer AL","2020","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent08","veterinary study of exenatide extended release in diabetic cats",1],["R0013278","The Efficacy of GLP-1 Analogues on Appetite Parameters, Gastric Emptying, Food Preference and Taste Among Adults with Obesity: Systematic Review of Randomized Controlled Trials.","Aldawsari M","2023","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent08","PROSPERO registered systematic review of RCTs of GLP-1 analogues on appetite and gastric emptying in obesity",1],["R0013376","Effectiveness of Liraglutide and Lixisenatide in the Treatment of Type 2 Diabetes: Real-World Evidence from The Health Improvement Network (THIN) Database in the United Kingdom.","Feher M","2017","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent08","THIN new user cohort of liraglutide versus lixisenatide; HbA1c, BMI, blood pressure and resource use only",1],["R0013451","Impact of exenatide on weight loss and eating behavior in adults with craniopharyngioma-related obesity: the CRANIOEXE randomized placebo-controlled trial.","Gatta-Cherifi B","2024","include_nma",null,"primary_report","P99",null,null,"high","first","opus-5.5-agent08","CRANIOEXE double blind RCT of exenatide versus placebo in craniopharyngioma related hypothalamic obesity; P99, possibly P02",1],["R0009629","Anti-Obesity Pharmacotherapy and Emerging Multimodal Interventions for Obstructive Sleep Apnea.","Preshy A","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent15","narrative review of antiobesity pharmacotherapy and multimodal treatment for obstructive sleep apnea",1],["R0009717","Concerns with the statistical analysis in \"Effect of combined GLP-1 analogue and bupropion/naltrexone on weight loss: a retrospective cohort study\".","Mokalla TR","2026","inventory_only","N9","ancillary",null,null,null,"high","first","opus-5.5-agent15","letter criticizing statistics of a retrospective cohort of GLP-1 analogue plus bupropion naltrexone versus monotherapy",1],["R0009830","Meta-analysis of the association between new hypoglycemic agents and digestive diseases.","Wang YW","2022","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent15","meta-analysis of large placebo controlled outcome trials of SGLT2i, GLP-1 RAs and DPP-4i on digestive diseases; three databases searched",1],["R0009911","Assessing the Effects of Modern Renoprotective Agents in Preventing Progression of Renal Composite Outcomes in Patients with Type 2 Diabetes: A Network Meta-analysis.","Ghosal S","2023","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent15","PRISMA network meta-analysis of 16 placebo controlled RCTs incl GLP-1 RAs on renal composite outcomes; Cochrane Library searched",1],["R0010013","A retrospective, case-note survey of type 2 diabetes patients prescribed incretin-based therapies in clinical practice.","Evans M","2013","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent15","retrospective case note comparison of liraglutide, exenatide and DPP-4i in UK practice; HbA1c, weight, hypoglycemia and costs only",1],["R0010086","The effects of GLP-1 receptor agonists on visceral fat and liver ectopic fat in an adult population with or without diabetes and nonalcoholic fatty liver disease: A systematic review and meta-analysis.","Liao C","2023","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent15","registered systematic review and meta-analysis of 30 RCTs of GLP-1 RAs on visceral and liver fat",1],["R0010168","Efficacy of a Digital Educational Intervention for Patients With Type 2 Diabetes Mellitus: Multicenter, Randomized, Prospective, 6-Month Follow-Up Study.","Caballero Mateos I","2025","inventory_only","N3","primary_report",null,null,null,"high","first","opus-5.5-agent15","RCT of digital education versus usual care in type 2 diabetes patients all starting GLP-1 RAs; GLP-1 regimen same in both arms",1],["R0010253","Glucagon-like Peptide-1 receptor agonist treatment patterns among type 2 diabetes patients in six European countries.","Divino V","2014","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent15","database study of GLP-1 RA treatment modification and persistence in six European countries; utilization only",1],["R0012820","Effects of subcutaneous semaglutide on weight loss and inflammatory markers in adults with overweight or obesity without diabetes: a systematic review and meta-analysis.","Milluzzo A","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent16","systematic review and meta-analysis of semaglutide vs placebo RCTs in obesity without diabetes; PubMed, Cochrane searched",1],["R0012898","The GLP-1 receptor agonists exendin-4 and liraglutide alleviate oxidative stress and cognitive and micturition deficits induced by middle cerebral artery occlusion in diabetic mice.","Li PC","2016","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent16","diabetic mouse stroke model treated with exendin-4 or liraglutide",1],["R0013003","Tirzepatide Is Associated With Improved Metabolic Outcomes in People With Type 1 Diabetes and Overweight or Obesity: A Retrospective Cohort Study.","Purcell AR","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent16","matched retrospective cohort of tirzepatide vs no tirzepatide in type 1 diabetes with obesity; weight and glycemic outcomes only",1],["R0013093","SGLT2 Inhibitors and GLP-1 Receptor Agonists in Diabetic Kidney Disease: Evolving Evidence and Clinical Application.","Bae JH","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent16","narrative review of SGLT2i and GLP-1RA in diabetic kidney disease",1],["R0013210","Mazdutide reduces body weight in adults with overweight or obesity: A high-dose Phase 1 trial.","Bhattachar SN","2025","include_nma",null,"primary_report","P02",null,null,"high","first","opus-5.5-agent16","double blind placebo controlled phase 1 RCT of high dose mazdutide in overweight or obesity without diabetes",1],["R0013301","Second revolution in cardiovascular prevention.","Chiang CE","2020","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent16","narrative review on cardiovascular prevention with new antidiabetic drugs",1],["R0013405","IDeglira vs insulin degludec for type 2 diabetes: a systematic review and meta-analysis.","Liu Y","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent16","PROSPERO registered systematic review and meta-analysis of IDegLira vs degludec RCTs",1],["R0013483","Efficacy and safety of European Medicines Agency (EMA)-approved pharmacological, endoscopic, and surgical treatments in different classes of obesity: A network meta-analysis of randomised controlled trials for the development of the SIO (Società Italiana Obesità) Italian guidelines for the diagnosis and treatment of overweight and obesity.","Barazzoni R","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent16","PROSPERO registered systematic review and NMA of obesity treatments by BMI class including GLP-1 based drugs",1],["R0009888","GLP-1 Agonists' Effect on Infection and Union after Tibiotalar Fusion, Subtalar Fusion, Triple Arthrodesis.","Levidy MF","2025","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent09","TriNetX matched cohort of GLP-1 users versus nonusers undergoing hindfoot fusion, infection and union outcomes only",1],["R0009976","Once-Weekly Exenatide Enhances Weight Loss Maintenance in Adolescents with Severe Obesity: A Randomized, Placebo-Controlled Trial","Fox C","2021","include_nma",null,"conference_abstract","P03",null,"abstract_only","high","first","opus-5.5-agent09","congress abstract of placebo controlled RCT of exenatide XR for weight maintenance after meal replacement in adolescents with severe obesity",1],["R0010144","The metabolic effects of adding exenatide to basal insulin therapy when targeting remission in early type 2 diabetes in a randomized clinical trial.","Retnakaran R","2022","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent09","RCT of glargine alone, glargine plus lispro or glargine plus exenatide for remission in early type 2 diabetes",1],["R0010299","Efficacy and Safety of Mazdutide in Adults with Obesity or Overweight, With or Without Diabetes: A Bayesian Network Meta-Analysis","Tuersun A","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent09","Bayesian NMA preprint of mazdutide RCTs in obesity with five named databases searched",1],["R0010428","Adverse Events Associated with Tirzepatide: Updated Pharmacovigilance Analysis Using FAERS (2022 Q1-2025 Q1) with an Adapted Time-to-Onset Method.","Gu S","2026","inventory_only","N5","other",null,null,null,"high","first","opus-5.5-agent09","FAERS disproportionality and time to onset analysis of tirzepatide adverse events",1],["R0010503","Liraglutide ameliorates diabetic-induced testicular dysfunction in male rats: role of GLP-1/Kiss1/GnRH and TGF-β/Smad signaling pathways.","Fathy MA","2023","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent09","randomized experiment in diabetic rats treated with liraglutide, no human participants",1],["R0012793","Benefits of insulin degludec/liraglutide are maintained even in patients discontinuing sulphonylureas or dipeptidyl peptidase-4 inhibitors upon initiation of degludec/liraglutide therapy: A post hoc analysis of the DUAL II and DUAL IX trials.","Janez A","2020","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent07","post hoc analysis of DUAL II and DUAL IX RCTs of IDegLira vs basal insulin by prior SU or DPP-4i use",1],["R0012859","Cost-Effectiveness of Liraglutide Versus Dapagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus in the UK.","Vega-Hernandez G","2017","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent07","CORE Diabetes Model cost effectiveness analysis of liraglutide vs dapagliflozin",1],["R0012971","Effects of Semaglutide Treatment on Psoriatic Lesions in Obese Patients with Type 2 Diabetes Mellitus: An Open-Label, Randomized Clinical Trial.","Petković-Dabić J","2025","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent07","open label RCT of semaglutide added to metformin vs metformin alone in obese T2D patients with psoriasis",1],["R0013050","Sarcopenia Is Associated With a Risk of Mortality in People With Type 2 Diabetes Mellitus.","Takahashi F","2021","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent07","cohort on sarcopenia and mortality in T2D; GLP-1RA only a covariate in the propensity score",1],["R0013450","Efficacy, Safety and PK of Once-Daily Oral Semaglutide 25 mg for Obesity With and Without Type 2 Diabetes in Comparison With Subcutaneous Semaglutide 2.4 mg: A Model-Informed Drug Development Approach.","Overgaard RV","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent07","model informed drug development with population PK, exposure response and simulated virtual trials of oral semaglutide",1],["R0011985","Time spent in glycaemic control with sustained body weight reduction with tirzepatide: A post hoc analysis of the SURPASS clinical trial programme.","Bergman BK","2025","include_nma",null,"pooled_analysis","P01",null,null,"high","first","opus-5.5-agent17","participant level post hoc pooled analysis of SURPASS 1 to 5 RCTs of tirzepatide versus comparators on time in glycemic control",1],["R0012093","Rationale, design and baseline characteristics of the TRANSCEND-CKD trial of retatrutide in patients with chronic kidney disease.","Heerspink HJL","2026","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent17","design and baseline paper of TRANSCEND-CKD placebo controlled retatrutide trial in CKD, no outcome results",1],["R0012183","Antidiabetic drugs in Parkinson's disease: a comprehensive meta-analysis on efficacy and safety with trial sequential analysis and GRADE evaluation.","Abou Elezz AM","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent17","registered meta-analysis of placebo controlled RCTs of antidiabetic drugs including GLP-1 RAs in Parkinson disease",1],["R0012288","Systemic evaluation of the effects of monomeric GLP-1R-based agonists on MASLD and its complications.","Cai Y","2025","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent17","drug target Mendelian randomization of GLP-1R, GIPR and GCGR genetic proxies on MASLD; no drug exposure",1],["R0012485","Improved treatment satisfaction in patients with type 2 diabetes treated with once-weekly semaglutide in the SUSTAIN trials.","Jendle J","2019","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent17","post hoc treatment satisfaction analysis of SUSTAIN 2 to 5 and 7 RCTs of semaglutide versus placebo or active comparators",1],["R0012570","Liraglutide for perioperative management of hyperglycaemia in cardiac surgery patients: a multicentre randomized superiority trial.","Hulst AH","2020","include_nma",null,"primary_report","P99",null,null,"high","first","opus-5.5-agent17","placebo controlled RCT of perioperative liraglutide in cardiac surgery patients with or without diabetes; P99 perioperative hyperglycemia",1],["R0012671","Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial.","Rodbard HW","2018","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent17","SUSTAIN 5 placebo controlled RCT of semaglutide added to basal insulin in type 2 diabetes, 30 weeks",1],["R0011102","Real-world prevalence of the inclusion criteria for the LEADER trial: Data from a national general practice network.","Hinton W","2019","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent02","cross sectional primary care analysis of LEADER eligibility prevalence and GLP-1 RA prescribing; no exposure comparison",1],["R0012753","Effects of Semaglutide on Body Weight in Clozapine-Treated Individuals with Schizophrenia and Obesity: A Randomized Controlled Trial","Siskind D",null,"include_nma",null,"conference_abstract","P15",null,"abstract_only","high","first","opus-5.5-agent18","abstract of COaST phase 2 RCT, semaglutide vs placebo for weight in clozapine treated schizophrenia with obesity",1],["R0011210","Semaglutide from Bench to Bedside: The Experimental Journey Towards a Transformative Therapy for Diabetes, Obesity and Metabolic Liver Disorders.","Weiskirchen R","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent02","narrative review of semaglutide development from bench to clinic",1],["R0011319","A Practical Guide for Cardiologists to the Pharmacological Treatment of Patients with Type 2 Diabetes and Cardiovascular Disease.","Ahmad T","2021","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent02","practical narrative guide for cardiologists on SGLT2 inhibitors and GLP-1 RA",1],["R0011400","Hierarchical network meta-analysis models for synthesis of evidence from randomised and non-randomised studies.","Hussein H","2023","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent02","methods paper on hierarchical network meta-analysis models with a diabetes drug illustrative example",1],["R0011615","The Cost-effectiveness of Dulaglutide 1.5mg versus Exenatide QW for the Treatment of Patients with Type 2 Diabetes Mellitus in France.","Basson M","2018","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent02","CORE diabetes model cost utility analysis of dulaglutide vs exenatide weekly in France",1],["R0011717","Pharmacological Management of Diabetes for Reducing Glucose Levels and Cardiovascular Disease Risk: What Evidence in South Asians?","Ghouri N","2021","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent02","narrative review of diabetes drug evidence in South Asians",1],["R0011825","MON-716 Real-world Weight Loss Observed With Semaglutide And Tirzepatide In Patients With Overweight Or Obesity And Without Type 2 Diabetes",null,"2025","inventory_only","N6","conference_abstract",null,null,"abstract_only","high","first","opus-5.5-agent02","conference abstract of claims cohort of semaglutide 2.4 mg vs tirzepatide weight loss without diabetes; no listed harm",1],["R0012824","Cardiovascular outcomes after initiating GLP-1 receptor agonist or basal insulin for the routine treatment of type 2 diabetes: a region-wide retrospective study.","Longato E","2021","include_harms",null,"primary_report",null,"O29; O38; O121",null,"high","first","opus-5.5-agent18","Veneto claims matched new user cohort GLP-1 RA vs basal insulin; pancreatitis, pancreatic cancer, acute kidney disease among adverse events",1],["R0013021","PSUN192 Therapeutic Benefit of GLP-1 Agonists in Patients with Type 1 Diabetes on Insulin Therapy: an Updated Systematic Review and Meta-analysis",null,"2022","include_review",null,"systematic_review",null,null,"abstract_only","high","first","opus-5.5-agent18","conference abstract of meta-analysis of placebo controlled GLP-1 RA RCTs in type 1 diabetes; PubMed, Embase, Cochrane",1],["R0013106","Effects of Anti-Diabetic Drugs on Fracture Risk: A Systematic Review and Network Meta-Analysis.","Zhang YS","2021","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent18","registered NMA of RCTs of antidiabetic drugs including GLP-1 RAs on fracture risk in T2D",1],["R0013219","Pharmacological management of obesity in adults: a systematic review and meta-analysis of randomized controlled trials to evaluate the efficacy and safety of obesity management medications","Ciudin A","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent18","registered systematic review and NMA of obesity management medication RCTs; Medline and Embase searched",1],["R0013314","A randomized controlled trial of the GLP-1 receptor agonist dulaglutide in primary polydipsia.","Winzeler B","2021","include_nma",null,"primary_report","P99",null,"crossover","high","first","opus-5.5-agent18","double blind placebo controlled crossover RCT of dulaglutide in primary polydipsia; fluid intake outcome",1],["R0013411","Effect of semaglutide on COVID-19 and other infections: an analysis from the FLOW randomized clinical trial.","Rayner B","2026","include_nma",null,"secondary_report","P08A",null,null,"high","first","opus-5.5-agent18","prespecified infection analysis of FLOW RCT, semaglutide vs placebo in T2D with CKD; serious adverse events reported",1],["R0011305","Prevalence and predictors of chronic kidney disease among type 2 diabetic patients worldwide, systematic review and meta-analysis.","Fenta ET","2023","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent19","meta-analysis of CKD prevalence and predictors in type 2 diabetes; GLP-1 RA not an exposure, only background mention",1],["R0011394","Efficacy and safety of tirzepatide, dual GLP-1/GIP receptor agonists, in the management of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.","Zhou Q","2023","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent19","meta-analysis of RCTs of tirzepatide vs placebo or active comparators in type 2 diabetes; Cochrane Web of Science Embase PubMed",1],["R0011505","Effectiveness and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in type 2 diabetes: an Italian cohort study.","Baviera M","2022","include_harms",null,"primary_report",null,"O121",null,"high","first","opus-5.5-agent19","Lombardy new user cohort GLP-1 RA vs SGLT2i, propensity matched; serious adverse events incl hospitalization for acute renal failure",1],["R0011599","Evaluation of the Cost Per Patient Achieving Treatment Targets with Oral Semaglutide: A Short-Term Cost-Effectiveness Analysis in the United States.","Hunt B","2019","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent19","short term cost of control analysis of oral semaglutide vs comparators using PIONEER results; economic evaluation",1],["R0011705","Decreased incidence of hidradenitis suppurativa and psoriasis in diabetic patients treated with GLP-1 receptor agonists: A retrospective cohort study.","Ching LM","2025","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent19","All of Us cohort of diabetic patients on GLP-1 RA vs other drugs; hidradenitis and psoriasis incidence, no listed harm",1],["R0011808","Long-Term Effect of Semaglutide on the Glomerular Filtration Rate Slope in High-Risk Patients with Diabetic Nephropathy: Analysis in Real-World Clinical Practice.","Luna E","2025","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent19","retrospective single group study of eGFR slope before and after semaglutide in diabetic CKD; no comparison group",1],["R0011906","Comparative effectiveness of glycemic control in patients with type 2 diabetes treated with GLP-1 receptor agonists: a network meta-analysis of placebo-controlled and active-comparator trials.","Orme ME","2017","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent19","Bayesian NMA of RCTs of GLP-1 RAs vs placebo or active comparators on A1C; Medline Embase Cochrane searched",1],["R0012003","Cardiovascular Effects of Glucagon-Like Peptide-1 Receptor Agonists.","Kang YM","2016","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent19","narrative review of cardiovascular effects of GLP-1 RA; no systematic methods",1],["R0013566","Effectiveness and Safety of iGlarLixi in People with Type 2 Diabetes in Adriatic Region Countries: ENSURE-ADR, a Real-World Study.","Đekić D","2023","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent14","retrospective single arm cohort of iGlarLixi initiators, before and after HbA1c, no comparison group",1],["R0013677","Proposed treatment strategy for reactive hypoglycaemia.","Younes YR","2024","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent14","case series of 11 reactive hypoglycemia patients, GLP-1 analogue added in two",1],["R0013766","Evaluation of the Efficacy of Semaglutide Dose Escalation in Reducing HbA1c Levels and Insulin Dose in Type 2 Diabetes Patients: Real-World Semaglutide Data from Türkiye, SEMA-TR Study.","Sumbul HE","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent14","retrospective semaglutide initiator cohort grouped by achieved dose, before and after outcomes, no concurrent unexposed comparison",1],["R0013844","Evidence-based treatment of hyperglycaemia with incretin therapies in patients with type 2 diabetes and advanced chronic kidney disease.","Tuttle KR","2020","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent14","narrative review with illustrative cases on incretin therapy in T2D with advanced CKD",1],["R0014026","Healthy weight loss maintenance with exercise, GLP-1 receptor agonist, or both combined followed by one year without treatment: a post-treatment analysis of a randomised placebo-controlled trial.","Jensen SBK","2024","include_nma",null,"extension","P02",null,null,"high","first","opus-5.5-agent14","post treatment follow up of S-LITE RCT of liraglutide, exercise, combination or placebo for weight maintenance",1],["R0014121","Patients' Experiences of Obstructive Sleep Apnea and Tirzepatide Treatment: An Exit Interview Study.","Shinde S","2026","include_nma",null,"secondary_report","P10",null,null,"high","first","opus-5.5-agent14","qualitative exit interviews of tirzepatide and placebo arms of SURMOUNT-OSA RCTs in sleep apnea",1],["R0019548","Efficacy and Safety of Dulaglutide Monotherapy Compared to Glimepiride in Oral Antihyperglycemic Medication-Naïve Chinese patients with Type 2 Diabetes: A Post Hoc Analysis of AWARD-CHN1.","Li YM","2020","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent05","post hoc analysis of AWARD-CHN1 RCT of dulaglutide doses versus glimepiride in drug naive Chinese type 2 diabetes",1],["R0019810","Obesity medications: A narrative review of current and emerging agents.","Qi QYD","2024","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent05","narrative review of current and emerging obesity medications selected by relevance",1],["R0019896","Exendin‑4 reverses endothelial dysfunction in mice fed a high‑cholesterol diet by a GTP cyclohydrolase‑1/tetrahydrobiopterin pathway.","Tang Z","2018","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent05","exendin-4 tested in ApoE knockout and wild type mice only",1],["R0020251","Gaps of Medication Treatment Management Between Guidelines and Real-World for Inpatients With Type 2 Diabetes in China From Pharmacist's Perspective.","Song ZH","2022","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent05","cross sectional pharmacist review of inpatient diabetes drug use against guidelines; drug utilization only",1],["R0012116","Glucagon-like Peptide-1 Receptor Analogues for the Treatment of Obesity.","Williams DM","2022","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent01","narrative review of GLP-1 RA outcome and obesity trials including SCALE and STEP",1],["R0012216","Once-Weekly Semaglutide Reduces HbA1c and Body Weight in Patients with Type 2 Diabetes Regardless of Background Common OAD: a Subgroup Analysis from SUSTAIN 2-4 and 10.","Capehorn M","2020","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent01","post hoc background drug subgroup analysis of SUSTAIN 2, 3, 4 and 10 RCTs of semaglutide versus active comparators",1],["R0012307","Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction.","Nauck MA","2022","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent01","narrative review of tirzepatide pharmacology and SURPASS trial results from published data",1],["R0012402","Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial.","Klausen MK","2022","include_nma",null,"primary_report","P14A",null,null,"high","first","opus-5.5-agent01","double blind RCT of exenatide once weekly versus placebo for 26 weeks in alcohol use disorder",1],["R0012514","Higher Derived Time in Range With IDegLira Versus Insulin Glargine U100 in People With Type 2 Diabetes.","Philis-Tsimikas A","2024","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent01","post hoc derived time in range analysis of DUAL V and DUAL VIII RCTs, IDegLira versus insulin glargine",1],["R0012592","Risk of any hypoglycaemia with newer antihyperglycaemic agents in patients with type 2 diabetes: A systematic review and meta-analysis.","Kamalinia S","2020","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent01","registered meta-analysis of placebo controlled RCTs of DPP-4i, GLP-1 RA and SGLT2i on hypoglycemia, three databases searched",1],["R0012681","Achieving the triple endpoint of body weight reduction thresholds, systolic blood pressure reduction ≥5 mmHg and non-HDL cholesterol <130 mg/dL with tirzepatide in people with obesity: A post hoc analysis from the SURMOUNT trials.","Sattar N","2026","include_nma",null,"secondary_report","P02; P01; P02W",null,null,"high","first","opus-5.5-agent01","post hoc triple endpoint analysis of SURMOUNT-1 to 4 RCTs of tirzepatide versus placebo, including maintenance trial",1],["R0012763","Impact of ethnicity and antihyperglycemic medications on dementia incidence in older adults with type 2 diabetes.","Chertok Shacham E","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent01","matched case control and cohort analyses of diabetes drug classes including GLP-1 RA and dementia incidence and mortality",1],["R0014352","Unmasking counterfeit semaglutide: analysis of real-world safety data from EudraVigilance.","Zinzi A","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent03","EudraVigilance descriptive and disproportionality analysis of counterfeit semaglutide adverse reaction reports",1],["R0014512","Dulaglutide Effect on Proteins Associated With CKD Progression.","McFarlin BE","2026","include_nma",null,"secondary_report","P08A",null,"mechanistic","high","first","opus-5.5-agent03","post hoc proteomic analysis of AWARD-7 RCT, dulaglutide vs insulin glargine in T2D with moderate to severe CKD",1],["R0014640","Glucose-Lowering Medication Use in CKD: Analysis of US Medicare Beneficiaries Between 2007 and 2016.","Zhao JZ","2021","exclude","E2","primary_report",null,null,null,"high","first","opus-5.5-agent03","Medicare drug utilization trend study of glucose lowering medication use in CKD",1],["R0014715","The impact of preadmission/prediagnosis use of GLP-1 receptor agonists on COVID-19 mortality in patients with diabetes: A systematic review and meta-analysis.","Kow CS","2023","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent03","meta-analysis of adjusted observational studies of prior GLP-1 RA use and COVID-19 mortality; PubMed, Web of Science, Scopus",1],["R0014787","Dulaglutide as a Bridging Therapy Before Insulin for Diabetes Following Pancreatectomy on Congenital Hyperinsulinism.","Motegi S","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent03","case report of dulaglutide in a teenager with postpancreatectomy diabetes after congenital hyperinsulinism",1],["R0014891","Effects of exenatide on cardiac function, perfusion, and energetics in type 2 diabetic patients with cardiomyopathy: a randomized controlled trial against insulin glargine.","Chen WJY","2017","include_nma",null,"primary_report","P01",null,"mechanistic","high","first","opus-5.5-agent03","26 week RCT of exenatide vs insulin glargine in T2D with LV systolic dysfunction; cardiac PET and MRI outcomes",1],["R0014954","Absolute treatment effects of novel antidiabetic drugs on a composite renal outcome: meta-analysis of digitalized individual patient data.","Brockmeyer M","2024","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent03","meta-analysis of digitized KM data from CVOTs chosen from summit reports, no named database search",1],["R0014175","Impact of glucagon-like peptide 1 analogs on cognitive function among patients with type 2 diabetes mellitus: A systematic review and meta-analysis.","Luan S","2022","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent04","systematic review and meta-analysis of GLP-1 analog effects on cognitive function in type 2 diabetes",1],["R0014253","Tirzepatide as an Add-on for Participants with Inadequate Glycemic Control Using Basal Insulin: Pooled Subgroup Analysis of SURPASS-5 and -6.","Bajaj HS","2026","include_nma",null,"pooled_analysis","P01",null,null,"high","first","opus-5.5-agent04","post hoc pooled subgroup analysis of SURPASS-5 and -6 RCTs of tirzepatide vs placebo or insulin lispro on basal insulin",1],["R0014361","Cardiovascular, renal and gastrointestinal effects of incretin-based therapies: an acute and 12-week randomised, double-blind, placebo-controlled, mechanistic intervention trial in type 2 diabetes.","Smits MM","2015","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent04","protocol of mechanistic RCT of liraglutide, sitagliptin or placebo and acute exenatide infusion in type 2 diabetes",1],["R0014437","Case Report: Oral semaglutide-associated depression in a patient with type 2 diabetes mellitus: a dose-dependent recurrence confirmed on rechallenge and managed with vortioxetine-bupropion combination therapy.","Alanazi AS","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent04","case report of depression with oral semaglutide recurring on rechallenge",1],["R0014513","Can glucose-lowering medications improve outcomes in non-diabetic heart failure patients? A Bayesian network meta-analysis.","Yeong T","2022","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent04","Bayesian network meta-analysis of RCTs of glucose lowering drugs incl GLP-1 RA in nondiabetic heart failure",1],["R0014642","Association of baseline characteristics with clinical outcomes of tirzepatide treatment in Japanese patients with obesity disease: A subgroup analysis of the SURMOUNT-J trial.","Yokote K","2026","include_nma",null,"secondary_report","P02",null,null,"high","first","opus-5.5-agent04","prespecified subgroup analysis of SURMOUNT-J RCT of tirzepatide vs placebo in Japanese adults with obesity disease",1],["R0014717","Low Preoperative Free Triiodothyronine, Particularly in Females, Is Associated With Reduced Weight Loss and Diabetes Remission After Bariatric Surgery in Euthyroid Adults.","Li S","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent04","bariatric surgery cohort on thyroid hormones and weight loss, no GLP-1 RA exposure studied",1],["R0014789","Retrospective comparison of the clinical effects of oral semaglutide and SGLT2 inhibitors treatment in patients with type 2 diabetes.","Omori Y","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent04","retrospective comparison of oral semaglutide vs SGLT2i, HbA1c, weight and body composition only",1],["R0014414","The Impact of GLP-1 Agonist Therapy in Tibiotalar and Subtalar Fusion: A Propensity-Matched Analysis",null,"2024","inventory_only","N6","conference_abstract",null,null,"abstract_only","high","first","opus-5.5-agent20","abstract of TriNetX matched cohort of GLP-1 RA users vs nonusers after ankle fusion, infection and pseudarthrosis only",1],["R0009158","Choice of Glucose-Lowering Drugs as Initial Monotherapy for Type 2 Diabetes Patients with Contraindications or Intolerance to Metformin: A Systematic Review and Meta-Analysis.","Gu S","2022","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent11","registered network meta-analysis of monotherapy RCTs including GLP-1RAs versus placebo or lifestyle; six named databases",1],["R0010635","Tirzepatide Treatment and Associated Changes in β-Cell Function and Insulin Sensitivity in People With Obesity or Overweight With Prediabetes or Normoglycemia: A Post Hoc Analysis From the SURMOUNT-1 Trial.","Mari A","2025","include_nma",null,"secondary_report","P02",null,null,"high","first","opus-5.5-agent10","post hoc of SURMOUNT-1 RCT tirzepatide doses versus placebo in obesity without diabetes; beta cell function and weight",1],["R0010735","GLP-1 receptor agonists in Parkinson's disease: an updated comprehensive systematic review with meta-analysis.","Helal MM","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent10","PROSPERO registered meta-analysis of GLP-1 RA trials in Parkinson disease; six sources searched",1],["R0010806","Cardiovascular morbidity and mortality in patients with type 2 diabetes using novel antidiabetic medicines as add-on therapy: an observational real-world study.","Zerovnik S","2021","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent10","Slovenian nationwide new add-on cohort SGLT2i or GLP-1 RA versus DPP-4i; MACE, CV death, HF only",1],["R0010899","GLP-1RAs and SGLT2is Reduce Cardiovascular Events Independent of Reductions of Systolic Blood Pressure and Body Weight: A Meta-Analysis with Meta-Regression.","Qiu M","2020","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent10","PROSPERO registered meta-analysis with meta-regression of GLP-1 RA and SGLT2i outcome RCTs; Embase and PubMed searched",1],["R0010974","Long-acting PYY3 -36 analogue with semaglutide for obesity: from preclinical assessment through randomized clinical studies.","Wulff BS","2025","inventory_only","N3","primary_report",null,null,null,"high","first","opus-5.5-agent10","rat studies plus phase 1 and 2 RCTs of PYY1875 versus placebo, alone or on semaglutide in both arms; GLP-1 regimen unchanged",1],["R0011061","FRI078 Real-World Weight Loss Outcomes And Safety Of Tirzepatide, A Novel Dual GIP And GLP-1 Receptor Agonist",null,"2023","inventory_only","N5","conference_abstract",null,null,"abstract_only","high","first","opus-5.5-agent10","conference abstract of retrospective single group tirzepatide weight loss cohort; no comparison group",1],["R0011152","Strategies for minimizing muscle loss during use of incretin-mimetic drugs for treatment of obesity.","Mechanick JI","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent10","narrative review of strategies to limit muscle loss with incretin drugs; no systematic methods",1],["R0011245","Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial.","Kaplan LM","2026","include_nma",null,"primary_report","P09; P02",null,null,"high","first","opus-5.5-agent10","SYNCHRONIZE-MASLD phase 3 RCT survodutide 6 mg versus placebo in obesity with at risk MASLD",1],["R0014508","New Insights on Using Oral Semaglutide versus Dapagliflozin in Patients with Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease.","Stratina E","2024","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent20","prospective nonrandomized comparison of oral semaglutide vs dapagliflozin in T2D with MASLD, physician selected, liver and metabolic outcomes",1],["R0014604","Semaglutide in non-diabetic obese Chinese patients with acute coronary syndrome: a multicenter retrospective study.","Jin CL","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent20","retrospective matched cohort of semaglutide vs control in nondiabetic obese ACS patients, MACE and metabolic outcomes only",1],["R0014711","Association of Semaglutide Treatment With Liver Cirrhosis and Hepatocellular Carcinoma in Type 2 Diabetes: A Population-Based Cohort Study.","Issachar A","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent20","Clalit matched cohort of semaglutide vs nonusers in T2D, outcomes cirrhosis and HCC only",1],["R0014767","Adaptive maintenance after incretin-induced weight loss: Moving beyond the continue-or-stop paradigm.","van Bruggen FH","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent20","narrative perspective on maintenance strategies after incretin induced weight loss",1],["R0014881","Pharmacokinetics and safety profiles of beinaglutide injection, a recombinant human GLP-1, in adults with overweight/obesity: results from a phase I clinical trial.","Lin P","2024","inventory_only","N1","primary_report",null,null,null,"high","first","opus-5.5-agent20","open label phase I multiple ascending dose study of beinaglutide in the same 16 obese volunteers, no concurrent comparison",1],["R0015032","Does intervention with GLP-1 receptor agonist semaglutide modulate perception of sweet taste in women with obesity: study protocol of a randomized, single-blinded, placebo-controlled clinical trial.","Jensterle M","2021","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent20","protocol of placebo controlled RCT of semaglutide on sweet taste in women with obesity and PCOS",1],["R0009213","Efficacy of once-daily glucagon-like peptide-1 receptor agonist lixisenatide as an add-on treatment to basal insulin in Asian and white adults with type 2 diabetes mellitus: An individual-level pooled analysis of phase III studies.","Liu F","2021","include_nma",null,"pooled_analysis","P01",null,null,"high","first","opus-5.5-agent11","individual level pooled analysis of GetGoal-L and GetGoal-L-C, lixisenatide versus placebo added to basal insulin",1],["R0009345","GLP-1 and dual GIP/GLP-1 agonists in obese patients with HFpEF: a systematic review and meta-analysis of RCTs.","Musa EYA","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent11","registered meta-analysis of GLP-1 and dual agonist RCTs in obese HFpEF; MEDLINE, CENTRAL and registries searched",1],["R0009436","Tirzepatide and metabolic dysfunction-associated steatotic liver disease (MASLD) in obesity: a real-world multicenter study.","Galasso M","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent11","retrospective single group study of tirzepatide in obesity with MASLD; no comparator",1],["R0009550","Systematic investigation of the underlying mechanisms of GLP-1 receptor agonists to prevent myocardial infarction in patients with type 2 diabetes mellitus using network pharmacology.","Deng G","2023","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent11","network pharmacology in silico target analysis of GLP-1RAs; no human study",1],["R0009620","[Peptide hormone analogue-based pharmacotherapy for obesity is effective : What is the evidence on hard end points and the long-term course?].","Hussain M","2026","exclude","E3","other",null,null,"non_english","high","first","opus-5.5-agent11","German narrative review of peptide based obesity drugs and hard endpoints",1],["R0009703","[Prognostic factors for the carbohydrate metabolism normalization in patients with type 2 diabetes mellitus and obesity using liraglutide 3.0 mg per day].","Sklyanik IA","2021","inventory_only","N1","primary_report",null,null,"non_english","high","first","opus-5.5-agent11","Russian single center prospective nonrandomized single arm study of liraglutide 3 mg in diabetes with obesity",1],["R0009799","Nationwide Real-World Retrospective Study of Oral Semaglutide Use in Adults Living With Type 2 Diabetes in Finland.","Vaden A","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent11","Finnish register study of oral semaglutide initiators without comparator group",1],["R0015842","Efficacy and Safety of Once-Weekly Semaglutide 2.0 mg as an Add-On to Dose-Reduced Insulin Glargine versus Dose-Titrated Insulin Glargine in People With Type 2 Diabetes and Overweight (SUSTAIN OPTIMIZE).","Rodbard HW","2026","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent06","SUSTAIN OPTIMIZE open label RCT of semaglutide 2.0 mg plus reduced glargine versus titrated glargine in T2D with overweight",1],["R0015943","Better cardiovascular outcomes of type 2 diabetic patients treated with GLP-1 receptor agonists versus DPP-4 inhibitors in clinical practice.","Longato E","2020","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent06","Veneto matched cohort of GLP-1 RA versus DPP-4 inhibitor initiators; MACE, MI, death, heart failure outcomes only",1],["R0016032","Weight Changes With Tirzepatide and Concomitant Weight-Inducing Medications: Post Hoc Analysis of Randomized Clinical Trials.","Galindo RJ","2026","include_nma",null,"pooled_analysis","P02; P02W",null,null,"high","first","opus-5.5-agent06","post hoc analysis of SURMOUNT-1, -3 and -4 RCTs of tirzepatide versus placebo in participants starting weight inducing drugs",1],["R0016116","Long-Term Efficacy of Bariatric Surgery Compared to Modern Medical Therapy in Type 2 Diabetes and Obesity: A Systematic Review.","Afzal A","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent06","systematic review of RCTs of bariatric surgery versus medical therapy incl GLP-1 RAs in T2D with obesity; four databases",1],["R0016204","Effect of beinaglutide combined with metformin versus aspart 30 with metformin on metabolic profiles and antidrug antibodies in patients with type 2 diabetes: a randomized clinical trial.","Han CY","2023","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent06","RCT of beinaglutide plus metformin versus premixed aspart 30 plus metformin in T2D over 6 months",1],["R0016319","Modeling potential cost-effectiveness of tirzepatide versus lifestyle modification for patients with overweight and obesity.","Hoog MM","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent06","discrete event simulation cost-effectiveness model of tirzepatide versus lifestyle modification",1],["R0016427","Effect of semaglutide and liraglutide in individuals with obesity or overweight without diabetes: a systematic review.","Deng Y","2022","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent06","registered systematic review of semaglutide and liraglutide versus placebo or other drugs in obesity without diabetes",1],["R0016516","Cardiovascular Therapy Benefits of Novel Antidiabetic Drugs in Patients With Type 2 Diabetes Mellitus Complicated With Cardiovascular Disease: A Network Meta-Analysis.","Shi S","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent06","NMA of RCTs of GLP-1 RAs, SGLT2 inhibitors and DPP-4 inhibitors in T2D with cardiovascular disease",1],["R0013684","OR08-07 Real-World Evidence on GLP-1 Analogues: Insights into NAION Risk in Type 2 Diabetes Mellitus Patients",null,"2025","include_harms",null,"conference_abstract",null,"O34","abstract_only","high","first","opus-5.5-agent16","conference abstract of TriNetX matched cohort of GLP-1RA users vs nonusers in T2D reporting NAION",1],["R0013776","A81 GASTROINTESTINAL ADVERSE EVENTS ASSOCIATED WITH GLUCAGON-LIKE PEPTIDE-1 (GLP-1) AGONISTS IN OVERWEIGHT PATIENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS",null,"2025","include_review",null,"systematic_review",null,null,"abstract_only","high","first","opus-5.5-agent16","conference abstract of systematic review and meta-analysis of GI adverse events in GLP-1RA obesity RCTs; five databases named",1],["R0013857","Effectiveness of Adjuvant Semaglutide Following Bariatric Metabolic Surgery.","Ferguson J","2025","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent16","single center cohort of semaglutide after bariatric surgery without comparison group",1],["R0013967","Renal tubular effects of prolonged therapy with the GLP-1 receptor agonist lixisenatide in patients with type 2 diabetes mellitus.","Tonneijck L","2019","include_nma",null,"secondary_report","P01",null,"mechanistic","high","first","opus-5.5-agent16","secondary mechanistic analysis of RCT of lixisenatide vs insulin glulisine in T2D; renal tubular effects",1],["R0014037","Cardiometabolic and atherosclerotic cardiovascular disease outcomes associated with tirzepatide: insights from a 1-year multicenter observational study.","Rivera Gutierrez RJ","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent16","retrospective single group cohort of continuous tirzepatide users with 12 month cardiometabolic changes",1],["R0014131","Sweetening the deal: an infodemiological study of worldwide interest in semaglutide using Google Trends extended for health application programming interface.","Raubenheimer JE","2024","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent16","infodemiology study of Google search interest in semaglutide; no drug exposure studied",1],["R0014221","Clinical Impact of Semaglutide in Patients with Heart Failure and Preserved Ejection Fraction.","Hida Y","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent16","retrospective pre post study of oral semaglutide in HFpEF with T2D, no concurrent comparison",1],["R0015008","Glucagon-like peptide-1 receptor PET/CT in patients with and without post gastric bypass hypoglycemia – a prospective, matched case-control study","Hepprich M","2022","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent12","GLP-1 receptor PET imaging with exendin-4 tracer after gastric bypass, diagnostic tracer not a therapeutic exposure",1],["R0015213","Efficacy and safety of once-weekly insulins in type 2 diabetes: A systematic review and meta-analysis.","Bourron O","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent12","registered SR and meta-analysis of once weekly insulin RCTs vs daily insulin or semaglutide, includes IcoSema",1],["R0015281","Feasibility study of Glucagon-like peptide-1 analogues for the optimization of Outcomes in obese patients undergoing AbLation for Atrial Fibrillation (GOAL-AF) protocol.","Win KZ","2024","inventory_only","N1","protocol_or_design","P99",null,null,"high","first","opus-5.5-agent12","protocol of uncontrolled single centre feasibility study of liraglutide before AF ablation in obesity; alternative N8",1],["R0015382","Long-Term Cost-Effectiveness Analyses of Empagliflozin Versus Oral Semaglutide, in Addition to Metformin, for the Treatment of Type 2 Diabetes in the UK.","Ramos M","2020","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent12","cost effectiveness modeling of empagliflozin vs oral semaglutide using PIONEER 2 inputs",1],["R0015550","Direct medical costs for patients with type 2 diabetes in 16 tertiary hospitals in urban China: A multicenter prospective cohort study.","Li X","2019","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent12","prospective cost of illness study of T2D in China, GLP-1RA use only a cost determinant",1],["R0015674","Analysis of Reporting Trends of Serious Adverse Events Associated With Anti-Obesity Drugs.","Raičević BB","2025","inventory_only","N5","other",null,null,null,"high","first","opus-5.5-agent12","EudraVigilance trend analysis of spontaneous adverse reaction reports for anti-obesity drugs",1],["R0020605","New horizon of the combined BCG vaccine with probiotic and liraglutide in augmenting beta cell survival via suppression of TXNIP/NLRP3 pyroptosis signaling in Streptozocin-Induced diabetes mellitestype-1 in rats.","Khalifa AK","2024","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent05","liraglutide combined with BCG and probiotics tested in streptozocin diabetic rats only",1],["R0021017","The Clinical Efficacy and Safety of Glucagon-Like Peptide-1 (GLP-1) Agonists in Adults with Type 2 Diabetes Mellitus.","Brice KR","2011","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent05","narrative review of exenatide and liraglutide efficacy and safety from a prioritized Medline search",1],["R0021264","Cost-effectiveness of the add-on exenatide to conventional treatment in patients with Parkinson's disease when considering the coexisting effects of diabetes mellitus.","Chen HC","2022","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent05","Markov cost effectiveness model of add-on exenatide in Parkinson disease",1],["R0021392","Exenatide with Metformin Ameliorated Visceral Adiposity and Insulin Resistance.","Du X","2018","inventory_only","N1","other",null,null,null,"high","first","opus-5.5-agent05","single group sequential exenatide then glargine added to metformin in 20 patients; no concurrent comparison",1],["R0013675","Effectiveness and Safety of Semaglutide in Type 1 Diabetes: A Danish Nationwide Cohort Study (2018-2024).","Würtz Yazdanfard PD","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent13","Danish matched cohort semaglutide initiators vs unexposed in type 1 diabetes, HbA1c, hypoglycemia and DKA hospitalization only",1],["R0013761","Metabolic Abnormalities Following Tirzepatide Monotherapy in Japanese Patients with Type 2 Diabetes: A Phase 3 SURPASS J-mono Post Hoc Analysis.","Onishi Y","2024","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent13","post hoc analysis of SURPASS J-mono RCT of tirzepatide doses vs dulaglutide in Japanese type 2 diabetes",1],["R0013953","Treatment with liraglutide or naltrexone-bupropion in patients with genetic obesity: a real-world study.","Welling MS","2024","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent13","real world series of genetic obesity patients on liraglutide or naltrexone-bupropion, each assessed against baseline",1],["R0014020","Digital Engagement Phenotypes and 6-Month Weight Loss in a Tirzepatide-Supported Digital Weight-Loss Program: A Retrospective Cohort Study.","Talay L","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent13","retrospective cohort of tirzepatide users compared by digital engagement phenotype, weight outcome only",1],["R0014110","Low incidence of gastrointestinal adverse events over time with a fixed-ratio combination of insulin glargine and lixisenatide versus lixisenatide alone.","Trujillo JM","2018","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent13","post hoc GI adverse event analysis of LixiLan-L and LixiLan-O RCTs of iGlarLixi vs glargine or lixisenatide",1],["R0014208","Association between patient-reported eating behaviours and weight change: Secondary analyses of a randomized, double-blind trial comparing retatrutide and placebo in people with obesity or overweight.","Kanu C","2025","include_nma",null,"secondary_report","P02",null,null,"high","first","opus-5.5-agent13","research letter with secondary analyses of phase 2 RCT of retatrutide doses vs placebo in obesity",1],["R0014299","Cardiometabolic Effects of Semaglutide in Individuals with Type 2 Diabetes in the United Arab Emirates: Real-World 12-Month Outcomes and Predictors of Response.","Mian MHS","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent13","retrospective single group cohort of semaglutide initiators in UAE without comparison group",1],["R0010335","Effects of Incretin-based Therapy on High-sensitivity C-reactive Protein in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis.","Wu Y","2020","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent15","systematic review and meta-analysis of 28 RCTs of incretin therapies including GLP-1 RAs on hs-CRP in type 2 diabetes",1],["R0010538","The First Successful Desensitization Protocol in Exenatide Allergy: A Case Report","Yeğit OO","2022","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent15","case report of two patients desensitized to exenatide after hypersensitivity reactions",1],["R0010760","Efficacy and safety of iGlarLixi versus IDegAsp by baseline β-cell function in Chinese people with type 2 diabetes: Exploratory analyses of the Soli-D study.","Gu W","2026","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent15","exploratory beta cell subgroup analysis of Soli-D RCT, iGlarLixi versus IDegAsp in Chinese type 2 diabetes",1],["R0010817","Preexisting Diabetes and Pregnancy: An Endocrine Society and European Society of Endocrinology Joint Clinical Practice Guideline.","Wyckoff JA","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent15","Endocrine Society and ESE clinical practice guideline on preexisting diabetes in pregnancy",1],["R0010916","Up-Titration Strategy After DPP-4 Inhibitor-Based Oral Therapy for Type 2 Diabetes: A Randomized Controlled Trial Shifting to a Single-Dose GLP-1 Enhancer Versus Adding a Variable Basal Insulin Algorithm.","Miyagi M","2018","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent15","open label RCT switching DPP-4i to liraglutide versus adding glargine in type 2 diabetes for 24 weeks",1],["R0010994","SAT-662 Effects of SGLT Inhibitors or GLP1 Analogues on Glucose Homeostasis and Body Weight in Patients with Type 1 Diabetes: A Network Meta-Analysis","Lim S","2020","include_review",null,"systematic_review",null,null,"abstract_only","high","first","opus-5.5-agent15","conference abstract of network meta-analysis of 23 RCTs of SGLT inhibitors or GLP-1 RAs added to insulin in type 1 diabetes",1],["R0013538","Nationwide trends in glucose-lowering drug use, Denmark, 1999-2014.","Christensen DH","2016","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent07","Danish aggregate sales statistics on glucose lowering drug use trends; no exposure outcome comparison",1],["R0013540","Diabetes medication regimens and patient clinical characteristics in the national patient-centered clinical research network, PCORnet.","Bachmann KN","2020","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent08","PCORnet description of type 2 diabetes prescribing patterns; utilization without outcome comparison",1],["R0013931","Treatment Satisfaction and Quality of Life with Tirzepatide Versus Dulaglutide Among Japanese Patients with Type 2 Diabetes: Exploratory Evaluation of the SURPASS J-mono Trial.","Ishii H","2023","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent08","exploratory treatment satisfaction analysis of SURPASS J-mono RCT of tirzepatide versus dulaglutide; labeled case report",1],["R0014003","Semaglutide versus placebo in individuals with poor weight loss after bariatric surgery: a double-blinded, randomized, placebo-controlled trial.","Stanley C","2026","include_nma",null,"primary_report","P02; P01",null,null,"high","first","opus-5.5-agent08","BARI-STEP double blind RCT of semaglutide 2.4 mg versus placebo after bariatric surgery; T2D share to confirm for population",1],["R0014087","Efficacy and Safety of Glucagon Like Peptide-1 Receptor Agonism Based Therapies in Obstructive Sleep Apnoea: A Systematic Review and Meta-Analysis.","Dutta D","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent08","PROSPERO registered meta-analysis of GLP-1 based therapies in obstructive sleep apnea",1],["R0014190","A pilot randomized controlled trial of liraglutide 3.0 mg for binge eating disorder.","Allison KC","2023","include_nma",null,"primary_report","P99",null,null,"high","first","opus-5.5-agent08","pilot double blind RCT of liraglutide 3.0 mg versus placebo in binge eating disorder with BMI 27 or more; P99, possibly P02",1],["R0013639","The fate of taspoglutide, a weekly GLP-1 receptor agonist, versus twice-daily exenatide for type 2 diabetes: the T-emerge 2 trial.","Rosenstock J","2013","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent07","T-emerge 2 open label RCT of taspoglutide 10 or 20 mg weekly vs exenatide twice daily in type 2 diabetes",1],["R0013731","Pathophysiology of type 2 diabetes: A focus on the metabolic differences among southeast Asian, Chinese and Indian populations and how this impacts treatment.","Cao Y","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent07","narrative review of type 2 diabetes pathophysiology and treatment in Asian populations",1],["R0013820","Metabolic reprogramming in chronic kidney disease-cardiovascular disease comorbidity: from molecular mechanisms to therapeutic strategies.","Chai XJ","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent07","narrative review of metabolic reprogramming in CKD and cardiovascular disease",1],["R0013929","Stratified analysis of the association between anti-obesity medications and digestive adverse events: a real-world study based on the FDA adverse event reporting system database.","Yang Q","2024","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent07","FAERS disproportionality analysis of digestive adverse event reports across anti obesity drugs including GLP-1RA",1],["R0014000","Experience with Tirzepatide and Weight Management During and After a Clinical Trial in Japanese Patients with Obesity Disease: A Qualitative Study.","Kiyosue A","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent07","qualitative exit interviews of SURMOUNT-J tirzepatide participants without exposure comparison",1],["R0014078","Assessing adverse drug reaction reports for antidiabetic medications approved by the food and drug administration between 2012 and 2017: a pharmacovigilance study.","Stottlemyer BA","2023","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent07","FAERS disproportionality analysis of adverse reaction reports for newly approved antidiabetic drugs including GLP-1RA",1],["R0014189","Incretin-based drugs for type 2 diabetes: Focus on East Asian perspectives.","Seino Y","2016","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent07","narrative review of incretin based drugs in East Asian type 2 diabetes",1],["R0013492","The pharmacodynamics-based prophylactic benefits of GLP-1 receptor agonists and SGLT2 inhibitors on neurodegenerative diseases: evidence from a network meta-analysis.","Tseng PT","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent18","registered NMA of RCTs of GLP-1 RAs and SGLT2i on incident neurodegenerative diseases; eight databases searched",1],["R0013578","Gallbladder-Related Adverse Events With Semaglutide 2.4 mg: Pooled Analysis of Placebo-Controlled STEP Trials.","Ukkonen M","2026","include_nma",null,"pooled_analysis","P02; P01; P02W",null,null,"high","first","opus-5.5-agent18","pooled analysis of placebo controlled STEP 1 to 5 RCTs of semaglutide 2.4 mg on gallbladder events; no systematic search",1],["R0013694","Association of dipeptidyl peptidase-4 inhibitor and recurrent pancreatitis risk among patients with type 2 diabetes: A retrospective cohort study.","Yang YS","2024","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent18","Taiwan cohort of DPP-4 inhibitor users vs nonusers on recurrent pancreatitis; no GLP-1 RA exposure studied",1],["R0013783","Efficacy of iGlarLixi in adults with type 2 diabetes inadequately controlled (glycated haemoglobin ≥8%, ≥64 mmol/mol) on two oral antidiabetes drugs: Post hoc analysis of the LixiLan-O randomized trial.","Davies MJ","2022","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent18","post hoc subgroup of LixiLan-O RCT, iGlarLixi vs glargine vs lixisenatide in T2D with HbA1c 8 percent or more",1],["R0013886","Real-World Evidence of the Effectiveness and Safety of Biosynthetic Semaglutide in Type 2 Diabetes: A Multicentre Study From Pakistan.","Hussain A","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent18","prospective non interventional single arm study of biosynthetic semaglutide in Pakistani T2D; no comparator group",1],["R0013970","Increased co-expression of PSMA2 and GLP-1 receptor in cervical cancer models in type 2 diabetes attenuated by Exendin-4: A translational case-control study.","Mao D","2021","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent18","translational study; exendin-4 given only to db/db mice and cell lines; human specimens analyzed for gene expression only",1],["R0014042","Efficacy and safety of lixisenatide in patients with type 2 diabetes and renal impairment.","Hanefeld M","2017","include_nma",null,"pooled_analysis","P01",null,null,"high","first","opus-5.5-agent18","sponsor pooled analysis of nine placebo controlled GetGoal RCTs of lixisenatide by renal function category; no systematic search",1],["R0011917","Acute GIP and GLP-1 Administration Exerts Differential Metabolic Effects in Totally Pancreatectomised Individuals.","Krogh LSL","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent02","randomized crossover of intravenous native GIP and GLP-1 infusions in pancreatectomised people; no therapeutic receptor agonist",1],["R0012017","Elevated Circulating Fetuin-B Levels Are Associated with Insulin Resistance and Reduced by GLP-1RA in Newly Diagnosed PCOS Women.","Mokou M","2020","inventory_only","N1","primary_report",null,null,null,"high","first","opus-5.5-agent02","cross sectional PCOS study plus self controlled single group GLP-1 RA intervention on fetuin-B; no concurrent control",1],["R0012119","Effects of canagliflozin on initiation of insulin and other antihyperglycaemic agents in the CANVAS Program.","Matthews DR","2020","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent02","CANVAS canagliflozin vs placebo analysis; GLP-1 RA appears only as subsequent therapy initiation outcome",1],["R0012220","Weight loss efficiency and safety of tirzepatide: A Systematic review.","Lin F","2023","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent02","systematic review and meta-analysis of tirzepatide RCTs on weight and safety; five databases searched",1],["R0012409","Age and Sex Differences in Efficacy of Treatments for Type 2 Diabetes: A Network Meta-Analysis.","Hanlon P","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent02","registered network meta-regression of RCTs of SGLT2 inhibitors, GLP-1 RA and DPP-4 inhibitors by age and sex",1],["R0012520","Evaluation of Glycemic Control and Cost Savings Associated With Liraglutide Dose Reduction at a Veterans Affairs Hospital.","Imarhia FI","2020","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent02","retrospective VA chart review of glycemic control after liraglutide dose reduction; single group before and after",1],["R0012593","Gastrointestinal Symptoms in Obesity Therapy: Mechanisms, Epidemiology, and Management Strategies.","Witaszek T","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent02","narrative review of gastrointestinal adverse effects of obesity therapies",1],["R0012104","Effect of once-weekly dulaglutide versus insulin glargine in people with type 2 diabetes and different baseline glycaemic patterns: A post hoc analysis of the AWARD-2 clinical trial.","Giorgino F","2019","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent19","post hoc glycemic pattern subgroup analysis of AWARD-2 RCT of dulaglutide vs insulin glargine in type 2 diabetes",1],["R0012293","OR03-1 Achievement of HbA1c <6.5% without weight gain and hypoglycemia in people with type 2 diabetes treated with tirzepatide across the phase 3 SURPASS program",null,"2022","include_nma",null,"conference_abstract","P01",null,"abstract_only","high","first","opus-5.5-agent19","abstract of composite HbA1c target analysis across SURPASS 1 to 5 RCTs of tirzepatide vs placebo or comparators",1],["R0012494","A Unique Multi- and Interdisciplinary Cardiology-Renal-Endocrine Clinic: A Description and Assessment of Outcomes.","Dubrofsky L","2022","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent19","retrospective description of a multidisciplinary cardiorenal endocrine clinic; GLP-1 RA uptake only, no exposure comparison",1],["R0012577","Missed Opportunities for Screening and Management of Dysglycemia among Patients Presenting with Acute Myocardial Infarction in North India: The Prospective NORIN STEMI Registry.","Ostrominski JW","2022","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent19","STEMI registry on dysglycemia screening; GLP-1 RA use only described at baseline",1],["R0012674","A greater proportion of participants with type 2 diabetes achieve treatment targets with insulin degludec/liraglutide versus insulin glargine 100 units/mL at 26 weeks: DUAL VIII, a randomized trial designed to resemble clinical practice.","Sesti G","2020","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent19","26 week results of DUAL VIII RCT of IDegLira vs insulin glargine in type 2 diabetes on oral drugs",1],["R0012758","Dulaglutide improves glucocorticoid-induced hyperglycemia in inpatient care and reduces dose and injection frequency of insulin.","Uchinuma H","2020","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent19","retrospective inpatient comparison of dulaglutide vs no dulaglutide for steroid hyperglycemia; glycemia and enzymes, no listed harm",1],["R0015053","Real-World Effectiveness of Insulin Glargine 300 U/ml in People with Type 2 Diabetes Previously Treated with Tirzepatide: The DELIVER-T Study.","Ritzel R","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent03","claims study of insulin glargine 300 after tirzepatide, single group before and after without comparator",1],["R0015164","Chronic Kidney Disease Stage G4 in a Diabetic Patient Improved by Multi-Disciplinary Treatments Based Upon Literature Search for Therapeutic Evidence.","Yanai H","2022","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent03","case report of CKD G4 improvement in diabetic patient on SGLT2i and GLP-1 RA with added therapies",1],["R0015249","Profile of semaglutide in the management of type 2 diabetes: design, development, and place in therapy.","Gomez-Peralta F","2019","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent03","narrative drug profile review of semaglutide in type 2 diabetes",1],["R0015337","iGlarLixi: A New Once-Daily Fixed-Ratio Combination of Basal Insulin Glargine and Lixisenatide for the Management of Type 2 Diabetes.","Hinnen D","2018","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent03","narrative review of iGlarLixi clinical evidence and dosing",1],["R0015424","Independent effects of 15 commonly prescribed drugs on all-cause mortality among US elderly patients with type 2 diabetes mellitus.","Baik SH","2020","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent03","Medicare cohort estimating mortality associations of 15 drugs incl. GLP-1 RA in elderly T2D; mortality only",1],["R0015495","Achievement of glycaemic control is associated with improvements in lipid profile with iGlarLixi versus iGlar: A post hoc analysis of the LixiLan-L trial.","Giorgino F","2019","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent03","post hoc lipid analysis of LixiLan-L RCT, iGlarLixi vs insulin glargine in T2D on basal insulin",1],["R0015613","Comparative efficacy and safety of antidiabetic agents in Alzheimer's disease: A network meta-analysis of randomized controlled trials.","Cai Z","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent03","NMA of RCTs of antidiabetic agents incl. liraglutide and exenatide in Alzheimer disease, four databases searched",1],["R0015733","Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes.","Hartman ML","2020","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent03","post hoc NASH biomarker analysis of phase 2 RCT tirzepatide vs dulaglutide vs placebo in T2D",1],["R0014214","The Cardiovascular Effect of Tirzepatide: A Glucagon-Like Peptide-1 and Glucose-Dependent Insulinotropic Polypeptide Dual Agonist.","Cho YK","2023","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent14","narrative review of cardiovascular effects of tirzepatide",1],["R0012844","Incidence and Predictors of Primary Nonadherence to Sodium Glucose Co-transporter 2 Inhibitors and Glucagon-Like Peptide 1 Agonists in a Large Integrated Healthcare System.","Luo J","2022","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent01","cohort describing primary nonadherence to newly prescribed SGLT2i or GLP-1 RA; prescribing and dispensing study without outcome comparison",1],["R0014310","Effectiveness, Simplification and Persistence of IDegLira in Poorly Controlled People with Type 2 Diabetes: A 4-Year Follow-Up Real-World Study.","Di Loreto C","2024","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent14","retrospective single arm chart review of IDegLira over 4 years by prior regimen, no comparison group",1],["R0014492","Combination of GLP-1 receptor agonists and behavioural treatment in type 2 diabetes elicits synergistic effects on body weight: A retrospective cohort study.","Petroni ML","2019","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent14","retrospective cohort of GLP-1 RA starters with vs without behavioral programmes, weight and HbA1c only",1],["R0014564","Paradigm shift in obesity treatment: an extensive review of current pipeline agents.","Çetin E","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent14","narrative review of obesity pipeline agents",1],["R0014683","Real-world use of oral semaglutide in adults with type 2 diabetes.","Roslind K","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent14","prospective non interventional single arm study of oral semaglutide in Danish primary care, no comparison group",1],["R0014758","Projected life-year gains with semaglutide in individuals with cardiovascular disease without type 2 diabetes in the UK.","Van Sloten T","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent14","modeling of projected life year gains applying SELECT effect estimates to a UK cohort, no observed exposure",1],["R0014844","Efficacy and safety of incretin-based therapies in patients with nonalcoholic fatty liver disease: A protocol for a systematic review and meta-analysis.","Fan SM","2020","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent14","protocol of a meta-analysis of incretin therapies in NAFLD, no results",1],["R0012908","Semaglutide in Japanese participants with metabolic dysfunction-associated steatohepatitis: a subgroup analysis of the ESSENCE trial.","Nakajima A","2026","include_nma",null,"secondary_report","P09",null,null,"high","first","opus-5.5-agent01","Japanese subgroup analysis of ESSENCE phase 3 RCT, semaglutide 2.4 mg versus placebo in MASH with fibrosis",1],["R0013035","Reducing Periprosthetic Joint Infection in Patients With Obesity: A Systematic Review and Meta-Analysis of the Emerging Role of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists.","Fernandes A","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent01","registered meta-analysis of cohorts comparing perioperative GLP-1 RA users and nonusers in arthroplasty, PubMed Embase Cochrane searched",1],["R0013118","What Is the Impact of Different Glucose-lowering Agents for Atrial Fibrillation Risk: A Systematic Review and a Network Meta-analysis&nbsp;","Shi W","2020","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent01","registered Bayesian network meta-analysis of glucose lowering agents including GLP-1 RA on atrial fibrillation",1],["R0013230","Increased Dipeptidyl Peptidase-4 Promotes Adipose Inflammation and Dysfunction in Mice Under Chronic Stress.","Zhang M","2025","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent01","mouse chronic stress model with DPP4 knockout and exenatide plus in vitro work; animal study only",1],["R0013420","Effects of Semaglutide on Glycemic Control and Body Weight in Patients With Type 2 Diabetes: A Retrospective Cohort Study in a Primary Care Setting.","Alzahrani M","2025","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent01","retrospective single group cohort of semaglutide initiators in primary care with before and after HbA1c and weight",1],["R0013516","Why Do We Lose Bone During Weight Loss: Can It Be Prevented?","Shapses SA","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent01","narrative review of mechanisms of bone loss during weight loss including incretin therapy",1],["R0012751","Dulaglutide and neurodegeneration biomarkers: REWIND post hoc analysis.","Wilson JM","2026","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent17","post hoc REWIND RCT analysis of dulaglutide versus placebo on neurodegeneration biomarkers and cognitive impairment",1],["R0012821","The use of GLP-1 receptor agonists in hospitalised patients: An untapped potential.","Mustafa OG","2019","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent17","self described narrative review of GLP-1 RAs in hospitalized patients",1],["R0012899","Evaluation of Pre-Treatment Assessment of Semaglutide Users: Balancing the Benefits of Weight Loss vs. Potential Health Consequences.","Bin Dayel FF","2025","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent17","single center audit of pre-treatment screening practices in semaglutide prescribing; no exposure outcome comparison",1],["R0013016","One-Year Weight Reduction With Semaglutide or Liraglutide in Clinical Practice.","Gasoyan H","2024","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent17","Cleveland Clinic cohort comparing semaglutide and liraglutide on one year weight change; no listed harm outcome",1],["R0013096","Incretin physiology and pathophysiology from an Asian perspective.","Cho YM","2015","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent17","narrative review of incretin physiology and therapy response in East Asians",1],["R0013212","Glucagon-like Peptide-1 Therapy in Obesity-Related Heart Failure with Preserved Ejection Fraction: Mechanisms, Clinical Evidence, and Implications.","Abedi MM","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent17","self described narrative review of GLP-1 based therapy in obesity related HFpEF",1],["R0013312","Effects from treating moderate- to high-risk obesity patients with anti-obesity medication from a societal perspective.","Reitzinger S","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent17","societal cost and prevalence modeling of semaglutide for obesity in Austria",1],["R0013407","Effect of Tirzepatide on Health-Related Quality of Life in Japanese Patients With Obesity Disease: Patient-Reported Outcomes From the SURMOUNT-J Study.","Masuzaki H","2026","include_nma",null,"secondary_report","P02",null,null,"high","first","opus-5.5-agent17","prespecified quality of life analysis of SURMOUNT-J RCT of tirzepatide versus placebo in Japanese obesity without diabetes",1],["R0021467","GDF15 acts synergistically with liraglutide but is not necessary for the weight loss induced by bariatric surgery in mice.","Frikke-Schmidt H","2019","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent05","mouse experiments of GDF15 and liraglutide on food intake; human material limited to postmortem brain staining",1],["R0021584","Efficacy of atomoxetine and oxybutynin in the treatment of pediatric obstructive sleep apnea, a three case report.","Larramona Carrera H","2025","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent05","case series of atomoxetine plus oxybutynin for pediatric sleep apnea; liraglutide only incidental background therapy",1],["R0021714","Glimepiride Compared to Liraglutide Increases Plasma Levels of miR-206, miR-182-5p, and miR-766-3p in Type 2 Diabetes Mellitus: A Randomized Controlled Trial (Diabetes Metab J 2023;47:668-81).","Scherbak NN","2023","inventory_only","N9","ancillary",null,null,null,"high","first","opus-5.5-agent05","authors reply to a comment on their RCT of glimepiride versus liraglutide on microRNAs",1],["R0021917","A phase 1 multiple-ascending dose study of tirzepatide in Japanese participants with type 2 diabetes.","Furihata K","2022","include_nma",null,"primary_report","P01",null,"mechanistic","high","first","opus-5.5-agent05","phase 1 placebo controlled multiple ascending dose RCT of tirzepatide in Japanese type 2 diabetes; adverse events and glycemia",1],["R0022086","Effect of dulaglutide 3.0 and 4.5 mg on weight in patients with type 2 diabetes: Exploratory analyses of AWARD-11.","Bonora E","2021","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent05","exploratory weight analyses of AWARD-11 RCT of dulaglutide 3.0 and 4.5 versus 1.5 mg",1],["R0022289","Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss.","Wharton S","2022","include_nma",null,"pooled_analysis","P02; P01; P02W",null,null,"high","first","opus-5.5-agent05","pooled STEP 1 to 3 placebo controlled RCTs and STEP 4 withdrawal trial on GI adverse events of semaglutide 2.4 mg",1],["R0022416","Systematic Review of Therapeutic Strategies for Reducing Parkinson's Disease Symptoms and Progression.","Tumu S","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent05","PRISMA systematic review of RCTs of Parkinson disease therapies including exenatide, six named databases",1],["R0010622","Real-world evaluation of care for type 2 diabetes in Malaysia: A cross-sectional analysis of the treatment adherence to guideline evaluation in type 2 diabetes (TARGET-T2D) study.","Lim LL","2024","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent09","cross sectional audit of diabetes care targets and guideline drug use in Malaysia, no GLP-1 exposure comparison",1],["R0010725","SGLT-2 Inhibitors and GLP-1 Receptor Agonists as Combination Therapy in Type 2 Diabetes.","Liakos A","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent09","narrative review of SGLT2 and GLP-1 combination therapy in type 2 diabetes",1],["R0010804","Post Hoc Analysis of SURPASS-1 to -5: Efficacy and Safety of Tirzepatide in Adults with Type 2 Diabetes are Independent of Baseline Characteristics.","De Block C","2025","include_nma",null,"pooled_analysis","P01",null,null,"high","first","opus-5.5-agent09","post hoc pooled analysis of SURPASS-1 to -5 randomized trials of tirzepatide versus placebo or active comparators",1],["R0010973","Racial and ethnic disparities in the uptake of SGLT2is and GLP-1RAs among Medicare beneficiaries with type 2 diabetes and heart failure, atherosclerotic cardiovascular disease and chronic kidney disease, 2013-2019.","Wang E","2025","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent09","Medicare study of racial disparities in initiating SGLT2 or GLP-1 drugs, prescribing without exposure outcome comparison",1],["R0011057","Trends in Pharmacological Treatment of Patients With New Onset Type 2 Diabetes: Usage Patterns in an Evolving Guideline Landscape.","Hou W","2025","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent09","repeated cross sectional trends in glucose lowering drug use in new type 2 diabetes, utilization only",1],["R0011147","Antidiabetic medications and risk of cognitive disorders in type 2 diabetes: A retrospective cohort study.","Nasir AB","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent09","TriNetX cohort of diabetes regimens including metformin plus GLP-1 on incident cognitive disorders, no eligible harm",1],["R0011241","Geographic Variation in Cardiovascular Disease Prevention by GLP-1 Receptor Agonists and SGLT2 Inhibitors: A Meta-Analysis","Ilany J","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent09","PROSPERO registered meta-analysis of GLP-1 and SGLT2 cardiovascular outcome trials by region, PubMed searched",1],["R0015161","Evaluation of the Safety, Efficacy and Pharmacokinetics of BGM0504 in Chinese Adults With Type 2 Diabetes: A Multicentre, Randomised, Controlled and Double-Blind Phase II Trial.","Jin P","2026","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent20","randomized double blind phase 2 trial of BGM0504 doses vs placebo with open label semaglutide control in Chinese T2D",1],["R0014900","Antiemetic effect of acupressure wristbands for GLP-1 medication associated nausea.","Ziemke F","2025","inventory_only","N1","primary_report",null,null,null,"high","first","opus-5.5-agent04","one arm nonrandomized study of acupressure wristbands for nausea in people on semaglutide or tirzepatide",1],["R0015240","Design and rationale for the SIB trial: a randomized parallel comparison of semaglutide versus placebo on intestinal barrier function in type 2 diabetes mellitus.","Rella S","2023","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent20","design and rationale paper of placebo controlled SIB trial of semaglutide on intestinal permeability in T2D",1],["R0015329","A new form of diabetes caused by INS mutations defined by zygosity, stem cell and population data.","Tong Y","2026","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent20","genetic, iPSC and mouse transplant study of INS variant; GLP-1 RA given only to mice",1],["R0015487","Boosting weight loss after conversional Roux-en-Y Gastric Bypass with liraglutide and placebo use. A double-blind-randomized controlled trial.","Hany M","2024","include_nma",null,"primary_report","P99",null,null,"high","first","opus-5.5-agent20","double blind RCT of liraglutide vs placebo after conversional Roux-en-Y gastric bypass, weight loss outcomes; post bariatric population",1],["R0015602","Liraglutide Versus Lixisenatide: Long-Term Cost-Effectiveness of GLP-1 Receptor Agonist Therapy for the Treatment of Type 2 Diabetes in Spain.","Mezquita-Raya P","2017","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent20","CORE model cost effectiveness analysis of liraglutide vs lixisenatide in Spain",1],["R0015711","Once-weekly semaglutide administered after laparoscopic sleeve gastrectomy: Effects on body weight, glycemic control, and measured nutritional metrics in Japanese patients having both obesity and type 2 diabetes.","Kanai R","2024","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent20","retrospective single center series of semaglutide after sleeve gastrectomy, diet subgroups only, no unexposed comparison",1],["R0015813","Evolving kidney disease phenotypes in type 2 diabetes: declining albuminuria and increasing isolated low eGFR.","De Cosmo SA","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent20","cross sectional Italian registry of renal phenotypes in T2D, drug classes only as covariates",1],["R0014955","Diabetic Ketoacidosis and the Use of New Hypoglycemic Groups: Real-World Evidence Utilizing the Food and Drug Administration Adverse Event Reporting System.","Thaibah HA","2025","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent04","FAERS disproportionality analysis of diabetic ketoacidosis reports with SGLT2i, GLP-1 RA and DPP-4i",1],["R0015054","GLP-1-Based Therapies in Type 1 Diabetes: Emerging Evidence on Cardiovascular, Renal, and Safety Outcomes.","Tentolouris A","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent04","narrative review of GLP-1 based therapies in type 1 diabetes without described search or criteria",1],["R0015168","Incretin-Based Therapy and Risk of Pancreatic Cancer in Patients with Type 2 Diabetes Mellitus: A Meta-analysis of Randomized Controlled Trials.","Chen H","2016","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent04","meta-analysis of RCTs from three databases on incretin therapy incl GLP-1 RA and pancreatic cancer risk",1],["R0015264","Efficacy and safety in tirzepatide-treated Korean adults with type 2 diabetes-A post hoc analysis of SURPASS-AP-combo and SURPASS-3.","Lee BW","2025","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent04","post hoc Korean subgroup analysis of SURPASS-AP-Combo and SURPASS-3 RCTs of tirzepatide vs basal insulin",1],["R0015340","Abstract 15: Glycemic and body weight responses to oral semaglutide in the PIONEER trial program",null,"2022","include_nma",null,"conference_abstract","P01",null,"abstract_only","high","first","opus-5.5-agent04","conference abstract of post hoc analysis of PIONEER 1-5 and 8 RCTs of oral semaglutide vs placebo or active comparators",1],["R0015500","Tirzepatide for the Maintenance of Body Weight Reduction: Rationale, Design, and Baseline Characteristics of SURMOUNT-MAINTAIN.","Horn DB","2025","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent04","design and baseline paper of SURMOUNT-MAINTAIN RCT of tirzepatide dose reduction or continuation vs placebo",1],["R0014318","Therapeutic Advances in Obesity: How Real-World Evidence Impacts Affordability Beyond Standard of Care.","Patoulias D","2024","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent16","narrative review of real world evidence and affordability of obesity drugs",1],["R0014400","Effect of liraglutide on anthropometric measurements, sagittal abdominal diameter and adiponectin levels in people with type 2 diabetes treated with multiple daily insulin injections: evaluations from a randomized trial (MDI-liraglutide study 5).","Ahmadi SS","2019","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent16","secondary analysis of MDI-liraglutide double blind RCT of liraglutide vs placebo in insulin treated T2D",1],["R0014500","Tirzepatide in Adults With Type 1 Diabetes: A Phase 2 Randomized Placebo-Controlled Clinical Trial.","Snaith JR","2026","include_nma",null,"primary_report","P05",null,null,"high","first","opus-5.5-agent16","phase 2 double blind RCT of tirzepatide vs placebo in adults with type 1 diabetes and obesity",1],["R0014593","Semaglutide in obesity and type 2 diabetes: A review of clinical trial evidence from 1 to 5 semaglutide treatment effect in people with obesity program.","Khanna A","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent16","narrative review of STEP 1 to 5 semaglutide trials",1],["R0014693","A Multicentre, Prospective, Non-Interventional Single-Arm Study Investigating the Impact of Once-Daily Oral Semaglutide in a Real-World Adult Population With Type 2 Diabetes in Mexico.","González-Gálvez G","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent16","PIONEER REAL Mexico prospective single arm noninterventional study of oral semaglutide",1],["R0014761","Potential Role of Imaging in the Evaluation of Adiposity and Approval of Anti-Obesity Drugs.","Kim SY","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent16","narrative review of imaging for adiposity assessment in anti obesity drug trials",1],["R0014850","Impact of Semaglutide as Weight Management Medication on Clinical Parameters and Health-Related Quality of Life: A Single-Center Study from Saudi Arabia.","Dayel FFB","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent16","single center retrospective pre post study of semaglutide on clinical parameters and quality of life, no comparator",1],["R0014931","Semaglutide on liver fibrosis and heart outcomes in patients at high risk of liver fibrosis: a prespecified analysis of the SELECT randomized trial.","Meyhöfer SM","2026","include_nma",null,"secondary_report","P02",null,null,"high","first","opus-5.5-agent16","prespecified analysis of SELECT RCT semaglutide vs placebo in patients at high risk of liver fibrosis",1],["R0011362","Laxative Properties of Microencapsulated Oleic Acid Delivered to the Distal Small Intestine in Patients with Constipation after Bariatric Surgery or Treatment with Glucagon-Like- Peptide 1 Analogues.","Al-Humadi AW","2024","inventory_only","N3","primary_report",null,null,"crossover","high","first","opus-5.5-agent10","crossover RCT of oleic acid release site in constipation after bariatric surgery or on GLP-1 RA; GLP-1 not randomized",1],["R0011465","Efficacy and safety of the glucagon-like peptide-1 receptor agonist liraglutide added to insulin therapy in poorly regulated patients with type 1 diabetes--a protocol for a randomised, double-blind, placebo-controlled study: the Lira-1 study.","Dejgaard TF","2015","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent10","protocol of Lira-1 RCT liraglutide versus placebo added to insulin in overweight type 1 diabetes",1],["R0011573","GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data.","Sposito AC","2018","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent10","narrative review of GLP-1 RA cardiovascular mechanisms and outcome trials; no search methods",1],["R0011650","Metabolic Syndrome Abolishes Glucagon-Like Peptide 1 Receptor Agonist Stimulation of SERCA in Coronary Smooth Muscle.","Dineen SL","2015","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent10","Ossabaw swine randomized to GLP-1 RA AC3174 or placebo plus isolated coronary cells; animal study only",1],["R0011864","Cancer risk with GLP-1RA: what can real-world data really tell us?","Jessen N","2025","inventory_only","N9","ancillary",null,null,null,"high","first","opus-5.5-agent10","commentary on Danish target trial emulation of GLP-1 RA versus DPP-4i and cancer risk",1],["R0011944","The emerging role of GLP-1 receptor agonists in treating or preventing cancer.","Benjamin DJ","2024","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent10","narrative review of GLP-1 RAs in cancer prevention and treatment; no systematic methods",1],["R0012066","Evaluation and comparison of efficacy and safety of tirzepatide, liraglutide and SGLT2i in patients with type 2 diabetes mellitus: a network meta-analysis.","Teng Y","2024","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent10","PROSPERO registered NMA of RCTs of tirzepatide, liraglutide and SGLT2i in T2D; three databases searched",1],["R0015763","Beyond safety: adverse events and unanticipated advantages of SGLT2 inhibitors.","Falsetti L","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent12","narrative review of SGLT2 inhibitor adverse and beneficial effects, GLP-1RAs only mentioned as comparators in cited studies",1],["R0015876","Neuroprotective effects of lixisenatide and liraglutide in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.","Liu W","2015","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent12","MPTP mouse model study of lixisenatide, liraglutide and exendin-4",1],["R0015962","Comparison of Fracture Risk Following Semaglutide Treatment vs Sleeve Gastrectomy.","Noreña JA","2025","inventory_only","N6","primary_report","P02",null,null,"high","first","opus-5.5-agent12","EHR matched cohort of semaglutide vs sleeve gastrectomy in obesity, fracture outcome only",1],["R0016041","Single-Center Experience of Using Liraglutide in Adolescents With Obesity +/- Type 2 Diabetes.","Dauleh H","2024","inventory_only","N5","primary_report","P03",null,null,"high","first","opus-5.5-agent12","retrospective single center series of adolescents with obesity treated with liraglutide, no comparison group",1],["R0016137","Real-world effectiveness, safety, and quality of life of biosynthetic semaglutide in Pakistani adults with type 2 diabetes mellitus: a study protocol.","Daoud Butt M","2026","inventory_only","N5","protocol_or_design","P01",null,null,"high","first","opus-5.5-agent12","protocol of single arm noninterventional study of biosynthetic semaglutide in T2D; alternative N8",1],["R0016230","The GLP-1 analogue lixisenatide decreases atherosclerosis in insulin-resistant mice by modulating macrophage phenotype.","Vinué Á","2017","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent12","mouse atherosclerosis study of lixisenatide and liraglutide with macrophage experiments",1],["R0016359","Quality and reliability of semaglutide content on different Chinese short video platforms: a study focusing on side effects.","Song J","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent12","content analysis of semaglutide short videos on Chinese platforms, no drug exposure",1],["R0016453","Body Composition Remodelling During GLP-1-Based Therapy: A Systematic Review and Meta-Analysis Using a Hierarchical Physiological Framework.","Lopes Menezes ML","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent12","registered SR and meta-analysis of GLP-1 based therapy studies on body composition, three databases",1],["R0016604","Combining Abdominal Hernia Repair With Abdominoplasty-Is it Safe?","Alaniz L","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent06","retrospective case series of combined abdominoplasty and hernia repair; GLP-1 RA not studied as exposure",1],["R0016786","Safety and Efficacy of Empagliflozin as Add-On Therapy to GLP-1 Receptor Agonist (Liraglutide) in Japanese Patients with Type 2 Diabetes Mellitus: A Randomised, Double-Blind, Parallel-Group Phase 4 Study.","Terauchi Y","2019","inventory_only","N3","primary_report",null,null,null,"high","first","opus-5.5-agent06","double blind RCT of empagliflozin 10 versus 25 mg added to liraglutide in Japanese T2D; GLP-1 regimen identical in both arms",1],["R0016909","PSUN113 Evaluating The Efficacy Of Anti-Obesity Medications In a Multidisciplinary Weight Management Clinic At a VA Medical Center",null,"2022","inventory_only","N5","conference_abstract",null,null,"abstract_only","high","first","opus-5.5-agent06","conference abstract of descriptive retrospective VA clinic data on anti-obesity drugs incl GLP-1 RAs; no comparison",1],["R0017083","Incretin-based drugs decrease the incidence of prostate cancer in type 2 diabetics: A pooling-up analysis.","Lin Y","2024","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent06","registered meta-analysis of RCTs and cohorts of incretin drugs incl GLP-1 RAs and prostate cancer in T2D",1],["R0017195","Proteomic signatures reflect effects of semaglutide treatment for MASH.","Schattenberg JM","2025","include_nma",null,"secondary_report","P02; P01; P09",null,null,"high","first","opus-5.5-agent06","post hoc proteomic analysis of STEP 1, STEP 2 and phase 2b MASH RCTs of semaglutide versus placebo",1],["R0017318","T44. 12-MONTH FOLLOW UP OF METABOLIC MEASURES FOLLOWING A RANDOMISED CONTROLLED TRIAL OF TREATMENT OF CLOZAPINE ASSOCIATED OBESITY AND DIABETES WITH EXENATIDE (CODEX)","Siskind D","2020","include_nma",null,"conference_abstract","P15",null,"abstract_only","high","first","opus-5.5-agent06","conference abstract of 12 month follow-up after CODEX open label RCT of exenatide versus usual care for clozapine obesity",1],["R0011186","Association of bodyweight loss with changes in lipids, blood pressure, and fasting serum glucose following tirzepatide treatment in Japanese participants with type 2 diabetes: A post hoc analysis of the SURPASS J-mono trial.","Mimura H","2025","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent15","post hoc weight mediation analysis of SURPASS J-mono RCT, tirzepatide doses versus dulaglutide 0.75 mg in Japanese type 2 diabetes",1],["R0011280","Can GLP-1 receptor agonists slow the progression of Autosomal Dominant Polycystic Kidney Disease?","Ali H","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent15","opinion letter on possible use of GLP-1 RAs in polycystic kidney disease",1],["R0011381","Efficacy and safety of polyethylene glycol loxenatide in treating mild-to-moderate diabetic kidney disease in type 2 diabetes patients: a randomized, open-label, clinical trial.","Cao Y","2024","include_nma",null,"primary_report","P01; P08A",null,null,"high","first","opus-5.5-agent15","open label RCT of PEG loxenatide versus dapagliflozin in type 2 diabetes with mild to moderate diabetic kidney disease",1],["R0011485","Potential Mediators of Efpeglenatide's Cardiovascular Benefit: An Exploratory Analysis of the AMPLITUDE-O Trial.","Raaschou-Oddershede D","2026","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent15","exploratory mediation analysis of AMPLITUDE-O RCT of efpeglenatide versus placebo on MACE in type 2 diabetes",1],["R0011582","Metformin and cardiorenal outcomes in diabetes: A reappraisal.","Petrie JR","2020","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent15","narrative review of metformin cardiorenal evidence; GLP-1 RAs only mentioned as context",1],["R0011676","Effect of semaglutide on arrhythmic, major cardiovascular, and microvascular outcomes in patients with type 2 diabetes: a systematic review and meta-analysis.","Wu R","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent15","registered systematic review and meta-analysis of 30 RCTs of semaglutide on arrhythmic, cardiovascular and microvascular outcomes",1],["R0009986","Real-World Outcomes of Individualized Targeted Therapy with Insulin Glargine 300 Units/mL in Insulin-Naïve Korean People with Type 2 Diabetes: TOBE Study.","Hong EG","2024","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent11","single arm study of insulin glargine 300; GLP-1RA only as prior background, not studied as exposure",1],["R0010147","Enteroendocrine cell regulation of the gut-brain axis.","Barton JR","2023","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent11","narrative review of enteroendocrine cell gut brain signaling",1],["R0010240","Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials.","Badve SV","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent11","registered meta-analysis of GLP-1RA RCTs on kidney and cardiovascular outcomes",1],["R0010302","Semaglutide reduces vascular inflammation investigated by PET in a rabbit model of advanced atherosclerosis.","Jensen JK","2022","exclude","E1","primary_report",null,null,null,"high","first","opus-5.5-agent11","rabbit atherosclerosis model randomized to semaglutide or placebo",1],["R0010440","Dapagliflozin plus exenatide on patients with type 2 diabetes awaiting bariatric surgery in the DEXBASU study.","López-Cano C","2022","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent11","DEXBASU pilot RCT, exenatide plus dapagliflozin versus control diet in diabetes awaiting bariatric surgery",1],["R0010519","Effect of Liraglutide on Arterial Inflammation Assessed as [18F]FDG Uptake in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial.","Ripa RS","2021","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent11","LIRAFLAME double blind RCT, liraglutide versus placebo for 26 weeks in type 2 diabetes",1],["R0014223","SUN-653 Impact of GLP-1 Agonist on Outcomes in Patients with Heart Failure with Preserved Ejection Fraction and Obesity: A Systematic Review and Meta-Analysis",null,"2025","include_review",null,"systematic_review",null,null,"abstract_only","high","first","opus-5.5-agent18","conference abstract of meta-analysis of GLP-1 RA vs placebo in obese HFpEF; PubMed, Embase, Scopus searched",1],["R0014383","Effect of the Glucagon-like Peptide-1 Receptor (GLP-1R) Agonists on Autonomic Function in Subjects With Diabetes: a Systematic Review and Meta-analysis.","Greco C","2021","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent13","PROSPERO registered meta-analysis of GLP-1 agonist trials on autonomic function in diabetes, preprint",1],["R0014323","Superior efficacy of insulin degludec/liraglutide versus insulin glargine U100 as add-on to sodium-glucose co-transporter-2 inhibitor therapy: A randomized clinical trial in people with uncontrolled type 2 diabetes.","Philis-Tsimikas A","2019","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent18","DUAL IX open label RCT of IDegLira vs insulin glargine U100 added to SGLT2i in T2D",1],["R0014403","Role of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Cardiovascular Risk Management in Patients With Type 2 Diabetes Mellitus: A Systematic Review.","Parab P","2023","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent18","PRISMA systematic review of GLP-1 RA and dual agonist CV effects in T2D; PubMed and Google Scholar; qualitative synthesis",1],["R0014491","Oral Semaglutide and Change in Cardiovascular Risk Factors in High-Risk Type 2 Diabetes: A Post Hoc Secondary Analysis of the SOUL Randomized Clinical Trial.","Mulvagh SL","2026","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent13","post hoc analysis of SOUL placebo controlled RCT of oral semaglutide on cardiovascular risk factors",1],["R0014505","Semaglutide in peripheral artery disease and diabetes by baseline disease severity and age: the STRIDE trial.","Nordanstig J","2026","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent18","post hoc subgroup analysis of STRIDE double blind RCT, semaglutide vs placebo in PAD with T2D",1],["R0014558","Effectiveness of oral semaglutide on glucose control and body weight up to 18 months: a multicenter retrospective real-world study.","Bonora BM","2024","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent13","retrospective multicenter cohort of oral semaglutide new users without comparison group",1],["R0014596","Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis.","Zeng Q","2023","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent18","registered systematic review and meta-analysis of tirzepatide RCTs on pancreatitis and biliary disease",1],["R0014679","Impact of Participant Characteristics on Clinical Outcomes with iGlarLixi in Type 2 Diabetes: Post Hoc Analysis of SPARTA Japan.","Yabe D","2024","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent13","post hoc analysis of single group observational SPARTA Japan iGlarLixi study",1],["R0014702","Metabolic Dysfunction and Metabolic Management in Episodic Migraine.","Denney DE","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent18","narrative review of metabolic syndrome and weight management in migraine",1],["R0014751","Use and effectiveness of dapagliflozin in routine clinical practice: An Italian multicentre retrospective study.","Fadini GP","2018","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent13","DARWIN-T2D retrospective study of dapagliflozin vs comparators incl GLP-1 agonists, effectiveness outcomes only",1],["R0014839","Efficacy and Safety of Semaglutide for Managing Antipsychotic-associated Weight Gain: A Systematic Review and Meta-analysis.","Jena S","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent13","systematic review and meta-analysis of semaglutide for antipsychotic associated weight gain from four databases",1],["R0014866","Long-acting GIPR agonist LY3537021 reduces body weight and fasting blood glucose in patients with T2D: Preclinical development and phase 1 randomized ascending dose studies.","Roell W","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent18","preclinical and phase 1 studies of selective GIP receptor agonist LY3537021; no GLP-1 receptor agonism",1],["R0014921","Dual GIP/GLP-1 Receptor Co-Agonism Reprograms White Adipose Tissue Toward a Thermogenic Phenotype: Mechanistic Insights and Implications for Obesity Pharmacotherapy","Andrade LJdO","2026","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent13","in silico analysis of public RNA-seq datasets on dual GIP and GLP-1 agonism",1],["R0015011","Tirzepatide Associated With Improved Health-Related Quality of Life in Adults With Obesity or Overweight in SURMOUNT-4.","Gibble TH","2025","include_nma",null,"secondary_report","P02W",null,null,"high","first","opus-5.5-agent13","SURMOUNT-4 randomized withdrawal RCT, continued tirzepatide vs placebo after lead-in, quality of life",1],["R0014268","A Systemic Review of Pharmacological Management of Pediatric Obesity.","Gupta S","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent07","systematic review of pediatric RCTs of anti obesity drugs including exenatide and liraglutide vs placebo",1],["R0014369","Efficacy and Safety of Tirzepatide in Japanese Participants With Obesity: A Subpopulation Analysis of the SURMOUNT-1 Trial.","Ishigaki Y","2026","include_nma",null,"secondary_report","P02",null,null,"high","first","opus-5.5-agent07","prespecified Japanese subpopulation analysis of SURMOUNT-1 RCT of tirzepatide vs placebo in obesity",1],["R0014448","GLP-1 Receptor Agonist Discontinuation Among Patients With Obesity and/or Type 2 Diabetes.","Do D","2024","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent07","claims cohort describing GLP-1RA discontinuation and adherence among new users; utilization without exposure outcome comparison",1],["R0014537","Feasibility study of Glucagon-like peptide-1 analogues for the optimization of Outcomes in Obese patients undergoing AbLation for Atrial Fibrillation (GOAL-AF)","Win KZ","2023","inventory_only","N1","protocol_or_design",null,null,null,"high","first","opus-5.5-agent07","protocol of an uncontrolled single arm feasibility study of liraglutide before AF ablation; also no results yet",1],["R0014662","Safety and clinical effectiveness of iGlarLixi in people with type 2 diabetes mellitus in Mexico.","Rosas-Guzman J","2025","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent07","prospective observational single group study of iGlarLixi in routine care in Mexico without comparator",1],["R0014725","Efficacy and safety of lixisenatide in a predominantly Asian population with type 2 diabetes insufficiently controlled with basal insulin: The GetGoal-L-C randomized trial.","Yang W","2018","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent07","GetGoal-L-C double blind RCT of lixisenatide vs placebo added to basal insulin in type 2 diabetes",1],["R0014806","Real world tirzepatide treatment for fatty liver disease.","Maung ST","2026","inventory_only","N9","ancillary",null,null,null,"high","first","opus-5.5-agent07","editorial commenting on a TriNetX new user cohort of tirzepatide vs SGLT2i in fatty liver disease",1],["R0014909","Persistence-Dependent Effectiveness of Tirzepatide on the Cardio-Metabolic-Kidney Syndrome Outcomes in Obesity: Real-World Evidence from the United Arab Emirates.","Rangraze IR","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent07","single center tirzepatide cohort compared by treatment persistence only; no unexposed or active comparator",1],["R0022523","Safety and Efficacy of Inpatient Diabetes Management with Non-insulin Agents: an Overview of International Practices.","Galindo RJ","2022","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent05","narrative review of inpatient diabetes management with non-insulin agents",1],["R0022641","Efficacy and Safety of Dulaglutide in Older Patients: A post hoc Analysis of the REWIND trial.","Riddle MC","2021","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent05","post hoc age subgroup analysis of REWIND RCT of dulaglutide versus placebo",1],["R0022757","Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension.","Wilding JPH","2022","include_nma",null,"extension","P02",null,null,"high","first","opus-5.5-agent05","STEP 1 off treatment extension following randomized semaglutide 2.4 mg versus placebo groups for one further year",1],["R0022841","Trends in incidence, prevalence and prescribing in type 2 diabetes mellitus between 2000 and 2013 in primary care: a retrospective cohort study.","Sharma M","2016","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent05","THIN analysis of type 2 diabetes incidence, prevalence and prescribing trends; drug utilization only",1],["R0022984","Efficacy and Safety of Semaglutide 2.4 MG Once-Weekly in Adults With Overweight or Obesity and Type 2 Diabetes (STEP 2)","Davies M","2021","include_nma",null,"conference_abstract","P01",null,"abstract_only","high","first","opus-5.5-agent05","abstract of STEP 2 RCT of semaglutide 2.4 mg or 1.0 mg versus placebo in overweight adults with type 2 diabetes",1],["R0023232","Comprehensive bioinformatics analysis of malignant transformation and potential therapeutic possibility of lung adenocarcinoma after lipopolysaccharide induction.","Xu W","2025","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent05","bioinformatics analysis with liraglutide tested only in lung cancer cell lines in vitro",1],["R0023346","Efficacy and Safety of Dulaglutide Versus Insulin Glargine in Chinese T2DM Patients: A Subgroup Analysis of a Randomized Trial (AWARD-CHN2).","Li Y","2019","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent05","Chinese subgroup analysis of AWARD-CHN2 RCT of dulaglutide doses versus insulin glargine",1],["R0013486","Negative effects of semaglutide on bone in obese mice.","Eisner K","2026","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent17","mouse study of semaglutide effects on bone",1],["R0013575","Low dose liraglutide in Indian patients with type 2 diabetes in the real world setting.","Sanyal D","2013","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent17","single center retrospective study of low dose liraglutide in Indian type 2 diabetes without comparison group",1],["R0013688","ODP014 Safety and Efficacy of IBI362 (LY3305677) 9 mg and 10 mg in Chinese Adults with Overweight or Obesity",null,"2022","include_nma",null,"conference_abstract","P02",null,"mechanistic; abstract_only","high","first","opus-5.5-agent17","abstract of high dose cohorts of a placebo controlled multiple ascending dose RCT of IBI362 in Chinese overweight or obesity; weight and safety",1],["R0014041","Effect of sleep apnoea interventions on multiple health outcomes: an umbrella review of meta-analyses of randomised controlled trials.","Figard C","2025","include_review",null,"systematic_review",null,null,"umbrella_review","high","first","opus-5.5-agent17","registered umbrella review of meta-analyses of RCTs of sleep apnea interventions including GLP-1 RAs",1],["R0014142","The diabetes cardiovascular outcomes trials and racial and ethnic minority enrollment: impact, barriers, and potential solutions.","Sinclair MR","2024","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent17","narrative review of racial and ethnic minority enrollment in diabetes cardiovascular outcome trials",1],["R0012683","Role of Exendin-4 Functional Imaging in Diagnosis of Insulinoma: A Systematic Review.","Sidrak MMA","2023","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent02","systematic review of radiolabelled exendin-4 imaging for insulinoma diagnosis; diagnostic tracer, not a therapeutic regimen",1],["R0012774","Efficacy and safety of semaglutide in glycemic control, body weight management, lipid profiles and other biomarkers among obese type 2 diabetes patients initiated or switched to semaglutide from other GLP-1 receptor agonists.","Okamoto A","2021","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent02","retrospective single arm cohort of switch to or start of semaglutide in obese T2D; no control group",1],["R0012849","FRI067 Efficacy And Safety Of Glucagon-like Peptide 1 Analogs And Agonists (aGLP1) In Overweight/Obese Patients: A Systematic Review And An Updated Network Meta-analysis",null,"2023","include_review",null,"systematic_review",null,null,"abstract_only","high","first","opus-5.5-agent02","conference abstract of Bayesian network meta-analysis of GLP-1 RA RCTs on weight and safety; three databases searched",1],["R0012921","Combining SGLT2is, GLP1-RAs and nsMRAs in Diabetes: A Scoping Review of Current and Future Perspectives.","Stougaard EB","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent02","narrative scoping overview of SGLT2 inhibitor, GLP-1 RA and nsMRA combinations without described systematic search",1],["R0013037","Pathogenesis and Treatment of Non-alcoholic Steatohepatitis and Its Fibrosis: A Systematic Review.","Ahmed T","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent02","systematic review of MASH treatment RCTs including GLP-1 RA with named databases and RoB 2 appraisal",1],["R0013232","A Review of the Dose Justification of Phase 3 Trials to Regulatory Authorities for Drugs Intended for the Treatment of Type 2 Diabetes in Europe.","Koomen JV","2021","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent02","review of regulatory dossiers on dose justification of antidiabetic drugs; not a primary patient study or systematic review",1],["R0013331","Effectiveness of tirzepatide in Japanese patients with type 2 diabetes but no obesity: A sub-analysis of Hokkaido-TZP study data.","Abe T","2026","inventory_only","N5","secondary_report",null,null,null,"high","first","opus-5.5-agent02","secondary analysis of retrospective observational Hokkaido-TZP tirzepatide cohort by BMI tertile; no untreated comparison",1],["R0015900","Reflections on the discovery GLP-1 as a satiety hormone: Implications for obesity therapy and future directions.","Astrup A","2024","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent20","personal narrative reflection on the discovery of GLP-1 as a satiety hormone",1],["R0016004","Separate and combined effects of long-term GIP and GLP-1 receptor activation in patients with type 2 diabetes: a structured summary of a study protocol for a double-blind, randomised, placebo-controlled clinical trial.","Helsted MM","2023","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent20","protocol of placebo controlled RCT of semaglutide run in with add on GIP infusion in T2D",1],["R0016082","Long-term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study.","Simó R","2015","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent20","secondary analysis of randomized EUREXA trial of exenatide twice daily vs glimepiride on CV risk markers",1],["R0016401","Exploration of Multiple Non-Invasive Tests for Assessing Response to Treatment in a Semaglutide Phase 2b Trial in Patients with MASH.","Nitze LM","2026","include_nma",null,"secondary_report","P09",null,null,"high","first","opus-5.5-agent20","secondary analysis of randomized phase 2b semaglutide vs placebo trial in MASH using noninvasive tests",1],["R0016491","Use of non-insulin diabetes medicines after insulin initiation: A retrospective cohort study.","Xu Y","2019","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent20","MarketScan drug utilization study of non insulin drug continuation after insulin start",1],["R0016571","Prevalence and risk factors of atherosclerotic cardiovascular disease in Egyptians with type 2 diabetes: findings from the PACT-MEA study and call for action.","Assaad-Khalil SH","2025","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent20","cross sectional ASCVD prevalence study in Egyptian T2D, drug use only described",1],["R0011356","Effectiveness of drug interventions in nonalcoholic fatty liver disease: A network meta-analysis.","Huang YZ","2021","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent09","PROSPERO registered NMA of RCTs of antidiabetic drugs including GLP-1 agonists in NAFLD, five databases",1],["R0014276","Cost-Effectiveness of Semaglutide 2.4 mg for Obesity Disease Management in Japan: A Lifetime Economic Modeling Study Incorporating Retreatment Scenarios.","Kamada Y","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent08","Markov cost effectiveness model of semaglutide 2.4 mg for obesity in Japan",1],["R0011463","Short-term combined treatment with exenatide and metformin for overweight/obese women with polycystic ovary syndrome.","Ma RL","2021","include_nma",null,"primary_report","P12",null,null,"high","first","opus-5.5-agent09","open label RCT of exenatide weekly plus metformin versus metformin alone in overweight women with PCOS",1],["R0011570","Exploring molecular targets in diabetic kidney disease.","Maruno S","2022","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent09","narrative review of molecular targets in diabetic kidney disease",1],["R0011643","Efficacy of polyethylene glycol loxenatide for type 2 diabetes mellitus patients: a systematic review and meta-analysis.","Liu Y","2024","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent09","PRISMA meta-analysis of RCTs of PEG loxenatide in type 2 diabetes, ten databases searched",1],["R0011746","Prescriber Uncertainty as Opportunity to Improve Care of Type 2 Diabetes with Chronic Kidney Disease: Mixed Methods Study.","Flory JH","2023","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent09","mixed methods study of prescriber interviews, survey and prescribing data, no GLP-1 exposure outcome comparison",1],["R0011939","Home-based Intervention with Semaglutide Treatment of Neuroleptic-Related Prediabetes (HISTORI): protocol describing a prospective, randomised, placebo controlled and double-blinded multicentre trial.","Ganeshalingam AA","2024","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent09","protocol of HISTORI randomized placebo controlled semaglutide trial in schizophrenia with prediabetes",1],["R0012060","Semaglutide 2.4 mg versus Liraglutide 3 mg for the Treatment of Obesity in Greece: A Short-Term Cost-Effectiveness Analysis.","Papantoniou P","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent09","short term cost effectiveness analysis of semaglutide versus liraglutide using STEP 8 data",1],["R0014370","SAT-669 Impact of GLP-1 agonist in patients with heart failure and dyslipidemia affected by Metabolic Dysfunction-Associated Steatotic Liver Disease: A prospective case control study",null,"2025","include_harms",null,"conference_abstract",null,"O121","abstract_only","high","first","opus-5.5-agent08","abstract of TriNetX matched cohort of GLP-1 RA users versus nonusers with MASLD and heart failure; acute kidney failure reported",1],["R0014460","Efficacy and safety of semaglutide injection in Indian patients with type 2 diabetes mellitus inadequately controlled on metformin: A phase 3, randomized, active-controlled, multicenter, non-inferiority trial (WIN-IND study).","C A","2026","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent08","phase 3 RCT of test versus reference semaglutide on metformin background in Indian type 2 diabetes",1],["R0014539","Semaglutide Effects on Insulin Sensitivity and β-Cell Function in Patients With Schizophrenia, Prediabetes, and Obesity Treated With Second-Generation Antipsychotics: Findings From the HISTORI Trial, a 30-Week Randomized, Placebo-Controlled Trial With Semaglutide 1.0 mg Weekly.","Ganeshalingam AA","2026","include_nma",null,"secondary_report","P15; P06",null,null,"high","first","opus-5.5-agent08","HISTORI RCT prespecified secondary analysis of semaglutide versus placebo in schizophrenia with prediabetes on antipsychotics",1],["R0014664","Modeling the Effect of Subcutaneous Lixisenatide on Glucoregulatory Endocrine Secretions and Gastric Emptying in Type 2 Diabetes to Simulate the Effect of iGlarLixi Administration Timing on Blood Sugar Profiles.","Gautier T","2022","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent08","in silico simulation of iGlarLixi dosing time with 100 virtual patients built from prior trial data",1],["R0014734","Incretin and insulin signaling as novel therapeutic targets for Alzheimer's and Parkinson's disease.","Nowell J","2023","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent08","narrative review of incretin and insulin signaling in Alzheimer and Parkinson disease",1],["R0014814","Current status of anti-obesity medications and performance, an EHR based survey","Ruan X","2024","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent08","EHR survey of real world weight and metabolic response across antiobesity drugs incl GLP-1 RAs; no harms list outcome",1],["R0014913","Response to Comment on Rossing et al. Nuances in Interpretation: Assessing the Interaction Between Semaglutide and MRAs in the FLOW Trial.","Rossing P","2026","inventory_only","N9","ancillary",null,null,null,"high","first","opus-5.5-agent08","authors reply to comment on FLOW trial analysis by baseline MRA use",1],["R0015834","Liraglutide prevents lupus-associated diffuse alveolar hemorrhage via inhibiting lymphocyte infiltration and promoting macrophage M2 polarization.","Jiang L","2026","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent03","mouse lupus alveolar hemorrhage model treated with liraglutide; animal only",1],["R0015916","Effect of a GLP-1 mimetic on the insulin response to oral sugar testing in horses.","Stefanovski D","2022","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent03","randomized crossover study of exenatide in six horses; veterinary, no humans",1],["R0016021","The GLP-1/GIP dual-receptor agonist DA5-CH inhibits the NF-κB inflammatory pathway in the MPTP mouse model of Parkinson's disease more effectively than the GLP-1 single-receptor agonist NLY01.","Lv M","2021","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent03","MPTP mouse Parkinson model comparing DA5-CH and NLY01; animal only",1],["R0016096","A randomized controlled trial investigating the effect of liraglutide on self-reported liking and neural responses to food stimuli in participants with obesity.","Coppin G","2023","include_nma",null,"secondary_report","P02",null,"mechanistic","high","first","opus-5.5-agent03","double blind RCT of liraglutide 3.0 mg vs placebo for 16 weeks in obesity without diabetes; food liking and fMRI report",1],["R0016184","Development of a risk prediction model for gastrointestinal adverse events associated with semaglutide administration in patients with type 2 diabetes mellitus.","Yue D","2025","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent03","single group cohort of semaglutide initiators with T2D modeling risk factors for GI adverse events, no comparator",1],["R0016297","Landscape of diabetic kidney disease drug clinical trials in China (2013-2023): global implications for innovation and policy.","Yang Y","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent03","landscape analysis of registered DKD drug trials in China; not a primary study of GLP-1 exposure",1],["R0016419","Focus on Semaglutide 2.4 mg/week for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis.","Petta S","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent03","narrative review of semaglutide 2.4 mg for MASH",1],["R0012827","Safety and Tolerability of Concomitant Administration of Multiple-Dose AM833 With Semaglutide 2.4 MG for Weight Management","Enebo L","2021","include_nma",null,"conference_abstract","P02",null,"mechanistic; abstract_only","high","first","opus-5.5-agent19","phase 1 RCT abstract of AM833 cagrilintide plus semaglutide vs placebo plus semaglutide in overweight adults; AEs primary, weight reported",1],["R0012903","The catcher in the gut: Tirzepatide, a dual incretin analog for the treatment of type 2 diabetes mellitus and obesity.","Lempesis IG","2022","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent19","narrative review of tirzepatide for type 2 diabetes and obesity",1],["R0013024","Incretin-based therapies.","Stonehouse AH","2012","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent19","narrative review of incretin based therapies in type 2 diabetes",1],["R0013110","166. Active GLP-1 RA Use Correlates With Lower Rates of Surgical Complications Across Diabetic BMI Cohorts: A Retrospective Analysis of 72,578 Surgical Encounters","Salingaros S","2025","inventory_only","N6","conference_abstract",null,null,"abstract_only","high","first","opus-5.5-agent19","surgical encounter cohort of diabetic patients with active GLP-1 RA vs none; wound, infection, readmission outcomes, no aspiration reported",1],["R0013225","Non-insulin antihyperglycaemic drugs and heart failure: an overview of current evidence from randomized controlled trials.","Savarese G","2020","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent19","narrative overview of RCT evidence on antihyperglycemic drugs and heart failure",1],["R0013414","Role of glucagon in metabolic diseases.","Kitamura T","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent19","narrative review of glucagon in metabolic disease",1],["R0013699","The Effect of Oral Semaglutide on Cardiovascular Risk Factors in Patients with Type 2 Diabetes: A Systematic Review.","Krishnanda SI","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent01","PRISMA systematic review of oral semaglutide versus placebo studies on cardiovascular risk factors, eight databases searched",1],["R0013791","Efficacy and safety of retatrutide for overweight/obesity or type 2 diabetes: a systematic review and meta-analysis","Xiao Y","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent01","systematic review and meta-analysis of retatrutide RCTs in obesity or type 2 diabetes, six sources searched",1],["R0013896","Regulation of fatty acid oxidation by liraglutide via SIRT1 in hepatocytes: A mechanistic study","Shen B","2026","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent01","bioinformatics and HepG2 cell experiments of liraglutide on fatty acid oxidation; in vitro only",1],["R0013976","Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials.","Giblin K","2026","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent01","rationale and design of TRIUMPH phase 3 RCTs of retatrutide versus placebo for obesity, sleep apnea and knee osteoarthritis",1],["R0014152","Clinical inertia in patients with type 2 diabetes treated with oral antidiabetic drugs: Results from a Japanese cohort study (JDDM53).","Maegawa H","2021","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent01","retrospective database study of clinical inertia and time to treatment intensification; drug utilization without GLP-1 RA outcome comparison",1],["R0014237","Ixekizumab With or Without Tirzepatide in Adults With Psoriasis and Overweight or Obesity: A Phase 3b Randomized Clinical Trial.","Lebwohl M","2026","include_nma",null,"primary_report","P02; P99",null,null,"high","first","opus-5.5-agent01","phase 3b open label RCT of ixekizumab with versus without tirzepatide in psoriasis with overweight or obesity",1],["R0015020","Familial Hypercholesterolaemia in a Bulgarian Population of Patients with Dyslipidaemia and Diabetes: An Observational Study.","Tankova T","2020","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent16","retrospective study of familial hypercholesterolemia in diabetes; GLP-1RA only a background treatment criterion",1],["R0014923","Residual cardiovascular risk beyond LDL-cholesterol control: what remains unaddressed?","Taha M","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent14","narrative review of residual cardiovascular risk beyond LDL cholesterol",1],["R0015016","Weight-Reduction and Safety Profile of Once-Weekly Non-Comparable Biotherapeutic Subcutaneous Semaglutide Among People With Obesity: A Real-World Retrospective Study.","Hasan MR","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent14","retrospective single arm study of non comparable biotherapeutic semaglutide in obesity, no comparison group",1],["R0015102","The long-term cost-effectiveness of once-weekly semaglutide 1 mg vs. dulaglutide 3 mg and 4.5 mg in the UK.","Viljoen A","2023","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent14","CORE Diabetes Model cost effectiveness analysis of semaglutide vs dulaglutide in the UK",1],["R0015127","ARD-101, a gut-restricted TAS2R agonist, reduces hunger in adults and promotes weight loss in DIO mice with DPP-4 inhibition.","Zheng Z","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent16","human RCTs test ARD-101 bitter receptor agonist vs placebo; tirzepatide used only in mice",1],["R0015233","Cardiometabolic and Renal Outcomes in Semaglutide Users with Type 2 Diabetes Achieving Glycemic and Weight Goals: An Observational Cohort Study.","Tan X","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent16","pre post claims cohort of semaglutide users meeting glycemic and weight goals, no concurrent comparator",1],["R0015303","Awareness and perceptions of systemic inflammation in atherosclerotic cardiovascular disease and chronic kidney disease: The SPARK-CVD China survey.","Liu X","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent14","cross sectional physician survey on systemic inflammation awareness, no GLP-1 exposure studied",1],["R0015307","Triple therapy in type 2 diabetes; a systematic review and network meta-analysis.","Downes MJ","2015","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent16","systematic review and NMA of triple therapy RCTs in T2D including GLP-1RA combinations; MEDLINE and Cochrane searched",1],["R0015386","A 1-year safety study of dulaglutide in Japanese patients with type 2 diabetes on a single oral hypoglycemic agent: an open-label, nonrandomized, phase 3 trial.","Emoto M","2015","inventory_only","N1","primary_report",null,null,null,"high","first","opus-5.5-agent14","nonrandomized open label phase 3 study of dulaglutide added to five different oral agents, no concurrent non GLP-1 control",1],["R0015390","Cost-effectiveness of semaglutide 2.4 mg in chronic weight management in Portugal.","Silva Miguel L","2024","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent16","Markov cost effectiveness model of semaglutide 2.4 mg in Portugal",1],["R0015461","Global use of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. Results from DISCOVER.","Arnold SV","2022","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent14","DISCOVER analysis of predictors and country variation in SGLT2i and GLP-1 RA use, utilization only",1],["R0015555","Beyond Weight Loss: the Emerging Role of Incretin-Based Treatments in Cardiometabolic HFpEF.","Capone F","2024","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent14","narrative review of incretin based treatments in cardiometabolic HFpEF",1],["R0015571","Two Cases of Diabetes Remission through Temporary Tirzepatide Treatment.","Sawamura T","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent16","case report of two patients with diabetes remission after tirzepatide",1],["R0023500","The Body Weight Alteration and Incidence of Neoplasm in Patients With Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials.","Lin C","2020","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent05","meta-analysis of RCTs of weight altering diabetes treatments including GLP-1 RA on neoplasm incidence, three named databases",1],["R0023615","Effect of Once-Weekly Dulaglutide on Glucose Levels in Japanese Patients with Type 2 Diabetes: Findings from a Phase 4, Randomized Controlled Trial.","Inoue M","2019","include_nma",null,"primary_report","P01",null,"mechanistic; crossover","high","first","opus-5.5-agent05","phase 4 single blind crossover RCT of dulaglutide 0.75 mg versus placebo on postprandial glucose with safety in Japanese type 2 diabetes",1],["R0023756","Efficacy and Safety of Liraglutide 3.0 mg in Patients with Overweight and Obese with or without Diabetes: A Systematic Review and Meta-Analysis.","Konwar M","2022","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent05","registered meta-analysis of placebo controlled RCTs of liraglutide 3.0 mg in overweight and obesity, named databases",1],["R0023924","Exenatide improves glucocorticoid-induced glucose intolerance in mice.","Zhao R","2011","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent05","single dose exenatide tested in glucocorticoid treated mice only",1],["R0024130","The gastrointestinal tract in hunger and satiety signalling.","Tack J","2021","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent05","narrative review of gastrointestinal hunger and satiety signalling",1],["R0024457","Achieving the composite end-point of glycated hemoglobin <7.0% without weight gain or hypoglycemia with once-weekly dulaglutide in Chinese patients with type 2 diabetes: A post-hoc analysis.","Xiao X","2020","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent05","post hoc analysis of AWARD-CHN1 and AWARD-CHN2 RCTs of dulaglutide versus glimepiride or glargine on composite endpoint",1],["R0011880","Comparative Efficacy and Safety of Weekly GLP-1/GIP Agonists vs. Weekly Insulin in Type 2 Diabetes: A Network Meta-Analysis of Randomized Controlled Trials.","Ayesh H","2024","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent15","registered network meta-analysis of 25 RCTs comparing weekly GLP-1 or GIP agonists and weekly insulins versus daily basal insulin",1],["R0011982","Cardiovascular Risk Reduction With Liraglutide: An Exploratory Mediation Analysis of the LEADER Trial.","Buse JB","2020","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent15","exploratory mediation analysis of LEADER RCT of liraglutide versus placebo on MACE in type 2 diabetes",1],["R0012084","Improvement of glycemic control and reduction of major cardiovascular events in 18 cardiovascular outcome trials: an updated meta-regression.","Maiorino MI","2021","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent15","systematic review and meta-regression of 18 cardiovascular outcome trials incl eight GLP-1 RA trials; five databases searched",1],["R0012168","MON-826 Impact Of Demographic And Social Determinants On Access To SGLT2 Inhibitors And GLP-1 Receptor Agonists: A Systematic Review And Meta-Analysis",null,"2025","exclude","E2","other",null,null,"abstract_only","high","first","opus-5.5-agent15","conference abstract meta-analysis of demographic disparities in SGLT2i and GLP-1 RA prescribing; utilization only, no drug effect contrast",1],["R0012279","Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail: a post hoc analysis.","Dagenais GR","2020","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent15","post hoc analysis of total cardiovascular events in REWIND RCT of dulaglutide versus placebo",1],["R0012376","Comparative efficacy of incretin drugs on glycemic control, body weight, and blood pressure in adults with overweight or obesity and with/without type 2 diabetes: a systematic review and network meta-analysis.","Liu S","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent15","registered systematic review and network meta-analysis of 24 RCTs of GLP-1 based multi receptor agonists in overweight or obesity",1],["R0012566","Effect of Anti-Diabetic Medication Use on Sepsis Risk in Type 2 Diabetes Mellitus: A Multivariate Analysis.","Ulambayar B","2025","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent15","hospital registry cohort of type 2 diabetes relating antidiabetic drug use incl GLP-1 RAs to sepsis risk; sepsis only",1],["R0014320","Effects of lixisenatide on elevated liver transaminases: systematic review with individual patient data meta-analysis of randomised controlled trials on patients with type 2 diabetes.","Gluud LL","2014","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent17","registered systematic review with individual patient data meta-analysis of lixisenatide RCTs on liver transaminases",1],["R0014402","Short-Term Combined Treatment With Tirzepatide and Metformin for Overweight/Obese Chinese Women With Polycystic Ovary Syndrome: A Prospective, Open-Label, Randomised Controlled Trial.","Yang Z","2026","include_nma",null,"primary_report","P12",null,null,"high","first","opus-5.5-agent17","open label RCT of tirzepatide plus metformin versus metformin in overweight Chinese women with PCOS, 16 weeks",1],["R0014501","Semaglutide 2.4 mg Cardiometabolic Long-Term Effects in Patients With Obesity or Overweight in a Real-World Setting: A Retrospective Cohort Study in the United States (SMILE).","Ruseva A","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent17","claims cohort of semaglutide 2.4 mg users versus non-users; cardiometabolic comorbidity, biomarker and ASCVD risk outcomes only",1],["R0014594","Systematic review of incretin therapy during peri-operative and intensive care.","Hulst AH","2018","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent17","registered systematic review of RCTs of incretin therapies including GLP-1 RAs in perioperative and ICU care",1],["R0014694","Real-World Clinical Experience of Semaglutide in Secondary Care Diabetes: A Retrospective Observational Study.","Williams DM","2021","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent17","retrospective single group evaluation of semaglutide in secondary care diabetes without comparison group",1],["R0014763","Effect of exenatide QW or placebo, both added to titrated insulin glargine, in uncontrolled type 2 diabetes: The DURATION-7 randomized study.","Guja C","2018","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent17","DURATION-7 placebo controlled RCT of exenatide once weekly added to titrated insulin glargine, 28 weeks",1],["R0014857","Superior efficacy with a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with insulin degludec and liraglutide in insulin-naïve Japanese patients with type 2 diabetes in a phase 3, open-label, randomized trial.","Kaku K","2019","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent17","open label RCT of IDegLira versus liraglutide or degludec in insulin naive Japanese type 2 diabetes, 52 weeks",1],["R0014937","Access Barriers and Variable Response to Semaglutide in Severe Adolescent Obesity: A Case Series.","Nguyen AT","2026","inventory_only","N5","other",null,null,null,"high","first","opus-5.5-agent18","case series of three adolescents with severe obesity treated with semaglutide; not a trial despite class",1],["R0015028","Association of novel antihyperglycaemic drugs versus metformin with COPD exacerbations.","Kimura Y","2025","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent18","Japanese active comparator new user cohorts GLP-1 RA, DPP-4i, SGLT2i vs metformin on COPD exacerbations; no listed harms",1],["R0015235","Subgroup analysis by sex and baseline BMI in people with a BMI ≥27 kg/m2 in the phase 2 trial of survodutide, a glucagon/GLP-1 receptor dual agonist.","le Roux CW","2025","include_nma",null,"secondary_report","P02",null,null,"high","first","opus-5.5-agent18","prespecified sex and BMI subgroup analysis of phase 2 RCT of survodutide doses vs placebo in obesity without diabetes",1],["R0015311","Effectiveness, Safety, and Appropriateness in the Use of the Fixed-Ratio Combination of Insulin Glargine and Lixisenatide in Type 2 Diabetes: The ENSURE Retrospective Real-World Study.","Candido R","2023","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent18","retrospective multicenter single arm cohort of iGlarLixi initiators; pre post HbA1c, no comparator",1],["R0015589","Superior HbA1c control with the fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with a maximum dose of 50 units of insulin degludec in Japanese individuals with type 2 diabetes in a phase 3, double-blind, randomized trial.","Watada H","2019","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent18","double blind RCT of IDegLira vs degludec capped at 50 U in Japanese T2D on insulin; HbA1c, weight",1],["R0015614","Six-month effects of liraglutide and dapagliflozin on lipid profile, cardiovascular risk, and NT-proBNP levels in patients with metabolic dysfunction-associated steatotic liver disease.","Cherniavskyi V","2026","include_nma",null,"primary_report","P09",null,null,"high","first","opus-5.5-agent04","randomized three arm trial of liraglutide vs dapagliflozin vs lifestyle control in MASLD over six months",1],["R0015838","Longitudinal changes in glycated haemoglobin following treatment intensification after inadequate response to two oral antidiabetic agents in patients with type 2 diabetes.","Kim K","2019","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent04","claims cohort of intensification with insulin, GLP-1 RA or third oral drug, HbA1c trajectory only",1],["R0016029","Current evidence on immune-driven depression.","Wessa C","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent04","narrative review of immune driven depression mentioning GLP-1 RA as emerging intervention",1],["R0016107","A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity.","Ji L","2023","include_nma",null,"primary_report","P02",null,null,"high","first","opus-5.5-agent04","phase 2 double blind RCT of mazdutide vs placebo in Chinese adults with overweight or obesity",1],["R0016196","Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events.","Ferdinand KC","2016","include_nma",null,"pooled_analysis","P01",null,null,"high","first","opus-5.5-agent04","sponsor meta-analysis of nine dulaglutide RCTs vs placebo or active comparators with adjudicated cardiovascular events, no systematic search",1],["R0010638","Cardiovascular, kidney related, and weight loss effects of therapeutics for type 2 diabetes: a living clinical practice guideline.","Agarwal A","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent11","BMJ living clinical practice guideline; evidence from a separately reported linked network meta-analysis",1],["R0010738","Immediate Glucose-Lowering Effect After the First Administration of Dulaglutide: A Retrospective, Single-Center, Observational Study.","Terui S","2021","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent11","retrospective single arm inpatient series after first dulaglutide dose; no comparator",1],["R0010808","The efficacy and safety of novel classes of glucose-lowering drugs for cardiovascular outcomes: a network meta-analysis of randomised clinical trials.","Lin DS","2021","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent11","registered network meta-analysis of RCTs of SGLT2i, GLP-1RA and DPP-4i on cardiovascular outcomes; three named databases",1],["R0010901","A roadmap to achieve pharmacological precision medicine in diabetes.","Florez JC","2022","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent11","narrative perspective on precision medicine roadmap in diabetes",1],["R0010976","The Impact of Substantial Improvements in HbA1c and Weight Loss on the Medication Preferences of People with Type 2 Diabetes.","Gelhorn HL","2023","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent11","online discrete choice survey of treatment preferences; no GLP-1RA exposure studied",1],["R0017417","Enhancing future liver remnant hypertrophy: innovative preoperative strategies and emerging technologies.","Ren Y","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent06","narrative review of strategies to enhance future liver remnant hypertrophy before hepatectomy",1],["R0017516","Effects of GLP-1 receptor agonists on asprosin levels in normal weight or overweight/obesity patients with type 2 diabetes mellitus.","Dai C","2022","inventory_only","N1","primary_report",null,null,null,"high","first","opus-5.5-agent06","nonrandomized prospective single arm liraglutide study in T2D on asprosin with untreated normal glucose controls",1],["R0017594","Effect of semaglutide 2.4 mg on use of antihypertensive and lipid-lowering treatment in five randomized controlled STEP trials.","Tchang BG","2025","include_nma",null,"pooled_analysis","P02; P01",null,null,"high","first","opus-5.5-agent06","post hoc pooled analysis of STEP 1, 2, 3, 6 and 8 RCTs of semaglutide 2.4 mg versus placebo on antihypertensive and lipid drug use",1],["R0017712","Real-World Usage of Once-Daily Oral Semaglutide in Adults with Type 2 Diabetes: Findings from PIONEER REAL India.","Sanyal D","2025","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent06","PIONEER REAL India noninterventional single arm cohort of oral semaglutide in T2D; no comparison group",1],["R0017819","The Potential of Semaglutide Once-Weekly in Patients Without Type 2 Diabetes with Weight Regain or Insufficient Weight Loss After Bariatric Surgery-a Retrospective Analysis.","Lautenbach A","2022","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent06","retrospective single group study of semaglutide for weight regain after bariatric surgery; not randomized",1],["R0017895","Exit Interviews Examining the Patient Experience in Clinical Trials of Tirzepatide for Treatment of Type 2 Diabetes.","Matza LS","2022","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent06","qualitative exit interviews of SURPASS tirzepatide participants; no exposure comparison",1],["R0018111","Use of Tirzepatide in Adults with Type 2 Diabetes Mellitus: Scientific Evidence and Practical Aspects.","Vázquez LA","2024","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent06","expert consensus review of practical aspects of tirzepatide use in T2D",1],["R0016534","The cardiovascular safety of incretin-based therapies: a review of the evidence.","Petrie JR","2013","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent12","narrative review of cardiovascular safety of incretin based therapies",1],["R0016631","Comparative analysis of the efficacies of probiotic supplementation and glucose-lowering drugs for the treatment of type 2 diabetes: A systematic review and meta-analysis.","Liang T","2022","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent12","PRISMA SR and meta-analysis of RCTs of probiotics and glucose lowering drugs including GLP-1RAs in T2D",1],["R0016715","Associations of body mass index on worsening of heart failure and mortality in patients with heart failure and reduced left ventricular ejection fraction: a 10-year follow-up study (a NorthStar substudy).","Malmborg M","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent12","registry follow up of HFrEF trial cohort by BMI category, no GLP-1RA exposure studied",1],["R0016831","Real-world use of tirzepatide among individuals without evidence of type 2 diabetes: Results from the Veradigm® database.","Hunter Gibble T","2025","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent12","descriptive EHR study of tirzepatide prescribing, dosing and persistence in people without T2D, no exposure comparison",1],["R0016941","Cost-effectiveness analysis of IDegLira versus basal-bolus insulin for patients with type 2 diabetes in the Slovak health system.","Psota M","2017","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent12","cost effectiveness modeling of IDegLira vs basal bolus insulin in Slovakia",1],["R0017010","How Effective Is the Fixed-Ratio Combination of Insulin Degludec and Liraglutide (IDegLira) in Different Patient Populations, and When Should It Be Used in Clinical Practice?","Tibaldi J","2020","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent12","focused narrative review of IDegLira DUAL program with two clinical cases",1],["R0017117","A multicenter, prospective, real-world study of oral semaglutide in adults with type 2 diabetes in Japanese clinical practice (PIONEER REAL Japan): Subgroup analyses.","Yabe D","2025","inventory_only","N5","secondary_report","P01",null,null,"high","first","opus-5.5-agent12","subgroup analyses of single arm noninterventional PIONEER REAL Japan study of oral semaglutide",1],["R0017239","Once-Weekly Semaglutide Versus Sodium-Glucose Co-transporter 2 Inhibitors: Real-World Impact on Weight, HbA1c, and Healthcare Resource Utilization in Type 2 Diabetes (PAUSE).","Amamoo J","2025","inventory_only","N6","primary_report","P01",null,null,"high","first","opus-5.5-agent12","claims and EMR weighted cohort of semaglutide vs SGLT2i initiators in T2D, weight, HbA1c and resource use",1],["R0013433","EQ-5D health utility gains with once-weekly semaglutide 2.4 mg in people with MASH and F2/F3 fibrosis: An analysis of ESSENCE.","Augusto M","2026","include_nma",null,"secondary_report","P09",null,null,"high","first","opus-5.5-agent02","exploratory EQ-5D analysis of ESSENCE placebo controlled RCT of semaglutide 2.4 mg in MASH with F2 or F3 fibrosis",1],["R0013522","Effect of liraglutide on body weight and pain in patients with overweight and knee osteoarthritis: protocol for a randomised, double-blind, placebo-controlled, parallel-group, single-centre trial.","Gudbergsen H","2019","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent02","protocol of placebo controlled RCT of liraglutide 3 mg in overweight knee osteoarthritis",1],["R0013596","418 Activation of the Glucagon-Like Peptide-1 Pathway in Obese Pre-Diabetic Individuals Improves Endothelial Function Independently of Weight Loss","Mashayekhi M",null,"include_nma",null,"conference_abstract","P02",null,"mechanistic; abstract_only","high","first","opus-5.5-agent02","conference abstract of RCT of liraglutide vs sitagliptin vs hypocaloric diet in obesity with prediabetes; weight and endothelial outcomes",1],["R0013705","An Indirect Treatment Comparison of Semaglutide 2.0 mg vs Dulaglutide 3.0 mg and 4.5 mg Using Multilevel Network Meta-regression.","Lingvay I","2022","include_nma",null,"pooled_analysis","P01",null,null,"high","first","opus-5.5-agent02","sponsor multilevel network meta-regression of SUSTAIN FORTE, SUSTAIN 7 and AWARD-11 RCTs without systematic search",1],["R0013792","MON-189 Comparative Effectiveness of GLP-1 Analogues and Metformin in Managing Polycystic Ovarian Syndrome: Insights from a Propensity-Matched Cohort Study",null,"2025","inventory_only","N6","conference_abstract",null,null,"abstract_only","high","first","opus-5.5-agent02","conference abstract of TriNetX cohort GLP-1 RA vs metformin in PCOS; reproductive, endocrine, anxiety and depression outcomes only",1],["R0013901","SAT-621 Real World Utilization of GLP-1 Agonists in Adolescents and Young Adults With Type 1 Diabetes (T1D) and Obesity",null,"2025","inventory_only","N5","conference_abstract",null,null,"abstract_only","high","first","opus-5.5-agent02","conference abstract of retrospective single group GLP-1 RA use in young people with type 1 diabetes and obesity",1],["R0013977","Efficacy and Safety of Twincretin Survodutide, a Dual Glucagon-Like Peptide-1 and Glucagon Receptor Agonist as an Anti-Obesity and Anti-Diabetes Medication: A Systematic Review and Meta-Analysis.","Dutta D","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent02","registered systematic review and meta-analysis of survodutide RCTs vs placebo or active control",1],["R0014056","Improved glycaemia correlates with liver fat reduction in obese, type 2 diabetes, patients given glucagon-like peptide-1 (GLP-1) receptor agonists.","Cuthbertson DJ","2012","inventory_only","N1","primary_report",null,null,null,"high","first","opus-5.5-agent02","prospective single group study of six months exenatide or liraglutide on liver fat in obese T2D; no control",1],["R0014964","Real-Life Data of Tirzepatide Use to Support Lifestyle Modification in Patients with Metabolic Syndrome.","Śledziona J","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent07","retrospective primary care comparison of tirzepatide plus dietary education vs education alone in metabolic syndrome; no listed harm",1],["R0015062","Real-World Effectiveness and Safety of Escalating Once-Weekly Semaglutide from 0.5 to 1.0 mg in Type 2 Diabetes.","Sato G","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent07","retrospective single group cohort of semaglutide escalation from 0.5 to 1.0 mg with within patient changes",1],["R0015269","Exenatide induces frataxin expression and improves mitochondrial function in Friedreich ataxia.","Igoillo-Esteve M","2020","inventory_only","N1","primary_report",null,null,null,"high","first","opus-5.5-agent07","mouse and stem cell experiments plus an open label uncontrolled pilot of exenatide in Friedreich ataxia patients",1],["R0015358","Hypoglycemia Abrogates the Vascular Endothelial Protective Effect of Exenatide in Type 2 Diabetes Mellitus.","Torimoto K","2019","inventory_only","N1","primary_report",null,null,null,"high","first","opus-5.5-agent07","nonrandomized fixed sequence meal tests without then with single dose exenatide in 17 T2D patients",1],["R0015517","Managing weight and glycaemic targets in people with type 2 diabetes-How far have we come?","Blüher M","2022","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent07","narrative review of weight and glycemic targets in type 2 diabetes with a simple PubMed search",1],["R0015093","Circulating GDF15 and HbA1c Response to Add-On Exenatide Therapy in Type 2 Diabetes: A Post Hoc Analysis from a Multicenter Trial.","Wu Q","2026","inventory_only","N1","secondary_report",null,null,null,"high","first","opus-5.5-agent13","post hoc analysis of single arm multicenter trial where all participants received add-on exenatide for 16 weeks",1],["R0015290","Survodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials (SYNCHRONIZE™-1 and -2).","Wharton S","2025","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent13","rationale and design paper of SYNCHRONIZE-1 and -2 placebo controlled survodutide RCTs",1],["R0015460","Successful treatment of binge eating disorder with the GLP-1 agonist semaglutide: A retrospective cohort study.","Richards J","2023","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent13","retrospective cohort semaglutide vs other anti-obesity drugs in binge eating disorder, binge eating scores only",1],["R0015554","Novel Plasma Proteomics and Phosphoproteomics Platform Captures Pleiotropic Cardiometabolic Spectrum Effects of Semaglutide in Patients with T2D and Atherosclerosis: A Companion Diagnostic Pilot Study from the STOP (Semaglutide Treatment On coronary atherosclerosis Progression) Randomized Trial","Manousopoulou A","2026","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent13","proteomics substudy of STOP placebo controlled RCT of semaglutide in type 2 diabetes with atherosclerosis",1],["R0015677","Effect of liraglutide on cardiometabolic profile and on bioelectrical impedance analysis in patients with obesity and metabolic syndrome.","Freitas FPC","2023","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent13","prospective nonrandomized comparison of liraglutide vs sibutramine in obesity with metabolic syndrome, no harms outcome",1],["R0014336","Risk factors for COVID-19 case fatality rate in people with type 1 and type 2 diabetes mellitus: A nationwide retrospective cohort study of 235,248 patients in the Russian Federation.","Shestakova MV","2022","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent01","registry cohort of COVID-19 case fatality in diabetes with GLP-1 RA among drug exposures; death only, no listed harm",1],["R0014510","Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4.","Arakawa M","2010","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent01","exendin-4 infusion in mice and in vitro macrophage and monocyte experiments; preclinical only",1],["R0014713","Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with kidney outcomes in patients with type 2 diabetes: A systematic review and network meta-analysis.","Yang S","2022","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent01","registered Bayesian network meta-analysis of SGLT2i, GLP-1 RA and DPP-4i RCTs on kidney outcomes and AKI",1],["R0014773","Oral Semaglutide and Heart Failure Outcomes in Persons With Type 2 Diabetes: A Secondary Analysis of the SOUL Randomized Clinical Trial.","Pop-Busui R","2026","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent01","secondary heart failure analysis of SOUL RCT, oral semaglutide versus placebo in type 2 diabetes with ASCVD or CKD",1],["R0014882","Effect of once-weekly dulaglutide on glycated haemoglobin (HbA1c) and fasting blood glucose in patient subpopulations by gender, duration of diabetes and baseline HbA1c.","Gallwitz B","2018","include_nma",null,"pooled_analysis","P01",null,null,"high","first","opus-5.5-agent01","pooled subgroup analysis of AWARD-1 to 6 and 8 RCTs of dulaglutide versus placebo or active comparators",1],["R0014946","Real-World Cohort Study of Semaglutide in Adults with Type 2 Diabetes Using an Electronic Health Records Database in Tianjin, China.","Wang S","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent01","SCHOLAR retrospective single group EHR cohort of semaglutide initiators with before and after HbA1c",1],["R0024725","Abstract 34: Time spent in glycemic control after initiating treatment with oral semaglutide versus empagliflozin: An exploratory analysis of the PIONEER 2 trial",null,"2022","include_nma",null,"conference_abstract","P01",null,"abstract_only","high","first","opus-5.5-agent05","abstract of exploratory PIONEER 2 analysis of oral semaglutide versus empagliflozin on time in glycemic control",1],["R0024871","Atorvastatin reduces alloxan-induced impairment of aversive stimulus memory in mice.","Kukula O","2022","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent05","atorvastatin and liraglutide tested in alloxan diabetic mice only",1],["R0024974","MON-120 Effect of Weight Loss on Physical Function Measured by the 6-Minute Walking Distance Test in Individuals with Obesity: Results from the SCALE IBT Trial of Liraglutide 3.0 Mg","Rubino D","2019","include_nma",null,"conference_abstract","P02",null,"abstract_only","high","first","opus-5.5-agent05","abstract of post hoc SCALE IBT analysis of liraglutide 3.0 mg versus placebo with behavior therapy on walking distance",1],["R0025102","Effect of metformin versus metformin plus liraglutide on gonadal and metabolic profiles in overweight patients with polycystic ovary syndrome.","Xing C","2022","include_nma",null,"primary_report","P12",null,null,"high","first","opus-5.5-agent05","12 week RCT of metformin plus liraglutide versus metformin alone in overweight women with PCOS",1],["R0025215","Clinical effectiveness of liraglutide vs basal insulin in a real-world setting: Evidence of improved glycaemic and weight control in obese people with type 2 diabetes.","Overbeek JA","2018","inventory_only","N6","other",null,null,null,"high","first","opus-5.5-agent05","PHARMO matched cohort liraglutide versus basal insulin in obese type 2 diabetes on HbA1c and weight; no listed harm",1],["R0025398","Efficacy and safety of liraglutide versus sitagliptin both in combination with metformin in patients with type 2 diabetes: A systematic review and meta-analysis.","Li M","2017","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent05","meta-analysis of RCTs of liraglutide versus sitagliptin with metformin searching five named databases",1],["R0025560","Exenatide Treatment Causes Suppression of Serum Ghrelin Levels following Mixed Meal Test in Obese Diabetic Women.","Topyildiz F","2016","inventory_only","N1","other",null,null,null,"high","first","opus-5.5-agent05","nonrandomized on versus 24 hour off exenatide meal test in 14 women; ghrelin and glucose only, no concurrent comparison",1],["R0025718","Effects of Liraglutide Combined with Insulin on Oxidative Stress and Serum MCP-1 and NF-kB Levels in Type 2 Diabetes.","Liu X","2019","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent05","RCT of liraglutide plus insulin versus insulin alone in type 2 diabetes on glucose and oxidative stress markers",1],["R0013582","Efficacy and safety of GLP-1 agonists in Parkinson's disease: a systematic review and meta-analysis of randomized controlled trials.","Messak M","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent19","meta-analysis of RCTs of GLP-1 RA vs placebo or conventional care in Parkinson disease; six named databases, PROSPERO",1],["R0013695","Glucagon-like peptide-1 receptor activation and mental health: a drug-target mendelian randomization study.","Yang G","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent19","drug target Mendelian randomization of genetic GLP-1 receptor activation and mental health; no drug exposure",1],["R0013888","Real-world use of once-weekly semaglutide in patients with type 2 diabetes at an outpatient clinic in Spain.","Garcia de Lucas MD","2022","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent19","retrospective cohort of semaglutide initiators split by prior GLP-1 RA use; no non semaglutide comparison group",1],["R0013974","The Nephroprotective Effects of Dulaglutide in Patients with Type 2 Diabetes and Chronic Kidney Disease: A Multicenter Saudi Arabian Study.","Jamal MH","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent19","retrospective single group cohort of dulaglutide in diabetic CKD with paired before and after comparisons",1],["R0014229","Efficacy and safety of dulaglutide monotherapy compared with glimepiride in East-Asian patients with type 2 diabetes in a multicentre, double-blind, randomized, parallel-arm, active comparator, phase III trial.","Chen YH","2018","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent19","double blind phase 3 RCT of dulaglutide 1.5 and 0.75 mg vs glimepiride in East Asian type 2 diabetes",1],["R0016665","Reasons for discontinuation of GLP1 receptor agonists: data from a real-world cross-sectional survey of physicians and their patients with type 2 diabetes.","Sikirica MV","2017","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent20","cross sectional physician and patient survey of reasons for GLP-1 RA discontinuation, no exposure comparison",1],["R0016768","Clinical Profile and Prognosis of Patients With Acute Decompensated Heart Failure Who Met the Obesity-Related Eligibility for Subcutaneous Semaglutide　- Findings From the CURE-HF Registry.","Nishikawa K","2025","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent20","heart failure registry comparing patients by eligibility for semaglutide, no semaglutide exposure studied",1],["R0016968","Dapagliflozin restores odour-induced functional integration of primary olfactory cortex circuit but not olfactory-related regional brain activation in patients with type 2 diabetes: A 16-week randomised comparative study.","Li X","2025","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent20","open label RCT of dapagliflozin vs liraglutide vs acarbose added to metformin in T2D with olfactory fMRI",1],["R0017066","Efficacy of dulaglutide on vascular health indexes in subjects with type 2 diabetes: a randomized trial.","Tuttolomondo A","2021","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent20","RCT of dulaglutide plus usual therapy vs usual therapy alone in T2D on vascular indexes and HbA1c",1],["R0017160","Optic disc edema during semaglutide therapy: case report and literature review.","Yang T","2025","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent20","case report of two semaglutide treated trial participants with optic disc edema plus literature review",1],["R0017289","MON-829 Sex-Specific Cardiometabolic Benefits of Tirzepatide: A Real-World Study on ASCVD Risk Mitigation",null,"2025","inventory_only","N5","conference_abstract",null,null,"abstract_only","high","first","opus-5.5-agent20","abstract of retrospective single arm tirzepatide cohort on ASCVD risk scores, no comparison group",1],["R0017401","Effect of additional treatment with EXenatide in patients with an Acute Myocardial Infarction (EXAMI): study protocol for a randomized controlled trial.","Scholte M","2011","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent20","protocol of placebo controlled EXAMI RCT of exenatide infusion in acute MI",1],["R0014985","Acute GLP-1 infusion in male adults lowers circulating angiotensin II without changing angiotensinogen, ACE, ACE2, or angiotensin-(1-7) concentrations.","Asmar A","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent08","post hoc analysis of native GLP-1 infusion versus vehicle in healthy men; native hormone not a therapeutic agonist",1],["R0015063","Change in pharmacodynamic variables following once-weekly tirzepatide treatment versus dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono substudy).","Yabe D","2023","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent08","SURPASS J-mono substudy of randomized tirzepatide doses versus dulaglutide on meal test and body composition",1],["R0015190","Comparative effectiveness of long-term anti-obesity medications in routine clinical practice: a retrospective cohort study using real-world data.","Kim CG","2025","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent08","Korean retrospective cohort comparing orlistat, phentermine topiramate and liraglutide on weight, HbA1c and persistence",1],["R0015273","Semaglutide and cardiovascular risk in type 1 diabetes: A predictive modelling analysis in a double-blind, randomised, placebo-controlled cross-over trial.","Kugathasan L","2026","include_nma",null,"secondary_report","P05",null,"crossover","high","first","opus-5.5-agent08","letter reporting secondary analysis of crossover RCT of semaglutide versus placebo in type 1 diabetes on predicted CVD risk",1],["R0015368","Sustained-Release Intra-Articular Drug Delivery: PLGA Systems in Clinical Context and Evolving Strategies.","Lee JW","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent08","narrative review of PLGA intra-articular sustained release systems",1],["R0015439","Racial Inequity in Prescription of Semaglutide Among Eligible People With HIV.","Hahn AW","2025","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent08","CNICS study of racial differences in semaglutide prescribing among people with HIV; utilization outcome",1],["R0015637","6926 Subgroup Analysis by Gender and Body Mass Index (BMI) in People Living With Overweight/Obesity in the Survodutide, a Glucagon/GLP-1 Receptor Dual Agonist, Phase II Trial",null,"2024","include_nma",null,"conference_abstract","P02",null,"abstract_only","high","first","opus-5.5-agent08","abstract of subgroup analysis of phase 2 RCT of survodutide doses versus placebo in obesity without diabetes",1],["R0015795","Clinical and metabolic profile of adults with obesity attending lifestyle medicine clinics.","AlTaib HN","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent18","retrospective matched cohort of liraglutide plus lifestyle vs lifestyle alone in obesity clinics; BMI, HbA1c, BP only",1],["R0015894","Pharmacological treatment options for metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes mellitus: A systematic review.","Konings LAM","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent18","PRISMA systematic review of T2D drugs including GLP-1 RAs in MASLD with T2D; MEDLINE, Cochrane, CINAHL searched",1],["R0015995","Efficacy and safety of once-weekly tirzepatide in Japanese participants with type 2 diabetes who have obesity or overweight: Subpopulation analysis of the SURMOUNT-2 trial.","Yamauchi T","2025","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent18","Japanese subpopulation analysis of SURMOUNT-2 double blind RCT, tirzepatide 10 and 15 mg vs placebo in obesity with T2D",1],["R0016078","Evaluation of the long-term cost-effectiveness of once-weekly semaglutide versus dulaglutide for treatment of type 2 diabetes mellitus in the UK.","Viljoen A","2019","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent18","cost effectiveness modeling of semaglutide vs dulaglutide in UK using CORE Diabetes Model",1],["R0016162","Effects of Antidiabetic Drugs on Endothelial Function in Patients With Type 2 Diabetes Mellitus: A Bayesian Network Meta-Analysis.","Wang Y","2022","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent18","Bayesian NMA of RCTs of antidiabetic drugs including GLP-1 RAs on flow mediated dilation; eight databases",1],["R0016263","Weight reduction over time in tirzepatide-treated participants by early weight loss response: Post hoc analysis in SURMOUNT-1.","Ard J","2025","include_nma",null,"secondary_report","P02",null,null,"high","first","opus-5.5-agent18","post hoc analysis of SURMOUNT-1 RCT by early weight response among tirzepatide arms; dose groups compared",1],["R0016387","Preliminary evidence of improved liver biomarkers in adolescents with obesity and suspected metabolic dysfunction-associated steatotic liver disease treated with semaglutide: A case series.","Schenker R","2026","inventory_only","N5","other",null,null,null,"high","first","opus-5.5-agent18","retrospective case series of five adolescents with obesity and suspected MASLD on semaglutide",1],["R0016600","Comparative effectiveness of Chinese herbal medicine versus liraglutide for weight loss in adults with obesity: A 12-month real-world target trial emulation study.","Liao YN","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent03","target trial emulation Chinese herbal formula vs liraglutide for weight loss in obesity; weight outcomes only",1],["R0016682","Adding Semaglutide to SGLT2 Inhibitors Reduces Liver Enzymes in Patients with Type 2 Diabetes Complicated by Metabolic Dysfunction Associated Steatotic Liver Disease: A Retrospective Observational Study.","Sato K","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent03","retrospective single group before and after study of semaglutide added to SGLT2i in T2D with MASLD",1],["R0016776","Effect of semaglutide versus placebo on cardiorenal outcomes by prior cardiovascular disease and baseline body mass index: Pooled post hoc analysis of SUSTAIN 6 and PIONEER 6.","Zhou J","2025","include_nma",null,"pooled_analysis","P01",null,null,"high","first","opus-5.5-agent03","pooled post hoc analysis of SUSTAIN 6 and PIONEER 6 RCTs, semaglutide vs placebo cardiorenal outcomes",1],["R0016891","Kidney Parameters with Tirzepatide in Obesity with or without Type 2 Diabetes.","Heerspink HJL","2025","include_nma",null,"secondary_report","P02; P01",null,null,"high","first","opus-5.5-agent03","post hoc kidney analysis of SURMOUNT-1 and SURMOUNT-2 RCTs, tirzepatide vs placebo",1],["R0016983","Choice of Treatment Regimen as Add-On to Insulin in Japanese Patients with Type 2 Diabetes Mellitus: Physicians' Perspective in a Real-World Setting, Insight from a Web Survey.","Imai K","2018","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent03","web survey of Japanese physicians on add-on drug choices to insulin; no patient exposure comparison",1],["R0017072","IDegLira improves patient-reported outcomes while using a simple regimen with fewer injections and dose adjustments compared with basal-bolus therapy.","Miller E","2019","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent03","post hoc analysis of DUAL VII RCT, IDegLira vs basal bolus insulin; injections, dose adjustments, PROs",1],["R0017182","Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes: A Long-Term Cost-Effectiveness Analysis in Estonia.","Malkin SJP","2019","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent03","CORE Diabetes Model cost effectiveness analysis of semaglutide vs liraglutide in Estonia",1],["R0017310","Switching from Multiple Insulin Injections to a Fixed Combination of Degludec and Liraglutide in Patients with Type 2 Diabetes Mellitus: Results from the Simplify Study After 6 Months.","Martinka E","2023","inventory_only","N1","primary_report",null,null,null,"high","first","opus-5.5-agent03","prospective single arm interventional study switching basal bolus insulin to IDegLira, no comparator",1],["R0015783","Impact of Oral Semaglutide on Kidney Outcomes in People With Type 2 Diabetes: Results From the SOUL Randomized Trial.","Mann JFE","2026","include_nma",null,"secondary_report","P01; P08A",null,null,"high","first","opus-5.5-agent16","prespecified kidney outcome analysis of SOUL RCT of oral semaglutide vs placebo in T2D, with eGFR below 60 subgroup",1],["R0015888","Efficacy and safety of GLP-1 receptor agonists as add-on to SGLT2 inhibitors in type 2 diabetes mellitus: A meta-analysis.","Castellana M","2019","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent16","PROSPERO registered systematic review and meta-analysis of GLP-1RA added to SGLT2i RCTs; six databases named",1],["R0015989","Cost-effectiveness of weight-management pharmacotherapies in Canada: a societal perspective.","Olivieri AV","2024","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent16","cost effectiveness model of weight management drugs including semaglutide and liraglutide in Canada",1],["R0016159","Efficacy and safety of once-weekly dulaglutide in combination with sulphonylurea and/or biguanide compared with once-daily insulin glargine in Japanese patients with type 2 diabetes: a randomized, open-label, phase III, non-inferiority study.","Araki E","2015","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent16","open label phase 3 RCT of dulaglutide vs insulin glargine in Japanese T2D",1],["R0016253","A model-based simulation of glycaemic control and body weight when switching from semaglutide to 3.0- and 4.5-mg doses of once-weekly dulaglutide.","Tham LS","2022","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent16","exposure response simulation of switching from semaglutide to high dose dulaglutide; modeled outcomes only",1],["R0016374","Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study.","Nahra R","2021","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent16","phase 2b RCT of cotadutide vs placebo vs open label liraglutide in T2D with overweight or obesity",1],["R0016472","Preventing obesity-related cancer with the revolution in obesity management: the challenges of undertaking a clinical trial and potential solutions.","Harris M","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent16","perspective review on designing cancer prevention trials of GLP-1 based drugs",1],["R0017348","7625 Functional and structural neuronal changes of dulaglutide compared to placebo during smoking cessation - a randomized placebo-controlled trial",null,"2024","include_nma",null,"conference_abstract","P14B",null,"abstract_only","high","first","opus-5.5-agent12","conference abstract of fMRI substudy of RCT dulaglutide vs placebo with varenicline for smoking cessation",1],["R0017455","Effect of semaglutide on arrhythmic, major cardiovascular, and renal outcomes in patients with overweight or obesity: a systematic review and meta-analysis.","Wu R","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent12","registered SR and meta-analysis of semaglutide RCTs vs control on arrhythmic, CV and renal outcomes in obesity",1],["R0017528","Comparative efficacy and safety profile of once-weekly Semaglutide versus once-daily Sitagliptin as an add-on to metformin in patients with type 2 diabetes: a systematic review and meta-analysis.","Patel T","2023","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent12","PRISMA meta-analysis of RCTs of semaglutide vs sitagliptin added to metformin in T2D",1],["R0017735","Response to the letter titled \"Comment on associations of semaglutide with first-time diagnosis of Alzheimer's disease in patients with type 2 diabetes: Target trial emulation using nationwide real-world data in the US\".","Xu R","2025","inventory_only","N9","ancillary",null,null,null,"high","first","opus-5.5-agent12","authors reply to comment on their semaglutide Alzheimer disease target trial emulation, an inventory study",1],["R0017927","Short-Term Effects of Tirzepatide in Obese Adults: A Real-World Prospective Study.","Adamidis N","2025","inventory_only","N5","primary_report","P02",null,null,"high","first","opus-5.5-agent12","prospective observational single group of tirzepatide initiators, short term body composition",1],["R0018048","First-in-Human Evaluation of Positron Emission Tomography/Computed Tomography With [18F]FB(ePEG12)12-Exendin-4: A Phase 1 Clinical Study Targeting GLP-1 Receptor Expression Cells in Pancreas.","Fujimoto H","2021","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent12","first in human PET imaging with radiolabeled exendin-4 tracer in healthy men, diagnostic not therapeutic",1],["R0012154","Beta cell function and mass in individuals with and without remission of type 2 diabetes after Roux-en-Y gastric bypass.","Tokgöz S","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent10","PET study of beta cell mass after gastric bypass using exendin 4 tracer; no therapeutic GLP-1 RA exposure",1],["R0012259","Treatment Intensification in Type 2 Diabetes: A Real-World Study of 2-OAD Regimens, GLP-1 RAs, or Basal Insulin.","Blonde L","2018","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent10","MarketScan cohorts initiating two OADs, GLP-1 RA or basal insulin; HbA1c and costs only, no harms_nrs outcome",1],["R0012338","A treat-to-target approach for obesity management: A post hoc analysis of the SURMOUNT-5 trial.","le Roux CW","2026","include_nma",null,"secondary_report","P02",null,null,"high","first","opus-5.5-agent10","post hoc of SURMOUNT-5 RCT tirzepatide versus semaglutide in obesity; proportions reaching treat to target thresholds",1],["R0012551","Medication Optimization Among People With Type 2 Diabetes Participating in a Continuous Glucose Monitoring-Driven Virtual Care Program: Prospective Study.","Majithia AR","2022","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent10","single arm virtual care program study describing medication changes including GLP-1 RA uptake; no exposure comparison",1],["R0012635","Trends in glycemic control in patients with insulin therapy compared with non-insulin or no drugs in type 2 diabetes in Japan: a long-term view of real-world treatment between 2002 and 2018 (JDDM 66).","Yokoyama H","2022","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent10","serial cross sectional study of diabetes treatment patterns and HbA1c by insulin use; no GLP-1 RA exposure comparison",1],["R0012721","Reduced insulin use and diabetes complications upon introduction of SGLT-2 inhibitors and GLP1-receptor agonists in low- and middle-income countries: A microsimulation.","Global Health & Population Project on Access to Care for Cardiometabolic Diseases (HPACC)","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent10","microsimulation of adding GLP-1 RA or SGLT2i in insulin users in LMICs; modeling study",1],["R0012799","Effect of sex on sodium-glucose co-transporter-2 antagonists and glucagon-like peptide-1 agonists in heart failure.","Philip MA","2024","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent10","PROSPERO registered meta-analysis of SGLT2i and GLP-1 RA RCTs in heart failure by sex; MEDLINE Embase Cochrane",1],["R0014936","Does GLP-1 receptor agonist liraglutide alter food-related sensory pleasure in patients with obesity? A randomized controlled trial","Coppin G","2022","include_nma",null,"primary_report","P02",null,"mechanistic","high","first","opus-5.5-agent17","preprint of placebo controlled RCT of liraglutide in obesity without diabetes on food reward brain responses; weight likely reported",1],["R0015027","The Bounce-back Effect: What Happens After Cessation of Low-dose Semaglutide in People With HIV.","Erlandson KM","2026","inventory_only","N1","extension",null,null,null,"high","first","opus-5.5-agent17","single arm semaglutide trial in people with HIV and MASLD describing weight regain after stopping",1],["R0015143","Cost-Utility Analysis of Once-Weekly Semaglutide, Dulaglutide, and Exenatide for Type 2 Diabetes Patients Receiving Metformin-Based Background Therapy in China.","Hu S","2022","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent17","UKPDS outcomes model cost utility analysis of weekly GLP-1 RAs in China",1],["R0015234","Semaglutide for the treatment of overweight and obesity: A review.","Bergmann NC","2023","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent17","narrative review of the STEP semaglutide obesity trial program",1],["R0015309","Exenatide Is Neuroprotective in a New Rabbit Model of Hypoxia-Ischemia.","Rocha-Ferreira E","2025","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent17","rabbit kit hypoxia ischemia model treated with exenatide",1],["R0015391","Comparative outcomes of heart failure among existent classes of anti-diabetic agents: a network meta-analysis of 171,253 participants from 91 randomized controlled trials.","Yang DY","2019","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent17","registered network meta-analysis of RCTs of antidiabetic drug classes including GLP-1 RAs on heart failure outcomes",1],["R0015468","Semaglutide for prevention of type 2 diabetes in women with postpartum prediabetes after gestational diabetes: protocol for a Belgian multicentre double-blind randomised placebo-controlled trial.","Vanlaer Y","2026","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent17","protocol of SERENA placebo controlled RCT of semaglutide for postpartum prediabetes after gestational diabetes",1],["R0015577","Survodutide, a glucagon receptor/glucagon-like peptide-1 receptor dual agonist, improves blood pressure in adults with obesity: A post hoc analysis from a randomized, placebo-controlled, dose-finding, phase 2 trial.","le Roux CW","2025","include_nma",null,"secondary_report","P02",null,null,"high","first","opus-5.5-agent17","post hoc blood pressure analysis of placebo controlled phase 2 RCT of survodutide doses in obesity without diabetes; letter format",1],["R0015679","Causal Inference in Non-Allergic Asthma Associated with Obesity: Application of the Bradford Hill Viewpoints to a Complex Epidemiological Association.","Leija-Martinez JJ","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent14","structured narrative review applying Bradford Hill viewpoints to obesity and asthma",1],["R0015770","The Use of Exenatide in Managing Markers of Cardiovascular Risk in Patients with Type 2 Diabetes: A Systematic Review.","Ojo O","2016","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent14","systematic review of RCTs of exenatide twice daily on cardiovascular risk markers, EBSCOhost databases with PICO criteria",1],["R0015879","Emulating the LEADER trial in China: a regulatory science case study on non-interventional research.","Zhao J","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent14","target trial emulation of LEADER with liraglutide vs DPP-4i new users in Beijing claims, MACE only",1],["R0016057","Effects of first-line antidiabetic drugs on the improvement of arterial stiffness: A Bayesian network meta-analysis.","Wang J","2023","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent14","Bayesian network meta-analysis of RCTs of antidiabetic drugs including GLP-1 RA on arterial stiffness",1],["R0016145","Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L).","Riddle MC","2013","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent14","GetGoal-L placebo controlled RCT of lixisenatide added to basal insulin in T2D, 24 weeks",1],["R0016365","Exenatide extended-release; clinical trials, patient preference, and economic considerations.","Doggrell SA","2013","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent14","narrative review of exenatide extended release trials, preference and economics",1],["R0011365","Influence of the combination of SGLT2 inhibitors and GLP-1 receptor agonists on eGFR decline in type 2 diabetes: post-hoc analysis of RECAP study.","Muta Y","2024","inventory_only","N6","secondary_report",null,null,null,"high","first","opus-5.5-agent11","RECAP post hoc comparing GLP-1RA first versus SGLT2i first before combination; eGFR decline only",1],["R0011466","Exenatide once weekly over 2 years as a potential disease-modifying treatment for Parkinson's disease: protocol for a multicentre, randomised, double blind, parallel group, placebo controlled, phase 3 trial: The 'Exenatide-PD3' study.","Vijiaratnam N","2021","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent11","protocol of Exenatide-PD3 placebo controlled phase 3 RCT in Parkinson disease; no results",1],["R0012152","Obesity Medication Treatment Perspectives Among People with Overweight or Obesity.","Ostrominski JW","2025","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent09","cross sectional online survey of obesity medication users on experiences and barriers, no exposure outcome comparison",1],["R0012257","Immunometabolic integration in therapeutic strategies for managing MASLD.","González-Serrano S","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent09","narrative review of immunometabolic therapeutic strategies for MASLD",1],["R0012337","Proteomic Profiling of GLP-1-Mediated Cardioprotection in a Large Animal Model of Chronic Coronary Artery Disease.","Zheng C","2025","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent09","swine model of chronic coronary disease with GLP-1 agonist proteomics, no humans",1],["R0012443","Efficacy and Safety of Mazdutide in Chinese Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial.","Zhang B","2024","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent09","phase 2 double blind RCT of mazdutide versus placebo with open label dulaglutide in Chinese type 2 diabetes",1],["R0012546","Real-World Evaluation of GLP-1 Receptor Agonist Therapy Persistence, Adherence and Therapeutic Inertia Among Obese Adults with Type 2 Diabetes.","Palanca A","2023","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent09","matched retrospective cohort comparing GLP-1 with SGLT2, insulin and other drugs on persistence and adherence only",1],["R0012622","Guideline-Directed Medical Therapies for Diabetic Kidney Disease Among Thai People With Type 2 Diabetes: A Real-World Data Based on Theptarin Diabetes Staging.","Chongvoranond P","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent09","retrospective audit of guideline drug use rates in Thai diabetic kidney disease, utilization only",1],["R0012715","Tirzepatide Improved Markers of Islet Cell Function and Insulin Sensitivity in People With T2D (SURPASS-2).","Frias JP","2024","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent09","post hoc SURPASS-2 analysis of tirzepatide versus semaglutide on beta cell and insulin sensitivity markers",1],["R0012797","Effects of glucose-lowering agents on ischemic stroke.","Avgerinos K","2017","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent09","narrative review of glucose lowering drugs and ischemic stroke",1],["R0018236","Early Fasting Serum Glucose or Weight Reduction With Tirzepatide and Metabolic Outcomes in People With Type 2 Diabetes: A Post Hoc Analysis of the SURPASS Trials.","Giorgino F","2025","include_nma",null,"pooled_analysis","P01",null,null,"high","first","opus-5.5-agent06","post hoc pooled analysis of SURPASS-1 to -5 RCT tirzepatide participants by early glycemic or weight response",1],["R0018317","Cost-Effectiveness of Antiobesity Drugs for Adolescents With Severe Obesity.","Mital S","2023","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent06","microsimulation cost-effectiveness model of anti-obesity drugs for adolescents",1],["R0018468","A critical analysis of the clinical use of incretin-based therapies: Are the GLP-1 therapies safe?","Butler PC","2013","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent06","point counterpoint opinion on safety of incretin therapies",1],["R0018680","A New Treatment Strategy for Parkinson's Disease through the Gut-Brain Axis: The Glucagon-Like Peptide-1 Receptor Pathway.","Kim DS","2017","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent06","narrative review of GLP-1 receptor pathway as Parkinson treatment strategy",1],["R0018811","Gut Microbiota-Derived Metabolites Orchestrate Metabolic Reprogramming in Diabetic Cardiomyopathy: Mechanisms and Therapeutic Frontiers.","Jin JY","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent06","narrative mechanistic review of gut microbiota metabolites in diabetic cardiomyopathy",1],["R0018947","Exenatide for obesity in children and adolescents: Systematic review and meta-analysis.","Chen B","2024","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent06","registered systematic review and meta-analysis of RCTs of exenatide versus control in pediatric obesity",1],["R0011574","Genetic Evidence for the Benefits and Risks of Glucose-Lowering Drugs on Cardiovascular-Kidney-Metabolic Syndrome: A Drug-Target Mendelian Randomization Study.","Lu J","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent11","drug target Mendelian randomization using genetic proxies; no GLP-1RA administered or exposure compared",1],["R0011652","The Effects of Exenatide Once Weekly (EXQW) and Exenatide Twice a Day (EXBID) on Beta-Cell Function in Type 2 Diabetes: A Systematic Review and Network Meta-Analysis.","Wang J","2019","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent11","network meta-analysis of RCTs of exenatide weekly versus twice daily and comparators; PubMed, Cochrane, Embase",1],["R0011750","The Potential Role of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists as a Type of Conservative Treatment of Endometrial Cancer in Women of Reproductive Age: A Review of the Literature and a Call for Study.","Bourou MZ","2024","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent11","narrative review of GLP-1RAs for conservative management of endometrial cancer",1],["R0011868","A review on the association between glucagon-like peptide-1 receptor agonists and thyroid cancer.","Chiu WY","2012","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent11","narrative review of GLP-1RAs and thyroid cancer evidence",1],["R0011954","EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD).","European Association for the Study of the Liver (EASL)","2024","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent11","EASL-EASD-EASO clinical practice guideline on MASLD",1],["R0012068","Impact of changes in conventional risk factors induced by once-weekly GLP-1 receptor agonist exenatide on cardiovascular outcomes: an EXSCEL post hoc analysis.","Coleman RL","2025","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent11","EXSCEL post hoc mediation and simulation analysis of once weekly exenatide versus placebo",1],["R0016503","IDegLira improves time in range in a cohort of patients with type 2 diabetes: TiREX study.","Malighetti ME","2025","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent04","TiREX retrospective pre post study of IDegLira initiators with CGM metrics, no comparison group",1],["R0016601","Effects of 6-month treatment with the glucagon like peptide-1 analogue liraglutide on arterial stiffness, left ventricular myocardial deformation and oxidative stress in subjects with newly diagnosed type 2 diabetes.","Lambadiari V","2018","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent04","RCT of liraglutide vs metformin for 6 months in newly diagnosed type 2 diabetes, vascular and cardiac function outcomes",1],["R0016686","Comparative Effectiveness of Long-Acting GLP-1 Receptor Agonists in Type 2 Diabetes: A Short Review on the Emerging Data.","Chudleigh RA","2020","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent04","short narrative review of comparative effectiveness of weekly GLP-1 RAs",1],["R0016780","Semaglutide: a key medication for managing cardiovascular-kidney-metabolic syndrome.","MacIsaac RJ","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent04","narrative review of semaglutide in cardiovascular kidney metabolic syndrome",1],["R0016903","Body weight reduction in women treated with tirzepatide by reproductive stage: a post hoc analysis from the SURMOUNT program.","Tchang BG","2025","include_nma",null,"secondary_report","P02; P02W",null,null,"high","first","opus-5.5-agent04","post hoc analysis by reproductive stage of SURMOUNT-1, -3 and -4 RCTs of tirzepatide vs placebo",1],["R0016990","From diabetes to tumor growth: unravelling the impact of glucose-lowering therapies.","Modica R","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent04","narrative review of glucose lowering drugs and cancer with targeted searches, no eligibility criteria or synthesis",1],["R0017075","Treatment patterns and clinical characteristics of patients with type 2 diabetes mellitus according to body mass index: findings from an electronic medical records database.","Weng W","2017","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent04","cross sectional EMR analysis of treatment patterns and glycemic control by BMI, no GLP-1 RA exposure comparison",1],["R0025848","Severe Obesity in A Specialist Type 2 Diabetes Outpatient Clinic: An Australian Retrospective Cohort Study","Thakur A","2020","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent05","retrospective clinic study of severe obesity prevalence and management in diabetes; GLP-1 RA use only a descriptive characteristic",1],["R0026074","Combination therapy with liraglutide and insulin in Japanese patients with type 2 diabetes: A 36-week, randomized, double-blind, parallel-group trial.","Seino Y","2016","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent05","36 week double blind RCT of liraglutide versus placebo added to insulin in Japanese type 2 diabetes",1],["R0026223","Cardiovascular Profile of Patients with Type 2 Diabetes in France Based on REWIND CVOT Inclusion Criteria: A Real-World Retrospective Study.","Dib A","2022","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent05","descriptive EMR study of French type 2 diabetes patients meeting REWIND criteria; no drug exposure studied",1],["R0026413","Nonalcoholic Fatty Liver Disease: A Drug Revolution Is Coming.","Jeong SW","2020","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent05","narrative review of emerging NAFLD drugs",1],["R0026511","Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease.","Kim KS","2020","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent05","narrative review of antidiabetic drugs for NAFLD",1],["R0012744","Both Elafibranor and Liraglutide Improve NAFLD / NASH but Affect Differentially the Hepatic Lipidome and Metabolome in a Diet-Induced Obese and Biopsy-Confirmed Mouse Model of NASH","Perakakis N","2021","exclude","E1","other",null,null,"abstract_only","high","first","opus-5.5-agent15","conference abstract of randomized mouse NASH model comparing liraglutide, elafibranor and vehicle; animals only",1],["R0012813","GLP-1 and PYY for the treatment of obesity: a pilot study on the use of agonists and antagonists in diet-induced rats.","Oertel M","2024","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent15","pilot study in diet induced obese rats of semaglutide with PYY analogs and antagonists; animals only",1],["R0013092","Glucagon-like peptide-1 attenuates diabetes-associated osteoporosis in ZDF rat, possibly through the RAGE pathway.","Cheng Y","2022","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent15","Zucker diabetic fatty rat and osteoblast culture study of liraglutide and GLP-1 on bone; no human data",1],["R0016480","The effect of a glucagon-like peptide-1 receptor agonist on glucose tolerance in women with previous gestational diabetes mellitus: protocol for an investigator-initiated, randomised, placebo-controlled, double-blinded, parallel intervention trial.","Foghsgaard S","2013","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent18","protocol of double blind RCT of liraglutide vs placebo in women with previous gestational diabetes; no results",1],["R0016567","Liraglutide reduces plasma dihydroceramide levels in patients with type 2 diabetes.","Denimal D","2023","inventory_only","N1","secondary_report",null,null,null,"high","first","opus-5.5-agent18","ancillary lipidomic study of single arm liraglutide treatment in T2D compared with untreated healthy controls only",1],["R0016652","Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5).","Nauck M","2014","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent18","AWARD-5 double blind RCT of dulaglutide 1.5 and 0.75 mg vs sitagliptin and placebo on metformin in T2D",1],["R0016758","Liraglutide and Weight Loss Among Suboptimal Responders to Metabolic Bariatric Surgery: A Randomized Clinical Trial.","Brown WA","2025","include_nma",null,"primary_report","P02",null,null,"high","first","opus-5.5-agent18","double blind RCT of liraglutide vs placebo for suboptimal weight loss after bariatric surgery; P02 assumed, some may have T2D",1],["R0016966","Tirzepatide leads to weight reduction in people with obesity due to MC4R deficiency.","Bhatnagar P","2025","include_nma",null,"secondary_report","P02",null,null,"high","first","opus-5.5-agent18","genetic subgroup analysis of SURMOUNT-1 RCT comparing tirzepatide weight response in MC4R carriers vs noncarriers",1],["R0017056","Liraglutide as a treatment option for weight regain after laparoscopic sleeve gastrectomy in patients with obesity and higher anaesthesiologist risk.","Martines G","2025","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent18","retrospective single arm cohort of liraglutide for weight regain after sleeve gastrectomy; no comparator",1],["R0017141","GLP-1 analogs reduce hepatocyte steatosis and improve survival by enhancing the unfolded protein response and promoting macroautophagy.","Sharma S","2011","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent18","in vitro human hepatocyte and mouse experiments with exendin-4; no human treatment",1],["R0015385","[Semaglutide and Metabolic Dysfunction-Associated Fatty Liver Disease: A Systematic Review].","Masson W","2026","include_review",null,"systematic_review",null,null,"non_english","high","first","opus-5.5-agent13","Spanish PRISMA systematic review of placebo controlled semaglutide RCTs in MAFLD searched in PubMed, LILACS and Cochrane",1],["R0015741","Short-Term Outcomes for Veterans Receiving Basal Insulin, Metformin, and a Sulfonylurea Who Are Started on a Third Noninsulin Agent Versus Prandial Insulin.","Santeusanio AD","2018","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent07","VA retrospective cohort adding GLP-1RA or DPP-4i vs prandial insulin; A1c, weight, hypoglycemia only",1],["R0016050","GLP-1 Receptor Agonist Effects on Lipid and Liver Profiles in Patients with Nonalcoholic Fatty Liver Disease: Systematic Review and Meta-Analysis.","Rezaei S","2021","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent13","meta-analysis of placebo controlled GLP-1 agonist RCTs in NAFLD on lipids and liver enzymes",1],["R0016142","Locally delivered GLP-1 analogues liraglutide and exenatide enhance microvascular perfusion in individuals with and without type 2 diabetes.","Aung MM","2019","inventory_only","N2","primary_report",null,null,null,"high","first","opus-5.5-agent13","randomized intradermal microinjection of liraglutide, exenatide or saline measuring skin perfusion only",1],["R0016233","Comparative cardiovascular outcomes in the era of novel anti-diabetic agents: a comprehensive network meta-analysis of 166,371 participants from 170 randomized controlled trials.","Zhuang XD","2018","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent13","PROSPERO registered network meta-analysis of antidiabetic drug RCTs including GLP-1 agonists on MACE and mortality",1],["R0016364","The NUTRI-OBEDIGITHUM Pathway: Integrating Personalized Exchange-Based Nutrition into Digitally Enabled Obesity Care and a Retrospective Real-World Cohort Analysis.","Vázquez C","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent13","descriptive cohort of digital obesity pathway with exploratory comparison by GLP-1 mention, weight only",1],["R0015843","Persistence of Weekly Injectable Semaglutide Use in Patients with Diabetes Mellitus and Obesity: A Retrospective Follow-Up in Colombia.","Machado-Duque ME","2025","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent07","Colombian dispensing cohort describing persistence of semaglutide new users without exposure outcome comparison",1],["R0015946","Impact of tirzepatide treatment on participant-reported food craving and food preference: Secondary analyses of a phase 1 randomised controlled trial in people with obesity with dietary restriction.","Kennedy SF","2025","include_nma",null,"secondary_report","P02",null,null,"high","first","opus-5.5-agent07","letter reporting secondary food craving analyses of phase 1 RCT of tirzepatide 15 mg vs placebo in obesity",1],["R0016034","Flexible dose of semaglutide reduces early discontinuation while maintaining comparable outcomes in obese patients: FLEX-SEMA 2.4 mg, an Italian real-world study.","Pampanelli S","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent07","retrospective single group semaglutide 2.4 mg obesity cohort describing titration and outcomes",1],["R0016123","Albiglutide Does Not Prolong QTc Interval in Healthy Subjects: A Thorough ECG Study.","Darpo B","2014","include_nma",null,"primary_report","P99",null,"mechanistic","high","first","opus-5.5-agent07","thorough QT RCT of albiglutide vs placebo in healthy volunteers; adverse events reported",1],["R0016205","Semaglutide-associated hyposalivation: A report of case series.","Mawardi HH","2023","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent07","case series of three patients with hyposalivation on semaglutide",1],["R0016428","Lower Drug Cost of Successfully Treating Patients with Type 2 Diabetes to Targets with Once-Weekly Semaglutide versus Once-weekly Dulaglutide in Japan: A Short-Term Cost-Effectiveness Analysis.","Igarashi A","2020","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent07","short term cost of control analysis of semaglutide vs dulaglutide based on SUSTAIN 7",1],["R0014160","Adoption and Prescribing Practices of Sodium-Glucose Transport Protein-2 (SGLT-2) Inhibitors and Glucagon-Like Peptide-1 (GLP-1) Agonists in Cardiology: A Cross-Sectional Study in Saudi Arabia.","Jamsheer F","2025","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent02","cross sectional survey of cardiologists on SGLT2 inhibitor and GLP-1 RA prescribing perceptions; no exposure comparison",1],["R0014327","GLP1 Receptor Agonists Reduce Fluid Intake in Primary Polydipsia","Winzeler B","2021","include_nma",null,"conference_abstract","P99",null,"crossover; abstract_only","high","first","opus-5.5-agent19","double blind placebo controlled crossover RCT of dulaglutide in primary polydipsia; P99 condition, fluid intake primary",1],["R0014240","Utilization of Proteomic Measures for Early Detection of Drug Benefits and Adverse Effects.","Chadwick J","2025","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent02","proteomic biomarker substudy including EXSCEL randomized once weekly exenatide vs placebo plus other drug trials",1],["R0014338","Insulin degludec/liraglutide (IDegLira) maintains glycaemic control and improves clinical outcomes, regardless of pre-trial insulin dose, in people with type 2 diabetes that is uncontrolled on basal insulin.","Meneghini L","2020","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent02","post hoc analysis of DUAL V and VII RCTs of IDegLira vs glargine or basal bolus by pre trial insulin dose",1],["R0014507","Safety, tolerability and efficacy of lixisenatide as monotherapy in Japanese patients with type 2 diabetes mellitus: An open-label, multicenter study.","Seino Y","2018","inventory_only","N1","primary_report",null,null,null,"high","first","opus-5.5-agent19","uncontrolled single arm phase 3 study of lixisenatide monotherapy in Japanese type 2 diabetes",1],["R0014597","The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics.","Wheeler DC","2020","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent19","baseline characteristics of DAPA-CKD dapagliflozin vs placebo trial; GLP-1 RA only background medication",1],["R0014705","Safety and Efficacy of GLP-1 Agonists in a Cohort of Patients with Fontan Circulation.","Freddo AM","2025","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent19","retrospective case series of eight adults with Fontan circulation prescribed GLP-1 agonists",1],["R0014714","Early onset stage III diabetic nephropathy in a child with Prader-Willi syndrome treated with dulaglutide: a case report.","He Y","2024","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent02","case report of child with Prader-Willi syndrome and diabetic nephropathy treated with dulaglutide",1],["R0014766","Semaglutide Induces Changes in Gastric Electrical Activity in Patients With Overweight and Obesity: A Pilot Study.","Abraham R","2026","inventory_only","N1","primary_report",null,null,null,"high","first","opus-5.5-agent19","single group pilot of gastric mapping before and on semaglutide in eight patients; no comparison group",1],["R0014780","Obesity medications and acquired hypothalamic obesity in adults: A two-case experience.","Lang H","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent02","two case report of tirzepatide plus phentermine in acquired hypothalamic obesity",1],["R0014876","Comment on Rossing et al. Nuances in Interpretation: Assessing the Interaction Between Semaglutide and MRAs in the FLOW Trial.","Liu Q","2026","inventory_only","N9","ancillary",null,null,null,"high","first","opus-5.5-agent19","letter commenting on FLOW trial secondary analysis of semaglutide and MRA interaction",1],["R0014938","Beyond the known: prospective research directions for the gut-brain axis in obesity and type 1 diabetes mellitus.","Yang D","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent19","letter proposing research directions on gut brain axis in type 1 diabetes obesity; opinion",1],["R0015037","SEMAGLUTIDE: Weight loss, glycaemic control and safety profile in obese patients with and without type-II diabetes-An experience from Karachi, Pakistan.","Memon MY","2024","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent01","single group observational cohort of semaglutide in obese patients with or without diabetes, before and after outcomes",1],["R0015162","Effectiveness of dapagliflozin versus comparators on renal endpoints in the real world: A multicentre retrospective study.","Fadini GP","2019","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent01","DARWIN-T2D retrospective comparison of dapagliflozin versus comparators including GLP-1 RA; albuminuria and eGFR only",1],["R0015242","Activation of glucagon-like peptide-1 receptors reduces the acquisition of aggression-like behaviors in male mice.","Vestlund J","2022","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent01","exendin-4 in mouse aggression model plus human GLP1R gene polymorphism association; no drug exposure in humans",1],["R0015331","Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors.","Scheen AJ","2018","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent01","narrative review of cardiovascular effects of DPP-4 and SGLT2 inhibitors",1],["R0015417","Lixisenatide reduces postprandial hyperglycaemia via gastrostatic and insulinotropic effects.","Becker RH","2015","include_nma",null,"primary_report","P99",null,"mechanistic; crossover","high","first","opus-5.5-agent01","randomized crossover of single lixisenatide doses versus placebo in healthy volunteers; gastric emptying with adverse events reported",1],["R0015492","Weight-centric treatment of type 2 diabetes mellitus.","Ghusn W","2022","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent01","clinical review with expert opinion on weight effects of diabetes drugs, no eligibility criteria or synthesis",1],["R0015605","Efficacy of a glucagon-like peptide-1 agonist and restrictive versus liberal oxygen supply in patients undergoing coronary artery bypass grafting or aortic valve replacement: study protocol for a 2-by-2 factorial designed, randomised clinical trial.","Wiberg S","2021","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent01","protocol of factorial RCT of exenatide versus placebo and oxygen strategy during cardiac surgery",1],["R0018147","Molecular Imaging to the Surgeons Rescue: Gallium-68 DOTA-Exendin-4 Positron Emission Tomography-Computed Tomography in Pre-operative Localization of Insulinomas.","Pallavi UN","2019","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent12","diagnostic Ga-68 exendin-4 PET study for insulinoma localization, tracer not a therapeutic exposure",1],["R0018273","Improved HbA1c and Body Weight in GADA-Positive Individuals Treated With Tirzepatide: A Post Hoc Analysis of SURPASS.","Peters AL","2025","include_nma",null,"pooled_analysis","P01",null,null,"high","first","opus-5.5-agent12","post hoc pooled analysis of SURPASS 2 to 5 RCTs of tirzepatide by GAD antibody status",1],["R0018396","FRI075 Single Center Retrospective Matched Cohort Study Of glp1ra-induced Weight Loss In Patients With Post-bariatric Weight Regain Vs Non-surgical Controls",null,"2023","inventory_only","N5","conference_abstract","P02",null,"abstract_only","high","first","opus-5.5-agent12","abstract of retrospective matched cohort of GLP-1RA users with vs without prior bariatric surgery, all exposed",1],["R0018599","Once-Weekly Semaglutide Improves Body Composition in Spanish Obese Adults with Type 2 Diabetes: A 48-Week Prospective Real-Life Study.","Caballero-Mateos I","2025","inventory_only","N5","secondary_report","P01",null,null,"high","first","opus-5.5-agent12","single site ancillary study of single arm real world semaglutide cohort, body composition before and after",1],["R0018966","Effectiveness, Safety, and Patient Satisfaction of Liraglutide in Type 2 Diabetic Patients.","Zameer R","2020","inventory_only","N5","primary_report","P01",null,null,"high","first","opus-5.5-agent12","retrospective single drug cohort of liraglutide users, before and after HbA1c, weight and satisfaction",1],["R0016563","Preoperative Glucagon-like Peptide-1 Therapy in Bariatric Surgery Patients With Morbid Obesity (PreMO): Rationale and Study Design for a Randomized Controlled Trial.","Jain V","2026","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent16","design paper of RCT of preoperative tirzepatide vs standard care before bariatric surgery, no results",1],["R0016638","Effect of Ebenatide on glycemic metabolism and body fat in patients with type 2 diabetes mellitus.","Xu CL","2025","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent16","RCT of ebenatide vs placebo for 24 weeks then open ebenatide in T2D; HbA1c and body composition",1],["R0016738","Effect of Long-term Incretin-Based Therapies on Ischemic Heart Diseases in Patients with Type 2 Diabetes Mellitus: A Network Meta-analysis.","Chou CY","2017","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent16","PROSPERO registered systematic review and NMA of incretin therapies on ischemic heart disease; PubMed, CENTRAL",1],["R0016845","Multi-ancestry Transcriptome-Wide Association Study (TWAS)-Informed Prioritization of Antipsychotic Metabolic Risk: Evaluation of GLP1R as a Shared Mechanistic Link.","Cheung N","2026","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent16","in silico transcriptome wide association and drug gene database analysis, no human drug exposure",1],["R0016959","Beyond the Scale: Changes in Pain, Physical Function (WOMAC), and Low-Grade Inflammation Following Semaglutide Treatment in Patients with Knee Osteoarthritis-Results from a Six-Month Real-World Cohort.","Conforti A","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent16","retrospective self controlled cohort of semaglutide in knee osteoarthritis, no concurrent comparator",1],["R0017039","Efficacy and Safety of Once-Weekly Semaglutide for the Treatment of Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.","Shi FH","2018","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent16","PROSPERO registered systematic review and meta-analysis of semaglutide phase 3 RCTs in T2D",1],["R0017137","Weight change from incretin-based weight loss medications across categories of second-generation antipsychotics.","Varghese JS","2025","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent16","Epic Cosmos cohort of incretin prescription vs none among antipsychotic users; weight change only",1],["R0017261","The cardiovascular effects of GLP-1 receptor agonists.","Okerson T","2012","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent16","narrative literature review of cardiovascular effects of GLP-1RAs",1],["R0015748","Sex-based differences in clinical outcomes among patients with obesity and heart failure with preserved ejection fraction treated with tirzepatide.","Mortada I","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent08","TriNetX cohort of tirzepatide users comparing outcomes by sex; no unexposed or alternative drug comparison group",1],["R0015954","Combination metformin and liraglutide in PCOS: clinical efficacy in women and preclinical insights from gut microbiome modulation in rats.","Long XF","2025","include_nma",null,"primary_report","P12",null,null,"high","first","opus-5.5-agent08","open label RCT of metformin, liraglutide or combination in overweight women with PCOS plus a rat substudy",1],["R0016124","Effects of Contemporary Therapies on Cardiovascular and Renal Outcomes in Diabetic Kidney Disease: A Systematic Review of Randomized Controlled Trials (RCTs).","Bachar Al Sumodi W","2025","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent08","systematic review of finerenone and RAS inhibitor trials in diabetic kidney disease; GLP-1 RA only a subgroup stratifier",1],["R0016438","Tirzepatide, a dual GIP/GLP1-receptor co-agonist preserves cardiac function and improves survival in angiotensin II-induced heart failure model in mice: comparison to liraglutide.","Hegedűs ZI","2025","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent08","mouse angiotensin II heart failure model comparing tirzepatide with liraglutide",1],["R0027030","Confirmatory psychometric evaluations of the Impact of Weight on Quality of Life-Lite Clinical Trials Version (IWQOL-Lite-CT).","Kolotkin RL","2021","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent05","psychometric validation of IWQOL-Lite-CT using STEP 1 and 2 trial data; measurement methods paper without treatment contrast",1],["R0027176","Improvement of postprandial endothelial function after a single dose of exenatide in individuals with impaired glucose tolerance and recent-onset type 2 diabetes.","Koska J","2010","inventory_only","N2","other",null,null,"crossover","high","first","opus-5.5-agent05","randomized crossover single dose exenatide versus placebo before a high fat meal on endothelial function; no review outcome",1],["R0027395","Anti-Obesity Drugs: Long-Term Efficacy and Safety: An Updated Review.","Tak YJ","2021","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent05","narrative review of long term anti-obesity drug efficacy and safety",1],["R0027641","Adults with early-onset type 2 diabetes (aged 18-39 years) are severely underrepresented in diabetes clinical research trials.","Sargeant JA","2020","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent05","meta-research on ages of participants in diabetes trials; no synthesized drug contrast",1],["R0027826","Valuing injection frequency and other attributes of type 2 diabetes treatments in Australia: a discrete choice experiment.","Fifer S","2018","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent05","discrete choice experiment of treatment preferences among exenatide and oral drug users; no drug exposure outcome comparison",1],["R0028445","Report from the CVOT Summit 2020: new cardiovascular and renal outcomes.","Schnell O","2021","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent05","congress summit commentary summarizing recent outcome trials",1],["R0029186","In reply: Comment on: Association of glucagon-like peptide receptor 1 agonist therapy with the presence of gastric contents in fasting patients undergoing endoscopy under anesthesia care: a historical cohort study.","Wu F","2024","inventory_only","N9","ancillary",null,null,null,"high","first","opus-5.5-agent05","authors reply to a comment on their cohort of GLP-1 RA use and gastric contents at endoscopy",1],["R0029732","Application of a mouse model humanized for cytochrome P450-mediated drug metabolism to predict drug-drug interactions between a peptide and small molecule drugs.","Kapelyukh Y","2025","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent05","humanized cytochrome mouse model study of the coagonist NN1177 drug interactions; animal only",1],["R0017487","The Cost-effectiveness of Subcutaneous Semaglutide 2.4 mg Injection for Chronic Weight Management in Canada: A Societal Perspective","Olivieri A","2022","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent20","Core Obesity Model cost effectiveness analysis of semaglutide 2.4 mg in Canada",1],["R0017551","An experimental medicine protocol for exploring the haemodynamic effects of dual agonism at the glucagon-like peptide-1 and glucagon receptor in healthy subjects.","Goodman J","2026","include_nma",null,"primary_report","P99",null,"mechanistic; crossover","high","first","opus-5.5-agent20","randomized saline controlled crossover IV infusions of exenatide, glucagon and co-infusion in healthy men, BP and adverse events reported",1],["R0017682","Medication Adherence in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE).","Gonzalez JS","2026","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent20","adherence substudy of randomized GRADE trial comparing liraglutide, glargine, glimepiride and sitagliptin",1],["R0017781","Cost-Effectiveness of Pharmacotherapy for the Treatment of Obesity in Adolescents.","Lim F","2023","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent20","microsimulation cost effectiveness of obesity drugs including semaglutide and liraglutide in adolescents",1],["R0017979","O064 Tirzepatide reduced sleep apnea severity in adults with obstructive sleep apnea and obesity: results from the SURMOUNT-OSA trial",null,"2024","include_nma",null,"conference_abstract","P10",null,"abstract_only","high","first","opus-5.5-agent20","congress abstract of randomized SURMOUNT-OSA trials of tirzepatide vs placebo in OSA with obesity",1],["R0018077","The Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors Reduce Platelet Activation and Thrombus Formation by Lowering NOX2-Related Oxidative Stress: A Pilot Study.","Pignatelli P","2022","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent20","nonrandomized pilot of gliflozins vs GLP-1 RA added to metformin, platelet and oxidative stress markers only",1],["R0018201","Tirzepatide-induced weight loss and obstructive sleep apnea improvement in an adult with type 2 diabetes: A case report.","Funamizu N","2025","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent20","single case report of tirzepatide weight loss and OSA improvement in T2D",1],["R0017408","Comparison of glucose control by added liraglutide to only insulin infusion in diabetic patient undergoing cardiac surgery: A preliminary randomized-controlled trial.","Sindhvananda W","2023","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent03","RCT of added liraglutide plus insulin infusion vs insulin infusion alone in T2D undergoing cardiac surgery",1],["R0017495","Effect of miR-19b on the protective effect of Exendin-4 on islet cells in non-obese diabetic mice.","He J","2019","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent03","NOD mouse study of exendin-4 doses with miR-19b interference; animal only",1],["R0017693","Effects of liraglutide vs. lifestyle changes on soluble suppression of tumorigenesis-2 (sST2) and galectin-3 in obese subjects with prediabetes or type 2 diabetes after comparable weight loss.","Simeone P","2022","include_nma",null,"secondary_report","P99",null,"mechanistic","high","first","opus-5.5-agent03","post hoc biomarker analysis of RCT liraglutide vs lifestyle to equal weight loss in obese prediabetes or early T2D, mixed population",1],["R0017879","Liraglutide Activates Type 2 Deiodinase and Enhances β3-Adrenergic-Induced Thermogenesis in Mouse Adipose Tissue.","Oliveira FCB","2021","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent03","mouse study of liraglutide on adipose thermogenesis; animal only",1],["R0018009","Real-world efficacy of tirzepatide in patients with heart failure without diabetes.","Augusto SN","2025","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent03","TriNetX matched cohort tirzepatide vs untreated HF without diabetes; HF, MACE, CKD, stroke outcomes only",1],["R0018097","Weight and body composition outcomes with liraglutide in individuals with well-treated hypothyroidism: A retrospective case-control study.","Chukir T","2025","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent03","retrospective comparison of liraglutide response in hypothyroid vs euthyroid patients, all exposed, no unexposed group",1],["R0015697","Effects of once-daily oral orforglipron on weight and metabolic markers: a systematic review and meta-analysis of randomized controlled trials.","Lütkemeyer C","2024","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent17","registered meta-analysis of RCTs of oral orforglipron versus placebo or other drugs on weight and metabolic markers",1],["R0015794","Impact of Liraglutide on Insulin Clearance in Patients with Type 2 Diabetes Mellitus: Evidence from a Randomized Controlled Trial.","Boelling M","2026","include_nma",null,"secondary_report","P01",null,"mechanistic","high","first","opus-5.5-agent17","letter reporting insulin clearance in a placebo controlled RCT of liraglutide after intensive insulin in type 2 diabetes, 48 weeks",1],["R0015891","Cardiovascular efficacy and safety of dipeptidyl peptidase-4 inhibitors: A meta-analysis of cardiovascular outcome trials.","Patoulias DI","2021","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent17","meta-analysis of DPP-4 inhibitor cardiovascular outcome trials only; no GLP-1 RA contrast",1],["R0015993","Glycaemic benefit of iGlarLixi in insulin-naive type 2 diabetes patients with high HbA1c or those with inadequate glycaemic control on two oral antihyperglycaemic drugs in the LixiLan-O randomized trial.","Davies MJ","2019","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent17","post hoc subgroup analysis of LixiLan-O RCT comparing iGlarLixi with insulin glargine and lixisenatide",1],["R0016074","Crosstalk Between Metabolic Dysfunction-Associated Steatotic Liver Disease and Atrial Fibrillation: Shared Mechanism, Diagnostic Integration, and Management Implications.","Morawska A","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent17","narrative review of MASLD and atrial fibrillation crosstalk",1],["R0016160","Oral Semaglutide Versus Empagliflozin, Sitagliptin and Liraglutide in the UK: Long-Term Cost-Effectiveness Analyses Based on the PIONEER Clinical Trial Programme.","Bain SC","2020","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent17","CORE Diabetes Model cost effectiveness analysis of oral semaglutide versus comparators in the UK",1],["R0016375","Effects of once-weekly semaglutide in obese/overweight patients: A systematic review and meta-analysis","Wang M","2022","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent17","preprint systematic review and meta-analysis of once weekly semaglutide RCTs in overweight or obesity",1],["R0012871","Treatment persistence, adherence and healthcare resource utilisation for iGlarLixi versus basal-bolus insulin or premixed insulin in older adult ethnic minorities with type 2 diabetes: SoliEthnicity study.","Umpierrez G","2025","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent10","Medicare matched cohort iGlarLixi versus basal bolus or premixed insulin; persistence, adherence, hypoglycemia only",1],["R0016459","PIONEER REAL Saudi Arabia: A multicentre, prospective, real-world study of once-daily oral semaglutide use in adults with type 2 diabetes in Saudi Arabia.","ElBadawi H","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent14","PIONEER REAL Saudi Arabia prospective single arm study of oral semaglutide initiators, no comparison group",1],["R0019155","Characteristics of patients with type 2 diabetes mellitus newly treated with GLP-1 receptor agonists (CHADIG Study): a cross-sectional multicentre study in Spain.","Conget I","2016","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent06","cross sectional description of characteristics of GLP-1 RA initiators in Spain; utilization profile without outcome comparison",1],["R0012976","Weight loss interventions and obesity-associated cancers in people with type 2 diabetes and overweight/obesity: A real-world observational study.","Ipaye T","2025","include_harms",null,"primary_report",null,"O32B; O38",null,"high","first","opus-5.5-agent10","TriNetX matched cohorts semaglutide or tirzepatide versus DPP-4i; obesity associated cancers including pancreatic and thyroid",1],["R0013061","Liraglutide exerts a bone-protective effect in ovariectomized rats with streptozotocin-induced diabetes by inhibiting osteoclastogenesis.","Wen B","2018","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent10","ovariectomized diabetic rats treated with liraglutide; animal study only",1],["R0013172","Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial.","Bain SC","2019","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent10","PIONEER 6 rationale, design and baseline characteristics paper; no outcome results",1],["R0013286","Weight Loss With Microdose Tirzepatide: Real-World Outcomes in Patients Initiating Treatment Below 2.5 mg Weekly","Hastings J","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent10","retrospective uncontrolled cohort of microdose compounded tirzepatide initiators; weight change without comparison group",1],["R0013380","Hormonal Contraception and Initiation of Semaglutide Therapy.","Bager MD","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent10","Danish nested case control of hormonal contraception predicting semaglutide initiation; GLP-1 RA use is the outcome",1],["R0013461","Safety and effects of anti-obesity medications on weight loss, cardiometabolic, and psychological outcomes in people living with overweight or obesity: a systematic review and meta-analysis.","Liu L","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent10","PROSPERO registered meta-analysis of placebo controlled RCTs of approved antiobesity drugs including GLP-1 RAs",1],["R0016554","Glycaemic outcomes of an Individualized treatMent aPproach for oldER vulnerable patIents: A randomized, controlled stUdy in type 2 diabetes Mellitus (IMPERIUM).","Heller SR","2018","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent14","IMPERIUM RCT in older vulnerable T2D comparing strategy with GLP-1 RA as first injectable vs sulfonylurea and glargine strategy",1],["R0016634","Use of GLP-1 Receptor Agonists and Occurrence of Thyroid Disorders: a Meta-Analysis of Randomized Controlled Trials.","Hu W","2022","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent14","PROSPERO registered meta-analysis of RCTs of GLP-1 RA and thyroid disorders, four databases searched",1],["R0016730","Digital Engagement Significantly Enhances Weight Loss Outcomes in Adults With Obesity Treated With Tirzepatide: Retrospective Cohort Study of a Digital Weight Loss Service.","Johnson H","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent14","retrospective cohort of tirzepatide users comparing digitally engaged vs not, weight outcomes only",1],["R0016836","The Impact of GLP-1 RAs and DPP-4is on Hospitalisation and Mortality in the COVID-19 Era: A Two-Year Observational Study.","Greco S","2023","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent14","retrospective cohort comparing GLP-1 RA and DPP-4i users for hospitalization and mortality in COVID-19 era, no harms_nrs outcome",1],["R0017119","R WE ready for reimbursement? A round-up of developments in real-world evidence relating to health technology assessment: part 25.","Arora P","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent14","editorial round up on real world evidence for health technology assessment",1],["R0019286","Comparison of exenatide alone or combined with metformin versus metformin in the treatment of polycystic ovaries: a systematic review and meta-analysis.","Hu Y","2023","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent06","systematic review and meta-analysis of RCTs of exenatide alone or with metformin versus metformin in PCOS",1],["R0019370","Psychiatric Safety of Semaglutide for Weight Management in People Without Known Major Psychopathology: Post Hoc Analysis of the STEP 1, 2, 3, and 5 Trials.","Wadden TA","2024","include_nma",null,"pooled_analysis","P02; P01",null,null,"high","first","opus-5.5-agent06","post hoc pooled analysis of STEP 1, 2, 3 and 5 RCTs of semaglutide 2.4 mg versus placebo on depression and suicidality",1],["R0019464","Glycemic Variability Impacted by SGLT2 Inhibitors and GLP 1 Agonists in Patients with Diabetes Mellitus: A Systematic Review and Meta-Analysis.","Lee H","2021","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent06","meta-analysis of RCTs of SGLT2 inhibitors and GLP-1 RAs on glycemic variability; PubMed and Embase",1],["R0019551","Improvement of quality of life through glycemic control by liraglutide, a GLP-1 analog, in insulin-naive patients with type 2 diabetes mellitus: the PAGE1 study.","Ishii H","2017","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent06","PAGE1 prospective observational pre post study of liraglutide on quality of life in T2D; no comparison group",1],["R0019678","Accessibility of Diabetes Therapy Management for Patients with Visual Impairment.","Nguyen C","2024","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent06","descriptive accessibility review of injectable diabetes product guides for visual impairment; no human exposure study",1],["R0019812","Precision Pharmacotherapy for Obstructive Sleep Apnea: Matching Targeted Drugs to Patient Endophenotypes.","Oh J","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent06","narrative review of precision pharmacotherapy for sleep apnea endotypes",1],["R0019897","Assessment of Second-Generation Diabetes Medication Initiation Among Medicare Enrollees From 2007 to 2015.","Gilstrap LG","2020","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent06","Medicare cross sectional study of diffusion of second generation diabetes drug initiation; utilization only",1],["R0017184","EndoCompass project: research roadmap for diabetes, obesity, and metabolism.","Mathieu C","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent04","EndoCompass research priority roadmap for diabetes and obesity, expert consultation, no primary data",1],["R0017314","A real-world disproportionality analysis of tirzepatide-related adverse events based on the FDA Adverse Event Reporting System (FAERS) database.","Li J","2025","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent04","FAERS disproportionality analysis of tirzepatide adverse event reports",1],["R0017410","Individualized virtual integrative medicine (IVIM): A clinical model for enhanced GLP-1 therapeutic outcomes.","Duncan J","2025","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent04","retrospective single group of semaglutide users in a telehealth program with weight change, no comparison group",1],["R0017505","Comparative efficacy and safety of glucose-lowering drugs in children and adolescents with type 2 diabetes: A systematic review and network meta-analysis.","Wu S","2022","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent04","registered systematic review and network meta-analysis of pediatric type 2 diabetes drug RCTs incl liraglutide and exenatide",1],["R0017573","Liraglutide improves peripheral perfusion and markers of angiogenesis and inflammation in people with type 2 diabetes and peripheral artery disease: An 18-month follow-up of a randomized clinical trial.","Caruso P","2025","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent04","18 month follow up of STARDUST RCT of liraglutide vs control in type 2 diabetes with peripheral artery disease",1],["R0017809","Role of Residual Inflammation as a Risk Factor Across Cardiovascular-Kidney-Metabolic (CKM) Syndrome: Unpacking the Burden in People with Type 2 Diabetes.","Ghafoury R","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent04","narrative review of residual inflammation in cardiovascular kidney metabolic syndrome",1],["R0015030","Efficacy of the glucagon-like peptide-1 agonist Exenatide in patients undergoing coronary artery bypass grafting or aortic valve replacement – a randomized double-blind clinical trial","Kjaergaard J","2024","include_nma",null,"primary_report","P99",null,null,"high","first","opus-5.5-agent19","randomized double blind trial of exenatide vs placebo in patients undergoing CABG or aortic valve replacement; P99 cardiac surgery",1],["R0015157","Effectiveness of semaglutide versus liraglutide for treating post-metabolic and bariatric surgery weight recurrence.","Murvelashvili N","2023","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent19","retrospective comparison of semaglutide vs liraglutide for weight recurrence after bariatric surgery; weight outcomes only",1],["R0015237","Risk stratification using coronary artery calcium and potential benefit of semaglutide therapy: A cost-effectiveness modelling study.","Ponnana SR","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent19","Markov cost effectiveness model of semaglutide across coronary calcium strata using registry risks; no drug exposure observed",1],["R0015318","Impact of Insulin Degludec/Liraglutide Fixed Combination on the Gut Microbiomes of Elderly Patients With Type 2 Diabetes: Results From A Subanalysis of A Small Non-Randomised Single Arm Study.","Rizza S","2023","inventory_only","N1","secondary_report",null,null,null,"high","first","opus-5.5-agent19","microbiome subanalysis of a single arm IDegLira trial in very old type 2 diabetes patients",1],["R0015402","Kidney and Survival Outcomes with Semaglutide by CKD Severity in the FLOW Trial.","Tuttle KR","2026","include_nma",null,"secondary_report","P08A",null,null,"high","first","opus-5.5-agent19","FLOW RCT subgroup analysis of semaglutide vs placebo by CKD severity in type 2 diabetes with CKD",1],["R0015479","DUTCH weight control in atrial fibrillation study (DUTCH-WAIST) : Design and rationale of a randomised controlled trial.","Voorhout L","2026","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent19","design of DUTCH-WAIST RCT of semaglutide 2.4 mg vs placebo in obese patients with persistent atrial fibrillation",1],["R0015592","Long-term comparative effectiveness of once-weekly semaglutide versus alternative treatments in a real-world US adult population with type 2 diabetes: a randomized pragmatic clinical trial.","Buse JB","2025","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent19","SEPRA pragmatic RCT of semaglutide vs physician chosen alternative add-on in type 2 diabetes over two years",1],["R0015703","Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease.","Mann JFE","2018","include_nma",null,"secondary_report","P01; P08A",null,null,"high","first","opus-5.5-agent19","post hoc LEADER analysis of liraglutide vs placebo by kidney function and albuminuria",1],["R0016519","Comparisons of efficacy and safety in insulin glargine and lixisenatide plus glulisine combination therapy with multiple daily injection therapy in Japanese patients with type 2 diabetes.","Kawaguchi Y","2022","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent07","open label RCT of iGlarLixi plus glulisine vs multiple daily insulin injections in hospitalized T2D patients",1],["R0016605","Resmetirom for MASH: A Comprehensive Review of a Novel Therapeutic Frontier.","Tiwari A","2025","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent07","review of resmetirom for MASH; GLP-1RA mentioned only as a future combination partner",1],["R0016699","Pharmacokinetics, Safety and Tolerability of Once-Weekly Subcutaneous Semaglutide in Healthy Chinese Subjects: A Double-Blind, Phase 1, Randomized Controlled Trial.","Shi A","2021","include_nma",null,"primary_report","P99",null,"mechanistic","high","first","opus-5.5-agent07","phase 1 RCT of semaglutide 0.5 or 1.0 mg vs placebo in healthy Chinese adults; PK with adverse events",1],["R0016802","Effects of oral semaglutide on kidney outcomes in people with type 2 diabetes: a nationwide, multicentre, retrospective, observational study (Renal_ENDO2S-RWD substudy).","Moreno-Pérez O","2025","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent07","retrospective single group cohort of oral semaglutide initiators with kidney outcomes, no comparator",1],["R0016914","The adverse effects associated with semaglutide use in patients at increased risk of cardiovascular events: a systematic review with meta-analysis and Trial Sequential Analysis.","Sillassen CDB","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent07","PROSPERO registered meta-analysis with TSA of RCTs of semaglutide vs placebo on adverse effects",1],["R0016993","Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial.","Sanyal AJ","2024","include_nma",null,"secondary_report","P09; P02",null,null,"high","first","opus-5.5-agent07","MASLD substudy of phase 2 RCT of retatrutide doses vs placebo in obesity, liver fat outcome",1],["R0017095","Finerenone is associated with pronounced uric acid reduction in hyperuricemic diabetic kidney disease: a real-world analysis.","Lin Y","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent07","retrospective finerenone cohort in diabetic kidney disease; GLP-1RA only a covariate",1],["R0017197","Comparison of the injection-site experience of the starting doses with semaglutide and dulaglutide: A randomized, double-blind trial in healthy subjects.","Snitker S","2021","include_nma",null,"primary_report","P99",null,"mechanistic; crossover","high","first","opus-5.5-agent07","randomized double blind crossover of single starting doses of semaglutide vs dulaglutide in healthy overweight adults; injection pain and AEs",1],["R0013052","Cardiovascular outcomes in patients who experienced a myocardial infarction while treated with liraglutide versus placebo in the LEADER trial.","Nauck MA","2018","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent09","post hoc LEADER analysis of liraglutide versus placebo outcomes after myocardial infarction",1],["R0013170","Liraglutide and cardiovascular outcomes in adults with overweight or obesity: A post hoc analysis from SCALE randomized controlled trials.","Davies MJ","2018","include_nma",null,"pooled_analysis","P02; P01",null,null,"high","first","opus-5.5-agent09","pooled post hoc cardiovascular analysis of five randomized SCALE trials of liraglutide 3 mg versus placebo or orlistat",1],["R0013456","Sight Unseen: Glucagon-Like Peptide-1 (GLP-1) Agonism Therapy and Nonarteritic Anterior Ischemic Optic Neuropathy.","Barnett MJ","2026","include_harms",null,"primary_report",null,"O34",null,"high","first","opus-5.5-agent09","TriNetX matched cohort of type 2 diabetes patients with versus without GLP-1 treatment on NAION over five years",1],["R0013402","Tirzepatide for Obesity in Adults ≥ 65 Years: A Post Hoc Analysis of the SURMOUNT and SUMMIT Clinical Trials.","Alfaris N","2026","include_nma",null,"pooled_analysis","P02; P01; P07A; P10",null,null,"high","first","opus-5.5-agent15","post hoc age subgroup analysis pooling SURMOUNT 1 to 5, SURMOUNT-OSA and SUMMIT RCTs of tirzepatide versus placebo or comparator",1],["R0013479","Evaluating the Efficacy and Safety of Tirzepatide on Glycaemic and Non-glycaemic Outcomes in Diabetes: A Systematic Review of Meta-Analyses.","Kaore S","2024","include_review",null,"systematic_review",null,null,"umbrella_review","high","first","opus-5.5-agent15","systematic review of six meta-analyses of tirzepatide in type 2 diabetes; PubMed and Google Scholar searched",1],["R0013568","Does Real World Use of Liraglutide Match its Use in the LEADER Cardiovascular Outcome Trial? Study Protocol.","Hinton W","2018","exclude","E2","protocol_or_design",null,null,null,"high","first","opus-5.5-agent15","protocol of cross sectional CPRD study comparing liraglutide users with LEADER eligibility; descriptive, no exposure outcome comparison",1],["R0013679","Short- and long-term effects of semaglutide 2.4 mg on energy intake, appetite, and food reward: a 60-week, double-blind randomized controlled trial.","Tronieri JS","2026","include_nma",null,"primary_report","P02",null,null,"high","first","opus-5.5-agent15","60 week double blind RCT of semaglutide 2.4 mg versus placebo on energy intake and appetite in overweight or obesity",1],["R0013772","The Utilization of Glucagon-like Peptide 1 Agonists and Risk of Following External Eye Diseases in Type 2 Diabetes Mellitus Individuals: A Population-Based Study.","Fan YC","2023","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent15","Taiwan NHIRD matched cohort of GLP-1 RA users versus nonusers in type 2 diabetes; dry eye and keratitis outcomes only",1],["R0013966","Contemporary (2019) prevalence of cardiovascular disease in adults with type 2 diabetes in Brazil: the cross-sectional CAPTURE study","Vencio S","2021","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent15","CAPTURE Brazil cross sectional prevalence of cardiovascular disease in type 2 diabetes; GLP-1 RA prescribing only described",1],["R0014030","Semaglutide cardiovascular outcomes align more closely with attained dose than achieved weight loss.","Murugadoss K","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent15","EHR cohort of semaglutide initiators by attained dose and matched versus other drugs; mortality and cardiovascular outcomes only",1],["R0017395","Clinical Profile and Management of Patients with Newly Diagnosed Type 2 Diabetes Mellitus in Hospital Setting.","Muñoz Moreno D","2025","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent18","retrospective description of newly diagnosed inpatients with T2D and discharge treatment patterns; no GLP-1 RA exposure comparison",1],["R0017474","Unmet needs in current clinical practice for insulinoma: Lessons from nationwide studies in Japan.","Murakami T","2022","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent18","commentary on insulinoma clinical practice in Japan; no GLP-1 RA studied; also E3",1],["R0017669","Use of semaglutide and risk of non-arteritic anterior ischemic optic neuropathy: A Danish-Norwegian cohort study.","Simonsen E","2025","include_harms",null,"primary_report",null,"O34",null,"high","first","opus-5.5-agent18","Danish-Norwegian active comparator new user cohort semaglutide vs SGLT2i on NAION, with self controlled supplementary analysis",1],["R0017772","Review on cardioprotective strategies in the setting of chemotherapy-induced cardiotoxicity.","Dao V","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent18","narrative review of cardioprotective strategies against chemotherapy cardiotoxicity; GLP-1 RA mentioned only briefly",1],["R0017864","Adverse effects with tirzepatide: a protocol for a systematic review with meta-analysis and Trial Sequential Analysis.","Sillassen CDB","2025","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent18","protocol of systematic review with meta-analysis and TSA of tirzepatide adverse effects; no results",1],["R0017959","Structural and Functional Diversity among Agonist-Bound States of the GLP-1 Receptor","Cary BP","2021","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent18","cryo-EM and in vitro functional study of GLP-1 receptor agonist bound states; no humans",1],["R0014885","IBI362 (LY3305677), a weekly-dose GLP-1 and glucagon receptor dual agonist, in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple ascending dose phase 1b study.","Ji L","2021","include_nma",null,"primary_report","P02",null,"mechanistic","high","first","opus-5.5-agent02","randomized placebo controlled multiple ascending dose phase 1b trial of IBI362 mazdutide in Chinese adults with overweight or obesity",1],["R0014951","Semaglutide and Hospitalizations in Patients With Obesity and Established Cardiovascular Disease: An Exploratory Analysis of the SELECT Randomized Clinical Trial.","Nicholls SJ","2026","include_nma",null,"secondary_report","P02",null,null,"high","first","opus-5.5-agent02","exploratory analysis of SELECT placebo controlled RCT of semaglutide 2.4 mg on hospitalizations in obesity with CVD",1],["R0015040","Reduced GLP-1R availability in the caudate nucleus with Alzheimer's disease.","Barrett E","2024","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent02","postmortem brain transcriptome study of GLP-1 receptor expression in Alzheimer disease; no drug exposure",1],["R0015163","The Metabolic Heart: Reframing Heart Failure With Preserved Ejection Fraction as a Systemic Cardio-Metabolic Syndrome.","Baidya D","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent02","self described non systematic narrative review of HFpEF as cardiometabolic syndrome",1],["R0015335","Tirzepatide and the 10-year predicted risk of cardiovascular disease and type 2 diabetes in adults with obesity and prediabetes: A post hoc analysis from the three-year SURMOUNT-1 trial.","Hankosky ER","2025","include_nma",null,"secondary_report","P02",null,null,"high","first","opus-5.5-agent02","post hoc analysis of three year SURMOUNT-1 RCT of tirzepatide vs placebo in obesity with prediabetes",1],["R0015423","Efficacy of Dulaglutide in a Patient With Type 2 Diabetes, High Cardiovascular Risk, and HIV: A Case Report.","Dardano A","2022","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent02","case report of dulaglutide in a woman with T2D, HIV and high cardiovascular risk",1],["R0015494","Real-World Kidney and Glycaemic Outcomes Following Semaglutide Initiation in Adults with Type 2 Diabetes and Mild Chronic Kidney Disease.","Rabbani SA","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent02","retrospective single arm cohort of semaglutide initiation in T2D with mild CKD; no comparator",1],["R0012262","Incretin effect of glucagon-like peptide 1 receptor agonist is preserved in presence of ABCC8/SUR1 mutation in β-cell.","Bourron O","2012","inventory_only","N1","primary_report",null,null,null,"high","first","opus-5.5-agent11","letter reporting three ABCC8 mutation patients tested off treatment, on sulfonylurea and on exenatide; no randomization or concurrent control",1],["R0012345","MON-684 Comparative Effectiveness and Safety of GLP-1 Receptor Agonist versus Traditional Anti-obesity Medications: A Real-world Evidence Study",null,"2025","inventory_only","N6","conference_abstract",null,null,"abstract_only","high","first","opus-5.5-agent11","TriNetX abstract of semaglutide versus other obesity drugs; mortality, cardiovascular, kidney and GI symptom outcomes, no listed harm",1],["R0012459","A Systematic Literature Review and Network Meta-Analysis Comparing Once-Weekly Semaglutide with Other GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Previously Receiving 1-2 Oral Anti-Diabetic Drugs.","Witkowski M","2018","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent11","systematic review and network meta-analysis of semaglutide versus other GLP-1RAs; MEDLINE, Embase, Cochrane searched",1],["R0012553","Glucagon-like peptide-1 receptor agonists and heart failure in type 2 diabetes: systematic review and meta-analysis of randomized and observational studies.","Li L","2016","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent11","meta-analysis of RCTs and observational studies of GLP-1RAs on heart failure; MEDLINE, Embase, CENTRAL searched",1],["R0012647","Sodium-glucose cotransporter-2 inhibitor luseogliflozin added to glucagon-like peptide 1 receptor agonist liraglutide improves glycemic control with bodyweight and fat mass reductions in Japanese patients with type 2 diabetes: A 52-week, open-label, single-arm study.","Seino Y","2018","inventory_only","N1","primary_report",null,null,null,"high","first","opus-5.5-agent11","single arm trial of luseogliflozin added to liraglutide; GLP-1RA background only, no comparator",1],["R0012724","Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials.","Karagiannis T","2024","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent11","registered network meta-analysis of RCTs of tirzepatide versus semaglutide in type 2 diabetes",1],["R0015903","Gastrointestinal adverse events of tirzepatide in the treatment of type 2 diabetes mellitus: A meta-analysis and trials sequential analysis.","Tong K","2023","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent01","meta-analysis with trial sequential analysis of tirzepatide RCTs on gastrointestinal adverse events, eight databases searched",1],["R0016019","Pharmacological Prevention in Breast Cancer: Current Evidence, Challenges, and Future Directions.","Sarti S","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent01","narrative review of breast cancer pharmacoprevention mentioning GLP-1 RA as emerging agents",1],["R0016088","Efficacy and safety of tirzepatide for weight loss in patients with obesity or type 2 diabetes: a systematic review and meta-analysis.","Tian Q","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent01","PRISMA meta-analysis of placebo controlled tirzepatide RCTs on weight and safety, four databases searched",1],["R0016179","A real-world, observational study of weekly exenatide added to basal insulin in patients with type 2 diabetes mellitus (NCT02895672).","Stryker MD","2018","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent01","retrospective pre and post comparison of weekly exenatide versus liraglutide added to basal insulin; glycemic, weight and general safety outcomes",1],["R0016288","Use of dipeptidyl peptidase-4 inhibitors was associated with a lower risk of Parkinson's disease in diabetic patients.","Lin YH","2023","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent01","cohort of DPP-4 inhibitor users versus other oral drug users and Parkinson disease; no GLP-1 RA exposure",1],["R0016413","Cardiovascular efficacy of liraglutide and semaglutide in individuals with diabetes and peripheral artery disease.","Verma S","2022","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent01","post hoc peripheral artery disease subgroup analysis of LEADER and SUSTAIN 6 RCTs versus placebo",1],["R0016494","Outcomes of GLP-1 receptor agonist therapy in adults with sickle cell disease and type 2 diabetes: a real-world cohort analysis.","Nguefang GL","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent01","matched cohort of GLP-1 RA users versus nonusers with sickle cell disease and diabetes; MACE, CKD, crises and hypoglycemia only",1],["R0019090","Comparative Efficacy and Safety of Tirzepatide in Asians and Non-Asians with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis.","Cui Y","2024","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent12","registered SR and meta-analysis of tirzepatide RCTs vs control in Asian and non Asian T2D",1],["R0019198","Contemporary treatment patterns of overweight and obesity: insights from the Mass General Brigham health care system.","Ostrominski JW","2025","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent12","cross sectional health system analysis of anti-obesity medication eligibility and prescribing, no exposure comparison",1],["R0019310","Real-World Safety and Effectiveness of iGlarLixi in People With Type 2 Diabetes who Fast During Ramadan: Results From Wave 1 of the SOLIRAM Study","Hassanein M","2021","inventory_only","N5","conference_abstract","P01",null,"abstract_only","high","first","opus-5.5-agent12","abstract of single arm observational SOLIRAM study of iGlarLixi during Ramadan fasting",1],["R0019497","A Real-World Study of the Effectiveness and Safety of Semaglutide for Weight Loss.","Tzoulis P","2024","inventory_only","N5","primary_report","P02",null,null,"high","first","opus-5.5-agent12","retrospective single arm chart review of semaglutide for weight loss without diabetes",1],["R0019591","Effect of medication adherence on clinical outcomes in type 2 diabetes: analysis of the SIMPLE study.","Patel S","2019","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent12","prespecified adherence analysis of SIMPLE RCT liraglutide plus basal insulin vs basal bolus insulin in T2D",1],["R0019723","Continuous Subcutaneous Insulin Infusion (CSII) Combined with Oral Glucose-Lowering Drugs in Type 2 Diabetes: A Systematic Review and Network Meta-Analysis of Randomized, Controlled Trials.","Li H","2022","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent12","registered SR and network meta-analysis of RCTs of CSII combined with oral agents or GLP-1RAs in T2D",1],["R0019846","Efficacy and safety of add-on treatment with finerenone in patients with diabetic kidney disease already treated with SGLT-2 inhibitors.","Antonič M","2025","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent12","retrospective single group finerenone add on to SGLT2i in DKD, GLP-1RA only background in some patients",1],["R0016458","Semaglutide Therapy and Accelerated Sarcopenia in Older Adults with Type 2 Diabetes: A 24-Month Retrospective Cohort Study.","Ren Q","2025","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent13","matched cohort of older adults on semaglutide vs controls, muscle mass and function only",1],["R0016543","Cardiovascular and microvascular outcomes of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized controlled cardiovascular outcome trials with trial sequential analysis.","Zhang X","2018","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent13","meta-analysis of GLP-1 agonist cardiovascular outcome RCTs from three databases with trial sequential analysis",1],["R0016833","Tirzepatide: A Novel, Once-weekly Dual GIP and GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes.","Kaneko S","2022","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent13","narrative review of tirzepatide pharmacology and trials",1],["R0016950","Impact of baseline FIB-4 score on efpeglenatide benefits on cardiovascular outcomes in people with type 2 diabetes: a participant-level exploratory analysis of the AMPLITUDE-O trial.","Del Prato S","2024","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent13","participant level exploratory analysis of AMPLITUDE-O RCT of efpeglenatide vs placebo by FIB-4",1],["R0017017","Analysis of acute pancreatitis associated with SGLT-2 inhibitors and predictive factors of the death risk: Based on food and drug administration adverse event report system database.","Zhang L","2022","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent13","FAERS disproportionality analysis of SGLT2 inhibitors and pancreatitis, no GLP-1 exposure",1],["R0017118","Review Article: Fibrosis Reversal in Metabolic Dysfunction-Associated Steatohepatitis-The Promise of Emerging Therapeutics.","Ayoub M","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent13","narrative review of anti-fibrotic therapies for MASH",1],["R0016474","206. EFFECTS OF SEMAGLUTIDE ON BODY WEIGHT IN CLOZAPINE-TREATED INDIVIDUALS WITH SCHIZOPHRENIA AND OBESITY: A RANDOMIZED CONTROLLED TRIAL",null,"2025","inventory_only","N8","protocol_or_design",null,null,"abstract_only","high","first","opus-5.5-agent17","conference abstract describing the design of the COaST placebo controlled semaglutide RCT in clozapine treated schizophrenia, no results yet",1],["R0017390","Estimating Cardiovascular Benefits of Tirzepatide in Sleep Apnea and Obesity: Insight from the SURMOUNT-OSA Trials.","Beccuti G","2024","inventory_only","N9","ancillary",null,null,null,"high","first","opus-5.5-agent16","commentary on the SURMOUNT-OSA tirzepatide trials estimating cardiovascular benefit from hypoxic burden",1],["R0016566","Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial).","Kuchay MS","2020","include_nma",null,"primary_report","P01; P09",null,null,"high","first","opus-5.5-agent17","D-LIFT RCT of dulaglutide added to usual care versus usual care in type 2 diabetes with NAFLD on liver fat",1],["R0016646","Real-world evidence on the use of a fixed-ratio combination of insulin glargine and lixisenatide (iGlarLixi) in people with suboptimally controlled type 2 diabetes in Romania: a prospective cohort study (STAR.Ro).","Bala C","2022","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent17","prospective single group cohort of iGlarLixi initiators in Romania without comparison group",1],["R0016740","Association between socioeconomic factors and semaglutide use for weight loss: a population-based cross-sectional study in Denmark.","Hasselbalch RB","2025","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent17","Danish register cross sectional analysis of income and semaglutide prescription redemption; prescribing study",1],["R0016848","Effectiveness of Oral Semaglutide in Management of Type 2 Diabetes: A Real-World Study from India.","Dutta A","2024","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent17","retrospective single group cohort of oral semaglutide in India without comparison group",1],["R0016962","Tirzepatide Was Associated with Improved Health-Related Quality of Life in Adults with Obesity or Overweight and Type 2 Diabetes: Results from the Phase 3 SURMOUNT-2 Trial.","Hunter Gibble T","2025","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent17","quality of life analysis of SURMOUNT-2 RCT of tirzepatide versus placebo in obesity with type 2 diabetes",1],["R0017043","Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial.","Loomba R","2023","include_nma",null,"primary_report","P09",null,null,"high","first","opus-5.5-agent17","phase 2 placebo controlled RCT of semaglutide 2.4 mg in NASH related compensated cirrhosis",1],["R0017139","Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight.","Look M","2025","include_nma",null,"secondary_report","P02",null,null,"high","first","opus-5.5-agent17","DXA body composition substudy of SURMOUNT-1 RCT of tirzepatide versus placebo in obesity without diabetes",1],["R0017470","Efficacy and safety of once-weekly semaglutide 2.4 mg for weight management in participants from China: A prespecified analysis of the STEP 7 randomized clinical trial.","Gu W","2025","include_nma",null,"secondary_report","P99",null,null,"high","first","opus-5.5-agent16","prespecified China subgroup of STEP 7 RCT semaglutide 2.4 mg vs placebo; obesity with or without T2D, likely P02",1],["R0017536","Comparison of safety and tolerability with continuous (exenatide once weekly) or intermittent (exenatide twice daily) GLP-1 receptor agonism in patients with type 2 diabetes.","Ridge T","2012","include_nma",null,"pooled_analysis","P01",null,null,"high","first","opus-5.5-agent16","pooled safety analysis of DURATION-1 and DURATION-5 RCTs of exenatide once weekly vs twice daily; not a systematic review",1],["R0017649","Semaglultide targets Spp1+ microglia/macrophage to attenuate neuroinflammation following perioperative stroke.","Li Y","2025","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent16","mouse perioperative stroke model treated with semaglutide",1],["R0017757","The GLP-1 analog, liraglutide prevents the increase of proinflammatory mediators in the hippocampus of male rat pups submitted to maternal perinatal food restriction.","Diz-Chaves Y","2018","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent16","rat maternal food restriction model treated with liraglutide",1],["R0017859","Efficacy and safety of Mazdutide on weight loss among diabetic and non-diabetic patients: a systematic review and meta-analysis of randomized controlled trials.","Nalisa DL","2024","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent16","PROSPERO registered systematic review and meta-analysis of mazdutide vs placebo RCTs",1],["R0017952","MON-241 Efficacy and Safety of Liraglutide in Managing Obesity in Children and Adolescents: A Systematic Review and Meta-Analysis",null,"2025","include_review",null,"systematic_review",null,null,"abstract_only","high","first","opus-5.5-agent16","conference abstract of systematic review and meta-analysis of liraglutide RCTs in pediatric obesity; PubMed, Cochrane, Scopus",1],["R0018065","9229 Tirzepatide Improved Mental and Psychosocial Health-Related Quality of Life in Adults with Obesity or Overweight: Results from the SURMOUNT-4 phase 3 Trial",null,"2024","include_nma",null,"conference_abstract","P02W",null,"abstract_only","high","first","opus-5.5-agent16","conference abstract of SURMOUNT-4 randomized withdrawal of tirzepatide vs placebo after lead in; quality of life",1],["R0018297","Safety and Effectiveness of Dulaglutide in the Treatment of Type 2 Diabetes Mellitus: A Korean Real-World Post-Marketing Study.","Han J","2024","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent20","Korean post marketing single arm surveillance of dulaglutide safety and effectiveness, no comparison group",1],["R0018438","PEX-168 improves insulin resistance, inflammatory response and adipokines in simple obese mice: a mechanistic exploration.","Guo Z","2021","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent20","randomized mouse experiment of PEG-loxenatide in diet induced obesity",1],["R0018551","Dulaglutide and Dapagliflozin Combination Concurrently Improves the Endothelial Glycocalyx and Vascular and Myocardial Function in Patients with T2DM and Albuminuria vs. DPP-4i.","Korakas E","2024","include_nma",null,"primary_report","P01; P08A",null,null,"high","first","opus-5.5-agent20","RCT of dulaglutide plus dapagliflozin vs DPP-4i added to metformin in T2D with albuminuria, 12 months",1],["R0018636","From Single Agents to Synergy: Redefining Therapeutic Strategies in MASLD.","Chrysavgis L","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent20","opinion review of combination therapies in MASLD",1],["R0018760","Clustering of intuitive eating and psychological health identifies subgroups associated with weight loss following semaglutide.","Avignon A","2025","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent20","observational clustering study, weight trajectories only in semaglutide treated patients by psychological cluster",1],["R0018885","The maintenance of long-term weight loss after semaglutide withdrawal in obese women with PCOS treated with metformin: a 2-year observational study.","Jensterle M","2024","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent20","two year observational follow-up after semaglutide withdrawal in 25 women with PCOS on metformin, single group",1],["R0019017","Tirzepatide-Induced Gastrointestinal Manifestations: A Systematic Review and Meta-Analysis.","Karrar HR","2023","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent20","PRISMA meta-analysis of RCTs on tirzepatide gastrointestinal adverse events, three databases",1],["R0019130","Efficacy and safety of finerenone in obesity-related glomerulopathy.","Qiu DD","2025","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent20","retrospective finerenone vs control study in obesity related glomerulopathy, GLP-1 RA only a covariate",1],["R0018216","Association of semaglutide treatment with coronary artery inflammation in type 2 diabetes mellitus patients: a retrospective study based on pericoronary adipose tissue attenuation.","Li Y","2024","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent03","cross sectional CCTA comparison of semaglutide users vs nonusers in T2D; pericoronary fat attenuation only",1],["R0018454","RF24 | PSUN116 Once-weekly semaglutide delays a late phase gastric emptying of solid meal measured by repeated scintigraphic imaging in obese women with PCOS",null,"2022","include_nma",null,"conference_abstract","P12",null,"abstract_only; mechanistic","high","first","opus-5.5-agent03","abstract of placebo controlled RCT of semaglutide 1 mg for 8 weeks in obese PCOS; gastric emptying, weight, HbA1c",1],["R0018571","SAT-680 Reduction of liver steatosis following semaglutide treatment, bariatric surgery, and conservative multimodal therapy in patients with obesity: real-world evidence from a german university obesity center",null,"2025","inventory_only","N6","conference_abstract",null,null,"abstract_only","high","first","opus-5.5-agent03","abstract comparing semaglutide, bariatric surgery and conservative therapy on liver steatosis; no listed harm",1],["R0018664","Liraglutide-Induced Hepatotoxicity.","Maor Y","2021","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent03","case report of liraglutide induced idiosyncratic liver injury in a woman with obesity",1],["R0018793","Clinical effectiveness of liraglutide on weight loss in South Koreans: First real-world retrospective data on Saxenda in Asia.","Park JS","2021","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent03","retrospective single clinic single group study of liraglutide for obesity in Korea, no comparator",1],["R0018927","Effect of COMBinAtion therapy with remote ischemic conditioning and exenatide on the Myocardial Infarct size: a two-by-two factorial randomized trial (COMBAT-MI).","García Del Blanco B","2021","include_nma",null,"primary_report","P99",null,null,"high","first","opus-5.5-agent03","COMBAT-MI 2x2 factorial RCT of remote ischemic conditioning and exenatide vs placebo in STEMI; infarct size",1],["R0016606","Progression to type 2 diabetes among post-myocardial infarction patients with overweight or obesity: a real-world cohort study.","Tonnesen PT","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent08","Danish post MI registry cohort of diabetes progression; semaglutide benefit only projected from SELECT, not an exposure",1],["R0016701","Efficacy of Glucagon-Like Peptide-1 Analogs in Nonalcoholic Fatty Liver Disease: A Systematic Review.","Teshome G","2020","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent08","PROSPERO registered systematic review of GLP-1 analogs in NAFLD; PubMed, MEDLINE, Cochrane searched",1],["R0016918","MON-LB079 A Multicenter, Randomized, Open-Label, Phase IV Study Investigating Management of Pasireotide-Associated Hyperglycemia with Incretin-Based Therapy or Insulin in Patients with Acromegaly or Cushing's Disease (CD)","Samson S","2019","include_nma",null,"conference_abstract","P99",null,"abstract_only","high","first","opus-5.5-agent08","abstract of phase 4 RCT of incretin therapy incl liraglutide versus insulin for pasireotide hyperglycemia in acromegaly or Cushing",1],["R0016995","The revolution of the anti-diabetic drugs in cardiology.","Verdecchia P","2020","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent08","narrative review of antidiabetic drug cardiovascular outcome trials",1],["R0017202","Efficacy of semaglutide in reducing atrial fibrillation recurrence post-catheter ablation: propensity score-matched analysis",null,"2025","inventory_only","N6","conference_abstract",null,null,"abstract_only","high","first","opus-5.5-agent08","abstract of matched cohort of semaglutide users versus nonusers on AF recurrence after ablation",1],["R0018010","Is liraglutide safe and effective in the elderly obese patients?: A single center experience.","Oral A","2025","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent04","retrospective single group of older adults with obesity on liraglutide, weight change and adverse effects, no comparison group",1],["R0018103","Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin.","Jensterle Sever M","2014","include_nma",null,"primary_report","P12",null,null,"high","first","opus-5.5-agent04","three arm RCT of metformin vs liraglutide vs combination in obese women with PCOS",1],["R0018230","Development of the Weight and Emotions Scale (WES).","Kanu C","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent04","development of a patient reported outcome scale from exit and cognitive interviews, methods paper",1],["R0018313","Incretin hormones and the satiation signal.","Holst JJ","2013","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent04","narrative review of incretin hormones and satiation",1],["R0018456","Polypharmacy in older patients with diabetes mellitus: a population based-study of northern Italy.","Succurro E","2025","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent04","Lombardy administrative study of polypharmacy trends and predictors in older adults with diabetes, drug utilization only",1],["R0018574","Comparison of the effects of twice-daily exenatide and insulin on carotid intima-media thickness in type 2 diabetes mellitus patients: a 52-week randomized, open-label, controlled trial.","Zhang J","2020","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent04","52 week open label RCT of exenatide twice daily vs premixed insulin aspart on carotid IMT in type 2 diabetes",1],["R0018665","Effect of the glucagon-like peptide-1 analogue liraglutide on coronary microvascular function in patients with type 2 diabetes - a randomized, single-blinded, cross-over pilot study.","Faber R","2015","include_nma",null,"primary_report","P01",null,"crossover","high","first","opus-5.5-agent04","randomized single blind crossover trial of liraglutide vs no added treatment on coronary flow reserve in type 2 diabetes",1],["R0018803","Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity.","Zile MR","2025","include_nma",null,"secondary_report","P07A",null,null,"high","first","opus-5.5-agent04","expanded analysis of SUMMIT RCT of tirzepatide vs placebo in HFpEF with obesity, KCCQ and clinical events",1],["R0019988","Non-Alcoholic Steatohepatitis Patient Characterization and Real-World Management Approaches in Italy.","Bugianesi E","2024","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent06","cross sectional physician survey describing NASH patient characteristics and management; no GLP-1 RA exposure comparison",1],["R0020140","Long-term benefits of dapagliflozin on renal outcomes of type 2 diabetes under routine care: a comparative effectiveness study on propensity score matched cohorts at low renal risk.","Fadini GP","2024","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent06","DARWIN-Renal dapagliflozin versus pooled comparators of which GLP-1 RA are a minority; GLP-1 RA not studied as exposure",1],["R0020256","Combination strategies for pharmacologic treatment of non-alcoholic steatohepatitis.","Suri J","2022","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent06","narrative review of combination drug strategies for NASH",1],["R0020393","Incretin-based injectable strategies versus intensified insulin for treatment intensification and simplification in type 2 diabetes: a systematic review and meta-analysis.","Mahmood T","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent06","meta-analysis of RCTs comparing incretin based injectables with intensified insulin in T2D; four sources searched",1],["R0020478","Neuroprotective effects of (Val8)GLP-1-Glu-PAL in the MPTP Parkinson's disease mouse model.","Zhang Y","2015","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent06","MPTP mouse model study of a GLP-1 analogue for Parkinson neuroprotection",1],["R0020610","GLP-1 analogues for neuroprotection after out-of-hospital cardiac arrest: study protocol for a randomized controlled trial.","Wiberg S","2016","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent06","protocol of double blind RCT of exenatide infusion versus placebo after out of hospital cardiac arrest; no results",1],["R0018071","Liraglutide for idiopathic intracranial hypertension: a real-world propensity score-matched study.","Azzam AY","2025","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent18","TriNetX matched cohort liraglutide plus standard therapy vs standard therapy in IIH; papilledema, headache, BMI; no listed harms",1],["R0018188","The NAVETA obesity consensus tool: a multidimensional framework for clinical and patient-reported outcome assessment.","Mercadal-Orfila G","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent18","Delphi consensus framework for outcome assessment in obesity care; consensus statement, no drug comparison",1],["R0018286","MON-516 Effectiveness of Semaglutide on Cardiovascular Outcomes in Chronic Kidney Disease (CKD) Patients with Type 2 Diabetes Mellitus: A Systemic Review and Meta-analysis",null,"2025","include_review",null,"systematic_review",null,null,"abstract_only","high","first","opus-5.5-agent18","conference abstract of registered meta-analysis of semaglutide RCTs on CV outcomes in CKD with T2D; PubMed, Cochrane, Embase",1],["R0018433","Evaluating the effects of liraglutide, empagliflozin and linagliptin on mild cognitive impairment remission in patients with type 2 diabetes (LIGHT-MCI): study protocol for a multicentre, randomised controlled trial with an extension phase.","Yu C","2025","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent18","protocol of LIGHT-MCI RCT of liraglutide vs empagliflozin vs linagliptin for MCI remission in T2D; no results",1],["R0018543","Evaluation of the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Dulaglutide and Sitagliptin in the Spanish Setting.","Martín V","2020","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent18","cost effectiveness modeling of semaglutide vs dulaglutide and sitagliptin in Spain using CORE Diabetes Model",1],["R0018632","Tirzepatide Improved Health-Related Quality of Life Compared with Insulin Lispro in Basal Insulin-Treated Adults with Type 2 Diabetes and Inadequate Glycaemic Control: A Randomised Controlled Phase 3b Trial (SURPASS-6).","Boye KS","2024","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent18","patient reported outcomes from SURPASS-6 open label RCT, tirzepatide vs insulin lispro added to basal insulin in T2D",1],["R0018881","Improved glycemic control and reduced bodyweight with exenatide: A double-blind, randomized, phase 3 study in Japanese patients with suboptimally controlled type 2 diabetes over 24 weeks.","Kadowaki T","2011","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent18","double blind phase 3 RCT of exenatide 5 or 10 mcg twice daily vs placebo on sulfonylurea in Japanese T2D",1],["R0013644","Association of Tirzepatide Use With Clinical Outcomes After TAVR in Obese Patients: A Propensity Score-Matched Real-World Study.","Mortada I","2026","include_harms",null,"primary_report",null,"O121",null,"high","first","opus-5.5-agent10","TriNetX matched cohort tirzepatide initiators versus nonusers after TAVR; acute kidney injury secondary outcome",1],["R0013752","Partially reversible bilateral non-arteritic anterior ischemic optic neuropathy and branch retinal artery occlusion following semaglutide use. a case report.","Alsakran WA","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent10","case report of bilateral NAION and retinal artery occlusion during semaglutide use",1],["R0013830","Emerging Strategies for Cardio-Renal Protection Beyond RAAS Blockade: Emphasis on Non-diabetic CKD and Resistant Hypertension.","Alrashidi FS","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent10","narrative review of cardiorenal protection strategies in nondiabetic CKD; no systematic methods",1],["R0013942","Post Hoc Analysis Evaluating the Impact of Antihyperglycemic Background Therapies on Attainment of A1C Targets Without Hypoglycemia in the ACHIEVE Control Pragmatic, Real-Life Study.","Bailey TS","2021","inventory_only","N3","secondary_report",null,null,null,"high","first","opus-5.5-agent10","post hoc of ACHIEVE Control RCT Gla-300 versus standard basal insulin by background GLP-1 RA use; GLP-1 not randomized",1],["R0014007","A single dose of exenatide had no effect on blood flow velocity in the middle cerebral artery in elderly healthy volunteers: Randomized, placebo-controlled, double-blind clinical trial.","Ölmestig J","2022","include_nma",null,"primary_report","P99",null,"mechanistic","high","first","opus-5.5-agent10","double blind RCT single dose exenatide versus placebo in healthy elderly volunteers; cerebral flow plus adverse events recorded",1],["R0014092","Optimization of patient and site engagement in the SYNCHRONIZE™ phase 3 clinical trial program for survodutide in obesity through clinical trial simulation.","Rubino DM","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent10","clinical trial simulation interviews with participants and site staff about survodutide trial design; qualitative, no exposure",1],["R0014201","Validation of radiolabelled exendin for beta cell imaging by ex vivo autoradiography and immunohistochemistry of human pancreas.","Jansen TJP","2024","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent10","validation of radiolabelled exendin 4 tracer for beta cell imaging in pancreatic surgery patients; diagnostic, not therapeutic",1],["R0014285","LBSUN319 Characteristics And Treatment Patterns Of Hispanic/latino Patients Initiating First Injectable Glp-1ra Or Basal Insulin",null,"2022","exclude","E2","conference_abstract",null,null,"abstract_only","high","first","opus-5.5-agent10","abstract describing characteristics and treatment patterns of Hispanic patients starting GLP-1 RA or basal insulin; descriptive utilization",1],["R0015606","Comparative efficacy of pharmacological interventions on metabolic and hormonal outcomes in polycystic ovary syndrome: a Network Meta-Analysis of Randomized controlled trials.","Bo Y","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent02","systematic review and network meta-analysis of RCTs of drugs including GLP-1 RA in PCOS; four databases searched",1],["R0017251","Acute Coronary Syndromes: State-of-the-Art Diagnosis, Management, and Secondary Prevention.","Yuan X","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent14","state of the art narrative review of acute coronary syndrome management",1],["R0015729","Adjunctive Semaglutide in Patients Undergoing Intragastric Balloon for Weight Loss: 12-Month Prospective Comparative Study.","Barakat KE","2025","include_nma",null,"primary_report","P02",null,null,"high","first","opus-5.5-agent02","randomized trial of intragastric balloon plus semaglutide vs balloon alone in adults with overweight or obesity",1],["R0015831","Pathogenesis of diabetic cardiomyopathy and emerging therapeutic strategies: a network-based perspective.","Ren H","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent02","narrative review of diabetic cardiomyopathy pathogenesis and therapies",1],["R0015908","Impact of semaglutide use on glycemic and metabolic profile in adults with type 1 diabetes having overweight or obesity: A systematic review and meta-analysis.","Dutta D","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent02","registered systematic review and meta-analysis of semaglutide in adults with type 1 diabetes and overweight",1],["R0016020","Effects of Tirzepatide on Low-Density Lipoprotein Cholesterol Levels in Adults: A Systematic Review.","Hong I","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent02","systematic review of tirzepatide RCTs and observational studies on LDL cholesterol; three databases searched",1],["R0016089","Weight Loss as a Determinant of Histological Improvement in Metabolic Dysfunction-Associated Steatotic Liver Disease in People With Obesity. A Systematic Review and Network Meta-Analysis of Randomised Clinical Trials.","Monami M","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent02","registered network meta-analysis of RCTs of obesity treatments including semaglutide and tirzepatide in MASH",1],["R0016183","Drug treatment for metabolic dysfunction-associated steatotic liver disease: Progress and direction.","Zhou D","2024","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent02","narrative review of drug therapy for MASLD and MASH",1],["R0016292","Effects of liraglutide on depressive behavior and cognitive function in the probe trial of Morris water maze test","Jon D","2025","exclude","E1","other",null,null,"abstract_only","high","first","opus-5.5-agent02","conference abstract of liraglutide in mice under chronic stress; animal study only",1],["R0017378","Role of liraglutide in Alzheimer's disease pathology.","Vargas-Soria M","2021","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent14","narrative minireview of liraglutide in Alzheimer disease pathology",1],["R0017458","Time to weight plateau with tirzepatide treatment in the SURMOUNT-1 and SURMOUNT-4 clinical trials.","Horn DB","2025","include_nma",null,"secondary_report","P02; P02W",null,null,"high","first","opus-5.5-agent14","post hoc analysis of SURMOUNT-1 and SURMOUNT-4 RCTs on time to weight plateau with tirzepatide",1],["R0017641","Efficacy and Safety of IDegLira in Participants with Type 2 Diabetes in India Uncontrolled on Oral Antidiabetic Drugs and Basal Insulin: Data from the DUAL Clinical Trial Program.","Khunti K","2017","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent14","post hoc analysis of Indian participants in DUAL I, II and IV RCTs of IDegLira vs comparators",1],["R0017744","From liver to hormones: The endocrine consequences of cirrhosis.","Quiroz-Aldave JE","2024","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent14","narrative review of endocrine consequences of cirrhosis",1],["R0017931","5183 Tirzepatide Improved Health-Related Quality of Life in People with Obesity or Overweight: Results from SURMOUNT-4 Phase 3 Trial",null,"2024","include_nma",null,"conference_abstract","P02W",null,"abstract_only","high","first","opus-5.5-agent14","conference abstract of SURMOUNT-4 randomized withdrawal of tirzepatide vs placebo, quality of life",1],["R0015895","Suboptimal therapeutic responses associated with semaglutide in type 2 diabetes and obesity: A meta-analysis of randomized controlled trials.","Ko D","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent19","meta-analysis of RCTs of semaglutide vs placebo or standard care on suboptimal response; Medline Embase searched, PROSPERO",1],["R0016000","Study design and baseline profile for adults with type 2 diabetes in the once-weekly subcutaneous SEmaglutide randomized PRAgmatic (SEPRA) trial.","Buse JB","2023","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent19","design and baseline profile of SEPRA pragmatic RCT of semaglutide vs standard care in type 2 diabetes",1],["R0016080","Long-Term Cost-Effectiveness Analysis of Once-Weekly Semaglutide versus Dulaglutide in Patients with Type 2 Diabetes with Inadequate Glycemic Control in China.","Ruan Z","2022","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent19","long term cost effectiveness model of semaglutide vs dulaglutide in China; economic evaluation",1],["R0016171","Consistent improvements in liver histology across subgroups in a post hoc analysis of the SYNERGY-NASH trial with tirzepatide.","Hartman ML","2025","include_nma",null,"secondary_report","P09",null,null,"high","first","opus-5.5-agent19","post hoc subgroup analysis of SYNERGY-NASH RCT of tirzepatide vs placebo in MASH with fibrosis",1],["R0016265","Effect of tirzepatide treatment on patient-reported outcomes among SURMOUNT-OSA participants with obstructive sleep apnea and obesity.","Kanu C","2025","include_nma",null,"secondary_report","P10",null,null,"high","first","opus-5.5-agent19","patient reported outcomes from SURMOUNT-OSA RCTs of tirzepatide vs placebo in sleep apnea with obesity",1],["R0016393","The Effectiveness of Semaglutide on a Composite Endpoint of Glycemic Control and Weight Reduction and Its Effect on Lipid Profile Among Obese Type 2 Diabetes Patients.","Alarfaj SJ","2025","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent19","retrospective single group cohort of semaglutide in obese type 2 diabetes, composite target achievement",1],["R0016485","Effect of Once Weekly Semaglutide in Patients with Type 2 Diabetes in National Guard Primary Health Care, Jeddah, Saudi Arabia: a retrospective cohort study.","Alzahrani MA","2023","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent19","retrospective single group cohort of semaglutide users in Saudi primary care with before and after HbA1c and weight",1],["R0016592","Effectiveness of tirzepatide in patients with HFpEF using a target trial emulation retrospective cohort study.","Lin YM","2025","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent01","target trial emulation cohort of tirzepatide versus nonusers in HFpEF; heart failure, death, MACE and dialysis or ESKD outcomes only",1],["R0016770","Metabolic Dysfunction-Associated Steatotic Liver Disease: Current Treatment Strategies and Novel Therapies.","Shenoy A","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent01","narrative review of current and novel MASLD treatments including semaglutide",1],["R0016877","Impact of liraglutide on albumin-to-creatinine ratio in type 2 diabetes mellitus: a meta-analysis.","Wang F","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent01","registered meta-analysis of liraglutide RCTs on albumin to creatinine ratio, five databases searched",1],["R0016969","Efficacy and safety of novel twincretin tirzepatide a dual GIP and GLP-1 receptor agonist in the management of type-2 diabetes: A Cochrane meta-analysis.","Dutta D","2021","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent01","registered meta-analysis of tirzepatide RCTs versus placebo or active comparators in type 2 diabetes",1],["R0017067","Safety and efficacy of liraglutide in patients with type 2 diabetes and end-stage renal disease: protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded, parallel intervention study.","Idorn T","2013","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent01","protocol of placebo controlled RCT of liraglutide in type 2 diabetes with ESRD and with normal kidney function",1],["R0017172","Gastrointestinal tolerability and weight reduction associated with tirzepatide in adults with obesity or overweight with and without type 2 diabetes in the SURMOUNT-1 to -4 trials.","Rubino DM","2025","include_nma",null,"secondary_report","P02; P01; P02W",null,null,"high","first","opus-5.5-agent01","post hoc GI tolerability analysis of SURMOUNT-1 to 4 RCTs of tirzepatide versus placebo",1],["R0017298","Risk of biliary diseases in patients with type 2 diabetes or obesity treated with tirzepatide: A meta-analysis.","Gong J","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent01","meta-analysis of tirzepatide RCTs on biliary disease and pancreatitis, four databases searched",1],["R0017331","Mode of administration of dulaglutide: implications for treatment adherence.","Amblee A","2016","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent07","narrative review of dulaglutide administration and adherence based on a PubMed search",1],["R0017419","Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer's disease: study protocol for a randomised controlled trial (ELAD study).","Femminella GD","2019","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent07","ELAD protocol for placebo controlled RCT of liraglutide in mild Alzheimer disease",1],["R0017517","A Critical View over the Newest Antidiabetic Molecules in Light of Efficacy-A Systematic Review and Meta-Analysis.","Salmen T","2023","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent07","PROSPERO registered meta-analysis of trials of newest antidiabetic drugs including GLP-1RA and tirzepatide on HbA1c",1],["R0017713","Efficacy of Semaglutide in Modulating Cardiac Remodeling in Mice: A Review of Mechanisms and Outcomes.","Fairy R","2025","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent07","review restricted to mouse studies of semaglutide on cardiac remodeling",1],["R0017820","Comparative Effects of Liraglutide-R-Alpha Lipoic Acid Combination and Donepezil on Diazepam-Induced Amnesia in Rats.","Kumar S","2025","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent07","randomized experiment in rats comparing liraglutide plus lipoic acid with donepezil on amnesia",1],["R0017896","Liraglutide, a glucagon-like peptide-1 analog, increased insulin sensitivity assessed by hyperinsulinemic-euglycemic clamp examination in patients with uncontrolled type 2 diabetes mellitus.","Jinnouchi H","2015","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent07","nonrandomized inpatient comparison of liraglutide vs intensive insulin on clamp insulin sensitivity; no listed harm",1],["R0018019","Predictive factors of response to liraglutide in patients with type 2 diabetes mellitus and metabolic syndrome.","Song J","2024","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent07","retrospective single drug liraglutide cohort comparing responders and nonresponders, no comparator treatment",1],["R0019250","Efficacy and safety of semaglutide combined with metformin in treating T2DM with overweight or obesity: a systematic review and meta-analysis.","Li J","2024","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent20","meta-analysis of RCTs of oral semaglutide plus metformin vs metformin in overweight T2D, eight databases",1],["R0019346","Effective treatment for fatty liver of liraglutide via inhibiting endoplasmic reticulum stress, oxidative stress and apoptosis pathways.","Li J","2025","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent20","bioinformatic, rat and cell study of liraglutide in fatty liver, no human intervention",1],["R0019436","Real-world clinical evidence of oral semaglutide on metabolic abnormalities in subjects with type 2 diabetes: a multicenter retrospective observational study (the Sapporo-Oral SEMA study).","Furusawa S","2024","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent20","multicenter retrospective single arm cohort of oral semaglutide initiators in Japan, no comparison group",1],["R0019536","Drug-Associated Parosmia: New Perspectives from the WHO Safety Database.","Merino D","2022","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent20","VigiBase disproportionality analysis of drug associated parosmia including incretin mimetics",1],["R0019643","Comparison of changes in adipokine and inflammatory cytokine levels in patients with newly diagnosed type 2 diabetes treated with exenatide, insulin, or pioglitazone: A post-hoc study of the CONFIDENCE trial.","Yang X","2024","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent20","post hoc cytokine analysis of randomized CONFIDENCE trial of exenatide vs insulin vs pioglitazone in new T2D",1],["R0019776","Efficacy and safety of oral semaglutide vs sitagliptin in a predominantly Chinese population with type 2 diabetes uncontrolled with metformin: PIONEER 12, a double-blind, Phase IIIa, randomised trial.","Ji L","2024","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent20","double blind phase 3a RCT PIONEER 12 of oral semaglutide doses vs sitagliptin on metformin",1],["R0019869","Genetic variants and characterization of MODY in a single, large pediatric referral center.","Deng L","2025","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent20","pediatric MODY chart review, GLP-1 RA use only described in a few patients, no exposure comparison",1],["R0019964","Glycemic Control and Body Weight Reduction with Once-Weekly Semaglutide in Colombian Adults with Type 2 Diabetes: Findings from the COLIBRI Study.","Serpa-Díaz D","2024","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent20","retrospective single arm multicenter COLIBRI study of weekly semaglutide in Colombia",1],["R0014127","Effect of Semaglutide on Insulin Sensitivity and Cardiometabolic Risk Factors in Adolescents With Obesity: The STEP TEENS Study.","Arslanian S","2026","include_nma",null,"secondary_report","P03",null,null,"high","first","opus-5.5-agent15","secondary analysis of STEP TEENS RCT of semaglutide 2.4 mg versus placebo in adolescents with obesity; insulin sensitivity outcomes",1],["R0014216","Liraglutide in adults with type 2 diabetes: global perspective on safety, efficacy and patient preference.","Yabe D","2011","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent15","narrative review of liraglutide trials and safety in type 2 diabetes",1],["R0014313","Updating the MASH pharmacotherapy landscape: a network meta-analysis incorporating SGLT2 inhibitors and emerging combination therapies.","Tang M","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent15","registered network meta-analysis of RCTs of MASH drugs incl GLP-1 RAs and dual agonists; five databases searched",1],["R0014394","Effect of GLP-1 Receptor Agonists on Renal Functions and Diabetic Nephropathy in Type 2 Diabetes Mellitus (T2DM) Patients: A Systematic Review and Meta-Analysis.","Mohamed AJ","2024","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent15","PRISMA systematic review and meta-analysis of 11 studies of GLP-1 RAs on renal function in type 2 diabetes; PubMed and Google Scholar",1],["R0014587","Resource use and outcomes associated with initiation of injectable therapies for patients with type 2 diabetes mellitus.","Brice R","2015","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent15","NHS service evaluation of GLP-1 RA versus basal insulin initiation; HbA1c, weight, staff costs and experience only",1],["R0014690","Tirzepatide modulates gut microbiota homeostasis to protect against diabetic kidney disease.","Ma J","2025","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent15","db/db mouse study of tirzepatide on diabetic kidney disease and gut microbiota; animals only",1],["R0014760","Emerging perspectives on once-weekly insulins in type 1 and type 2 diabetes: a mini-review.","Denimal D","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent15","mini review of once weekly insulin trials incl IcoSema",1],["R0012874","Cardiovascular and renal outcomes of GLP-1 receptor agonists vs. DPP-4 inhibitors and basal insulin in type 2 diabetes mellitus: A systematic review and meta-analysis.","Evans M","2023","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent11","registered meta-analysis of observational comparisons of GLP-1RA versus DPP-4i or basal insulin on cardiorenal outcomes; named databases",1],["R0012981","Combination therapy with GLP-1 receptor agonists and basal insulin: a systematic review of the literature.","Balena R","2013","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent11","systematic review of GLP-1RA plus basal insulin combination trials and observational studies; Medline, Embase, Biosis searched",1],["R0013175","FRAILTY AND THE EFFECTIVENESS AND SAFETY OF NEW GLUCOSE-LOWERING DRUGS IN OLDER ADULTS WITH TYPE 2 DIABETES","Kim D","2019","inventory_only","N6","conference_abstract",null,null,"abstract_only","high","first","opus-5.5-agent11","symposium abstract of Medicare cohorts including SGLT2i versus GLP-1RA; cardiovascular and hypoglycemia outcomes only",1],["R0013289","Comparison of antidiabetic drugs added to sulfonylurea monotherapy in patients with type 2 diabetes mellitus: A network meta-analysis.","Qian D","2018","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent11","network meta-analysis of RCTs of add on drugs including GLP-1RA to sulfonylurea; PubMed, Cochrane, Embase",1],["R0013463","The Management of Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide: A Long-Term Cost-Effectiveness Analysis in Slovakia.","Malkin SJP","2019","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent11","CORE Diabetes Model cost effectiveness analysis of semaglutide versus dulaglutide in Slovakia",1],["R0013555","The glucagon-like peptide-1 receptor agonist, liraglutide, attenuates the progression of overt diabetic nephropathy in type 2 diabetic patients.","Imamura S","2013","inventory_only","N1","primary_report",null,null,null,"high","first","opus-5.5-agent11","single arm 12 month liraglutide study in overt diabetic nephropathy; no comparator",1],["R0013643","The role of endothelial nitric oxide in the anti-restenotic effects of liraglutide in a mouse model of restenosis.","Kushima H","2017","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent09","mouse restenosis model and endothelial cell experiments with liraglutide, no humans",1],["R0019149","FRI068 Gender Differences In Smoking Cessation? Results Of A Randomized Controlled Trial Of Dulaglutide-assisted Smoking Cessation",null,"2023","include_nma",null,"conference_abstract","P14B",null,"abstract_only","high","first","opus-5.5-agent03","abstract of predefined secondary analysis of RCT dulaglutide vs placebo for smoking cessation by gender",1],["R0013748","Benefit-Risk Assessment of Alogliptin for the Treatment of Type 2 Diabetes Mellitus.","Kaku K","2019","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent09","narrative benefit risk review of the DPP-4 inhibitor alogliptin",1],["R0013823","Metabolic reprogramming in diabetic panvascular disease: Molecular mechanism and therapeutic strategies.","Bai Y","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent09","narrative review of metabolic reprogramming in diabetic vascular disease",1],["R0014005","Efficacy and Safety of Pharmacological, Endoscopic, and Surgical Treatments for Obesity: A GRADE-Based Network Meta-Analysis.","De Luca M","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent09","PROSPERO registered NMA of RCTs of obesity drugs including GLP-1 agents, endoscopy and surgery, MEDLINE and Embase",1],["R0014191","Liraglutide protects against diastolic dysfunction and improves ventricular protein translation","Rutledge C","2022","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent09","mouse angiotensin II model of diastolic dysfunction treated with liraglutide, no humans",1],["R0014278","Targeting Cellulite as a Metabolic-Dermal Interface: Effects of Tirzepatide and a Multi-Pathway Topical Therapy (G21) in a 12-Month Observational Study.","Adamidis N","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent09","retrospective three group comparison of tirzepatide, topical G21 or both on cellulite and body composition, no eligible harm",1],["R0019269","Effect of the Glucagon-like Peptide-1 Analogue Exenatide Extended Release in Cats with Newly Diagnosed Diabetes Mellitus.","Riederer A","2016","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent03","placebo controlled trial of exenatide ER in diabetic cats; veterinary, no humans",1],["R0019355","Change in HbA1c Across the Baseline HbA1c Range in Type 2 Diabetes Patients Receiving Once-Weekly Dulaglutide Versus Other Incretin Agents.","Gentilella R","2019","include_nma",null,"pooled_analysis","P01",null,null,"high","first","opus-5.5-agent03","post hoc analysis of AWARD-1, -5, -6 RCTs, dulaglutide vs sitagliptin, liraglutide, exenatide on HbA1c",1],["R0019458","Impact of Semaglutide on Body Composition in Adults With Overweight or Obesity: Exploratory Analysis of the STEP 1 Study","Wilding J","2021","include_nma",null,"conference_abstract","P02",null,"abstract_only","high","first","opus-5.5-agent03","abstract of STEP 1 DEXA substudy, semaglutide 2.4 mg vs placebo in overweight or obesity",1],["R0019542","Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population.","Wang W","2024","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent03","TriNetX cohort semaglutide vs other anti-obesity drugs; alcohol use disorder incidence and recurrence only",1],["R0019663","Efficacy and safety of oral semaglutide monotherapy vs placebo in a predominantly Chinese population with type 2 diabetes (PIONEER 11): a double-blind, Phase IIIa, randomised trial.","Wang W","2024","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent03","PIONEER 11 double blind RCT of oral semaglutide 3, 7, 14 mg vs placebo in mainly Chinese T2D",1],["R0019796","S90. A SYSTEMATIC REVIEW AND META-ANALYSIS OF PHARMACOLOGICAL INTERVENTIONS FOR REDUCTION OF WEIGHT GAIN IN PEOPLE WITH SCHIZOPHRENIA: 2019 UPDATE","Agarwal S","2020","include_review",null,"systematic_review",null,null,"abstract_only","high","first","opus-5.5-agent03","abstract of Cochrane based meta-analysis of drugs for weight gain in schizophrenia incl. GLP-1 RA vs placebo",1],["R0019887","Comparisons of weight changes between sodium-glucose cotransporter 2 inhibitors treatment and glucagon-like peptide-1 analogs treatment in type 2 diabetes patients: A meta-analysis.","Cai X","2017","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent03","meta-analysis of placebo controlled RCTs comparing weight change with SGLT2i and GLP-1 RA in T2D; MEDLINE searched",1],["R0018168","Reducing or Discontinuing Insulin or Sulfonylurea When Initiating a Glucagon-like Peptide-1 Agonist.","Herron E","2024","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent16","single center QI chart review of insulin or sulfonylurea reduction after GLP-1RA initiation, no comparison group",1],["R0018283","Glucagon-Like Peptide Receptor-1 Agonists Used for Medically-Supervised Weight Loss in Patients With Hip and Knee Osteoarthritis: Critical Considerations for the Arthroplasty Surgeon.","Heckmann ND","2024","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent16","narrative review of GLP-1RAs for arthroplasty surgeons",1],["R0018624","Lixisenatide Reduces Chylomicron Triacylglycerol by Increased Clearance.","Whyte MB","2019","include_nma",null,"primary_report","P01",null,"mechanistic; crossover","high","first","opus-5.5-agent16","double blind randomized crossover of lixisenatide vs placebo in obese men with T2D; lipid and glucose kinetics",1],["R0018741","Once-weekly semaglutide doubles the five-year risk of nonarteritic anterior ischemic optic neuropathy in a Danish cohort of 424,152 persons with type 2 diabetes.","Grauslund J","2024","include_harms",null,"primary_report",null,"O34",null,"high","first","opus-5.5-agent16","Danish registry cohort of semaglutide exposed vs unexposed persons with T2D; incident NAION",1],["R0018867","Semaglutide for the management of diabesity: The real-world experience.","Alkhalifah M","2024","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent16","retrospective single group review of semaglutide in T2D with obesity, no comparator",1],["R0018987","Clinical and Patient-Related Variables Associated with Initiating GLP-1 Receptor Agonist Therapy in Type 2 Diabetes Patients in Primary Care in Germany.","Qiao Q","2016","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent16","prescribing study of factors associated with initiating GLP-1RA vs other drugs; no outcome comparison by exposure",1],["R0019923","A commentary on 'Boosting weight loss after conversional Roux-en-Y Gastric Bypass with liraglutide and placebo use. A double-blind-randomized controlled trial'.","Han T","2024","inventory_only","N9","ancillary",null,null,null,"high","first","opus-5.5-agent12","letter commenting on an RCT of liraglutide vs placebo after conversional gastric bypass, an in scope trial",1],["R0020013","Semaglutide in Heart Failure: A Systematic Review of Outcomes of Semaglutide in Heart Failure Patients.","Gupta N","2024","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent12","SR of semaglutide RCTs and observational study in heart failure, named databases and inclusion criteria, qualitative synthesis",1],["R0020165","Development and Content Evaluation of the Eating Behavior and Appetite Questionnaire (EBAQ) for Individuals with Obesity.","Kanu C","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent12","development and content validation of an eating behavior questionnaire, methods paper drawing on retatrutide trial exit interviews",1],["R0020306","Blood-Brain Glucose Transfer in Alzheimer's disease: Effect of GLP-1 Analog Treatment.","Gejl M","2017","include_nma",null,"secondary_report","P13A",null,null,"high","first","opus-5.5-agent12","secondary PET analysis of 26 week RCT of liraglutide vs placebo in Alzheimer disease",1],["R0020425","The short-term cost-effectiveness of once-daily liraglutide versus once-weekly exenatide for the treatment of type 2 diabetes mellitus in the United States.","Wang B","2015","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent12","short term cost effectiveness decision model of liraglutide vs exenatide once weekly",1],["R0020532","Fragment-Guided New Therapeutic Molecule Discovery and Mapping of Clinically Relevant Interactomes","Kanapeckaitė A","2025","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent12","in silico fragment guided drug discovery including GLP-1 receptor targets, no human participants",1],["R0020678","Clinical Trial Highlights - GLP-1 agonists.","McFarthing K","2020","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent12","clinical trial highlights overview of GLP-1RA trials in Parkinson disease, news style review",1],["R0020836","The Durable Safety and Effectiveness of Lixisenatide in Japanese People with Type 2 Diabetes: The Post-Marketing Surveillance PRANDIAL Study.","Terauchi Y","2022","inventory_only","N5","primary_report","P01",null,null,"high","first","opus-5.5-agent12","single arm post marketing surveillance cohort of lixisenatide in Japanese T2D",1],["R0017333","Comparative Efficacy and Safety of Oral Semaglutide in Asians and Non-Asians Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis.","Wang T","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent08","meta-analysis of oral semaglutide RCTs comparing Asian and non-Asian subgroups; PubMed, Cochrane, CNKI searched",1],["R0017423","Liraglutide inhibits the proliferation of rat hepatic stellate cells under high glucose conditions by suppressing the ERK signaling pathway.","Fan B","2025","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent08","in vitro study of liraglutide on rat hepatic stellate cells",1],["R0017597","Comparative effectiveness of tirzepatide versus thiazolidinedione in adults with MASLD: a propensity score-matched cohort study.","Wu JY","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent08","TriNetX new user cohort of tirzepatide versus TZD in MASLD; composite mortality, liver, cardiovascular, kidney events only",1],["R0017714","Exploratory analysis of eating- and physical activity-related outcomes from a randomized controlled trial for weight loss maintenance with exercise and liraglutide single or combination treatment.","Jensen SBK","2022","include_nma",null,"secondary_report","P02",null,null,"high","first","opus-5.5-agent08","exploratory outcomes of factorial RCT of liraglutide, exercise, both or placebo for weight maintenance after diet",1],["R0017824","Anti-atherosclerotic effect of incretin mimetics: a meta-analysis of randomized controlled trials.","Barbarawi M","2018","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent08","meta-analysis of RCTs of incretin mimetics incl GLP-1 RA versus conventional therapy on carotid IMT",1],["R0017897","The potential antidepressant effect of antidiabetic agents: New insights from a pharmacovigilance study based on data from the reporting system databases FAERS and VigiBase.","Battini V","2023","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent08","FAERS and VigiBase case non-case disproportionality analysis of antidiabetic drugs and antidepressant failure",1],["R0018021","Impact of patient characteristics on efficacy and safety of once-weekly semaglutide versus dulaglutide: SUSTAIN 7 post hoc analyses.","Pratley RE","2020","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent08","SUSTAIN 7 post hoc subgroup analyses of randomized semaglutide versus dulaglutide in type 2 diabetes",1],["R0018118","Investigating the effects of semaglutide in early Alzheimer’s disease using single‐cell transcriptomics and proteomics – rationale and design","Johannsen P","2024","inventory_only","N8","protocol_or_design",null,null,"abstract_only","high","first","opus-5.5-agent07","abstract describing rationale and design of a placebo controlled RCT of semaglutide in early Alzheimer disease",1],["R0018243","Comparison of GLP-1 analogues versus sitagliptin in the management of type 2 diabetes: systematic review and meta-analysis of head-to-head studies.","Wang T","2014","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent07","meta-analysis of head to head RCTs of GLP-1RA vs sitagliptin in type 2 diabetes",1],["R0018327","Liraglutide and Colesevelam Change Serum and Fecal Bile Acid Levels in a Randomized Trial With Patients With Bile Acid Diarrhea.","Ellegaard AM","2024","include_nma",null,"secondary_report","P99",null,null,"high","first","opus-5.5-agent07","secondary bile acid analysis of double blind RCT of liraglutide vs colesevelam in bile acid diarrhea",1],["R0018469","Liraglutide Treatment Improves Glycaemic Dysregulation, Body Composition, Cardiometabolic Variables and Uncontrolled Eating Behaviour in Adolescents with Severe Obesity.","Apperley L","2025","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent07","retrospective single group cohort of adolescents with severe obesity started on liraglutide",1],["R0018588","Efficacy and safety of switching to ezetimibe 10 mg/rosuvastatin 2.5 mg in Korean patients with type 2 diabetes mellitus and dyslipidaemia: A multicentre, prospective study (EROICA study).","Hong S","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent07","single arm ezetimibe rosuvastatin study in T2D; GLP-1RA users only a background subgroup",1],["R0018688","Glycemic variability in type 2 diabetes mellitus and acute coronary syndrome: liraglutide compared with insulin glargine: a pilot study.","Del Olmo-García MI","2020","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent07","open label pilot RCT of liraglutide vs insulin glargine in T2D with acute coronary syndrome",1],["R0018820","Pharmacokinetics and Safety of Cotadutide, a GLP-1 and Glucagon Receptor Dual Agonist, in Individuals with Renal Impairment: A Single-Dose, Phase I, Bridging Study.","Klein G","2023","inventory_only","N1","primary_report",null,null,null,"high","first","opus-5.5-agent07","open label single dose phase 1 PK study of cotadutide across renal function groups, no randomized comparator",1],["R0018948","Atrial Fibrillation and Semaglutide Effects in Obesity-Related Heart Failure With Preserved Ejection Fraction: STEP-HFpEF Program.","Verma S","2024","include_nma",null,"pooled_analysis","P07A; P01",null,null,"high","first","opus-5.5-agent07","pooled secondary analysis of STEP-HFpEF and STEP-HFpEF DM RCTs of semaglutide vs placebo by atrial fibrillation history",1],["R0017274","Greater Combined Reductions of HbA1c ≥ 1.0% and Body Weight Loss ≥ 5.0% or ≥ 10.0% with Orally Administered Semaglutide Versus Comparators.","Dungan KM","2023","include_nma",null,"pooled_analysis","P01",null,null,"high","first","opus-5.5-agent17","post hoc composite endpoint analysis across PIONEER 1 to 5 and 8 RCTs of oral semaglutide versus comparators; mislabeled case report",1],["R0017394","Chronic low-grade inflammation drives skeletal aging and neurocognitive decline: inflammaging as a central hub coupling bone-brain aging.","Yu M","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent17","narrative review of inflammaging linking skeletal and cognitive aging",1],["R0017471","GLP-1-Based Therapies Have No Microvascular Effects in Type 2 Diabetes Mellitus: An Acute and 12-Week Randomized, Double-Blind, Placebo-Controlled Trial.","Smits MM","2016","include_nma",null,"primary_report","P01",null,"mechanistic","high","first","opus-5.5-agent17","placebo controlled RCT of liraglutide versus sitagliptin versus placebo for 12 weeks plus acute exenatide infusion on microvascular function in type 2 diabetes",1],["R0017538","Atypical Presentation of a Preexisting Pancreatic Pseudocyst with Glucagon-Like Peptide-1 Agonist as a Possible Trigger for Exacerbation: A Case Report.","Raza MM","2023","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent17","case report of pancreatic pseudocyst exacerbation with GLP-1 RA use",1],["R0017654","Effect of tirzepatide on OSA-related cardiometabolic risk measures in SURMOUNT-OSA","Bednarik J","2025","include_nma",null,"secondary_report","P10",null,null,"high","first","opus-5.5-agent17","preprint secondary analysis of SURMOUNT-OSA RCTs of tirzepatide versus placebo on cardiometabolic risk measures",1],["R0017954","Economic value and clinical association of a supervised lifestyle-improving program for MASLD.","Polignano M","2025","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent17","cost utility and cohort analysis of a supervised lifestyle program in MASLD; GLP-1 RAs only mentioned as context",1],["R0017250","Effects of switching from dipeptidyl peptidase 4 inhibitors to oral semaglutide on oxidative stress and glycemic variability in patients with type 2 diabetes: an open-label, prospective, randomized, multicenter, parallel-group comparison study.","Ohara M","2025","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent13","open label RCT switching DPP-4 inhibitor to oral semaglutide vs continuing DPP-4 inhibitor in type 2 diabetes",1],["R0017530","Metabolic Dysfunction-Associated Steatotic Liver Disease Complicated by Diabetes: Pathophysiology and Emerging Therapies.","Goto H","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent13","narrative review of MASLD with diabetes pathophysiology and therapies",1],["R0017639","METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE: UPDATE.","Dezan MGF","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent13","broad literature update on MASLD without systematic synthesis",1],["R0017739","Potentials of incretin-based therapies in dementia and stroke in type 2 diabetes mellitus.","Groeneveld ON","2016","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent13","narrative review of incretin therapies in dementia and stroke",1],["R0017930","HFpEF as the predominant and underrecognized heart failure phenotype in type 2 diabetes: evidence from the DIABET-IC study.","Gil-Millan P","2025","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent13","DIABET-IC subanalysis comparing HFpEF and HFrEF in diabetes; GLP-1 use only described as treatment pattern",1],["R0018937","Collecting Real-World Patient Reported Outcome Through Community Pharmacies A Pilot Exploratory Study Applied on the Effects of Introducing the Fixed Dose Combination Xultophy in the Management of Type 2 Diabetes Mellitus","Alkis NB","2023","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent04","pharmacy based pilot of patient reported outcomes before and after starting IDegLira, no concurrent comparison group",1],["R0019035","Efficacy and Safety of Once-Weekly Subcutaneous Semaglutide 2.4 MG in Adults With Overweight or Obesity (STEP 1)","Wilding J","2021","include_nma",null,"conference_abstract","P02",null,"abstract_only","high","first","opus-5.5-agent04","conference abstract of STEP 1 double blind RCT of semaglutide 2.4 mg vs placebo in overweight or obesity",1],["R0019150","Genetic Assessment and Clinical Correlates in Severe Hypertriglyceridemia: A Systematic Review.","De Luca C","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent04","PRISMA systematic review of four databases on severe hypertriglyceridemia incl GLP-1 RA intervention results, narrative synthesis",1],["R0019278","Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).","Davies MJ","2018","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent04","ADA and EASD consensus report on hyperglycemia management in type 2 diabetes",1],["R0019361","12-month neurological and psychiatric outcomes of semaglutide use for type 2 diabetes: a propensity-score matched cohort study.","De Giorgi R","2024","include_harms",null,"primary_report",null,"O35A",null,"high","first","opus-5.5-agent04","TriNetX matched cohorts semaglutide vs sitagliptin, empagliflozin or glipizide, 22 neuropsychiatric outcomes incl suicidality",1],["R0019545","Glucagon-like peptide-1, fibroblast growth factor 21, and other endocrine responses to alcohol ingestion in women before and after metabolic surgery.","Molina-Castro M","2025","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent04","crossover alcohol challenge before and after bariatric surgery measuring endogenous GLP-1, no GLP-1 RA given",1],["R0019674","Tirzepatide Reduces 24-Hour Ambulatory Blood Pressure in Adults With Body Mass Index ≥27 kg/m2: SURMOUNT-1 Ambulatory Blood Pressure Monitoring Substudy.","de Lemos JA","2024","include_nma",null,"secondary_report","P02",null,null,"high","first","opus-5.5-agent04","research letter reporting SURMOUNT-1 ambulatory blood pressure substudy of tirzepatide vs placebo",1],["R0013658","Management of High Cardiovascular Risk in Diabetic Patients: Focus on Low Density Lipoprotein Cholesterol and Appropriate Drug Use in General Practice.","Rottura M","2021","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent11","general practice drug utilization study of statin and glucose lowering prescribing in diabetes; no GLP-1RA exposure comparison",1],["R0013754","Effects of the glucagon-like peptide-1 receptor agonist liraglutide on systolic function in patients with coronary artery disease and type 2 diabetes: a randomized double-blind placebo-controlled crossover study.","Kumarathurai P","2016","include_nma",null,"primary_report","P01",null,"crossover","high","first","opus-5.5-agent11","double blind placebo controlled crossover RCT of liraglutide in type 2 diabetes with coronary disease",1],["R0013831","Switch-to-Semaglutide Study (STS-Study): a Retrospective Cohort Study.","Hepprich M","2021","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent11","retrospective single group study of switching to semaglutide from other GLP-1RAs; no comparator",1],["R0013943","Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials.","Vilsbøll T","2012","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent11","meta-analysis of RCTs of GLP-1RAs versus control on weight loss; Cochrane, Medline, Embase, Web of Science",1],["R0014008","Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes.","Kodera R","2011","exclude","E1","primary_report",null,null,null,"high","first","opus-5.5-agent11","streptozotocin rat model and in vitro study of exendin-4 renal effects",1],["R0014097","Adverse events associated with tirzepatide: a focus on subgroup-specific differences.","Yu Z","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent11","FAERS and JADER subgroup disproportionality analysis of tirzepatide adverse events",1],["R0014204","Cardiovascular Safety of Incretin-Based Therapies in Type 2 Diabetes: Systematic Review of Integrated Analyses and Randomized Controlled Trials.","Mannucci E","2017","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent11","PRISMA systematic review of pooled analyses, meta-analyses and RCTs of incretin drugs on MACE; Medline searched",1],["R0014296","Factors Associated With Semaglutide Initiation Among Adults With Obesity.","Podolsky MI","2025","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent11","claims study of factors associated with semaglutide initiation; drug utilization without exposure comparison",1],["R0018051","Meta-analysed numbers needed to treat of novel antidiabetic drugs for cardiovascular outcomes.","Wolff G","2023","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent14","meta-analysis of reconstructed CVOT data selected from a published list without a named database search",1],["R0018158","Therapeutic Potential of Glucagon-like Peptide-1 Agonists in Polycystic Ovary Syndrome: From Current Clinical Evidence to Future Perspectives.","Jensterle M","2022","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent14","narrative review of GLP-1 RAs in polycystic ovary syndrome",1],["R0018276","MON-641 Effectiveness Of Semaglutide On Renal Outcomes In Chronic Kidney Disease (CKD) Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis",null,"2025","include_review",null,"systematic_review",null,null,"abstract_only","high","first","opus-5.5-agent14","conference abstract of systematic review and meta-analysis of semaglutide renal outcomes in CKD with T2D, PubMed Cochrane Web of Science",1],["R0018721","Unravelling Shared Pathways Linking Metabolic Syndrome, Mild Cognitive Impairment, Dementia, and Sarcopenia.","Ceccarelli Ceccarelli D","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent14","narrative review of shared pathways of metabolic syndrome, cognition and sarcopenia, GLP-1 RA only mentioned",1],["R0018858","Effect of Semaglutide on Regression and Progression of Glycemia in People With Overweight or Obesity but Without Diabetes in the SELECT Trial.","Kahn SE","2024","include_nma",null,"secondary_report","P02",null,null,"high","first","opus-5.5-agent14","SELECT RCT secondary analysis of semaglutide vs placebo on glycemic regression and progression",1],["R0019120","Efficacy and Safety of Once Weekly Dulaglutide in East Asian Patients with Type 2 Diabetes: Subgroup Analysis by Potential Influential Factors.","Ma J","2021","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent16","subgroup analysis of AWARD-CHN2 RCT dulaglutide 1.5 vs 0.75 mg arms in East Asian T2D",1],["R0019220","Effects of different hypoglycaemic drugs on beta-cell function in type 2 diabetes mellitus: a systematic review and network meta-analysis.","Guo Z","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent16","PROSPERO registered systematic review and NMA of hypoglycemic drugs incl. GLP-1RA on beta cell function",1],["R0019318","Sweetening the deal: An infodemiological study of worldwide interest in semaglutide using Google Trends","RAUBENHEIMER JE","2024","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent16","preprint infodemiology study of Google search interest in semaglutide; no drug exposure studied",1],["R0019426","GWAS of random glucose in 476,326 individuals provide insights into diabetes pathophysiology, complications and treatment stratification.","Lagou V","2023","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent16","GWAS meta-analysis of random glucose with in vitro GLP1R variant work; no therapeutic GLP-1RA exposure in humans",1],["R0019518","Prior metabolic surgery attenuates the weight-loss efficacy of liraglutide in patients with mild obesity.","Ouyang Y","2025","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent16","retrospective single cohort of liraglutide comparing responders vs nonresponders, no comparator to drug",1],["R0019632","Lixisenatide in type 1 diabetes: A randomised control trial of the effect of lixisenatide on post-meal glucose excursions and glucagon in type 1 diabetes patients.","Ballav C","2020","include_nma",null,"primary_report","P05",null,"crossover","high","first","opus-5.5-agent16","double blind randomized crossover of lixisenatide vs placebo in type 1 diabetes",1],["R0019740","Semaglutide lowers body weight in rodents via distributed neural pathways.","Gabery S","2020","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent16","rodent study of semaglutide neural pathways",1],["R0019857","SAT658 Tirzepatide Reduces The Predicted Risk Of Developing Atherosclerotic Cardiovascular Disease: A Post-hoc Analysis Of The Surmount-1 Trial",null,"2023","include_nma",null,"conference_abstract","P02",null,"abstract_only","high","first","opus-5.5-agent16","conference abstract of post hoc SURMOUNT-1 RCT analysis of tirzepatide vs placebo on predicted ASCVD risk",1],["R0016417","Cost-Effectiveness of iGlarLixi Versus Premix BIAsp 30 in People with Type 2 Diabetes Suboptimally Controlled by Basal Insulin in the US.","Shao H","2022","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent02","Core Diabetes Model cost effectiveness of iGlarLixi vs BIAsp 30 based on SoliMix trial",1],["R0017405","Effect of Semaglutide Versus Placebo on Heart Failure With Preserved Ejection Fraction in Obese Patients: A Systematic Review.","Umaña Mejia CA","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent01","PRISMA systematic review of semaglutide versus placebo studies in obese HFpEF, PubMed and ScienceDirect searched",1],["R0017489","The Impact of Different Antidiabetic Drugs on Fracture Risk in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Network Meta-analysis of Randomized Controlled Trials With a Focus on SGLT2 Inhibitors.","Admani B","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent01","network meta-analysis of antidiabetic drug RCTs including GLP-1 RAs on fracture risk, four sources searched",1],["R0017559","Anti-inflammatory effects of glucagon-like peptide-1 (GLP-1) in coronary artery disease: a comprehensive review.","Skrobucha A","2024","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent01","narrative review of anti-inflammatory effects of GLP-1 in coronary artery disease",1],["R0017787","PIONEER REAL Italy: Real-World Usage of Once-Daily Oral Semaglutide in Adults with Type 2 Diabetes.","Manti R","2025","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent01","PIONEER REAL Italy prospective non-interventional single arm study of oral semaglutide",1],["R0017876","Disparities in liver-related care among transgender adults with steatotic liver disease: a retrospective cohort study.","Ortega Abad M","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent01","cohort comparing liver care in transgender versus cisgender adults; GLP-1 RA prescribing only as care outcome",1],["R0017989","Diabetes, Drug Treatment, and Mortality in COVID-19: A Multinational Retrospective Cohort Study.","Nyland JE","2021","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent01","matched TriNetX cohort of GLP-1 RA, DPP-4i or pioglitazone users with COVID-19; admission, respiratory and death outcomes only",1],["R0018082","Tirzepatide and blood pressure reduction: stratified analyses of the SURMOUNT-1 randomised controlled trial.","Krumholz HM","2024","include_nma",null,"secondary_report","P02",null,null,"high","first","opus-5.5-agent01","post hoc blood pressure analyses of SURMOUNT-1 RCT of tirzepatide versus placebo",1],["R0019008","Real-World Evaluation of Once-Weekly Subcutaneous Semaglutide in Patients with Type 2 Diabetes Mellitus in Spain (SEMA-RW Study).","Caballero Mateos I","2024","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent18","ambispective multicenter single arm cohort of semaglutide in Spanish T2D; pre post HbA1c and weight; not randomized",1],["R0019127","Impact of semaglutide on high-sensitivity C-reactive protein: exploratory patient-level analyses of SUSTAIN and PIONEER randomized clinical trials.","Mosenzon O","2022","include_nma",null,"pooled_analysis","P01; P08A",null,null,"high","first","opus-5.5-agent18","sponsor patient level pooled analysis of SUSTAIN 3 and PIONEER 1, 2, 5 RCTs on hsCRP vs comparators in T2D",1],["R0019240","Trends in prognosis and use of SGLT2i and GLP-1 RA in patients with diabetes and coronary artery disease.","Ritsinger V","2024","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent18","Swedish registry cohort of diabetes with CAD, SGLT2i or GLP-1 RA use vs other drugs; MACE and trends only",1],["R0019327","Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022.","Bays HE","2022","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent18","obesity society clinical practice statement summarizing anti-obesity medications and investigational agents",1],["R0019432","Effect of Dulaglutide Versus Liraglutide on Glucose Variability, Oxidative Stress, and Endothelial Function in Type 2 Diabetes: A Prospective Study.","Nagaike H","2019","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent18","open label RCT of continuing liraglutide vs switching to dulaglutide in T2D; glucose variability, HbA1c, weight",1],["R0019640","A Systematic Review and Meta-Analysis of Malnutrition and Metabolic Failure in High-Potency Incretin Therapy.","Ampofo E","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent18","PRISMA meta-analysis of incretin RCTs on energy intake, fat free mass and malnutrition; PubMed, Scopus, Web of Science",1],["R0019747","Adverse effects with semaglutide: a protocol for a systematic review with meta-analysis and trial sequential analysis.","Sillassen CDB","2024","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent18","protocol of systematic review with meta-analysis and TSA of semaglutide adverse effects; no results",1],["R0021028","RENEWAL: REpurposing study to find NEW compounds with Activity for Lewy body dementia-an international Delphi consensus.","O'Brien JT","2022","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent06","international Delphi consensus prioritizing repurposed drugs for Lewy body dementia",1],["R0021183","Efficacy of Intragastric Balloon versus Liraglutide as Bridge to Surgery in Super-Obese Patients.","Martines G","2023","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent06","retrospective comparison of liraglutide versus intragastric balloon before sleeve gastrectomy; weight and surgical complications only",1],["R0021267","GLP-1R-GIPR-PPARα/γ/δ quintuple agonism corrects obesity and diabetes in mice.","Liskiewicz D","2026","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent06","mouse and in vitro study of GLP-1, GIP and PPAR quintuple agonist versus semaglutide",1],["R0021469","Semaglutide 2.4 mg clinical outcomes in patients with obesity or overweight in a real-world setting: A 6-month retrospective study in the United States (SCOPE).","Ruseva A","2024","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent06","SCOPE retrospective single group cohort of semaglutide 2.4 mg users; no comparison group",1],["R0021613","Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial.","Ratner RE","2010","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent06","13 week double blind RCT of lixisenatide doses once or twice daily versus placebo on metformin in T2D",1],["R0021722","Once-weekly semaglutide versus insulin aspart for the treatment of type 2 diabetes in the UK: A long-term cost-effectiveness analysis based on SUSTAIN 11.","Evans M","2023","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent06","CORE model cost-effectiveness analysis of semaglutide versus insulin aspart based on SUSTAIN 11",1],["R0021932","Impact of intravenous exenatide infusion for perioperative blood glucose control on myocardial ischemia-reperfusion injuries after coronary artery bypass graft surgery: sub study of the phase II/III ExSTRESS randomized trial.","Besch G","2018","include_nma",null,"secondary_report","P99",null,null,"high","first","opus-5.5-agent06","substudy of ExSTRESS RCT of IV exenatide versus insulin for perioperative glucose control in CABG; mixed diabetes status, P99",1],["R0016495","Effect of tirzepatide-induced weight loss on adipose tissue in obesity: rationale and design of the randomized placebo-controlled Tirzepatide Brown and Beige Adipose Tissue Activation (TABFAT) trial.","Herman R","2025","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent02","design paper of TABFAT placebo controlled RCT of tirzepatide on brown adipose tissue in women with obesity",1],["R0016671","Combined metformin and exenatide versus only metformin treatments in polycystic ovary syndrome with abdominal obesity and network pharmacology of gene expression: evidence from a randomized clinical trial.","Xuesong D","2025","include_nma",null,"primary_report","P12",null,null,"high","first","opus-5.5-agent02","randomized trial of metformin plus exenatide vs metformin alone for 12 weeks in PCOS with abdominal obesity",1],["R0016771","From RAAS blockade to regenerative medicine: evolving treatment strategies in Alport syndrome.","Lo Re C","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent02","narrative review of treatment strategies in Alport syndrome",1],["R0016882","Very low-calorie ketogenic diet and liraglutide as a synergistic strategy for the treatment of obesity: A short-term, non-randomised, observational, real-world clinical evaluation.","Camajani E","2025","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent02","prospective nonrandomized self selected VLCKD vs VLCKD plus liraglutide comparison on weight; no listed harm",1],["R0016982","Effect of empagliflozin on brachial artery shear stress and endothelial function in subjects with type 2 diabetes: Results from an exploratory study.","Irace C","2020","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent02","nonrandomized prospective cohort empagliflozin vs incretin therapy including liraglutide on endothelial function; no listed harm",1],["R0017068","Benefit of Semaglutide in Symptomatic Peripheral Artery Disease by Baseline Type 2 Diabetes Characteristics: Insights From STRIDE, a Randomized, Placebo-Controlled, Double-Blind Trial.","Rasouli N","2025","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent02","subgroup analysis of STRIDE placebo controlled RCT of semaglutide in PAD with type 2 diabetes",1],["R0014849","Nutritional status with tirzepatide in obesity: A post hoc analysis of the SURMOUNT-1-4 randomized clinical trials.","Almandoz JP","2026","include_nma",null,"pooled_analysis","P02; P01; P02W",null,null,"high","first","opus-5.5-agent15","post hoc pooled nutritional status analysis of SURMOUNT 1 to 4 placebo controlled RCTs of tirzepatide",1],["R0014928","Retrospective analysis of liraglutide and basal insulin combination therapy in Japanese type 2 diabetes patients: The association between remaining β-cell function and the achievement of the glycated hemoglobin target 1 year after initiation.","Usui R","2018","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent15","single center retrospective series switching to liraglutide plus basal insulin; predictors of HbA1c target, no comparator",1],["R0015017","Real-World Retrospective Study into the Effects of Oral Semaglutide (As a Switchover or Add-On Therapy) in Type 2 Diabetes.","Candido R","2023","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent15","retrospective study of oral semaglutide users as switch or add on; before and after changes without comparator",1],["R0015114","Subtype-Specific Causal Effects of Antidiabetic Drug Targets on Ovarian Cancer: Mendelian Randomization and Colocalization Evidence.","Tang E","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent15","drug target Mendelian randomization of antidiabetic gene targets and ovarian cancer; genetic proxies, no drug exposure",1],["R0015230","Pathophysiological and pharmacological rationale for the use of exenatide once weekly in patients with type 2 diabetes.","Grossman SS","2014","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent15","narrative review of exenatide once weekly pharmacology and trials from a PubMed search",1],["R0015306","C-Peptide Area Under the Curve at Glucagon Stimulation Test Predicts Glucose Improvements by GLP-1 Receptor Analogue: A Retrospective Observational Study.","Ohbatake A","2019","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent15","retrospective series of GLP-1 RA initiators examining C-peptide predictors of response; no comparator",1],["R0015389","The renoprotective effect of once-weekly GLP-1 receptor agonist dulaglutide on progression of nephropathy in Japanese patients with type 2 diabetes and moderate to severe chronic kidney disease (JDDM67).","Tsuchida KI","2022","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent15","propensity weighted database comparison of dulaglutide versus no dulaglutide in type 2 diabetes with CKD; eGFR, UACR, HbA1c only",1],["R0015463","Retrospective Study of Real-World Treatment Patterns of Subcutaneous Semaglutide Use Among Patients with Metabolic Dysfunction-Associated Steatohepatitis in the United States.","Kim Y","2025","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent15","claims and EHR study of semaglutide treatment persistence patterns in MASH; utilization only",1],["R0019969","Weight neutrality with the DPP-4 inhibitor, vildagliptin: mechanistic basis and clinical experience.","Foley JE","2010","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent03","narrative review of vildagliptin weight neutrality mechanisms; no GLP-1 RA synthesis",1],["R0014379","Weight and Glucose Reduction Observed with a Combination of Nutritional Agents in Rodent Models Does Not Translate to Humans in a Randomized Clinical Trial with Healthy Volunteers and Subjects with Type 2 Diabetes.","Hodge RJ","2016","inventory_only","N3","primary_report",null,null,null,"high","first","opus-5.5-agent10","mouse studies plus RCT of nutritional combination GSK457 versus placebo, in T2D on liraglutide in both arms; GLP-1 unchanged",1],["R0014543","Liraglutide and not lifestyle intervention reduces soluble CD163 after comparable weight loss in obese participants with prediabetes or type 2 diabetes mellitus.","Grannes H","2024","include_nma",null,"secondary_report","P01; P02",null,null,"high","first","opus-5.5-agent10","post hoc of RCT liraglutide versus lifestyle for equal weight loss in obese prediabetes or early T2D; immune markers",1],["R0014915","Effect of Liraglutide on Fat Mass Percentage Among Overweight and Obese Adults with Type 2 Diabetes: A Systematic Review.","Aladel A","2023","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent10","PROSPERO registered systematic review and meta-analysis of liraglutide on fat mass in T2D; three databases",1],["R0015000","Monotherapy with the once weekly GLP-1 receptor agonist dulaglutide for 12 weeks in Japanese patients with type 2 diabetes: dose-dependent effects on glycaemic control in a randomised, double-blind, placebo-controlled study.","Terauchi Y","2014","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent10","12 week double blind RCT dulaglutide 0.25, 0.5, 0.75 mg versus placebo in Japanese T2D; HbA1c",1],["R0020125","Real-World Use of Oral Semaglutide in Adults with Type 2 Diabetes: The PIONEER REAL Switzerland Multicentre, Prospective, Observational Study.","Kick A","2024","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent03","PIONEER REAL Switzerland prospective noninterventional single arm study of oral semaglutide, no comparator",1],["R0020237","Real-World Use of Oral Semaglutide in Adults with Type 2 Diabetes in the PIONEER REAL Netherlands Multicentre, Prospective, Observational Study.","van Houtum W","2024","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent03","PIONEER REAL Netherlands prospective noninterventional single arm study of oral semaglutide, no comparator",1],["R0020376","Efficacy and safety of dulaglutide compared with the first-line hypoglycemic drugs in Asian patients with type 2 diabetes: a systematic review and meta-analysis.","Yu B","2022","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent03","meta-analysis of dulaglutide vs first line drugs in Asian T2D; Cochrane, PubMed, Embase searched",1],["R0020464","Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial.","Borlaug BA","2023","include_nma",null,"secondary_report","P07A",null,null,"high","first","opus-5.5-agent03","prespecified analysis of STEP-HFpEF RCT, semaglutide 2.4 mg vs placebo by obesity class and weight loss",1],["R0020594","Exendin-4 protects retinal cells from early diabetes in Goto-Kakizaki rats by increasing the Bcl-2/Bax and Bcl-xL/Bax ratios and reducing reactive gliosis.","Fan Y","2014","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent03","Goto-Kakizaki rat retinopathy study of intravitreal exendin-4; animal only",1],["R0020755","Treatment of antipsychotic-associated obesity with a GLP-1 receptor agonist--protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded intervention study: the TAO study protocol.","Ishøy PL","2014","inventory_only","N8","protocol_or_design","P15",null,null,"high","first","opus-5.5-agent03","protocol of TAO RCT of exenatide weekly vs placebo for antipsychotic associated obesity; no results",1],["R0020875","US Population Eligibility and Estimated Impact of Semaglutide Treatment on Obesity Prevalence and Cardiovascular Disease Events.","Wong ND","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent03","NHANES based modeling of semaglutide eligibility and projected CVD events",1],["R0020096","Effects of dulaglutide combined with insulin degludec on glucose fluctuations and appetite in type 2 diabetes.","Huang J","2023","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent20","retrospective cohort of dulaglutide plus degludec vs degludec alone, glucose variability and appetite only, no listed harm",1],["R0020209","Clinical Efficacy and Safety of Anti-Obesity Medications Among Adult East Asian People with Obesity: A Systematic Literature Review and Indirect Treatment Comparison.","Yokote K","2024","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent20","systematic literature review of semaglutide and mazindol RCTs in East Asian obesity with indirect comparison, three databases",1],["R0020368","Liraglutide Attenuates Aortic Valve Calcification in a High-Cholesterol-Diet-Induced Experimental Calcific Aortic Valve Disease Model in Apolipoprotein E-Deficient Mice.","Zhou Y","2023","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent20","randomized mouse experiment of liraglutide in calcific aortic valve disease",1],["R0020448","Successful outcome of assisted reproductive technology in women with polycystic ovary syndrome combined with empty follicle syndrome: A case report.","Guo D","2025","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent20","case report of PCOS with empty follicle syndrome treated with beinaglutide among other measures",1],["R0020578","Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy.","Vilsbøll T","2018","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent20","post hoc analysis of diabetic retinopathy across randomized SUSTAIN trials of semaglutide vs placebo or comparators",1],["R0020750","Effectiveness of finerenone in Chinese patients with type 2 diabetes mellitus and chronic kidney disease with microalbuminuria: A retrospective real-world study.","Wu Y","2025","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent20","retrospective single arm finerenone study in T2D CKD, GLP-1 RA only a co-medication subgroup",1],["R0020869","Effect of lixisenatide on natriuretic peptides in people with type 2 diabetes and recent acute coronary syndrome: The ELIXA trial.","Gerstein HC","2023","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent20","secondary analysis of randomized ELIXA trial of lixisenatide vs placebo on natriuretic peptides after ACS",1],["R0020980","Type 2 Diabetes Management in Aotearoa New Zealand: A Comparison of Urban and Rural Primary Care Clinics.","Mustafa S","2025","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent20","cross sectional study of diabetes care and prescribing in urban vs rural New Zealand clinics",1],["R0014377","Neutral Effects of Combined Treatment With GLP-1R Agonist Exenatide and MR Antagonist Potassium Canrenoate on Cardiac Function in Porcine and Murine Chronic Heart Failure Models.","Demkes EJ","2021","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent09","randomized pig and mouse heart failure experiments with exenatide plus canrenoate, no humans",1],["R0014466","Identifying high-risk combinations of metformin during COVID-19.","Dimnjaković J","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent09","Croatian registry analysis of metformin combinations including GLP-1 versus metformin alone on COVID-19 death only",1],["R0014540","Improved glycaemic control and weight benefit with iGlarLixi versus insulin glargine 100 U/mL in Chinese people with type 2 diabetes advancing their therapy from basal insulin plus oral antihyperglycaemic drugs: Results from the LixiLan-L-CN randomized controlled trial.","Yuan X","2022","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent09","LixiLan-L-CN open label RCT of iGlarLixi versus insulin glargine in Chinese type 2 diabetes on basal insulin",1],["R0014665","Effect of Semaglutide on Insulin Dose Reduction in Adults With Type 1 Diabetes and Obesity Using Automated Insulin Delivery Systems: ADJUST-T1D Post Hoc Analysis.","Karakus KE","2026","include_nma",null,"secondary_report","P05",null,null,"high","first","opus-5.5-agent09","post hoc ADJUST-T1D analysis of semaglutide versus placebo on insulin dose in type 1 diabetes with obesity",1],["R0014736","Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in Japanese people with type 2 diabetes.","Seino Y","2018","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent09","phase 3 RCT of weekly semaglutide versus sitagliptin monotherapy in Japanese type 2 diabetes",1],["R0014817","Spending, utilization, and price trends for anti-obesity medications in U.S. Medicaid programs: an empirical analysis from 1999 to 2023.","Alsuhibani AA","2025","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent09","descriptive Medicaid utilization and spending trends for anti-obesity drugs, no exposure comparison",1],["R0014914","More patients reach glycaemic control with a fixed-ratio combination of insulin glargine and lixisenatide (iGlarLixi) than with basal insulin at 12 weeks of treatment: A post hoc time-to-control analysis of LixiLan-O and LixiLan-L.","Frias J","2018","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent09","post hoc time to control analysis of LixiLan-O and LixiLan-L RCTs of iGlarLixi versus insulin glargine",1],["R0014992","Comparative Effect of Glucose-Lowering Drugs for Type 2 Diabetes Mellitus on Stroke Prevention: A Systematic Review and Network Meta-Analysis.","Kim JS","2024","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent09","PROSPERO registered NMA of glucose lowering drug RCTs including GLP-1 agonists on stroke, three databases",1],["R0018253","Efficacy and safety of once-weekly semaglutide for the treatment of type 2 diabetes: Protocol for a systematic review and meta-analysis.","Shi FH","2018","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent08","protocol for systematic review and meta-analysis of once weekly semaglutide RCTs; no results",1],["R0018339","Response to the letter titled reply to \"Associations of semaglutide with first-time diagnosis of Alzheimer's disease in patients with type 2 diabetes: Target trial emulation using nationwide real-world data in the US\".","Xu R","2025","inventory_only","N9","ancillary",null,null,null,"high","first","opus-5.5-agent08","authors reply to letter on semaglutide and Alzheimer disease target trial emulation",1],["R0018590","Cost Effectiveness of Once-Weekly Semaglutide Versus Once-Weekly Dulaglutide in the Treatment of Type 2 Diabetes in Canada.","Johansen P","2019","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent08","cohort model cost effectiveness analysis of semaglutide versus dulaglutide in Canada",1],["R0018689","Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis.","Robinson LE","2013","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent08","meta-analysis of RCTs of exenatide and liraglutide on heart rate, blood pressure and weight; MEDLINE, Embase, CENTRAL",1],["R0018822","Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.","Palmer SC","2021","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent08","BMJ network meta-analysis of SGLT2i and GLP-1 RA RCTs in type 2 diabetes; Medline, Embase, CENTRAL",1],["R0018949","Insulin Sensitizers for Improving the Endocrine and Metabolic Profile in Overweight Women With PCOS.","Xing C","2020","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent08","network meta-analysis of insulin sensitizers incl GLP-1 RA RCTs in overweight women with PCOS",1],["R0019051","A review of the evidence on cardiovascular outcomes from obesity treatment.","Abdul Wahab R","2023","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent07","narrative review of cardiovascular outcome trials of obesity treatments",1],["R0019159","7808 Effect of Oral Semaglutide on Hepatic Steatosis and Fibrosis, and Bone Microarchitecture in Non-alcoholic Fatty Liver Disease Complicating Type 2 Diabetes Mellitus: A Prospective, Interventional, Open-Label, Paired Study",null,"2024","inventory_only","N1","conference_abstract",null,null,"abstract_only","high","first","opus-5.5-agent07","abstract of open label single arm prospective study of oral semaglutide in T2D with NAFLD",1],["R0019374","Semaglutide improves metabolic dysfunction-associated steatohepatitis: A 10-year retrospective study.","Shah P","2024","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent07","retrospective single group VA cohort of semaglutide users with before after liver enzymes",1],["R0019470","Meta-analysis of the clinical efficacy of liraglutide in treating type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease.","Xu YY","2024","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent07","meta-analysis of studies comparing liraglutide with placebo or insulin in T2D with NAFLD",1],["R0019558","Effect of liraglutide on thigh muscle fat and muscle composition in adults with overweight or obesity: Results from a randomized clinical trial.","Pandey A","2024","include_nma",null,"secondary_report","P02",null,null,"high","first","opus-5.5-agent07","prespecified secondary analysis of RCT of liraglutide 3.0 mg vs placebo in obesity without diabetes; thigh muscle fat",1],["R0019821","Semaglutide Effects on Metabolic Outcomes in Diabetes Mellitus Patients - Real World Study.","Balcázar-Valencia CM","2024","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent07","retrospective single group cohort of semaglutide in T2D in Colombia, before after outcomes",1],["R0016569","Safety and Pharmacokinetics of Single and Multiple Ascending Doses of the Novel Oral Human GLP-1 Analogue, Oral Semaglutide, in Healthy Subjects and Subjects with Type 2 Diabetes.","Granhall C","2019","include_nma",null,"primary_report","P01; P99",null,"mechanistic","high","first","opus-5.5-agent19","two randomized placebo controlled phase 1 trials of oral semaglutide in healthy males and type 2 diabetes; safety and PK",1],["R0016767","Clinical inertia with regard to intensifying therapy in people with type 2 diabetes treated with basal insulin.","Khunti K","2016","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent19","CPRD study of clinical inertia in intensifying basal insulin; GLP-1 RA only as an intensification category",1],["R0016859","Effectiveness of semaglutide on survival outcomes in patients with type 2 diabetes and chronic kidney disease.","Kishimori T","2025","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent19","TriNetX new user cohort semaglutide vs sitagliptin in diabetic CKD, matched; death and cardiovascular outcomes only",1],["R0016967","Analysis of Tirzepatide Acquisition Costs and Weight Reduction Outcomes in the United Kingdom: Insights from the SURMOUNT-1 Study.","Evans M","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent19","drug acquisition cost per weight loss analysis using SURMOUNT-1 data; economic evaluation",1],["R0017063","Emerging Role of GLP-1 Agonists in Obesity: A Comprehensive Review of Randomised Controlled Trials.","Popoviciu MS","2023","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent19","narrative review of GLP-1 agonist trials in obesity without systematic methods",1],["R0017144","Real-World Persistence and Characteristics of Type 2 Diabetes Patients Prescribed Semaglutide in Scotland.","Dickie DA","2025","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent19","letter on persistence and BMI change among semaglutide users in Glasgow records; no comparison group",1],["R0017285","Glycemic and non-glycemic benefits of initial triple therapy versus sequential add-on therapy in patients with new-onset diabetes: results from the EDICT study.","Abdul-Ghani M","2025","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent19","EDICT RCT 6 year report of initial metformin pioglitazone exenatide vs sequential conventional therapy; cIMT and liver fat",1],["R0017456","SAT-688 One-Year Real-World Weight Loss Outcomes with Tirzepatide in Postmenopausal Women with and without Hormone Therapy",null,"2025","inventory_only","N6","primary_report",null,null,"abstract_only","high","first","opus-5.5-agent13","abstract of tirzepatide users with vs without menopausal hormone therapy, weight only",1],["R0017839","Monitoring the Comparative Safety of SGLT2i vs GLP-1 RA in Older Adults With Type 2 Diabetes by Frailty Status","Kutz A","2021","inventory_only","N6","primary_report",null,null,"abstract_only","high","first","opus-5.5-agent13","abstract of Medicare sequential cohort SGLT2 vs GLP-1 initiators, diabetic ketoacidosis only",1],["R0018050","Efficacy of Liraglutide for Weight Loss in Overweight and Obese Non-diabetic Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.","Quinapanta Castro NI","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent13","PROSPERO registered meta-analysis of liraglutide RCTs in non-diabetic overweight adults from three databases",1],["R0018274","Cardiovascular, Metabolic, and Safety Outcomes with Semaglutide by Baseline Age: Post Hoc Analysis of SUSTAIN 6 and PIONEER 6.","Bain SC","2025","include_nma",null,"pooled_analysis","P01",null,null,"high","first","opus-5.5-agent13","pooled post hoc analysis of SUSTAIN 6 and PIONEER 6 RCTs of semaglutide vs placebo by age",1],["R0018404","Youth-Onset Type 2 Diabetes Before and After COVID-19 Pandemic-Related Public Health Restrictions: Trends in Incidence, Severity, and Remission.","Grundman JB","2025","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent13","chart review of youth-onset type 2 diabetes with GLP-1 use among remission predictors, no harms outcome",1],["R0018604","Continued efforts to translate diabetes cardiovascular outcome trials into clinical practice.","Avogaro A","2016","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent13","narrative review of diabetes cardiovascular outcome trials",1],["R0018174","Reply to \"Associations of semaglutide with first-time diagnosis of Alzheimer's disease in patients with type 2 diabetes: Target trial emulation using nationwide real-world data in the US\".","Rydberg MG","2025","inventory_only","N9","ancillary",null,null,null,"high","first","opus-5.5-agent17","letter commenting on a target trial emulation of semaglutide and Alzheimer disease diagnosis",1],["R0018536","Management of diabetes across the course of disease: minimizing obesity-associated complications.","Apovian CM","2011","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent17","narrative review of diabetes management and obesity related complications",1],["R0018631","The Potential Effect of Dapagliflozin and Liraglutide in Attenuating Cardio-Renal Injuries in Diabetic Rats.","Albanna AA","2025","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent17","diabetic rat study of dapagliflozin and liraglutide",1],["R0018742","Estimating the real world daily usage and cost for exenatide twice daily and liraglutide in Germany, the Netherlands, and the UK based on volumes dispensed by pharmacies.","McDonell AL","2015","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent17","pharmacy dispensing analysis of daily dose and cost of exenatide and liraglutide; drug utilization without exposure outcome comparison",1],["R0019933","Effectiveness and safety of semaglutide in overweight/obese adults with or without type 2 diabetes: A systematic review and meta-analysis.","Yang L","2024","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent16","PROSPERO registered systematic review and meta-analysis of semaglutide RCTs in overweight or obese adults",1],["R0020035","Effects of DPP-4 inhibitor linagliptin and GLP-1 receptor agonist liraglutide on physiological response to hypoglycaemia in Japanese subjects with type 2 diabetes: A randomized, open-label, 2-arm parallel comparative, exploratory trial.","Yabe D","2017","include_nma",null,"primary_report","P01",null,"mechanistic","high","first","opus-5.5-agent16","randomized open label 2 week mechanistic trial of linagliptin vs liraglutide in Japanese T2D; reports adverse events",1],["R0020192","Treatment patterns of antidiabetic and kidney protective therapies among patients with type 2 diabetes mellitus and chronic kidney disease in Colombia. The KDICO descriptive study.","Machado-Duque ME","2023","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent16","cross sectional description of treatment patterns in T2D with CKD in Colombia; no exposure comparison",1],["R0020329","Insulin Glargine is More Suitable Than Exenatide in Preventing Muscle Loss in Non-Obese Type 2 Diabetic Patients with NAFLD.","Liu L","2023","include_nma",null,"secondary_report","P01; P09",null,null,"high","first","opus-5.5-agent16","post hoc analysis of RCT randomizing insulin glargine vs exenatide in newly diagnosed T2D with NAFLD",1],["R0020435","The incretin/glucagon system as a target for pharmacotherapy of obesity.","Del Prato S","2022","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent16","narrative review of incretin and glucagon agonists for obesity",1],["R0020542","A double-blind, placebo-controlled, randomised trial to assess the effect of liraglutide on ectopic fat accumulation in South Asian type 2 diabetes patients.","van Eyk HJ","2019","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent16","double blind RCT of liraglutide vs placebo in South Asian T2D; ectopic fat and HbA1c",1],["R0020702","Impact of Type 2 Diabetes Duration on the Efficacy and Safety of Add-on Lixisenatide in Asian Individuals Receiving Basal Insulin: A Pooled Analysis.","Yao J","2023","include_nma",null,"pooled_analysis","P01",null,null,"high","first","opus-5.5-agent16","pooled post hoc analysis of Asian participants in GetGoal placebo controlled lixisenatide RCTs on basal insulin",1],["R0020855","Effectiveness of integrating a pragmatic pathway for prescribing liraglutide 3.0 mg in weight management services (STRIVE study): a multicentre, open-label, parallel-group, randomized controlled trial.","Papamargaritis D","2024","include_nma",null,"primary_report","P99",null,null,"high","first","opus-5.5-agent16","STRIVE open label RCT of liraglutide 3 mg prescribing pathway vs specialist care alone; BMI 35 plus mixed comorbidities incl. T2D, likely P02",1],["R0018203","SUN-675 Very Low Energy Ketogenic Therapy In Combination With Liraglutide As A Synergic Strategy For The Treatment Of Obesity: A Real-world Clinical Evaluation",null,"2025","inventory_only","N6","conference_abstract",null,null,"abstract_only","high","first","opus-5.5-agent01","abstract of prospective nonrandomized comparison of ketogenic diet alone versus with liraglutide; weight and GI symptoms, no listed harm",1],["R0018556","Semaglutide and diuretic use in obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF-DM trials.","Shah SJ","2024","include_nma",null,"pooled_analysis","P07A; P01",null,null,"high","first","opus-5.5-agent01","prespecified pooled analysis of STEP-HFpEF and STEP-HFpEF-DM RCTs of semaglutide versus placebo by diuretic use",1],["R0018645","Glucagon-Like Peptide-1: A Focus on Neurodegenerative Diseases.","Grieco M","2019","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent01","narrative review of GLP-1 and neurodegenerative diseases, largely preclinical",1],["R0018767","Liraglutide + PYY3-36 Combination Therapy Mimics Effects of Roux-en-Y Bypass on Early NAFLD Whilst Lacking-Behind in Metabolic Improvements.","Metzner V","2022","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent01","rat NAFLD model comparing gastric bypass with liraglutide and PYY3-36; animal study only",1],["R0018891","Tirzepatide Reduces Fat Mass and Provides Good Glycaemic Control in Type 2 Diabetes Patients Undergoing Haemodialysis: A Single-Centre Retrospective Study.","Mima A","2024","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent01","retrospective single group series of nine hemodialysis patients given tirzepatide with before and after measures",1],["R0019021","Clinically-Relevant Weight Loss is Achieved Independently of Early Weight Loss Response to Once-Weekly Subcutaneous Semaglutide 2.4 MG (STEP 4)","Mosenzon O","2021","include_nma",null,"conference_abstract","P02W",null,"abstract_only","high","first","opus-5.5-agent01","abstract of post hoc STEP 4 randomized withdrawal analysis of semaglutide 2.4 mg versus placebo after run in",1],["R0019893","Localization of Hidden Insulinomas with ⁶⁸Ga-DOTA-Exendin-4 PET/CT: A Pilot Study.","Antwi K","2015","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent04","randomized crossover of radiolabeled exendin-4 PET vs SPECT for insulinoma localization, diagnostic tracer not therapeutic",1],["R0019970","Efficacy of oral semaglutide after switching from DPP-4 inhibitors in Japanese type 2 diabetes patients with obesity","Okamoto A","2024","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent04","retrospective single group switching from DPP-4i to oral semaglutide with before and after measures",1],["R0020126","Efficacy of High-dose Liraglutide 3.0 mg in Patients with Poor Response to Bariatric Surgery: Real-world Experience and Updated Meta-analysis.","Vinciguerra F","2024","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent04","retrospective liraglutide cohort plus systematic review and meta-analysis of liraglutide after bariatric surgery",1],["R0020250","Comparison of Diabetes Medications Used by Adults With Commercial Insurance vs Medicare Advantage, 2016 to 2019.","McCoy RG","2021","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent04","claims study of GLP-1 RA, SGLT2i and DPP-4i initiation rates by insurance type, drug utilization only",1],["R0020380","Glucagon-like peptide-1 agonists protect pancreatic beta-cells from lipotoxic endoplasmic reticulum stress through upregulation of BiP and JunB.","Cunha DA","2009","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent04","in vitro study of exendin-4 in rat beta cells, cell lines and donor islets",1],["R0020474","Artificial intelligence scoring of liver biopsies in a phase II trial of semaglutide in nonalcoholic steatohepatitis.","Ratziu V","2024","include_nma",null,"secondary_report","P09",null,null,"high","first","opus-5.5-agent04","post hoc AI liver histology analysis of phase 2 RCT of semaglutide vs placebo in NASH",1],["R0020596","Kidney effects of Glucagon-Like Peptide 1 (GLP1): from molecular foundations to a pharmacophysiological perspective.","Rico-Fontalvo J","2024","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent04","narrative review of GLP-1 RA kidney mechanisms",1],["R0022090","HOXD9/APOC1 axis promotes macrophage M1 polarization to exacerbate diabetic kidney disease progression through activating NF-κB signaling pathway.","Feng Y","2024","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent06","in vitro podocyte and macrophage experiments with bioinformatics, including liraglutide exposure of cells",1],["R0022186","Non-insulin anti-diabetic agents in patients with type 2 diabetes and COVID-19: A Critical Appraisal of Literature.","Singh AK","2021","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent06","narrative appraisal of observational literature on non-insulin antidiabetic drugs in COVID-19",1],["R0022424","Efficacy and safety of sitagliptin treatment in older adults with moderately controlled type 2 diabetes: the STREAM study.","Nagao M","2023","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent06","STREAM open label RCT of sitagliptin versus no sitagliptin in older T2D; DPP-4 inhibitor only, no GLP-1 RA arm",1],["R0022525","Glycemic Control in a Real-Life Setting in Patients with Type 2 Diabetes Treated with IDegLira at a Single Swiss Center.","Sofra D","2017","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent06","prospective single center observational follow-up of IDegLira initiators; no comparison group",1],["R0022643","Role of glucagon-like peptide-1 agonist in patients undergoing percutaneous coronary intervention or coronary artery bypass grafting: A meta-analysis.","Ogbu IR","2021","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent06","meta-analysis of RCTs of GLP-1 RAs versus placebo or insulin in patients undergoing PCI or CABG; five databases",1],["R0022761","Pancreatitis associated with the use of GLP-1 analogs and DPP-4 inhibitors: a case/non-case study from the French Pharmacovigilance Database.","Faillie JL","2014","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent06","case non-case disproportionality analysis of pancreatitis with GLP-1 analogs in French pharmacovigilance database",1],["R0022843","Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono).","Fonseca VA","2012","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent06","GetGoal-Mono double blind RCT of lixisenatide one-step or two-step versus placebo monotherapy in T2D",1],["R0019860","Systemic and gut microbiome changes with metformin and liraglutide in youth-onset type 2 diabetes: the MIGHTY study.","Glaros SB","2025","include_nma",null,"secondary_report","P04; P01",null,"mechanistic","high","first","opus-5.5-agent18","exploratory microbiome analysis of MIGHTY RCT, metformin vs metformin plus liraglutide in youth onset T2D aged 12 to 25; HbA1c measured",1],["R0019953","Obesity management for kidney TRANSPLANTation: protocol for the vanguard phase of an innovative randomised controlled trial, embedded in routine care (OK-TRANSPLANT 2).","Clemens KK","2026","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent18","protocol of vanguard phase RCT of weight program with semaglutide vs standard care in advanced CKD; no results",1],["R0020078","[Pharmacological profile and clinical trial results of a long-acting, once weekly human GLP-1 receptor agonist Dulaglutide (Genetical Recombination)].","Tamaki C","2015","exclude","E3","other",null,null,"non_english","high","first","opus-5.5-agent18","Japanese language drug profile review of dulaglutide pharmacology and trials; not a trial report",1],["R0020348","Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial.","Ludvik B","2018","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent18","AWARD-10 double blind RCT of dulaglutide 1.5 and 0.75 mg vs placebo added to SGLT2i in T2D",1],["R0020736","Sulphonylurea efficacy and end-organ outcomes in the management of HNF4A-MODY.","Crowley MT","2025","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent18","HNF4A MODY cohort on sulfonylurea efficacy and complications; GLP-1 RA only mentioned as possible adjunct, no exposure comparison",1],["R0018979","Real-world use of oral versus subcutaneous semaglutide in a cohort of type 2 diabetic patients: which option to which patient?","Formichi C","2024","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent14","retrospective comparison of oral vs subcutaneous semaglutide prescribing and outcomes in T2D, no harms_nrs outcome",1],["R0019111","Effectiveness of a Psychiatrist-Led Clinic for Metabolic Health in Severe Mental Illness: A Retrospective Chart Review Study.","Stogios N","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent14","chart review of a metabolic clinic in severe mental illness comparing weight loss across interventions including semaglutide, no harms_nrs outcome",1],["R0019211","Predictors of ≥15% Weight Reduction and Associated Changes in Cardiometabolic Risk Factors With Tirzepatide in Adults With Type 2 Diabetes in SURPASS 1-4.","Małecki MT","2023","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent14","post hoc analysis of tirzepatide arms of SURPASS 1 to 4 RCTs, predictors of 15 percent weight loss",1],["R0019315","A real-world disproportionality analysis of semaglutide: Post-marketing pharmacovigilance data.","Du Y","2024","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent14","FAERS disproportionality analysis of semaglutide adverse event reports",1],["R0019417","Effect of SGLT-2 inhibitors on COPD exacerbations in individuals with type 2 diabetes: A meta-analysis and Bayesian sensitivity analysis.","Shabil M","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent14","meta-analysis of SGLT2i and COPD exacerbations including a pooled SGLT2i vs GLP-1 RA comparison, PubMed Embase Web of Science",1],["R0019503","Prediction of response to GLP-1 receptor agonist therapy in Japanese patients with type 2 diabetes.","Imai K","2014","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent14","retrospective review of 43 GLP-1 RA initiators comparing responders vs non responders, no unexposed comparison",1],["R0019598","The potential of precision diabetology for type 2 diabetes treatment-evidence from a meta-regression for all-cause mortality from large cardiovascular outcome trials.","Kuss O","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent14","meta-regression of digitized CVOT mortality data selected from summit reports without a database search",1],["R0019726","Cost-Effectiveness of iGlarLixi Versus Premix BIAsp 30 in Patients with Type 2 Diabetes Suboptimally Controlled by Basal Insulin in the UK.","McCrimmon RJ","2022","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent14","CORE Diabetes Model cost effectiveness of iGlarLixi vs premix insulin in the UK",1],["R0021009","Evaluation of the impact of once weekly dulaglutide on patient-reported outcomes in Japanese patients with type 2 diabetes: comparisons with liraglutide, insulin glargine, and placebo in two randomized studies.","Suzuki S","2017","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent03","PRO analysis of two Japanese RCTs, dulaglutide vs liraglutide and placebo, and dulaglutide vs insulin glargine in T2D",1],["R0021162","The Influence of Lifestyle and Treatment on Oxidative Stress and Inflammation in Diabetes.","Wronka M","2022","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent03","narrative review of lifestyle and treatment effects on oxidative stress and inflammation in diabetes",1],["R0021256","Efficacy and safety of semaglutide in non-alcoholic fatty liver disease.","Zhu K","2023","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent03","meta-analysis of RCTs of semaglutide in NAFLD; MEDLINE, CENTRAL, EMBASE searched",1],["R0021380","UTILIZATION TRENDS OF GLUCOSE-LOWERING DRUGS FOR TYPE 2 DIABETES IN OLDER ADULTS WITH AND WITHOUT DEMENTIA",null,"2022","exclude","E2","conference_abstract",null,null,"abstract_only","high","first","opus-5.5-agent03","abstract of Medicare drug utilization trends by dementia status; no exposure comparison on outcomes",1],["R0021464","Real-World Use of Once-Weekly Semaglutide in Type 2 Diabetes: Results from SemaglUtide Real-world Evidence (SURE) Germany.","Menzen M","2023","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent03","SURE Germany prospective observational single arm study of weekly semaglutide, no comparator",1],["R0021709","A Study on Weight Loss Cause as per the Side Effect of Liraglutide.","Yu J","2022","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent03","retrospective chart review of liraglutide users grouped by side effects and discontinuation, no unexposed group",1],["R0021896","Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial.","Garvey WT","2022","include_nma",null,"primary_report","P02",null,null,"high","first","opus-5.5-agent03","STEP 5 two year double blind RCT of semaglutide 2.4 mg vs placebo in overweight or obesity",1],["R0014380","LBSUN213 An Investigation Into The Effects Of Dapagliflozin On Ketogenesis In Type 1 Diabetes",null,"2022","include_nma",null,"conference_abstract","P05",null,"abstract_only","high","first","opus-5.5-agent11","abstract of placebo controlled RCT in type 1 diabetes with exenatide, dapagliflozin and combination arms",1],["R0014555","Improved total shoulder arthroplasty outcomes associated with semaglutide utilization in patients with type II diabetes: a promising new addition to preoperative optimization.","Seddio AE","2025","include_harms",null,"primary_report",null,"O121",null,"high","first","opus-5.5-agent11","PearlDiver matched cohort of semaglutide users versus non users before shoulder arthroplasty; acute kidney injury among 90 day events",1],["R0014676","Protocol for Meal-time Administration of Exenatide for Glycaemic Control in Type 1 Diabetes Cases (The MAG1C trial): a randomised, double-blinded, placebo-controlled trial.","Johansen NJ","2018","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent11","protocol of MAG1C placebo controlled RCT of mealtime exenatide in type 1 diabetes",1],["R0014746","Recent advances in the treatment of patients with obesity and chronic kidney disease.","Abdul Wahab R","2023","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent11","narrative review of obesity and CKD treatments with informal PubMed search",1],["R0014831","The association of the treatment with glucagon-like peptide-1 receptor agonist exenatide or insulin with cardiovascular outcomes in patients with type 2 diabetes: a retrospective observational study.","Paul SK","2015","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent11","US EMR cohort of exenatide twice daily versus insulin; heart failure, MI and stroke only",1],["R0014917","Extended-release naltrexone/bupropion is safe and effective among subjects with type 2 diabetes already taking incretin agents: a post-hoc analysis of the LIGHT trial.","Wharton S","2021","inventory_only","N3","secondary_report",null,null,null,"high","first","opus-5.5-agent11","LIGHT post hoc of naltrexone bupropion versus placebo in patients on stable GLP-1RA or DPP-4i background",1],["R0015004","Employee perceptions and experiences with tirzepatide treatment for obesity or overweight in the US: Insights from the PERCEPTIONS Survey.","Gibble TH","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent11","baseline cross sectional survey of employed adults initiating tirzepatide; no comparator",1],["R0015082","PSUN276 GLP1RAs use for treating NALFD in a multidisciplinary clinic in low socioeconomic community",null,"2022","inventory_only","N5","conference_abstract",null,null,"abstract_only","high","first","opus-5.5-agent10","abstract of retrospective chart review of 11 NAFLD clinic patients mostly on semaglutide; no comparison group",1],["R0015199","Safety and efficacy of insulin degludec/liraglutide (IDegLira) added to sulphonylurea alone or to sulphonylurea and metformin in insulin-naïve people with Type 2 diabetes: the DUAL IV trial.","Rodbard HW","2017","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent10","DUAL IV double blind RCT IDegLira versus placebo added to sulphonylurea with or without metformin",1],["R0015276","Acute Administration of the GLP-1 Receptor Agonist Lixisenatide Diminishes Postprandial Insulin Secretion in Healthy Subjects But Not in Type 2 Diabetes, Associated with Slowing of Gastric Emptying.","Marathe CS","2022","include_nma",null,"secondary_report","P01; P99",null,"mechanistic; crossover","high","first","opus-5.5-agent10","crossover RCT single dose lixisenatide versus placebo in healthy subjects and T2D; gastric emptying and glycemia",1],["R0015372","From Product to Patient: An Integrated Product Profile for Access, Adoption, and Health Impact","Mathur A","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent10","methods and policy paper proposing an integrated product profile with a fictional oral GLP-1 example",1],["R0015540","Effect of survodutide, a glucagon and GLP-1 receptor dual agonist, on weight loss: a meta-analysis of randomized controlled trials.","Wan H","2024","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent10","meta-analysis of RCTs of survodutide versus control on weight; five databases searched",1],["R0015649","Absence of QTc Prolongation with Sodium N-(8-[2-Hydroxybenzoyl] Amino) Caprylate (SNAC), an Absorption Enhancer Co-Formulated with the GLP-1 Analogue Semaglutide for Oral Administration.","Granhall C","2021","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent10","thorough QT RCT of the absorption enhancer SNAC alone versus placebo and moxifloxacin; no semaglutide given",1],["R0021084","Type 2 Diabetes Patients Reach Target Glycemic Control Faster Using IDegLira than Either Insulin Degludec or Liraglutide Given Alone.","Vilsbøll T","2016","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent12","post hoc early time course analysis of DUAL I and II RCTs, IDegLira vs degludec or liraglutide",1],["R0021157","Activation of GLP-1 receptor signalling alleviates cellular stresses and improves beta cell function in a mouse model of Wolfram syndrome.","Kondo M","2018","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent20","Wolfram syndrome mouse study plus a single human case treated with liraglutide, no human comparison group",1],["R0021201","Outcomes of concomitant antiobesity medication use with endoscopic sleeve gastroplasty in clinical US settings.","Gala K","2024","inventory_only","N6","primary_report","P02",null,null,"high","first","opus-5.5-agent12","retrospective ESG cohort with vs without concomitant anti-obesity medication including GLP-1RA, weight loss outcomes only",1],["R0021244","One-year efficacy and safety of a fixed combination of insulin degludec and liraglutide in patients with type 2 diabetes: results of a 26-week extension to a 26-week main trial.","Gough SC","2015","include_nma",null,"extension","P01",null,null,"high","first","opus-5.5-agent20","preplanned 26 week extension of randomized DUAL I trial of IDegLira vs degludec vs liraglutide",1],["R0021302","Generalizability of the SURPASS-2 Trial and Effect of Tirzepatide on US Diabetes and Obesity Control.","Chiu N","2022","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent12","research letter simulating tirzepatide effects in NHANES population eligible for SURPASS-2, modeling study",1],["R0021361","Preserving renal function: gliflozins, GLP1 agonists, and antialdosterones.","Cice G","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent20","narrative review of renal protection with gliflozins, GLP-1 RAs and antialdosterones",1],["R0021411","Real-world evidence on the association of novel antidiabetic medication use with cancer risk and protective effects: a systematic review and network meta-analysis.","Kenawy AS","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent12","registered SR and network meta-analysis of observational studies of SGLT2i, DPP4i and GLP-1RA vs other drugs on cancer risk",1],["R0021508","Effect of expanded dulaglutide weekly doses (3.0 mg and 4.5 mg) on cardiovascular disease risk factors in participants with type 2 diabetes at increased cardiovascular disease risk: a post hoc analysis of the AWARD-11 study.","Cox DA","2022","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent12","post hoc CVD risk factor analysis of AWARD-11 RCT of dulaglutide 1.5 vs 3.0 vs 4.5 mg",1],["R0021544","Association of inflammation with glycemic control, insulin sensitivity, and beta-cell function in diabetic cats.","Thalmeier S","2026","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent20","veterinary study of diabetic cats treated with insulin with or without exenatide",1],["R0021652","Gout Flares and Mortality After Sodium-Glucose Cotransporter-2 Inhibitor Treatment for Gout and Type 2 Diabetes.","Wei J","2023","inventory_only","N6","primary_report","P01",null,null,"high","first","opus-5.5-agent12","IMRD new user cohort SGLT2i vs GLP-1RA or DPP4i in gout and T2D, gout flares and mortality only",1],["R0021701","Long-term efficacy of liraglutide in Indian patients with Type 2 diabetes in a real-world setting.","Kaur P","2016","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent20","single arm observational cohort of liraglutide in Indian T2D for one year",1],["R0021768","The potent synergistic effects of the combination of liraglutide and canagliflozin on glycemic control and weight loss.","Bell DS","2014","inventory_only","N5","primary_report","P01",null,null,"high","first","opus-5.5-agent12","single patient case report of liraglutide plus canagliflozin",1],["R0021818","Factors Correlated to the Renoprotective Effect of Sitagliptin in Patients with Type 2 Diabetes Mellitus: Retrospective Observational Study.","Khunkit P","2024","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent20","retrospective study of sitagliptin only, GLP-1 RA users excluded",1],["R0022051","Switch to Combined GLP1 Receptor Agonist Lixisenatide with Basal Insulin Glargine in Poorly Controlled T2DM Patients with Premixed Insulin Therapy: A Clinical Observation and Pilot Study in Nine Patients.","Harreiter J","2017","inventory_only","N1","primary_report",null,null,null,"high","first","opus-5.5-agent20","nonrandomized single arm pilot switching nine patients from premixed insulin to lixisenatide plus glargine",1],["R0015570","Rates of hypoglycaemia are lower in patients treated with insulin degludec/liraglutide (IDegLira) than with IDeg or insulin glargine, regardless of the hypoglycaemia definition used.","Norwood P","2017","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent15","post hoc hypoglycemia reanalysis of DUAL I and DUAL V RCTs of IDegLira versus degludec, liraglutide or glargine",1],["R0019053","Risk Factor Control in a Portuguese Vascular Risk Clinic: A 16-Month Retrospective Cohort Study.","Gante C","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent08","vascular risk clinic audit of risk factor control and drug use incl GLP-1 RA; no exposure comparison",1],["R0015686","New possibilities for neuroprotection in neonatal hypoxic-ischemic encephalopathy.","Victor S","2022","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent15","narrative review of neuroprotective drugs for neonatal hypoxic ischemic encephalopathy incl exendin-4",1],["R0015772","Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing.","Rosenstock J","2009","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent15","phase 2 RCT of albiglutide weekly, biweekly or monthly doses versus placebo with exenatide reference in type 2 diabetes",1],["R0015886","Reply to \"Comment on: GLP-1-ra and heart failure-related outcomes in patients with and without history of heart failure: an updated systematic review and meta-analysis\".","Villaschi A","2024","inventory_only","N9","ancillary",null,null,null,"high","first","opus-5.5-agent15","authors reply to a comment on their GLP-1 RA heart failure systematic review and meta-analysis",1],["R0015987","Association Between Early Weight Loss and Metabolic Outcomes with Tirzepatide in Japanese Patients with Type 2 Diabetes: A SURPASS J Post Hoc Analysis.","Mimura H","2025","include_nma",null,"pooled_analysis","P01",null,null,"high","first","opus-5.5-agent15","post hoc pooled SURPASS J-mono and J-combo RCT data on early weight loss with tirzepatide in Japanese type 2 diabetes",1],["R0016059","Comparing major and mild cognitive impairment risks in older type-2 diabetic patients: a Danish register-based study on dipeptidyl peptidase-4 inhibitors vs. glucagon-like peptide-1 analogues.","Battini V","2024","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent15","Danish register active comparator cohort of GLP-1 analogues versus DPP-4i in older type 2 diabetes; cognitive impairment only",1],["R0016154","Relationship Between Metabolic and Histological Responses in People With Metabolic Dysfunction- Associated Steatohepatitis With and Without Type 2 Diabetes: Participant-Level Exploratory Analysis of the SYNERGY-NASH Trial With Tirzepatide.","Caussy C","2025","include_nma",null,"secondary_report","P09; P01",null,null,"high","first","opus-5.5-agent15","participant level post hoc analysis of SYNERGY-NASH RCT of tirzepatide versus placebo in MASH with and without diabetes",1],["R0016244","Cardiovascular Outcomes in a SELECT-Like Obesity Cohort: Real-World Insights From the Swedish AROS Database.","Ritsinger V","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent15","Swedish registry description of cardiovascular risk in a SELECT like obesity cohort; semaglutide effect only applied from trial, no exposure",1],["R0019160","The Effect of Lifestyle Coaching Design on Patient Engagement and Weight Loss in Non-diabetic Patients of a Semaglutide-Supported Digital Obesity Program in the UK: A Comparative Retrospective Cohort Study.","Talay LA","2024","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent08","retrospective comparison of two coaching designs within a semaglutide digital program; GLP-1 exposure same in both groups",1],["R0019293","The long-term cost-effectiveness of once-weekly semaglutide versus sitagliptin for the treatment of type 2 diabetes in China.","Gu S","2024","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent08","microsimulation cost effectiveness of semaglutide versus sitagliptin in China based on SUSTAIN China",1],["R0019378","Anti-Diabetic Therapies and Cancer: From Bench to Bedside.","Kounatidis D","2024","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent08","narrative review of antidiabetic therapies and cancer biology",1],["R0019475","Real-World Treatment Patterns Among Patients with Type 2 Diabetes Mellitus Initiating Treatment with Oral Semaglutide.","Swift C","2024","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent08","claims based description of treatment lines after oral semaglutide initiation; utilization only",1],["R0019562","The metabolic effect of combined liraglutide treatment and lifestyle modification on obese adolescents in a tertiary center, Riyadh.","Babiker A","2025","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent08","retrospective matched cohort of liraglutide plus lifestyle versus lifestyle alone in adolescents with obesity; BMI and HbA1c only",1],["R0019822","Liraglutide relieves cardiac dilated function than DPP-4 inhibitors.","Hiramatsu T","2018","include_nma",null,"primary_report","P08A; P01",null,null,"high","first","opus-5.5-agent08","randomized allocation to liraglutide, sitagliptin or linagliptin over 48 months in type 2 diabetes with renal impairment",1],["R0017400","Ketamine in Diabetes Care: Metabolic Insights and Clinical Applications.","Sukhram SD","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent19","scoping review of ketamine in diabetes; GLP-1 RA mentioned only as possible interacting co-therapy",1],["R0017480","iGlarLixi Reduces Glycated Hemoglobin to a Greater Extent Than Basal Insulin Regardless of Levels at Screening: Post Hoc Analysis of LixiLan-L.","Niemoeller E","2018","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent19","post hoc analysis of LixiLan-L RCT of iGlarLixi vs insulin glargine by screening HbA1c; mislabeled as case report",1],["R0017547","Short-term exenatide treatment leads to significant weight loss in a subset of obese women without diabetes.","Dushay J","2012","include_nma",null,"primary_report","P02",null,"crossover","high","first","opus-5.5-agent19","double blind placebo controlled crossover RCT of exenatide for 16 week periods in obese women without diabetes",1],["R0017671","Proteomic changes upon treatment with semaglutide in individuals with obesity.","Maretty L","2025","include_nma",null,"secondary_report","P01; P02",null,"mechanistic","high","first","opus-5.5-agent19","proteomic analysis of STEP 1 and STEP 2 RCTs of semaglutide 2.4 mg vs placebo in obesity with or without diabetes",1],["R0017776","GLP-1 receptor agonists and delayed gastric emptying: implications for invasive cardiac interventions and surgery.","Shankar A","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent19","narrative review of GLP-1 RA, gastric emptying and aspiration risk in cardiac procedures",1],["R0017871","Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial.","Lau DCW","2021","include_nma",null,"primary_report","P02",null,null,"high","first","opus-5.5-agent19","phase 2 RCT of cagrilintide doses vs placebo and vs liraglutide 3.0 mg in overweight and obesity",1],["R0017965","Ipragliflozin Add-on Therapy to a GLP-1 Receptor Agonist in Japanese Patients with Type 2 Diabetes (AGATE): A 52-Week Open-Label Study.","Ishihara H","2018","inventory_only","N1","primary_report",null,null,null,"high","first","opus-5.5-agent19","single arm open label study of ipragliflozin added to GLP-1 RA background in Japanese type 2 diabetes",1],["R0018075","Beat it early: putative renoprotective haemodynamic effects of oral hypoglycaemic agents.","Gnudi L","2016","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent19","narrative review of renal hemodynamic effects of glucose lowering agents",1],["R0017175","Population-level impact of semaglutide 2.4 mg in patients with obesity or overweight and cardiovascular disease: A modelling study based on the SELECT trial.","Nanna MG","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent02","Markov population model projecting MACE prevented by semaglutide 2.4 mg using NHANES and SELECT effect",1],["R0017406","Physicians' real-world experience with IDegLira: results of a European survey.","Drummond R","2018","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent02","online survey of physicians on IDegLira prescribing experience; no patient exposure comparison",1],["R0017490","New-generation antidiabetic medications and dementia risk in older adults with type 2 diabetes: A retrospective cohort study.","Cohen A","2025","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent02","Israeli HMO cohort with time varying DPP-4 inhibitor, SGLT2 inhibitor or GLP-1 RA exposure vs unexposed; dementia only",1],["R0017561","Oral semaglutide for the treatment of obesity: a retrospective real-world study.","Krajnc M","2025","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent02","retrospective single group study of oral semaglutide 14 mg for obesity without diabetes",1],["R0017687","Treatment with exenatide once weekly or twice daily for 30 weeks is associated with changes in several cardiovascular risk markers.","Chiquette E","2012","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent02","post hoc lipoprotein analysis of DURATION-1 RCT of exenatide once weekly vs twice daily in T2D",1],["R0017800","Association between ranolazine therapy and cognitive decline in elderly patients with ischemic heart disease.","Severini G","2025","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent02","prospective cohort of ranolazine and cognitive decline; GLP-1 RA appears only as a covariate",1],["R0017878","U.S. Eligibility and Preventable Cardiovascular, Diabetes, and Kidney Outcomes From Semaglutide in the SELECT Trial.","Yan H","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent02","NHANES projection of preventable events applying SELECT trial event rates; modeling study",1],["R0015074","Use of Oral Semaglutide and Associated Clinical Outcomes in Thai Patients With Type 2 Diabetes: Real-World Evidence From the REALISED Study.","Wannachalee T","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent09","retrospective single arm multicentre cohort of oral semaglutide in Thai type 2 diabetes, no comparison group",1],["R0015193","Insulin Sensitivity and Beta Cell Function With Macupatide Alone or With Dulaglutide in Type 2 Diabetes: A Phase 1b, Randomised Controlled Trial.","Heise T","2026","include_nma",null,"primary_report","P01",null,"mechanistic","high","first","opus-5.5-agent09","phase 1b double blind RCT of macupatide, dulaglutide or both on clamp insulin sensitivity in type 2 diabetes",1],["R0015275","Effectiveness of Liraglutide in Patients With Obesity Who Are Early Non-Responders to Lifestyle Intervention: A Real-World Study.","Gilardini L","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent09","prospective observational comparison of lifestyle nonresponders who accepted versus declined liraglutide, weight outcomes only",1],["R0015370","Comparative effectiveness of liraglutide in the treatment of type 2 diabetes.","Rigato M","2014","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent09","narrative review of liraglutide efficacy and tolerability in type 2 diabetes",1],["R0015440","Oral Semaglutide, A New Option in the Management of Type 2 Diabetes Mellitus: A Narrative Review.","Sofogianni A","2020","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent09","self described narrative review of oral semaglutide",1],["R0015537","Quality of care for migrant populations with type 2 diabetes mellitus in Italy: a retrospective analysis of data from the the Italian AMD (Associations of Medical Diabetologists) annals initiative.","Occhipinti M","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent09","quality of care indicators for migrant versus European diabetes patients, GLP-1 use only described",1],["R0015639","Pharmacological Treatment of MASLD: Contemporary Treatment and Future Perspectives.","Drygalski K","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent09","self described narrative review of investigational MASLD drugs based on trial registry search",1],["R0015751","Efficacy and Safety of 1:1 Fixed-Ratio Combination of Insulin Glargine and Lixisenatide Versus Lixisenatide in Japanese Patients With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs: The LixiLan JP-O1 Randomized Clinical Trial.","Watada H","2020","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent09","LixiLan JP-O1 open label RCT of iGlarLixi versus lixisenatide in Japanese type 2 diabetes on oral drugs",1],["R0019221","Effects of liraglutide on diastolic function parameters in patients with type 2 diabetes and coronary artery disease: a randomized crossover study.","Kumarathurai P","2021","include_nma",null,"secondary_report","P01",null,"crossover; mechanistic","high","first","opus-5.5-agent17","crossover RCT of liraglutide versus placebo in newly diagnosed type 2 diabetes with CAD reporting diastolic function",1],["R0019324","Improved patient-reported outcomes with iGlarLixi versus premix BIAsp 30 in people with type 2 diabetes in the SoliMix trial.","Polonsky WH","2022","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent17","patient reported outcomes from SoliMix RCT of iGlarLixi versus premix BIAsp 30 in type 2 diabetes on basal insulin",1],["R0019427","IDegLira for the Real-World Treatment of Type 2 Diabetes in Italy: Protocol and Interim Results from the REX Observational Study.","Fadini GP","2022","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent17","protocol and baseline interim analysis of REX single cohort observational study of IDegLira in Italy",1],["R0019520","Associations of finerenone with reduced insulin resistance in patients with type 2 diabetes and chronic kidney disease: A real-world observational study.","Zhao X","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent17","single center finerenone cohort; GLP-1 RA use only a baseline characteristic",1],["R0019634","PIONEER REAL Sweden: A Multicentre, Prospective, Real-World Observational Study of Oral Semaglutide Use in Adults with Type 2 Diabetes in Swedish Clinical Practice.","Catrina SB","2024","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent17","non-interventional single arm prospective study of oral semaglutide in Swedish practice",1],["R0019745","Hypoglycaemia events with iGlarLixi versus premix biphasic insulin aspart 30 (BIAsp 30) in people with type 2 diabetes advancing from basal insulin: An analysis of the SoliMix trial.","McCrimmon RJ","2022","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent17","exploratory hypoglycemia analysis of SoliMix RCT of iGlarLixi versus premix BIAsp 30",1],["R0019899","Cost of Achieving HbA1c Treatment Targets and Weight Loss Responses with Once-Weekly Semaglutide Versus Dulaglutide in the United States.","Wilkinson L","2018","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent07","cost of control economic analysis of semaglutide vs dulaglutide using SUSTAIN 7 results",1],["R0019990","Liraglutide reduces attenuation coefficient as a measure of hepatic steatosis during 16 weeks' treatment in nondiabetic obese patients: A pilot trial.","Wang XJ","2021","include_nma",null,"primary_report","P02",null,null,"high","first","opus-5.5-agent07","double blind pilot RCT of liraglutide 3.0 mg vs placebo for 16 weeks in nondiabetic obesity; hepatic steatosis and weight",1],["R0020145","Structural and functional diversity among agonist-bound states of the GLP-1 receptor.","Cary BP","2022","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent07","structural and cell based study of peptide agonists at the GLP-1 receptor without human participants",1],["R0020258","Exploratory Biomarker-Defined Phenotypic Heterogeneity Beyond a Single Physiological Reserve Construct.","AlTaweel MO","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent07","cross sectional biomarker phenotyping using baseline values of a dapagliflozin or semaglutide cohort; no exposure comparison",1],["R0020617","Real-world outcomes of US employees with type 2 diabetes mellitus treated with insulin glargine or neutral protamine Hagedorn insulin: a comparative retrospective database study.","Wang L","2013","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent07","claims cohort comparing insulin glargine with NPH; GLP-1RA only prior therapy, not an exposure",1],["R0020797","Short-Term Effectiveness and Reduction in Insulin Requirements in Patients With Type 2 Diabetes Treated With IdegLira in a Real-World Setting.","Ramírez-Rincón A","2022","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent07","observational single group study of IDegLira in routine care with before after outcomes",1],["R0019138","Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis.","Armstrong MJ","2016","include_nma",null,"secondary_report","P09",null,"mechanistic","high","first","opus-5.5-agent01","mechanistic substudy of LEAN RCT, liraglutide 1.8 mg versus placebo in biopsy proven NASH, with BMI and HbA1c",1],["R0019347","Predictors of rapid eGFR decline in early to moderate chronic kidney disease (stages G1-G4): insights from a real-world Thai cohort incorporating KDIGO 2024 guidelines.","Anumas S","2025","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent01","CKD cohort of predictors of rapid eGFR decline with GLP-1 RA use among covariates; no listed harm",1],["R0019537","The effects of liraglutide on liver enzymes and metabolic factors in patients with nonalcoholic steatohepatitis: a meta-analysis of randomized controlled trials.","Malik A","2023","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent01","meta-analysis of liraglutide RCTs in NASH, four databases searched",1],["R0019646","Investigating Risk of Cancer with Sodium-Glucose Cotransporter 2 Inhibitors: A Disproportionality Analysis in the WHO Global Pharmacovigilance Database Vigibase®.","Gautier P","2025","inventory_only","N5","other",null,null,null,"high","first","opus-5.5-agent01","Vigibase disproportionality analysis of cancer reports with SGLT2i using GLP-1 RA and DPP-4i as comparators",1],["R0019785","The efficacy and safety of liraglutide added to metformin in patients with diabetes: a meta-analysis of randomized controlled trials.","Gu J","2016","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent01","meta-analysis of RCTs of liraglutide added to metformin versus other treatments, four databases searched",1],["R0018714","Effects of semaglutide on gut microbiota, cognitive function and inflammation in obese mice.","Feng J","2024","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent13","semaglutide study in high fat diet obese mice only",1],["R0018857","Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk.","Husain M","2020","include_nma",null,"pooled_analysis","P01",null,null,"high","first","opus-5.5-agent13","patient level pooled post hoc analysis of SUSTAIN 6 and PIONEER 6 RCTs of semaglutide vs placebo on MACE by CV risk",1],["R0018976","Fragment-Guided New Therapeutic Molecule Discovery and Mapping of Clinically Relevant Interactomes.","Kanapeckaitė A","2026","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent13","computational fragment based drug discovery study, in silico only",1],["R0019105","Characteristics and outcomes of patients with type 2 diabetes mellitus treated with canagliflozin: a real-world analysis.","Buysman EK","2015","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent13","single cohort study of canagliflozin users, no GLP-1 exposure studied",1],["R0019200","Pharmacokinetics and Tolerability of a Single Dose of Semaglutide, a Human Glucagon-Like Peptide-1 Analog, in Subjects With and Without Renal Impairment.","Marbury TC","2017","inventory_only","N1","primary_report",null,null,null,"high","first","opus-5.5-agent13","single dose semaglutide PK study across renal function groups, all participants received semaglutide",1],["R0019413","The Effect of Open-Label Semaglutide on Metabolic Dysfunction-Associated Steatotic Liver Disease in People With HIV.","Lake JE","2024","inventory_only","N1","primary_report",null,null,null,"high","first","opus-5.5-agent13","SLIM LIVER single arm open label trial of semaglutide in people with HIV and MASLD",1],["R0022990","Comprehensive analysis of the safety of semaglutide in type 2 diabetes: a meta-analysis of the SUSTAIN and PIONEER trials.","Yin DG","2021","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent06","registered meta-analysis of SUSTAIN and PIONEER RCTs of semaglutide versus control on serious adverse events; Embase, PubMed searched",1],["R0023128","Clinical effectiveness of liraglutide across body mass index in patients with type 2 diabetes in the United States: a retrospective cohort study.","Chitnis AS","2014","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent06","retrospective EMR cohort of liraglutide initiators stratified by BMI; no comparison treatment group",1],["R0023233","The effect of liraglutide on cardiac autonomic function in type 2 diabetes: A prespecified secondary analysis from the LIRAFLAME randomized, double-blinded, placebo-controlled trial.","Sivalingam S","2022","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent06","prespecified secondary analysis of LIRAFLAME double blind RCT of liraglutide versus placebo on cardiac autonomic function in T2D",1],["R0023353","Effects of Exenatide and Humalog Mix25 on Fat Distribution, Insulin Sensitivity, and β-Cell Function in Normal BMI Patients with Type 2 Diabetes and Visceral Adiposity.","Wang X","2020","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent06","RCT of exenatide versus premixed insulin lispro Mix25 for 24 weeks in normal BMI T2D with visceral adiposity",1],["R0023520","Cardiovascular outcomes and safety with antidiabetic drugs.","Aldossari KK","2018","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent06","narrative literature review of cardiovascular outcomes and safety with antidiabetic drugs",1],["R0023626","Efficacy and safety of dulaglutide in patients with absolute insulin deficiency.","Kutoh E","2019","inventory_only","N1","primary_report",null,null,null,"high","first","opus-5.5-agent06","single arm study of dulaglutide added in 10 patients with absolute insulin deficiency; no control group",1],["R0023771","Liraglutide decreases carotid intima-media thickness in patients with type 2 diabetes: 8-month prospective pilot study.","Rizzo M","2014","inventory_only","N1","primary_report",null,null,null,"high","first","opus-5.5-agent06","prospective single arm pilot of liraglutide added to metformin on carotid IMT in T2D; no control group",1],["R0023950","Precision Medicine in Type 2 Diabetes: Using Individualized Prediction Models to Optimize Selection of Treatment.","Dennis JM","2020","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent06","perspective on precision medicine prediction models for T2D treatment selection",1],["R0022267","Severe obesity in a specialist type 2 diabetes outpatient clinic: an Australian retrospective cohort study.","Thakur A","2021","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent20","retrospective clinic audit of severe obesity in T2D, GLP-1 RA use only described by BMI group",1],["R0022364","GLUcose COntrol Safety & Efficacy in type 2 DIabetes, a systematic review and NETwork meta-analysis.","Grenet G","2019","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent20","PROSPERO registered Bayesian NMA of RCTs of glucose lowering drugs including GLP-1 RAs on mortality and MACE",1],["R0022507","Use of Diabetes Treatment Satisfaction Questionnaire in Diabetes Care: Importance of Patient-Reported Outcomes.","Saisho Y","2018","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent20","narrative review of the diabetes treatment satisfaction questionnaire",1],["R0022617","Metformin use is associated with a lower risk of uterine leiomyoma in female type 2 diabetes patients.","Tseng CH","2019","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent20","Taiwan cohort of metformin and uterine leiomyoma, incretin drugs only a sensitivity exclusion",1],["R0022723","Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin.","Kapitza C","2013","include_nma",null,"primary_report","P01",null,"mechanistic","high","first","opus-5.5-agent20","randomized open label 28 day PD study of lixisenatide vs liraglutide on metformin, HbA1c weight and adverse events reported",1],["R0022825","Determining predictors of early response to exenatide in patients with type 2 diabetes mellitus.","Khan M","2015","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent20","retrospective single arm study of predictors of exenatide response, no comparison group",1],["R0022935","Short-term effectiveness of low dose liraglutide in combination with metformin versus high dose liraglutide alone in treatment of obese PCOS: randomized trial.","Jensterle M","2017","include_nma",null,"primary_report","P12",null,null,"high","first","opus-5.5-agent20","randomized open label trial of liraglutide 1.2 mg plus metformin vs liraglutide 3 mg in obese PCOS",1],["R0016372","Pharmacoeconomic analysis (CER) of Dulaglutide and Liraglutide in the treatment of patients with type 2 diabetes.","Su Y","2023","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent15","RCT of dulaglutide versus liraglutide for 24 weeks in women with type 2 diabetes with cost effectiveness ratios",1],["R0016470","Two birds one stone: semaglutide is highly effective against severe psoriasis in a type 2 diabetic patient.","Costanzo G","2021","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent15","single case report of semaglutide improving psoriasis in a patient with type 2 diabetes",1],["R0016561","The glucagon-like peptide 1 analogue Exendin-4 attenuates the nicotine-induced locomotor stimulation, accumbal dopamine release, conditioned place preference as well as the expression of locomotor sensitization in mice.","Egecioglu E","2013","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent15","mouse experiments of exendin-4 on nicotine induced dopamine and behavior; animals only",1],["R0016637","Pioneering pharmacometrics practice in Korea: an eight-year retrospective analysis of 192 projects from the first dedicated service organization (2016-2024).","Lee SJ","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent15","retrospective overview of a Korean pharmacometrics service portfolio; methods and modeling, no primary GLP-1 data",1],["R0016735","Is semaglutide cost-effective at closing the gap for Aboriginal and Torres Strait Islander Australians with cardiovascular disease and obesity without type 2 diabetes?","Hargovan S","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent15","Markov cost effectiveness model of semaglutide for Aboriginal and Torres Strait Islander adults with CVD and obesity",1],["R0016956","Efficacy and safety of oral semaglutide by baseline age in Japanese patients with type 2 diabetes: A subgroup analysis of the PIONEER 9 and 10 Japan trials.","Yamada Y","2022","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent15","age subgroup analysis of PIONEER 9 and 10 RCTs of oral semaglutide versus placebo, liraglutide or dulaglutide in Japan",1],["R0017025","Duration of diabetes and cardiorenal efficacy of liraglutide and semaglutide: A post hoc analysis of the LEADER and SUSTAIN 6 clinical trials.","Verma S","2019","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent15","post hoc diabetes duration analysis of LEADER and SUSTAIN 6 placebo controlled RCTs on cardiorenal outcomes",1],["R0022075","A randomized trial to investigate the efficacy and safety of once-daily liraglutide 1.8 mg in Japanese adults with type 2 diabetes exhibiting an inadequate response to liraglutide 0.9 mg.","Seino Y","2022","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent03","26 week RCT of liraglutide 1.8 mg vs continued 0.9 mg in Japanese T2D with inadequate response after run in",1],["R0022279","Efficacy and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately controlled on metformin: a 24-week, randomized, open-label, active-controlled study (GetGoal-X).","Rosenstock J","2013","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent03","GetGoal-X 24 week open label RCT of lixisenatide once daily vs exenatide twice daily on metformin",1],["R0022384","The Changes of Lipidomic Profiles Reveal Therapeutic Effects of Exenatide in Patients With Type 2 Diabetes.","Zhang L","2022","inventory_only","N1","primary_report",null,null,null,"high","first","opus-5.5-agent03","single arm 12 week exenatide study in new T2D with lipidomics; healthy controls only for baseline comparison",1],["R0022514","Long-Term Cost Effectiveness of Oral Semaglutide Versus Empagliflozin and Sitagliptin for the Treatment of Type 2 Diabetes in the Swedish Setting.","Eliasson B","2022","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent03","cost effectiveness model of oral semaglutide vs empagliflozin and sitagliptin in Sweden",1],["R0022631","Ipragliflozin Improves the Hepatic Outcomes of Patients With Diabetes with NAFLD.","Takahashi H","2022","exclude","E2","primary_report",null,null,null,"high","first","opus-5.5-agent03","RCT of ipragliflozin vs control without GLP-1 RA in T2D with NAFLD; two non GLP-1 regimens",1],["R0022834","Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial.","Samson SL","2011","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent03","12 month RCT of pioglitazone plus exenatide vs pioglitazone alone in T2D with NAFLD; also mouse data",1],["R0020768","The Comparison of the Kidney Effects of Dipeptidyl Peptidase 4 Inhibitors and Glucagon-Like Peptide 1 Agonist-Administered Concomitant with Sodium-Glucose Cotransporter 2 Inhibitors in Japanese Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease.","Kobayashi K","2021","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent04","retrospective matched comparison of GLP-1 RA vs DPP-4i added to SGLT2i in diabetes with CKD, ACR, eGFR and HbA1c only",1],["R0020887","Adherence to ADA Clinical Guidelines in Type 2 Diabetes Management in Public Health Clinics in Palestine.","Abukhalil AD","2024","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent04","cross sectional record review of ADA guideline adherence in Palestinian clinics, prescribing only",1],["R0021011","Incretin-based therapies: viewpoints on the way to consensus.","Nauck MA","2009","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent04","viewpoint review on incretin based therapies",1],["R0021258","Safety and tolerability of high doses of taspoglutide, a once-weekly human GLP-1 analogue, in diabetic patients treated with metformin: a randomized double-blind placebo-controlled study.","Ratner R","2010","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent04","phase 2 double blind RCT of taspoglutide dose titration vs placebo on metformin in type 2 diabetes",1],["R0021387","Mechanisms of action of metformin with special reference to cardiovascular protection.","Zilov AV","2019","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent04","narrative review of metformin mechanisms and cardiovascular protection",1],["R0021466","Effect of GLP-1 Receptor Activation on Offspring Kidney Health in a Rat Model of Maternal Obesity.","Glastras SJ","2016","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent04","rat model of maternal obesity with offspring randomized to exendin-4 or placebo, animal only",1],["R0021582","Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis.","Tan HC","2022","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent04","systematic review and meta-analysis of RCTs of semaglutide vs placebo for weight loss in obesity without diabetes",1],["R0017991","Effect of semaglutide on kidney function across different levels of baseline HbA1c, blood pressure, body weight and albuminuria in SUSTAIN 6 and PIONEER 6.","Apperloo EM","2025","include_nma",null,"pooled_analysis","P01",null,null,"high","first","opus-5.5-agent02","pooled post hoc analysis of SUSTAIN 6 and PIONEER 6 placebo controlled RCTs of semaglutide on eGFR slope",1],["R0018311","The Composite Number Needed to Treat for Semaglutide in Populations with Overweight or Obesity and Established Cardiovascular Disease Without Diabetes.","Lübker C","2025","include_nma",null,"secondary_report","P02",null,null,"high","first","opus-5.5-agent02","secondary NNT analysis of SELECT placebo controlled RCT of semaglutide in obesity with CVD",1],["R0018451","Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial.","Mahaffey KW","2025","include_nma",null,"secondary_report","P08A",null,null,"high","first","opus-5.5-agent02","prespecified FLOW RCT analysis of semaglutide vs placebo cardiovascular outcomes by CKD severity in T2D",1],["R0018570","Next Generation Antiobesity Medications: Setmelanotide, Semaglutide, Tirzepatide and Bimagrumab: What do They Mean for Clinical Practice?","Ryan DH","2021","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent02","narrative review of next generation antiobesity medications",1],["R0018660","Effects of combined metformin and semaglutide therapy on body weight, metabolic parameters, and reproductive outcomes in overweight/obese women with polycystic ovary syndrome: a prospective, randomized, controlled, open-label clinical trial.","Chen H","2025","include_nma",null,"primary_report","P12",null,null,"high","first","opus-5.5-agent02","open label RCT of metformin plus semaglutide vs metformin in overweight or obese women with PCOS",1],["R0018786","Effects of Tirzepatide Versus Basal Insulins in People With Type 2 Diabetes and Different Baseline Glycemic Patterns: Post Hoc Analyses of the SURPASS-3 and SURPASS-4 Trials.","Giorgino F","2024","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent02","post hoc analyses of SURPASS-3 and SURPASS-4 RCTs of tirzepatide vs basal insulins by glycemic pattern",1],["R0015869","Antidiabetic treatment patterns and specialty care utilization among patients with type 2 diabetes and cardiovascular disease.","Pantalone KM","2018","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent10","cross sectional EHR study of antidiabetic treatment patterns and specialty visits by CVD status; utilization only",1],["R0019859","Risk of prostatitis in patients with type 2 diabetes mellitus: An observational retrospective cohort study of canagliflozin versus other antihyperglycemic agents using propensity score matching.","Yuan Z","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent17","new user claims cohort of canagliflozin versus comparators including liraglutide; prostatitis outcome only",1],["R0015957","Assessing patient PREFERence between the dulaglutide pen and the semaglutide pen: A crossover study (PREFER).","Matza LS","2020","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent10","randomized crossover device preference study with mock injections into a pad; no drug administered",1],["R0016039","Effect of incretin-based therapies on cancers of digestive system among 101 595 patients with type 2 diabetes mellitus: a systematic review and network meta-analysis combining 84 trials with a median duration of 30 weeks.","Chai S","2019","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent10","PROSPERO registered NMA of RCTs of incretin drugs on digestive cancers in T2D; four databases searched",1],["R0016217","Tirzepatide on obstructive sleep apnea-related cardiometabolic risk: secondary outcomes of the SURMOUNT-OSA randomized trial.","Malhotra A","2026","include_nma",null,"secondary_report","P10; P02",null,null,"high","first","opus-5.5-agent10","prespecified secondary outcomes of SURMOUNT-OSA RCTs tirzepatide versus placebo; cardiometabolic risk factors",1],["R0016342","Obeticholic Acid and Other Farnesoid-X-Receptor (FXR) Agonists in the Treatment of Liver Disorders.","Fiorucci S","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent10","narrative review of obeticholic acid and FXR agonists in liver disease",1],["R0016446","Early-Onset Obesity and Tirzepatide Treatment: A Post Hoc Analysis of the SURMOUNT Clinical Trials.","Gourgari E","2025","include_nma",null,"secondary_report","P02; P02W",null,null,"high","first","opus-5.5-agent10","post hoc of SURMOUNT-1, 3 and 4 RCTs tirzepatide versus placebo by early versus later onset obesity; weight",1],["R0016525","Effect of Liraglutide on Intermittent Hypoxia-Induced Metabolic Dysfunction: From Bench to Bedside.","O'Donnell C","2026","include_nma",null,"primary_report","P10",null,null,"high","first","opus-5.5-agent10","cell and mouse work plus proof of concept RCT liraglutide versus CPAP in nondiabetic OSA; insulin sensitivity and weight",1],["R0019948","Semaglutide improved sperm morphology in obese men with type 2 diabetes mellitus and functional hypogonadism.","Gregorič N","2025","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent17","open label RCT of semaglutide versus testosterone in obese men with type 2 diabetes and functional hypogonadism, 24 weeks",1],["R0020040","Selecting GLP-1 agonists in the management of type 2 diabetes: differential pharmacology and therapeutic benefits of liraglutide and exenatide.","Pinkney J","2010","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent17","narrative review comparing liraglutide and exenatide pharmacology and benefits",1],["R0020203","Safety and efficacy of semaglutide in post kidney transplant patients with type 2 diabetes or Post-Transplant diabetes.","Mahzari MM","2024","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent17","retrospective single group study of semaglutide after kidney transplant without comparison group",1],["R0020332","Effect of Semaglutide and Empagliflozin on Pulmonary Structure and Proteomics in Obese Mice.","Yang Y","2024","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent17","obese mouse study of semaglutide and empagliflozin on lung structure",1],["R0020439","THU283 Oral Semaglutide, Effectiveness, Safety And Tolerability In Real Life: A Short-term Retrospective Observational Study",null,"2023","inventory_only","N5","conference_abstract",null,null,"abstract_only","high","first","opus-5.5-agent17","conference abstract of a retrospective single group real world oral semaglutide study",1],["R0020555","Loss of dorsomedial hypothalamic GLP-1 signaling reduces BAT thermogenesis and increases adiposity.","Lee SJ","2018","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent17","rat study of hypothalamic GLP-1 signaling and receptor knockdown",1],["R0019928","Association of the gallbladder or biliary diseases with dipeptidyl peptidase 4 inhibitors in patients with type 2 diabetes: a meta-analysis of randomized controlled trials.","Yu M","2022","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent14","meta-analysis of DPP-4 inhibitor RCTs and gallbladder events, no GLP-1 RA contrast",1],["R0020327","Efficacy and tolerability of the Subcutaneous Semaglutide for type 2 Diabetes patients: an updated systematic review and meta-analysis.","Hu S","2023","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent14","PROSPERO registered meta-analysis of RCTs of subcutaneous semaglutide in T2D, nine databases searched",1],["R0020428","Plasma metabolites associated with functional and clinical outcomes in heart failure with reduced ejection fraction with and without type 2 diabetes.","Lerman JB","2022","include_nma",null,"secondary_report","P07B",null,"mechanistic","high","first","opus-5.5-agent14","metabolomics secondary analysis of FIGHT RCT of liraglutide vs placebo in HFrEF",1],["R0020536","Effect of Semaglutide on the Pharmacokinetics of Metformin, Warfarin, Atorvastatin and Digoxin in Healthy Subjects.","Hausner H","2017","inventory_only","N1","primary_report",null,null,"mechanistic","high","first","opus-5.5-agent14","one sequence drug interaction PK studies of semaglutide in healthy subjects, before vs with semaglutide, no concurrent control",1],["R0020689","T160. TREATMENT OF CLOZAPINE-ASSOCIATED OBESITY AND DIABETES WITH EXENATIDE (CODEX) IN ADULTS WITH SCHIZOPHRENIA: A RANDOMISED CONTROLLED TRIAL","Siskind D","2018","include_nma",null,"conference_abstract","P15",null,"abstract_only","high","first","opus-5.5-agent14","conference abstract of open label RCT of exenatide vs usual care in clozapine treated obese adults with schizophrenia",1],["R0021982","Efficacy of liraglutide in patients with diabetic nephropathy: a meta-analysis of randomized controlled trials.","Mali N","2022","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent12","meta-analysis of RCTs of liraglutide vs control in diabetic nephropathy searching eight named databases",1],["R0022117","Effects of Pharmacotherapy for the Treatment of Obesity in an Urban, Safety-Net Population.","Kim EK","2023","inventory_only","N6","primary_report","P02",null,null,"high","first","opus-5.5-agent12","retrospective safety net clinic comparison of GLP-1RA, phentermine topiramate and lifestyle, weight and HbA1c only",1],["R0022207","Efficacy and safety of semaglutide on weight loss in obese or overweight patients without diabetes: A systematic review and meta-analysis of randomized controlled trials.","Gao X","2022","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent12","SR and meta-analysis of semaglutide vs placebo RCTs for weight loss without diabetes",1],["R0022315","Value of 68Ga-DOTATOC and Carbidopa-Assisted 18F-DOPA PET/CT for Insulinoma Localization.","Imperiale A","2022","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent12","insulinoma localization with DOTATOC and DOPA PET, no GLP-1RA exposure",1],["R0022453","Treatment of clozapine-associated obesity and diabetes with exenatide (CODEX) in adults with schizophrenia: study protocol for a pilot randomised controlled trial.","Mayfield K","2015","inventory_only","N8","protocol_or_design","P15",null,null,"high","first","opus-5.5-agent12","protocol of pilot RCT of exenatide once weekly vs usual care in clozapine treated obese adults with schizophrenia",1],["R0022547","Tolerability, effectiveness and predictive parameters for the therapeutic usefulness of exenatide in obese, Korean patients with type 2 diabetes.","Song SO","2014","inventory_only","N1","primary_report","P01",null,null,"high","first","opus-5.5-agent12","prospective single arm open label study of exenatide twice daily in obese Korean T2D",1],["R0022686","Does combining liraglutide with intragastric balloon insertion improve sustained weight reduction?","Mosli MM","2017","inventory_only","N6","primary_report","P02",null,null,"high","first","opus-5.5-agent12","retrospective comparison of intragastric balloon with vs without liraglutide, weight outcomes only",1],["R0022783","Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11).","Frias JP","2021","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent12","double blind RCT AWARD-11 of dulaglutide 3.0 and 4.5 mg vs 1.5 mg on metformin in T2D",1],["R0015087","Impact of socioeconomic position on initiation of SGLT-2 inhibitors or GLP-1 receptor agonists in patients with type 2 diabetes - a Danish nationwide observational study.","Falkentoft AC","2022","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent11","Danish register study of socioeconomic predictors of SGLT2i or GLP-1RA initiation; drug utilization without exposure outcome comparison",1],["R0018189","[Synergistic effects of GABA and hypoglycemic drugs].","Tyurenkov IN","2023","exclude","E3","other",null,null,"non_english","high","first","opus-5.5-agent19","Russian narrative review of GABA combined with glucose lowering drugs; no primary data or systematic synthesis",1],["R0015205","Is Bariatric Surgery at Risk Due to Semaglutide?","Tian J","2025","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent11","single center cohort of preoperative semaglutide users versus non users in bariatric pathway; surgery timing, cancellation and weight only",1],["R0015279","Long-term efficacy and safety of tirzepatide in participants with type 2 diabetes with inadequate glycaemic control on metformin and/or sulfonylurea: Post-hoc analysis of SURPASS-4.","Guan H","2025","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent11","SURPASS-4 post hoc subgroup at 104 weeks; randomized tirzepatide versus insulin glargine",1],["R0015377","The management of type 2 diabetes with fixed-ratio combination insulin degludec/liraglutide (IDegLira) versus basal-bolus therapy (insulin glargine U100 plus insulin aspart): A short-term cost-effectiveness analysis in the UK setting.","Drummond R","2018","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent11","short term cost utility model of IDegLira versus basal bolus insulin using DUAL VII inputs",1],["R0015454","Data-Driven Multidimensional Clinical Phenotypes and Longitudinal Changes in Type 2 Diabetes Mellitus: A Retrospective Cohort Study.","Igna AD","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent11","clustering of clinical phenotypes in type 2 diabetes; GLP-1RA use only described, not studied as exposure",1],["R0015549","Reduced-Frequency GLP1 Therapy Maintains Weight, Body Composition, and Metabolic Syndrome Improvements: A Case Series.","Wong M","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent11","retrospective case series of reduced frequency semaglutide or tirzepatide dosing; no comparator",1],["R0015658","Semaglutide and Non-arteritic Anterior Ischemic Optic Neuropathy: A Systematic Review and Narrative Synthesis.","Eisa N","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent11","registered systematic review of observational studies on semaglutide and NAION; PubMed, Embase, CENTRAL searched",1],["R0015754","Effects of Tirzepatide on Skeletal Muscle Mass in Adults: A Systematic Review.","Hidalgo Ramos RA","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent11","PRISMA systematic review of tirzepatide RCTs on skeletal muscle; PubMed, Embase, Web of Science, Cochrane searched",1],["R0018437","Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions.","Cusi K","2016","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent19","narrative review of NAFLD treatment options in type 2 diabetes",1],["R0018546","LBODP002 Phase II Open-label Pilot Trial Of Liraglutide In Adolescents With Obesity After Vertical Sleeve Gastrectomy: Interim Results From 8-weeks Of Treatment",null,"2022","inventory_only","N1","conference_abstract",null,null,"abstract_only","high","first","opus-5.5-agent19","interim abstract of open label single arm pilot of liraglutide in adolescents with obesity after sleeve gastrectomy",1],["R0018635","Comparison of Glycemic Variability in Chinese T2DM Patients Treated with Exenatide or Insulin Glargine: A Randomized Controlled Trial.","Yin TT","2018","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent19","RCT of exenatide vs insulin glargine for 16 weeks on glycemic variability in metformin treated type 2 diabetes",1],["R0018756","Effects of switching from dipeptidyl peptidase 4 inhibitors to oral semaglutide on oxidative stress and glycemic variability in patients with type 2 diabetes: an open-label, prospective, randomized, multicenter, parallel-group comparison study","Ohara M","2024","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent19","open label multicenter RCT switching DPP-4 inhibitor to oral semaglutide vs continuing, oxidative stress and glucose variability",1],["R0018883","Cardiovascular Effect of Incretin-Based Therapy in Patients with Type 2 Diabetes Mellitus: Systematic Review and Meta-Analysis.","Kim JY","2016","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent19","meta-analysis of trials of DPP-4i or GLP-1 RA vs placebo or other agents on cardiovascular events; MEDLINE Embase CENTRAL",1],["R0019012","Retrospective Study on the Efficacy and Safety of Dulaglutide in Patients with Diabetes and Moderate-Advanced Chronic Kidney Disease.","Kosaraju S","2024","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent19","retrospective single group review of dulaglutide tolerability and efficacy in moderate to advanced CKD",1],["R0020859","Clinical Effectiveness of Oral Semaglutide in Women with Type 2 Diabetes: A Nationwide, Multicentre, Retrospective, Observational Study (Women_ENDO2S-RWD Substudy).","Reyes-Garcia R","2025","inventory_only","N5","secondary_report",null,null,null,"high","first","opus-5.5-agent18","substudy of retrospective single arm oral semaglutide cohort comparing women and men; no drug comparator",1],["R0020964","Effects of semaglutide on body weight in clozapine-treated people with schizophrenia and obesity: study protocol for a placebo-controlled, randomised multicentre trial (COaST)","Siskind D","2023","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent18","protocol of COaST placebo controlled RCT of semaglutide in clozapine treated schizophrenia with obesity",1],["R0021147","Evaluating potential predictors of weight loss response to liraglutide in adolescents with obesity: A post hoc analysis of the randomized, placebo-controlled SCALE Teens trial.","Bensignor MO","2023","include_nma",null,"secondary_report","P03",null,null,"high","first","opus-5.5-agent18","post hoc predictor analysis of SCALE Teens RCT, liraglutide 3.0 mg vs placebo in adolescents with obesity",1],["R0021354","Management of Early-Onset Type 2 Diabetes in Adults: Current Evidence and Future Directions.","Savage MJ","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent18","narrative review of management of early onset T2D; not a trial report",1],["R0021537","Elderly rats fed with a high-fat high-sucrose diet developed sex-dependent metabolic syndrome regardless of long-term metformin and liraglutide treatment.","Ivić V","2023","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent18","randomized experiment in elderly rats on high fat diet treated with metformin or liraglutide; animals only",1],["R0021681","The Effect of Additional Treatment with Empagliflozin or Semaglutide on Endothelial Function and Arterial Stiffness in Subjects with Type 1 Diabetes Mellitus-ENDIS Study.","Navodnik MP","2023","include_nma",null,"primary_report","P05",null,"mechanistic","high","first","opus-5.5-agent18","ENDIS RCT of add on semaglutide vs empagliflozin vs insulin alone in type 1 diabetes; endothelial function primary",1],["R0020959","Thromboxane-Dependent Platelet Activation in Obese Subjects with Prediabetes or Early Type 2 Diabetes: Effects of Liraglutide- or Lifestyle Changes-Induced Weight Loss.","Simeone P","2018","include_nma",null,"secondary_report","P01; P02",null,null,"high","first","opus-5.5-agent16","RCT of liraglutide vs lifestyle to equal weight loss in obese adults with prediabetes or new T2D on metformin; platelet markers",1],["R0021122","Comparison of the Efficacy of Anti-Obesity Medications in Real-World Practice.","Song JE","2024","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent16","retrospective comparison of anti obesity drugs incl. liraglutide on weight and body composition; no listed harm",1],["R0021215","Effects of Treatment with Liraglutide Early after Surgical Intervention on Clinical Outcomes in Patients with Short Bowel Syndrome: A Pilot Observational \"Real-Life\" Study.","Merlo FD","2023","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent16","pilot observational comparison of liraglutide vs untreated short bowel syndrome patients; stomal output outcomes only",1],["R0021344","Low Levels of Adropin Predict Adverse Clinical Outcomes in Outpatients with Newly Diagnosed Prediabetes after Acute Myocardial Infarction.","Berezina TA","2024","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent16","prospective biomarker cohort of adropin after STEMI; GLP-1RA use only a regression covariate",1],["R0021426","Efficacy of metformin combined with liraglutide on the glucose and lipid metabolism, vascular endothelial function, and oxidative stress of patients with T2DM and metabolic syndrome.","Liu Z","2024","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent16","retrospective comparison of metformin plus liraglutide vs metformin alone in T2D with metabolic syndrome; metabolic outcomes only",1],["R0021531","Anti-Obesity Medications and the Risk of Obesity-Related Cancers in Older Women: A Propensity Score Matching Analysis of 2007-2015 SEER-Medicare Data.","Abdelgadir O","2025","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent16","SEER-Medicare matched cohort of anti obesity drug and liraglutide users; breast, colorectal, endometrial, ovarian cancer only",1],["R0021798","Changes in Glucose Metabolism and Glycemic Status With Once-Weekly Subcutaneous Semaglutide 2.4 mg Among Participants With Prediabetes in the STEP Program.","Perreault L","2022","include_nma",null,"secondary_report","P02; P02W",null,null,"high","first","opus-5.5-agent16","analysis of prediabetes participants across STEP 1, 3 and 4 semaglutide vs placebo RCTs incl. randomized withdrawal",1],["R0015861","Comparative Analysis of Resmetirom vs. FGF21 Analogs vs. GLP-1 Agonists in MASLD and MASH: Network Meta-Analysis of Clinical Trials.","Ayesh H","2024","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent09","PRISMA NMA of trials of resmetirom, FGF21 analogs and GLP-1 agonists in MASLD, four databases",1],["R0015956","Bispecific GLP-1/GLP-2 agonism in advanced type 2 diabetes: preclinical characterization and a randomized, double-blind, placebo-controlled phase I trial.","Yang SI","2026","include_nma",null,"primary_report","P99",null,"mechanistic","high","first","opus-5.5-agent09","preclinical work plus phase 1 placebo controlled RCT of PG-102 in overweight adults reporting adverse events; P99 overweight volunteers",1],["R0016038","A 24-week study to evaluate the efficacy and safety of once-weekly dulaglutide added on to glimepiride in type 2 diabetes (AWARD-8).","Dungan KM","2016","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent09","AWARD-8 double blind RCT of dulaglutide versus placebo added to glimepiride in type 2 diabetes",1],["R0016130","Comparing Quality of Life in Type 2 Diabetic Patients Using Dulaglutide and Liraglutide","Ghosh A","2021","inventory_only","N5","conference_abstract",null,null,"abstract_only","high","first","opus-5.5-agent09","congress abstract cross sectional comparison of quality of life in dulaglutide versus liraglutide users",1],["R0016216","Reduced Glucose Variability With Glucose-Dependent Versus Glucose-Independent Therapies Despite Similar Glucose Control and Hypoglycemia Rates in a Randomized, Controlled Study of Older Patients With Type 2 Diabetes Mellitus.","Pratley RE","2018","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent09","CGM substudy of IMPERIUM RCT comparing GLP-1 based strategy with sulfonylurea and glargine strategy in older type 2 diabetes",1],["R0016337","Pharmacodynamics of the glucagon-like peptide-1 receptor agonist lixisenatide in Japanese and Caucasian patients with type 2 diabetes mellitus poorly controlled on sulphonylureas with/without metformin.","Seino Y","2014","include_nma",null,"primary_report","P01",null,"mechanistic","high","first","opus-5.5-agent09","double blind RCT of lixisenatide versus placebo pharmacodynamics in Japanese and Caucasian type 2 diabetes, HbA1c and adverse events reported",1],["R0016444","Indirect comparison of lixisenatide versus neutral protamine Hagedorn insulin as add-on to metformin and sulphonylurea in patients with type 2 diabetes mellitus.","Fournier M","2014","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent09","systematic search based indirect comparison of lixisenatide versus NPH insulin via common comparators, PubMed, Embase, CENTRAL",1],["R0019594","Cost-effectiveness of empagliflozin in patients with type 2 diabetes and established cardiovascular disease in China.","Ramos M","2021","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent13","model based cost-effectiveness analysis of empagliflozin vs sitagliptin or liraglutide in China",1],["R0019725","Impact of Cotadutide drug on patients with type 2 diabetes mellitus: a systematic review and meta-analysis.","Ali MM","2022","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent13","PROSPERO registered meta-analysis of cotadutide RCTs in type 2 diabetes from four databases",1],["R0019848","Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.","Nauck M","2009","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent13","LEAD-2 RCT of liraglutide three doses vs placebo vs glimepiride added to metformin",1],["R0019924","Impact of Cotadutide Drug on Obese Individuals with Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis","Ali MM","2022","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent13","preprint version of PROSPERO registered cotadutide meta-analysis from four databases",1],["R0020030","Overview of oxidative stress and inflammation in diabetes.","Weinberg Sibony R","2024","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent13","narrative review of oxidative stress and inflammation in diabetes",1],["R0020167","Effect of liraglutide on cardiac function in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of double-blind, randomized, placebo-controlled trials.","Xia W","2024","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent13","meta-analysis of placebo controlled liraglutide RCTs on cardiac function from four databases",1],["R0020310","Effects of once-weekly dulaglutide on juvenile type 2 diabetes mellitus and obesity in Korea: a pilot study.","Seo JY","2023","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent13","retrospective case series of five adolescents with type 2 diabetes on dulaglutide",1],["R0020426","Biliary effects of liraglutide and sitagliptin, a 12-week randomized placebo-controlled trial in type 2 diabetes patients.","Smits MM","2016","include_nma",null,"primary_report","P01",null,"mechanistic","high","first","opus-5.5-agent13","12 week placebo controlled RCT of liraglutide vs sitagliptin vs placebo on biliary effects in type 2 diabetes",1],["R0020895","Glycemia reduction in type 2 diabetes-Hypoglycemia outcomes: A randomized clinical trial.","Seaquist ER","2024","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent07","GRADE RCT report comparing hypoglycemia with glargine, glimepiride, liraglutide and sitagliptin added to metformin",1],["R0019907","A Novel Multiphase Modified Ketogenic Diet: An Effective and Safe Tool for Weight Loss in Chinese Obese Patients.","Wu W","2022","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent08","self selected comparison of ketogenic diet, beinaglutide or lifestyle in obesity; not randomized; no harms list outcome",1],["R0019993","Linking Cardiovascular Disease and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): The Role of Cardiometabolic Drugs in MASLD Treatment.","Zisis M","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent08","narrative review of cardiometabolic drugs in MASLD and cardiovascular disease",1],["R0020281","A Fixed Ratio Combination of Insulin Degludec and Liraglutide (IDegLira) Reduces Glycemic Fluctuation and Brings More Patients with Type 2 Diabetes Within Blood Glucose Target Ranges.","King AB","2017","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent08","post hoc glucose variability analysis of DUAL I and DUAL II RCTs of IDegLira versus IDeg or liraglutide",1],["R0020401","Safety and Efficacy of Liraglutide on Cardiovascular Outcomes in Patients With Diabetes Mellitus: A Meta-Analysis of Randomized Controlled Trials.","Vemulapalli HS","2023","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent08","meta-analysis of liraglutide RCTs on cardiovascular outcomes in diabetes; six databases searched",1],["R0020489","Tirzepatide mitigates Stroke-Induced Blood-Brain barrier disruption by modulating Claudin-1 and C/EBP-α pathways.","Wang D","2025","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent08","mouse stroke model and endothelial cell study of tirzepatide on blood brain barrier",1],["R0020798","Very low energy ketogenic diet vs. Mediterranean diet for MASLD: Superior steatosis reduction in a randomised pilot study.","Farrell AM","2026","include_nma",null,"primary_report","P09",null,null,"high","first","opus-5.5-agent08","pilot RCT of ketogenic VLED followed by semaglutide versus Mediterranean diet without semaglutide in MASLD",1],["R0021038","GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice.","Noyan-Ashraf MH","2009","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent07","mouse study of liraglutide pretreatment before experimental myocardial infarction",1],["R0021272","Efficacy and safety of tirzepatide in patients with type 2 diabetes: A systematic review and meta-analysis.","Tang Y","2022","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent07","PROSPERO registered meta-analysis of RCTs of tirzepatide vs placebo or active drugs in type 2 diabetes",1],["R0021397","Improving Adherence to Weight-Loss Medication (Liraglutide 3.0 mg) Using Mobile Phone Text Messaging and Healthcare Professional Support.","Li A","2020","inventory_only","N3","primary_report",null,null,null,"high","first","opus-5.5-agent07","randomized SMS reminder frequencies among liraglutide 3.0 mg users; GLP-1 regimen same across arms",1],["R0021615","Analysis of patient characteristics and safety of insulin glargine U300 use in 21 359 patients with type-2 diabetes and chronic kidney disease: DPV registry study.","Vijayan A","2025","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent07","cross sectional registry study of glargine U300 users in CKD; GLP-1RA only a concomitant drug",1],["R0021728","Glimepiride Compared to Liraglutide Increases Plasma Levels of miR-206, miR-182-5p, and miR-766-3p in Type 2 Diabetes Mellitus: A Randomized Controlled Trial.","Scherbak NN","2023","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent07","post hoc microRNA analysis of RCT of liraglutide vs glimepiride added to metformin in T2D with subclinical heart failure",1],["R0017131","Efficacy and Safety of Tirzepatide on Weight Loss in Patients Without Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.","Kommu S","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent15","registered systematic review and meta-analysis of six placebo controlled RCTs of tirzepatide in obesity without diabetes",1],["R0017256","The Effects of Semaglutide on Inflammation and Immune Activation in HIV-associated Lipohypertrophy.","Funderburg NT","2025","include_nma",null,"secondary_report","P99",null,null,"high","first","opus-5.5-agent15","secondary analysis of phase 2b RCT of semaglutide versus placebo in HIV associated lipohypertrophy; inflammation markers",1],["R0017380","Once-Weekly Exenatide in Youth With Type 2 Diabetes.","Tamborlane WV","2022","include_nma",null,"primary_report","P04",null,null,"high","first","opus-5.5-agent15","phase 3 RCT of once weekly exenatide versus placebo in youth aged 10 to 17 with type 2 diabetes",1],["R0017461","Systematic Review and Meta-Analysis of Liraglutide Treatment in Children Who Are Overweight or Obese: A Therapeutic Paradigm Shift?","Muñoz Rossi FA","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent15","systematic review and meta-analysis of four RCTs of liraglutide in children and adolescents with overweight or obesity",1],["R0017535","The effects of dipeptidyl peptidase-4 inhibitors on bone fracture among patients with type 2 diabetes mellitus: A network meta-analysis of randomized controlled trials.","Yang J","2017","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent15","registered network meta-analysis of 75 RCTs of DPP-4i versus comparators incl GLP-1 RAs on fractures",1],["R0017645","Advancing Cardiorenal Interaction: From Pathophysiological Paradigms to Novel Therapeutic Strategies.","Wei L","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent15","narrative review of cardiorenal pathophysiology and therapies incl GLP-1 RAs",1],["R0017749","Sodium-Glucose Co-Transporter 2 Inhibitors and Severe Urinary Tract Infections: Real-World Meta-Analysis of Cohort Studies.","Aboukaoud M","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent15","registered meta-analysis of 11 cohorts comparing SGLT2i with GLP-1 RAs and other drugs on severe urinary tract infection",1],["R0017858","Comprehensive treatment of diabetic endothelial dysfunction based on pathophysiological mechanism.","Liu Z","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent15","narrative review of antidiabetic and herbal treatments for diabetic endothelial dysfunction",1],["R0019966","PIONEER REAL Japan: Baseline characteristics of a multicenter, prospective, real-world study of oral semaglutide in adults with type 2 diabetes in clinical practice in Japan.","Suzuki R","2024","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent01","baseline characteristics of PIONEER REAL Japan single arm non-interventional study of oral semaglutide",1],["R0020099","Muscle Atrophy-Related Adverse Events of Antidiabetic Drug Classes: A Pharmacovigilance Analysis Using VigiBase Data.","Ueta S","2026","inventory_only","N5","other",null,null,null,"high","first","opus-5.5-agent01","VigiBase disproportionality analysis of muscle atrophy reports across antidiabetic classes including GLP-1 analogues",1],["R0020217","Lixisenatide: evidence for its potential use in the treatment of type 2 diabetes.","Barnett AH","2011","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent01","narrative evidence review of lixisenatide phase II and III data",1],["R0020370","Glycemic Control Among Patients Newly Prescribed IDegLira Across Prior Therapy Group in US Real-World Practice.","Egede LE","2020","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent01","retrospective single group EMR study of IDegLira initiators with before and after HbA1c by prior therapy",1],["R0020452","Tirzepatide and prevention of chronic kidney disease.","Bosch C","2023","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent01","narrative review of tirzepatide and kidney disease prevention",1],["R0020581","Changes in SGLT2i and GLP-1RA real-world initiator profiles following cardiovascular outcome trials: A Danish nationwide population-based study.","Knudsen JS","2020","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent01","nationwide cross sectional study of characteristics of SGLT2i, GLP-1 RA and DPP-4i initiators; drug utilization only",1],["R0020751","Association of glucose-lowering drugs with incident stroke and transient ischaemic attacks in primary care patients with type 2 diabetes: disease analyzer database.","Rathmann W","2022","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent01","primary care cohort of glucose lowering drug classes including GLP-1 RA and incident stroke or TIA; no listed harm",1],["R0020870","Patient Adherence to a Real-World Digital, Asynchronous Weight Loss Program in Australia That Combines Behavioural and GLP-1 RA Therapy: A Mixed Methods Study.","Talay L","2024","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent01","mixed methods study of adherence and discontinuation reasons in a digital GLP-1 RA weight program without exposure comparison",1],["R0024134","Austrian Experience with Lixisenatide Under Real-Life Conditions: A Prospective Observational Study.","Brath H","2019","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent06","PATIO prospective observational single group study of lixisenatide in Austrian practice; not randomized, no comparison",1],["R0024277","Antidiabetic Therapy in the Treatment of Nonalcoholic Steatohepatitis.","Sumida Y","2020","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent06","narrative review of antidiabetic therapies for NASH",1],["R0024611","SAT-140 A Drug-Drug Interaction Trial of Oral Semaglutide with Levothyroxine and Multiple Coadministered Tablets","Hauge C","2019","inventory_only","N1","conference_abstract",null,null,"abstract_only","high","first","opus-5.5-agent06","conference abstract of open label one sequence drug interaction study of oral semaglutide with levothyroxine in healthy subjects; not randomized",1],["R0024733","A prospective, claims-based assessment of the risk of pancreatitis and pancreatic cancer with liraglutide compared to other antidiabetic drugs.","Funch D","2014","include_harms",null,"primary_report",null,"O29; O38",null,"high","first","opus-5.5-agent06","claims based new user cohort of liraglutide versus other antidiabetic drugs; acute pancreatitis and pancreatic cancer outcomes",1],["R0024881","Comparative efficacy of once-weekly semaglutide versus SGLT-2 inhibitors in patients inadequately controlled with one to two oral antidiabetic drugs: a systematic literature review and network meta-analysis.","Kanters S","2019","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent06","SLR and Bayesian NMA of RCTs comparing once weekly semaglutide with SGLT2 inhibitors in T2D on oral drugs",1],["R0024975","Liraglutide Therapy for Type 2 Diabetes: Overcoming Unmet Needs.","Sjöholm Å","2010","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent06","narrative review of liraglutide therapy for T2D",1],["R0025109","Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity.","Hjerpsted JB","2018","include_nma",null,"primary_report","P02",null,"crossover; mechanistic","high","first","opus-5.5-agent06","double blind crossover RCT of semaglutide versus placebo in obesity without diabetes; postprandial metabolism and gastric emptying",1],["R0020847","Predicting responsiveness to GLP-1 pathway drugs using real-world data.","Zhu X","2024","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent14","EHR cohort predicting HbA1c response among GLP-1 RA or DPP-4i users with machine learning, no exposure comparison",1],["R0021117","FibroScan-aspartate aminotransferase (FAST) score for monitoring histological improvement in non-alcoholic steatohepatitis activity during semaglutide treatment: post-hoc analysis of a randomised, double-blind, placebo-controlled, phase 2b trial.","Wai-Sun Wong V","2023","include_nma",null,"secondary_report","P09",null,null,"high","first","opus-5.5-agent14","post hoc analysis of phase 2b placebo controlled RCT of semaglutide in NASH, FAST score vs histology",1],["R0021207","Diastolic Cardiac Function Improvement by Liraglutide Is Mainly Body Weight Reduction Dependent but Independently Contributes to B-Type Natriuretic Peptide Reduction in Patients with Type 2 Diabetes with Preserved Ejection Fraction.","Yagi K","2021","inventory_only","N1","primary_report",null,null,null,"high","first","opus-5.5-agent14","single arm prospective study of liraglutide on BNP and diastolic function in T2D",1],["R0021314","Effects of dulaglutide on endothelial progenitor cells and arterial elasticity in patients with type 2 diabetes mellitus.","Xie D","2022","include_nma",null,"primary_report","P01",null,"mechanistic","high","first","opus-5.5-agent14","12 week RCT of metformin plus dulaglutide vs metformin alone, endothelial progenitor cells and arterial stiffness",1],["R0021420","Cost-benefit comparison of liraglutide and sitagliptin in the treatment of type 2 diabetes in Thailand.","Deerochanawong C","2019","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent14","cost benefit model comparing liraglutide and sitagliptin in Thailand using trial results",1],["R0021514","Exenatide and Metformin Improve Serum Indices and Intestinal Flora in patients with Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease.","Jiang X","2024","include_nma",null,"primary_report","P01; P09",null,null,"high","first","opus-5.5-agent14","RCT of exenatide plus metformin vs metformin in T2D with NAFLD, 24 weeks",1],["R0021669","Beinaglutide showed significant weight-loss benefit and effective glycaemic control for the treatment of type 2 diabetes in a real-world setting: a 3-month, multicentre, observational, retrospective, open-label study.","Zhang YL","2019","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent14","retrospective single arm study of beinaglutide in T2D, no comparison group",1],["R0021710","Efficacy and safety of once-weekly semaglutide in Japanese individuals with type 2 diabetes in the SUSTAIN 1, 2, 5 and 9 trials: Post-hoc analysis.","Araki E","2022","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent04","post hoc Japanese subgroup analysis of SUSTAIN 1, 2, 5 and 9 RCTs of semaglutide vs placebo or sitagliptin",1],["R0021902","Glucagon-like peptide-1 (GLP-1) and the regulation of human invariant natural killer T cells: lessons from obesity, diabetes and psoriasis.","Hogan AE","2011","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent04","case series of patients with psoriasis started on exenatide or liraglutide plus in vitro immune cell experiments",1],["R0022078","LBSUN306 Effects Of Glp-1 Receptor Agonism, Dpp4 Inhibition, And Hypocaloric Diet On Metabolic Parameters In Obese Pre-diabetic Individuals: A Randomized-controlled Trial",null,"2022","include_nma",null,"conference_abstract","P02",null,"abstract_only","high","first","opus-5.5-agent04","conference abstract of double blind RCT of liraglutide vs sitagliptin vs diet in obese prediabetic adults",1],["R0022183","The Effects of Dual GLP-1/GIP Receptor Agonism on Glucagon Secretion-A Review.","Mathiesen DS","2019","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent04","narrative review of dual GLP-1 and GIP agonism effects on glucagon secretion",1],["R0022281","Achieving the composite endpoint of glycated haemoglobin <7.0%, no weight gain and no hypoglycaemia in the once-weekly dulaglutide AWARD programme.","Dungan KM","2016","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent04","post hoc composite endpoint analysis of five AWARD RCTs of dulaglutide vs placebo or active comparators, each trial separately",1],["R0022386","Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise.","Nauck MA","2016","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent04","HARMONY 2 placebo controlled RCT of albiglutide monotherapy in type 2 diabetes",1],["R0022521","Efficacy and safety of taspoglutide versus sitagliptin for type 2 diabetes mellitus (T-emerge 4 trial).","Bergenstal RM","2012","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent04","T-emerge 4 double blind RCT of taspoglutide vs sitagliptin vs placebo on metformin",1],["R0022978","Study protocol of the randomised placebo-controlled GLOBE trial: GLP-1 for bridging of hyperglycaemia during cardiac surgery.","Hulst AH","2018","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent03","protocol of GLOBE RCT of perioperative liraglutide vs placebo in cardiac surgery; no results",1],["R0023103","Validity and analysis of the Diabetes Injection Device Preference Questionnaire (DID-PQ).","Boye KS","2020","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent03","questionnaire validation from crossover device preference study with mock injections; no drug administered",1],["R0023604","A Remotely Delivered, Semaglutide-Supported Specialist Weight Management Program: Preliminary Findings From a Retrospective Service Evaluation.","Richards R","2023","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent03","retrospective service evaluation of remote semaglutide supported weight program, single group, no comparator",1],["R0023734","Distribution-based sub-population selection (DSPS): A method for in-silico reproduction of clinical trials outcomes.","Ganji M","2025","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent03","in silico virtual population selection method reproducing an IDegLira trial arm; simulation only",1],["R0023916","Efficacy and safety of switching from the DPP-4 inhibitor sitagliptin to the human GLP-1 analog liraglutide after 52 weeks in metformin-treated patients with type 2 diabetes: a randomized, open-label trial.","Pratley RE","2012","include_nma",null,"extension","P01",null,null,"high","first","opus-5.5-agent03","26 week extension of RCT liraglutide vs sitagliptin with randomized switch to liraglutide 1.2 or 1.8 mg",1],["R0023078","Explore the Effect and Target of Liraglutide on Islet Function in Type 2 Diabetic Rats by miRNA Omics Technology.","Guo Q","2021","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent20","randomized rat experiment of liraglutide with pancreatic miRNA profiling",1],["R0022025","Does a GLP-1 receptor agonist change glucose tolerance in patients treated with antipsychotic medications? Design of a randomised, double-blinded, placebo-controlled clinical trial.","Larsen JR","2014","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent16","design paper of double blind RCT of liraglutide vs placebo in prediabetic patients on clozapine or olanzapine",1],["R0023220","An Overview of Appetite-Regulatory Peptides in Addiction Processes; From Bench to Bed Side.","Shevchouk OT","2021","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent20","narrative overview of appetite peptides in addiction without systematic methods despite review label",1],["R0023324","Efficacy and safety of lixisenatide as add-on therapy to basal insulin in older adults with type 2 diabetes in the GetGoal-O Study.","Dailey GE","2019","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent20","post hoc non frail subgroup analysis of randomized GetGoal-O trial of lixisenatide vs placebo in older T2D",1],["R0023467","A systematic review and mixed-treatment comparison of dapagliflozin with existing anti-diabetes treatments for those with type 2 diabetes mellitus inadequately controlled by sulfonylurea monotherapy.","Orme M","2014","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent20","systematic review and NMA of add-on therapies to sulfonylurea including a GLP-1 analogue vs dapagliflozin",1],["R0023595","Liraglutide suppresses the proliferation of endometrial cancer cells through the adenosine 5'-monophosphate (AMP)-activated protein kinase signaling pathway.","Zhu XX","2021","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent20","in vitro endometrial cancer cell line study of liraglutide",1],["R0023721","Lifetime cost-effectiveness simulation of once-weekly exenatide in type 2 diabetes: A cost-utility analysis based on the EXSCEL trial.","Becker F","2022","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent20","lifetime cost utility simulation based on EXSCEL trial of weekly exenatide",1],["R0023899","Comparative efficacy and safety of long-acting insulin analogs in patients with type 2 diabetes failing on oral therapy: Systemic review and meta-analyses.","Bi Y","2012","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent20","meta-analysis of RCTs of long acting insulin vs other injectables including GLP-1 analogues, MEDLINE Embase CENTRAL searched",1],["R0022129","Effect of liraglutide on atrial natriuretic peptide, adrenomedullin, and copeptin in PCOS.","Frøssing S","2018","include_nma",null,"secondary_report","P12",null,null,"high","first","opus-5.5-agent16","secondary analysis of LIPT RCT of liraglutide vs placebo in overweight women with PCOS; cardiovascular biomarkers",1],["R0022238","Effectiveness and safety of insulin glargine Gla-300 in insulin-naïve type 2 diabetes subjects in a real-life setting-the GOAL_RO trial.","Stegaru D","2021","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent16","noninterventional single arm study of insulin glargine 300; GLP-1RA only prior background therapy",1],["R0022332","Risks and Benefits of SGLT-2 Inhibitors for Type 1 Diabetes Patients Using Automated Insulin Delivery Systems-A Literature Review.","Elian V","2024","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent16","literature review of SGLT2 inhibitors in type 1 diabetes with automated insulin delivery; GLP-1RAs only mentioned",1],["R0022481","A Comparison of the Effects of the GLP-1 Analogue Liraglutide and Insulin Glargine on Endothelial Function and Metabolic Parameters: A Randomized, Controlled Trial Sapporo Athero-Incretin Study 2 (SAIS2).","Nomoto H","2015","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent16","open label RCT of liraglutide vs insulin glargine in T2D; endothelial function and HbA1c",1],["R0022591","Incretin based treatments and mortality in patients with type 2 diabetes: systematic review and meta-analysis.","Liu J","2017","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent16","systematic review and meta-analysis of incretin therapy RCTs on all cause mortality; Medline, Embase, CENTRAL",1],["R0022709","Efficacy of Various Hypoglycemic Agents in the Treatment of Patients With Nonalcoholic Liver Disease With or Without Diabetes： A Network Meta-Analysis.","Lian J","2021","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent16","PROSPERO registered systematic review and NMA of hypoglycemic agents incl. GLP-1RA in NAFLD",1],["R0022802","Glucagon-like peptide-1 analog liraglutide in combination with sulfonylurea safely improves blood glucose measures vs sulfonylurea monotherapy in Japanese patients with type 2 diabetes: Results of a 52-week, randomized, multicenter trial.","Seino Y","2011","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent16","52 week report of randomized trial of liraglutide 0.6 or 0.9 mg plus sulfonylurea vs sulfonylurea alone in Japanese T2D",1],["R0015872","Liraglutide 3.0 mg and mental health: can psychiatric symptoms be associated to adherence to therapy? Insights from a clinical audit.","Tempia Valenta S","2023","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent11","retrospective clinical audit of liraglutide 3 mg users relating psychiatric scores to adherence; no comparator",1],["R0015960","Real -world experience with anti-obesity medications treatment in children and adolescents with overweight and obesity in Israel.","Shalitin S","2025","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent11","Clalit pediatric anti obesity drug prescribing study with before and after changes among users; no outcome comparator",1],["R0016040","Effects of once-weekly subcutaneous retatrutide on weight and metabolic markers: A systematic review and meta-analysis of randomized controlled trials.","Pasqualotto E","2024","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent11","registered meta-analysis of placebo controlled retatrutide RCTs; PubMed, Embase, Cochrane searched",1],["R0016133","Semaglutide reduces cardiovascular events in type 2 diabetes: a systematic review and meta-analysis highlighting enhanced benefits in chronic kidney disease.","Yao Y","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent11","registered meta-analysis of semaglutide trials and studies on cardiovascular events; four named databases",1],["R0016222","Exendin-4 Improves Diabetic Kidney Disease in C57BL/6 Mice Independent of Brown Adipose Tissue Activation.","Fang S","2020","exclude","E1","primary_report",null,null,null,"high","first","opus-5.5-agent11","diabetic mouse and cell culture experiments with exendin-4",1],["R0016349","Safety of GLP-1 Receptor Agonists and Other Second-Line Antidiabetics in Early Pregnancy.","Cesta CE","2024","include_harms",null,"primary_report",null,"O120",null,"high","first","opus-5.5-agent11","multinational pregnancy cohort of periconceptional GLP-1RA and other drugs versus insulin; major congenital malformations",1],["R0016451","Treat to target in weight management with semaglutide: Real-world evidence from an eHealth clinic.","Seier S","2025","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent11","retrospective single group eHealth program cohort of semaglutide users; no comparator",1],["R0016530","Effect of Semaglutide versus placebo on prediabetes, psychotic symptoms, and quality of life (HISTORI): A randomized clinical trial among patients with schizophrenia","Uhrenholt N","2025","include_nma",null,"conference_abstract","P15; P06",null,"abstract_only","high","first","opus-5.5-agent11","HISTORI abstract; randomized semaglutide versus placebo in schizophrenia with prediabetes and overweight on antipsychotics",1],["R0022047","The effect of liraglutide on renal function in type 2 diabetes: a meta-analysis of randomized controlled studies.","Luo C","2022","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent18","systematic review and meta-analysis of liraglutide vs placebo RCTs on renal function in T2D; five named databases",1],["R0022144","The Effects of Exercise Combined with Pharmacotherapy on Body Composition and Metabolic Parameters in Overweight/Obese Adults: A Meta-Analysis and Network Pharmacology Study.","Peng T","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent18","registered meta-analysis of RCTs of exercise plus drugs incl. liraglutide vs exercise or drug alone in obesity; network pharmacology add on",1],["R0022251","Second-line pharmacotherapy intensification after metformin monotherapy in type 2 diabetes: a nationwide register study from Finland during 2011-2022.","Rättö H","2024","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent18","Finnish register study of second line drug initiation patterns after metformin; utilization only, no outcome comparison",1],["R0022345","IDegLira Improves Glycemic Control in Japanese Patients with Uncontrolled Type 2 Diabetes on Premixed Insulin Therapy.","Watada H","2020","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent18","post hoc analysis of DUAL II Japan RCT, IDegLira vs degludec, by prior premixed or basal insulin",1],["R0022488","Comparison of twelve single-drug regimens for the treatment of type 2 diabetes mellitus.","Wang SL","2017","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent18","NMA of RCTs of twelve monotherapies incl. exenatide and liraglutide in T2D; PubMed, Embase, Cochrane searched",1],["R0022609","Efficacy and Safety of Dulaglutide in Type 2 Diabetes Patients in Endocrinology Clinics of Islamabad, Pakistan.","Kamin M","2021","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent18","prospective observational single arm study of dulaglutide in Pakistani T2D; no comparator",1],["R0022711","In Alzheimer's Disease, 6-Month Treatment with GLP-1 Analog Prevents Decline of Brain Glucose Metabolism: Randomized, Placebo-Controlled, Double-Blind Clinical Trial.","Gejl M","2016","include_nma",null,"primary_report","P13A",null,null,"high","first","opus-5.5-agent18","double blind RCT of liraglutide vs placebo for 26 weeks in Alzheimer disease; amyloid, brain glucose metabolism, cognition",1],["R0023008","Gender differences in adverse event reports associated with antidiabetic drugs.","Joung KI","2020","inventory_only","N5","other",null,null,null,"high","first","opus-5.5-agent12","Korean spontaneous adverse event report analysis by gender across antidiabetic drugs including GLP-1RA",1],["R0023153","Efficacy and Safety of Once-Weekly Dulaglutide in Type 2 Diabetes Patients Using Insulin: Exploratory Subgroup Analysis by Insulin Regimen.","Onishi Y","2020","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent12","exploratory subgroup analysis by insulin regimen of phase 4 RCT of dulaglutide vs placebo in insulin treated Japanese T2D",1],["R0023286","Hepatoprotective effects of semaglutide, lanifibranor and dietary intervention in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH.","Møllerhøj MB","2022","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent12","diet induced obese NASH mouse model treated with semaglutide, lanifibranor or diet",1],["R0023399","Once-Weekly Semaglutide in Adults with Overweight or Obesity.","Wilding JPH","2021","include_nma",null,"primary_report","P02",null,null,"high","first","opus-5.5-agent12","STEP 1 double blind RCT of semaglutide 2.4 mg vs placebo in adults with overweight or obesity without diabetes",1],["R0023553","Gastroparesis With the Initiation of Liraglutide: A Case Report.","Almustanyir S","2020","inventory_only","N5","primary_report","P01",null,null,"high","first","opus-5.5-agent12","case report of gastroparesis after starting liraglutide",1],["R0023656","Clinical characteristics and healthcare utilisation associated with undiagnosed cognitive impairment in elderly patients with diabetes in a primary care setting: a population-based cohort study.","Merzon E","2024","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent12","cohort describing characteristics of elderly T2D by cognitive score, GLP-1RA use only a descriptive correlate",1],["R0023818","Realisation of Remission of Diabetes Using Pharmacotherapy (DiaRem-1).","Sudhayakumar A","2025","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent12","open label RCT of liraglutide, dapagliflozin and metformin vs vildagliptin, glimepiride and metformin for diabetes remission",1],["R0018895","Real-world GLP-1 RA therapy in type 2 diabetes: A long-term effectiveness observational study.","Tofé S","2019","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent02","retrospective single centre cohort of GLP-1 RA starters with before and after effectiveness; no untreated comparison",1],["R0019147","Weight Loss Maintenance With Once-Weekly Semaglutide 2.4 MG in Adults With Overweight or Obesity Reaching Maintenance Dose (STEP 4)","Rubino D","2021","include_nma",null,"conference_abstract","P02W",null,"abstract_only","high","first","opus-5.5-agent02","conference abstract of STEP 4 randomized withdrawal trial, continued semaglutide 2.4 mg vs switch to placebo after run in",1],["R0019349","Correlation between long-term glycemic variability and cognitive function in middle-aged and elderly patients with type 2 diabetes mellitus: a retrospective study.","Ding J","2023","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent02","retrospective study of glycemic variability and cognition in T2D; GLP-1 RA use only a covariate",1],["R0019447","Long-term effects of different hypoglycemic drugs on carotid intima-media thickness progression: a systematic review and network meta-analysis.","Lv Q","2024","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent02","registered network meta-analysis of antidiabetic drugs including exenatide on carotid intima-media thickness",1],["R0019540","Urinary Peptidomic Profiling In Post-Acute Sequelae of SARS-CoV-2 Infection: A Case-Control Study.","Gülmez D","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent02","urinary peptidomic case control study of long COVID with in silico drug suggestions; no GLP-1 RA exposure",1],["R0019649","Areas of Interest and Attitudes Toward Antiobesity Drugs: Thematic and Quantitative Analysis Using Twitter.","Alvarez-Mon MA","2021","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent02","Twitter content analysis of antiobesity drugs; qualitative without exposure comparison",1],["R0020534","Effect of once-weekly dulaglutide on renal function in patients with chronic kidney disease.","Kim S","2022","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent13","retrospective before after study of dulaglutide in diabetic CKD without concurrent comparison group",1],["R0020681","Effects of Dichrostachys glomerata and Cissus quadrangularis Extracts on GLP-1 Secretion and DPP-4 Activity in Overweight and Obese Individuals: A Randomized Controlled Trial.","Youovop J","2025","include_nma",null,"primary_report","P02",null,null,"high","first","opus-5.5-agent13","placebo controlled RCT with botanical extract arms and an oral semaglutide arm in overweight or obese adults",1],["R0020839","Efficacy and Tolerability of Semaglutide in Patients With Type-2 Diabetes Mellitus: Experience of a Tertiary Care Hospital, Pakistan.","Wajid M","2023","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent13","ambidirectional single group cohort of semaglutide users with type 2 diabetes in Pakistan",1],["R0020933","Exenatide extended-release: a once weekly treatment for patients with type 2 diabetes.","Mann KV","2014","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent13","narrative drug review of exenatide extended release",1],["R0021107","Efficacy and safety of oral semaglutide in older patients with type 2 diabetes: a retrospective observational study (the OTARU-SEMA study).","Oe Y","2024","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent13","retrospective single arm observational study of oral semaglutide in older adults",1],["R0021202","Status of diabetes mellitus in different regions of KSA and update on its management.","Al-Rasheedi M","2024","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent13","descriptive survey of diabetes control, medications and complications in Saudi regions, no GLP-1 exposure comparison",1],["R0021418","Degree of obesity and gastrointestinal adverse reactions influence the weight loss effect of liraglutide in overweight or obese patients with type 2 diabetes.","Zhou F","2023","inventory_only","N1","primary_report",null,null,null,"high","first","opus-5.5-agent13","prospective single arm study of liraglutide in overweight type 2 diabetes",1],["R0024109","Semaglutide improves health-related quality of life versus placebo when added to standard of care in patients with type 2 diabetes at high cardiovascular risk (SUSTAIN 6).","Jódar E","2020","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent03","post hoc HRQoL mediator analysis of SUSTAIN 6 RCT, semaglutide vs placebo in high CV risk T2D",1],["R0024267","Liraglutide as add-on to sodium-glucose co-transporter-2 inhibitors in patients with inadequately controlled type 2 diabetes: LIRA-ADD2SGLT2i, a 26-week, randomized, double-blind, placebo-controlled trial.","Blonde L","2020","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent03","LIRA-ADD2SGLT2i 26 week double blind RCT of liraglutide vs placebo added to SGLT2i in T2D",1],["R0024442","Adverse events associated with incretin-based drugs in Japanese spontaneous reports: a mixed effects logistic regression model.","Narushima D","2016","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent03","JADER spontaneous report analysis of adverse events with DPP4i and GLP-1 RA",1],["R0024592","Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults.","van Can J","2014","include_nma",null,"primary_report","P02",null,"mechanistic; crossover","high","first","opus-5.5-agent03","randomized incomplete crossover of liraglutide 1.8, 3.0 mg vs placebo in obese nondiabetic adults; gastric emptying, glucose, intake",1],["R0024715","OR14-2 Liraglutide Treatment in Overweight and Obese Patients with Type 1 Diabetes: A 26 weeks Randomized Controlled Trial","Dandona P","2019","include_nma",null,"conference_abstract","P05",null,"abstract_only","high","first","opus-5.5-agent03","abstract of 26 week RCT of liraglutide 1.8 mg vs placebo in overweight or obese type 1 diabetes",1],["R0024860","Liraglutide, Sitagliptin, and Insulin Glargine Added to Metformin: The Effect on Body Weight and Intrahepatic Lipid in Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease.","Yan J","2019","include_nma",null,"primary_report","P01; P09",null,null,"high","first","opus-5.5-agent03","Light-On 26 week RCT of liraglutide vs sitagliptin vs glargine added to metformin in T2D with NAFLD",1],["R0024961","OR30-06 Assessment of Dulaglutide Safety in Older Patient Populations in Rewind","Konig M","2020","include_nma",null,"conference_abstract","P01",null,"abstract_only","high","first","opus-5.5-agent03","abstract of post hoc age subgroup safety analysis of REWIND RCT, dulaglutide vs placebo",1],["R0025092","Comparative efficacy and safety of antidiabetic drug regimens added to metformin monotherapy in patients with type 2 diabetes: a network meta-analysis.","Mearns ES","2015","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent03","NMA of RCTs of add-on agents to metformin incl. GLP-1 analogs; MEDLINE and CENTRAL searched",1],["R0016709","Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity.","Newsome P","2019","include_nma",null,"secondary_report","P01; P02",null,null,"high","first","opus-5.5-agent10","post hoc of SUSTAIN-6 and phase 2 weight RCT semaglutide versus placebo; ALT and hsCRP changes",1],["R0016821","Cardiovascular Effectiveness and Safety of Antidiabetic Drugs in Patients with Type 2 Diabetes and Peripheral Artery Disease: Systematic Review.","Cimellaro A","2024","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent10","PRISMA systematic review of Medline on glucose lowering drugs including GLP-1 RAs in T2D with peripheral artery disease",1],["R0016935","Nephroprotective effects of GLP-1 receptor agonists: where do we stand?","Mosterd CM","2020","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent10","narrative review of nephroprotective effects of GLP-1 RAs; no systematic methods",1],["R0017113","Depot-Specific Cardiorenal Adipose Remodeling with SGLT2i in Chronic Kidney Disease.","Checa-Ros A","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent10","observational CKD cohort comparing SGLT2i users with nonusers; GLP-1 RA only a covariate",1],["R0017226","Key Predictors of Relevant Weight Loss in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease.","Pugliese N","2025","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent10","retrospective MASLD cohort with GLP-1 RA use among predictors of 7 percent weight loss; no harms_nrs outcome",1],["R0017335","The Effect of SGLT-2 inhibitors and GLP-1RA on Major Cardiovascular Conditions: A Meta-Analysis","Jogimahanti A","2022","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent10","meta-analysis of SGLT2i and GLP-1 RA outcome trials on CV conditions; PubMed and Google Scholar with criteria",1],["R0019128","Could setmelanotide be the game-changer for acquired hypothalamic obesity?","van Santen HM","2023","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent19","perspective on setmelanotide for acquired hypothalamic obesity; GLP-1 RA only mentioned; mislabeled as RCT",1],["R0019342","Empagliflozin influences blood viscosity and wall shear stress in subjects with type 2 diabetes mellitus compared with incretin-based therapy.","Irace C","2018","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent19","nonrandomized prospective cohort empagliflozin vs incretin therapy incl liraglutide; viscosity and carotid outcomes, no listed harm",1],["R0019642","Correlation of HbA1c levels with CT-based body composition biomarkers in diabetes mellitus and metabolic syndrome.","Warner JD","2024","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent19","CT body composition biomarkers by HbA1c category; no GLP-1 RA exposure studied",1],["R0019766","Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial.","Colhoun HM","2024","include_nma",null,"secondary_report","P02",null,null,"high","first","opus-5.5-agent19","kidney outcomes of SELECT RCT of semaglutide 2.4 mg vs placebo in obesity with cardiovascular disease",1],["R0019868","Clinical Characteristics Associated with Adherence and Persistence in Patients with Type 2 Diabetes Mellitus Treated with Dulaglutide.","Lee DSU","2023","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent19","predictors of adherence and persistence among dulaglutide initiators; utilization without exposure comparison",1],["R0020858","Effects of Semaglutide on Albuminuria and Kidney Function in People With Overweight or Obesity With or Without Type 2 Diabetes: Exploratory Analysis From the STEP 1, 2, and 3 Trials.","Heerspink HJL","2023","include_nma",null,"secondary_report","P02; P01",null,null,"high","first","opus-5.5-agent17","post hoc kidney analysis of STEP 1 to 3 placebo controlled RCTs of semaglutide in overweight or obesity with or without diabetes",1],["R0020960","Tirzepatide: A Systematic Update.","Forzano I","2022","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent17","narrative update on tirzepatide without search methods despite systematic label",1],["R0021228","Liraglutide efficacy and action in non-alcoholic steatohepatitis (LEAN): study protocol for a phase II multicentre, double-blinded, randomised, controlled trial.","Armstrong MJ","2013","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent17","protocol of LEAN placebo controlled RCT of liraglutide in NASH",1],["R0021353","Racial/ethnic and socioeconomic disparities in the use of newer diabetes medications in the Look AHEAD study.","Elhussein A","2022","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent17","Look AHEAD secondary analysis of racial and socioeconomic differences in initiating newer diabetes drugs; prescribing study",1],["R0021435","\"Digital Clinicians\" Performing Obesity Medication Self-Injection Education: Feasibility Randomized Controlled Trial.","Coleman S","2025","inventory_only","N3","primary_report",null,null,null,"high","first","opus-5.5-agent17","feasibility RCT of avatar chatbot versus nurse education for semaglutide self-injection; both arms start semaglutide",1],["R0021532","Report from the CVOT Summit 2021: new cardiovascular, renal, and glycemic outcomes.","Schnell O","2022","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent17","conference summit report on cardiovascular outcome trials",1],["R0021679","Efficacy of Liraglutide in Obesity in Children and Adolescents: Systematic Review and Meta-Analysis of Randomized Controlled Trials.","Cornejo-Estrada A","2023","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent17","registered meta-analysis of RCTs of liraglutide versus placebo in pediatric obesity, four databases searched",1],["R0021159","Gut peptide GLP-1 and its analogue, Exendin-4, decrease alcohol intake and reward.","Shirazi RH","2013","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent01","rat and mouse experiments of GLP-1 and exendin-4 on alcohol intake and reward",1],["R0021251","Rationale and design of Short-Term EXenatide therapy in Acute ischaemic Stroke (STEXAS): a randomised, open-label, parallel-group study.","McGrath RT","2016","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent01","design of STEXAS open label RCT of intravenous exenatide versus insulin in acute ischemic stroke with hyperglycemia",1],["R0021364","From seven combination hypotheses to one testable interaction: a gated agentic AI–QSP workflow applied to healthy-ageing interventions","Goryanin I","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent01","AI driven quantitative systems pharmacology modeling workflow for ageing interventions; simulation only",1],["R0021458","Effect of Liraglutide on Times in Glycaemic Ranges as Assessed by CGM for Type 2 Diabetes Patients Treated With Multiple Daily Insulin Injections.","Sofizadeh S","2019","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent01","secondary CGM analysis of double blind RCT of liraglutide versus placebo in type 2 diabetes on multiple daily insulin",1],["R0021546","Weight Loss of Semaglutide Treatment for Patients With Overweight or Obesity: A Retrospective Observational Study in China","Zhang X","2023","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent01","retrospective single center cohort of semaglutide treated patients with overweight or obesity, no comparison group",1],["R0021702","Glimepiride Compared to Liraglutide Increases Plasma Levels of miR-206, miR-182-5p, and miR-766-3p in Type 2 Diabetes Mellitus: A Randomized Controlled Trial (Diabetes Metab J 2023;47:668-81).","Lee DY","2023","inventory_only","N9","ancillary",null,null,null,"high","first","opus-5.5-agent01","letter commenting on RCT of glimepiride versus liraglutide on plasma microRNAs in type 2 diabetes",1],["R0021858","Exploring potential mediators of the cardiovascular benefit of dulaglutide in type 2 diabetes patients in REWIND.","Konig M","2021","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent01","post hoc mediation analysis of REWIND RCT, dulaglutide versus placebo on MACE",1],["R0021954","Effects of once-weekly semaglutide 2.4 mg on C-reactive protein in adults with overweight or obesity (STEP 1, 2, and 3): Exploratory analyses of three randomised, double-blind, placebo-controlled, phase 3 trials.","Verma S","2023","include_nma",null,"secondary_report","P02; P01",null,null,"high","first","opus-5.5-agent07","exploratory CRP analyses of STEP 1, 2 and 3 RCTs of semaglutide 2.4 mg vs placebo or 1.0 mg",1],["R0022091","Glycaemic efficacy of an expanded dose range of dulaglutide according to baseline glycated haemoglobin (HbA1c) subgroup: Post hoc analysis of AWARD-11.","Frias JP","2021","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent07","post hoc HbA1c subgroup analysis of AWARD-11 RCT comparing dulaglutide 1.5, 3.0 and 4.5 mg",1],["R0022188","Academic Detailing Compared with Group Meetings to Change Drug Prescribing for Type 2 Diabetes-A Randomized Controlled Trial.","Langaas HC","2024","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent07","cluster RCT of academic detailing vs group meetings for GPs; GLP-1RA only a prescribing outcome, not an intervention",1],["R0022292","Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system.","Shu Y","2022","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent07","FAERS disproportionality analysis of gastrointestinal adverse event reports with semaglutide",1],["R0022430","Glucagon-like peptide-1 receptor expression in the human eye.","Hebsgaard JB","2018","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent07","immunohistochemistry of GLP-1 receptor expression in donor human eyes; no drug exposure studied",1],["R0022533","Effects of exenatide and liraglutide on 24-hour glucose fluctuations in type 2 diabetes.","Nagakura J","2016","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent07","open label RCT of add on exenatide vs liraglutide in T2D on sulfonylureas with CGM glucose profiles",1],["R0022766","Fifty-two-week, randomized, multicenter trial to compare the safety and efficacy of the novel glucagon-like peptide-1 analog liraglutide vs glibenclamide in patients with type 2 diabetes.","Kaku K","2011","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent07","52 week RCT of liraglutide 0.9 mg vs glibenclamide in Japanese type 2 diabetes",1],["R0016608","The role of GLP-1 mimetics and basal insulin analogues in type 2 diabetes mellitus: guidance from studies of liraglutide.","Barnett AH","2012","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent09","narrative review of GLP-1 agonists and basal insulin informed by liraglutide trials and NICE guidance",1],["R0016811","GIP Receptor Antagonists in the Pharmacotherapy of Obesity: Physiologic, Genetic, and Clinical Rationale.","Rosenkilde MM","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent09","narrative review on GIP receptor antagonists for obesity",1],["R0016921","The Upcoming Weekly Tides (Semaglutide vs. Tirzepatide) against Obesity: STEP or SURPASS?","Jung HN","2022","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent09","narrative review comparing semaglutide and tirzepatide trial programs for obesity",1],["R0016996","Changes to insulin requirements over time with semaglutide in adults with type 1 diabetes on insulin pump therapy: A post-hoc analysis of a double-blinded, randomised, crossover trial.","Pasqua MR","2026","include_nma",null,"secondary_report","P05",null,"crossover","high","first","opus-5.5-agent09","post hoc analysis of double blind crossover RCT of semaglutide versus placebo in type 1 diabetes on insulin pumps",1],["R0017102","Liraglutide Lowers Palmitoleate Levels in Type 2 Diabetes. A Post Hoc Analysis of the LIRAFLAME Randomized Placebo-Controlled Trial.","Wretlind A","2022","include_nma",null,"secondary_report","P01",null,"mechanistic","high","first","opus-5.5-agent09","post hoc metabolomics of LIRAFLAME randomized liraglutide versus placebo trial in type 2 diabetes",1],["R0017216","A novel GLP-1/GIP dual receptor agonist protects from 6-OHDA lesion in a rat model of Parkinson's disease.","Jalewa J","2017","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent09","rat 6-OHDA Parkinson model treated with dual GLP-1 GIP agonist, no humans",1],["R0017334","Safety and Efficacy of Liraglutide, 3.0 mg, Once Daily vs Placebo in Patients With Poor Weight Loss Following Metabolic Surgery: The BARI-OPTIMISE Randomized Clinical Trial.","Mok J","2023","include_nma",null,"primary_report","P02; P01",null,null,"high","first","opus-5.5-agent09","BARI-OPTIMISE double blind RCT of liraglutide 3 mg versus placebo after metabolic surgery, randomization stratified by diabetes status",1],["R0025222","Dapagliflozin once daily plus exenatide once weekly in obese adults without diabetes: Sustained reductions in body weight, glycaemia and blood pressure over 1 year.","Lundkvist P","2017","include_nma",null,"extension","P02",null,null,"high","first","opus-5.5-agent06","52 week report of double blind RCT of dapagliflozin plus weekly exenatide versus placebo in obesity without diabetes with open label extension",1],["R0025399","A crossover study of the combination therapy of metformin and exenatide or biphasic insulin aspart 30 in overweight or obese patients newly diagnosed with type 2 diabetes mellitus.","Quan H","2017","include_nma",null,"primary_report","P01",null,"crossover","high","first","opus-5.5-agent06","randomized crossover trial of exenatide plus metformin versus biphasic insulin aspart 30 plus metformin in new T2D with obesity",1],["R0025563","Liraglutide and Glycaemic Outcomes in the LEADER Trial.","Zinman B","2018","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent06","post hoc analysis of LEADER RCT of liraglutide versus placebo on glycemic deterioration in T2D",1],["R0025720","Efficacy and safety of switching from sitagliptin to liraglutide in subjects with type 2 diabetes (LIRA-SWITCH): a randomized, double-blind, double-dummy, active-controlled 26-week trial.","Bailey TS","2016","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent06","LIRA-SWITCH double blind RCT of switching to liraglutide versus continuing sitagliptin on metformin in T2D",1],["R0025866","Efficacy and Tolerability of Exenatide Once Weekly Over 6 Years in Patients with Type 2 Diabetes: An Uncontrolled Open-Label Extension of the DURATION-1 Study.","Henry RR","2016","inventory_only","N1","extension",null,null,null,"high","first","opus-5.5-agent06","uncontrolled open label 6 year extension of DURATION-1 where all received weekly exenatide; randomized phase ended at 30 weeks",1],["R0025980","Type 2 diabetes care: Improvement by standardization at a diabetes rehabilitation clinic. An observational report.","Haslacher H","2019","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent06","pre post observational report of standardized lifestyle care at a diabetes rehabilitation clinic; GLP-1 RA not an exposure",1],["R0026079","What's next after metformin? focus on sulphonylurea: add-on or combination therapy.","Lim PC","2015","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent06","literature review of sulfonylurea as second line after metformin; no GLP-1 RA focus",1],["R0026225","A higher non-severe hypoglycaemia rate is associated with an increased risk of subsequent severe hypoglycaemia and major adverse cardiovascular events in individuals with type 2 diabetes in the LEADER study.","Heller SR","2022","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent06","post hoc analysis of LEADER RCT of liraglutide versus placebo on non severe hypoglycemia and later events",1],["R0020908","Genetic Variation in Targets of Antidiabetic Drugs and Alzheimer Disease Risk: A Mendelian Randomization Study.","Tang B","2022","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent08","drug target Mendelian randomization of antidiabetic targets incl GLP-1R and Alzheimer risk; genetic proxies, no drug exposure",1],["R0021188","Hepatic triglyceride content does not affect circulating CETP: lessons from a liraglutide intervention trial and a population-based cohort.","van Eyk HJ","2019","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent08","secondary analysis of MAGNA VICTORIA RCT of liraglutide versus placebo on hepatic fat and CETP plus a cohort",1],["R0021273","Cost-Utility of Liraglutide Plus Standard of Care Versus Standard of Care in People with Type 2 Diabetes and Cardiovascular Risk in Thailand.","Deerochanawong C","2023","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent08","Markov cost utility model of liraglutide added to standard care in Thailand based on LEADER",1],["R0021478","A bibliometric analysis of systematic reviews and meta-analyses on diabetes mellitus: global research trends from scopus database (1988-2024).","Dalvand A","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent08","bibliometric analysis of diabetes systematic reviews from Scopus; no synthesized contrast",1],["R0021630","891. Minimum Manufacturing Costs and National Prices for Weight Loss Treatments, as Potential Mitigation for Anti-Retroviral Related Weight Gain in HIV","Levi J","2021","exclude","E2","other",null,null,"abstract_only","high","first","opus-5.5-agent08","conference abstract estimating manufacturing costs and prices of weight loss drugs incl semaglutide; cost only",1],["R0021736","Association between different diabetes medication classes and risk of Parkinson's disease in people with diabetes.","Sunnarborg K","2022","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent08","Finnish nested case control of diabetes drug classes incl GLP-1 analogues and Parkinson disease; outcome not in harms list",1],["R0017942","Comparative analysis of semaglutide induced adverse reactions: Insights from FAERS database and social media reviews with a focus on oral vs subcutaneous administration.","Zhang J","2024","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent15","FAERS disproportionality and social media review analysis of semaglutide adverse reactions by route",1],["R0018055","Cardio-Reno-Microvascular Phenotypes and Multifactorial Cardiometabolic Target Achievement in Type 2 Diabetes.","Luca SA","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent15","cross sectional study of cardiometabolic target attainment by phenotype in type 2 diabetes; GLP-1 RA use only described",1],["R0018161","Cardiovascular Risk Reduction in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis.","Bernhard J","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent15","narrative review of cardiovascular risk reduction in MASLD and MASH incl GLP-1 RAs",1],["R0018410","Risk Factors for Hypoglycemia in Type 2 Diabetes Mellitus Patients Using Once-Weekly Semaglutide: A Matched Case-Control Study.","Amirthalingam P","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent15","case control study of hypoglycemia risk factors among semaglutide users only; no GLP-1 exposure comparison",1],["R0018529","Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials.","Husain M","2020","include_nma",null,"pooled_analysis","P01",null,null,"high","first","opus-5.5-agent15","post hoc pooled analysis of 18 SUSTAIN and PIONEER RCTs by randomized treatment on MACE across CV risk",1],["R0018623","Use of liraglutide after bariatric surgery: a 36-month follow-up in a real-world setting in Chile.","Farías MM","2024","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent15","retrospective single arm pre post study of liraglutide after bariatric surgery in Chile",1],["R0022750","[Indicators of diabetes mellitus after liraglutide, sitagliptin/metformin, linagliptin, and sitagliptin].","Atonal-Flores B","2023","inventory_only","N5","primary_report",null,null,"non_english","high","first","opus-5.5-agent04","Spanish language before and after record review of patients switched to liraglutide or DPP-4i regimens, no concurrent comparison",1],["R0022836","Cost-effectiveness analysis of liraglutide versus sitagliptin or exenatide in patients with inadequately controlled Type 2 diabetes on oral antidiabetic drugs in Greece.","Tzanetakos C","2014","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent04","CORE Diabetes Model cost effectiveness analysis of liraglutide vs sitagliptin or exenatide in Greece",1],["R0022981","Efficacy and Safety of Empagliflozine and Semaglutide (Once Weekly) in T2DM Patients in Shtip.","Nakova VV","2023","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent04","retrospective comparison of weekly semaglutide vs empagliflozin initiators, HbA1c, weight, deaths and hospitalizations, no listed harm",1],["R0023230","Oral semaglutide improves postprandial glucose and lipid metabolism, and delays gastric emptying, in subjects with type 2 diabetes.","Dahl K","2021","include_nma",null,"primary_report","P01",null,"crossover; mechanistic","high","first","opus-5.5-agent04","phase 1 double blind crossover RCT of oral semaglutide vs placebo in type 2 diabetes, fasting glucose and gastric emptying",1],["R0023345","Achieving glycaemic control without weight gain, hypoglycaemia, or gastrointestinal adverse events in type 2 diabetes in the SUSTAIN clinical trial programme.","DeVries JH","2018","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent04","analysis of composite endpoints across SUSTAIN 1 to 5 RCTs of semaglutide vs placebo or active comparators",1],["R0023497","Short term monotherapy with GLP-1 receptor agonist liraglutide or PDE 4 inhibitor roflumilast is superior to metformin in weight loss in obese PCOS women: a pilot randomized study.","Jensterle M","2015","include_nma",null,"primary_report","P12",null,null,"high","first","opus-5.5-agent04","pilot RCT of liraglutide vs roflumilast vs metformin in obese women with PCOS",1],["R0023606","PRISMA-efficacy and safety of lixisenatide for type 2 diabetes mellitus: A meta-analysis of randomized controlled trials.","Wei ZG","2018","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent04","meta-analysis of RCTs from seven databases on lixisenatide vs placebo in type 2 diabetes",1],["R0021791","Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses.","Kosiborod MN","2023","include_nma",null,"secondary_report","P02; P02W",null,null,"high","first","opus-5.5-agent14","exploratory analyses of STEP 1 and STEP 4 RCTs of semaglutide 2.4 mg on cardiometabolic risk factors",1],["R0021992","Crosstalk of kidney and brain in diabetes-related cognitive impairment and therapeutic strategies.","Xu C","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent14","narrative review of kidney brain crosstalk in diabetic cognitive impairment",1],["R0022214","Current Practices and Challenges in Pediatric Obesity Management (POM): A Nationwide Survey of Physicians in Korea.","Lee Y","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent14","nationwide physician survey on pediatric obesity management practices, no exposure comparison",1],["R0022324","Real-World Efficacy and Safety of Dulaglutide in Korean Patients with Type 2 Diabetes Mellitus: A Retrospective Study in a Tertiary Referral Center.","Yoon JH","2021","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent14","retrospective single arm review of dulaglutide add on in Korean T2D, no comparison group",1],["R0022460","Analysis of efficacy and safety of dulaglutide 0.75 mg stratified by sex in patients with type 2 diabetes in 2 randomized, controlled phase 3 studies in Japan.","Onishi Y","2017","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent14","sex subgroup analysis of two Japanese phase 3 RCTs of dulaglutide vs liraglutide or glargine",1],["R0022574","Lixisenatide is effective and safe as add-on treatment to basal insulin in Asian individuals with type 2 diabetes and different body mass indices: a pooled analysis of data from the GetGoal Studies.","Feng W","2021","include_nma",null,"pooled_analysis","P01",null,null,"high","first","opus-5.5-agent14","pooled post hoc analysis of Asian participants in three placebo controlled GetGoal RCTs of lixisenatide by BMI",1],["R0024376","Comprehensive Evaluation of Combination Therapy with Basal Insulin and Either Lixisenatide or Vildagliptin in Japanese Patients with Type 2 Diabetes: A Randomized, Open-Label, Parallel-Group, Multicenter Study.","Otowa-Suematsu N","2018","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent20","randomized open label trial switching sitagliptin to lixisenatide vs vildagliptin on top of glargine in Japanese T2D",1],["R0024691","The DIVE/DPV registries: evolution of empagliflozin use in clinical practice in Germany.","Bramlage P","2020","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent20","German registry describing empagliflozin users over time, no GLP-1 RA exposure studied",1],["R0024841","SAT-097 Weight Loss With Liraglutide 3.0 Mg Versus Placebo For Individuals Who Adhere To The Trial Drug: A Secondary Analysis From SCALE IBT","Shaw Tronieri J","2019","include_nma",null,"conference_abstract","P02",null,"abstract_only","high","first","opus-5.5-agent20","abstract of prespecified adherence analysis of randomized SCALE IBT trial of liraglutide 3 mg vs placebo",1],["R0024942","Real-World Clinical Effectiveness and Cost Savings of Liraglutide Versus Sitagliptin in Treating Type 2 Diabetes for 1 and 2 Years.","Li Q","2018","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent20","MarketScan cohort of persistent liraglutide vs sitagliptin users, HbA1c and costs only, no listed harm",1],["R0025073","Liraglutide ameliorates beta-cell function, alleviates oxidative stress and inhibits low grade inflammation in young patients with new-onset type 2 diabetes.","Zhang WQ","2018","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent20","RCT of liraglutide vs metformin for 8 weeks in young adults with new onset T2D",1],["R0025186","Pharmacokinetics and tolerability of semaglutide in people with hepatic impairment.","Jensen L","2018","inventory_only","N1","primary_report",null,null,null,"high","first","opus-5.5-agent20","open label single dose PK study of semaglutide in groups by hepatic function, all received semaglutide, no randomized contrast",1],["R0016627","Integrating the management of ultra-processed food addiction into type 2 diabetes care: a clinical response to De Silva et al, (2025) and practical recommendations for practitioners.","Bennett E","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent11","clinical commentary responding to a food addiction prevalence study with practice recommendations",1],["R0016711","Assessing Clinical Inertia on Implementing Clinical Guideline Recommendations in Patients with Type 2 Diabetes: A Clinician Survey Study.","Stephenson JJ","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent11","clinician survey linked to claims on guideline concordant care; no GLP-1RA exposure comparison",1],["R0016825","Real world effectiveness of subcutaneous semaglutide in type 2 diabetes: A retrospective, cohort study (Sema-MiDiab01).","Berra CC","2022","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent11","multicenter retrospective single group study of subcutaneous semaglutide; no comparator",1],["R0016938","The impact of weekly semaglutide, a glucagon-like peptide-1 agonist, on kidney outcomes in adults with type 2 diabetes mellitus.","Algarni AA","2024","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent11","retrospective single group study of weekly semaglutide on kidney measures; no comparator",1],["R0017003","Liraglutide as add-on therapy to insulin in type 2 diabetes mellitus: a retrospective, observational study from a daily clinical practice setting in Switzerland.","Lipowsky C","2015","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent11","retrospective single group study of liraglutide added to insulin; no comparator",1],["R0017116","Effect of finerenone on urinary protein and inflammatory factor levels in type 2 diabetes mellitus patients with diabetic kidney disease.","Song J","2025","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent11","single arm finerenone study; GLP-1RA only as background therapy, not studied",1],["R0017236","The glucose tolerance test in mice: Sex, drugs and protocol.","Kennard MR","2022","exclude","E1","primary_report",null,null,null,"high","first","opus-5.5-agent11","mouse glucose tolerance test protocol study including exendin-4",1],["R0017338","Effect of Oral Semaglutide on the Pharmacokinetics of Lisinopril, Warfarin, Digoxin, and Metformin in Healthy Subjects.","Bækdal TA","2019","inventory_only","N1","primary_report",null,null,null,"high","first","opus-5.5-agent11","two one sequence drug interaction trials of oral semaglutide in healthy subjects; no randomized or concurrent comparator",1],["R0024012","Liraglutide 3.0 mg and Intensive Behavioral Therapy (IBT) for Obesity in Primary Care: The SCALE IBT Randomized Controlled Trial.","Wadden TA","2020","include_nma",null,"primary_report","P02",null,null,"high","first","opus-5.5-agent12","SCALE IBT double blind RCT of liraglutide 3.0 mg vs placebo plus intensive behavioral therapy in obesity",1],["R0024178","Lixisenatide resensitizes the insulin-secretory response to intravenous glucose challenge in people with type 2 diabetes--a study in both people with type 2 diabetes and healthy subjects.","Becker RH","2014","include_nma",null,"primary_report","P01; P99",null,"mechanistic; crossover","high","first","opus-5.5-agent12","two single dose crossover RCTs of lixisenatide vs placebo in T2D and healthy subjects, insulin response, adverse events collected",1],["R0024307","Addressing Drug Shortages at Mediclinic Parkview Hospital: A ‎Five-Year Study of ‎Challenges, Impact, and Strategies.","Sallam M","2024","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent12","hospital drug shortage descriptive study, tirzepatide only among shortage items",1],["R0024503","PYY3-36 and oxyntomodulin can be additive in their effect on food intake in overweight and obese humans.","Field BC","2010","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent12","infusion experiment of native oxyntomodulin and PYY in overweight volunteers, native hormone physiology not a therapeutic regimen",1],["R0024641","DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide.","Wysham C","2011","inventory_only","N1","extension","P01",null,null,"high","first","opus-5.5-agent12","open label uncontrolled 26 week extension of DURATION-2 where all patients received exenatide once weekly",1],["R0024774","Expression of glucagon-like Peptide-1 receptor in papillary thyroid carcinoma and its clinicopathologic significance.","Jung MJ","2014","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent12","immunohistochemistry of GLP-1 receptor expression in thyroid tissue, no drug exposure",1],["R0024910","SAT-105 Weight Loss As Determined By Adherence To Reduced Caloric Diet, Increased Physical Activity, Liraglutide 3.0 Mg and Placebo: A Sub-analysis Of The SCALE IBT Trial","Shaw Tronieri J","2019","include_nma",null,"conference_abstract","P02",null,"abstract_only","high","first","opus-5.5-agent12","abstract of prespecified adherence sub-analysis of SCALE IBT RCT liraglutide vs placebo",1],["R0025024","Safety and efficacy of once-weekly semaglutide vs additional oral antidiabetic drugs in Japanese people with inadequately controlled type 2 diabetes: A randomized trial.","Kaku K","2018","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent12","open label phase 3 RCT of semaglutide 0.5 or 1.0 mg vs additional oral agent in Japanese T2D",1],["R0021509","MON-LB028 Comparing Cardiovascular Effects of GLP-1 Agonists in a Real World Setting","Wallia A","2019","inventory_only","N6","primary_report",null,null,"abstract_only","high","first","opus-5.5-agent13","abstract of claims active comparator cohort comparing GLP-1 agents on cardiovascular events only",1],["R0021663","GLP-1 receptor agonist attenuates endoplasmic reticulum stress-mediated β-cell damage in Akita mice.","Yamane S","2011","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent13","exendin-4 study in Akita mice only",1],["R0021772","Gender disparities in time-to-initiation of cardioprotective glucose-lowering drugs in patients with type 2 diabetes and cardiovascular disease: a Danish nationwide cohort study.","Funck KL","2022","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent13","nationwide cohort of time to initiation of SGLT2 or GLP-1 drugs by gender, drug utilization outcome only",1],["R0022119","Interleukin-1β in circulating mononuclear cells predicts steatotic liver disease improvement after weight loss in subjects with obesity and prediabetes or type 2 diabetes.","Simeone PG","2025","include_nma",null,"secondary_report","P01; P06",null,null,"high","first","opus-5.5-agent13","post hoc analysis of RCT of liraglutide vs lifestyle counselling in obesity with prediabetes or early type 2 diabetes",1],["R0022210","Neuropsychiatric safety with liraglutide 3.0 mg for weight management: Results from randomized controlled phase 2 and 3a trials.","O'Neil PM","2017","include_nma",null,"pooled_analysis","P02; P01",null,null,"high","first","opus-5.5-agent13","pooled post hoc neuropsychiatric safety analysis of liraglutide 3.0 mg vs placebo phase 2 and 3a RCTs",1],["R0022323","Risk of adverse events with liraglutide in heart failure with reduced ejection fraction: A post hoc analysis of the FIGHT trial.","Neves JS","2023","include_nma",null,"secondary_report","P07B",null,null,"high","first","opus-5.5-agent13","post hoc analysis of FIGHT RCT of liraglutide vs placebo in HFrEF",1],["R0022456","Effects of semaglutide on cardiovascular risk factors and eating behaviors in type 2 diabetes.","Di Folco U","2022","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent13","retrospective single group study of semaglutide in type 2 diabetes without comparison group",1],["R0023034","Critical appraisal of once-weekly formulation of exenatide in the control of type 2 diabetes mellitus.","Seewoodhary J","2010","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent16","narrative critical appraisal of exenatide once weekly without systematic methods",1],["R0023199","Cost-utility analysis of glucagon-like Peptide-1 agonists compared with dipeptidyl peptidase-4 inhibitors or neutral protamine hagedorn Basal insulin as add-on to metformin in type 2 diabetes in sweden.","Kiadaliri AA","2014","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent16","cohort model cost utility analysis of GLP-1RA vs DPP-4i or NPH insulin in Sweden",1],["R0023302","Diabetes medications and risk of Parkinson's disease: a cohort study of patients with diabetes.","Brauer R","2020","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent16","THIN cohort comparing GLP-1RA, DPP-4i and glitazone users with other oral drugs; incident Parkinson disease only",1],["R0023427","Association between exenatide use and incidence of Alzheimer's disease.","Zhou B","2021","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent16","Medicare cohort of exenatide fills vs nonuse; incident Alzheimer disease only",1],["R0023564","GLP-1 Improves Adipocyte Insulin Sensitivity Following Induction of Endoplasmic Reticulum Stress.","Jiang Y","2018","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent16","mouse and cultured adipocyte study of GLP-1 and liraglutide on ER stress",1],["R0023848","The Effects of Once-Weekly Dulaglutide and Insulin Glargine on Glucose Fluctuation in Poorly Oral-Antidiabetic Controlled Patients with Type 2 Diabetes Mellitus.","Wang J","2019","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent16","single center randomized comparison of dulaglutide vs glargine within AWARD-CHN2 registration; glucose variability",1],["R0022810","Cost-effectiveness and budget impact of liraglutide in type 2 diabetes patients with elevated cardiovascular risk: a US-managed care perspective.","Shah D","2018","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent18","cost effectiveness and budget impact model of liraglutide vs standard care based on LEADER inputs",1],["R0022917","Efficacy and safety of liraglutide monotherapy compared with metformin in Japanese overweight/obese patients with type 2 diabetes.","Tanaka K","2015","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent18","open label 24 week RCT of liraglutide vs metformin monotherapy in overweight or obese Japanese T2D",1],["R0023214","A Randomized Controlled Trial of Dapagliflozin Plus Once-Weekly Exenatide Versus Placebo in Individuals with Obesity and Without Diabetes: Metabolic Effects and Markers Associated with Bodyweight Loss.","Pereira MJ","2018","include_nma",null,"secondary_report","P02",null,null,"high","first","opus-5.5-agent18","post hoc analysis of double blind RCT of dapagliflozin plus exenatide QW vs placebo in obesity without diabetes; weight markers",1],["R0023306","Efficacy of Liraglutide 3.0 Mg Treatment on Weight-Loss in Patients with Weight Regain After Bariatric Surgery","Muratori F","2021","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent18","retrospective single arm series of liraglutide 3.0 mg for weight regain after bariatric surgery",1],["R0023580","Effect of Weight Loss Medications on Hepatic Steatosis and Steatohepatitis: A Systematic Review.","Pan CS","2020","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent18","systematic review of weight loss drug trials incl. GLP-1 RAs on hepatic steatosis; PubMed search with selection process",1],["R0023700","Linagliptin and cardiovascular outcomes in type 2 diabetes after acute coronary syndrome or acute ischemic stroke.","Li YR","2018","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent18","Taiwan cohort of linagliptin vs no incretin therapy after ACS or stroke; GLP-1 RA users excluded",1],["R0022053","Structural basis for the identification of short novel peptides as potential GLP1R agonists using in silico approaches","Ghosh k","2022","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent01","in silico docking design of short GLP-1 receptor agonist peptides; no human data",1],["R0022168","Marked weight loss on liraglutide 3.0 mg: Real-life experience of a Swiss cohort with obesity.","Santini S","2023","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent01","prospective single group cohort of liraglutide 3.0 mg in adults with obesity, no comparison group",1],["R0022276","Safety, tolerability, pharmacokinetics, and pharmacodynamics of TG103 injection in participants who are overweight or obese: a randomized, double-blind, placebo-controlled, multiple-dose phase 1b study.","Lin D","2024","include_nma",null,"primary_report","P02",null,"mechanistic","high","first","opus-5.5-agent01","phase 1b double blind RCT of TG103 doses versus placebo in overweight or obesity without diabetes; safety, PK and weight",1],["R0022378","The effects of GLP-1 analogues on pre-diabetes of the children.","Zhou QX","2017","include_nma",null,"primary_report","P99",null,null,"high","first","opus-5.5-agent01","RCT of liraglutide plus lifestyle versus lifestyle alone in children with prediabetes; pediatric prediabetes population",1],["R0022508","Efficacy of Liraglutide in Patients With Diabetic Nephropathy: A Meta-Analysis of Randomized Controlled Trials","Mali N","2021","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent01","meta-analysis of liraglutide RCTs in diabetic nephropathy, eight databases searched",1],["R0022619","Effects of the Topical Administration of Semaglutide on Retinal Neuroinflammation and Vascular Leakage in Experimental Diabetes.","Simó R","2021","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent01","db/db mouse study of topical semaglutide eye drops on retinal neuroinflammation; animal only",1],["R0022730","South Asian Consensus Guideline: Use of GLP-1 analogue therapy in diabetes during Ramadan.","Pathan MF","2012","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent01","South Asian consensus guideline on GLP-1 analogue use during Ramadan",1],["R0025206","Effects of liraglutide on obesity-associated functional hypogonadism in men.","Jensterle M","2019","include_nma",null,"primary_report","P99",null,null,"high","first","opus-5.5-agent03","16 week open label RCT of liraglutide 3.0 mg vs transdermal testosterone in obese men with functional hypogonadism",1],["R0025391","Safety and efficacy of once-weekly dulaglutide versus sitagliptin after 2 years in metformin-treated patients with type 2 diabetes (AWARD-5): a randomized, phase III study.","Weinstock RS","2015","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent03","AWARD-5 104 week final report, dulaglutide 1.5 and 0.75 mg vs sitagliptin on metformin",1],["R0025553","Liraglutide restores chronic ER stress, autophagy impairments and apoptotic signalling in SH-SY5Y cells.","Panagaki T","2017","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent03","SH-SY5Y cell line study of liraglutide on ER stress; in vitro only",1],["R0025695","Using QALYs as an Outcome for Assessing Global Prediction Accuracy in Diabetes Simulation Models.","Dakin HA","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent03","simulation model validation of UKPDS outcome models against EXSCEL trial data; modeling methods paper",1],["R0025836","Efficacy and safety of liraglutide versus sitagliptin, both in combination with metformin, in Chinese patients with type 2 diabetes: a 26-week, open-label, randomized, active comparator clinical trial.","Zang L","2016","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent03","26 week open label RCT of liraglutide 1.8 mg vs sitagliptin with metformin in Chinese T2D",1],["R0026203","Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial.","Blackman A","2016","include_nma",null,"primary_report","P10",null,null,"high","first","opus-5.5-agent03","SCALE Sleep Apnea 32 week RCT of liraglutide 3.0 mg vs placebo in obesity with moderate or severe OSA",1],["R0019790","Glucagon-like Peptide-1 Improves Fatty Liver and Enhances Thermogenesis in Brown Adipose Tissue via Inhibiting BMP4-Related Signaling Pathway in High-Fat-Diet-Induced Obese Mice.","Wang X","2021","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent02","randomized exenatide experiment in high fat diet obese mice; animal study only",1],["R0019872","Friend or foe? ACE2 inhibitors and GLP-1R agonists in COVID-19 treatment.","Pang J","2021","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent02","commentary review on ACE inhibitors and GLP-1 RA in COVID-19",1],["R0019968","The effect of Dulaglutide on glycemic and weight control in patients with type 2 diabetes.","Ruda AI","2023","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent02","retrospective single group record review of dulaglutide initiation in T2D; no comparison group",1],["R0020110","Adverse events of hepatic anti-fibrotic agents in phase 3 and above clinical trials: a descriptive analysis of the WHO-VigiAccess database.","Liu Y","2025","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent02","WHO VigiAccess descriptive and disproportionality analysis of antifibrotic drugs including liraglutide",1],["R0020221","Sex-Differences in Response to Treatment with Liraglutide 3.0 mg.","Milani I","2024","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent02","retrospective single group liraglutide 3.0 mg cohort comparing response by sex; no untreated comparison",1],["R0020462","Glucagon-Like Peptide-1 Receptor PET/CT with 68Ga-NOTA-Exendin-4 for Detecting Localized Insulinoma: A Prospective Cohort Study.","Luo Y","2016","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent02","prospective diagnostic cohort of exendin-4 PET tracer for insulinoma localization; not a therapeutic regimen",1],["R0020593","Semaglutide reduces tumor burden in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH-HCC with advanced fibrosis.","Hansen HH","2023","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent02","semaglutide and lanifibranor in diet induced NASH-HCC mice; animal study only",1],["R0022043","Deciding oral drugs after metformin in type 2 diabetes: An evidence-based approach.","Singh AK","2014","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent17","narrative review on choosing oral drugs after metformin",1],["R0022337","Treatment with the human once-weekly glucagon-like peptide-1 analog taspoglutide in combination with metformin improves glycemic control and lowers body weight in patients with type 2 diabetes inadequately controlled with metformin alone: a double-blind placebo-controlled study.","Nauck MA","2009","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent17","phase 2 placebo controlled RCT of taspoglutide doses added to metformin in type 2 diabetes, 8 weeks",1],["R0022482","Maintenance of glycaemic control with liraglutide versus oral antidiabetic drugs as add-on therapies in patients with type 2 diabetes uncontrolled with metformin alone: A randomized clinical trial in primary care (LIRA-PRIME).","Unger J","2022","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent17","LIRA-PRIME open label RCT of liraglutide versus investigator chosen oral drug added to metformin in primary care",1],["R0022605","Systematic review of influence of ethnicity on efficacy and safety of pharmacotherapy for childhood and adolescent obesity.","Gupta S","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent17","registered systematic review of RCTs of pediatric obesity drugs including liraglutide by ethnicity, four databases searched",1],["R0019955","The effectiveness and safety of exenatide in the treatment of polycystic ovary syndrome: A systematic review and meta-analysis","Hu Y","2023","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent19","meta-analysis of RCTs of exenatide in PCOS; PubMed Embase Web of Science Cochrane searched; preprint",1],["R0020089","Comprehensive Evaluation of a Levonorgestrel Intrauterine Device (LNG-IUD), Metformin, and Liraglutide for Fertility Preservation in Endometrial Cancer: Protocol for a Randomized Clinical Trial.","Leipold G","2024","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent19","protocol of RCT of LNG-IUD alone, plus metformin, or plus metformin and liraglutide in obese women with endometrial hyperplasia or cancer",1],["R0020208","Applying REWIND cardiovascular disease criteria to SUSTAIN 6 and PIONEER 6: An exploratory analysis of cardiovascular outcomes with semaglutide.","Verma S","2021","include_nma",null,"pooled_analysis","P01",null,null,"high","first","opus-5.5-agent19","post hoc pooled SUSTAIN 6 and PIONEER 6 RCTs of semaglutide vs placebo recategorized by REWIND cardiovascular criteria",1],["R0020353","Tirzepatide: A Promising Drug for Type 2 Diabetes and Beyond.","Dutta P","2023","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent19","narrative review of tirzepatide for type 2 diabetes",1],["R0020446","Response to Comment on Gan et al. Efficacy of Modern Diabetes Treatments DPP-4i, SGLT-2i, and GLP-1RA in White and Asian Patients With Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Diabetes Care 2020;43:1948-1957.","Gan S","2020","inventory_only","N9","ancillary",null,null,null,"high","first","opus-5.5-agent19","authors reply to comment on a meta-analysis of DPP-4i, SGLT2i and GLP-1 RA efficacy by ethnicity",1],["R0020569","A novel, long-acting glucagon-like peptide receptor-agonist: dulaglutide.","Gurung T","2015","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent19","systematic review of dulaglutide AWARD RCTs vs comparators; MEDLINE Embase searched with inclusion criteria",1],["R0020749","Glucagon-like-1 receptor agonists and sodium/glucose cotransporter-2 inhibitors combination-are we exploiting their full potential in a real life setting?","Berkovic MC","2020","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent19","cohort comparing sequences of adding GLP-1 RA and SGLT2i in poorly controlled type 2 diabetes; effectiveness only",1],["R0020868","Exenatide once weekly for smoking cessation: study protocol for a randomized clinical trial.","Yammine L","2018","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent19","protocol of placebo controlled RCT of exenatide once weekly for smoking cessation with nicotine patch",1],["R0017438","OCT1 Variants Are Associated with Metformin Clearance and Gluconeogenesis: Mechanistic Insights for Youth-Onset Type 2 Diabetes in the MIGHTY Study.","Cantor SL","2026","include_nma",null,"secondary_report","P04; P01",null,"mechanistic","high","first","opus-5.5-agent10","MIGHTY youth onset T2D subset randomized to metformin versus metformin plus liraglutide; PK model and fasting glucose; age band unclear",1],["R0017523","12-month outcomes of GLP - 1 in severe pediatric obesity: real-world data.","Cominato L","2025","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent10","real world single group cohort of liraglutide in severe pediatric obesity in Brazil; no comparison group",1],["R0017609","Safety profile of semaglutide versus placebo in the SELECT study: a randomized controlled trial.","Kushner RF","2025","include_nma",null,"secondary_report","P02",null,null,"high","first","opus-5.5-agent10","prespecified safety analyses of SELECT RCT semaglutide 2.4 mg versus placebo; gallbladder, suicidality and other AEs",1],["R0017720","Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects with Renal Impairment.","Granhall C","2018","inventory_only","N1","primary_report",null,null,null,"high","first","opus-5.5-agent10","open PK trial of oral semaglutide in groups by renal function, all exposed; no concurrent unexposed comparison",1],["R0017828","MON-705 Initiation of Semaglutide: Understanding National Prescription Behaviors in Real-World Practice",null,"2025","exclude","E2","conference_abstract",null,null,"abstract_only","high","first","opus-5.5-agent10","abstract on semaglutide initiation dose prescribing patterns in MarketScan; utilization without exposure comparison",1],["R0017915","Effectiveness of Sodium-Glucose Transporter 2 Inhibitors and Semaglutide on Body Composition in Type 2 Diabetes Mellitus and Chronic Kidney Disease: A Real-World Cohort Study with Bioelectrical Impedance Analysis.","Yang Q","2025","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent10","retrospective cohort SGLT2i alone versus plus semaglutide in T2D CKD; body composition only, no harms_nrs outcome",1],["R0018142","Changes in Serum Testosterone After Sublingual Enclomiphene Citrate Combined With a Mineral Oxide Delivery System: A Retrospective Case Series of 15 Men.","Warren S","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent10","case series of enclomiphene formulation for hypogonadism; GLP-1 RA only incidental in one patient",1],["R0017521","The Bidirectional Relationship Between Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease: A Retrospective Cohort Study.","Williams DM","2024","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent09","retrospective biopsy proven MASLD cohort comparing diabetes treatments including GLP-1 on liver measures, no eligible harm",1],["R0017606","Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD).","Zinman B","2009","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent09","LEAD-4 double blind RCT of liraglutide 1.2 or 1.8 mg versus placebo added to metformin and rosiglitazone",1],["R0017825","Combined liraglutide and metformin therapy in overweight or obese women with polycystic ovary syndrome: A systematic review and meta-analysis.","Ling J","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent09","PROSPERO registered meta-analysis of RCTs of liraglutide plus metformin versus metformin in PCOS, seven databases",1],["R0017903","Association between various dosage forms of semaglutide and ocular adverse events in a real-world setting.","Zhao T","2025","inventory_only","N5","other",null,null,null,"high","first","opus-5.5-agent09","FAERS disproportionality comparison of ocular adverse event reports for oral versus subcutaneous semaglutide",1],["R0018035","Impact of Short-Term Liraglutide Therapy on Non-Invasive Markers of Liver Fibrosis in Patients with MASLD.","Bołdys A","2025","inventory_only","N1","primary_report",null,null,null,"high","first","opus-5.5-agent09","prospective single arm study of liraglutide with diet counseling on fibrosis markers in MASLD with obesity",1],["R0018135","Effects of antidiabetic drugs on bone metabolism.","Padilla Apuntate N","2024","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent09","descriptive cross sectional comparison of bone turnover markers across diabetes drug groups including GLP-1",1],["R0025374","HARMONY 4: randomised clinical trial comparing once-weekly albiglutide and insulin glargine in patients with type 2 diabetes inadequately controlled with metformin with or without sulfonylurea.","Weissman PN","2014","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent20","randomized open label HARMONY 4 trial of weekly albiglutide vs insulin glargine on metformin with or without SU",1],["R0025517","Continuous positive airway pressure but not Liraglutide-mediated weight loss improves early cardiovascular disease in obstructive sleep apnea: Data from a randomized proof-of-concept study","O’Donnell C","2023","include_nma",null,"primary_report","P10",null,null,"high","first","opus-5.5-agent20","randomized proof of concept trial of CPAP vs liraglutide regimen vs both in nondiabetic OSA, preprint",1],["R0025665","Liraglutide Versus SGLT-2 Inhibitors in People with Type 2 Diabetes: A Network Meta-Analysis.","Lorenzi M","2017","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent20","NMA from systematic search of MEDLINE Embase CENTRAL comparing liraglutide with SGLT2 inhibitors in T2D",1],["R0025798","Towards a multidimensional scientific approach to improve clinical practices for infertility treatment.","Zhu YH","2018","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent20","editorial on approaches to infertility treatment in PCOS",1],["R0025934","Optimal dose of tirzepatide for type 2 diabetes mellitus: A meta-analysis and trial sequential analysis.","Yu Y","2022","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent20","PROSPERO registered meta-analysis of RCTs comparing tirzepatide doses in T2D, eight databases",1],["R0026169","Glucagon-like peptide-1 versus somatostatin receptor targeting reveals 2 distinct forms of malignant insulinomas.","Wild D","2011","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent20","diagnostic imaging study using radiolabeled exendin-4 tracer in malignant insulinoma, no therapeutic GLP-1 RA",1],["R0026364","Medications in type-2 diabetics and their association with liver fibrosis.","Siddiqui MT","2020","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent20","retrospective biopsy cohort of medication classes including liraglutide and advanced liver fibrosis, no listed harm",1],["R0022851","Fibroblast growth factor-23 is associated with imaging markers of diabetic cardiomyopathy and anti-diabetic therapeutics.","Sørensen MH","2020","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent07","cross sectional imaging study in T2D comparing FGF-23 between GLP-1 analogue users and nonusers",1],["R0022991","Liraglutide therapy beyond glycemic control: an observational study in Indian patients with type 2 diabetes in real world setting.","Kesavadev J","2012","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent07","prospective single arm observational study of liraglutide in 14 overweight Indian T2D patients",1],["R0023137","Tirzepatide-Friend or Foe in Diabetic Cancer Patients?","Samuel SM","2022","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent07","narrative review of tirzepatide and cancer in diabetes",1],["R0023240","Exposure-response analyses of liraglutide 3.0 mg for weight management.","Wilding JP","2016","include_nma",null,"pooled_analysis","P02; P01; P06",null,null,"high","first","opus-5.5-agent07","exposure response analyses pooling phase 2 and SCALE RCTs of liraglutide vs placebo; weight, HbA1c and adverse events",1],["R0023366","Striking the Balance: GLP-1/Glucagon Co-Agonism as a Treatment Strategy for Obesity.","Hope DCD","2021","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent07","mini review of GLP-1 and glucagon co-agonists for obesity",1],["R0023522","Energy intake as a short-term biomarker for weight loss in adults with obesity receiving liraglutide: A randomized trial.","Saxena AR","2021","include_nma",null,"primary_report","P02",null,null,"high","first","opus-5.5-agent07","double blind RCT of liraglutide 3.0 mg vs placebo for 6 weeks in obesity without diabetes; energy intake and weight",1],["R0023627","Will oral semaglutide be used to reduce cardiovascular risk in subjects with type 2 diabetes instead of subcutaneous semaglutide?","Doggrell SA","2020","inventory_only","N9","ancillary",null,null,null,"high","first","opus-5.5-agent07","expert evaluation commentary on the PIONEER 6 RCT of oral semaglutide",1],["R0023778","Evaluating the Cost-Effectiveness of Once-Weekly Semaglutide 1 mg Versus Empagliflozin 25 mg for Treatment of Patients with Type 2 Diabetes in the UK Setting.","Capehorn M","2021","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent07","CORE Diabetes Model cost effectiveness analysis of semaglutide vs empagliflozin in the UK",1],["R0023748","Cost-Effectiveness of MASH Diagnosis and Management Approaches Among Those With Type 2 Diabetes.","Lazarus JV","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent04","generalized cost effectiveness analysis of MASH management approaches incl semaglutide across 12 countries",1],["R0023921","Effects of liraglutide and empagliflozin added to insulin therapy in patients with type 2 diabetes: A randomized controlled study.","Nakaguchi H","2020","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent04","open label RCT of liraglutide vs empagliflozin added to insulin in type 2 diabetes",1],["R0024112","Evaluation of Glycemic Control and Predictors of Severe Illness and Death in Patients with Diabetes Hospitalized With COVID-19.","Milosavljevic J","2022","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent04","COVID-19 inpatient diabetes cohort, preadmission GLP-1 RA use among predictors of severe disease and death, no listed harm",1],["R0024453","Early glycaemic control in metformin users receiving their first add-on therapy: a population-based study of 4,734 people with type 2 diabetes.","Thomsen RW","2015","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent04","Danish cohort of metformin users by first add-on drug incl GLP-1 RA, HbA1c goal attainment only",1],["R0024602","The combination of dulaglutide and biguanide reduced bodyweight in Japanese patients with type 2 diabetes.","Inagaki N","2016","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent04","subgroup analysis by background drug of phase 3 RCT of dulaglutide vs insulin glargine in Japanese type 2 diabetes",1],["R0024716","SUN-221 Effects of Liraglutide on Obesity-Associated Functional Hypogonadism in Men: A Randomized, Testosterone Replacement Treatment-Controlled Study","Jensterle Sever M","2019","include_nma",null,"conference_abstract","P99",null,"abstract_only","high","first","opus-5.5-agent04","abstract of RCT of liraglutide 3.0 mg vs testosterone in obese men with functional hypogonadism, P99 diabetes status mixed",1],["R0024869","The Effectiveness of Adding Pharmacotherapy to Dietary Counseling for Veterans in a Veterans Health Administration Move! Weight Management Program","Alvarez D","2021","inventory_only","N5","conference_abstract",null,null,null,"high","first","opus-5.5-agent04","abstract of chart review of veterans on weight loss drugs incl GLP-1 RA, descriptive weight change without comparison",1],["R0026421","Effectiveness of Liraglutide in Type II Diabetes Mellitus Management: Experience in Emirati Patients.","Ghuman NK","2015","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent06","retrospective single group cohort of liraglutide users in Emirati T2D; no comparison group",1],["R0018863","Diabetes-Related Effectiveness and Cost of Liraglutide or Insulin in German Patients with Type 2 Diabetes: A 5-Year Retrospective Claims Analysis.","Wilke T","2020","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent15","German claims PSM cohort of liraglutide versus insulin initiators; HbA1c, BMI, diabetes hospitalization and costs only",1],["R0026512","Risk Estimates of Imminent Cardiovascular Death and Heart Failure Hospitalization Are Improved Using Serial Natriuretic Peptide Measurements in Patients With Coronary Artery Disease and Type 2 Diabetes.","Wolsk E","2022","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent06","secondary analysis of ELIXA RCT of lixisenatide versus placebo using serial natriuretic peptides for risk prediction",1],["R0026703","Effect of exenatide on the pharmacokinetics of a combination oral contraceptive in healthy women: an open-label, randomised, crossover trial.","Kothare PA","2012","include_nma",null,"primary_report","P99",null,"mechanistic; crossover","high","first","opus-5.5-agent06","randomized crossover PK trial of oral contraceptive alone versus with exenatide in healthy women; adverse events reported, P99 healthy volunteers",1],["R0027037","Type 1 diabetes and cardiovascular disease.","Schnell O","2013","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent06","narrative review of type 1 diabetes and cardiovascular disease",1],["R0027184","Weight and Glycemic Control Outcomes of Bariatric Surgery and Pharmacotherapy in Patients With Melanocortin-4 Receptor Deficiency.","Fojas EGF","2021","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent06","small retrospective case series of MC4R deficiency comparing bariatric surgery and liraglutide; not a cohort with eligible harms",1],["R0027399","An enhanced participant information leaflet and multimedia intervention to improve the quality of informed consent to a randomised clinical trial enrolling people living with HIV and obesity: a protocol for a Study Within A Trial (SWAT).","O'Sullivan L","2022","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent06","protocol of a study within a trial on consent materials embedded in the SWIFT semaglutide RCT; no results",1],["R0027644","Beyond lifestyle interventions: exploring the potential of anti-obesity medications in the UK.","Wilding JPH","2018","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent06","narrative review of anti-obesity medications in the UK",1],["R0018985","Real-World Clinical Experience of Oral Semaglutide in a Secondary Diabetes Clinic in the UK: A Retrospective Observational Study.","Williams DM","2024","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent15","retrospective single group evaluation of oral semaglutide in UK secondary care; before and after changes",1],["R0019117","Gender differences in weight gain during attempted and successful smoking cessation on dulaglutide treatment: a predefined secondary analysis of a randomised trial.","Baur F","2023","include_nma",null,"secondary_report","P14B",null,null,"high","first","opus-5.5-agent15","predefined secondary analysis of RCT of dulaglutide versus placebo with varenicline for smoking cessation; weight gain by gender",1],["R0019218","Efficacy and safety of cotadutide, a dual glucagon-like peptide-1 and glucagon receptor agonist, in a randomized phase 2a study of patients with type 2 diabetes and chronic kidney disease.","Parker VER","2022","include_nma",null,"primary_report","P01; P08A",null,null,"high","first","opus-5.5-agent15","phase 2a RCT of cotadutide versus placebo for 32 days in type 2 diabetes with CKD",1],["R0019317","Real-World Clinical Effectiveness of Liraglutide for Weight Management in Türkiye: Insights from the LIRA-TR Study.","Oral A","2024","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent15","retrospective single group cohort of liraglutide for weight management in Turkey; no comparator",1],["R0019517","One-year safety and efficacy results of insulin treatment simplification with IDegLira in type 2 diabetes.","Taybani ZJ","2023","inventory_only","N1","primary_report",null,null,null,"high","first","opus-5.5-agent15","prospective one arm 12 month study switching multiple daily insulin to IDegLira in type 2 diabetes",1],["R0019619","Rationale and design of the glycemia reduction approaches in diabetes: a comparative effectiveness study (GRADE).","Nathan DM","2013","inventory_only","N8","protocol_or_design","P01",null,null,"high","first","opus-5.5-agent15","rationale and design of GRADE pragmatic RCT comparing liraglutide, sitagliptin, glimepiride and glargine added to metformin",1],["R0022094","PET with Different Radiopharmaceuticals in Neuroendocrine Neoplasms: An Umbrella Review of Published Meta-Analyses.","Treglia G","2021","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent08","umbrella review of PET radiopharmaceuticals incl diagnostic exendin-4 tracer; no therapeutic GLP-1 RA",1],["R0022190","Weight loss, glycemic control, and changes in cardiovascular biomarkers in patients with type 2 diabetes receiving incretin therapies or insulin in a large cohort database.","Horton ES","2010","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent08","retrospective EMR cohort of exenatide, sitagliptin or insulin initiators; weight, glycemia and biomarkers only",1],["R0022433","Changes in physical activity during a one-year weight loss trial with liraglutide vs placebo in participants with knee osteoarthritis: Secondary analyses of a randomised controlled trial.","Bartholdy C","2022","include_nma",null,"secondary_report","P11",null,null,"high","first","opus-5.5-agent08","secondary analysis of RCT of liraglutide 3 mg versus placebo after diet run in knee osteoarthritis",1],["R0022649","Cardioprotective effects of lixisenatide in rat myocardial ischemia-reperfusion injury studies.","Wohlfart P","2013","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent08","rat ischemia reperfusion and cardiomyocyte studies of lixisenatide",1],["R0022767","Effects of glucagon-like peptide 1 analogs in combination with insulin on myocardial infarct size in rats with type 2 diabetes mellitus.","Zykov VA","2018","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent08","diabetic rat myocardial infarction model of GLP-1 analog with insulin",1],["R0022792","Trends in the Degree of Control and Treatment of Cardiovascular Risk Factors in People With Type 2 Diabetes in a Primary Care Setting in Catalonia During 2007-2018.","Mata-Cases M","2021","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent14","serial cross sectional study of risk factor control and drug use trends in Catalonia, utilization only",1],["R0022884","Comparing the Efficacy and Safety of Obeticholic Acid and Semaglutide in Patients With Non-Alcoholic Fatty Liver Disease: A Systematic Review.","Ahmed NR","2022","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent14","systematic review of RCTs and meta-analyses comparing obeticholic acid and semaglutide in NAFLD, several databases searched",1],["R0023021","Once-Weekly Dulaglutide with Insulin Therapy for Type 2 Diabetes: Efficacy and Safety Results from a Phase 4, Randomized, Placebo-Controlled Study.","Ishii H","2020","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent14","phase 4 placebo controlled RCT of dulaglutide added to insulin in Japanese T2D, 16 week double blind period",1],["R0023184","Current treatment of non-alcoholic fatty liver disease.","Paternostro R","2022","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent14","narrative review of current treatment of NAFLD",1],["R0023297","The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity.","Friedrichsen M","2021","include_nma",null,"primary_report","P02",null,"mechanistic","high","first","opus-5.5-agent14","20 week placebo controlled RCT of semaglutide 2.4 mg on gastric emptying, appetite and energy intake in obesity",1],["R0023410","Comparative effectiveness of dipeptidyl peptidase-4 (DPP-4) inhibitors and human glucagon-like peptide-1 (GLP-1) analogue as add-on therapies to sulphonylurea among diabetes patients in the Asia-Pacific region: a systematic review.","Wong MC","2014","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent14","systematic review of DPP-4i and GLP-1 analogue add on to sulfonylurea in Asia Pacific, MEDLINE Embase",1],["R0023561","Evaluation of the Clinical Efficacy of the Treatment of Overweight and Obesity in Type 2 Diabetes Mellitus by the Telemedicine Management System Based on the Internet of Things Technology.","Lin K","2022","inventory_only","N3","primary_report","P01",null,null,"high","first","opus-5.5-agent14","RCT of empagliflozin plus liraglutide vs liraglutide alone in obese T2D, randomized contrast does not change GLP-1 regimen",1],["R0025150","2024 update in heart failure.","Beghini A","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent12","narrative annual update review of heart failure research",1],["R0025294","Efficacy of liraglutide in treating type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease.","Tian F","2018","include_nma",null,"primary_report","P01; P09",null,null,"high","first","opus-5.5-agent12","12 week RCT of liraglutide vs metformin in T2D with NAFLD, liver enzymes, HbA1c and weight",1],["R0025439","Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide.","Astrup A","2012","include_nma",null,"extension","P02",null,null,"high","first","opus-5.5-agent12","2 year extension of RCT of liraglutide doses vs placebo vs orlistat in obesity, randomized comparison kept to year 1",1],["R0025603","Reduction of visceral fat by liraglutide is associated with ameliorations of hepatic steatosis, albuminuria, and micro-inflammation in type 2 diabetic patients with insulin treatment: a randomized control trial.","Bouchi R","2017","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent12","open label RCT of liraglutide plus insulin vs insulin alone in insulin treated T2D, visceral fat and HbA1c",1],["R0025756","Efficacy and safety of liraglutide compared to sulphonylurea during Ramadan in patients with type 2 diabetes (LIRA-Ramadan): a randomized trial.","Azar ST","2016","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent12","LIRA-Ramadan open label RCT liraglutide vs sulfonylurea with metformin in T2D fasting during Ramadan",1],["R0025885","Effects on Subclinical Heart Failure in Type 2 Diabetic Subjects on Liraglutide Treatment vs. Glimepiride Both in Combination with Metformin: A Randomized Open Parallel-Group Study.","Nyström T","2017","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent12","open parallel RCT of liraglutide vs glimepiride with metformin in T2D with subclinical heart failure",1],["R0026002","Long-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone.","Sullivan SD","2009","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent12","CORE diabetes model simulation of long term outcomes of liraglutide vs rosiglitazone using LEAD-1 inputs",1],["R0026120","Combination Therapy With Exenatide Plus Pioglitazone Versus Basal/Bolus Insulin in Patients With Poorly Controlled Type 2 Diabetes on Sulfonylurea Plus Metformin: The Qatar Study.","Abdul-Ghani M","2017","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent12","Qatar RCT of exenatide plus pioglitazone vs basal bolus insulin in poorly controlled T2D",1],["R0017445","Glycaemic control and antidiabetic treatment trends in primary care centres in patients with type 2 diabetes mellitus during 2007-2013 in Catalonia: a population-based study.","Mata-Cases M","2016","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent11","SIDIAP cross sectional trends in antidiabetic prescribing and glycemic control; no GLP-1RA exposure comparison",1],["R0017620","Effect of tirzepatide on weight and metabolism in a multiethnic cohort with and without diabetes.","El Ghandour S","2025","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent11","retrospective single group study of tirzepatide users in Dubai; no comparator",1],["R0017723","Semaglutide Versus Empagliflozin in Uncontrolled Type 2 Diabetes: A Cohort Study With 18 Months of Follow-Up (SEMPA18).","Aristizabal-Colorado D","2025","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent11","small retrospective cohort of semaglutide versus empagliflozin; glycemic, weight and renal measures only",1],["R0017835","Subcutaneous weekly semaglutide with automated insulin delivery in type 1 diabetes: a double-blind, randomized, crossover trial.","Pasqua MR","2025","include_nma",null,"primary_report","P05",null,"crossover","high","first","opus-5.5-agent11","double blind randomized crossover trial of semaglutide versus placebo with automated insulin delivery in type 1 diabetes",1],["R0018039","Efficacy of switching from dipeptidyl peptidase-4 inhibitors to dulaglutide in patients with type 2 diabetes","Chiba K","2019","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent11","retrospective single group study of switching DPP-4i to dulaglutide; no comparator",1],["R0018145","Efficacy and safety of oral semaglutide in Japanese patients with type 2 diabetes: A subgroup analysis by baseline variables in the PIONEER 9 and PIONEER 10 trials.","Yabe D","2022","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent11","PIONEER 9 and 10 subgroup analysis; randomized oral semaglutide versus placebo, liraglutide or dulaglutide",1],["R0023880","Prescription Drugs in Pregnancy and Congenital Malformations: A Population-Based Safety Screening Study.","Broe A","2025","include_harms",null,"primary_report",null,"O120",null,"high","first","opus-5.5-agent18","Danish registry cohort of first trimester exposure to all prescription drugs vs unexposed births; major malformations, liraglutide among flagged drugs",1],["R0024085","Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents.","Buse JB","2010","inventory_only","N1","extension",null,null,null,"high","first","opus-5.5-agent18","nonrandomized 14 week extension of LEAD-6 where exenatide arm switched to liraglutide; arms not compared",1],["R0024240","Treatment of patients with type 2 diabetes with exenatide once weekly versus oral glucose-lowering medications or insulin glargine: achievement of glycemic and cardiovascular goals.","Meloni AR","2013","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent18","retrospective goal attainment analysis of DURATION-2, -3, -4 RCTs, exenatide QW vs metformin, sitagliptin, pioglitazone, glargine",1],["R0024354","The efficacy and tolerability of exenatide in comparison to placebo; a systematic review and meta-analysis of randomized clinical trials.","Nikfar S","2012","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent18","systematic review and meta-analysis of placebo controlled exenatide RCTs in T2D; PubMed, Web of Science, Scopus, Cochrane",1],["R0024551","Effect of treatment with exenatide and pioglitazone or basal-bolus insulin on diabetic neuropathy: a substudy of the Qatar Study.","Ponirakis G","2020","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent18","neuropathy substudy of Qatar open label RCT, exenatide plus pioglitazone vs basal bolus insulin in T2D; HbA1c, weight reported",1],["R0024678","Continuous subcutaneous insulin infusion combined with liraglutide reduced glycemic variability and oxidative stress in type 2 diabetes mellitus: a study based on the flash glucose monitoring system.","Li LQ","2019","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent18","open label RCT of CSII plus liraglutide vs CSII alone in newly diagnosed hospitalized T2D; glycemic variability",1],["R0024789","Real World Use of Antidiabetic Drugs in the Years 2011-2017: A Population-Based Study from Southern Italy.","Ingrasciotta Y","2020","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent18","population based description of antidiabetic drug utilization and persistence in southern Italy; no exposure outcome comparison",1],["R0024932","Effects of liraglutide on gallbladder emptying: A randomized, placebo-controlled trial in adults with overweight or obesity.","Nexøe-Larsen CC","2018","include_nma",null,"primary_report","P02",null,"mechanistic","high","first","opus-5.5-agent18","double blind RCT of liraglutide 3.0 mg vs placebo on gallbladder emptying in overweight or obesity; adverse events reported",1],["R0022805","Weight Loss Outcomes Associated With Semaglutide Treatment for Patients With Overweight or Obesity.","Ghusn W","2022","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent17","retrospective single group Mayo cohort of semaglutide for weight loss; mislabeled as RCT; no comparison group",1],["R0022913","Lixisenatide for Type 2 Diabetes Mellitus Patients Inadequately Controlled on Oral Antidiabetic Drugs: A Mixed-Treatment Comparison Meta-analysis and Cost-Utility Analysis.","Men P","2020","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent17","mixed treatment comparison meta-analysis of RCTs of lixisenatide versus insulin regimens with cost utility, four databases searched",1],["R0023036","Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial.","Smits MM","2016","include_nma",null,"secondary_report","P01",null,"mechanistic","high","first","opus-5.5-agent17","placebo controlled RCT of liraglutide versus sitagliptin versus placebo for 12 weeks on hepatic fat in type 2 diabetes",1],["R0023212","Cost-Effectiveness of Once-Weekly Semaglutide 1 mg versus Canagliflozin 300 mg in Patients with Type 2 Diabetes Mellitus in a Canadian Setting.","Stafford S","2022","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent17","economic simulation of semaglutide versus canagliflozin cost effectiveness from SUSTAIN 8 data",1],["R0023454","A retrospective audit of type 2 diabetes patients prescribed liraglutide in real-life clinical practice.","Mulligan CM","2013","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent17","retrospective single center audit of liraglutide initiators without comparison group",1],["R0023565","Ultrasonographic assessment of the effect of metoclopramide, erythromycin, and exenatide on solid-phase gastric emptying in healthy cats.","Husnik R","2020","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent17","veterinary crossover study of gastric emptying drugs including exenatide in healthy cats",1],["R0023696","Liraglutide Versus Sitagliptin in a 24-week, Multicenter, Open-label, Randomized, Parallel-group Study in Japanese Type 2 Diabetes Mellitus Patients Responding Inadequately to a Sulfonylurea and/or One or Two Other Oral Antidiabetic Drugs (JDDM 33).","Yokoyama H","2014","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent17","open label RCT of liraglutide versus sitagliptin added to sulfonylurea in Japanese type 2 diabetes, 24 weeks",1],["R0024063","Efficacy and Safety of Liraglutide 3.0 mg in Individuals With Overweight or Obesity and Type 2 Diabetes Treated With Basal Insulin: The SCALE Insulin Randomized Controlled Trial.","Garvey WT","2020","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent16","SCALE Insulin double blind RCT of liraglutide 3.0 mg vs placebo in overweight T2D on basal insulin",1],["R0024343","Real-World Effectiveness and Safety of Lixisenatide as Add-On to Oral Antidiabetic Drugs as Part of Routine Clinical Practice in Bulgaria: LIXODAR Study.","Temelkova N","2019","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent16","LIXODAR prospective observational single arm study of lixisenatide add-on in T2D, no comparator",1],["R0024532","Chinese herbal medicine is associated with higher body weight reduction than liraglutide among the obese population: A real-world comparative cohort study.","Liao YN","2022","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent16","retrospective weighted cohort of Chinese herbal medicine vs liraglutide for obesity; weight and hypertension events only",1],["R0024670","SAT-139 Clinical Impact of Oral Semaglutide Compared with Sitagliptin in T2D on Metformin ± Sulfonylurea: The Pioneer 3 Trial","Rosenstock J","2019","include_nma",null,"conference_abstract","P01",null,"abstract_only","high","first","opus-5.5-agent16","conference abstract of PIONEER 3 double blind RCT of oral semaglutide doses vs sitagliptin in T2D",1],["R0024780","Liraglutide and weight loss among patients with advanced heart failure and a reduced ejection fraction: insights from the FIGHT trial.","Sharma A","2018","include_nma",null,"secondary_report","P07B",null,null,"high","first","opus-5.5-agent16","post hoc analysis of FIGHT RCT of liraglutide vs placebo in advanced HFrEF; weight change",1],["R0024928","OR22-1 Liraglutide as Add-on to SGLT2 Inhibitors in Patients with Inadequately Controlled Type 2 Diabetes (LIRA-ADD2SGLT2i): A 26-Week, Randomized, Double-Blind, Placebo-Controlled Trial","Blonde L","2019","include_nma",null,"conference_abstract","P01",null,"abstract_only","high","first","opus-5.5-agent16","conference abstract of LIRA-ADD2SGLT2i double blind RCT of liraglutide vs placebo added to SGLT2i in T2D",1],["R0025036","Cancer and cardiovascular disease: can understanding the mechanisms of cardiovascular injury guide us to optimise care in cancer survivors?","Truong LL","2022","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent16","narrative review of cardiovascular disease prevention in cancer survivors",1],["R0020967","Evaluating the Clinical Effectiveness and Safety of Semaglutide in Individuals with Uncontrolled Type 2 Diabetes. Real-World Evidence from Saudi Arabia: The Observational, Multicenter, 15-Month EVOLUTION Study.","Alsheikh A","2024","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent19","retrospective single arm chart review of semaglutide in uncontrolled type 2 diabetes at Saudi centers",1],["R0022942","Effect of GLP-1 agonists on weight loss in patients with polycystic ovary syndrome and obesity: A single-center study.","Srinivasan D","2022","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent01","retrospective cohort of GLP-1 RA versus metformin monotherapy in PCOS with obesity; weight outcomes only, not randomized",1],["R0023964","Effects of Liraglutide on Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis.","Song T","2021","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent07","meta-analysis of RCTs of liraglutide vs placebo, pioglitazone, metformin or insulin for NAFLD in T2D",1],["R0024139","Glucagon-like peptide 1 (GLP-1).","Müller TD","2019","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent07","narrative review of GLP-1 physiology and pharmacology",1],["R0024462","Anti-atherogenic and anti-inflammatory properties of glucagon-like peptide-1, glucose-dependent insulinotropic polypepide, and dipeptidyl peptidase-4 inhibitors in experimental animals.","Hirano T","2016","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent07","review of the authors animal and cell experiments on incretin agents and atherosclerosis",1],["R0024621","ODP240 Routine Glucose-lowering Therapies and Risk of Adverse Outcomes in COVID-19 Patients with Diabetes: a Network Meta-analysis",null,"2022","include_review",null,"systematic_review",null,null,"abstract_only","high","first","opus-5.5-agent07","conference abstract of Bayesian network meta-analysis of observational studies of glucose lowering drugs including GLP-1RA in COVID-19",1],["R0024734","Response to Comment on Nauck et al. Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial. Diabetes Care 2019;42:1912-1920.","Nauck MA","2020","inventory_only","N9","ancillary",null,null,null,"high","first","opus-5.5-agent07","authors reply on competing risk analysis of gallbladder events in the LEADER RCT",1],["R0024885","Major adverse cardiovascular events' reduction and their association with glucose-lowering medications and glycemic control among patients with type 2 diabetes: A retrospective cohort study using electronic health records.","Hsu H","2024","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent07","EHR cohort of glucose lowering medications including semaglutide and MACE risk in T2D; no listed harm",1],["R0024986","Safety, tolerability and efficacy of lixisenatide in combination with oral antidiabetic treatment in Japanese patients with type 2 diabetes: An open-label, multicenter study.","Seino Y","2018","inventory_only","N1","primary_report",null,null,null,"high","first","opus-5.5-agent07","uncontrolled open label phase 3 study of lixisenatide with four oral drug backgrounds in Japanese T2D",1],["R0021154","Telehealth Intervention to Improve Uptake of Evidence-Based Medications among Patients with Type 2 Diabetes and Heart Failure or Cardiovascular Disease.","Silva-Almodóvar A","2023","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent19","telehealth medication review program to increase SGLT2i or GLP-1 RA uptake; prescribing outcome only",1],["R0021236","Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Lixisenatide and Insulin Glargine, Versus Insulin Glargine in Type 2 Diabetes Inadequately Controlled on Metformin Monotherapy: The LixiLan Proof-of-Concept Randomized Trial.","Rosenstock J","2016","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent19","phase 2 proof of concept RCT of LixiLan fixed ratio lixisenatide glargine vs glargine in metformin treated type 2 diabetes",1],["R0021358","Exenatide once weekly: clinical outcomes and patient satisfaction.","Jose B","2010","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent19","narrative review of exenatide once weekly outcomes and satisfaction with simple Medline search",1],["R0021543","Automated versus manual prior authorization for diabetes mellitus drugs: A retrospective study from Israel.","Moshel S","2023","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent19","automated vs manual prior authorization for SGLT2i and GLP-1 RA; access time outcome only",1],["R0021697","Effect of Liraglutide on Cardiovascular Function and Myocardial Tissue Characteristics in Type 2 Diabetes Patients of South Asian Descent Living in the Netherlands: A Double-Blind, Randomized, Placebo-Controlled Trial.","Paiman EHM","2020","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent19","double blind RCT of liraglutide vs placebo for 26 weeks in South Asian type 2 diabetes, cardiac MRI outcomes",1],["R0021815","Liraglutide dictates macrophage phenotype in apolipoprotein E null mice during early atherosclerosis.","Bruen R","2017","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent19","liraglutide in ApoE null mice and macrophage cell lines; preclinical only",1],["R0023082","The prevalence of cardiovascular diseases, chronic kidney disease, and obesity in patients with type 2 diabetes mellitus and the description of concurrent treatments: A two-center retrospective cross-sectional study in Saudi Arabia.","Alshaya OA","2024","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent01","cross sectional study of comorbidity prevalence and antidiabetic drug use in type 2 diabetes; drug utilization only",1],["R0023223","Effect of race on cardiometabolic responses to once-weekly exenatide: insights from the Exenatide Study of Cardiovascular Event Lowering (EXSCEL).","Davis TME","2022","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent01","race subgroup analysis of EXSCEL RCT, exenatide once weekly versus placebo",1],["R0023325","SGLT2 Inhibitors vs. GLP-1 Agonists to Treat the Heart, the Kidneys and the Brain.","Rolek B","2023","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent01","narrative review comparing SGLT2 inhibitors and GLP-1 RAs for cardiac, renal and brain outcomes",1],["R0023470","Vildagliptin vs liraglutide as a second-line therapy switched from sitagliptin-based regimens in patients with type 2 diabetes: A randomized, parallel-group study.","Takeshita Y","2015","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent01","open label RCT switching from sitagliptin to vildagliptin versus liraglutide in type 2 diabetes",1],["R0023599","Treatment of type 2 diabetes in chronic kidney disease: a case for linagliptin in the treatment of diabetes in severe renal impairment.","Scott D","2013","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent01","commentary on a linagliptin RCT in severe renal impairment; DPP-4 inhibitor only, no GLP-1 RA",1],["R0023722","Efficacy and safety of once-weekly dulaglutide versus insulin glargine in mainly Asian patients with type 2 diabetes mellitus on metformin and/or a sulphonylurea: A 52-week open-label, randomized phase III trial.","Wang W","2019","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent01","52 week open label RCT of dulaglutide 1.5 or 0.75 mg versus insulin glargine in mainly Asian type 2 diabetes",1],["R0023905","Prevention and intervention against obesity and overweight in the military: a systematic review.","Scheit L","2025","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent01","systematic review of military obesity interventions; pharmacological studies concern fat absorption drugs, no GLP-1 RA contrast",1],["R0020754","Effects of Aerobic Training and Semaglutide Treatment on Pancreatic β-Cell Secretory Function in Patients With Type 2 Diabetes.","Ingersen A","2023","include_nma",null,"primary_report","P01",null,"mechanistic","high","first","opus-5.5-agent02","randomized trial of aerobic training alone vs training plus semaglutide in T2D on beta cell function",1],["R0020871","Liraglutide combined with routine therapy improves renal function, renal fibrosis, immune status, and prognosis of type 2 diabetes patients.","Xiong W","2024","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent02","retrospective comparison of liraglutide plus routine therapy vs routine therapy in T2D; renal markers and nonspecific adverse reactions",1],["R0020993","A Randomized Trial Investigating the Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Semaglutide Once-Weekly in Healthy Male Japanese and Caucasian Subjects.","Ikushima I","2018","include_nma",null,"primary_report","P99",null,"mechanistic","high","first","opus-5.5-agent02","randomized double blind placebo controlled semaglutide PK trial in healthy Japanese and Caucasian men reporting weight and safety",1],["R0021160","Identifying and predicting fast versus slow Parkinson's disease motor progressors using clinical and digital data.","Aubourg T","2026","include_nma",null,"secondary_report","P13B",null,null,"high","first","opus-5.5-agent02","digital substudy of Exenatide-PD3 placebo controlled RCT in Parkinson disease comparing progression by arm",1],["R0021254","Cost-minimization analysis of degludec/liraglutide versus glargine/aspart: economic implications of the DUAL VII study outcomes.","Torre E","2018","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent02","cost minimization model of IDegLira vs basal bolus based on DUAL VII results",1],["R0021370","HbA1c Reduction in Dulaglutide-Treated Patients Irrespective of Duration of Diabetes, Microvascular Disease, and BMI: A Post Hoc Analysis From the REWIND Trial.","Kwan AYM","2022","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent02","post hoc HbA1c analysis of REWIND placebo controlled RCT of dulaglutide in T2D",1],["R0021460","Semaglutide 2.4 Mg for the Management of Overweight and Obesity: Systematic Literature Review and Meta-Analysis.","Smith I","2022","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent02","systematic literature review with network meta-analysis of semaglutide 2.4 mg vs weight management comparators",1],["R0021555","Chronic administration of the glucagon-like peptide-1 analog, liraglutide, delays the onset of diabetes and lowers triglycerides in UCD-T2DM rats.","Cummings BP","2010","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent02","liraglutide vs food restriction vs control in UCD-T2DM rats; animal study only",1],["R0026503","Effect of liraglutide on physical performance in type 2 diabetes (LIPER2): A randomised, double-blind, controlled trial.","Wägner AM","2016","inventory_only","N8","protocol_or_design","P01",null,null,"high","first","opus-5.5-agent03","design paper of LIPER2 RCT of liraglutide vs placebo on physical performance in T2D; recruitment ongoing, no results",1],["R0026826","Clinical and Physiological Characterization of Elevated Plasma Glucagon-Like Peptide-1 Levels (Hyperglipemia) in a Dipeptidyl Peptidase IV Mutation Carrier.","Zhao D","2018","exclude","E2","primary_report",null,null,null,"high","first","opus-5.5-agent03","genetic study of a DPP4 mutation carrier with high endogenous GLP-1; no GLP-1 RA drug",1],["R0027008","Short-term use of liraglutide in the management of patients with weight regain after bariatric surgery.","Pajecki D","2013","inventory_only","N5","primary_report",null,null,"non_english","high","first","opus-5.5-agent03","Portuguese retrospective case series of 15 post bariatric patients given liraglutide for weight regain",1],["R0027162","Four weeks of treatment with liraglutide reduces insulin dose without loss of glycemic control in type 1 diabetic patients with and without residual beta-cell function.","Kielgast U","2011","include_nma",null,"primary_report","P05",null,null,"high","first","opus-5.5-agent03","4 week study in type 1 diabetes; C-peptide negative patients randomized to liraglutide plus insulin vs insulin alone",1],["R0027336","Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial.","Russell-Jones D","2009","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent03","LEAD-5 26 week RCT of liraglutide vs placebo vs insulin glargine on metformin and glimepiride",1],["R0027636","Coadministration of glucagon-like peptide-1 during glucagon infusion in humans results in increased energy expenditure and amelioration of hyperglycemia.","Tan TM","2013","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent03","randomized crossover infusion of native GLP-1 and glucagon in overweight volunteers; no therapeutic GLP-1 RA",1],["R0022565","The Antidiabetic Armamentarium: Reducing the Residual Cardiovascular Risk with HbA1c(v)-Lowering Medications : Editorial to: \"GLP-1 Receptor Agonists and Cardiovascular Disease: A Meta-Analysis of Recent Cardiac Outcome Trials\" by Jia X, Alam M, Ye Y et al.","Stryker MD","2018","inventory_only","N9","ancillary",null,null,null,"high","first","opus-5.5-agent13","editorial commenting on a meta-analysis of GLP-1 agonist cardiovascular outcome trials",1],["R0022689","Efficacy and safety of oral semaglutide in patients with non-alcoholic fatty liver disease complicated by type 2 diabetes mellitus: A pilot study.","Arai T","2022","inventory_only","N1","primary_report",null,null,null,"high","first","opus-5.5-agent13","single arm open label pilot of oral semaglutide in NAFLD with type 2 diabetes",1],["R0022785","Cost of achieving HbA1c and weight loss treatment targets with IDegLira vs insulin glargine U100 plus insulin aspart in the USA.","Billings LK","2019","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent13","cost of control economic analysis of IDegLira vs basal bolus insulin using DUAL VII data",1],["R0022880","Quality of care and prescription patterns among patients with diabetic kidney disease-a large-scale cohort study from Taiwanese clinics.","Tsai KY","2022","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent13","chart review of quality of care and prescribing patterns in diabetic kidney disease, no GLP-1 exposure comparison",1],["R0023012","Evaluation of the Effectiveness of Liraglutide on Metabolic Parameters in the Treatment of Obesity.","Akkurt Kocaeli A","2023","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent13","retrospective single center series of liraglutide 3.0 mg users without comparison group",1],["R0023164","Involvement of a serotonin/GLP-1 circuit in adolescent isolation-induced diabetes.","Kolling LJ","2023","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent13","mouse study of adolescent isolation and serotonin GLP-1 circuit, no human participants",1],["R0023293","Empagliflozin and Decreased Risk of Nephrolithiasis: A Potential New Role for SGLT2 Inhibition?","Balasubramanian P","2022","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent13","pooled analysis of empagliflozin vs placebo RCTs on nephrolithiasis, no GLP-1 exposure",1],["R0023408","Beyond lecanemab: Examining Phase III potential in Alzheimer's therapeutics.","Osaka H","2024","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent13","narrative review of phase 3 Alzheimer drug candidates including semaglutide",1],["R0026485","Islet Autoimmunity in Adults With Impaired Glucose Tolerance and Recently Diagnosed, Treatment Naïve Type 2 Diabetes in the Restoring Insulin SEcretion (RISE) Study.","Brooks-Worrell BM","2021","include_nma",null,"secondary_report","P06; P01",null,null,"high","first","opus-5.5-agent20","ancillary islet autoimmunity study within randomized RISE trial including liraglutide plus metformin vs metformin or placebo",1],["R0026640","Liraglutide effect in reducing HbA1c and weight in Arab population with type2 diabetes, a prospective observational trial.","Bashier AM","2015","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent20","prospective observational single arm study of liraglutide add-on in Arab T2D, no comparison group",1],["R0026788","A comparison of clinical pharmacist management of type 2 diabetes versus usual care in a federally qualified health center.","Fink RM","2019","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent20","cohort comparing pharmacist vs usual care prescribing patterns in T2D, GLP-1 RA only as a prescribing outcome",1],["R0026992","Effects of intravenous exenatide in type 2 diabetic patients with congestive heart failure: a double-blind, randomised controlled clinical trial of efficacy and safety.","Nathanson D","2012","include_nma",null,"primary_report","P01; P07B",null,"mechanistic; crossover","high","first","opus-5.5-agent20","double blind randomized crossover of IV exenatide vs placebo in T2D with HFrEF, hemodynamics and adverse events",1],["R0027147","Painful diabetic neuropathy is associated with increased nerve regeneration in patients with type 2 diabetes undergoing intensive glycemic control.","Ponirakis G","2021","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent20","exploratory neuropathy substudy of RCT of exenatide plus pioglitazone vs basal bolus insulin in T2D",1],["R0027284","Sequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by randomized addition of basal insulin prompted by A1C targets.","DeVries JH","2012","inventory_only","N3","primary_report",null,null,null,"high","first","opus-5.5-agent20","randomized addition of detemir vs none on liraglutide plus metformin in both arms after liraglutide run in",1],["R0027602","Non-invasive quantification of the beta cell mass by SPECT with ¹¹¹In-labelled exendin.","Brom M","2014","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent20","radiolabeled exendin SPECT imaging of beta cell mass in rats and humans, diagnostic tracer only",1],["R0027861","SUN-LB115 Is the Stepping-Down Approach a Better Option Than Multiple Daily Injections in Patients With Chronic Poorly-Controlled Diabetes on Advanced Insulin Therapy?","Naing S","2020","include_nma",null,"conference_abstract","P01",null,"abstract_only","high","first","opus-5.5-agent06","conference abstract of pilot RCT of step down to basal insulin plus dulaglutide and empagliflozin versus continued MDI in obese T2D",1],["R0028447","The Association Between Metformin Treatment and Outcomes in Type 2 Diabetes Mellitus Patients With Heart Failure With Preserved Ejection Fraction: A Retrospective Study.","Wang J","2021","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent06","retrospective cohort of metformin versus no metformin in T2D with HFpEF; no GLP-1 RA exposure",1],["R0029187","Comment on: Association of glucagon-like peptide receptor 1 agonist therapy with the presence of gastric contents in fasting patients undergoing endoscopy under anesthesia care: a historical cohort study.","Mizubuti GB","2024","inventory_only","N9","ancillary",null,null,null,"high","first","opus-5.5-agent06","letter commenting on a cohort of GLP-1 RA use and residual gastric contents at endoscopy",1],["R0029781","Monomeric GLP-1/GIP/glucagon triagonism corrects obesity, hepatosteatosis, and dyslipidemia in female mice.","Jall S","2017","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent06","diet induced obese mouse study of GLP-1, GIP and glucagon triagonist",1],["R0018262","IDegLira Improves Both Fasting and Postprandial Glucose Control as Demonstrated Using Continuous Glucose Monitoring and a Standardized Meal Test.","Holst JJ","2015","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent10","meal test and CGM substudy of DUAL I RCT IDegLira versus degludec versus liraglutide; postprandial glucose",1],["R0018384","Obesity Treatments to Improve Type 1 Diabetes (OTID): a randomized controlled trial of the combination of glucagon-like peptide 1 analogues and sodium-glucose cotransporter 2 inhibitors-protocol for Obesity Treatments to Improve Type 1 Diabetes (the OTID trial).","Al-Ozairi E","2024","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent10","protocol of OTID RCT of GLP-1 RA and SGLT2i combinations in type 1 diabetes with CKD",1],["R0018480","OR09-07 Dynamic Proteomic Profiling in a 5-week Crossover Trial of Liraglutide in Obesity Reveals Weight-Dependent Myostatin Downregulation and Multi-Pathway Effects Beyond Weight Reduction",null,"2025","include_nma",null,"conference_abstract","P02",null,"abstract_only; crossover; mechanistic","high","first","opus-5.5-agent10","abstract of 5 week crossover RCT liraglutide 3 mg versus placebo in obesity; proteomics plus weight",1],["R0018596","Suitability and Usefulness of a Flexible Dosing Timing of Oral Semaglutide to Maximize Benefit in Clinical Practice: An Expert Panel.","Candido R","2024","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent10","Italian expert panel review and recommendations on flexible oral semaglutide dosing; opinion",1],["R0018951","Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical Trial.","Merola JF","2026","include_nma",null,"primary_report","P99",null,null,"high","first","opus-5.5-agent10","TOGETHER-PsA RCT ixekizumab plus tirzepatide versus ixekizumab alone in psoriatic arthritis with obesity",1],["R0019060","Anti-inflammatory effect of semaglutide: updated systematic review and meta-analysis.","Masson W","2024","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent10","PROSPERO registered meta-analysis of semaglutide RCTs on CRP versus placebo or control; four databases",1],["R0018258","Treatment with a GLP-1 receptor agonist diminishes the decrease in free plasma leptin during maintenance of weight loss.","Iepsen EW","2015","include_nma",null,"primary_report","P02",null,null,"high","first","opus-5.5-agent09","RCT of liraglutide 1.2 mg versus no drug for weight maintenance after diet induced weight loss in obese adults, leptin outcomes",1],["R0018364","US Population Eligibility and Estimated Impact of Tirzepatide Treatment on Obesity Prevalence and Cardiovascular Disease Events.","Wong ND","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent09","NHANES based projection of tirzepatide eligibility and preventable cardiovascular events, modeling",1],["R0018479","Exenatide once weekly: sustained improvement in glycemic control and cardiometabolic measures through 3 years.","Macconell L","2013","inventory_only","N1","extension",null,null,null,"high","first","opus-5.5-agent09","DURATION-1 three year open label extension where all patients received exenatide weekly regardless of randomization",1],["R0018595","Sperm count is increased by diet-induced weight loss and maintained by exercise or GLP-1 analogue treatment: a randomized controlled trial.","Andersen E","2022","include_nma",null,"secondary_report","P02",null,null,"high","first","opus-5.5-agent09","semen substudy of S-LiTE RCT randomizing liraglutide, exercise, both or placebo after diet induced weight loss in men with obesity",1],["R0018825","Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials.","Ahrén B","2018","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent09","post hoc by trial analysis of SUSTAIN 1 to 5 randomized semaglutide trials on weight loss by BMI and GI events",1],["R0018950","Cost Effectiveness of Insulin Degludec Plus Liraglutide (IDegLira) in a Fixed Combination for Uncontrolled Type 2 Diabetes Mellitus in Sweden.","Ericsson Å","2017","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent09","cohort model cost effectiveness analysis of IDegLira in Sweden",1],["R0019732","Glucagon-like peptide-1 receptors in the brain: controlling food intake and body weight.","Baggio LL","2014","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent15","journal commentary on two animal studies of central GLP-1 receptors and weight",1],["R0019855","The effects of exenatide and insulin glargine treatments on bone turnover markers and bone mineral density in postmenopausal patients with type 2 diabetes mellitus.","Akyay OZ","2023","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent15","open label RCT of exenatide versus insulin glargine for 24 weeks in postmenopausal women with type 2 diabetes; bone markers",1],["R0019929","The effects of subcutaneous Tirzepatide on obesity and overweight: a systematic review and meta-regression analysis of randomized controlled trials.","Rohani P","2023","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent15","systematic review and meta-regression of RCTs of subcutaneous tirzepatide on weight; five databases searched",1],["R0020033","Evolution of exenatide as a diabetes therapeutic.","Bhavsar S","2013","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent15","narrative review of exenatide development from preclinical work to phase 3 trials",1],["R0020184","Clinical experience with Liraglutide in 196 patients with type 2 diabetes from a tertiary care center in India.","Kaur P","2014","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent15","observational single group series of 196 liraglutide treated patients in India; before and after changes",1],["R0020430","Impact of GLP-1 receptor agonists on major gastrointestinal disorders for type 2 diabetes mellitus: a mixed treatment comparison meta-analysis.","Sun F","2012","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent15","mixed treatment comparison meta-analysis of RCTs of exenatide and liraglutide doses on GI adverse events; three databases",1],["R0020538","Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept.","Briere DA","2025","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent15","discovery and phase 1 study of eloralintide, an amylin receptor agonist without GLP-1 activity",1],["R0022852","Comparisons between dipeptidyl peptidase-4 inhibitors and other classes of hypoglycemic drugs using two distinct biomarkers of pancreatic beta-cell function: A meta-analysis.","Takahashi M","2020","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent08","meta-analysis of RCTs comparing DPP-4i with other classes incl GLP-1 analogues on beta cell biomarkers; MEDLINE, CENTRAL",1],["R0022995","Pathophysiology and Management of Glycemic Alterations before and after Surgery for Pheochromocytoma and Paraganglioma.","Lopez C","2023","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent08","narrative review of glycemic alterations in pheochromocytoma and paraganglioma",1],["R0023138","Report from the 5th cardiovascular outcome trial (CVOT) summit.","Schnell O","2020","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent08","meeting report of the 5th cardiovascular outcome trial summit",1],["R0023259","Efficacy and safety of dulaglutide monotherapy compared with glimepiride in Chinese patients with type 2 diabetes: Post-hoc analyses of a randomized, double-blind, phase III study.","Shi LX","2020","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent08","post hoc Chinese subgroup of double blind RCT of dulaglutide doses versus glimepiride monotherapy",1],["R0023369","Long-term efficacy and safety of oral semaglutide and the effect of switching from sitagliptin to oral semaglutide in patients with type 2 diabetes: a 52-week, randomized, open-label extension of the PIONEER 7 trial.","Buse JB","2020","include_nma",null,"extension","P01",null,null,"high","first","opus-5.5-agent08","PIONEER 7 extension with rerandomization of sitagliptin users to oral semaglutide or continued sitagliptin",1],["R0023631","Effects of oral semaglutide on energy intake, food preference, appetite, control of eating and body weight in subjects with type 2 diabetes.","Gibbons C","2021","include_nma",null,"primary_report","P01",null,"crossover; mechanistic","high","first","opus-5.5-agent08","crossover RCT of oral semaglutide versus placebo for 12 weeks on energy intake and body weight in type 2 diabetes",1],["R0023785","Effect of Liraglutide on Cardiometabolic Risk Profile in People with Coronary Artery Disease with or without Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.","Nowrouzi-Sohrabi P","2021","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent08","meta-analysis of RCTs of liraglutide versus placebo on cardiometabolic risk in coronary artery disease; six databases",1],["R0026299","Cardiac Autonomic Neuropathy in Obesity, the Metabolic Syndrome and Prediabetes: A Narrative Review.","Williams SM","2019","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent12","narrative review of cardiac autonomic neuropathy in obesity, metabolic syndrome and prediabetes",1],["R0024962","Effectiveness and safety of exenatide in Korean patients with type 2 diabetes inadequately controlled with oral hypoglycemic agents: an observational study in a real clinical practice.","Hwang YC","2017","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent04","post hoc of single arm observational post marketing study of exenatide twice daily in Korea, no comparison group",1],["R0025208","Effects of incretin treatment on cardiovascular outcomes in diabetic STEMI-patients with culprit obstructive and multivessel non obstructive-coronary-stenosis.","Marfella R","2018","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent04","STEMI cohort of diabetic incretin users incl GLP-1 RA or DPP-4i vs never users, deaths and MACE only",1],["R0025397","Exenatide once weekly improved 24-hour glucose control and reduced glycaemic variability in metformin-treated participants with type 2 diabetes: a randomized, placebo-controlled trial.","Frías JP","2017","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent04","double blind RCT of exenatide once weekly vs placebo on metformin with continuous glucose monitoring",1],["R0025557","The Diabetes Unmet Need with Basal Insulin Evaluation (DUNE) study in type 2 diabetes: Achieving HbA1c targets with basal insulin in a real-world setting.","Meneghini LF","2019","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent04","DUNE single arm observational study of basal insulin initiators, GLP-1 RA only permitted background",1],["R0025971","An association between liraglutide treatment and reduction in excessive daytime sleepiness in obese subjects with type 2 diabetes.","Gomez-Peralta F","2015","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent04","retrospective single group of obese type 2 diabetes patients starting liraglutide, sleepiness change, no comparison group",1],["R0026443","The glucagon-like peptide-1 receptor as a potential treatment target in alcohol use disorder: evidence from human genetic association studies and a mouse model of alcohol dependence.","Suchankova P","2015","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent12","human GLP1R genetic association studies plus mouse GLP-1RA experiment, no GLP-1RA given to humans",1],["R0026563","Baseline factors associated with glycemic control and weight loss when exenatide twice daily is added to optimized insulin glargine in patients with type 2 diabetes.","Rosenstock J","2012","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent12","exploratory subgroup analysis of RCT of exenatide twice daily vs placebo added to optimized insulin glargine",1],["R0026751","New Horizons. A New Paradigm for Treating to Target with Second-Generation Obesity Medications.","Garvey WT","2022","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent12","perspective review proposing treat to target paradigm with second generation obesity drugs",1],["R0026932","Clinical trial risk in type-2 diabetes: importance of patient history.","Aiyere EO","2014","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent12","analysis of clinical trial success rates of diabetes drug candidates from registry, no patient level drug exposure comparison",1],["R0027085","Descriptive analysis of reported adverse events associated with anti-obesity medications using FDA Adverse Event Reporting System (FAERS) databases 2013-2020.","Alsuhibani A","2022","inventory_only","N5","other",null,null,null,"high","first","opus-5.5-agent12","descriptive FAERS analysis of adverse event reports for anti-obesity medications including liraglutide",1],["R0027243","The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men.","Agersø H","2002","include_nma",null,"primary_report","P99",null,"mechanistic","high","first","opus-5.5-agent12","phase 1 dose escalation RCT of NN2211 liraglutide vs placebo in healthy men, PK and adverse events including nausea",1],["R0018267","Efficacy and safety of tirzepatide versus placebo in overweight or obese adults without diabetes: a systematic review and meta-analysis of randomized controlled trials.","Liu L","2024","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent11","registered meta-analysis of tirzepatide versus placebo RCTs in obesity without diabetes; PubMed, Embase, Cochrane",1],["R0018388","Biological and Biosimilar Medicines in Contemporary Pharmacotherapy for Metabolic Syndrome.","Górecka W","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent11","narrative review of biologic and biosimilar drugs for metabolic syndrome",1],["R0018489","Impact of Ambulatory Care Pharmacist-Led Management on Hemoglobin A1c Values among Patients with Uncontrolled Diabetes in a Primary Care Clinic vs Usual Care over Two Years.","Mohammad I","2023","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent11","pharmacist led care versus usual care cohort; GLP-1RA prescribing only an outcome, not an exposure",1],["R0018598","5185 A Meta-Analysis Evaluating the Efficacy of Liraglutide in Reducing Cardiovascular Complications Among Patients With Type 2 Diabetes",null,"2024","include_review",null,"systematic_review",null,null,"abstract_only","high","first","opus-5.5-agent11","abstract of meta-analysis of liraglutide versus placebo RCTs on cardiovascular outcomes; PubMed and ScienceDirect searched",1],["R0018843","Effects of 3-month liraglutide treatment on oxidative stress and inflammation in type 2 diabetes patients with different urinary albumin-to-creatinine ratio categories.","Chen S","2024","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent11","observational single group liraglutide initiators stratified by albuminuria; no untreated comparator",1],["R0018963","Liraglutide Effect on Weight and A1C in Patients with Type 2 Diabetes Mellitus: Real-World Data from a Single Tertiary Care Center in Saudi Arabia.","AlRashidi A","2024","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent11","retrospective single group liraglutide study in Saudi Arabia; no comparator",1],["R0019087","The adolescent with obesity: what perspectives for treatment?","Nicolucci A","2022","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent11","narrative review of adolescent obesity treatment",1],["R0025051","Effects of liraglutide, metformin and gliclazide on body composition in patients with both type 2 diabetes and non-alcoholic fatty liver disease: A randomized trial.","Feng WH","2019","include_nma",null,"primary_report","P01; P09",null,null,"high","first","opus-5.5-agent18","RCT of liraglutide vs metformin vs gliclazide monotherapy for 24 weeks in T2D with NAFLD; body composition, HbA1c",1],["R0025180","Sustained usage of an app-based clinical-decision making aid for the management of atherosclerotic cardiovascular disease",null,"2022","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent18","conference abstract on usage of a clinical decision app for ASCVD risk therapies; no GLP-1 RA exposure comparison",1],["R0025354","Liraglutide suppresses non-esterified free fatty acids and soluble vascular cell adhesion molecule-1 compared with metformin in patients with recent-onset type 2 diabetes.","Chen XM","2018","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent18","8 week RCT of liraglutide vs metformin in young adults with recent onset T2D; NEFA, sVCAM-1, insulin secretion",1],["R0025480","Effectiveness and tolerability of second-line treatment with vildagliptin versus other oral drugs for type 2 diabetes in a real-world setting in the Middle East: results from the EDGE study.","Saab C","2015","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent18","EDGE observational study of vildagliptin vs other oral drugs; GLP-1 RA users excluded",1],["R0025660","Population pharmacokinetics of exenatide.","Cirincione B","2017","inventory_only","N2","other",null,null,null,"high","first","opus-5.5-agent18","population PK model of immediate release exenatide pooled from eight studies; no review outcome reported",1],["R0025791","A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study.","Nauck MA","2007","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent18","52 week open label noninferiority RCT of exenatide twice daily vs biphasic insulin aspart on metformin and sulfonylurea",1],["R0025923","Exenatide Add-on to Continuous Subcutaneous Insulin Infusion Therapy Reduces Bolus Insulin Doses in Patients with Type 2 Diabetes: A Randomized, Controlled, Open-Label Trial.","Li FF","2017","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent18","open label RCT of exenatide add on to CSII vs CSII alone in uncontrolled T2D for 5 weeks",1],["R0026019","LBSUN151 The Impact Of The COVID-19 Pandemic On Diabetes & Weight Management",null,"2022","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent18","abstract on pandemic effects on HbA1c and weight in a diabetes clinic; GLP-1 RA use only a covariate",1],["R0024039","OR33-01 Liraglutide for Weight Management in Pubertal Adolescents with Obesity: A Randomized Controlled Trial","Kelly A","2020","include_nma",null,"conference_abstract","P03",null,"abstract_only","high","first","opus-5.5-agent14","conference abstract of placebo controlled RCT of liraglutide 3.0 mg in adolescents with obesity",1],["R0024329","A Multidisciplinary Approach for Improving Quality of Life and Self-Management in Diabetic Kidney Disease: A Crossover Study.","Helou N","2020","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent14","randomized crossover trial of multidisciplinary self management in diabetic kidney disease, no GLP-1 RA intervention",1],["R0024515","Liraglutide use and evaluation of pancreatic outcomes in a US commercially insured population.","Funch D","2019","include_harms",null,"primary_report",null,"O29; O38",null,"high","first","opus-5.5-agent14","new user active comparator cohort of liraglutide vs other antidiabetic initiators, acute pancreatitis and pancreatic cancer",1],["R0024661","Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly alone, or dapagliflozin alone added to metformin monotherapy in subgroups of patients with type 2 diabetes in the DURATION-8 randomized controlled trial.","Frías JP","2018","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent14","subgroup analysis of DURATION-8 RCT of exenatide plus dapagliflozin vs each alone",1],["R0028958","A Survey of Patient-Relevant Outcomes in Pediatric Craniopharyngioma: Focus on Hypothalamic Obesity.","Craven M","2022","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent20","caregiver survey in pediatric craniopharyngioma, GLP-1 RA only among medications reported tried, no exposure comparison",1],["R0029656","Renal Impairment Does Not Affect Pharmacokinetics, Safety or Tolerability of Zenagamtide.","Oldenburg LIK","2026","inventory_only","N1","primary_report",null,null,null,"high","first","opus-5.5-agent20","open label single dose PK study of zenagamtide across renal function groups, all received drug, no randomized contrast",1],["R0025171","Lixisenatide improves glycemic outcomes of Japanese patients with type 2 diabetes: a meta-analysis.","Seino H","2016","include_nma",null,"pooled_analysis","P01",null,null,"high","first","opus-5.5-agent16","meta-analysis of Japanese participants pooled from GetGoal-L-Asia and GetGoal-S lixisenatide vs placebo RCTs; not a systematic search",1],["R0025346","Efficacy and safety of taspoglutide monotherapy in drug-naive type 2 diabetic patients after 24 weeks of treatment: results of a randomized, double-blind, placebo-controlled phase 3 study (T-emerge 1).","Raz I","2012","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent16","T-emerge 1 double blind RCT of taspoglutide 10 or 20 mg vs placebo in drug naive T2D",1],["R0025476","Prescription of glucose-lowering therapies and risk of COVID-19 mortality in people with type 2 diabetes: a nationwide observational study in England.","Khunti K","2021","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent16","national cohort of glucose lowering drug prescription incl. GLP-1RA and COVID-19 mortality; no listed harm",1],["R0025628","The Multicenter, Open-Label, Observational LEAD-Ph Study: Real-World Safety and Effectiveness of Liraglutide in Filipino Participants with Type 2 Diabetes.","Jimeno C","2018","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent16","LEAD-Ph prospective single arm observational study of liraglutide safety in Filipino T2D",1],["R0025914","Association between metformin use and below-the-knee arterial calcification score in type 2 diabetic patients.","Mary A","2017","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent16","cross sectional DIACART study of antidiabetic drugs incl. GLP-1 analogues and arterial calcification",1],["R0026149","New association of bone morphogenetic protein 4 concentrations with fat distribution in obesity and Exenatide intervention on it.","Wang X","2017","inventory_only","N1","primary_report",null,null,null,"high","first","opus-5.5-agent16","single group 18 week exenatide treatment in obese patients with cross sectional BMP-4 analysis, no concurrent comparator",1],["R0021706",null,null,null,"include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent02","post hoc cytokine analysis of CONFIDENCE RCT of exenatide vs insulin vs pioglitazone in newly diagnosed T2D",1],["R0027805","Effects of exenatide plus rosiglitazone on beta-cell function and insulin sensitivity in subjects with type 2 diabetes on metformin.","DeFronzo RA","2010","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent03","20 week RCT of exenatide vs rosiglitazone vs combination on metformin in T2D with clamp studies",1],["R0021892","Effects of semaglutide on beta cell function and glycaemic control in participants with type 2 diabetes: a randomised, double-blind, placebo-controlled trial.","Kapitza C","2017","include_nma",null,"primary_report","P01",null,"mechanistic","high","first","opus-5.5-agent02","randomized double blind placebo controlled 12 week semaglutide trial on beta cell function and glycemic control in T2D",1],["R0022065","Discontinuation and reinitiation of SGLT-2 inhibitors and GLP-1R agonists in patients with type 2 diabetes: a nationwide study from 2013 to 2021.","Malik ME","2023","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent02","Danish registry persistence and reinitiation of SGLT2 inhibitors and GLP-1 RA; drug utilization without outcome comparison",1],["R0022179","New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2024.","Tamargo J","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent02","narrative annual review of new cardiovascular pharmacotherapy in 2024",1],["R0022277","Efficacy and safety of once-weekly semaglutide in Japanese individuals with type 2 diabetes by baseline age and body mass index.","Yabe D","2022","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent02","post hoc subgroup analysis of SUSTAIN Japan RCTs of semaglutide vs sitagliptin or oral drugs",1],["R0022511","Semaglutide as a therapeutic option for elderly patients with type 2 diabetes: Pooled analysis of the SUSTAIN 1-5 trials.","Warren M","2018","include_nma",null,"pooled_analysis","P01",null,null,"high","first","opus-5.5-agent02","pooled post hoc analysis of SUSTAIN 1 to 5 RCTs of semaglutide vs comparators by age group",1],["R0022626","Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia).","Seino Y","2012","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent02","GetGoal-L-Asia randomized placebo controlled trial of lixisenatide on basal insulin in Asian T2D",1],["R0028201","Endogenous GLP-1 mediates postprandial reductions in activation in central reward and satiety areas in patients with type 2 diabetes.","ten Kulve JS","2015","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent03","randomized crossover infusion of GLP-1 antagonist exendin 9-39 vs saline to study endogenous GLP-1; no therapeutic GLP-1 RA",1],["R0029103","Potential of Sodium-Glucose Cotransporter-2 Inhibitors in the Management of Heart Failure With Preserved Ejection Fraction: A Narrative Review.","Alsuwayh AF","2024","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent03","narrative review of SGLT2 inhibitors in HFpEF",1],["R0029688","Innovative Glucagon-based Therapies for Obesity.","Enyew Belay K","2024","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent03","narrative review of glucagon based and multi agonist obesity therapies",1],["R0023867","Simplification of complex insulin regimens using canagliflozin or liraglutide in patients with well-controlled type 2 diabetes: A 24-week randomized controlled trial.","Ando Y","2021","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent17","open label RCT switching bolus insulin to canagliflozin versus liraglutide in well controlled type 2 diabetes, 24 weeks",1],["R0024071","Effects of Liraglutide on Left Ventricular Function: A Meta-Analysis of Randomized, Placebo-Controlled Trials.","Zhong Z","2021","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent17","meta-analysis of placebo controlled RCTs of liraglutide on left ventricular function, four databases searched",1],["R0024237","Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5.","Kushner RF","2020","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent17","design and baseline characteristics paper for STEP 1 to 5 semaglutide RCTs before results",1],["R0024352","Lower rates of cardiovascular events and mortality associated with liraglutide use in patients treated with basal insulin: A DEVOTE subanalysis (DEVOTE 10).","Brown-Frandsen K","2019","inventory_only","N6","secondary_report",null,null,null,"high","first","opus-5.5-agent17","DEVOTE subanalysis comparing nonrandomized concomitant liraglutide use versus none on MACE and mortality",1],["R0024549","Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial.","McCrimmon RJ","2020","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent17","DXA body composition substudy of SUSTAIN 8 RCT of semaglutide versus canagliflozin in type 2 diabetes",1],["R0024672","Effect of liraglutide on cardiac function in patients with type 2 diabetes mellitus: randomized placebo-controlled trial.","Bizino MB","2019","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent17","MAGNA VICTORIA placebo controlled RCT of liraglutide on cardiac function in type 2 diabetes, 26 weeks",1],["R0024787","Circulating zinc-α2-glycoprotein is reduced in women with polycystic ovary syndrome, but can be increased by exenatide or metformin treatment.","Zheng S","2019","include_nma",null,"primary_report","P12",null,"mechanistic","high","first","opus-5.5-agent17","PCOS case control biomarker study with nested 12 week RCT of exenatide versus metformin in overweight women",1],["R0024929","Understanding the cardiovascular effects of incretin.","Yoon JS","2011","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent17","narrative review of cardiovascular effects of incretin therapies",1],["R0022050","The effect of liraglutide on weight loss in women with polycystic ovary syndrome: an observational study.","Rasmussen CB","2014","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent19","observational single group study of liraglutide weight loss in women with PCOS; no comparison group; mislabeled as RCT",1],["R0023556","Assessment of Cardiovascular Risk Categories and Achievement of Therapeutic Targets in European Patients with Type 2 Diabetes.","Reurean-Pintilei D","2024","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent13","cross sectional study of cardiovascular risk categories, target attainment and drug use rates in diabetes, no GLP-1 exposure comparison",1],["R0025110","Diabetes, metformin and glucose lowering therapies after myocardial infarction: Insights from the SWEDEHEART registry.","Ritsinger V","2020","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent07","SWEDEHEART registry cohort after MI comparing glucose lowering regimens including an SGLT2i or GLP-1RA group; MACE and mortality only",1],["R0022146","Prevalence of Sarcopenia in Insulin Treated Older Adults with Type 2 Diabetes","Leite SAO","2023","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent19","cross sectional sarcopenia prevalence in insulin treated older adults; GLP-1 RA users excluded",1],["R0022256","Serum Fetuin-B Levels Are Elevated in Women with Metabolic Syndrome and Associated with Increased Oxidative Stress.","Xue S","2021","inventory_only","N1","primary_report",null,null,null,"high","first","opus-5.5-agent19","fetuin-B cross sectional study with a single arm 6 month liraglutide subgroup in women with metabolic syndrome",1],["R0022346","Effect of once-weekly semaglutide versus thrice-daily insulin aspart, both as add-on to metformin and optimized insulin glargine treatment in participants with type 2 diabetes (SUSTAIN 11): A randomized, open-label, multinational, phase 3b trial.","Kellerer M","2022","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent19","SUSTAIN 11 RCT of once weekly semaglutide vs thrice daily insulin aspart added to glargine and metformin",1],["R0022506","Effect of Exenatide Therapy on Platelet Function in Type 2 Diabetes Mellitus.","Çalapkulu M","2021","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent19","exenatide initiators followed for 6 months vs nondiabetic controls on platelet indices; no exposure comparison group",1],["R0022615","Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics.","Lingvay I","2023","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent19","baseline characteristics of SELECT RCT of semaglutide vs placebo in obesity with cardiovascular disease",1],["R0022714","Systematic Review of Left Ventricular Remodeling in Response to Hypoglycemic Medications: Assessing Changes in End-Systolic and End-Diastolic Diameters.","Buz BF","2024","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent19","systematic review of glucose lowering drugs incl liraglutide on LV dimensions; PubMed Scopus Web of Science with criteria",1],["R0022816","Effects of liraglutide or lifestyle interventions combined with other antidiabetic drugs on abdominal fat distribution in people with obesity and type 2 diabetes mellitus evaluated by the energy spectrum ct: A prospective randomized controlled study.","Yu D","2022","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent19","RCT of liraglutide vs lifestyle intervention with other antidiabetic drugs for 12 weeks in obese type 2 diabetes",1],["R0023659","Clinical Efficacy and Parameters Affecting the Response to Dulaglutide Treatment in Patients with Type 2 Diabetes: A Retrospective, Real-World Data Study.","Yoo JH","2019","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent13","retrospective single group study of dulaglutide initiators without comparison group",1],["R0023833","Systematic review and meta-analysis of head-to-head trials comparing sulfonylureas and low hypoglycaemic risk antidiabetic drugs.","Volke V","2022","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent13","PROSPERO registered meta-analysis of head to head RCTs of sulfonylureas vs drugs incl GLP-1 agonists from six databases",1],["R0024029","Efficacy of liraglutide added to sodium-glucose cotransporter-2 inhibitors in type 2 diabetes, stratified by baseline characteristics: Post-hoc analysis of LIRA-ADD2SGLT2i.","Blonde L","2021","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent13","post hoc analysis of LIRA-ADD2SGLT2i placebo controlled RCT of liraglutide added to SGLT2 inhibitors",1],["R0024181","Glucagon-like peptide-1 inhibits adipose tissue macrophage infiltration and inflammation in an obese mouse model of diabetes.","Lee YS","2012","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent13","adenoviral GLP-1 and exendin-4 study in ob/ob mice and cell lines only",1],["R0024506","Monitoring Utilization Trends of Glucose-Lowering Drugs for Type 2 Diabetes in Older Adults by Frailty Status","Gopalakrishnan C","2021","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent13","abstract on utilization trends of glucose lowering drugs by frailty, no outcome comparison by exposure",1],["R0024656","Liraglutide Reduces Vascular Damage, Neuronal Loss, and Cognitive Impairment in a Mixed Murine Model of Alzheimer's Disease and Type 2 Diabetes.","Carranza-Naval MJ","2021","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent13","liraglutide in a mixed Alzheimer and diabetes mouse model only",1],["R0025227","The Impact of Liraglutide on Diabetes-Related Foot Ulceration and Associated Complications in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events: Results From the LEADER Trial.","Dhatariya K","2018","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent07","post hoc LEADER analysis of liraglutide vs placebo on diabetic foot ulcers and amputations",1],["R0025416","Patient and public involvement and engagement in the ASCEND PLUS trial: reflections from the design of a streamlined and decentralised clinical trial.","El-Nayir M","2024","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent07","report on patient involvement in designing the ASCEND PLUS RCT of oral semaglutide; no trial results",1],["R0025579","A Placebo-Controlled Study on the Effects of the Glucagon-Like Peptide-1 Mimetic, Exenatide, on Insulin Secretion, Body Composition and Adipokines in Obese, Client-Owned Cats.","Hoelmkjaer KM","2016","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent07","placebo controlled randomized study of exenatide in obese client owned cats",1],["R0025870","Lessons From LEADER - All-round Leadership.","Kalra S","2016","inventory_only","N9","ancillary",null,null,null,"high","first","opus-5.5-agent07","editorial discussing results of the LEADER RCT of liraglutide",1],["R0025983","Metformin use in prediabetes: A review of evidence and a focus on metabolic features among peri-menopausal women.","Lim BSY","2025","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent07","narrative review of metformin in prediabetes and perimenopausal women; GLP-1RA not studied",1],["R0026099","Improvements in health-related quality of life with liraglutide 3.0 mg compared with placebo in weight management.","Kolotkin RL","2016","include_nma",null,"secondary_report","P02; P06",null,null,"high","first","opus-5.5-agent07","SCALE Obesity and Prediabetes RCT report of liraglutide 3.0 mg vs placebo on health related quality of life",1],["R0024099","Real-world use of cardioprotective glucose-lowering drugs in patients with type 2 diabetes and cardiovascular disease: A Danish nationwide cohort study, 2012 to 2019.","Funck KL","2021","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent01","nationwide cohort of time to initiation of SGLT2i and GLP-1 RA after diabetes and CVD diagnosis; drug utilization only",1],["R0024257","Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes.","Garber A","2011","include_nma",null,"extension","P01",null,null,"high","first","opus-5.5-agent01","two year LEAD-3 RCT with open label extension, liraglutide 1.2 or 1.8 mg versus glimepiride monotherapy",1],["R0024402","Compared to commercially insured patients, Medicare advantage patients adopt newer diabetes drugs more slowly and adhere to them less.","Flory JH","2021","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent01","claims cohort of second line diabetes drug uptake and adherence by insurance type; drug utilization only",1],["R0024589","Reduction of postprandial glucose by lixisenatide vs sitagliptin treatment in Japanese patients with type 2 diabetes on background insulin glargine: A randomized phase IV study (NEXTAGE Study).","Yamada Y","2017","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent01","NEXTAGE open label RCT of lixisenatide versus sitagliptin on background insulin glargine in Japanese type 2 diabetes",1],["R0024692","Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies.","Li L","2014","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent01","systematic review and meta-analysis of RCTs and observational studies of incretin drugs and pancreatitis",1],["R0024953","The impact of obesity and weight loss treatment on metabolic parameters, cardiovascular autonomic and sensory nerve function and in vitro fertilization outcomes in infertile women: a pilot study.","Vágvölgyi A","2025","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent01","retrospective cohort of infertile women with obesity before and after lifestyle plus liraglutide; healthy controls only at baseline",1],["R0025090","Similar efficacy and safety of once-weekly dulaglutide in patients with type 2 diabetes aged ≥65 and <65 years.","Boustani MA","2016","include_nma",null,"pooled_analysis","P01",null,null,"high","first","opus-5.5-agent01","pooled age subgroup analysis of six AWARD RCTs of dulaglutide versus placebo or active comparators",1],["R0023972","Effect of exenatide, sitagliptin, or glimepiride on β-cell secretory capacity in early type 2 diabetes.","Gudipaty L","2014","include_nma",null,"primary_report","P01; P06",null,null,"high","first","opus-5.5-agent08","six month RCT of exenatide, sitagliptin or glimepiride on beta cell secretory capacity in early type 2 diabetes or impaired fasting glucose",1],["R0024141","Efficacy and safety of subgroup analysis stratified by baseline HbA1c in a Japanese phase 3 study of dulaglutide 0.75 mg compared with insulin glargine in patients with type 2 diabetes.","Kaneko S","2017","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent08","HbA1c subgroup analysis of Japanese phase 3 RCT of dulaglutide 0.75 mg versus insulin glargine",1],["R0024285","Real-world persistence with liraglutide 3.0 mg for weight management and the SaxendaCare® patient support program.","Wharton S","2020","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent08","retrospective liraglutide 3.0 mg users comparing support program enrollees with nonenrollees; persistence and weight only",1],["R0024634","Heart rate variability in type 2 diabetic subjects randomized to liraglutide or glimepiride treatment, both in combination with metformin: A randomized, open, parallel-group study.","Nyström T","2019","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent08","post hoc analysis of RCT of liraglutide versus glimepiride with metformin on heart rate variability",1],["R0024738","Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly, or dapagliflozin, added to metformin monotherapy, on body weight, systolic blood pressure, and triglycerides in patients with type 2 diabetes in the DURATION-8 study.","Jabbour SA","2018","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent08","DURATION-8 post hoc subgroups of randomized exenatide weekly plus dapagliflozin versus either alone",1],["R0024894","Influence of hepatic impairment on pharmacokinetics of the human GLP-1 analogue, liraglutide.","Flint A","2010","inventory_only","N1","primary_report",null,null,null,"high","first","opus-5.5-agent08","single dose liraglutide pharmacokinetics across hepatic function groups; all treated, no drug comparison",1],["R0019172","Short-term effect of beinaglutide combined with metformin versus metformin alone on weight loss and metabolic profiles in obese patients with polycystic ovary syndrome: a pilot randomized trial.","Wen Q","2023","include_nma",null,"primary_report","P12",null,null,"high","first","opus-5.5-agent09","pilot open label RCT of beinaglutide plus metformin versus metformin alone in obese women with PCOS",1],["R0019296","The influence of incretin mimetics on cardiovascular risk factors in diabetes.","Kinalska I","2012","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent09","narrative review of incretin mimetics and cardiovascular risk factors based on LEAD trials",1],["R0019384","Incretin-based drugs and the risk of gallbladder or biliary tract diseases among patients with type 2 diabetes across categories of body mass index: a nationwide cohort study.","Ko HY","2025","include_harms",null,"primary_report",null,"O28",null,"high","first","opus-5.5-agent09","Korean active comparator new user cohort of incretin drugs on gallbladder and biliary disease stratified by BMI",1],["R0019476","Rationale and design of the randomised controlled trial to assess the impact of liraglutide on cardiac function and structure in young adults with type 2 diabetes (the LYDIA study).","Htike ZZ","2016","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent09","design paper of LYDIA RCT of liraglutide versus sitagliptin on cardiac function in young type 2 diabetes",1],["R0019570","A Phase 1 Multiple Dose Study of Tirzepatide in Chinese Patients with Type 2 Diabetes.","Feng P","2023","include_nma",null,"primary_report","P01",null,"mechanistic","high","first","opus-5.5-agent09","phase 1 double blind RCT of tirzepatide versus placebo in Chinese type 2 diabetes with safety and PK outcomes",1],["R0019698","Retrospective Analysis of an Insulin-to-Liraglutide Switch in Patients with Type 2 Diabetes Mellitus.","Bruinstroop E","2018","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent09","retrospective single group analysis of switching from insulin to liraglutide, no comparison group",1],["R0019824","Effects of Dulaglutide in Doxorubicin Induced Renal Toxicity in Rats.","Hama Said HJ","2025","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent09","rat doxorubicin kidney injury model treated with dulaglutide, no humans",1],["R0019918","Assessing Nutraceuticals for Hepatic Steatosis: A Standardized In Vitro Approach.","Palasantzas VEJM","2026","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent09","in vitro HepG2 study of nutraceuticals with semaglutide as a reference compound, no humans",1],["R0027703","CHALLENGES AND NEW DIRECTIONS IN OBESITY MANAGEMENT: LIFESTYLE MODIFICATION PROGRAMMES, PHARMACOTHERAPY AND BARIATRIC SURGERY.","El Ghoch M","2019","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent12","editorial on challenges in obesity management including pharmacotherapy and surgery",1],["R0027922","Effectiveness, tolerability and practical application of the newer generation anti-obesity medications.","MacDaniels JS","2016","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent12","brief nonexhaustive review of anti-obesity drugs with NNT and NNH calculations, no systematic search or eligibility criteria",1],["R0028567","High-throughput identification of peptide agonists against GPCRs by co-culture of mammalian reporter cells and peptide-secreting yeast cells using droplet microfluidics.","Yaginuma K","2019","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent12","in vitro droplet microfluidics screen of peptide agonists of GLP-1 receptor in reporter cells and yeast",1],["R0029344","Individualized Treatment Approaches for Obstructive Sleep Apnea in Older Adults: Beyond Continuous Positive Airway Pressure.","Jaganathan N","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent12","narrative review of obstructive sleep apnea treatments in older adults",1],["R0019193","Comparative efficacy and safety of liraglutide versus metformin, naltrexone/bupropion, and phentermine-topiramate in psychiatric patients.","Choi WS","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent10","retrospective chart review comparing liraglutide with metformin, NB and PT in psychiatric outpatients; weight and general AEs only",1],["R0019304","Real-world clinical outcomes in adult patients with Fabry disease: A 20-year retrospective observational cohort study from a single centre.","McCarron EP","2025","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent10","Fabry disease outcome cohort; GLP-1 RA use only noted as low, no exposure analysis",1],["R0019483","Effects of exenatide on urinary albumin in overweight/obese patients with T2DM: a randomized clinical trial.","Kang C","2021","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent10","24 week RCT exenatide versus insulin glargine in overweight T2D; urinary albumin, weight, HbA1c",1],["R0019572","Effects of Initial Combinations of Gemigliptin Plus Metformin Compared with Glimepiride Plus Metformin on Gut Microbiota and Glucose Regulation in Obese Patients with Type 2 Diabetes: The INTESTINE Study.","Lim S","2023","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent10","RCT gemigliptin plus metformin versus glimepiride plus metformin; DPP-4 inhibitor only, no GLP-1 RA",1],["R0019704","Use of flash glucose-sensing technology in patients with type 2 diabetes treated with liraglutide combined with CSII: a pilot study.","Yao MY","2020","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent10","pilot RCT CSII versus CSII plus liraglutide for 14 days in poorly controlled T2D; glycemic variability and weight",1],["R0019831","Incretin mimetics and DPP-IV inhibitors: new paradigms for the treatment of type 2 diabetes.","Hinnen D","2006","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent10","2006 narrative review of incretin mimetics and DPP-IV inhibitors; no systematic methods",1],["R0019919","Clinical comments related to medullary thyroid cancer diagnosis and management.","Duntas LH","2013","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent10","clinical commentary on medullary thyroid cancer guidelines including incretin question; narrative",1],["R0020690","Exenatide in obesity with accelerated gastric emptying: a randomized, pharmacodynamics study.","Acosta A","2015","include_nma",null,"primary_report","P02",null,"mechanistic","high","first","opus-5.5-agent15","30 day RCT of exenatide versus placebo in obesity with accelerated gastric emptying; gastric emptying, intake and weight",1],["R0020851","Cardiovascular outcomes of liraglutide in patients with type 2 diabetes: A systematic review and meta-analysis.","Duan CM","2019","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent15","systematic review and meta-analysis of eight RCTs of liraglutide on cardiovascular outcomes; three databases searched",1],["R0020952","Cost-Effectiveness of Semaglutide vs. Empagliflozin, Canagliflozin, and Sitagliptin for Treatment of Patients with Type 2 Diabetes in Denmark: A Decision-Analytic Modelling Study.","Pulleyblank R","2023","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent15","Markov cost effectiveness model of oral and subcutaneous semaglutide versus SGLT2i and sitagliptin in Denmark",1],["R0021121","Dipeptidyl peptidase 4 promotes peritoneal fibrosis and its inhibitions prevent failure of peritoneal dialysis.","Li YC","2021","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent15","human cohort part studies DPP-4 inhibitors only; exendin-4 used only in rat and cell experiments",1],["R0021422","Efficacy of Dulaglutide in Chinese Patients with Type 2 Diabetes and Different Glycemic Patterns: a Post-hoc Analysis of the Phase 3 AWARD-CHN2 Trial.","Li Q","2022","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent15","post hoc glycemic pattern analysis of AWARD-CHN2 RCT of dulaglutide doses versus glargine in Chinese type 2 diabetes",1],["R0021521","CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes.","Schnell O","2023","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent15","conference summit report summarizing outcome trials and guideline discussions",1],["R0026073","Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU).","Marre M","2009","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent04","LEAD-1 SU double blind RCT of liraglutide vs rosiglitazone or placebo added to glimepiride",1],["R0026209","Early Weight Loss with Liraglutide 3.0 mg Predicts 1-Year Weight Loss and is Associated with Improvements in Clinical Markers.","Fujioka K","2016","include_nma",null,"pooled_analysis","P02; P01",null,null,"high","first","opus-5.5-agent04","pooled post hoc early responder analysis of SCALE Obesity and Prediabetes and SCALE Diabetes RCTs of liraglutide 3.0 mg vs placebo",1],["R0026397","Total parenteral nutrition drives glucose metabolism disorders by modulating gut microbiota and its metabolites","Sun H","2021","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent04","TPN cohort and mouse experiments on gut microbiota, liraglutide given only to mice, no human GLP-1 RA exposure",1],["R0026509","A nationwide pharmacovigilance investigation on trends and seriousness of adverse events induced by anti-obesity medication.","Choi YJ","2023","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent04","Korean spontaneous report disproportionality analysis of anti obesity drug adverse events incl liraglutide",1],["R0026681","Meta-Analysis of Sulfonylurea Therapy on Long-Term Risk of Mortality and Cardiovascular Events Compared to Other Oral Glucose-Lowering Treatments.","Powell WR","2018","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent04","meta-analysis of studies from MEDLINE and registry comparing sulfonylureas with other drugs incl GLP-1 RA on mortality and CV events",1],["R0026850","Gliptins and Cardiovascular Outcomes: A Comparative and Critical Analysis after TECOS.","Ghosal S","2016","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent04","critical review of gliptin cardiovascular outcome trials, DPP-4 inhibitors only",1],["R0025031","Effect of once-weekly semaglutide on the counterregulatory response to hypoglycaemia in people with type 2 diabetes: A randomized, placebo-controlled, double-blind, crossover trial.","Korsatko S","2018","include_nma",null,"primary_report","P01",null,"crossover; mechanistic","high","first","opus-5.5-agent14","placebo controlled crossover RCT of semaglutide on counterregulatory response to hypoglycemia in T2D",1],["R0025162","Antidiabetic Agents for Treatment of Parkinson's Disease: A Meta-Analysis.","Wang SY","2020","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent14","meta-analysis of RCTs of antidiabetic agents including exenatide in Parkinson disease, six databases searched",1],["R0025454","Glucose Control and Weight Change Associated with Treatment with Exenatide Compared with Basal Insulin: A Retrospective Study.","Morgan CL","2018","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent14","CPRD matched cohort exenatide vs basal insulin initiators, HbA1c and weight only",1],["R0025907","Combined antidiabetic benefits of exenatide and dapagliflozin in diabetic mice.","Tatarkiewicz K","2014","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent14","ob/ob mouse study of exenatide and dapagliflozin",1],["R0026006","The Genetics of Adverse Drug Outcomes in Type 2 Diabetes: A Systematic Review.","Baye AM","2021","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent14","systematic review of pharmacogenetics of adverse effects of oral glucose lowering drugs, GLP-1 RA not included",1],["R0026156","Effects of Lifestyle Modification and Anti-diabetic Medicine on Prediabetes Progress: A Systematic Review and Meta-Analysis.","Sheng Z","2019","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent18","registered NMA of RCTs of lifestyle and drugs incl. GLP-1 RAs on diabetes progression in prediabetes; three databases",1],["R0026340","Randomised, phase 1, dose-finding study of MEDI4166, a PCSK9 antibody and GLP-1 analogue fusion molecule, in overweight or obese patients with type 2 diabetes mellitus.","Jain M","2019","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent18","phase 1 randomized placebo controlled dose finding study of PCSK9 antibody GLP-1 analogue fusion MEDI4166 in overweight T2D",1],["R0026475","Clinical Effects of Liraglutide in a Real-World Setting in Spain: eDiabetes-Monitor SEEN Diabetes Mellitus Working Group Study.","Mezquita-Raya P","2015","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent18","retrospective single arm registry of liraglutide users in Spain; pre post HbA1c and weight; not a trial",1],["R0026634","Report from the 1st Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group.","Schnell O","2016","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent18","meeting report summarizing CVOT summit presentations; conference proceedings, no data synthesis",1],["R0026785","Efficacy of liraglutide therapy in Japanese type 2 diabetic patients insufficiently controlled with basal-supported oral therapy.","Takahara M","2012","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent18","retrospective single arm series of Japanese T2D switched from basal supported oral therapy to liraglutide",1],["R0026984","Hypoglycemia hospitalization frequency in patients with type 2 diabetes mellitus: a comparison of dipeptidyl peptidase 4 inhibitors and insulin secretagogues using the French health insurance database.","Detournay B","2015","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent18","French claims cohort of DPP-4i vs insulin secretagogues on hypoglycemia hospitalization; GLP-1 RA users excluded",1],["R0027132","Efficacy and safety of saxagliptin in patients with type 2 diabetes: A systematic review and meta-analysis.","Men P","2018","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent18","systematic review and meta-analysis of saxagliptin RCTs including pooled contrasts vs liraglutide; six named databases",1],["R0022748","Efficacy of liraglutide 3.0 mg treatment on weight loss in patients with weight regain after bariatric surgery.","Muratori F","2022","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent02","retrospective single group liraglutide 3.0 mg for weight regain after bariatric surgery; no comparison group",1],["R0022829","The Effects of Dipeptidyl Peptidase 4 Inhibitors on Renal Function in Patients with Type 2 Diabetes Mellitus.","Hsu WC","2022","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent02","retrospective cohort of DPP-4 inhibitors vs other drugs on eGFR decline; GLP-1 RA users excluded",1],["R0022973","Adherence to and Dropout from Liraglutide 3.0 mg Obesity Treatment in a Real-World Setting.","Ko HJ","2022","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent02","secondary analysis of adherence and dropout predictors among liraglutide 3.0 mg users; utilization without exposure comparison",1],["R0023085","Disorder of Glucose Metabolism and Therapy: Implications on the Natural History of Advanced Chronic Liver Disease.","Garcês Soares S","2025","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent02","advanced chronic liver disease cohort on glucose disorders; only one patient on GLP-1 RA, excluded from drug analysis",1],["R0023224","Comparison of Blood Glucose Variability Between Exenatide and Biphasic Insulin Aspart 30 in Chinese Participants with Type 2 Diabetes Inadequately Controlled with Metformin Monotherapy: A Multicenter, Open-Label, Randomized Trial.","Wang L","2020","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent02","open label RCT of exenatide vs biphasic insulin aspart 30 on metformin in Chinese T2D",1],["R0023476","Impact of Anti-obesity Medication Initiation and Duration on Weight Loss.","Bailony MR","2025","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent02","retrospective digital obesity program cohort of antiobesity drug users including semaglutide vs non users on weight; no listed harm",1],["R0023600","Efficacy and safety of once-weekly exenatide after switching from twice-daily exenatide in patients with type 2 diabetes.","Watanabe Y","2020","inventory_only","N1","primary_report",null,null,null,"high","first","opus-5.5-agent02","prospective single arm switch from exenatide twice daily to once weekly in Japanese T2D",1],["R0026325","Prevalence and treatment of diabetes mellitus and hypertension among older adults with intellectual disability in comparison with the general population.","Axmon A","2017","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent16","register study comparing diabetes and hypertension prescription patterns in intellectual disability; utilization only",1],["R0026461","Twenty-four-week effects of liraglutide on body composition, adherence to appetite, and lipid profile in overweight and obese patients with type 2 diabetes mellitus.","Rondanelli M","2016","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent16","single group cohort adding liraglutide to metformin in overweight T2D, before and after body composition",1],["R0026612","Effectiveness and Tolerability of Therapy With Once-Weekly Exenatide Versus Basal Insulin Among Injectable-Naive Patients With Type 2 Diabetes in a Real-World Setting in the United States.","Loughlin AM","2018","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent16","propensity matched EHR cohort of exenatide once weekly vs basal insulin; HbA1c, weight, hypoglycemia and nausea only",1],["R0026955","Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes.","Rosenstock J","2010","include_nma",null,"primary_report","P02",null,null,"high","first","opus-5.5-agent16","RCT of exenatide vs placebo with lifestyle in obese adults without diabetes incl. prediabetes subgroup",1],["R0027123","Advances in non-dopaminergic treatments for Parkinson's disease.","Stayte S","2014","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent16","narrative review of non dopaminergic Parkinson disease treatments",1],["R0027264","One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial.","Bunck MC","2009","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent16","RCT of exenatide vs insulin glargine for 52 weeks in metformin treated T2D; beta cell function",1],["R0027561","RF24 | PSUN127 Congenital Leptin Deficiency: Metabolic, Reproductive, and Psychological Impacts of Therapy",null,"2022","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent16","case abstract of metreleptin in congenital leptin deficiency; liraglutide only prior background therapy",1],["R0025197","Intensive management of obesity in people with Prader-Willi syndrome.","Nolan BJ","2022","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent01","retrospective audit case series of Prader-Willi patients treated with diets, phentermine-topiramate or liraglutide, no comparison group",1],["R0025377","Health-related quality of life in people with type 2 diabetes participating in the LEADER trial.","Nauck MA","2019","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent01","EQ-5D quality of life secondary analysis of LEADER RCT, liraglutide versus placebo",1],["R0025539","Improvements in health-related quality of life over 3 years with liraglutide 3.0 mg compared with placebo in participants with overweight or obesity.","Kolotkin RL","2018","include_nma",null,"secondary_report","P02",null,null,"high","first","opus-5.5-agent01","three year quality of life analysis of SCALE Obesity and Prediabetes RCT, liraglutide 3.0 mg versus placebo",1],["R0025667","A novel dual GLP-1 and GIP receptor agonist is neuroprotective in the MPTP mouse model of Parkinson's disease by increasing expression of BNDF.","Ji C","2016","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent01","MPTP mouse Parkinson model testing a GLP-1 and GIP dual agonist; animal study only",1],["R0025812","Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand?","Tak YJ","2021","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent01","narrative review of long term efficacy and safety of anti-obesity drugs",1],["R0026064","Incretin mimetics and dipeptidyl peptidase-4 inhibitors: innovative treatment therapies for type 2 diabetes.","Davidson JA","2008","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent01","narrative review of incretin mimetic and DPP-4 inhibitor clinical trials",1],["R0026180","Individualized HbA1c Goals, and Patient Awareness and Attainment of Goals in Type 2 Diabetes Mellitus: A Real-World Multinational Survey.","Lautsch D","2022","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent01","physician and patient survey of individualized HbA1c goals and attainment; no GLP-1 RA exposure comparison",1],["R0026244","Cost-Effectiveness Analysis of Incretin Therapy for Type 2 Diabetes in Spain: 1.8 mg Liraglutide Versus Sitagliptin.","Pérez A","2015","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent07","CORE Diabetes Model cost effectiveness analysis of liraglutide 1.8 mg vs sitagliptin in Spain",1],["R0026423","Recombinant Incretin-Secreting Microbe Improves Metabolic Dysfunction in High-Fat Diet Fed Rodents.","Ryan PM","2017","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent07","rodent study of a recombinant GLP-1 analogue secreting Lactobacillus",1],["R0026527","Treatment outcomes after initiation of exenatide twice daily or insulin in clinical practice: 12-month results from CHOICE in six European countries.","Ostenson CG","2013","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent07","CHOICE observational cohort of exenatide twice daily vs insulin initiators; treatment change, glycemia, weight, hypoglycemia, GI events",1],["R0026705","Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults.","Lean ME","2014","include_nma",null,"secondary_report","P02",null,null,"high","first","opus-5.5-agent07","secondary analysis of RCT of liraglutide doses vs placebo and orlistat in obesity on nausea, vomiting and weight",1],["R0026876","Long-term safety and efficacy of exenatide twice daily in Japanese patients with suboptimally controlled type 2 diabetes.","Inagaki N","2011","include_nma",null,"extension","P01",null,null,"high","first","opus-5.5-agent07","open label extension of Japanese RCT keeping randomized exenatide 5 vs 10 mcg twice daily arms to 52 weeks",1],["R0027047","Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis.","Garg R","2010","include_harms",null,"primary_report",null,"O29",null,"high","first","opus-5.5-agent07","claims cohort of exenatide or sitagliptin initiators vs other diabetes drugs with acute pancreatitis outcome",1],["R0027188","Non-Alcoholic Steatohepatitis (NASH) - A Review of a Crowded Clinical Landscape, Driven by a Complex Disease.","Fraile JM","2021","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent07","narrative review of the NASH drug development landscape including semaglutide",1],["R0019195","Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot study.","Gill A","2010","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent11","double blind placebo controlled RCT of exenatide twice daily for 12 weeks in type 2 diabetes",1],["R0019305","Bariatric surgery, novel glucose-lowering agents, and insulin for type 2 diabetes and obesity: Bayesian network meta-analysis of randomized controlled trials.","Wu T","2023","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent11","registered Bayesian network meta-analysis of RCTs including GLP-1RA, surgery and other drugs; PubMed, Embase, MEDLINE, Cochrane",1],["R0019397","Laser Acupuncture versus Liraglutide in Treatment of Obesity: A Multi-Institutional Retrospective Cohort Study.","Yu WL","2024","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent11","Taiwan hospital cohort of laser acupuncture versus liraglutide; weight and cardiovascular adverse events only",1],["R0019488","The Cost-Effectiveness of Empagliflozin Versus Liraglutide Treatment in People with Type 2 Diabetes and Established Cardiovascular Disease.","Ehlers LH","2021","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent11","Core Diabetes Model cost effectiveness analysis of empagliflozin versus liraglutide",1],["R0019583","Effects of novel glucose-lowering drugs on the lipid parameters: A systematic review and meta-analysis.","Dar S","2022","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent11","meta-analysis of RCTs of SGLT2i, GLP-1RA and DPP-4i on lipids; MEDLINE searched",1],["R0019710","Randomized trial of continuous subcutaneous delivery of exenatide by ITCA 650 versus twice-daily exenatide injections in metformin-treated type 2 diabetes.","Henry RR","2013","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent11","phase 2 RCT of ITCA 650 continuous exenatide versus twice daily exenatide in metformin treated diabetes",1],["R0019834","Effects of exenatide on postprandial vascular endothelial dysfunction in type 2 diabetes mellitus.","Torimoto K","2015","inventory_only","N1","primary_report",null,null,null,"high","first","opus-5.5-agent11","nonrandomized within patient meal test without then with single exenatide dose; no concurrent comparator",1],["R0019922","Heart failure in 2025: new insights, therapies, and clinical directions.","Shen Z","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent11","narrative review of heart failure advances in 2025",1],["R0025116","Variables associated with HbA1c and weight reductions when adding liraglutide to multiple daily insulin injections in persons with type 2 diabetes (MDI Liraglutide trial 3).","Dahlqvist S","2018","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent08","reanalysis of MDI Liraglutide double blind RCT of liraglutide versus placebo added to multiple daily insulin",1],["R0025421","Diabetes drugs for nonalcoholic fatty liver disease: a systematic review.","Blazina I","2019","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent08","DERP systematic review of RCTs of diabetes drugs incl GLP-1 RAs for NAFLD; MEDLINE, EMBASE, Cochrane",1],["R0025590","Efficacy and safety of vildagliptin, Saxagliptin or Sitagliptin as add-on therapy in Chinese patients with type 2 diabetes inadequately controlled with dual combination of traditional oral hypoglycemic agents.","Li CJ","2014","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent08","RCT comparing three DPP-4 inhibitors as add-on therapy; no GLP-1 RA arm",1],["R0025872","Efficacy and safety of lixisenatide once-daily morning or evening injections in type 2 diabetes inadequately controlled on metformin (GetGoal-M).","Ahrén B","2013","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent08","GetGoal-M double blind RCT of lixisenatide morning or evening versus placebo on metformin",1],["R0025987","Nonalcoholic Fatty liver: a possible new target for type 2 diabetes prevention and treatment.","Fruci B","2013","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent08","narrative review of NAFLD and antidiabetic drugs",1],["R0025039","Prevalence of Established Cardiovascular Disease in Patients with Type 2 Diabetes Mellitus in the UK.","Lautsch D","2019","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent17","CPRD prevalence study of cardiovascular disease in type 2 diabetes; no GLP-1 RA exposure analysis",1],["R0025175","Liraglutide reverses pronounced insulin-associated weight gain, improves glycaemic control and decreases insulin dose in patients with type 2 diabetes: a 26 week, randomised clinical trial (ELEGANT).","de Wit HM","2014","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent17","ELEGANT RCT of adding liraglutide versus intensifying insulin in type 2 diabetes with insulin associated weight gain, 26 weeks",1],["R0025350","Dulaglutide-combined basal plus correction insulin therapy contributes to ideal glycemic control in non-critical hospitalized patients.","Fushimi N","2020","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent17","pilot RCT of dulaglutide plus basal plus insulin versus basal plus insulin in hospitalized type 2 diabetes",1],["R0025655","Glucagon-Like Peptide-1: A Promising Agent for Cardioprotection During Myocardial Ischemia.","Giblett JP","2016","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent17","narrative review of GLP-1 cardioprotection during myocardial ischemia",1],["R0025790","Exenatide Treatment Alone Improves β-Cell Function in a Canine Model of Pre-Diabetes.","Ionut V","2016","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent17","canine prediabetes model randomized to exenatide or placebo",1],["R0025920","Clinical Effectiveness of Liraglutide vs Sitagliptin on Glycemic Control and Body Weight in Patients with Type 2 Diabetes: A Retrospective Assessment in Sweden.","Lind M","2016","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent17","Swedish registry propensity matched comparison of liraglutide versus sitagliptin on HbA1c and weight only",1],["R0024777","The Effect of Exenatide on Cardiovascular Risk Markers in Women With Polycystic Ovary Syndrome.","Dawson AJ","2019","inventory_only","N1","primary_report",null,null,null,"high","first","opus-5.5-agent13","open label single arm study of exenatide in overweight women with PCOS",1],["R0024915","Role of saxagliptin as monotherapy or adjunct therapy in the treatment of type 2 diabetes.","Sharma MD","2010","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent13","review of the DPP-4 inhibitor saxagliptin, no GLP-1 receptor agonist studied",1],["R0025027","Patterns and trends of utilization of incretin-based medicines between 2008 and 2014 in three Italian geographic areas.","Roberto G","2019","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent13","descriptive drug utilization study of GLP-1 analogues and DPP-4 inhibitors in Italy without outcome comparison",1],["R0025157","Shifting Paradigms in the Medical Management of Type 2 Diabetes: Reflections on Recent Cardiovascular Outcome Trials.","Ismail-Beigi F","2017","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent13","perspective review of cardiovascular outcome trials in type 2 diabetes management",1],["R0025300","Predictors of early discontinuation of dapagliflozin versus other glucose-lowering medications: a retrospective multicenter real-world study.","Fadini GP","2020","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent13","DARWIN-T2D analysis of predictors of early discontinuation of dapagliflozin and other drugs, utilization only",1],["R0025451","Drug Therapy in Obesity: A Review of Current and Emerging Treatments.","Williams DM","2020","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent13","narrative review of current and emerging obesity drugs",1],["R0025612","Clinical Effectiveness of Liraglutide in Type 2 Diabetes Treatment in the Real-World Setting: A Systematic Literature Review.","Ostawal A","2016","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent13","NICE guided systematic literature review of real world liraglutide effectiveness from Medline, Embase and Cochrane",1],["R0025770","Liraglutide as an Alternative to Insulin for Glycemic Control in Intensive Care Unit: A Randomized, Open-label, Clinical Study.","Verma V","2017","include_nma",null,"primary_report","P99",null,null,"high","first","opus-5.5-agent13","open label RCT of liraglutide vs insulin for hyperglycemia in ICU patients",1],["R0021671","Once-Weekly Subcutaneous Semaglutide 2.4 mg Injection is Cost-Effective for Weight Management in the United Kingdom.","Sandhu H","2023","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent15","cost effectiveness analysis of semaglutide 2.4 mg for weight management in the UK using the Core Obesity Model",1],["R0021795","Efficacy and safety of oral semaglutide by subgroups of patient characteristics in the PIONEER phase 3 programme.","Aroda VR","2022","include_nma",null,"pooled_analysis","P01",null,null,"high","first","opus-5.5-agent15","subgroup analysis across PIONEER phase 3 RCTs of oral semaglutide versus placebo or active comparators",1],["R0022023","A randomized, double-blind, placebo-controlled study of liraglutide 3 mg [LIRA 3mg] on weight, body composition, hormonal and metabolic parameters in women with obesity and polycystic ovary syndrome (PCOS)","Elkind-Hirsch K","2021","include_nma",null,"primary_report","P12",null,null,"high","first","opus-5.5-agent15","double blind RCT of liraglutide 3 mg versus placebo for 32 weeks in women with obesity and PCOS",1],["R0022126","Effects of antidiabetic drugs on left ventricular function/dysfunction: a systematic review and network meta-analysis.","Zhang DP","2020","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent15","systematic review and network meta-analysis of antidiabetic drugs incl GLP-1 agonists on left ventricular function; four databases",1],["R0022219","Mortality in People with Type 2 Diabetes Following SARS-CoV-2 Infection: A Population Level Analysis of Potential Risk Factors.","Heald AH","2022","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent15","matched COVID-19 mortality study in type 2 diabetes with GLP-1 agonist use among risk factors; mortality only",1],["R0022328","Evolving Role for Pharmacotherapy in NAFLD/NASH.","Attia SL","2021","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent15","narrative review of emerging NAFLD and NASH pharmacotherapies incl liraglutide",1],["R0022468","BEYOND 2 years: durability of metabolic benefits by simplification of complex insulin regimens in type 2 diabetes.","Giugliano D","2024","include_nma",null,"extension","P01",null,null,"high","first","opus-5.5-agent15","two year extension of BEYOND RCT, fixed ratio basal insulin plus GLP-1 RA versus basal bolus or basal plus SGLT2i",1],["R0022588","Systematic Review of Treatment of Beta-Cell Monogenic Diabetes.","Naylor RN","2023","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent15","registered systematic reviews of treatments in monogenic diabetes incl crossover trials of GLP-1 RAs; three databases",1],["R0020154","Efficacy and hypoglycemic risk of sitagliptin in obese/overweight patients with type 2 diabetes compared with GLP-1 receptor agonists: A meta-analysis.","Dai D","2019","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent09","meta-analysis of RCTs of sitagliptin versus GLP-1 agonists in obese type 2 diabetes, four sources searched",1],["R0020289","Effects of NPY-2 Receptor Antagonists, Semaglutide, PYY3-36, and Empagliflozin on Early MASLD in Diet-Induced Obese Rats.","Kloock S","2024","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent09","diet induced obese rats randomized to semaglutide, empagliflozin or NPY2R antagonists, no humans",1],["R0020409","Effects of Semaglutide on Symptoms, Function, and Quality of Life in Patients With Heart Failure With Preserved Ejection Fraction and Obesity: A Prespecified Analysis of the STEP-HFpEF Trial.","Kosiborod MN","2024","include_nma",null,"secondary_report","P07A",null,null,"high","first","opus-5.5-agent09","prespecified KCCQ analysis of STEP-HFpEF RCT of semaglutide 2.4 mg versus placebo in HFpEF with obesity",1],["R0020498","Emodin, a rising star in the treatment of glycolipid metabolism disorders: a preclinical systematic review and meta-analysis.","Xiao Y","2025","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent09","preclinical systematic review of emodin in diabetic animal models, no humans and no GLP-1 drug",1],["R0020645","Non-invasive quantification of stem cell-derived islet graft size and composition.","Lithovius V","2024","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent09","mouse study of human stem cell islet grafts imaged with exendin based PET tracer, no human participants",1],["R0020809","Efficacy and safety of dulaglutide in patients with type 2 diabetes: a meta-analysis and systematic review.","Zhang L","2016","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent09","meta-analysis of RCTs of dulaglutide versus placebo or active drugs in type 2 diabetes, Medline, Embase, Cochrane",1],["R0020912","Increased Risk of Hypoglycemia Following Roux-en-Y Gastric Bypass Surgery in Patients Without Diabetes: a Propensity Score-Matched Analysis.","Toraih EA","2024","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent09","TriNetX cohort of gastric bypass versus no surgery on hypoglycemia, GLP-1 users excluded",1],["R0020004","Exendin-4 improves neuron protection and functional recovery in experimental spinal cord injury in rats through regulating PCBP2 expression","Luo H","2020","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent10","exendin 4 in rat spinal cord injury model; animal study only",1],["R0020156","Effectiveness of DialBetesPlus, a self-management support system for diabetic kidney disease: Randomized controlled trial.","Waki K","2024","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent10","RCT of mHealth self-management app in diabetic kidney disease; GLP-1 RA only a covariate",1],["R0020297","Efficacy and safety of oral semaglutide in Japanese patients with type 2 diabetes: A post hoc subgroup analysis of the PIONEER 1, 3, 4 and 8 trials.","Araki E","2021","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent10","post hoc Japanese subgroups of PIONEER 1, 3, 4, 8 RCTs oral semaglutide versus placebo, sitagliptin or liraglutide",1],["R0020413","Response to semaglutide of non-drinker subjects with type 2 diabetes.","Petralli G","2024","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent10","single group cohort of T2D MASLD patients starting semaglutide, compared by alcohol intake; no unexposed group",1],["R0020503","Systematic Review of Cardiovascular Outcome Trials Using New Antidiabetic Agents in CKD Stratified by Estimated GFR.","Arshad A","2021","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent10","PROSPERO registered meta-analysis of CVOTs of GLP-1 analogues, DPP-4i and SGLT2i stratified by eGFR",1],["R0020646","Effects of multicomponent exercise on frailty in older adults with type 2 diabetes: Differential responses by metabolic frailty phenotype.","Zha X","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent10","RCT of multicomponent exercise versus usual care in frail older T2D; GLP-1 RA only a covariate",1],["R0020914","The role of adjuvant pharmacotherapy with liraglutide for patients with inadequate weight loss following bariatric surgery.","Colbourne JRM","2023","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent10","noncontrolled cohort of liraglutide after inadequate weight loss post bariatric surgery; no comparison group",1],["R0022923","A meta-analysis of the therapeutic effects of glucagon-like Peptide-1 agonist in heart failure.","Munaf M","2012","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent19","meta-analysis of GLP-1 agonist trials vs placebo in heart failure incl animal data; Cochrane MEDLINE Embase searched",1],["R0023067","Estimating the risk of cardiovascular outcomes and all-cause mortality in individuals with type 2 diabetes: Validation of the UKPDS outcomes model using TECOS and EXSCEL data.","Coleman RL","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent19","validation of UKPDS outcomes model against TECOS and EXSCEL event rates; modeling methods paper",1],["R0023215","Efficacy and Safety of the New Appetite Suppressant, Liraglutide: A Meta-Analysis of Randomized Controlled Trials.","Moon S","2021","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent19","meta-analysis of placebo controlled RCTs of liraglutide on weight in overweight and obesity; PubMed Embase Cochrane",1],["R0023317","Does teneligliptin reverse the non-glycemic effects among the non-diabetic obesity subjects?","Pelluri R","2022","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent19","teneligliptin DPP-4 inhibitor study in nondiabetic obesity; no GLP-1 RA given",1],["R0023464","Toward a Medical Gastric Bypass: Chronic Feeding Studies With Liraglutide + PYY3-36 Combination Therapy in Diet-Induced Obese Rats.","Dischinger U","2020","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent19","randomized experiment of liraglutide, PYY3-36 and gastric bypass in obese rats; animal only",1],["R0023717","Effects of liraglutide, a human glucagon-like peptide-1 analogue, on body weight, body fat area and body fat-related markers in patients with type 2 diabetes mellitus.","Suzuki D","2013","inventory_only","N1","primary_report",null,null,null,"high","first","opus-5.5-agent19","single arm six month liraglutide study on fat areas and markers in Japanese type 2 diabetes",1],["R0023884","DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials.","Scheen AJ","2012","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent19","critical narrative review of head to head DPP-4 inhibitor trials",1],["R0027374","Choice of therapy in patients with type 2 diabetes inadequately controlled with metformin and a sulphonylurea: a systematic review and mixed-treatment comparison meta-analysis.","McIntosh B","2012","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent04","systematic review and mixed treatment comparison of RCTs of add on drugs incl GLP-1 analogues after metformin and sulfonylurea",1],["R0027638","Clinical course and outcomes of type-2 diabetic patients after treatment intensification for insufficient glycaemic control - results of the 2 year prospective DiaRegis follow-up.","Bramlage P","2014","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent04","DiaRegis registry of treatment intensification and comorbidity predictors, GLP-1 use described only, no exposure comparison",1],["R0027808","Exenatide once weekly for the treatment of type 2 diabetes: effectiveness and tolerability in patient subpopulations.","Pencek R","2012","include_nma",null,"pooled_analysis","P01",null,null,"high","first","opus-5.5-agent04","pooled post hoc subpopulation analysis of exenatide once weekly arms from seven sponsor phase 3 RCTs",1],["R0028435","GLP-1 vasodilatation in humans with coronary artery disease is not adenosine mediated.","Aetesam-Ur-Rahman M","2021","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent04","native GLP-1 7-36 amide infusion with or without theophylline after PCI, physiological experiment not therapeutic agonist",1],["R0029104","Why People Seek Obesity Care Through Digital Rather Than In-Person Services: A Quantitative Multinational Analysis of Patients From a Large Unsubsidized Digital Obesity Provider.","Talay LA","2024","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent04","survey of reasons for using a digital obesity service, no GLP-1 RA exposure comparison",1],["R0029711","Determinants of plasma levels of proglucagon and the metabolic impact of glucagon receptor signalling: a UK Biobank study.","Winther-Sørensen M","2024","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent04","UK Biobank study of proglucagon levels and glucagon receptor variants, endogenous physiology, no GLP-1 RA exposure",1],["R0026134","Liraglutide is effective and well tolerated in combination with an oral antidiabetic drug in Japanese patients with type 2 diabetes: A randomized, 52-week, open-label, parallel-group trial.","Kaku K","2016","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent14","52 week open label RCT of liraglutide plus OAD vs two OADs in Japanese T2D",1],["R0026372","Exenatide improves type 2 diabetes concomitant with non-alcoholic fatty liver disease.","Fan H","2013","include_nma",null,"primary_report","P01; P09",null,null,"high","first","opus-5.5-agent01","RCT of exenatide versus metformin for 12 weeks in type 2 diabetes with NAFLD",1],["R0026313","Exenatide and dapagliflozin combination improves markers of liver steatosis and fibrosis in patients with type 2 diabetes.","Gastaldelli A","2020","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent14","post hoc analysis of DURATION-8 RCT of exenatide plus dapagliflozin vs each alone on liver markers",1],["R0026447","Using Exenatide Twice Daily or Insulin in Clinical Practice: Results from CHOICE.","Mathieu C","2013","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent14","CHOICE prospective observational cohorts of exenatide BID vs insulin initiators, treatment change, HbA1c and weight",1],["R0026493","Efficacy of liraglutide in a real-life cohort.","Heymann A","2014","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent01","retrospective single group HMO cohort of liraglutide users with before and after HbA1c and weight",1],["R0026574","Relative risk of acute pancreatitis in initiators of exenatide twice daily compared with other anti-diabetic medication: a follow-up study.","Wenten M","2012","include_harms",null,"primary_report",null,"O29",null,"high","first","opus-5.5-agent14","claims cohort of exenatide BID initiators vs other antidiabetic initiators, hospitalized acute pancreatitis",1],["R0026648","Changes in liraglutide-induced body composition are related to modifications in plasma cardiac natriuretic peptides levels in obese type 2 diabetic patients.","Li CJ","2014","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent01","prospective single group observational study of 12 weeks liraglutide add-on in obese type 2 diabetes",1],["R0026758","Roles of increased glycaemic variability, GLP-1 and glucagon in hypoglycaemia after Roux-en-Y gastric bypass.","Tharakan G","2017","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent14","physiology study of endogenous GLP-1 and glucagon in hypoglycemia after gastric bypass, no GLP-1 RA given",1],["R0026794","Efficacy and safety comparison between liraglutide as add-on therapy to insulin and insulin dose-increase in Chinese subjects with poorly controlled type 2 diabetes and abdominal obesity.","Li CJ","2012","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent01","open label RCT of liraglutide added to insulin versus insulin dose increase in Chinese type 2 diabetes with abdominal obesity",1],["R0026944","Second-line therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a systematic review and mixed-treatment comparison meta-analysis.","McIntosh B","2011","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent14","systematic review and mixed treatment comparison of second line T2D drugs including GLP-1 analogues, several databases",1],["R0027103","Gender difference in response predictors after 1-year exenatide therapy twice daily in type 2 diabetic patients: a real world experience.","Anichini R","2013","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent14","retrospective single arm cohort of exenatide BID by sex, response predictors, no comparison group",1],["R0027148","Assessment of channeling bias among initiators of glucose-lowering drugs: A UK cohort study.","Ankarfeldt MZ","2017","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent01","CPRD cohort assessing channeling bias, GLP-1 RA versus basal insulin initiators; HbA1c and weight only",1],["R0027258","Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?","Nauck MA","2011","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent14","review and meta-analysis of endogenous GLP-1 secretion in T2D vs healthy individuals, no GLP-1 RA exposure",1],["R0027326","Comparative effects of prolonged and intermittent stimulation of the glucagon-like peptide 1 receptor on gastric emptying and glycemia.","Umapathysivam MM","2014","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent01","randomized crossover of native GLP-1 infusions versus saline on gastric emptying in healthy men; native hormone, not a therapeutic agonist",1],["R0027621","Exenatide exhibits dose-dependent effects on glycemic control over 12 weeks in Japanese patients with suboptimally controlled type 2 diabetes.","Kadowaki T","2009","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent01","12 week RCT of exenatide 2.5, 5 or 10 micrograms versus placebo in Japanese type 2 diabetes on sulfonylurea",1],["R0027582","Alpelisib-Induced Hyperglycemia- A Small Case Series","Ekanayake P","2021","inventory_only","N5","other",null,null,null,"high","first","opus-5.5-agent18","abstract case series of alpelisib induced hyperglycemia; one patient managed with dulaglutide among other drugs",1],["R0027780","Effects of exogenous glucagon-like peptide-1 on blood pressure, heart rate, gastric emptying, mesenteric blood flow and glycaemic responses to oral glucose in older individuals with normal glucose tolerance or type 2 diabetes.","Trahair LG","2015","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent18","crossover physiology study of intravenous native GLP-1 vs saline infusion in older adults and T2D; no therapeutic agonist",1],["R0028855","Results from three phase 1 trials of NNC9204-1177, a glucagon/GLP-1 receptor co-agonist: Effects on weight loss and safety in adults with overweight or obesity.","Friedrichsen MH","2023","include_nma",null,"primary_report","P02",null,"mechanistic","high","first","opus-5.5-agent18","three phase 1 trials incl. placebo controlled SAD and MAD RCTs of glucagon/GLP-1 co-agonist NN1177 in overweight; weight and safety",1],["R0029581","Clinical characteristics and intensification patterns in subjects with \"early\" type 2 diabetes in Italy- an analysis from the AMD annals initiative.","Russo GT","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent18","AMD Annals description of early T2D characteristics and intensification patterns; utilization only",1],["R0023724","Effect of Hypoglycemic Drugs on Patients with Heart Failure with or without T2DM: A Bayesian Network Meta-analysis.","Zhang Z","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent02","Bayesian network meta-analysis of RCTs of antidiabetic drugs including GLP-1 RA in heart failure; four databases searched",1],["R0024100","A New 2-Step Acceleration Protocol Using a Histone Deacetylase Inhibitor to Generate Insulin-Producing Cells From Adipose-Derived Mesenchymal Stem Cells.","Ikemoto T","2018","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent02","in vitro differentiation of stem cells into insulin producing cells using exendin-4 in culture",1],["R0024264","The efficacy and safety of liraglutide in the obese, non-diabetic individuals: a systematic review and meta-analysis.","Zhang P","2019","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent02","systematic review and meta-analysis of liraglutide vs placebo RCTs in obese nondiabetic adults; three databases searched",1],["R0024438","Effects of exenatide versus insulin glargine on body composition in overweight and obese T2DM patients: a randomized controlled trial.","Yin TT","2018","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent02","randomized trial of exenatide vs insulin glargine on metformin in overweight or obese T2D, body composition outcomes",1],["R0024591","Meta-analysis of the efficacy of liraglutide in patients with type 2 diabetes accompanied by incipient nephropathy.","Liu W","2019","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent02","meta-analysis of RCTs of liraglutide in T2D with early nephropathy; five databases searched",1],["R0024694","Comparison of Exenatide and Metformin Monotherapy in Overweight/Obese Patients with Newly Diagnosed Type 2 Diabetes.","Liu J","2017","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent02","prospective nonrandomized patient choice comparison of exenatide vs metformin in newly diagnosed obese T2D; no listed harm",1],["R0024844","Effect of exenatide after short-time intensive insulin therapy on glycaemic remission maintenance in type 2 diabetes patients: a randomized controlled trial.","Shi X","2017","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent02","open label RCT of exenatide after short term intensive insulin vs intensive insulin alone on remission in new T2D",1],["R0027756","Patient-reported outcomes in a trial of exenatide and insulin glargine for the treatment of type 2 diabetes.","Secnik Boye K","2006","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent16","patient reported outcome analysis of open label RCT of exenatide vs insulin glargine added to metformin and sulfonylurea",1],["R0027988","One for All? Hitting Multiple Alzheimer's Disease Targets with One Drug.","Hughes RE","2016","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent16","narrative review of multi target drug design for Alzheimer disease",1],["R0028732","Aggressive clinical approach to obesity improves metabolic and clinical outcomes and can prevent bariatric surgery: a single center experience.","Cadegiani FA","2017","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent16","retrospective single center series of intensive multidrug obesity protocol incl. liraglutide, no comparison group",1],["R0029513","Management of subjects with type 2 diabetes hospitalized in internal medicine units: a cluster-randomized, multicenter study before and after an educational program.","Ceriello A","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent16","cluster randomized educational program on guideline adherence in hospitalized T2D; GLP-1RA not an assigned intervention",1],["R0026247","Efficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without metformin) in patients with type 2 diabetes: a randomized, placebo-controlled trial.","Ahmann A","2015","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent08","double blind RCT of liraglutide 1.8 mg versus placebo added to basal insulin with or without metformin",1],["R0026424","Retinopathy, Neuropathy, and Subsequent Cardiovascular Events in Patients with Type 2 Diabetes and Acute Coronary Syndrome in the ELIXA: The Importance of Disease Duration.","Seferovic JP","2018","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent08","ELIXA post hoc analysis of retinopathy and neuropathy as predictors of events in lixisenatide versus placebo trial",1],["R0026732","Effectiveness and cost of integrating a pragmatic pathway for prescribing liraglutide 3.0 mg in obesity services (STRIVE study): study protocol of an open-label, real-world, randomised, controlled trial.","Papamargaritis D","2020","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent08","STRIVE protocol of randomized liraglutide 3 mg prescribing pathway versus standard specialist weight care",1],["R0026895","Efficacy and safety of exenatide once-weekly vs exenatide twice-daily in Asian patients with type 2 diabetes mellitus.","Ji L","2013","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent08","open label RCT of exenatide once weekly versus twice daily in Asian patients with type 2 diabetes",1],["R0027056","Effects of exenatide on circulating glucose, insulin, glucagon, cortisol and catecholamines in healthy volunteers during exercise.","Khoo EY","2010","include_nma",null,"primary_report","P99",null,"crossover; mechanistic","high","first","opus-5.5-agent08","randomized crossover of single dose exenatide versus placebo during exercise in healthy men; hypoglycemia reported",1],["R0027199","Improved treatment satisfaction and weight-related quality of life with exenatide once weekly or twice daily.","Best JH","2009","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent08","treatment satisfaction and quality of life from RCT of exenatide once weekly versus twice daily",1],["R0027419","Exenatide: a new promising antidiabetic agent.","Chakraborti CK","2010","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent08","narrative drug review of exenatide",1],["R0020161","Adherence of physicians to evidence-based management guidelines for treating type 2 diabetes and atherosclerotic cardiovascular disease in Ajman, United Arab Emirates.","Alliabi FJA","2022","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent11","cross sectional study of physician guideline adherence in prescribing SGLT2i or GLP-1RA; no exposure comparison",1],["R0020300","Anti-Obesity Medication Use in Children and Adolescents with Prader-Willi Syndrome: Case Review and Literature Search.","Goldman VE","2021","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent11","case series of anti obesity drugs including semaglutide and liraglutide in Prader-Willi youth with informal literature review",1],["R0020420","Changes in body weight and composition, metabolic parameters, and quality of life in patients with type 2 diabetes treated with subcutaneous semaglutide in real-world clinical practice.","Pantanetti P","2024","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent11","prospective single group real world study of semaglutide on body composition; no comparator",1],["R0020510","BrazIliaN Type 1 & 2 DiabetEs Disease Registry (BINDER): longitudinal, real-world study of diabetes mellitus control in Brazil.","de Almeida-Pititto B","2022","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent11","Brazilian diabetes registry of care patterns and control; GLP-1RA use only described",1],["R0020667","Effect of Liraglutide on Cardiac Function in Individuals With Type 2 Diabetes: A Meta-Analysis.","Haroon H","2023","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent11","PRISMA meta-analysis of liraglutide versus control on cardiac function; PubMed, Google Scholar, Cochrane searched",1],["R0020827","Glucose Variability and β- Cell Response by GLP-1 Analogue added-on CSII for Patients with Poorly Controlled Type 2 Diabetes.","Lin CH","2015","include_nma",null,"primary_report","P01",null,"mechanistic","high","first","opus-5.5-agent11","RCT of exenatide versus placebo added to insulin pump for 3 days in poorly controlled type 2 diabetes; glucose outcomes",1],["R0020916","Weight loss outcomes with semaglutide based on diabetes severity using the individualized metabolic surgery score.","Ghusn W","2024","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent11","retrospective single group semaglutide cohort stratified by metabolic surgery score; no untreated comparator",1],["R0024244","Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Continued Up-Titration of Insulin Glargine U100 in Patients with Type 2 Diabetes in the USA.","Hunt B","2017","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent19","short term cost of control analysis of IDegLira vs glargine using DUAL V results; economic evaluation",1],["R0024373","Short-term treatment with high dose liraglutide improves lipid and lipoprotein profile and changes hormonal mediators of lipid metabolism in obese patients with no overt type 2 diabetes mellitus: a randomized, placebo-controlled, cross-over, double-blind clinical trial.","Peradze N","2019","include_nma",null,"primary_report","P02",null,"crossover; mechanistic","high","first","opus-5.5-agent19","double blind placebo controlled crossover RCT of liraglutide 3 mg for 5 weeks in obese adults without diabetes; lipid metabolomics",1],["R0024568","Comparison of efficacy and safety of three novel hypoglycemic agents in patients with severe diabetic kidney disease: A systematic review and network meta-analysis of randomized controlled trials.","Li Y","2022","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent19","network meta-analysis of RCTs of GLP-1 RA, DPP-4i, SGLT2i in type 2 diabetes with severe CKD; Embase PubMed Cochrane",1],["R0024805","Pleiotropic effects of liraglutide in patients with type 2 diabetes and moderate renal impairment: Individual effects of treatment.","Zobel EH","2019","include_nma",null,"secondary_report","P01; P08A",null,null,"high","first","opus-5.5-agent19","secondary responder analysis of LIRA-RENAL RCT of liraglutide vs placebo in type 2 diabetes with moderate renal impairment",1],["R0024936","Comparative Efficacy of Dual and Single Initiation of Add-On Oral Antihyperglycemic Agents in Type 2 Diabetes Uncontrolled on Metformin Alone: A Systematic Literature Review and Network Meta-Analysis.","Lautsch D","2021","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent19","network meta-analysis of RCTs of single or dual oral add-on agents incl oral GLP-1 RA after metformin; MEDLINE Embase CENTRAL",1],["R0025067","Efficacy and safety of adding liraglutide to existing insulin regimens in Japanese patients with type 2 diabetes mellitus: A post-hoc analysis of a phase 3 randomized clinical trial.","Kaneko S","2018","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent19","post hoc analysis by insulin regimen of LIRA-ADD2INSULIN JAPAN RCT of liraglutide vs placebo",1],["R0027648","Effects of sitagliptin beyond glycemic control: focus on quality of life.","Sakamoto Y","2013","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent07","single arm study of the DPP-4 inhibitor sitagliptin; no GLP-1RA given or studied",1],["R0027879","NASH Therapy: omega 3 supplementation, vitamin E, insulin sensitizers and statin drugs.","Caldwell S","2017","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent07","narrative review of older NASH therapies mentioning a liraglutide trial",1],["R0028454","Clinical profiles and quality of care of subjects with type 2 diabetes according to their cardiovascular risk: an observational, retrospective study.","Pintaudi B","2021","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent07","quality of care study describing drug prescribing by cardiovascular risk class in T2D; no exposure outcome comparison",1],["R0029215","Synthetic polypeptides using a biologic as a reference medicinal product - the European landscape of regulatory approvals.","Klein K","2024","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent07","mini review of European regulatory pathways for synthetic peptide generics such as liraglutide",1],["R0029822","Is Glucagon Receptor Activation the Thermogenic Solution for Treating Obesity?","Conceição-Furber E","2022","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent07","narrative review on glucagon receptor agonism for obesity thermogenesis",1],["R0026152","Effectiveness and tolerability of therapy with exenatide once weekly vs basal insulin among injectable-drug-naïve elderly or renal impaired patients with type 2 diabetes in the United States.","Loughlin AM","2018","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent17","EHR matched cohort of exenatide once weekly versus basal insulin in elderly or renal impaired diabetes; GI symptoms and hypoglycemia, no listed harm",1],["R0026329","Current and future pharmacological therapies for NAFLD/NASH.","Sumida Y","2018","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent17","narrative review of current and future NAFLD and NASH drug therapies",1],["R0026465","The use of electronic health records for recruitment in clinical trials: a mixed methods analysis of the Harmony Outcomes Electronic Health Record Ancillary Study.","O'Brien EC","2021","exclude","E2","ancillary",null,null,null,"high","first","opus-5.5-agent17","mixed methods survey of trial sites on EHR use for recruitment in Harmony Outcomes; no drug effect analysis",1],["R0026622","Effects of a 6-Month Exenatide Therapy on HbA1c and Weight in Korean Patients with Type 2 Diabetes: A Retrospective Cohort Study.","Shin J","2012","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent17","retrospective single group cohort of exenatide in Korean type 2 diabetes without comparison group",1],["R0026783","Retrospective analysis of safety and efficacy of insulin-to-liraglutide switch in Japanese type 2 diabetes: A caution against inappropriate use in patients with reduced β-cell function.","Usui R","2013","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent17","retrospective single group analysis of insulin to liraglutide switch in Japanese type 2 diabetes",1],["R0027127","Exenatide twice daily versus premixed insulin aspart 70/30 in metformin-treated patients with type 2 diabetes: a randomized 26-week study on glycemic control and hypoglycemia.","Gallwitz B","2011","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent17","open label RCT of exenatide twice daily versus premixed insulin aspart in metformin treated type 2 diabetes, 26 weeks",1],["R0025897","Safety and efficacy of pharmacologic weight loss in patients with cirrhosis.","Fakhreddine AY","2021","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent13","retrospective chart review of weight loss drugs incl GLP-1 in cirrhosis assessed before and after initiation",1],["R0026128","Lessons from a cardiovascular outcome trial with liraglutide in type 2 diabetes.","Kim HJ","2017","inventory_only","N9","ancillary",null,null,null,"high","first","opus-5.5-agent13","commentary on the LEADER cardiovascular outcome trial of liraglutide",1],["R0026303","OR26-08 Efficacy and Safety of Higher Dulaglutide Doses (3.0 MG and 4.5 MG) When Added to Metformin in Patients With Type 2 Diabetes: A Phase 3, Randomized, Double-Blind, Parallel ARM Study (Award-11)","Frias J","2020","include_nma",null,"conference_abstract","P01",null,"abstract_only","high","first","opus-5.5-agent13","abstract of AWARD-11 RCT randomizing dulaglutide 1.5, 3 or 4.5 mg added to metformin",1],["R0026572","Predictors of treatment response to liraglutide in type 2 diabetes in a real-world setting.","Simioni N","2018","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent13","observational retrospective cohort of liraglutide initiators analyzing response predictors, no comparison group",1],["R0026752","Effects of exenatide twice daily versus sitagliptin on 24-h glucose, glucoregulatory and hormonal measures: a randomized, double-blind, crossover study.","Berg JK","2011","include_nma",null,"primary_report","P01",null,"mechanistic; crossover","high","first","opus-5.5-agent13","randomized double blind crossover of exenatide twice daily vs sitagliptin with glucose measures and adverse events",1],["R0029659","Does Incretin Agonism Have Sustainable Efficacy?","Janket SJ","2024","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent01","narrative review on sustainability of incretin agonist efficacy",1],["R0022706","Glucose-Lowering Medications and Post-Dementia Survival in Patients with Diabetes and Dementia.","Secnik J","2022","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent15","Swedish registry cohorts with diabetes with and without dementia comparing glucose lowering drugs incl GLP-1 analogues; all cause mortality only",1],["R0022794","Comparative risk of musculoskeletal adverse reactions among new users of dipeptidyl peptidase-4 inhibitors: A retrospective cohort study.","Park T","2021","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent15","claims new user cohort of DPP-4i versus other initiators incl GLP-1 RAs; musculoskeletal conditions only",1],["R0022887","Glycemic variability and all-cause mortality in a large prospective southern European cohort of patients with differences in glycemic status.","Salinero-Fort MA","2022","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent15","cohort of glycemic variability and mortality; GLP-1 RA use only an adjustment covariate",1],["R0023032","The Efficacy and Safety of Liraglutide 3.0 mg for Weight Management in Obese Non-Diabetic Saudi Outpatients.","Albaker W","2021","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent15","retrospective single group cohort of liraglutide 3.0 mg users in Saudi Arabia; no comparator",1],["R0023191","EndoC-βH5 cells are storable and ready-to-use human pancreatic beta cells with physiological insulin secretion.","Blanchi B","2023","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent15","characterization of the EndoC-betaH5 human beta cell line in vitro, incl incretin analog stimulation",1],["R0023298","Real-World Use of Once-Weekly Semaglutide in Type 2 Diabetes: Results from the SURE UK Multicentre, Prospective, Observational Study.","Holmes P","2021","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent15","SURE UK prospective observational single group study of once weekly semaglutide users; no comparator",1],["R0023422","Prevalence, risk factors, and interventions for obesity in Saudi Arabia: A systematic review.","Salem V","2022","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent15","systematic review of obesity prevalence and interventions in Saudi Arabia; no GLP-1 RA studies synthesized",1],["R0023562","Efficacy and Safety of Once-Weekly Dulaglutide in Elderly Chinese Patients with Type 2 Diabetes: A Post Hoc Analysis of AWARD-CHN Studies.","Kuang J","2020","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent15","post hoc age subgroup analysis of AWARD-CHN1 and CHN2 RCTs of dulaglutide versus glimepiride or glargine",1],["R0021060","Impact of Different Anti-Hyperglycaemic Treatments on Bone Turnover Markers and Bone Mineral Density in Type 2 Diabetes Mellitus Patients: A Systematic Review and Meta-Analysis.","Saadi MSS","2024","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent10","meta-analysis of RCTs of antidiabetic drugs including GLP-1 RAs on BMD and bone markers in T2D; PubMed and Cochrane searched",1],["R0021197","Cardiovascular outcomes with glucagon-like peptide 1 agonists and sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes: A meta-analysis.","Lee YM","2022","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent10","meta-analysis of GLP-1 RA and SGLT2i outcome RCTs in T2D; PubMed and EMBASE searched",1],["R0021292","Pharmacotherapy for obesity: moving towards efficacy improvement.","Coutinho W","2024","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent10","narrative review of obesity pharmacotherapy focusing on semaglutide; no methods",1],["R0021400","Metabolic and gut microbiome changes following GLP-1 or dual GLP-1/GLP-2 receptor agonist treatment in diet-induced obese mice.","Madsen MSA","2019","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent10","diet induced obese mice given liraglutide or dual GLP-1/GLP-2 agonist; animal study only",1],["R0021488","Simplifying Complex Insulin Regimens While Preserving Good Glycemic Control in Type 2 Diabetes.","Taybani Z","2019","inventory_only","N1","primary_report",null,null,null,"high","first","opus-5.5-agent10","prospective single arm trial switching MDI insulin to IDegLira in well controlled T2D",1],["R0021634","Liraglutide for Weight Management in Children and Adolescents With Prader-Willi Syndrome and Obesity.","Diene G","2022","include_nma",null,"primary_report","P03; P99",null,null,"high","first","opus-5.5-agent10","RCT liraglutide 3 mg versus placebo in children and adolescents with Prader-Willi syndrome and obesity",1],["R0021968","Efficacy and safety of dulaglutide 3.0 and 4.5 mg in patients aged younger than 65 and 65 years or older: Post hoc analysis of the AWARD-11 trial.","Frias JP","2021","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent10","post hoc by age of AWARD-11 RCT dulaglutide 3.0 and 4.5 mg versus 1.5 mg; HbA1c and weight",1],["R0027511","Zinc-α2-glycoprotein is associated with insulin resistance in humans and is regulated by hyperglycemia, hyperinsulinemia, or liraglutide administration: cross-sectional and interventional studies in normal subjects, insulin-resistant subjects, and subjects with newly diagnosed diabetes.","Yang M","2013","include_nma",null,"primary_report","P01",null,"mechanistic","high","first","opus-5.5-agent14","12 week liraglutide vs placebo randomized substudy in new T2D within cross sectional ZAG study, metabolic markers",1],["R0027747","Safety and efficacy of once-weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes over 84 weeks.","Diamant M","2012","include_nma",null,"extension","P01",null,null,"high","first","opus-5.5-agent14","84 week extension of randomized trial of exenatide once weekly vs insulin glargine in T2D",1],["R0027965","A case of severe acute necrotizing pancreatitis after administration of sitagliptin.","Sue M","2013","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent14","case report of acute pancreatitis with sitagliptin, DPP-4 inhibitor only",1],["R0028706","No Association of Proton Pump Inhibitor Use with Fasting or Postload Glycaemia in Patients with Cardiovascular Disease: A Cross-Sectional Retrospective Study.","Kruszelnicka O","2017","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent14","cross sectional study of proton pump inhibitor use and glycemia, no GLP-1 RA exposure",1],["R0029360","Real-World Adherence Patterns and Predictors of GLP-1 Receptor Agonist Use for Obesity Management in a Medicaid Population.","Bazzazzadehgan S","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent14","Medicaid claims study of adherence and persistence among GLP-1 RA initiators, utilization without exposure comparison",1],["R0021058","Efficacy and safety of liraglutide in patients with type 2 diabetes mellitus and severe obstructive sleep apnea.","Jiang W","2023","include_nma",null,"primary_report","P01; P10",null,null,"high","first","opus-5.5-agent09","open label RCT of liraglutide added to CPAP and usual drugs versus no liraglutide in type 2 diabetes with severe sleep apnea",1],["R0021192","Critical evaluation of real-world evidence of repurposable medicines in the Alzheimer's disease drug development pipeline using a target trial emulation.","Tonegawa-Kuji R","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent09","claims target trial emulations of repurposable drugs including liraglutide versus same class comparators on Alzheimer incidence",1],["R0021286","Glycaemic variability in patients with type 2 diabetes mellitus treated with dulaglutide, with and without concomitant insulin: Post hoc analyses of randomized clinical trials.","Jódar E","2022","include_nma",null,"pooled_analysis","P01",null,null,"high","first","opus-5.5-agent09","post hoc pooled analyses of six randomized AWARD trials of dulaglutide on glycaemic variability",1],["R0021399","Change in Urine Albumin-Creatinine Ratio and Occurrence of Hyperkalemia in Patients Initiating Finerenone in the USA: A Cohort Study from the FOUNTAIN Platform.","Kovesdy CP","2025","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent09","single drug finerenone cohort, GLP-1 agonists only recorded as concomitant medication",1],["R0021483","Pharmacology, efficacy and safety of liraglutide in the management of type 2 diabetes.","Neumiller JJ","2010","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent09","narrative review of liraglutide pharmacology and LEAD trials based on MEDLINE search without criteria",1],["R0021631","Subgroup Analysis Stratified by Baseline Pancreatic β-cell Function in a Japanese Study of Dulaglutide in Patients with Type 2 Diabetes.","Iwamoto N","2018","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent09","subgroup analysis by beta cell function of Japanese RCT of dulaglutide versus liraglutide and placebo",1],["R0021749","Comparative efficacy of SGLT2 Inhibitors and Obeticholic Acid in MAFLD and Fibrosis: A Systematic Review","Ganesh T","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent09","systematic review of SGLT2 inhibitors versus obeticholic acid in MAFLD, GLP-1 drugs not studied",1],["R0024958","L-arginine as a potential GLP-1-mediated immunomodulator of Th17-related cytokines in people with obesity and asthma.","Liao SY","2021","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent02","post hoc analysis of L-arginine vs placebo crossover trial in asthma; no GLP-1 receptor agonist given",1],["R0025091","Liraglutide and the management of overweight and obesity in people with schizophrenia, schizoaffective disorder and first-episode psychosis: protocol for a pilot trial.","Whicher CA","2019","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent02","protocol of placebo controlled pilot RCT of liraglutide 3.0 mg in obese people with schizophrenia or psychosis",1],["R0025198","Insulin resistance limits corneal nerve regeneration in patients with type 2 diabetes undergoing intensive glycemic control.","Ponirakis G","2021","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent02","substudy of open label RCT of exenatide plus pioglitazone vs basal bolus insulin in T2D on corneal nerves",1],["R0025382","Effects of Glucagon-like Peptide-1 on the Reproductive Axis in Healthy Men.","Izzi-Engbeaya C","2020","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent02","randomized crossover native GLP-1 vs vehicle intravenous infusion in healthy men; not a receptor agonist drug",1],["R0025541","HbA1c-Triggered Endocrinology Electronic Consultation for Type 2 Diabetes Management.","Oseran AS","2022","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent02","cluster randomized endocrinology e-consultation trial; GLP-1 RA appears only as a prescribing outcome",1],["R0025674","Health and economic outcomes for exenatide once weekly, insulin, and pioglitazone therapies in the treatment of type 2 diabetes: a simulation analysis.","Gaebler JA","2012","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent02","Archimedes simulation of exenatide weekly vs insulin and pioglitazone outcomes and costs",1],["R0025814","Effectiveness and Persistence of Liraglutide Treatment Among Patients with Type 2 Diabetes Treated in Primary Care and Specialist Settings: A Subgroup Analysis from the EVIDENCE Study, a Prospective, 2-Year Follow-up, Observational, Post-Marketing Study.","Martinez L","2017","inventory_only","N5","secondary_report",null,null,null,"high","first","opus-5.5-agent02","EVIDENCE prospective observational liraglutide cohort subgroup by care setting; no untreated comparison",1],["R0025954","Glucagon-Like Peptide-1 Infusion Suppresses Aldosterone Levels in Healthy Normal-Weight Individuals: Double-Blind, Placebo-Controlled Crossover Study.","Baretić M","2018","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent02","randomized crossover native GLP-1 vs saline infusion in healthy volunteers on aldosterone",1],["R0027655","Identifying good responders to glucose lowering therapy in type 2 diabetes: implications for stratified medicine.","Jones AG","2014","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent08","PRIBA prospective cohort of GLP-1 RA initiators defining treatment response; single group without comparison",1],["R0028483","Receptor occupancy of dual glucagon-like peptide 1/glucagon receptor agonist SAR425899 in individuals with type 2 diabetes.","Eriksson O","2020","inventory_only","N1","primary_report",null,null,null,"high","first","opus-5.5-agent08","open label phase 1b of dual GLP-1 and glucagon agonist SAR425899 with nonrandomized dose groups; PET receptor occupancy",1],["R0029217","Trends and regional differences in antidiabetic medication use: a nationwide retrospective observational study.","Csatordai M","2024","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent08","Hungarian drug utilization study of antidiabetic classes incl GLP-1 analogues by region; no exposure comparison",1],["R0029840","Fibroblast growth factor 21 mediates specific glucagon actions.","Habegger KM","2013","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent08","glucagon receptor agonist studies in mice and native glucagon injection in humans; no GLP-1 receptor agonist given",1],["R0027761","Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study.","Russell-Jones D","2012","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent17","DURATION-4 double blind RCT of exenatide once weekly versus metformin, pioglitazone, sitagliptin monotherapy, 26 weeks",1],["R0028809","Comparison of short-term energy intake and appetite responses to active and seated video gaming, in 8-11-year-old boys.","Allsop S","2016","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent17","crossover study of active versus seated video gaming on appetite and endogenous GLP-1 in boys; no GLP-1 RA drug",1],["R0029569","Clinical perspectives of new insights and tools to minimize the hypoglycaemia burden connected with type 2 diabetes pharmacotherapy.","Standl E","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent17","clinical perspective comment on minimizing hypoglycemia in type 2 diabetes pharmacotherapy",1],["R0025356","Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity.","Blundell J","2017","include_nma",null,"primary_report","P02",null,"crossover; mechanistic","high","first","opus-5.5-agent19","double blind placebo controlled crossover RCT of semaglutide 1.0 mg for 12 weeks in obesity; energy intake, weight, nausea",1],["R0025503","Evaluation of the cost effectiveness of exenatide versus insulin glargine in patients with sub-optimally controlled type 2 diabetes in the United Kingdom.","Woehl A","2008","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent19","discrete event simulation cost utility analysis of exenatide vs insulin glargine in the UK",1],["R0025661","Liraglutide in polycystic ovary syndrome: a randomized trial, investigating effects on thrombogenic potential.","Nylander M","2017","include_nma",null,"primary_report","P12",null,null,"high","first","opus-5.5-agent19","double blind RCT of liraglutide 1.8 mg vs placebo for 26 weeks in overweight women with PCOS; weight and thrombogenic markers",1],["R0025795","The Impact of a Clinical Pharmacist in an Interdisciplinary Weight Loss Service: A Follow-Up Study.","Francis BR","2021","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent19","retrospective comparison of pharmacist led weight service vs usual care; liraglutide use only described, not the exposure contrast",1],["R0025926","MON-601 Obesity Pharmacotherapy Is Effective in the United States Veterans Affairs Patient Population: A Local and Virtual Cohort Study","Pendse J","2020","inventory_only","N6","conference_abstract",null,null,"abstract_only","high","first","opus-5.5-agent19","VA cohort abstract comparing weight change across obesity drugs incl liraglutide vs metformin; effectiveness only",1],["R0026033","Disparities in glycaemic control, monitoring, and treatment of type 2 diabetes in England: A retrospective cohort analysis.","Whyte MB","2019","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent19","disparities in glycemic monitoring and prescribing in English primary care; GLP-1 RA prescribing as outcome only",1],["R0026157","Liraglutide in people treated for type 2 diabetes with multiple daily insulin injections: randomised clinical trial (MDI Liraglutide trial).","Lind M","2015","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent19","double blind RCT of liraglutide vs placebo in type 2 diabetes on multiple daily insulin injections, 24 weeks",1],["R0021074","Retrospective cohort study of the predictors of weight loss after 3 months of treatment with Liraglutide for patients with obesity/overweight at the “Centre d’Obésité et de Contrôle du Poids” (COCP)","Moujaes G","2023","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent11","retrospective single group study of liraglutide weight loss predictors in Lebanon; no comparator",1],["R0021198","Once Weekly Dulaglutide Therapy in Type 2 Diabetic Subjects, Real-world Evidence from a Tertiary Care Diabetes Center in India.","Wasir JS","2018","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent11","retrospective single group observational study of dulaglutide in Indian clinic; no comparator",1],["R0021299","Metformin Use and Leukemia Risk in Patients With Type 2 Diabetes Mellitus.","Tseng CH","2020","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent11","Taiwan cohort of metformin initiators and leukemia; incretin therapy only a sensitivity exclusion, not an exposure",1],["R0021409","Recent Advances in the Emerging Therapeutic Strategies for Diabetic Kidney Diseases.","Huang W","2022","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent11","narrative review of therapeutic strategies for diabetic kidney disease",1],["R0021507","Safety and effectiveness of dulaglutide 0.75 mg in Japanese patients with type 2 diabetes in real-world clinical practice: 36 month post-marketing observational study.","Chin R","2023","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent11","prospective post marketing surveillance of dulaglutide users in Japan without comparator",1],["R0021650","Effects of combined GIP and GLP-1 infusion on energy intake, appetite and energy expenditure in overweight/obese individuals: a randomised, crossover study.","Bergmann NC","2019","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent11","randomized crossover of native GIP and GLP-1 infusions in overweight men; native hormone infusions out of scope",1],["R0021766","Pancreatic safety in Japanese patients with type 2 diabetes treated with once weekly dulaglutide 0.75 mg up to 52 weeks in phase 3 clinical trials.","Emoto M","2017","include_nma",null,"pooled_analysis","P01",null,null,"high","first","opus-5.5-agent11","pooled pancreatic safety analysis of three Japanese phase 3 trials of dulaglutide versus liraglutide, glargine or placebo",1],["R0021973","Identification of key candidate genes and pathways revealing the protective effect of liraglutide on diabetic cardiac muscle by integrated bioinformatics analysis.","Dong Y","2020","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent11","bioinformatic reanalysis of rat cardiac gene expression after liraglutide",1],["R0027094","Estimating and reporting treatment effects in clinical trials for weight management: using estimands to interpret effects of intercurrent events and missing data.","Wharton S","2021","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent13","methods review on estimands and missing data in weight management trials",1],["R0027247","Evaluation of Pharmacologic Interventions for Weight Management in a Veteran Population.","Hood SR","2021","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent13","retrospective descriptive chart review of veterans on weight management drugs incl liraglutide",1],["R0027494","Descriptive Analysis of Reported Adverse Events Associated with Antiobesity Medications Using FDA Adverse Event Reporting System (FAERS) Databases 2013-2020","Alsuhibani A","2021","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent13","descriptive FAERS analysis of adverse event reports for anti-obesity drugs incl liraglutide",1],["R0027721","Current and emerging pharmacological therapy for non-alcoholic fatty liver disease.","Eshraghian A","2017","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent13","editorial review of current and emerging NAFLD pharmacotherapy",1],["R0027938","SAT-LB116 Extreme Insulin Resistance: The Diagnostic Challenges When Cost Is a Limitation","Cavalcante Parr N","2020","inventory_only","N5","primary_report",null,null,"abstract_only","high","first","opus-5.5-agent13","case report abstract of extreme insulin resistance where liraglutide was tried",1],["R0028644","SGLT inhibitor adjunct therapy in type 1 diabetes.","McCrimmon RJ","2018","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent13","review of SGLT inhibitor adjunct therapy in type 1 diabetes, GLP-1 agonists not studied",1],["R0029347","Oral small-molecule GLP-1RA safiglipron versus dapagliflozin in type 2 diabetes: a randomized, double-blind, active-comparator-controlled phase 3 trial.","Guo L","2026","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent13","OUTSTAND-2 phase 3 RCT of oral small molecule GLP-1 agonist safiglipron doses vs dapagliflozin",1],["R0023675","Comparable liraglutide pharmacokinetics in pediatric and adult populations with type 2 diabetes: a population pharmacokinetic analysis.","Petri KC","2015","inventory_only","N2","secondary_report",null,null,null,"high","first","opus-5.5-agent15","population pharmacokinetic model of liraglutide exposure pooling pediatric and adult trials; no review outcome reported",1],["R0023843","Patient-reported outcomes are superior in patients with Type 2 diabetes treated with liraglutide as compared with exenatide, when added to metformin, sulphonylurea or both: results from a randomized, open-label study.","Schmidt WE","2011","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent15","patient reported outcomes from LEAD-6 RCT of liraglutide versus exenatide added to metformin or sulfonylurea",1],["R0024060","IDegLira Versus Insulin Glargine U100: A Long-term Cost-effectiveness Analysis in the US Setting.","Hunt B","2017","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent15","CORE Diabetes Model cost effectiveness analysis of IDegLira versus glargine based on DUAL V",1],["R0024199","One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial.","Pratley R","2011","include_nma",null,"extension","P01",null,null,"high","first","opus-5.5-agent15","52 week extension keeping randomized arms of liraglutide 1.2 or 1.8 mg versus sitagliptin added to metformin",1],["R0024335","Integrative network analysis highlights biological processes underlying GLP-1 stimulated insulin secretion: A DIRECT study.","Gudmundsdottir V","2018","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent15","GWAS of native GLP-1 stimulated insulin secretion in clamps plus liraglutide in ob/ob mice; no human GLP-1 RA exposure",1],["R0024524","Combination Therapy With Canagliflozin Plus Liraglutide Exerts Additive Effect on Weight Loss, but Not on HbA1c, in Patients With Type 2 Diabetes.","Ali AM","2020","include_nma",null,"primary_report","P01",null,"mechanistic","high","first","opus-5.5-agent15","RCT of canagliflozin, liraglutide or combination for 16 weeks in type 2 diabetes; HbA1c, weight and glucose production",1],["R0024666","Liraglutide effects in a paediatric (7-11 y) population with obesity: A randomized, double-blind, placebo-controlled, short-term trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics.","Mastrandrea LD","2019","include_nma",null,"primary_report","P03",null,null,"high","first","opus-5.5-agent15","short term RCT of liraglutide versus placebo in children aged 7 to 11 with obesity; safety, PK and weight",1],["R0024779","Reducing HbA1c in Type 2 Diabetes Using Digital Twin Technology-Enabled Precision Nutrition: A Retrospective Analysis.","Shamanna P","2020","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent15","retrospective study of a digital twin precision nutrition program in type 2 diabetes; no GLP-1 RA exposure studied",1],["R0026189","Early liraglutide treatment improves β-cell function in patients with type 2 diabetes: a retrospective cohort study.","Kondo Y","2015","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent02","retrospective single group cohort switching insulin to liraglutide with beta cell function before and after",1],["R0026391","Exenatide twice daily versus insulin glargine for the treatment of type 2 diabetes in Poland - subgroup data from a randomised multinational trial GWAA.","Matyjaszek-Matuszek B","2013","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent02","Polish subgroup of GWAA RCT of exenatide twice daily vs insulin glargine in T2D",1],["R0026500","Satisfaction of switching to combination therapy with lixisenatide and basal insulin in patients with type 2 diabetes receiving multiple daily insulin injection therapy: A randomized controlled trial.","Miya A","2018","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent02","open label RCT of switch to lixisenatide plus basal insulin vs continued multiple daily injections in T2D",1],["R0026656","Study protocol of a randomised controlled trial comparing perioperative intravenous insulin, GIK or GLP-1 treatment in diabetes-PILGRIM trial.","Polderman JA","2014","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent02","protocol of PILGRIM RCT comparing perioperative GIK, insulin boluses and liraglutide pretreatment",1],["R0026810","Effect of pharmacological interventions and placebo on liver Histology in nonalcoholic steatohepatitis: A network meta-analysis.","Pennisi G","2022","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent02","registered network meta-analysis of NASH drug RCTs including semaglutide on liver histology",1],["R0027157","Metformin as an initial adjunct to low-dose liraglutide enhances the weight-decreasing potential of liraglutide in obese polycystic ovary syndrome: Randomized control study.","Jensterle M","2016","inventory_only","N3","primary_report",null,null,null,"high","first","opus-5.5-agent02","RCT of metformin plus liraglutide 1.2 mg vs liraglutide 1.2 mg alone in obese PCOS; GLP-1 regimen unchanged",1],["R0022103","Endogenous incretin levels and risk of first incident cancer: a prospective cohort study.","Jujić A","2023","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent10","population cohort of endogenous fasting and post-load GLP-1 and GIP levels and incident cancer; no drug exposure",1],["R0022203","Abstract 10: Efficacy and safety of semaglutide 2.4 mg once- weekly in adults with overweight or obesity and type 2 diabetes (STEP 2)",null,"2022","include_nma",null,"conference_abstract","P01",null,"abstract_only","high","first","opus-5.5-agent10","abstract of STEP 2 RCT semaglutide 2.4 mg versus 1.0 mg versus placebo in T2D with obesity",1],["R0022308","Placebo-controlled randomised trial with liraglutide on magnetic resonance endpoints in individuals with type 2 diabetes: a pre-specified secondary study on ectopic fat accumulation.","Bizino MB","2020","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent10","prespecified secondary MRI study of MAGNA VICTORIA RCT liraglutide versus placebo in T2D; ectopic fat",1],["R0022441","[Development of disease-modifying drugs for Parkinson's disease. Is it a tough road?].","Nagai M","2023","exclude","E3","other",null,null,"non_english","high","first","opus-5.5-agent10","Japanese narrative review of disease modifying drugs for Parkinson disease mentioning GLP-1 RA trials",1],["R0022544","A multidisciplinary, shared care clinic using personalized medicine and coordinated care in patients with concomitant type 2 diabetes and cardiovascular disease. Protocol and baseline characteristics.","Pontoppidan JRN","2024","exclude","E2","protocol_or_design",null,null,null,"high","first","opus-5.5-agent10","protocol and baseline of nonrandomized shared care clinic pilot in T2D with CVD; GLP-1 RA only background",1],["R0022665","Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes.","Courrèges JP","2008","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent10","letter reporting exploratory CV biomarkers from 14 week RCT liraglutide three doses versus placebo in T2D",1],["R0022776","Improved glycaemic control in patients with type 2 diabetes has a beneficial impact on NAFLD, independent of change in BMI or glucose lowering agent.","Colosimo S","2023","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent10","retrospective cohort of DPP-4i, GLP-1 RA, SGLT2i initiators; fatty liver index changes only, no harms_nrs outcome",1],["R0022856","GLP-1 receptors exist in the parietal cortex, hypothalamus and medulla of human brains and the GLP-1 analogue liraglutide alters brain activity related to highly desirable food cues in individuals with diabetes: a crossover, randomised, placebo-controlled trial.","Farr OM","2016","include_nma",null,"primary_report","P01",null,"crossover; mechanistic","high","first","opus-5.5-agent10","crossover RCT liraglutide versus placebo in T2D with fMRI food cue responses; adverse effects and nausea reported",1],["R0024925","Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin (HEELA) study.","Davies MJ","2009","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent15","HEELA open label RCT of exenatide versus insulin glargine added to oral drugs in overweight type 2 diabetes for 26 weeks",1],["R0025168","Prediction and validation of exenatide risk marker effects on progression of renal disease: Insights from EXSCEL.","Idzerda NMA","2020","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent15","post hoc risk marker prediction analysis of EXSCEL RCT of exenatide once weekly versus placebo on renal outcomes",1],["R0025338","The once-daily human glucagon-like peptide-1 (GLP-1) analog liraglutide improves postprandial glucose levels in type 2 diabetes patients.","Flint A","2011","include_nma",null,"primary_report","P01",null,"crossover; mechanistic","high","first","opus-5.5-agent15","randomized placebo controlled crossover trial of liraglutide doses on postprandial and fasting glucose in type 2 diabetes",1],["R0025474","Patient-reported outcomes following treatment with the human GLP-1 analogue liraglutide or glimepiride in monotherapy: results from a randomized controlled trial in patients with type 2 diabetes.","Bode BW","2010","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent15","patient reported outcomes from LEAD-3 RCT of liraglutide 1.2 or 1.8 mg versus glimepiride monotherapy",1],["R0025627","Dapagliflozin once-daily and exenatide once-weekly dual therapy: A 24-week randomized, placebo-controlled, phase II study examining effects on body weight and prediabetes in obese adults without diabetes.","Lundkvist P","2017","include_nma",null,"primary_report","P02",null,null,"high","first","opus-5.5-agent15","phase 2 RCT of dapagliflozin plus exenatide once weekly versus placebo for 24 weeks in obese adults without diabetes",1],["R0025777","Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial.","Leiter LA","2019","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent15","post hoc gender, age and CV risk subgroup analysis of SUSTAIN 6 RCT of semaglutide versus placebo",1],["R0025908","Once daily injection of exendin-4 to diabetic mice achieves long-term beneficial effects on blood glucose concentrations.","Greig NH","1999","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent15","exendin-4 experiments in rats and diabetic mice; animals only",1],["R0022102","Weight Loss Outcomes Among Early High Responders to Exenatide Treatment: A Randomized, Placebo Controlled Study in Overweight and Obese Women.","Rodgers M","2021","include_nma",null,"secondary_report","P02",null,null,"high","first","opus-5.5-agent09","responder analysis of RCT of exenatide versus placebo injections with hypocaloric diet in overweight and obese women",1],["R0022195","A protocol for a randomised, double-blind, placebo-controlled study of the effect of LIraglutide on left VEntricular function in chronic heart failure patients with and without type 2 diabetes (The LIVE Study).","Jorsal A","2014","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent09","protocol of LIVE double blind RCT of liraglutide versus placebo in chronic heart failure with and without diabetes",1],["R0022306","The once-daily human glucagon-like peptide-1 analog, liraglutide, improves β-cell function in Japanese patients with type 2 diabetes.","Seino Y","2012","include_nma",null,"pooled_analysis","P01",null,null,"high","first","opus-5.5-agent09","analysis of two Japanese RCTs of liraglutide versus glibenclamide or placebo on beta cell function",1],["R0022434","Effect of Oral Semaglutide on Cardiovascular Parameters and Their Mechanisms in Patients with Type 2 Diabetes: Rationale and Design of the Semaglutide Anti-Atherosclerotic Mechanisms of Action Study (SAMAS).","Janić M","2022","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent09","design paper of SAMAS randomized trial of oral semaglutide versus placebo in type 2 diabetes",1],["R0022543","Synergistic effects of metformin with liraglutide against endothelial dysfunction through GLP-1 receptor and PKA signalling pathway.","Ke J","2017","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent09","HUVEC and ApoE knockout mouse experiments with liraglutide and metformin, no humans",1],["R0022652","GLP-1 and hunger modulate incentive motivation depending on insulin sensitivity in humans.","Hanssen R","2021","inventory_only","N2","primary_report",null,null,"crossover","high","first","opus-5.5-agent09","placebo controlled crossover of single dose liraglutide on incentive motivation in lean and obese volunteers, no review outcome reported",1],["R0022770","Evidence for Cardiorenal Protection with SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Patients with Diabetic Kidney Disease.","Georgianos PI","2022","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent09","narrative review of SGLT2 and GLP-1 cardiorenal evidence in diabetic kidney disease",1],["R0022855","Roux-en-Y Gastric Bypass and Caloric Restriction but Not Gut Hormone-Based Treatments Profoundly Impact the Hypothalamic Transcriptome in Obese Rats.","Dischinger U","2021","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent09","obese rats randomized to gastric bypass, liraglutide, PYY or combinations, hypothalamic transcriptome, no humans",1],["R0022111","Liraglutide treatment improves postprandial lipid metabolism and cardiometabolic risk factors in humans with adequately controlled type 2 diabetes: A single-centre randomized controlled study.","Matikainen N","2019","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent11","single blind RCT of liraglutide 1.8 mg versus placebo for 16 weeks in type 2 diabetes",1],["R0025032","Pharmacological Treatment in Diabetes Mellitus Type 1 - Insulin and What Else?","Otto-Buczkowska E","2018","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent15","narrative review of adjunct non insulin drugs in type 1 diabetes incl GLP-1 RAs",1],["R0022206","Adding liraglutide to the backbone therapy of biguanide in patients with coronary artery disease and newly diagnosed type-2 diabetes (the AddHope2 study): a randomised controlled study protocol.","Anholm C","2014","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent11","protocol of AddHope2 placebo controlled crossover RCT of liraglutide added to metformin",1],["R0022313","Ease-of-use and acceptability of the novel semaglutide 2.4 mg single-dose pen-injector in people with overweight or obesity in the STEP 8 phase III trial.","Snitker S","2022","include_nma",null,"secondary_report","P02",null,null,"high","first","opus-5.5-agent11","STEP 8 secondary report of pen injector ease of use within RCT of semaglutide, liraglutide and placebo",1],["R0022443","Efficacy of Liraglutide in Non-Diabetic Obese Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.","Barboza JJ","2022","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent11","registered meta-analysis of liraglutide versus placebo RCTs in obesity without diabetes; five named databases",1],["R0022685","Examining Weight Suppression, Leptin Levels, Glucagon-Like Peptide 1 Response, and Reward-Related Constructs in Severity and Maintenance of Bulimic Syndromes: Protocol and Sample Characteristics for a Cross-Sectional and Longitudinal Study.","Keel PK","2025","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent11","protocol and sample characteristics of bulimia study measuring endogenous GLP-1 response; no GLP-1RA given",1],["R0022779","Real-world HbA1c changes and prescription characteristics among type 2 diabetes mellitus patients initiating treatment with once weekly semaglutide for diabetes.","Frazer M","2024","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent11","claims study of HbA1c change and prescribing among semaglutide initiators; no comparator group",1],["R0022862","Effects of exenatide vs. metformin on endothelial function in obese patients with pre-diabetes: a randomized trial.","Kelly AS","2012","include_nma",null,"primary_report","P06",null,null,"high","first","opus-5.5-agent11","open label RCT of exenatide versus metformin for 3 months in obese adults with prediabetes",1],["R0026787","MON-632 The Effects of a High Intensity Glycemic Program on Weight and BMI","Guzman H","2020","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent19","abstract of intensive glycemic program single group weight change; GLP-1 RA use only recorded as covariate",1],["R0026987","Association of serum fetuin-B with insulin resistance and pre-diabetes in young Chinese women: evidence from a cross-sectional study and effect of liraglutide.","Xia X","2021","inventory_only","N1","primary_report",null,null,null,"high","first","opus-5.5-agent19","cross sectional fetuin-B study with a single arm 24 week liraglutide subgroup in overweight young women",1],["R0027283","Non-alcoholic fatty liver disease and steatohepatitis: State of the art on effective therapeutics based on the gold standard method for diagnosis.","Mahjoubin-Tehran M","2021","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent19","narrative review of biopsy based NAFLD drug trials",1],["R0027591","Baseline Predictors of Glycemic Worsening in Youth and Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes in the Restoring Insulin Secretion (RISE) Study.","Sam S","2021","include_nma",null,"secondary_report","P06; P01",null,null,"high","first","opus-5.5-agent19","RISE adult RCT analysis of predictors of glycemic worsening incl liraglutide plus metformin vs placebo in IGT or new type 2 diabetes",1],["R0027331","The efficacy of incretin therapy in patients with type 2 diabetes undergoing hemodialysis.","Terawaki Y","2013","include_nma",null,"primary_report","P08A",null,"crossover; mechanistic","high","first","opus-5.5-agent02","randomized crossover of liraglutide vs vildagliptin vs alogliptin in hemodialysis T2D with CGM and adverse effects",1],["R0028096","Restoring Insulin Secretion (RISE): design of studies of β-cell preservation in prediabetes and early type 2 diabetes across the life span.","RISE Consortium","2014","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent02","RISE consortium design paper of randomized protocols including liraglutide plus metformin; no results",1],["R0029679","Coated glucose microbeads stimulate enteric hormone release and improve glucose tolerance in Phase 1 and 2 clinical trials.","Deusch K","2025","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent02","randomized trials of coated glucose microbeads stimulating endogenous GLP-1; no receptor agonist drug",1],["R0022999","Liraglutide on type 2 diabetes mellitus with nonalcoholic fatty liver disease: A systematic review and meta-analysis of 16 RCTs.","Zhao Y","2023","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent10","meta-analysis of 16 RCTs of liraglutide versus control in T2D with NAFLD; five databases searched",1],["R0023143","Prognosis and Personalized In Silico Prediction of Treatment Efficacy in Cardiovascular and Chronic Kidney Disease: A Proof-of-Concept Study.","Jaimes Campos MA","2023","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent10","retrospective peptidomic classifier study with in silico simulated treatment effects including GLP-1 RA; modeling",1],["R0023389","Cardiovascular outcomes and healthcare costs of liraglutide versus basal insulin for type 2 diabetes patients at high cardiovascular risk.","Huang WC","2021","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent10","Taiwan matched cohort liraglutide versus basal insulin initiators; CV outcomes, mortality and costs only",1],["R0023542","Effect of liraglutide treatment on body mass index and weight parameters in children and adolescents with type 2 diabetes: Post hoc analysis of the ellipse trial.","Bensignor MO","2021","include_nma",null,"secondary_report","P04",null,null,"high","first","opus-5.5-agent10","post hoc of ellipse RCT liraglutide versus placebo in pediatric T2D; BMI and weight parameters",1],["R0023797","Renal Outcomes in Type 2 Diabetes: A Review of Cardiovascular and Renal Outcome Trials.","Williams DM","2020","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent10","narrative review of renal outcomes in CVOTs of SGLT2i, DPP-4i and GLP-1 RAs",1],["R0023990","Weight Loss Induces Changes in Vitamin D Status in Women With Obesity But Not in Men: A Randomized Clinical Trial.","Holt R","2025","include_nma",null,"secondary_report","P02",null,null,"high","first","opus-5.5-agent10","secondary analysis of S-LiTE RCT liraglutide, exercise, both or placebo after diet induced weight loss; vitamin D and weight",1],["R0027787","Effects of exenatide on measures of β-cell function after 3 years in metformin-treated patients with type 2 diabetes.","Bunck MC","2011","include_nma",null,"extension","P01",null,null,"high","first","opus-5.5-agent19","3 year extension of RCT of exenatide vs insulin glargine on metformin keeping randomized arms; beta cell function and HbA1c",1],["R0028052","Incretins, insulin secretion and Type 2 diabetes mellitus.","Vilsbøll T","2004","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent19","narrative review of incretin physiology and type 2 diabetes",1],["R0028876","AWARE A novel web application to rapidly assess cardiovascular risk in type 2 diabetes mellitus.","Berra C","2023","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent19","development of a cardiovascular risk web app with retrospective feasibility testing; GLP-1 RA prescribing only described",1],["R0029634","Cardiac digital twins: a tool to investigate the function and treatment of the diabetic heart.","Strocchi M","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent19","narrative review of cardiac digital twin computational models in diabetes",1],["R0026011","Glycaemic impact of treatment intensification in patients with type 2 diabetes uncontrolled with oral antidiabetes drugs or basal insulin.","Buysman EK","2018","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent15","claims cohort comparing treatment intensification incl GLP-1 RA addition versus no intensification; HbA1c and hypoglycemia only",1],["R0026141","Addressing Unmet Medical Needs in Type 1 Diabetes: A Review of Drugs Under Development.","Mittermayer F","2017","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent15","narrative review of drugs under development for type 1 diabetes incl GLP-1 agonists",1],["R0026322","Alteration of BDNF, SPARC, FGF-21, and GDF-15 circulating levels after 1 year of anti-obesity treatments and their association with 1-year weight loss.","Chaiyasoot K","2023","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent15","prospective observational cohort of obesity treatments incl liraglutide versus lifestyle alone; circulating biomarkers and weight only",1],["R0026460","The effects of first-line pharmacological treatments for reproductive outcomes in infertile women with PCOS: a systematic review and network meta-analysis.","Peng G","2023","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent15","registered network meta-analysis of 27 RCTs of first line drugs incl exenatide combinations for infertility in PCOS",1],["R0026608","G-CSF and Exenatide Might Be Associated with Increased Long-Term Survival of Allogeneic Pancreatic Islet Grafts.","Zoso A","2016","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent15","retrospective islet transplant cohort in type 1 diabetes relating exenatide and G-CSF use to graft survival; no harms list outcome",1],["R0026773","The effectiveness of liraglutide in nonalcoholic fatty liver disease patients with type 2 diabetes mellitus compared to sitagliptin and pioglitazone.","Ohki T","2012","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent15","retrospective comparison of liraglutide, sitagliptin and pioglitazone in NAFLD with type 2 diabetes; liver tests, HbA1c, weight only",1],["R0026951","Cost-utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add-on to metformin monotherapy in Type 2 diabetes mellitus.","Davies MJ","2012","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent15","CORE Diabetes Model cost utility analysis of liraglutide versus glimepiride or sitagliptin added to metformin",1],["R0027116","Safety, tolerability, pharmacokinetics, and pharmacodynamics of exenatide once weekly in Japanese patients with type 2 diabetes.","Iwamoto K","2009","include_nma",null,"primary_report","P01",null,"mechanistic","high","first","opus-5.5-agent15","10 week RCT of exenatide once weekly 0.8 or 2.0 mg versus placebo in Japanese type 2 diabetes; PK, HbA1c, adverse events",1],["R0023005","Efficacy and Safety of Subcutaneous and Oral Semaglutide Administration in Patients With Type 2 Diabetes: A Meta-Analysis.","Zhong P","2021","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent11","registered meta-analysis of phase 3 RCTs of subcutaneous and oral semaglutide; PubMed, Embase, Cochrane",1],["R0023149","Noninvasive monitoring of liver fat during treatment with GLP-1 analogues and SGLT-2 inhibitors in a real-world setting.","Mittag-Roussou V","2020","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent11","prospective real world study of SGLT2i or GLP-1RA initiators with steatosis; liver fat and metabolic measures only",1],["R0023285","SGLT-2 Inhibitors and Cardiovascular Protection: Lessons and Gaps in Understanding the Current Outcome Trials and Possible Benefits of Combining SGLT-2 Inhibitors With GLP-1 Agonists.","Abdelgadir E","2018","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent11","narrative review of SGLT2i cardiovascular trials and combination with GLP-1RAs",1],["R0023545","Subcutaneous adipose tissue composition and function are unaffected by liraglutide-induced weight loss in adults with type 1 diabetes.","Wegeberg AM","2021","include_nma",null,"secondary_report","P05",null,null,"high","first","opus-5.5-agent11","secondary analysis of RCT of liraglutide versus placebo in type 1 diabetes with polyneuropathy; adipose tissue and weight",1],["R0023651","Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes.","Ratner R","2011","include_nma",null,"pooled_analysis","P01",null,null,"high","first","opus-5.5-agent11","pooled individual data from 12 sponsor RCTs of exenatide twice daily versus placebo or insulin on cardiovascular events",1],["R0023815","The neuroprotective effects of glucagon-like peptide 1 in Alzheimer's and Parkinson's disease: An in-depth review.","Reich N","2022","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent11","narrative review of GLP-1 neuroprotection in Alzheimer and Parkinson disease",1],["R0024004","A Real-World Precision Medicine Program Including the KidneyIntelX Test Effectively Changes Management Decisions and Outcomes for Patients With Early-Stage Diabetic Kidney Disease.","Tokita J","2024","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent11","real world program of a kidney risk test; GLP-1RA prescribing only an outcome, not an exposure",1],["R0022996","Liraglutide: A review of its therapeutic use as a once daily GLP-1 analog for the management of type 2 diabetes mellitus.","Dharmalingam M","2011","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent09","narrative review of liraglutide therapeutic use in type 2 diabetes",1],["R0023140","Pancreatic Safety of Once-Weekly Dulaglutide in Chinese Patients with Type 2 Diabetes Mellitus: Subgroup Analysis by Potential Influencing Factors.","Zhou Y","2021","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent09","post hoc subgroup analysis of pancreatic enzymes in AWARD-CHN2 RCT of dulaglutide versus insulin glargine",1],["R0023261","Evaluation of Alternative Treatment Strategies for Bile Acid Malabsorption in Inflammatory Bowel Disease Patients: A Network Meta-Analysis.","Merza N","2024","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent09","PRISMA NMA of RCTs for bile acid malabsorption including liraglutide versus colesevelam and placebo, five databases",1],["R0023541","A comparison between weight loss outcomes with anti-obesity medications before and during Covid-19 pandemic at a tertiary weight management center.","De la Rosa A","2022","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent09","retrospective comparison of anti-obesity drug weight loss including liraglutide before versus during the pandemic, no eligible harm",1],["R0023644","Hedgehog interacting protein as a circulating biomarker in women with obesity: a cross-sectional study and intervention studies.","Wang H","2023","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent09","cross sectional biomarker study plus nonrandomized metformin versus liraglutide groups allocated by condition and preference",1],["R0023796","Metabolic surgery versus usual care effects on diabetes remission: a systematic review and meta-analysis.","Mirghani H","2023","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent09","meta-analysis of surgery versus usual care for diabetes remission, GLP-1 use only a baseline covariate",1],["R0023978","A review of exenatide: optimizing glycemic control and associated cardiovascular risk factors in type 2 diabetes.","Htike ZZ","2012","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent09","narrative review of exenatide for glycemic control and cardiovascular risk factors",1],["R0024165","Dipeptidyl Peptidase 4 Inhibitors and the Risk of Cardiovascular Disease in Patients with Type 2 Diabetes: A Tale of Three Studies.","Son JW","2015","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent10","narrative review of DPP-4 inhibitor cardiovascular outcome trials; no systematic methods",1],["R0024295","The importance of addressing multiple risk markers in type 2 diabetes: Results from the LEADER and SUSTAIN 6 trials.","Zobel EH","2022","include_nma",null,"pooled_analysis","P01",null,null,"high","first","opus-5.5-agent10","pooled post hoc of LEADER and SUSTAIN 6 RCTs relating risk marker improvements to CV and kidney outcomes",1],["R0024483","Analysis of the effect of liraglutide on glycemic variability in patients with type 2 diabetes.","Xing Y","2020","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent10","meta-analysis of liraglutide studies on glycemic variability in T2D; four databases searched",1],["R0024896","SAT-099 Liraglutide 3.0 mg as an Adjunct to Intensive Behavior Therapy in Individuals with Obesity: SCALE IBT 56-Week Randomized, Double-Blind, Placebo-Controlled Trial","Wadden T","2019","include_nma",null,"conference_abstract","P02",null,"abstract_only","high","first","opus-5.5-agent10","abstract of SCALE IBT RCT liraglutide 3 mg versus placebo with intensive behavior therapy in obesity",1],["R0025016","An Abbreviated Protocol for In Vitro Generation of Functional Human Embryonic Stem Cell-Derived Beta-Like Cells.","Massumi M","2016","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent10","in vitro protocol generating stem cell derived beta like cells with exendin 4 in culture",1],["R0025124","Precision medicine in diabetes and diabetic kidney disease: Regulatory considerations.","Mol PGM","2018","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent10","review of regulatory considerations for precision medicine in diabetes and DKD",1],["R0024175","Efficacy of Liraglutide in clinical practice: Single centre experience.","Rashid MO","2020","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent11","retrospective single group liraglutide study in Pakistan; no comparator",1],["R0024305","Insufficient sleep predicts poor weight loss maintenance after 1 year.","Bogh AF","2023","include_nma",null,"secondary_report","P02",null,null,"high","first","opus-5.5-agent11","S-LiTE secondary analysis of sleep and weight maintenance; randomized liraglutide versus placebo with or without exercise",1],["R0024484","Antidiabetic Drugs in NAFLD: The Accomplishment of Two Goals at Once?","Tacelli M","2018","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent11","narrative review of antidiabetic drugs in NAFLD",1],["R0024640","Effects of liraglutide addition to multiple diabetes regimens on weight and risk of hypoglycemia for a cohort with type 2 diabetes followed in primary care clinics in Saudi Arabia.","Albarkah YA","2019","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent11","observational single group cohort adding liraglutide to diabetes regimens in Saudi primary care; no comparator",1],["R0024773","Using RWE research to extend clinical trials in diabetes: An example with implications for the future.","Seeger JD","2020","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent11","methods review of real world evidence illustrated by a previously reported exenatide study",1],["R0024906","A study to assess the unmet medical needs associated with the use of basal insulin in patients with type 2 diabetes.","Frechtel G","2021","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent11","single cohort observational study of basal insulin initiators; GLP-1RA only permitted background",1],["R0025019","Relationship between weight change and glycaemic control in patients with type 2 diabetes receiving once-weekly dulaglutide treatment.","Umpierrez GE","2016","include_nma",null,"pooled_analysis","P01",null,null,"high","first","opus-5.5-agent11","analysis across six AWARD RCTs of dulaglutide relating weight and HbA1c change in dulaglutide arms",1],["R0025148","Model-Based Evaluation of Exenatide Effects on the QT Interval in Healthy Subjects Following Continuous IV Infusion.","Cirincione B","2017","inventory_only","N1","primary_report",null,null,null,"high","first","opus-5.5-agent11","open label phase 1 stepped intravenous exenatide infusion in healthy subjects with QT modeling; no comparator arm",1],["R0027261","Tolerability and Effectiveness of Exenatide Once Weekly Relative to Basal Insulin Among Type 2 Diabetes Patients of Different Races in Routine Care.","Nunes AP","2017","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent15","EHR cohort of exenatide once weekly versus basal insulin initiators by race; HbA1c, weight, GI symptoms and hypoglycemia only",1],["R0027544","Liraglutide in the treatment of type 2 diabetes mellitus: clinical utility and patient perspectives.","Edavalath M","2010","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent15","narrative review of liraglutide pharmacology, efficacy and patient perspectives",1],["R0027750","Blood glucose profiles in East Asian and Caucasian injection-naive patients with type 2 diabetes inadequately controlled on oral medication: a pooled analysis.","Zhang XM","2018","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent15","pooled baseline glucose profiles by race from lispro and dulaglutide trials; no treatment comparison analyzed",1],["R0028716","GLP-1/glucagon receptor co-agonism for treatment of obesity.","Sánchez-Garrido MA","2017","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent15","narrative review of GLP-1 and glucagon receptor co-agonists for obesity",1],["R0024156","A randomized controlled trial protocol of the cardiovascular safety and efficacy of liraglutide in the treatment of type 2 diabetes.","Liang Y","2021","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent09","protocol of active controlled RCT of liraglutide cardiovascular safety in type 2 diabetes on metformin",1],["R0024290","Utilization of model-based meta-analysis to delineate the net efficacy of taspoglutide from the response of placebo in clinical trials.","Li HQ","2015","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent09","model based meta-analysis of taspoglutide trials versus placebo identified through PubMed and registries with criteria",1],["R0024466","Growth differentiation factor-15, treatment with liraglutide, and clinical outcomes among patients with heart failure.","Sharma A","2021","include_nma",null,"secondary_report","P07B",null,null,"high","first","opus-5.5-agent09","GDF-15 biomarker analysis of FIGHT RCT of liraglutide versus placebo in HFrEF after recent hospitalization",1],["R0024635","A Randomized Study to Compare the Effects of Once-Weekly Dulaglutide Injection and Once-Daily Glimepiride on Glucose Fluctuation of Type 2 Diabetes Mellitus Patients: A 26-Week Follow-Up.","Li H","2019","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent09","small RCT of weekly dulaglutide versus daily glimepiride on CGM glucose fluctuation in type 2 diabetes",1],["R0024746","'A Missed Therapeutic Opportunity? SGLT-2 Inhibitor Use in General Medicine Patients With Heart Failure: A Retrospective Audit of Admissions to a Tertiary Health Service'.","Perera P","2022","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent09","retrospective audit of SGLT2 inhibitor prescribing in heart failure admissions, no GLP-1 exposure studied",1],["R0024895","Liraglutide Enhances the Activity of the ACE-2/Ang(1-7)/Mas Receptor Pathway in Lungs of Male Pups from Food-Restricted Mothers and Prevents the Reduction of SP-A.","Fandiño J","2018","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent09","rat model of maternal food restriction with gestational liraglutide, lung outcomes in pups, no humans",1],["R0025007","Association Between Anti-diabetic Agents and Clinical Outcomes of COVID-19 in Patients with Diabetes: A Systematic Review and Meta-Analysis.","Han T","2022","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent09","PROSPERO registered meta-analysis of cohort studies of antidiabetic agents including GLP-1 on COVID-19 outcomes",1],["R0025278","Liraglutide and Metformin alone or combined therapy for type 2 diabetes patients complicated with coronary artery disease.","Liu Y","2017","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent10","randomized pilot liraglutide versus metformin and liraglutide versus liraglutide plus metformin in T2D with CAD; cardiac function, HbA1c",1],["R0025429","Clinical Impact of 5 Years of Liraglutide Treatment on Cardiovascular Risk Factors in Patients with Type 2 Diabetes Mellitus in a Real-Life Setting in Italy: An Observational Study.","Frison V","2018","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent10","retrospective single group cohort of 5 years liraglutide treatment in Italian T2D; no comparison group",1],["R0025596","Follow the LEADER-Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results Trial.","Kalra S","2016","inventory_only","N9","ancillary",null,null,null,"high","first","opus-5.5-agent10","editorial commentary on the LEADER trial of liraglutide",1],["R0025732","Weight Loss Outcomes With Telemedicine During COVID-19.","Tchang BG","2022","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent10","retrospective weight clinic study by telemedicine visit type; antiobesity drug use only descriptive",1],["R0025877","Impact of diabetes duration on achieved reductions in glycated haemoglobin, fasting plasma glucose and body weight with liraglutide treatment for up to 28 weeks: a meta-analysis of seven phase III trials.","Seufert J","2016","include_nma",null,"pooled_analysis","P01",null,null,"high","first","opus-5.5-agent10","pooled analysis of seven phase III RCTs liraglutide versus placebo by diabetes duration; HbA1c, FPG, weight",1],["R0025996","Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis.","Engel SS","2010","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent10","review and pooled trial analysis of pancreatitis with sitagliptin; DPP-4 inhibitor only",1],["R0026431","Effects of Liraglutide Combined with Short-Term Continuous Subcutaneous Insulin Infusion on Glycemic Control and Beta Cell Function in Patients with Newly Diagnosed Type 2 Diabetes Mellitus: A Pilot Study.","Ke W","2016","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent10","pilot RCT short term CSII alone versus CSII plus liraglutide in newly diagnosed T2D; beta cell function and HbA1c",1],["R0026539","Defining criteria for the introduction of liraglutide using the glucagon stimulation test in patients with type 2 diabetes.","Kondo Y","2013","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent10","retrospective single group of patients switched from insulin to liraglutide; C-peptide predictors of response",1],["R0026742","Relevance of positive cardiovascular outcome trial results in clinical practice: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes (ACROSS T2D).","Schernthaner G","2017","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent10","expert faculty opinion piece interpreting EMPA-REG OUTCOME and LEADER for practice",1],["R0026909","The effects of treatment with liraglutide on atherothrombotic risk in obese young women with polycystic ovary syndrome and controls.","Kahal H","2015","inventory_only","N1","primary_report",null,null,null,"high","first","opus-5.5-agent10","nonrandomized trial giving liraglutide to obese women with PCOS and to weight matched controls; all exposed",1],["R0027078","Exenatide affects circulating cardiovascular risk biomarkers independently of changes in body composition.","Bunck MC","2010","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent10","RCT exenatide versus insulin glargine on metformin for 1 year; body composition and CV biomarkers",1],["R0027218","Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes.","Zhang Z","2017","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent10","meta-analysis of GLP-1 RA and DPP-4i CVOTs on CV and pancreatic outcomes; Medline, Embase, Cochrane searched",1],["R0027429","Comparison of insulin lispro protamine suspension versus insulin glargine once daily added to oral antihyperglycaemic medications and exenatide in type 2 diabetes: a prospective randomized open-label trial.","Arakaki RF","2014","inventory_only","N3","primary_report",null,null,null,"high","first","opus-5.5-agent10","RCT insulin lispro protamine versus glargine added to exenatide in both arms; GLP-1 regimen unchanged",1],["R0027692","Radiopeptide imaging and therapy in Europe.","Ambrosini V","2011","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent10","narrative review of radiopeptide imaging and therapy in Europe including exendin tracers",1],["R0025277","External Validation of the BRAVO Diabetes Model Using the EXSCEL Clinical Trial Data.","Shao Y","2023","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent09","external validation of the BRAVO diabetes microsimulation model using EXSCEL data, modeling study",1],["R0025427","New Antihyperglycemic Drugs and Heart Failure: Synopsis of Basic and Clinical Data.","von Lewinski D","2017","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent09","narrative synopsis of basic and clinical data on new antihyperglycemic drugs and heart failure",1],["R0025594","Combined exenatide and dapagliflozin has no additive effects on reduction of hepatocellular lipids despite better glycaemic control in patients with type 2 diabetes mellitus treated with metformin: EXENDA, a 24-week, prospective, randomized, placebo-controlled pilot trial.","Harreiter J","2021","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent09","EXENDA pilot RCT of exenatide plus dapagliflozin versus placebo plus dapagliflozin on liver fat in type 2 diabetes",1],["R0025729","Exploratory Approach to Incorporating Carbon Footprint in Health Technology Assessment (HTA) Modelling: Cost-Effectiveness Analysis of Health Interventions in the United Kingdom.","Kindred M","2024","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent09","Markov model HTA with carbon footprint comparing semaglutide and bariatric surgery",1],["R0025873","Treatment with liraglutide may improve markers of CVD reflected by reduced levels of apoB.","Engelbrechtsen L","2017","include_nma",null,"secondary_report","P02",null,null,"high","first","opus-5.5-agent09","lipidomic secondary analysis of RCT of liraglutide versus no drug for weight maintenance after low calorie diet",1],["R0025991","Comparison of exenatide with biphasic insulin aspart 30 on glucose variability in type 2 diabetes: study protocol for a randomized controlled trial.","Xu S","2016","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent09","protocol of RCT comparing exenatide with biphasic insulin aspart on glucose variability",1],["R0026107","Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal-Duo 1).","Riddle MC","2013","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent09","GetGoal-Duo 1 double blind RCT of lixisenatide versus placebo added to newly titrated glargine",1],["R0026261","Empagliflozin and dulaglutide: community awareness project promotes improved access to newly funded medications for Pacific patients with type 2 diabetes.","Sundborn G","2023","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent09","community awareness campaign viewpoint on access to empagliflozin and dulaglutide, no exposure outcome comparison",1],["R0025286","Relationship of body mass index with efficacy of exenatide twice daily added to insulin glargine in patients with type 2 diabetes.","Wolffenbuttel BH","2016","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent11","post hoc BMI subgroup analysis of two RCTs of exenatide twice daily versus insulin lispro or placebo on glargine",1],["R0025435","Evaluation of the risk of fracture in type 2 diabetes mellitus patients with incretins: an updated meta-analysis.","Kong QX","2021","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent11","registered meta-analysis of RCTs of incretin drugs including GLP-1RAs on fracture; PubMed, Embase, Web of Science, Cochrane",1],["R0025601","Exenatide infusion decreases atrial natriuretic peptide levels by reducing cardiac filling pressures in type 2 diabetes patients with decompensated congestive heart failure.","Nathanson D","2016","include_nma",null,"secondary_report","P07B; P01",null,"mechanistic","high","first","opus-5.5-agent11","post hoc analysis of RCT of 6 hour exenatide versus placebo infusion in diabetes with decompensated HFrEF",1],["R0025746","Effect of adding insulin degludec to treatment in patients with type 2 diabetes inadequately controlled with metformin and liraglutide: a double-blind randomized controlled trial (BEGIN: ADD TO GLP-1 Study).","Aroda VR","2016","inventory_only","N3","primary_report",null,null,null,"high","first","opus-5.5-agent11","BEGIN ADD TO GLP-1 RCT of insulin degludec versus placebo added to liraglutide in both arms",1],["R0025881","Diabetic ketoacidosis in patients with type 2 diabetes treated with sodium glucose co-transporter 2 inhibitors versus other antihyperglycemic agents: An observational study of four US administrative claims databases.","Wang L","2019","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent11","claims new user cohorts of SGLT2i versus comparators including GLP-1RA; diabetic ketoacidosis only",1],["R0026001","Greater glucagon-like peptide-1 responses to oral glucose are associated with lower central and peripheral blood pressures.","Lundgren JR","2019","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent11","cross sectional study of endogenous GLP-1 response and blood pressure; no incretin drug users",1],["R0026114","Effectiveness and Persistence with Liraglutide Among Patients with Type 2 Diabetes in Routine Clinical Practice--EVIDENCE: A Prospective, 2-Year Follow-Up, Observational, Post-Marketing Study.","Gautier JF","2015","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent11","EVIDENCE prospective post marketing single group cohort of liraglutide users in France",1],["R0026295","Efficacy and safety over 26 weeks of an oral treatment strategy including sitagliptin compared with an injectable treatment strategy with liraglutide in patients with type 2 diabetes mellitus inadequately controlled on metformin: a randomised clinical trial.","Charbonnel B","2013","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent11","open label RCT of oral sitagliptin strategy versus injectable liraglutide strategy on metformin",1],["R0027899","Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof-of-concept study.","Arnolds S","2010","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent10","RCT adding exenatide or sitagliptin versus neither to glargine plus metformin for 4 weeks; postprandial glucose and HbA1c",1],["R0028499","Primary Care Physicians' Knowledge of the Cardiovascular Effects of Diabetes Medications: Findings from an Online Survey.","Shubrook JH","2020","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent10","online survey of primary care physicians on knowledge of CV effects of diabetes drugs; no exposure",1],["R0029879","Non-alcoholic Steatohepatitis in Asians: Current Perspectives and Future Directions.","Choudhuri G","2023","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent10","narrative review of NASH in Asians; no systematic methods",1],["R0026436","Efficacy and safety of liraglutide 3.0 mg for weight management are similar across races: subgroup analysis across the SCALE and phase II randomized trials.","Ard J","2016","include_nma",null,"pooled_analysis","P02; P01",null,null,"high","first","opus-5.5-agent11","pooled post hoc analysis of four SCALE and one phase 2 RCT of liraglutide 3.0 mg versus placebo by race",1],["R0026560","Resource use and costs of exenatide bid or insulin in clinical practice: the European CHOICE study.","Kiiskinen U","2013","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent11","CHOICE prospective observational cohorts of exenatide twice daily versus insulin; treatment change, costs and GI events, no listed harm",1],["R0026750","Safety and tolerability of exenatide twice daily in patients with type 2 diabetes: integrated analysis of 5594 patients from 19 placebo-controlled and comparator-controlled clinical trials.","Macconell L","2012","include_nma",null,"pooled_analysis","P01",null,null,"high","first","opus-5.5-agent11","integrated safety analysis of 19 RCTs of exenatide twice daily versus placebo or insulin",1],["R0027082","Characteristics, Treatment Patterns, and Economic Outcomes of Patients Initiating Injectable Medications for Management of Type 2 Diabetes Mellitus in Japan: Results from a Retrospective Claims Database Analysis.","Suzuki S","2018","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent11","Japanese claims description of injectable initiators by prescriber setting; drug utilization without GLP-1RA exposure comparison",1],["R0027226","LEADER 2: baseline calcitonin in 9340 people with type 2 diabetes enrolled in the Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results (LEADER) trial: preliminary observations.","Daniels GH","2015","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent11","LEADER baseline calcitonin report before randomized outcomes; no between arm results",1],["R0027450","Lack of cardioprotection from subcutaneously and preischemic administered liraglutide in a closed chest porcine ischemia reperfusion model.","Kristensen J","2009","exclude","E1","primary_report",null,null,null,"high","first","opus-5.5-agent11","porcine ischemia reperfusion model randomized to liraglutide or control",1],["R0027699","LEADER 5: prevalence and cardiometabolic impact of obesity in cardiovascular high-risk patients with type 2 diabetes mellitus: baseline global data from the LEADER trial.","Masmiquel L","2016","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent11","LEADER baseline obesity characteristics report; no between arm outcomes",1],["R0026430","Safety of exenatide once weekly for 52 weeks in Japanese patients with type 2 diabetes mellitus.","Onishi Y","2013","inventory_only","N1","extension",null,null,null,"high","first","opus-5.5-agent09","uncontrolled 26 week extension in Japanese patients where all received exenatide weekly after the randomized period",1],["R0026536","Alteration of Circulating levels of BDNF, SPARC, FGF-21, and GDF-15 after 1 Year of Anti-Obesity Treatments and Their Association with 1-Year Weight Loss","Chaiyasoot K","2023","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent09","prospective nonrandomized comparison of lifestyle plus surgery, topiramate, liraglutide or orlistat on circulating cytokines, no eligible harm",1],["R0026736","Benefits of liraglutide treatment in overweight and obese older individuals with prediabetes.","Kim SH","2013","include_nma",null,"primary_report","P02",null,null,"high","first","opus-5.5-agent09","double blind RCT of liraglutide 1.8 mg versus placebo with calorie restriction in overweight older adults with prediabetes",1],["R0026900","Weight-related quality of life, health utility, psychological well-being, and satisfaction with exenatide once weekly compared with sitagliptin or pioglitazone after 26 weeks of treatment.","Best JH","2011","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent09","patient reported outcomes of DURATION-2 RCT of exenatide weekly versus sitagliptin or pioglitazone on metformin",1],["R0027063","Strategies to Make Ramadan Fasting Safer in Type 2 Diabetics: A Systematic Review and Network Meta-analysis of Randomized Controlled Trials and Observational Studies.","Lee SWH","2016","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent09","NMA of RCTs and observational studies of diabetes strategies during Ramadan including incretin mimetics, eight databases",1],["R0027200","The use of exenatide in severely burned pediatric patients.","Mecott GA","2010","include_nma",null,"primary_report","P99",null,null,"high","first","opus-5.5-agent09","small block randomized open label trial of exenatide versus intensive insulin in severely burned children; P99 burn hyperglycemia",1],["R0027428","Changes in Albuminuria Predict Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Post Hoc Analysis of the LEADER Trial.","Persson F","2021","include_nma",null,"secondary_report","P01",null,null,"high","first","opus-5.5-agent09","post hoc LEADER analysis of albuminuria change and outcomes in liraglutide versus placebo trial",1],["R0027663","Once-weekly exenatide versus once- or twice-daily insulin detemir: randomized, open-label, clinical trial of efficacy and safety in patients with type 2 diabetes treated with metformin alone or in combination with sulfonylureas.","Davies M","2013","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent09","open label RCT of exenatide weekly versus insulin detemir in type 2 diabetes on metformin with or without sulfonylurea",1],["R0027910","LEADER 7: cardiovascular risk profiles of US and European participants in the LEADER diabetes trial differ.","Rutten GE","2016","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent11","LEADER baseline comparison of US and European participants; no between arm outcomes",1],["R0029327","Novel device-based and catheter-directed therapies for heart failure with preserved ejection fraction.","Yamamoto E","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent11","invited narrative review of device therapies for HFpEF",1],["R0027883","Prevalence of cardiovascular disease and evaluation of standard of care in type 2 diabetes: a nationwide study in primary care.","Rungby J","2017","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent09","cross sectional prevalence and standard of care study of Danish primary care diabetes patients with CVD, drug use only described",1],["R0028487","Circulating levels of soluble Dipeptidylpeptidase-4 are reduced in human subjects hospitalized for severe COVID-19 infections.","Schlicht K","2020","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent09","short report of soluble DPP-4 levels in hospitalized COVID-19 patients, no GLP-1 drug exposure",1],["R0029271","Metabolic dysfunction-associated fatty liver disease: redefining the conceptual framework from nomenclature to emerging therapeutic paradigms.","Wang R","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent09","narrative review of MAFLD nomenclature and emerging therapies",1],["R0029864","[Basic and clinical studies of fleroxacin on infectious enteritis. Research Group of AM-833 on infectious enteritis].","Sagara H","1994","exclude","E2","other",null,null,"non_english","high","first","opus-5.5-agent09","Japanese 1994 study of fleroxacin for infectious enteritis, unrelated to GLP-1 drugs",1],["R0000407","Association of Tirzepatide versus Glucagon-Like Peptide-1 Receptor Agonists with Incident Glaucoma in Patients with Type 2 Diabetes: A Retrospective Cohort Study.","Pan SY","2026","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck02","R7: new user cohort tirzepatide vs GLP-1 RA; outcomes are glaucoma and negative controls only; retinopathy is a matching covariate, not an outcome",2],["R0000077","The association between glucagon-like peptide-1 receptor agonist and rheumatoid arthritis: a population-based case-control study.","Israel A","2026","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck02","case control of GLP-1 RA exposure and incident rheumatoid arthritis; cancers appear only as baseline comorbidities, no listed harm as outcome",2],["R0000153","Comparative outcomes for tirzepatide versus glucagon-like peptide-1 receptor agonists in patients with inflammatory bowel disease: a national propensity matched study.","Patel KS","2026","include_harms",null,"primary_report",null,"O28; O29; O37B",null,"high","recheck","opus-5.5-recheck02","R7: new user cohort tirzepatide vs other GLP-1 RAs in IBD; reports pancreatitis, cholecystitis and ileus or obstruction by group with aHR",2],["R0000532","Clinical Characterization of Enzyme and Transporter Precipitants to Evaluate Drug-Drug Interactions for Orforglipron, a Small Molecule Glucagon-Like Peptide-1 Receptor Agonist.","Morse BL","2026","inventory_only","N2","primary_report",null,null,null,"high","recheck","opus-5.5-recheck02","R5: fixed sequence phase 1 DDI studies of orforglipron; placebo cohorts used only for CP-I PK; no adverse event, weight or glycemic outcome reported",2],["R0000395","Glucagon-Like Peptide 1 Receptor Agonists and Early Colorectal Neoplasia: A Colonoscopy-Anchored Target Trial Emulation","Kwan AT","2026","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck04","R7: TriNetX target trial emulation GLP-1 RA vs SGLT2i; outcome is benign colorectal polyps and adenomas, no cancer or other listed harm",2],["R0000739","Cardiovascular outcome of glucagon-like peptide-1 receptor agonists vs dipeptidyl peptidase-4 inhibitor on end-stage kidney disease patients with heart failure: an emulated target trial in patients with diabetes.","Liu PY","2026","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck04","TriNetX emulation GLP-1 RA vs DPP-4i in dialysis HF; cardiovascular, mortality, hospitalization outcomes; neoplasms only a baseline covariate",2],["R0000754","Impact of Glucagon-like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors on Post-liver Transplant New-onset Major Adverse Cardiovascular Events, Graft Failure, Renal Outcome, and Mortality.","Kosako Yost KC","2026","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck04","retrospective liver transplant cohort; MACE, graft failure, dialysis, mortality compared; pancreatitis only noted as absent in exposed group, no comparison",2],["R0000841","Impact of Glucagon-Like Peptide-1 Receptor Agonists on the Dementia Incidence in Patients With Type 2 Diabetes Mellitus: A Population-Based Longitudinal Cohort Study.","Cheng HW","2025","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck04","Taiwan claims cohort GLP-1 RA users vs nonusers; dementia only outcome; malignancy appears only as baseline comorbidity",2],["R0000327","The Role of Glucagon-like Peptide-1 Receptor Agonists in Alzheimer's and Parkinson's Disease: A Literature Review of Clinical Trials.","Pilśniak J","2025","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck01","R1: called narrative but searched four named databases with stated criteria and tabulated synthesis of GLP-1 RA trials in AD and PD",2],["R0000049","Association of Glucagon-Like Peptide-1 Receptor Agonists and Suicidality: A Systematic Review.","Au HCT","2026","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck01","R1: PRISMA review of named databases with criteria, tabulated synthesis of GLP-1 RA suicidality studies",2],["R0000099","Effects of Treatment with Glucagon-like Peptide-1 Receptor Analogues on the Diabetic Foot.","Ortiz Romero M","2026","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck01","R1: self described narrative yet named databases, stated eligibility and tabulated synthesis of GLP-1 RA studies on diabetic foot outcomes",2],["R0000540","Relationship Between GLP-1-Based Therapies and Periodontal Health: A Systematic Review of Current Evidence and Future Perspectives.","Nijakowski K","2026","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck01","R1: PRISMA review with named databases and PICOS criteria; synthesis includes a human cohort comparing GLP-1 RA users with nonusers, not only preclinical",2],["R0000011","Tirzepatide versus GLP-1 receptor agonists and stroke in patients with atrial fibrillation and type 2 diabetes.","Lin CL","2026","include_harms",null,"primary_report",null,"O35A",null,"high","recheck","opus-5.5-recheck03","R7: tirzepatide vs other GLP-1 RA cohort reports suicide attempt or ideation as negative control outcome with between group estimate",2],["R0000106","Combining Sodium-Glucose Co-Transporter-2 Inhibitor Plus Glucagon-Like Peptide-1 Receptor Agonist for Glucose-Lowering in Type 2 Diabetes: Effects of Drug Initiation Sequence on Kidney Function in Real-World Clinical Practice (CombiKid Study).","Hinton W","2026","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck03","R7: combination vs monotherapy cohort reports only eGFR, UACR, HbA1c and BMI; retinopathy is a baseline covariate",2],["R0000193","Risk of Diabetic Ketoacidosis with Glucagon-Like Peptide-1 Receptor Agonists: A Systematic Review and Meta-analysis","Alkhushaym N","2026","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck03","R1: PubMed, Scopus and Cochrane search with criteria; random effects pooling of DKA frequency in GLP-1 RA users",2],["R0000216","Glucagon-like peptide 1 receptor agonists in substance use disorders: A systematic review of ClinicalTrials.Gov.","Patil S","2026","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck03","R1: preregistered ClinicalTrials.gov search with criteria; structured tabulation of 33 GLP-1 RA trials in substance use disorders",2],["R0000170","Comparative Cardiovascular Outcomes of Tirzepatide and Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease.","Wu JY","2026","include_harms",null,"primary_report",null,"O29",null,"high","recheck","opus-5.5-recheck08","R7: new user TriNetX cohort tirzepatide versus other GLP-1 RA; pancreatitis prespecified as safety outcome; within class comparator qualifies",2],["R0000231","GLP-1 therapies and hair loss: A systematic review of current evidence and implications for counseling.","Gupta AK","2026","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck08","R1: four named databases, stated eligibility criteria, structured tabulated synthesis of GLP-1 RA studies on hair loss",2],["R0001198","Dermatologic outcomes associated with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a large-scale target trial emulation.","Chiang YL","2026","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck08","R7: GLP-1 RA versus DPP-4i cohort with dermatologic outcomes; acute kidney injury only inside MAKE composite, no listed harm",2],["R0000130","Association of glucagon-like peptide-1 receptor agonist use with clinical outcomes in patients with rheumatoid arthritis and type 2 diabetes.","Yu YT","2026","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck10","R7: acute kidney injury appears only inside the MAKE composite; other outcomes mortality, MACE, ESRD, sepsis, pneumonia are not listed harms",2],["R0000281","Integrated Evidence from VigiBase and Clinical Trials: A Comprehensive Pharmacovigilance Analysis of Seven Glucagon-Like Peptide 1 Receptor Agonists (GLP-1 RAs).","Li J","2026","inventory_only","N5","primary_report",null,null,null,"high","recheck","opus-5.5-recheck10","VigiBase disproportionality analysis; methods describe no database search or eligibility criteria for the trial summary table",2],["R0000561","Glucagon-like Peptide-1 Receptor Agonist Therapy and Risk of Pulmonary and Systemic Infections in Diabetic Gastroparesis: A Propensity-Matched Cohort Study.","Kazi MAI","2026","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck10","R7: gastroparesis is baseline; aspiration pneumonitis outcome is not in a procedure cohort, so O36A design ineligible; infections not listed harms",2],["R0001020","Impact of glucagon-like peptide-1 receptor agonists on the incidence of atrial fibrillation.","Glaser K","2025","include_review",null,"systematic_review",null,null,"umbrella_review","high","recheck","opus-5.5-recheck10","R1: PubMed and Medline search, stated inclusion of AF focused systematic reviews, structured synthesis by GLP-1 drug; minireview label",2],["R0000017","Recent Studies on the Effectiveness and Safety of Anti-Obesity Medications: A Scoping Review.","Puspitasari IM","2026","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck09","R1: scoping review with PubMed and Scopus search, stated criteria and charted synthesis of GLP-1 RA obesity trials",2],["R0000538","Is There a Better Day of the Week to Administer Semaglutide or Tirzepatide? A Systematic Literature Review.","La Vignera S","2026","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck09","R1: PubMed among named sources, PICO criteria, structured synthesis of semaglutide or tirzepatide dosing timing studies",2],["R0001326","Modulation of the Incretin Axis (GLP-1/GIP) in Behavioral Compulsions: A New Neuropsychopharmacology Frontier","Andrade LJdO","2026","inventory_only","N5","primary_report",null,null,null,"high","recheck","opus-5.5-recheck09","narrative review that adds two original tirzepatide case reports on compulsive behaviors; case reports are N5",2],["R0000912","Comparison of Perioperative Glycemic Control in Patients Continuing Versus Temporarily Holding Glucagon-Like Peptide-1 Receptor Agonists or Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists Preoperatively.","Trykall CC","2026","include_harms",null,"primary_report",null,"O36A",null,"high","recheck","opus-5.5-recheck08","R7: perioperative cohort of surgical encounters continuing versus holding weekly GLP-1 RA; intraoperative pulmonary aspiration collected and compared as an outcome",2],["R0000086","Gastroparesis induced by glucagon-like peptide-1 receptor agonists: A systematic review of clinical features, diagnosis, management, and outcomes.","Olubodun T","2026","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck06","R1: four named databases, PICOS eligibility, tabulated synthesis of GLP-1 RA gastroparesis case reports; reviews of case reports qualify",2],["R0000434","The GLP-1 Nutritional Paradox: A Structured Review with Novel Quantitative Frameworks for Sarcopenic Risk and Micronutrient Adequacy in GLP-1 Receptor Agonist Pharmacotherapy","Hungund S","2026","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck07","R1: named PubMed search, stated inclusion criteria and tabulated synthesis of GLP-1 RA body composition and nutrition studies; self labeled narrative but meets a to c",2],["R0000658","Harnessing Facebook to Investigate Real-World Mentions of Adverse Events of Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Medications: Observational Study of Facebook Posts From 2022 to 2024.","Alibilli AS","2025","inventory_only","N5","other",null,null,null,"high","recheck","opus-5.5-recheck07","R3: descriptive count of adverse event mentions in Facebook posts about GLP-1 RAs, a spontaneous report style signal analysis without exposure comparison",2],["R0000856","Glucagon-like Peptide-1 Receptor Agonists in Rheumatoid Arthritis: A Scoping Review of Metabolic, Anti-Inflammatory, and Cardioprotective Effects.","Buonanno S","2026","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck07","R1: scoping review with named databases, PCC eligibility, dual screening and tabulated synthesis of clinical GLP-1 RA studies in rheumatoid arthritis",2],["R0001061","Secondary Ocular Complications Associated with GLP-1 Receptor Agonist Use for Weight Loss: A Large Retrospective Cohort Study","Juran TM","2026","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck07","R7: GLP-1 RA users vs nonusers cohort reports overall ocular pathology, cataract, glaucoma, other retinal disorders; no diabetic retinopathy or NAION outcome",2],["R0000012","Does Combination Therapy With a Glucagon-Like Peptide-1 Receptor Agonist and a Sodium-Glucose Cotransporter 2 Inhibitor Enhance Cardiovascular and Renal Protection in People With Type 2 Diabetes Mellitus?","Medeiros R","2026","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck06","retrospective cohort GLP-1 RA plus SGLT2i vs either alone; MACE, HF, CKD and side effects nausea, hypoglycemia, UTI only; no listed harm",2],["R0000048","Gastrointestinal adverse effects of GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists: A narrative expert review of approved therapies, oral formulations, and pipeline agents.","Singhani V","2026","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck06","R1: self labeled narrative but names three databases, states eligibility, dual screening, tabulated GI adverse event synthesis with evidence grading",2],["R0000590","Association between glucagon-like peptide-1 receptor agonist therapy and respiratory illness in patients with type 2 diabetes: a retrospective observational cohort study.","Ho LT","2025","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck06","R7: new user cohort GLP-1 RA vs DPP-4i; lung cancer is single site; malignant neoplasm appears only as baseline history",2],["R0000125","Decoding the hallmarks of GLP-1RA weight-loss super-responders.","Venkatakrishnan AJ","2026","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck05","R3 not applied: EHR cohort compares weight response odds between GLP-1 RA brands; no listed harm reported",2],["R0000756","Glucagon-like Peptide-1 Receptor Agonists and Risk of Pneumonia and Postprocedure Hospitalization Among Patients Undergoing Gastrointestinal Endoscopy.","Qiu C","2026","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck09","R7: endoscopy cohort reports all cause pneumonia codes and hospitalization, no aspiration or retained gastric content outcome",2],["R0000938","Glucagon-like Peptide-1 Receptor Agonist Use and Risk of Postmastectomy Lymphedema in Breast Cancer Survivors: A Multicenter Real-World Cohort Study","Yesho DH","2026","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck05","matched TriNetX cohort, GLP-1 RA vs none, outcome is postmastectomy lymphedema only; cancer appears only as eligibility condition",2],["R0001378","Benefits of glucagon-like peptide-1 receptor agonists versus pioglitazone for cardio-hepatic outcomes: a territory-wide target trial emulation.","Li L","2025","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck05","R7: GLP-1 RA vs pioglitazone emulation; MALO, MACE, HF outcomes; pancreatitis and retinopathy only exclusion or baseline items",2],["R0000810","The Effect of Glucagon-Like Peptide-1 Receptor Agonists on Pain Management in Chronic Pancreatitis: A Real-World Cohort Study.","Dhali A","2026","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck05","chronic pancreatitis cohort, GLP-1 RA vs none; outcomes are opioids, OUD, pancreatic procedures; no listed harm",2],["R0000442","Urological Complications of Morbid Obesity and the Role of Bariatric Surgery and Glucagon-Like Peptide-1 Receptor Agonists in Their Management: A Systematic Review.","Khalil W","2026","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck02","R1: four named databases, PICO eligibility table, structured synthesis with GRADE summary including GLP-1 RA effects on testosterone, erectile function and albuminuria",2],["R0000635","Association of GLP-1 Receptor Agonist Prescriptions and Alcohol Consumption in the National Institutes of Health's All of Us Cohort.","Tyndall B","2026","inventory_only","N5","primary_report",null,null,null,"high","recheck","opus-5.5-recheck02","not randomized; single cross sectional AUDIT-C survey compared across current, former and future GLP-1 RA users; alternative N6, no listed harm either way",2],["R0001030","Diabetic Ketoacidosis Risk in Sodium-Glucose Cotransporter 2 Inhibitors versus Glucagon-Like Peptide-1 Receptor Agonists Initiators with CKD Stages 3-4 and Type 2 Diabetes.","Hansrivijit P","2026","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck02","new user active comparator cohort SGLT2i vs GLP-1 RA in CKD; only outcome is DKA; AKI, retinopathy, pancreatitis are baseline or exclusion only",2],["R0001601","Impact of Preoperative Glucagon-Like Peptide-1 Receptor Agonist on Outcomes Following Major Surgery.","Rashid Z","2025","include_harms",null,"primary_report",null,"O36A; O37B; O121",null,"high","recheck","opus-5.5-recheck02","R7: perioperative cohort GLP-1 RA exposed vs unexposed after PSM; reports acute renal failure separately, aspiration and ileus by group",2],["R0000610","Glucagon-like peptide-1 receptor agonists are associated with cardiac, cancer- and mortality-related benefits in diabetic patients treated with anthracyclines.","Chen ST","2026","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck01","R7: matched cohort in patients already with cancer; outcomes mortality, NED, cardiac; no incident cancer or separate AKI outcome",2],["R0001325","Association of Glucagon-like Peptide-1 Receptor Agonists with Mortality and Aspiration Pneumonia in Patients with Type 2 Diabetes After Gastrostomy: A Target Trial Emulation Study.","Tseng YT","2026","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck01","R7: aspiration pneumonia over follow up after drug initiation post gastrostomy, not exposure at a procedure as O36A row requires; alternative include_harms O36A",2],["R0001542","Impact of Glucagon-Like Peptide-1 Agonists on Hepatocellular Carcinoma Risk and Management in Type 2 Diabetes Mellitus: A Scoping Review.","Tungekar B","2025","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck01","R1: scoping review searching EMBASE, MEDLINE and Web of Science with criteria; tabulated synthesis of GLP-1 RA versus comparator HCC studies",2],["R0002001","Physiological and perceptual effects of GLP-1 receptor agonists during alcohol consumption in people with obesity: a pilot study","Quddos F","2025","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck01","existing GLP-1 RA users versus nonusers given alcohol challenge, not randomized; breath alcohol and subjective effects, no listed harm",2],["R0000748","Glucagon-like peptide-1 receptor agonists and rotator cuff disease: a scoping review.","Duru DO","2026","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck03","R1: PRISMA-ScR scoping review searching MEDLINE, Embase, PubMed, Cochrane with criteria; structured synthesis of GLP-1 RA exposed cohorts",2],["R0000572","GLP-1 Receptor Agonists for Treating Alcohol Use Disorder: A Critical Review.","Woo S","2026","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck03","R1: self-described narrative but names PubMed and ClinicalTrials.gov searches, states inclusion rules, tabulates all clinical GLP-1 RA AUD studies",2],["R0000716","Glucagon-Like Peptide 1 Receptor Agonists, Sodium-Glucose Cotransporter 2 Inhibitors, and Risk of Autoimmune Rheumatic Diseases.","Karacabeyli D","2026","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck03","R7: new user cohort GLP-1 RA vs DPP4i reports only autoimmune rheumatic disease incidence; cancer and retinopathy are baseline covariates",2],["R0001570","Perceptions, attitudes, and experiences of GLP-1 receptor agonists for weight management in the United Kingdom: a cross-sectional survey study.","Tallis J","2026","inventory_only","N5","primary_report",null,null,null,"high","recheck","opus-5.5-recheck03","R3: cross sectional online survey of GLP-1 RA users and non-users reporting self-reported side effects and perceptions",2],["R0001259","Alopecia as an Emerging Adverse Effect Associated With Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists for Weight Loss: A Scoping Review.","Rojas Lopez RF","2025","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck10","R1: scoping review with five named databases, stated inclusion criteria and tabulated synthesis of GLP-1 RA studies on alopecia",2],["R0001469","Injectable semaglutide and reductions in HbA1c and weight in the real world in people switched from alternative glucagon-like peptide-1 receptor agonists.","Crabtree TSJ","2022","inventory_only","N5","secondary_report",null,null,null,"high","recheck","opus-5.5-recheck10","R3: observational audit of semaglutide users only, stratified by prior GLP-1 RA; no unexposed comparator, effectiveness outcomes only",2],["R0001882","Trajectory of weight regain after cessation of GLP-1 receptor agonists: a systematic review and nonlinear meta-regression.","Budini B","2026","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck10","R1: PROSPERO registered review, five databases, eligibility criteria, meta-regression pooling GLP-1 RA arms after cessation",2],["R0001960","The Real-World Clinical Benefits of GLP-1 Receptor Agonist Treatment","Coetzer H","2025","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck10","claims cohort versus matched nonusers; ESRD, ESLD (hepatocellular carcinoma component only) and MACE; no listed harm reported",2],["R0000553","Glucagon-Like Peptide-1 Receptor Agonists and Incident Major Adverse Liver Outcomes in People With Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease.","Maier GA","2026","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck09","R7: new user cohort versus SGLT2 inhibitors on liver outcomes; hepatocellular carcinoma is single site, other harms only baseline",2],["R0001402","Glaucoma Risk Reduction as a Secondary Benefit of Glucagon-like Peptide-1 Receptor Agonists: A Review of Emerging Evidence.","Lang MV","2025","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck09","R1: PubMed, Embase and Scopus search, stated criteria, tabulated synthesis of GLP-1 RA and glaucoma risk studies",2],["R0001751","Cardiovascular and diabetes outcomes among patients with obesity and type 2 diabetes after metabolic bariatric surgery or glucagon-like peptide 1 receptor agonist treatment.","Stenberg E","2024","include_harms",null,"primary_report",null,"O33; O35A",null,"high","recheck","opus-5.5-recheck09","R7: matched registry cohort, bariatric surgery versus GLP-1 RA, reports new retinopathy and self harm hazard ratios",2],["R0001766","Effect of Beta-Cell Function on Glucose Variability When Switching From Insulin Degludec Plus a Dipeptidyl Peptidase-4 Inhibitor to Insulin Degludec/Liraglutide: Preliminary Results From a Pilot Study.","Oe Y","2025","inventory_only","N1","secondary_report",null,null,null,"high","recheck","opus-5.5-recheck09","R3: protocol mandated within patient switch to IDegLira without a comparison group, an uncontrolled interventional design despite observational label",2],["R0001731","GLP-1R Agonists Improve Ocular Surface Parameters in Type 2 Diabetes Mellitus.","Ottonelli G","2025","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck06","GLP-1 RA users vs non users with T2D compared on tear tests and OSDI over follow up; dry eye is not a listed harm",2],["R0001181","Benefits of Incretin Therapy on Ovarian Function: A Scientific Literature Review.","La Vignera S","2026","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck06","R1: four named databases, stated inclusion and exclusion criteria, dual screening, RoB 2 and AMSTAR appraisal, structured synthesis of GLP-1 RA PCOS studies",2],["R0001246","Auditable large language model curation of clinical notes refines glucagon-like peptide-1 initiation, persistence ascertainment, and compounding use beyond prescription records.","Varma G","2026","exclude","E2","other",null,null,null,"high","recheck","opus-5.5-recheck06","R8: LLM ascertainment of semaglutide and tirzepatide initiation, persistence and compounding; no clinical outcome compared between exposures",2],["R0001946","GLP-1 Receptor Agonists and Cancer: Interpreting a Wave of Real-World Signals From the 2026 ASCO Annual Meeting","Starasvetskaya N","2026","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck06","R1: named ASCO 2026 abstract library search with terms and counts, stated exclusions, tabulated synthesis of 28 GLP-1 RA cancer abstracts",2],["R0000852","Safety and Efficacy of Glucagon-Like Peptide-1 Receptor Agonists Use in Elderly People With Obesity-A Meta-Analysis.","Rego de Figueiredo I","2026","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck05","R1: PubMed, Embase, Scopus search, stated PICO criteria, random effects pooling of GLP-1 RA safety and efficacy outcomes by age",2],["R0000784","Risk of Retinal Vein Occlusion between Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes: A Retrospective Cohort Study.","Pan SY","2025","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck05","R7: new user GLP-1 RA vs DPP-4i cohort; outcome retinal vein occlusion, not a diabetic retinopathy complication under O33",2],["R0001029","GLP-1 Receptor Agonist Therapy in Older Adults with Diabetes: A Qualitative Analysis of Phase 4 ClinicalTrials.gov Studies.","Alourfi NM","2026","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck05","R1: structured ClinicalTrials.gov search with stated criteria; tabulated structured synthesis of 37 GLP-1 RA phase 4 trials",2],["R0001878","Beyond Weight Loss: Optimizing GLP-1 Receptor Agonist Use in Children.","Zaitoon H","2025","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck05","R1: PubMed, Embase, Cochrane search with inclusion criteria; structured synthesis of 11 pediatric GLP-1 RA RCTs in a table",2],["R0001160","Association between glucagon-like peptide-1 receptor agonists and risk of dementia in older adults with type 2 diabetes: A target trial emulation.","Zhou T","2026","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck08","target trial emulation of GLP-1 RA versus DPP4i or SGLT2i; only dementia and Alzheimer outcomes; retinopathy only a baseline covariate",2],["R0001694","Glucagon-Like Peptide-1 Receptor Agonists and Prior Major Adverse Limb Events in Patients With Diabetes.","Hsiao FC","2026","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck08","GLP-1 RA versus DPP-4i cohort; limb, cardiovascular, dialysis and mortality outcomes; retinopathy and malignancy only baseline covariates",2],["R0002419","Cardiovascular outcomes of empagliflozin-GLP-1RA combination therapy in type 2 diabetes: EMPRISE study.","Htoo PT","2026","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck08","emulated trials of empagliflozin with GLP-1 RA combinations; cardiovascular, heart failure and mortality outcomes; retinopathy only at baseline",2],["R0000656","Outcomes of GLP-1 Receptor Agonist Therapy after Liver Transplantation in Patients with Type 2 Diabetes: A Real-World Cohort Study.","Nguefang GL","2026","include_harms",null,"primary_report",null,"O28",null,"high","recheck","opus-5.5-recheck04","R7: TriNetX matched cohort GLP-1 RA vs conventional therapy after liver transplant reports biliary stricture HR; alternative N6 as graft complication",2],["R0000700","Perioperative Glucagon-Like Peptide-1 Receptor Agonist Therapy and Postoperative Outcomes in Adult Foot and Ankle Surgery: A Scoping Review.","Zahed M","2026","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck04","R1: scoping review searching five named databases with PCC eligibility, charting two cohorts of perioperative GLP-1 RA exposure in foot and ankle surgery",2],["R0001062","Roux-en-Y Gastric Bypass Compared to Glucagon-like Peptide-1 Receptor Agonists is Associated with Lower Out-of-Pocket Costs in Insured Patients with Type 2 Diabetes and Obesity","Thiyagarajan S","2025","exclude","E2","other",null,null,null,"high","recheck","opus-5.5-recheck04","R8: matched claims comparison of gastric bypass vs semaglutide or tirzepatide compares out of pocket costs only, no clinical outcome",2],["R0001633","Bridging Innovation and Practice in Type 2 Diabetes Mellitus: Novel Antidiabetic Therapies and the Expanding Role of Community Pharmacists.","Spanakis M","2026","exclude","E3","other",null,null,null,"high","recheck","opus-5.5-recheck04","R1: narrative review with named databases, but structured synthesis only covers pharmacist interventions; GLP-1 drugs only overviewed by class; alternative include_review",2],["R0001150","Comparison of IBD-related outcomes in patients with obesity treated with GLP-1 receptor agonists versus bariatric surgery.","Nanah MH","2026","include_harms",null,"primary_report",null,"O37B",null,"high","recheck","opus-5.5-recheck02","R7: matched cohort GLP-1 RA vs bariatric surgery in obese IBD; reports incident intestinal obstruction by group with OR",2],["R0001072","GLP-1 receptor agonists in eye disease: a comprehensive review of current research and future potential.","Luo Y","2026","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck02","R1: PubMed, Embase, Web of Science searched, stated inclusion criteria, dual screening, structured table of clinical GLP-1 RA eye disease evidence",2],["R0002106","Diagnostic Evaluation of an Increased Risk of Developing Small Intestinal Bacterial Overgrowth Associated with Glucagon-like Peptide-1 (GLP-1) Receptor Agonists and Dual GLP-1/GIP Receptor Agonists: A Global Retrospective Multicenter Cohort Analysis.","Sun Y","2025","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck02","new user cohort GLP-1 RA or tirzepatide vs other second line agents; only outcome SIBO; gastroparesis is an exclusion criterion",2],["R0002192","Combination GLP-1 receptor agonist and SGLT2 inhibitor therapy versus GLP-1 receptor agonist monotherapy on arrhythmia outcomes in non-diabetic obese patients: A real-world time-dependent analysis.","Blankson GA","2026","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck02","matched cohort GLP-1 RA plus SGLT2i vs GLP-1 RA alone in nondiabetic obesity; arrhythmia outcomes only, no listed harm",2],["R0001553","GLP-1 Receptor Agonists and Fertility: What Is Known So Far?","Becker AS","2026","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck01","R1: called narrative but searched PubMed, SciELO and LILACS with stated criteria, dual screening and table of included GLP-1 RA studies",2],["R0001942","Incretin-based therapy in the management of metabolic dysfunction-associated steatotic liver disease (MASLD): one piece of the puzzle: Editorial on \"Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: A network meta-analysis\".","Ren TY","2024","inventory_only","N9","ancillary",null,null,null,"high","recheck","opus-5.5-recheck01","editorial commenting on an in scope network meta-analysis of GLP-1 RA versus thiazolidinediones in MASLD",2],["R0002092","Weight Regain After Liraglutide, Semaglutide or Tirzepatide Interruption: A Narrative Review of Randomized Studies.","Quarenghi M","2025","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck01","R1: called narrative but three named databases, RCT only criteria, dual screening and tabulated synthesis of 13 GLP-1 RA trials",2],["R0002338","Retrospective Comparative Study of Oral Versus Subcutaneous Semaglutide in Patients with Type 2 Diabetes Mellitus.","Toffoli B","2026","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck03","Oral vs subcutaneous semaglutide cohort reports HbA1c, BMI, BP, lipids and nonspecific GI adverse events; no listed harm outcome",2],["R0001480","Effects of Glucagon-Like Peptide 1 Receptor Agonist Initiation in Patients With Heart Failure With Reduced Ejection Fraction and Implantable Cardiac Devices.","Marques P","2025","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck03","Full text readable; matched GLP-1 RA users vs nonusers with HFrEF devices; heart rate, arrhythmia, BMI and labs only, no listed harm",2],["R0001949","Adverse event comparison between glucagon-like peptide-1 receptor agonists and other antiobesity medications following bariatric surgery.","Samuels JM","2024","include_harms",null,"primary_report",null,"O28; O37A; O37B",null,"high","recheck","opus-5.5-recheck03","R7: GLP-1 RA vs other antiobesity drug cohort after bariatric surgery tabulates bowel obstruction, gallstone disease and gastroparesis by group",2],["R0002879","Efficacy of GLP-1 receptor agonists on obesity and metabolic profile in patients with inflammatory bowel disease: a systematic review and meta-analysis.","Shirmard FO","2025","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck03","R1: PROSPERO registered review searching four databases with criteria; random effects pooling of weight change on GLP-1 RAs in IBD",2],["R0001568","Semaglutide in cognitive dysfunction: neuroprotective potential, clinical trial limitations, and a prevention-focused framework.","Alhowail AH","2026","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck09","R1: PRISMA search of PubMed and Scopus with stated criteria and tabulated synthesis of GLP-1 RA dementia studies and semaglutide trials",2],["R0001844","Comparative risk of hepatocellular carcinoma and mortality among initiators of GLP-1 receptor agonists versus other glucose-lowering therapies: a target trial emulation.","Hernández-Pérez JG","2026","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck09","R7: target trial emulation with hepatocellular carcinoma as the only cancer outcome, a single site not listed; other harms only exclusions",2],["R0001847","Nurse-led supportive care interventions for adults with type 2 diabetes and/or obesity receiving glucagon-like peptide-1 receptor agonists: a scoping review","Dong H","2026","exclude","E2","other",null,null,null,"high","recheck","opus-5.5-recheck09","R1: scoping review of nurse led care where GLP-1 RA is background therapy in every included comparison",2],["R0002550","Retrospective case-control study of pre-diagnosis observational and prescription data in Parkinson's disease.","Doherty P","2026","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck09","CPRD case control relating prior GLP-1 RA prescriptions among other drugs to Parkinson disease, not a listed harm",2],["R0001252","Glucagon-like Peptide-1 Receptor Agonists Improve Liver and Metabolic Health Outcomes in Type 2 Diabetes and Obesity Regardless of Prior Liver Disease","Sanyal A","2026","include_harms",null,"primary_report","P01","O33; O32B; O38; O39",null,"high","recheck","opus-5.5-recheck07","R7: TriNetX GLP-1 RA vs matched nonusers in T2D with obesity reports diabetic ophthalmic complications, thyroid, pancreatic and overall cancer incidence",2],["R0001269","Healthcare costs and treatment patterns associated with glucagon-like peptide 1 receptor agonist use among patients with metabolic dysfunction-associated steatohepatitis.","Tapper EB","2025","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck07","R7: MASH cohort of GLP-1 RA vs other diabetes drug initiators; outcomes are costs, BMI and liver events; hepatocellular carcinoma is a single site cancer",2],["R0001539","GLP-1 receptor agonists in patients with cancer are associated with reduced all-cause mortality and hospitalization.","Mahadevan A","2026","inventory_only","N6","primary_report","P01",null,null,"high","recheck","opus-5.5-recheck07","R7: GLP-1 RA vs metformin in T2D with active cancer; mortality, hospitalization, MACE, sepsis, pneumonia outcomes; cancer types are baseline only",2],["R0002166","Comparative change in HbA1c and weight outcomes between obese and non-obese adults with type 2 diabetes mellitus treated with SGLT-2 inhibitors or GLP-1 receptor agonists.","Almohammed OA","2026","inventory_only","N6","primary_report","P01",null,null,"high","recheck","opus-5.5-recheck07","SGLT2 inhibitor or GLP-1 RA initiators by obesity; HbA1c and weight outcomes only; retinopathy and thyroid disease appear only as baseline covariates",2],["R0001525","Residual gastric content after holding of glucagon-like peptide-1 receptor agonists before elective surgery: a cross-sectional study - the RESIDUAL study.","Boudreau C","2026","include_harms",null,"primary_report",null,"O36B",null,"high","recheck","opus-5.5-recheck06","R7: prospective perioperative cohort, GLP-1 RA users held 7 days vs nonusers, ultrasound residual gastric content compared with overlap weighting",2],["R0001356","GLP-1 Receptor Agonists Versus Bariatric Surgery: Effects of Weight Loss and BMI on Subsequent General Surgical Procedures.","Zindani S","2026","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck06","R7: weighted cohort GLP-1 RA vs bariatric surgery before general surgery; composite complications, LOS, readmission; gallbladder only a procedure type",2],["R0002162","Current Insights, Advantages and Challenges of Small Molecule Glucagon-like Peptide 1 Receptor Agonists: A Scoping Review.","Luna Ceron E","2025","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck06","R1: scoping review, PubMed, MEDLINE and ClinicalTrials.gov searched, design, language and date limits stated, tabulated trials of small molecule GLP-1 RAs",2],["R0002220","Impact of tirzepatide on systemic arterial stiffness assessed by cardio-ankle vascular index in individuals with obesity complicated by type 2 diabetes: A retrospective cohort study in Japan.","Nagayama D","2026","inventory_only","N5","primary_report",null,null,null,"high","recheck","opus-5.5-recheck06","R3: retrospective observational before and after cohort of 24 tirzepatide users; no comparison group",2],["R0003050","A Multicenter, Open-Label Study of Combined Poly-L-Lactic Acid and Hyaluronic Midface Filler Regimen Enhances Facial Harmony and Skin Quality in GLP-1 Medication Users.","Lorenc ZP","2026","exclude","E2","primary_report",null,null,null,"high","recheck","opus-5.5-recheck02","R1 by analogy: single arm filler study in people already on GLP-1 RAs; drug is background only, neither intervention nor compared exposure; alternative N1",2],["R0001904","Comparative effectiveness of semaglutide and dulaglutide combined with hypocaloric diet in newly diagnosed type 2 diabetes: a retrospective real-world study.","Cetiner S","2026","inventory_only","N6","primary_report","P01",null,null,"high","recheck","opus-5.5-recheck04","retrospective semaglutide vs dulaglutide cohort; weight, HbA1c, enzymes and mild GI events; pancreatic enzyme rises are not pancreatitis",2],["R0001989","GLP-1 Receptor Agonists, Fertility Restoration, and Reproductive Safety in Women of Reproductive Age: A Narrative Review.","Abedi MM","2026","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck04","R1: self labeled narrative but searched four named databases with stated eligibility and structured evidence matrix of GLP-1 RA reproductive studies",2],["R0001997","GLP-1RA comparative effectiveness against dementia onset relative to other antidiabetic medications in a large, multi-site cohort of patients with type 2 diabetes.","Nance N","2025","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck04","three emulated trials GLP-1 RA vs SGLT2i, DPP-4i, SU; dementia only outcome; pancreatitis appears only as exclusion criterion",2],["R0002499","Glucagon-like peptide-1 receptor agonist use is associated with reduced risk of out-of-hospital cardiac arrest in women with type 2 diabetes: A nationwide nested case-control study.","Eroglu TE","2024","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck02","nested case control GLP-1 RA vs DPP-4i; only outcome out of hospital cardiac arrest; retinopathy is a baseline characteristic only",2],["R0002657","Use of GLP-1 receptor agonists and risks of suicide attempts or self-harm in patients with type 2 diabetes: a multicountry self-control case series study.","Peng ZY","2025","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck04","R7: self controlled case series of suicide attempt or self harm; self controlled design qualifies only for O34",2],["R0002803","Wernicke's Encephalopathy Following Semaglutide Treatment for Obesity: A Systematic PRISMA Review of Case-Based Evidence.","Bidesie J","2026","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck02","R1: reviews of case reports qualify; four named databases, PICO eligibility, structured synthesis of six semaglutide associated Wernicke cases",2],["R0001372","Pharmacological interventions for obesity in patients with inflammatory bowel disease: A systematic review of GLP-1 receptor agonist efficacy and safety.","Jan A","2026","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck10","R1: PubMed, Embase and Web of Science search, stated eligibility criteria, tabulated narrative synthesis of GLP-1 RA cohorts in IBD",2],["R0001807","Adherence Patterns of Oral vs Injectable GLP-1 Receptor Agonists: A National Real-World Analysis of Commercial Claims Data, 2010–2021","Wang Y","2025","exclude","E2","other",null,null,null,"high","recheck","opus-5.5-recheck10","R8: claims study compares only adherence and persistence across GLP-1 RA agents; no clinical outcome compared",2],["R0002342","Real-world glycemic control, exploratory cardiorenal indicators, and safety of polyethylene glycol loxenatide versus semaglutide in type 2 diabetes patients: a Chinese two-center retrospective cohort study.","Yu Z","2026","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck10","matched cohort PEG-loxenatide versus semaglutide; pancreatitis only an exclusion criterion and retinopathy only baseline; GI and hypoglycemia events reported",2],["R0001825","Do GLP-1 Receptor Agonists Alter Brain Responses to Reward-Related Cues? A Systematic Review.","Dang V","2026","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck08","R1: searched Embase, Medline, PubMed, Scopus and others; stated inclusion criteria; tabulated structured synthesis of 11 GLP-1 RA fMRI studies",2],["R0001428","Phenome-wide analysis of downstream health outcomes following second-line antidiabetic agent prescriptions in All of Us.","Salvatore M","2026","include_harms",null,"primary_report",null,"O28; O29",null,"low","recheck","opus-5.5-recheck08","new user PheWAS GLP-1 RA versus SGLT2i or DPP4i over 974 phecodes; listed harm results only in supplementary data, not visible; alternative N6",2],["R0001718","The Glucagon-like Peptide-1 Receptor Agonist Era and Its Influence on Body-Contouring Referrals After Weight Loss in Appalachia.","Rahimpour A","2026","inventory_only","N5","primary_report",null,null,null,"high","recheck","opus-5.5-recheck08","R3: descriptive registry review of body contouring referrals by weight loss method; no clinical outcome compared after exposure; alternative E2 under R8",2],["R0002772","Efficacy and Safety of Semaglutide in Patients with Polycystic Ovary Syndrome: A Scoping Review.","La Vignera S","2026","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck08","R1: scoping review with PubMed and other named sources, stated eligibility, structured tabulated synthesis of semaglutide studies in PCOS",2],["R0001614","Patterns of prescription and discontinuation of glucagon-like peptide-1 receptor agonists among patients with irritable bowel syndrome.","Gautam M","2025","exclude","E2","other",null,null,null,"high","recheck","opus-5.5-recheck09","R8: switching and persistence study of GLP-1 RA agents in IBS; compares discontinuation timing, no clinical outcome compared between exposures",2],["R0001668","GLP-1 receptor agonist and risk of erectile dysfunction in men with type 2 diabetes: a target trial emulation.","Tang H","2026","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck09","R7: target trial emulation versus DPP-4 inhibitors with erectile dysfunction as the only outcome; retinopathy appears only as baseline covariate",2],["R0003446","Molecular Insights into the Potential Cardiometabolic Effects of GLP-1 Receptor Analogs and DPP-4 Inhibitors.","Król M","2025","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck09","R1: PubMed search with stated criteria and tabulated synthesis of clinical and preclinical GLP-1 RA cardiovascular studies",2],["R0003489","Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors on Intima-Media Thickness: Systematic Review and Meta-Analysis.","Akbari A","2024","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck09","R1: four named databases, criteria, random effects meta-analysis of carotid IMT change with GLP-1 RA; pooled single arms qualify",2],["R0002518","GLP-1 Receptor Agonists Plus Progestins and Endometrial Cancer Risk in Nonmalignant Uterine Diseases.","Yen TT","2026","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck01","R7: only endometrial cancer (single site, not thyroid or pancreas) and hysterectomy reported; no any cancer outcome",2],["R0001896","Cardiovascular outcome of Glucagon-Like Peptide-1 Receptor Agonists vs Dipeptidyl Peptidase-4 Inhibitor on End-stage Renal Disease patients with Heart Failure: An Emulated Target Trial in Patients with Diabetes","Yu C","2025","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck01","whole preprint read: TTE of GLP-1 RA versus DPP-4i in dialysis with HF; CV composite, mortality, hospitalization; skin cancer only a negative control",2],["R0001987","Glycated hemoglobin and body mass index as mediators of GLP-1RAs and Alzheimer's disease and related dementias in patients with type 2 diabetes.","Tang H","2025","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck01","active comparator new user cohort with dementia outcome and mediation; pancreatitis, cancer and retinopathy appear only as baseline characteristics",2],["R0001437","Roux-en-Y Gastric Bypass Compared to Glucagon-Like Peptide-1 Receptor Agonists is Associated with Lower Out-of-Pocket Costs in Insured Patients with Type 2 Diabetes and Obesity: A Matched Analysis Over Two Years.","Thiyagarajan S","2026","exclude","E2","other",null,null,null,"high","recheck","opus-5.5-recheck05","R8: matched claims cohort of gastric bypass vs GLP-1 RA compares only out of pocket costs, no clinical outcome",2],["R0002048","Synergistic associations of metformin and GLP-1 receptor agonist use with adiposity-related cancer incidence in people living with type 2 diabetes.","Henney AE","2026","include_harms",null,"primary_report",null,"O32B; O38",null,"high","recheck","opus-5.5-recheck05","R7: new user GLP-1 RA vs DPP-4i cohort; individual pancreatic and thyroid cancers are stated secondary outcomes; composite is not O39",2],["R0002170","Sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists improve indices of atrial cardiomyopathy: a systematic review and meta-analysis",null,"2025","include_review",null,"systematic_review",null,null,"abstract_only","high","recheck","opus-5.5-recheck05","R1: congress abstract; MEDLINE, Scopus, Cochrane search with criteria; random effects pooling of GLP-1 RA atrial indices",2],["R0002337","Role of GLP-1 Receptor Agonists in Managing Cancer Therapy-Related Cardiac Dysfunction.","Vignarajah A","2025","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck05","matched TriNetX cohort GLP-1 RA vs none in cancer therapy cardiac dysfunction; HF, mortality, arrhythmia outcomes; thyroid cancer only baseline",2],["R0002300","Heterogeneous treatment effects of GLP-1RAs and SGLT2is on risk of Alzheimer's disease and related dementia in patients with type 2 diabetes: Insights from a real-world target trial emulation.","Tang H","2025","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck02","target trial emulations GLP-1 RA vs other glucose lowering drugs or SGLT2i; only outcome dementia; pancreatitis and cancer are baseline covariates",2],["R0002533","The Effect of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists on 24-Hour Urine Parameters: A Retrospective Cohort Study.","Schaub JA","2025","inventory_only","N5","primary_report",null,null,null,"high","recheck","opus-5.5-recheck02","R3: cross sectional exposure control comparison of 24 hour urine chemistry plus uncontrolled before after subset; no listed harm outcome",2],["R0003620","Population profile and glycemic control following initiation or switch of injectable therapies in Tianjin, China: A real-world retrospective cohort study of adults with type 2 diabetes.","Zhang Q","2025","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck02","R8: EMR cohorts initiating GLP-1 RA vs insulin regimens compared on glycemic control; retinopathy only at baseline, no listed harm",2],["R0002718","Information pharmacists assist in the construction of GLP-1RA prescription review rules in a tertiary hospital in China.","Zhou L","2025","inventory_only","N5","other",null,null,null,"high","recheck","opus-5.5-recheck02","R8: FAERS disproportionality analysis of liraglutide and semaglutide adverse events plus before after prescribing audit; alternative E2 for audit part only",2],["R0002655","Switching patterns of GLP-1 receptor agonists from 2018 to 2025 in the largest private healthcare network in Poland.","Łupina K","2026","exclude","E2","other",null,null,null,"high","recheck","opus-5.5-recheck04","R8: EHR study of switching between GLP-1 RA agents; outcome is switching only, no clinical outcome compared between exposures",2],["R0002629","Systemic Metabolic and Skeletal Muscle-Related Profiles Associated with Annual Axial Elongation Across Optical Myopia-Control Strategies in Adolescents: A Retrospective Cohort Study.","Wang X","2026","inventory_only","N6","primary_report","P99",null,null,"high","recheck","opus-5.5-recheck04","adolescent myopia cohort comparing recorded GLP-1 RA users vs nonusers with IPTW on axial elongation; no listed harm; alternative E2 as marker only",2],["R0003078","Comparative Effectiveness of Current Glucose-lowering Medications in Type 2 Diabetes Mellitus: Emulation of a Modified GRADE Trial.","Ray A","2026","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck04","four arm target trial emulation of GLP-1 RA, SGLT2i, SU, DPP-4i; HbA1c failure, MACE, heart failure, hypoglycemia; no listed harm",2],["R0003235","Glycemic Improvement with Low-Dose Dulaglutide Is Associated with Leptin and Obestatin Modulation in Type 2 Diabetes Mellitus.","Jung I","2026","inventory_only","N1","primary_report","P01",null,null,"high","recheck","opus-5.5-recheck04","R3: single arm study starting dulaglutide 0.75 mg per protocol after enrollment with scheduled visits; interventional despite observational label, no comparator",2],["R0002537","Effectiveness of Pre-Transplant Dual GLP-1 Receptor Agonist and SGLT2 Inhibitor Therapy on All-Cause Mortality in Organ Transplantation Candidates with Obesity and Type 2 Diabetes: a Target-Trial Emulation.","Huang YN","2026","include_harms",null,"primary_report",null,"O28; O29; O32B; O33; O34; O35A; O37A; O121",null,"high","recheck","opus-5.5-recheck06","target trial emulation, GLP-1 RA plus SGLT2i vs SGLT2i or usual care; prespecified safety HRs for pancreatitis, biliary, AKI, retinopathy, NAION, thyroid cancer, suicidality",2],["R0002521","The Effects of GLP-1 Receptor Agonists on Alzheimer's Pathophysiology: A Systematic Review","Corcoran E","2025","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck06","R1: PubMed, Embase, Cochrane searched, stated criteria, PROSPERO registered; synthesis includes two GLP-1 RA clinical trials besides preclinical work",2],["R0003217","Comparative effectiveness of antidiabetic therapies on hepatic decompensation in patients with type 2 diabetes: A target trial emulation.","Choi J","2025","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck06","new user target trial emulation GLP-1 RA vs other antidiabetics; hepatic decompensation only; biliary term is baseline cholangitis",2],["R0003445","Real-world clinical and budget impact of semaglutide in type 2 diabetes mellitus in tertiary hospital in Saudi Arabia.","Al-Abdulkarim HA","2025","inventory_only","N5","primary_report",null,null,null,"high","recheck","opus-5.5-recheck06","R3: retrospective chart review of semaglutide initiators, before and after HbA1c, BMI and costs; no comparison group",2],["R0001725","GLP-1 receptor agonists in systemic lupus erythematosus: a scoping review.","Sia R","2026","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck10","R1: scoping review searching PubMed, Embase, Scopus and Cochrane with stated eligibility and descriptive synthesis including GLP-1 RA cohorts and case reports in SLE",2],["R0003016","Survival Benefits of GLP-1 Receptor Agonists in Patients with Neuroendocrine Neoplasms: A Large-Scale Propensity-Matched Cohort Study.","Fawzy MS","2025","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck10","TriNetX cohort of GLP-1 RA users versus nonusers with neuroendocrine neoplasms; cancer is the population, only all-cause mortality reported",2],["R0003785","Glucagon-like peptide-1 receptor agonists reverse nerve morphological abnormalities in diabetic peripheral neuropathy.","Dhanapalaratnam R","2024","inventory_only","N5","primary_report",null,null,null,"high","recheck","opus-5.5-recheck10","R3: observational before and after cohort of 22 patients prescribed GLP-1 RA in routine care, STROBE reported, no comparison group",2],["R0002383","Association of GLP-1 Receptor Agonist Use With Risk of Lumbar Degenerative Disease and Spine Surgery in Patients With Type 2 Diabetes: A Propensity Score-matched Cohort Study.","Chang Y","2026","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck09","R7: matched TriNetX cohort versus nonusers on lumbar degenerative disease and spine surgery only, no listed harm outcome",2],["R0003586","Tirzepatide vs. semaglutide for obesity, glycemic control, and cardiovascular outcomes: a narrative review of clinical trials.","Harbi MH","2026","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck09","R1: self labeled narrative but PubMed and ClinicalTrials.gov search, PICOS criteria and tabulated tirzepatide versus semaglutide synthesis",2],["R0004567","Adherence and treatment discontinuation of oral semaglutide and once-weekly semaglutide injection at 12 month follow-up: Japanese real-world data.","Horii T","2024","exclude","E2","other",null,null,null,"high","recheck","opus-5.5-recheck09","R8: matched claims cohort oral versus injectable semaglutide comparing adherence and discontinuation only, no clinical outcome",2],["R0004570","Outcomes in New User Cohorts of SGLT2 Inhibitors or GLP-1 Receptor Agonists with Type 2 Diabetes and Chronic Kidney Disease.","Layton JB","2025","inventory_only","N5","primary_report",null,null,null,"high","recheck","opus-5.5-recheck09","R3: separate descriptive new user cohorts of SGLT2i and GLP-1 RA with crude incidence only, no between exposure comparison",2],["R0003040","AI-Enabled Personalization of Semaglutide Therapy in Type 2 Diabetes: Systematic Review With an Integration Framework.","Barakat G","2026","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck05","R1: named MIAGE Scholar search, stated criteria, structured thematic synthesis of 18 studies with semaglutide as exposure of interest",2],["R0002193","Effect of GLP-1 Receptor Agonists on Patients with Thyroid Carcinomas Undergoing Active Surveillance.","Patrizio A","2026","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck05","matched cohort of existing papillary thyroid carcinomas; outcome is tumor growth on surveillance, not incident thyroid cancer O32B",2],["R0003042","Exploring the link between GLP-1 receptor agonists and dementia: A comprehensive review.","Chuansangeam M","2025","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck05","R1: PubMed search with stated eligibility; structured tabulated synthesis of ten GLP-1 RA dementia studies including six RCTs",2],["R0003375","Long-Acting Lipid-Lowering Injectables and Behavioral Moral Hazard: A Systematic Review of Adherence, Lifestyle Measurement, and Structural Evidence Gaps.","Cumpăt CM","2026","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck05","R1: four database search, stated criteria, structured synthesis of four RCTs including semaglutide STEP 1 as an intervention of interest",2],["R0002745","The relative risk of clinically relevant cholelithiasis among glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus, real-world study.","Gameil MA","2024","include_harms",null,"primary_report",null,"O28",null,"high","recheck","opus-5.5-recheck08","R7: multicenter cohort of liraglutide, dulaglutide, semaglutide versus non GLP-1 therapy over 12 months; ultrasound cholelithiasis compared between groups",2],["R0002746","Mortality and major adverse cardiovascular events after glucagon-like peptide-1 receptor agonist initiation in patients with immune-mediated inflammatory diseases and type 2 diabetes: A population-based study.","Karacabeyli D","2024","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck08","new user GLP-1 RA versus DPP-4i cohort in immune mediated disease; mortality and MACE only; retinopathy and malignancy only baseline covariates",2],["R0003102","Treatment Strategies for Weight Loss Insufficiency and Weight Regain After Sleeve Gastrectomy: A Network Meta-Analysis and Systematic Review","Min Y","2026","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck08","R1: PubMed, Embase, Web of Science; eligibility stated; structured synthesis includes GLP-1 RA versus revision surgery studies after sleeve gastrectomy",2],["R0003303","Glucagon-like peptide-1 receptor agonists compared with bariatric metabolic surgery and the risk of obesity-related cancer: an observational, retrospective cohort study.","Wolff Sagy Y","2025","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck08","R7: GLP-1 RA versus bariatric surgery cohort; outcome is composite obesity related cancer, not any cancer; no separate thyroid or pancreas contrast",2],["R0003496","The time-varying cardiovascular benefits of glucagon-like peptide-1 receptor agonist therapy in patients with type 2 diabetes mellitus: Evidence from large multinational trials.","Deo SV","2022","include_nma",null,"pooled_analysis","P01",null,null,"high","recheck","opus-5.5-recheck03","R4: pools randomized GLP-1 RA vs placebo contrasts from eight CVOTs; trials taken from an earlier review, no own database search",2],["R0002561","Glucagon-like peptide-1 receptor agonists and risk for cardiovascular events in older adults treated with levothyroxine: a target trial emulation.","Du F","2025","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck03","R7: emulated GLP-1 RA vs SGLT2i trial reports atrial fibrillation and stroke only; thyroid cancer appears only as exclusion",2],["R0003175","Semaglutide and Cardiovascular Outcomes in People with Type 2 Diabetes: A SUSTAIN-6 Post Hoc Analysis by Weight Loss Category.","Navas A","2026","inventory_only","N1","secondary_report","P01",null,null,"high","recheck","opus-5.5-recheck03","R4: SUSTAIN-6 post hoc uses semaglutide arm only, comparing MACE across weight loss categories without the placebo contrast",2],["R0003001","Semaglutide promotes bone marrow-derived progenitor cell flux towards an anti-inflammatory and pro-regenerative profile in high-risk patients: the SEMA-VR CardioLink-15 trial.","Park B","2026","include_nma",null,"primary_report","P01; P02",null,"mechanistic","high","recheck","opus-5.5-recheck04","R5: open label RCT semaglutide vs usual care on progenitor cells; reports body weight, HbA1c and adverse events by arm",2],["R0002808","Enrollment of Females in Randomized Trials for Glucagon-Like Peptide 1 Receptor Agonists: A Systematic Review.","Rivera FB","2024","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck04","R1: PROSPERO registered review searching named databases with criteria, structured synthesis of 98 GLP-1 RA RCTs on female enrollment; alternative E3, no effect contrast",2],["R0002694","Comparison of New-Onset Peripheral Artery Disease in Patients With Type 2 Diabetes Exposed to Sodium-Glucose Cotransporter-2 Inhibitors, Dipeptidyl Peptidase-4 Inhibitors, or Glucagon-Like Peptide-1 Agonists: A Population-Based Cohort Study.","Chou OH","2025","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck04","Hong Kong cohort SGLT2i vs DPP-4i with GLP-1 RA third arm; peripheral artery disease, cardiovascular and death outcomes only; cancer only baseline",2],["R0002784","SGLT2 inhibitors, GLP-1 RAs, and DPP4 inhibitors and the risk of hypomagnesemia in type 2 diabetes: A target trial emulation.","Shao SC","2026","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck04","TriNetX emulation GLP-1 RA vs DPP-4i vs SGLT2i; hypomagnesemia, hyperkalemia and appendicitis controls only; pancreatitis, neoplasms are exclusions",2],["R0004641","Association between incretin-based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: A large population-based matched cohort study.","Krishnan A","2024","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck02","R7: cholangiocarcinoma is not O28 and single site cancers other than thyroid or pancreas are N6; new user cohort GLP-1 RA vs other agents",2],["R0005429","Transitional changes in medication-initiator cohort profiles in persons with chronic kidney disease and type 2 diabetes-A hospital-based cohort study in Japan.","Yano Y","2025","exclude","E2","other",null,null,null,"high","recheck","opus-5.5-recheck02","R8: describes characteristics of SGLT2i and GLP-1 RA initiators across two periods; no clinical outcome compared between exposures",2],["R0005769","Biguanides and glucagon like peptide 1 receptor agonists in the amelioration of post liver transplant weight gain; a scoping review of the mechanism of action, safety and efficacy.","Mac Curtain BM","2024","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck02","R1: scoping review searching PubMed, Embase, CENTRAL with stated criteria; structured table of GLP-1 RA safety and efficacy after liver transplant",2],["R0003840","Fasting Duration, Not Timing of Last GLP-1 Dose, Predicts Aspiration Risk Indicators: A Prospective Point-of-Care Gastric Ultrasound Study.","Shahidifar E","2026","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck06","outpatient research ultrasound in fasted GLP-1 RA users vs controls, not at any procedure; O36B requires a procedure cohort or case control",2],["R0003682","Effectiveness of glucagon-like peptide-1 receptor agonists for reduction of body mass index and blood glucose control in patients with type 2 diabetes mellitus and obesity: A retrospective cohort study and difference-in-difference analysis.","Siriyotha S","2024","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck06","retrospective difference in differences cohort GLP-1 RA vs other second line drugs; BMI, FPG, HbA1c only; retinopathy is a baseline variable",2],["R0003626","Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors Improve Renal Resistive Index in Patients With Type 2 Diabetes: A 26-Week Prospective Observational Real-Life Study.","Vozza A","2025","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck06","prospective observational GLP-1 RA vs SGLT2i vs other therapy; renal resistive index and metabolic changes; retinopathy only at baseline",2],["R0004875","Clinical Profile and Treatment Patterns in Individuals with Type 2 Diabetes and Chronic Kidney Disease Who Initiate a GLP-1 Receptor Agonist: A Multinational Cohort Study.","Pladevall-Vila M","2025","exclude","E2","other",null,null,null,"high","recheck","opus-5.5-recheck06","R8: multinational description of GLP-1 RA initiators with CKD, baseline profile, initiation trends and persistence; no clinical outcome compared",2],["R0002439","Dual GIP/GLP-1 Receptor Agonist Versus Selective GLP-1 Receptor Agonist in Patients Undergoing Primary Total Knee or Hip Arthroplasty","Davis SC","2026","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck10","R7: tirzepatide versus semaglutide arthroplasty cohort; full outcome list is infections, wound, mechanical, readmission; aspiration only mentioned in introduction",2],["R0003933","Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan.","Tuccinardi D","2025","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck10","R1: self-labeled structured narrative review but names PubMed, Scopus, CENTRAL, gives inclusion criteria, PRISMA flow, synthesis tabulated by phenotype",2],["R0003981","GLP-1 receptor agonists' impact on cardio-renal outcomes and mortality in T2D with acute kidney disease.","Pan HC","2024","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck10","acute kidney disease is the population; outcomes mortality, MACE and MAKE without AKI; no listed harm",2],["R0004194","Effectiveness of GLP-1RA according to different type 2 diabetes phenotypes: A retrospective study.","Caruso I","2025","inventory_only","N5","primary_report",null,null,null,"high","recheck","opus-5.5-recheck10","R3: retrospective single center cohort of GLP-1 RA initiators only, compared across diabetes phenotypes; no unexposed comparator",2],["R0004710","Beyond Glycemic Control: GLP-1 Receptor Agonists and Their Impact on Calcium Homeostasis in Real-World Patients.","Alenezi BT","2024","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck09","R7: matched TriNetX cohort on calcium disorders, utilization, cardiovascular events and mortality; pancreatitis and thyroid only exclusions",2],["R0004957","Indirect Comparative Efficacy and Safety of Tirzepatide Versus Oral Semaglutide for the Treatment of Overweight and Obesity.","Ciudin A","2026","inventory_only","N6","secondary_report","P02",null,null,"high","recheck","opus-5.5-recheck09","R4: ML-NMR across SURMOUNT-1 and OASIS 1 without a shared randomized tirzepatide versus oral semaglutide contrast",2],["R0005528","Treatment with GLP-1 receptor agonists is associated with significant weight loss and favorable headache outcomes in idiopathic intracranial hypertension.","Krajnc N","2023","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck09","R7: self selected GLP-1 RA versus matched usual care in IIH; weight, headache, vision and general adverse events only",2],["R0003263","Real-world persistence and dose titration of GLP-1 receptor agonists in type 2 diabetes: A UK population-based cohort study by obesity and cardiovascular disease status.","Ulrich FS","2026","exclude","E2","other",null,null,null,"high","recheck","opus-5.5-recheck08","R8: persistence and dose titration of GLP-1 RA initiators compared by agent and patient group; no clinical outcome compared",2],["R0004349","Improvement of Quality of Life by Switching from Oral Semaglutide to Tirzepatide in Patients with Type 2 Diabetes.","Fukaishi T","2025","inventory_only","N5","primary_report",null,null,null,"high","recheck","opus-5.5-recheck08","R3: prospective observational cohort of 11 patients switched from oral semaglutide to tirzepatide; no concurrent comparison group",2],["R0004862","Real-World Comparative Evaluation of Add-On Glucagon-like Peptide 1 Receptor Agonist in Type 2 Diabetes Treated with or without Insulin.","Chou HW","2022","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck02","retrospective cohort of GLP-1 RA add on in insulin vs non insulin users on HbA1c and weight; zero gallbladder events noted without exposure contrast",2],["R0005459","Baseline characteristics from evoke and evoke+: Two phase 3 randomized placebo-controlled trials of semaglutide in participants with early-stage symptomatic Alzheimer's disease.","Scheltens P","2026","inventory_only","N8","protocol_or_design",null,null,null,"high","recheck","opus-5.5-recheck02","R2: pooled baseline characteristics of evoke and evoke+ oral semaglutide vs placebo trials in early Alzheimer disease; no between arm outcome",2],["R0005561","Divergent Renal Benefits of Sodium-Glucose Cotransporter-2 Inhibitors and Mineralocorticoid Receptor Antagonists in Nondiabetic Kidney Disease.","Chen R","2026","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck02","R1: registered Bayesian NMA searching five databases; three GLP-1 RA trials in network with GLP-1 RA vs RASi eGFR slope contrast reported",2],["R0006054","Patient Experience of Treatment with Tirzepatide for Weight Management: Exit Interviews from SURMOUNT-4.","Carmichael C","2025","include_nma",null,"secondary_report","P02W",null,null,"high","recheck","opus-5.5-recheck02","R5: SURMOUNT-4 exit interview substudy reports body weight by randomized arm, tirzepatide continuation vs placebo, plus side effects",2],["R0004517","Sociodemographic Disparities in Sodium-Glucose Co-Transporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists Prescription Patterns Among Patients With Poorly Controlled Diabetes.","Antwi-Amoabeng D","2024","inventory_only","N5","primary_report",null,null,null,"high","recheck","opus-5.5-recheck09","R8: cross sectional prescribing study comparing users of SGLT2i or GLP-1 RA with nonusers including mortality; cross sectional design is N5",2],["R0002541","Autoimmune Disease Risk With GLP-1RA, DPP-4i, and SGLT2i Treatment in Patients With Diabetes.","Mahajan A","2026","inventory_only","N6","primary_report","P01",null,null,"high","recheck","opus-5.5-recheck07","R7: target trial emulations GLP-1 RA vs DPP-4i or SGLT2i on autoimmune diseases; autoimmune thyroiditis is not thyroid cancer; no listed harm",2],["R0003422","Healthcare Resource Utilization and Costs in Individuals Who Discontinue Liraglutide and Who Switch from Liraglutide to Once-Weekly Injectable Semaglutide.","Tan X","2025","inventory_only","N6","primary_report","P01",null,null,"high","recheck","opus-5.5-recheck07","R8: liraglutide discontinuers vs switchers to semaglutide; healthcare use and costs only; malignancy and retinopathy appear only as baseline comorbidities",2],["R0003971","Safety of iGlarLixi in Japanese People with Type 2 Diabetes: A Post-marketing Database Study.","Kaneto H","2025","inventory_only","N6","primary_report","P01",null,null,"high","recheck","opus-5.5-recheck07","iGlarLixi vs insulin glargine database cohorts; hospital treated hypoglycemia and hyperglycemia only; malignancy and retinopathy are baseline characteristics",2],["R0004618","Effects of glucagon-like peptide-1 receptor agonists on secretions of insulin and glucagon and gastric emptying in Japanese individuals with type 2 diabetes: A prospective, observational study.","Kuwata H","2021","inventory_only","N1","primary_report",null,null,null,"high","recheck","opus-5.5-recheck09","R3: protocol registered before and after meal test study, investigators initiated one of three GLP-1 RAs, no concurrent control",2],["R0005157","What is the association between insulin dependence and the incidence of postoperative complications, perioperative glucose control, and five-year reoperation rates after total joint replacement?","Wong J","2026","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck09","R7: arthroplasty cohort; GLP-1 RA use is an adjusted covariate for composite 90 day complications, AKI not reported by GLP-1 exposure",2],["R0005752","Exploring Combined Use of Continuous Glucose Monitoring and Anti-Diabetes Medications on Glycaemic Control for People With Type 2 Diabetes Not Using Insulin.","Nemlekar PM","2025","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck09","claims cohort estimating GLP-1 RA use effects and CGM interaction on A1c; effectiveness only, no listed harm",2],["R0003749","Once-weekly glucagon-like peptide receptor agonist polyethylene glycol loxenatide protects against major adverse cardiovascular events in patients with type 2 diabetes: a multicenter ambispective cohort study (FLYING trial).","Li J","2025","include_harms",null,"primary_report",null,"O29; O39; O32A; O121; O33",null,"high","recheck","opus-5.5-recheck05","R7: cohort PEG-loxenatide vs non-incretin therapy reports acute pancreatitis, any cancer, thyroid C-cell neoplasm, acute kidney failure and diabetic blindness by group",2],["R0004097","Glucose-Lowering Medication Classes and Cardiovascular Outcomes in Patients With Type 2 Diabetes.","Neugebauer R","2025","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck04","emulated two and four arm trials of glucose lowering classes in six US systems; MACE only outcome; no listed harm reported",2],["R0003065","Comparative effectiveness of insulin glargine, glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors in veterans with type 2 diabetes.","Shen J","2025","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck04","VA active comparator new user cohort glargine vs GLP-1 RA vs SGLT2i; death, cardiovascular events, hypoglycemia; cancer and retinopathy only baseline",2],["R0003493","Achievement of HbA1c and weight targets in adults with type 2 diabetes on once weekly injectable glucagon-like peptide-1 receptor agonist therapy in UK primary care: A retrospective, real-world study.","Gulati K","2025","inventory_only","N5","primary_report",null,null,null,"high","recheck","opus-5.5-recheck05","R3: observational CPRD new user cohort of weekly GLP-1 RA describing HbA1c and weight targets without a comparison group",2],["R0003552","Type 2 diabetes risk alleles in peptidyl-glycine alpha-amidating monooxygenase influence GLP-1 levels and response to GLP-1 receptor agonists.","Umapathysivam MM","2026","inventory_only","N5","primary_report",null,null,null,"high","recheck","opus-5.5-recheck05","R3: GLP-1 RA response compared across PAM genotypes among treated users only; no comparison between exposures",2],["R0003594","Effect of Submaximal Doses of Semaglutide in Patients with Obesity on Metabolic Profile and Serum Levels of Adipocytokines.","Péč MJ","2025","inventory_only","N5","primary_report","P02",null,null,"high","recheck","opus-5.5-recheck04","R3: consecutive obesity clinic patients on routine semaglutide followed 12 weeks without comparator; uncontrolled observational cohort",2],["R0004762","The cardiovascular and renal effects of glucagon-like peptide 1 receptor agonists in patients with advanced diabetic kidney disease.","Lin Y","2023","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck05","R7: GLP-1 RA vs DPP-4i cohort in advanced DKD; CV, renal composite, dialysis, hypoglycemia, DKA outcomes; no listed harm",2],["R0004206","A meta-analysis of the incidence of acne vulgaris in patients treated with GLP-1 agonists.","Ogunremi OO","2024","exclude","E3","other",null,null,null,"high","recheck","opus-5.5-recheck06","R1: PubMed keyword tally of acne mentions; no stated inclusion or exclusion criteria beyond search hits, so not a systematic review",2],["R0003243","Effect of Semaglutide on Recurrence of Intracranial Hypertension After Venous Sinus Stenting: A Two-Phase Cohort Study","Lu C","2026","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck06","phase 2 allocated semaglutide or standard care after stenting by shared decision and preference, not random or quasi random; no listed harm",2],["R0003739","Comparative effectiveness of sleeve gastrectomy and semaglutide for weight loss and metabolic outcomes: a prospective non-randomized study.","Yen Y","2026","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck06","methods state allocation to sleeve gastrectomy or semaglutide by shared decision, randomized only in a figure legend; weight outcomes; thyroid term is withdrawal reason",2],["R0005204","Clinical studies on anti-obesity medications in Arab countries.","AlOtaibi HF","2025","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck06","R1: scoping review, five named databases, stated eligibility, risk of bias, structured summary of anti-obesity drug studies mostly GLP-1 RA",2],["R0002330","Glucagon-like Peptide-1 Receptor Agonists: A New Frontier in Treating Alcohol Use Disorder.","Oesterle TS","2025","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck03","R1: PRISMA search of PubMed, Medline, Web of Science and registries with criteria; tabulated synthesis of seven GLP-1 RA AUD studies",2],["R0003965","No dose adjustment required for warfarin or metformin when coadministered with the novel GLP-1 receptor agonist ecnoglutide: an open-label, fixed-sequence, crossover study.","Chen Z","2026","inventory_only","N1","primary_report",null,null,null,"high","recheck","opus-5.5-recheck03","R3: interventional fixed sequence drug interaction study of ecnoglutide in healthy volunteers, no randomized or concurrent comparison group",2],["R0004339","Glucagon-like peptide-1 receptor agonists use and associations with outcomes in heart failure and type 2 diabetes: data from the Swedish Heart Failure and Swedish National Diabetes Registries.","Wallner M","2024","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck03","R7: matched registry cohort GLP-1 RA use vs nonuse in HF and T2D reports HF, MACE and death only; retinopathy only baseline",2],["R0005089","Outcomes With Finerenone by Baseline Treatment Goals in Type 2 Diabetes and Chronic Kidney Disease: A FIDELITY Analysis.","Neves JS","2026","exclude","E2","secondary_report",null,null,null,"high","recheck","opus-5.5-recheck03","Finerenone vs placebo FIDELITY subgroup by treatment goals; GLP-1 RA only an occasional background drug inside a composite goal, never an exposure",2],["R0002468","Effect of Glucagon-like Peptide-1 Receptor Agonists on Outcomes After Hip Hemiarthroplasty for Femoral Neck Fractures in Patients With Type 2 Diabetes.","Box MW","2025","include_harms",null,"primary_report",null,"O36A; O121",null,"high","recheck","opus-5.5-recheck01","R7: self labelled cross sectional but a hemiarthroplasty procedure cohort, users at surgery versus nonusers; per arm aspiration pneumonitis and separate AKI counts",2],["R0004007","Comparative Effectiveness of Semaglutide, Liraglutide, Orlistat, and Phentermine for Weight Loss in Obese Individuals: A Systematic Review.","Patel JP","2025","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck01","R1: PRISMA review with PubMed search string, stated criteria, dual screening and tabulated synthesis of semaglutide and liraglutide trials",2],["R0004008","Effects of SGLT2 inhibitors and GLP-1 receptor agonists on glycemic variability, islet cell function, and insulin resistance in patients with type 2 diabetes mellitus and renal cell carcinoma.","Zhang A","2025","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck01","whole PDF read: retrospective matched cohort SGLT2i with versus without GLP-1 RA in RCC; glycemic, insulin resistance and renal markers only",2],["R0003948","Risk of hepatic events associated with use of sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 receptor agonists, and thiazolidinediones among patients with metabolic dysfunction-associated steatotic liver disease.","Bea S","2025","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck06","new user active comparator cohort SGLT2i vs GLP-1 RA in MASLD; hepatic decompensation and death only; biliary and retinopathy are baseline covariates",2],["R0004170","Oral Semaglutide in Type 2 Diabetes: Clinical-Metabolic Outcomes and Quality of Life in Real-World Practice.","Pantanetti P","2024","inventory_only","N5","primary_report",null,null,null,"high","recheck","opus-5.5-recheck06","R3: prospective single arm observational cohort of oral semaglutide in routine care; no comparison group",2],["R0006194","Risks of stroke, its subtypes and atrial fibrillation associated with glucagon-like peptide 1 receptor agonists versus sodium-glucose cotransporter 2 inhibitors: a real-world population-based cohort study in Hong Kong.","Lui DTW","2023","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck06","matched cohort SGLT2i vs GLP-1 RA; stroke subtypes and atrial fibrillation only; retinopathy appears as baseline covariate",2],["R0003463","The Effects of Glucagon-Like Peptide-1 Receptor Agonists on Mitochondrial Function Within Skeletal Muscle: A Systematic Review.","Old VJ","2025","exclude","E2","systematic_review",null,null,null,"high","recheck","opus-5.5-recheck10","R1: registered systematic review but all eight included studies are animal or cell models; GLP-1 RA appears only in preclinical work",2],["R0004741","Effect of Food Consumption on the Pharmacokinetics, Safety, and Tolerability of Once-Daily Orally Administered Orforglipron (LY3502970), a Non-peptide GLP-1 Receptor Agonist.","Ma X","2024","inventory_only","N3","primary_report",null,null,null,"high","recheck","opus-5.5-recheck10","R6 by analogy: crossover randomizes fed versus fasted dosing of the same orforglipron dose and route; regimen node unchanged",2],["R0005094","GLP-1RA vs DPP-4i Use and Rates of Hyperkalemia and RAS Blockade Discontinuation in Type 2 Diabetes.","Huang T","2024","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck10","new user cohort GLP-1 RA versus DPP-4i; hyperkalemia and RAS inhibitor discontinuation only; pancreatitis an exclusion, retinopathy baseline",2],["R0005527","New developments in GLP-1 agonist therapy for gestational diabetes: Systematic review on liraglutide, semaglutide, and exenatide from ClinicalTrials.gov.","Alshehri FS","2025","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck04","R1: systematic ClinicalTrials.gov search with stated inclusion rule and structured tabulation of eight GLP-1 RA trials in gestational diabetes",2],["R0006281","Glucagon-Like Peptide 1 Receptor Agonists in Type 2 Diabetes Mellitus: Data from a Real-World Study in Spain.","Norrbacka K","2021","inventory_only","N6","primary_report","P01",null,null,"high","recheck","opus-5.5-recheck04","R8: Spanish database cohorts of dulaglutide, exenatide, liraglutide initiators compare persistence, costs and HbA1c; no listed harm",2],["R0006432","The association between GLP-1 receptor agonists and fractures: a nationwide Danish nested case-control study.","Kvist AV","2026","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck04","Danish nested case control of GLP-1 RA use and fractures; fracture outcomes only; pancreatitis appears only as adjustment covariate",2],["R0004910","Effects of glucagon-like peptide-1 analogues on hard binary outcomes for patients at increased risk of cardiovascular events: a protocol for a systematic review with network meta-analysis and Trial Sequential Analysis.","Sillassen CDB","2025","inventory_only","N8","protocol_or_design",null,null,null,"high","recheck","opus-5.5-recheck02","R2: protocols of any design are N8; registered protocol of planned NMA of GLP-1 analogues on hard outcomes, no results",2],["R0004934","The Impact of Glucagon-like Peptide 1 Receptor Agonists on Obstructive Sleep Apnoea: A Scoping Review.","Le KDR","2024","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck02","R1: scoping review searching Medline and Embase with stated criteria; structured tables of GLP-1 RA studies on sleep apnea with risk of bias",2],["R0005452","GLP-1 Agonists and Risk of Atrial Fibrillation in Non-Dialysis Chronic Kidney Disease.","Dhamelia P","2026","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck02","R7: matched cohort GLP-1 RA users vs nonusers with CKD; acute kidney injury only inside MAKE composite; other outcomes cardiorenal",2],["R0004234","Adherence and Persistence with GLP-1-Based Therapies: International Real-World Evidence and the Role of Nutritional and Lifestyle Support-A Narrative Review.","Dziewierz A","2026","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck05","R1: self called narrative but names PubMed and Embase search and eligibility criteria; structured tabulated synthesis of GLP-1 RA persistence studies",2],["R0003190","Treatment Intensification Strategies and Metabolic Outcomes in Individuals With Type 2 Diabetes on GLP-1 RA Therapy.","Falcetta P","2025","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck05","AMD Annals cohort comparing intensification strategies on GLP-1 RA, including FRC switch; HbA1c and weight only, no listed harm",2],["R0003531","Preliminary Real-World Experience with Semaglutide in Obese Patients with Type 2 Diabetes on Chronic Hemodialysis: A Multicenter Pilot Study.","Yugueros A","2026","inventory_only","N5","primary_report",null,null,null,"high","recheck","opus-5.5-recheck05","R3: self described real-world uncontrolled observational cohort of semaglutide starters on hemodialysis, no comparison group",2],["R0005019","Tirzepatide-induced Weight Loss in Overweight or Obese Midlife Adults with and without Type 2 Diabetes: A Real-world Comparative Cohort Study.","Agrawal PK","2026","inventory_only","N5","primary_report",null,null,null,"high","recheck","opus-5.5-recheck05","R3: observational cohort of tirzepatide initiators compared by diabetes status only; no unexposed or comparator drug group",2],["R0004230","GLP-1 Receptor Agonists Associated With Improved Survival After Infrainguinal Bypass in Diabetic Patients.","Yehualashet E","2025","include_harms",null,"primary_report",null,"O121",null,"low","recheck","opus-5.5-recheck06","R7: perioperative bypass cohort GLP-1 RA users vs nonusers reports in-hospital renal complications separately but undefined; alternative N6 if not AKI",2],["R0006308","Forecasting Trial Milestones: A Predictive Analysis for Early Termination of the SOUL Study.","Sinha B","2024","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck06","R1: INPLASY registered PRISMA meta-analysis, Cochrane Library search, stated criteria, pooled semaglutide CVOT hazard ratios before forecasting SOUL",2],["R0006597","Evidence that tirzepatide protects against diabetes-related cardiac damages.","Taktaz F","2024","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck06","R1: PubMed search for tirzepatide RCTs with stated eligibility and random effects pooling of MACE hazard ratios; cell and in silico parts additional",2],["R0007195","Comparing the effectiveness and cost-effectiveness of sulfonylureas and newer diabetes drugs as second-line therapy for patients with type 2 diabetes.","Franchi M","2024","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck06","matched cohort second line GLP-1 RA, SGLT2i, DPP-4i vs sulfonylurea; MACE, death, costs; retinopathy and cancer only baseline comorbidities",2],["R0004525","Linking pediatric obesity to youth-onset type 2 diabetes: integrated longitudinal and cross-sectional evidence from population-based studies worldwide.","Soliman AT","2026","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck03","R1: self-styled narrative systematic review with PubMed and Scopus search and criteria; structured table of weight reduction RCTs including GLP-1 RAs",2],["R0004790","Real-World Effectiveness and Safety of Tirzepatide, Semaglutide, and Liraglutide in Adults with Overweight or Obesity without Diabetes: A Comparative Study.","Cetiner S","2026","include_harms",null,"primary_report",null,"O29",null,"high","recheck","opus-5.5-recheck03","R7: cohort comparing tirzepatide, semaglutide and liraglutide reports pancreatitis by group (no events); completer selection judged at extraction",2],["R0004897","Associations Between Common Hip and Knee Osteoarthritis Treatments and All-Cause Mortality.","Orchard JW","2025","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck03","R1: structured review with Web of Science search and stated criteria; tabulates GLP-1 RA vs no use mortality cohorts",2],["R0006110","Treating Type 2 Diabetes With Early, Intensive, Multimodal Pharmacotherapy: Real-World Evidence From an International Collaborative Database.","Anson M","2024","include_harms",null,"primary_report",null,"O29",null,"high","recheck","opus-5.5-recheck03","R7: matched cohort of quadruple therapy including GLP-1 RA vs insulin plus sulfonylurea compares acute pancreatitis between groups",2],["R0004335","The potential biomarker value of soluble CD36 in the treatment of diabetic kidney disease: evidence from GLP-1 and insulin interventions.","Li W","2025","include_nma",null,"primary_report","P01; P08A",null,"mechanistic","low","recheck","opus-5.5-recheck01","R9: labelled observational yet methods describe computer generated block randomization to GLP-1 RA, insulin or metformin alone; reports HbA1c and UACR",2],["R0004732","Suicide and suicide attempt in users of GLP-1 receptor agonists: a nationwide case-time-control study.","Bezin J","2025","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck01","R7: case time control design for suicide and attempts is self controlled, which qualifies only for O34, not O35A or O35B",2],["R0005352","Periconceptional GLP-1 receptor agonist exposure and obstetric outcomes: a Danish nationwide cohort study.","Hviid KVR","2026","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck01","periconceptional exposure cohort analyzing obstetric outcomes only; congenital malformations mentioned only as background, not analyzed",2],["R0006703","Concomitant iGlarLixi and Sodium-Glucose Co-transporter-2 Inhibitor Therapy in Adults with Type 2 Diabetes: LixiLan-G Trial and Real-World Evidence Results.","Guja C","2022","inventory_only","N1","secondary_report","P01",null,null,"high","recheck","opus-5.5-recheck09","R4: LixiLan-G analysis uses only the iGlarLixi arm split by SGLT2i use, plus real world data; randomized contrast not kept",2],["R0006812","The effect of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across baseline blood pressure categories: Analysis of the LEADER and SUSTAIN 6 trials.","Leiter LA","2020","include_nma",null,"secondary_report","P01",null,null,"high","recheck","opus-5.5-recheck09","R2 not applicable: post hoc LEADER and SUSTAIN 6 analysis reports drug versus placebo MACE and nephropathy by baseline blood pressure",2],["R0007422","Efficacy of 12-week treatment with polyethylene glycol loxenatide in obesity or overweight patients with type 2 diabetes: a multicenter, prospective cohort study based on the flash glucose monitoring system.","Zhu L","2026","inventory_only","N1","primary_report",null,null,null,"high","recheck","opus-5.5-recheck09","R3: registered prospective interventional pre post study adding PEG loxenatide for 12 weeks without a concurrent control",2],["R0005984","Glucagon-like peptide-1 receptor agonists and risk of major adverse liver outcomes in patients with chronic liver disease and type 2 diabetes.","Wester A","2024","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck10","target trial emulation GLP-1 RA versus noninitiation in chronic liver disease; MALO composite with hepatocellular carcinoma only; pancreatitis an exclusion",2],["R0005262","Comparative real-world outcomes of tirzepatide vs semaglutide in patients with obesity and type2 diabetes: A retrospective propensity-matched cohort study.","Qadeer A","2026","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck10","R7 by analogy: tirzepatide versus semaglutide cohort reports only an undefined GI adverse effects composite; no separate gastroparesis or obstruction outcome",2],["R0005444","Clinical Advances in Heart Failure with Preserved Ejection Fraction: A Systematic Review of Therapeutic and Mechanistic Evidence.","Parizad R","2026","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck10","R1: four named databases, stated eligibility, PRISMA, qualitative synthesis including semaglutide and tirzepatide HFpEF trials",2],["R0006170","From needles to pills: oral GLP-1 therapy enters the obesity arena.","Santulli G","2025","inventory_only","N9","ancillary",null,null,null,"high","recheck","opus-5.5-recheck10","editorial discussing the ATTAIN-1 and OASIS-4 randomized trials of oral GLP-1 RAs, both in scope",2],["R0004463","Indirect comparative efficacy and safety of tirzepatide vs semaglutide for the treatment of obesity or overweight in patients without type 2 diabetes.","Ciudin A","2026","inventory_only","N6","secondary_report","P02",null,null,"high","recheck","opus-5.5-recheck08","R4: Bucher and MAIC indirect comparison of tirzepatide in SURMOUNT-1 with semaglutide in STEP 1; no shared randomized comparison",2],["R0004736","Pharmacotherapy agents in prevention and treatment of breast cancer-related lymphedema: a systematic scoping review.","Lommer C","2026","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck08","R1: scoping review of four named databases with eligibility criteria; structured table includes GLP-1 RA cohort on lymphedema incidence",2],["R0005609","Sodium-glucose cotransporter 2 (SGLT2) inhibitors and risk of chronic kidney disease-mineral and bone disorders in patients with type 2 diabetes mellitus and stage 1-3 chronic kidney disease.","Tsai DH","2025","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck08","SGLT2i versus GLP-1 RA new user cohort; outcomes are CKD mineral and bone biochemical abnormalities; acute kidney injury only baseline",2],["R0007276","Effects of Blood-Glucose Lowering Therapies on Body Composition and Muscle Outcomes in Type 2 Diabetes: A Narrative Review.","Bujdei-Tebeică I","2025","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck06","R1: self labeled narrative but names PubMed, Scopus, Web of Science, states inclusion and exclusion criteria, comparative summary table across drug classes",2],["R0005242","\"Ozempic Face\" in Plastic Surgery: A Systematic Review of the Literature on GLP-1 Receptor Agonist Mediated Weight Loss and Analysis of Public Perceptions.","Daneshgaran G","2025","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck06","R1: PRISMA PubMed search, stated inclusion and exclusion criteria, bias checklists, thematic synthesis of GLP-1 RA plastic surgery literature",2],["R0006410","Cardiovascular Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Older Patients in Routine Clinical Care With or Without History of Atherosclerotic Cardiovascular Diseases or Heart Failure.","Htoo PT","2022","include_harms",null,"primary_report",null,"O39",null,"high","recheck","opus-5.5-recheck06","Medicare active comparator new user cohort SGLT2i vs GLP-1 RA; all cancer incidence estimated as negative control outcome in cancer free cohort, supplement table",2],["R0008806","iGlarlixi for the simplification of more complex insulin regimens in type 2 diabetes patients with good glycaemic control.","Taybani ZJ","2026","inventory_only","N5","primary_report",null,null,null,"high","recheck","opus-5.5-recheck06","R3: retrospective observational cohort switching to iGlarLixi, trajectories without any comparison group",2],["R0003896","The perioperative use of GLP-1 receptor agonists in patients undergoing hip and knee arthroplasty: a scoping review.","Dworsky-Fried J","2026","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck05","R1: scoping review searching EMBASE, MEDLINE, Scopus, CINAHL with criteria; tabulated structured synthesis of 11 perioperative GLP-1 RA cohorts",2],["R0007032","Oral Adverse Effects of Semaglutide Therapy: A Narrative Review.","Al-Zawawi AS","2024","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck04","R1: self labeled narrative but searched five named databases with criteria, flow diagram and tabulated synthesis of 13 semaglutide oral adverse effect studies",2],["R0005637","Real-World Utilization and Effectiveness of Glucagon-Like Peptide-1 Receptor Agonists Dosed Weekly and Daily in Patients with Type 2 Diabetes Mellitus: Results from Retrospective Electronic Medical Records in China.","Ruan Z","2024","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck05","EMR cohort comparing weekly vs daily GLP-1 RA on HbA1c, lipids, hypoglycemia; retinopathy only a baseline characteristic",2],["R0005920","Superior Cerebrovascular Outcomes with Tirzepatide versus Semaglutide in Diabetic CABG Patients: A Global Network Study of Propensity-Matched Patients.","Chunduri S","2026","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck04","TriNetX tirzepatide vs semaglutide after CABG; postoperative complications are wound, infection, sepsis, bleeding, thrombosis; kidney failure only baseline",2],["R0006232","Efficacy and safety of semaglutide in patients with heart failure with preserved ejection fraction and obesity.","Rehman A","2024","deferred","D2","primary_report","P07A",null,null,"low","recheck","opus-5.5-recheck04","R9: called retrospective cohort yet has placebo arm and cites original trial; no allocation procedure described, randomization undeterminable",2],["R0006422","The effectiveness of 0.5 mg and 1mg of semaglutide in patients with type two diabetes and predictors of response: a retrospective cohort study.","Alenzi S","2024","inventory_only","N6","primary_report","P01",null,null,"high","recheck","opus-5.5-recheck04","retrospective cohort comparing semaglutide 0.5 vs 1 mg maintenance doses on HbA1c and weight; nonrandomized, retinopathy only baseline, no listed harm",2],["R0006584","Real-world weight change, adherence, and discontinuation among patients with type 2 diabetes initiating glucagon-like peptide-1 receptor agonists in the UK.","Weiss T","2022","inventory_only","N5","primary_report",null,null,null,"high","recheck","opus-5.5-recheck05","R3: observational CPRD cohort of GLP-1 RA initiators describing weight change, adherence and discontinuation; no comparison group",2],["R0006711","[Meta-analysis evaluating the risk of respiratory tract infections and acute respiratory distress syndrome with glucagon-like peptide-1 receptor agonists in cardiovascular outcome trials: Useful implications for the COVID-19 pandemic].","Patoulias D","2022","include_nma",null,"pooled_analysis","P01",null,"non_english","high","recheck","opus-5.5-recheck05","R4: no named database search, so not a review; pools GLP-1 RA vs placebo CVOT arms keeping randomized contrast for respiratory infections",2],["R0008515","Outcomes of SGLT-2i and GLP-1RA Therapy Among Patients With Type 2 Diabetes and Varying NAFLD Status.","Bea S","2023","inventory_only","N6","other",null,null,null,"high","recheck","opus-5.5-recheck02","new user active comparator cohorts SGLT2i or GLP-1 RA vs DPP-4i by NAFLD status; MACE and heart failure only; retinopathy baseline only",2],["R0007158","Effectiveness and Safety of Oral Quadruple Combination Therapy in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis.","Bae J","2025","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck02","R1: PubMed and Cochrane searched with stated criteria; pooled HbA1c contrast of oral quadruple therapy vs GLP-1 RA containing regimen",2],["R0007726","Major adverse cardiovascular and limb events in people with diabetes treated with GLP-1 receptor agonists vs SGLT2 inhibitors.","Lin DS","2022","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck02","matched cohort GLP-1 RA vs SGLT2i initiators; limb, cardiovascular, death and heart failure outcomes; malignancy and retinopathy are baseline only",2],["R0003165","Risk of Esophageal and Gastric Cancer in Patients with Type 2 Diabetes Receiving Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs): A National Analysis.","Ayoub M","2024","inventory_only","N6","primary_report","P01",null,null,"high","recheck","opus-5.5-recheck07","R7: TriNetX GLP-1 RA users vs nonusers with T2D; outcomes are gastric and esophageal cancer only, single site cancers not listed",2],["R0010797","Comparative Effects of Tirzepatide and Semaglutide on Asthma-Related Complications: A Target Trial Emulation Using the TriNetX Networks","Chen BS","2025","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck06","TriNetX cohort tirzepatide vs semaglutide in asthma; sleep apnea and bronchodilator use only; malformation codes are baseline matching covariates",2],["R0003032","GLP-1 Receptor Agonists and SGLT2 Inhibitors in Stable Kidney Transplantation: Clinical Outcomes from a Cohort of Patients with Post-Transplant Diabetes Mellitus.","Navarrete RET","2025","inventory_only","N6","primary_report","P99",null,null,"high","recheck","opus-5.5-recheck07","kidney transplant PTDM cohort comparing GLP-1 RA, SGLT2i and both add on; metabolic, kidney function, infections, GI symptoms, hypoglycemia; no listed harm",2],["R0004191","GLP-1 Receptor Agonists: Beyond Diabetes-What the Neurosurgeon Needs to Know.","Abdulrazeq H","2024","exclude","E3","other",null,null,null,"high","recheck","opus-5.5-recheck07","R1: self described qualitative review; PubMed and Embase named but results are textbook narrative with only a drug overview table, no structured synthesis",2],["R0004274","Semaglutide and Suicidality in Adults with Overweight or Obesity: A Bayesian Meta-Analysis of Randomized Trials","Campos-Garcia F","2026","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck07","R1: PROSPERO registered meta-analysis searching MEDLINE, CENTRAL, Web of Science, PsycINFO; pools semaglutide vs placebo RCTs on suicidality",2],["R0006396","Cardiometabolic outcomes of once-weekly IcoSema in adults with type 2 diabetes: systematic review and meta-analysis of the COMBINE trials.","Alper A","2026","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck06","R1: MEDLINE, Embase, CENTRAL, Web of Science searched, stated eligibility, RoB 2, random effects pooling of IcoSema vs insulin trials",2],["R0008567","A Review of the Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors on Lean Body Mass in Humans.","Sargeant JA","2019","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck06","R1: PubMed search with stated inclusion on imaging methods and therapy duration, structured extraction of body composition change with GLP-1 RAs and SGLT2i",2],["R0010115","Influence of semaglutide use on the presence of residual gastric solids on gastric ultrasound: a prospective observational study in volunteers without obesity recently started on semaglutide.","Sherwin M","2023","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck06","research gastric ultrasound in volunteer semaglutide users vs controls, not at any procedure; O36B requires a procedure cohort or case control",2],["R0005231","Prevalence of Hypercortisolism in Difficult-to-Control Type 2 Diabetes.","Buse JB","2025","inventory_only","N5","primary_report","P01",null,null,"high","recheck","opus-5.5-recheck01","cross sectional screening study; GLP-1 RA dose appears only as a correlate of hypercortisolism prevalence; alternative E2",2],["R0005412","Comparative Effect of SGLT2 Inhibitors and GLP-1 Agonists on Glycemic Control in Type 2 Diabetes Mellitus.","Prakash V","2025","include_nma",null,"primary_report","P01",null,null,"low","recheck","opus-5.5-recheck01","states random allocation to empagliflozin 10 mg or liraglutide 1.8 mg for 24 weeks with HbA1c; drug lists mix in DPP-4 inhibitors, integrity uncertain",2],["R0005570","Chronic kidney outcomes associated with GLP-1 receptor agonists versus long-acting insulins among type 2 diabetes patients requiring intensive glycemic control: a nationwide cohort study.","Peng ZY","2023","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck01","new user cohort GLP-1 RA versus long acting insulin; chronic kidney outcomes (eGFR below 15, dialysis, renal death); no acute kidney injury",2],["R0006102","Effect of combination treatment with glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on incidence of cardiovascular and serious renal events: population based cohort study.","Simms-Williams N","2024","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck01","R7: prevalent new user cohort; acute kidney injury only inside the serious renal events composite; no other listed harm reported separately",2],["R0005525","Long-term effects of duodenal mucosal resurfacing and liraglutide on glycaemic control in patients with type 2 diabetes.","Busch CBE","2025","inventory_only","N1","extension","P01",null,null,"high","recheck","opus-5.5-recheck03","R3: retrospective long term follow up of single arm interventional INSPIRE study of duodenal resurfacing plus liraglutide; no concurrent control",2],["R0005387","Potential preventive properties of GLP-1 receptor agonists against prostate cancer: a nationwide cohort study.","Skriver C","2023","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck03","R7: GLP-1 RA vs basal insulin new user cohort reports prostate cancer only, a single site not in the harms list",2],["R0006041","Using GLP-1 Receptor Agonists in Patients with Inflammatory Bowel Disease: A Systematic Review and Single-Arm Meta-Analysis.","Khasawneh O","2026","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck03","R1: PROSPERO registered review searching eight databases with criteria; single arm pooling of weight and metabolic outcomes on GLP-1 RAs in IBD",2],["R0006103","Healthcare Resource Utilization and Costs for Empagliflozin Versus Glucagon-Like Peptide-1 Receptor Agonists in Routine Clinical Care in Denmark.","Thomsen RW","2022","exclude","E2","other",null,null,null,"high","recheck","opus-5.5-recheck03","R8: empagliflozin vs GLP-1 RA new user cohort compares only healthcare utilization and costs, no clinical outcome; alternative N6",2],["R0005478","Comparing Insulin Against Glucagon-Like Peptide-1 Receptor Agonists, Dipeptidyl Peptidase-4 Inhibitors, and Sodium-Glucose Cotransporter 2 Inhibitors on 5-Year Incident Heart Failure Risk for Patients With Type 2 Diabetes Mellitus: Real-World Evidence Study Using Insurance Claims.","Wang X","2024","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck10","claims cohort insulin versus GLP-1 RA, DPP-4i, SGLT2i on incident heart failure only; retinopathy only a covariate",2],["R0006760","Cost consequence analysis of adding semaglutide to treatment regimen for patients with Type II diabetes in Saudi Arabia.","AlRuthia Y","2024","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck10","R8: primary matched cohort semaglutide versus other drugs comparing HbA1c and weight plus costs; no listed harm, retinopathy baseline only",2],["R0006937","Glucagonlike Peptide-1 (GLP-1) Receptor Agonists for Cardiometabolic Risk in Severe Mental Illness: A Narrative Review.","Domingues C","2026","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck10","R1: self-labeled narrative but PubMed and Cochrane search, PICO eligibility criteria, tabulated synthesis of GLP-1 RA RCTs in severe mental illness",2],["R0008289","Effect of Semaglutide on Subclinical Atherosclerosis and Cardiometabolic Compensation: A Real-World Study in Patients with Type 2 Diabetes.","Patti AM","2023","inventory_only","N5","primary_report",null,null,null,"high","recheck","opus-5.5-recheck10","R3: retrospective observational before and after study of 40 semaglutide users in routine care; no comparison group",2],["R0005260","Association of semaglutide use with outcomes in chronic plantar heel pain: a prospective observational cohort and a pilot interventional study.","Yang F","2025","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck09","R7: nonrandomized semaglutide versus control heel pain cohort plus single arm pilot; pain and function outcomes only, no listed harm",2],["R0007297","Use of Tirzepatide in the Management of Obesity and Overweight: Feasibility Analysis for Incorporation into the Public Health System of Mato Grosso, Brazil","Pereira P","2026","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck09","R1: PubMed, Embase, Cochrane and others searched with PICO criteria; synthesizes SURMOUNT-5 tirzepatide versus semaglutide alongside budget impact",2],["R0007466","Favorable liver and skeletal muscle changes in patients with MASLD and T2DM receiving glucagon-like peptide-1 receptor agonist: A prospective cohort study.","Kakegawa T","2024","inventory_only","N1","primary_report","P09",null,null,"high","recheck","opus-5.5-recheck09","R3: prospective single arm open label semaglutide study with protocol MRI before and after, no concurrent control",2],["R0009412","GLP-1 receptor agonists are a transformative prehabilitation tool for weight loss in obese patients undergoing elective hernia repair.","Spurzem GJ","2025","include_harms",null,"primary_report",null,"O37B",null,"high","recheck","opus-5.5-recheck09","R7: perioperative cohort, GLP-1 RA versus lifestyle before hernia repair, reports postoperative ileus by group",2],["R0004135","Association of GLP-1 Receptor Agonists and Hepatocellular Carcinoma Incidence and Hepatic Decompensation in Patients With Type 2 Diabetes.","Wang L","2024","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck08","R7: GLP-1 RA versus other antidiabetic drug cohorts; outcomes are hepatocellular carcinoma and hepatic decompensation only; single site liver cancer not listed",2],["R0004478","Mortality and cardiovascular events in diabetes mellitus patients at dialysis initiation treated with glucagon-like peptide-1 receptor agonists.","Lai HW","2024","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck08","GLP-1 RA versus long acting insulin at dialysis start; mortality, MACE and MAKE defined as dialysis dependence or death; no listed harm",2],["R0004488","Frailty-stratified effectiveness of SGLT2 inhibitors versus DPP-4 inhibitors and GLP-1 receptor agonists on pulmonary outcomes in type 2 diabetes: a nationwide cohort study.","Meng LC","2025","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck08","SGLT2i versus DPP-4i or GLP-1 RA cohort in COPD; pulmonary hospitalization, all cause hospitalization and mortality only; retinopathy baseline",2],["R0006013","Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials.","Apperloo EM","2024","exclude","E2","systematic_review",null,null,null,"high","recheck","opus-5.5-recheck08","R1: meta-analysis of SGLT2i versus placebo trials stratified by baseline GLP-1 RA use; GLP-1 RA only background in every comparison",2],["R0007202","Empagliflozin and Risk of Incident Gout: Analysis from the EMPagliflozin Comparative Effectiveness and SafEty (EMPRISE) Cohort Study.","Tesfaye H","2024","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck04","EMPRISE claims cohorts empagliflozin vs DPP-4i or GLP-1 RA; incident gout only outcome; malignancy appears only as exclusion",2],["R0005914","Comparison of the glucagon-like-peptide-1 receptor agonists dulaglutide and liraglutide for the management of diabetes in solid organ transplant: A retrospective study.","Singh P","2020","include_harms",null,"primary_report",null,"O28; O29; O32B; O38; O39",null,"high","recheck","opus-5.5-recheck04","R7: chart review cohort dulaglutide vs liraglutide in transplant recipients; prespecified safety endpoints cholelithiasis, pancreatitis, thyroid and pancreatic cancer, new malignancy by arm",2],["R0006179","Healthcare utilization, mortality, and cardiovascular events following GLP1-RA initiation in chronic kidney disease.","Zhang S","2024","inventory_only","N6","primary_report","P08A",null,null,"high","recheck","opus-5.5-recheck04","R7: VA emulation GLP-1 RA vs DPP-4i in CKD; ileus only inside a GI symptom composite, by analogy to AKI composites not O37B",2],["R0006699","Transitioning to active-controlled trials to evaluate cardiovascular safety and efficacy of medications for type 2 diabetes.","McGuire DK","2022","inventory_only","N8","protocol_or_design",null,null,null,"high","recheck","opus-5.5-recheck04","R2: statistical design paper for SURPASS CVOT tirzepatide vs dulaglutide without between arm results; alternative E3 methods paper",2],["R0004504","GLP-1 receptor agonists and acute diabetes complications in adults with type 1 diabetes.","Dai H","2026","inventory_only","N6","primary_report","P05",null,null,"high","recheck","opus-5.5-recheck07","R7: target trial emulation GLP-1 RA initiators vs noninitiators with T1D; DKA, severe hypoglycemia, utilization; AKI and biliary disease only baseline covariates",2],["R0003454","Real-World Clinical Effectiveness of Glucagon-Like Peptide-1 Receptor Agonist on Mild-to-Moderate Diabetic Kidney Disease in Patients with Type 2 Diabetes: A Retrospective, Single-Arm Clinical Trial.","Cao Y","2024","inventory_only","N5","primary_report",null,null,null,"high","recheck","opus-5.5-recheck07","R3: retrospective chart review of GLP-1 RA users with diabetic kidney disease, before and after design without comparison; observational despite trial label",2],["R0004362","Efficacy and Safety of GLP-1 Receptor Agonists in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.","Njei B","2024","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck07","R1: PRISMA meta-analysis searching PubMed, CINAHL, Medline, Embase, Web of Science, PsycINFO; pools 27 GLP-1 RA RCTs in MASLD",2],["R0005411","Adverse Liver and Renal Outcomes After Initiating SGLT-2i and GLP-1RA Therapy Among Patients With Diabetes and MASLD.","Krishnan A","2025","inventory_only","N6","primary_report","P01; P09",null,null,"high","recheck","opus-5.5-recheck07","R7: new user cohorts SGLT2i vs GLP-1 RA and others in MASLD; cirrhosis, decompensation, hepatocellular carcinoma, CKD progression; no listed harm",2],["R0007587","Unveiling the Therapeutic Potential of the Second-Generation Incretin Analogs Semaglutide and Tirzepatide in Type 1 Diabetes and Latent Autoimmune Diabetes in Adults.","Infante M","2025","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck06","R1: self labeled narrative but searches PubMed and Scopus with stated inclusion rules, structured study by study synthesis by drug and population",2],["R0009426","Major adverse cardiovascular and limb events in patients with diabetes treated with GLP-1 receptor agonists vs DPP-4 inhibitors.","Lin DS","2021","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck06","Taiwan matched cohort GLP-1 RA vs DPP-4i; limb and cardiovascular events only; retinopathy appears as baseline covariate and subgroup",2],["R0009772","Persistence to Treatment with Novel Antidiabetic Drugs (Dipeptidyl Peptidase-4 Inhibitors, Sodium-Glucose Co-Transporter-2 Inhibitors, and Glucagon-Like Peptide-1 Receptor Agonists) in People with Type 2 Diabetes: A Nationwide Cohort Study.","Jermendy G","2018","exclude","E2","other",null,null,null,"high","recheck","opus-5.5-recheck06","R8: nationwide claims comparison of persistence with DPP-4i, SGLT2i and GLP-1 RA; no clinical outcome compared",2],["R0006748","Cardiovascular and mortality outcomes with GLP-1 receptor agonists vs other glucose-lowering drugs in individuals with NAFLD and type 2 diabetes: a large population-based matched cohort study.","Krishnan A","2024","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck02","new user matched cohort GLP-1 RA vs SGLT2i or other agents in NAFLD with T2D; cardiovascular events and mortality only; retinopathy baseline",2],["R0007994","GLP-1 receptor agonists for weight reduction in people living with obesity but without diabetes: a living benefit-harm modelling study.","Moll H","2024","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck02","R1: PubMed and registry search with stated criteria; pairwise meta-analysis of eight GLP-1 RA vs placebo obesity RCTs feeding benefit harm model",2],["R0005630","EVIDENCE OF THE INFLUENCE OF GLUCAGON-LIKE PEPTIDE ANALOGS IN INFLAMMATORY BOWEL DISEASE: A SCOPING REVIEW.","Rezende LDA","2026","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck03","R1: registered PRISMA-ScR scoping review searching nine named databases with criteria; tabulates human GLP-1 RA cohorts in IBD",2],["R0005644","Influence of early use of sodium-glucose transport protein 2 inhibitors, glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors on the legacy effect of hyperglycemia.","Deng S","2024","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck03","Cohort on early HbA1c and later CVD with SGLT2i or GLP-1 RA users as a stratum vs nonusers; CVD only, no listed harm; alternative E2",2],["R0005955","Real-world effectiveness of liraglutide versus dulaglutide in Japanese patients with type 2 diabetes: a retrospective study.","Tanaka K","2022","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck03","R7: IPTW cohort liraglutide vs dulaglutide reports HbA1c and clinical parameters only; retinopathy only a baseline characteristic",2],["R0006120","Ease of Use of the iGlarLixi SoloStar Pen from the LixiLan ONE CAN Pen Sub-Study: Questionnaire Findings from People Living with Type 2 Diabetes and Their HealthCare Providers.","Yale JF","2023","inventory_only","N3","secondary_report","P01",null,null,"high","recheck","opus-5.5-recheck01","parent trial randomizes daily versus weekly self titration of iGlarLixi, same drug node in both arms; substudy pools pen questionnaire answers",2],["R0004863","Dose-Response and Clinical Equivalence of Semaglutide and Tirzepatide for Weight Loss in Type 2 Diabetes: A Model-Based Analysis.","Builes-Montaño CE","2026","inventory_only","N6","secondary_report","P01",null,null,"high","recheck","opus-5.5-recheck01","R4: arm level dose response model across separate semaglutide and tirzepatide trials without a shared randomized contrast; no systematic search",2],["R0005378","Heterogeneity of Cardiovascular Effects of Second-Line Glucose-Lowering Therapies in Adults With Type 2 Diabetes Across the Range of Moderate Baseline Cardiovascular Risk.","Deng Y","2025","inventory_only","N6","secondary_report",null,null,null,"high","recheck","opus-5.5-recheck01","claims trial emulation of second line drugs with MACE heterogeneity; pancreatitis, cancer, AKI appear only as baseline characteristics",2],["R0006617",null,null,null,"inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck01","matched cohort tirzepatide versus semaglutide after CABG; wound, cardiovascular and cerebrovascular outcomes; kidney failure only as baseline characteristic",2],["R0007490","Safety and Efficacy of GLP-1 Receptor Agonists and SGLT2 Inhibitors Among Veterans With Type 2 Diabetes.","McCulley L","2022","inventory_only","N5","primary_report",null,null,null,"high","recheck","opus-5.5-recheck08","R3: retrospective pre post chart review of veterans on combined GLP-1 RA and SGLT2i; observational, no concurrent comparison group",2],["R0006429","Cardioprotective glucose-lowering drugs, statins, and secondary major adverse cardiovascular events: a nationwide cohort study of individuals with type 2 diabetes and cardiovascular disease.","Ternhamar T","2026","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck08","Danish registry cohorts of cardioprotective glucose lowering drugs and statins; MACE and mortality outcomes only; retinopathy only baseline",2],["R0007550","Cardiovascular outcomes of semaglutide and tirzepatide for patients with type 2 diabetes in clinical practice.","Krüger N","2026","inventory_only","N6","primary_report",null,null,null,"low","recheck","opus-5.5-recheck08","R7 by analogy: tirzepatide, semaglutide cohorts; only composite GI adverse events, components in unseen supplement; alternative include_harms if listed harm separate",2],["R0007759","Immediate Impact of Switching from Dipeptidyl Peptidase 4 (DPP4) Inhibitors to Low-Dose (0.3 mg) Liraglutide on Glucose Profiles: A Retrospective Observational Study.","Terui S","2024","inventory_only","N5","primary_report",null,null,null,"high","recheck","opus-5.5-recheck08","R3: retrospective observational single arm study of inpatients switched from DPP4 inhibitor to liraglutide 0.3 mg; no concurrent comparator",2],["R0010243","Association of COVID-19 outcomes with diabetes in the Veneto region (north-east italy): Epidemiological insights for the endemic phase?","Piarulli F","2023","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck06","retrospective COVID-19 cohort of diabetic patients comparing prior drug use including GLP-1 RA by prognosis; no listed harm outcome",2],["R0009025","Repurposing Semaglutide and Liraglutide for Alcohol Use Disorder.","Lähteenvuo M","2025","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck06","R7: within individual self controlled Cox of GLP-1 RA use periods in AUD; suicide attempt outcome but self controlled qualifies only for O34",2],["R0009367","Cardiorenal outcomes of tirzepatide versus semaglutide in adults with type 2 diabetes and chronic kidney disease: a target trial emulation in the TriNetX Global Collaborative Network","Chiang P","2026","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck06","target trial emulation tirzepatide vs semaglutide in T2D with CKD, not randomized; cardiorenal outcomes; AKI only an exclusion criterion",2],["R0011428","LEADER-4: blood pressure control in patients with type 2 diabetes and high cardiovascular risk: baseline data from the LEADER randomized trial.","Petrie JR","2016","inventory_only","N8","protocol_or_design","P01",null,null,"high","recheck","opus-5.5-recheck06","R2: LEADER baseline blood pressure data before randomization; no between arm outcome reported",2],["R0005557","The Safety Profile of Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-like Peptide 1 Receptor Agonists in the Standard of Care Treatment of Type 2 Diabetes Mellitus.","Salmen T","2023","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck10","R7 by analogy: pancreatitis appears only inside a GI adverse reaction composite whose GLP-1 cases are all nausea; labs and UTI otherwise",2],["R0007043","From metabolism to mind: The expanding role of the GLP-1 receptor in neurotherapeutics.","Roy A","2025","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck10","R1: PubMed, Web of Science and Embase search, stated inclusion criteria, structured tables of GLP-1 RA clinical trials in neurological disease",2],["R0007768","Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) Therapy Adherence for Patients with Type 2 Diabetes in a Medicare Population.","Nguyen H","2017","exclude","E2","other",null,null,null,"high","recheck","opus-5.5-recheck10","R8: Medicare claims cohort compares only adherence (PDC) across exenatide and liraglutide; no clinical outcome compared",2],["R0005447","Comparative renal outcomes of matched cohorts of patients with type 2 diabetes receiving SGLT2 inhibitors or GLP-1 receptor agonists under routine care.","Fadini GP","2024","inventory_only","N6","primary_report","P01",null,null,"high","recheck","opus-5.5-recheck07","R7: DARWIN-Renal matched new users of SGLT2i vs GLP-1 RA; eGFR, albuminuria, CKD class and BP outcomes; retinopathy only at baseline",2],["R0004239","Remission of polycystic ovary syndrome based on the recovery of ovarian morphology identified by three-dimensional ultrasonography: a retrospective study.","Su K","2026","inventory_only","N6","primary_report","P12",null,null,"high","recheck","opus-5.5-recheck07","retrospective PCOS cohort with drugs assigned by BMI; compares remission vs nonremission and drug use frequency; no listed harm; alternative N5",2],["R0004305","GLP-1 RA-Exacerbated Gut Microbiome Dysbiosis in Obesity Mediates Post-Cessation Weight Regain","Song D","2026","include_nma",null,"primary_report","P02",null,null,"high","recheck","opus-5.5-recheck07","randomized trial of semaglutide vs high fibre diet in overweight or obese adults, 12 week weight change and post cessation regain; diabetes status not stated in extract",2],["R0006772","De-Intensification from Basal-Bolus Insulin Therapy to Liraglutide in Type 2 Diabetes: Predictive Value of Mean Glycaemia during Fasting Test.","Pavlikova B","2024","inventory_only","N5","primary_report","P01",null,null,"high","recheck","opus-5.5-recheck07","R3: retrospective observational cohort of poorly controlled T2D switched from basal bolus insulin to liraglutide; responders vs nonresponders, no exposure comparison",2],["R0010491","Adherence, persistence, glycaemic control and costs among patients with type 2 diabetes initiating dulaglutide compared with liraglutide or exenatide once weekly at 12-month follow-up in a real-world setting in the United States.","Mody R","2019","inventory_only","N6","primary_report","P01",null,null,"high","recheck","opus-5.5-recheck04","R8: claims cohort dulaglutide vs liraglutide or exenatide weekly compares adherence, persistence, costs and HbA1c; no listed harm outcome",2],["R0007482","Cardiorenal effectiveness of empagliflozin vs. glucagon-like peptide-1 receptor agonists: final-year results from the EMPRISE study.","Htoo PT","2024","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck04","EMPRISE new user cohort empagliflozin vs GLP-1 RA; cardiorenal outcomes and ESKD; acute kidney injury and malignancy appear only at baseline",2],["R0007667","Safety of SGLT2 inhibitors, DPP-4 inhibitors, and GLP-1 receptor agonists in US veterans with and without chronic kidney disease: a population-based study.","Narasaki Y","2024","include_harms",null,"primary_report",null,"O121",null,"high","recheck","opus-5.5-recheck04","VA new user cohort SGLT2i vs DPP-4i vs GLP-1 RA; time to first acute kidney injury analyzed as a separate outcome alongside infections",2],["R0012141","Combined Semaglutide and Sodium-Glucose Cotransporter-2 Inhibitor Use and Metabolic Outcomes in Chinese Adults With Diabetes: Post Hoc Analysis.","Wang S","2026","inventory_only","N5","secondary_report",null,null,null,"high","recheck","opus-5.5-recheck02","R3: post hoc single group analysis of SCHOLAR retrospective EHR semaglutide users also on SGLT2i; uncontrolled observational cohort, not interventional",2],["R0008991","Non-alcoholic fatty liver disease (NAFLD) and risk of hospitalization for Covid-19.","Bramante CT","2020","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck02","EHR cohort of COVID-19 hospitalization by NAFLD; reports OR for home GLP-1 RA use as an exposure, so not E2; no listed harm",2],["R0009865","Semaglutide and tirzepatide effects on cardiovascular outcomes in people with overweight or obesity in the real world (STEER).","Wilson L","2026","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck02","R7: matched cohort semaglutide vs tirzepatide in obesity with ASCVD; MACE outcomes only; pancreatitis and thyroid cancer are exclusions",2],["R0013720","Comparative Effectiveness of Once-Weekly Semaglutide Versus Sulfonylureas, DPP4 Inhibitors, and Thiazolidinediones in Patients with Type 2 Diabetes and Chronic Kidney Disease.","Amamoo J","2026","inventory_only","N6","other",null,null,null,"high","recheck","opus-5.5-recheck02","claims cohort semaglutide vs SU, DPP-4i or TZD in diabetic CKD; HbA1c, eGFR, weight and renal composite only; no acute kidney injury reported",2],["R0008363","Comparative cardiovascular effectiveness of newer glucose-lowering drugs in elderly with type 2 diabetes: a target trial emulation cohort study.","Kosjerina V","2025","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck01","new user trial emulation of GLP-1 RA, SGLT2i and DPP-4i in older adults; MACE and heart failure only; harms terms are baseline covariates",2],["R0006898","Stratifying cardiovascular benefits from GLP-1RA: a multisource analysis of patient-level CVOT and real-world data using AI-driven methods.","Morieri ML","2025","include_nma",null,"pooled_analysis","P01",null,null,"high","recheck","opus-5.5-recheck01","R4: pooled IPD of LEADER and SUSTAIN-6 keeps GLP-1 RA versus placebo randomized contrast for MACE by subgroup, plus transport analysis",2],["R0007323","Levels of circulating semaglutide determine reductions in HbA1c and body weight in people with type 2 diabetes.","Overgaard RV","2021","inventory_only","N6","secondary_report","P01",null,null,"high","recheck","opus-5.5-recheck01","R4: exposure response modeling within semaglutide arms and matched cross program comparison of oral versus subcutaneous; no randomized between arm contrast analyzed",2],["R0007665","Weight-lowering Effects of Glucagon-like Peptide-1 Receptor Agonists and Detection of Breast Cancer Among Obese Women with Diabetes.","Santella C","2020","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck01","R7: whole PDF read; new user cohort reports only breast cancer, a single site cancer that is not O32A, O32B or O38",2],["R0006244","Real-World Use of Oral and Subcutaneous Semaglutide in Routine Clinical Practice in the UK: A Single-Centre, Retrospective Observational Study.","Roy Chowdhury S","2024","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck05","retrospective comparison of oral vs subcutaneous semaglutide on HbA1c and weight; retinopathy only a baseline characteristic",2],["R0006377","Thiazolidinediones and Glucagon-Like Peptide-1 Receptor Agonists and the Risk of Nonalcoholic Fatty Liver Disease: A Cohort Study.","van Dalem J","2021","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck05","R7: CPRD cohort GLP-1 RA vs insulin on incident NAFLD; hepatocellular carcinoma is a single site cancer, not O39",2],["R0006387","Effectiveness and safety of once-weekly semaglutide: findings from the SEMACOL-REAL retrospective multicentric observational study in Colombia.","Buenaventura-Collazos DC","2024","inventory_only","N5","primary_report",null,null,null,"high","recheck","opus-5.5-recheck05","R3: observational EMR cohort of once weekly semaglutide users with before and after changes; no comparison group",2],["R0006627","High-intensity statin therapy is associated with reduced coronary inflammation on CT in patients with type 2 diabetes mellitus.","Wu B","2025","inventory_only","N5","primary_report",null,null,null,"high","recheck","opus-5.5-recheck03","R3: cross sectional CT study; GLP-1 RA use reported with an adjusted association with coronary inflammation, no longitudinal comparison",2],["R0008582","SAVOR-TIMI to DECLARE-TIMI: A Review on Cardiovascular Outcome Trials of Incretin-modulators and Gliflozins.","Singh AK","2019","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck03","R1: dated PubMed and ClinicalTrials.gov search with criteria for placebo controlled CVOTs; forest plot synthesis includes five GLP-1 RA trials",2],["R0006010","Major adverse cardiovascular events among patients with type-2 diabetes, a nationwide cohort study comparing primary metabolic and bariatric surgery to GLP-1 receptor agonist treatment.","Stenberg E","2023","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck03","R7: matched cohort bariatric surgery vs GLP-1 RA reports MACE, death and metabolic outcomes; bowel obstruction only in surgical arm",2],["R0006579","Exploring Adults' Experiences with Tirzepatide for Weight Loss: A Mixed-Methods Study.","Adam S","2025","inventory_only","N5","primary_report",null,null,null,"high","recheck","opus-5.5-recheck03","R3: cross sectional mixed methods survey of tirzepatide users with self-reported weight loss and side effects; no comparison group",2],["R0009647","Impact of high glucose levels and glucose lowering on risk of ischaemic stroke: a Mendelian randomisation study and meta-analysis.","Benn M","2021","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck06","R1: PubMed, Web of Science, ClinicalTrials.gov searched with stated RCT criteria and PRISMA flow; pooled stroke risk ratio for GLP-1 RAs",2],["R0012158","GLP1 receptor agonism ameliorates Parkinson’s disease through modulation of neuronal insulin signalling and glial suppression","Athauda D","2024","include_nma",null,"secondary_report","P13B",null,"mechanistic","high","recheck","opus-5.5-recheck06","R4: Exenatide-PD2 exenatide vs placebo samples compared by arm; motor responders by MDS-UPDRS III reported by arm alongside iPSC work",2],["R0012206","Glucose-Lowering Drugs with Proven Cardiovascular Benefit Following Acute Coronary Syndrome in Patients with Type 2 Diabetes: Treatment Gaps and Outcomes.","Naoum I","2024","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck06","Israeli post ACS cohort, time dependent GLP-1 RA and SGLT2i use vs MACE and death; pancreatitis exclusion and retinopathy baseline only",2],["R0013728","Comparative 24-month cardiovascular outcomes and biomarker trajectories with semaglutide, empagliflozin, and sitagliptin in people with obesity and type 2 diabetes: a multicenter real-world study.","Chen JC","2026","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck06","R7: TriNetX new user cohorts semaglutide vs empagliflozin or sitagliptin; AKI only inside MAKE composite with dialysis and transplant",2],["R0008171","Impact of GLP-1 receptor agonists on cranial nerve palsies in type 2 diabetes: a retrospective cohort study.","Bhatia R","2025","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck10","TriNetX cohort GLP-1 RA users versus nonusers; only third, sixth nerve and Bell palsy outcomes; no listed harm",2],["R0007149","Incidence of hematologic malignancies and mortality associated with GLP-1 receptor agonist and SGLT2 inhibitor use in type 2 diabetes mellitus: results of a retrospective cohort study of electronic health records.","Irons EE","2026","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck10","R7: cohort reports only four single hematologic malignancies, not all cancers combined, so not O39; no other listed harm",2],["R0008649","Acupuncture for patients with glucagon-like peptide-1 receptor agonists-induced nausea and vomiting: A systematic review protocol.","Ding N","2020","inventory_only","N8","protocol_or_design",null,null,null,"high","recheck","opus-5.5-recheck10","R2: protocol of a systematic review of acupuncture for GLP-1 RA induced nausea; no results; GLP-1 RA is background only (R1 alternative E2)",2],["R0008843","Sodium-Glucose Cotransporter 2 Inhibitors vs Incretin-Based Drugs and Risk of Fractures for Type 2 Diabetes.","Ko HY","2023","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck10","new user cohort SGLT2i versus DPP-4i or GLP-1 RA; fracture outcomes only; retinopathy and cancer only baseline or exclusion",2],["R0006919","Concomitant Use of Sodium-Glucose Cotransporter 2 Inhibitors and Overactive Bladder Drugs and the Risk of Urinary Tract Infection.","Bea S","2024","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck08","SGLT2i versus DPP-4i or GLP-1 RA new users on overactive bladder drugs; only urinary tract infection outcomes; retinopathy baseline",2],["R0009200","Effectiveness and Tolerability of Once-Weekly GLP-1 Receptor Agonists in Clinical Practice: A Focus on Switching Between Once-Weekly Molecules in Type 2 Diabetes.","Di Dalmazi G","2022","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck08","clinic cohort comparing once weekly GLP-1 RA agents and switchers on HbA1c, weight and dropout; retinopathy only a baseline complication",2],["R0007569","Treatment patterns in patients with type 2 diabetes mellitus treated with glucagon-like peptide-1 receptor agonists: Higher adherence and persistence with dulaglutide compared with once-weekly exenatide and liraglutide.","Alatorre C","2017","exclude","E2","other",null,null,null,"high","recheck","opus-5.5-recheck09","R8: matched claims comparison of adherence, persistence and switching across GLP-1 RAs; no clinical outcome compared",2],["R0008160","Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk factors: A narrative review of head-to-head comparisons.","Dalsgaard NB","2018","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck09","R1: self labeled narrative but dated PubMed search, stated criteria and tabulated synthesis of 16 head to head GLP-1 RA trials",2],["R0008373","Comparative Effectiveness and Safety of Once-Weekly Injectable Semaglutide Versus Dulaglutide in Individuals with Type 2 Diabetes Managed in UK Primary Care: A Population-Based Cohort Study.","Ulrich FS","2026","deferred","D2","primary_report",null,null,null,"low","recheck","opus-5.5-recheck09","new user semaglutide versus dulaglutide cohort; predefined safety events summarized but their list is not in the text, only GI events named",2],["R0008763","Higher semaglutide dose is associated with lower neuropsychiatric event incidence independent of weight loss.","Murugadoss K","2026","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck09","R7: EHR cohorts of semaglutide versus other drugs and by dose on neuropsychiatric diagnoses; no suicidal ideation or behavior outcome reported",2],["R0006175","Phenotypic and genomic frameworks for precision pharmacotherapy in obesity: a narrative review.","Lopez Delgado DS","2026","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck07","R1: self labeled narrative but searched MEDLINE, Embase, Scopus, Web of Science with stated selection and dual screening; tabulates GLP-1 RA trials and predictors",2],["R0004455","Comparative Efficacy of Tirzepatide Versus GLP-1 Receptor Agonists on Glycaemic Control and Body Weight in Adults With Type 2 Diabetes: A Systematic Review and Meta-Analysis of Head-to-Head Randomised Controlled Trials","Khan OO","2026","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck07","R1: PRISMA meta-analysis searching PubMed, Embase, CENTRAL; pools five head to head RCTs of tirzepatide vs GLP-1 RAs in T2D",2],["R0006365","Prescription of glucagon-like peptide 1 agonists and risk of subsequent open-angle glaucoma in individuals with type 2 diabetes mellitus.","Chuang CC","2024","inventory_only","N6","primary_report","P01",null,null,"high","recheck","opus-5.5-recheck07","R7: Taiwan NHIRD GLP-1 RA users vs nonusers with T2D; outcome is open angle glaucoma; DME and PDR appear only as covariate abbreviations",2],["R0007800","Higher Rates of Persistence and Adherence in Patients with Type 2 Diabetes Initiating Once-Weekly vs Daily Injectable Glucagon-Like Peptide-1 Receptor Agonists in US Clinical Practice (STAY Study).","Polonsky WH","2022","inventory_only","N6","primary_report","P01",null,null,"high","recheck","opus-5.5-recheck04","R8: matched claims cohort once weekly vs daily GLP-1 RA compares persistence, adherence and also HbA1c and weight change; no listed harm",2],["R0005879","Transforming body composition with semaglutide in adults with obesity and type 2 diabetes mellitus.","Rodríguez Jiménez B","2024","inventory_only","N6","primary_report","P01",null,null,"high","recheck","opus-5.5-recheck04","retrospective cohort oral vs subcutaneous semaglutide on body composition, HbA1c, lipids; retinopathy only baseline, no listed harm",2],["R0007342","Real-World Evidence for Existing Anti-Obesity Therapies-The Realities of Treatment Adherence, Tolerability, Access and Patient Satisfaction.","Kassem S","2026","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck04","R1: self labeled narrative but structured PubMed search with stated eligibility and tables synthesizing real world vs trial data for incretin and other therapies",2],["R0008984","Visual demonstration of weight loss and health risk improvement with a dual GIP and GLP-1 receptor agonist.","Ramirez S","2025","inventory_only","N1","secondary_report","P02",null,null,"high","recheck","opus-5.5-recheck04","R4: avatar visualization using only SURMOUNT-1 tirzepatide maximal dose arm baseline and week 72 data; no placebo contrast shown",2],["R0010204","Efficacy of Dulaglutide as a First Injectable Option for Patients with Type 2 Diabetes: A Post-Hoc Pooled Analysis.","Patel H","2019","inventory_only","N1","secondary_report",null,null,null,"high","recheck","opus-5.5-recheck02","R4: post hoc pooling of dulaglutide 1.5 mg arms only from seven AWARD RCTs by background therapy; comparator arms not pooled",2],["R0008485","Association of Glucagon-Like Peptide-1 Receptor Agonist vs Dipeptidyl Peptidase-4 Inhibitor Use With Mortality Among Patients With Type 2 Diabetes and Advanced Chronic Kidney Disease.","Chen JJ","2022","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck02","NHIRD cohort GLP-1 RA vs DPP-4i in advanced CKD; all cause, infection and MACCE mortality only; malignancy is an exclusion",2],["R0010981","Cardiovascular Outcomes with Finerenone According to Glycemic Status at Baseline and Prior Treatment with Newer Antidiabetics among Patients with Type 2 Diabetes Mellitus.","Patoulias D","2022","exclude","E2","systematic_review",null,null,null,"high","recheck","opus-5.5-recheck02","R1: meta-analysis of finerenone vs placebo RCTs; GLP-1 RA only defines background subgroups in every comparison",2],["R0012906","Clinical benefits of tirzepatide in patients with steatotic liver disease and cardiometabolic dysfunction.","Shiau BW","2026","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck06","full PDF readable: TriNetX matched cohort tirzepatide vs nonusers in steatotic liver disease; liver outcomes, MACE, MAKE; HCC single site, no listed harm",2],["R0009455","Efficacy of Exenatide Administered Twice Daily in Body Mass Index Reduction in Patients with Type 2 Diabetes Mellitus.","Zhang J","2022","inventory_only","N1","secondary_report","P01",null,null,"high","recheck","opus-5.5-recheck06","R4: uses only the exenatide plus metformin arm of an exenatide vs insulin RCT; before and after BMI change, no randomized contrast",2],["R0013193","Safety of add-on sulfonylurea therapy in patients with type 2 diabetes using metformin: a population-based real-world study.","Hougen I","2021","exclude","E2","other",null,null,null,"high","recheck","opus-5.5-recheck06","sulfonylurea vs pooled other add on drugs; GLP-1 RAs are 4 percent of the comparator with no separate GLP-1 RA estimate",2],["R0014836","What Is Best for Weight Loss? A Comparative Review of the Safety and Efficacy of Bariatric Surgery Versus Glucagon-Like Peptide-1 Analogue.","Klair N","2023","exclude","E3","other",null,null,null,"high","recheck","opus-5.5-recheck06","R1: review of semaglutide vs bariatric surgery trials with no database search or eligibility criteria described",2],["R0006400","Hemoglobin A1c Reduction With the GLP-1 Receptor Agonist Semaglutide Is Independent of Baseline eGFR: post hoc Analysis of the SUSTAIN and PIONEER Programs.","Cherney DZI","2022","include_nma",null,"secondary_report","P01; P08A",null,null,"high","recheck","opus-5.5-recheck05","R2 not applicable, R4: post hoc SUSTAIN and PIONEER analysis reports semaglutide vs comparator HbA1c, weight and adverse events by eGFR",2],["R0007920","Sodium-Glucose Cotransporter 2 Inhibitors and the Short-term Risk of Bladder Cancer: An International Multisite Cohort Study.","Abrahami D","2022","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck01","R7: whole PDF read; new user cohort SGLT2i versus GLP-1 RA or DPP-4i reporting only bladder cancer, a single site not in the list",2],["R0008337","A glycosylated Fc-fused glucagon-like peptide-1 receptor agonist exhibits equivalent glucose lowering to but fewer gastrointestinal side effects than dulaglutide.","An IB","2020","include_nma",null,"primary_report","P99",null,"mechanistic","high","recheck","opus-5.5-recheck01","R5: randomized double blind placebo controlled single ascending dose study of GLP-1-gFc in healthy men; reports nausea and vomiting",2],["R0008791","An indirect treatment comparison of the efficacy of semaglutide 1.0 mg versus dulaglutide 3.0 and 4.5 mg.","Pratley RE","2021","inventory_only","N6","secondary_report","P01",null,null,"high","recheck","opus-5.5-recheck01","R4: Bucher indirect comparison of semaglutide versus dulaglutide high doses across SUSTAIN 7 and AWARD-11, no shared randomized contrast",2],["R0008998","A 2-Years Comparative Analysis of Tirzepatide, Semaglutide, Qsymia, Contrave, and Phentermine on Ocular Health in Individuals with Obesity: A Propensity-Score Matched Cohort Study","Su P","2025","inventory_only","N6","primary_report","P02",null,null,"high","recheck","opus-5.5-recheck01","matched cohort of anti obesity drugs; prespecified outcomes cataract, dry eye, visual disturbance; optic neuropathy mentioned only in discussion, not NAION",2],["R0005976","Association of tirzepatide with changes in OSA-related measures based on baseline characteristics - post hoc analyses of SURMOUNT-OSA.","Falcon B","2026","include_nma",null,"secondary_report","P10; P02",null,null,"high","recheck","opus-5.5-recheck05","R2 not applicable, R4: post hoc SURMOUNT-OSA subgroup analyses report tirzepatide vs placebo AHI, weight and blood pressure changes",2],["R0006347","Real-World Effectiveness of Liraglutide Versus Dulaglutide In Japanese Patients With Type 2 Diabetes: A Retrospective Study","Tanaka K","2021","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck05","retrospective cohort of liraglutide vs dulaglutide on HbA1c; retinopathy appears only as a baseline characteristic",2],["R0007715","Risk of Stroke in Real-World US Individuals with Type 2 Diabetes Receiving Semaglutide or a Dipeptidyl Peptidase 4 Inhibitor.","Evans M","2024","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck05","matched claims cohort semaglutide vs DPP-4i initiators; outcomes stroke and resource use only; retinopathy only at baseline",2],["R0005959","Efficacy and Safety of Tirzepatide and Semaglutide for Obesity Management: A Real-World Comparison.","Shil KK","2025","include_harms",null,"primary_report",null,"O28; O29",null,"high","recheck","opus-5.5-recheck03","R7: tirzepatide vs semaglutide cohort tabulates pancreatitis and cholecystitis by drug group as adverse events",2],["R0007336","Balancing metabolic optimization and reproductive safety in Polycystic Ovary Syndrome: a Bayesian-informed framework for GLP-1 receptor agonists.","Song E","2026","exclude","E3","other",null,null,null,"high","recheck","opus-5.5-recheck03","R1: self-described narrative synthesis with exploratory weight NMA; no named database search or eligibility criteria reported",2],["R0007356","Effectiveness and use of evidence-based cardiovascular preventive therapies in type 2 diabetes patients with established or high risk of atherosclerotic cardiovascular disease.","Tian JQ","2025","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck03","R7: hospital cohort of preventive therapies including GLP-1 RA reports MACE, HF and kidney composite; no listed harm outcome",2],["R0008323","The risk of major osteoporotic fractures with GLP-1 receptor agonists when compared to DPP-4 inhibitors: A Danish nationwide cohort study.","Al-Mashhadi ZK","2022","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck03","R7: matched GLP-1 RA vs DPP-4i cohort reports osteoporotic fractures only; pancreatitis and retinopathy appear only as baseline characteristics",2],["R0008767","Synthetic target trial emulation and predictive modeling of amylin-pathway therapies for obesity and type 2 diabetes.","Al-Harbi FA","2025","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck10","R1: PRISMA search of named databases with RCT eligibility criteria and Bayesian NMA of CagriSema, amycretin and semaglutide arms; modeling is additional",2],["R0002838","GYG1 as a Dual Biomarker of Glucagon-Like Peptide-1 Receptor Agonist Weight-Loss Response: Findings from an Integrative Multi-Omics Substudy of a Phase II Trial.","Li L","2026","include_nma",null,"secondary_report","P02",null,"mechanistic","high","recheck","opus-5.5-recheck10","R4: multi-omics substudy of randomized GZR18 phase II trial reporting BMI change by dose versus placebo, keeping the randomized contrast",3],["R0010028","The effect of exenatide on fasting bile acids in newly diagnosed type 2 diabetes mellitus patients, a pilot study.","Li B","2020","inventory_only","N1","primary_report",null,null,null,"high","recheck","opus-5.5-recheck10","R3: registered interventional single arm exenatide study; healthy subjects untreated baseline reference only, no concurrent comparison",2],["R0010611","Real-world weight change among patients treated with glucagon-like peptide-1 receptor agonist, dipeptidyl peptidase-4 inhibitor and sulfonylureas for type 2 diabetes and the influence of medication adherence.","Carls GS","2017","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck10","claims and EMR cohort of GLP-1 RA, DPP-4i and SU initiators; weight change and adherence only; no listed harm",2],["R0011747","A scoping review on weight loss injections and eating disorders: therapeutic impact, risks of misuse, and emerging harms.","Barrett P","2026","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck06","R1: OSF registered scoping review, six named databases, inclusion and exclusion table, structured synthesis of GLP-1 RA studies in eating disorders",2],["R0012378","Glucagon-like peptide-1 receptor agonist exenatide has no acute effect on MRI-measured exocrine pancreatic function in patients with type 2 diabetes: a randomized trial.","Smits MM","2016","include_nma",null,"primary_report","P01",null,"mechanistic; crossover","high","recheck","opus-5.5-recheck06","R5: randomized crossover IV exenatide vs placebo; results report adverse events and one hypoglycemia episode at 2.9 mmol/L under exenatide",2],["R0013572","Novel Antidiabetic Drugs and Risk of Venous Thromboembolism: A Literature Review.","Chen Q","2025","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck06","R1: PubMed search with stated inclusion criteria on comparative VTE risk, 25 studies synthesized including GLP-1 RA contrasts",2],["R0013732","Tirzepatide for Recurrent Weight Gain after Bariatric Procedures: Real-World Evidence of Efficacy and Safety.","Vinciguerra F","2026","inventory_only","N5","primary_report",null,null,null,"high","recheck","opus-5.5-recheck06","R3: prospective observational cohort of tirzepatide after bariatric weight regain chosen in routine care; no comparison group",2],["R0004610","Impact of glucagon-like peptide 1 receptor agonist liraglutide and dipeptidyl peptidase-4 inhibitor sitagliptin on bowel cleaning and gastrointestinal symptoms in type 2 diabetes.","Tong Y","2023","inventory_only","N6","primary_report","P01",null,null,"high","recheck","opus-5.5-recheck07","prospective nonrandomized colonoscopy cohort, liraglutide vs sitagliptin vs control; bowel cleansing quality, GI symptoms, hypoglycemia; no retained gastric content or aspiration",2],["R0007477","SGLT-2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors and risk of hyperkalemia among people with type 2 diabetes in clinical practice: population based cohort study.","Fu EL","2024","inventory_only","N6","primary_report","P01",null,null,"high","recheck","opus-5.5-recheck07","R7: active comparator new user cohorts of SGLT2i, GLP-1 RA and DPP-4i; outcome hyperkalemia only; AKI and retinopathy are baseline covariates",2],["R0009129","Semaglutide in type 2 diabetes with chronic kidney disease at high risk progression-real-world clinical practice.","Aviles Bueno B","2022","inventory_only","N5","primary_report","P08A",null,null,"high","recheck","opus-5.5-recheck07","R3: retrospective observational series of semaglutide in T2D with CKD, before and after changes only, no comparison group",2],["R0001830","Perioperative Glucagon-like Peptide-1 Receptor Agonist Use Is Associated With Lower Pseudoarthrosis Rates Following Long-Segment Spinal Deformity Correction: A Propensity-Matched Analysis.","Stump K","2026","include_harms",null,"primary_report",null,"O121",null,"high","recheck","opus-5.5-recheck09","R7: perioperative matched TriNetX cohort, GLP-1 RA users versus nonusers in spinal fusion, reports acute kidney failure separately",3],["R0008748","Effects of the switch from dulaglutide to tirzepatide on glycemic control, body weight, and fatty liver: a retrospective study.","Sawamura T","2024","inventory_only","N5","primary_report",null,null,null,"high","recheck","opus-5.5-recheck09","R3: retrospective chart review of clinical switch from dulaglutide to tirzepatide, before and after only, uncontrolled observational",2],["R0009411","Exploring the off-label use of liraglutide in the treatment of obesity: a review.","Braga CBA","2026","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck08","R1: PubMed search, stated inclusion and exclusion criteria, tabulated synthesis of nine human liraglutide studies on obesity",2],["R0007874","Downstream Treatment Burden and Health-Care Utilization Following Initiation of GLP-1 Receptor Agonists or SGLT2 Inhibitors in Type 2 Diabetes.","Alhamdan Y","2026","include_harms",null,"primary_report",null,"O35A",null,"high","recheck","opus-5.5-recheck08","new user TriNetX cohort GLP-1 RA versus SGLT2i; incident suicidal ideation reported with hazard ratio among secondary outcomes",2],["R0008051","Healthcare Resource Utilization and Associated Costs in New Users of Empagliflozin versus DPP-4 Inhibitors and GLP-1 Agonists: A Comparative Analysis Based on Retrospective Real-World Data from German Sickness Funds.","Wilke T","2022","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck08","R8: empagliflozin versus DPP-4i or GLP-1 RA claims cohort on costs with hospitalization reasons; acute renal failure only baseline characteristic",2],["R0011333","Association of Sodium-Glucose Cotransporter-2 Inhibitors With Fracture Risk in Older Adults With Type 2 Diabetes.","Zhuo M","2021","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck08","SGLT2i versus DPP-4i or GLP-1 RA new user Medicare cohort; fracture with ketoacidosis and heart failure controls; no listed harm",2],["R0006943","Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial.","Mann JFE","2024","include_nma",null,"secondary_report","P08A; P01",null,null,"high","recheck","opus-5.5-recheck05","R2 not applicable, R4: FLOW subgroup analysis reports semaglutide vs placebo kidney and CV outcomes by baseline SGLT2i use",2],["R0008050","The use of sodium-glucose co-transporter-2 inhibitors or glucagon-like peptide-1 receptor agonists versus sulfonylureas and the risk of lower limb amputations: a nation-wide cohort study.","Werkman NCC","2023","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck05","R7: new user cohort GLP-1 RA vs sulfonylurea; outcomes lower limb amputation and foot ulcer only; retinopathy only at baseline",2],["R0010043","Pre-Treatment Concerns and Their Association With Functioning and Well-Being During Incretin-Based Therapy: A Cross-Sectional Study.","Kapan A","2026","inventory_only","N5","primary_report",null,null,null,"high","recheck","opus-5.5-recheck05","R3: cross sectional online survey of incretin therapy users relating pretreatment concerns to well-being; no exposure comparison",2],["R0010710","Once-Weekly Semaglutide Is Associated With Improvement in Vascular Endothelial Function in Patients With Type 2 Diabetes Mellitus: A Retrospective Observational Study.","Sugiyama S","2025","inventory_only","N5","primary_report",null,null,null,"high","recheck","opus-5.5-recheck05","R3: retrospective observational before and after cohort of semaglutide initiators measuring endothelial function; no comparison group",2],["R0008992","A validated, modifiable proteomic score from the EXSCEL trial predicts cardiovascular events in diabetes.","Corey KM","2026","include_nma",null,"secondary_report","P01",null,null,"high","recheck","opus-5.5-recheck02","R4: EXSCEL proteomic substudy reports MACE by randomized arm and exenatide vs placebo effect on protein score; prediction work does not remove contrast",2],["R0010998","Use of Glucagon-Like-Peptide 1 Receptor Agonists and Risk of Fracture as Compared to Use of Other Anti-hyperglycemic Drugs.","Driessen JH","2015","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck02","Danish case control of GLP-1 RA use vs other agents and fracture; fracture not listed; cancer and retinopathy are adjustment covariates",2],["R0011938","Exploring the off-Label use of liraglutide in the treatment of obesity: a review","Braga CBA","2025","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck02","R1: PubMed search with explicit inclusion and exclusion criteria; structured table synthesizing nine human liraglutide studies in obesity",2],["R0013049","Favorable Appendicular Skeletal Muscle Mass Changes in Older Patients With Type 2 Diabetes Receiving GLP-1 Receptor Agonist and Basal Insulin Co-Therapy.","Osaka T","2023","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck02","retrospective comparison of glargine lixisenatide vs basal insulin in hospitalized older T2D; muscle mass only; retinopathy is a baseline covariate",2],["R0008640","Genetic variability in sodium-glucose cotransporter 2 and glucagon-like peptide 1 receptor effect on glycemic and pressure control in type 2 diabetes patients treated with SGLT2 inhibitors and GLP-1RA in the everyday clinical practice.","Tonin G","2025","inventory_only","N5","primary_report","P01",null,null,"high","recheck","opus-5.5-recheck04","R3: routine care users of GLP-1 RA or SGLT2i followed 3 to 6 months for genotype response; no exposure comparison; alternative N1 given interventional label",2],["R0008950","Ambulatory BP and Weight Reduction as Predictors of GLP-1RA CV Benefit","Renna NF","2025","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck04","R1: PROSPERO registered review searching PubMed, Embase, ClinicalTrials.gov with RCT criteria; meta-analysis of GLP-1 RA vs placebo on MACE",2],["R0010149","Cardiovascular outcomes of type 2 diabetic patients treated with SGLT-2 inhibitors versus GLP-1 receptor agonists in real-life.","Longato E","2020","deferred","D2","primary_report","P01",null,null,"low","recheck","opus-5.5-recheck04","matched new user cohort SGLT2i vs GLP-1 RA reports adverse events as secondary endpoint; event types not visible in full text, listed harm undeterminable",2],["R0011044","Long-term efficacy and safety of combined insulin and glucagon-like peptide-1 therapy: Evidence from the LEADER trial.","Tack CJ","2019","include_nma",null,"secondary_report","P01",null,null,"high","recheck","opus-5.5-recheck04","R4: post hoc LEADER analysis by baseline insulin use keeps randomized liraglutide vs placebo contrast for HbA1c, weight, MACE, hypoglycemia",2],["R0016177","Semaglutide withdrawal in adults with type 1 diabetes on pump therapy: A post-hoc analysis from a double-blinded randomized controlled trial.","Pasqua MR","2026","inventory_only","N1","secondary_report","P05",null,null,"high","recheck","opus-5.5-recheck06","R4: post hoc withdrawal follow up of semaglutide period participants only, compared with their own enrolment values; no randomized contrast used",2],["R0015437","Revolutionizing type 2 diabetes management: the role of the pharmacist in unlocking the potential of tirzepatide.","Banji D","2025","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck06","R1: four named databases, stated inclusion and exclusion criteria, 56 tirzepatide studies selected and tabulated key trials and adverse reactions",2],["R0015694","Role of Sodium-Glucose Cotransporter-2 Inhibitors in Managing Polycystic Ovary Syndrome: A Systematic Review.","Kamrul-Hasan A","2025","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck06","R1: PROSPERO registered, PubMed and ClinicalTrials.gov searched, stated criteria; synthesis includes exenatide arms vs dapagliflozin in one trial",2],["R0015698","A phase I study comparing the pharmacokinetics of the biosimilar (RD12014) with liraglutide (Victoza) in healthy Chinese male subjects.","Zhou R","2022","inventory_only","N3","primary_report","P99",null,"crossover","high","recheck","opus-5.5-recheck06","R6: biosimilar RD12014 vs reference liraglutide, same molecule, dose and route in healthy men; randomized contrast does not change the node",2],["R0007884","Phenotype-based targeted treatment of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes.","Cardoso P","2024","inventory_only","N6","primary_report","P01",null,null,"high","recheck","opus-5.5-recheck07","R7: CPRD SGLT2i vs GLP-1 RA treatment selection model; kidney outcome is eGFR decline or CKD5 and microvascular composite by concordance; no listed harm",2],["R0006449","Association of Changes in A1C Following Continuous Glucose Monitoring Acquisition in People with Sub-Optimally Treated Type 2 Diabetes Taking GLP-1 RA Therapy.","Miller E","2024","exclude","E2","other",null,null,null,"high","recheck","opus-5.5-recheck07","claims study of CGM acquisition in T2D already on GLP-1 RA; CGM is the exposure, GLP-1 RA is background only, pre post A1c without comparison",2],["R0007601","Real-world evidence of the effectiveness on glycaemic control of early simultaneous versus later sequential initiation of basal insulin and glucagon-like peptide-1 receptor agonists.","Rosenstock J","2020","inventory_only","N6","primary_report","P01",null,null,"high","recheck","opus-5.5-recheck07","retrospective cohort of simultaneous vs sequential basal insulin and GLP-1 RA initiation; glycemic targets only; retinopathy and hypoglycemia are baseline",2],["R0007982","Time to Insulin Initiation Among Patients With Type 2 Diabetes Treated With Second-Line Antidiabetic Drugs.","Yu YH","2026","inventory_only","N6","primary_report","P01",null,null,"high","recheck","opus-5.5-recheck07","R8: CPRD target trial emulation of second line classes incl GLP-1 RA; outcomes time to insulin and treatment modification; harms terms only covariates",2],["R0006324","Perioperative GLP1-RA management and risk of aspiration in patients with diabetes undergoing fast-track hip and knee arthroplasty.","Mahmoud LI","2025","inventory_only","N5","primary_report","P01",null,null,"high","recheck","opus-5.5-recheck01","R3: whole PDF read; prospective cohort of GLP-1 RA users undergoing arthroplasty, zero aspiration, no nonuser or paused comparison analyzed",2],["R0008816","Real-world semaglutide in obesity cohort: effectiveness, safety and persistence across sex, BMI, and prior GLP-1RA treatment.","Milani I","2026","inventory_only","N5","primary_report","P02",null,null,"high","recheck","opus-5.5-recheck01","R3: retrospective observational cohort of semaglutide users only; switcher versus naive subgroups both on semaglutide, no comparator",2],["R0010490","The comparative effects of metabolic surgery, SGLT2i, or GLP-1RA in patients with obesity and type 2 diabetes: a retrospective cohort study.","Wu T","2022","inventory_only","N6","primary_report","P01",null,null,"high","recheck","opus-5.5-recheck01","full PDF now readable; cohort of metabolic surgery, SGLT2i and GLP-1 RA with weight, metabolic and cost outcomes; no listed harm",2],["R0013919","Effects of Semaglutide on Cardiometabolic Risk in People with Obesity, With and Without Type 2 Diabetes: A Retrospective Observational Study.","Deaconu L","2026","inventory_only","N5","other",null,null,null,"high","recheck","opus-5.5-recheck03","R3: retrospective observational cohort of semaglutide users compared only by diabetes status; no unexposed or comparator drug group",2],["R0012238","Predictive factors for HbA1c and weight loss associated with semaglutide treatment in type 2 diabetes mellitus: real-world clinical evidence.","Milushewa P","2025","inventory_only","N5","other",null,null,null,"high","recheck","opus-5.5-recheck03","R3: retrospective uncontrolled observational cohort of semaglutide users with T2D; predictors of HbA1c and weight change only",2],["R0006452","Oral semaglutide improves body composition and preserves lean mass in patients with type 2 diabetes: a 26-week prospective real-life study.","Volpe S","2023","inventory_only","N5","primary_report",null,null,null,"high","recheck","opus-5.5-recheck10","R3: prospective real-life cohort of 32 patients prescribed oral semaglutide in routine care; no comparison group (alternative N1 if viewed interventional)",2],["R0010214","Glucagon-Like Peptide-1 Receptor Agonist Differentially Affects Brain Activation in Response to Visual Food Cues in Lean and Obese Individuals with Type 2 Diabetes Mellitus.","Bae JH","2020","include_nma",null,"primary_report","P01",null,"mechanistic; crossover","high","recheck","opus-5.5-recheck03","R5: randomized crossover lixisenatide vs saline fMRI study reports nausea incidence by arm (34.5% vs 20.7%)",2],["R0007329","Federated target trial emulation for time-to-event outcomes via POLARIS: Pooled-equivalent One-shot Likelihood Aggregation for Real-world Inference in Survival.","Wang T","2026","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck10","federated target trial emulation GLP-1 RA versus SGLT2i or DPP-4i; outcomes abdominal pain, constipation, GERD, nausea, vomiting; none listed harms",2],["R0010084","Circulating alarin concentrations are high in patients with type 2 diabetes and increased by glucagon-like peptide-1 receptor agonist treatment: An Consort-compliant study.","Hu W","2019","inventory_only","N1","secondary_report",null,null,null,"high","recheck","opus-5.5-recheck10","R4: alarin substudy sampled only the PEX168 200 microgram arm of the RCT; before and after change, no randomized contrast",2],["R0026856","The role of adjunctive exenatide therapy in pediatric type 1 diabetes.","Raman VS","2010","include_nma",null,"primary_report","P05",null,"mechanistic; crossover","high","recheck","opus-5.5-recheck06","R5: randomized double blind crossover of exenatide 1.25 vs 2.5 ug in adolescents with T1D; nausea and hypoglycemia reported by dose; not a baseline paper",2],["R0013378","A small-molecule oral agonist of the human glucagon-like peptide-1 receptor","Griffith DA","2020","include_nma",null,"primary_report","P99",null,"mechanistic","high","recheck","opus-5.5-recheck06","R5: discovery paper includes randomized placebo controlled single ascending dose study of PF-06882961 in healthy adults; nausea, vomiting and AEs by treatment",2],["R0014404","The Probability of A1C Goal Attainment in Patients With Uncontrolled Type 2 Diabetes in a Large Integrated Delivery System: A Prediction Model.","Pantalone KM","2020","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck06","EHR cohort predicting A1C goal attainment with GLP-1 RA use as an adjusted exposure among predictors; no listed harm outcome",2],["R0017569","Metformin and beyond: glucose-lowering therapy as a potential modulator of abdominal aortic aneurysm growth and stability- systematic review with narrative synthesis.","Dimova MP","2026","exclude","E2","other",null,null,null,"high","recheck","opus-5.5-recheck06","R1: systematic review on glucose lowering drugs and AAA states no human GLP-1 RA studies were found; GLP-1 RA evidence only preclinical",2],["R0001331","Effects of GLP-1 receptor agonists on the incidence of contrast-induced acute kidney injury in patients with Type 2 diabetes mellitus undergoing coronary interventions.","Oksen D","2026","include_harms",null,"primary_report",null,"O121",null,"high","recheck","opus-5.5-recheck08","R7: procedure cohort of prevalent GLP-1 RA users versus nonusers undergoing coronary angiography; contrast induced acute kidney injury compared",3],["R0006920","Endoscopic Ultrasound Guided Gastric Botulinum Toxin Injections versus Glucagon like peptide 1 Receptor Agonist in weight loss. A Prospective randomized study","Gameel A","2023","include_nma",null,"primary_report","P02",null,null,"low","recheck","opus-5.5-recheck08","titled randomized, registered, BTA versus liraglutide in obesity, few diabetics; methods only say divided into groups; alternative N4",2],["R0008174","Evoke (+) trials of semaglutide for early alzheimer's disease: Innovations, lessons, and implications.","Cummings JL","2026","inventory_only","N9","ancillary",null,null,null,"high","recheck","opus-5.5-recheck08","investigator commentary on lessons of the evoke and evoke+ semaglutide RCTs in early Alzheimer disease; no new study",2],["R0008523","Do Fasting GLP-1 and GIP Levels Predict the Initial Pharmacological Response to Semaglutide and Tirzepatide?","La Vignera S","2026","deferred","D2","primary_report","P02",null,null,"low","recheck","opus-5.5-recheck08","R9: labels itself observational non interventional yet says patients randomly assigned to semaglutide or tirzepatide; no allocation procedure described",2],["R0007877","Non-Insulin Novel Antidiabetic Drugs Mechanisms in the Pathogenesis of COVID-19.","Salmen T","2022","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck05","R1: PubMed and Web of Science search with stated criteria, dual screening, tabulated synthesis of seven studies including GLP-1 RA exposure in COVID-19",2],["R0006239","Assessing the Renal Outcomes of Semaglutide in Diabetic Kidney Disease: A Systematic Review.","Rehman SU","2024","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck05","R1: MEDLINE, Embase, CENTRAL, Web of Science search, PRISMA criteria, tabulated synthesis of semaglutide cohorts and case reports in DKD",2],["R0007401","Evaluating video capsule endoscopy in diabetes mellitus: transit times, preparation adequacy, and the influence of insulin and GLP-1 receptor agonist use.","Akerman N","2025","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck05","capsule endoscopy cohort; GLP-1 RA vs controls on small bowel preparation and transit, not retained gastric content O36B or aspiration",2],["R0009587","Brain Activation in Response to Low-Calorie Food Pictures: An Explorative Analysis of a Randomized Trial With Dapagliflozin and Exenatide.","van Ruiten CC","2022","include_nma",null,"secondary_report","P01",null,"mechanistic","high","recheck","opus-5.5-recheck05","R5: fMRI analysis of DECREASE RCT; results report exenatide vs placebo weight and HbA1c changes and a nausea discontinuation",2],["R0010518","Impact of delaying treatment intensification with a glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes uncontrolled on basal insulin: A longitudinal study of a US administrative claims database.","Tong L","2018","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck02","R8: claims cohort early, delayed or no GLP-1 RA intensification on basal insulin; HbA1c, hypoglycemia and costs only; retinopathy baseline",2],["R0010955","Prediction of the Effects of Liraglutide on Kidney and Cardiovascular Outcomes Based on Short-Term Changes in Multiple Risk Markers.","Tye SC","2022","include_nma",null,"secondary_report","P01",null,null,"high","recheck","opus-5.5-recheck02","R4: LEADER secondary analysis reports liraglutide vs placebo HbA1c, weight and observed outcome RRR alongside prediction score",2],["R0011518","Switching from Insulin Degludec plus Dipeptidyl Peptidase-4 Inhibitor to Insulin Degludec/Liraglutide Improves Glycemic Variability in Patients with Type 2 Diabetes: A Preliminary Prospective Observation Study.","Oe Y","2022","inventory_only","N1","primary_report",null,null,null,"high","recheck","opus-5.5-recheck02","R3: protocol switched consenting participants from degludec plus DPP-4i to IDegLira with before after CGM; interventional, no concurrent comparator",2],["R0014439","SGLT2 inhibitor treatment is not associated with an increased risk of osteoporotic fractures when compared to GLP-1 receptor agonists: A nationwide cohort study.","Al-Mashhadi ZK","2022","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck09","R7: matched registry cohort SGLT2i versus GLP-1 RA on osteoporotic fractures; pancreatitis and retinopathy appear only as baseline",2],["R0016991","Weight-Lowering Drugs and Natural Female Fertility-A Systematic Review and Meta-Analysis.","Alnaimi SJ","2026","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck02","R1: registered review searching five sources with PICOS criteria; structured synthesis includes semaglutide plus metformin vs metformin pregnancy RR",2],["R0008684","A Small-Molecule Oral Agonist of the Human Glucagon-like Peptide-1 Receptor.","Griffith DA","2022","inventory_only","N2","other",null,null,null,"high","recheck","opus-5.5-recheck04","R5: mainly preclinical discovery of danuglipron; human part reports only dose proportional PK exposure in healthy volunteers, no review outcome shown",2],["R0010360","Semaglutide and non-arteritic anterior ischaemic optic neuropathy: Review and interpretation of reported association.","Amini A","2025","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck04","R1: searched PubMed, Cochrane, Google Scholar with explicit inclusion rule; structured study by study appraisal of semaglutide NAION cohorts and trial meta-analysis",2],["R0007069","Do relationships between ambient temperature and serious adverse health outcomes vary among users of different antidiabetes drugs? A retrospective cohort study of US Medicaid beneficiaries with type 2 diabetes.","Leonard CE","2024","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck08","Medicaid cohort of temperature and hypoglycemia, ketoacidosis, cardiac arrest compared across drug class subcohorts including GLP-1 RA; no listed harm",2],["R0008888","Semaglutide 25 mg Oral Versus Semaglutide 2.4 mg Injectable: An Indirect Treatment Comparison of Weight Loss Outcomes.","Plotkin M","2026","inventory_only","N6","secondary_report","P02",null,null,"high","recheck","opus-5.5-recheck08","R4: Bucher indirect comparison of oral semaglutide in OASIS 4 with injectable semaglutide in STEP 1; no shared randomized comparison",2],["R0006860","Usefulness of Once-Weekly GLP-1 Receptor Agonist Semaglutide on Glycemic Control in Subjects with Type 2 Diabetes Mellitus: Switching from the Same Class Dulaglutide in a Retrospective Observation Study.","Kimura T","2024","inventory_only","N6","primary_report","P01",null,null,"high","recheck","opus-5.5-recheck07","retrospective switch from dulaglutide to semaglutide vs matched continuation; HbA1c, BMI, lipids; retinopathy and malignancy only baseline or exclusion",2],["R0007954","Effects of acute GLP-1 analogue infusion on the glycemic and neurohormonal responses to meal test in non- hypoglycemic subjects after gastric bypass.","Almby KE","2025","include_nma",null,"primary_report","P99",null,"mechanistic; crossover","high","recheck","opus-5.5-recheck07","R5: randomized crossover exenatide vs saline infusion after gastric bypass in nondiabetic adults; reports glucose nadir below 3.0 mmol/L by arm",2],["R0009623","Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors for new-onset gastric cancer and gastric diseases in patients with type 2 diabetes mellitus: a population-based cohort study.","Chou OHI","2024","inventory_only","N6","primary_report","P01",null,null,"high","recheck","opus-5.5-recheck07","R7: Hong Kong new user cohorts SGLT2i, DPP4i and GLP-1 RA; gastric cancer, ulcer, gastritis, GERD; gastric cancer is a single site cancer",2],["R0012856","Surgical Outcomes in Patients with Preoperative GLP-1 Therapy: A Retrospective Analysis.","Poljo A","2025","include_harms",null,"primary_report",null,"O29; O37B",null,"high","recheck","opus-5.5-recheck07","R7: perioperative cohort of preoperative GLP-1 RA vs none before bariatric surgery; complications table reports pancreatitis and intestinal obstruction by group",2],["R0010106","Exploring the Evidence for Personalized Pharmacotherapy in Type 2 Diabetes-A Systematic Review.","Altabas V","2025","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck10","R1: PROSPERO registered review, three named databases, eligibility criteria, tabulated synthesis including six GLP-1 RA interventional studies",2],["R0010463","Efficacy and safety of novel formulation of semaglutide injection: A multicentre, randomized, comparative, active controlled, phase 3 study in comparison with reference biologic in Indian patients with type 2 diabetes mellitus.","Sharma PK","2026","inventory_only","N3","primary_report",null,null,null,"high","recheck","opus-5.5-recheck10","R6: randomized test semaglutide product versus reference Ozempic at the same doses and route; same molecule, node unchanged",2],["R0010953","Cardiac resynchronization therapy with a defibrillator (CRTd) in failing heart patients with type 2 diabetes mellitus and treated by glucagon-like peptide 1 receptor agonists (GLP-1 RA) therapy vs. conventional hypoglycemic drugs: arrhythmic burden, hospitalizations for heart failure, and CRTd responders rate.","Sardu C","2018","include_nma",null,"primary_report","P01; P07B",null,null,"low","recheck","opus-5.5-recheck10","R9: labeled observational yet methods describe computer generated random allocation to GLP-1 RA versus conventional drugs; reports HHF and mortality",2],["R0012425","Maximizing Metabolic Synergy: A Review of Dual Incretin Therapy as a Step-Up Strategy Following Glucagon-Like Peptide-1 (GLP-1) Monotherapy Failure or Optimization.","Ansari Lari S","2026","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck10","R1: PubMed, Embase and Google Scholar search, stated inclusion criteria for RCTs and switching cohorts, structured synthesis of tirzepatide versus GLP-1 RA trials",2],["R0008409","PEGylated exenatide injection (PB-119) improves beta-cell function and insulin resistance in treatment-naïve type 2 diabetes mellitus patients.","Liu X","2023","include_nma",null,"secondary_report","P01",null,"mechanistic","high","recheck","opus-5.5-recheck03","R5: randomized PB-119 25 and 50 ug vs exenatide trial reports HbA1c between groups alongside beta cell model indices",2],["R0007915","Weight Regain Trajectories After Discontinuation of Semaglutide or Tirzepatide: A Reconstructed Aggregate-Data Bayesian Longitudinal Meta-Analysis.","Kow CS","2026","include_nma",null,"pooled_analysis","P01; P02; P02W; P06",null,null,"high","recheck","opus-5.5-recheck03","R4: re-analysis of six trials from an earlier review without own search; primary pools single arms but sensitivity keeps randomized contrasts; alternative N1",2],["R0008558","Exploring a Synergistic Approach: Dual GLP-1 Agonist Combined with Degludec Basal Insulin for Early Type 1 Diabetes Treatment and its Impact on Albumin-Insulin Producing Cells Expression.","Ahmed A","2024","inventory_only","N9","ancillary",null,null,null,"high","recheck","opus-5.5-recheck03","Editorial commentary on the Dandona retrospective semaglutide case series in early type 1 diabetes, an in scope inventory study",2],["R0009009","Comparative cardiovascular and renal outcomes of Liraglutide versus Dulaglutide in Asian type 2 diabetes patients.","Dai JW","2024","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck03","R7: new user cohort liraglutide vs dulaglutide reports CV and renal composites only; retinopathy only a baseline characteristic",2],["R0010102","Second-Line Pharmaceutical Treatments for Patients with Type 2 Diabetes.","Vashisht R","2023","include_harms",null,"primary_report",null,"O121",null,"low","recheck","opus-5.5-recheck01","R7: new user cohort GLP-1 RA versus sulfonylurea; kidney failure reported separately from CKD but acute definition and 28 outcome list only in supplement; alternative N6",2],["R0006605","Cardiovascular outcomes with tirzepatide versus semaglutide in type 2 diabetes.","Al-Nusair M","2026","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck01","whole PDF read; matched cohort tirzepatide versus semaglutide with cardiovascular composite, mortality and atrial fibrillation; thyroid cancer only an exclusion",2],["R0010130","Tirzepatide in Metabolically Dysfunctional-Associated Steatohepatitis (MASH): A Bibliometric and Evidence-Based Review.","Pantea I","2026","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck01","R1: Web of Science search with stated inclusion criteria, dual screening and tabulated synthesis of tirzepatide MASH trials",2],["R0010496","Weight reduction and treatment adherence with tirzepatide using the Individualized Virtual Integrative Medicine (IVIM) protocol.","Duncan J","2026","inventory_only","N5","primary_report","P02",null,null,"high","recheck","opus-5.5-recheck01","R3: retrospective observational cohort of tirzepatide users in a telehealth program, no comparison group",2],["R0016723","Long-Term Assessment of Weight Loss Medications in a Veteran Population.","Rodriguez AD","2024","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck06","retrospective veteran cohort liraglutide vs phentermine-topiramate and others; weight outcomes only; gallbladder disease mentioned only in introduction",2],["R0014672","Lower Risk of Cardiovascular Events in Patients With Clinical Atherosclerotic Cardiovascular Disease Who Initiated Semaglutide 2.4 mg in the Real-World: Results From the SCORE-Clinical ASCVD Study.","Nanna MG","2026","include_harms",null,"primary_report",null,"O121",null,"high","recheck","opus-5.5-recheck06","matched cohort semaglutide 2.4 mg initiators vs nonusers with ASCVD; AKI reported as a separate outcome with its own hazard ratio",2],["R0017361","The GLP-1 receptor agonist lixisenatide reduces postprandial glucose in patients with diabetes secondary to total pancreatectomy: a randomised, placebo-controlled, double-blinded crossover trial.","Juel CTB","2020","inventory_only","N2","primary_report","P99",null,"crossover","high","recheck","opus-5.5-recheck06","R5: single dose lixisenatide vs placebo crossover after pancreatectomy; glucose, glucagon and gastric emptying only; no adverse events, nausea or review outcome reported",2],["R0017595","Comparing Efficacy of Chiglitazar, Pioglitazone, and Semaglutide in Type 2 Diabetes: A Retrospective Study.","Li W","2025","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck06","retrospective 4 week comparison of chiglitazar, semaglutide, pioglitazone; metabolic outcomes; retinopathy only a baseline subgroup variable",2],["R0011920","High serum Fetuin-B levels are associated with the presence of metabolic syndrome in women: a case-controlled study and interventional studies","Xue S","2020","inventory_only","N1","primary_report","P99",null,null,"high","recheck","opus-5.5-recheck09","R3: case control fetuin-B study with an uncontrolled 6 month liraglutide intervention in 24 women, no concurrent control arm",2],["R0009576","Glucose-Lowering Agents and the Risk of Hypoglycemia: a Real-world Study.","Lyu B","2023","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck09","R7: new user EHR cohort of GLP-1 RA and other classes versus sulfonylureas on hypoglycemia only; AKI appears only as covariate",2],["R0009660","Examining the Omission of Dietary Quality Data in Glucagon-Like Peptide 1 Clinical Trials: A Scoping Review.","Babazadeh D","2025","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck09","R1: PRISMA-ScR scoping review with PubMed search, criteria and charted synthesis of 129 liraglutide, semaglutide, tirzepatide RCTs on diet outcomes",2],["R0010702","Differential Cardiovascular and Renal Benefits of SGLT2 Inhibitors and GLP1 Receptor Agonists in Patients With Type 2 Diabetes Mellitus","Kim CH","2021","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck09","R7: matched cohort SGLT2i versus GLP-1 RA versus others; AKI admissions only inside a renal composite",2],["R0011535","Assessment of Thyroid Carcinogenic Risk and Safety Profile of GLP1-RA Semaglutide (Ozempic) Therapy for Diabetes Mellitus and Obesity: A Systematic Literature Review.","Feier CVI","2024","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck08","R1: PubMed, Scopus, Embase search with stated eligibility; tabulated synthesis of semaglutide RCTs on thyroid cancer and adverse events",2],["R0007784","Change in circulating irisin level and its association with lipid metabolism after exenatide treatment in patients with type 2 diabetes mellitus.","Gao Y","2026","inventory_only","N3","secondary_report","P01",null,null,"high","recheck","opus-5.5-recheck08","R6: post hoc irisin analysis of RCT comparing generic with branded exenatide, same molecule and dose; arms pooled",2],["R0011895","Real-world utilization of pharmacotherapy with new evidence-based cardiovascular indications in an academic preventive cardiology practice.","Warden BA","2021","inventory_only","N5","primary_report",null,null,null,"high","recheck","opus-5.5-recheck08","R3: descriptive retrospective clinic review of new prescriptions for four drug classes incl GLP-1 RA; access, tolerability, events; no comparative analysis",2],["R0012413","Comparative cardiovascular effects of GLP-1 agonists using real-world data.","Wallia A","2023","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck08","new user claims cohort exenatide ER or IR versus liraglutide; cardiovascular events and components only; retinopathy only at baseline",2],["R0010060","Use of real-world evidence data to evaluate the comparative effectiveness of second-line type 2 diabetes medications on chronic kidney disease.","Deng Y","2022","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck02","EHR cohort comparing second line diabetes drug classes incl GLP-1 RA on incident CKD, CKD hospitalization and eGFR; no acute kidney injury",2],["R0013843","Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial.","Tonneijck L","2016","include_nma",null,"primary_report","P01",null,"mechanistic","high","recheck","opus-5.5-recheck02","R5: acute randomized IV exenatide vs placebo renal physiology trial reports nausea and adverse events by arm plus blood pressure",2],["R0019976","Impact of microvascular disease on cardiovascular outcomes in type 2 diabetes: Results from the LEADER and SUSTAIN 6 clinical trials.","Verma S","2020","include_nma",null,"secondary_report","P01",null,null,"high","recheck","opus-5.5-recheck02","R4: post hoc LEADER and SUSTAIN 6 analysis reports liraglutide and semaglutide vs placebo MACE effects within microvascular subgroups; not baseline only",2],["R0022184","Real-world evaluation of weekly subcutaneous treatment with semaglutide in a cohort of Italian diabetic patients.","Marzullo P","2022","inventory_only","N5","primary_report",null,null,null,"high","recheck","opus-5.5-recheck02","R3: retrospective single center observational cohort of once weekly semaglutide users over 12 months; no comparison group",2],["R0010148","Combination therapy with exenatide decreases the dapagliflozin-induced changes in brain responses to anticipation and consumption of palatable food in patients with type 2 diabetes: A randomized controlled trial.","van Ruiten CC","2022","include_nma",null,"secondary_report","P01",null,"mechanistic","high","recheck","opus-5.5-recheck05","R5: fMRI report of DECREASE RCT; results give exenatide vs placebo weight and HbA1c differences at 16 weeks",2],["R0007312","Mediterranean diet adherence and tirzepatide: real-world evidence on adiposity indices and insulin resistance beyond weight loss.","Paternò V","2025","inventory_only","N5","primary_report",null,null,null,"high","recheck","opus-5.5-recheck05","R3: prospective real-world observational cohort of tirzepatide per clinical practice with diet advice; no comparison group",2],["R0008781","A comparison of virtual and in person delivery of a full meal replacement program for obesity.","Skeldon M","2024","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck05","R8: meal replacement cohort compares weight loss by baseline GLP-1 RA use among predictors; no listed harm reported",2],["R0009181","Early Use of Liraglutide for the Treatment of Acute COVID-19 Infection: An Open-Label Single-Center Phase II Safety Study with Biomarker Profiling.","Ferreira EVM","2025","inventory_only","N1","primary_report",null,null,null,"high","recheck","opus-5.5-recheck05","R3: interventional open label phase II trial giving liraglutide to all 13 COVID-19 inpatients; no concurrent control group",2],["R0006939","Safety and effectiveness of tirzepatide during Ramadan fasting: Real-world evidence from patients with type 2 diabetes in Bangladesh.","Rahman MH","2026","inventory_only","N5","primary_report","P01",null,null,"high","recheck","opus-5.5-recheck07","R3: prospective real world single arm cohort of tirzepatide during Ramadan; pre and post Ramadan changes only, no comparison group",2],["R0007779","Myocardial deformation links combined liraglutide-empagliflozin therapy with improved cardiovascular and economic outcomes in type 2 diabetes: a 6-year study.","Thymis J","2026","deferred","D2","secondary_report","P01",null,null,"low","recheck","opus-5.5-recheck07","R9: 6 year follow up of liraglutide, empagliflozin, combination and insulin groups formed by randomization or propensity matching; no allocation procedure described",2],["R0008654","Differential cardiovascular and renal benefits of SGLT2 inhibitors and GLP1 receptor agonists in patients with type 2 diabetes mellitus.","Kim CH","2022","inventory_only","N6","primary_report","P01",null,null,"high","recheck","opus-5.5-recheck07","R7: SGLT2i vs GLP-1 RA vs control cohort; acute kidney injury admissions only inside a renal event composite with CKD progression",2],["R0018067","Comparative Efficacy, Safety, and Cost-Utility of DPP-4 Inhibitors and Metformin Combination Therapy in Type 2 Diabetes: A Systematic Review of Real-World Clinical and Economic Outcomes.","Jimoh AO","2026","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck06","R1: PubMed, Scopus, Cochrane and others searched with stated criteria; structured synthesis includes DPP-4i plus metformin vs GLP-1 RA plus metformin comparisons",2],["R0020399","Effects of liraglutide on hemodynamic parameters in patients with heart failure.","Zhang JY","2017","include_nma",null,"primary_report","P07B",null,"mechanistic","high","recheck","opus-5.5-recheck06","R5: 7 day randomized liraglutide vs placebo in HF with EF below 50 percent; hypoglycemia, nausea, HF hospitalization and death reported by arm",2],["R0021170","Pulse Oximetry Desaturation in the Postoperative Recovery Room in Patients with Obesity and Diabetes Using GLP-1 Agonists: A Retrospective Observational Study.","Skidmore KL","2025","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck06","GLP-1 RA users only, long vs short preoperative hold; oxygen desaturation and glucose, no pulmonary aspiration or gastric content outcome",2],["R0021580","Fat-Secreted Ceramides Regulate Vascular Redox State and Influence Outcomes in Patients With Cardiovascular Disease.","Akawi N","2021","include_nma",null,"secondary_report","P02",null,"mechanistic","high","recheck","opus-5.5-recheck06","R4: includes 52 week randomized liraglutide vs no treatment after diet run in; ceramides and BMI reported by arm",2],["R0008831","Three-step matching algorithm to enhance between-group comparability and minimize confounding in comparative effectiveness studies.","Yang CY","2022","inventory_only","N6","other",null,null,null,"high","recheck","opus-5.5-recheck04","matching methods paper with applied Taiwan cohort GLP-1 RA vs sulfonylurea on cardiovascular events and mortality; no listed harm; alternative E3 methods paper",2],["R0009916","Effects of an Intervention to Improve Evidence-Based Care for People With Diabetes and Cardiovascular Disease Across Sex, Race, and Ethnicity Subgroups: Insights From the COORDINATE-Diabetes Trial.","Tannu M","2024","exclude","E2","secondary_report",null,null,"cluster","high","recheck","opus-5.5-recheck08","R8: subgroup analysis of cluster RCT of clinic care coordination; outcome is prescribing of evidence based therapies, no GLP-1 regimen contrast",2],["R0012437","Association Between Preoperative GLP-1 Receptor Analog Use and Postoperative Complications and Mortality Following Lumbar Fusion Surgery.","Kesaria AA","2026","include_harms",null,"primary_report",null,"O121",null,"high","recheck","opus-5.5-recheck04","R7: TriNetX perioperative cohort preoperative GLP-1 RA users vs nonusers in lumbar fusion reports acute kidney failure N17 separately at one year",2],["R0012655","Sodium-glucose cotransporter 2 inhibitors and risk of nephrolithiasis.","Kristensen KB","2021","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck04","Danish active comparator new user cohort SGLT2i vs GLP-1 RA; nephrolithiasis incident and recurrent only, no listed harm",2],["R0018810","Initiation of iGlarLixi Versus Basal-Bolus Insulin in Adults With Type 2 Diabetes Advancing From Basal Insulin Therapy: The SoliComplex Real-World Study.","Pantalone KM","2023","inventory_only","N6","primary_report","P01",null,null,"high","recheck","opus-5.5-recheck04","R8: claims cohort iGlarLixi vs basal bolus insulin compares persistence plus hypoglycemia and A1C; no listed harm outcome",2],["R0013081","Efficacy and Safety of a Biosimilar Liraglutide (Melitide®) Versus the Reference Liraglutide (Victoza®) in People with Type 2 Diabetes Mellitus: A Randomized, Double-Blind, Noninferiority Clinical Trial.","Esteghamati A","2023","inventory_only","N3","primary_report","P01",null,null,"high","recheck","opus-5.5-recheck08","R6: RCT of biosimilar liraglutide versus reference liraglutide, both 1.8 mg daily; same molecule, dose and route",2],["R0013807","SAT-405 TSH testing patterns for patients with type 2 diabetes and hypothyroidism after GLP-1 RA initiation in a target trial setting",null,"2025","exclude","E2","conference_abstract",null,null,"abstract_only","high","recheck","opus-5.5-recheck08","R8: Medicare cohort of GLP-1 RA versus SGLT2i initiators on levothyroxine; only TSH testing frequency compared, no clinical outcome",2],["R0008155","Effects of GLP-1 agonists and SGLT2 inhibitors during pregnancy and lactation on offspring outcomes: a systematic review of the evidence.","Muller DRP","2023","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck01","R1: PROSPERO registered review searching Medline, Embase, Cochrane with criteria; tabulated synthesis includes human GLP-1 RA pregnancy exposure data",2],["R0008531","Efficacy, safety, and patient satisfaction with oral semaglutide: first single-centre clinical experience.","Janić M","2023","inventory_only","N1","primary_report","P01",null,null,"high","recheck","opus-5.5-recheck01","R3: prospective open label interventional single arm study of oral semaglutide in 20 patients, no comparison group",2],["R0011710","Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial.","Clegg LE","2019","inventory_only","N6","secondary_report","P01",null,null,"high","recheck","opus-5.5-recheck01","R4: post hoc EXSCEL comparison of nonrandomized SGLT2i drop in users with matched arms; randomized contrast not kept; MACE, mortality, eGFR only",2],["R0009093","GLP-1 RA Use and Major Adverse Cardiovascular Events in Patients With Monoclonal Gammopathy of Undetermined Significance.","Chi KY","2025","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck03","R7: GLP-1 RA users vs nonusers with MGUS; AKI reported only combined with ESKD progression, so no eligible harm outcome",2],["R0009977","Comparative cardiovascular safety of GLP-1 receptor agonists versus other glucose-lowering agents in real-world patients with type 2 diabetes: a nationwide population-based cohort study.","Yang CT","2020","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck10","Taiwan prevalent new user cohort GLP-1 RA versus DPP-4i, SU, insulin; cardiovascular composites and mortality only",2],["R0010763","Non-Insulin Antidiabetic Agents and Lung Cancer Risk in Drug-Naive Patients with Type 2 Diabetes Mellitus: A Nationwide Retrospective Cohort Study.","Tabernacki T","2024","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck10","R7: TriNetX new user cohort reports only lung cancer, a single site other than thyroid or pancreas, so not O39",2],["R0012972","Effectiveness of a hybrid approach in integrating GLP-1 agonists and lifestyle guidance for obesity and pre-diabetes management: RWE retrospective study.","Zakaria H","2024","inventory_only","N5","primary_report",null,null,null,"high","recheck","opus-5.5-recheck10","R3: retrospective observational records review of GLP-1 RA users in a lifestyle program; no comparison group",2],["R0014530","A feasibility study of the combination of intranasal insulin with dulaglutide for cognition in older adults with metabolic syndrome at high dementia risk - Study rationale and design.","Davidy T","2023","inventory_only","N8","protocol_or_design",null,null,"retracted","high","recheck","opus-5.5-recheck10","R2: retracted rationale and design paper of pilot RCT of intranasal insulin with dulaglutide; no results",2],["R0011096","Efficacy and Safety of Dulaglutide Biosimilar LY05008 Versus the Reference Product Dulaglutide (Trulicity) in Chinese Adults With Type 2 Diabetes Mellitus: A Randomized, Open-Label, Active Comparator Study.","Liu L","2025","inventory_only","N3","primary_report","P01",null,null,"high","recheck","opus-5.5-recheck03","R6: randomized trial of biosimilar LY05008 vs reference dulaglutide at same 1.5 mg weekly dose and route",2],["R0013166","Real-world glycemic outcomes in patients with type 2 diabetes initiating exenatide once weekly and liraglutide once daily: a retrospective cohort study.","Saunders WB","2016","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck03","R7: EMR cohort exenatide weekly vs liraglutide daily reports HbA1c change and secondary clinical measures only; retinopathy only at baseline",2],["R0013638","Consistent findings in glycaemic control, body weight and hypoglycaemia with iGlarLixi (insulin glargine/lixisenatide titratable fixed-ratio combination) vs insulin glargine across baseline HbA1c, BMI and diabetes duration categories in the LixiLan-L trial.","Wysham C","2017","include_nma",null,"secondary_report","P01",null,null,"high","recheck","opus-5.5-recheck03","R2 not applicable: LixiLan-L subgroup analysis reports between arm HbA1c, weight and hypoglycemia for iGlarLixi vs glargine",2],["R0007382","Achieving Normoglycemia With Tirzepatide: Analysis of SURPASS 1-4 Trials.","Rosenstock J","2023","inventory_only","N1","secondary_report","P01",null,null,"high","recheck","opus-5.5-recheck07","R4: pooled SURPASS 1 to 4 analysis restricted to tirzepatide treated participants grouped by HbA1c attained; no randomized contrast analyzed",2],["R0009730","Effect of once-weekly exenatide on estimated glomerular filtration rate slope depends on baseline renal risk: A post hoc analysis of the EXSCEL trial.","van der Aart-van der Beek AB","2020","include_nma",null,"secondary_report","P01",null,null,"high","recheck","opus-5.5-recheck07","R2 not applicable, R4: post hoc EXSCEL analysis keeps exenatide vs placebo contrast on eGFR slope and UACR; between arm outcomes reported",2],["R0011487","Reduction of Hepatic Fat Content by Dulaglutide for the Treatment of Diabetes Mellitus: A Two-Centre Open, Single-Arm Trial.","Liu C","2025","inventory_only","N1","primary_report","P01; P09",null,null,"high","recheck","opus-5.5-recheck07","R3: prospective two centre open single arm trial of dulaglutide in T2D with NAFLD, before and after comparison only",2],["R0012761","Comparative effectiveness of glucagon-like peptide-1 agonists, dipeptidyl peptidase-4 inhibitors, and sulfonylureas on the risk of dementia in older individuals with type 2 diabetes in Sweden: an emulated trial study.","Tang B","2024","inventory_only","N6","primary_report","P01",null,null,"high","recheck","opus-5.5-recheck07","R7: Swedish emulated trial of GLP-1 RA vs DPP-4i vs SU on dementia; GI reactions as positive control; cancer only baseline",2],["R0009567","Non-Hormonal Treatment Options for Regulation of Menstrual Cycle in Adolescents with PCOS.","Reiser E","2022","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck05","R1: five named databases, PRISMA flow with dual screening, criteria limited to adolescent PCOS non-hormonal drugs; tabulated synthesis including GLP-1 RA studies",2],["R0011094","Impact of Glucose-Lowering Medications on Cardiovascular and Metabolic Risk in Type 2 Diabetes.","Patti AM","2020","exclude","E3","other",null,null,null,"high","recheck","opus-5.5-recheck05","R1: narrative overview of CVOTs; names databases but states no eligibility criteria or selection process",2],["R0011277","The development of an oral GLP-1 receptor agonist for the management of type 2 diabetes: evidence to date.","Antza C","2019","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck05","R1: Medline and Cochrane search for semaglutide T2D studies with selection flow; tabulated semaglutide vs control HbA1c and weight synthesis",2],["R0012563","Association between GLP-1-based therapy and small-bowel transit time during capsule endoscopy: a prospective, multicentre, observational study.","Baker FA","2026","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck05","R7: capsule endoscopy cohort GLP-1 exposed vs not; outcomes transit times, completion, preparation; no retained gastric content or aspiration",2],["R0014143","Efficacy and safety of semaglutide injection in Indian patients with type 2 diabetes mellitus inadequately controlled on metformin: a phase 3, randomized, active-controlled trial (SIZE-DM study).","Kapoor N","2026","inventory_only","N3","primary_report","P01",null,null,"high","recheck","opus-5.5-recheck08","R6: RCT of generic versus innovator semaglutide with same escalation to 2 mg weekly; same molecule, dose and route",2],["R0020475","Effect of semaglutide on major adverse cardiovascular events by baseline kidney parameters in participants with type 2 diabetes and at high risk of cardiovascular disease: SUSTAIN 6 and PIONEER 6 post hoc pooled analysis.","Rossing P","2023","include_nma",null,"pooled_analysis","P01; P08A",null,null,"high","recheck","opus-5.5-recheck08","R4: post hoc pooled SUSTAIN 6 and PIONEER 6 keeping randomized semaglutide versus placebo contrast on MACE, HbA1c, weight by kidney subgroup",2],["R0021126","Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: population based cohort study.","Abrahami D","2018","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck06","R7: CPRD cohort of GLP-1 RA vs other second line drugs on cholangiocarcinoma only; cholangiocarcinoma is not O28 and single site cancer",2],["R0021678","Comparative effectiveness of second line glucose lowering drug treatments using real world data: emulation of a target trial.","Deng Y","2023","include_harms",null,"primary_report",null,"O28; O29; O32B; O33; O38; O39",null,"high","recheck","opus-5.5-recheck06","new user target trial emulation liraglutide vs glimepiride, sitagliptin, glargine, canagliflozin; reports retinopathy, pancreatitis, thyroid, pancreatic, any cancer, cholecystitis control",2],["R0022693","Liraglutide pharmacokinetics and exposure-response in adolescents with obesity.","Carlsson Petri KC","2021","include_nma",null,"pooled_analysis","P03; P02; P01",null,"mechanistic","high","recheck","opus-5.5-recheck06","R4: exposure response pooling liraglutide vs placebo trials incl. adolescent RCT; placebo E0 and BMI SDS, weight by exposure vs placebo reported",2],["R0023480","Effects of SGLT-2 inhibitors on clinical and biological hyperandrogenism and menstruation irregularities in patients with polycystic ovary syndrome: A systematic review of randomized trials.","Mrabet HE","2024","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck06","R1: PubMed, ScienceDirect, Cochrane searched with stated RCT criteria; synthesis includes SGLT2i vs exenatide comparison as GLP-1 RA comparator",2],["R0010687","Cardiovascular safety trials of incretin-based drugs: What do they mean?","Yabe D","2017","exclude","E3","other",null,null,null,"high","recheck","opus-5.5-recheck09","invited commentary discussing several DPP-4 inhibitor and GLP-1 RA outcome trials in general; opinion piece, not tied to one study",2],["R0018314","Liraglutide and the management of overweight and obesity in people with severe mental illness: qualitative sub-study.","Barnard-Kelly K","2022","inventory_only","N2","secondary_report","P15",null,null,"high","recheck","opus-5.5-recheck09","R5: qualitative interview substudy of the liraglutide versus placebo SMI trial; interview themes only, no between arm review outcome",2],["R0009342","Improved Glycaemic and Weight Management Are Associated with Better Quality of Life in People with Type 2 Diabetes Treated with Tirzepatide.","Boye KS","2023","inventory_only","N1","secondary_report","P01",null,null,"high","recheck","opus-5.5-recheck07","R4: pooled SURPASS 1 to 5 PRO analysis limited to tirzepatide assigned participants grouped by HbA1c and weight targets; no randomized contrast used",2],["R0013444","Fixed versus flexible combination of GLP-1 receptor agonists with basal insulin in type 2 diabetes: A retrospective multicentre comparative effectiveness study.","Morieri ML","2019","inventory_only","N6","primary_report","P01",null,null,"high","recheck","opus-5.5-recheck07","GLP-1REWIN retrospective fixed vs flexible basal insulin plus GLP-1 RA; HbA1c, weight, FPG, SBP; retinopathy and DME only baseline characteristics",2],["R0014919","Comparison of Placebo Effect between Asian and Caucasian Type 2 Diabetic Patients: A Meta-Analysis.","Guo W","2018","exclude","E2","other",null,null,null,"high","recheck","opus-5.5-recheck07","R1: registered meta-analysis pooling only placebo arm HbA1c changes of antidiabetic RCTs by ethnicity; no GLP-1 RA contrast synthesized",2],["R0010667","SGLT2 inhibitors or GLP-1 receptor agonists as second-line therapy in type 2 diabetes: patient selection and perspectives.","Gurgle HE","2016","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck04","R1: Medline search with stated inclusion criteria, flow diagrams and tabulated synthesis of GLP-1 RA and SGLT2i placebo controlled trials",2],["R0015412","Comparing a daily versus weekly titration algorithm in people with type 2 diabetes switching from basal insulin to iGlarLixi in the LixiLan ONE CAN randomized trial.","Hramiak I","2022","inventory_only","N3","primary_report","P01",null,null,"high","recheck","opus-5.5-recheck04","RCT randomizes daily vs weekly self titration of iGlarLixi to the same glucose target; drug and regimen node unchanged; alternative include_nma dose contrast",2],["R0020384","Real-World Hemoglobin A1c Changes, Prescribing Provider Types, and Medication Dose Among Patients with Type 2 Diabetes Mellitus Initiating Treatment with Oral Semaglutide.","Frazer M","2023","inventory_only","N5","primary_report","P01",null,null,"high","recheck","opus-5.5-recheck04","R3: claims cohort of oral semaglutide initiators describing dose, prescriber and HbA1c change; uncontrolled observational users, no comparator",2],["R0013958","Wegovy (semaglutide): a new weight loss drug for chronic weight management.","Singh G","2022","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck10","R1: NCBI (PubMed) search with stated terms, selection of original pre-approval semaglutide RCTs, tabulated efficacy and safety synthesis; self-labeled literature review",2],["R0010236","Real-world clinical outcomes following treatment intensification with GLP-1 RA, OADs or insulin in patients with type 2 diabetes on two oral agents (PATHWAY 2-OADs).","Desouza C","2020","inventory_only","N6","primary_report","P01",null,null,"high","recheck","opus-5.5-recheck01","matched EHR cohort of intensification with GLP-1 RA versus OADs or insulin; HbA1c and weight only; retinopathy and renal terms are baseline",2],["R0010378","Transition from Continuous Subcutaneous Insulin Infusion to IDeg-Based Regimens in Hospitalized T2DM Patients: A Single-Center Retrospective Analysis.","Dong R","2026","inventory_only","N6","primary_report","P01",null,null,"high","recheck","opus-5.5-recheck01","retrospective cohort of IDeg, IDegAsp and IDegLira after insulin pump; CGM and satisfaction outcomes; retinopathy only at baseline",2],["R0010827","Real-world medication persistence and outcomes associated with basal insulin and glucagon-like peptide 1 receptor agonist free-dose combination therapy in patients with type 2 diabetes in the US.","Lin J","2017","inventory_only","N6","primary_report","P01",null,null,"high","recheck","opus-5.5-recheck01","R8: claims cohort compares glycemia, hypoglycemia and costs between persistent and nonpersistent GLP-1 RA plus basal insulin users; no listed harm",2],["R0011774","Comparative effectiveness of subcutaneous GLP-1 receptor agonists versus SGLT2 inhibitors on metabolic and hepatic outcomes in T2DM with MASLD: a propensity score-matched study.","Toffoli B","2026","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck10","matched cohort GLP-1 RA versus SGLT2i in T2D with MASLD; HbA1c, BMI, transaminases only; retinopathy baseline only",2],["R0011863","Evaluating Cardio-Protective Molecules by Efficacy Based on Weight Reduction and HbA1c Targets.","Salmen T","2025","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck08","retrospective comparison of SGLT2i, GLP-1 RA and metformin users on HbA1c and weight targets; retinopathy only a baseline characteristic",2],["R0012390","Nonalcoholic fatty liver disease as a metabolic disease in humans: A literature review.","Cariou B","2021","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck10","R1: PubMed search with prespecified inclusion criteria, 95 studies categorized and synthesized, treatment section covers GLP-1 RA trials in NAFLD",2],["R0012473","Changes in weight and glycemic control following obesity treatment with semaglutide or tirzepatide by discontinuation status.","Gasoyan H","2025","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck08","EHR cohort of semaglutide or tirzepatide initiators compared by discontinuation status; weight and HbA1c only, no listed harm",2],["R0012948","Semaglutide reduces proteomic organ-specific biological age across randomized clinical trials","Dermit M","2026","include_nma",null,"secondary_report","P02; P07A; P01; P08A",null,null,"high","recheck","opus-5.5-recheck01","R4: full preprint now readable; post hoc proteomic analysis of five placebo controlled semaglutide trials keeps the randomized contrast",2],["R0015769","Relationship Between Oral Semaglutide Tablet Erosion and Pharmacokinetics: A Pharmacoscintigraphic Study.","Baekdal TA","2021","inventory_only","N3","primary_report","P99",null,"crossover","high","recheck","opus-5.5-recheck08","crossover in healthy men of the same 10 mg oral semaglutide dose taken with 50 or 240 mL water; regimen unchanged",2],["R0017837","Lipid level stabilization following combination therapy with IdaGlar and Semaglutide in type 2 diabetes: a retrospective study.","Li F","2025","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck08","retrospective comparison of semaglutide plus insulin degludec aspart versus semaglutide alone; glycemic and lipid outcomes, pancreatic imaging only",2],["R0020889","Daily Glucose Profiles after Switching from Injectable to Oral Semaglutide in Patients with Type 2 Diabetes Mellitus.","Takahara M","2024","inventory_only","N5","primary_report",null,null,null,"high","recheck","opus-5.5-recheck10","R3: prospective observational before and after study of 23 patients switching injectable to oral semaglutide; no comparison group",2],["R0013478","Survodutide for treatment of obesity: Baseline characteristics of participants in a randomized, double-blind, placebo-controlled, phase 3 trial (SYNCHRONIZE™-1).","le Roux CW","2026","inventory_only","N8","protocol_or_design","P02",null,null,"high","recheck","opus-5.5-recheck09","R2: SYNCHRONIZE-1 baseline characteristics paper of survodutide versus placebo, no between arm outcome reported",2],["R0020777","Effectiveness and tolerability of liraglutide for the management of weight regain following sleeve gastrectomy.","Jamal M","2024","inventory_only","N5","other",null,null,null,"high","recheck","opus-5.5-recheck09","R3: retrospective record review of liraglutide for weight regain after sleeve gastrectomy, uncontrolled observational series",2],["R0020373","FDA-Approved Pharmacotherapy for Weight Loss Over the Last Decade.","Idrees Z","2022","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck06","R1: self labeled narrative but PubMed search with stated design, language, adult and date criteria and summary table of obesity drug studies incl. liraglutide, semaglutide",2],["R0019418","Data-driven prioritization of high-risk individuals for weight loss interventions.","Demircan K","2026","include_nma",null,"secondary_report","P02",null,null,"high","recheck","opus-5.5-recheck06","R4: applies OBSCORE to SURMOUNT-1 data; percent weight change and risk scores reported for tirzepatide vs placebo arms by risk quartile",2],["R0025696","Improvement in glycated haemoglobin evaluated by baseline body mass index: a meta-analysis of the liraglutide phase III clinical trial programme.","Montanya E","2016","include_nma",null,"pooled_analysis","P01",null,null,"high","recheck","opus-5.5-recheck06","R4: patient level pooled analysis of seven randomized liraglutide trials; HbA1c change vs baseline BMI by liraglutide and placebo arms; not a baseline paper",2],["R0026396","Medication utilization patterns among type 2 diabetes patients initiating Exenatide BID or insulin glargine: a retrospective database study.","Pawaskar M","2013","exclude","E2","other",null,null,null,"high","recheck","opus-5.5-recheck06","R8: matched claims cohort exenatide vs glargine comparing treatment modification, discontinuation, switching and intensification only; no clinical outcome compared",2],["R0011815","Treatment Options for Patients with Maturity-Onset Diabetes of the Young (MODY): A Systematic Review of Literature: 2026 Update.","Zagaroli L","2026","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck03","R1: PRISMA update with PubMed search and PICOS criteria; structured qualitative synthesis of MODY treatments including GLP-1 RA adjunct studies",2],["R0013908","Safety and efficacy of tirzepatide in transplant recipients: a systematic review and meta-analysis.","Provenzani A","2026","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck03","R1: PROSPERO registered search of PubMed, Embase, Cochrane with criteria; pools single group tirzepatide studies in transplant recipients",2],["R0013948"," Advancing Diabetes Management: A Study of BIOS Health and Continuous Glucose Monitoring for Diabetes Remission","Shaikh A","2023","deferred","D2","primary_report","P01",null,null,"low","recheck","opus-5.5-recheck03","R9: preprint calls itself randomized controlled and randomized observational retrospective; no allocation procedure described, sample sizes inconsistent",2],["R0009175","Propensity-score-matched comparative analyses of simultaneously administered fixed-ratio insulin glargine 100 U and lixisenatide (iGlarLixi) vs sequential administration of insulin glargine and lixisenatide in uncontrolled type 2 diabetes.","Rosenstock J","2018","inventory_only","N6","secondary_report",null,null,null,"high","recheck","opus-5.5-recheck05","R4: propensity matched cross trial comparison of LixiLan iGlarLixi arms vs GetGoal Duo arms; no shared randomized contrast",2],["R0011294","Effectiveness and tolerability of liraglutide as add-on treatment in patients with obesity and high-frequency or chronic migraine: A prospective pilot study.","Braca S","2025","inventory_only","N1","primary_report",null,null,null,"high","recheck","opus-5.5-recheck05","R3: prospective interventional open label single arm pilot of add-on liraglutide in obese refractory migraine; no concurrent comparison",2],["R0012892","Clinical Effectiveness and Safety of Once-Weekly GLP-1 Receptor Agonist Dulaglutide as Add-On to Metformin or Metformin Plus Insulin Secretagogues in Obesity and Type 2 Diabetes.","Mirabelli M","2021","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck05","retrospective dulaglutide cohort with matched liraglutide efficacy comparison; pancreatitis only as a zero discontinuation reason, not compared",2],["R0019038","PIONEER REAL Spain: A multicentre, prospective, real-world study of oral semaglutide use in adults with type 2 diabetes.","Delgado Álvarez E","2025","inventory_only","N5","primary_report",null,null,null,"high","recheck","opus-5.5-recheck05","R3: PIONEER REAL Spain is a non-interventional single arm cohort of oral semaglutide in routine care; no comparison group",2],["R0011523","An indirect comparison of HbA1c treatment effect with albiglutide and exenatide 2.0 mg QW using the Bucher method.","Martin AA","2016","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck07","R1: named EMBASE, MEDLINE, Cochrane search with eligibility and dual screening; anchored Bucher comparison of albiglutide vs exenatide QW via liraglutide",2],["R0013822","Real-World Effectiveness and Treatment Patterns of Tirzepatide in a Large UK Digital Health Cohort.","Rosenior-Patten O","2026","inventory_only","N5","primary_report","P02",null,null,"high","recheck","opus-5.5-recheck07","R3: retrospective UK digital prescribing cohort of tirzepatide initiators; weight change and persistence without comparison group",2],["R0015456","Efficacy and Safety of iGlarLixi, Fixed-Ratio Combination of Insulin Glargine and Lixisenatide, Compared with Basal-Bolus Regimen in Patients with Type 2 Diabetes: Propensity Score Matched Analysis.","Tabák ÁG","2020","inventory_only","N6","secondary_report","P01",null,null,"high","recheck","opus-5.5-recheck07","R4: propensity matched cross trial comparison of iGlarLixi arm from LixiLan-L vs basal bolus arm from GetGoal Duo-2; no shared randomized contrast",2],["R0016698","Long-term preservation of kidney function with SGLT-2 inhibitors versus comparator drugs in people with type 2 diabetes and chronic kidney disease.","Fadini GP","2025","inventory_only","N6","secondary_report","P08A",null,null,"high","recheck","opus-5.5-recheck07","R7: DARWIN-Renal SGLT2i vs comparators incl GLP-1 RA in T2D with CKD; eGFR, albuminuria, 40 percent eGFR decline; retinopathy only baseline",2],["R0012893","Real-World Analysis of Short-Term Effectiveness of Oral Semaglutide: Impact on Glycometabolic Control and Cardiovascular Risk.","Palazzi S","2025","inventory_only","N5","primary_report",null,null,null,"high","recheck","opus-5.5-recheck08","R3: prospective observational single arm real world cohort of oral semaglutide initiators; prescribing by physician discretion, no control group",2],["R0016256","Effects of Hypolipidemic Drugs on Psoriasis.","Matwiejuk M","2023","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck08","R1: PubMed and Google Scholar search, stated exclusions, dual screening; tabulated summaries of liraglutide and exenatide studies in psoriasis",2],["R0017282","Liraglutide Reduces Carotid Intima-Media Thickness by Reducing Small Dense Low-Density Lipoproteins in a Real-World Setting of Patients with Type 2 Diabetes: A Novel Anti-Atherogenic Effect.","Nikolic D","2021","inventory_only","N1","primary_report",null,null,null,"high","recheck","opus-5.5-recheck08","R3: registered prospective study adding liraglutide 1.2 mg to metformin per protocol in 62 patients; pre post only, no comparator",2],["R0018492","Efficacy of Once-Weekly Semaglutide vs Empagliflozin Added to Metformin in Type 2 Diabetes: Patient-Level Meta-analysis.","Lingvay I","2020","inventory_only","N6","secondary_report","P01",null,null,"high","recheck","opus-5.5-recheck08","R4: unanchored IPD meta-regression comparing semaglutide arms of SUSTAIN trials with empagliflozin arm of PIONEER 2; no shared randomized comparison",2],["R0022382","Acute metabolic effects of exenatide in patients with type 1 diabetes with and without residual insulin to oral and intravenous glucose challenges.","Ghazi T","2014","inventory_only","N2","primary_report","P05",null,"crossover","high","recheck","opus-5.5-recheck06","R5: randomized order single dose exenatide vs none before meal and IV glucose tests in T1D; glucose, insulin secretion, glucagon only; no review outcome reported",2],["R0024087","Clinical Benefits of Therapeutic Interventions Targeting Mitochondria in Parkinson's Disease Patients.","Ciocca M","2024","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck06","R1: MEDLINE search 1982 to 2022 restricted to randomized double blind trials in idiopathic PD, tabulated synthesis incl. exenatide trials",2],["R0025728","Liraglutide Improves Cardiovascular Risk as an Add-on to Metformin and Not to Insulin Secretagogues in Type 2 Diabetic Patients: A Real-life 48-Month Retrospective Study.","Ciresi A","2018","inventory_only","N5","primary_report",null,null,null,"high","recheck","opus-5.5-recheck06","R3: retrospective observational cohort, all on liraglutide, grouped by metformin vs secretagogue background; no GLP-1 unexposed comparison",2],["R0027173","The INITIATOR study: pilot data on real-world clinical and economic outcomes in US patients with type 2 diabetes initiating injectable therapy.","Thayer S","2013","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck06","claims comparison liraglutide vs glargine pen initiators; A1C, hypoglycemia, utilization and costs; retinopathy only a baseline comorbidity",2],["R0014044","Epidemiology of hypoglycaemic episodes leading to hospitalisations in Denmark in 1998-2018.","Jensen MH","2021","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck02","Danish registry cohort of hypoglycemia hospitalization by glucose lowering drug class incl GLP-1 RA; retinopathy only as baseline complication",2],["R0013169","IDegLira Versus Alternative Intensification Strategies in Patients with Type 2 Diabetes Inadequately Controlled on Basal Insulin Therapy.","Freemantle N","2015","inventory_only","N6","secondary_report","P01",null,null,"high","recheck","opus-5.5-recheck01","R4: pools single arms from five different sponsor trials to compare IDegLira indirectly with other strategies; no shared randomized contrast",2],["R0013326","Baseline characteristics in the SYNCHRONIZE™-2 randomized phase 3 trial of survodutide, a glucagon receptor/GLP-1 receptor dual agonist, for obesity in people with type 2 diabetes.","Wharton S","2026","inventory_only","N8","protocol_or_design","P01",null,null,"high","recheck","opus-5.5-recheck01","R2: baseline characteristics paper of SYNCHRONIZE-2 survodutide versus placebo RCT, no between arm outcome reported",2],["R0019676","Exenatide once weekly treatment maintained improvements in glycemic control and weight loss over 2 years.","Taylor K","2011","inventory_only","N1","extension","P01",null,null,"high","recheck","opus-5.5-recheck01","DURATION-1 open label extension: after week 30 all patients on exenatide QW and results pooled regardless of initial randomization",2],["R0021178","Long-Term Effectiveness of Liraglutide for Treatment of Type 2 Diabetes in a Real-Life Setting: A 24-Month, Multicenter, Non-interventional, Retrospective Study.","Lapolla A","2018","inventory_only","N5","primary_report","P01",null,null,"high","recheck","opus-5.5-recheck01","R3: non interventional retrospective observational study of liraglutide initiators, no comparison group",2],["R0011156","Efficacy, Safety and Pharmacokinetics of Semaglutide 1.7 mg for Obesity Treatment in Adolescents: A Model-Informed Drug Development Approach.","Strathe A","2026","inventory_only","N2","secondary_report","P03",null,null,"high","recheck","opus-5.5-recheck04","R4: exposure response modeling and simulation of STEP TEENS and adult STEP data predicting 1.7 mg effects; no observed between arm outcome; alternative E3 modeling",2],["R0013968","Peripheral nerve complications from medications utilised for weight loss: a systematic review.","O'Gorman C","2026","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck04","R1: PROSPERO registered review of PubMed, Embase, CINAHL with criteria; structured synthesis of case reports and a cohort of nerve complications mostly with GLP-1 RA",2],["R0015228","Effects of Semaglutide With or Without Concomitant Mineralocorticoid Receptor Antagonist Use in Participants With Type 2 Diabetes and Chronic Kidney Disease: A FLOW Trial Prespecified Secondary Analysis.","Rossing P","2025","include_nma",null,"secondary_report","P08A; P01",null,null,"high","recheck","opus-5.5-recheck04","R4: prespecified FLOW subgroup analysis by baseline MRA use keeps randomized semaglutide vs placebo contrast for kidney, MACE and mortality outcomes",2],["R0016867","Semaglutide 2.4 mg Clinical Outcomes in Patients with Obesity or Overweight: A Real-World Retrospective Comparative Cohort Study.","Ruseva A","2025","inventory_only","N6","primary_report","P02",null,null,"high","recheck","opus-5.5-recheck04","Komodo matched cohort semaglutide 2.4 mg vs no obesity medication; weight and cardiometabolic risk factors only; MTC appears only as exclusion",2],["R0010235","Indirect comparative efficacy and safety of tirzepatide 10 and 15 mg versus semaglutide 2.4 mg for the management of obesity and overweight in patients with type 2 diabetes.","Ciudin A","2025","inventory_only","N6","secondary_report","P01",null,null,"high","recheck","opus-5.5-recheck03","R4: Bucher indirect comparison of tirzepatide (SURMOUNT-2) vs semaglutide (STEP 2) via placebo; no shared randomized comparison",2],["R0010452","Nutrition Strategies for Next-Generation Incretin Therapies: A Systematic Scoping Review of the Current Evidence.","Spreckley M","2026","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck03","R1: scoping review searching five named databases with criteria; structured synthesis of 12 semaglutide or tirzepatide nutrition studies",2],["R0010884","Is there an association between liraglutide use and female breast cancer in a real-world setting?","Funch D","2018","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck03","R7: matched new user cohort liraglutide vs other antidiabetics reports breast cancer only, a single site not in the harms list",2],["R0020138","GLP-1 based therapies and disease course of inflammatory bowel disease.","Villumsen M","2021","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck03","R7: Danish new user cohort GLP-1 RA or DPP-4i vs other antidiabetics reports IBD course outcomes only; no listed harm",2],["R0021755","The CTRB1/2 locus affects diabetes susceptibility and treatment via the incretin pathway.","'t Hart LM","2013","inventory_only","N5","other",null,null,null,"high","recheck","opus-5.5-recheck06","R3: genetic analysis of A1C response among GLP-1 RA treated T2D patients by genotype, no GLP-1 unexposed comparison; clamp part uses native GLP-1",2],["R0024760","Analysis of the Relationship between Type II Diabetes Mellitus and Parkinson's Disease: A Systematic Review.","Camargo Maluf F","2019","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck06","R1: PubMed MeSH search with stated eligibility and exclusions, tabulated synthesis of antidiabetic drugs in PD incl. exenatide placebo controlled trial",2],["R0026479","Real-world clinical and economic outcomes of liraglutide versus sitagliptin in patients with type 2 diabetes mellitus in the United States.","Li Q","2014","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck06","claims cohort liraglutide vs sitagliptin initiators; A1C change, target attainment and costs; retinopathy only a baseline comorbidity",2],["R0015630","Effectiveness of oral semaglutide versus empagliflozin for the management of type 2 diabetes. PIONEER-2 trial emulation with real-world data.","Fadini GP","2025","inventory_only","N6","primary_report","P01",null,null,"high","recheck","opus-5.5-recheck07","PIONEER-2 emulation of oral semaglutide vs empagliflozin new users; HbA1c, weight and persistence only; retinopathy appears only at baseline",2],["R0016281","Exenatide-induced reduction in energy intake is associated with increase in hypothalamic connectivity.","Schlögl H","2013","include_nma",null,"primary_report","P02",null,"mechanistic; crossover","high","recheck","opus-5.5-recheck07","R5: randomized double blind crossover IV exenatide vs placebo fMRI study in obese men; nausea ratings and energy intake reported by condition",2],["R0017635","Novel antihyperglycaemic drugs and prevention of chronic obstructive pulmonary disease exacerbations among patients with type 2 diabetes: population based cohort study.","Pradhan R","2022","inventory_only","N6","primary_report","P01",null,null,"high","recheck","opus-5.5-recheck07","R7: CPRD active comparator new user cohorts GLP-1 RA vs sulfonylurea in T2D with COPD; outcome severe COPD exacerbation; cancer only baseline",2],["R0024276","Weight loss and persistence with liraglutide 3.0 mg by obesity class in the real-world effectiveness study in Canada.","Wharton S","2020","inventory_only","N5","secondary_report","P02",null,null,"high","recheck","opus-5.5-recheck07","R3: post hoc analysis of a retrospective observational single arm liraglutide 3.0 mg cohort by obesity class; no exposure comparison",2],["R0013316","Effect of once weekly dulaglutide by baseline beta-cell function in people with type 2 diabetes in the AWARD programme.","Mathieu C","2018","inventory_only","N1","secondary_report",null,null,null,"high","recheck","opus-5.5-recheck10","R4: post hoc pooling of dulaglutide arms of AWARD 1, 3, 6 analyzed by baseline beta cell tertile within dose; no randomized contrast reported",2],["R0014631","A systematic review of semaglutide-associated kidney injury case reports.","Xiu X","2026","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck10","R1: PRISMA review of semaglutide kidney injury case reports, five named databases, inclusion criteria, tabulated synthesis; reviews of case reports qualify",2],["R0015736","Treatment Landscape of Metabolic-Dysfunction-Associated Steatotic Liver Disease.","Patel P","2025","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck10","R1: PubMed and Google Scholar search, stated inclusion and exclusion criteria, tabulated comparison of antidiabetic drugs including GLP-1 RA trials in MASLD",2],["R0016240","Cardioprotective effect of diabetic medication on cancer patients undergoing proven cardiotoxic chemotherapy: a systematic review and meta-analysis.","El-Helbawy A","2026","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck10","R1: PROSPERO registered review, named databases, PICO criteria incl GLP-1 RA, meta-analysis with drug class subgroups; a GLP-1 RA cohort in qualitative synthesis",2],["R0013072","Perceived benefits of treatment for obesity with retatrutide: A qualitative study of patients in a phase 2 clinical trial.","Goetz IA","2025","inventory_only","N2","secondary_report","P02",null,null,"high","recheck","opus-5.5-recheck08","R5: qualitative exit interview substudy of phase 2 retatrutide versus placebo RCT; perceived benefits themes, no review outcome by arm",2],["R0018407","Managing post-bariatric hypoglycemia: a systematic review of pharmacological therapies.","Sridharan K","2025","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck08","R1: MEDLINE, CENTRAL, Google Scholar search with eligibility; mixed treatment comparison includes liraglutide and exenatide RCTs for post bariatric hypoglycemia",2],["R0019033","Ten Year Follow-Up After Explantation of the Duodenal-jejunal Bypass Liner.","Beeren FMM","2025","inventory_only","N5","primary_report",null,null,null,"high","recheck","opus-5.5-recheck08","R3: cross sectional questionnaire follow-up of former duodenal jejunal liner patients; GLP-1 RA use only compared within survey",2],["R0014415","Lixisenatide as add-on treatment among patients with different β-cell function levels as assessed by HOMA-β index.","Bonadonna RC","2017","inventory_only","N1","secondary_report","P01",null,null,"high","recheck","opus-5.5-recheck09","R4: pooled GetGoal analysis uses only lixisenatide arms split by HOMA-beta, randomized contrast with placebo not kept",2],["R0015470","People With Lowest Physical Functioning Scores Showed Greatest Improvement After Tirzepatide Treatment.","Li X","2026","include_nma",null,"secondary_report","P02",null,null,"high","recheck","opus-5.5-recheck09","R4: post hoc SURMOUNT-1 and -3 analysis compares tirzepatide versus placebo weight and function within baseline quartiles",2],["R0016501","Impact of real-time glucose monitoring using FreeStyle Libre 3 on glycaemia in type 2 diabetes managed with basal insulin plus SGLT2 inhibitor and/or GLP-1 agonist: the FreeDM2 randomised controlled trial protocol.","Wilmot EG","2025","inventory_only","N8","protocol_or_design","P01",null,null,"high","recheck","opus-5.5-recheck09","R2: protocol of CGM versus SMBG RCT with GLP-1 RA only as background therapy; protocols of any design are N8",2],["R0019046","The Effects of a GLP-1 Analog on Glucose Homeostasis in Type 2 Diabetes Mellitus Quantified by an Integrated Glucose Insulin Model.","Røge RM","2015","inventory_only","N2","secondary_report",null,null,null,"high","recheck","opus-5.5-recheck02","R4: pharmacometric glucose insulin model fitted to two randomized liraglutide vs placebo crossovers; reports model parameters, no review outcome by arm",2],["R0015219","350 Effects of GLP-1 Agonist on Pediatric Populations in a Real-World Setting","Barajas G",null,"inventory_only","N8","protocol_or_design",null,null,"abstract_only","high","recheck","opus-5.5-recheck02","R2: conference abstract describing planned pediatric GLP-1 RA chart review with anticipated results only; no data reported",2],["R0016035","Efficacy of Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists for Weight Loss Management in Non-Diabetic Patients.","Vahora I","2024","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck02","R1: PRISMA review searching PubMed and other databases with explicit criteria; structured table of GLP-1 RA weight studies in nondiabetic adults",2],["R0017705","Cardio-Kidney-Metabolic Therapy Use Among Adults With Type 1 Diabetes and Chronic Kidney Disease.","Caramori ML","2026","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck02","matched cohort of mixed CKM therapy incl GLP-1 RA vs none in type 1 diabetes with CKD; UACR, hypoglycemia, DKA; pancreatitis not reported",2],["R0012664","A pharmacokinetic study comparing the biosimilar HEC14028 and Dulaglutide (Trulicity®) in healthy Chinese subjects.","Gao X","2024","inventory_only","N3","primary_report","P99",null,null,"high","recheck","opus-5.5-recheck07","R6: randomized PK comparison of biosimilar HEC14028 vs reference dulaglutide at the same 0.75 mg dose and route in healthy men",2],["R0013851","Effect of preoperative liraglutide 3.0 mg on incidence of intraoperative adhesions in laparoscopic sleeve gastrectomy.","Martines G","2024","inventory_only","N6","primary_report","P02",null,null,"high","recheck","opus-5.5-recheck07","R7: sleeve gastrectomy cohort with vs without preoperative liraglutide; adhesions, operative time, Clavien-Dindo complications and leaks; no listed harm",2],["R0014636","Association between semaglutide 2.4 mg and risk of cardiovascular events in people with overweight or obesity without atherosclerotic cardiovascular disease in the real-world: The SCORE - primary prevention study.","Smolderen KG","2026","inventory_only","N6","primary_report","P02",null,null,"high","recheck","opus-5.5-recheck07","R7: semaglutide 2.4 mg initiators vs matched nonusers; AKI appears only inside the MAKE composite with ESKD and death; MACE outcomes",2],["R0017802","Primary-care observational database study of the efficacy of GLP-1 receptor agonists and insulin in the UK.","Hall GC","2013","inventory_only","N6","primary_report","P01",null,null,"high","recheck","opus-5.5-recheck07","THIN cohort of GLP-1 RA vs basal insulin starters; HbA1c and weight change only; pancreatitis, gastroparesis and cancer are exclusion or baseline items",2],["R0013496","Benefits of combination of insulin degludec and liraglutide are independent of baseline glycated haemoglobin level and duration of type 2 diabetes.","Rodbard HW","2016","include_nma",null,"secondary_report","P01",null,null,"high","recheck","opus-5.5-recheck01","R4: post hoc subgroup analysis of DUAL I and DUAL II keeps IDegLira versus IDeg or liraglutide randomized contrasts by baseline HbA1c",2],["R0013789","The Effects of Exenatide and Metformin on Endothelial Function in Newly Diagnosed Type 2 Diabetes Mellitus Patients: A Case-Control Study.","Hu Y","2018","inventory_only","N6","primary_report","P01",null,null,"high","recheck","opus-5.5-recheck01","exenatide versus metformin groups formed by treatment, authors state not randomized; endothelial and metabolic outcomes, no listed harm",2],["R0025979","Liraglutide effect and action in diabetes-In (LEAD-In): A prospective observational study assessing safety and effectiveness of liraglutide in patients with type 2 diabetes mellitus treated under routine clinical practice conditions in India.","Wangnoo SK","2016","inventory_only","N5","primary_report","P01",null,null,"high","recheck","opus-5.5-recheck04","R3: LEAD-In prospective observational study of liraglutide prescribed in routine practice by physician judgment; uncontrolled cohort of users",2],["R0012861","Managing pasireotide-associated hyperglycemia: a randomized, open-label, Phase IV study.","Samson SL","2021","include_nma",null,"primary_report","P99",null,null,"high","recheck","opus-5.5-recheck04","randomized open label trial of incretin strategy sitagliptin then liraglutide vs insulin for pasireotide hyperglycemia in acromegaly or Cushing; alternative N3",2],["R0015965","Diabetes Optimization in Total Joint Arthroplasty: Perioperative Markers, Pharmacologic Strategies, and Wound Care Best Practices.","Khan U","2026","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck04","R1: PubMed search with stated eligibility, 162 studies graded with GRADE in a structured recommendations table including GLP-1 RA perioperative use",2],["R0018428","Infected necrotizing pancreatitis: clinical features, microbial patterns, and outcomes in a Saudi tertiary center.","Abulfaraj M","2025","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck08","acute pancreatitis cohort comparing infected necrosis by risk factors incl GLP-1 RA exposure; outcome infected necrosis, not a listed harm",2],["R0018204","Abstract 9: Once-weekly subcutaneous semaglutide 2.4 mg reduces body weight in adults with overweight or obesity regardless of baseline characteristics (STEP 1)",null,"2022","include_nma",null,"conference_abstract","P02",null,"abstract_only","high","recheck","opus-5.5-recheck08","R2 not applicable: STEP 1 post hoc reports weight loss by subgroup with treatment by subgroup interaction versus placebo",2],["R0019253","Presentation and Management of Liraglutide-Related Pancreatitis: Systematic Review of Case Reports","Singh S","2021","include_review",null,"systematic_review",null,null,"abstract_only","high","recheck","opus-5.5-recheck08","R1: MEDLINE, Google Scholar, Cochrane search under PRISMA; meta-analysis of liraglutide related pancreatitis case reports qualifies as review of case reports",2],["R0020929","Exenatide and glucagon co-infusion increases myocardial glucose uptake and improves markers of diastolic dysfunction in adults with type 2 diabetes.","Goodman J","2025","inventory_only","N2","primary_report","P01",null,"mechanistic; crossover","high","recheck","opus-5.5-recheck08","R5: randomized crossover infusion of exenatide with glucagon versus glucagon or saline; myocardial glucose uptake and strain only, no review outcome",2],["R0013641","Determinants of good metabolic control without weight gain in type 2 diabetes management: a machine learning analysis.","Giorda CB","2020","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck05","AMD Annals machine learning analysis of determinants incl GLP-1 RA use for HbA1c target without weight gain; harms terms only baseline",2],["R0014943","Clinical Outcomes Associated with the Use of a Family-Based Digital Support Program in Patients with Pharmacologic Treatment for Obesity.","de Arriba Muñoz A","2025","inventory_only","N1","primary_report",null,null,null,"high","recheck","opus-5.5-recheck05","R3: investigator delivered digital family program, single arm pre-post in adolescents all on semaglutide; no comparison group",2],["R0015426","Hormonal Modulation in Chronic Coronary Syndrome: From Neurohormonal Activation to Endocrine Targets.","Brie AD","2026","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck05","R1: self called narrative but four named databases, predefined eligibility, screening flow; qualitative synthesis of 34 studies including GLP-1 RA",2],["R0011067","Positioning Incretin-Based and Next-Generation Obesity Management Medications: A Methodological Framework for a Series of Systematic Reviews and Network Meta-Analyses.","Monami M","2026","inventory_only","N8","protocol_or_design",null,null,null,"high","recheck","opus-5.5-recheck03","R2: PROSPERO registered framework and protocol for planned obesity drug systematic reviews and NMAs; no results",2],["R0014054","Liraglutide improves follicle development in polycystic ovary syndrome by inhibiting CXCL10 secretion.","Zhao M","2024","exclude","E1","other",null,null,null,"high","recheck","opus-5.5-recheck03","Liraglutide applied only to cultured human granulosa cells and mouse follicles in vitro; human samples compare PCOS with controls without drug",2],["R0014144","Effectiveness and Safety of iGlarLixi (Insulin Glargine 100 U/mL Plus Lixisenatide) in Type 2 Diabetes According to the Timing of Daily Administration: Data from the REALI Pooled Analysis.","Haluzík M","2023","inventory_only","N6","pooled_analysis",null,null,null,"high","recheck","opus-5.5-recheck03","R7: pooled observational iGlarLixi initiators compared by injection timing; HbA1c, weight, GI events, hypoglycemia only; alternative N5",2],["R0017544","The effect of obesity interventions on male fertility: a systematic review and meta-analysis.","Peel A","2026","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck09","R1: registered review with five named databases, criteria, tabulated synthesis including liraglutide studies on male fertility",2],["R0018713","Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial.","Ryan DH","2024","include_nma",null,"secondary_report","P02",null,null,"high","recheck","opus-5.5-recheck09","R2 not applicable: prespecified SELECT analysis reports semaglutide versus placebo weight and adverse events by baseline BMI",2],["R0023122","Real-world Efficacy and Safety of Dulaglutide in Korean Patients with Type 2 Diabetes Mellitus: A Retrospective Study in a Tertiary Referral Center","Yoon JH","2020","inventory_only","N5","other",null,null,null,"high","recheck","opus-5.5-recheck03","R3: retrospective chart review of dulaglutide initiators at one center; uncontrolled observational cohort without comparison group",2],["R0020151","Non-Persistence and Non-Adherence of Patients with Type 2 Diabetes Mellitus in Therapy with GLP-1 Receptor Agonists: A Retrospective Analysis.","Wilke T","2016","exclude","E2","other",null,null,null,"high","recheck","opus-5.5-recheck08","R8: claims and CPRD cohorts comparing persistence and adherence of twice daily exenatide with once daily liraglutide; no clinical outcome compared",2],["R0021814","FDG-PET/CT-based respiration-gated lung segmentation and quantification of lung inflammation in COPD patients.","Dogan ADA","2024","inventory_only","N2","secondary_report","P02",null,"mechanistic","high","recheck","opus-5.5-recheck08","R5: FDG PET substudy of liraglutide 3.0 mg versus placebo RCT in obese COPD; lung uptake and inflammatory markers only, weight only baseline",2],["R0022648","Efficacy and Safety of Dapagliflozin versus Liraglutide in Patients with Overweight or Obesity and Type 2 Diabetes Mellitus: A Randomised Controlled Clinical Trial in Tianjin, China.","Zhaohu H","2022","include_nma",null,"primary_report","P01",null,null,"low","recheck","opus-5.5-recheck08","R9: called randomized and observational; allocation by random number table with enrolment order, dapagliflozin versus liraglutide; alternative N4",2],["R0024573","Dulaglutide 1.5 mg as an add-on option for patients uncontrolled on insulin: Subgroup analysis by age, duration of diabetes and baseline glycated haemoglobin concentration.","Pantalone KM","2018","include_nma",null,"pooled_analysis","P01",null,null,"high","recheck","opus-5.5-recheck08","R4: pooled AWARD-4 and AWARD-9 subgroup analysis compares dulaglutide with glargine or placebo arms within each trial on HbA1c, weight, hypoglycemia",2],["R0013194","Bone fracture risk is not associated with the use of glucagon-like peptide-1 receptor agonists: a population-based cohort analysis.","Driessen JH","2015","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck10","CPRD cohort of GLP-1 RA current users versus never users; fracture outcomes only; cancer and retinopathy only covariates",2],["R0015246","Efficacy comparison of dapagliflozin combined with liraglutide versus monotherapy in obese patients with heart failure.","Zhou G","2026","include_nma",null,"primary_report","P07A",null,null,"low","recheck","opus-5.5-recheck10","R9: labeled retrospective yet methods describe statistician randomization with matching placebos to dapagliflozin plus liraglutide versus monotherapies",2],["R0018853","No QTc Prolongation with Semaglutide: A Thorough QT Study in Healthy Subjects.","Demmel V","2018","include_nma",null,"primary_report","P99",null,"mechanistic","high","recheck","opus-5.5-recheck10","R5: randomized placebo controlled thorough QT trial of semaglutide in healthy volunteers; results report withdrawals due to adverse events by arm",2],["R0018312","The Real-World Use of Semaglutide to Promote Weight Loss in Obese Adults With Hemodialysis: A Multicenter Cross-Sectional Descriptive Study.","Couture J","2025","inventory_only","N6","primary_report","P99",null,null,"high","recheck","opus-5.5-recheck07","R3: hemodialysis patients using semaglutide vs nonuser control group with weight change treatment differences; adverse events only nausea, vomiting, diarrhea; no listed harm",2],["R0014495","Cardiometabolic Parameter Change by Weight Regain on Tirzepatide Withdrawal in Adults With Obesity: A Post Hoc Analysis of the SURMOUNT-4 Trial.","Horn DB","2026","inventory_only","N1","secondary_report","P02W",null,null,"high","recheck","opus-5.5-recheck07","R4: SURMOUNT-4 post hoc analysis restricted to participants randomized to placebo after tirzepatide, grouped by weight regain; randomized contrast unused",2],["R0014740","Semaglutide in Non-diabetic Obese East Asian Patients with Acute Coronary Syndrome: A Multicenter Retrospective Study","Jin C","2026","inventory_only","N6","primary_report","P99",null,null,"high","recheck","opus-5.5-recheck07","R7: retrospective matched cohort of semaglutide vs none after PCI in nondiabetic obese ACS; MACE, troponin, lipids, LVEF; thyroid and gastroparesis only exclusions",2],["R0019460","How amenable is type 2 diabetes treatment for precision diabetology? A meta-regression of glycaemic control data from 174 randomised trials.","Kuss O","2023","exclude","E3","other",null,null,null,"high","recheck","opus-5.5-recheck07","R1: meta-regression of HbA1c variability in 174 placebo controlled RCTs taken from three prior reviews; no own named database search",2],["R0018582","Clinical Pharmacokinetics of Semaglutide: A Systematic Review.","Yang XD","2024","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck01","R1: PRISMA review searching PubMed and Embase with stated criteria; tabulated synthesis of semaglutide PK studies by route and dose",2],["R0013300","Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: An updated systematic review of randomized controlled trials.","Mantovani A","2020","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck01","R1: whole PDF read; searched PubMed, ClinicalTrials.gov and Cochrane with RCT criteria; tabulated synthesis includes six GLP-1 RA RCTs in NAFLD",2],["R0015846","The Neuroprotective Potentials of Dual GIP/GLP1-RA (Tirzepatide): From Preclinical Experiments to Clinical Trials: A Scoping Review.","Hawas Y","2026","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck01","R1: PROSPERO registered scoping review of five named databases with criteria; tabulates human tirzepatide cohorts and case reports besides preclinical work",2],["R0017021","Cardiovascular Events, Acute Hospitalizations, and Mortality in Patients With Type 2 Diabetes Mellitus Who Initiate Empagliflozin Versus Liraglutide: A Comparative Effectiveness Study.","Thomsen RW","2021","inventory_only","N6","primary_report","P01",null,null,"high","recheck","opus-5.5-recheck01","new user cohort empagliflozin versus liraglutide; MACE, heart failure, hospitalization and death; retinopathy and cancer only at baseline",2],["R0022244","Liraglutide 3.0 mg for Weight Management: A Population Pharmacokinetic Analysis.","Overgaard RV","2016","inventory_only","N2","secondary_report","P02; P01",null,"mechanistic","high","recheck","opus-5.5-recheck08","R5: population pharmacokinetic analysis of SCALE and phase 2 liraglutide samples; exposure covariates only, exposure response deferred to another paper",2],["R0022305","Lowering blood glucose during hip surgery does not influence coagulation activation.","Sechterberger MK","2015","include_nma",null,"primary_report","P02; P06",null,"mechanistic","high","recheck","opus-5.5-recheck08","R5: block randomized double blind liraglutide versus placebo around hip surgery; nausea and adverse events reported by arm",2],["R0027789","Baseline Characteristics of Randomized Participants in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE).","Wexler DJ","2019","inventory_only","N8","protocol_or_design","P01",null,null,"high","recheck","opus-5.5-recheck08","R2: baseline characteristics of randomized GRADE participants including liraglutide arm compared with NHANES; no between arm outcome",2],["R0013120","Real-world cardiovascular effects of liraglutide: transportability analysis of the LEADER trial.","Josey K","2026","include_nma",null,"secondary_report","P01",null,null,"high","recheck","opus-5.5-recheck05","R4: reweights LEADER individual data to veterans and reports liraglutide vs placebo cardiovascular and mortality effects, keeping randomized contrast",2],["R0011253","Comparative Effectiveness of Semaglutide and Tirzepatide for Weight Loss in Adults with Overweight and Obesity in the US: A Real-World Evidence Study","Rodriguez PJ","2023","include_harms",null,"primary_report",null,"O28; O29; O37A; O37B",null,"high","recheck","opus-5.5-recheck05","R7: new user tirzepatide vs semaglutide cohort compares bowel obstruction, cholecystitis, cholelithiasis, gastroparesis and pancreatitis rates",2],["R0015536","Liraglutide Improved Cardiometabolic Parameters More in Obese than in Non-obese Patients with Type 2 Diabetes: A Real-World 18-Month Prospective Study.","Nikolic D","2022","inventory_only","N1","primary_report",null,null,null,"high","recheck","opus-5.5-recheck05","R3: registered prospective interventional study giving liraglutide to all, compared obese vs non-obese; no untreated or comparator arm",2],["R0012803","Metabolic and cardiovascular benefits with combination therapy of SGLT-2 inhibitors and GLP-1 receptor agonists in type 2 diabetes.","Singh AK","2022","exclude","E3","other",null,null,null,"high","recheck","opus-5.5-recheck02","R1: self described comprehensive opinion review with ad hoc pooling of outcome trials; no named database search or eligibility criteria",2],["R0018427","Glycemic levels and cardiovascular events in type 2 diabetes: A cohort study of drugs with different hypoglycemic potentials.","Lin YC","2025","exclude","E2","primary_report",null,null,null,"high","recheck","opus-5.5-recheck02","EHR cohort studies HbA1c level and MACE within drug risk groups; GLP-1 RA pooled among low risk drugs, never studied as an exposure",2],["R0019533","Risk of amputation with canagliflozin across categories of age and cardiovascular risk in three US nationwide databases: cohort study.","Fralick M","2020","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck02","new user claims cohorts canagliflozin vs GLP-1 RA; only outcome lower limb amputation; retinopathy and cancer baseline or exclusion only",2],["R0020891","Trial design and baseline data for LIRA-PRIME: A randomized trial investigating the efficacy of liraglutide in controlling glycaemia in type 2 diabetes in a primary care setting.","Unger J","2019","inventory_only","N8","protocol_or_design",null,null,null,"high","recheck","opus-5.5-recheck02","R2: design and baseline data paper of LIRA-PRIME liraglutide vs oral drugs RCT; no between arm outcome reported",2],["R0016422","Predicting Long-Term Weight Loss Using Self-Reported, Digitally Collected, Real-World Data After Initiation of Semaglutide for Overweight or Obesity.","Færch K","2026","inventory_only","N5","primary_report",null,null,null,"high","recheck","opus-5.5-recheck03","R3: trial-derived weight predictor applied to single group of app users on semaglutide; uncontrolled real world data without comparator",2],["R0015878","Lower risk of cardiovascular events in patients initiated on semaglutide 2.4 mg in the real-world: Results from the SCORE study (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity in the Real World).","Smolderen KG","2025","include_harms",null,"primary_report",null,"O121",null,"high","recheck","opus-5.5-recheck03","R7: matched cohort semaglutide 2.4 mg vs nonuse reports acute kidney injury separately (HR 0.38) besides MACE and MAKE composites",2],["R0016209","Liraglutide 3.0 mg and Mental Health: Can Psychiatric Symptoms Predict Adherence to Therapy? Insights from a clinical audit","Tempia Valenta S","2023","inventory_only","N5","primary_report",null,null,null,"high","recheck","opus-5.5-recheck03","R3: retrospective clinical audit of liraglutide 3.0 mg users relating psychiatric symptoms to adherence; observational, no comparison group",2],["R0017891","Validation of a Questionnaire for Assessing the Emotional Impact of Treatment for Type 2 Diabetes.","Matza LS","2025","inventory_only","N5","primary_report",null,null,null,"high","recheck","opus-5.5-recheck03","Questionnaire validation study with cross sectional exploratory comparison of tirzepatide vs semaglutide users; alternative E3 methods paper",2],["R0013385","Pharmacogenomics of GLP-1 Receptor Agonists: A genome wide analysis of observational data and large randomized controlled trials","Dawed AY","2022","inventory_only","N1","secondary_report","P01",null,null,"high","recheck","opus-5.5-recheck09","R4: pharmacogenomic analysis of GLP-1 RA arms and cohorts; comparator arms analyzed separately, no randomized between arm contrast",2],["R0016520","Lower Risk of Death and Cardiovascular Events in Unselected Type 2 Diabetes Patients Initiated on GLP-1 Receptor Agonists and SGLT-2 Inhibitors in Two Large Italian Cohorts","Baviera M","2020","include_harms",null,"primary_report",null,"O121",null,"high","recheck","opus-5.5-recheck09","R7: matched new user cohorts GLP-1 RA versus other agents; hospital admission for acute renal failure reported as a separate serious adverse event by group",2],["R0018120","Semaglutide use in people with obesity and type 2 diabetes from real-world utilization data: An analysis of the All of US Program.","Mayer CS","2024","inventory_only","N5","primary_report",null,null,null,"high","recheck","opus-5.5-recheck09","R3: All of Us descriptive cohort of semaglutide users with before and after changes, no comparison group",2],["R0018506","Use of incretin-based drugs and risk of cholangiocarcinoma: Scandinavian cohort study.","Ueda P","2021","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck09","R7: active comparator cohort versus sulfonylureas on cholangiocarcinoma only, which is neither O28 nor a listed cancer site",2],["R0017098","Real-World Use of Once-Weekly Semaglutide in Thai Patients With Type 2 Diabetes Mellitus in a Private Hospital Setting.","Thewjitcharoen Y","2023","inventory_only","N5","primary_report",null,null,null,"high","recheck","opus-5.5-recheck10","R3: retrospective observational review of semaglutide users only; SGLT2i subgroups both on semaglutide; no pancreatitis comparison across GLP-1 exposure",2],["R0013933","Quality of Life in Japanese People with Type 2 Diabetes Switching from Multiple Daily Insulin Injections to Once-Daily iGlarLixi: SIMPLIFY Japan.","Ishii H","2024","inventory_only","N5","primary_report",null,null,null,"high","recheck","opus-5.5-recheck10","R3: prospective observational cohort of patients switched to iGlarLixi at physician discretion; no comparison group",2],["R0018470","Changes in food preferences after oral semaglutide administration in Japanese patients with type 2 diabetes: KAMOGAWA-DM cohort.","Hironaka J","2025","inventory_only","N5","secondary_report",null,null,null,"high","recheck","opus-5.5-recheck10","R3: retrospective observational KAMOGAWA-DM subanalysis of oral semaglutide initiators only; no comparison group",2],["R0014486","Differential Impact of Metabolic Bariatric Surgery Versus Semaglutide on Adverse Hepatic and Extrahepatic Outcomes in Individuals With Metabolic Dysfunction-Associated Steatotic Liver Disease and Type 2 Diabetes.","Stupalkowska W","2026","inventory_only","N6","primary_report","P01; P09",null,null,"high","recheck","opus-5.5-recheck07","R7: TriNetX bariatric surgery vs semaglutide in MASLD with T2D; obesity associated cancer is a selected site composite, not all cancers; liver and MACE outcomes",2],["R0018094","Role of Liraglutide in weight management and reproductive health in women with obesity and PCOS- A critical review of the evidence.","Shetty S","2025","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck07","R1: four named databases, inclusion criteria, dual screening and flow diagram; tables synthesize clinical studies of liraglutide in obese women with PCOS",2],["R0020479","Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study.","Patorno E","2018","inventory_only","N6","primary_report","P01",null,null,"high","recheck","opus-5.5-recheck07","R7: matched new user cohorts of canagliflozin vs GLP-1 RA, DPP-4i or SU; heart failure and MI or stroke outcomes; retinopathy only baseline",2],["R0019410","Comparison of Sodium-Glucose Cotransporter 2 Inhibitors vs Glucagonlike Peptide-1 Receptor Agonists and Incidence of Dry Eye Disease in Patients With Type 2 Diabetes in Taiwan.","Su YC","2022","inventory_only","N6","primary_report","P01",null,null,"high","recheck","opus-5.5-recheck04","Taiwan active comparator new user cohort SGLT2i vs GLP-1 RA; dry eye disease, vitreous floater control and HbA1c, eGFR; no listed harm",2],["R0017853","Target Trial of Glucagon-Like Peptide-1 Agonists versus Dipeptidyl Peptidase-4 Inhibitors and Mortality in Hemodialysis.","Le D","2026","include_harms",null,"primary_report",null,"O28; O29; O33",null,"high","recheck","opus-5.5-recheck04","USRDS target trial emulation GLP-1 RA vs DPP-4i in hemodialysis reports cholecystitis, pancreatitis and retinopathy HRs as secondary outcomes; GI composite also",2],["R0025727","SUN-544 Immunologic Effects of GLP-1 Activation in Obese Adipose Tissue","Mashayekhi M","2020","inventory_only","N2","conference_abstract","P06",null,"mechanistic; abstract_only","high","recheck","opus-5.5-recheck08","R5: randomized liraglutide or sitagliptin pooled as drug versus diet in prediabetes; only adipose and blood immune cell markers, no review outcome",2],["R0025478","Effect of metformin on all-cause mortality and major adverse cardiovascular events: An updated meta-analysis of randomized controlled trials.","Monami M","2021","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck08","R1: MEDLINE and EMBASE meta-analysis of metformin RCTs whose pooled comparators include GLP-1 RA trials, with sensitivity analysis excluding them",2],["R0026961","Blood pressure and mortality in patients with type 2 diabetes and a recent coronary event in the ELIXA trial.","Wijkman MO","2020","inventory_only","N2","secondary_report","P01",null,null,"high","recheck","opus-5.5-recheck08","R4: ELIXA post hoc on baseline blood pressure and mortality, lixisenatide allocation only a covariate; no between arm outcome",2],["R0017520","A85 PATTERN OF SEMAGLUTIDE PRESCRIPTION IN A REAL-WORLD PATIENT COHORT",null,"2025","inventory_only","N5","conference_abstract",null,null,"abstract_only","high","recheck","opus-5.5-recheck04","R3: retrospective family practice cohort of semaglutide prescriptions with weight and HbA1c change; uncontrolled observational users",2],["R0012157","GIP as a Potential Therapeutic Target for Atherosclerotic Cardiovascular Disease-A Systematic Review.","Mori Y","2020","exclude","E2","other",null,null,null,"high","recheck","opus-5.5-recheck01","R1: PubMed review whose human studies are native GIP infusions; no GLP-1 RA containing drug in any synthesized study, only preclinical and hormone work",2],["R0014091","Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors for recurrent nephrolithiasis among patients with pre-existing nephrolithiasis or gout: target trial emulation studies.","McCormick N","2024","inventory_only","N6","primary_report","P01",null,null,"high","recheck","opus-5.5-recheck01","trial emulation SGLT2i versus GLP-1 RA or DPP-4i on recurrent kidney stones and gout; acute kidney injury and retinopathy only at baseline",2],["R0017683","An intervention study of the general practice management of older adults with cardiovascular metabolic comorbidities.","Li Y","2026","exclude","E2","other",null,null,null,"high","recheck","opus-5.5-recheck01","RCT of general practice management versus routine discharge care; GLP-1 RA appears only as a medication adherence outcome, not an intervention",2],["R0020781","Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: A real-world systematic review and meta-analysis","Li C","2020","exclude","E2","other",null,null,null,"high","recheck","opus-5.5-recheck01","R1: whole preprint read; meta-analysis of SGLT2i versus pooled other drugs; GLP-1 RA only background stratifier or part of mixed comparator; alternative include_review",2],["R0018876","Semaglutide and Cardiovascular Outcomes by Baseline HbA1c and Change in HbA1c in People With Overweight or Obesity but Without Diabetes in SELECT.","Lingvay I","2024","include_nma",null,"secondary_report","P02",null,null,"high","recheck","opus-5.5-recheck09","R2 not applicable: prespecified SELECT analysis reports semaglutide versus placebo cardiovascular outcomes by baseline HbA1c",2],["R0015446","Insulin degludec/liraglutide (IDegLira) was effective across a range of dysglycaemia and body mass index categories in the DUAL V randomized trial.","Lingvay I","2018","include_nma",null,"secondary_report","P01",null,null,"high","recheck","opus-5.5-recheck09","R2 not applicable: post hoc DUAL V analysis compares IDegLira versus insulin glargine HbA1c, weight, hypoglycemia by baseline categories",2],["R0016131","A retrospective observational study on case reports of adverse drug reactions (ADRs) to tirzepatide.","Huang M","2025","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck09","R1: five named databases, stated criteria, descriptive statistical synthesis of 43 tirzepatide adverse reaction case reports",2],["R0019440","Predictive factors and the management of hyperglycemia in patients with acromegaly and Cushing's disease receiving pasireotide treatment: post hoc analyses from the SOM230B2219 study.","Feldt-Rasmussen U","2024","inventory_only","N2","secondary_report","P99",null,null,"high","recheck","opus-5.5-recheck09","R4: post hoc of pasireotide trial on predictors of needing glucose lowering therapy before randomization; no between arm outcome reported",2],["R0027145","Effectiveness of triple therapy with dapagliflozin add-on to dual therapy over 52 weeks in patients with uncontrolled type 2 diabetes mellitus in a centre of high complexity, Cali-Colombia.","Joaqui VB","2021","inventory_only","N6","primary_report","P01",null,null,"high","recheck","opus-5.5-recheck08","historical cohort of dapagliflozin added to dual therapies, one with exenatide background, compared on HbA1c, weight, BP; no listed harm",2],["R0027881","Descriptions of Adverse Drug Reactions Are Less Informative in Forums Than in the French Pharmacovigilance Database but Provide More Unexpected Reactions.","Karapetiantz P","2018","inventory_only","N5","primary_report",null,null,null,"high","recheck","opus-5.5-recheck08","comparison of web forum posts with French pharmacovigilance reports of adverse reactions for six drugs including exenatide; spontaneous report analysis",2],["R0029365","Weight Loss Measurements Under the Microscope: How Type and Baseline Definition Shape Clinical Response After Metabolic-Bariatric Surgery - A 2-Year Follow-up Analysis of 17,568 Patients.","Fink M","2026","exclude","E2","other",null,null,null,"high","recheck","opus-5.5-recheck08","bariatric registry study of weight loss metrics and preoperative BMI; GLP-1 RA use in under 1 percent only described, not studied as exposure",2],["R0015818","Efficacy of tirzepatide 5, 10 and 15 mg versus semaglutide 2 mg in patients with type 2 diabetes: An adjusted indirect treatment comparison.","Vadher K","2022","inventory_only","N6","secondary_report","P01",null,null,"high","recheck","opus-5.5-recheck03","R4: Bucher indirect comparison of tirzepatide (SURPASS-2) vs semaglutide 2 mg (SUSTAIN FORTE) via semaglutide 1 mg; no shared randomized comparison",2],["R0018531","Food-drug interactions of novel drugs used in cardiologic and diabetic patients - a PRISMA scoping review.","Pawłowska I","2026","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck03","R1: PRISMA-ScR search of PubMed, Scopus, Cochrane with criteria; structured synthesis of food effect studies including oral semaglutide",2],["R0018749","Semaglutide and blood pressure: an individual patient data meta-analysis.","Kennedy C","2024","include_nma",null,"pooled_analysis","P02; P02W",null,null,"high","recheck","opus-5.5-recheck03","R4: IPD pooling of STEP 1, 3 and 4 keeps semaglutide vs placebo randomized contrast for blood pressure; trials taken from earlier review",2],["R0021393","Association of antidiabetic therapies with lower extremity amputation, mortality and healthcare cost from a nationwide retrospective cohort study in Taiwan.","Chang HY","2021","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck03","R7: Taiwan new user cohort including GLP-1 RA reports amputation, vascular outcomes, mortality and costs; retinopathy only at baseline",2],["R0016524","Using real-world data to predict findings of an ongoing phase IV trial: glycemic control of semaglutide versus standard of care.","Kattinakere Sreedhara S","2025","inventory_only","N6","primary_report","P01",null,null,"high","recheck","opus-5.5-recheck07","R7: claims emulation of SEPRA comparing semaglutide vs standard care initiators on A1C below 7 percent; retinopathy and nephropathy only baseline",2],["R0015752","Integrated Management Strategies for Hypertension and Diabetes in Cardiovascular Disease Prevention: A Systematic Review.","Sen N","2026","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck10","R1: PubMed, Scopus, Web of Science, Embase search, PRISMA screening, NOS appraisal, tabulated narrative synthesis including a GLP-1 RA comparative cohort",2],["R0018306","Liraglutide improves metabolic parameters and carotid intima-media thickness in diabetic patients with the metabolic syndrome: an 18-month prospective study.","Rizzo M","2016","inventory_only","N1","primary_report",null,null,null,"high","recheck","opus-5.5-recheck10","R3: registered single arm study adding liraglutide 1.2 mg per protocol to metformin for 18 months; no comparison group (alternative N5)",2],["R0019871","Safety and efficacy of IDegLira titrated once weekly versus twice weekly in patients with type 2 diabetes uncontrolled on oral antidiabetic drugs: DUAL VI randomized clinical trial.","Harris SB","2017","inventory_only","N3","primary_report",null,null,null,"high","recheck","opus-5.5-recheck10","R6 by analogy: DUAL VI randomizes only titration frequency of the same IDegLira product to the same glucose target; regimen node unchanged",2],["R0026693","Clinical outcomes associated with anti-obesity medications in real-world practice: A systematic literature review.","Ahmad NN","2021","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck05","R1: five named databases, tabulated eligibility criteria, structured synthesis of real-world anti-obesity drug studies including liraglutide",2],["R0013284","Cardiovascular protection in type 2 diabetes: Insights from recent outcome trials.","Bailey CJ","2019","deferred","D1","other",null,null,null,"high","recheck","opus-5.5-recheck05","stored file is a Bailey commentary on EMA approvals, not the titled review of cardiovascular outcome trials",2],["R0016333","Switching From Daily DPP-4 Inhibitor to Once-Weekly GLP-1 Receptor Activator Dulaglutide Significantly Ameliorates Glycemic Control in Subjects With Poorly Controlled Type 2 Diabetes Mellitus: A Retrospective Observational Study.","Sanada J","2021","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck05","switch from DPP-4i to dulaglutide vs matched non-switchers on glycemic outcomes; retinopathy and malignancy only baseline or exclusion items",2],["R0018150","A Randomized Phase 1 Pharmacokinetic Study Comparing the Potential Biosimilar LRG201902 With Liraglutide (Victoza®) in Healthy Male Subjects.","Mai G","2020","inventory_only","N3","primary_report","P99",null,"crossover","high","recheck","opus-5.5-recheck04","R6: crossover PK trial of biosimilar LRG201902 vs reference liraglutide, both single 0.6 mg subcutaneous doses in healthy men; same molecule node",2],["R0016843","Effect of liraglutide biosimilar vs. reference liraglutide on weight reduction in T2DM patients with obesity: post hoc analysis of phase III trial.","Ghosh S","2025","inventory_only","N3","secondary_report","P01",null,null,"high","recheck","opus-5.5-recheck04","R6: post hoc analysis of phase 3 RCT of biosimilar vs reference liraglutide at same doses and route; same molecule, node unchanged",2],["R0018990","Liraglutide to Improve corONary haemodynamics during Exercise streSS (LIONESS): a double-blind randomised placebo-controlled crossover trial.","Myat A","2021","include_nma",null,"primary_report","P99",null,"mechanistic; crossover","high","recheck","opus-5.5-recheck04","R5: LIONESS placebo controlled crossover RCT of liraglutide in stable angina reports weight, hypoglycemia and pancreatitis safety endpoints",2],["R0020440","Precision treatment of beta-cell monogenic diabetes: a systematic review.","Naylor RN","2024","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck04","R1: PROSPERO registered review of PubMed, MEDLINE, Embase with criteria; tabulated synthesis includes a GLP-1 RA vs sulfonylurea crossover trial in HNF1A diabetes",2],["R0019679","Cardiovascular and renal outcomes by baseline albuminuria status and renal function: Results from the LEADER randomized trial.","Mosenzon O","2020","include_nma",null,"secondary_report","P01; P08A",null,null,"high","recheck","opus-5.5-recheck02","R4: post hoc LEADER analysis reports liraglutide vs placebo cardiorenal outcomes across baseline UACR and eGFR subgroups; not a baseline paper",2],["R0019502","Safety and Effectiveness of Tirzepatide Use in Obesity Without Type 2 Diabetes Mellitus.","Al Zweihary AM","2024","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck02","R1: PubMed, Embase and Cochrane searched with explicit inclusion and exclusion criteria; structured table of tirzepatide vs placebo outcomes",2],["R0019685","Study of postprandial lipaemia in type 2 diabetes mellitus: exenatide versus liraglutide.","Voukali M","2014","inventory_only","N2","primary_report",null,null,null,"high","recheck","opus-5.5-recheck02","R5: two week RCT exenatide vs liraglutide on postprandial lipids, glucose and insulin; no adverse events, weight or HbA1c by arm",2],["R0022290","Treatment Costs of Basal Insulin Regimens for Type 2 Diabetes Mellitus in France.","Detournay B","2021","inventory_only","N5","primary_report",null,null,null,"high","recheck","opus-5.5-recheck02","R8: cross sectional pharmacy survey compares costs and severe hypoglycemia across insulins incl IDegLira; cross sectional design, not E2",2],["R0021955","Efficacy and safety outcomes of dulaglutide by baseline HbA1c: A post hoc analysis of the REWIND trial.","Franek E","2022","include_nma",null,"secondary_report","P01",null,null,"high","recheck","opus-5.5-recheck07","R2 not applicable, R4: REWIND post hoc keeps randomized dulaglutide vs placebo contrast within baseline HbA1c subgroups; MACE, HbA1c, BMI, safety",2],["R0022135","Changes in glycemic variability, gastric emptying and vascular endothelial function after switching from twice-daily to once-weekly exenatide in patients with type 2 diabetes: a subpopulation analysis of the twin-exenatide study.","Inaishi J","2022","inventory_only","N1","secondary_report","P01",null,null,"high","recheck","opus-5.5-recheck07","R3: substudy of a prospective interventional single arm trial switching exenatide BID to QW; before and after CGM, gastric emptying, endothelial function",2],["R0025845","Subgroup analysis of phase 3 studies of dulaglutide in Japanese patients with type 2 diabetes.","Onishi Y","2016","inventory_only","N1","secondary_report","P01",null,null,"high","recheck","opus-5.5-recheck07","R4: post hoc subgroup analysis pooling only dulaglutide 0.75 mg arms from three Japanese phase 3 trials, one nonrandomized; no randomized contrast",2],["R0026679","Systematic Review of Efficacy and Safety of Newer Antidiabetic Drugs Approved from 2013 to 2017 in Controlling HbA1c in Diabetes Patients.","Palanisamy S","2018","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck07","R1: PRISMA review naming PubMed and Google Scholar with RCT inclusion criteria; tabulates HbA1c and safety results incl. semaglutide vs comparators",2],["R0019028","The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Baseline Patient-Reported Outcomes.","Boye KS","2020","inventory_only","N8","protocol_or_design",null,null,null,"high","recheck","opus-5.5-recheck10","R2 by extension: baseline patient reported outcomes paper of the observational TROPHIES cohorts; no follow-up outcome compared",2],["R0021054","Durability of glucose-lowering effect of dulaglutide in patients with type 2 diabetes mellitus: A real-world data study.","Kim HS","2022","inventory_only","N5","primary_report",null,null,null,"high","recheck","opus-5.5-recheck10","R3: retrospective observational records review of dulaglutide users only; no comparison group",2],["R0021184","Tirzepatide Immunogenicity on Pharmacokinetics, Efficacy, and Safety: Analysis of Data From Phase 3 Studies.","Mullins GR","2024","inventory_only","N1","secondary_report",null,null,null,"high","recheck","opus-5.5-recheck10","R4: pooled immunogenicity analysis of tirzepatide arms of SURPASS trials; review outcomes only within tirzepatide by antibody status, placebo compared only for antibodies",2],["R0021985","Application of the integrated data platform combined with dietary management for adults with diabetes: A prospective randomized controlled trial.","Liu X","2024","inventory_only","N3","primary_report",null,null,null,"high","recheck","opus-5.5-recheck10","RCT randomizes a digital data platform with diet management versus standard care; semaglutide use nonrandom and similar in both arms",2],["R0019289","Semaglutide in MASLD Patients: Improved Survival and Liver Outcomes.","Suki M","2025","inventory_only","N6","primary_report","P09",null,null,"high","recheck","opus-5.5-recheck01","R7: matched cohort semaglutide versus none in MASLD; mortality, cardiovascular and liver outcomes; hepatocellular carcinoma is a single site cancer",2],["R0019313","iGlarLixi versus basal plus Rapid-Acting insulin in adults with type 2 diabetes advancing from basal insulin therapy: The SoliSimplify Real-World study.","McCrimmon RJ","2023","inventory_only","N6","primary_report","P01",null,null,"high","recheck","opus-5.5-recheck01","matched EHR cohort iGlarLixi versus basal plus rapid acting insulin; HbA1c, weight, hypoglycemia; retinopathy only at baseline",2],["R0019805","Impact of dose-escalation schemes and drug discontinuation on weight loss outcomes with liraglutide 3.0 mg: A model-based approach.","Papathanasiou T","2020","inventory_only","N2","secondary_report","P02",null,null,"high","recheck","opus-5.5-recheck01","R4: population PK/PD model of liraglutide weight trajectories built on three RCTs with dose escalation simulations; no randomized between arm outcome; alternative E3",2],["R0021452","A Pilot Study Showing Acute Inhibitory Effect of GLP-1 on the Bone Resorption Marker CTX in Humans.","Nissen A","2019","inventory_only","N2","primary_report","P99",null,"crossover","high","recheck","opus-5.5-recheck01","R5: randomized crossover of GLP-1 peptides, exenatide or saline in eight healthy adults; only bone turnover markers, no outcome from outcomes.csv",2],["R0022868","Mitochondrial metabolites predict adverse cardiovascular events in individuals with diabetes.","Regan JA","2023","inventory_only","N2","secondary_report","P01",null,null,"high","recheck","opus-5.5-recheck09","R4: metabolomic prognosis study in TECOS placebo arm and EXSCEL substudy; exenatide effect only on metabolites, no review outcome by arm",2],["R0022890","A Systematic Review of Treatment Approaches for Individuals With Coexisting Diabetes and Substance Use Disorder.","Husain B","2025","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck09","R1: PubMed and Embase search, predefined criteria, tabulated synthesis including semaglutide or GLP-1 RA exposure studies in diabetes with SUD",2],["R0024315","Real-world Effectiveness of Liraglutide vs. Sitagliptin Among Older Patients with Type 2 Diabetes Enrolled in a Medicare Advantage Prescription Drug Plan: A Retrospective Observational Study.","Dang-Tan T","2020","inventory_only","N6","primary_report","P01",null,null,"high","recheck","opus-5.5-recheck07","R8: Medicare Advantage cohort of liraglutide vs sitagliptin in older adults; HbA1c, glycemic goals and costs; retinopathy and nephropathy only baseline",2],["R0019433","PIONEER REAL Japan: Primary results from a multicenter, prospective, real-world study of oral semaglutide in adults with type 2 diabetes in Japanese clinical practice.","Yabe D","2024","inventory_only","N5","primary_report","P01",null,null,"high","recheck","opus-5.5-recheck04","R3: PIONEER REAL Japan non-interventional single arm study of oral semaglutide initiated in routine practice; uncontrolled observational cohort",2],["R0021233","Assessment of Glucose Lowering Medications' Effectiveness for Cardiovascular Clinical Risk Management of Real-World Patients with Type 2 Diabetes: Targeted Maximum Likelihood Estimation under Model Misspecification and Missing Outcomes.","Sciannameo V","2022","inventory_only","N6","other","P01",null,null,"high","recheck","opus-5.5-recheck04","estimator methods paper reanalyzing DARWIN-T2D dapagliflozin vs GLP-1 RA on composite HbA1c, weight, SBP goals plus simulation; no listed harm; alternative E3",2],["R0022632","Further improvement in glycemic control after switching from exenatide two times per day to exenatide once-weekly autoinjected suspension in patients with type 2 diabetes: 52-week results from the DURATION-NEO-1 study.","Wysham CH","2020","include_nma",null,"extension","P01",null,null,"high","recheck","opus-5.5-recheck04","R4: DURATION-NEO-1 52 week report restates randomized 28 week exenatide weekly autoinjector vs twice daily contrast with AEs before nonrandomized switch",2],["R0024683","Efficacy of Dulaglutide Expanded Doses by Baseline A1C Categories: Post Hoc Analysis of AWARD-11","Frias J","2021","include_nma",null,"conference_abstract","P01",null,"abstract_only","high","recheck","opus-5.5-recheck07","R2 not applicable: AWARD-11 post hoc abstract keeps randomized dulaglutide 3 and 4.5 mg vs 1.5 mg contrast by baseline A1C subgroup",2],["R0025316","Effect of Once-Weekly Exenatide on Clinical Outcomes According to Baseline Risk in Patients With Type 2 Diabetes Mellitus: Insights From the EXSCEL Trial.","Mentz RJ","2018","include_nma",null,"secondary_report","P01",null,null,"high","recheck","opus-5.5-recheck07","R2 and R4: EXSCEL risk score analysis keeps exenatide vs placebo assignment and reports treatment by baseline risk interaction for MACE and mortality",2],["R0020031","Mild-to-moderate depressive symptoms impact on self-reported outcome measures in clinical trials for neurodegenerative diseases.","Girges C","2026","inventory_only","N8","protocol_or_design",null,null,null,"high","recheck","opus-5.5-recheck02","R2: baseline cross sectional analysis of depressive symptoms within Exenatide PD3 and MSA RCTs; no between arm outcome",2],["R0018277","Mo1622: EFFICACY OF GLP-1 ANALOGS AND AGONISTS ON PROPORTION OF WEIGHT LOSS IN OVERWEIGHT OR OBESE DIABETICS AND NONDIABETICS: A SYSTEMATIC REVIEW AND META-ANALYSIS",null,"2022","deferred","D1","other",null,null,"abstract_only","high","recheck","opus-5.5-recheck02","stored file holds only a placeholder pointing to a PDF; the meta-analysis abstract content is not available",2],["R0024459","Exploring Analysis Approaches for Using the Dopamine Transporter Striatal Binding Ratio in Early- to Mid-Stage Parkinson's Disease Modification Trials.","Vijiaratnam N","2024","inventory_only","N8","protocol_or_design",null,null,null,"high","recheck","opus-5.5-recheck02","R2: baseline DAT imaging analysis of Exenatide PD2 and PD3 trial participants before drug exposure; baseline papers are N8 whatever else applies",2],["R0014479","A novel data mining application to detect safety signals for newly approved medications in routine care of patients with diabetes.","Fralick M","2021","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck05","tree scan of canagliflozin vs GLP-1 RA initiators flags only DKA and genital infection signals for canagliflozin; no listed GLP-1 harm reported",2],["R0015802","Effect of Various Dosing Conditions on the Pharmacokinetics of Oral Semaglutide, a Human Glucagon-Like Peptide-1 Analogue in a Tablet Formulation.","Bækdal TA","2021","inventory_only","N3","primary_report",null,null,null,"high","recheck","opus-5.5-recheck05","R6 by analogy: randomized arms differ only in food, water and fasting conditions for the same oral semaglutide dose and route",2],["R0016633","Glucose-Lowering Drugs and Primary Prevention of Chronic Kidney Disease in Type 2 Diabetes Patients: A Real-World Primary Care Study.","Rodríguez-Miguel A","2024","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck05","BIFAP cohort with nested case control of glucose lowering drugs incl GLP-1 RA; outcome incident CKD, not acute kidney injury O121",2],["R0017763","Cardioprotective therapy in type 2 diabetes guided by a proteomic risk model: A randomized trial.","Gill R","2026","exclude","E2","other",null,null,null,"high","recheck","opus-5.5-recheck05","R8: randomized disclosure of proteomic risk scores with prescribing of cardioprotective drugs as outcome; GLP-1 RA not an assigned intervention",2],["R0016653","Addition of dipeptidyl peptidase-4 inhibitors to insulin treatment in type 2 diabetes patients: A meta-analysis.","Yang W","2018","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck03","R1: MEDLINE, CENTRAL and Embase search with RCT criteria; pools seven GLP-1 RA plus insulin vs placebo plus insulin trials as a comparator node",2],["R0017304","Risk of pancreatitis in patients treated with incretin-based therapies.","Meier JJ","2014","include_nma",null,"pooled_analysis","P01",null,null,"high","recheck","opus-5.5-recheck03","R4: pooled phase III and outcome trial data on pancreatitis comparing GLP-1 RA arms with their randomized comparators; no systematic search",2],["R0020207","Pilot study to test the safety, tolerability and feasibility of dulaglutide during a low-energy diet for weight loss and improved glycaemic control.","Shand JAD","2023","inventory_only","N1","primary_report","P01",null,null,"high","recheck","opus-5.5-recheck03","R3: interventional single arm pilot of dulaglutide with low energy diet in T2D with obesity; no control group",2],["R0022161","Association of Time in Range with Endothelial Injury in Patients with Type 2 Diabetes Treated with Exenatide.","Le Y","2022","inventory_only","N1","secondary_report","P01",null,null,"high","recheck","opus-5.5-recheck03","R4: analysis of branded vs generic exenatide RCT pools both arms pre-post by time in range; no randomized contrast used (R6 would also give N3)",2],["R0022710","Weight Loss Outcomes in a Veterans Affairs Pharmacotherapy-based Weight Management Clinic.","Ni K","2024","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck09","R7: VA clinic cohort comparing weight loss across anti-obesity drugs including liraglutide; harms appear only as formulary criteria",2],["R0018700","Liraglutide and the Management of Overweight and Obesity in People with Severe Mental Illness: Qualitative Sub-Study","Barnard-Kelly K","2021","inventory_only","N2","secondary_report","P15",null,null,"high","recheck","opus-5.5-recheck09","R5: preprint of qualitative interview substudy of the liraglutide versus placebo SMI pilot RCT; no between arm review outcome",2],["R0018708","Absolute treatment effects for the primary outcome and all-cause mortality in the cardiovascular outcome trials of new antidiabetic drugs: a meta-analysis of digitalized individual patient data.","Kuss O","2022","include_nma",null,"pooled_analysis","P01",null,null,"high","recheck","opus-5.5-recheck09","R4: pools digitized KM data of CVOTs keeping each trial GLP-1 RA versus placebo contrast; no database search so not a review",2],["R0022541","Long-Term Effectiveness of Liraglutide in Association with Patients' Baseline Characteristics in Real-Life Setting in Croatia: An Observational, Retrospective, Multicenter Study.","Berkovic MC","2017","inventory_only","N5","primary_report",null,null,null,"high","recheck","opus-5.5-recheck09","R3: retrospective record based cohort of liraglutide users followed 36 months, uncontrolled observational, no comparison group",2],["R0021964","Long-Term Effectiveness and Cost-Effectiveness of Metformin Combined with Liraglutide or Exenatide for Type 2 Diabetes Mellitus Based on the CORE Diabetes Model Study.","Zhang X","2016","inventory_only","N6","primary_report","P01",null,null,"high","recheck","opus-5.5-recheck07","52 week observational cohort of liraglutide vs exenatide with metformin feeding a CORE model; retinopathy outcomes are simulated only; alternative E3",2],["R0026637","Impact of medication adherence and persistence on clinical and economic outcomes in patients with type 2 diabetes treated with liraglutide: a retrospective cohort study.","Buysman EK","2015","inventory_only","N6","primary_report","P01",null,null,"high","recheck","opus-5.5-recheck07","R8: claims cohort of liraglutide users comparing adherent vs nonadherent and persistent vs not on A1C goals and costs; no listed harm",2],["R0027975","12-month effects of incretins versus SGLT2-Inhibitors on cognitive performance and metabolic profile. A randomized clinical trial in the elderly with Type-2 diabetes mellitus.","Perna S","2018","include_nma",null,"primary_report","P01",null,null,"low","recheck","opus-5.5-recheck07","randomized trial of incretins (liraglutide or DPP-4i) vs SGLT2i in elderly T2D; share on liraglutide not reported; alternative N3 if no GLP-1 contrast",2],["R0019850","Comparison of effectiveness between phentermine/topiramate and liraglutide in obese patients with nonalcoholic fatty liver disease","Park SJ","2024","inventory_only","N6","primary_report","P09",null,null,"high","recheck","opus-5.5-recheck01","whole preprint read; retrospective comparison of phentermine topiramate versus liraglutide in NAFLD; steatosis, fibrosis, weight; adverse events itemized only in supplement",2],["R0021303","Outcomes of Different Lifestyle Approaches in a Multicentre, Open-Label, Parallel-Group, Randomised Controlled Trial of the Effectiveness of Integrating a Pragmatic Pathway for Prescribing Liraglutide 3.0 mg in Weight Management Services (STRIVE Study).","Al-Najim W","2025","inventory_only","N1","secondary_report","P02",null,null,"high","recheck","opus-5.5-recheck01","R4: post hoc analysis restricted to the standard care arm of STRIVE comparing sites; no randomized GLP-1 RA contrast used; alternative E2",2],["R0021398","Subclinical Changes in Type 2 Diabetes Patients with Heart Failure Stage A and B Treated with Oral Semaglutide.","Dăniluc L","2025","inventory_only","N5","primary_report","P01",null,null,"high","recheck","opus-5.5-recheck01","R3: prospective observational single center cohort of oral semaglutide users with echocardiography, no comparison group",2],["R0021471","Assessment of real-time and quantitative changes in renal hemodynamics in healthy overweight males: Contrast-enhanced ultrasonography vs para-aminohippuric acid clearance.","Muskiet MHA","2019","inventory_only","N1","secondary_report","P02",null,null,"high","recheck","opus-5.5-recheck01","exenatide always followed saline or L-NMMA within the same day, a fixed before and after sequence; renal hemodynamics only, also N2",2],["R0025958","Role of Metformin, Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, and Orlistat based Multidrug Therapy in Glycemic Control, Weight Loss, and Euglycemia in Diabesity: A Real-World Experience.","Dutta D","2019","inventory_only","N6","primary_report","P01",null,null,"high","recheck","opus-5.5-recheck04","retrospective records comparing multidrug groups partly containing GLP-1 RA on weight and HbA1c in diabesity; no listed harm; alternative N5 descriptive",2],["R0023538","CauReL: Dynamic Counterfactual Learning for Precision Drug Repurposing in Alzheimer's Disease.","Wang Y","2025","inventory_only","N6","other",null,null,null,"high","recheck","opus-5.5-recheck04","counterfactual learning EHR study estimating liraglutide and other drug effects on Alzheimer onset vs untreated; no listed harm; alternative E3 methods paper",2],["R0024275","Duodenal mucosal resurfacing with a GLP-1 receptor agonist increases postprandial unconjugated bile acids in patients with insulin-dependent type 2 diabetes.","Meiring S","2022","inventory_only","N1","secondary_report","P01",null,null,"high","recheck","opus-5.5-recheck04","single arm interventional pilot of duodenal mucosal resurfacing plus protocol liraglutide replacing insulin; bile acid before and after, no comparator",2],["R0024284","The association between liver function tests abnormalities and type 2 diabetes mellitus patients in Saudi Arabia: a cross-sectional study.","Mehyar N","2025","inventory_only","N5","other","P01",null,null,"high","recheck","opus-5.5-recheck04","cross sectional chart review of liver test abnormalities in T2D analyzes liraglutide use as an exposure (AST OR); design not eligible for harms synthesis",2],["R0023041","Comparative Effectiveness of Empagliflozin vs Liraglutide or Sitagliptin in Older Adults With Diverse Patient Characteristics.","Htoo PT","2022","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck02","Medicare new user cohorts empagliflozin vs liraglutide or sitagliptin; MACE and heart failure hospitalization only; cancer is an exclusion",2],["R0017715","A population-adjusted indirect comparison of cardiovascular benefits of once-weekly subcutaneous semaglutide and dulaglutide in the treatment of patients with type 2 diabetes, with or without established cardiovascular disease.","Evans LM","2021","inventory_only","N6","secondary_report",null,null,null,"high","recheck","opus-5.5-recheck02","R4: matching adjusted indirect comparison of SUSTAIN 6 individual data with REWIND aggregate data; cross trial comparison without shared randomized arm",2],["R0024843","Bullous Pemphigoid and Diabetes medications: A disproportionality analysis based on the FDA Adverse Event Reporting System.","Huang L","2021","inventory_only","N5","other",null,null,null,"high","recheck","opus-5.5-recheck09","FAERS disproportionality analysis of bullous pemphigoid that includes GLP-1 RAs among diabetes drug classes; spontaneous report design is N5",2],["R0020001","Durability of Effectiveness Between Users of Once-Weekly Semaglutide and Dipeptidyl Peptidase 4 Inhibitors (DPP-4i) in US Adults with Type 2 Diabetes.","Tan X","2024","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck09","R7: claims cohort semaglutide versus DPP-4i on HbA1c and BMI durability; pancreatitis and cancer only baseline covariates",2],["R0025772","The cardiovascular benefits of GLP1-RAs are related to their positive effect on glycemic control: A meta-regression analysis.","Ghosal S","2022","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck09","R1: INPLASY registered review, Cochrane Library search, stated criteria, meta-regression of GLP-1 RA versus placebo CVOTs",2],["R0023665","Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database.","Best JH","2011","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck10","claims cohort exenatide initiators versus other glucose lowering therapy; CVD events and hospitalization only; retinopathy and neoplasms only covariates",2],["R0023839","Liraglutide Use in A Real-World Setting: Patient Characteristics at Antidiabetic Treatment Initiation Modulate Cardiovascular Safety Outcomes","Gallagher A","2020","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck10","CPRD liraglutide versus other NIAD initiators; authors state this paper reports only CV outcomes, pancreatitis and cancers captured but not reported here",2],["R0019122","Dapagliflozin as monotherapy or combination therapy in Japanese patients with type 2 diabetes: an open-label study.","Kaku K","2014","inventory_only","N1","primary_report",null,null,null,"high","recheck","opus-5.5-recheck05","single arm open label dapagliflozin trial; GLP-1 RA only a background therapy in one subgroup, no comparison group",2],["R0020563","[Genetic aspects of type 1 glucagon peptide agonists clinical efficacy: A review].","Golovina EL","2023","exclude","E3","other",null,null,"non_english","high","recheck","opus-5.5-recheck05","R1: Russian pharmacogenetic review names PubMed, Web of Science, eLIBRARY search but states no eligibility criteria or selection",2],["R0022182","Maternal-to-Infant Transfer of Medications for Type 2 Diabetes Mellitus Via Breastmilk: A Systematic Review of Available Evidence and Clinical Guidelines.","Richardson K","2026","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck05","R1: PRISMA search of Scopus, PubMed, LactMed with stated criteria; structured synthesis of breastmilk transfer studies including semaglutide",2],["R0020178","Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: A real-world systematic review and meta-analysis.","Li CX","2021","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck03","R1: PubMed and Embase search with criteria; pools SGLT2i vs other drugs including SGLT2i vs GLP-1 RA cohort comparisons; alternative E2",2],["R0016998","Achieving BMI <25 kg/m2 was associated with reduced predicted risk of atherosclerotic cardiovascular disease in people with obesity or overweight on tirzepatide or placebo: a post hoc analysis of SURMOUNT-1, -3, and -CN.","Guo L","2026","inventory_only","N2","secondary_report","P02",null,null,"high","recheck","opus-5.5-recheck03","R4: pooled SURMOUNT post hoc compares predicted ASCVD risk by achieved BMI group, not by randomized arm; risk equation without between arm outcome",2],["R0018732","Predicting heart failure in asymptomatic diabetes: derivation and internal validation of a clinical prediction model for early detection of diabetic cardiomyopathy.","Cao Y","2026","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck03","Retrospective prediction model cohort; combined SGLT2i or GLP-1 RA use is one predictor of HF composite; no listed harm; alternative E2",2],["R0020941","Real-world effectiveness of Semaglutide treatment on weight loss maintenance after weight loss in patients with obesity or overweight and diabetes.","Del Prete M","2025","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck03","R7: retrospective injectable vs oral semaglutide cohort reports weight, BMI and HbA1c only; no listed harm outcome",2],["R0017425","Dry eye disease in patients with type II diabetes mellitus: A retrospective, population-based cohort study in Taiwan.","Pan LY","2022","inventory_only","N6","primary_report","P01",null,null,"high","recheck","opus-5.5-recheck01","retrospective cohort of dry eye disease risk factors including GLP-1 agonist use; retinopathy is a covariate, no listed harm outcome",2],["R0018697","Analysis of clinical studies on clozapine from 2012-2022.","Freibüchler A","2024","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck01","R1: PubMed search with stated inclusion criteria and tabulated synthesis including liraglutide and exenatide trials for clozapine weight gain",2],["R0028055","Type 1 diabetic patients with peripheral neuropathy have pan-enteric prolongation of gastrointestinal transit times and an altered caecal pH profile.","Farmer AD","2017","inventory_only","N8","protocol_or_design","P05",null,null,"high","recheck","opus-5.5-recheck04","R2: baseline data of a liraglutide RCT in T1D neuropathy compared with healthy controls; no between arm outcome reported",2],["R0021340","Comparing Real-World Effectiveness of Dulaglutide and Insulin as the First Injectable for Patients with Type 2 Diabetes: An Australian Single-Site Retrospective Chart Review.","Houssarini JA","2022","inventory_only","N6","primary_report","P01",null,null,"high","recheck","opus-5.5-recheck04","retrospective chart review dulaglutide vs insulin initiators with AIPW; HbA1c, weight, hypoglycemia only; retinopathy only baseline",2],["R0026533","Exenatide's effect in reducing weight and glycosylated hemoglobin level in an Arab population with type 2 diabetes.","Bashier AM","2014","inventory_only","N5","primary_report","P01",null,null,"high","recheck","opus-5.5-recheck04","R3: retrospective chart review of routine exenatide initiators with before and after HbA1c and weight; uncontrolled observational cohort",2],["R0027405","OR10-3 Long-term Weight Loss Maintenance with Obesity Pharmacotherapy: a 5-Year Retrospective Study",null,"2022","inventory_only","N5","conference_abstract",null,null,"abstract_only","high","recheck","opus-5.5-recheck04","R3: retrospective weight center cohort of patients on various anti obesity drugs including semaglutide; no comparison group, descriptive users",2],["R0027568","Patient-reported outcomes among patients using exenatide twice daily or insulin in clinical practice in six European countries: the CHOICE prospective observational study.","Reaney M","2013","inventory_only","N5","primary_report",null,null,null,"high","recheck","opus-5.5-recheck09","R3: CHOICE exenatide and insulin initiator cohorts described separately; authors made no between cohort comparison, descriptive study of users",2],["R0025120","A Retrospective Database Study of Liraglutide Persistence Associated with Glycemic and Body Weight Control in Patients with Type 2 Diabetes.","Melzer-Cohen C","2019","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck09","R7: matched liraglutide continuers versus discontinuers on HbA1c and weight; pancreatitis and gallbladder disease appear only at baseline",2],["R0027629","Effect of renal impairment on the pharmacokinetics of exenatide.","Linnebjerg H","2007","inventory_only","N1","primary_report","P99",null,null,"high","recheck","opus-5.5-recheck09","open label single dose exenatide PK study grouped by renal function, doses not randomized, no comparison of regimens",2],["R0019392","Evaluation of Characteristics of Gastrointestinal Adverse Events with Once-Weekly Dulaglutide Treatment in Chinese Patients with Type 2 Diabetes: A Post Hoc Pooled Analysis of Two Randomized Trials.","Guo L","2020","include_nma",null,"pooled_analysis","P01",null,null,"high","recheck","opus-5.5-recheck02","R4: pooled AWARD-CHN1 and CHN2 analysis reports GI adverse events by randomized dulaglutide 1.5 mg vs 0.75 mg arms; dose contrast kept",2],["R0023591","Testing a new platform to screen disease-modifying therapy in type 1 diabetes.","Lord SM","2023","inventory_only","N1","primary_report",null,null,null,"high","recheck","opus-5.5-recheck10","R3: nonrandomized sequential single arm interventional pilots (liraglutide, then verapamil, golimumab) each analyzed before and after; no concurrent comparison",2],["R0024464","Available Treatments and Adjunctive Therapies for Polycystic Ovarian Syndrome (PCOS) Patients of Reproductive Age: A Scoping Review.","Cochran L","2024","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck10","R1: scoping review searching PubMed, CINAHL and ScienceDirect with predetermined inclusion criteria; tabulated synthesis includes liraglutide and exenatide studies in PCOS",2],["R0024778","Real-world cost-effectiveness: lower cost of treating patients to glycemic goal with liraglutide versus exenatide.","DeKoven M","2014","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck02","R8: claims cohort liraglutide vs exenatide on cost per patient at HbA1c goal; clinical outcome HbA1c only; retinopathy is a baseline covariate",2],["R0026775","Estimating Effects Of Second Line Therapy For Type 2 Diabetes Mellitus: Retrospective Cohort Study","Gottlieb A","2017","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck02","EHR causal inference cohort of four second line classes incl GLP-1 RA; HbA1c and BMI effects only, no listed harm outcome",2],["R0027271","Effects of exenatide alone and in combination with daclizumab on beta-cell function in long-standing type 1 diabetes.","Rother KI","2009","include_nma",null,"primary_report","P05",null,"mechanistic; crossover","high","recheck","opus-5.5-recheck10","randomized open label crossover of exenatide on versus off (with or without daclizumab) in type 1 diabetes; reports weight, HbA1c, insulin dose, hypoglycemia",2],["R0028039","A real-world study of treatment patterns and outcomes in US managed-care patients with type 2 Diabetes initiating injectable therapies.","Wei W","2017","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck02","INITIATOR claims and chart cohort glargine vs liraglutide initiators; HbA1c, weight, hypoglycemia, costs; retinopathy baseline only",2],["R0026004","An Indirect Comparison of Changes in the Impact of Weight on Quality of Life Among Subjects with Type 2 Diabetes Treated with Antihyperglycemic Agents in Dual Therapy with Metformin.","Traina SB","2018","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck10","R1: MEDLINE, Embase, CENTRAL search with eligibility criteria and anchored Bayesian indirect comparison of exenatide QW versus canagliflozin via sitagliptin",2],["R0023328","Development of Cardiovascular Risk Equations in People with Overweight or Obesity and Established Cardiovascular Disease Without Diabetes Based on the SELECT Trial.","Bøg M","2026","include_nma",null,"secondary_report","P02",null,null,"high","recheck","opus-5.5-recheck01","R4: risk equation paper on SELECT patient data reports semaglutide versus placebo adjusted hazard ratios for ACS and stroke, keeping the randomized contrast",2],["R0024194","Renoprotective Effects of the Combination of Empagliflozin and Liraglutide Compared With Roux-en-Y Gastric Bypass in Early-Stage Diabetic Kidney Disease: A Post Hoc Analysis of the Microvascular Outcomes after Metabolic Surgery (MOMS) Randomized Controlled Clinical Trial.","Cohen RV","2021","inventory_only","N6","secondary_report","P08A; P01",null,null,"high","recheck","opus-5.5-recheck01","R4: post hoc MOMS letter compares medical arm patients who chose empagliflozin plus liraglutide with RYGB arm; GLP-1 use not randomized; renal metabolic outcomes",2],["R0025005","Real-World Clinical Effectiveness of Liraglutide 3.0 mg for Weight Management in Canada.","Wharton S","2019","inventory_only","N5","primary_report","P02",null,null,"high","recheck","opus-5.5-recheck01","R3: real world observational cohort of liraglutide 3.0 mg initiators from clinic records, before and after, no comparison group",2],["R0027001","LEADER 3--lipase and amylase activity in subjects with type 2 diabetes: baseline data from over 9000 subjects in the LEADER Trial.","Steinberg WM","2014","inventory_only","N8","protocol_or_design","P01",null,null,"high","recheck","opus-5.5-recheck01","R2: LEADER baseline lipase and amylase before randomization; no between arm outcome reported",2],["R0028087","A review of exenatide as adjunctive therapy in patients with type 2 diabetes.","Robles GI","2009","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck04","R1: searched MEDLINE, IPA, Cochrane with RCT design criteria; tabulated results of exenatide placebo and active controlled trials",2],["R0021439","Lixisenatide Improves Glycemic Control in Asian Type 2 Diabetic Patients Inadequately Controlled With Oral Antidiabetic Drugs: An Individual Patient Data Meta-Analysis.","Shu H","2016","include_nma",null,"pooled_analysis","P01",null,null,"high","recheck","opus-5.5-recheck05","R4: sponsor funded pooling of five GetGoal lixisenatide vs placebo RCTs found by registry lookup, not a systematic search; randomized contrast kept",2],["R0022545","Liraglutide Effect on Weight, Glycated Hemoglobin, and Blood Pressure: A Single-Center Experience in the Eastern Province of Saudi Arabia.","Alsafwani DM","2022","inventory_only","N5","primary_report","P01",null,"retracted","high","recheck","opus-5.5-recheck04","R3: retracted retrospective single center review of routine liraglutide users with before and after outcomes; N5 precedes N7 in order",2],["R0023395","Glycemic Outcomes of Second-Line Diabetes Drug Choice in a Real-World Population.","Wallia A","2021","inventory_only","N6","primary_report","P01",null,null,"high","recheck","opus-5.5-recheck04","claims new user cohort of second line classes incl GLP-1 RA vs sulfonylurea; hypoglycemia and acute metabolic complications only, no listed harm",2],["R0019534","Glucagon-like peptide 1 agonists for treatment of patients with type 2 diabetes who fail metformin monotherapy: systematic review and meta-analysis of economic evaluation studies.","Bagepally BS","2020","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck05","R1: PROSPERO registered search of PubMed, Scopus, CENTRAL and others with criteria; pooled net benefit of GLP-1 RA vs other second line drugs",2],["R0022123","Comparison of the injection-site experience of semaglutide in a single-dose and a multidose pen-injector.","Snitker S","2022","inventory_only","N3","primary_report",null,null,"crossover","high","recheck","opus-5.5-recheck05","R6: randomized order crossover of semaglutide 0.25 mg in two pen formulations differing only in excipients, same dose and route",2],["R0027989","Predictors and prognostic value of left atrial remodelling after acute myocardial infarction.","Kyhl K","2015","inventory_only","N2","secondary_report",null,null,null,"high","recheck","opus-5.5-recheck10","R4: prognostic subgroup analysis of exenatide STEMI RCT; exenatide only a covariate, MACE reported by atrial remodelling tertile, no between-arm review outcome",2],["R0026109","Effect of hemodialysis on plasma glucose profile and plasma level of liraglutide in patients with type 2 diabetes mellitus and end-stage renal disease: a pilot study.","Osonoi T","2014","inventory_only","N1","primary_report",null,null,null,"high","recheck","opus-5.5-recheck10","R3: registered interventional single arm PK pilot of liraglutide on versus off hemodialysis days; no comparison changing GLP-1 exposure",2],["R0027799","Effectiveness of Combining Antiobesity Medication With an Employer-Based Weight Management Program for Treatment of Obesity: A Randomized Clinical Trial.","Pantalone KM","2021","include_nma",null,"primary_report","P02",null,null,"low","recheck","opus-5.5-recheck10","RCT of weight program plus antiobesity medication access (liraglutide 3.0 mg among five options) versus program alone; share on liraglutide not visible; alternative N3",2],["R0020328","A comprehensive assessment of the association between common drugs and psychiatric disorders using Mendelian randomization and real-world pharmacovigilance database.","Chen Z","2024","inventory_only","N5","primary_report",null,null,null,"high","recheck","opus-5.5-recheck03","FAERS disproportionality across 19 drug targets including antidiabetic classes plus drug target Mendelian randomization; no cohort comparison; alternative E2",2],["R0022828","Efficacy and Safety of Dulaglutide by Baseline HbA1c in Chinese Patients with Type 2 Diabetes: A Post Hoc Analysis.","Yu M","2020","include_nma",null,"secondary_report","P01",null,null,"high","recheck","opus-5.5-recheck03","R2 not applicable: AWARD-CHN1 and CHN2 post hoc reports dulaglutide vs glimepiride or glargine HbA1c, weight and hypoglycemia by baseline HbA1c",2],["R0026046","Evaluation of the efficacy and safety of lixisenatide add-on treatment to basal insulin therapy among T2DM patients with different body mass indices from GetGoal trials.","Eto K","2015","inventory_only","N1","secondary_report","P01",null,null,"high","recheck","opus-5.5-recheck03","R4: pooled GetGoal analysis uses lixisenatide arms only, compared across BMI categories; placebo arms not analyzed",2],["R0026069","A systematic literature review on the efficacy-effectiveness gap: comparison of randomized controlled trials and observational studies of glucose-lowering drugs.","Ankarfeldt MZ","2017","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck02","R1: four named databases with explicit criteria; structured table of GLP-1 RA vs insulin HbA1c effect sizes from RCTs and cohorts",2],["R0026940","A Review of Interventional Trials in Youth-Onset Type 2 Diabetes: Challenges and Opportunities.","Currie BM","2021","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck02","R1: Medline, Embase and ClinicalTrials.gov searched with stated criteria; structured design and key results table includes pediatric liraglutide and exenatide trials",2],["R0029294","The impact of semaglutide initiated six months after laparoscopic sleeve gastrectomy on long-term weight loss and metabolic outcomes: single-center preliminary study.","Jeske P","2026","include_harms",null,"primary_report",null,"O28; O29",null,"high","recheck","opus-5.5-recheck02","R7: retrospective cohort semaglutide started after sleeve gastrectomy vs standard follow up; adverse event table reports acute pancreatitis and cholecystitis by group",2],["R0026275","Renal Outcomes Associated with the Use of Non-Insulin Antidiabetic Pharmacotherapy: A Review of Current Evidence and Recommendations.","Elnaem MH","2020","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck01","R1: searched PubMed, ScienceDirect and Google Scholar with tabulated criteria and dual screening; tabulated synthesis includes six GLP-1 RA renal outcome studies",2],["R0026444","Exenatide at therapeutic and supratherapeutic concentrations does not prolong the QTc interval in healthy subjects.","Darpö B","2013","include_nma",null,"primary_report","P99",null,"mechanistic; crossover","high","recheck","opus-5.5-recheck01","R5: randomized placebo and moxifloxacin controlled crossover thorough QT study of IV exenatide in healthy adults; reports adverse events, nausea and vomiting by treatment",2],["R0029071","Systematic review of peptide nanoparticles for improved diabetes outcomes: insights and opportunities.","Dangana RS","2025","exclude","E2","other",null,null,null,"high","recheck","opus-5.5-recheck01","R1: whole PDF read; review of peptide nanoparticles in which GLP-1 RA (oral exenatide and liraglutide particles) appears only in animal studies",2],["R0021451","[Semaglutide - effectiveness in weight loss and side effects when used according to studies by SUSTAIN, PIONEER, STEP].","Shabutdinova OR","2023","include_review",null,"systematic_review",null,null,"non_english","high","recheck","opus-5.5-recheck05","R1: PubMed search with stated limits to original SUSTAIN, PIONEER, STEP RCTs; tabulated synthesis of semaglutide efficacy and safety",2],["R0025094","Disease duration as an indicator of the efficacy of liraglutide in patients with type 2 diabetes mellitus.","Wilbrink FJ","2018","inventory_only","N5","primary_report",null,null,null,"high","recheck","opus-5.5-recheck05","R3: letter reporting own retrospective cohort switching insulin to liraglutide, response by disease duration; no comparison group",2],["R0026071","Efficacy and safety analyses across 4 subgroups combining low and high age and body mass index groups in Japanese phase 3 studies of dulaglutide 0.75 mg after 26 weeks of treatment.","Hamano K","2017","inventory_only","N1","secondary_report",null,null,null,"high","recheck","opus-5.5-recheck05","R4: post hoc analysis pools only dulaglutide-treated patients from three Japanese phase 3 trials by age and BMI; no randomized contrast",2],["R0026859","Incidence and predictors of hypoglycaemia in type 2 diabetes - an analysis of the prospective DiaRegis registry.","Tschöpe D","2012","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck05","DiaRegis registry of hypoglycemia predictors incl GLP-1 RA use; retinopathy is a baseline predictor, no listed harm outcome",2],["R0021214","The Necessity of POMC and MC3R Analysis in the First-Level Diagnosis of Monogenic Obesity: The Experience of Two Italian Centers.","Miedviedieva K","2026","inventory_only","N5","primary_report",null,null,null,"high","recheck","opus-5.5-recheck03","Genetic screening study; tirzepatide appears only as a single patient follow-up with poor weight response, a case report element",2],["R0023915","Acetyl-CoA Carboxylase Inhibitors for Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.","Hasanatuludhhiyah N","2025","exclude","E2","systematic_review",null,null,null,"high","recheck","opus-5.5-recheck03","R1: ACC inhibitor meta-analysis; semaglutide appears only as background in semaglutide plus firsocostat vs semaglutide comparison",2],["R0024924","What's New in the Treatment of Non-Alcoholic Fatty Liver Disease (NAFLD).","Kosmalski M","2023","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck03","R1: PRISMA PubMed search with stated criteria for NAFLD RCTs; tabulated synthesis of treatments includes GLP-1 RA trials such as dulaglutide",2],["R0025942","Should Studies of Diabetes Treatment Stratification Correct for Baseline HbA1c?","Jones AG","2016","inventory_only","N5","primary_report",null,null,null,"high","recheck","opus-5.5-recheck03","Methodological analysis in an uncontrolled GLP-1 RA initiator cohort and a separate sulfonylurea cohort; no drug comparison; alternative E3",2],["R0017921","A study to evaluate the impact of PB-119 injection (a pegylated exenatide formulation) on the pharmacokinetic profiles of Digoxin and Warfarin sodium in healthy subjects.","Yu Y","2026","inventory_only","N1","primary_report",null,null,null,"high","recheck","opus-5.5-recheck02","PB-119 interaction study gives probe drug alone then with PB-119 in fixed within subject sequence; no randomized GLP-1 RA contrast despite label",3],["R0026012","Surrogate endpoint evaluation using data from one large global randomized controlled trial.","Geybels M","2021","include_nma",null,"secondary_report","P01",null,null,"high","recheck","opus-5.5-recheck05","R4: surrogate endpoint methods analysis of LEADER reporting liraglutide vs placebo hazard ratios by country group; alternative E3 methods paper",2],["R0020007","ODP632 Preadmission Use Of Antidiabetic Medications And Mortality Among Patients With Covid-19 Having Type 2 Diabetes: A Meta-analysis",null,"2022","exclude","E3","other",null,null,"abstract_only","high","recheck","opus-5.5-recheck05","R1: congress abstract of meta-analysis on antidiabetic drugs and COVID-19 mortality names no database and states no eligibility criteria",2],["R0025248","Onset of Glycemic and Weight Outcomes in Patients Initiating Exenatide Once Weekly: The Relationship of Exenatide Exposure with Efficacy over the First 24 Weeks of Treatment.","Blevins T","2016","inventory_only","N1","secondary_report",null,null,null,"high","recheck","opus-5.5-recheck05","R4: DURATION-5 post hoc restricted to the exenatide weekly arm on onset of response and exposure; randomized contrast not used",2],["R0027026","Selection of Antiobesity Medications Based on Phenotypes Enhances Weight Loss: A Pragmatic Trial in an Obesity Clinic.","Acosta A","2021","inventory_only","N3","primary_report",null,null,null,"high","recheck","opus-5.5-recheck05","pragmatic trial of phenotype-guided vs standard antiobesity drug selection; arms are selection strategies, not a GLP-1 RA regimen; allocation by appointment",2],["R0027796","Combining phenome-driven drug-target interaction prediction with patients' electronic health records-based clinical corroboration toward drug discovery.","Zhou M","2020","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck03","Drug target prediction plus EHR case control comparing liraglutide prescription vs none on Alzheimer diagnosis; not a listed harm; alternative E3",2],["R0023645","Clinical and economic outcomes among injection-naïve patients with type 2 diabetes initiating dulaglutide compared with basal insulin in a US real-world setting: the DISPEL Study.","Mody R","2019","inventory_only","N6","primary_report",null,null,null,"high","recheck","opus-5.5-recheck03","R7: DISPEL matched claims cohort dulaglutide vs basal insulin reports HbA1c and costs only; retinopathy only at baseline",2],["R0026910","Prophylactic use of anti-emetic medications reduced nausea and vomiting associated with exenatide treatment: a retrospective analysis of an open-label, parallel-group, single-dose study in healthy subjects.","Ellero C","2010","inventory_only","N1","primary_report","P99",null,null,"high","recheck","opus-5.5-recheck03","R3: all healthy volunteers got the same single exenatide dose; nonrandomized antiemetic premedication contrast never varies GLP-1 exposure; alternative N3",2],["R0027006","Patients with Type 2 Diabetes Initiating Exenatide Twice Daily or Insulin in Clinical Practice: CHOICE Study.","Matthaei S","2012","inventory_only","N8","protocol_or_design",null,null,null,"high","recheck","opus-5.5-recheck03","R2 by analogy: CHOICE cohort baseline report of exenatide vs insulin initiators; only predictors of treatment choice, no outcomes yet",2],["R0029009","GLP-1 and GIP receptor agonists in the treatment of Parkinson's disease: Translational systematic review and meta-analysis protocol of clinical and preclinical studies.","Vaccari C","2021","inventory_only","N8","protocol_or_design",null,null,null,"high","recheck","opus-5.5-recheck05","R2: registered report protocol of a translational systematic review of GLP-1 and GIP agonists in Parkinson disease; no results",2],["R0024638","Effects of Liraglutide on Cardiovascular Outcomes in Type 2 Diabetes Patients With and Without Baseline Metformin Use: Post Hoc Analyses of the LEADER Trial.","Crowley MJ","2020","include_nma",null,"secondary_report","P01",null,null,"high","recheck","opus-5.5-recheck05","R2 not applicable, R4: LEADER post hoc letter reports liraglutide vs placebo CV outcomes by baseline metformin use",2],["R0026357","Currently prescribed drugs in the UK that could upregulate or downregulate ACE2 in COVID-19 disease: a systematic review.","Dambha-Miller H","2020","exclude","E2","other",null,null,null,"high","recheck","opus-5.5-recheck05","R1: systematic review of drugs affecting ACE2; GLP-1 agonist evidence comes only from two rat studies",2],["R0003505","Effectiveness and cost-effectiveness of six GLP-1RAs for treatment of Chinese type 2 diabetes mellitus patients that inadequately controlled on metformin: a micro-simulation model.","Yuan S","2023","exclude","E3","other",null,null,null,"high","coordinator","opus-5.5-coordinator","R14: cost effectiveness model whose embedded NMA shows no search; a modeling study",3],["R0000689","Estimating the True MACE Benefits From Tirzepatide in SURPASS-CVOT Using an Imputed Placebo Analysis of REWIND.","Sattar N","2026","include_nma",null,"secondary_report","P01",null,null,"high","coordinator","opus-5.5-coordinator","R4: reports a REWIND subgroup dulaglutide versus placebo randomized HR",3],["R0001639","Prognostic benefit of glucagon-like peptide-1 receptor agonists addition to sodium-glucose cotransporter 2 inhibitors in patients with atherosclerotic cardiovascular disease and heart failure: a cohort study.","Chen SY","2025","include_harms",null,"primary_report",null,"O28",null,"high","coordinator","opus-5.5-coordinator","R11: acute cholecystitis compared by group as a negative control outcome",3],["R0001662","Gastrointestinal Adverse Effects of GLP-1 and Dual GLP-1/GIP Receptor Agonists: A Comprehensive Update in Diabetic and Obese Populations.","Yılmaz N","2026","exclude","E3","other",null,null,null,"high","coordinator","opus-5.5-coordinator","R14: no study count, flow or table; cannot tell which studies met its criteria",4],["R0002056","Long-term comparison of renal and metabolic outcomes after sodium-glucose co-transporter 2 inhibitor or glucagon-like peptide-1 receptor agonist therapy in type 2 diabetes.","Sohn M","2024","include_harms",null,"primary_report",null,"O39",null,"high","coordinator","opus-5.5-coordinator","R10: supplement gives malignancy by group; pancreatitis not reported by group",3],["R0002057","GLP-1 receptor agonists for treating obesity without diabetes: A systematic review and meta-analysis of economic evaluations.","Dhippayom T","2026","exclude","E3","other",null,null,null,"high","coordinator","opus-5.5-coordinator","R14: review pooling economic evaluations of semaglutide and liraglutide only",3],["R0002145","Effect of Glucagon-like Peptide-1 Receptor Agonists on Outcomes and Complications Following Arthroscopic Rotator Cuff Repair: A Matched-Cohort Analysis.","Lauck BJ","2026","include_harms",null,"primary_report",null,"O121",null,"high","coordinator","opus-5.5-coordinator","R7: 90 day postoperative renal failure by group, an acute outcome",3],["R0002607","Economic evaluation of liraglutide vs dulaglutide or oral semaglutide in patients with type 2 diabetes mellitus: a systematic review.","Wang L","2025","exclude","E3","other",null,null,null,"high","coordinator","opus-5.5-coordinator","R14: systematic review of cost effectiveness studies only",3],["R0002684","SUN-114 Comparative Analysis of Glucagon-Like Peptide-1 Receptor Agonists, Metformin, and Inositol in Managing Polycystic Ovary Syndrome: A Network Meta-Analysis",null,"2025","include_review",null,"systematic_review",null,null,"abstract_only","high","coordinator","opus-5.5-coordinator","R14: congress abstract of a network meta-analysis of PCOS RCTs of GLP-1 RA",3],["R0003020","Effect of GLP-1RA on coronary progression and cardiovascular outcomes in type 2 diabetic patients after PCI: a prospective cohort study.","Zeng H","2025","include_harms",null,"primary_report",null,"O29",null,"high","coordinator","opus-5.5-coordinator","R10: states no pancreatitis occurred in either group of the matched cohort",3],["R0003029","GLP-1 Receptor Agonists: A Promising Therapy for Modern Lifestyle Diseases with Unforeseen Challenges.","Kupnicka P","2024","include_review",null,"systematic_review",null,null,null,"high","coordinator","opus-5.5-coordinator","R14: PubMed search and criteria; reports results of included thyroid and pancreatic studies in text",3],["R0004219","New Perspectives in Modulating the Entero-Insular Axis in Pediatric Obesity.","Dira LM","2025","include_review",null,"systematic_review",null,null,null,"high","coordinator","opus-5.5-coordinator","R14: ClinicalTrials.gov search of pediatric GLP-1 RA trials with tabulated efficacy and safety results",3],["R0004350","Glucagon-like peptide-1 receptor agonists rescued diabetic vascular endothelial damage through suppression of aberrant STING signaling.","He X","2024","include_harms",null,"primary_report",null,"O33",null,"high","coordinator","opus-5.5-coordinator","R13: human cohort compares incident diabetic retinopathy between GLP-1 RA and other drugs",3],["R0004495","Pharmacotherapy for Obstructive Sleep Apnea: From Pathophysiology to Emerging Treatments.","Zhou R","2026","include_review",null,"systematic_review",null,null,null,"high","coordinator","opus-5.5-coordinator","R14: self described narrative review with four databases, criteria and graded results of included studies",3],["R0005168","Potential therapeutic targets for nonalcoholic fatty liver disease: Glucagon-like peptide 1.","Yin YH","2023","inventory_only","N9","ancillary",null,null,null,"high","coordinator","opus-5.5-coordinator","letter on a semaglutide NASH article; ancillary either way",3],["R0006567","Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity.","Rodriguez PJ","2024","include_harms",null,"primary_report",null,"O28; O29; O37A; O37B",null,"high","coordinator","opus-5.5-coordinator","journal version of R0011253, which compares obstruction, cholecystitis, gastroparesis and pancreatitis",3],["R0006716","Are Semaglutide and Tirzepatide Cost-Effective for Weight Management? A Systematic Review and Meta-analysis","Xu Y","2026","exclude","E3","other",null,null,null,"high","coordinator","opus-5.5-coordinator","R14: review pooling cost effectiveness results of semaglutide and tirzepatide only",3],["R0006745","Activation of Glucagon-Like Peptide-1 Receptor Ameliorates Cognitive Decline in Type 2 Diabetes Mellitus Through a Metabolism-Independent Pathway.","Li Q","2021","inventory_only","N6","primary_report",null,null,null,"high","coordinator","opus-5.5-coordinator","allocation by BMI with no random procedure; nonrandomized comparison without a listed harm",3],["R0007513","GLP-1 receptor agonists: A novel pharmacotherapy for binge eating (Binge eating disorder and bulimia nervosa)? A systematic review.","Aoun L","2024","include_review",null,"systematic_review",null,null,null,"high","coordinator","opus-5.5-coordinator","R14: named databases and stated criteria; reports results of included binge eating studies in text",3],["R0007579","Approach to weight management in patients with advanced chronic kidney disease in a real-life clinical setting.","Lockhart Pastor P","2024","inventory_only","N6","primary_report",null,null,null,"high","coordinator","opus-5.5-coordinator","R10: pancreatitis only a discontinuation reason in the GLP-1 group, not compared",3],["R0007985","Impact of chronic GLP-1 RA and SGLT-2I therapy on in-hospital outcome of diabetic patients with acute myocardial infarction.","Trombara F","2023","inventory_only","N6","primary_report",null,null,null,"high","coordinator","opus-5.5-coordinator","R16: exposure pools GLP-1 RA with SGLT2 inhibitor users; AKI not attributable",3],["R0008421","Characteristics of subjects with type 2 diabetes enrolled in randomized controlled trials and non-randomized controlled trials in Japan: A systematic review.","Kadowaki T","2023","exclude","E3","other",null,null,null,"high","coordinator","opus-5.5-coordinator","R14: synthesizes only baseline characteristics of trial arms, no results",3],["R0008630","Case study of semaglutide and cardiovascular outcomes: An application of the Causal Roadmap to a hybrid design for augmenting an RCT control arm with real-world data.","Dang LE","2023","include_nma",null,"secondary_report","P01",null,null,"high","coordinator","opus-5.5-coordinator","R4: methods case study reporting PIONEER 6 MACE by randomized arm",3],["R0008785","The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists.","Urva S","2020","include_nma",null,"secondary_report","P01; P99",null,"mechanistic","high","coordinator","opus-5.5-coordinator","R5: adverse events by arm reported in the appendix",3],["R0009043","Antidiabetic Drug Efficacy in Reduction of Mortality during the COVID-19 Pandemic.","Gonikman D","2023","include_review",null,"systematic_review",null,null,null,"high","coordinator","opus-5.5-coordinator","R14: three databases and criteria; reports included study results by drug class in text",3],["R0009363","Insulin treatment in patients with diabetes mellitus and heart failure in the era of new antidiabetic medications.","Staszewsky L","2022","include_harms",null,"primary_report",null,"O121",null,"low","coordinator","opus-5.5-coordinator","R7: hospital admission for renal failure by group; acuity to verify at extraction",3],["R0009517","Glucagon-like Peptide-1 Receptor Agonists versus Sodium-Glucose Cotransporter Inhibitors for Treatment of T2DM.","McKee A","2020","include_nma",null,"pooled_analysis","P01",null,null,"high","coordinator","opus-5.5-coordinator","R18: pools CVOT GLP-1 RA versus placebo contrasts without a database search",3],["R0009891","Association Between Semaglutide or Tirzepatide Therapy and Residual Gastric Content: A Potential Danger During Upper Endoscopy.","Wen J","2025","include_harms",null,"primary_report",null,"O36B",null,"high","coordinator","opus-5.5-coordinator","R12: endoscopy procedure cohort comparing retained gastric content by GLP-1 RA use",3],["R0011093","Economic Evaluation of Medications in Prevention and Treatment of Obesity: A Systematic Review.","Afshari S","2025","exclude","E3","other",null,null,null,"high","coordinator","opus-5.5-coordinator","R14: review of economic evaluations only, no clinical effects",3],["R0011744","Risk Factors of Pancreatic Cancer in Patients With Type 2 Diabetes Mellitus: The Hong Kong Diabetes Study.","Chan RNC","2022","include_harms",null,"primary_report",null,"O38",null,"high","coordinator","opus-5.5-coordinator","R7: prevalent GLP-1 RA use with an adjusted pancreatic cancer HR; design judged at extraction",3],["R0012900","Injectable Antihyperglycemics: A Systematic Review and Critical Analysis of the Literature on Adherence, Persistence, and Health Outcomes.","Hamersky CM","2019","include_review",null,"systematic_review",null,null,null,"high","coordinator","opus-5.5-coordinator","R14: four databases and criteria; synthesizes outcomes by GLP-1 RA adherence, the exposure of interest",3],["R0013254","12590 Glp1 Agonists Role On Prediabetes Reversal, A Meta-analysis",null,"2024","include_review",null,"systematic_review",null,null,"abstract_only","high","coordinator","opus-5.5-coordinator","R14: conference abstract of a meta-analysis of GLP-1 RA RCTs in prediabetes with criteria",3],["R0013277","GLP-1 Receptor Agonist Therapy and Cardiorenal Outcomes in Type 1 Diabetes: A Propensity-Matched Real-World Analysis.","Tentolouris A","2026","include_harms",null,"primary_report",null,"O29",null,"high","coordinator","opus-5.5-coordinator","R10: pancreatitis reported per group with counts masked below 10",3],["R0014829","A Review of the Safety and Adverse Event Profile of the Fixed-Ratio Combination of Insulin Glargine and Lixisenatide.","Frias JP","2019","include_nma",null,"pooled_analysis","P01",null,null,"high","coordinator","opus-5.5-coordinator","R18: pools LixiLan RCTs keeping randomized comparisons of adverse events",3],["R0015839","Weight management medications for chronic use in 37 veterans affairs medical centers-A medication use evaluation.","Walczuk S","2024","include_harms",null,"primary_report",null,"O28; O29",null,"high","coordinator","opus-5.5-coordinator","R7: new initiator cohort tabulating cholelithiasis and pancreatitis by drug",3],["R0015924","Effect of Various Dosing Schedules on the Pharmacokinetics of Oral Semaglutide: A Randomised Trial in Healthy Subjects.","van Hout M","2023","inventory_only","N3","primary_report",null,null,null,"high","coordinator","opus-5.5-coordinator","R17: same oral semaglutide dose under different fasting schedules",3],["R0015929","7792 Efficacy of Retatrutide for Weight Reduction and Its Cardiometabolic Effects Among Adults: A Systematic Review and Meta-Analysis",null,"2024","include_review",null,"systematic_review",null,null,"abstract_only","high","coordinator","opus-5.5-coordinator","R14: abstract of a meta-analysis of retatrutide RCTs with eligibility and pooling",3],["R0016598","Renal and metabolic effects of semaglutide plus canagliflozin vs canagliflozin alone in type 2 diabetic nephropathy.","Miao Y","2026","include_harms",null,"primary_report",null,"O33",null,"high","coordinator","opus-5.5-coordinator","R13: diabetic retinopathy reported as an adverse event by group",3],["R0016623","Meta-analysis on GLP-1 mediated modulation of autophagy in islet β-cells: Prospectus for improved wound healing in type 2 diabetes.","Xia W","2024","inventory_only","N7","systematic_review",null,null,"retracted","high","coordinator","opus-5.5-coordinator","R15: retracted meta-analysis of GLP-1 RA trials",3],["R0016992","A Pharmacometric Method for Quantitative Determination of Improvement in Body Composition and Characterization of the Exposure-Response Relationship during Treatment of Obesity with Tirzepatide.","Chigutsa E","2025","inventory_only","N2","secondary_report",null,null,"mechanistic","high","coordinator","opus-5.5-coordinator","R4: exposure response model of predicted weight; no observed between arm result beyond the primary report",3],["R0017527","Cost-effectiveness of Semaglutide Compared With Other Glucose-Lowering Medications in Treating Type 2 Diabetes: A Comprehensive Systematic Review and Meta-analysis.","Liu Z","2025","exclude","E3","other",null,null,null,"high","coordinator","opus-5.5-coordinator","R14: review of QALY and cost results from economic models only",3],["R0018285","SUN-676 Impact Of Once-weekly Semaglutide On Heart Failure Hospitalizations And Weight Loss In Obese Patients With Preserved Ejection Fraction (Hfpef): A Meta-analysis",null,"2025","include_review",null,"systematic_review",null,null,"abstract_only","high","coordinator","opus-5.5-coordinator","R14: congress abstract of a PRISMA meta-analysis of semaglutide in obese HFpEF",3],["R0018609","7347 The Efficacy And Safety Of Oral Semaglutide In Asian Patients With Type 2 Diabetes:A Systematic Review And Meta-Analysis",null,"2024","include_review",null,"systematic_review",null,null,"abstract_only","high","coordinator","opus-5.5-coordinator","R14: conference abstract of a meta-analysis of oral semaglutide RCTs",3],["R0018839","Instrumental Variable Methods to Target Hypothetical Estimands With Longitudinal Repeated Measures Data: Application to the STEP 1 Trial.","Bowden J","2025","include_nma",null,"secondary_report","P02",null,null,"high","coordinator","opus-5.5-coordinator","R4: instrumental variable reanalysis of STEP 1 keeping the randomized contrast",3],["R0019054","DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks.","Buse JB","2010","include_nma",null,"extension","P01",null,null,"high","coordinator","opus-5.5-coordinator","52 week DURATION-1 report keeps randomized arms: exenatide QW throughout versus BID then QW",3],["R0020727","Exposure-response analysis for evaluation of semaglutide dose levels in type 2 diabetes.","Petri KCC","2018","inventory_only","N2","pooled_analysis",null,null,"mechanistic","high","coordinator","opus-5.5-coordinator","R4: exposure response modeling of SUSTAIN arms; dose contrasts are model derived",3],["R0020989","Semaglutide treatment for obesity in teenagers: a plain language summary of the STEP TEENS research study.","Weghuber D","2023","inventory_only","N9","ancillary",null,null,null,"high","coordinator","opus-5.5-coordinator","plain language summary of STEP TEENS with no new data",3],["R0023226","Emulating the GRADE trial using real world data: retrospective comparative effectiveness study.","Deng Y","2022","include_harms",null,"primary_report",null,"O29; O38; O32B",null,"high","coordinator","opus-5.5-coordinator","R10: prespecified pancreatitis, pancreatic and thyroid cancer reported with suppressed small counts",3],["R0023269","Acute effects of glucagon-like peptide-1, GLP-19-36 amide, and exenatide on mesenteric blood flow, cardiovascular parameters, and biomarkers in healthy volunteers.","Bremholm L","2017","include_nma",null,"primary_report","P99",null,"mechanistic; crossover","high","coordinator","opus-5.5-coordinator","R5: randomized crossover reports blood pressure by arm, a review outcome",4],["R0023688","Exploring Promising Therapies for Non-Alcoholic Fatty Liver Disease: A ClinicalTrials.gov Analysis.","Hegazi OE","2024","exclude","E3","other",null,null,null,"high","coordinator","opus-5.5-coordinator","R14: registry review mapping designs of NAFLD trials; no study results synthesized",3],["R0024090","Efficacy & safety of sodium-glucose cotransporter-2 inhibitors in polycystic ovary syndrome: A meta-analysis with trial sequential analysis.","Ahsan M","2025","exclude","E2","other",null,null,null,"high","coordinator","opus-5.5-coordinator","R1: SGLT2 inhibitor review in PCOS; exenatide only inside pooled control arms",3],["R0025185","A Systematic Review of Cost-Effectiveness Studies of Newer Non-Insulin Antidiabetic Drugs: Trends in Decision-Analytical Models for Modelling of Type 2 Diabetes Mellitus.","Laursen HVB","2023","exclude","E3","other",null,null,null,"high","coordinator","opus-5.5-coordinator","R14: review tabulating cost effectiveness of GLP-1 RA versus SGLT2i from models only",3],["R0025616","The best drug supplement for obesity treatment: a systematic review and network meta-analysis.","Salari N","2021","inventory_only","N7","systematic_review",null,null,"retracted","high","coordinator","opus-5.5-coordinator","R15: retracted network meta-analysis including liraglutide",3],["R0026103","An updated systematic review and meta-analysis on the efficacy and tolerability of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes with moderate to severe chronic kidney disease.","Singh-Franco D","2016","exclude","E2","other",null,null,null,"high","coordinator","opus-5.5-coordinator","R1: DPP-4 inhibitor review; one albiglutide comparator trial listed but no GLP-1 RA contrast of interest",3],["R0027270","The effectiveness of SGLT2 inhibitor in the incidence of atrial fibrillation/atrial flutter in patients with type 2 diabetes mellitus/heart failure: a systematic review and meta-analysis.","Wang M","2022","exclude","E2","other",null,null,null,"high","coordinator","opus-5.5-coordinator","R1: SGLT2 inhibitor review; liraglutide appears only inside some control arms",3],["R0027467","Incorporating and interpreting regulatory guidance on estimands in diabetes clinical trials: The PIONEER 1 randomized clinical trial as an example.","Aroda VR","2019","include_nma",null,"secondary_report","P01",null,null,"high","coordinator","opus-5.5-coordinator","R4: methods paper reporting PIONEER 1 semaglutide versus placebo HbA1c and weight",3],["R0007549","Exit Interviews Examining Patient Experiences with Tirzepatide and Dulaglutide for Treatment of Type 2 Diabetes in the SURPASS-CVOT Trial.","Stewart KD","2026","inventory_only","N2","secondary_report",null,null,null,"high","coordinator","opus-5.5-coordinator","R5: qualitative exit interviews of a trial; no review outcome",3],["R0009818","[Features of the course of COVID-19 in patients with type 2 diabetes mellitus].","Karaseva EA","2023","inventory_only","N6","primary_report",null,null,"non_english","high","coordinator","opus-5.5-coordinator","R16: pooled DPP-4 inhibitor, GLP-1 RA or SGLT2 inhibitor exposure group",3],["R0010803","A joint industry-sponsored data monitoring committee model for observational, retrospective drug safety studies in the real-world setting.","Major-Pedersen A","2021","inventory_only","N8","protocol_or_design",null,null,null,"high","coordinator","opus-5.5-coordinator","R2: describes oversight of a registry study, no results",3],["R0011204","Cost-effectiveness of GLP-1 receptor agonists versus insulin for the treatment of type 2 diabetes: a real-world study and systematic review.","Yang CY","2021","inventory_only","N6","primary_report",null,null,null,"high","coordinator","opus-5.5-coordinator","matched cohort with MACE, mortality and hypoglycemia only, inside a cost effectiveness analysis",3],["R0012457","Liver-derived fibroblast growth factor 21 mediates effects of glucagon-like peptide-1 in attenuating hepatic glucose output.","Liu J","2019","inventory_only","N1","other",null,null,null,"high","coordinator","opus-5.5-coordinator","human component measures exenatide treated patients before and after, no comparator",3],["R0013549","Long-term safety and efficacy of imeglimin as monotherapy or in combination with existing antidiabetic agents in Japanese patients with type 2 diabetes (TIMES 2): A 52-week, open-label, multicentre phase 3 trial.","Dubourg J","2022","exclude","E2","other",null,null,null,"high","coordinator","opus-5.5-coordinator","R17: single arm imeglimin trial with GLP-1 RA only as background",3],["R0016309","Major Adverse Cardiovascular Event Outcomes in Patients With Obesity and Type 2 Diabetes Undergoing Medical Weight Management.","Dutta N","2025","inventory_only","N6","primary_report",null,null,null,"high","coordinator","opus-5.5-coordinator","R16: weight management exposure only partly GLP-1 RA; MACE only",3],["R0001664","Exploring the Role of GLP-1 Agents in Managing Diabetic Foot Ulcers: A Narrative and Systematic Review.","Gruzmark FS","2025","include_review",null,"systematic_review",null,null,null,"high","coordinator","opus-5.5-coordinator","R14: registered PRISMA review searching PubMed and Embase with criteria; tabulates diabetic foot outcomes with GLP-1 RA",3],["R0002458","The hidden impact of GLP-1 receptor agonists on endometrial receptivity and implantation.","Sola-Leyva A","2025","include_review",null,"systematic_review",null,null,null,"high","coordinator","opus-5.5-coordinator","R14: PubMed and Cochrane search with exclusion criteria; thematic synthesis of included GLP-1 RA studies",3],["R0002683","Understanding the risk of diabetic retinopathy from glucagon-like peptide-1 receptor agonists: a Mendelian randomization study and systematic review of European populations.","Shen B","2025","include_review",null,"systematic_review",null,null,null,"high","coordinator","opus-5.5-coordinator","R14: PubMed, Embase and Cochrane search with criteria; tabulates GLP-1 RA cohorts on retinopathy",3],["R0003740","Comparison of Clinical Efficacy and Safety of Tirzepatide, Liraglutide and Semaglutide in Patients with Obesity and Without T2D: A Bayesian Network Meta-Analysis of Randomised Controlled Trials.","Ciudin A","2026","include_review",null,"systematic_review",null,null,null,"high","coordinator","opus-5.5-coordinator","R14: systematic literature review with stated eligibility and NMA of tirzepatide, semaglutide and liraglutide RCTs",3],["R0004857","The Therapeutic Potential of GLP-1 Receptor Agonists in the Management of Hidradenitis Suppurativa: A Systematic Review of Anti-Inflammatory and Metabolic Effects.","Krajewski PK","2024","include_review",null,"systematic_review",null,null,null,"high","coordinator","opus-5.5-coordinator","R14: MEDLINE and Google Scholar search with inclusion criteria; reports GLP-1 RA studies in hidradenitis",3],["R0005190","Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Idiopathic Inflammatory Myopathy: From Mechanisms of Action to Clinical Applications.","Rajagopal S","2023","include_review",null,"systematic_review",null,null,null,"high","coordinator","opus-5.5-coordinator","R14: review of GLP-1 RA in myopathy and muscle atrophy with human and mouse studies tabulated",3],["R0006478","Agent-specific, histopathology-stratified hematologic malignancy risk among dpp-4 inhibitors, glp-1 receptor agonists, and SGLT2 inhibitors: a network meta-analysis of 270,471 participants.","Lin PY","2026","include_review",null,"systematic_review",null,null,null,"high","coordinator","opus-5.5-coordinator","R14: PROSPERO registered NMA of RCTs including GLP-1 RA arms; search in appendix",3],["R0007391","Basal insulin intensification with GLP-1RA and dual GIP and GLP-1RA in patients with uncontrolled type 2 diabetes mellitus: A rapid review of randomized controlled trials and meta-analysis.","Lisco G","2022","include_review",null,"systematic_review",null,null,null,"high","coordinator","opus-5.5-coordinator","R14: PubMed and Cochrane search; meta-analysis of incretin therapy added to basal insulin",3],["R0009429","Incretins beyond type 2 diabetes.","Mathieu C","2023","include_review",null,"systematic_review",null,null,null,"high","coordinator","opus-5.5-coordinator","R14: described PubMed search defining scope; tabulates GLP-1 RA trials in type 1 and monogenic diabetes",3],["R0013375","Effects of Incretin Therapy on Skeletal Health in Type 2 Diabetes-A Systematic Review.","Viggers R","2023","include_review",null,"systematic_review",null,null,null,"high","coordinator","opus-5.5-coordinator","R14: systematic PubMed search with tabulated incretin bone and fracture studies",3],["R0015061","Cardiovascular Implications of Diabetes Mellitus: A Systematic Literature Review.","Gupta PK","2026","include_review",null,"systematic_review",null,null,null,"high","coordinator","opus-5.5-coordinator","R14: four databases and criteria; tables include GLP-1 RA outcome trials such as LEADER",3],["R0016952","The Role of Glucagon-like Peptide 1 Receptor Modulators for the Management of Dumping Syndrome in Patients Who have Undergone Metabolic and Bariatric Surgery: a Scoping Review.","Rogers-Seeley M","2026","include_review",null,"systematic_review",null,null,null,"high","coordinator","opus-5.5-coordinator","R14: JBI scoping review searching Medline and Embase; tabulates GLP-1 RA cases in dumping syndrome",3],["R0017872","Comparative effectiveness of dulaglutide versus liraglutide in Asian type 2 diabetes patients: a multi-institutional cohort study and meta-analysis.","Chang KC","2020","inventory_only","N6","primary_report",null,null,null,"high","coordinator","opus-5.5-coordinator","dulaglutide versus liraglutide cohort with effectiveness only; added meta-analysis shows no database search",3],["R0018038","Visceral Obesity and Metabolic Dysfunction in IgA Nephropathy: Nutritional and Metabolic Perspectives on Disease Progression.","Skibicka A","2025","exclude","E2","other",null,null,null,"high","coordinator","opus-5.5-coordinator","R1: review of obesity in IgA nephropathy; GLP-1 RA only discussed, not synthesized",3],["R0020643","Comparative effectiveness of exenatide once-weekly versus liraglutide in routine clinical practice: A retrospective multicentre study and meta-analysis of observational studies.","Fadini GP","2019","inventory_only","N6","primary_report",null,null,null,"high","coordinator","opus-5.5-coordinator","DARWIN-T2D exenatide versus liraglutide cohort pooled with studies without a database search; no listed harm",3],["R0009114","Examining the risk of depression or self-harm associated with incretin-based therapies used to manage hyperglycaemia in patients with type 2 diabetes: a cohort study using the UK Clinical Practice Research Datalink.","Gamble JM","2018","inventory_only","N6","primary_report",null,null,null,"high","coordinator","opus-5.5-coordinator","R10: self harm reported only inside a composite with depression; no separate result shown",3],["R0003476","Comparative effectiveness of combination therapy with SGLT-2 inhibitors and GLP-1 RAs compared with SGLT-2 inhibitors in individuals with type 2 diabetes: A prevalent new-user cohort study.","Maier GA","2026","inventory_only","N6","primary_report",null,null,null,"high","coordinator","opus-5.5-coordinator","R10: renal failure outcome pools acute and chronic codes N17 to N19; not acute kidney injury alone",3],["R0010095","Preserved pharmacokinetics and pharmacodynamics of insulin degludec and liraglutide when administered as insulin degludec/liraglutide in a Chinese population.","Liu H","2022","inventory_only","N2","secondary_report",null,null,"mechanistic; crossover","high","coordinator","opus-5.5-coordinator","R5: pharmacokinetic crossover and population model; no review outcome by arm",3],["R0012999","Real-World Effectiveness and Safety of Tirzepatide in Type 1 Diabetes and Obesity: Impact on Glycaemia, Weight, and Cardiometabolic Risk Markers.","Berry SA","2026","include_harms",null,"primary_report",null,"O33",null,"high","coordinator","opus-5.5-coordinator","R13: retinopathy progression on screening grades reported by group, tirzepatide versus controls",3],["R0014764","Neprilysin activity is increased in metabolic dysfunction-associated steatotic liver disease and normalizes after bariatric surgery or GLP-1 therapy.","Kjeldsen SAS","2023","inventory_only","N2","secondary_report",null,null,"mechanistic","high","coordinator","opus-5.5-coordinator","R5: neprilysin activity only from the randomized liraglutide maintenance samples; no review outcome by arm",3],["R0023304","Brain reward-system activation in response to anticipation and consumption of palatable food is altered by glucagon-like peptide-1 receptor activation in humans.","van Bloemendaal L","2015","include_nma",null,"primary_report","P01; P02; P99",null,"mechanistic; crossover","high","coordinator","opus-5.5-coordinator","R5: nausea scores compared between exenatide and placebo infusion days",3],["R0000043","Beyond Weight Loss: Skeletal Muscle Health During Incretin-Based Therapy in Patients with Diabesity.","Mollero ELM","2026","include_review",null,"systematic_review",null,null,null,"high","coordinator","opus-5.5-coordinator","R14: self described narrative review naming PubMed and Embase with stated criteria; reports included incretin muscle studies",2],["R0000530","Glucagon-like peptide-1 receptor agonists for major cardiovascular and kidney outcomes in type 1 diabetes.","Xu Y","2026","inventory_only","N6","primary_report",null,null,null,"high","coordinator","opus-5.5-coordinator","R10: GI events reported only as a composite of biliary disease, pancreatitis, obstruction and gastroparesis",2],["R0006681","Trends in Cost of Care With Tirzepatide in Adults Aged Over 55 Years With Obesity or Overweight Without Diabetes: A Matched Cohort Analysis.","Upadhyay N","2026","exclude","E2","other",null,null,null,"high","coordinator","opus-5.5-coordinator","R8: tirzepatide versus untreated cohort comparing healthcare costs and utilization only",2],["R0010802","Dual incretin analogue tirzepitide - SURMOUNTing the challenge of obesity induced obstructive sleep apnea.","Bajpai J","2025","include_review",null,"systematic_review",null,null,null,"high","coordinator","opus-5.5-coordinator","R14: self described narrative review naming three databases and study types; reports included tirzepatide OSA studies",2],["R0011326","Comparative Efficacy and Safety of Once-Weekly Semaglutide Formulations in Indian Adults With Obesity: A Phase III, Randomized Non-inferiority Active-Controlled Study (Size Plus Study).","Kapoor N","2026","inventory_only","N3","primary_report",null,null,null,"high","coordinator","opus-5.5-coordinator","R6: synthetic versus innovator semaglutide at the same dose and route",2],["R0018499","The Efficacy and Safety of Liraglutide in Patients Remaining Obese 6 Months after Metabolic Surgery.","Shen Y","2024","include_harms",null,"primary_report",null,"O28",null,"high","coordinator","opus-5.5-coordinator","R10: adverse event table gives cholelithiasis by group, liraglutide versus controls after metabolic surgery",3],["R0023383","Impact of Initiating a GLP1 Agonist and/or SGLT2 Inhibitor Therapy on De-Escalation and Discontinuation of Insulin and Diabetes Control When Managed by an Interprofessional Collaborative Team.","Champion M","2024","exclude","E2","other",null,null,null,"high","coordinator","opus-5.5-coordinator","R17: collaborative versus standard care; GLP-1 RA or SGLT2i only background, not a compared exposure",2],["R0000139","Current review of glucagon-like peptide 1 receptor agonists and risk of nonarteritic anterior ischemic optic neuropathy.","Ruan F","2026","include_review",null,"systematic_review",null,null,null,"high","coordinator","opus-5.5-coordinator","R14: PubMed search with stated exclusion criteria and study level synthesis of NAION reports with GLP-1 RA",2],["R0001327","Unconventional Applications of Semaglutide and Tirzepatide: From Oncology to Human Reproduction.","La Vignera S","2026","include_review",null,"systematic_review",null,null,null,"high","coordinator","opus-5.5-coordinator","R14: self described narrative review naming four databases with inclusion criteria; reports included semaglutide and tirzepatide studies",2],["R0024204","Screening, Diagnosis, and Treatment of Cardiometabolic Risk in Persons With Spinal Cord Injury/Disease: A Scoping Review.","Nageswaran L","2025","include_review",null,"systematic_review",null,null,null,"high","coordinator","opus-5.5-coordinator","R1 read literally: JBI scoping review with named databases and criteria whose synthesis includes a semaglutide study",2],["R0024248","Acupuncture and moxibustion as effective treatments for simple obesity in children: a meta-analysis.","Cui F","2025","exclude","E2","other",null,null,null,"high","coordinator","opus-5.5-coordinator","R1: every included comparison is acupuncture; the semaglutide sentence in the abstract has no matching study",4],["R0024610","Liraglutide - Indian Experience.","Anirban M","2018","include_review",null,"systematic_review",null,null,null,"high","coordinator","opus-5.5-coordinator","R14: PubMed and Index Copernicus search for Indian liraglutide studies; reports each included study",2],["R0006639","Global Long-Term Cost Effectiveness of Newer Antidiabetic Drugs for Type 2 Diabetes Mellitus: A Systematic Review.","Li D","2026","exclude","E3","other",null,null,null,"high","coordinator","opus-5.5-coordinator","R14: systematic review whose included studies are all economic evaluations",3],["R0008069","Cost-Effectiveness of Newer Antidiabetic Drugs as Second-Line Treatment for Type 2 Diabetes: A Systematic Review.","Zhu J","2023","exclude","E3","other",null,null,null,"high","coordinator","opus-5.5-coordinator","R14: systematic review whose included studies are all economic evaluations",3],["R0010067","Efficacy and safety of semaglutide injection in comparison with reference semaglutide for chronic weight management in indian adults with obesity: A phase III randomized non-inferiority trial.","Sharma PK","2026","inventory_only","N3","primary_report",null,null,null,"high","coordinator","opus-5.5-coordinator","R6: test semaglutide formulation versus reference semaglutide at the same dose and route",2],["R0011095","8699 ​​Efficacy of Glucagon-like Peptide-1 Analogs In Women With Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis of Randomized Clinical Trials",null,"2024","include_review",null,"systematic_review",null,null,"abstract_only","high","coordinator","opus-5.5-coordinator","R14: conference abstract of a meta-analysis of GLP-1 analog RCTs in PCOS with three databases",2],["R0013780","SUN-031 Efficacy Of The Glp-1 Agonists In The Treatment Of Idiopathic Intracranial Hypertension: A Systematic Review And Meta-analysis",null,"2025","include_review",null,"systematic_review",null,null,"abstract_only","high","coordinator","opus-5.5-coordinator","R14: conference abstract of a meta-analysis of GLP-1 RA RCTs in idiopathic intracranial hypertension",2],["R0014511","Two-Year Biomarker Trends and Kidney/Mortality Outcomes After Semaglutide Versus Phentermine-Topiramate and Naltrexone-Bupropion in People With Obesity and Without Diabetes.","Chen SC","2026","include_harms",null,"primary_report",null,"O29",null,"high","coordinator","opus-5.5-coordinator","R10: acute pancreatitis compared by group; AKI only inside a kidney composite, so O121 removed",2],["R0015466","Systematic review of cost-effectiveness analyses of weight loss interventions for knee osteoarthritis.","Gao Y","2026","exclude","E3","other",null,null,null,"high","coordinator","opus-5.5-coordinator","R14: systematic review whose included studies are all economic evaluations",3],["R0023113","Pharmacoeconomic evaluation of anti-obesity drugs for chronic weight management: a systematic review of literature.","Xue Y","2023","exclude","E3","other",null,null,null,"high","coordinator","opus-5.5-coordinator","R14: systematic review whose included studies are all economic evaluations",3],["R0001551","Weight-loss dynamics with tirzepatide versus semaglutide.","Venkatakrishnan AJ","2026","inventory_only","N6","primary_report",null,null,null,"high","coordinator","opus-5.5-coordinator","R10: main text and supplement report no listed harm by group",3],["R0002201","Preoperative Weight Loss Intervention With Glucagon-Like Peptides 1 Receptor Agonists Is Associated With Lower Complication Rates Following Primary Total Knee Arthroplasty Than Preoperative Bariatric Surgery.","Bcharah G","2026","inventory_only","N6","primary_report",null,null,null,"high","coordinator","opus-5.5-coordinator","R10: AKI named as an outcome but no result by group in the text, tables or supplement",3],["R0005594","Exploratory associations between co-occurring opioid and alcohol use disorders and GIP/GLP-1 receptor agonist treatment.","Qeadan F","2026","inventory_only","N6","primary_report",null,null,null,"high","coordinator","opus-5.5-coordinator","R10: suicide codes only inside a mental health crises composite; no separate suicidality result",4],["R0000009","Oral Health Implications of GLP-1 Receptor Agonists and Other Incretin-Based Therapies.","Bijoch J","2026","exclude","E3","other",null,null,null,"high","recheck","opus-5.5-recheck11","narrative review with database search but citation stated as purposive, not which sources met criteria; selective citation under ruling 14",2],["R0000818","Weight maintenance after discontinuation of GLP-1 therapies.","Moiz A","2026","exclude","E3","other",null,null,null,"high","recheck","opus-5.5-recheck11","narrative review; sources chosen for relevance and rigor without eligibility criteria or list of studies meeting them; ruling 14",2],["R0001102","Integrating Precision Nutrition with GLP-1 Receptor Agonist Therapy: Mechanisms, Clinical Outcomes, and Pharmacoeconomic Implications.","Ruga S","2026","exclude","E3","other",null,null,null,"high","recheck","opus-5.5-recheck11","narrative synthesis with prioritized source types and personal libraries; no study by study results of sources meeting criteria; ruling 14",2],["R0000248","Comparative Positioning of Orforglipron Among Selected GLP-1 Receptor Agonist Benchmarks: A Narrative Review.","Castro-Gamboa J","2026","include_review",null,"systematic_review","P01; P02",null,null,"high","recheck","opus-5.5-recheck11","self described narrative review naming databases, predefined eligibility criteria, 35 retained sources and trial results by domain; ruling 14",2],["R0000338","Harnessing GLP-1 Receptor Agonists for Obesity Treatment: Prospects and Obstacles on the Horizon.","Abdelrahman RM","2025","exclude","E3","other",null,null,null,"high","recheck","opus-5.5-recheck13","databases and broad criteria named but trials cited selectively in prose; no defined included set; ruling 14",2],["R0000946","Effects of GLP-1 analogs on metabolic alterations including male sexual function, hypogonadism and erectile dysfunction: a narrative review.","Olivares A","2026","exclude","E3","other",null,null,null,"high","recheck","opus-5.5-recheck13","search table with criteria but only mechanistic summary tables; key studies cited selectively, no included set; ruling 14",2],["R0000268","Nutrition-First Support for GLP-1 and Dual Incretin Therapy in Obesity: A Practical Framework for Dietary Management, Symptom Tolerability, and Long-Term Weight Maintenance.","Zambrano-Villacres R","2026","exclude","E3","other",null,null,null,"high","recheck","opus-5.5-recheck12","narrative framework; eligible sources include guidelines and consensus; no included set, tables are recommendations; ruling 14",2],["R0000352","Incretin-Based Therapies: A Novel Pathway in Addiction Treatment.","Dawid R","2026","exclude","E3","other",null,null,null,"high","recheck","opus-5.5-recheck12","studies chosen by thematic relevance, no formal criteria, selective citation of preclinical and human work; ruling 14",2],["R0000275","Evolution of incretin-based therapies: From GLP-1 monotherapy to dual and triple agonists: A new era in metabolic therapy.","Gupta M","2026","exclude","E3","other",null,null,null,"high","recheck","opus-5.5-recheck12","criteria admit guidelines and animal work; 77 references kept by rigor and relevance; thematic text, no included set; ruling 14",2],["R0000436","Nutritional Care for Adults With Obesity Treated With Glucagon-Like Peptide (GLP)-1 and Dual Glucose-Dependent Insulinotropic Polypeptide (GIP)/GLP-1 Receptor Agonists: A Review of Evidence, Gaps, and Clinical Implications.","McGuane C","2026","exclude","E3","other",null,null,null,"high","recheck","opus-5.5-recheck12","narrative review; criteria admit guidelines and consensus; trial tables cover selected pivotal trials, no included set named; ruling 14",2],["R0000908","GLP-1 receptor agonists beyond glycemic control: integrated cardio-renal-metabolic protection across the cardiovascular kidney metabolic continuum.","Elsayed A","2026","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck13","PubMed, Embase and CENTRAL search, stated criteria, flow with 88 included, trial results tabulated; narrative label irrelevant; ruling 14",2],["R0002294","Mapping Global Research on Adverse Effects of GLP-1 Receptor Agonists (2006-2025): A Scopus-Based Bibliometric and Thematic Analysis.","Abdelrahman RM","2026","exclude","E3","other",null,null,null,"high","recheck","opus-5.5-recheck13","bibliometric mapping of Scopus records; reports publication metrics, not results of included studies; ruling 14",2],["R0000666","GLP-1 receptor agonists at the crossroads of diabetes, hepatic steatosis, and hepatocellular carcinoma.","Vozza A","2026","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck12","PubMed search, design and outcome criteria, table of included studies with liver and cancer results by study for GLP-1 RA; ruling 14",2],["R0001360","Research hotspots and trends of GLP-1 receptor agonists in the treatment of Parkinson's disease: a bibliometric analysis.","Yu T","2026","exclude","E3","other",null,null,null,"high","recheck","opus-5.5-recheck12","bibliometric analysis of publication counts, authors and keywords; no results of included studies reported; ruling 14 part c",2],["R0001489","Real-World vs. Randomized Trial Evidence for Incretin-Based Therapies: A Narrative Review.","Bloomgarden Z","2026","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck12","PubMed search, 26 real world studies meeting criteria plus seven meta-analyses, results tabulated by outcome and population; ruling 14",2],["R0000735","Medical nutrition therapy in incretin-treated obesity-related heart failure with preserved ejection fraction.","Ming Q","2026","exclude","E3","other",null,null,null,"high","recheck","opus-5.5-recheck11","names PubMed and Web of Science but gives only priorities, no eligibility criteria; key trial table is selective; rulings 1 and 14",2],["R0001170","GLP-1 receptor agonists and psychiatric outcomes: a bibliometric analysis of research trends, thematic evolution, and collaboration networks.","Roca Mora MM","2026","exclude","E3","other",null,null,null,"high","recheck","opus-5.5-recheck11","bibliometric mapping of publication counts and networks; reports no results of individual studies; fails part c of rulings 1 and 14",2],["R0002583","Beyond Weight Loss: GLP-1 Usage and Appetite Regulation in the Context of Eating Disorders and Psychosocial Processes.","Krug I","2025","exclude","E3","other",null,null,null,"high","recheck","opus-5.5-recheck11","conceptual narrative synthesis citing examples selectively; never states which sources met its guiding criteria; ruling 14",2],["R0002881","GLP-1 Receptor Agonists in Periodontology: Mechanisms, Clinical Evidence, and Implications for Care.","Sufaru IG","2026","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck11","named databases, inclusion criteria per evidence type, appraisal of each included study and table of human GLP-1 RA exposure studies; ruling 14",2],["R0003617","Targeting Inflammation in Chronic Kidney Disease: Pathophysiological Insights and Emerging Therapeutic Strategies.","Tsalouchos A","2026","exclude","E3","other",null,null,null,"high","recheck","opus-5.5-recheck13","purposive CKD inflammation review; tabulated included set covers anti-inflammatory agents only, GLP-1 results cited selectively; ruling 14",2],["R0004115","Guideline-Directed Medical Therapy for Diabetic Kidney Disease: Advances in Primary and Secondary Prevention.","Verma S","2026","exclude","E3","other",null,null,null,"high","recheck","opus-5.5-recheck13","broad DKD therapy review incl guidelines; trial table has no GLP-1 trial, GLP-1 evidence cited selectively; ruling 14",2],["R0005156","Artificial intelligence in obesity management: clinical evidence, translational gaps, and implementation priorities-a structured narrative review.","Liu W","2026","exclude","E2","other",null,null,null,"high","recheck","opus-5.5-recheck13","systematic search and 94 included AI studies, but AI tools are the interventions; GLP-1 drugs not an intervention or exposure of interest; ruling 1",2],["R0005372","Metabolic dysfunction, antidiabetic drugs, and asthma: bibliometric evidence, emerging trends, and translational frontiers from 2006 to 2025.","Jiang R","2026","exclude","E3","other",null,null,null,"high","recheck","opus-5.5-recheck13","bibliometric analysis of publication trends on antidiabetic drugs and asthma; no study results reported; ruling 14",2],["R0005468","Non-diabetic Kidney Disease in Type 2 Diabetes: From Kidney Biopsy to Precision Medicine.","Sreedharan S","2026","exclude","E3","other",null,null,null,"high","recheck","opus-5.5-recheck13","NDKD review; trial table omits GLP-1 trials, GLP-1 mentioned only as adjunct therapy with selective citation; ruling 14",2],["R0002316","Global trends and focuses of GLP-1RA in obesity: a bibliometric analysis and visualization from 2014 to 2024","Abdelrahman RM","2025","exclude","E3","other",null,null,null,"high","recheck","opus-5.5-recheck11","bibliometric analysis of Scopus records reporting publication trends only, no results of individual studies; fails part c of rulings 1 and 14",2],["R0003008","Preoperative weight loss by noninvasive approach in patients with obesity scheduled for bariatric and metabolic surgery: an update narrative review of indications and results available until 2024.","Grandone I","2025","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck11","four databases, stated criteria, flow of 42 selected studies and tables of results by study including GLP-1 RA studies; ruling 14",2],["R0003792","GLP-1 Receptor Agonists and Diabetic Kidney Disease: A Game Charger in the Field?","Doumani G","2024","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck11","PubMed and Embase search, stated selection criteria applied by two reviewers, table of GLP-1 RA kidney trial results by study; ruling 14",2],["R0004122","Systemic pathways linking subcutaneous therapies to gastrointestinal adverse effects: A Narrative review of mechanisms and mitigation strategies.","Singh A","2026","exclude","E3","other",null,null,null,"high","recheck","opus-5.5-recheck11","criteria define drug classes, tables give label incidence per drug, never which studies met criteria; selective narrative under ruling 14",2],["R0003046","GLP-1 Agonism for Kidney Transplant Recipients: A Narrative Review of Current Evidence and Future Directions Across the Research Spectrum.","Riehl-Tonn VJ","2024","exclude","E3","other",null,null,null,"high","recheck","opus-5.5-recheck12","search of MEDLINE, PubMed, Google Scholar with iterative scope; no eligibility criteria beyond language; overview table of selected studies; ruling 14",2],["R0003499","Mapping GLP-1 receptor agonist research across the MASLD-MASH-HCC continuum: a bibliometric and translational analysis.","Xie Y","2026","exclude","E3","other",null,null,null,"high","recheck","opus-5.5-recheck12","bibliometric mapping of 534 publications; results are publication metrics, clinical studies cited selectively; ruling 14 part c",2],["R0004719","Pharmacological interventions for alcohol use disorder: novel insights from recent clinical trials.","McManus KR","2026","exclude","E3","other",null,null,null,"high","recheck","opus-5.5-recheck12","expert review of AUD drugs; PubMed and registry searches but no included set named, GLP-1 trials cited selectively; ruling 14",2],["R0004137","The Influence of GLP1 on Body Weight and Glycemic Management in Patients with Diabetes-A Scientometric Investigation and Visualization Study.","Pantea I","2024","exclude","E3","other",null,null,null,"high","recheck","opus-5.5-recheck13","scientometric mapping of Web of Science records; publication metrics only, no results of included studies; ruling 14",2],["R0004975","Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists: Exploring Their Impact on Diabetes, Obesity, and Cardiovascular Health Through a Comprehensive Literature Review.","Hamed K","2024","exclude","E3","other",null,null,null,"high","recheck","opus-5.5-recheck13","databases and vague criteria incl guidelines; tables only describe the drug class, studies cited selectively in prose; ruling 14",2],["R0005887","Glucagon-Like Peptide-1 (GLP-1)-Based Therapies and Hematological Malignancies: A Narrative Review of Current and Emerging Evidence.","Krishnan Nair H","2026","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck13","four databases incl CENTRAL, stated eligibility, table of clinical studies of GLP-1 drugs and hematologic cancers with findings; ruling 14",2],["R0008279","Evaluating the Efficacy, Safety, and Practical Considerations of Semaglutide for Weight Loss in Non-Diabetic Adults: A Narrative Review.","Laraib A","2026","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck13","three databases, PICO criteria, flow with 27 included studies, semaglutide results by outcome; narrative label irrelevant; ruling 14",2],["R0004624","Therapeutic Advances in Diabetic Kidney Disease: 30 Years of Evidence and the Rise of the \"Fantastic Four\" in Nephrology.","Husain-Syed F","2026","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck11","PubMed search with explicit trial inclusion and exclusion criteria; GLP-1 RA kidney trials tabulated with results by trial; ruling 14",2],["R0005345","Beyond GLP-1 Agonists: Plant-Derived Bioactive Compounds as Adjunctive Strategies for Obesity Management.","Vasile A","2026","exclude","E2","other",null,null,null,"high","recheck","opus-5.5-recheck11","PICO criteria cover plant compound trials only; GLP-1 RA is never an intervention, comparator or exposure in included studies; ruling 1",2],["R0005578","Type 5 diabetes mellitus: nutritional-imprinted β-cell insufficiency, diagnostic gaps, and emerging therapeutic strategies.","Chen S","2026","exclude","E3","other",null,null,null,"high","recheck","opus-5.5-recheck11","conceptual narrative review naming PubMed and Embase but no eligibility criteria or study level GLP-1 RA results; rulings 1 and 14",2],["R0006717","Cardiovascular safety outcomes of once-weekly GLP-1 receptor agonists in people with type 2 diabetes.","Goldman JD","2020","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck11","PubMed search with criteria for primary CVOT reports; three included weekly GLP-1 RA trials with results tabulated; ruling 14",2],["R0007492","Changes in food preferences and ingestive behaviors after glucagon-like peptide-1 analog treatment: techniques and opportunities.","Bettadapura S","2025","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck11","PubMed search with stated eligibility criteria; table reports each included GLP-1 analog study and its findings; ruling 14",2],["R0009876","2021 Consensus Pathway of the Taiwan Society of Cardiology on Novel Therapy for Type 2 Diabetes.","Chiang CE","2021","exclude","E3","other",null,null,null,"high","recheck","opus-5.5-recheck11","society consensus pathway; consensus statements are E3 regardless of search statement; rulings 1 and 14",2],["R0004367","From Weight Loss to Organ-Specific Disease Modification: A Narrative Review of Incretin-Based Therapies in Obesity-Related Cardiometabolic Disease, Chronic Kidney Disease, Metabolic Dysfunction-Associated Steatohepatitis, and Obstructive Sleep Apnoea.","Joshi D","2026","exclude","E3","other",null,null,null,"high","recheck","opus-5.5-recheck12","self described narrative review; criteria admit guidelines and regulatory sources; high impact evidence chosen, landmark table only; ruling 14",2],["R0004952","Guideline for the Management of Obesity in Adult Patients With Obstructive Sleep Apnea.","Park SK","2026","exclude","E3","other",null,null,null,"high","recheck","opus-5.5-recheck12","society guideline with consensus statements on obesity in sleep apnea; guidelines stay E3 despite named database search; ruling 14",2],["R0006647","A Bibliometric Analysis Review of the Top 50 Most Cited Articles on Incretin-Based Therapy for Weight Reduction and Diabetes Management.","Alsaygh EF","2026","exclude","E3","other",null,null,null,"high","recheck","opus-5.5-recheck12","bibliometric analysis of 50 most cited articles; reports citation and journal metrics, not study results; ruling 14 part c",2],["R0007724","Pharmacological intervention: Challenges and promising outcomes for fat loss and preservation of lean body mass in the treatment of overweight and type 2 diabetes.","Aimelet V","2026","include_review",null,"systematic_review",null,null,null,"low","recheck","opus-5.5-recheck12","PubMed and ClinicalTrials.gov search, stated criteria, studies tabulated by compound incl semaglutide arms; alternative E3 or E2 if GLP-1 background; ruling 1",2],["R0007605","Safety and tolerability of once-weekly GLP-1 receptor agonists in type 2 diabetes.","Trujillo J","2020","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck13","PubMed search with criteria for phase 3 trials of weekly GLP-1 drugs versus comparators; safety results reported by outcome; ruling 14",2],["R0010296","Obesity, Low-Grade Chronic Inflammation, and Clinical Outcomes in Spondyloarthritis: A Translational Synthesis.","Belančić A","2026","exclude","E3","other",null,null,null,"high","recheck","opus-5.5-recheck13","obesity and spondyloarthritis review; GLP-1 studies cited selectively in prose, no report of included GLP-1 studies; ruling 14",2],["R0010811","Dipeptidyl-Peptidase-4 and Glucagon-like-Peptide-1, a Link in the Connection between Periodontitis and Diabetes Mellitus-What Do We Know So Far?-A Scoping Review.","Gheonea TC","2024","exclude","E2","other",null,null,null,"high","recheck","opus-5.5-recheck13","scoping review of periodontitis; GLP-1 agonists appear only in animal and cell studies; ruling 1",2],["R0011632","A Pharmacological and Clinical Overview of Oral Semaglutide for the Treatment of Type 2 Diabetes.","Andersen A","2021","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck13","PubMed and Embase search, stated exclusions, 46 included articles, PIONEER efficacy and adverse events tabulated; ruling 14",2],["R0005951","Tirzepatide for type 2 diabetes.","Anderson SL","2023","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck11","Medline search with stated criterion of all human tirzepatide efficacy studies in T2D; SURPASS results tabulated by trial; ruling 14",2],["R0006077","GLP-1 Receptor Agonist Use in Cancer Survivors-Challenges and Opportunities: A Narrative Review.","Agurs-Collins T","2026","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck11","PubMed search, explicit inclusion and exclusion criteria, dual screening, 13 included GLP-1 RA studies tabulated with outcomes; ruling 14",2],["R0007866","Incretins and SGLT-2 inhibitors in diabetic patients with neuroendocrine tumors: current updates and future directions.","Ruggeri RM","2025","exclude","E3","other",null,null,null,"high","recheck","opus-5.5-recheck11","three databases named but only language and peer review limits; clinical GLP-1 RA evidence cited selectively without results by study; ruling 14",2],["R0008569","Review: Special Issue: Real-world evidence on the use of GLP1 receptor agonists: Emerging concepts in obesity management: focus on glucagon receptor agonist combinations.","Anderson SL","2025","exclude","E3","other",null,null,null,"high","recheck","opus-5.5-recheck11","names a MEDLINE search but states no eligibility criteria; narrative overview of multi-agonists; rulings 1 and 14",2],["R0008773","Metabolic Syndrome: An Updated Review on Diagnosis and Treatment for Primary Care Clinicians.","Peterseim CM","2024","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck11","scoping review with PubMed and Cochrane search, stated eligibility, flow counts and table including GLP-1 RA trial results; rulings 1 and 14",2],["R0009782","Beyond GLP-1 Agonists: An Adaptive Ketogenic-Mediterranean Protocol to Counter Metabolic Adaptation in Obesity Management.","García-Gorrita C","2025","exclude","E3","other",null,null,null,"high","recheck","opus-5.5-recheck11","structured mapping covers ketogenic Mediterranean diet studies only; GLP-1 RA trials appear in argumentative narrative chosen by relevance; ruling 14",2],["R0012308","Obesity and respiratory diseases: mechanisms, phenotypes, and clinical implications.","Soliman AR","2026","exclude","E3","other",null,null,null,"high","recheck","opus-5.5-recheck13","broad obesity and lung disease review; GLP-1 trials cited selectively in one section, no report of included studies; ruling 14",2],["R0013167","GLP1 receptor agonists in heart failure with preserved ejection fraction (HFpEF) - beyond weight loss: a condensed scientific review.","Roy E","2026","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck13","PubMed search with stated filters and outcome criteria; table of all included GLP-1 HFpEF studies with outcomes; ruling 14",2],["R0015975","On-demand peptide therapeutics for multi-year space exploration: analysis of clinical and operational relevance and recombinant production feasibility.","Donovan JJ","2026","exclude","E3","other",null,null,null,"high","recheck","opus-5.5-recheck13","scoring analysis of peptide drugs for space production feasibility; no synthesis of clinical study results; ruling 14",2],["R0018017","Unintended Consequences of Obesity Pharmacotherapy: A Nutritional Approach to Ensuring Better Patient Outcomes.","Al-Najim W","2025","exclude","E3","other",null,null,null,"high","recheck","opus-5.5-recheck13","criteria admit guidelines and narrative reviews; tables give dietary advice, GLP-1 studies cited selectively in prose; ruling 14",2],["R0006690","Global Landscape and Thematic Evolution of Selective GLP-1 Receptor Agonists and GLP-1-Based Multi-Receptor Agonists in Type 2 Diabetes Mellitus: A Bibliometric Analysis.","Wang Y","2026","exclude","E3","other",null,null,null,"high","recheck","opus-5.5-recheck12","bibliometric analysis of GLP-1 agonist literature; results are country, author, keyword and citation metrics, no study results; ruling 14 part c",2],["R0007745","A new era in the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD): clinical breakthroughs and challenges.","You Z","2026","exclude","E3","other",null,null,null,"high","recheck","opus-5.5-recheck12","clinical perspective; authors call selection of pivotal trials and guidelines inherently selective; no included set; ruling 14",2],["R0009445","Dietary Recommendations for the Management of Gastrointestinal Symptoms in Patients Treated with GLP-1 Receptor Agonist.","Gentinetta S","2024","exclude","E3","other",null,null,null,"high","recheck","opus-5.5-recheck12","commentary proposing a dietary plate tool; search and criteria stated but no results of included studies reported; ruling 14 part c",2],["R0014903","Development of the European Association for the Study of Obesity (EASO) Grade-Based Framework on the Pharmacological Treatment of Obesity: Design and Methodological Aspects.","McGowan B","2026","exclude","E3","other",null,null,null,"high","recheck","opus-5.5-recheck12","guideline design and methods paper; systematic reviews only planned, no results reported; ruling 14",2],["R0012997","Registered clinical trials targeting type 2 diabetes remission with pharmacological interventions.","Shoung N","2025","exclude","E3","other",null,null,null,"high","recheck","opus-5.5-recheck11","registry mapping of 34 trial registrations reporting design features only, no results of included trials; fails part c of rulings 1 and 14",2],["R0014384","Glucagon and heart in type 2 diabetes: new perspectives.","Ceriello A","2016","exclude","E3","other",null,null,null,"high","recheck","opus-5.5-recheck11","narrative review of glucagon physiology; PubMed search with language limits only and no study results by study; ruling 14",2],["R0014432","Bridging the gap in early cardio-renal risk prevention in type 2 diabetes: evidence, guidelines, and real-world insights from the PRECARE NO LiMITS initiative.","Bucciarelli L","2026","exclude","E3","other",null,null,null,"high","recheck","opus-5.5-recheck11","narrative review with clinician survey; PubMed search stated as non systematic with no eligibility criteria; ruling 14",2],["R0015145","Mitochondrial Dysfunction in Type 2 Diabetes and Metabolic Syndrome: Mechanisms, Biomarkers, and Emerging Therapies.","Alghzawi HM","2026","exclude","E3","other",null,null,null,"high","recheck","opus-5.5-recheck11","structured narrative review stated as non exhaustive; per agent summaries of selected therapies, not results of studies meeting criteria; ruling 14",2],["R0015189","Geroprotective Effects of Drugs Modulating Metabolic Pathways: Perspectives of Pharmacology in Anti-Aging Therapy.","Grycan M","2026","exclude","E3","other",null,null,null,"high","recheck","opus-5.5-recheck11","focused non exhaustive selection of geroprotection literature; GLP-1 RA appears only in per intervention summaries; selective citation under ruling 14",2],["R0015728","Adiponectin Signaling Dysfunction and Pro-inflammation in Perivascular Adipose Tissue in Non-obstructive Ischemic Heart Disease: A Narrative Literature Review of New Endocrine-Metabolic Therapeutic Targets.","Cisneros Clavijo PE","2026","exclude","E3","other",null,null,null,"high","recheck","opus-5.5-recheck13","broad PVAT review with loose criteria incl preclinical; no tables, GLP-1 evidence cited selectively in prose; ruling 14",2],["R0016805","Restoring Satiety After GLP-1/GIP Pharmacotherapy: Metabolic Stability, Diet Quality, and the Gut Microbiota.","Lasik L","2026","exclude","E3","other",null,null,null,"high","recheck","opus-5.5-recheck13","PubMed and Google Scholar search with priorities only; mechanism table, GLP-1 trials cited selectively; ruling 14",2],["R0018290","A Clinical Review of the Connections Between Diabetes Mellitus, Periodontal Disease, and Cardiovascular Pathologies.","Țica O","2025","exclude","E2","other",null,null,null,"high","recheck","opus-5.5-recheck13","PRISMA style review of diabetes, periodontal and heart links; GLP-1 trials only cited as background, not among synthesized studies; ruling 1",2],["R0019243","Prospects for Neuroprotective Therapies in Glaucoma: Drug Targets and Emerging Clinical Strategies.","Rho S","2026","exclude","E2","other",null,null,null,"high","recheck","opus-5.5-recheck13","glaucoma review; GLP-1 evidence preclinical plus one ongoing semaglutide trial without results; ruling 1",2],["R0025787","Choice across 10 pharmacologic combination strategies for type 2 diabetes: a cost-effectiveness analysis.","Gu S","2020","exclude","E3","other",null,null,null,"high","recheck","opus-5.5-recheck13","cost effectiveness simulation with the Cardiff diabetes model; economic modeling, not a primary study or review; ruling 14",2],["R0009144","Research progress in precision medicine for type 2 diabetes based on the GLP-1.","Wang S","2025","exclude","E3","other",null,null,null,"high","recheck","opus-5.5-recheck13","PubMed, Embase, SciELO search but only topical relevance criteria; table covers metabolic surgery, GLP-1 studies cited selectively; ruling 14",3],["R0028507","Portuguese-Brazilian evidence-based guideline on the management of hyperglycemia in type 2 diabetes mellitus.","Bertoluci MC","2020","exclude","E3","other",null,null,null,"high","recheck","opus-5.5-recheck13","joint society clinical practice guideline with graded recommendations; guidelines are E3 regardless of the MEDLINE search; ruling 14",2],["R0012377","Developing a Comprehensive Approach for Managing Cardiorenal Metabolic Diseases (CRMD) in Saudi Arabia: Thinking beyond Single Disease-Literature Review and Multidisciplinary Consensus Report.","Alshaikh A","2026","exclude","E3","other",null,null,null,"high","recheck","opus-5.5-recheck12","multidisciplinary consensus report with recommendations; references kept by relevance and rigor; consensus documents stay E3; ruling 14",2],["R0013873","Off-label and investigational drugs in the treatment of gambling disorder: a critical review.","Bissig L","2026","exclude","E2","other",null,null,null,"high","recheck","opus-5.5-recheck12","gambling drug review; no human GLP-1 RA study in gambling, only preclinical addiction rationale; ruling 1",2],["R0015090","Emerging technologies for early risk stratification and precision management of diabetic kidney disease: a multimodal framework integrating digital phenotypes and clinical biomarkers.","Meng L","2025","exclude","E3","other",null,null,null,"high","recheck","opus-5.5-recheck12","non exhaustive search prioritizing DKD risk technologies; no included set, GLP-1 RA studies not synthesized; ruling 14",2],["R0015394",null,null,null,"exclude","E3","other",null,null,null,"high","recheck","opus-5.5-recheck12","preprint of guideline design and methods; reviews and network meta-analyses only planned, no results; ruling 14",2],["R0016060","Epicardial adipose tissue as a metabolically active visceral fat depot: an emerging target in cardiovascular disease.","Rojas-Bergés I","2026","exclude","E3","other",null,null,null,"high","recheck","opus-5.5-recheck12","narrative review of epicardial fat; criteria stated but no included set, GLP-1 RA effects mentioned in passing; ruling 14",2],["R0012975","Understanding Obesity as a Multisystem Disease: Advancing Research, Redefining Diagnostic Criteria, and Establishing Modern Therapeutic Approaches.","Abdallah H","2026","exclude","E3","other",null,null,null,"high","recheck","opus-5.5-recheck11","comprehensive narrative with prioritized selection; GLP-1 RA results given as per drug summaries, not results of studies meeting criteria; ruling 14",2],["R0016850","Metabolic Syndrome and Periodontitis-From Shared Mechanisms to Interdisciplinary Care: A Narrative Review of Clinical Evidence.","Gherbon AM","2026","exclude","E2","other",null,null,null,"high","recheck","opus-5.5-recheck11","included studies concern metabolic syndrome and periodontitis; GLP-1 RA appears only as a background medication remark, not an exposure studied; ruling 1; E3 also fits",2],["R0017531","Erectile dysfunction, type 2 diabetes, and cardiovascular disease: a narrative review and insights from a global real-world cohort analysis.","Martínez Mores S","2026","exclude","E3","other",null,null,null,"high","recheck","opus-5.5-recheck11","narrative review on erectile dysfunction; GLP-1 RA evidence is a brief selective paragraph and own cohort studies no GLP-1 exposure; ruling 14",2],["R0018442","Combating the dual burden: therapeutic targeting of common pathways in obesity and type 2 diabetes.","Scheen AJ","2014","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck11","names Medline, Cochrane and others with RCT and meta-analysis criteria; tables report GLP-1 RA trial and meta-analysis results; ruling 14",2],["R0023333","Redefining Obstructive Sleep Apnea: Treatment in the Modern Era.","Redondo J","2026","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck11","three databases, explicit eligibility, dual screening and extraction; table of GLP-1 based RCT results in sleep apnea; ruling 14",2],["R0023461","A critical review of natural products driven correction of bile acid dysregulation: a therapeutic strategy for nonalcoholic fatty liver disease.","Peng Q","2025","exclude","E2","other",null,null,null,"high","recheck","opus-5.5-recheck11","included studies are natural products, mostly animal; semaglutide only named as background comparator in narrative; ruling 1; E3 also fits",2],["R0008480","Incretin-Based Therapies: A Promising Approach for Modulating Oxidative Stress and Insulin Resistance in Sarcopenia.","Alnaser RI","2024","exclude","E3","other",null,null,null,"high","recheck","opus-5.5-recheck11","names PubMed, Cochrane and Google Scholar but never states its selection criteria; mechanistic narrative with selective citation; rulings 1 and 14",3],["R0013547","Clinical potential of treatment with semaglutide in type 2 diabetes patients.","Røder ME","2019","exclude","E3","other",null,null,null,"high","recheck","opus-5.5-recheck12","MEDLINE search on two terms with no eligibility criteria; trial program table only; ruling 1 part b",2],["R0014425","Observational studies on the association of outpatient antidiabetic medication use and COVID-19 outcomes: are the findings more relevant to diabetes management than to COVID-19 pathology? A mini-review.","Dimnjaković J","2026","include_review",null,"systematic_review",null,null,"umbrella_review","high","recheck","opus-5.5-recheck12","PubMed search with stated criteria for meta-analyses; 23 included, GLP-1 RA and COVID-19 mortality estimates tabulated by review; ruling 14",2],["R0019254","The role of glucagon-like peptide-1 in reproduction: from physiology to therapeutic perspective.","Jensterle M","2019","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck12","narrative review but PubMed search, PICO criteria, selection flow, 15 human interventional studies reported narratively; ruling 14",2],["R0021800","The liver-gut-brain axis in metabolic dysfunction-associated steatotic liver disease: bidirectional communication, clinical implications, and future perspectives.","Ren Y","2026","exclude","E3","other",null,null,null,"high","recheck","opus-5.5-recheck12","PubMed search prioritizing guidelines and trials, no eligibility criteria or included set; representative studies only; ruling 14",2],["R0022749","Mesoporous Silica Nanoparticle as a Potential Nanocarrier to Improve the Effectiveness of Antiobesity Drugs.","Aulifa DL","2025","exclude","E2","other",null,null,null,"high","recheck","opus-5.5-recheck12","review of nanoparticle carriers for antiobesity drugs; liraglutide appears only in animal and in vitro studies; ruling 1",2],["R0020811","Lean Metabolic-Dysfunction-Associated Steatotic Liver Disease (MASLD): Pathophysiology, Diagnostic Challenges, Clinical Outcomes, and Management.","Albusta N","2026","exclude","E3","other",null,null,null,"high","recheck","opus-5.5-recheck12","self described narrative review; criteria admit guidelines and consensus; no included set, semaglutide only in approved drug table; ruling 14",2],["R0013988","Addition of a single short-acting insulin bolus to basal insulin-supported oral therapy: a systematic review of data on the basal-plus regimen.","Seufert J","2019","exclude","E3","other",null,null,null,"high","recheck","opus-5.5-recheck12","PRISMA style review but authors state no eligibility criteria beyond language; part b unmet, ruling 14 changes only part c; ruling 1",3],["R0000347","Glucagon-like Peptide-1 Receptor Agonists and Upper Gastrointestinal Endoscopy: A Narrative Review of Residual Gastric Contents Aspiration Risk and Periprocedural Management.","Bandaranaike R","2026","exclude","E3","other",null,null,null,"high","recheck","opus-5.5-recheck11","self described narrative review; authors say they applied no formal criteria and chose studies for relevance; rulings 1 and 14",3],["R0000063","Glucagon-like Peptide-1 Receptor Agonists and Dual Incretin Therapies Across HFpEF and Cardiovascular Outcomes Trials in Patients with Obesity.","Belančić A","2026","include_review",null,"systematic_review",null,null,null,"high","coordinator","opus-5.5-coordinator","R14: search for all semaglutide and tirzepatide RCTs, each reported by study",3],["R0000091","Diabetes Mellitus and Stroke: Pathophysiological Connections and Therapeutic Potential of GLP-1 and GLP-1/GIP Receptor Agonists.","Paceana MA","2026","exclude","E3","other",null,null,null,"high","coordinator","opus-5.5-coordinator","R19: literature chosen by relevance; registry table lists trials without results",3],["R0000172","The GLP-1 Nutritional Paradox: A Global Meta-Analysis of Sarcopenic Risks and Micronutrient Gaps in the Post-Obesity Era","Hungund S","2026","include_review",null,"systematic_review",null,null,null,"high","coordinator","opus-5.5-coordinator","R14: PubMed search and criteria; included trials tabulated by study with results",3],["R0000217","Weight Recurrence After Bariatric Surgery: Incretin-Based Therapies and the Evolving Role of Revisional Surgery.","Huerta Díaz LA","2026","exclude","E3","other",null,null,null,"high","coordinator","opus-5.5-coordinator","R19: key studies chosen selectively",3],["R0000302","Are Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Central Nervous System (CNS) Penetrant: A Narrative Review.","West J","2025","exclude","E3","other",null,null,null,"high","coordinator","opus-5.5-coordinator","R19: authors state selection by relevance",3],["R0000307","Potential Role of the Triple Receptor Agonist Retatrutide in Antipsychotic-Associated Metabolic Dysfunction Among Clozapine- and Olanzapine-Treated Schizophrenia Spectrum Disorders: A Narrative Review and Theoretical Framework.","Kaczynski MM","2026","exclude","E3","other",null,null,null,"high","coordinator","opus-5.5-coordinator","R19: studies chosen by relevance, not all that met its criteria",3],["R0000815","Effects of GLP-1 receptor agonists on aesthetic surgery practice: A contemporary review.","Ersan M","2026","exclude","E3","other",null,null,null,"high","coordinator","opus-5.5-coordinator","R19: key evidence selected, including opinion pieces",3],["R0001022","Adverse Events Associated with Incretin-Based Therapies: A Narrative Review on Mechanisms, Clinical Management, and Risk Mitigation.","Tobaiqy M","2026","exclude","E3","other",null,null,null,"high","coordinator","opus-5.5-coordinator","R19: representative selection by relevance",3],["R0001059","Glucagon-like Peptide-1 Receptor Agonists and Ocular Disease: Mechanisms, Evidence and Therapeutic Perspectives.","Gong X","2026","exclude","E3","other",null,null,null,"high","coordinator","opus-5.5-coordinator","R19: presents key studies only",3],["R0001575","GLP-1-based therapeutics for cardiorenal protection in metabolic diseases.","Apperloo EM","2026","include_review",null,"systematic_review",null,null,null,"high","coordinator","opus-5.5-coordinator","R14: three databases restricted to clinical studies; cardiorenal outcomes tabulated by trial",3],["R0001840","GLP-1 Receptor Signaling and Oral Dysfunction: A Narrative Review on the Mechanistic Basis of Semaglutide-Related Oral Adverse Effects.","Barać M","2025","include_review",null,"systematic_review",null,null,null,"high","coordinator","opus-5.5-coordinator","R14: four databases and criteria; reports all 78 included articles by domain",3],["R0002387","Beyond Glycemic Control: GLP-1RA-Based Therapies and Emerging Targets Beyond the Metabolic Axis.","Matuszewski W","2026","exclude","E3","other",null,null,null,"high","coordinator","opus-5.5-coordinator","R19: presents representative evidence only",3],["R0002441","Testosterone Replacement Therapy as a Potential Strategy to Preserve Lean Mass in Men With Persistently Low Serum Testosterone Receiving GLP-1 Receptor Agonists: A Narrative Review.","Canal de Velasco LM","2026","exclude","E3","other",null,null,null,"high","coordinator","opus-5.5-coordinator","R19: major trials picked selectively",3],["R0003057","A Review of the Oral Semaglutide in Adults with Overweight or Obesity (OASIS) Trials Evaluating Oral Semaglutide (Wegovy) for Chronic Weight Management in Adults With Overweight or Obesity.","Ojinna BT","2026","include_review",null,"systematic_review",null,null,null,"high","coordinator","opus-5.5-coordinator","R14: PubMed and registry search with limits; all three trials found reported by trial",3],["R0003088","Transforming steatotic liver disease management: The emerging role of GLP-1 receptor agonists.","Jensen EL","2024","include_review",null,"systematic_review",null,null,null,"high","coordinator","opus-5.5-coordinator","R14: Medline search with RCT and biopsy criteria; three GLP-1 RA trials tabulated with results",3],["R0003168","Real-world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP-1RA-based weight-loss therapies.","Thomsen RW","2025","include_review",null,"systematic_review",null,null,null,"high","coordinator","opus-5.5-coordinator","R14: PubMed and Cochrane search; included observational GLP-1 RA studies tabulated by study",3],["R0003317","Therapeutic Potential of Anti-Obesity Drugs in Obesity-Associated Female Reproductive Dysfunction: Translating Mechanistic Evidence into Personalized Clinical Strategies.","Varra FN","2026","include_review",null,"systematic_review",null,null,null,"high","coordinator","opus-5.5-coordinator","R14: six databases and criteria; tabulates included liraglutide and semaglutide trials with results",3],["R0003786","Skeletal Muscle Effects of GLP 1 Receptor Agonists: Molecular Mechanisms and Comparative Insights on Semaglutide and Tirzepatide, a Narrative Review.","Cautela D","2026","exclude","E3","other",null,null,null,"high","coordinator","opus-5.5-coordinator","R19: table of key trials only",3],["R0003846","Clinical Implications of Mounjaro (Tirzepatide) for Breast Cancer Detection and Management: A Narrative Review.","Mady R","2026","include_review",null,"systematic_review",null,null,null,"high","coordinator","opus-5.5-coordinator","R14: two databases, predefined criteria, flow to 31 included studies reported by outcome",3],["R0004026","The clinical relevance of obesity and glucagon-like peptide-1-based therapies for chronic weight management in patients treated by obstetrician-gynecologists and gynecologists: A non-systematic narrative review.","Mackey S","2026","include_review",null,"systematic_review",null,null,null,"high","coordinator","opus-5.5-coordinator","R14: PubMed search with criteria; findings of each included publication tabulated",3],["R0004701","The Potential Indirect Impact of GLP-1 Receptor Agonists in the Management of Fibromyalgia.","Quodling N","2026","exclude","E3","other",null,null,null,"high","coordinator","opus-5.5-coordinator","R19: no study met its registered criteria",3],["R0005050","A narrative review on tirzepatide's therapeutic potential in glycemic control and cardioprotection.","Thiriveedi M","2026","exclude","E3","other",null,null,null,"high","coordinator","opus-5.5-coordinator","R19: prioritized selection of trials, not all that met its criteria",3],["R0005612","Exploring the therapeutic potential of GLP-1 receptor agonists in pulmonary arterial hypertension.","Aguado B","2026","include_review",null,"systematic_review",null,null,null,"high","coordinator","opus-5.5-coordinator","R1 and R14: PubMed search and criteria; reports human GLP-1 RA studies besides preclinical work",3],["R0005974","Tirzepatide in Obesity-Related Obstructive Sleep Apnea: Beyond Weight Loss Toward Disease Modification?","Mihălțan FD","2026","exclude","E3","other",null,null,null,"high","coordinator","opus-5.5-coordinator","R19: final selection by relevance",3],["R0006448","Long-Acting Injectable GLP-1 Receptor Agonists for the Treatment of Adults with Type 2 Diabetes: Perspectives from Clinical Practice.","Morieri ML","2020","include_review",null,"systematic_review",null,null,null,"high","coordinator","opus-5.5-coordinator","R14: two databases and inclusion criteria; tables of included RCT and real world results by outcome",3],["R0008162","Retatrutide-A Game Changer in Obesity Pharmacotherapy.","Katsi V","2025","exclude","E3","other",null,null,null,"high","coordinator","opus-5.5-coordinator","R19: key studies only",3],["R0008315","Should antidiabetic medicines be considered to reduce cardiometabolic risk in patients with serious mental illness?","Mc Namara KP","2022","include_review",null,"systematic_review",null,null,"umbrella_review","high","coordinator","opus-5.5-coordinator","R14: PubMed and Embase search for reviews; all 20 included reviews reported with GLP-1 RA results",3],["R0010826","Efficacy and safety profile of once-weekly dulaglutide in type 2 diabetes: a report on the emerging new data.","Kugler AJ","2018","include_review",null,"systematic_review",null,null,null,"high","coordinator","opus-5.5-coordinator","R14: three databases with limits; AWARD trial results tabulated by trial",3],["R0011549","The new era of MASH pharmacotherapy: a comprehensive review of FDA-approved and emerging agents.","Qasim A","2026","exclude","E3","other",null,null,null,"high","coordinator","opus-5.5-coordinator","R19: table of pivotal trials only",3],["R0012013","Structured Exercise During and After Incretin-Based Pharmacotherapy Discontinuation: A Narrative Review of Mechanisms, Evidence, and Prescription Guidance.","Zeigler Z","2026","include_review",null,"systematic_review",null,null,null,"high","coordinator","opus-5.5-coordinator","R14: three databases; all 41 retained studies tabulated with results",3],["R0012268","A Narrative Review of Weight Management Strategies: From Lifestyle Interventions to Emerging Pharmacotherapies.","Ahmed IS","2026","include_review",null,"systematic_review",null,null,null,"high","coordinator","opus-5.5-coordinator","R14: four databases, criteria and dual screening; reports GLP-1 RA efficacy across included studies by drug",5],["R0014222","Liraglutide for weight management: a critical review of the evidence.","Mehta A","2017","include_review",null,"systematic_review",null,null,null,"high","coordinator","opus-5.5-coordinator","R14: PubMed search for liraglutide RCTs; all five trials found tabulated with results",3],["R0016335","Uncertainties around incretin-based therapies: A literature review.","Al Tulaihi B","2017","include_review",null,"systematic_review",null,null,null,"high","coordinator","opus-5.5-coordinator","R14: five databases with design and outcome criteria; 17 included studies reported by drug",4],["R0016708","Addition of exenatide twice daily to basal insulin for the treatment of type 2 diabetes: clinical studies and practical approaches to therapy.","Tobin GS","2012","exclude","E3","other",null,null,null,"high","coordinator","opus-5.5-coordinator","R19: studies selected case by case",4],["R0017861","Recent Developments in the Drug Treatment of Parkinson's Disease.","Leiter S","2026","include_review",null,"systematic_review",null,null,null,"high","coordinator","opus-5.5-coordinator","R14: PubMed, congress and registry search; table of included exenatide and GLP-1 trials with results",3],["R0017892","Therapeutic peptides in gerontology: mechanisms and applications for healthy aging.","Mavrych V","2026","exclude","E3","other",null,null,null,"high","coordinator","opus-5.5-coordinator","R19: 20 sources selected by relevance",3],["R0018940","Pathological Evolution and Internal Medicine Management of Nonalcoholic Fatty Liver Disease (NAFLD) in the Era of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).","Hashim MMA","2025","include_review",null,"systematic_review",null,null,null,"high","coordinator","opus-5.5-coordinator","R14: four databases, criteria and dual screening; 98 included studies synthesized, GLP-1 RA trials among them",3],["R0026014","Filling the Knowledge Gap in Diabetes Management During Ramadan: the Evolving Role of Trial Evidence.","Al Sifri S","2016","include_review",null,"systematic_review",null,null,null,"high","coordinator","opus-5.5-coordinator","R14: PubMed search with criteria; reports all 30 included studies, with liraglutide trial results",4],["R0008657","Hypothalamic obesity in pediatric vs. adult craniopharyngioma: mechanisms, management, and cardiometabolic outcomes.","Gupta K","2026","include_review",null,"systematic_review",null,null,null,"low","recheck","opus-5.5-recheck12","scoping review: PubMed search, stated criteria, GLP-1 RA studies incl exenatide trial tabulated by outcome; no count; alternative E3; rulings 1 and 14",4],["R0016667","A Review of the Long-Term Efficacy, Tolerability, and Safety of Exenatide Once Weekly for Type 2 Diabetes.","Genovese S","2017","include_review",null,"systematic_review",null,null,null,"low","recheck","opus-5.5-recheck12","PubMed search; trials over 3 months with exenatide as test or comparator; results tabulated by trial; authors deny criteria; alternative E3; ruling 14",4],["R0012198","Pharmacokinetic Bioequivalence of Orforglipron Tablets and Capsules in Healthy Participants With Obesity or Overweight.","Ma X","2026","include_nma",null,"primary_report","P02",null,"mechanistic; crossover","high","coordinator","opus-5.5-coordinator","node rules: formulation defines the node, so tablet versus capsule orforglipron is a randomized node contrast; adverse events by arm",4],["R0013595","A Bioequivalence Study of Two Formulations of Oral Semaglutide in Healthy Participants.","Nielsen MS","2025","include_nma",null,"primary_report","P99",null,"mechanistic; crossover","high","coordinator","opus-5.5-coordinator","node rules: reformulated oral semaglutide tablets are separate nodes, so the randomized contrast changes the node; TEAEs by arm",4],["R0006304","Off-label GLP-1 receptor agonist and tirzepatide use for weight loss: patient safety and regulatory oversight.","Maqsood A","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent34","editorial on off-label semaglutide and tirzepatide use and regulation, no original data",1],["R0013648","Risk of biliary diseases in patients with type 2 diabetes or obesity treated with tirzepatide: A critical appraisal.","Corrao S","2026","inventory_only","N9","ancillary",null,null,null,"high","first","opus-5.5-agent34","letter critiquing a meta-analysis of tirzepatide biliary risk, which is an in scope systematic review",1],["R0021205","Efficacy and safety of subcutaneous semaglutide in adults with overweight or obese: a subgroup meta-analysis of randomized controlled trials.","Zhang R","2023","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent34","PROSPERO registered meta-analysis of RCTs of subcutaneous semaglutide versus placebo in adults with overweight or obesity, named databases",1],["R0029479","New Opportunities Beyond Intensive Insulin Therapy for Improving Vascular Health of People Living With Type 1 Diabetes.","Popovic DS","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent34","editorial discussing therapies beyond insulin for vascular health in type 1 diabetes, no original data",1],["R0030272","Glucose-Lowering and the Risk of Cardiovascular Events with Novel Antidiabetic Therapies: A Systematic Review and Additive-effects Network Meta-Analysis","de Carvalho LSF","2021","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent34","systematic review and network meta-analysis of RCTs including GLP-1 receptor agonists for MACE in type 2 diabetes, named databases",1],["R0037788","Comparative Efficacy of Tirzepatide and Semaglutide in the Treatment of Obesity: A Meta-analysis","Isadora Roza","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent34","meta-analysis of RCTs comparing tirzepatide and semaglutide for obesity, four named databases, stated criteria, forest plots",1],["R0039954","Comparative effects of liraglutide and dapagliflozin on lipid profile and cardiovascular risk in patients with metabolic dysfunction-associated steatotic liver disease and type 2 diabetes: a 6-month randomized study","Artem Akimov","2025","include_nma",null,"primary_report","P01; P09",null,null,"high","first","opus-5.5-agent34","computer randomized three arm trial of liraglutide versus dapagliflozin versus lifestyle in MASLD with type 2 diabetes, 6 months",1],["R0040164","Heterogeneity, MCID, and missed trials: comments on “efficacy and safety of glucagon-like peptide-1 receptor agonists in Parkinson’s disease: A systematic review and meta-analysis”","Yuanyuan Zou","2026","inventory_only","N9","ancillary",null,null,null,"high","first","opus-5.5-agent34","letter commenting on a systematic review of GLP-1 receptor agonists in Parkinson disease, an in scope review",1],["R0001600","Impact of GLP-1 Receptor Agonists on Chronic Low Back Pain in Patients with Obesity: A Prospective Pilot Cohort Study.","Benedict B","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent22","uncontrolled prospective observational cohort of adults with obesity and back pain starting GLP-1 drugs in clinical care",1],["R0009046","Predicted cardiovascular risk reduction with tirzepatide vs. semaglutide: interpretative considerations from the SURMOUNT-5 post hoc analysis.","Ghosal S","2026","inventory_only","N9","ancillary",null,null,null,"high","first","opus-5.5-agent22","letter commenting on a SURMOUNT-5 post hoc analysis of tirzepatide versus semaglutide, an in scope trial report",1],["R0028966","Spotlight on the Human Brain: Central Actions of SGLT2 Inhibitors?","Hummel J","2022","inventory_only","N9","ancillary",null,null,null,"high","first","opus-5.5-agent22","editorial commentary on a randomized placebo controlled trial of exenatide, dapagliflozin and their combination",1],["R0030006","Precision medicine in type 2 diabetes: A systematic review of treatment effect heterogeneity for GLP1-receptor agonists and SGLT2-inhibitors.","Young KG","2023","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent22","registered systematic review searching PubMed and Embase of treatment effect heterogeneity for GLP-1 agonists and SGLT2 inhibitors",1],["R0030507","Glycemic control: a combination of lifestyle management and the use of drugs.","Standl E","2013","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent22","narrative review of glycemic management in cardiology patients without a named database search",1],["R0038874","Comment on: Safety of GLP-1 receptor agonists in body contouring surgery: a systematic review and meta-analysis","Syeda Bareera","2026","inventory_only","N9","ancillary",null,null,null,"high","first","opus-5.5-agent22","letter commenting on a systematic review and meta-analysis of GLP-1 agonist safety in body contouring surgery",1],["R0040070","The effects of discontinuing GLP-1 receptor agonists on body habitus - A systematic review and meta-analysis","Sara Berg","2024","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent22","INPLASY registration of a planned meta-analysis on stopping GLP-1 agonists, no results",1],["R0002571","Evidence-based ranking of diabetes prevention in prediabetes: A comprehensive network meta-analysis of 378 randomised controlled trials.","Maria B","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent27","registered NMA of RCTs in prediabetes searching MEDLINE, Embase and CENTRAL; ranks GLP-1 RA and GLP-1/GIP RA against control",1],["R0010639","Glycemic monitoring with once-weekly Glucagon-like peptide 1 receptor agonist (GLP1RA) use.","Kalra S","2015","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent27","editorial giving suggestions on glucose self monitoring for people on once weekly GLP-1 RA; no study data",1],["R0012418","Implicit Rationing of Incretin Therapy in Diabetic Kidney Disease: A Call for Deliberate Allocation.","de Silva D","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent31","editorial on access and rationing of GLP-1 receptor agonists in diabetic kidney disease",1],["R0018564","Making semaglutide accessible in Pakistan: A crucial step for heart failure treatment.","Sattar S","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent27","opinion letter urging semaglutide access in Pakistan for heart failure; summarizes trials without being a commentary on one record",1],["R0020431","Addition of very low calorie diet (VLCD) during initiation of semaglutide in individuals with type 2 diabetes – interim results","Anyiam O","2023","include_nma",null,"conference_abstract","P01",null,"abstract_only","high","first","opus-5.5-agent31","randomized semaglutide versus VLCD versus both for 12 weeks in type 2 diabetes; weight and HbA1c reported in short interim report",1],["R0029106","Commentary on Qeadan et al.: Leveraging opportunities to expand the substance use disorder treatment arsenal.","Schepis TS","2025","inventory_only","N9","ancillary",null,null,null,"high","first","opus-5.5-agent27","commentary on Qeadan et al EHR cohort of GLP-1 and GIP RA users with substance use disorders, an in scope comparative study",1],["R0030142","Genetic proxies of GLP1R expression in whole blood are associated with lower risk of psoriasis and psoriatic arthritis","Ramessur R","2025","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent27","Mendelian randomization using genetic proxies of GLP1R expression for psoriasis risk; no drug given or studied as exposure",1],["R0030204","Pharmacological advances in the treatment of nonalcoholic fatty liver diseases : focused on global results of randomized controlled trials.","An J","2023","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent31","narrative review of NAFLD pharmacotherapy trials without systematic search methods",1],["R0036818","Application of GLP-1 Receptor Agonists in Cardiorenometabolic Syndrome","Eldorbek Nomozov","2026","exclude","E3","other",null,null,"non_english","high","first","opus-5.5-agent27","narrative review in Uzbek of key trials on GLP-1 RA in cardiorenometabolic syndrome; no named database search, selective per rulings 14 and 19",1],["R0037727","Factors Influencing Adherence to GLP-1 Receptor Agonist Therapy Among Patients Receiving Weight-Loss Injections","Rasha Salem Salama Alrehaili","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent31","narrative review of adherence determinants for GLP-1 receptor agonist weight loss therapy; no search methods",1],["R0039457","Meta-Analysis of the Efficacy of GLP-1RA in the Treatment of Metabolic-Associated Fatty Liver Disease","玲 徐","2025","include_review",null,"systematic_review",null,null,"non_english","high","first","opus-5.5-agent27","Chinese meta-analysis of 13 RCTs of GLP-1 RA versus control in MAFLD; searched CNKI, VIP, Wanfang, Cochrane, PubMed, Embase",1],["R0039642","Glucagon-like peptide-1 (GLP-1) receptor agonists and cardiovascular events in patients with type 2 diabetes mellitus: A meta-analysis of double-blind, randomized, placebo-controlled clinical trials","Jing Qin","2019","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent31","meta-analysis of six placebo controlled GLP-1 receptor agonist outcome trials found through PubMed and Embase search",1],["R0040112","Real-world weight loss outcomes of semaglutide with lifestyle intervention in adults with obesity and cardiometabolic comorbidities in an Asian population of Bangladesh: A 20-patient case series","Md. Abdul Mukid","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent27","retrospective case series of 20 adults with obesity on semaglutide plus lifestyle counseling; no comparison group",1],["R0040152","Enhanced Outcomes of SGLT2 Inhibitors and GLP-1 Receptor Agonists: A Systematic Review of Major Adverse Cardiovascular Events and Renal Outcomes","Abdulrahman Mazki J Alanazi","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent31","PRISMA systematic review searching PubMed, Web of Science, Scopus; 11 cohorts with GLP-1 receptor agonist contrasts for MACE and renal outcomes",1],["R0007537","Editorial: Incretin-based therapies in the treatment of metabolic syndrome: expanding roles beyond weight management.","Zhang K","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent37","editorial introducing a research topic collection on incretin therapies, no original data or systematic search",1],["R0015544","Combination of Intranasal insulin and oral semaglutide for cognition in older adults with metabolic syndrome at high dementia risk","Shamrok H","2025","inventory_only","N8","protocol_or_design",null,null,"abstract_only","high","first","opus-5.5-agent37","factorial feasibility RCT of intranasal insulin and oral semaglutide in MCI with MetS, only recruitment and baseline data so far",1],["R0025808","Exenatide Improves HDL Particle Counts and Size Distribution in Patients With Long-standing Type 1 Diabetes.","Gourgari EA","2017","include_nma",null,"secondary_report","P05",null,"mechanistic; crossover","high","first","opus-5.5-agent37","ancillary lipoprotein analysis of randomized crossover exenatide trial in type 1 diabetes, reports weight and insulin need on versus off exenatide",1],["R0029622","Efficacy and safety of CT-868, a novel, fully biased, dual glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide receptor agonist, in type 2 diabetes: A double-blind, randomized placebo controlled phase 2 trial.","Chakravarthy MV","2026","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent37","phase 2 placebo controlled RCT of dual GLP-1/GIP agonist CT-868 in type 2 diabetes, HbA1c primary endpoint",1],["R0030344","Anti-atherosclerotic effects of the glucagon-like peptide-1 (GLP-1) based therapies in patients with type 2 Diabetes Mellitus: A meta-analysis.","Song X","2015","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent37","meta-analysis of GLP-1 based therapies including analogues on atherosclerotic markers in type 2 diabetes, multiple named databases and criteria",1],["R0038505","COMPARISON OF RENAL PROTECTIVE EFFECTS BETWEEN SGLT2 INHIBITORS AND DPP4 INHIBITORS IN TYPE 2 DIABETES IN REAL-WORLD CLINICAL PRACTICE","Hyeong-Kyu Park","2023","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent37","conference abstract cohort comparing SGLT2 versus DPP-4 inhibitors on renal outcomes, GLP-1 agonist users excluded",1],["R0040013","A brief approach to hypertension in type 2 diabetes mellitus","Yılmaz Güneş","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent37","narrative review of hypertension management in type 2 diabetes without systematic search",1],["R0040235","Tirzepatide: The Most Effective Drug Therapy for Prevention of Type 2 Diabetes","Nasser Mikhail","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent37","narrative review of tirzepatide for diabetes prevention summarizing SURMOUNT-1 extension, no systematic search",1],["R0029183","Glucagon-Like Peptide-1 Receptor Agonism and Suicide Risk: Evidence From Mendelian Randomization.","Zhao SS","2024","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent31","Mendelian randomization using GLP1R gene variants as genetic proxy; no drug given or drug exposure studied",1],["R0003036","Perioperative glucagon-like peptide-1 receptor agonists-induced gastroparesis - Is gastric ultrasound the answer?","Narayanasamy S","2024","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent28","editorial on perioperative gastric emptying with GLP-1 RA and gastric ultrasound, no original data",1],["R0010868","Fast-tracked innovation: orforglipron approval under the FDA's National Priority Voucher program.","Sheikh M","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent28","letter commenting on FDA approval of orforglipron, no study data",1],["R0019491","Role of glucagon-like peptide-1 agonists in obesity and heart failure with preserved ejection fraction.","Temporelli PL","2024","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent28","narrative review of semaglutide trials in HFpEF and obesity, no systematic search",1],["R0029113","Glucagon-like peptide 1 (GLP1) receptor agonists and risk for ischemic optic neuropathy: A meta-analysis of randomised controlled trials.","Silverii GA","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent28","research letter meta-analysis of GLP-1 RA RCTs on ischemic optic neuropathy, Medline Embase CENTRAL search with criteria",1],["R0030171","Management of Acquired Hypothalamic Obesity After Childhood-Onset Craniopharyngioma-A Narrative Review.","Müller HL","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent28","self described narrative review of hypothalamic obesity treatment, no eligibility criteria or structured synthesis",1],["R0039484","Relative Risk of Nephrolithiasis in Type 2 Diabetes Patients Using Sodium-Glucose Cotransporter 2 Inhibitors Compared to Those Using DPP-4 Inhibitors or GLP-1 Receptor Agonists: A Protocol of Systematic Review and Meta-analysis","Jia-Ai Yeh","2024","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent28","INPLASY protocol of SR on nephrolithiasis, SGLT2i versus DPP4i or GLP-1 RA comparators, no results",1],["R0040115","Resilience selection: a grave potential bias in clinical trials","Milind Watve","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent28","hypothesis paper proposing resilience selection bias in trials, no primary data or systematic review",1],["R0003373","Glucagon-like peptide-1 receptor agonists for treating chronic kidney disease in patients with type 2 diabetes.","Khan I","2024","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent29","short educational practice article summarizing GLP-1 RA evidence for CKD in diabetes; no primary data or systematic search",1],["R0011471","Efficacy and safety of visepegenatide, a long-acting weekly GLP-1 receptor agonist as monotherapy in type 2 diabetes mellitus: a randomised, double-blind, parallel, placebo-controlled phase 3 trial.","Yan X","2024","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent29","double blind placebo controlled phase 3 RCT of weekly visepegenatide (PB-119) monotherapy in treatment naive type 2 diabetes, 24 weeks",1],["R0020029","Can glucagon-like peptide-1 (GLP-1) analogues make neuroprotection a reality?","Basalay MV","2020","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent29","perspective article on GLP-1 analogues for neuroprotection in ischemic stroke; no original data",1],["R0029121","Population Health Management and Guideline-Concordant Care in CKD: A Secondary Analysis of Kidney Coordinated HeAlth Management Partnership.","Weltman MR","2025","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent29","cluster RCT of CKD population health management versus usual care; GLP-1 RA use is only a prescribing outcome, not a randomized drug; alternative N3",1],["R0030174","Beyond Glucose-Rethinking Prediabetes for Precision Prevention.","Wagner R","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent29","narrative review of prediabetes subtypes and precision prevention; no systematic search",1],["R0040120","Comparative Efficacy of Tirzepatide, Teneligliptin, and Empagliflozin in HbA1c Reduction in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis","Jordan Llerena‐Velastegui","2023","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent29","systematic review and meta-analysis searching PubMed, CT.gov and ICTRP with criteria; pools tirzepatide versus placebo HbA1c",1],["R0007063","Glucagon-Like Peptide 1 Receptor Agonists, Carotid Atherosclerosis, and Cardiovascular Outcomes.","Marquis-Gravel G","2021","inventory_only","N9","ancillary",null,null,null,"high","first","opus-5.5-agent36","commentary on the Koska randomized trial of weekly exenatide versus placebo on carotid plaque, an in scope trial",1],["R0015395","The evolving role of GLP-1 agonists in ischemic stroke prevention in diabetic patients.","Shankar A","2024","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent36","narrative review of GLP-1 receptor agonists and stroke prevention without a stated search or eligibility criteria",1],["R0029551","Editorial: Non-insulin pharmacotherapies for the treatment of type 2 diabetes and obesity - old and new players.","Patoulias D","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent36","editorial introducing a research topic on diabetes and obesity drugs, no original data",1],["R0030319","Diabetic kidney disease in type 2 diabetes: a consensus statement from the Swiss Societies of Diabetes and Nephrology.","Zanchi A","2023","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent36","Swiss consensus statement on diabetic kidney disease management",1],["R0038182","The Effects of GLP-1 Agonists on Cardiac Structure and Function: A Systematic Review","Sarin Sarjian","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent36","PubMed search with stated criteria, results of all 15 included GLP-1 receptor agonist studies tabulated for cardiac outcomes",1],["R0039970","A Scientometrics survey of GLP-1 receptor agonists in neurodegenerative disorders: An evolving paradigm from metabolic to brain health","Nastaran Makoui","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent36","scientometric mapping of Scopus publications reporting no study results, per ruling 19",1],["R0008464","SUN-164 Use of Metformin, Premixed Insulin, and Glucagon-Like Peptide-1 Receptor Agonist as a Therapeutic Approach for Uncontrolled Type 2 Diabetes Mellitus","Fazeli S","2019","inventory_only","N5","conference_abstract",null,null,"abstract_only","high","first","opus-5.5-agent39","retrospective single group cohort given premixed insulin plus GLP-1 RA, no comparison group; uncontrolled observational study",1],["R0016317","Can tirzepatide transform HFpEF management in Pakistan? A call for action.","Soomro AM","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent39","letter to the editor advocating tirzepatide policy for HFpEF in Pakistan; opinion piece, not commentary on one specific study",1],["R0028439","REWIND Diabetes for Octogenarians.","Geberhiwot T","2021","inventory_only","N9","ancillary",null,null,null,"high","first","opus-5.5-agent39","editorial commenting on the REWIND post hoc analysis of dulaglutide in older adults",1],["R0029967","Treatment effect heterogeneity following type 2 diabetes treatment with GLP1-receptor agonists and SGLT2-inhibitors: a systematic review.","Young KG","2023","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent39","registered systematic review searching PubMed and Embase on treatment effect heterogeneity with GLP-1 RA and SGLT2 inhibitors",1],["R0030378","Association Between Diabetes Medications and the Risk of Parkinson's Disease: A Systematic Review and Meta-Analysis.","Qin X","2021","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent39","meta-analysis of diabetes drugs and Parkinson risk, PubMed Embase CENTRAL searched; pooled GLP-1 agonist hazard ratio from two cohorts",1],["R0040032","GLP-1 Receptor Agonists in Obesity and Type 2 Diabetes: A Narrative Review of Clinical Effectiveness, Safety, And Future Directions","Harry S Patel","2024","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent39","self described narrative review of selected landmark GLP-1 RA trials without systematic search",1],["R0040242","Transient Effects of Exenatide on Intraocular Pressure in a Rat Bone Defect Model","Candemir Özcan","2026","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent39","randomized experiment of exenatide on intraocular pressure in rats",1],["R0009984","GLP-1 Receptor Agonist Exposure During Pregnancy: A Systematic Review and Meta-Analysis of Adverse Pregnancy Outcomes.","Kodali LSM","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent26","meta-analysis of comparative cohorts on GLP-1RA exposure in pregnancy versus other antidiabetics; PubMed searched, criteria stated",1],["R0030125","Pharmacological interventions to manage cardiometabolic outcomes in adults with severe mental illness: umbrella review.","Carolan A","2025","include_review",null,"systematic_review",null,null,"umbrella_review","high","first","opus-5.5-agent26","umbrella review of pharmacological cardiometabolic interventions in severe mental illness; named databases, criteria, GLP-1RA reviews synthesized",1],["R0039414","Comparative Efficacy of Dual and Triple GLP-1, GIP, and Glucagon Receptor Agonists: A Systematic Review and Network Meta-analysis","Qiannan Jia","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent26","network meta-analysis of RCTs of dual and triple incretin agonists versus placebo; PubMed, Embase, Scopus searched",1],["R0040104","EFFECTS OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS ON CIRCULATING ADIPOKINE LEVELS IN ADULTS WITH OVERWEIGHT, OBESITY, OR TYPE 2 DIABETES MELLITUS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS","Gabriella Vasconcelos Mariano Branquinho Leocadio","2026","include_review",null,"systematic_review",null,null,"non_english","high","first","opus-5.5-agent26","Portuguese language meta-analysis of RCTs of GLP-1RAs on adiponectin and leptin; MEDLINE, Embase, CENTRAL searched",1],["R0040225","CLINICAL EFFECTIVENESS OF ONCE-WEEKLY DULAGLUTIDE AS ADD-ON TO SGLT2i IN THAI PATIENTS WITH T2DM","Yotsapon Thewjitcharoen","2022","inventory_only","N5","conference_abstract",null,null,"abstract_only","high","first","opus-5.5-agent36","retrospective cohort of dulaglutide initiators only, subgrouped by SGLT2 inhibitor background, no unexposed comparator",1],["R0037005","Pharmacological Synergy: Systematic Review Of Glp-1 And Gip Receptor Co-Activation By Tirzepatide","Aishwarya Mishra","2022","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent29","names databases and criteria but tabulates only key SURPASS trials without reporting which studies met criteria (ruling 19)",1],["R0004724","Statistical declarations versus scientific inferences and clinical judgments: the association of Glucagon-like peptide-1 receptor agonist use with the risk of biliary disease.","Most DE","2024","inventory_only","N9","ancillary",null,null,null,"high","first","opus-5.5-agent30","commentary critiquing interpretation of a claims cohort comparing GLP-1 RA with bupropion naltrexone for biliary and other GI harms",1],["R0020321","SUN-165 The Largest Single-Center Experience of GLP-1 Receptor Agonists as a Safe and Effective Agent for the Management of Diabetes in Solid Organ Transplant (SOT) Recipients","Singh P","2019","inventory_only","N5","conference_abstract",null,null,"abstract_only","high","first","opus-5.5-agent30","retrospective chart review of transplant recipients on dulaglutide with pre post comparison only, no control group",1],["R0029149","Nephrology: a flourishing field with plentiful emerging topics.","Yoo KD","2024","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent30","opinion editorial on emerging nephrology topics, GLP-1 RA mentioned only in passing",1],["R0030198","The glucagon-like peptide-1 and other endocrine responses to alcohol ingestion in women with versus without metabolic surgery.","Molina-Castro M","2024","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent30","alcohol versus placebo drink crossover measuring endogenous GLP-1 after bariatric surgery; no GLP-1 RA drug given",1],["R0037276","Efficacy Comparison of Sodium-Glucose Cotransporter-2 Inhibitors, Glucagon-Like Peptide-1 Receptor Agonists, and Dipeptidyl Peptidase-4 Inhibitors in Heart Failure with Preserved Ejection Fraction: A Systematic Review And Network Meta-Analysis","Dr Mohd Fazal Ahmed Makki Dr Mohd Fazal Ahmed Makki","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent30","network meta-analysis of RCTs in HFpEF with named databases, criteria, and pooled GLP-1 RA versus placebo contrasts",1],["R0040144","From pills to pounds: prospective insights into the weight effects of antidepressant use","R. Musil","2026","exclude","E3","other",null,null,"abstract_only","high","first","opus-5.5-agent30","congress abstract of a selective literature review on antidepressant weight gain; GLP-1 RA only mentioned as option",1],["R0002497","Phenome-Wide Risk Evaluation of GLP-1 Receptor Agonist Use in Type 2 Diabetes with Real-World Data Across Multiple Healthcare Systems.","Vashisht R","2025","include_harms",null,"primary_report",null,"O121",null,"high","first","opus-5.5-agent26","propensity matched new user EHR cohort, GLP-1RA versus sulfonylurea, SGLT2i, DPP-4i; acute renal failure reported separately by comparison",1],["R0018430","An overview of the once-weekly GLP-1 receptor agonists from the pharmacist's perspective.","Patel D","2020","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent26","editorial introducing a supplement on once-weekly GLP-1RAs for pharmacists; no primary data or systematic search",1],["R0029105","Novel antidiabetic therapies in patients with peripheral artery disease: current perspective.","Janić M","2024","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent26","narrative perspective on SGLT2i and GLP-1RA in peripheral artery disease; no systematic search or primary data",1],["R0036471","ORAL HEALTH CONSEQUENCES OF SEMAGLUTIDE (GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST) THERAPY: SYSTEMATIC REVIEW WITH EVIDENCE GRADING AND CLINICAL RECOMMENDATIONS","Dr. Jaideep Kour Raina","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent26","oral health review names databases but tabulates only representative studies of 52 and cites selectively; ruling 19; alternative include_review",1],["R0009274","Editorial: Optimizing GLP-1 receptor agonist use: mechanisms, clinical applications, and safety profiles.","Rasineni K","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent23","editorial introducing a journal research topic collection on GLP-1RAs, no primary data",1],["R0017925","Reasons for screening failure in the evoke and evoke+ trials of semaglutide for early AD","Sano M","2024","inventory_only","N8","protocol_or_design","P13A",null,"abstract_only","high","first","opus-5.5-agent23","abstract on screening failure reasons in evoke trials of semaglutide in early AD, no between arm outcome",1],["R0029051","Frailty in randomized controlled trials of glucose-lowering therapies for type 2 diabetes: An individual participant data meta-analysis of frailty prevalence, treatment efficacy, and adverse events.","Wightman H","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent23","IPD network meta-analysis of glucose lowering trials found by Medline and Embase search, frailty by treatment effect including GLP-1RA",1],["R0030007","8687 The Efficacy of GLP1 Receptor Agonists in Obese Women with PCOS in Promoting Weight Loss and Hormonal Regulation: A Systematic Review and Meta-Analysis",null,"2024","include_review",null,"systematic_review",null,null,"abstract_only","high","first","opus-5.5-agent23","abstract of meta-analysis of GLP-1RA versus placebo RCTs in women with PCOS, PubMed Cochrane Scopus searched",1],["R0034271","A randomized clinical trial ofexenatide onT2D v1","Jing Xu","2020","inventory_only","N8","protocol_or_design","P01",null,null,"high","first","opus-5.5-agent23","protocols.io protocol of exenatide RCT on urinary albumin in overweight T2D, no results",1],["R0039262","Manejo actual del síndrome de ovario poliquístico en mujeres con deseo genésico","Germania Elizabeth Yugcha Andino","2024","exclude","E3","other",null,null,"non_english","high","first","opus-5.5-agent23","Spanish PCOS management review selecting best evidence articles, liraglutide cited selectively; ruling 19 selective review",1],["R0040087","GLP-1 Receptor Agonists and Skeletal Muscle Health: Overview of Reviews Examining Muscle Mass, Strength, and Physical Function in Adults with Obesity","Kelly Chen","2025","inventory_only","N8","protocol_or_design",null,null,"umbrella_review","high","first","opus-5.5-agent23","INPLASY protocol of an overview of reviews on GLP-1RA and skeletal muscle in obesity, no results",1],["R0002122","Glucagon-like-peptide 1 receptor agonist for metabolic dysfunction-associated steatotic liver disease: hype or hope?","Wong YJ","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent24","commentary on GLP-1 receptor agonists in MASLD without original data or systematic search",1],["R0009304","The GLP-1 Receptor Agonist Paradox in Dermatology: Why We Cannot Afford the Knowledge Gap.","Awadalla R","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent24","opinion piece on dermatologic benefits and harms of GLP-1 receptor agonists, no primary data",1],["R0018195","Outbreak of metabolic dysfunction-associated steatohepatitis pharmacotherapies in 2024: From resmetirom to tirzepatide.","Huang R","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent24","editorial summarizing 2024 MASH drug trials including tirzepatide, no original data",1],["R0030059","Fish oil supplements in patients with chronic kidney disease.","Ferro CJ","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent24","narrative review of fish oil in CKD; GLP-1 receptor agonists only mentioned in background, E3 also applies",1],["R0039287","Involvement of Vascular Endothelial Cells in the Anti-atherogenic Effects of Liraglutide in Diabetic Apolipoprotein E-null Mice","Masakazu Koshibu","2019","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent24","liraglutide versus vehicle study in diabetic apolipoprotein E null mice only",1],["R0040096","Ped Endo Journal Scan","Kriti Joshi","2023","inventory_only","N9","ancillary",null,null,null,"high","first","opus-5.5-agent24","journal scan commentary summarizing the STEP TEENS semaglutide placebo controlled trial in adolescents",1],["R0013997","Association of Tirzepatide With Kidney Parameters in Participants With Obesity and Prediabetes From SURMOUNT-1 Over 176 Weeks.","Heerspink HJL","2026","include_nma",null,"secondary_report","P02",null,null,"high","first","opus-5.5-agent35","post hoc SURMOUNT-1 analysis of the prediabetes subgroup, tirzepatide versus placebo, kidney parameters to 176 weeks",1],["R0022259","Long-Term Mortality and SGLT2 Inhibitors in Type 2 Diabetes with and without Renal Impairment: An Observational Cohort Study.","Al-Muhaiteeb A","2024","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent35","cohort of SGLT2 inhibitor use and mortality; GLP-1 RA appears only as a matching covariate",1],["R0029508","Do no harm: managing nausea and vomiting in GLP-1 based obesity therapies.","Alhazmi A","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent35","opinion article on mechanisms and management of nausea and vomiting with GLP-1 based obesity drugs",1],["R0030284","Clinical utility of a novel test for assessing cardiovascular disease risk in type 2 diabetes: a randomized controlled trial.","Peabody JW","2023","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent35","randomized trial of a diagnostic risk test among physicians with simulated patients; GLP-1 RA only a prescribing outcome",1],["R0037826","New generations of GLP-1 agonists in the treatment of obesity: Evolution of weight-loss pens and clinical impact","Jamile Zampieri Fernandes","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent35","self described narrative review prioritizing landmark trials; selective, no structured synthesis of studies meeting criteria",1],["R0040206","GLP-1 RA and SGLT2 – Inhibitor Treatment","Diana Teneva","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent35","PRISMA review with MEDLINE and Embase search, PICO criteria, pooled GLP-1 RA plus SGLT2 inhibitor versus monotherapy MACE",1],["R0002455","We have much more to learn about sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists.","Agewall S","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent25","journal issue editorial summarizing several published articles, not a primary study or systematic review",1],["R0009584","GLP-1 receptor agonists and functional gastrointestinal obstruction: mechanistic rationale, emerging evidence, and clinical implications.","Riaz L","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent25","letter to the editor giving opinion on GLP-1 agonists and functional bowel obstruction, no original data",1],["R0018198","Alopecia and Semaglutide: Connecting the Dots for Patient Safety.","Haykal D","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent25","letter to the editor discussing alopecia reports with semaglutide, opinion without original data",1],["R0029090","Response to the letter titled \"Analysis of semaglutide's effect on Alzheimer's disease risk\".","Xu R","2025","inventory_only","N9","ancillary",null,null,null,"high","first","opus-5.5-agent25","authors reply to a letter about their target trial emulation of semaglutide and Alzheimer disease risk, an in scope cohort",1],["R0030099","A nitroalkene derivative of salicylate, SANA, induces creatine-dependent thermogenesis and promotes weight loss.","Cal K","2025","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent25","phase 1 placebo controlled trial of SANA, a salicylate derivative thermogenic agent; no GLP-1 receptor agonist arm",1],["R0036256","IMPACT OF SMOKING CESSATION ON GLYCAEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: A SYSTEMATIC REVIEW","Abdulelah Saad Alzahrani","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent25","systematic review of smoking cessation and glycemic control; GLP-1 agonists appear only in discussion (ruling 19)",1],["R0039309","Impact of GLP-1 Receptor Agonists and Dual/Triple Incretin Therapies on Cardiometabolic Outcomes Beyond Glycemic Control: Evidence from Recent Randomized Trials","Javaria Ismail","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent25","PRISMA review searching PubMed, Scopus, Cochrane, Web of Science with criteria; pools 10 incretin RCTs on cardiometabolic outcomes",1],["R0040100","EFFICACY AND SAFETY OF INJECTABLE INCRETIN THERAPIES IN THE MANAGEMENT OF OBESITY: A SYSTEMATIC REVIEW","Fernanda Rodrigues Lopes","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent25","PRISMA-ScR review reports only pivotal trials (SCALE, STEP 1, SURMOUNT-1) of 7 RCTs, rated with narrative review scale (ruling 19)",1],["R0005498","Glucagon-like peptide-1 receptor agonists, weight loss, and gastric emptying: have I gut news for you.","Jalleh RJ","2022","inventory_only","N9","ancillary",null,null,null,"high","first","opus-5.5-agent33","editorial commentary on an in scope placebo controlled liraglutide RCT on gastric emptying and weight in obesity",1],["R0013558","Evaluation of Novel GLP‐1 analogue in the treatment of Alzheimer’s disease","Edison P","2024","include_nma",null,"conference_abstract","P13A",null,"abstract_only","high","first","opus-5.5-agent33","abstract of phase IIb RCT of liraglutide versus placebo for 12 months in mild to moderate Alzheimer disease",1],["R0020664","More on Semaglutide in Early Type 1 Diabetes.","DeVries JH","2024","inventory_only","N9","ancillary",null,null,null,"high","first","opus-5.5-agent33","letters and reply about an uncontrolled semaglutide case series in new onset type 1 diabetes, an in scope study",1],["R0030253","In silico prediction of optimal multifactorial intervention in CKD","Latosinska A","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent33","in silico simulation of drug combinations including GLP-1 RA on urinary peptide classifier scores; modeling, no trial",1],["R0037784","Glucagon-like Peptide Receptor Agonists (GLP-1 receptor agonists): A Powerful Addition to Foundational Therapy Kidney Care in Patients with Type 2 Diabetes Mellitus","Louis Girard","2024","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent33","narrative review of GLP-1 receptor agonists for kidney protection in type 2 diabetes without systematic methods",1],["R0040163","GLP-1 Receptor Agonists in Preconception Management of Obese Women with Polyendocrine Metabolic Ovarian Syndrome (PMOS): Metabolic and Reproductive Implications","Turan Kaan Karakaya","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent33","review with named databases and criteria but topic based narrative citing studies selectively without listing included studies",1],["R0001400","Improved cardiovascular outcomes with glucagon-like peptide-1 receptor agonists - what is the role of weight reduction?","Jacob S","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent21","editorial discussing whether weight loss explains cardiovascular benefit across GLP-1 RA outcome trials; no original data",1],["R0017120","Cardiovascular benefits of Tirzepatide: A breakthrough in cardio-metabolic care.","Majid M","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent21","letter to the editor giving an opinion on tirzepatide cardiovascular benefit; no original data or systematic search",1],["R0028960","Glucose-Lowering and the Risk of Cardiovascular Events With Antidiabetic Therapies: A Systematic Review and Additive-Effects Network Meta-Analysis.","de Carvalho LSF","2022","include_review",null,"systematic_review","P01",null,null,"high","first","opus-5.5-agent21","systematic review and additive network meta-analysis of RCTs of glucose lowering drugs including GLP-1 RA on MACE; databases named, PROSPERO registered",1],["R0030002","12624 The Efficacy Of Glp1 Receptor Agonists As Adjunct Therapy To Insulin In Patients With Type 1 Diabetes: A Meta-analysis",null,"2024","include_review",null,"systematic_review","P05",null,"abstract_only","high","first","opus-5.5-agent21","conference abstract of a meta-analysis of RCTs adding GLP-1 RA to insulin in type 1 diabetes; databases named, pooled HbA1c reported",1],["R0030447","Glucagon-like peptide-1: effect on pro-atrial natriuretic peptide in healthy males.","Skov J","2014","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent21","crossover experiment infusing synthetic native GLP-1 versus saline in healthy men; no therapeutic receptor agonist drug",1],["R0038829","Glucagon-like Peptide-1 Receptor Agonists and Gastrointestinal Neoplasms","Yu Jin Kim","2025","exclude","E3","other",null,null,"non_english","high","first","opus-5.5-agent21","Korean narrative review of GLP-1 RA and gastrointestinal cancer risk; no database search or eligibility criteria described",1],["R0008063","Diabetes Mellitus in Acute Coronary Syndrome.","Stampouloglou PK","2023","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent38","narrative review of diabetes in acute coronary syndrome with no described literature search or eligibility criteria",1],["R0025871","Liraglutide in diabetes mellitus: More facts and findings.","Rahman IU","2016","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent38","randomized experiment in streptozotocin diabetic rats given liraglutide or vehicle",1],["R0029641","Type 2 MI a legitimate efficacy endpoint in cardiovascular trials? A critical appraisal.","van Bruggen FH","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent38","opinion appraisal of type 2 myocardial infarction as an endpoint in lipid and glucose lowering outcome trials",1],["R0030374","The 2021-2022 position of Brazilian Diabetes Society on diabetic kidney disease (DKD) management: an evidence-based guideline to clinical practice. Screening and treatment of hyperglycemia, arterial hypertension, and dyslipidemia in the patient with DKD.","de Sá JR","2022","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent38","national society guideline on diabetic kidney disease based on an expert narrative review",1],["R0040024","Exploring the Efficacy of Triple Therapy with SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Mineralocorticoid Receptor Antagonists on Cardiovascular and Renal Outcomes in Advanced Heart Failure: A Meta-analysis","Bassem Ashraf","2024","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent38","meta-analysis searching PubMed, Scopus and Google Scholar with criteria, pooling heart failure outcomes with a GLP-1 RA subgroup estimate",1],["R0040241","Racial and Ethnic Disparities Across the MASLD/MASH Care Continuum in the United States: A Narrative Review","Rowan Bandaranaike","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent38","self described nonsystematic narrative review of MASLD disparities; sources chosen by expert appraisal",1],["R0005205","Editorial: Incretin-based therapies: economic sustainability and health impact in the global management of metabolic syndrome.","Provenzani A","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent32","editorial introducing a research topic collection; summarizes contributed reviews, no own search or data",1],["R0020449","Advent of tirzepatide: boon for diabetic and obese?","Bhusal A","2023","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent32","letter to the editor describing tirzepatide; no primary data or systematic search",1],["R0030249","Effects of Empagliflozin on Sarcopenia Risk, Body Composition, and Muscle Strength in Type 2 Diabetes: A 24-Week Real-World Observational Study.","Çetin D","2025","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent32","empagliflozin versus non SGLT2 observational cohort; GLP-1 RA users excluded from both groups",1],["R0037745","COMPARISON OF GLP-1 AGONIST, LIFE STYLE AND DIET MODIFICATION VS GLP-1 AGONIST ALONE FOR TREATMENT OF DIABETIC PATIENTS WITH MASLD","Fabiha Faiz","2026","inventory_only","N3","primary_report","P09; P01",null,null,"high","first","opus-5.5-agent32","lottery randomized trial; GLP-1 RA in both arms, lifestyle added in one arm only; contrast leaves GLP-1 regimen unchanged",1],["R0039741","SKALE Kids Trial: liraglutide efficace nell’obesità anche nei bambini: l’effetto è bello finché dura","Elena Arosio","2025","inventory_only","N9","ancillary",null,null,"non_english","high","first","opus-5.5-agent32","Italian journal club appraisal of SCALE Kids liraglutide trial in children; alternative E3 as news item",1],["R0040157","Glucagon-like peptide-1 receptor agonists and muscle: interpreting lean mass changes in clinical care","Muhammad Sameer Arshad","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent32","editorial narrative review of lean mass with GLP-1 RA; no named database search, selected studies only",1],["R0015718","HISTORI Experience – a qualitative study of HISTORI patients´ experiences with Semaglutide and placebo","Rasmussen B","2025","inventory_only","N2","conference_abstract",null,null,"abstract_only","high","first","opus-5.5-agent38","qualitative interview substudy of a semaglutide versus placebo trial in schizophrenia; no review outcome reported",1],["R0040396","Efficacy and Safety of Once-Weekly Semaglutide versus Tirzepatide in Type 2 Diabetes: A 24-Week Randomized Clinical Trial","Tahir Siddique","2025","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent34","open label randomized trial of semaglutide versus tirzepatide on metformin and empagliflozin in type 2 diabetes with obesity, 24 weeks",1],["R0040552","The impact of SGLT-2i and GLP-1RA on liver-related events in patients with metabolic dysfunction-associated steatotic liver disease and type 2 diabetes mellitus: a systematic review and network meta-analysis","Lu Li","2025","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent31","INPLASY registration of planned network meta-analysis of SGLT2i and GLP-1RA on liver events; no results reported",1],["R0041847","Glucagon-like peptide-1 receptor agonists and risk of cancer: a systematic review and meta-analysis of randomized controlled trials","Weiming Liang","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent31","PROSPERO registered systematic review and meta-analysis of randomized trials on GLP-1 receptor agonists and cancer risk",1],["R0043108","Observational Study on the Effectiveness of Treatment with the GLP1-Receptor Agonist Dulaglutide in Patients with Type 2 Diabetes Mellitus: Real-Life Study in Spain","Laura Oleaga","2022","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent31","retrospective single cohort of dulaglutide users in Spain; compared only with published trials, no concurrent unexposed comparator",1],["R0044175","Diabetes Treatment: Recent Developments","Aristidis Veves","2013","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent31","letter from the editor summarizing recent diabetes drug developments",1],["R0045133","Glucagon-like peptide-1 analogs for Alzheimer’s disease -- A systematic meta-analysis","Cindy Wang","2024","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent31","meta-analysis of two placebo controlled GLP-1 analog trials in Alzheimer disease after search of several named databases",1],["R0045997","Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD","Hirokazu Takahashi","2025","exclude","E2","other",null,null,"non_english","high","first","opus-5.5-agent31","randomized trial of ipragliflozin versus control in diabetic NAFLD; GLP-1 receptor agonists excluded from both arms",1],["R0040567","Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial","Alina Velescu","2026","inventory_only","N9","ancillary",null,null,"non_english","high","first","opus-5.5-agent34","Spanish letter commenting on the STRIDE placebo controlled semaglutide trial in peripheral artery disease with type 2 diabetes",1],["R0042149","Eficácia e segurança dos agonistas do receptor de GLP-1 na redução de eventos cardiovasculares e mortalidade em pacientes com obesidade e Diabetes Mellitus tipo 2: uma umbrella review.","Juliana Oliveira de Toledo","2026","include_review",null,"systematic_review",null,null,"umbrella_review; non_english","high","first","opus-5.5-agent34","Portuguese umbrella review of five meta-analyses of GLP-1 receptor agonist RCTs on MACE and mortality, four named databases, stated criteria",1],["R0042815","Semaglutide’s Trail of Success in Weight Loss Management and HbA1c Reduction: A Systematic Review","Shayne Paff","2023","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent34","self described systematic review that picked four studies from high impact journals via Google Scholar, a selective review under ruling 19",1],["R0043193","A minireview of pharmacotherapy of type 2 diabetes – drugs and mechanisms","Érick Bryan de Sousa Lima","2022","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent34","narrative minireview of type 2 diabetes drug classes and mechanisms without structured synthesis of studies",1],["R0044286","Metabolic Insights and Reproductive Health Challenges: High-Protein Hypocaloric Diets in PCOS Management [Letter]","Weilan Liu","2025","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent34","letter on a randomized diet trial in PCOS, GLP-1 agonists only suggested for future research; alternative E4",1],["R0045257","MORPHOFUNCTIONAL STATE OF PANCREAS IN RATS WITH DIABETES MELLITUS","О. Р. Іванців","2024","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent34","literature review of pancreas morphology and treatment in diabetic rats; also a narrative review (E3)",1],["R0040385","The Impact of GLP-1 Receptor Agonists (GLP-1 RAs) on Mental Health: A Systematic Review","Silvia Tempia Valenta","2025","include_review",null,"systematic_review",null,null,"abstract_only","high","first","opus-5.5-agent31","conference abstract of systematic review searching PubMed and Web of Science; synthesizes 81 studies of GLP-1 receptor agonists on mental health",1],["R0008877","Acute plasma amylase increase after glucagon-like peptide -1 receptor agonist exenatide administration in Type 2 diabetes.","Smits MM","2017","inventory_only","N2","secondary_report",null,null,null,"high","first","opus-5.5-agent40","letter on randomized IV exenatide versus saline infusion in type 2 diabetes; reports only plasma amylase and lipase, no review outcome",1],["R0016869","Atrial Fibrillation Risk Management and Emerging Therapies.","Vaughan M","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent40","narrative review of atrial fibrillation management; PubMed keywords only, evidence weighted selectively, no eligibility criteria",1],["R0028441","Is the stepping-down approach a better option than multiple daily injections in obese patients with poorly controlled Type 2 diabetes on advanced insulin therapy?","Naing S","2021","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent40","randomized open label trial in obese T2D: step down to basal insulin, metformin, SGLT2i and GLP-1 RA versus continued MDI, 16 weeks",1],["R0029972","If treating obesity with GLP-1-based therapies protects the heart, could it also prevent cancer or improve cancer outcomes? The case for randomized trials.","Tentolouris A","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent40","opinion commentary arguing for randomized cancer outcome trials of GLP-1 based drugs; no original data",1],["R0038663","Dose-dependent acute effects of liraglutide on liver function and metabolic parameters in healthy rats","Aytaç Gül","2025","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent40","randomized dose study of single liraglutide injections in healthy Wistar rats; no human participants",1],["R0040037","Metabolic-Associated Steatotic Liver Disease and Cognitive Impairment: Shared Pathophysiological Mechanisms and Clinical Implications: A Narrative Review","George P. Roy","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent40","self described narrative review of MASLD and cognition; studies prioritized selectively, organized by mechanism; GLP-1 agonists mentioned only as therapy",1],["R0013010","Potential impact of GLP-1 receptor agonists on male fertility: a fable of caution.","Du Plessis SS","2024","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent32","opinion piece on male fertility; mentions one PubMed search but no eligibility criteria and cites studies selectively",1],["R0040333","10.51847/GSN_4aH","Fatmah S. Alhawyan","2000","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent27","review searching PubMed, Scopus, Web of Science and others; qualitative synthesis of seven placebo controlled GLP-1 RA outcome trials for stroke",1],["R0040521","COMPARATIVE EFFECTIVENESS OF CONTEMPORARY WEIGHT-LOSS INJECTIONS AND ESTABLISHED BARIATRIC PROCEDURES","Dvir Levin","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent27","self described structured narrative review benchmarking pivotal GLP-1 drug trials against bariatric surgery; selective evidence per ruling 19",1],["R0041643","Comparative Efficacy of Resmetirom, GLP-1 Receptor Agonists, and Pioglitazone for Fibrosis Regression and MASH Resolution in Metabolic Dysfunction-Associated Steatohepatitis: A Systematic Review and Narrative Synthesis of Network Meta-Analyses with Implications for Pakistan","Sameed Qureshi","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent27","names databases but summarizes key metrics from selected NMAs and major phase 3 trials without listing studies meeting criteria; rulings 14 and 19",1],["R0042601","Liraglutide as Add-on to Oral Antidiabetic Agents or Insulin in Routine Practice of Patients with Type 2 Diabetes","Christian Anholm","2014","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent27","retrospective uncontrolled cohort of routine care liraglutide initiators in Copenhagen clinics; before and after HbA1c and weight",1],["R0043016","Effects of Glucagon-Like Peptide-1 Receptor Agonists on β-Cell Function in Patients with Type 2 Diabetes","Susan Grandy","2015","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent27","sponsor written review of GLP-1 RA effects on beta cell function; PubMed searched but studies picked individually without stated criteria",1],["R0044096","Efficacy and safety of semaglutide compared with dulaglutide in patients with type 2 diabetes:a meta-analysis","Guochao Xu","2023","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent27","INPLASY registered protocol for a meta-analysis of semaglutide versus dulaglutide in type 2 diabetes; review not yet started",1],["R0045046","How do Dual GLP-1/GIP Receptor Agonists Differ from GLP-1 Agonists for Diabetes Management: A Systematic Review","Prisha Bhat","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent27","undergraduate structured review naming databases but narrating major SURPASS and SURMOUNT trials without stating which studies met criteria; rulings 14 and 19",1],["R0045757","The clinical importance of the cardiovascular–kidney–metabolic syndrome and related mortality","Karolina Hoffmann","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent27","opinion article on cardiovascular kidney metabolic syndrome mortality mentioning GLP-1 RA among therapies; no study data",1],["R0040278","Causal relationship between GLP-1 agonists and depressive symptomatology in patients with type 2 Diabetes: A systematic review","F Barroso","2024","include_review",null,"systematic_review",null,null,"non_english","high","first","opus-5.5-agent22","Spanish systematic review searching PubMed and Cochrane with stated criteria, reporting seven studies of GLP-1 agonists versus other therapies on depression",1],["R0040957","The emerging role of glucagon-like peptide-1 receptor agonists in male infertility: mechanisms, experimental evidence, and future clinical perspectives","Shubham Biswas","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent22","self described narrative review of GLP-1 agonists and male infertility, relevance based selection without eligibility criteria",1],["R0042540","Cardiovascularis biztonságossági vizsgálatok 2-es típusú diabetesben – az első 10 év tapasztalatai","György Jermendy","2017","exclude","E3","other",null,null,"non_english","high","first","opus-5.5-agent22","Hungarian narrative review of completed cardiovascular safety trials of new antidiabetic drugs, no systematic search",1],["R0042925","Pharmacologic Weight Loss: An Underutilized Practice in the Fight Against Obesity","Megumi Howard","2021","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent22","review of 24 trials of five weight loss drugs including liraglutide without a named database search or eligibility criteria",1],["R0044005","Evolution of Biochemical Effects of Byetta® in Type 2 Diabetics with Cardiovascular Risk","Alfonso López Ruiz","2013","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent22","uncontrolled record based series of ten type 2 diabetes patients treated with exenatide in primary care; alternative N1",1],["R0044971","Endoscopic Safety and Risk of Retained Gastric Content in Patients Treated with GLP-1 Receptor Agonists: A Systematic Review and Meta-analysis","pofeng huang","2026","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent22","INPLASY registration of a planned meta-analysis on GLP-1 agonists and retained gastric content at endoscopy, no results",1],["R0045579","GLP-1 RECEPTOR AGONISTS AS EMERGING THERAPEUTICS FOR SUBSTANCE USE DISORDERS: A REVIEW OF MECHANISMS, EFFICACY, AND PUBLIC HEALTH IMPLICATIONS","Natalia Bylak","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent22","self described narrative review on GLP-1 agonists for substance use disorders, selection prioritizing high quality evidence without listing included studies",1],["R0040255","Effects of Lifestyle and GLP-1RA based Interventions on Waist Circumference: A Systematic Review and Meta-Analysis","Samit Ghosal","2025","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent21","INPLASY registration of a planned meta-analysis of lifestyle and GLP-1 RA trials on waist circumference; methods only, no results",1],["R0040481","GLP-1 Receptor Agonist and Structured Exercise on Glycemic Con-trol and Epigenetic Modulation in Diabetic Rats","Qurat-ul-Ain Adnan","2026","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent21","randomized experiment in diabetic Wistar rats comparing a GLP-1 RA with exercise; no human participants",1],["R0040917","Semaglutide and Risk of Non-arteritic Anterior Ischemic Optic Neuropathy: Systematic Review and Meta-analysis","Eugene Yu-Chuan Kang","2025","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent21","INPLASY protocol for a meta-analysis of semaglutide and NAION cohorts; review not yet started, no results",1],["R0042531","GLP-1 receptor agonists for NAFLD treatment in patients with and without type 2 diabetes: an updated meta-analysis","Alessandro Mantovani","2020","include_review",null,"systematic_review","P09",null,null,"high","first","opus-5.5-agent21","meta-analysis of RCTs of GLP-1 RA for NAFLD or NASH; PubMed and ClinicalTrials.gov searched, pooled liver outcomes reported",1],["R0042919","Effect of Lixisenatide (Short-acting Glucagon-Like Peptide 1 Receptor Agonist) as an Add-on to Insulin in Lowering HbA1C among Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis","Ashwaq Ali Abusalem","2023","include_review",null,"systematic_review","P01",null,null,"high","first","opus-5.5-agent21","meta-analysis of RCTs of lixisenatide added to insulin in type 2 diabetes; PubMed, Embase and Cochrane searched, pooled HbA1c reported",1],["R0043830","Metformin, Liraglutide, Orlistat, and Phentermine for Childhood Obesity and Blood Lipids: A Systematic Review and Meta-Analysis","Yuhang Chen","2023","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent21","INPLASY protocol for a meta-analysis including liraglutide trials in pediatric obesity; only preliminary searches, no results",1],["R0044819","GLP-1 Receptor Agonists Beyond Metabolic Disease: A Systematic Review of Cardiovascular, Renal, Neurological, and Emerging Therapeutic Evidence","Dr. Swati.Fulmali","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent21","PROSPERO registered review searching four databases with a priori criteria; tabulates results of all 14 included GLP-1 RA studies across indications",1],["R0045564","Association between glucagon-like peptide-1 receptor agonists and thyroid carcinoma; a systematic review and meta-analysis of observational studies","Mojtaba Lotfi","2025","include_review",null,"systematic_review","P01",null,null,"high","first","opus-5.5-agent21","meta-analysis of observational studies on GLP-1 RA use and thyroid cancer; seven databases searched, pooled HR, OR and IRR reported",1],["R0040315","Management of Overweight and Obese People with the Dual GIP/GLP-1 Receptor Agonist Tirzepatide: A Systematic Review","Liya Fu","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent25","searched Embase, PubMed, Web of Science, Cochrane and Chinese databases with stated criteria; meta-analysis of 11 tirzepatide RCTs",1],["R0040502","Lifestyle and Pharmacological Interventions for Metabolic Dysfunction-Associated Fatty Liver Disease: A Systematic Review","Tatia Khachidze","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent25","PubMed, Embase, Cochrane search with PICOS criteria; 10 studies tabulated, including liraglutide or semaglutide versus lifestyle in MAFLD",1],["R0041346","Tirzepatide (Mounjaro)","CDA-AMC","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent25","national drug agency reimbursement recommendation for tirzepatide, a health technology assessment document, not a primary study or systematic review",1],["R0042596","Lixisenatide: a once-daily glucagon-like peptide-1 receptor agonist","Tushar B. Chudiwal","2016","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent25","narrative review of lixisenatide and the GetGoal program without a described literature search",1],["R0045012","The Effectiveness of Glucagon-Like Peptide-1 Receptor Agonists on Peripheral Neuropathy Among Diabetic Patients: A Systematic Review","Dr Sara Mahmoud Humaida","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent25","PRISMA search of PubMed, Embase, Cochrane; 15 studies of GLP-1 agonists and diabetic peripheral neuropathy met criteria and are synthesized",1],["R0045711","Treating obesity with GLP-1 RAs: does sex matter? A commentary on the meta-analysis by Yang et al. (J Diabetes 2025;17(3):e70063)","Ralf Weiskirchen","2026","inventory_only","N9","ancillary",null,null,null,"high","first","opus-5.5-agent25","commentary on a published meta-analysis of sex differences in GLP-1 agonist weight loss, an in scope review",1],["R0040302","Effect of Glucagon-like Peptide-1 Receptor Agonists on Gastric Residual Volume and Quality of Bowel Preparation in Patients Undergoing Painless Gastroenteroscopy: A Meta-Analysis","xinying yang","2025","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent24","INPLASY registered protocol of a meta-analysis on GLP-1 RA and gastric residue at endoscopy, preliminary search stage, no results",1],["R0040492","Beyond bariatrics: A systematic review and meta-analysis of glucagon-like peptide-1 receptor agonists and novel anti-obesity medications in critical care settings","Shibu Sasidharan","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent24","searched PubMed, Embase and Cochrane with stated criteria; meta-analysis of GLP-1 RA versus insulin in ICU patients",1],["R0041255","Semaglutide and the Risk of Non-Arteritic Anterior Ischaemic Optic Neuropathy: A Systematic Review and Meta-Analysis","Jovita Jutamulia","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent24","searched PubMed, Embase and Google Scholar with predefined criteria; pooled six observational studies of semaglutide and NAION",1],["R0042594","Obesità e terapie incretiniche nel diabete di tipo 1: razionale ed evidenze su GLP-1RA e tirzepatide","Giuseppe Daniele","2026","exclude","E3","other",null,null,"non_english","high","first","opus-5.5-agent24","Italian narrative symposium review of GLP-1 RA and tirzepatide in type 1 diabetes without systematic search",1],["R0042955","Semaglutide for Type 2 Diabetes (2 mg)","Deepa Jahagirdar","2023","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent24","CADTH rapid review searching MEDLINE with selection criteria; one RCT of semaglutide 2 mg summarized",1],["R0044046","IMPACT OF GLP-1 RECEPTOR AGONIST SEMAGLUTIDE ON CAROTID INTIMA-MEDIA THICKNESS IN DIABETES MELLITUS","Lijiang Li","2024","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent24","RCT randomizing 148 type 2 diabetes patients to semaglutide or liraglutide, reports HbA1c, BMI and adverse reactions",1],["R0045004","Impact of baseline heart failure status on glucagon-like peptide-1 receptor agonists heart failure-related outcomes in type2 diabetes:a systematic review and meta-analysis of seven cardiovascular outcome trials","Jian Cheng Cao","2023","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent24","INPLASY protocol of a meta-analysis of GLP-1 RA outcome trials by heart failure status, no results",1],["R0045676","Pleiotropic effects of GLP-1 receptor agonists — a narrative review of extra-metabolic outcomes in adults","Julia Maria Koperdowska","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent24","self described narrative review prioritizing selected trials and reviews, no stated eligibility criteria",1],["R0040338","Glucagon-Like Peptide-1 Receptor Agonists' Effect on Polycystic Ovary Syndrome: A Meta Analysis","Xinrui Li","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent28","meta-analysis of 14 RCTs of GLP-1 RA in PCOS, PubMed and Cochrane search with stated inclusion criteria and PRISMA flow",1],["R0041749","Editorial: Effects of nonpharmacological interventions on HbA1c variability and glycemic control","João Soares Felício","2024","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent28","editorial introducing a research topic on nonpharmacological diabetes interventions, no original data",1],["R0042619","Blood glucose, antidiabetic drugs, and risk of stroke","Meng Lee","2021","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent28","narrative review of glucose lowering drugs and stroke risk without systematic search",1],["R0043018","Pharmacological management of obesity: a comprehensive narrative review of diagnostic classification, incretin-based and legacy drug therapy, and landmark trial evidence","Mosrur Ahmed","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent28","narrative review presenting landmark obesity drug trials, selective per ruling 19",1],["R0044124","Victosa: the experience with clinical application in patients with type 2 diabetes mellitus","Э. А. Войчик","2011","inventory_only","N5","primary_report",null,null,"non_english","high","first","opus-5.5-agent28","Russian clinical experience report describing one patient started on liraglutide plus metformin, case report without comparison",1],["R0045093","EARLY REAL-WORLD EVIDENCE FOR THE USE OF ORAL SEMAGLUTIDE IN A TERTIARY CENTRE IN MALAYSIA","Jun Kit Khoo","2025","inventory_only","N5","conference_abstract",null,null,"abstract_only","high","first","opus-5.5-agent28","poster abstract of prospective single centre before and after study of oral semaglutide, no comparison group",1],["R0045763","COMPREHENSIVE TREATMENT OF TYPE 2 DIABETES IN PATIENTS WITH OBESITY: THE ROLE OF PATIENT EDUCATION, WEIGHT REDUCTION, PHARMACOTHERAPY AND LIFESTYLE MODIFICATION - A NARRATIVE REVIEW","Magdalena Fąfara","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent28","self described narrative review of T2D and obesity management with selective PubMed literature, no criteria",1],["R0040356","Cost-effectiveness analysis of Oral Semaglutide treatment for type 2 diabetes mellitus patients: a systematic review","I Kadek Suardiana","2024","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent29","systematic review whose 12 included studies are all cost effectiveness analyses of oral semaglutide (ruling 14)",1],["R0040548","Glucagon-like Peptide-1 Receptor Agonists and Thyroid Cancer: Myth or Reality?","Ronald Goldenberg","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent29","single author narrative review of GLP-1 RA and thyroid cancer evidence without systematic search",1],["R0041753","PP93 Efficacy Of Pharmacological Treatments For Type 2 Diabetes In China","Shuyan Gu","2019","include_review",null,"systematic_review",null,null,"abstract_only","high","first","opus-5.5-agent29","poster abstract PP93 of systematic review and meta-analysis of Chinese T2D drug RCTs including GLP-1 RA contrasts; states systematic database search (ruling 14)",1],["R0042637","Effects of treatment with GLP-1RA on prediabetes: a systematic review and meta-analysis","Weihao Wang","2022","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent29","INPLASY registration of a meta-analysis of GLP-1 RA RCTs in prediabetes; no results reported",1],["R0043049","Comparative Effectiveness of Dulaglutide Versus Iiraglutide in Asian type 2 Diabetes Patients: A Multi-Institutional Cohort Study and Meta-Analysis","Kai-Cheng Chang","2020","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent29","Taiwan cohort plus meta-analysis pooling dulaglutide versus liraglutide studies from PubMed and Embase search; cohort alone would be N6",1],["R0045116","Effects of novel glucose-lowering drugs on the COVID-19 patients with diabetes: A network meta-analysis of clinical outcomes","Yang Yang","2023","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent29","network meta-analysis of SGLT2i, GLP-1 RA and DPP4i in diabetes with COVID-19; four named databases, 12 studies",1],["R0045917","Letter: Increased Risk of Hospitalization for Heart Failure with Newly Prescribed Dipeptidyl Peptidase-4 Inhibitors and Pioglitazone Using the Korean Health Insurance Claims Database (Diabetes Metab J2015;39:247-52)","Dae Ho Lee","2015","exclude","E4","other",null,null,null,"high","first","opus-5.5-agent29","letter commenting on a Korean claims study of DPP-4 inhibitors and pioglitazone; parent record out of scope",1],["R0040432","Sex Representation and Sex-Specific Treatment Effects in Randomized Trials of Novel Cardio-Renoprotective Therapies for Chronic Kidney Disease: A Meta-Epidemiological Study v1","Ioannis Bellos","2026","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent39","protocols.io protocol for a meta-epidemiological study of sex representation in CKD trials including GLP-1 RA; no results",1],["R0040789","Retatrutide (LY3437943) for metabolic disorders: A systematic review of clinical outcomes in obesity and type 2 diabetes","Shruti Singh","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent39","systematic review searching PubMed, Google Scholar, ScienceDirect; reports all four retatrutide trials versus placebo and dulaglutide by outcome",1],["R0042490","Clinical Application and Mechanistic Investigation of GLP-1 Receptor Agonists in the Treatment of Polycystic Ovary Syndrome","Yan Liu","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent39","narrative review of GLP-1 RA in PCOS with no search methods or eligibility criteria",1],["R0042840","A Systematic Review and Network Meta-Analysis: Effect of of GLP-1 drugs on weight loss in obese people","Yunhui Xie","2022","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent39","INPLASY registration of a planned systematic review and NMA of GLP-1 drugs for weight loss; no results",1],["R0043711","Glucagon-Like Peptide-1 Receptor Agonists and Dual GIP/GLP-1 Receptor Co-Agonism in Heart Failure with Preserved Ejection Fraction: A Systematic Review of Randomized and Real-World Evidence","Ritu Raj Kumar","2026","include_review",null,"systematic_review",null,null,"umbrella_review","high","first","opus-5.5-agent39","registered review searching five databases; structured synthesis of all six eligible GLP-1 RA and tirzepatide HFpEF trial sources plus meta-analyses",1],["R0044469","Metabolic Dysfunction–Associated Steatotic Liver Disease in Endocrine Practice: Risk Assessment, Fibrosis Stratification, and Treatment Considerations","Melike Yakut","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent39","self described narrative review on MASLD that prioritizes guidelines and selected trials; ruling 19",1],["R0045543","Dose Response Effects of Liraglutide (Saxenda) on Weight Loss among Overweight and Obese Individuals: A Three Arm Randomized Controlled Trial","Uzma Dost Muhammad Rajar","2024","include_nma",null,"primary_report","P02",null,null,"high","first","opus-5.5-agent39","envelope randomized to liraglutide 0.6, 1.2 or 1.8 mg with or without walking in obese adults; diabetes status not stated",1],["R0046294","The impact of novel hypoglycemic medications on hormonal and metabolic parameters in patients with polycystic ovary syndrome: a Bayesian network meta-analysis","Haoyu Wu","2024","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent39","INPLASY registration of a planned network meta-analysis of novel glucose lowering drugs in PCOS; no results",1],["R0040402","The efficacy and safety of Rybelsus in Asian patients with type 2 diabetes：A systematic review and meta-analysis","Tianzuo Wang","2023","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent35","INPLASY registration of a planned meta-analysis of oral semaglutide in Asian type 2 diabetes; review not yet started, no results",1],["R0040568","Effect of Exenatide on Aortic Stiffness and Blood Pressure Parameters","Eren Gürkan","2017","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent35","26 week RCT of exenatide versus insulin glargine on metformin in type 2 diabetes; blood pressure, aortic stiffness, weight",1],["R0042327","Glucagon-like peptide 1 receptor agonists in obesity treatment: efficacy, safety and clinical implications","Sylwia Lepak","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent35","self described narrative review of selected articles including reviews; no structured synthesis of studies meeting criteria",1],["R0042827","Recent updates on pharmacologic therapy in non-alcoholic fatty liver disease","Young Woon Chang","2023","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent35","short narrative snapshot review of NASH drug pipelines including semaglutide; no systematic search",1],["R0043229","The impact of diet on male semen quality and fertility: A comprehensive review","Bingxin Ma","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent35","comprehensive narrative review of diet and semen quality; GLP-1 RA mentioned only in passing, no systematic search",1],["R0045350","Tirzepatide and semaglutide in obesity management and their impact on health-related quality of life – a comparative narrative review","Weronika Kopniak","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent35","comparative narrative review centered on six pivotal STEP and SURMOUNT trials chosen for relevance; selective per ruling 19",1],["R0046218","Cardiovascular effects of GLP-1 receptor agonists: atherosclerotic outcomes, obesity, HFpEF, and kidney disease — a narrative review.","Marcel Gisal","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent35","narrative review guided by SANRA, landmark outcome trials and selected studies; not a systematic review",1],["R0040423","Bariatric Surgery and Glucagon-Like Receptor-1 Agonists' Effects on Weight, HbA1c, and Cardiovascular Outcomes: A Meta-Analysis","Salah Alghamdi","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent37","meta-analysis of bariatric surgery versus GLP-1 agonists on BMI, HbA1c and MACE, four named databases, stated criteria, seven studies pooled",1],["R0042424","GLP-1 Receptor Agonists in Addiction: From Observational Signals to Research Priorities","Augusta Okoro","2026","exclude","E3","other",null,null,"abstract_only","high","first","opus-5.5-agent37","conference abstract of a targeted evidence synthesis on GLP-1 agonists in addiction, no named databases or eligibility criteria",1],["R0042838","Role of nutrition in depression and other mental illnesses","Omveer Singh","2022","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent37","narrative review of nutrition in depression without systematic search, exenatide only mentioned in passing",1],["R0043527","Systematic Review on the Association Between Tirzepatide and Gastroparesis in Diabetic and Non-Diabetic Populations","Sabrina Ait Gacem","2024","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent37","INPLASY registration of a planned systematic review on tirzepatide and gastroparesis, results in progress",1],["R0045444","Charting the future of cardiorenal medicine: a vision for integration, innovation, and impact","Amir Kazory","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent37","specialty grand challenge editorial on cardiorenal medicine, no original data",1],["R0046276","EFFICACY OF TIRZEPATIDE ON WEIGHT LOSS, MUSCLE MASS AND CARDIOVASCULAR HEALTH IN THE ADULT POPULATION WITH DIABETES TYPE 2, OVERWEIGHT OR OBESITY: A SYSTEMATIC REVIEW","Zuzanna Strojek","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent37","systematic review of tirzepatide on weight, muscle mass and cardiometabolic markers, PubMed search, stated criteria, 33 studies reported by outcome",1],["R0040394","GLP-1 and GIP analogues in the treatment of obesity – Current State of Knowledge","Marta Grycan","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent33","narrative revision review of incretin drugs for obesity; PubMed mentioned but no criteria and studies chosen selectively",1],["R0040560","GLP-1 receptor agonists and suicidal ideation/behavior: subject-level analysis of clinical trials","Van Hung Tran","2026","include_nma",null,"pooled_analysis","P01; P02",null,null,"high","first","opus-5.5-agent33","FDA subject level pooling of 91 placebo controlled GLP-1 RA RCTs keeping trial stratified contrasts for suicidal ideation",1],["R0042049","PERIOPERATIVE ANESTHETIC IMPLICATIONS OF TIRZEPATIDE (MOUNJARO) IN SAUDI ARABIA","Alanoud K. Albanna","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent33","narrative review of perioperative anesthetic implications of tirzepatide without systematic methods or own data",1],["R0042774","Efficacy and Safety of Exenatide versus Insulin in Type 2 Diabetes Mellitus: Systematic Review and Meta-Analysis","Bao-Ju Chen","2019","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent33","meta-analysis of RCTs from a PubMed search comparing exenatide with placebo and insulin in type 2 diabetes",1],["R0043190","Effect of hyperandrogenism in obese PCOS patients: GLP-1 receptor agonists plus metformin versus metformin monotherapy–a systematic review and meta-analysis","Gilang Rizqy Perdana Aries Rohman","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent33","meta-analysis of trials from three named databases comparing GLP-1 RA plus metformin with metformin in PCOS",1],["R0044262","Role of oral semaglutide in management of type 2 diabetes","Nasser Mikhail","2019","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent33","mini review of oral semaglutide citing PIONEER trials by topic; includes opinions and editorials, no list of included studies",1],["R0045247","TIRZEPATIDE VERSUS SEMAGLUTIDE: A COMPREHENSIVE REVIEW OF COMPARATIVE EFFICACY, SAFETY, AND METABOLIC OUTCOMES IN TYPE 2 DIABETES AND OBESITY","Mandy Schulz","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent33","self described systematic review of tirzepatide versus semaglutide with criteria but no named database searched",1],["R0046107","GLP-1 Receptor Agonists: A New Hope in the Global Fight Against Obesity — Benefits and Health Risks","Oskar Pastuszek","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent33","narrative review of GLP-1 RA benefits and risks in obesity; PubMed search with prioritized, selectively cited studies",1],["R0040426","Long-Term Adverse Effects of Semaglutide Use: A Systematic Review","Eveline Moreira de Souza","2025","include_review",null,"systematic_review",null,null,"non_english","high","first","opus-5.5-agent38","Spanish systematic review of long term semaglutide adverse effects; PubMed, Embase, Cochrane searched, criteria stated, eight studies tabulated",1],["R0040605","Efficacy and Safety of GLP-1 Receptor Agonists as Adjuvant Pharmacotherapy After Bariatric Surgery: A Narrative Review","Natanael Sinaga","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent38","self described narrative review with systematic PubMed search, a priori criteria and eleven post bariatric GLP-1 RA studies tabulated (ruling 14)",1],["R0042455","GLP-1 Agonist As Adjunct To Antidepressants In Patients With Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial.","A. N. R. B. Saad","2026","include_nma",null,"conference_abstract","P99; P02",null,"abstract_only","high","first","opus-5.5-agent38","double blind placebo controlled RCT of liraglutide added to escitalopram in depression with BMI 27 or more; weight reported; diabetes status unstated",1],["R0042839","Effects of Glucagon-Like Peptide-1 on Arteriovenous Fistula Remodelling and Vascular Smooth Muscle Cell Phenotype Switching in Diabetic Rats","Jun‐Neng Roan","2016","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent38","randomized exendin-4 versus saline experiment in diabetic rats with arteriovenous fistulas",1],["R0044367","Effect of GLP-1 receptor agonist on cardiac remodelling: a systematic review and meta-analysis","Yang Yu","2024","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent38","INPLASY registration of a planned GLP-1 RA cardiac remodeling meta-analysis at preliminary search stage; no results",1],["R0045535","Pharmacokinetic bioequivalence of semaglutide injection in healthy adults under fasting conditions: A randomized study","Sohel Mohammed Khan","2026","inventory_only","N3","primary_report",null,null,null,"high","first","opus-5.5-agent38","randomized PK bioequivalence of a generic semaglutide 0.5 mg injection versus the reference product in healthy adults (ruling 6)",1],["R0046293","Comparative Efficacy and Safety of Semaglutide, Cagrilintide, and CagriSema in Adults with Overweight or Obesity: A Bayesian Network Meta-Analysis","Yange Meng","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent38","network meta-analysis of RCTs of semaglutide, cagrilintide, CagriSema and liraglutide in obesity; four databases searched with stated criteria",1],["R0044308","Eficácia de Agonistas GLP-1 e Co-agonistas GIP/GLP-1 na Insuficiência Cardíaca com Fração de Ejeção Preservada Relacionada à Obesidade: Revisão Sistemática","Vitor Daniel Picinin","2025","include_review",null,"systematic_review",null,null,"non_english","high","first","opus-5.5-agent35","Portuguese systematic review with PubMed search and stated criteria; tabulates semaglutide and tirzepatide RCTs in obesity related HFpEF",1],["R0040323","Semaglutide for Treatment of Obesity-Related Heart Failure with Preserved Ejection Fraction in Patients with and without Diabetes","Nasser Mikhail","2024","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent26","mini review critically discussing the two STEP-HFpEF trials; no systematic search or stated eligibility criteria",1],["R0040517","The efficacy of oral semaglutide in weight loss and glycemic control","Caroline Augusto Lopes","2024","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent26","integrative review of oral semaglutide trials; PubMed and VHL searched, criteria stated, all 16 included trials tabulated with weight and HbA1c results; ruling 14",1],["R0041417","GLP-1 Receptor Agonists and Total Hip Arthroplasty Outcomes: A Systematic Review","Rolanda Willacy","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent26","systematic review of cohorts comparing GLP-1RA users and nonusers after total hip arthroplasty; PubMed and Google Scholar, criteria stated, 11 studies",1],["R0042599","Tirzepatide: A Useful Addition for Treatment of Type 2 Diabetes and Obesity","Nasser Mikhail","2021","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent26","narrative review of tirzepatide focused on SURPASS-1 and 2; PubMed search but selection of pertinent sources without criteria; ruling 19",1],["R0043007","Recent Updates on Glucagon-Like Peptide 1 Receptor Agonist","Hae Jin Kim","2021","exclude","E3","other",null,null,"non_english","high","first","opus-5.5-agent26","Korean narrative update on GLP-1RAs; no systematic search or primary data",1],["R0044066","Efficacy And Safety Of Semaglutide Injection (Generic) Compared With Ozempic® In Patients With Type 2 Diabetes Mellitus - A Multicentric, Prospective, Randomized, Open-Label, ActiveControlled, Parallel-Group Study","Piyush Agarwal","2026","inventory_only","N3","primary_report","P01",null,null,"high","first","opus-5.5-agent26","open label RCT of generic semaglutide versus Ozempic, same weekly subcutaneous dose on metformin; same molecule contrast, ruling 6",1],["R0045030","Glucagon-Like Peptide-1 Receptor Agonist potential in AUD treatment. Neurobiological Mechanisms and Clinical Evidence","Paulina Wądołowska","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent26","literature review on GLP-1RAs in alcohol use disorder mixing preclinical and clinical evidence; no list or count of included studies; ruling 14; alternative include_review",1],["R0045715","GLP-1 Receptor Agonists: Therapeutic Benefits in Renal Function, Cardiovascular Risk, and Physical Activity - A Systematic Review","Łukasz Karaban","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent26","review labeled systematic with PubMed keyword search only, no eligibility criteria, narrative discussion of selected trials",1],["R0046642","ASSOCIATION BETWEEN SEMAGLUTIDE AND NON-ARTERITIC ANTERIOR ISCHEMIC OPTIC NEUROPATHY: A SYSTEMATIC REVIEW","S. AGRAWAL","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent31","systematic review searching PubMed, Embase, Cochrane, ScienceDirect; tabulates all eight cohort studies of semaglutide and NAION",1],["R0047897","Weight Regain After Discontinuation of High-Dose GLP-1 Receptor Agonists in Adults with Obesity Without Type 2 Diabetes: A Meta-Analysis of Long-Term Follow-Up Studies","Saja Saad Merzah Almusaferi","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent31","PRISMA meta-analysis searching PubMed, Embase, CENTRAL; pools weight regain after stopping high dose GLP-1 receptor agonists across 11 studies",1],["R0049355","GLP-1 receptor agonists and tendon healing: a systematic review and meta-analysis","Mohammed Y. Khayyat","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent31","systematic review and meta-analysis with named databases; pools two cohorts of GLP-1RA users versus nonusers for shoulder arthroplasty revision",1],["R0050758","The use of GLP-1 agonist therapy, liraglutide, is associated with significant weight loss in morbidly obese people without diabetes","Syed M.R. Gillani","2015","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent31","clinical audit of liraglutide use in nondiabetic morbid obesity without comparison group; alternative N1 uncontrolled intervention",1],["R0054005","Glucagon-like peptide-1 receptor agonists in metabolic dysfunction-associated steatotic liver disease: a narrative review","Martyna Małek","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent31","self described narrative review of GLP-1RA in MASLD including reviews and guidelines; no account of which studies met criteria",1],["R0054354","Combination Gastrokinetic Therapy for the Treatment of Gastrointestinal Side Effects of GLP-1 Receptor Agonists: A Randomized Controlled Trial","Abdel Raouf Fouad","2024","inventory_only","N3","primary_report",null,null,null,"high","first","opus-5.5-agent31","randomized gastrokinetic combination versus placebo in patients already on GLP-1 receptor agonists; regimen identical in both arms",1],["R0040489","Efficacy and Safety of Oral Semaglutide for Weight Loss in Patients Without Diabetes: A Systematic Review and Meta-Analyses","Andrés Mauricio García Sierra","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent23","meta-analysis of RCTs of oral semaglutide versus placebo in adults without diabetes, MEDLINE EMBASE Cochrane searched",1],["R0041063","Effect of Semaglutide on Obese Female Patients with Polycystic Ovarian Disease: A Retrospective Observational Study and Systematic Review","Prakash Narayan Gupta","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent23","PRISMA review with PubMed Cochrane Scopus search pooling semaglutide or GLP-1RA studies in obese PCOS, plus single arm retrospective series",1],["R0042933","Glucagon-Like Peptide-1 Receptor Agonist Effects on Gastric Motility: A Systematic Review","Nicha Wongjarupong","2020","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent23","systematic review of controlled studies of GLP-1RA on gastric emptying, PubMed Scopus Web of Science searched, 19 studies",1],["R0044017","The Expanding Cardiovascular and Cardiorenal Role of GLP-1 Receptor Agonists","Marianne Koleng","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent23","PRISMA-ScR scoping review with PubMed search and PCC criteria, reports 17 included GLP-1RA cardiovascular and renal studies",1],["R0045646","The role of glucagon-like peptide-1 receptor agonists in the correction of immune and metabolic disorders in women with reproductive dysfunction","N. D. Kozhukhov","2025","exclude","E3","other",null,null,"non_english","high","first","opus-5.5-agent23","Russian narrative review on GLP-1RA immune and metabolic effects in female reproductive disorders, no search methods",1],["R0040407","Role and Efficacy of GLP 1 Agonists in the Management of PCOS","Nithisha Chitteti","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent36","PCOS review mentioning multiple databases without naming them or stating eligibility criteria",1],["R0042362","Modern approaches to the management of patients with obesity (according to the materials of the Consensus of the American Gastroenterological Association in 2022)","Ткач, С. М.","2023","exclude","E3","other",null,null,"non_english","high","first","opus-5.5-agent36","Ukrainian narrative review summarizing the 2022 AGA obesity pharmacotherapy guideline",1],["R0042836","Antidiabetic drugs and the risk of cancer: beneficial, neutral, or detrimental?","Taoreed Adegoke Azeez","2021","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent36","narrative review of antidiabetic drugs and cancer risk without a systematic search",1],["R0044340","Current trends in bariatric surgery","А. Е. Неймарк","2025","exclude","E3","other",null,null,"non_english","high","first","opus-5.5-agent36","Russian literature review of bariatric trends with keyword search but no criteria and selective citation",1],["R0045384","The Potential Role of Antidiabetic Agents in Bipolar Disorder","Eliana Landivar","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent36","narrative review of antidiabetic agents in bipolar disorder without a stated search",1],["R0046270","Comparative Effects of Empagliflozin and Semaglutide on Left Ventricular Diastolic Function in HFpEF Patients with Type 2 Diabetes: A Systematic Review of Randomized Controlled Trials","Syed Ali Hussein Abdi","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent36","systematic review of RCTs with PubMed, Cochrane and registry search comparing empagliflozin and semaglutide in HFpEF with diabetes",1],["R0040603","NAFLD in overweight adolescents: Lifestyle intervention vs. GLP-1 agonist: A pilot RCT","Emily R Thompson","2025","include_nma",null,"primary_report","P09; P03",null,null,"high","first","opus-5.5-agent37","pilot RCT of intensive lifestyle versus liraglutide or semaglutide per formulary in adolescents with NAFLD and overweight, reports BMI z and adverse events",1],["R0040375","Efficacy of polyethylene glycol loxenatide for type 2 diabetes mellitus patients: A systematic review and meta-analysis","Yibo Liu","2023","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent30","INPLASY registered protocol at preliminary search stage for a meta-analysis of PEG loxenatide in type 2 diabetes; no results",1],["R0040549","Surgical versus medical treatment of obesity in the New Era: A systematic review","Hamad Abdulaziz AlSubaie","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent30","review naming databases but prioritizing landmark trials and tabulating key studies only, selective per ruling 19",1],["R0041828","Editorial: Obesity and type 2 diabetes mellitus: novel and alternative functional bioactive nutritional interventions","Renato Chaves Souto Branco","2024","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent30","research topic editorial summarizing a collection on nutritional interventions; GLP-1 RA papers only briefly summarized",1],["R0043097","Pharmacologic Therapy for Nonalcoholic Fatty Liver Disease","Sang Hoon Park","2014","exclude","E3","other",null,null,"non_english","high","first","opus-5.5-agent30","Korean narrative special review of NAFLD drug therapy without search methods or eligibility criteria",1],["R0044172","Combination of synbiotic and sitagliptin in nonalcoholic fatty liver disease: Is it better than sitagliptin alone?","Yong Kyun Cho","2018","exclude","E4","other",null,null,null,"high","first","opus-5.5-agent30","editorial on a trial of synbiotic plus sitagliptin versus sitagliptin in NAFLD; commented study has no GLP-1 RA",1],["R0045129","Beyond Standard Renoprotection: Palm Tocotrienol-Rich Vitamin E and Multi-Hit Residual Renal Risk in Diabetic Kidney Disease-A Translational Review","Loso Judijanto","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent30","self described qualitative translational review on tocotrienol in diabetic kidney disease, not systematic",1],["R0045979","Next Step in Incretin-Based Therapy: From Single to Dual Agonism","Subhodip Pramanik","2022","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent30","narrative review of dual GIP GLP-1 agonism and tirzepatide trials without systematic search",1],["R0046634","Efficacy and Safety of Semaglutide in Obese Patients with Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-Analysis","Ibraheem Altamimi","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent29","meta-analysis of semaglutide versus placebo in obese HFpEF; PubMed, Google Scholar and Cochrane searched, 3 studies pooled",1],["R0047528","Navigating retatrutide safety: comprehensive insights from systematic review and meta-analysis","Vikas Maharshi","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent29","PRISMA meta-analysis of retatrutide adverse events versus placebo; PubMed, Google Scholar and ScienceDirect searched, 4 studies pooled",1],["R0051830","Impact of GLP-1 Receptor Agonists on Male Fertility: A Systematic Review of Human Studies","Arnold Peter Paul Achermann","2025","include_review",null,"systematic_review",null,null,"abstract_only","high","first","opus-5.5-agent29","congress abstract of systematic review of GLP-1 RA effects on semen parameters; named databases, criteria, reports all 4 included studies",1],["R0053437","GLP-1 RECEPTOR AGONISTS IN CHRONIC KIDNEY DISEASE: NEPHROPROTECTION BEYOND GLYCEMIC CONTROL - A REVIEW OF CURRENT LITERATURE","Anna Mamach","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent29","self described narrative review of GLP-1 RA nephroprotection; studies chosen by relevance without stated criteria (ruling 19)",1],["R0053844","Comparative effectiveness of once-weekly semaglutide versus daily liraglutide on weight reduction and glycemic control in obese type 2 diabetics","Tomás Antonio Pérez Herrera","2023","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent29","52 week RCT randomizing obese type 2 diabetes adults to weekly semaglutide 1 mg or daily liraglutide 1.8 mg",1],["R0054291","A review on recent advances in cardiovascular pharmacotherapy: Emerging therapies, novel anticoagulants, and cardiometabolic innovations","Sajid Muhammad Arsalan Ali","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent29","narrative review of new cardiovascular drugs; studies selected by author consensus (ruling 19)",1],["R0046675","GLP-1 Receptor Agonists in Recreational Athletes: Emerging Weight-Reduction Strategy or Potential Health Risk? A Review of Current Evidence","Kamil Topolski","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent34","self described narrative review of GLP-1 agonists in recreational athletes, PubMed search but no count or report of all included studies",1],["R0048003","IS OBESITY PHARMACOTHERAPY A LIFETIME COMMITMENT? A STRUCTURED REVIEW OF WEIGHT REGAIN AND STRATEGIES FOLLOWING INCRETIN CESSATION","Kornelia Domagała","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent34","structured narrative review of weight regain after incretin cessation, prioritized core publications, does not report all eligible studies",1],["R0049616","Long-term results of transferring the patient from therapy with glucagon-like peptide-1 receptor agonists in combination with metformin to a dipeptidyl peptidase-4 inhibitor in combination with pioglitazone and inhibitor of type 2 sodium-glucose cotransporter in type 2 diabetes","В. В. Салухов","2024","inventory_only","N5","primary_report",null,null,"non_english","high","first","opus-5.5-agent34","Russian single patient case report of switching from semaglutide plus metformin to alogliptin, pioglitazone and empagliflozin",1],["R0051035","Association between Cancer and Glucagon-Like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes: A Systematic Review of Retrospective Cohort Studies","Hyun Jin Park","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent34","systematic review of nine retrospective cohorts on GLP-1 receptor agonists and cancer in type 2 diabetes, three named databases",1],["R0052046","Effectiveness of Different Prandial Regulators in Patients with Type 2 Diabetes and Morbid Obesity","V.V. Fadeev","2020","include_nma",null,"primary_report","P01",null,"non_english","high","first","opus-5.5-agent34","Russian open block randomized trial of GLP-1 agonist versus sulfonylurea versus bolus insulin added to basal insulin in morbidly obese T2D",1],["R0053556","The role of the Mediterranean diet in the treatment of cognitive dysfunction in patients with type 2 diabetes mellitus","Chunyan Zheng","2025","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent34","opinion article on Mediterranean diet for cognitive dysfunction in T2D, GLP-1 agonists only mentioned in passing; alternative E3",1],["R0054050","GLP-1 ANALOGUES IN OBESITY THERAPY: CURRENT EVIDENCE AND FUTURE DIRECTIONS – A SYSTEMATIC REVIEW","Natalia Strumnik","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent34","narrative synthesis of ten key studies from a targeted PubMed search on GLP-1 agonists for obesity, selective under ruling 19",1],["R0054365","Efficacy and Safety of Tirzepatide in the Treatment of Obesity: A Review of Current Clinical Trials","Wojciech. Kijowski","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent34","narrative review of key SURMOUNT trials and meta-analyses of tirzepatide in obesity, no systematic search",1],["R0054751","Effects of Glucagon-like Peptide-1 Receptor Agonists on Upper Endoscopy (EGD)","Eleazar Enrique. Montalvan-Sanchez","2024","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent31","INPLASY registration of planned review on GLP-1RA and endoscopy outcomes; review not yet started, no results",1],["R0055623","The Incretin Revolution: Transforming Metabolic Medicine Review Article","Kola prudvika","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent31","narrative overview of key incretin trials and drug development without named database search",1],["R0056136","Economic evaluation of SGLT2 inhibitors and GLP-1 receptor agonists in Thai patients with type 2 diabetes and established atherosclerotic cardiovascular disease","Tanawan Kongmalai","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent31","Markov model cost utility evaluation of SGLT2i and GLP-1RA add on therapy in Thailand",1],["R0056422","GLP1 Agonists Beyond Established Therapeutic Indications: A Narrative Review of Emerging Therapeutic Applications","Usmaan Hafeez Farooq","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent31","narrative review of emerging GLP-1RA indications; unnamed literature search, studies chosen selectively",1],["R0048126","Antidiabetic effect of withanolides and liraglutide on serum insulin level and pancreatic histology in diabetic rats.","Abdul Samad","2019","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent35","randomized experiment in streptozotocin diabetic rats comparing withanolides and liraglutide; no human participants",1],["R0049671","Glucagon like peptide-1 receptor agonist (GLP-1RA) therapy in management of type 2 diabetes: choosing the right agent for individualised care","Zin Zin Htike","2016","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent35","current topics narrative review comparing GLP-1 RA agents for individualized type 2 diabetes care; no systematic search",1],["R0052076","Doxorubicin-induced cardiometabolic disturbances: what can we do?","Ashot A. Avagimyan","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent35","opinion article on doxorubicin cardiometabolic toxicity and possible drug strategies; not a primary study or systematic review",1],["R0054082","Exploring GnRH pulsatility in PCOS and the role of GLP-1 as a targeted therapeutic approach","Vidya Bhat","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent35","narrative review on GnRH pulsatility in PCOS and GLP-1 RA mechanisms; no systematic search or structured synthesis",1],["R0046532","Comparative Effectiveness of SGLT2 Inhibitors Versus GLP-1 Receptor Agonists in Reducing Cardiovascular Events in Type 2 Diabetes","Olaniran Olabode","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent26","systematic review of RCTs and cohorts comparing SGLT2i and GLP-1RA cardiovascular outcomes in type 2 diabetes; four databases, criteria, pooled estimates",1],["R0047386","Efficacy of dulaglutide to improve Vascular Health indexes in subjects with Type 2 Diabetes: A Randomized Trial","Antonino Tuttolomondo","2020","include_nma",null,"primary_report","P01",null,null,"high","first","opus-5.5-agent26","preprint of RCT adding weekly dulaglutide to usual glucose lowering therapy versus usual therapy alone; HbA1c and vascular indexes",1],["R0049041","Combined Therapy of GLP-1 Receptor Agonists and Basal Insulin in Type 2 Diabetes: An Updated Review","Helena Tristão Sanches","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent26","literature review of GLP-1RA plus basal insulin highlighting key trials and guidelines; no stated eligibility criteria or full study synthesis; ruling 19",1],["R0050510","GLP-1 receptor agonists in Parkinson’s disease progression: A systematic review and meta-analysis with trial sequential analysis","Wen-Wen Tsai","2024","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent26","INPLASY registration of a planned meta-analysis of GLP-1RA RCTs in Parkinson disease; preliminary search stage, no results",1],["R0051594","Editorial: Novel pathophysiologic mechanisms and reno-protective pharmacotherapies in diabetic kidney disease","Elias John Elenjickal","2024","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent26","editorial introducing a research topic on diabetic kidney disease therapies; no primary data or systematic search",1],["R0053786","Tirzepatide and Cancer Risk","Reena Alassam","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent26","descriptive review of tirzepatide and cancer risk drawing on a meta-analysis and FAERS; no systematic search or eligibility criteria",1],["R0054183","Fluorescence Optical Imaging of Juvenile Arthritis","S. G. Werner","2011","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent26","images report of fluorescence optical imaging in juvenile arthritis; no GLP-1 receptor agonist anywhere in the text",1],["R0046384","Pleiotropic Neuroprotection of GLP-1 Receptor Agonists:From Synaptic Plasticity to Autophagy-Mediated Proteostasis in Neurodegeneration","Divyanshu Tripathi","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent21","narrative review of neuroprotective mechanisms and clinical data for GLP-1 RA; no database search or eligibility criteria",1],["R0047093","Impact of SGLT2 inhibitors and GLP1 receptor agonists on respiratory infections: a meta-analysis","Mei Hong Qiu","2021","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent21","INPLASY protocol for a meta-analysis of SGLT2 inhibitor and GLP-1 RA outcome trials on respiratory infections; preliminary searches only",1],["R0048394","The Role of GLP-1 Receptor Agonists (Ozempic and Mounjaro) as Secondary Therapy in Chronic Kidney Disease","Erick Adolfo Meza Soto","2025","include_nma",null,"primary_report","P01; P08A",null,null,"high","first","opus-5.5-agent21","multicenter RCT with computer generated allocation of semaglutide or tirzepatide versus standard care in type 2 diabetes with CKD, 36 months",1],["R0050275","Semaglutide in Overweight and Obese patients: Cardiovascular and/or Renal Metabolic Benefits","Jorge E. Rico-Fontalvo","2022","inventory_only","N9","ancillary",null,null,null,"high","first","opus-5.5-agent21","letter to the editor commenting on the STEP 6 placebo controlled semaglutide trial; ancillary to an in scope RCT",1],["R0051377","Corrigendum: Shifting the paradigm of type 1 diabetes: a narrative review of disease-modifying therapies","Alexander J. O’Donovan","2025","exclude","E4","other",null,null,null,"high","first","opus-5.5-agent21","corrigendum fixing title and citations of a narrative review on type 1 diabetes disease modifying therapies; parent record out of scope",1],["R0053699","Editorial: Expanding therapeutic horizons with non-invasive vagus nerve stimulation","Claire-Marie Rangon","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent21","editorial introducing a research topic on vagus nerve stimulation; GLP-1 RA appears only in one citation, never as exposure",1],["R0054142","A Systematic Review of Oral Semaglutide for Type II Diabetes","A.Suseendra kumar","2021","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent21","review of oral semaglutide titled systematic but without any database search or eligibility criteria",1],["R0040388","Effect of Liraglutide and Dapagliflozin on Cardiovascular Risk in Metabolic Dysfunction-associated Steatotic Liver Disease Patients","Volodymyr Chernyavskiy","2025","include_nma",null,"primary_report","P09",null,null,"high","first","opus-5.5-agent32","computer randomized three arm trial in MASLD: lifestyle alone, plus dapagliflozin, plus liraglutide; diabetes share unclear so P09 only",1],["R0040556","Comparative Effectiveness of SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus at High Cardiovascular Risk","Knizhenko Egor","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent32","self described narrative review; databases named but evidence prioritized selectively, no study level synthesis",1],["R0041930","Tirzepatide (Zepbound)","CDA-AMC","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent32","HTA reimbursement recommendation for tirzepatide with cost effectiveness conclusions; not a primary study or systematic review",1],["R0042737","Comparative Treatment between Sitagliptin vs. Metformin, Alone or In Combination, In Patients with Polycystic Ovarian Syndrome. A Clinical Entity with a High Risk of Developing Diabetes Mellitus and Gestational Diabetes",null,"2019","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent32","randomized PCOS trial of sitagliptin, metformin or both; no GLP-1 receptor agonist arm",1],["R0043123","Oral Semaglutide for the Treatment of Type 2 Diabetes: A Mini Review","Nasser Mikhail","2019","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent32","mini review with PubMed search admitting opinions and editorials; discusses selected trials without reporting which met criteria",1],["R0044223","Treatment of Cardiometabolic Risk Factors in Adults with Cardiovascular-Kidney-Metabolic Syndrome: A Narrative Review of Evidence-Based and Real-World Observational Data: A Clinical Review for Practising Physicians","Ranjit Gain","2026","exclude","E4","other",null,null,"retracted","high","first","opus-5.5-agent32","file is only a retraction notice for a narrative review, itself out of scope",1],["R0046045","Pharmacological and Non-Pharmacological Interventions for the Treatment of Obesity: A Review of Guidelines and Clinical Trials (2020–2025)","Anna Gęborys","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent32","review of guidelines and trials; databases named but studies prioritized by size and relevance, selective per ruling 19",1],["R0046399","GLP-1 Receptor Agonists in the Treatment of Obesity: A Narrative Review of Current Therapeutic Methods","Konrad Borkowski","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent22","self described narrative review of GLP-1 agonists for obesity with prioritized literature, no eligibility criteria or study selection",1],["R0047180","Drugs Used in the Treatment of Obesity – A Systematic Review","Olga Plinta","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent22","labeled systematic but names databases only, no eligibility criteria or list of included studies; descriptive review of obesity drugs",1],["R0048520","Treatment completion rates with tirzepatide in adults with obesity: a systematic review and meta-analysis of randomized and real-world studies","Limna Mahaboob","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent22","systematic review searching PubMed, Embase and others pooling completion in tirzepatide arms of four SURMOUNT trials",1],["R0050292","Cardiovascular effects of semaglutide: Multifaceted mechanisms of systemic organoprotection","Tatiana Yu. Demidova","2025","exclude","E3","other",null,null,"non_english","high","first","opus-5.5-agent22","Russian narrative review of cardiovascular effects of semaglutide without a systematic search",1],["R0051410","The Role of New Treatments in Managing Eating Behavior Disorders: A Systematic Review","Carlos Siopa","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent22","PROSPERO registered systematic review searching PubMed, PsycInfo and Cochrane, six RCTs including liraglutide for binge eating",1],["R0052835","Addressing cardio-metabolic risks in type 2 diabetes: evidence-based insights on efpeglenatide","Rajesh Kumar","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent22","PRISMA systematic review of ten efpeglenatide trials found through PubMed and other databases, results tabulated by study",1],["R0053726","Pharmacological Rescue After Bariatric Surgery Failure: The Role of GLP-1 Receptor Agonists in Weight Regain Management","Gabriela Piotrowska","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent22","self described narrative review of GLP-1 agonists after bariatric surgery presenting key findings without stating which studies met criteria",1],["R0054149","GLP‑1 RECEPTOR AGONISTS IN THE MANAGEMENT OF OBESE WOMEN WITH POLYCYSTIC OVARY SYNDROME: EFFECTS ON BODY WEIGHT, METABOLIC PROFILE, AND REPRODUCTIVE FUNCTION – A LITERATURE REVIEW","Patrycja Mularczyk","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent22","narrative literature review on GLP-1 agonists in PCOS naming databases but without criteria or selection reporting",1],["R0046788","Clinical Efficacy, Mechanism of Action, and Adverse Effects of SGLT2 Inhibitors and GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes – a Systematic Review","Łukasz Starczewski","2026","exclude","E3","other",null,null,"non_english","high","first","opus-5.5-agent38","Polish literature review of SGLT2 inhibitors and GLP-1 RAs; PubMed keyword search only, no eligibility criteria or defined included studies",1],["R0048265","Effects of SGLT2 inhibitors and GLP1 receptor agonists on risk of various arrhythmias: a meta-analysis of large randomized trials","Mei Hong Qiu","2021","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent38","INPLASY registration of a planned meta-analysis of SGLT2 inhibitor and GLP-1 RA trials on arrhythmias; preliminary search stage",1],["R0049995","Effect of Liraglutide on Weight Loss and BMI Among Patients Who Are Overweight and Obese with Type 2 Diabetes: A Systematic Review and Meta-analysis","C. Zorampari","2023","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent38","meta-analysis of ten liraglutide RCTs on weight and BMI in overweight type 2 diabetes; CENTRAL, MEDLINE and Web of Science searched",1],["R0051178","The effects of combination therapy with Glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporters 2 inhibitors on cardiometabolic indices: A GRADE assessed systematic review and meta-analysis","Seyyed Mostafa Arabi","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent38","registered meta-analysis of randomized trials of GLP-1 RA plus SGLT2 inhibitor combination on cardiometabolic markers; three databases searched",1],["R0052657","Repurposing Existing Drugs For Dual Treatment of Alzheimer'S Disease and Type 2 Diabetes Mellitus: A Network Pharmacology Approach","ASKAROV Ibragim Rakhmanovich","2026","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent38","in silico network pharmacology ranking antidiabetic drugs including liraglutide for Alzheimer disease; no participants studied",1],["R0053656","Comparative analysis of the pharmacokinetics, immunogenicity and safety of semaglutide drugs Semvelica and Ozempic in an open-label, randomized-controlled, parallel-group trial","V.V. Pisarev","2025","inventory_only","N3","primary_report",null,null,"non_english","high","first","opus-5.5-agent38","Russian randomized bioequivalence trial of a semaglutide 1 mg biosimilar versus Ozempic 1 mg in healthy volunteers (ruling 6)",1],["R0054131","The foundation and the four pillars of treatment for cardiorenal protection in people with chronic kidney disease and type 2 diabetes","Rajiv Agarwal","2022","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent38","editorial on cardiorenal treatment pillars in CKD with type 2 diabetes; mentions the FLOW trial only in passing",1],["R0054431","Comparative Effectiveness of SGLT2 Inhibitors and GLP-1 Receptor Agonists in Heart Failure: A Systematic Review","Evira Agustina Putri","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent38","systematic review of RCTs of SGLT2 inhibitors and GLP-1 RAs in heart failure; PubMed, EMBASE, Scopus searched with pooled estimates",1],["R0040436","Ped endo journal scan","Kriti Joshi","2025","inventory_only","N9","ancillary",null,null,null,"high","first","opus-5.5-agent40","journal scan digest summarizing the SURPASS-PEDS tirzepatide trial among other papers; no original data",1],["R0040915","The Impact of Glucagon-Like Peptide-1 Receptor Agonists on the Quality Indicators of Colonoscopy – Systematic Review and Meta-analysis","Yu‐Tse Chiu","2025","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent40","INPLASY registration of a planned SR of GLP-1 RA use and colonoscopy quality; piloting stage, no results",1],["R0042492","PD53 Glucagon-Like Peptide-1 Receptor Agonists And Polyagonists For Severe Obesity: Rapid Overview Of Outcomes Measurement","Thiago Trindade","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent40","poster on an overview of GLP-1 RA meta-analyses in severe obesity mapping which outcomes were measured; reports no study results",1],["R0042918","Semaglutida e Ganho ponderal","Felipe Passareli Diniz","2026","exclude","E3","other",null,null,"non_english","high","first","opus-5.5-agent40","Portuguese literature review on weight regain after semaglutide; PubMed search but thematic citation without stating which studies met criteria",1],["R0043822","Influence of glucagon-like peptide-1 receptor agonists on fat distribution in patients with diabetes mellitus or obesity: A systematic review and meta-analysis of randomized control trials","Wanrun Xie","2023","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent40","INPLASY registration of an SR of GLP-1 RA effects on fat distribution; protocol only, no results reported",1],["R0044656","PERIOPERATIVE ANESTHETIC MANAGEMENT OF ADULTS WITH OBESITY: A PRACTICAL NARRATIVE REVIEW","Ali Rıza Ata","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent40","self described practical narrative review of anesthesia in obesity; no predefined criteria, thematic synthesis by perioperative phase",1],["R0045561","Editorial: Clinical trials in cardiovascular medicine: 2025—addressing residual cardiovascular risks through precision-guided approaches","Euscia Y. Wang","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent40","editorial introducing a cardiovascular clinical trials research topic; no original data",1],["R0046339","Semaglutide and metformin improve menstrual cyclicity in overweight/obese women with polycystic ovary syndrome: a randomized trial","Weihan Zhang","2026","include_nma",null,"primary_report","P12",null,null,"high","first","opus-5.5-agent40","randomized trial in overweight women with PCOS: semaglutide plus metformin versus metformin alone for 12 weeks, both with lifestyle",1],["R0046492","Epiploic appendagitis during rapid weight loss associated with tirzepatide therapy: a case report","Beshoy M. Astfanous","2026","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent25","single patient case report of epiploic appendagitis during tirzepatide treatment",1],["R0047340","First Russian DPP-4 inhibitor Gosogliptin comparing to Vildagliptin in type 2 diabetes mellitus patients","Karina Oganesovna Galstyan","2015","exclude","E2","other",null,null,"non_english","high","first","opus-5.5-agent25","Russian open label RCT comparing two DPP-4 inhibitors, gosogliptin versus vildagliptin; no GLP-1 receptor agonist arm",1],["R0048907","Once-weekly Insulin Icodec – An emerging treatment option for type 2 Diabetes","Rubab Zahra","2024","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent25","letter to the editor about once weekly insulin icodec versus glargine; GLP-1 agonists mentioned only as background therapy",1],["R0051550","Comprehensive analysis of the safety of semaglutide in type 2 diabetes: a meta-analysis of the SUSTAIN and PIONEER trials","Mei Hong Qiu","2020","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent25","INPLASY registration of planned meta-analysis of semaglutide SUSTAIN and PIONEER safety at preliminary search stage, no results",1],["R0053176","Effects of SGLT2 inhibitors and GLP1 receptor agonists on risk of various fractures: a meta-analysis of large randomized trials","Mei Hong Qiu","2021","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent25","INPLASY registration of planned meta-analysis of SGLT2 inhibitors and GLP-1 agonists on fractures, preliminary searches, no results",1],["R0053738","Effects of Combined Exercise and GLP-1 Receptor Agonist Liraglutide Therapy on Weight Loss and Metabolic Health in Obese Patients: A Systematic Review and Meta-Analysis","Salma Tamer Abdelrahman","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent25","PROSPERO registered review searching PubMed, Cochrane, Web of Science, Scopus; meta-analysis of 7 RCTs of liraglutide plus exercise",1],["R0054172","The role of bariatric and metabolic surgery in the management of obstructive sleep apnea and obesity: a narrative review","Qing Zhou","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent25","self described narrative review of bariatric surgery for sleep apnea built on a supplied literature set, selective citation",1],["R0046769","Mind over metabolism: a systematic review of GLP-1 receptor agonists in the treatment of stress-related disorders","Charlotte Rye","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent37","systematic review of GLP-1 agonists for depression and PTSD, three named databases, quality appraisal, 15 human studies synthesized by drug",1],["R0048236","A randomised controlled, trial of the GLP-1 receptor agonist exenatide in idiopathic intracranial hypertension","James Michael Mitchell","2022","include_nma",null,"primary_report","P99",null,null,"high","first","opus-5.5-agent37","placebo controlled double blind RCT of exenatide in women with idiopathic intracranial hypertension, P99 condition, safety reported",1],["R0049945","The Impact of Diabetes Type 2 Treatment Interventions on Cardiovascular Outcomes – A Comprehensive Review","Ali Ahmed Al Qarni","2023","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent37","comprehensive narrative review of diabetes therapies and cardiovascular outcomes, databases named but trials cited selectively without criteria",1],["R0051166","Comparative efficacy of GLP-1 RAs and SGLT2is for prevention of major adverse cardiovascular events in type 2 diabetes: a network meta-analysis","Liang‐Liang Ding","2020","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent37","INPLASY registration of a planned network meta-analysis of GLP-1 agonists and SGLT2 inhibitors on MACE, no results",1],["R0052528","Editorial: Diabetes and cardiovascular disease: new therapeutic interventions","Maria Consiglia Trotta","2024","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent37","editorial introducing a research topic on diabetes and cardiovascular therapies, no original data",1],["R0053619","METFORMIN’S IMPACT ON BODY WEIGHT IN TYPE 2 DIABETES: A NARRATIVE REVIEW OF MECHANISMS, CLINICAL EVIDENCE, AND COMPARATIVE EFFICACY","Aleksandra Jóźwik-Szymańska","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent37","self described narrative review of metformin and body weight, GLP-1 agonist trials cited selectively for comparison, ruling 19",1],["R0054127","Managing Hyperphagia, Obesity, and Hyperglycemia in Prader-Willi Syndrome: A Meta-Analysis of GLP-1 Agonists and SGLT2 Inhibitors","Saumika Mulluri","2025","include_review",null,"systematic_review",null,null,"abstract_only","high","first","opus-5.5-agent37","conference abstract meta-analysis of GLP-1 agonists and SGLT2 inhibitors in Prader-Willi syndrome, four named sources, 45 studies met criteria",1],["R0046544","Shoulder Arthroplasty Outcomes Using Glucagon-Like Peptide-1 Receptor Agonists: A Systematic Review","Kha Minh Kami P. Nguyen","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent27","PRISMA review searching PubMed, Embase and Scopus; four studies of GLP-1 RA users versus nonusers after shoulder arthroplasty synthesized",1],["R0047411","RETATRUTIDE IN INTERNAL MEDICINE: A NOVEL TRIPLE HORMONE RECEPTOR AGONIST FOR OBESITY, TYPE 2 DIABETES, AND CARDIOMETABOLIC RISK","Lívia de Oliveira Cardoso","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent27","self described narrative review of retatrutide prioritizing landmark trials; no eligibility criteria or account of included studies",1],["R0049075","418 Activation of the Glucagon-Like Peptide-1 Pathway in Obese Pre-Diabetic Individuals Improves Endothelial Function Independently of Weight Loss","Mona Mashayekhi","2022","include_nma",null,"conference_abstract","P02",null,"mechanistic","high","first","opus-5.5-agent27","abstract 418 in a supplement: obese prediabetic adults randomized to liraglutide, sitagliptin or diet for 14 weeks; endothelial endpoints and weight change",1],["R0051605","Prevention of CV outcomes in antihyperglycaemic drug-naïve patients with type 2 diabetes with, or at elevated risk of, ASCVD: to start or not to start with metformin","Naveed A. Sattar","2020","inventory_only","N9","ancillary",null,null,null,"high","first","opus-5.5-agent27","editorial on the post hoc REWIND analysis of dulaglutide effect by baseline metformin use, an in scope trial report",1],["R0053411","From Gut to Ovary: The Expanding Role of GLP-1 Analogues in PCOS and Fertility in Women","Aleksandra Maria Śledziewska","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent27","self described narrative review of GLP-1 RA in PCOS mixing reviews and preclinical work; no account of which studies met criteria",1],["R0053815","Diabetes mellitus: Clinical characteristics, glycemic outcomes, and insights from recent therapeutic trials - research study","Suyash Saurabh","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent27","semaglutide versus empagliflozin comparison run on a hypothetical simulated dataset; no real participants, so a simulation",1],["R0054221","Comparative Efficacy of Metformin and Liraglutide in Pediatric Type 2 Diabetes","Aamir Naseem","2024","include_nma",null,"primary_report","P04",null,null,"high","first","opus-5.5-agent27","open label 24 week RCT of liraglutide versus metformin in children with type 2 diabetes in Lahore; HbA1c and hypoglycemia",1],["R0046951","Perspective strategies for non-alcoholic fatty liver disease therapy: from trial to practice","Игорь Геннадьевич Бакулин","2020","exclude","E3","other",null,null,"non_english","high","first","opus-5.5-agent39","Russian narrative review of emerging NAFLD drug therapies with no systematic search",1],["R0050168","Chronic heart failure and type 2 diabetes mellitus: prospects for optimizing pharmacotherapy of comorbid pathology","Sergey V. Povetkin","2021","exclude","E3","other",null,null,"non_english","high","first","opus-5.5-agent39","Russian narrative literature review on drug therapy for heart failure with type 2 diabetes; no systematic search",1],["R0051228","Effects of GLP-1 analogs combined with physical exercise on total body mass in Individuals with obesity: a systematic review","Ana Maria Sales Gomes Filha","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent39","PROSPERO registered review searching five databases; nine studies of liraglutide or semaglutide with exercise on body mass in obesity",1],["R0052681","Real World Effectiveness of fixed combination of glargine 100 U/ml and lixisenatide therapy in outpatients with Type 2 Diabetes: A Retrospective Cohort Study SOLO","Mikhail Borisovich Antsiferov","2022","inventory_only","N5","primary_report",null,null,"non_english","high","first","opus-5.5-agent39","SOLO retrospective single group cohort of iGlarLixi starters with before and after HbA1c; no comparison group",1],["R0053666","GLP-1 Receptor Agonists in Heart Failure with Preserved Ejection Fraction and Obesity: A Systematic Review and Meta-Analysis","Antonino de Jesus da Silva Francisco","2025","include_review",null,"systematic_review",null,null,"abstract_only","high","first","opus-5.5-agent39","congress abstract of a meta-analysis searching PubMed, Embase, Cochrane; pools two RCTs of GLP-1 RA versus placebo in obese HFpEF",1],["R0054132","Post Stroke Epilepsy: Epidemiology, Risk Factors, Prevention, Management, and Future Directions","Joseph Nguyen","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent39","narrative review of post stroke epilepsy without systematic search; GLP-1 RA mentioned only briefly",1],["R0054472","GLP-1 Receptor Agonists in Alcohol Use Disorder: Neurobiological Mechanisms and Therapeutic Potential","Zuzanna Czach","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent39","self described narrative review of GLP-1 RA in alcohol use disorder selecting articles by relevance; ruling 19",1],["R0046658","Pharmacological Interventions in the Management of Antipsychotic-Induced Metabolic Disturbances","João Vasco Barreira","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent33","congress abstract of a self described non systematic review of drugs for antipsychotic induced metabolic effects",1],["R0049509","Appetite Regulation and Gastric Emptying of Semaglutide in Non-Diabetic Obese Adults: A Systematic Review","Uchechukwu Bethel Abioke","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent33","systematic review from four named databases of semaglutide effects on appetite and gastric emptying in obesity, four studies",1],["R0050920","Practical application of semaglutide: From evidence-based research to expert decisions","В. В. Салухов","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent33","Russian narrative review with expert practical recommendations on semaglutide use, no systematic methods",1],["R0051905","Risk of Acute Pancreatitis with Tirzepatide: A Systematic Review and Meta-Analysis of Randomized and Observational Studies v1","Olivia Benny","2025","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent33","protocols.io protocol of a planned meta-analysis of tirzepatide and acute pancreatitis, no results",1],["R0054029","The Ozempic Pregnancy Phenomenon: What Medical Research Reveals","N Heimann","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent33","narrative review of semaglutide, fertility and pregnancy without systematic search or criteria",1],["R0054357","Efficacy of liraglutide in combination therapy of patients with psoriasis combined with metabolic disorders: a meta-analysis of observational and controlled studies","T. V. Korotaeva","2025","include_review",null,"systematic_review",null,null,"non_english","high","first","opus-5.5-agent33","Russian meta-analysis of five liraglutide studies in psoriasis from a PubMed search with selection criteria, pooled pre post changes",1],["R0054688","Management of Hirsutism and Acne in Women with Polycystic Ovary Syndrome: A Narrative Review of Current Evidence and Emerging Therapies","Aleksandra Papuga","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent26","self-described narrative review of hirsutism and acne treatments in PCOS; no eligibility criteria or synthesis of all retrieved studies",1],["R0055106","Obstructive Sleep Apnea in Obesity: The Role of Tirzepatide and Incretin Therapies","Natalia Kasterka","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent26","narrative review of tirzepatide in sleep apnea with targeted search prioritizing pivotal trials; selective, ruling 19",1],["R0055526","Effect of retatrutide on body weight, lipid profile, liver function, oxidative stress, and inflammation in experimental obesity in male rats","Zinah Meteab Rah AL-shibil","2026","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent26","diet induced obesity experiment in male rats treated with retatrutide; animal study only",1],["R0055922","GLP-1-Based therapies for obesity-related heart failure with preserved ejection fraction: an umbrella review incorporating broader heart failure and cardiometabolic evidence","Qiang Li","2026","include_review",null,"systematic_review",null,null,"umbrella_review","high","first","opus-5.5-agent26","umbrella review of systematic reviews of GLP-1 based therapies in obesity related HFpEF; four databases, AMSTAR 2, review level synthesis",1],["R0056371","Cardiovascular outcomes of oral incretin-based drugs in type 2 diabetes: a GRADE-assessed meta-analysis of 67,679 patients","Muhammad Faizan Ali","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent26","meta-analysis of cardiovascular outcome trials of oral semaglutide and DPP-4 inhibitors with subgroup estimates for oral semaglutide; PROSPERO registered",1],["R0056690","From Lifestyle Advice to GLP-1 Agonists: The Transformation of Pediatric Obesity Care","Surendra Gupta","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent26","narrative review of pediatric obesity care; studies chosen for relevance without predefined protocol",1],["R0046744","Glucagon-Like Peptide-1 Receptor Agonists in People With Human Immunodeficiency Virus: An Expanded Meta-Analysis of Metabolic Outcomes","Thomas Barnett","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent36","updated meta-analysis of GLP-1 receptor agonists in people with HIV, PubMed and registry search, stated criteria, pooled weight and HbA1c",1],["R0048152","Efficacy and safety of GLP-1 receptor agonists on motor function for patients with Parkinson's disease: a meta-analysis of randomized controlled trials","Jing Ping Zhao","2025","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent36","INPLASY registration of a meta-analysis of GLP-1 receptor agonists in Parkinson disease, no results reported",1],["R0051059","Tirzepatide vs. Semaglutide in Type 2 Diabetes and Obesity: A Systematic Review and Meta-Analysis of Metabolic Efficacy, Weight Loss, and Cardiovascular Safety","Matheus Jannuzzi Moreira de Mendonça","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent36","systematic review and meta-analysis of tirzepatide versus semaglutide with PubMed, Cochrane and registry search and pooled estimates",1],["R0052261","Editorial: Advancing Health Technology Assessment and patient-reported outcomes: innovations and implications for health economics and outcomes research","George Gourzoulidis","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent36","editorial introducing a research topic on health technology assessment and patient reported outcomes",1],["R0053599","Strategies to Prevent and Delay Chronic Kidney Disease Progression: A Pathway to Sustainability and Green Nephrology","João Venda","2023","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent36","mini review on preventing chronic kidney disease progression and green nephrology without a systematic search",1],["R0054088","THE ROLE OF INCRETIN-BASED THERAPIES IN ALZHEIMER’S DISEASE: FOCUS ON SEMAGLUTIDE - LITERATURE REVIEW","Honorata Derlatka","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent36","self described narrative review naming PubMed and Google Scholar, stating criteria and tabulating all 16 included semaglutide Alzheimer studies",1],["R0055372","GLP-1 Receptor Agonists: Emerging Indications, Limitations, and Future Directions","Simran Kaur","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent34","narrative review of emerging indications and limitations of GLP-1 receptor agonists without a systematic search",1],["R0055731","The new slim: Rising use of glp-1 receptor agonists for weight loss in India—promise, pitfalls, and public health concerns","Amol Hartalkar","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent34","short communication on off-label GLP-1 agonist use for weight loss in India, opinion without original data",1],["R0056166","Efficacy of low-dose semaglutide added to metformin on clinical and metabolic parameters in women with polyendocrine metabolic ovarian syndrome and obesity: A phase II randomized controlled trial","Md. Rafayel Islam","2026","include_nma",null,"conference_abstract","P12",null,"abstract_only","high","first","opus-5.5-agent34","randomized trial abstract of semaglutide plus metformin versus metformin in obese women with PCOS, 16 weeks",1],["R0056450","Dual and triple incretin agonists in type 2 diabetes: A new frontier in metabolic therapy","Syed Afzal Uddin Biyabani","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent34","structured narrative review of tirzepatide and retatrutide in T2D, no screening log or report of all eligible studies",1],["R0046454","Risk of pancreatic cancer associated with GLP-1 receptor agonist therapy","Shreyas Krishna","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent23","self described narrative review on GLP-1RA and pancreatic cancer, PubMed search but most pertinent studies chosen; ruling 19",1],["R0047215","The time-varying cardiovascular benefits of glucagon like peptide-1 agonist (GLP-RA)therapy in patients with type 2 diabetes mellitus: A meta-analysis of multinational randomized trials","Salil Vasudeo Deo","2021","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent23","INPLASY protocol of meta-analysis of GLP-1RA cardiovascular outcome trials, preliminary search stage, no results",1],["R0048655","Combined insulin detemir and liraglutide therapy in type 2 diabetic patients: a base for an alliance","Lyudmila Alexandrovna Ruyatkina","2016","exclude","E3","other",null,null,"non_english","high","first","opus-5.5-agent23","Russian narrative literature review of insulin detemir plus liraglutide in T2D, no search methods",1],["R0050431","Comparative safety of glucagon like peptide‑1 receptor agonists in patients with type 2 diabetes: a network meta-analysis of cardiovascular outcome trials","Chuanjun Zhuo","2020","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent23","INPLASY protocol of network meta-analysis of GLP-1RA CVOT safety, no results reported",1],["R0051464","Comparative efficacy of GLP-1 RAs and SGLT2 inhibitors for prevention of cardiorenal events in type 2 diabetes: a network meta-analysis of cardiovascular outcome trails","Liang‐Liang Ding","2020","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent23","INPLASY protocol of network meta-analysis of GLP-1RA and SGLT2i cardiorenal outcome trials, no results",1],["R0052977","Efficacy and Safety of Semaglutide in Glycemic Control, Body Weight Management, and Lipid Profile among Obese Type 2 Diabetes Patients: A Systematic Review","Wurud Muteb D. Alshammari","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent23","PRISMA review with PubMed Scopus Web of Science ScienceDirect search, criteria and 7 included semaglutide studies in obese T2D tabulated",1],["R0053733","Semaglutide in MASH with F2-F3 fibrosis: a holistic perspective on the ESSENCE phase 3 trial","Carlos Jose Pirola","2026","inventory_only","N9","ancillary","P09",null,null,"high","first","opus-5.5-agent23","commentary appraising the ESSENCE phase 3 RCT of semaglutide in MASH, no new data",1],["R0054156","Impact of Semaglutide on Body Composition and Muscle Mass Maintenance in Patients Undergoing Semaglutide Induced Weight Loss Therapy: A Systematic Review","Daniel Zieliński","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent23","thematic review of semaglutide and muscle, PubMed and criteria stated but selected studies cited without inclusion list; ruling 14",1],["R0054390","Efficacy and safety of Glucagon-Like Peptide-1 receptor agonists in polycystic ovary syndrome: A systematic review and Meta-Analysis","Yeri Estu Risunang","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent35","meta-analysis searching five named databases for comparative studies of GLP-1 RA in PCOS; pooled weight, glycemic and GI adverse events",1],["R0055378","MULTIDISCIPLINARY MANAGEMENT OF LIPEDEMA: EVIDENCE ON DIETARY, PHYSIOTHERAPEUTIC, PHARMACOLOGICAL, AND SURGICAL INTERVENTIONS","Katarzyna Kraska","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent35","self described narrative review of lipedema management including guidelines and expert opinion; no structured synthesis of GLP-1 RA studies",1],["R0055744","Tirzepatide - a new drug with great potential in controlling glycemia and body weight","Magdalena Stabrawa","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent35","self described narrative review of tirzepatide efficacy and safety drawing on trials, meta-analyses and regulatory documents",1],["R0056177","Effects of intensive insulin therapy combined with non-insulin antihyperglycemic agents on glycemic control, variability, and metabolic outcomes in patients with type 2 diabetes mellitus: a systematic review and meta-analysis","Zixuan Shen","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent35","PROSPERO registered meta-analysis of RCTs comparing intensive insulin alone versus plus GLP-1 RA or other agents; named databases",1],["R0056466","Effects of liraglutide on blood pressure and renal function in patients with type 2 diabetic nephropathy: a meta-analysis of randomized controlled trials","Shengning GAO","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent35","PROSPERO registered meta-analysis of 23 RCTs of liraglutide versus control in diabetic nephropathy; seven named databases",1],["R0046461","Patient-reported outcome assessment in heart failure with preserved ejection fraction: A systematic review of semaglutide trials using the Kansas City Cardiomyopathy Questionnaire","Razan Abdulaal","2026","deferred","D1","other",null,null,null,"low","first","opus-5.5-agent24","stored file is the STEP-HFpEF supplementary site list and table, not the titled systematic review of semaglutide KCCQ trials",1],["R0047328","2 A Randomized, Double-blinded, Placebo-controlled Trial of Liraglutide in Patients with Parkinson’s Disease: Neuropsychological Outcomes","Jeffrey C. Wertheimer","2023","include_nma",null,"conference_abstract","P13B",null,"abstract_only","high","first","opus-5.5-agent24","abstract of double blind RCT randomizing 63 Parkinson disease patients to liraglutide or placebo for 52 weeks",1],["R0048862","Outpatient Diuretic Intensification Across the Cardiovascular-Kidney-Metabolic Spectrum","Pedro Sousa Marques","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent24","editorial on outpatient diuretic intensification accompanying a canagliflozin trial analysis; GLP-1 trials only discussed, E4 alternative",1],["R0050458","ASSOCIAÇÃO ENTRE BALÃO INTRAGÁSTRICO AJUSTÁVEL E TERAPIAS COM PEPTÍDEOS: EFEITOS NA PERDA DE PESO E DESFECHOS METABÓLICOS – REVISÃO SISTEMÁTICA E METANÁLISE","Bruno Sander","2026","include_review",null,"systematic_review",null,null,"non_english","high","first","opus-5.5-agent24","Portuguese systematic review naming six databases with criteria, meta-analysis of intragastric balloon with or without GLP-1 agonists",1],["R0051483","Economic evaluation of type 2 diabetes mellitus T2DM pharmaceutical treatment compared to an alternative, conducted alongside randomized controlled trials: A scoping review","Emma Agahi","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent24","scoping review whose included studies are all trial based economic evaluations of diabetes drugs, ruling 14",1],["R0053011","Testosterone replacement therapy in metabolic dysfunction-associated steatotic liver disease: a bench-to-bedside narrative review","Yuchang Li","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent24","narrative review of testosterone therapy in MASLD; semaglutide only mentioned as background, E3 also applies",1],["R0053734","GLP-1 Receptor Agonists in Heart Failure and Cardiometabolic Disease: Emerging Evidence for Integrated Cardiovascular and Metabolic Care Across the Americas","Erik Fernández Godínez","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent24","structured literature review naming databases but stating no eligibility criteria or included study set, narrative synthesis of GLP-1 RA in heart failure",1],["R0054674","Efficacy of SGLT2 Inhibitors Versus GLP-1 Receptor Agonists in Type 2 Diabetes Patients with Non-alcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis","Mohamed Nabil Elnaggar","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent25","searched PubMed, Scopus, Ovid, Cochrane, Web of Science with stated criteria; meta-analysis of 37 RCTs of SGLT2 inhibitors and GLP-1 agonists in NAFLD",1],["R0055090","Glucagon-Like Peptide-1 Receptor Agonists in Obesity Management: Mechanisms, Efficacy, and Safety","Michał Stasiak","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent25","narrative review of GLP-1 agonist mechanisms, efficacy and safety in obesity without a described literature search",1],["R0055484","Efficacy and Safety of Tirzepatide in Overweight and Obese Individuals: A Meta-Analysis of Randomized Controlled Trials","Liya Fu","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent25","searched Embase, PubMed, Web of Science, Cochrane and Chinese databases; meta-analysis of 11 tirzepatide RCTs, apparently duplicate of R0040315",1],["R0055886","Restoring Metabolic Architecture in the South Asian Thin-Outside-Fat-Inside (TOFI) Phenotype: A Mechanistic Rationale for Combining Abscisic Acid and β-Aminoisobutyric Acid","Anshu Bhutani","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent25","self described narrative mechanistic review proposing abscisic acid and BAIBA for the TOFI phenotype; not systematic",1],["R0056340","Tirzepatide versus other glucose-lowering therapies and risk of COPD exacerbations in patients with comorbid type 2 diabetes: a retrospective cohort study","Wan-Hsuan Hsu","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent25","TriNetX cohort of tirzepatide versus other glucose lowering drugs on COPD exacerbation; negative controls skin cancer and cataract, no listed harm",1],["R0054728","BEYOND GLYCEMIC CONTROL AND WEIGHT REDUCTION: PLEIOTROPIC EFFECTS OF GLP-1 RECEPTOR AGONISTS ON HUMAN PHYSIOLOGY - A NARRATIVE REVIEW","Matylda Król","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent29","self described narrative review of GLP-1 RA pleiotropic effects; literature prioritized by relevance without criteria (ruling 19)",1],["R0055594","Impact of GLP-1 Receptor Agonists on Body Weight and Cardiovascular Outcomes: A Systematic Review","Ahmed Al Mutairi","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent29","systematic review of GLP-1 RAs on weight and cardiovascular outcomes; six named sources searched, 21 studies with RoB 2 and GRADE",1],["R0056111","Use of GLP-1 receptor agonists and dual agonists in patients with inflammatory bowel disease","Michał Dróżdż","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent29","review of GLP-1 RAs in inflammatory bowel disease naming databases but stating no eligibility criteria; narrative thematic synthesis",1],["R0056405","Renal and cardiovascular effects of glucagon-like peptide receptor agonists in established chronic kidney disease: Systematic review and meta-analysis","Kirolos Eskandar","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent29","meta-analysis of RCTs of GLP-1 RAs versus placebo or other care in established CKD; four databases, stated criteria",1],["R0056882","Addition of sitagliptin or metformin to insulin monotherapy improves blood glucose control via different effects on insulin and glucagon secretion in hyperglycemic Japanese patients with type 2 diabetes.","Otsuka Y","2015","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent29","RCT of sitagliptin versus metformin added to insulin; no GLP-1 receptor agonist in any arm",1],["R0054630","Efficacy and Safety of High-Dose Retatrutide in Adults with Obesity and Type 2 Diabetes: A Systematic Review and Bayesian Meta-Analysis","Matheus Hissa Lourenço Ferreira","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent22","PROSPERO registered systematic review and Bayesian meta-analysis of five retatrutide RCTs found through PubMed, Embase and CENTRAL",1],["R0055050","CURRENT THERAPEUTIC APPROACHES IN THE MANAGEMENT OF POLYCYSTIC OVARY SYNDROME","A. Wojtala","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent22","narrative literature review of PCOS treatments including GLP-1 agonists, keyword search without eligibility criteria or study selection",1],["R0055449","Short-Term Effects of Liraglutide versus Vildagliptin on Insulin Secretion and Sensitivity in Type 2 Diabetes: A Single Blinded Randomized Controlled Trial (LIRAVIS Study)","Martine Claude Etoa Etoga","2023","include_nma",null,"primary_report","P01",null,"mechanistic","high","first","opus-5.5-agent22","small two week RCT of liraglutide versus vildagliptin add-on in type 2 diabetes reporting weight and side effects by arm",1],["R0055819","Childhood Obesity: An Update on Prevention, Evaluation, and the Expanding Treatment Landscape","Olivia Lennon","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent22","self described narrative review of childhood obesity prevention and treatment",1],["R0056301","GLP-1 AGONISTS IN PSYCHIATRY — A NEW THERAPEUTIC DIRECTION FOR DEPRESSION, ADDICTIONS, AND EATING DISORDERS","Karolina Klusek","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent22","self described narrative synthesis of GLP-1 agonists in psychiatric disorders without structured study selection",1],["R0056650","Beyond Weight Loss: Facial Remodeling Associated with GLP-1 Receptor Agonists-A Systematic Review and Therapeutic Framework.","Maglitto F","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent22","systematic review of aesthetic treatments for facial changes after weight loss; GLP-1 agonist is only background in uncontrolled included studies",1],["R0054940","Holistic Treatment of Obesity: The Importance of Integrating Pharmacotherapy, Dietary Therapy, and Physical Activity for Effective and Sustained Weight Loss","Magdalena Maria Iwaszko","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent38","narrative review of combined pharmacotherapy, diet and exercise for obesity; sources preferred by type, no eligibility based selection",1],["R0055402","A Systematic Review of the Cutaneous Adverse Effects of GLP-1 Agonists","Sydney DeVore","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent38","review of cutaneous adverse effects of GLP-1 RAs with no named database search or eligibility criteria; discussion only",1],["R0055768","Body Composition Changes With Standard Versus Low-Dose Tirzepatide Titration in Women With Lipedema: A Retrospective Observational Study","Paula Frederichi de Souza","2026","inventory_only","N6","primary_report",null,null,null,"high","first","opus-5.5-agent38","retrospective cohort comparing low and standard tirzepatide titration in lipedema; body composition only, no listed harm outcome",1],["R0056582","Effects of Incretin-Based Pharmacotherapies on Lean Body Mass in Adults With Overweight, Obesity, or Type 2 Diabetes: A Systematic Review With Prespecified Network Meta-Analysis Feasibility Assessment","Zahi M Alhamad","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent38","systematic review of incretin drug RCTs on DXA lean mass with PubMed and registry search and pooled placebo contrasts",1],["R0054918","What is new and what has changed in the 2026 Global Heart Failure Implementation Guidelines and why","Vijay Chopra","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent37","focused update of global heart failure implementation guidelines, guideline document without original data",1],["R0055391","A Meta-Analysis Evaluating the Efficacy of Liraglutide in Reducing Cardiovascular Complications Among Patients with Type 2 Diabetes","Michelle Panol Del Rosario","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent37","meta-analysis of RCTs of liraglutide versus placebo on cardiovascular outcomes in type 2 diabetes, PubMed and ScienceDirect searched, two trials pooled",1],["R0056200","Efficacy and safety of once-weekly Semaglutide for weight management in adults with overweight or obesity with or without type 2 diabetes: A real-world clinical trial in Bangladesh","Quazi Tarikul Islam","2026","inventory_only","N1","conference_abstract",null,null,"abstract_only","high","first","opus-5.5-agent37","single arm nonrandomized study of semaglutide 2.4 mg for weight in Bangladeshi adults with overweight or obesity",1],["R0056548","Semaglutide and Drug Craving: Emerging Perspectives in Addiction Psychiatry","Vincenzo Maria Romeo","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent37","mini review of semaglutide and drug craving from a targeted narrative search without stated eligibility criteria",1],["R0046636","INCRETIN-BASED PHARMACOTHERAPY FOR OBESITY: A COMPARATIVE NARRATIVE REVIEW OF GLP-1, DUAL AND TRIPLE AGONISTS AND COMBINATION THERAPIES","Łukasz Krzystek","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent30","self described narrative review analyzing key trials and selected reviews despite naming databases; selective per ruling 19",1],["R0050756","Addressing weight loss management in obese gout patients: guidance for future trials","Robin Christensen","2024","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent30","commentary proposing a hypothetical ideal GLP-1 RA versus placebo trial in gout; no actual study or data",1],["R0051868","Cardiovascular Outcomes of Tirzepatide Compared with Glucagon-Like Peptide-1 Receptor Agonist (GLP-1) and Insulin in Patients with Type-2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","I Gusti Sri Agung Jaya Kusumadewi","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent30","PRISMA meta-analysis of RCTs from four named databases pooling tirzepatide versus GLP-1 RA, insulin or placebo cardiovascular outcomes",1],["R0053892","Safety of GLP-1 receptor agonists in body contouring surgery: a systematic review and meta-analysis","Bernardo G. Collaco","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent30","systematic review and meta-analysis pooling body contouring surgery outcomes with versus without GLP-1 RA exposure",1],["R0054321","Cardiometabolic Continuum and Integrated Cardiovascular-Endocrine Risk Management in Contemporary Clinical Practice","Martín Gómez-Luján","2026","exclude","E3","other",null,null,"non_english","high","first","opus-5.5-agent30","self described narrative review prioritizing guidelines and recent trials without eligibility criteria",1],["R0046654","GLP-1 agonists in addiction therapy – review","Paweł Gwałt","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent32","PRISMA review searching PubMed, Scopus and Web of Science with PICOS criteria; qualitative synthesis of nine GLP-1 RA studies in substance use disorders",1],["R0047901","The effectiveness and safety of exenatide in the treatment of polycystic ovary syndrome: A systematic review and meta-analysis","Yan Ping Hu","2022","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent32","INPLASY registered protocol of a planned exenatide PCOS meta-analysis; no results",1],["R0049415","Semaglutide: The First Anti-Obesity Agent Shown to Decrease Cardiovascular Events","Nasser E. Mikhail","2024","inventory_only","N9","ancillary",null,null,null,"high","first","opus-5.5-agent32","commentary article summarizing and appraising the SELECT semaglutide trial; alternative E3 narrative review",1],["R0050784","Effects of GLP-1RAs on cardiovascular outcomes in patients with type 2 diabetes mellitus: review of real-world data on target populations from diabetes registry in Russian Federation","Ol'ga Konstantinovna Vikulova","2022","exclude","E3","other",null,null,"non_english","high","first","opus-5.5-agent32","Russian narrative review of selected GLP-1 RA outcome trials plus registry estimate of eligible patients; no exposure comparison",1],["R0051882","Reductions in alanine aminotransferase levels with liraglutide treatment are greatest in those with raised baseline levels and are independent of weight loss: real-world outcome data from the ABCD Nationwide Liraglutide Audit","Thomas SJ Crabtree","2019","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent32","nationwide audit of liraglutide users with before and after ALT change; observational cohort without comparison group",1],["R0053540","Editorial: Metainflammation and metabolism in hidradenitis suppurativa","Nessr Abu Rached","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent32","editorial introducing a hidradenitis research topic; mentions GLP-1 RA only in passing",1],["R0054012","GLP-1 RECEPTOR AGONISTS AND ALCOHOL USE DISORDER: PROMISE FOR A NEW TREATMENT APPROACH","Jakub Fidelus","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent32","self described narrative review on alcohol use disorder; databases named but no record of which studies met criteria",1],["R0054355","The Role of SGLT2 Inhibitors and GLP-1 Receptor Agonists in Preventing Cardiovascular Complications in Type 2 Diabetes Mellitus","Saffanah Rizkah Muttaqinah Anwar","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent32","PRISMA guided PubMed review with stated criteria; tabulates and synthesizes 15 included studies of SGLT2 inhibitors and GLP-1 RA",1],["R0046570","Comparative Efficacy and Safety of Semaglutide, Cagrilintide, and CagriSema for the Treatment of Type 2 Diabetes Mellitus: A Bayesian Network Meta-Analysis","Ting Jin","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent28","Bayesian NMA of five RCTs of semaglutide, cagrilintide and CagriSema in T2D, PubMed Embase Cochrane WoS search with criteria",1],["R0047449","Editorial: World diabetes day 2024: exploring mechanisms, innovations, and holistic approaches in diabetes care","Åke Sjöholm","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent28","editorial summarizing a World Diabetes Day research topic collection, no original data",1],["R0049196","Potential Cardiovascular Effects of the Glucagon-like Peptide-1 Receptor Agonists","ROBERT J. CHILTON","2015","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent28","review of cardiovascular effects of GLP-1 RA focusing on key phase 3 trials, selective per ruling 19",1],["R0050643","Semaglutide in patients with obesity and heart failure with preserved ejection fraction: A systematic review and meta-analysis","Maneeth Mylavarapu","2026","deferred","D1","systematic_review",null,null,null,"high","first","opus-5.5-agent28","stored PDF is a different 2020 HFpEF review, not the semaglutide meta-analysis named in the title",1],["R0051741","The role of glucagon-like peptide-1 receptor agonists in the treatment of dyslipidemia in patients with overweight and obesity (review)","M. G. Chashchin","2026","exclude","E3","other",null,null,"non_english","high","first","opus-5.5-agent28","Russian narrative review of GLP-1 RA and dyslipidemia, no described search or eligibility criteria",1],["R0053415","The Impact of GLP-1 Receptor Agonists on Semen Parameters and the Hypothalamic–Pituitary–Gonadal Axis in Men with Obesity — A Literature Review","Aleksandra Mliczek","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent28","self described narrative review on semen and gonadal axis, names databases but never states which studies met criteria",1],["R0053826","Effectiveness and safety of once-weekly semaglutide for weight loss in adults with overweight or obesity: a systematic review of randomized controlled trials","Snehashis Singha","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent28","SR of semaglutide RCTs for weight loss, seven named databases, stated criteria, 41 trials pooled",1],["R0055368","Effects of combined GLP-1 receptor agonist therapy and exercise on body composition in individuals with obesity: a systematic review","Paulina Żuk","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent33","PRISMA review of RCTs from PubMed and PEDro on GLP-1 RA plus exercise for body composition in obesity",1],["R0055686","OBSTRUCTIVE SLEEP APNOEA SYNDROME: ETIOLOGY, DIAGNOSIS, AND CURRENT TREATMENT METHODS","Zuzanna Muszkiet","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent33","narrative review of sleep apnea diagnosis and treatment; studies chosen by relevance, not a systematic synthesis",1],["R0056150","Clinical outcome and safety profile of combination therapy with low dose semaglutide and metformin vs. metformin alone in polycystic ovary syndrome with obesity","Md Rafayel Islam","2026","include_nma",null,"conference_abstract","P12",null,"abstract_only","high","first","opus-5.5-agent33","abstract of RCT of low dose semaglutide plus metformin versus metformin alone in obese women with PCOS, 16 weeks",1],["R0056446","GLP-1 Receptor Agonists and Total Knee Arthroplasty Outcomes: A Systematic Review","Damon Ross","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent33","PRISMA review from four named databases of perioperative GLP-1 RA use and knee arthroplasty outcomes, 18 studies",1],["R0047080","The role of glucagon-like peptide-1 receptor agonists in cardiometabolic health management","Tatiana Yu. Demidova","2024","exclude","E3","other",null,null,"non_english","high","first","opus-5.5-agent40","Russian literature review on mechanisms and cardiometabolic effects of GLP-1 receptor agonists; no search or eligibility criteria",1],["R0048358","Semaglutide as Treatment for Obesity in Adolescents","Nasser E. Mikhail","2023","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent40","mini review critically appraising semaglutide in adolescents, centered on STEP TEENS; PubMed search but selective, no account of studies meeting criteria",1],["R0050206","Incidence of nonarteritic anterior ischemic optic neuropathy among adults treated with GLP‑1 receptor agonists: A systematic review and single‑arm proportion meta‑analysis","Maria Isabel Arias Gallardo","2025","inventory_only","N8","protocol_or_design",null,null,null,"high","first","opus-5.5-agent40","INPLASY registration of a planned proportion meta-analysis of NAION incidence with GLP-1 RA; preliminary searches, no results",1],["R0051250","Editorial: Gastrointestinal damage and metabolic disorders","Carolina Silva Schiebel","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent40","editorial summarizing a research topic on gastrointestinal damage; mentions a GLP-1 RA pharmacovigilance paper but no original data",1],["R0052737","The association between the utilization of SGLT2 inhibitors and diabetic retinopathy; a systematic review and meta-analysis of cohort studies","Shahriar Barkhordari","2024","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent40","SR and meta-analysis of cohort studies on SGLT2 inhibitors and diabetic retinopathy; pools SGLT2i versus GLP-1 RA odds ratio",1],["R0053675","Comparative Effectiveness of SGLT2 Inhibitors Versus GLP-1 Receptor Agonists in Reducing Cardiovascular Events in Type 2 Diabetes","Ahmed S.F. Belal","2025","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent40","PRISMA SR of RCTs and cohorts comparing SGLT2 inhibitors with GLP-1 RAs on cardiovascular outcomes; four databases, 21 studies",1],["R0054133","Efficacy and safety of metformin and liraglutide combination therapy in comparison with metformin in managing metabolic and endocrine levels of PCOS: A systematic review","Carl Jefferson E. Bernales","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent40","PRISMA SR of RCTs of liraglutide plus metformin versus metformin in PCOS; three databases, three RCTs synthesized narratively",1],["R0054537","SEMAGLUTIDE FOR WEIGHT REDUCTION: A COMPARATIVE ANALYSIS WITH OTHER PHARMACOLOGICAL TREATMENTS","Marta Handzel","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent40","review of semaglutide versus other obesity drugs; databases named but studies prioritized by preference, no account of which met criteria",1],["R0055042","Association Between Plausible Genetic Factors and Weight Loss from GLP-1 Receptor Agonists and Bariatric Surgery: A Review","Deborah Mayne","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent21","narrative review of genetic predictors of weight loss with GLP-1 RA and bariatric surgery; no database search or criteria described",1],["R0055428","The Neuroprotective Potential Of Semaglutide In Modulating Brain Cravings For Alcohol, Nicotine, And Opioids: A Comprehensive Review","Sujal E Durge","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent21","review of semaglutide for substance cravings naming databases but stating no eligibility criteria nor which studies were included",1],["R0055818","Perioperative Safety Considerations and Surgical Outcomes Associated With GLP-1-Based Therapies: A Systematic Review","Mayte Rodrigues da Cunha","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent21","PROSPERO registered PubMed based review of perioperative gastric findings with GLP-1 RA; all 16 included studies tabulated",1],["R0056298","COMORBIDITY BETWEEN OBESITY AND MIGRAINE, POSSIBLE IMPACT OF GLP-1 RECEPTOR AGONISTS ON THE COURSE OF MIGRAINE – A NARRATIVE REVIEW","Inga Kokuszko","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent21","self described narrative review on GLP-1 RA and migraine with loose selection and no list of included studies",1],["R0056632","Emerging Anti-Obesity Medications for Obesity Management: A Systematic Review of Efficacy, Safety, and Outcomes","Kishna Ram","2026","include_review",null,"systematic_review",null,null,"umbrella_review","high","first","opus-5.5-agent21","umbrella review of eight meta-analyses of anti obesity drugs including semaglutide, tirzepatide and retatrutide; five databases searched with stated criteria",1],["R0054636","Adjuvant therapy in glucagon-like peptide-1 receptor agonist treatment: Enhancement of efficacy and mitigation of adverse events. A review","Д. Н. Андреев","2026","exclude","E3","other",null,null,"non_english","high","first","opus-5.5-agent23","Russian narrative review proposing adjuvant therapies alongside GLP-1RA treatment, no search methods",1],["R0055073","Risk of suicidal thoughts and dizziness associated with tirzepatide: A systematic review and meta-analysis","Ranakishor Pelluri","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent23","PRISMA meta-analysis of RCTs of tirzepatide versus placebo for dizziness and suicidal ideation, PubMed EMBASE Web of Science searched",1],["R0055833","24 | IXEKIZUMAB WITH OR WITHOUT TIRZEPATIDE IN ADULTS WITH PSORIASIS AND OVERWEIGHT OR OBESITY: THE TOGETHER-PSO PHASE 3B RANDOMIZED CLINICAL TRIAL","Associazione Dermatologi-Venereologi Ospedalieri Italiani e della Sanità Pubblica","2026","include_nma",null,"conference_abstract","P99",null,"abstract_only","high","first","opus-5.5-agent23","abstract of open label RCT of ixekizumab plus tirzepatide versus ixekizumab in psoriasis with overweight or obesity; P99 psoriasis",1],["R0056302","Cutaneous Adverse Events With Semaglutide: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","Samyak Ganjre","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent23","PROSPERO registered meta-analysis of RCTs of semaglutide versus comparators for cutaneous adverse events, PubMed and Europe PMC searched",1],["R0056653","Efficacy and Safety of Oral Orforglipron for Weight Reduction in Adults With Overweight or Obesity: A Systematic Review","Gabriel Jose Paredes Yacaman","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent23","systematic review of RCTs of oral orforglipron for weight loss, PubMed and ScienceDirect searched",1],["R0054908","TIRZEPATIDE, ELAMIPRETIDE (SS-31), TESAMORELIN AND BREMELANOTIDE: MECHANISTIC FOUNDATIONS, CLINICAL EVIDENCE AND THERAPEUTIC APPLICATIONS IN METABOLIC, MITOCHONDRIAL AND NEUROENDOCRINE CONTEXTS","Luiz Felippe Mendes Caquetti","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent36","structured narrative review of tirzepatide and three other peptides, unnamed databases and prioritized pivotal trials",1],["R0055388","Role of physical activity in GLP-1 receptor agonist therapy for obesity treatment","Łukasz Zdziebkowski","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent36","literature review on exercise with GLP-1 receptor agonists; PubMed named but studies cited selectively without listing those meeting criteria",1],["R0055746","Neuroprotective Potential of GLP-1 Receptor Agonists in Neurodegenerative Diseases: Narrative Review","Paulina Orzechowska","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent36","narrative review of GLP-1 receptor agonists in neurodegeneration; databases named but no eligibility criteria and only key studies tabulated",1],["R0056188","GLP-1 Receptor Agonists Across the Coronary Disease Continuum in Type 2 Diabetes: A Systematic Review of Ischemic Events, Revascularization, and Stent Healing","Batool I Abuzenah","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent36","systematic review of randomized GLP-1 receptor agonist trials on coronary outcomes, four named databases, criteria, seven reports tabulated",1],["R0056533","GLP-1 Receptor Agonists And Osseointegration: Bone Health Implications For Implant Dentistry In The Era Of Widespread Weight-Loss Therapy","Paulo Vinícius de Oliveira Bastos","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent36","narrative review of GLP-1 receptor agonists and dental implant osseointegration without a systematic search",1],["R0054750","Weighing up the options: childhood intervention to tackle obesity","Owen R. Vaughan","2025","inventory_only","N9","ancillary",null,null,null,"high","first","opus-5.5-agent30","journal comment on a meta-analysis of GLP-1 RA trials for pediatric obesity published in the same issue",1],["R0055270","Impact of GLP-1 Receptor Agonists on Body Composition and Physical Performance in Patients with Obesity: A Comprehensive Review of Current Research","Konrad Turczynowski","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent30","narrative review built on a provided set of 30 publications with thematic synthesis, no search or eligibility criteria",1],["R0055600","Pharmacological, behavioral, and sociocultural dimensions of GLP-1 and dual incretin therapies in Saudi Arabia: clinical evidence, misuse patterns, and policy priorities","Lamar K. Aloufi","2025","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent30","narrative policy review of GLP-1 RA use in Saudi Arabia; keyword search named but no eligibility criteria or study level synthesis",1],["R0056123","GLP-1 receptor agonists in cardiometabolic disease: a meta-analysis of 102,486 patients","Zena Adel Alwaily","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent30","meta-analysis of 28 placebo controlled GLP-1 RA RCTs found via PubMed, Cochrane Library and Google Scholar",1],["R0056417","Insulin Deintensification After Glucagon-Like Peptide-1 (GLP-1)-Based Therapy in Type 2 Diabetes: Evidence and a Practical Clinical Framework","Ahmed Elhassan","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent30","narrative clinical review on insulin deintensification after GLP-1 based therapy using targeted searches, no criteria",1],["R0056937","Latest Developments and Future Perspectives in the Field Of Obesity.","Pérez-Pevida B","2017","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent30","short opinion editorial summarizing recent obesity trials; not a primary study or systematic review",1],["R0054714","Editorial: Prevention and treatment advancements in diabetic retinopathy","Tomislav Bulum","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent27","editorial introducing a research topic collection on diabetic retinopathy; mentions a GLP-1 RA review among several articles; no data",1],["R0055568","Pharmacological treatment options for obesity in children with insulin resistance: a targeted review","Marta Drozdowska","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent27","targeted review of pediatric obesity drugs naming databases but giving no selection flow or list of studies meeting criteria; ruling 14",1],["R0056069","Tirzepatide: a new treatment for obesity - literature review","Sara Correia","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent27","narrative tirzepatide review selecting articles by relevance and focusing on SURPASS and SURMOUNT programmes; ruling 19",1],["R0056389","Differential functions of ROCK1 and ROCK2 in liver fibrosis and advances in targeted therapeutic strategies","Ting He","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent27","preclinical review of ROCK isoforms in liver fibrosis; GLP-1 RA named only as a possible combination partner",1],["R0056711","Patient-centred outcomes with incretin-based therapies and sodium-glucose cotransporter 2 inhibitors in obesity-related heart failure with preserved ejection fraction: a programme-level systematic review and meta-analysis","Muhammad Daniyal Khan","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent27","PRISMA meta-analysis searching PubMed and ClinicalTrials.gov; pools STEP-HFpEF and SUMMIT incretin trials versus placebo for KCCQ and walk distance",1],["R0054975","Neuroprotective and Disease-Modifying Potential of GLP-1 Receptor Agonists in Parkinson’s Disease: A systematic Review of randomized Controlled Trials and Cohort Study","Rizqiana Arum Sari","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent40","SR of five RCTs and one cohort of GLP-1 RAs in Parkinson disease; three databases, stated criteria, narrative synthesis",1],["R0055811","Impact of GLP1Ra and SGLT2i on atrial fibrillation in overweight, non-diabetic patients: A meta-analysis of randomized evidence","Luca Sgarra","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent40","PRISMA meta-analysis of RCTs of GLP-1 RAs and SGLT2 inhibitors on atrial fibrillation in nondiabetic overweight adults",1],["R0056293","GLP-1 receptor agonists for organ protection and survival in preclinical models of sepsis: a systematic review and meta-analysis","Sai‐Wai Ho","2026","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent40","INPLASY protocol for an SR of GLP-1 RAs in animal sepsis models only; no human studies",1],["R0056600","The Effect of Exanatide on Recovery of the Facial Nerve Crush Injury in the Rat.","Yılmaz B","2026","exclude","E1","other",null,null,null,"high","first","opus-5.5-agent40","randomized study of exenatide on facial nerve crush injury in Sprague Dawley rats; no human participants",1],["R0055366","THE EXERCISE PILLAR OF LIFESTYLE MEDICINE: EMERGING EVIDENCE, NOVEL MODALITIES, MOLECULAR MECHANISMS, AND PHARMACOLOGICAL SYNERGIES A NARRATIVE REVIEW","Chatbongkoch Khemacheewakul","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent32","self described narrative review of exercise in lifestyle medicine; GLP-1 RA only as an adjunct topic, no structured synthesis",1],["R0055669","CARDIOVASCULAR BENEFITS OF GLP-1 RECEPTOR AGONISTS: EVIDENCE FROM CARDIOVASCULAR OUTCOMES TRIALS (CVOTs)","Nicol Szerenos","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent32","narrative review of GLP-1 RA outcome trials built on key publications; no named search or eligibility criteria",1],["R0056438","CagriSema versus Semaglutide 2.4 mg monotherapy for weight management in adults with overweight or obesity, with or without type 2 diabetes: a systematic review, meta-analysis, and trial sequential analysis","Zehra Khatoon Rasool","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent32","PROSPERO registered PRISMA meta-analysis searching named databases for RCTs of CagriSema versus semaglutide 2.4 mg or placebo",1],["R0054970","One-Year Outcomes of Compounded Semaglutide Therapy in a High-Touch Telehealth Platform: A Retrospective Cohort Study","Melissa M Rubio","2025","inventory_only","N5","primary_report",null,null,null,"high","first","opus-5.5-agent39","retrospective single group telehealth cohort on compounded semaglutide; authors state there was no control group",1],["R0055808","Comparative Effectiveness and Safety of Tirzepatide Versus Semaglutide in Adults with Obesity and Metabolic Syndrome: A One-Year Prospective Comparative Study","Md Momenuzzaman Khan","2025","include_harms",null,"primary_report",null,"O28; O29",null,"high","first","opus-5.5-agent39","prospective nonrandomized cohort of tirzepatide versus semaglutide in obesity; gallbladder events and acute pancreatitis reported by group, none occurred",1],["R0056282","CHILDHOOD OBESITY AND GLP-1 RECEPTOR AGONISTS: CURRENT EVIDENCE, CHALLENGES AND FUTURE PERSPECTIVES – A NARRATIVE REVIEW","Wiktoria Skowron","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent39","self described narrative review of GLP-1 RA in pediatric obesity; keyword search prioritizing selected sources, no eligibility criteria",1],["R0056586","Dual Benefits of Antidiabetic Drugs: Mechanistic Insights into Blood Glucose Control and Cancer Suppression","Al Darraji Raad kareem Alwan","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent39","self described narrative review of anticancer mechanisms of glucose lowering drugs; no eligibility criteria or study level synthesis",1],["R0055081","TIRZEPATIDE BEYOND WEIGHT LOSS: A NARRATIVE REVIEW OF METABOLIC AND ORGAN-SPECIFIC EFFECTS","Jowita Wiktoria Maksymiuk","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent24","self described narrative review of tirzepatide using PubMed with prioritized, relevance based selection and no formal criteria, ruling 19",1],["R0055475","Prevention of biliary diseases associated with GLP-1 receptor agonist therapy","Е.А. Лялюкова","2026","exclude","E3","other",null,null,"non_english","high","first","opus-5.5-agent24","Russian narrative review of biliary disease with GLP-1 receptor agonists and ursodeoxycholic acid, no described search",1],["R0055885","Editorial: The gut-liver axis in MASLD: microbiome, metabolism, disease progression and therapeutic pathways","Zhengyang Bao","2026","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent24","editorial introducing a research topic on the gut liver axis in MASLD; incretin therapy only mentioned in passing, E3 also applies",1],["R0056309","OBESITY, ENDOMETRIOSIS, AND GLP-1 RECEPTOR AGONISTS: A NARRATIVE REVIEW","Oliwia Wróblewska","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent24","narrative review of obesity, endometriosis and GLP-1 RA with studies selected by relevance, ruling 19",1],["R0056675","A Randomized, Multicentric, Double-Blind, Active Controlled, Parallel Group, Phase III, Non-Inferiority Clinical Trial To Evaluate The Efficacy, Safety And Tolerability Of Oral Semaglutide Tablets Of Dr. Reddy’s Laboratories Ltd. Compared With Rybelsus® (Semaglutide) Tablets In Adult Patients With Inadequately Controlled Type 2 Diabetes Mellitus.","Dilip Shah","2026","inventory_only","N3","primary_report",null,null,null,"high","first","opus-5.5-agent24","RCT of generic oral semaglutide tablets versus Rybelsus at the same doses and route in type 2 diabetes, rulings 6 and 17",1],["R0054727","OPTIONS AND LIMITATIONS OF OBESITY TREATMENT WITH GLP-1 RECEPTOR AGONISTS","Katarína Babíková","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent28","self described narrative review of GLP-1 RA in obesity, broad search but no account of which studies met criteria",1],["R0055174","Dietary Modulation and Clinical Outcomes During GLP-1 Receptor Agonist Therapy. A Literature Review","Kacper Rychlica","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent28","narrative review of diet during GLP-1 RA therapy without systematic search or criteria",1],["R0055583","Orforglipron as a Small-Molecule GLP-1 Receptor Agonist: A New Era of Incretin-Based Oral Therapy?","Małgorzata Blecharczyk","2026","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent28","narrative review of orforglipron trials from PubMed without eligibility criteria or structured synthesis",1],["R0056079","Editorial: Bone: Endocrine Target and Organ","Giacomina Brunetti","2017","exclude","E3","other",null,null,null,"high","first","opus-5.5-agent28","editorial introducing a research topic on bone as endocrine organ, no original data",1],["R0056392","IcoSema in Weight Management and Glycaemic Control: A Systematic Review and Meta-Analysis","Mahmoud Ismail Nouh","2026","include_review",null,"systematic_review",null,null,null,"high","first","opus-5.5-agent28","SR and meta-analysis of IcoSema RCTs in T2D, eight named sources searched, four COMBINE trials pooled by comparator",1],["R0056789","The metabolite generated by dipeptidyl-peptidase 4 metabolism of glucagon-like peptide-1 has no influence on plasma glucose levels in patients with type 2 diabetes.","Zander M","2006","exclude","E2","other",null,null,null,"high","first","opus-5.5-agent28","randomized crossover of native GLP-1 7-36 amide infusions with or without DPP-4 inhibitor, no therapeutic GLP-1 RA drug",1],["R0054170","DIFFERENCES IN SAFETY PROFILE AND ADVERSE EFFECTS OF ORAL AND SUBCUTANEOUS GLP-1 ANALOGUES: A SYSTEMATIC REVIEW AND REAL-WORLD DATA ANALYSIS (2024–2026)","Aleksandra Olga Pakulska","2026","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck15","R14: PubMed and PMC search with stated criteria, all 23 retained publications named and tabulated; oral versus subcutaneous semaglutide safety synthesized",2],["R0054410","ROLE OF LIRAGLUTIDE IN A MAJOR COMPLICATION OF DIABETES: A CRITICAL REVIEW OF CLINICAL STUDIES","Gaurav Gupta","2018","exclude","E3","other",null,null,null,"high","recheck","opus-5.5-recheck15","R19: critical review citing selected small studies and a registry table of trials without results; no statement of which studies met criteria",2],["R0054654","Once weekly semaglutide for treatment of obesity","Nasser E. Mikhail","2021","exclude","E3","other",null,null,null,"high","recheck","opus-5.5-recheck15","R19: mini review taking pertinent animal studies and reviews from PubMed, no accounting of which studies met criteria; relevance selection",2],["R0056685","Adherence and Persistence to Injectable versus Oral GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus: A Comparative Systematic Review and Analysis","Ahmed M. Ashour","2026","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck15","R1: PubMed and ClinicalTrials.gov search, PRISMA, 13 studies; pooled oral versus injectable GLP-1 RA adherence and discontinuation for adverse events",2],["R0029316","Preventing Weight Regain After Glucagon-Like Peptide‑1 Therapy Discontinuation: A Pilot Randomized Controlled Trial.","Hollis-Hansen K","2026","exclude","E2","other",null,null,null,"high","recheck","opus-5.5-recheck14","R17 not met: no arm receives a GLP-1 drug, all stopped before randomization; app or meals versus usual care. Alternative N3",2],["R0038519","A Systematic Review of Weight-Loss Medications and Their Impact on Oral Health","Ana Keohane","2026","exclude","E3","other",null,null,null,"high","recheck","opus-5.5-recheck14","R14: five databases and criteria named, but the eight included studies are never identified nor their results reported; thematic prose only",2],["R0053478","Safety analysis of semaglutide as part of comprehensive therapy for knee osteoarthritis in patients with obesity: data from a 24-week randomized study","Anatoly I. Surov","2026","include_nma",null,"secondary_report","P11; P01",null,"non_english","high","recheck","opus-5.5-recheck14","Correct article now; T2D patients block randomized to metformin, semaglutide 1.0 mg or 2.4 mg with diacerein; adverse events reported; safety paper of the trial",2],["R0055356","De-escalating Therapy in Obstructive Sleep Apnoea After Glucagon-Like Peptide-1 Receptor Agonist-Induced Weight Loss: A Narrative Review","Wares Jalil","2026","exclude","E3","other",null,null,null,"high","recheck","opus-5.5-recheck14","R19: self described narrative review; PubMed records screened for relevance and 23 selected; interpretive synthesis with no criteria beyond relevance",2],["R0001856","Glucagon-Like Peptide-1 Receptor Agonists in Cognitive and Mental Health Disorders: A Comprehensive Review of Pre-Clinical and Clinical Evidence","Ghenciulescu A","2025","include_review",null,"systematic_review",null,null,"abstract_only","high","recheck","opus-5.5-recheck15","R14: conference abstract stating a systematic multi database search with duplicate screening; 96 clinical GLP-1 RA studies synthesized by domain",2],["R0029290","Gut-kidney signaling is impaired in individuals with type 2 diabetes.","Mosterd CM","2026","include_nma",null,"primary_report","P01",null,"crossover; mechanistic","high","recheck","opus-5.5-recheck15","R5: randomized placebo controlled crossover of exenatide infusion in T2D men; ambulatory systolic blood pressure reported per condition",2],["R0056220","Semaglutide for metabolic dysfunction-associated steatotic liver disease in Asian and lean populations","Yeo Wool Kang","2026","exclude","E3","other",null,null,null,"high","recheck","opus-5.5-recheck15","R1: replaced file is the titled article, a narrative review of semaglutide in lean Asian MASLD with no search or eligibility criteria",2],["R0006389","In Reply to 'Glucagon-like Peptide-1 Receptor Agonists and the Risk of Acute Kidney Injury: Alarming, or Not?'.","Leehey DJ","2021","inventory_only","N9","ancillary",null,null,null,"high","recheck","opus-5.5-recheck14","Authors reply to a letter on their semaglutide acute kidney injury case report, itself an in scope N5 record",2],["R0040292","CHANGES IN HbA1c AND ANTHROPOMETRY IN REAL-WORLD SETTINGS IN PATIENTS WITH TYPE 2 DIABETES RECEIVING GLP-1 RECEPTOR ANALOGUES (CHARGE AUDIT)","Goh Kian Guan","2023","inventory_only","N6","conference_abstract","P01",null,"abstract_only","high","recheck","opus-5.5-recheck14","R7: audit of 14 T2D initiators comparing weight change on semaglutide (12) versus dulaglutide (2); no listed harm. Alternative N5",2],["R0054797","DUAL GIP/GLP-1 AGONISM AND LEAN MASS PRESERVATION: AN INTEGRATIVE REVIEW OF TIRZEPATIDE AND A PROPOSED AMAZONIAN DIETARY MODEL","Ana Tereza Gomes Braga","2026","exclude","E3","other",null,null,null,"high","recheck","opus-5.5-recheck14","R1: integrative review naming no database; thirteen studies chosen from highly ranked journals and summarized by author positions; no systematic search",2],["R0011959","Glucagon-like peptide-1 receptor agonists and their effects on weight reduction.","Shin SJ","2012","inventory_only","N9","ancillary",null,null,null,"high","recheck","opus-5.5-recheck14","Commentary centered on the Vilsboll 2012 BMJ meta-analysis of GLP-1 RA weight effects, an in scope review; reproduces its trial table",2],["R0017636","Targeting dementia prevention with semaglutide: The case for APOE4 homozygotes.","Daly T","2025","inventory_only","N9","ancillary",null,null,null,"high","recheck","opus-5.5-recheck14","Letter responding to the Wang semaglutide target trial emulation on Alzheimer disease, an in scope study; advocates trials in APOE4 homozygotes",2],["R0054419","PD55 Living Recommendations Within A Type 2 Diabetes Mellitus Guideline","Soledad Isern de Val","2024","include_review",null,"systematic_review",null,null,"abstract_only","high","recheck","opus-5.5-recheck14","R14: abstract of a living systematic review searching LOVE and Epistemonikos; six RCTs of GLP-1 RA versus rapid insulin synthesized with GRADE",2],["R0055755","Incretin-based pharmacotherapy in the obesity phenotype of heart failure with preserved ejection fraction - Pathophysiology and clinical evidence","Tomaszek Barbara","2026","exclude","E3","other",null,null,null,"high","recheck","opus-5.5-recheck14","R19: three databases and criteria named, 62 articles retrieved, but the review concentrates on major trials and tabulates key studies only",2],["R0042732","L'antibioticoterapia topica è efficace nel trattamento della congiuntivite acuta nei bambini","Gruppo di lettura di Parma","2023","inventory_only","N9","ancillary",null,null,"non_english","high","recheck","opus-5.5-recheck15","file is the item at the record DOI despite a wrong metadata title; Italian journal club critique of the STEP TEENS semaglutide RCT",2],["R0039525","A Comprehensive Systematic Review of the Role of Semaglutide Anti-Obesity Therapy in Multiple Metabolic Diseases: A Systematic Review of Randomized Controlled Trials and Primary Studies","Jeffy Marta","2026","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck15","R14: PubMed, ClinicalTrials.gov, Semantic Scholar and Cochrane searched with criteria, PRISMA; 27 semaglutide studies tabulated with results by outcome",2],["R0042663","Pharmacotherapeutics efficacy in obesity treatment: A systematic review","Tarboush BA","2023","exclude","E3","other",null,null,null,"high","recheck","opus-5.5-recheck15","R19: the 35 accepted articles are the bibliography incl WHO fact sheets and narrative reviews; results given only for selected studies, no results table",2],["R0054585","Emerging Therapeutic Strategies Targeting Insulin Resistance in PCOS to Improve Fertility","Mishaal Noor","2026","exclude","E3","other",null,null,null,"high","recheck","opus-5.5-recheck15","R19: rapid scoping review selecting guidelines and major reviews by clinical relevance and distinct contribution; nine sources, not an exhaustive set",2],["R0008993","Interpreting Pregnancy Risk After GLP-1 Receptor Agonists Discontinuation.","Scairati R","2026","inventory_only","N9","ancillary",null,null,null,"high","recheck","opus-5.5-recheck14","Commentary critiquing the Maya 2025 JAMA cohort of pregnancies after GLP-1 RA discontinuation, an in scope study; proposes weight trajectory phenotypes",2],["R0040482","Intersections of Inflammatory Bowel Disease (IBD) and Non‑Alcoholic Fatty Liver Disease (NAFLD): A PRISMA‑ScR Guided Scoping Review","Asrul Lubis","2025","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck14","R1: PRISMA-ScR scoping review searching four databases with criteria; tabulates all 30 included studies, including semaglutide and GLP-1 analog RCTs with results",2],["R0054834","Novel Approaches in the Treatment of Type 2 Diabetes","Sawera Saleem Khan","2024","exclude","E3","other",null,null,null,"high","recheck","opus-5.5-recheck14","R14: self described quantitative narrative review naming databases and criteria, but no included study is identified; results given only as unnamed group means",2],["R0055468","Liraglutide-Metformin Combination Therapy in Type 2 Diabetes: A Comprehensive Review of Clinical Efficacy, Safety and Cost-Effectiveness","Aashish Choudhary","2025","exclude","E3","other",null,null,null,"high","recheck","opus-5.5-recheck14","R14: names databases and criteria but never states which or how many studies met them; landmark trials emphasized and a PCOS trial cited outside criteria",2],["R0040588","Systematic Review Protocol: Impact of Physical Exercise as an Adjuvant in Weight Loss Treatment Associated with Liraglutide Use v1","R Silva","2024","inventory_only","N8","protocol_or_design",null,null,null,"high","recheck","opus-5.5-recheck15","R2: protocol without results for a review of exercise added to liraglutide; R1 alternative E2 if liraglutide is background in every comparison",2],["R0044126","The Analysis Study of Association of Type 2 Diabetes Mellitus and Hepatocellular Carcinoma : A Comprehensive Systematic Review","Muhammad Ilham Wira Tri Putra","2024","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck15","R1: four databases, criteria, eight cohorts tabulated; one reports GLP-1 RA versus insulin, sulfonylurea and metformin HCC hazard, so R19 E2 does not apply",2],["R0049307","Diabetes, Obesidad y Lípidos","Asociación Colombiana de Endocrinología Diabetes y Metabolismo","2017","inventory_only","N5","conference_abstract",null,null,"abstract_only; non_english","high","recheck","opus-5.5-recheck15","poster compilation whose only GLP-1 RA item is a case report of liraglutide for post bypass hypoglycemia",2],["R0053596","The Relationship Between Insulin Sensitivity And Insulin Therapy Effectiveness In Patients With Type 2 Diabetes: A Systematic Review And Meta-Analysis","Moamen Abdelfadil Ismail","2025","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck15","R1: four databases with criteria naming fixed ratio combinations; 11 studies tabulated incl iGlarLixi single arm HbA1c results",2],["R0030382","The Effect of Dipeptidyl Peptidase-4 Inhibitors on Macrovascular and Microvascular Complications of Diabetes Mellitus: A Systematic Review.","Taylor OM","2020","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck15","R1: PubMed and Ovid search, PROSPERO, criteria; tabulated trials include sitagliptin versus liraglutide versus placebo with liraglutide GFR results reported",2],["R0034535","The Effects of Semaglutide in Adults (18+) with Overweight or Obesity and Diabetes type 2. A Narrative Review","Anzhelika Magomedova","2025","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck15","R14: replaced file readable; self described narrative review with PubMed and Google Scholar search, criteria, eight selected studies each described with results",2],["R0049853","Semaglutide: The first anti-obesity agent shown to decrease cardiovascular events","Nasser E. Mikhail","2023","inventory_only","N9","ancillary",null,null,null,"high","recheck","opus-5.5-recheck15","appraisal article summarizing and commenting on the SELECT semaglutide versus placebo trial, an in scope RCT reported elsewhere",2],["R0055123","ORAL GLP-1 RECEPTOR AGONIST (ORFORGLIPRON) IN THE MANAGEMENT OF OBESITY AND TYPE 2 DIABETES","Valéria Goulart Viana","2026","exclude","E3","other",null,null,null,"high","recheck","opus-5.5-recheck15","R19: narrative chapter admitting reviews of proven relevance; 19 studies neither listed nor tabulated, results cited from a few reviews",2],["R0004935","Bias in the Composite Outcomes of Kidney-Cardio Protective Trials in Chronic Kidney Disease: A Meta-Epidemiological Study.","Bellos I","2026","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck14","R1: registered meta-epidemiological review searching four databases; eight CKD trials including FLOW semaglutide reported by trial. Alternative E3 methods paper",2],["R0042572","The Cardiovascular Events in Metabolic Surgery Compared to the New Classes of Glucose-Lowering Agents in Patients with T2DM","Najla Shamsi","2021","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck14","R14: MEDLINE and Cochrane searched with PRISMA flow; tabulates all 18 included studies, including seven GLP-1 RA outcome trials with MACE results",2],["R0046737","IMPACT OF SEMAGLUTIDE USE ON LEAN MASS AND SARCOPENIA RISK: AN INTEGRATIVE REVIEW OF CLINICAL EVIDENCE","Valéria Goulart Viana","2026","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck14","R14: self described narrative review searching three named databases with explicit criteria; reports all 19 included studies by outcome with counts",2],["R0054264","COMPARISON BETWEEN TIRZEPATIDE AND SEMAGLUTIDE IN OBESITY MANAGEMENT: CURRENT EVIDENCE ON WEIGHT REDUCTION, METABOLIC PROFILE, AND TOLERABILITY","Valéria Goulart Viana","2025","exclude","E3","other",null,null,null,"high","recheck","opus-5.5-recheck14","R14: six databases and criteria named, but the number and identity of included studies are never stated; results cite trials and meta-analyses selectively",2],["R0043477","Pharmacological management of heart failure with preserved ejection fraction: a narrative review of diagnosis, drug classes, and trial evidence","Mosrur Ahmed","2025","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck15","R14: self described narrative review searching PubMed, Cochrane and ClinicalTrials.gov with trial criteria; all qualifying HFpEF outcome trials incl tirzepatide tabulated",2],["R0053480","The Impact of Ramadan Fasting on Glycemic Control in Patients with Type 2 Diabetes : A Comprehensive Systematic Review","Gusti Arlan Tio","2026","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck15","R14: PubMed, Springer, Semantic Scholar, Google Scholar and Wiley search, PRISMA, 80 studies tabulated; GLP-1 RA, semaglutide and iGlarLixi results synthesized",2],["R0056139","Tirzepatide: A new indication for cardiovascular risk reduction in type 2 diabetes","Md Kamrul Azad","2026","inventory_only","N9","ancillary",null,null,"abstract_only","high","recheck","opus-5.5-recheck15","sponsored congress talk abstract presenting the SURPASS CVOT tirzepatide versus dulaglutide trial results, an in scope RCT reported elsewhere",2],["R0029062","Patients' experiences with GLP1-RAs - a systematic review.","Ibsen CK","2025","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck15","R1: PubMed, PsycINFO, Embase and Sociological Abstracts search with criteria; nine studies of GLP-1 RA users synthesized thematically",2],["R0043592","Dapagliflozin-Associated Weight Reduction in Overweight Adults with Type 2 Diabetes: A Systematic Review","Liliane Mfeukeu Kuaté","2026","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck15","R1: PRISMA review searching PubMed and Google Scholar with criteria; six dapagliflozin studies synthesized, incl a dapagliflozin versus liraglutide weight contrast",2],["R0050693","Comparison of GLP-1RAs vs Other Pharmacotherapy for Obesity","Andrew Overholser","2025","include_review",null,"systematic_review",null,null,"umbrella_review","low","recheck","opus-5.5-recheck15","R14: four databases, criteria, results of all six included meta-analyses and two RCTs reported; how the 21 full texts were chosen is unstated, alternative E3 under R19",2],["R0055226","EFFECT OF TIRZEPATIDE ON THE REDUCTION OF CARDIOVASCULAR OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES MELLITUS","Pedro Henrique Souza e Silva","2026","exclude","E3","other",null,null,null,"high","recheck","opus-5.5-recheck15","R19: integrative chapter selecting 13 studies after analysis of scientific relevance, incl narrative reviews; results cited thematically, no study table",2],["R0045199","Impact of GLP-1 agonists on the progression of Alzheimer's disease: a systematic review","Nathália Carvalho Figuerêdo","2025","include_review",null,"systematic_review",null,null,"abstract_only","high","recheck","opus-5.5-recheck14","R14: titled abstract found in the congress supplement; four databases searched, PROSPERO registered, five studies with dementia risk results reported",2],["R0052783","Do GLP-1 receptor agonists have a place in the treatment of people with type 1 diabetes?","Thomas Fremming Dejgaard","2024","exclude","E3","other",null,null,null,"high","recheck","opus-5.5-recheck14","R19: PubMed searched for all relevant articles, but no count or list of included studies; trials prioritized and uncontrolled studies added selectively",2],["R0053541","Comparative effects of liraglutide doses with and without exercise on glycemic control and lipid profiles: A Randomized Controlled Trial.","Uzma Dost Muhammad Rajar","2024","include_nma",null,"primary_report","P01; P06; P99",null,null,"low","recheck","opus-5.5-recheck14","R9: computer generated randomization described, yet dose groups track diabetes status; liraglutide 0.6, 1.2, 1.8 mg with or without exercise. Alternative D2",2],["R0054801","GLP-1-BASED THERAPIES BEYOND DIABETES: EMERGING CLINICAL APPLICATIONS AND FUTURE PERSPECTIVES","Anna Maria Szeszko","2026","exclude","E3","other",null,null,null,"high","recheck","opus-5.5-recheck14","R19: SANRA guided narrative review naming PubMed and Cochrane; an evidence hierarchy prioritized trials and used observational studies only when trials were lacking",2],["R0039604","The Analysis Study of Effects of Glucagon-Like Peptide-1 Receptor to Reduce Adverse Cardiovascular Events in Patients with Type 2 Diabetes Mellitus: A Comprehensive Systematic Review","Radian Tommy Firmansyah","2024","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck15","R14: PubMed, SagePub and ScienceDirect search with criteria, PRISMA flow; eight GLP-1 RA cardiovascular studies tabulated with results",2],["R0047921","Impact of GLP-1 receptor agonists on cardiovascular risk reduction in patients with obesity without type 2 diabetes mellitus: a systematic review","Paquita del Rocío Quizhpe Donoso","2026","exclude","E3","other",null,null,null,"high","recheck","opus-5.5-recheck15","R19: synthesis built on 40 key references chosen as the most contemporary and significant evidence, not all studies meeting its criteria",2],["R0055422","TIRZEPATIDE IN OBESITY MANAGEMENT: EFFICACY AND SAFETY - INSIGHTS FROM RECENT CLINICAL TRIALS","Jakub Cecot","2024","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck15","R14: PubMed and Google Scholar search with RCT criteria; SURMOUNT 1 to 4, OSA and SYNERGY NASH placebo controlled tirzepatide results reported by trial",2],["R0024217","The efficacy of placebo-adjusted taspoglutide on body weight reduction in clinical trials.","Li HQ","2015","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck14","R1: model based meta-analysis of nine taspoglutide placebo controlled trials found through PubMed with criteria; synthesizes placebo adjusted weight loss. Alternative E3 modeling",2],["R0036843","Efficacy and safety of glucagon-like peptide-1 receptor agonists in Parkinson’s disease: A systematic review and meta-analysis","Madhusudan Prasad Singh","2025","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck14","R1: correct article now; CENTRAL, Medline and Embase searched with criteria; five RCTs of GLP-1 RA versus placebo in Parkinson disease meta-analyzed",2],["R0051877","Infographic: Landmark trials in Neuro-Ophthalmology—results of the phase II Idiopathic Intracranial Hypertension Pressure Trial","Gabriele Berman","2025","inventory_only","N9","ancillary",null,null,null,"high","recheck","opus-5.5-recheck14","Infographic caption summarizing the published exenatide versus placebo IIH Pressure Trial; no new data, ancillary to that in scope trial",2],["R0054880","EFFICACY OF GLP-1 RECEPTOR AGONISTS ON GLYCAEMIC CONTROL AND WEIGHT REDUCTION IN TYPE 2 DIABETES MELLITUS: A SYSTEMATIC REVIEW OF RANDOMIZED CONTROLLED TRIALS","Nadhira Iriani Djatmiko","2026","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck14","R14: PubMed, Cochrane, a registry and Semantic Scholar searched with PICOS criteria; all 32 included RCTs tabulated with HbA1c and weight results",2],["R0039917","GLP-1 receptor agonists for weight loss, benefits and risks: A systematic review of the literature","Silva Pacheco de Moraes, Diego","2024","include_review",null,"systematic_review",null,null,"non_english","low","recheck","opus-5.5-recheck15","R14: PubMed search with criteria, ten eligible studies tabulated with results; text also says 30 met criteria, so completeness is unclear, alternative E3 under R19",2],["R0047620","Comparative analysis of pharmacokinetic parameters, bioequivalence, safety, tolerability and immunogenicity of semaglutide-based drug for the treatment of obesity","Ametov As","2025","include_nma",null,"primary_report","P99",null,"mechanistic; non_english","low","recheck","opus-5.5-recheck15","R5: 60 volunteers randomized to four groups, test or reference semaglutide at 0.5 or 2.4 mg single dose, nausea and vomiting reported; alternative N3 under R6 if dose not randomized",2],["R0038551","A COMPREHENSIVE SYSTEMATIC REVIEW OF THE ASSOCIATION BETWEEN VISCERAL OBESITY AND INCREASED CARDIOMETABOLIC DISEASE RISK: A SYSTEMATIC REVIEW OF RANDOMIZED CONTROLLED TRIALS AND PRIMARY STUDIES","Jeffy Marta","2026","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck14","R1: PRISMA review searching PubMed, a registry and Semantic Scholar; tabulates 52 studies including liraglutide versus placebo RCTs on visceral fat",2],["R0039962","Treatment of people with type 1 diabetes with Semaglutide or Tirzepatide – Relevant in the future?","Sten Madsbad","2025","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck14","R14: self described narrative review with PubMed search for semaglutide or tirzepatide in T1D; reports each identified RCT and retrospective study with results",2],["R0050512","Combination Therapy Using Sodium-Glucose CoTransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Type 2 Diabetes","Nasser E. Mikhail","2020","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck14","R14: PubMed search with criteria for GLP-1 RA plus SGLT2 inhibitor RCTs; tabulates DURATION-8, AWARD-10 and SUSTAIN 9 with results",2],["R0055412","BEYOND WEIGHT LOSS: THE DUAL IMPACT OF GLP-1 AND DUAL GIP/GLP-1 RECEPTOR AGONISTS ON THE SKIN A SYSTEMATIC REVIEW OF SAFETY, ADVERSE REACTIONS, AND THERAPEUTIC POTENTIAL IN INFLAMMATORY DERMATOSES","Adrian Mikołajuk","2026","exclude","E3","other",null,null,null,"high","recheck","opus-5.5-recheck14","R19: four databases and criteria named, but the synthesis prioritized 53 sources and narrates landmark STEP, SURPASS and SURMOUNT trials; no included study list",2],["R0042968","Antidiabetic Medications and the Risk of Prostate Cancer in Patients with Diabetes Mellitus: A Systematic Review and Meta-analysis","Haiying Cui","2020","inventory_only","N8","protocol_or_design",null,null,null,"high","recheck","opus-5.5-recheck14","R2: INPLASY protocol of a meta-analysis of antidiabetic drugs, GLP-1 RA listed separately, and prostate cancer; no results reported",2],["R0044058","The Effect of Liraglutide on Hypoglycemia in Type 1 Diabetes Mellitus: A Meta-Analysis","Yan Wang","2024","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck14","R1: INPLASY record of a completed meta-analysis searching eight databases; pooled liraglutide versus insulin alone hypoglycemia ORs reported, so not an N8 protocol",2],["R0044343","GLP-1 analogues in the treatment of alcohol dependence: a new direction in pharmacotherapy – a literature review","Milena Kędzierska","2026","exclude","E3","other",null,null,null,"high","recheck","opus-5.5-recheck14","R19: three databases named, but the author prioritized high level evidence and key animal studies and tabulates selected agents only",2],["R0050491","Role of obesity-management medications before and after metabolic bariatric surgery: a systematic review","RICARDO VITOR COHEN","2024","include_review",null,"systematic_review",null,null,null,"high","recheck","opus-5.5-recheck14","R14: Medline, Embase and CENTRAL searched with PRISMA flow and design criteria; tables summarize included pre and postoperative studies of liraglutide and semaglutide",2],["R0040049","Comparison of the Effectiveness and Safety of GLP-1 Receptor Agonists in Type 2 Diabetes Mellitus Patients with Overweight or Obesity","Asma Luqman","2025","include_harms",null,"primary_report",null,"O28; O29",null,"high","coordinator","opus-5.5-coordinator","R21: alternate allocation of semaglutide or liraglutide initiators, pancreatitis and gallbladder events reported by group; blind disagreement (N4) settled",3],["R0040249","OBESITY MANAGEMENT - A COMPARATIVE REVIEW OF THE EFFICACY AND SAFETY OF BARIATRIC SURGERY AND TIRZEPATIDE THERAPY","Wojciech Gąska","2025","exclude","E3","other",null,null,null,"high","coordinator","opus-5.5-coordinator","R19: priority given to reviews, trials and large cohorts, guidelines included, key findings only; blind disagreement settled",2],["R0040542","RETATRUTIDE-BASED TRIPLE AGONISM VERSUS TIRZEPATIDE-BASED DUAL AGONISM IN THE TREATMENT OF OBESITY: SYSTEMATIC REVIEW AND COMPARATIVE ANALYSIS OF RANDOMIZED CLINICAL TRIALS","Luiz Felippe Mendes Caquetti","2026","exclude","E3","other",null,null,"non_english","high","coordinator","opus-5.5-coordinator","R19: selection by relevance and journal impact, reports two trials only; blind disagreement settled",3],["R0044981","OUTCOME-DIRECTED USE OF GLP-1 RECEPTOR AGONISTS AND SGLT2 INHIBITORS IN TYPE 2 DIABETES","Didar Muratbek","2026","exclude","E3","other",null,null,null,"high","coordinator","opus-5.5-coordinator","R19: search built on names of pivotal trials, guidelines as eligible evidence, aim is treatment priority; blind disagreement settled",2],["R0046217","EFFICACY AND SAFETY OF DUAL GLP-1/GIP RECEPTOR AGONISTS FOR GASTROINTESTINAL AND HEPATIC OUTCOMES IN ADULTS WITH OBESITY AND TYPE 2 DIABETES: A SYSTEMATIC REVIEW","Dr. Mohid Ayub","2026","exclude","E3","other",null,null,null,"high","coordinator","opus-5.5-coordinator","R19: 24 reports included but only principal trials and meta-analyses reported; blind disagreement settled",3],["R0051050","Harnessing the Incretin System with Multi-Agonists","Martin Whyte","2022","exclude","E3","other",null,null,null,"high","coordinator","opus-5.5-coordinator","R14: self described narrative history of incretin drug development, no report of the studies meeting criteria; blind disagreement settled",2],["R0053409","Beyond Weight Loss: Reproductive Outcomes of GLP-1 Use in Women with PCOS - A Review of Current Evidence","Alice Scalzilli Becker","2025","exclude","E3","conference_abstract",null,null,"abstract_only","high","coordinator","opus-5.5-coordinator","R14: poster of a self described narrative review giving key findings, not results of the 47 articles; blind disagreement settled",2],["R0048351","A Systematic Review of Effective Fertility Adjuvant Therapy, Dulaglutide (GLP-1) in PCOD for Short Term","Hend Ahmado","2024","include_nma",null,"primary_report","P12",null,null,"high","coordinator","opus-5.5-coordinator","R22: own 200 patient PCOS trial called randomized, no allocation method; drug naming inconsistent, noted for risk of bias at extraction",5],["R0049243","Efficacy and safety of dulaglutide in patients with type 2 diabetes and obesity","D.G. Gusenbekova","2025","include_nma",null,"primary_report","P01",null,"non_english","high","coordinator","opus-5.5-coordinator","R22: called randomized with no allocation method described; judged in risk of bias at extraction",5],["R0016215","Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.","Frias JP","2018","include_nma",null,"primary_report","P01",null,null,"high","coordinator","opus-5.5-coordinator","manually downloaded paywalled report; phase 2 tirzepatide main report",1],["R0007808","Effects of Tirzepatide, a Dual GIP and GLP-1 RA, on Lipid and Metabolite Profiles in Subjects With Type 2 Diabetes.","Pirro V","2022","include_nma",null,"secondary_report","P01",null,null,"high","coordinator","opus-5.5-coordinator","manually downloaded paywalled report; phase 2 tirzepatide lipid and metabolite report",1],["R0018381","Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis.","Loomba R","2024","include_nma",null,"primary_report","P09",null,null,"high","coordinator","opus-5.5-coordinator","manually downloaded paywalled report; SYNERGY-NASH main report",1],["R0013589","The efficacy and safety of iGlarLixi versus IDegAsp in Chinese people with type 2 diabetes suboptimally controlled with oral antidiabetic drugs: The Soli-D randomized controlled trial.","Liu M","2024","include_nma",null,"primary_report","P01",null,null,"high","coordinator","opus-5.5-coordinator","manually downloaded paywalled report; Soli-D main report",1],["R0004227","Tirzepatide did not impact metabolic adaptation in people with obesity, but increased fat oxidation.","Ravussin E","2025","include_nma",null,"primary_report","P02",null,null,"high","coordinator","opus-5.5-coordinator","manually downloaded paywalled report; tirzepatide energy metabolism trial main report",1],["R0013656","Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.","Frías JP","2021","include_nma",null,"primary_report","P01",null,null,"high","coordinator","opus-5.5-coordinator","manually downloaded paywalled report; SURPASS-2 main report",1],["R0009666","Tirzepatide vs Insulin Lispro Added to Basal Insulin in Type 2 Diabetes: The SURPASS-6 Randomized Clinical Trial.","Rosenstock J","2023","include_nma",null,"primary_report","P01",null,null,"high","coordinator","opus-5.5-coordinator","manually downloaded paywalled report; SURPASS-6 main report",1],["R0015836","Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial.","Pratley R","2019","include_nma",null,"primary_report","P01",null,null,"high","coordinator","opus-5.5-coordinator","manually downloaded paywalled report; PIONEER 4 main report",1],["R0018537","Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.","Gerstein HC","2019","include_nma",null,"primary_report","P01",null,null,"high","coordinator","opus-5.5-coordinator","manually downloaded paywalled report; REWIND main report",1],["R0018694","Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial.","Gerstein HC","2019","include_nma",null,"secondary_report","P01",null,null,"high","coordinator","opus-5.5-coordinator","manually downloaded paywalled report; REWIND renal analysis",1],["R0020309","Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial.","Cukierman-Yaffe T","2020","include_nma",null,"secondary_report","P01",null,null,"high","coordinator","opus-5.5-coordinator","manually downloaded paywalled report; REWIND cognitive analysis",1],["R0021071","The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial.","Gerstein HC","2020","include_nma",null,"secondary_report","P01",null,null,"high","coordinator","opus-5.5-coordinator","manually downloaded paywalled report; REWIND stroke analysis",1],["R0018616","Erectile function in men with type 2 diabetes treated with dulaglutide: an exploratory analysis of the REWIND placebo-controlled randomised trial.","Bajaj HS","2021","include_nma",null,"secondary_report","P01",null,null,"high","coordinator","opus-5.5-coordinator","manually downloaded paywalled report; REWIND erectile function analysis",1],["R0018977","Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity.","Malhotra A","2024","include_nma",null,"primary_report","P10; P02",null,null,"high","coordinator","opus-5.5-coordinator","manually downloaded paywalled report; SURMOUNT-OSA main report",1],["R0011011","Tirzepatide for sleep-disordered breathing in SURMOUNT-OSA: Time course and association with body weight.","Malhotra A","2025","include_nma",null,"secondary_report","P10; P02",null,null,"high","coordinator","opus-5.5-coordinator","manually downloaded paywalled report; SURMOUNT-OSA sleep disordered breathing analysis",1],["R0020223","Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes.","Kosiborod MN","2024","include_nma",null,"primary_report","P07A; P01",null,null,"high","coordinator","opus-5.5-coordinator","manually downloaded paywalled report; STEP-HFpEF DM main report",1],["R0018972","Semaglutide in obesity-related heart failure with preserved ejection fraction and type 2 diabetes across baseline HbA1c levels (STEP-HFpEF DM): a prespecified analysis of heart failure and metabolic outcomes from a randomised, placebo-controlled trial.","Davies MJ","2025","include_nma",null,"secondary_report","P07A; P01",null,null,"high","coordinator","opus-5.5-coordinator","manually downloaded paywalled report; STEP-HFpEF DM prespecified HbA1c analysis",1],["R0016793","Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials.","Butler J","2024","include_nma",null,"pooled_analysis","P07A; P02; P01",null,null,"high","coordinator","opus-5.5-coordinator","manually downloaded paywalled report; pooled STEP-HFpEF program analysis",1],["R0015844","Semaglutide and Exercise Function in Obesity-Related HFpEF: Insights From the STEP-HFpEF Program.","Borlaug BA","2025","include_nma",null,"pooled_analysis","P07A; P02; P01",null,null,"high","coordinator","opus-5.5-coordinator","manually downloaded paywalled report; pooled STEP-HFpEF exercise function analysis",1],["R0015625","Frailty and Effects of Semaglutide in Obesity-Related HFpEF: Findings From the STEP-HFpEF Program.","Pandey A","2025","include_nma",null,"pooled_analysis","P07A; P02; P01",null,null,"high","coordinator","opus-5.5-coordinator","manually downloaded paywalled report; pooled STEP-HFpEF frailty analysis",1],["R0018703","Semaglutide and NYHA Functional Class in Obesity-Related Heart Failure With Preserved Ejection Fraction: The STEP-HFpEF Program.","Schou M","2024","include_nma",null,"pooled_analysis","P07A; P02; P01",null,null,"high","coordinator","opus-5.5-coordinator","manually downloaded paywalled report; pooled STEP-HFpEF NYHA class analysis",1],["R0018369","Effect of Semaglutide on Cardiac Structure and Function in Patients With Obesity-Related Heart Failure.","Solomon SD","2024","include_nma",null,"pooled_analysis","P07A; P02; P01",null,null,"high","coordinator","opus-5.5-coordinator","manually downloaded paywalled report; pooled STEP-HFpEF echocardiography analysis",1],["R0019167","Efficacy of Semaglutide by Sex in Obesity-Related Heart Failure With Preserved Ejection Fraction: STEP-HFpEF Trials.","Verma S","2024","include_nma",null,"pooled_analysis","P07A; P02; P01",null,null,"high","coordinator","opus-5.5-coordinator","manually downloaded paywalled report; pooled STEP-HFpEF analysis by sex",1],["R0019395","Inflammation in Obesity-Related HFpEF: The STEP-HFpEF Program.","Verma S","2024","include_nma",null,"pooled_analysis","P07A; P02; P01",null,null,"high","coordinator","opus-5.5-coordinator","manually downloaded paywalled report; pooled STEP-HFpEF inflammation analysis",1],["R0019192","Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials.","Kosiborod MN","2024","include_nma",null,"pooled_analysis","P07A; P07B; P02; P01",null,null,"high","coordinator","opus-5.5-coordinator","manually downloaded paywalled report; pooled SELECT, FLOW and STEP-HFpEF heart failure analysis",1],["R0013321","Efficacy and safety benefits of iGlarLixi versus insulin glargine 100 U/mL or lixisenatide in Asian Pacific people with suboptimally controlled type 2 diabetes on oral agents: The LixiLan-O-AP randomized controlled trial.","Yang W","2022","include_nma",null,"primary_report","P01",null,null,"high","coordinator","opus-5.5-coordinator","manually downloaded paywalled report; LixiLan-O-AP main report",1],["R0010585","iGlarLixi provides a higher derived time-in-range versus insulin glargine 100 U/mL or lixisenatide in Asian Pacific people with type 2 diabetes: A post hoc analysis.","Guo X","2023","include_nma",null,"secondary_report","P01",null,null,"high","coordinator","opus-5.5-coordinator","manually downloaded paywalled report; LixiLan-O-AP time in range analysis",1],["R0018421","Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial.","Yabe D","2020","include_nma",null,"primary_report","P01",null,null,"high","coordinator","opus-5.5-coordinator","manually downloaded paywalled report; PIONEER 10 main report",1],["R0016788","Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes.","Diamant M","2014","include_nma",null,"primary_report","P01",null,null,"high","coordinator","opus-5.5-coordinator","manually downloaded paywalled report; 4B trial main report",1],["R0017387","Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial.","Tuttle KR","2018","include_nma",null,"primary_report","P01; P08A",null,null,"high","coordinator","opus-5.5-coordinator","manually downloaded paywalled report; AWARD-7 main report",1],["R0012580","Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial.","Inagaki N","2022","include_nma",null,"primary_report","P01",null,null,"high","coordinator","opus-5.5-coordinator","manually downloaded paywalled report; SURPASS J-mono main report",1],["R0018941","Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial.","Aronne LJ","2024","include_nma",null,"primary_report","P02W",null,null,"high","coordinator","opus-5.5-coordinator","manually downloaded paywalled report; SURMOUNT-4 main report",1],["R0018256","Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial.","Rodbard HW","2019","include_nma",null,"primary_report","P01",null,null,"high","coordinator","opus-5.5-coordinator","manually downloaded paywalled report; PIONEER 2 main report; only its supplement is stored",1],["R0027392","Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study.","Moretto TJ","2008","include_nma",null,"primary_report","P01",null,null,"high","coordinator","opus-5.5-coordinator","manually downloaded paywalled report; exenatide monotherapy main report",1],["R0020680","Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial.","Ahmann AJ","2018","include_nma",null,"primary_report","P01",null,null,"high","coordinator","opus-5.5-coordinator","manually downloaded paywalled report; SUSTAIN 3 main report; only its supplement is stored",1],["R0013158","Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials.","Aroda VR","2019","include_nma",null,"pooled_analysis","P01",null,null,"high","coordinator","opus-5.5-coordinator","manually downloaded paywalled report; SUSTAIN 1 to 7 per trial overview",1],["R0009827","GREATER COMBINED REDUCTIONS IN HbA1C ≥1.0% AND WEIGHT ≥5.0% WITH SEMAGLUTIDE VERSUS COMPARATORS IN TYPE 2 DIABETES.","Rodbard HW","2019","include_nma",null,"pooled_analysis","P01",null,null,"high","coordinator","opus-5.5-coordinator","manually downloaded paywalled report; pooled SUSTAIN combined HbA1c and weight responders",1],["R0015927","Efficacy and Safety of Semaglutide for Type 2 Diabetes by Race and Ethnicity: A Post Hoc Analysis of the SUSTAIN Trials.","DeSouza C","2020","include_nma",null,"pooled_analysis","P01",null,null,"high","coordinator","opus-5.5-coordinator","manually downloaded paywalled report; pooled SUSTAIN analysis by race and ethnicity",1],["R0027069","Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial.","Buse JB","2011","include_nma",null,"primary_report","P01",null,null,"high","coordinator","opus-5.5-coordinator","manually downloaded paywalled report; exenatide added to basal insulin main report",1],["R0016299","Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study.","Buse JB","2013","include_nma",null,"primary_report","P01",null,null,"high","coordinator","opus-5.5-coordinator","manually downloaded paywalled report; DURATION-6 main report",1],["R0012919","Tirzepatide 5, 10 and 15 mg versus injectable semaglutide 0.5 mg for the treatment of type 2 diabetes: An adjusted indirect treatment comparison.","Osumili B","2024","exclude","E3","other","P01",null,null,"high","coordinator","opus-5.5-coordinator","manually downloaded; adjusted indirect treatment comparison, not a trial report",1],["R0014630","Semaglutide versus tirzepatide for people with type 2 diabetes: cost of glycemic control in Austria, the Netherlands, Lithuania, and the United Arab Emirates.","Reitzel SB","2023","exclude","E3","other","P01",null,null,"high","coordinator","opus-5.5-coordinator","manually downloaded; cost of glycemic control analysis, not a trial report",1]]}